8752018
D008094_D003072 CID lithium_0\NN\14625458| (r_npadvmod) associated_2\VBN\628491|lithium|- (r_amod) deficits_6\NNS\5113133|associated|cognitive|reduced|.
D008094_D003072 CID lithium_15\NN\14625458| (r_pobj) of_14\IN\0|lithium (r_prep) effects_13\NNS\13245626|the|common|adverse|of|,|as (r_pobj) of_8\IN\0|effects (r_prep) management_7\NN\1123598|the|of (r_pobj) about_5\IN\0|management (r_prep) written_4\VBN\1697816|although|much|has|been|about (r_advcl) remain_40\VBP\2604760|written|,|effects|understudied|. (l_nsubj) effects_27\NNS\13245626|subtle|lithium|side|as (l_prep) as_29\IN\14622893|such|deficits (l_pobj) deficits_31\NNS\5113133|cognitive|,|loss
D008094_D003072 CID lithium_15\NN\14625458| (r_pobj) of_14\IN\0|lithium (r_prep) effects_13\NNS\13245626|the|common|adverse|of|,|as (r_pobj) of_8\IN\0|effects (r_prep) management_7\NN\1123598|the|of (r_pobj) about_5\IN\0|management (r_prep) written_4\VBN\1697816|although|much|has|been|about (r_advcl) remain_40\VBP\2604760|written|,|effects|understudied|. (l_nsubj) effects_27\NNS\13245626|subtle|lithium|side|as (l_prep) as_29\IN\14622893|such|deficits (l_pobj) deficits_31\NNS\5113133|cognitive|,|loss (l_conj) loss_33\NN\13252973|of|,|and|impairments (l_prep) of_34\IN\0|creativity (l_pobj) creativity_35\NN\5616246|
D008094_D003072 CID lithium_15\NN\14625458| (r_pobj) of_14\IN\0|lithium (r_prep) effects_13\NNS\13245626|the|common|adverse|of|,|as (r_pobj) of_8\IN\0|effects (r_prep) management_7\NN\1123598|the|of (r_pobj) about_5\IN\0|management (r_prep) written_4\VBN\1697816|although|much|has|been|about (r_advcl) remain_40\VBP\2604760|written|,|effects|understudied|. (l_nsubj) effects_27\NNS\13245626|subtle|lithium|side|as (l_prep) as_29\IN\14622893|such|deficits (l_pobj) deficits_31\NNS\5113133|cognitive|,|loss (l_conj) loss_33\NN\13252973|of|,|and|impairments (l_conj) impairments_39\NNS\7296428|functional
D008094_D003072 CID lithium_25\NN\14625458| (r_compound) effects_27\NNS\13245626|subtle|lithium|side|as (l_prep) as_29\IN\14622893|such|deficits (l_pobj) deficits_31\NNS\5113133|cognitive|,|loss
D008094_D003072 CID lithium_25\NN\14625458| (r_compound) effects_27\NNS\13245626|subtle|lithium|side|as (l_prep) as_29\IN\14622893|such|deficits (l_pobj) deficits_31\NNS\5113133|cognitive|,|loss (l_conj) loss_33\NN\13252973|of|,|and|impairments (l_prep) of_34\IN\0|creativity (l_pobj) creativity_35\NN\5616246|
D008094_D003072 CID lithium_25\NN\14625458| (r_compound) effects_27\NNS\13245626|subtle|lithium|side|as (l_prep) as_29\IN\14622893|such|deficits (l_pobj) deficits_31\NNS\5113133|cognitive|,|loss (l_conj) loss_33\NN\13252973|of|,|and|impairments (l_conj) impairments_39\NNS\7296428|functional
D008094_D003072 CID lithium_10\NN\14625458| (r_pobj) from_9\IN\0|lithium (r_prep) switching_6\VBG\191142|patients|from|divalproex (l_advcl) divalproex_12\NN\0|to|sodium|alleviate (l_xcomp) alleviate_15\VB\205885|to|impairments (l_dobj) impairments_20\NNS\7296428|such|cognitive
D008094_D003072 CID lithium_8\NN\14625458| (r_pobj) of_7\IN\0|lithium (r_prep) substitution_6\NN\7337390|of|,|fully|,|with (r_nsubj) was_18\VBD\0|where|substitution|helpful (l_acomp) helpful_20\JJ\0|extremely|in (l_prep) in_21\IN\13603305|reducing (l_pcomp) reducing_22\VBG\13447361|cognitive (l_dobj) cognitive_24\JJ\0|the|,|motivational|attributed (l_conj) motivational_26\JJ\0|,|or|deficits (l_conj) deficits_30\NNS\5113133|creative
D008094_D003072 CID lithium_33\NN\14625458|in (r_pobj) to_32\IN\0|lithium (r_prep) attributed_31\VBN\670261|to (r_acl) cognitive_24\JJ\0|the|,|motivational|attributed (l_conj) motivational_26\JJ\0|,|or|deficits (l_conj) deficits_30\NNS\5113133|creative
D008094_D003072 CID lithium_12\NN\14625458|in (l_prep) in_13\IN\13603305|patients (l_pobj) patients_15\NNS\9898892|bipolar|experiencing (l_acl) experiencing_16\VBG\2108377|deficits (l_dobj) deficits_18\NNS\5113133|cognitive|,|loss
D008094_D003072 CID lithium_12\NN\14625458|in (l_prep) in_13\IN\13603305|patients (l_pobj) patients_15\NNS\9898892|bipolar|experiencing (l_acl) experiencing_16\VBG\2108377|deficits (l_dobj) deficits_18\NNS\5113133|cognitive|,|loss (l_conj) loss_20\NN\13252973|of (l_prep) of_21\IN\0|creativity (l_pobj) creativity_22\NN\5616246|,|and|impairments
D008094_D003072 CID lithium_12\NN\14625458|in (l_prep) in_13\IN\13603305|patients (l_pobj) patients_15\NNS\9898892|bipolar|experiencing (l_acl) experiencing_16\VBG\2108377|deficits (l_dobj) deficits_18\NNS\5113133|cognitive|,|loss (l_conj) loss_20\NN\13252973|of (l_prep) of_21\IN\0|creativity (l_pobj) creativity_22\NN\5616246|,|and|impairments (l_conj) impairments_26\NNS\7296428|functional
D014635_D003072 NONE sodium_13\NN\14625458|:|series (r_dobj) divalproex_12\NN\0|to|sodium (r_advcl) reduced_7\VBN\441445|by|divalproex (r_acl) deficits_6\NNS\5113133|associated|cognitive|reduced|.
D014635_D003072 NONE sodium_13\NN\14625458| (r_dobj) divalproex_12\NN\0|to|sodium|alleviate (l_xcomp) alleviate_15\VB\205885|to|impairments (l_dobj) impairments_20\NNS\7296428|such|cognitive
D014635_D003072 NONE sodium_17\NN\14625458|divalproex (r_pobj) with_15\IN\0|sodium (r_prep) substitution_6\NN\7337390|of|,|fully|,|with (r_nsubj) was_18\VBD\0|where|substitution|helpful (l_acomp) helpful_20\JJ\0|extremely|in (l_prep) in_21\IN\13603305|reducing (l_pcomp) reducing_22\VBG\13447361|cognitive (l_dobj) cognitive_24\JJ\0|the|,|motivational|attributed (l_conj) motivational_26\JJ\0|,|or|deficits (l_conj) deficits_30\NNS\5113133|creative
D014635_D003072 NONE sodium_6\NN\14625458|divalproex (r_nsubj) was_7\VBD\0|in|,|sodium|alternative|. (l_attr) alternative_10\NN\5788149|a|superior|to (l_prep) to_11\IN\0|lithium (l_pobj) lithium_12\NN\14625458|in (l_prep) in_13\IN\13603305|patients (l_pobj) patients_15\NNS\9898892|bipolar|experiencing (l_acl) experiencing_16\VBG\2108377|deficits (l_dobj) deficits_18\NNS\5113133|cognitive|,|loss
D014635_D003072 NONE sodium_6\NN\14625458|divalproex (r_nsubj) was_7\VBD\0|in|,|sodium|alternative|. (l_attr) alternative_10\NN\5788149|a|superior|to (l_prep) to_11\IN\0|lithium (l_pobj) lithium_12\NN\14625458|in (l_prep) in_13\IN\13603305|patients (l_pobj) patients_15\NNS\9898892|bipolar|experiencing (l_acl) experiencing_16\VBG\2108377|deficits (l_dobj) deficits_18\NNS\5113133|cognitive|,|loss (l_conj) loss_20\NN\13252973|of (l_prep) of_21\IN\0|creativity (l_pobj) creativity_22\NN\5616246|,|and|impairments
D014635_D003072 NONE sodium_6\NN\14625458|divalproex (r_nsubj) was_7\VBD\0|in|,|sodium|alternative|. (l_attr) alternative_10\NN\5788149|a|superior|to (l_prep) to_11\IN\0|lithium (l_pobj) lithium_12\NN\14625458|in (l_prep) in_13\IN\13603305|patients (l_pobj) patients_15\NNS\9898892|bipolar|experiencing (l_acl) experiencing_16\VBG\2108377|deficits (l_dobj) deficits_18\NNS\5113133|cognitive|,|loss (l_conj) loss_20\NN\13252973|of (l_prep) of_21\IN\0|creativity (l_pobj) creativity_22\NN\5616246|,|and|impairments (l_conj) impairments_26\NNS\7296428|functional
D008094_D001714 NONE lithium_0\NN\14625458| (r_nsubj) remains_1\VBZ\2684|lithium|treatment|. (l_attr) treatment_6\NN\654885|a|line|for (l_prep) for_7\IN\0|treatment (l_pobj) treatment_12\NN\654885|the|acute|of (l_prep) of_13\IN\0|disorder (l_pobj) disorder_15\NN\14034177|bipolar
D008094_D001714 NONE lithium_10\NN\14625458| (r_pobj) from_9\IN\0|lithium (r_prep) switching_6\VBG\191142|patients|from|divalproex (l_dobj) patients_8\NNS\9898892|bipolar (l_amod) bipolar_7\JJ\0|
D008094_D001714 NONE lithium_8\NN\14625458| (r_pobj) of_7\IN\0|lithium (r_prep) substitution_6\NN\7337390|of|,|fully|,|with (r_nsubj) was_18\VBD\0|where|substitution|helpful (l_acomp) helpful_20\JJ\0|extremely|in (l_prep) in_21\IN\13603305|reducing (l_pcomp) reducing_22\VBG\13447361|cognitive (l_dobj) cognitive_24\JJ\0|the|,|motivational|attributed (l_acl) attributed_31\VBN\670261|to (l_prep) to_32\IN\0|lithium (l_pobj) lithium_33\NN\14625458|in (l_prep) in_34\IN\13603305|patients (l_pobj) patients_37\NNS\9898892|our|bipolar (l_amod) bipolar_36\JJ\0|
D008094_D001714 NONE lithium_33\NN\14625458|in (l_prep) in_34\IN\13603305|patients (l_pobj) patients_37\NNS\9898892|our|bipolar (l_amod) bipolar_36\JJ\0|
D008094_D001714 NONE lithium_12\NN\14625458|in (l_prep) in_13\IN\13603305|patients (l_pobj) patients_15\NNS\9898892|bipolar|experiencing (l_amod) bipolar_14\JJ\0|
D008094_D011141 NONE lithium_15\NN\14625458| (r_pobj) of_14\IN\0|lithium (r_prep) effects_13\NNS\13245626|the|common|adverse|of|,|as (l_prep) as_18\IN\14622893|such|polyuria (l_pobj) polyuria_19\NN\14113228|and|tremor
D008094_D011141 NONE lithium_25\NN\14625458| (r_compound) effects_27\NNS\13245626|subtle|lithium|side|as (r_nsubj) remain_40\VBP\2604760|written|,|effects|understudied|. (l_advcl) written_4\VBN\1697816|although|much|has|been|about (l_prep) about_5\IN\0|management (l_pobj) management_7\NN\1123598|the|of (l_prep) of_8\IN\0|effects (l_pobj) effects_13\NNS\13245626|the|common|adverse|of|,|as (l_prep) as_18\IN\14622893|such|polyuria (l_pobj) polyuria_19\NN\14113228|and|tremor
D008094_D014202 NONE lithium_15\NN\14625458| (r_pobj) of_14\IN\0|lithium (r_prep) effects_13\NNS\13245626|the|common|adverse|of|,|as (l_prep) as_18\IN\14622893|such|polyuria (l_pobj) polyuria_19\NN\14113228|and|tremor (l_conj) tremor_21\NN\345926|
D008094_D014202 NONE lithium_25\NN\14625458| (r_compound) effects_27\NNS\13245626|subtle|lithium|side|as (r_nsubj) remain_40\VBP\2604760|written|,|effects|understudied|. (l_advcl) written_4\VBN\1697816|although|much|has|been|about (l_prep) about_5\IN\0|management (l_pobj) management_7\NN\1123598|the|of (l_prep) of_8\IN\0|effects (l_pobj) effects_13\NNS\13245626|the|common|adverse|of|,|as (l_prep) as_18\IN\14622893|such|polyuria (l_pobj) polyuria_19\NN\14113228|and|tremor (l_conj) tremor_21\NN\345926|
D014635_D001714 NONE sodium_13\NN\14625458| (r_dobj) divalproex_12\NN\0|to|sodium|alleviate (r_advcl) switching_6\VBG\191142|patients|from|divalproex (l_dobj) patients_8\NNS\9898892|bipolar (l_amod) bipolar_7\JJ\0|
D014635_D001714 NONE sodium_17\NN\14625458|divalproex (r_pobj) with_15\IN\0|sodium (r_prep) substitution_6\NN\7337390|of|,|fully|,|with (r_nsubj) was_18\VBD\0|where|substitution|helpful (l_acomp) helpful_20\JJ\0|extremely|in (l_prep) in_21\IN\13603305|reducing (l_pcomp) reducing_22\VBG\13447361|cognitive (l_dobj) cognitive_24\JJ\0|the|,|motivational|attributed (l_acl) attributed_31\VBN\670261|to (l_prep) to_32\IN\0|lithium (l_pobj) lithium_33\NN\14625458|in (l_prep) in_34\IN\13603305|patients (l_pobj) patients_37\NNS\9898892|our|bipolar (l_amod) bipolar_36\JJ\0|
D014635_D001714 NONE sodium_6\NN\14625458|divalproex (r_nsubj) was_7\VBD\0|in|,|sodium|alternative|. (l_attr) alternative_10\NN\5788149|a|superior|to (l_prep) to_11\IN\0|lithium (l_pobj) lithium_12\NN\14625458|in (l_prep) in_13\IN\13603305|patients (l_pobj) patients_15\NNS\9898892|bipolar|experiencing (l_amod) bipolar_14\JJ\0|
18464113
D019259_D006509 NONE lamivudine_0\NNP\3834836|for|. (l_prep) for_1\IN\0|prevention (l_pobj) prevention_3\NN\1073995|the|of (l_prep) of_4\IN\0|reactivation (l_pobj) reactivation_8\NN\0|virus|in (l_compound) virus_7\NN\9312843|b (l_compound) b_6\NNP\1355326|hepatitis
D019259_D006509 NONE lamivudine_20\NN\3834836|the|agent (r_dobj) received_16\VBD\2210855|in|,|patients|lamivudine|prior|compared|. (l_nsubj) patients_5\NNS\9898892|cancer|have (l_relcl) have_7\VBP\7846|who|malignancies (l_dobj) malignancies_11\NNS\14070360|solid|with (l_prep) with_12\IN\0|infection (l_pobj) infection_15\NN\14052046|chronic|hbv
D019259_D006509 NONE lamivudine_34\NN\3834836| (r_dobj) receive_33\VB\2210855|who|did|not|lamivudine (r_relcl) group_29\NN\2137|historical|control|receive (r_pobj) with_26\IN\0|group (r_prep) compared_25\VBN\644583|with (r_prep) received_16\VBD\2210855|in|,|patients|lamivudine|prior|compared|. (l_nsubj) patients_5\NNS\9898892|cancer|have (l_relcl) have_7\VBP\7846|who|malignancies (l_dobj) malignancies_11\NNS\14070360|solid|with (l_prep) with_12\IN\0|infection (l_pobj) infection_15\NN\14052046|chronic|hbv
D019259_D009369 NONE lamivudine_0\NNP\3834836|for|. (l_prep) for_1\IN\0|prevention (l_pobj) prevention_3\NN\1073995|the|of (l_prep) of_4\IN\0|reactivation (l_pobj) reactivation_8\NN\0|virus|in (l_prep) in_9\IN\13603305|patients (l_pobj) patients_20\NNS\9898892|antigen|(|hbsag|)|seropositive|cancer|undergoing (l_compound) cancer_19\NN\14239425|
D019259_D009369 NONE lamivudine_20\NN\3834836|the|agent (r_dobj) received_16\VBD\2210855|in|,|patients|lamivudine|prior|compared|. (l_nsubj) patients_5\NNS\9898892|cancer|have (l_compound) cancer_4\NN\14239425|
D019259_D009369 NONE lamivudine_34\NN\3834836| (r_dobj) receive_33\VB\2210855|who|did|not|lamivudine (r_relcl) group_29\NN\2137|historical|control|receive (r_pobj) with_26\IN\0|group (r_prep) compared_25\VBN\644583|with (r_prep) received_16\VBD\2210855|in|,|patients|lamivudine|prior|compared|. (l_nsubj) patients_5\NNS\9898892|cancer|have (l_compound) cancer_4\NN\14239425|
D019259_D009369 NONE lamivudine_5\NN\3834836|prophylactic (r_nsubj) decreases_7\VBZ\7296428|that|lamivudine|significantly|incidence|during (l_dobj) incidence_9\NN\13821570|the|of (l_prep) of_10\IN\0|reactivation (l_pobj) reactivation_12\NN\0|hbv|and|morbidity (l_conj) morbidity_15\NN\13826959|overall|in (l_prep) in_16\IN\13603305|patients (l_pobj) patients_18\NNS\9898892|cancer (l_compound) cancer_17\NN\14239425|
D006514_D006509 CID antigen_14\NN\20090|b|surface (r_nmod) patients_20\NNS\9898892|antigen|(|hbsag|)|seropositive|cancer|undergoing (r_pobj) in_9\IN\13603305|patients (r_prep) reactivation_8\NN\0|virus|in (l_compound) virus_7\NN\9312843|b (l_compound) b_6\NNP\1355326|hepatitis
D006514_D006509 CID hbsag_16\NNP\0| (r_nmod) patients_20\NNS\9898892|antigen|(|hbsag|)|seropositive|cancer|undergoing (r_pobj) in_9\IN\13603305|patients (r_prep) reactivation_8\NN\0|virus|in (l_compound) virus_7\NN\9312843|b (l_compound) b_6\NNP\1355326|hepatitis
D006514_D009369 NONE antigen_14\NN\20090|b|surface (r_nmod) patients_20\NNS\9898892|antigen|(|hbsag|)|seropositive|cancer|undergoing (l_compound) cancer_19\NN\14239425|
D006514_D009369 NONE hbsag_16\NNP\0| (r_nmod) patients_20\NNS\9898892|antigen|(|hbsag|)|seropositive|cancer|undergoing (l_compound) cancer_19\NN\14239425|
D019259_D019337 NONE lamivudine_20\NN\3834836|the|agent (r_dobj) received_16\VBD\2210855|in|,|patients|lamivudine|prior|compared|. (l_nsubj) patients_5\NNS\9898892|cancer|have (l_relcl) have_7\VBP\7846|who|malignancies (l_dobj) malignancies_11\NNS\14070360|solid|with
D019259_D019337 NONE lamivudine_34\NN\3834836| (r_dobj) receive_33\VB\2210855|who|did|not|lamivudine (r_relcl) group_29\NN\2137|historical|control|receive (r_pobj) with_26\IN\0|group (r_prep) compared_25\VBN\644583|with (r_prep) received_16\VBD\2210855|in|,|patients|lamivudine|prior|compared|. (l_nsubj) patients_5\NNS\9898892|cancer|have (l_relcl) have_7\VBP\7846|who|malignancies (l_dobj) malignancies_11\NNS\14070360|solid|with
D019259_D056486 NONE lamivudine_3\NN\3834836| (r_compound) group_4\NN\2137|the|prophylactic|lamivudine (r_pobj) in_0\IN\13603305|group (r_prep) observed_8\VBN\2163746|in|hepatitis|were|patient|. (l_nsubjpass) hepatitis_6\NN\14127211|severe
7504976
D002231_D056486 CID carbimazole_16\NN\0|and|benzylthiouracil (r_pobj) between_15\IN\0|carbimazole (r_prep) reactivity_14\NN\5652926|cross|-|between (r_pobj) with_11\IN\0|reactivity (r_prep) one_10\CD\13741022|with (r_pobj) including_9\VBG\0|one (r_prep) cases_8\NNS\7283608|four|including (r_appos) induced_2\VBN\1627355|hepatitis|by|:|cases|. (l_nsubj) hepatitis_1\NN\14127211|toxic
D002231_D056486 CID carbimazole_8\NN\0|(|omercazole|) (r_pobj) by_7\IN\0|carbimazole (r_agent) induced_6\VBN\1627355|hepatitis|by (l_nsubj) hepatitis_5\NN\14127211|a|cholestatic
D002231_D056486 CID omercazole_11\NN\0|n (r_appos) carbimazole_8\NN\0|(|omercazole|) (r_pobj) by_7\IN\0|carbimazole (r_agent) induced_6\VBN\1627355|hepatitis|by (l_nsubj) hepatitis_5\NN\14127211|a|cholestatic
D002231_D056486 CID carbimazole_12\NN\0|a|mixed|)|following (l_amod) following_11\VBG\8180190|hepatitis (l_compound) hepatitis_10\NN\14127211|
D002231_D056486 CID carbimazole_21\NN\0| (r_dobj) replaced_20\VBN\1631072|experienced|had|carbimazole|. (l_nsubj) experienced_7\VBD\2108377|one|further|hepatitis|) (l_dobj) hepatitis_10\NN\14127211|a|cytolytic|appeared
C019269_D056486 NONE benzylthiouracil_18\NN\0| (r_conj) carbimazole_16\NN\0|and|benzylthiouracil (r_pobj) between_15\IN\0|carbimazole (r_prep) reactivity_14\NN\5652926|cross|-|between (r_pobj) with_11\IN\0|reactivity (r_prep) one_10\CD\13741022|with (r_pobj) including_9\VBG\0|one (r_prep) cases_8\NNS\7283608|four|including (r_appos) induced_2\VBN\1627355|hepatitis|by|:|cases|. (l_nsubj) hepatitis_1\NN\14127211|toxic
C019269_D056486 NONE benzylthiouracil_14\NNP\0|ne (r_pobj) after_13\IN\0|benzylthiouracil (r_prep) appeared_12\VBD\2604760|which|after (r_relcl) hepatitis_10\NN\14127211|a|cytolytic|appeared
C019269_D056486 NONE ne_17\NNP\14622893|(|basd (r_appos) benzylthiouracil_14\NNP\0|ne (r_pobj) after_13\IN\0|benzylthiouracil (r_prep) appeared_12\VBD\2604760|which|after (r_relcl) hepatitis_10\NN\14127211|a|cytolytic|appeared
D002231_D002779 CID carbimazole_8\NN\0|(|omercazole|) (r_pobj) by_7\IN\0|carbimazole (r_agent) induced_6\VBN\1627355|hepatitis|by (l_nsubj) hepatitis_5\NN\14127211|a|cholestatic
D002231_D002779 CID omercazole_11\NN\0|n (r_appos) carbimazole_8\NN\0|(|omercazole|) (r_pobj) by_7\IN\0|carbimazole (r_agent) induced_6\VBN\1627355|hepatitis|by (l_nsubj) hepatitis_5\NN\14127211|a|cholestatic
D002231_D002779 CID carbimazole_12\NN\0|a|mixed|)|following (l_amod) mixed_4\JJ\140123|(|cholestatic (l_conj) cholestatic_6\JJ\0|and|cytolytic
15515654
D003676_D006311 NONE dfo_6\NNP\0| (r_pobj) than_5\IN\0|dfo (r_prep) other_4\JJ\0|than (r_amod) factor_2\NN\7326557|no|ototoxic|,|other|, (l_compound) ototoxic_1\JJ\0|
D003676_D006319 CID dfo_6\NNP\0| (r_compound) reduction_7\NN\351485|dfo|or|withdrawal (r_pobj) to_5\IN\0|reduction (r_prep) submitted_4\VBN\1952898|subjects|were|to|. (l_nsubjpass) subjects_0\NNS\6598915|with (l_prep) with_1\IN\0|snhl (l_pobj) snhl_2\NNP\0|
D003676_D034381 NONE dfo_5\NNP\0|'s (r_poss) role_8\NN\719494|dfo|contributing|in (l_prep) in_9\IN\13603305|development (l_pobj) development_11\NN\248977|the|of (l_prep) of_12\IN\0|impairment (l_pobj) impairment_14\NN\7296428|hearing
3409645
D008727_D007172 CID methotrexate_23\NNP\2722166| (r_pobj) of_22\IN\0|methotrexate (r_prep) taking_21\NN\37396|the|of (r_conj) was_1\VBD\0|impotence|common|and|found|and|taking|. (l_nsubj) impotence_0\NN\4723816|
16740173
2024540
D004656_D006333 NONE enalapril_11\NN\2673637|and|prazosin (r_pobj) of_10\IN\0|enalapril (r_prep) safety_9\NN\13920835|of|in (l_prep) in_14\IN\13603305|phase (l_pobj) phase_18\NN\15113229|the|initial|treatment|of (l_prep) of_19\IN\0|patients (l_pobj) patients_20\NNS\9898892|with (l_prep) with_21\IN\0|failure (l_pobj) failure_24\NN\66216|heart
D011224_D006333 NONE prazosin_13\NN\2698769| (r_conj) enalapril_11\NN\2673637|and|prazosin (r_pobj) of_10\IN\0|enalapril (r_prep) safety_9\NN\13920835|of|in (l_prep) in_14\IN\13603305|phase (l_pobj) phase_18\NN\15113229|the|initial|treatment|of (l_prep) of_19\IN\0|patients (l_pobj) patients_20\NNS\9898892|with (l_prep) with_21\IN\0|failure (l_pobj) failure_24\NN\66216|heart
D000806_D006333 NONE inhibitors_10\NNS\20090|(|ace|) (r_appos) enzyme_6\NN\14723628|inhibitors (r_dobj) converting_5\VBG\126264|enzyme|into (l_prep) into_11\IN\0|treatment (l_pobj) treatment_14\NN\654885|the|adjunctive|of (l_prep) of_15\IN\0|patients (l_pobj) patients_16\NNS\9898892|with (l_prep) with_17\IN\0|failure (l_pobj) failure_20\NN\66216|congestive|heart|,|cases
D000806_D007022 CID inhibitors_10\NNS\20090|(|ace|) (r_appos) enzyme_6\NN\14723628|inhibitors (r_dobj) converting_5\VBG\126264|enzyme|into (l_prep) into_11\IN\0|treatment (l_pobj) treatment_14\NN\654885|the|adjunctive|of (l_prep) of_15\IN\0|patients (l_pobj) patients_16\NNS\9898892|with (l_prep) with_17\IN\0|failure (l_pobj) failure_20\NN\66216|congestive|heart|,|cases (l_conj) cases_22\NNS\7283608|of (l_prep) of_23\IN\0|hypotension (l_pobj) hypotension_25\NN\14057371|severe
D000806_D007022 CID inhibitor_7\NN\20090|the|ace|enalapril (r_pobj) of_4\IN\0|inhibitor (r_prep) safety_3\NN\13920835|the|of (r_dobj) assess_1\VB\5220461|to|safety (r_advcl) designed_19\VBN\1631534|assess|trial|was|that|compared|. (l_prep) compared_21\VBD\644583|incidence (l_pobj) incidence_23\NN\13821570|the|and|severity|of (l_prep) of_26\IN\0|hypotension (l_pobj) hypotension_28\NN\14057371|symptomatic|on
D004656_D007022 NONE enalapril_8\NN\2673637| (r_appos) inhibitor_7\NN\20090|the|ace|enalapril (r_pobj) of_4\IN\0|inhibitor (r_prep) safety_3\NN\13920835|the|of (r_dobj) assess_1\VB\5220461|to|safety (r_advcl) designed_19\VBN\1631534|assess|trial|was|that|compared|. (l_prep) compared_21\VBD\644583|incidence (l_pobj) incidence_23\NN\13821570|the|and|severity|of (l_prep) of_26\IN\0|hypotension (l_pobj) hypotension_28\NN\14057371|symptomatic|on
D004656_D007022 NONE enalapril_3\RB\2673637| (r_dobj) received_2\VBD\2210855|who|enalapril (r_relcl) patients_0\NNS\9898892|received (r_nsubj) experienced_4\VBD\2108377|patients|hypotension|. (l_dobj) hypotension_11\NN\14057371|clinically|(|%|)|than
D011224_D007022 CID prazosin_14\NN\2698769| (r_npadvmod) controlled_16\VBN\0|prazosin|- (r_amod) trial_17\NN\786195|a|multicenter|,|randomized|,|controlled (r_nsubjpass) designed_19\VBN\1631534|assess|trial|was|that|compared|. (l_prep) compared_21\VBD\644583|incidence (l_pobj) incidence_23\NN\13821570|the|and|severity|of (l_prep) of_26\IN\0|hypotension (l_pobj) hypotension_28\NN\14057371|symptomatic|on
D011224_D007022 CID prazosin_21\NN\2698769|(|%|) (r_dobj) received_20\VBD\2210855|who|prazosin (r_relcl) patients_18\NNS\9898892|the|received (r_pobj) than_16\IN\0|patients (r_prep) hypotension_11\NN\14057371|clinically|(|%|)|than
10791295
D001058_D010554 CID apomorphine_2\NN\3786417| (r_pobj) of_1\IN\0|apomorphine (r_prep) development_0\NN\248977|of (r_nsubj) induced_4\VBN\1627355|development|-|behavior|:|comparison|. (l_dobj) behavior_6\NN\407535|aggressive
D001058_D010554 CID apomorphine_3\NN\3786417| (r_pobj) of_2\IN\0|apomorphine (r_prep) development_1\NN\248977|the|of (r_nsubj) induced_5\VBN\1627355|development|-|s.c.|daily|)|behavior|studied|. (l_dobj) behavior_14\NN\407535|aggressive|of|obtained
D001058_D010554 CID apomorphine_5\NN\3786417| (r_compound) treatment_6\NN\654885|repeated|apomorphine (r_nsubj) induced_7\VBD\1627355|in|,|treatment|development|evidenced|. (l_dobj) development_10\NN\248977|a|gradual|of (l_prep) of_11\IN\0|behavior (l_pobj) behavior_13\NN\407535|aggressive
D001058_D010554 CID apomorphine_5\NN\3786417| (r_compound) treatment_6\NN\654885|repeated|apomorphine (r_nsubj) induced_7\VBD\1627355|in|,|treatment|development|evidenced|. (l_advcl) evidenced_15\VBN\1015244|as|by|and|shortened (l_agent) by_16\IN\0|intensity (l_pobj) intensity_19\NN\5090441|the|increased|of (l_prep) of_20\IN\0|aggressiveness (l_pobj) aggressiveness_21\NN\4835724|
D001058_D010554 CID apomorphine_14\NN\3786417| (r_preconj) the_13\DT\0|apomorphine (r_det) behavior_18\NN\407535|the|induced|aggressive
14698717
D010672_D011605 NONE phenytoin_6\NN\3550533| (r_pobj) with_5\IN\0|phenytoin (r_prep) treatment_4\NN\654885|with|in (r_pobj) due_2\IN\5174653|to|treatment (r_amod) psychosis_1\NN\14380140|acute|due|.
D010672_D011605 NONE phenytoin_10\JJ\3550533| (r_compound) treatment_11\NN\654885|phenytoin|for (r_dobj) following_9\VBG\8180190|treatment (r_acl) psychosis_8\NN\14380140|following
D010672_D011605 NONE phenytoin_10\JJ\3550533| (r_compound) treatment_11\NN\654885|phenytoin|in (r_pobj) following_9\VBG\8180190|treatment (r_prep) occur_8\VBP\0|that|following (r_relcl) symptoms_6\NNS\5823932|the|psychotic|occur
D010672_D014277 NONE phenytoin_10\JJ\3550533| (r_compound) treatment_11\NN\654885|phenytoin|for (l_prep) for_12\IN\0|neuralgia (l_pobj) neuralgia_14\NN\14322699|trigeminal
D010672_D004827 NONE phenytoin_10\JJ\3550533| (r_compound) treatment_11\NN\654885|phenytoin|in (l_prep) in_12\IN\13603305|patients (l_pobj) patients_15\NNS\9898892|some|epileptic (l_amod) epileptic_14\JJ\10595647|
D010672_D012640 NONE phenytoin_10\JJ\3550533| (r_compound) treatment_11\NN\654885|phenytoin|in (r_pobj) following_9\VBG\8180190|treatment (r_prep) occur_8\VBP\0|that|following (r_relcl) symptoms_6\NNS\5823932|the|psychotic|occur (r_nsubj) be_17\VB\14625458|that|symptoms|may|result (l_attr) result_20\NN\34213|the|direct|of|,|unrelated (l_amod) unrelated_24\JJ\0|to (l_prep) to_25\IN\0|seizures (l_pobj) seizures_26\NNS\14081375|
150790
D011736_D002653 NONE pyridoxine_1\JJ\15090742| (r_advmod) dependent_3\JJ\9627906|pyridoxine|- (r_amod) disorder_5\NN\14034177|a|dependent|behavioral|unmasked|.
D007538_D002653 CID isoniazid_8\NN\2716205| (r_pobj) by_7\IN\0|isoniazid (r_agent) unmasked_6\VBD\853195|by (r_acl) disorder_5\NN\14034177|a|dependent|behavioral|unmasked|.
D007538_D002653 CID isoniazid_22\NN\2716205| (r_pobj) of_21\IN\0|isoniazid (r_prep) administration_20\NN\1133281|the|therapeutic|of (r_pobj) after_17\IN\0|administration (r_prep) sleeping_15\VBG\14024882|difficulties|after (r_conj) irritability_12\NN\7552087|,|and|sleeping (r_conj) hyperkinesis_10\NN\0|,|irritability (r_pobj) with_9\IN\0|hyperkinesis (r_prep) had_5\VBD\0|girl|deterioration|,|with|. (l_dobj) deterioration_7\NN\14560612|behavioral
D007538_D006948 CID isoniazid_22\NN\2716205| (r_pobj) of_21\IN\0|isoniazid (r_prep) administration_20\NN\1133281|the|therapeutic|of (r_pobj) after_17\IN\0|administration (r_prep) sleeping_15\VBG\14024882|difficulties|after (r_conj) irritability_12\NN\7552087|,|and|sleeping (r_conj) hyperkinesis_10\NN\0|,|irritability
D007538_D001523 NONE isoniazid_22\NN\2716205| (r_pobj) of_21\IN\0|isoniazid (r_prep) administration_20\NN\1133281|the|therapeutic|of (r_pobj) after_17\IN\0|administration (r_prep) sleeping_15\VBG\14024882|difficulties|after (r_conj) irritability_12\NN\7552087|,|and|sleeping
D007538_D012893 NONE isoniazid_22\NN\2716205| (r_pobj) of_21\IN\0|isoniazid (r_prep) administration_20\NN\1133281|the|therapeutic|of (r_pobj) after_17\IN\0|administration (r_prep) sleeping_15\VBG\14024882|difficulties|after (l_dobj) difficulties_16\NNS\621627|
D011736_D006948 NONE pyridoxine_3\NN\15090742| (r_pobj) of_2\IN\0|pyridoxine (r_prep) withdrawal_1\NN\7206096|periodic|of (r_nsubjpass) associated_5\VBN\628491|withdrawal|was|with|. (l_prep) with_6\IN\0|return (l_pobj) return_7\NN\6479665|of (l_prep) of_8\IN\0|hyperkinesis (l_pobj) hyperkinesis_10\NN\0|the
20698227
D012254_D000743 NONE ribavirin_8\RB\2725367| (r_pobj) for_7\IN\0|ribavirin (r_prep) treatment_6\NN\654885|for (r_pobj) of_5\IN\0|treatment (r_prep) target_4\NN\7258332|a|of|associated (l_acl) associated_9\VBN\628491|anemia (l_dobj) anemia_11\NN\14189204|hemolytic
D012254_D006461 NONE ribavirin_1\RB\2725367|recently (r_nsubjpass) found_4\VBN\13279262|ribavirin|has|been|inhibit|found (l_conj) found_21\VBN\13279262|number|have|been|cause|. (l_advcl) cause_23\VB\7323922|to|hemolysis (l_dobj) hemolysis_25\NN\13509528|acute
C473478_D006461 CID sunitinib_16\JJ\0|and|sorafenib (r_pobj) as_15\IN\14622893|such|sunitinib (r_prep) inhibitors_13\NNS\20090|angiogenesis|as (r_pobj) of_11\IN\0|inhibitors (r_prep) number_10\NN\5107765|a|of (r_nsubjpass) found_21\VBN\13279262|number|have|been|cause|. (l_advcl) cause_23\VB\7323922|to|hemolysis (l_dobj) hemolysis_25\NN\13509528|acute
C471405_D006461 CID sorafenib_18\NNS\0| (r_conj) sunitinib_16\JJ\0|and|sorafenib (r_pobj) as_15\IN\14622893|such|sunitinib (r_prep) inhibitors_13\NNS\20090|angiogenesis|as (r_pobj) of_11\IN\0|inhibitors (r_prep) number_10\NN\5107765|a|of (r_nsubjpass) found_21\VBN\13279262|number|have|been|cause|. (l_advcl) cause_23\VB\7323922|to|hemolysis (l_dobj) hemolysis_25\NN\13509528|acute
C100416_D019698 NONE 2a_14\CD\0|pegylated|interferon|alpha|and|ribavirin (r_pobj) by_10\IN\0|2a (r_agent) treated_9\VBN\2376958|infected|were|by|. (l_csubjpass) infected_3\VBN\2316868|patients|chronically|with (l_prep) with_4\IN\0|virus (l_pobj) virus_7\NN\9312843|c
D012254_D019698 NONE ribavirin_16\RB\2725367| (r_conj) 2a_14\CD\0|pegylated|interferon|alpha|and|ribavirin (r_pobj) by_10\IN\0|2a (r_agent) treated_9\VBN\2376958|infected|were|by|. (l_csubjpass) infected_3\VBN\2316868|patients|chronically|with (l_prep) with_4\IN\0|virus (l_pobj) virus_7\NN\9312843|c
D012254_D019698 NONE ribavirin_16\RB\2725367| (r_conj) markers_14\NNS\21939|soluble|and|ribavirin (r_dobj) angiogenesis_12\NN\13489037|markers (r_pobj) between_11\IN\0|angiogenesis (r_prep) link_10\NN\13792579|a|between (r_dobj) investigating_8\VBG\575741|link (r_acl) study_4\NN\635850|the|first|in|investigating (r_attr) is_1\VBZ\0|this|study|induced (l_advcl) induced_17\VBD\1627355|anemia|and|find (l_dobj) anemia_18\NN\14189204|in (l_prep) in_19\IN\13603305|patients (l_pobj) patients_20\NNS\9898892|with (l_prep) with_21\IN\0|c (l_pobj) c_23\NNP\13714184|hepatitis
D012254_D000740 NONE ribavirin_16\RB\2725367| (r_conj) markers_14\NNS\21939|soluble|and|ribavirin (r_dobj) angiogenesis_12\NN\13489037|markers (r_pobj) between_11\IN\0|angiogenesis (r_prep) link_10\NN\13792579|a|between (r_dobj) investigating_8\VBG\575741|link (r_acl) study_4\NN\635850|the|first|in|investigating (r_attr) is_1\VBZ\0|this|study|induced (l_advcl) induced_17\VBD\1627355|anemia|and|find (l_dobj) anemia_18\NN\14189204|in
3107448
D005905_D056486 CID glyburide_0\NN\2719105| (r_npadvmod) induced_2\VBN\1627355|glyburide|- (r_amod) hepatitis_3\NN\14127211|induced|.
D005905_D056486 CID glyburide_1\NN\2719105| (r_pobj) for_0\IN\0|glyburide (r_prep) exist_15\VBP\0|for|,|sulfonylurea|,|reports|. (l_nsubj) reports_12\NNS\6470073|two|brief|of (l_prep) of_13\IN\0|hepatotoxicity (l_pobj) hepatotoxicity_14\NN\0|
D005905_D056486 CID glyburide_18\NN\2719105| (r_amod) therapy_19\NN\657604|glyburide (r_pobj) of_17\IN\0|therapy (r_prep) initiation_16\NN\7450842|of (r_pobj) after_15\IN\0|soon|initiation (r_prep) developed_7\VBD\1753788|patients|syndrome|after|. (l_dobj) syndrome_13\NN\5870365|an|acute|like
D005905_D056486 CID glyburide_0\NNP\2719105| (r_nsubj) produce_2\VB\7555863|glyburide|can|illness|. (l_dobj) illness_8\NN\14052046|an|acute|like|in
D013453_D056486 NONE sulfonylureas_14\NNS\2719105| (r_pobj) with_13\IN\0|sulfonylureas (r_prep) reported_10\VBN\831651|hepatotoxicity|,|common|,|has|been|infrequently|with|. (l_nsubjpass) hepatotoxicity_3\NN\0|induced
D013453_D056486 NONE sulfonylurea_7\NN\2719105|a|generation (r_nsubj) exist_15\VBP\0|for|,|sulfonylurea|,|reports|. (l_nsubj) reports_12\NNS\6470073|two|brief|of (l_prep) of_13\IN\0|hepatotoxicity (l_pobj) hepatotoxicity_14\NN\0|
D005905_D003924 NONE glyburide_18\NN\2719105| (r_amod) therapy_19\NN\657604|glyburide (r_pobj) of_17\IN\0|therapy (r_prep) initiation_16\NN\7450842|of (r_pobj) after_15\IN\0|soon|initiation (r_prep) developed_7\VBD\1753788|patients|syndrome|after|. (l_nsubj) patients_1\NNS\9898892|two|with (l_prep) with_2\IN\0|mellitus (l_pobj) mellitus_6\NN\0|diabetes
20520283
C522667_D012559 NONE asenapine_4\NN\0| (r_pobj) of_3\IN\0|asenapine (r_prep) efficacy_0\NN\5199286|and|safety|of|in|. (l_prep) in_5\IN\13603305|trial (l_pobj) trial_12\NN\786195|placebo-|controlled|in (l_prep) in_13\IN\13603305|patients (l_pobj) patients_14\NNS\9898892|with (l_prep) with_15\IN\0|exacerbation (l_pobj) exacerbation_17\NN\374224|acute|of (l_prep) of_18\IN\0|schizophrenia (l_pobj) schizophrenia_19\NN\14398067|
C522667_D012559 NONE asenapine_0\NNP\0| (r_nsubjpass) approved_2\VBN\803325|asenapine|is|by|in|. (l_prep) in_9\IN\13603305|adults (l_pobj) adults_10\NNS\7846|for (l_prep) for_11\IN\0|treatment|or|of (l_pobj) treatment_13\NN\654885|acute|of (l_prep) of_14\IN\0|schizophrenia (l_pobj) schizophrenia_15\NN\14398067|
C522667_D012559 NONE asenapine_22\NN\0| (r_pobj) with_21\IN\0|asenapine (r_prep) treatment_20\NN\654885|dose|with (r_pobj) to_16\IN\0|treatment (r_prep) assigned_15\VBN\2475922|in|,|patients|were|randomly|to|at|,|asenapine|)|. (l_nsubjpass) patients_9\NNS\9898892|458|with (l_prep) with_10\IN\0|schizophrenia (l_pobj) schizophrenia_12\NN\14398067|acute
C522667_D012559 NONE asenapine_32\NN\0|at|verify (r_dep) assigned_15\VBN\2475922|in|,|patients|were|randomly|to|at|,|asenapine|)|. (l_nsubjpass) patients_9\NNS\9898892|458|with (l_prep) with_10\IN\0|schizophrenia (l_pobj) schizophrenia_12\NN\14398067|acute
D006220_D012559 NONE haloperidol_9\NN\3713736| (r_npadvmod) controlled_11\VBN\0|haloperidol|- (r_amod) trial_12\NN\786195|placebo-|controlled|in (l_prep) in_13\IN\13603305|patients (l_pobj) patients_14\NNS\9898892|with (l_prep) with_15\IN\0|exacerbation (l_pobj) exacerbation_17\NN\374224|acute|of (l_prep) of_18\IN\0|schizophrenia (l_pobj) schizophrenia_19\NN\14398067|
D006220_D012559 NONE haloperidol_41\NN\3713736|at (r_conj) placebo_38\NN\3740161|,|or|haloperidol (r_conj) bid_36\NN\7160883|mg|,|placebo (r_pobj) at_33\IN\14622893|bid (r_prep) asenapine_32\NN\0|at|verify (r_dep) assigned_15\VBN\2475922|in|,|patients|were|randomly|to|at|,|asenapine|)|. (l_nsubjpass) patients_9\NNS\9898892|458|with (l_prep) with_10\IN\0|schizophrenia (l_pobj) schizophrenia_12\NN\14398067|acute
C522667_D001714 NONE asenapine_0\NNP\0| (r_nsubjpass) approved_2\VBN\803325|asenapine|is|by|in|. (l_prep) in_9\IN\13603305|adults (l_pobj) adults_10\NNS\7846|for (l_prep) for_11\IN\0|treatment|or|of (l_conj) of_17\IN\0|episodes (l_pobj) episodes_21\NNS\7283608|manic|associated (l_amod) manic_18\JJ\0|or|mixed
C522667_D001714 NONE asenapine_0\NNP\0| (r_nsubjpass) approved_2\VBN\803325|asenapine|is|by|in|. (l_prep) in_9\IN\13603305|adults (l_pobj) adults_10\NNS\7846|for (l_prep) for_11\IN\0|treatment|or|of (l_conj) of_17\IN\0|episodes (l_pobj) episodes_21\NNS\7283608|manic|associated (l_acl) associated_22\VBN\628491|with (l_prep) with_23\IN\0|disorder (l_pobj) disorder_26\NN\14034177|bipolar|i|with
C522667_D011618 NONE asenapine_0\NNP\0| (r_nsubjpass) approved_2\VBN\803325|asenapine|is|by|in|. (l_prep) in_9\IN\13603305|adults (l_pobj) adults_10\NNS\7846|for (l_prep) for_11\IN\0|treatment|or|of (l_conj) of_17\IN\0|episodes (l_pobj) episodes_21\NNS\7283608|manic|associated (l_acl) associated_22\VBN\628491|with (l_prep) with_23\IN\0|disorder (l_pobj) disorder_26\NN\14034177|bipolar|i|with (l_prep) with_27\IN\0|or|without (l_conj) without_29\IN\0|features (l_pobj) features_31\NNS\5849040|psychotic (l_amod) psychotic_30\JJ\10595647|
C522667_D001480 CID asenapine_21\NN\0|the (r_pobj) of_19\IN\0|asenapine (r_prep) %_18\NN\0|10|of|at (r_conj) %_14\NN\0|34|,|and|% (r_appos) %_8\NN\0|15|and|%|,|%|respectively (r_pobj) in_6\IN\13603305|% (r_prep) occurred_5\VBD\0|as|aes|in (r_advcl) reported_2\VBD\831651|symptoms|occurred|. (l_nsubj) symptoms_1\NNS\5823932|extrapyramidal
C522667_D001480 CID asenapine_9\NN\0|and|haloperidol (r_pobj) with_8\IN\0|asenapine (r_prep) similar_7\JJ\0|with (r_acomp) was_6\VBD\0|that|efficacy|similar (r_ccomp) indicated_3\VBD\952524|analyses|was (r_ccomp) seen_16\VBN\2106506|indicated|;|contrasts|were|in|. (l_prep) in_17\IN\13603305|aes (l_pobj) aes_18\NNS\0|,|symptoms (l_appos) symptoms_22\NNS\5823932|extrapyramidal
D006220_D001480 CID haloperidol_29\NN\3713736|,|and|groups (r_conj) bid_27\NN\7160883|mg|,|haloperidol (r_pobj) at_22\IN\14622893|bid (r_prep) %_18\NN\0|10|of|at (r_conj) %_14\NN\0|34|,|and|% (r_appos) %_8\NN\0|15|and|%|,|%|respectively (r_pobj) in_6\IN\13603305|% (r_prep) occurred_5\VBD\0|as|aes|in (r_advcl) reported_2\VBD\831651|symptoms|occurred|. (l_nsubj) symptoms_1\NNS\5823932|extrapyramidal
D006220_D001480 CID haloperidol_11\NN\3713736| (r_conj) asenapine_9\NN\0|and|haloperidol (r_pobj) with_8\IN\0|asenapine (r_prep) similar_7\JJ\0|with (r_acomp) was_6\VBD\0|that|efficacy|similar (r_ccomp) indicated_3\VBD\952524|analyses|was (r_ccomp) seen_16\VBN\2106506|indicated|;|contrasts|were|in|. (l_prep) in_17\IN\13603305|aes (l_pobj) aes_18\NNS\0|,|symptoms (l_appos) symptoms_22\NNS\5823932|extrapyramidal
17466854
D008775_D002386 NONE methylprednisolone_13\NN\0| (r_pobj) of_12\IN\0|methylprednisolone (r_prep) administration_11\NN\1133281|the|of (r_pobj) after_9\IN\0|administration (r_prep) incidence_3\NN\13821570|the|of|after (r_dobj) assess_1\VB\5220461|to|incidence|and|gentamicin|. (l_conj) gentamicin_15\NN\2716866|into|at (l_prep) at_24\IN\14622893|end (l_pobj) end_26\NN\8568978|the|of (l_prep) of_27\IN\0|surgery (l_pobj) surgery_30\NN\6045562|routine|cataract (l_compound) cataract_29\NN\14252864|
D005839_D002386 NONE gentamicin_15\NN\2716866|into|at (l_prep) at_24\IN\14622893|end (l_pobj) end_26\NN\8568978|the|of (l_prep) of_27\IN\0|surgery (l_pobj) surgery_30\NN\6045562|routine|cataract (l_compound) cataract_29\NN\14252864|
D008775_D020250 CID methylprednisolone_3\NN\0| (r_pobj) of_2\IN\0|methylprednisolone (r_prep) administration_1\NN\1133281|the|of|and|gentamicin (r_nsubjpass) related_15\VBN\628491|administration|was|to|. (l_prep) to_16\IN\0|incidence (l_pobj) incidence_19\NN\13821570|a|high|of (l_prep) of_20\IN\0|effects (l_pobj) effects_22\NNS\13245626|side|including (l_prep) including_23\VBG\0|nausea (l_pobj) nausea_24\NN\14299637|,|vomiting (l_conj) vomiting_26\NN\116687|,|and|headache
D008775_D006261 CID methylprednisolone_3\NN\0| (r_pobj) of_2\IN\0|methylprednisolone (r_prep) administration_1\NN\1133281|the|of|and|gentamicin (r_nsubjpass) related_15\VBN\628491|administration|was|to|. (l_prep) to_16\IN\0|incidence (l_pobj) incidence_19\NN\13821570|a|high|of (l_prep) of_20\IN\0|effects (l_pobj) effects_22\NNS\13245626|side|including (l_prep) including_23\VBG\0|nausea (l_pobj) nausea_24\NN\14299637|,|vomiting (l_conj) vomiting_26\NN\116687|,|and|headache (l_conj) headache_29\NN\5829480|
D005839_D020250 CID gentamicin_5\NN\2716866|in (r_conj) administration_1\NN\1133281|the|of|and|gentamicin (r_nsubjpass) related_15\VBN\628491|administration|was|to|. (l_prep) to_16\IN\0|incidence (l_pobj) incidence_19\NN\13821570|a|high|of (l_prep) of_20\IN\0|effects (l_pobj) effects_22\NNS\13245626|side|including (l_prep) including_23\VBG\0|nausea (l_pobj) nausea_24\NN\14299637|,|vomiting (l_conj) vomiting_26\NN\116687|,|and|headache
D005839_D006261 CID gentamicin_5\NN\2716866|in (r_conj) administration_1\NN\1133281|the|of|and|gentamicin (r_nsubjpass) related_15\VBN\628491|administration|was|to|. (l_prep) to_16\IN\0|incidence (l_pobj) incidence_19\NN\13821570|a|high|of (l_prep) of_20\IN\0|effects (l_pobj) effects_22\NNS\13245626|side|including (l_prep) including_23\VBG\0|nausea (l_pobj) nausea_24\NN\14299637|,|vomiting (l_conj) vomiting_26\NN\116687|,|and|headache (l_conj) headache_29\NN\5829480|
2224762
C027260_D009369 NONE 4'-0-tetrahydropyranyladriamycin_10\NNP\0|pirarubicin (r_dobj) bolus_9\NN\13899404|4'-0-tetrahydropyranyladriamycin (r_appos) phase_1\NN\15113229|a|study|bolus|) (r_nsubjpass) done_15\VBN\0|phase|was|in|. (l_prep) in_16\IN\13603305|patients (l_pobj) patients_18\NNS\9898892|55|in (l_prep) in_19\IN\13603305|status (l_pobj) status_22\NN\24720|good|performance|with (l_prep) with_23\IN\0|tumors (l_pobj) tumors_25\NNS\14234074|refractory
C027260_D009369 NONE pirarubicin_12\NNP\0|( (r_appos) 4'-0-tetrahydropyranyladriamycin_10\NNP\0|pirarubicin (r_dobj) bolus_9\NN\13899404|4'-0-tetrahydropyranyladriamycin (r_appos) phase_1\NN\15113229|a|study|bolus|) (r_nsubjpass) done_15\VBN\0|phase|was|in|. (l_prep) in_16\IN\13603305|patients (l_pobj) patients_18\NNS\9898892|55|in (l_prep) in_19\IN\13603305|status (l_pobj) status_22\NN\24720|good|performance|with (l_prep) with_23\IN\0|tumors (l_pobj) tumors_25\NNS\14234074|refractory
19299179
D015662_D002779 NONE trimoxazole_11\NN\0|- (r_amod) treatment_12\NN\654885|dose|trimoxazole|for|--|report (r_pobj) after_5\IN\0|treatment (r_prep) cholestasis_4\NN\14052403|severe|after|.
D015662_D011020 NONE trimoxazole_11\NN\0|- (r_amod) treatment_12\NN\654885|dose|trimoxazole|for|--|report (l_prep) for_13\IN\0|pneumonia (l_pobj) pneumonia_15\NN\14145095|pneumocystis|in
D015662_D011020 NONE trimoxazole_25\NN\0|- (r_punct) ._26\.\0|trimoxazole (r_punct) treated_18\VBN\2376958|pneumonia|is|generally|with|. (l_nsubjpass) pneumonia_1\NN\14145095|pneumocystis|(|pcp|)|,|infection|,
D015662_D011020 NONE trimoxazole_25\NN\0|- (r_punct) ._26\.\0|trimoxazole (r_punct) treated_18\VBN\2376958|pneumonia|is|generally|with|. (l_nsubjpass) pneumonia_1\NN\14145095|pneumocystis|(|pcp|)|,|infection|, (l_appos) pcp_3\NNP\10480253|
D015662_D011020 NONE trimoxazole_35\NN\0|- (r_amod) treatment_36\NN\654885|trimoxazole|for (l_prep) for_37\IN\0|pcp (l_pobj) pcp_38\NNP\10480253|
D015662_D015658 NONE trimoxazole_11\NN\0|- (r_amod) treatment_12\NN\654885|dose|trimoxazole|for|--|report (l_prep) for_13\IN\0|pneumonia (l_pobj) pneumonia_15\NN\14145095|pneumocystis|in (l_prep) in_16\IN\13603305|patients (l_pobj) patients_20\NNS\9898892|infected (l_amod) infected_19\VBN\2316868|hiv|-
D015662_D015658 NONE trimoxazole_25\NN\0|- (r_punct) ._26\.\0|trimoxazole (r_punct) treated_18\VBN\2376958|pneumonia|is|generally|with|. (l_nsubjpass) pneumonia_1\NN\14145095|pneumocystis|(|pcp|)|,|infection|, (l_appos) infection_9\NN\14052046|a|common|opportunistic|in (l_prep) in_10\IN\13603305|individuals (l_pobj) individuals_14\NNS\7347|infected (l_amod) infected_13\VBN\2316868|hiv|-
D015662_D015658 NONE trimoxazole_35\NN\0|- (r_amod) treatment_36\NN\654885|trimoxazole|for (r_dobj) report_3\VBP\6470073|here|,|we|cases|treatment|. (l_dobj) cases_5\NNS\7283608|two|of|and|in (l_prep) of_6\IN\0|patients (l_pobj) patients_12\NNS\9898892|immunocompromised|infected|developed (l_amod) infected_11\VBN\2316868|hiv|-
D015662_D009894 NONE trimoxazole_25\NN\0|- (r_punct) ._26\.\0|trimoxazole (r_punct) treated_18\VBN\2376958|pneumonia|is|generally|with|. (l_nsubjpass) pneumonia_1\NN\14145095|pneumocystis|(|pcp|)|,|infection|, (l_appos) infection_9\NN\14052046|a|common|opportunistic|in
D015662_D002780 CID trimoxazole_35\NN\0|- (r_amod) treatment_36\NN\654885|trimoxazole|for (r_dobj) report_3\VBP\6470073|here|,|we|cases|treatment|. (l_dobj) cases_5\NNS\7283608|two|of|and|in (l_prep) of_6\IN\0|patients (l_pobj) patients_12\NNS\9898892|immunocompromised|infected|developed (l_relcl) developed_14\VBD\1753788|who|cholestasis|, (l_dobj) cholestasis_17\NN\14052403|severe|intrahepatic
D015662_D008100 NONE trimoxazole_35\NN\0|- (r_amod) treatment_36\NN\654885|trimoxazole|for (r_dobj) report_3\VBP\6470073|here|,|we|cases|treatment|. (l_dobj) cases_5\NNS\7283608|two|of|and|in (l_conj) in_20\IN\13603305|lesions|, (l_pobj) lesions_23\NNS\14204950|one|patient|mimicking (l_acl) mimicking_24\VBG\1742886|formation (l_dobj) formation_27\NN\7938773|liver|abscess|on (l_compound) abscess_26\NN\14299637|
424937
D008750_D056486 CID methyldopa_6\NN\2721160| (r_pobj) by_5\IN\0|methyldopa (r_agent) induced_4\VBN\1627355|patterns|by|. (l_nsubj) patterns_0\NNS\5726345|of (l_prep) of_1\IN\0|injury (l_pobj) injury_3\NN\14052046|hepatic
D008750_D056486 CID methyldopa_22\NN\2721160| (r_npadvmod) induced_24\VBN\1627355|methyldopa|- (r_amod) hepatitis_25\NN\14127211|induced
D008750_D056486 CID methyldopa_14\NN\2721160|and|dysfunction (r_pobj) between_13\IN\0|methyldopa (r_prep) relationship_12\NN\31921|the|causal|between (r_nsubjpass) proved_19\VBN\2604760|in|in|,|relationship|was|with|. (l_prep) with_20\IN\0|recurrence (l_pobj) recurrence_22\NN\7342049|the|of|within|to (l_prep) of_23\IN\0|hepatitis (l_pobj) hepatitis_24\NN\14127211|
D008750_D008107 NONE methyldopa_7\NN\2721160| (r_pobj) to_6\IN\0|methyldopa (r_prep) related_5\VBN\628491|to (r_acl) disease_4\NN\14061805|liver|related
D008750_D008107 NONE methyldopa_14\NN\2721160|and|dysfunction (l_conj) dysfunction_17\NN\14204950|hepatic
D008750_D017093 NONE methyldopa_17\NN\2721160| (r_dobj) taking_16\VBG\37396|who|had|been|methyldopa|for (r_relcl) another_11\DT\0|,|taking|, (r_nsubj) showed_22\VBD\2137132|another|resolution|over (r_conj) presented_5\VBN\2137132|having|in|,|and|showed (l_prep) in_6\IN\13603305|failure (l_pobj) failure_8\NN\66216|hepatic
D008750_D017114 NONE methyldopa_22\NN\2721160| (r_npadvmod) induced_24\VBN\1627355|methyldopa|- (r_amod) hepatitis_25\NN\14127211|induced (r_pobj) of_21\IN\0|hepatitis (r_prep) episode_20\NN\7283608|a|prior|of (r_pobj) after_17\IN\0|episode (r_prep) recommenced_14\VBN\348746|when|drug|was|accidentally|year|after (r_advcl) developed_6\VBD\1753788|patient|hepatitis|recommenced|. (l_dobj) hepatitis_8\NN\14127211|fulminant
12041669
D000961_D000741 NONE globulin_1\NN\14736972|antithymocyte|in|. (l_prep) in_2\IN\13603305|treatment (l_pobj) treatment_4\NN\654885|the|of (l_prep) of_5\IN\0|anemia (l_pobj) anemia_12\NN\14189204|induced|aplastic
D000961_D000741 NONE globulin_5\NN\14736972| (r_compound) therapy_6\NN\657604|globulin (r_dobj) received_3\VBD\2210855|who|antithymocyte|therapy|for|due (l_prep) for_7\IN\0|anemia (l_pobj) anemia_9\NN\14189204|aplastic
D000961_D000741 NONE globulin_3\NN\14736972| (r_dobj) use_0\NN\407535|of|globulin (r_nsubj) be_5\VB\14625458|use|may|treatment|. (l_attr) treatment_8\NN\654885|the|optimal|of (l_prep) of_9\IN\0|anemia (l_pobj) anemia_16\NN\14189204|induced|aplastic
D010396_D000741 CID penicillamine_8\NN\3740161|d|- (r_npadvmod) induced_10\VBN\1627355|penicillamine|- (r_amod) anemia_12\NN\14189204|induced|aplastic
D010396_D000741 CID penicillamine_14\NN\3740161|d|- (r_compound) therapy_15\NN\657604|penicillamine (r_nsubjpass) described_17\VBN\1001294|patient|therapy|is|. (l_nsubjpass) patient_1\NN\9898892|a|received (l_relcl) received_3\VBD\2210855|who|antithymocyte|therapy|for|due (l_prep) for_7\IN\0|anemia (l_pobj) anemia_9\NN\14189204|aplastic
D010396_D000741 CID penicillamine_12\NN\3740161|d|- (r_npadvmod) induced_14\VBN\1627355|penicillamine|- (r_amod) anemia_16\NN\14189204|induced|aplastic
6133211
D012460_D015212 NONE sulphasalazine_15\NN\0|throughout (r_pobj) with_14\IN\0|sulphasalazine (r_prep) treatment_13\NN\654885|with (r_dobj) received_12\VBD\2210855|who|treatment (r_relcl) disease_10\NN\14061805|inflammatory|bowel|received
D012460_D000013 NONE sulphasalazine_15\NN\0|throughout (r_pobj) with_14\IN\0|sulphasalazine (r_prep) treatment_13\NN\654885|with (r_dobj) received_12\VBD\2210855|who|treatment (r_relcl) disease_10\NN\14061805|inflammatory|bowel|received (r_pobj) with_7\IN\0|disease (r_prep) mothers_6\NNS\10399491|two|with (r_pobj) of_4\IN\0|mothers (r_prep) born_3\VBN\0|of (r_acl) infants_1\NNS\9918248|three|,|born|, (r_nsubjpass) found_20\VBN\13279262|infants|were|have|. (l_xcomp) have_22\VB\7846|to|anomalies (l_dobj) anomalies_25\NNS\14501726|major|congenital
2802551
D012964_D007674 NONE sodium_0\NN\14625458| (r_compound) status_1\NN\24720|sodium (r_nsubj) influences_2\VBZ\5190804|status|nephrotoxicity|. (l_dobj) nephrotoxicity_6\NN\0|chronic|b|in
D000666_D007674 CID b_5\NN\1355326|amphotericin (r_compound) nephrotoxicity_6\NN\0|chronic|b|in
D000666_D007674 CID b_5\NNP\1355326|amphotericin|mg/kg (r_pobj) of_3\IN\0|b (r_prep) potential_2\NN\14481929|the|nephrotoxic|of (l_amod) nephrotoxic_1\JJ\0|
8073369
C007112_D001176 CID coniine_2\NN\0| (r_nsubj) failed_4\VBN\0|however|,|coniine|has|produce|and|is|. (l_xcomp) produce_6\VB\7555863|to|arthrogryposis (l_dobj) arthrogryposis_7\NN\0|in
C007112_D001176 CID coniine_15\RB\0| (r_npadvmod) induced_17\VBN\1627355|coniine|- (r_amod) arthrogryposis_18\NN\0|induced
C007112_D009140 NONE coniine_5\NN\0|both|and|sulfate (r_pobj) by_3\IN\0|coniine (r_agent) caused_2\VBN\1617192|by (r_acl) deformations_1\NNS\7420770|the|caused
C007112_D009140 NONE coniine_5\NN\0|both|and|sulfate (r_pobj) by_3\IN\0|coniine (r_agent) caused_2\VBN\1617192|by (r_acl) deformations_1\NNS\7420770|the|caused (r_nsubj) were_9\VBD\0|deformations|flexion|. (l_attr) flexion_11\NN\14034177|excessive|or|extension|of (l_prep) of_14\IN\0|toes (l_pobj) toes_18\NNS\5566097|one
D009538_D009140 NONE nicotine_7\NN\14712692| (r_compound) sulfate_8\NN\15010703|nicotine (r_conj) coniine_5\NN\0|both|and|sulfate (r_pobj) by_3\IN\0|coniine (r_agent) caused_2\VBN\1617192|by (r_acl) deformations_1\NNS\7420770|the|caused
D009538_D009140 NONE nicotine_7\NN\14712692| (r_compound) sulfate_8\NN\15010703|nicotine (r_conj) coniine_5\NN\0|both|and|sulfate (r_pobj) by_3\IN\0|coniine (r_agent) caused_2\VBN\1617192|by (r_acl) deformations_1\NNS\7420770|the|caused (r_nsubj) were_9\VBD\0|deformations|flexion|. (l_attr) flexion_11\NN\14034177|excessive|or|extension|of (l_prep) of_14\IN\0|toes (l_pobj) toes_18\NNS\5566097|one
D009538_D002543 CID nicotine_30\NN\14712692| (r_nmod) chicks_34\NNS\1791625|all|nicotine|treated (r_pobj) in_28\IN\13603305|chicks (r_prep) occurred_27\VBD\0|seen|;|however|,|hemorrhage|in|. (l_nsubj) hemorrhage_26\NN\14285662|extensive|cranial
15009014
D002211_D006940 CID capsaicin_0\NNS\15032661|mm (r_nsubj) applied_7\VBN\0|capsaicin|to|induced|. (l_conj) induced_13\VBN\1627355|increases|provoked (l_dobj) increases_14\NNS\13576355|in|and (l_prep) in_15\IN\13603305|flow (l_pobj) flow_20\NN\7311115|dural|blood
D001285_D006940 NONE atropine_16\NN\14712692|of|mm (r_pobj) by_10\IN\0|atropine (r_agent) abolished_9\VBN\0|increases|were|also|by|. (l_nsubjpass) increases_2\NNS\13576355|the|evoked|in (l_prep) in_3\IN\13603305|flow (l_pobj) flow_6\NN\7311115|dural|blood
15338796
D000420_D014202 CID salbutamol_4\NN\0| (r_pobj) of_3\IN\0|salbutamol (r_prep) effects_2\NNS\13245626|tremor|side|of|,|quantified|. (l_compound) tremor_0\NNP\345926|
D000420_D014202 CID salbutamol_6\NN\0| (r_pobj) of_5\IN\0|salbutamol (r_prep) effects_4\NNS\13245626|tremor|side|of (l_compound) tremor_2\JJ\345926|
D000420_D014202 CID salbutamol_19\NN\0| (r_pobj) of_18\IN\0|salbutamol (r_prep) doses_17\NNS\3740161|cumulative|of (r_pobj) of_15\IN\0|doses (r_prep) administration_14\NN\1133281|of (r_pobj) after_13\IN\0|administration (r_prep) disease_12\NN\14061805|obstructive|lung|after (r_pobj) with_9\IN\0|disease (r_prep) patients_8\NNS\9898892|44|with (r_pobj) in_6\IN\13603305|patients (r_prep) assessed_4\VBD\670261|determine|we|tremor|in|. (l_dobj) tremor_5\NN\345926|
D000420_D014202 CID salbutamol_0\NNP\0| (r_nsubj) increased_2\VBD\169651|salbutamol|significantly|severity|in|. (l_dobj) severity_4\NN\5036394|tremor (l_compound) tremor_3\NN\345926|
D000420_D008173 NONE salbutamol_19\NN\0| (r_pobj) of_18\IN\0|salbutamol (r_prep) doses_17\NNS\3740161|cumulative|of (r_pobj) of_15\IN\0|doses (r_prep) administration_14\NN\1133281|of (r_pobj) after_13\IN\0|administration (r_prep) disease_12\NN\14061805|obstructive|lung|after
11642480
D015283_D004409 CID citalopram_7\NN\0| (r_pobj) on_6\IN\0|citalopram (r_prep) adolescent_5\NN\9622049|a|depressed|on (r_pobj) in_2\IN\13603305|adolescent (r_prep) twitching_1\VBG\14360459|palpebral|in|.
D015283_D004409 CID citalopram_8\NN\0| (r_pobj) with_7\IN\0|citalopram (r_prep) treatment_6\NN\654885|with|by (l_prep) by_9\IN\0|boy (l_pobj) boy_14\NN\9624168|a|old|with (l_prep) with_15\IN\0|depression (l_pobj) depression_17\NN\14373582|major|exhibited (l_relcl) exhibited_19\VBD\2632167|who|twitching|during (l_dobj) twitching_21\NN\14360459|palpebral
D015283_D003866 NONE citalopram_7\NN\0| (r_pobj) on_6\IN\0|citalopram (r_prep) adolescent_5\NN\9622049|a|depressed|on (l_amod) depressed_4\JJ\1819147|
D015283_D003865 NONE citalopram_8\NN\0| (r_pobj) with_7\IN\0|citalopram (r_prep) treatment_6\NN\654885|with|by (l_prep) by_9\IN\0|boy (l_pobj) boy_14\NN\9624168|a|old|with (l_prep) with_15\IN\0|depression (l_pobj) depression_17\NN\14373582|major|exhibited
18261172
D020123_D011507 CID sirolimus_6\NN\0| (r_npadvmod) based_8\VBN\0|sirolimus|- (r_amod) immunosuppression_9\NN\13973990|based|in (r_pobj) to_5\IN\0|immunosuppression (r_prep) switch_4\NN\3096960|to (r_pobj) after_3\IN\0|switch (r_prep) development_0\NN\248977|of|after|. (l_prep) of_1\IN\0|proteinuria (l_pobj) proteinuria_2\NN\14299637|
D020123_D011507 CID sirolmus_7\NN\0|)|drug|(|srl|) (r_nsubj) lacks_11\VBZ\14449126|immunosuppressive|(|is|sirolmus|effects (r_ccomp) reported_23\VBN\831651|lacks|;|however|,|proteinuria|has|been|following|. (l_nsubjpass) proteinuria_17\NN\14299637|associated
D020123_D011507 CID srl_9\NNP\0| (r_appos) sirolmus_7\NN\0|)|drug|(|srl|) (r_nsubj) lacks_11\VBZ\14449126|immunosuppressive|(|is|sirolmus|effects (r_ccomp) reported_23\VBN\831651|lacks|;|however|,|proteinuria|has|been|following|. (l_nsubjpass) proteinuria_17\NN\14299637|associated
D020123_D011507 CID srl_20\NNP\0| (r_pobj) with_19\IN\0|srl (r_prep) associated_18\VBN\628491|with (r_acl) proteinuria_17\NN\14299637|associated
D020123_D011507 CID srl_10\NNP\0| (r_pobj) with_9\IN\0|srl (r_prep) associated_8\VBN\628491|with (r_acl) incidence_5\NN\13821570|the|of|associated (l_prep) of_6\IN\0|proteinuria (l_pobj) proteinuria_7\NN\14299637|
D020123_D011507 CID srl_12\NNP\0|,|have (r_pobj) to_11\IN\0|srl (r_prep) switch_10\NN\3096960|to (r_pobj) after_9\IN\0|switch (r_prep) develop_4\VB\1753788|thus|,|proteinuria|may|in|after|. (l_nsubj) proteinuria_2\NN\14299637|
D020123_D011507 CID srl_0\NNP\0| (r_nsubjpass) used_3\VBN\0|srl|should|be|with|and|increased|. (l_prep) with_4\IN\0|therapy (l_pobj) therapy_8\NN\657604|acei|/|arb|and|patients|monitored (l_acl) monitored_11\VBD\2169352|for (l_prep) for_12\IN\0|proteinuria (l_pobj) proteinuria_13\NN\14299637|
D020123_D007674 NONE sirolmus_7\NN\0|)|drug|(|srl|) (r_nsubj) lacks_11\VBZ\14449126|immunosuppressive|(|is|sirolmus|effects (l_dobj) effects_13\NNS\13245626|nephrotoxic (l_amod) nephrotoxic_12\JJ\0|
D020123_D007674 NONE srl_9\NNP\0| (r_appos) sirolmus_7\NN\0|)|drug|(|srl|) (r_nsubj) lacks_11\VBZ\14449126|immunosuppressive|(|is|sirolmus|effects (l_dobj) effects_13\NNS\13245626|nephrotoxic (l_amod) nephrotoxic_12\JJ\0|
D020123_D007674 NONE srl_20\NNP\0| (r_pobj) with_19\IN\0|srl (r_prep) associated_18\VBN\628491|with (r_acl) proteinuria_17\NN\14299637|associated (r_nsubjpass) reported_23\VBN\831651|lacks|;|however|,|proteinuria|has|been|following|. (l_ccomp) lacks_11\VBZ\14449126|immunosuppressive|(|is|sirolmus|effects (l_dobj) effects_13\NNS\13245626|nephrotoxic (l_amod) nephrotoxic_12\JJ\0|
D020123_D007674 NONE srl_0\NNP\0| (r_nsubjpass) used_3\VBN\0|srl|should|be|with|and|increased|. (l_conj) increased_15\VBD\169651|dysfunction (l_dobj) dysfunction_17\NN\14204950|renal
D000806_D011507 NONE inhibitor_1\NN\20090|ace|and|therapy (r_nsubj) reduced_11\VBN\441445|inhibitor|development|. (l_dobj) development_13\NN\248977|proteinuria (l_compound) proteinuria_12\NN\14299637|
D000806_D011507 NONE acei_5\NNP\0| (r_nmod) therapy_8\NN\657604|acei|/|arb|and|patients|monitored (l_acl) monitored_11\VBD\2169352|for (l_prep) for_12\IN\0|proteinuria (l_pobj) proteinuria_13\NN\14299637|
D057911_D011507 NONE blocker_6\NN\10101634|releasing (r_nmod) therapy_10\NN\657604|blocker|(|arb|) (r_conj) inhibitor_1\NN\20090|ace|and|therapy (r_nsubj) reduced_11\VBN\441445|inhibitor|development|. (l_dobj) development_13\NN\248977|proteinuria (l_compound) proteinuria_12\NN\14299637|
D057911_D011507 NONE arb_8\NNP\9882007| (r_nmod) therapy_10\NN\657604|blocker|(|arb|) (r_conj) inhibitor_1\NN\20090|ace|and|therapy (r_nsubj) reduced_11\VBN\441445|inhibitor|development|. (l_dobj) development_13\NN\248977|proteinuria (l_compound) proteinuria_12\NN\14299637|
D057911_D011507 NONE arb_7\NNP\9882007| (r_compound) therapy_8\NN\657604|acei|/|arb|and|patients|monitored (l_acl) monitored_11\VBD\2169352|for (l_prep) for_12\IN\0|proteinuria (l_pobj) proteinuria_13\NN\14299637|
D000806_D007674 NONE acei_5\NNP\0| (r_nmod) therapy_8\NN\657604|acei|/|arb|and|patients|monitored (r_pobj) with_4\IN\0|therapy (r_prep) used_3\VBN\0|srl|should|be|with|and|increased|. (l_conj) increased_15\VBD\169651|dysfunction (l_dobj) dysfunction_17\NN\14204950|renal
D057911_D007674 NONE arb_7\NNP\9882007| (r_compound) therapy_8\NN\657604|acei|/|arb|and|patients|monitored (r_pobj) with_4\IN\0|therapy (r_prep) used_3\VBN\0|srl|should|be|with|and|increased|. (l_conj) increased_15\VBD\169651|dysfunction (l_dobj) dysfunction_17\NN\14204950|renal
7628595
D014805_D064420 NONE b12_6\NN\0|vitamin|and|supplementation (l_conj) supplementation_10\NN\5108947|folinic|acid|in (l_prep) in_11\IN\13603305|preventing (l_pcomp) preventing_12\VBG\0|toxicity (l_dobj) toxicity_14\NN\13576101|hematologic|of
D002955_D064420 NONE acid_9\NN\14818238| (r_compound) supplementation_10\NN\5108947|folinic|acid|in (l_prep) in_11\IN\13603305|preventing (l_pcomp) preventing_12\VBG\0|toxicity (l_dobj) toxicity_14\NN\13576101|hematologic|of
D015215_D064420 NONE zidovudine_16\NN\3834836| (r_pobj) of_15\IN\0|zidovudine (r_prep) toxicity_14\NN\13576101|hematologic|of
D014805_D001855 NONE b12_13\NN\0|vitamin|and|supplementation (l_conj) supplementation_17\NN\5108947|folinic|acid|in (l_prep) in_18\IN\13603305|preventing (l_pcomp) preventing_19\VBG\0|suppression (l_dobj) suppression_25\NN\13489037|zidovudine|(|zdv)-induced|marrow
D014805_D001855 NONE b12_6\NN\0|vitamin|or|levels (l_conj) levels_9\NNS\4916342|folate|and|development (l_conj) development_11\NN\248977|of (l_prep) of_12\IN\0|myelosuppression (l_pobj) myelosuppression_13\NN\0|
D014805_D001855 NONE b12_1\NN\0|vitamin|and|supplementation (r_nsubj) seem_11\VB\2604760|b12|does|not|useful|,|excluded|. (l_oprd) useful_12\JJ\0|in (l_prep) in_13\IN\13603305|preventing (l_pcomp) preventing_14\VBG\0|or|reducing (l_conj) reducing_16\VBG\13447361|myelotoxicity|in (l_dobj) myelotoxicity_20\NN\0|induced
D002955_D001855 NONE acid_16\NN\14818238| (r_compound) supplementation_17\NN\5108947|folinic|acid|in (l_prep) in_18\IN\13603305|preventing (l_pcomp) preventing_19\VBG\0|suppression (l_dobj) suppression_25\NN\13489037|zidovudine|(|zdv)-induced|marrow
D002955_D001855 NONE acid_4\NN\14818238| (r_compound) supplementation_5\NN\5108947|folinic|acid|of (r_conj) b12_1\NN\0|vitamin|and|supplementation (r_nsubj) seem_11\VB\2604760|b12|does|not|useful|,|excluded|. (l_oprd) useful_12\JJ\0|in (l_prep) in_13\IN\13603305|preventing (l_pcomp) preventing_14\VBG\0|or|reducing (l_conj) reducing_16\VBG\13447361|myelotoxicity|in (l_dobj) myelotoxicity_20\NN\0|induced
D015215_D001855 CID zidovudine_20\NNP\3834836| (r_nmod) suppression_25\NN\13489037|zidovudine|(|zdv)-induced|marrow
D015215_D001855 CID zdv)-induced_22\VBN\0| (r_amod) suppression_25\NN\13489037|zidovudine|(|zdv)-induced|marrow
D015215_D001855 CID zdv_7\NNP\3834836| (r_compound) therapy_8\NN\657604|zdv (r_pobj) of_6\IN\0|therapy (r_prep) supplementation_5\NN\5108947|folinic|acid|of (r_conj) b12_1\NN\0|vitamin|and|supplementation (r_nsubj) seem_11\VB\2604760|b12|does|not|useful|,|excluded|. (l_oprd) useful_12\JJ\0|in (l_prep) in_13\IN\13603305|preventing (l_pcomp) preventing_14\VBG\0|or|reducing (l_conj) reducing_16\VBG\13447361|myelotoxicity|in (l_dobj) myelotoxicity_20\NN\0|induced
D015215_D001855 CID zdv_17\NNP\3834836| (r_npadvmod) induced_19\VBN\1627355|zdv|- (r_amod) myelotoxicity_20\NN\0|induced
D015215_D015658 NONE zdv_21\NNP\3834836|either|(|daily|) (r_dobj) receive_19\VB\2210855|to|zdv|alone (r_xcomp) randomized_17\VBN\278117|virus|were|receive (l_nsubjpass) virus_5\NN\9312843|five|human|immunodeficiency|patients (l_appos) patients_8\NNS\9898892|(|hiv)-infected|with (l_amod) hiv)-infected_7\VBN\0|
D005492_D001855 NONE folate_8\JJ\15090742| (r_compound) levels_9\NNS\4916342|folate|and|development (l_conj) development_11\NN\248977|of (l_prep) of_12\IN\0|myelosuppression (l_pobj) myelosuppression_13\NN\0|
20882060
D009496_D002375 NONE neurotensin_3\NN\0|pallidal|on (l_prep) on_4\IN\0|catalepsy (l_pobj) catalepsy_9\NN\14023236|induced|parkinsonian|:|studies
D009496_D002375 NONE neurotensin_3\NN\0|into (r_pobj) of_2\IN\0|neurotensin (r_prep) infusions_1\NNS\14589223|bilateral|of (r_nsubj) reversed_8\VBD\109660|infusions|catalepsy|in|. (l_dobj) catalepsy_13\NN\14023236|induced|parkinsonian
D006220_D002375 CID haloperidol_5\NN\3713736| (r_npadvmod) induced_7\VBN\1627355|haloperidol|- (r_amod) catalepsy_9\NN\14023236|induced|parkinsonian|:|studies
D006220_D002375 CID haloperidol_9\NN\3713736| (r_npadvmod) induced_11\VBN\1627355|haloperidol|- (r_amod) catalepsy_13\NN\14023236|induced|parkinsonian
D009496_D010302 NONE neurotensin_10\NN\0|pallidal|on (l_prep) on_11\IN\0|symptoms (l_pobj) symptoms_16\NNS\5823932|induced|parkinsonian
D006220_D010302 NONE haloperidol_12\NN\3713736| (r_npadvmod) induced_14\VBN\1627355|haloperidol|- (r_amod) symptoms_16\NNS\5823932|induced|parkinsonian
16755009
D003975_D000647 CID diazepam-_0\NN\0|,|amnesia|. (l_appos) amnesia_7\NN\5669934|scopolamine-|served
D003975_D000647 CID diazepam_16\NN\2830852|mg/kg (r_conj) scopolamine_8\NN\14712692|(|mg/kg|)|and|diazepam (r_pobj) by_7\IN\0|scopolamine (r_agent) induced_6\VBN\1627355|by (r_acl) amnesia_5\NN\5669934|the|induced
D012601_D000647 CID scopolamine-_2\NN\0|and|induced (r_nmod) amnesia_7\NN\5669934|scopolamine-|served
D012601_D000647 CID scopolamine_8\NN\14712692|(|mg/kg|)|and|diazepam (r_pobj) by_7\IN\0|scopolamine (r_agent) induced_6\VBN\1627355|by (r_acl) amnesia_5\NN\5669934|the|induced
D010936_D000647 NONE dce_2\NNP\0| (r_nsubj) reversed_3\VBD\109660|furthermore|,|dce|amnesia|. (l_dobj) amnesia_5\NN\5669934|the|induced
D010936_D003072 NONE dce_2\NNP\0| (r_nsubj) prove_4\VB\2604760|therefore|,|dce|may|be|. (l_xcomp) be_6\VB\14625458|to|remedy (l_attr) remedy_9\NN\258854|a|useful|for|improving (l_prep) for_10\IN\0|management (l_pobj) management_12\NN\1123598|the|of (l_prep) of_13\IN\0|dysfunctions (l_pobj) dysfunctions_15\NNS\14204950|cognitive|on
D002784_D003072 NONE cholesterol_30\NN\15058310| (r_nsubj) lowering_31\VBG\351638|cholesterol|activity (r_conj) property_28\NN\32613|,|lowering (r_dobj) improving_27\VBG\126264|memory|property (r_acl) remedy_9\NN\258854|a|useful|for|improving (l_prep) for_10\IN\0|management (l_pobj) management_12\NN\1123598|the|of (l_prep) of_13\IN\0|dysfunctions (l_pobj) dysfunctions_15\NNS\14204950|cognitive|on
6773726
D005996_D007022 CID nitroglycerin_5\NN\15015501|in (r_pobj) by_4\IN\0|nitroglycerin (r_prep) hypotension_3\NN\14057371|postural|by
D005996_D003929 NONE nitroglycerin_5\NN\15015501|in (l_prep) in_6\IN\13603305|neuropathy (l_pobj) neuropathy_9\NN\14204950|diabetic|autonomic
D005996_D003920 NONE nitroglycerin_3\NN\15015501|on (r_pobj) of_2\IN\0|nitroglycerin (r_prep) effect_1\NN\34213|the|of (r_nsubjpass) compared_12\VBN\644583|effect|was|in|. (l_prep) in_13\IN\13603305|subjects (l_pobj) subjects_16\NNS\6598915|5|normal|,|subjects (l_appos) subjects_20\NNS\6598915|12|diabetic|without|,|and|subjects (l_amod) diabetic_19\JJ\10595647|
D005996_D003920 NONE nitroglycerin_3\NN\15015501|on (r_pobj) of_2\IN\0|nitroglycerin (r_prep) effect_1\NN\34213|the|of (r_nsubjpass) compared_12\VBN\644583|effect|was|in|. (l_prep) in_13\IN\13603305|subjects (l_pobj) subjects_16\NNS\6598915|5|normal|,|subjects (l_appos) subjects_20\NNS\6598915|12|diabetic|without|,|and|subjects (l_conj) subjects_28\NNS\6598915|5|diabetic|with (l_amod) diabetic_27\JJ\10595647|
D005996_D003920 NONE nitroglycerin_19\NN\15015501| (r_pobj) after_18\IN\0|nitroglycerin (r_prep) decrease_13\NN\7296428|the|in|after (r_conj) increase_7\NN\13576355|the|in|and|decrease (r_pobj) of_5\IN\0|increase (r_prep) course_4\NN\883297|magnitude|of (r_nsubj) were_20\VBD\0|course|similar|,|occurred|. (l_acomp) similar_21\JJ\0|in (l_prep) in_22\IN\13603305|subjects (l_pobj) subjects_27\NNS\6598915|the|normal|without (l_amod) normal_24\JJ\5667196|and|diabetic (l_conj) diabetic_26\JJ\10595647|
D005996_D003920 NONE nitroglycerin_19\NN\15015501| (r_pobj) after_18\IN\0|nitroglycerin (r_prep) decrease_13\NN\7296428|the|in|after (r_conj) increase_7\NN\13576355|the|in|and|decrease (r_pobj) of_5\IN\0|increase (r_prep) course_4\NN\883297|magnitude|of (r_nsubj) were_20\VBD\0|course|similar|,|occurred|. (l_advcl) occurred_47\VBD\0|whereas|increase|in (l_prep) in_48\IN\13603305|subjects (l_pobj) subjects_51\NNS\6598915|the|diabetic|with (l_amod) diabetic_50\JJ\10595647|
D005996_D009422 NONE nitroglycerin_3\NN\15015501|on (r_pobj) of_2\IN\0|nitroglycerin (r_prep) effect_1\NN\34213|the|of (r_nsubjpass) compared_12\VBN\644583|effect|was|in|. (l_prep) in_13\IN\13603305|subjects (l_pobj) subjects_16\NNS\6598915|5|normal|,|subjects (l_appos) subjects_20\NNS\6598915|12|diabetic|without|,|and|subjects (l_prep) without_21\IN\0|neuropathy (l_pobj) neuropathy_23\NN\14204950|autonomic
D005996_D009422 NONE nitroglycerin_3\NN\15015501|on (r_pobj) of_2\IN\0|nitroglycerin (r_prep) effect_1\NN\34213|the|of (r_nsubjpass) compared_12\VBN\644583|effect|was|in|. (l_prep) in_13\IN\13603305|subjects (l_pobj) subjects_16\NNS\6598915|5|normal|,|subjects (l_appos) subjects_20\NNS\6598915|12|diabetic|without|,|and|subjects (l_conj) subjects_28\NNS\6598915|5|diabetic|with (l_prep) with_29\IN\0|neuropathy (l_pobj) neuropathy_31\NN\14204950|autonomic
D005996_D009422 NONE nitroglycerin_19\NN\15015501| (r_pobj) after_18\IN\0|nitroglycerin (r_prep) decrease_13\NN\7296428|the|in|after (r_conj) increase_7\NN\13576355|the|in|and|decrease (r_pobj) of_5\IN\0|increase (r_prep) course_4\NN\883297|magnitude|of (r_nsubj) were_20\VBD\0|course|similar|,|occurred|. (l_acomp) similar_21\JJ\0|in (l_prep) in_22\IN\13603305|subjects (l_pobj) subjects_27\NNS\6598915|the|normal|without (l_prep) without_28\IN\0|neuropathy (l_pobj) neuropathy_30\NN\14204950|autonomic
D005996_D009422 NONE nitroglycerin_19\NN\15015501| (r_pobj) after_18\IN\0|nitroglycerin (r_prep) decrease_13\NN\7296428|the|in|after (r_conj) increase_7\NN\13576355|the|in|and|decrease (r_pobj) of_5\IN\0|increase (r_prep) course_4\NN\883297|magnitude|of (r_nsubj) were_20\VBD\0|course|similar|,|occurred|. (l_advcl) occurred_47\VBD\0|whereas|increase|in (l_prep) in_48\IN\13603305|subjects (l_pobj) subjects_51\NNS\6598915|the|diabetic|with (l_prep) with_52\IN\0|neuropathy (l_pobj) neuropathy_54\NN\14204950|autonomic
12574103
D003907_D006973 CID dexamethasone_1\NN\2721538| (r_compound) programs_2\NNS\5833840|prenatal|dexamethasone (r_compound) hypertension_3\NN\14057371|programs|and|injury|in|.
D003907_D006973 CID dexamethasone_11\NN\2721538|prenatal (r_nsubj) programmed_12\VBD\794981|if|dexamethasone|increase (l_dobj) increase_15\NN\13576355|a|progressive|in (l_prep) in_16\IN\13603305|pressure (l_pobj) pressure_18\NN\11419404|blood|and|injury
D003907_D006973 CID dexamethasone_5\NN\2721538|prenatal (r_dobj) received_3\VBD\2210855|that|dexamethasone|on (r_relcl) rats_1\NNS\2329401|male|received (r_nsubj) elevated_23\VBN\4048568|rats|had|pressures|at (l_dobj) pressures_25\NNS\11419404|blood
D003907_D006973 CID dexamethasone_5\NN\2721538|prenatal|in (r_nsubj) results_8\VBZ\34213|that|dexamethasone|in (l_prep) in_9\IN\13603305|reduction (l_pobj) reduction_11\NN\351485|a|in (l_prep) in_12\IN\13603305|number (l_pobj) number_14\NN\5107765|glomerular|,|glomerulosclerosis|administered (l_conj) glomerulosclerosis_16\NN\0|,|and|hypertension (l_conj) hypertension_19\NN\14057371|
D003907_D007674 CID dexamethasone_1\NN\2721538| (r_compound) programs_2\NNS\5833840|prenatal|dexamethasone (r_compound) hypertension_3\NN\14057371|programs|and|injury|in|. (l_conj) injury_6\NN\14052046|renal
D003907_D007674 CID dexamethasone_11\NN\2721538|prenatal (r_nsubj) programmed_12\VBD\794981|if|dexamethasone|increase (l_dobj) increase_15\NN\13576355|a|progressive|in (l_prep) in_16\IN\13603305|pressure (l_pobj) pressure_18\NN\11419404|blood|and|injury (l_conj) injury_21\NN\14052046|renal|in
D003907_D007674 CID dexamethasone_4\NN\2721538| (r_dobj) administered_3\VBN\2436349|offspring|dexamethasone|on (r_csubj) had_11\VBD\0|administered|reduction|compared|. (l_dobj) reduction_15\NN\351485|a|%|in (l_prep) in_16\IN\13603305|number (l_pobj) number_18\NN\5107765|glomerular
D003907_D007674 CID dexamethasone_5\NN\2721538|prenatal (r_dobj) received_3\VBD\2210855|that|dexamethasone|on (r_relcl) rats_1\NNS\2329401|male|received (r_nsubj) elevated_23\VBN\4048568|rats|had|pressures|at (r_ccomp) have_37\VB\7846|elevated|;|group|did|not|reduction|. (l_dobj) reduction_39\NN\351485|a|in (l_prep) in_40\IN\13603305|number (l_pobj) number_42\NN\5107765|glomerular
D003907_D007674 CID dexamethasone_5\NN\2721538|prenatal|in (r_nsubj) results_8\VBZ\34213|that|dexamethasone|in (l_prep) in_9\IN\13603305|reduction (l_pobj) reduction_11\NN\351485|a|in (l_prep) in_12\IN\13603305|number (l_pobj) number_14\NN\5107765|glomerular|,|glomerulosclerosis|administered
D003907_D005921 NONE dexamethasone_3\NN\2721538| (r_dobj) given_2\VBN\5892096|rats|dexamethasone|on|had|. (l_advcl) had_11\VBD\0|glomeruli (l_dobj) glomeruli_13\NNS\5425910|more|with|than (l_prep) with_14\IN\0|glomerulosclerosis (l_pobj) glomerulosclerosis_15\NN\0|
D003907_D005921 NONE dexamethasone_5\NN\2721538|prenatal|in (r_nsubj) results_8\VBZ\34213|that|dexamethasone|in (l_prep) in_9\IN\13603305|reduction (l_pobj) reduction_11\NN\351485|a|in (l_prep) in_12\IN\13603305|number (l_pobj) number_14\NN\5107765|glomerular|,|glomerulosclerosis|administered (l_conj) glomerulosclerosis_16\NN\0|,|and|hypertension
17639754
D014859_D006470 CID warfarin_18\NN\2718259|and|levofloxacin (r_pobj) between_17\IN\0|warfarin (r_prep) interaction_16\NN\37396|the|between (r_pobj) of_14\IN\0|interaction (r_prep) result_13\NN\34213|the|of (r_attr) be_11\VB\14625458|to|result (r_xcomp) appear_9\VBP\2604760|that|be (r_relcl) complications_7\NNS\1073995|serious|bleeding|appear (l_compound) bleeding_6\NN\14285662|
D064704_D006470 CID levofloxacin_20\JJ\0| (r_conj) warfarin_18\NN\2718259|and|levofloxacin (r_pobj) between_17\IN\0|warfarin (r_prep) interaction_16\NN\37396|the|between (r_pobj) of_14\IN\0|interaction (r_prep) result_13\NN\34213|the|of (r_attr) be_11\VB\14625458|to|result (r_xcomp) appear_9\VBP\2604760|that|be (r_relcl) complications_7\NNS\1073995|serious|bleeding|appear (l_compound) bleeding_6\NN\14285662|
2549018
D005473_D017109 CID fluoxetine_0\NNP\4169152| (r_npadvmod) induced_2\VBN\1627355|fluoxetine|- (r_amod) akathisia_3\NN\0|induced|:|implications|.
D005473_D017109 CID fluoxetine_3\NN\4169152| (r_dobj) receiving_2\VBG\2210855|fluoxetine|for (r_acl) patients_1\NNS\9898892|five|receiving (r_nsubj) developed_14\VBD\1753788|patients|akathisia|. (l_dobj) akathisia_15\NN\0|
D005473_D017109 CID fluoxetine_2\NN\4169152| (r_npadvmod) induced_4\VBN\1627355|fluoxetine|- (r_amod) symptoms_5\NNS\5823932|the|typical|induced|of (r_nsubj) were_23\VBD\0|symptoms|indistinguishable|. (l_acomp) indistinguishable_24\JJ\0|from (l_prep) from_25\IN\0|those (l_pobj) those_26\DT\0|of (l_prep) of_27\IN\0|akathisia (l_pobj) akathisia_31\NN\0|induced
D005473_D017109 CID fluoxetine_17\NN\4169152| (r_advmod) induced_19\VBN\1627355|fluoxetine|- (r_amod) akathisia_20\NN\0|induced (r_pobj) of_16\IN\0|akathisia (r_prep) symptoms_15\NNS\5823932|the|of (r_nsubj) were_21\VBD\0|that|symptoms|identical|,|milder (r_ccomp) reported_12\VBD\831651|patients|were|. (l_nsubj) patients_1\NNS\9898892|three|experienced (l_relcl) experienced_4\VBN\2108377|who|had|akathisia (l_dobj) akathisia_8\NN\0|induced|in
D005473_D017109 CID fluoxetine_17\NN\4169152| (r_advmod) induced_19\VBN\1627355|fluoxetine|- (r_amod) akathisia_20\NN\0|induced
D005473_D017109 CID fluoxetine_9\NN\4169152| (r_pobj) of_8\IN\0|fluoxetine (r_prep) effect_7\NN\34213|a|common|side|of (r_attr) be_3\VB\14625458|to|effect (r_xcomp) appeared_1\VBD\2604760|akathisia|be|and|responded|. (l_nsubj) akathisia_0\NNP\0|
D005473_D017109 CID fluoxetine_4\NN\4169152| (r_advmod) induced_6\VBN\1627355|fluoxetine|- (r_amod) akathisia_7\NN\0|induced
D005473_D017109 CID fluoxetine_4\NN\4169152| (r_advmod) induced_6\VBN\1627355|fluoxetine|- (r_amod) akathisia_7\NN\0|induced (r_nsubjpass) caused_10\VBN\1617192|that|akathisia|may|be|by|be (l_conj) be_36\VB\14625458|that|pathophysiology|"|may|identical (l_nsubj) pathophysiology_21\NN\0|the|of (l_prep) of_22\IN\0|akathisia (l_pobj) akathisia_26\NN\0|induced|and|jitteriness
D005473_D017109 CID fluoxetine_23\NN\4169152| (r_advmod) induced_25\VBN\1627355|fluoxetine|- (r_amod) akathisia_26\NN\0|induced|and|jitteriness (r_pobj) of_22\IN\0|akathisia (r_prep) pathophysiology_21\NN\0|the|of (r_nsubj) be_36\VB\14625458|that|pathophysiology|"|may|identical (r_conj) caused_10\VBN\1617192|that|akathisia|may|be|by|be (l_nsubjpass) akathisia_7\NN\0|induced
D005473_D017109 CID fluoxetine_23\NN\4169152| (r_advmod) induced_25\VBN\1627355|fluoxetine|- (r_amod) akathisia_26\NN\0|induced|and|jitteriness
D005473_D009771 NONE fluoxetine_3\NN\4169152| (r_dobj) receiving_2\VBG\2210855|fluoxetine|for (l_prep) for_4\IN\0|treatment (l_pobj) treatment_6\NN\654885|the|of (l_prep) of_7\IN\0|disorder (l_pobj) disorder_10\NN\14034177|obsessive|compulsive|or|depression
D005473_D003865 NONE fluoxetine_3\NN\4169152| (r_dobj) receiving_2\VBG\2210855|fluoxetine|for (l_prep) for_4\IN\0|treatment (l_pobj) treatment_6\NN\654885|the|of (l_prep) of_7\IN\0|disorder (l_pobj) disorder_10\NN\14034177|obsessive|compulsive|or|depression (l_conj) depression_13\NN\14373582|major
D005473_D001008 NONE fluoxetine_2\NN\4169152| (r_npadvmod) induced_4\VBN\1627355|fluoxetine|- (r_amod) symptoms_5\NNS\5823932|the|typical|induced|of (l_prep) of_6\IN\0|restlessness (l_pobj) restlessness_7\NN\4773351|,|pacing (l_conj) pacing_10\NN\15122011|constant|,|movements (l_conj) movements_13\NNS\191142|purposeless|of|,|and|anxiety (l_conj) anxiety_22\NN\14373582|marked
D011433_D017109 NONE propranolol_22\NN\0| (r_acl) antagonist_21\NN\7846|the|adrenergic|propranolol|,|reduction (r_pobj) with_16\IN\0|antagonist (r_prep) treatment_15\NN\654885|with (r_pobj) to_14\IN\0|treatment (r_prep) responded_12\VBD\2367363|generally|well|to (r_conj) appeared_1\VBD\2604760|akathisia|be|and|responded|. (l_nsubj) akathisia_0\NNP\0|
D000928_D017109 NONE antidepressant_29\NN\3740161| (r_npadvmod) induced_31\VBN\1627355|antidepressant|- (r_amod) jitteriness_33\NN\7523905|tricyclic|induced|" (r_conj) akathisia_26\NN\0|induced|and|jitteriness (r_pobj) of_22\IN\0|akathisia (r_prep) pathophysiology_21\NN\0|the|of (r_nsubj) be_36\VB\14625458|that|pathophysiology|"|may|identical (r_conj) caused_10\VBN\1617192|that|akathisia|may|be|by|be (l_nsubjpass) akathisia_7\NN\0|induced
D000928_D017109 NONE antidepressant_29\NN\3740161| (r_npadvmod) induced_31\VBN\1627355|antidepressant|- (r_amod) jitteriness_33\NN\7523905|tricyclic|induced|" (r_conj) akathisia_26\NN\0|induced|and|jitteriness
6692345
D001241_D001749 NONE aspirin_5\NN\2707683|with (r_pobj) of_4\IN\0|aspirin (r_prep) administration_3\NN\1133281|the|-|of|to (r_nsubj) resulted_13\VBD\2633881|administration|in|. (l_prep) in_14\IN\13603305|incidence (l_pobj) incidence_17\NN\13821570|a|reduced|of|but|induction (l_prep) of_18\IN\0|carcinomas (l_pobj) carcinomas_23\NNS\14239918|induced|bladder
D001241_D013274 NONE aspirin_5\NN\2707683|with (r_pobj) of_4\IN\0|aspirin (r_prep) administration_3\NN\1133281|the|-|of|to (r_nsubj) resulted_13\VBD\2633881|administration|in|. (l_prep) in_14\IN\13603305|incidence (l_pobj) incidence_17\NN\13821570|a|reduced|of|but|induction (l_conj) induction_27\NN\7450842|a|concomitant|of (l_prep) of_28\IN\0|tumors (l_pobj) tumors_30\NNS\14234074|forestomach
D005200_D001749 CID n-[4-(5-nitro-2-furyl)-2-thiazolyl]-formamide_7\NNP\0|fanft (r_pobj) with_6\IN\0|n-[4-(5-nitro-2-furyl)-2-thiazolyl]-formamide (r_prep) aspirin_5\NN\2707683|with (r_pobj) of_4\IN\0|aspirin (r_prep) administration_3\NN\1133281|the|-|of|to (r_nsubj) resulted_13\VBD\2633881|administration|in|. (l_prep) in_14\IN\13603305|incidence (l_pobj) incidence_17\NN\13821570|a|reduced|of|but|induction (l_prep) of_18\IN\0|carcinomas (l_pobj) carcinomas_23\NNS\14239918|induced|bladder
D005200_D001749 CID fanft_9\NNP\0|(|) (r_appos) n-[4-(5-nitro-2-furyl)-2-thiazolyl]-formamide_7\NNP\0|fanft (r_pobj) with_6\IN\0|n-[4-(5-nitro-2-furyl)-2-thiazolyl]-formamide (r_prep) aspirin_5\NN\2707683|with (r_pobj) of_4\IN\0|aspirin (r_prep) administration_3\NN\1133281|the|-|of|to (r_nsubj) resulted_13\VBD\2633881|administration|in|. (l_prep) in_14\IN\13603305|incidence (l_pobj) incidence_17\NN\13821570|a|reduced|of|but|induction (l_prep) of_18\IN\0|carcinomas (l_pobj) carcinomas_23\NNS\14239918|induced|bladder
D005200_D001749 CID fanft_19\NNP\0| (r_npadvmod) induced_21\VBN\1627355|fanft|- (r_amod) carcinomas_23\NNS\14239918|induced|bladder
D005200_D013274 CID n-[4-(5-nitro-2-furyl)-2-thiazolyl]-formamide_7\NNP\0|fanft (r_pobj) with_6\IN\0|n-[4-(5-nitro-2-furyl)-2-thiazolyl]-formamide (r_prep) aspirin_5\NN\2707683|with (r_pobj) of_4\IN\0|aspirin (r_prep) administration_3\NN\1133281|the|-|of|to (r_nsubj) resulted_13\VBD\2633881|administration|in|. (l_prep) in_14\IN\13603305|incidence (l_pobj) incidence_17\NN\13821570|a|reduced|of|but|induction (l_conj) induction_27\NN\7450842|a|concomitant|of (l_prep) of_28\IN\0|tumors (l_pobj) tumors_30\NNS\14234074|forestomach
D005200_D013274 CID fanft_9\NNP\0|(|) (r_appos) n-[4-(5-nitro-2-furyl)-2-thiazolyl]-formamide_7\NNP\0|fanft (r_pobj) with_6\IN\0|n-[4-(5-nitro-2-furyl)-2-thiazolyl]-formamide (r_prep) aspirin_5\NN\2707683|with (r_pobj) of_4\IN\0|aspirin (r_prep) administration_3\NN\1133281|the|-|of|to (r_nsubj) resulted_13\VBD\2633881|administration|in|. (l_prep) in_14\IN\13603305|incidence (l_pobj) incidence_17\NN\13821570|a|reduced|of|but|induction (l_conj) induction_27\NN\7450842|a|concomitant|of (l_prep) of_28\IN\0|tumors (l_pobj) tumors_30\NNS\14234074|forestomach
D005200_D013274 CID fanft_19\NNP\0| (r_npadvmod) induced_21\VBN\1627355|fanft|- (r_amod) carcinomas_23\NNS\14239918|induced|bladder (r_pobj) of_18\IN\0|carcinomas (r_prep) incidence_17\NN\13821570|a|reduced|of|but|induction (l_conj) induction_27\NN\7450842|a|concomitant|of (l_prep) of_28\IN\0|tumors (l_pobj) tumors_30\NNS\14234074|forestomach
D005200_D063646 NONE fanft_16\NNP\0| (r_compound) carcinogenesis_17\NN\0|fanft|in
D005200_D063646 NONE fanft_30\NNP\0| (r_pobj) on_29\IN\0|fanft (r_prep) effect_28\NN\34213|aspirin|on|in (r_nsubj) is_34\VBZ\0|that|effect|not|due (r_conj) involved_14\VBN\2676054|that|mechanisms|are|in|,|and|is (l_prep) in_15\IN\13603305|carcinogenesis (l_pobj) carcinogenesis_17\NN\0|fanft|in
D001241_D063646 NONE aspirin_26\NN\2707683|'s (r_poss) effect_28\NN\34213|aspirin|on|in (r_nsubj) is_34\VBZ\0|that|effect|not|due (r_conj) involved_14\VBN\2676054|that|mechanisms|are|in|,|and|is (l_prep) in_15\IN\13603305|carcinogenesis (l_pobj) carcinogenesis_17\NN\0|fanft|in
11431197
D011899_D009395 CID ranitidine_0\NNP\14778019| (r_npadvmod) induced_2\VBN\1627355|ranitidine|- (r_amod) nephritis_5\NN\14113228|induced|acute|interstitial|in|.
D011899_D009395 CID ranitidine_5\NN\14778019| (r_npadvmod) induced_7\VBN\1627355|ranitidine|- (r_amod) nephritis_10\NN\14113228|induced|acute|interstitial
18410508
D008694_D020258 NONE methamphetamine_0\NN\2704153| (r_npadvmod) induced_2\VBN\1627355|methamphetamine|- (r_amod) activation_6\NN\13561719|induced|neurotoxicity (l_nmod) neurotoxicity_3\NN\0|and|microglial
D008694_D020258 NONE meth_6\NNP\2704153|and|mptp (r_pobj) by_5\IN\0|meth (r_agent) caused_4\VBN\1617192|by (r_acl) damage_3\NN\7296428|the|cns|caused (r_nsubj) is_9\VBZ\0|because|damage|selective|for (l_prep) for_12\IN\0|system (l_pobj) system_16\NN\3575240|the|da|neuronal|in (l_prep) in_17\IN\13603305|models (l_pobj) models_19\NNS\5888929|mouse|of (l_prep) of_20\IN\0|neurotoxicity (l_pobj) neurotoxicity_21\NN\0|
D008694_D020258 NONE meth_6\NNP\2704153|and|mptp (r_pobj) by_5\IN\0|meth (r_agent) caused_4\VBN\1617192|by (r_acl) damage_3\NN\7296428|the|cns|caused (r_nsubj) is_9\VBZ\0|because|damage|selective|for (r_advcl) hypothesized_24\VBD\719734|is|,|we|plays|. (l_ccomp) plays_28\VBZ\7007684|that|cx3cr1|role (l_dobj) role_30\NN\719494|a|in (l_prep) in_31\IN\13603305|neurotoxicity (l_pobj) neurotoxicity_35\NN\0|induced|and|activation
D008694_D020258 NONE meth_32\NNP\2704153| (r_npadvmod) induced_34\VBN\1627355|meth|- (r_amod) neurotoxicity_35\NN\0|induced|and|activation (r_pobj) in_31\IN\13603305|neurotoxicity (r_prep) role_30\NN\719494|a|in (r_dobj) plays_28\VBZ\7007684|that|cx3cr1|role (r_ccomp) hypothesized_24\VBD\719734|is|,|we|plays|. (l_advcl) is_9\VBZ\0|because|damage|selective|for (l_prep) for_12\IN\0|system (l_pobj) system_16\NN\3575240|the|da|neuronal|in (l_prep) in_17\IN\13603305|models (l_pobj) models_19\NNS\5888929|mouse|of (l_prep) of_20\IN\0|neurotoxicity (l_pobj) neurotoxicity_21\NN\0|
D008694_D020258 NONE meth_32\NNP\2704153| (r_npadvmod) induced_34\VBN\1627355|meth|- (r_amod) neurotoxicity_35\NN\0|induced|and|activation
D008694_D020258 NONE meth_25\NNP\2704153| (r_pobj) with_24\IN\0|meth (r_prep) treated_23\VBN\2376958|mice|were|with|and|examined|. (l_conj) examined_27\VBN\0|for (l_prep) for_28\IN\0|neurotoxicity (l_pobj) neurotoxicity_30\NN\0|striatal
D008694_D020258 NONE meth_11\NNP\2704153| (r_compound) neurotoxicity_12\NN\0|meth|or|activation
D015632_D009422 CID mptp_17\NNP\0| (r_npadvmod) induced_19\VBN\1627355|mptp|- (r_amod) neurodegeneration_20\NN\0|induced|of
D015632_D009422 CID mptp_8\NNP\0| (r_conj) meth_6\NNP\2704153|and|mptp (r_pobj) by_5\IN\0|meth (r_agent) caused_4\VBN\1617192|by (r_acl) damage_3\NN\7296428|the|cns|caused
D004298_D009422 NONE da_22\NNP\10484858| (r_compound) neurons_23\NNS\5430628|da (r_pobj) of_21\IN\0|neurons (r_prep) neurodegeneration_20\NN\0|induced|of
D004298_D009422 NONE da_14\NNP\10484858| (r_compound) system_16\NN\3575240|the|da|neuronal|in (r_pobj) for_12\IN\0|system (r_prep) is_9\VBZ\0|because|damage|selective|for (l_nsubj) damage_3\NN\7296428|the|cns|caused
D008694_D009422 CID meth_6\NNP\2704153|and|mptp (r_pobj) by_5\IN\0|meth (r_agent) caused_4\VBN\1617192|by (r_acl) damage_3\NN\7296428|the|cns|caused
D008694_D009422 CID meth_32\NNP\2704153| (r_npadvmod) induced_34\VBN\1627355|meth|- (r_amod) neurotoxicity_35\NN\0|induced|and|activation (r_pobj) in_31\IN\13603305|neurotoxicity (r_prep) role_30\NN\719494|a|in (r_dobj) plays_28\VBZ\7007684|that|cx3cr1|role (r_ccomp) hypothesized_24\VBD\719734|is|,|we|plays|. (l_advcl) is_9\VBZ\0|because|damage|selective|for (l_nsubj) damage_3\NN\7296428|the|cns|caused
D015632_D020258 NONE mptp_8\NNP\0| (r_conj) meth_6\NNP\2704153|and|mptp (r_pobj) by_5\IN\0|meth (r_agent) caused_4\VBN\1617192|by (r_acl) damage_3\NN\7296428|the|cns|caused (r_nsubj) is_9\VBZ\0|because|damage|selective|for (l_prep) for_12\IN\0|system (l_pobj) system_16\NN\3575240|the|da|neuronal|in (l_prep) in_17\IN\13603305|models (l_pobj) models_19\NNS\5888929|mouse|of (l_prep) of_20\IN\0|neurotoxicity (l_pobj) neurotoxicity_21\NN\0|
D015632_D020258 NONE mptp_8\NNP\0| (r_conj) meth_6\NNP\2704153|and|mptp (r_pobj) by_5\IN\0|meth (r_agent) caused_4\VBN\1617192|by (r_acl) damage_3\NN\7296428|the|cns|caused (r_nsubj) is_9\VBZ\0|because|damage|selective|for (r_advcl) hypothesized_24\VBD\719734|is|,|we|plays|. (l_ccomp) plays_28\VBZ\7007684|that|cx3cr1|role (l_dobj) role_30\NN\719494|a|in (l_prep) in_31\IN\13603305|neurotoxicity (l_pobj) neurotoxicity_35\NN\0|induced|and|activation
D004298_D020258 NONE da_14\NNP\10484858| (r_compound) system_16\NN\3575240|the|da|neuronal|in (l_prep) in_17\IN\13603305|models (l_pobj) models_19\NNS\5888929|mouse|of (l_prep) of_20\IN\0|neurotoxicity (l_pobj) neurotoxicity_21\NN\0|
D004298_D020258 NONE da_14\NNP\10484858| (r_compound) system_16\NN\3575240|the|da|neuronal|in (r_pobj) for_12\IN\0|system (r_prep) is_9\VBZ\0|because|damage|selective|for (r_advcl) hypothesized_24\VBD\719734|is|,|we|plays|. (l_ccomp) plays_28\VBZ\7007684|that|cx3cr1|role (l_dobj) role_30\NN\719494|a|in (l_prep) in_31\IN\13603305|neurotoxicity (l_pobj) neurotoxicity_35\NN\0|induced|and|activation
11379838
D000928_D001714 CID antidepressant_0\NNP\3740161| (r_npadvmod) induced_2\VBN\1627355|antidepressant|- (r_amod) mania_3\NN\9180259|induced|in|:|identification|.
D000928_D001714 CID antidepressant_0\NNP\3740161| (r_npadvmod) induced_2\VBN\1627355|antidepressant|- (r_amod) mania_3\NN\9180259|induced|in|:|identification|. (l_prep) in_4\IN\13603305|patients (l_pobj) patients_6\NNS\9898892|bipolar (l_amod) bipolar_5\JJ\0|
D000928_D001714 CID antidepressants_10\NNS\3740161| (r_pobj) with_9\IN\0|antidepressants (r_prep) associated_8\VBN\628491|with (r_acl) mania_7\NN\9180259|associated
D000928_D001714 CID antidepressants_10\NNS\3740161| (r_pobj) with_9\IN\0|antidepressants (r_prep) associated_8\VBN\628491|with (r_acl) mania_7\NN\9180259|associated (r_pobj) to_6\IN\0|mania (r_prep) switching_5\VBG\191142|to (r_pcomp) of_4\IN\0|switching (r_prep) risks_3\NNS\14541044|possible|of (r_pobj) about_1\IN\0|risks (r_prep) concerns_0\NNS\5682950|about (r_nsubj) continue_11\VBP\2367363|concerns|interfere|. (l_xcomp) interfere_13\VB\2451370|to|with (l_prep) with_14\IN\0|establishment (l_pobj) establishment_16\NN\235435|the|of (l_prep) of_17\IN\0|paradigm (l_pobj) paradigm_21\NN\13803782|an|optimal|treatment|for (l_prep) for_22\IN\0|depression (l_pobj) depression_24\NN\14373582|bipolar
D000928_D001714 CID antidepressant_43\NN\3740161| (r_amod) therapy_44\NN\657604|antidepressant (r_pobj) of_42\IN\0|therapy (r_prep) type_41\NN\5839024|of (r_appos) episodes_39\NNS\7283608|previous|manic|,|type|used|inhibitors|assessed (r_pobj) of_36\IN\0|episodes (r_prep) number_35\NN\5107765|of (r_appos) those_11\DT\0|did|,|number (r_pobj) with_10\IN\0|those (r_prep) compared_9\VBN\644583|patients|were|with|. (l_nsubjpass) patients_0\NNS\9898892|experienced (l_relcl) experienced_2\VBD\2108377|who|switch (l_dobj) switch_7\NN\3096960|a|manic (l_amod) manic_4\JJ\0|or|hypomanic
D000928_D001714 CID antidepressant_43\NN\3740161| (r_amod) therapy_44\NN\657604|antidepressant (r_pobj) of_42\IN\0|therapy (r_prep) type_41\NN\5839024|of (r_appos) episodes_39\NNS\7283608|previous|manic|,|type|used|inhibitors|assessed (r_pobj) of_36\IN\0|episodes (r_prep) number_35\NN\5107765|of (r_appos) those_11\DT\0|did|,|number (r_pobj) with_10\IN\0|those (r_prep) compared_9\VBN\644583|patients|were|with|. (l_nsubjpass) patients_0\NNS\9898892|experienced (l_relcl) experienced_2\VBD\2108377|who|switch (l_dobj) switch_7\NN\3096960|a|manic (l_amod) manic_4\JJ\0|or|hypomanic (l_conj) hypomanic_6\JJ\0|
D000928_D001714 CID antidepressant_43\NN\3740161| (r_amod) therapy_44\NN\657604|antidepressant (r_pobj) of_42\IN\0|therapy (r_prep) type_41\NN\5839024|of (r_appos) episodes_39\NNS\7283608|previous|manic|,|type|used|inhibitors|assessed (r_pobj) of_36\IN\0|episodes (r_prep) number_35\NN\5107765|of (r_appos) those_11\DT\0|did|,|number (l_relcl) did_13\VBD\0|who|not|on (l_prep) on_15\IN\0|variables (l_pobj) variables_17\NNS\2452|several|including (l_prep) including_18\VBG\0|age (l_pobj) age_19\NN\4916342|,|sex (l_conj) sex_21\NN\13440063|,|diagnosis (l_conj) diagnosis_23\NN\152018|iv (l_appos) iv_27\NNP\13741022|(|dsm|-|bipolar|i|) (l_appos) i_29\PRP\14622893|vs.
D000928_D001714 CID antidepressant_43\NN\3740161| (r_amod) therapy_44\NN\657604|antidepressant (r_pobj) of_42\IN\0|therapy (r_prep) type_41\NN\5839024|of (r_appos) episodes_39\NNS\7283608|previous|manic|,|type|used|inhibitors|assessed (r_pobj) of_36\IN\0|episodes (r_prep) number_35\NN\5107765|of (r_appos) those_11\DT\0|did|,|number (l_relcl) did_13\VBD\0|who|not|on (l_prep) on_15\IN\0|variables (l_pobj) variables_17\NNS\2452|several|including (l_prep) including_18\VBG\0|age (l_pobj) age_19\NN\4916342|,|sex (l_conj) sex_21\NN\13440063|,|diagnosis (l_conj) diagnosis_23\NN\152018|iv (l_appos) iv_27\NNP\13741022|(|dsm|-|bipolar|i|) (l_appos) i_29\PRP\14622893|vs. (l_prep) vs._30\IN\0|ii (l_pobj) ii_32\NNP\13741022|bipolar
D000928_D001714 CID antidepressant_43\NN\3740161| (r_amod) therapy_44\NN\657604|antidepressant (r_pobj) of_42\IN\0|therapy (r_prep) type_41\NN\5839024|of (r_appos) episodes_39\NNS\7283608|previous|manic|,|type|used|inhibitors|assessed (l_amod) manic_38\JJ\0|
D000928_D001714 CID antidepressant_50\NN\3740161| (r_amod) drugs_51\NNS\14778436|antidepressant (r_pobj) vs._49\IN\0|drugs (r_prep) therapy_48\NN\657604|electroconvulsive|vs.|and (r_dobj) used_45\VBN\0|therapy|, (r_acl) episodes_39\NNS\7283608|previous|manic|,|type|used|inhibitors|assessed (r_pobj) of_36\IN\0|episodes (r_prep) number_35\NN\5107765|of (r_appos) those_11\DT\0|did|,|number (r_pobj) with_10\IN\0|those (r_prep) compared_9\VBN\644583|patients|were|with|. (l_nsubjpass) patients_0\NNS\9898892|experienced (l_relcl) experienced_2\VBD\2108377|who|switch (l_dobj) switch_7\NN\3096960|a|manic (l_amod) manic_4\JJ\0|or|hypomanic
D000928_D001714 CID antidepressant_50\NN\3740161| (r_amod) drugs_51\NNS\14778436|antidepressant (r_pobj) vs._49\IN\0|drugs (r_prep) therapy_48\NN\657604|electroconvulsive|vs.|and (r_dobj) used_45\VBN\0|therapy|, (r_acl) episodes_39\NNS\7283608|previous|manic|,|type|used|inhibitors|assessed (r_pobj) of_36\IN\0|episodes (r_prep) number_35\NN\5107765|of (r_appos) those_11\DT\0|did|,|number (r_pobj) with_10\IN\0|those (r_prep) compared_9\VBN\644583|patients|were|with|. (l_nsubjpass) patients_0\NNS\9898892|experienced (l_relcl) experienced_2\VBD\2108377|who|switch (l_dobj) switch_7\NN\3096960|a|manic (l_amod) manic_4\JJ\0|or|hypomanic (l_conj) hypomanic_6\JJ\0|
D000928_D001714 CID antidepressant_50\NN\3740161| (r_amod) drugs_51\NNS\14778436|antidepressant (r_pobj) vs._49\IN\0|drugs (r_prep) therapy_48\NN\657604|electroconvulsive|vs.|and (r_dobj) used_45\VBN\0|therapy|, (r_acl) episodes_39\NNS\7283608|previous|manic|,|type|used|inhibitors|assessed (r_pobj) of_36\IN\0|episodes (r_prep) number_35\NN\5107765|of (r_appos) those_11\DT\0|did|,|number (l_relcl) did_13\VBD\0|who|not|on (l_prep) on_15\IN\0|variables (l_pobj) variables_17\NNS\2452|several|including (l_prep) including_18\VBG\0|age (l_pobj) age_19\NN\4916342|,|sex (l_conj) sex_21\NN\13440063|,|diagnosis (l_conj) diagnosis_23\NN\152018|iv (l_appos) iv_27\NNP\13741022|(|dsm|-|bipolar|i|) (l_appos) i_29\PRP\14622893|vs.
D000928_D001714 CID antidepressant_50\NN\3740161| (r_amod) drugs_51\NNS\14778436|antidepressant (r_pobj) vs._49\IN\0|drugs (r_prep) therapy_48\NN\657604|electroconvulsive|vs.|and (r_dobj) used_45\VBN\0|therapy|, (r_acl) episodes_39\NNS\7283608|previous|manic|,|type|used|inhibitors|assessed (r_pobj) of_36\IN\0|episodes (r_prep) number_35\NN\5107765|of (r_appos) those_11\DT\0|did|,|number (l_relcl) did_13\VBD\0|who|not|on (l_prep) on_15\IN\0|variables (l_pobj) variables_17\NNS\2452|several|including (l_prep) including_18\VBG\0|age (l_pobj) age_19\NN\4916342|,|sex (l_conj) sex_21\NN\13440063|,|diagnosis (l_conj) diagnosis_23\NN\152018|iv (l_appos) iv_27\NNP\13741022|(|dsm|-|bipolar|i|) (l_appos) i_29\PRP\14622893|vs. (l_prep) vs._30\IN\0|ii (l_pobj) ii_32\NNP\13741022|bipolar
D000928_D001714 CID antidepressant_50\NN\3740161| (r_amod) drugs_51\NNS\14778436|antidepressant (r_pobj) vs._49\IN\0|drugs (r_prep) therapy_48\NN\657604|electroconvulsive|vs.|and (r_dobj) used_45\VBN\0|therapy|, (r_acl) episodes_39\NNS\7283608|previous|manic|,|type|used|inhibitors|assessed (l_amod) manic_38\JJ\0|
D017367_D001714 CID inhibitors_60\NNS\20090|particularly|,|selective|serotonin|reuptake|ssris|,|use|, (r_appos) episodes_39\NNS\7283608|previous|manic|,|type|used|inhibitors|assessed (r_pobj) of_36\IN\0|episodes (r_prep) number_35\NN\5107765|of (r_appos) those_11\DT\0|did|,|number (r_pobj) with_10\IN\0|those (r_prep) compared_9\VBN\644583|patients|were|with|. (l_nsubjpass) patients_0\NNS\9898892|experienced (l_relcl) experienced_2\VBD\2108377|who|switch (l_dobj) switch_7\NN\3096960|a|manic (l_amod) manic_4\JJ\0|or|hypomanic
D017367_D001714 CID inhibitors_60\NNS\20090|particularly|,|selective|serotonin|reuptake|ssris|,|use|, (r_appos) episodes_39\NNS\7283608|previous|manic|,|type|used|inhibitors|assessed (r_pobj) of_36\IN\0|episodes (r_prep) number_35\NN\5107765|of (r_appos) those_11\DT\0|did|,|number (r_pobj) with_10\IN\0|those (r_prep) compared_9\VBN\644583|patients|were|with|. (l_nsubjpass) patients_0\NNS\9898892|experienced (l_relcl) experienced_2\VBD\2108377|who|switch (l_dobj) switch_7\NN\3096960|a|manic (l_amod) manic_4\JJ\0|or|hypomanic (l_conj) hypomanic_6\JJ\0|
D017367_D001714 CID inhibitors_60\NNS\20090|particularly|,|selective|serotonin|reuptake|ssris|,|use|, (r_appos) episodes_39\NNS\7283608|previous|manic|,|type|used|inhibitors|assessed (r_pobj) of_36\IN\0|episodes (r_prep) number_35\NN\5107765|of (r_appos) those_11\DT\0|did|,|number (l_relcl) did_13\VBD\0|who|not|on (l_prep) on_15\IN\0|variables (l_pobj) variables_17\NNS\2452|several|including (l_prep) including_18\VBG\0|age (l_pobj) age_19\NN\4916342|,|sex (l_conj) sex_21\NN\13440063|,|diagnosis (l_conj) diagnosis_23\NN\152018|iv (l_appos) iv_27\NNP\13741022|(|dsm|-|bipolar|i|) (l_appos) i_29\PRP\14622893|vs.
D017367_D001714 CID inhibitors_60\NNS\20090|particularly|,|selective|serotonin|reuptake|ssris|,|use|, (r_appos) episodes_39\NNS\7283608|previous|manic|,|type|used|inhibitors|assessed (r_pobj) of_36\IN\0|episodes (r_prep) number_35\NN\5107765|of (r_appos) those_11\DT\0|did|,|number (l_relcl) did_13\VBD\0|who|not|on (l_prep) on_15\IN\0|variables (l_pobj) variables_17\NNS\2452|several|including (l_prep) including_18\VBG\0|age (l_pobj) age_19\NN\4916342|,|sex (l_conj) sex_21\NN\13440063|,|diagnosis (l_conj) diagnosis_23\NN\152018|iv (l_appos) iv_27\NNP\13741022|(|dsm|-|bipolar|i|) (l_appos) i_29\PRP\14622893|vs. (l_prep) vs._30\IN\0|ii (l_pobj) ii_32\NNP\13741022|bipolar
D017367_D001714 CID inhibitors_60\NNS\20090|particularly|,|selective|serotonin|reuptake|ssris|,|use|, (r_appos) episodes_39\NNS\7283608|previous|manic|,|type|used|inhibitors|assessed (l_amod) manic_38\JJ\0|
D017367_D001714 CID ssris_62\NNPS\2718811|[|]|) (r_appos) inhibitors_60\NNS\20090|particularly|,|selective|serotonin|reuptake|ssris|,|use|, (r_appos) episodes_39\NNS\7283608|previous|manic|,|type|used|inhibitors|assessed (r_pobj) of_36\IN\0|episodes (r_prep) number_35\NN\5107765|of (r_appos) those_11\DT\0|did|,|number (r_pobj) with_10\IN\0|those (r_prep) compared_9\VBN\644583|patients|were|with|. (l_nsubjpass) patients_0\NNS\9898892|experienced (l_relcl) experienced_2\VBD\2108377|who|switch (l_dobj) switch_7\NN\3096960|a|manic (l_amod) manic_4\JJ\0|or|hypomanic
D017367_D001714 CID ssris_62\NNPS\2718811|[|]|) (r_appos) inhibitors_60\NNS\20090|particularly|,|selective|serotonin|reuptake|ssris|,|use|, (r_appos) episodes_39\NNS\7283608|previous|manic|,|type|used|inhibitors|assessed (r_pobj) of_36\IN\0|episodes (r_prep) number_35\NN\5107765|of (r_appos) those_11\DT\0|did|,|number (r_pobj) with_10\IN\0|those (r_prep) compared_9\VBN\644583|patients|were|with|. (l_nsubjpass) patients_0\NNS\9898892|experienced (l_relcl) experienced_2\VBD\2108377|who|switch (l_dobj) switch_7\NN\3096960|a|manic (l_amod) manic_4\JJ\0|or|hypomanic (l_conj) hypomanic_6\JJ\0|
D017367_D001714 CID ssris_62\NNPS\2718811|[|]|) (r_appos) inhibitors_60\NNS\20090|particularly|,|selective|serotonin|reuptake|ssris|,|use|, (r_appos) episodes_39\NNS\7283608|previous|manic|,|type|used|inhibitors|assessed (r_pobj) of_36\IN\0|episodes (r_prep) number_35\NN\5107765|of (r_appos) those_11\DT\0|did|,|number (l_relcl) did_13\VBD\0|who|not|on (l_prep) on_15\IN\0|variables (l_pobj) variables_17\NNS\2452|several|including (l_prep) including_18\VBG\0|age (l_pobj) age_19\NN\4916342|,|sex (l_conj) sex_21\NN\13440063|,|diagnosis (l_conj) diagnosis_23\NN\152018|iv (l_appos) iv_27\NNP\13741022|(|dsm|-|bipolar|i|) (l_appos) i_29\PRP\14622893|vs.
D017367_D001714 CID ssris_62\NNPS\2718811|[|]|) (r_appos) inhibitors_60\NNS\20090|particularly|,|selective|serotonin|reuptake|ssris|,|use|, (r_appos) episodes_39\NNS\7283608|previous|manic|,|type|used|inhibitors|assessed (r_pobj) of_36\IN\0|episodes (r_prep) number_35\NN\5107765|of (r_appos) those_11\DT\0|did|,|number (l_relcl) did_13\VBD\0|who|not|on (l_prep) on_15\IN\0|variables (l_pobj) variables_17\NNS\2452|several|including (l_prep) including_18\VBG\0|age (l_pobj) age_19\NN\4916342|,|sex (l_conj) sex_21\NN\13440063|,|diagnosis (l_conj) diagnosis_23\NN\152018|iv (l_appos) iv_27\NNP\13741022|(|dsm|-|bipolar|i|) (l_appos) i_29\PRP\14622893|vs. (l_prep) vs._30\IN\0|ii (l_pobj) ii_32\NNP\13741022|bipolar
D017367_D001714 CID ssris_62\NNPS\2718811|[|]|) (r_appos) inhibitors_60\NNS\20090|particularly|,|selective|serotonin|reuptake|ssris|,|use|, (r_appos) episodes_39\NNS\7283608|previous|manic|,|type|used|inhibitors|assessed (l_amod) manic_38\JJ\0|
D017367_D001714 CID ssris_29\NNS\2718811|[|8/33|] (r_pobj) with_28\IN\0|ssris (r_prep) treated_27\VBN\2376958|with (r_acl) patients_26\NNS\9898892|treated (r_pobj) of_25\IN\0|patients (r_prep) subgroup_24\NN\31264|the|of (r_pobj) of_22\IN\0|subgroup (r_prep) %_21\NN\0|24|of (r_pobj) in_19\IN\13603305|%|) (r_prep) experienced_42\JJ\2108377|(|(|and|in|;|%|episodes|, (r_parataxis) patients_11\NNS\9898892|all|experienced (r_pobj) of_9\IN\0|patients (r_prep) %_8\NN\0|27|of|and|% (r_pobj) in_6\IN\13603305|% (r_prep) occurred_5\VBD\0|switches|in|episodes|. (l_nsubj) switches_0\NNS\3096960|to (l_prep) to_1\IN\0|hypomania (l_pobj) hypomania_2\NN\0|or|mania
D017367_D001714 CID ssris_29\NNS\2718811|[|8/33|] (r_pobj) with_28\IN\0|ssris (r_prep) treated_27\VBN\2376958|with (r_acl) patients_26\NNS\9898892|treated (r_pobj) of_25\IN\0|patients (r_prep) subgroup_24\NN\31264|the|of (r_pobj) of_22\IN\0|subgroup (r_prep) %_21\NN\0|24|of (r_pobj) in_19\IN\13603305|%|) (r_prep) experienced_42\JJ\2108377|(|(|and|in|;|%|episodes|, (r_parataxis) patients_11\NNS\9898892|all|experienced (r_pobj) of_9\IN\0|patients (r_prep) %_8\NN\0|27|of|and|% (r_pobj) in_6\IN\13603305|% (r_prep) occurred_5\VBD\0|switches|in|episodes|. (l_nsubj) switches_0\NNS\3096960|to (l_prep) to_1\IN\0|hypomania (l_pobj) hypomania_2\NN\0|or|mania (l_conj) mania_4\NN\9180259|
D017367_D001714 CID ssris_29\NNS\2718811|[|8/33|] (r_pobj) with_28\IN\0|ssris (r_prep) treated_27\VBN\2376958|with (r_acl) patients_26\NNS\9898892|treated (r_pobj) of_25\IN\0|patients (r_prep) subgroup_24\NN\31264|the|of (r_pobj) of_22\IN\0|subgroup (r_prep) %_21\NN\0|24|of (r_pobj) in_19\IN\13603305|%|) (r_prep) experienced_42\JJ\2108377|(|(|and|in|;|%|episodes|, (l_dobj) episodes_44\NNS\7283608|manic (l_amod) manic_43\JJ\0|
D017367_D001714 CID ssris_29\NNS\2718811|[|8/33|] (r_pobj) with_28\IN\0|ssris (r_prep) treated_27\VBN\2376958|with (r_acl) patients_26\NNS\9898892|treated (r_pobj) of_25\IN\0|patients (r_prep) subgroup_24\NN\31264|the|of (r_pobj) of_22\IN\0|subgroup (r_prep) %_21\NN\0|24|of (r_pobj) in_19\IN\13603305|%|) (r_prep) experienced_42\JJ\2108377|(|(|and|in|;|%|episodes|, (r_parataxis) patients_11\NNS\9898892|all|experienced (r_pobj) of_9\IN\0|patients (r_prep) %_8\NN\0|27|of|and|% (r_pobj) in_6\IN\13603305|% (r_prep) occurred_5\VBD\0|switches|in|episodes|. (l_npadvmod) episodes_56\NNS\7283608|experienced|hypomanic (l_amod) hypomanic_55\JJ\0|
D008094_D001714 NONE lithium_73\NN\14625458|vs. (r_appos) stabilizers_71\NNS\14806838|mood|(|lithium|) (r_pobj) of_69\IN\0|stabilizers (r_prep) type_68\NN\5839024|of (r_conj) use_66\NN\407535|and|type|,|and|temperament (r_conj) inhibitors_60\NNS\20090|particularly|,|selective|serotonin|reuptake|ssris|,|use|, (r_appos) episodes_39\NNS\7283608|previous|manic|,|type|used|inhibitors|assessed (r_pobj) of_36\IN\0|episodes (r_prep) number_35\NN\5107765|of (r_appos) those_11\DT\0|did|,|number (r_pobj) with_10\IN\0|those (r_prep) compared_9\VBN\644583|patients|were|with|. (l_nsubjpass) patients_0\NNS\9898892|experienced (l_relcl) experienced_2\VBD\2108377|who|switch (l_dobj) switch_7\NN\3096960|a|manic (l_amod) manic_4\JJ\0|or|hypomanic
D008094_D001714 NONE lithium_73\NN\14625458|vs. (r_appos) stabilizers_71\NNS\14806838|mood|(|lithium|) (r_pobj) of_69\IN\0|stabilizers (r_prep) type_68\NN\5839024|of (r_conj) use_66\NN\407535|and|type|,|and|temperament (r_conj) inhibitors_60\NNS\20090|particularly|,|selective|serotonin|reuptake|ssris|,|use|, (r_appos) episodes_39\NNS\7283608|previous|manic|,|type|used|inhibitors|assessed (r_pobj) of_36\IN\0|episodes (r_prep) number_35\NN\5107765|of (r_appos) those_11\DT\0|did|,|number (r_pobj) with_10\IN\0|those (r_prep) compared_9\VBN\644583|patients|were|with|. (l_nsubjpass) patients_0\NNS\9898892|experienced (l_relcl) experienced_2\VBD\2108377|who|switch (l_dobj) switch_7\NN\3096960|a|manic (l_amod) manic_4\JJ\0|or|hypomanic (l_conj) hypomanic_6\JJ\0|
D008094_D001714 NONE lithium_73\NN\14625458|vs. (r_appos) stabilizers_71\NNS\14806838|mood|(|lithium|) (r_pobj) of_69\IN\0|stabilizers (r_prep) type_68\NN\5839024|of (r_conj) use_66\NN\407535|and|type|,|and|temperament (r_conj) inhibitors_60\NNS\20090|particularly|,|selective|serotonin|reuptake|ssris|,|use|, (r_appos) episodes_39\NNS\7283608|previous|manic|,|type|used|inhibitors|assessed (r_pobj) of_36\IN\0|episodes (r_prep) number_35\NN\5107765|of (r_appos) those_11\DT\0|did|,|number (l_relcl) did_13\VBD\0|who|not|on (l_prep) on_15\IN\0|variables (l_pobj) variables_17\NNS\2452|several|including (l_prep) including_18\VBG\0|age (l_pobj) age_19\NN\4916342|,|sex (l_conj) sex_21\NN\13440063|,|diagnosis (l_conj) diagnosis_23\NN\152018|iv (l_appos) iv_27\NNP\13741022|(|dsm|-|bipolar|i|) (l_appos) i_29\PRP\14622893|vs.
D008094_D001714 NONE lithium_73\NN\14625458|vs. (r_appos) stabilizers_71\NNS\14806838|mood|(|lithium|) (r_pobj) of_69\IN\0|stabilizers (r_prep) type_68\NN\5839024|of (r_conj) use_66\NN\407535|and|type|,|and|temperament (r_conj) inhibitors_60\NNS\20090|particularly|,|selective|serotonin|reuptake|ssris|,|use|, (r_appos) episodes_39\NNS\7283608|previous|manic|,|type|used|inhibitors|assessed (r_pobj) of_36\IN\0|episodes (r_prep) number_35\NN\5107765|of (r_appos) those_11\DT\0|did|,|number (l_relcl) did_13\VBD\0|who|not|on (l_prep) on_15\IN\0|variables (l_pobj) variables_17\NNS\2452|several|including (l_prep) including_18\VBG\0|age (l_pobj) age_19\NN\4916342|,|sex (l_conj) sex_21\NN\13440063|,|diagnosis (l_conj) diagnosis_23\NN\152018|iv (l_appos) iv_27\NNP\13741022|(|dsm|-|bipolar|i|) (l_appos) i_29\PRP\14622893|vs. (l_prep) vs._30\IN\0|ii (l_pobj) ii_32\NNP\13741022|bipolar
D008094_D001714 NONE lithium_73\NN\14625458|vs. (r_appos) stabilizers_71\NNS\14806838|mood|(|lithium|) (r_pobj) of_69\IN\0|stabilizers (r_prep) type_68\NN\5839024|of (r_conj) use_66\NN\407535|and|type|,|and|temperament (r_conj) inhibitors_60\NNS\20090|particularly|,|selective|serotonin|reuptake|ssris|,|use|, (r_appos) episodes_39\NNS\7283608|previous|manic|,|type|used|inhibitors|assessed (l_amod) manic_38\JJ\0|
6534871
D007545_D009203 CID isoproterenol_8\NN\3740161| (r_npadvmod) induced_10\VBN\1627355|isoproterenol|- (r_amod) infarction_12\NN\14204950|induced|myocardial
19957053
D010656_D002534 CID phenylephrine_0\NNP\2682038|but|ephedrine (r_nsubj) reduces_4\VBZ\441445|phenylephrine|oxygenation|. (l_dobj) oxygenation_7\NN\13518963|frontal|lobe|following
D010656_D007022 NONE phenylephrine_0\NNP\2682038|but|ephedrine (r_nsubj) reduces_4\VBZ\441445|phenylephrine|oxygenation|. (l_dobj) oxygenation_7\NN\13518963|frontal|lobe|following (l_prep) following_8\VBG\8180190|hypotension (l_dobj) hypotension_12\NN\14057371|induced
D010656_D007022 NONE phenylephrine_5\NN\2682038|and|ephedrine (r_pobj) of_4\IN\0|phenylephrine (r_prep) effect_3\NN\34213|the|of|on (r_dobj) describe_1\VBP\1001294|we|effect|following|. (l_prep) following_16\VBG\8180190|hypotension (l_dobj) hypotension_20\NN\14057371|induced
D010656_D007022 NONE phenylephrine_3\NN\2682038| (r_pobj) of_2\IN\0|phenylephrine (r_prep) utilization_1\NN\407535|the|of|correct (l_acl) correct_5\VB\138508|to|hypotension (l_dobj) hypotension_6\NN\14057371|induced
D004809_D002534 NONE ephedrine_3\JJ\14712692|not (r_conj) phenylephrine_0\NNP\2682038|but|ephedrine (r_nsubj) reduces_4\VBZ\441445|phenylephrine|oxygenation|. (l_dobj) oxygenation_7\NN\13518963|frontal|lobe|following
D004809_D007022 NONE ephedrine_3\JJ\14712692|not (r_conj) phenylephrine_0\NNP\2682038|but|ephedrine (r_nsubj) reduces_4\VBZ\441445|phenylephrine|oxygenation|. (l_dobj) oxygenation_7\NN\13518963|frontal|lobe|following (l_prep) following_8\VBG\8180190|hypotension (l_dobj) hypotension_12\NN\14057371|induced
D004809_D007022 NONE ephedrine_7\JJ\14712692| (r_conj) phenylephrine_5\NN\2682038|and|ephedrine (r_pobj) of_4\IN\0|phenylephrine (r_prep) effect_3\NN\34213|the|of|on (r_dobj) describe_1\VBP\1001294|we|effect|following|. (l_prep) following_16\VBG\8180190|hypotension (l_dobj) hypotension_20\NN\14057371|induced
D004809_D007022 NONE ephedrine_18\JJ\14712692| (r_nsubj) maintains_19\VBZ\0|while|ephedrine|oxygenation (r_advcl) has_10\VBZ\13888491|utilization|impact|)|maintains|. (l_nsubj) utilization_1\NN\407535|the|of|correct (l_acl) correct_5\VB\138508|to|hypotension (l_dobj) hypotension_6\NN\14057371|induced
18631865
D020123_D051436 NONE rapamycin_16\NNS\0| (r_nmod) inhibitors_20\NNS\20090|rapamycin|mtor|,|sirolimus|, (r_pobj) of_15\IN\0|inhibitors (r_prep) target_14\NN\7258332|mammalian|of (r_pobj) to_12\IN\0|target (r_prep) conversion_8\NN\7359599|from|to|in (l_prep) in_25\IN\13603305|recipients (l_pobj) recipients_28\NNS\9764201|renal|transplant|with (l_prep) with_29\IN\0|nephropathy (l_pobj) nephropathy_32\NN\14573196|chronic|allograft
D020123_D051436 NONE sirolimus_23\NN\0|especially (r_appos) inhibitors_20\NNS\20090|rapamycin|mtor|,|sirolimus|, (r_pobj) of_15\IN\0|inhibitors (r_prep) target_14\NN\7258332|mammalian|of (r_pobj) to_12\IN\0|target (r_prep) conversion_8\NN\7359599|from|to|in (l_prep) in_25\IN\13603305|recipients (l_pobj) recipients_28\NNS\9764201|renal|transplant|with (l_prep) with_29\IN\0|nephropathy (l_pobj) nephropathy_32\NN\14573196|chronic|allograft
D020123_D011507 CID sirolimus_5\NN\0|or|consequence (r_pobj) to_4\IN\0|sirolimus (r_prep) due_3\JJ\5174653|to (r_acomp) was_2\VBD\0|whether|proteinuria|due (l_nsubj) proteinuria_1\NN\14299637|
D020123_D011507 CID sirolimus_5\NN\0|or|consequence (r_pobj) to_4\IN\0|sirolimus (r_prep) due_3\JJ\5174653|to (r_acomp) was_2\VBD\0|whether|proteinuria|due (r_csubj) remained_14\VBD\2604760|was|unsolved|observed|. (l_advcl) observed_22\VBN\2163746|until|proteinuria|has|been|during|in (l_nsubjpass) proteinuria_19\NN\14299637|range
D020123_D011507 CID sirolimus_24\NN\0| (r_compound) therapy_25\NN\657604|sirolimus (r_pobj) during_23\IN\0|therapy (r_prep) observed_22\VBN\2163746|until|proteinuria|has|been|during|in (r_advcl) remained_14\VBD\2604760|was|unsolved|observed|. (l_csubj) was_2\VBD\0|whether|proteinuria|due (l_nsubj) proteinuria_1\NN\14299637|
D020123_D011507 CID sirolimus_24\NN\0| (r_compound) therapy_25\NN\657604|sirolimus (r_pobj) during_23\IN\0|therapy (r_prep) observed_22\VBN\2163746|until|proteinuria|has|been|during|in (l_nsubjpass) proteinuria_19\NN\14299637|range
D020123_D011507 CID sirolimus_34\NN\0| (r_nmod) novo_36\NNP\0|sirolimus|de (r_dobj) received_33\VBD\2210855|who|novo (r_relcl) patients_31\NNS\9898892|received (r_pobj) in_30\IN\13603305|patients (r_conj) in_26\IN\13603305|transplantation|and|in (r_prep) observed_22\VBN\2163746|until|proteinuria|has|been|during|in (r_advcl) remained_14\VBD\2604760|was|unsolved|observed|. (l_csubj) was_2\VBD\0|whether|proteinuria|due (l_nsubj) proteinuria_1\NN\14299637|
D020123_D011507 CID sirolimus_34\NN\0| (r_nmod) novo_36\NNP\0|sirolimus|de (r_dobj) received_33\VBD\2210855|who|novo (r_relcl) patients_31\NNS\9898892|received (r_pobj) in_30\IN\13603305|patients (r_conj) in_26\IN\13603305|transplantation|and|in (r_prep) observed_22\VBN\2163746|until|proteinuria|has|been|during|in (l_nsubjpass) proteinuria_19\NN\14299637|range
7088431
D004054_D018262 CID des_6\NNP\14749794| (r_npadvmod) exposed_8\VBN\2110927|des|- (r_amod) offspring_9\NN\10235549|exposed|under (r_pobj) in_5\IN\13603305|offspring (r_prep) development_0\NN\248977|of|in|. (l_prep) of_1\IN\0|adenocarcinoma (l_pobj) adenocarcinoma_4\NN\14242337|clear|cell
D004054_D018262 CID diethylstilbestrol_21\NN\14749794| (r_pobj) to_20\IN\0|diethylstilbestrol (r_prep) exposed_17\VBN\2110927|in|to (r_acl) women_16\NNS\9605289|young|exposed (r_pobj) in_14\IN\13603305|women (r_prep) up_13\NN\153263|follow|-|in (r_pobj) at_10\IN\14622893|up (r_prep) detected_9\VBD\2163746|cases|at (l_nsubj) cases_1\NNS\7283608|two|of (l_prep) of_2\IN\0|adenocarcinoma (l_pobj) adenocarcinoma_5\NN\14242337|clear|cell|of (l_prep) of_6\IN\0|vagina (l_pobj) vagina_8\NN\5250659|the
D004054_D014625 CID diethylstilbestrol_21\NN\14749794| (r_pobj) to_20\IN\0|diethylstilbestrol (r_prep) exposed_17\VBN\2110927|in|to (r_acl) women_16\NNS\9605289|young|exposed (r_pobj) in_14\IN\13603305|women (r_prep) up_13\NN\153263|follow|-|in (r_pobj) at_10\IN\14622893|up (r_prep) detected_9\VBD\2163746|cases|at (l_nsubj) cases_1\NNS\7283608|two|of (l_prep) of_2\IN\0|adenocarcinoma (l_pobj) adenocarcinoma_5\NN\14242337|clear|cell|of (l_prep) of_6\IN\0|vagina (l_pobj) vagina_8\NN\5250659|the
16160878
D014579_D006973 NONE ii_8\NNP\13741022|u|- (r_pobj) of_5\IN\0|ii (r_prep) injection_4\NN\320852|of (r_nsubj) causes_9\NNS\7323922|intracerebroventricular|injection|hypertension|and|stimulates|. (l_dobj) hypertension_10\NN\14057371|and|bradycardia
D014579_D001919 NONE ii_8\NNP\13741022|u|- (r_pobj) of_5\IN\0|ii (r_prep) injection_4\NN\320852|of (r_nsubj) causes_9\NNS\7323922|intracerebroventricular|injection|hypertension|and|stimulates|. (l_dobj) hypertension_10\NN\14057371|and|bradycardia (l_conj) bradycardia_12\NN\14110674|
D014579_D010409 NONE ii_11\NNP\13741022|u|- (r_pobj) of_8\IN\0|ii (r_prep) administration_7\NN\1133281|the|central|of (r_nsubj) had_12\VBD\0|was|,|administration|effect|erection|,|and|level|. (l_dobj) erection_25\NN\14037619|induced|penile|and|behavior
D001058_D010409 CID apomorphine_21\NN\3786417| (r_npadvmod) induced_23\VBN\1627355|apomorphine|- (r_amod) erection_25\NN\14037619|induced|penile|and|behavior
D003345_D010409 NONE corticosterone_35\NN\14752057|plasma (r_compound) level_36\NN\4916342|induced|corticosterone (r_conj) had_12\VBD\0|was|,|administration|effect|erection|,|and|level|. (l_dobj) erection_25\NN\14037619|induced|penile|and|behavior
D014579_D001523 NONE ii_6\NNP\13741022|u|- (r_nsubjpass) involved_9\VBN\2676054|that|ii|may|be|in (l_prep) in_10\IN\13603305|aspects (l_pobj) aspects_12\NNS\5849789|some|of (l_prep) of_13\IN\0|disorders (l_pobj) disorders_15\NNS\14034177|psychiatric
16298782
D019331_D006311 NONE ester_6\NN\14727670|arginine|methyl|:|protector|. (l_appos) protector_10\NN\10466918|a|potential|against (l_prep) against_11\IN\0|ototoxicity (l_pobj) ototoxicity_13\NN\0|gentamicin
D005839_D006311 NONE gentamicin_12\NN\2716866| (r_compound) ototoxicity_13\NN\0|gentamicin
D009569_D006316 NONE oxide_2\NN\14818238|the|nitric|(|ester (r_nsubj) act_20\VB\6479665|oxide|may|as|,|but|needed (l_prep) as_21\IN\14622893|otoprotectant (l_pobj) otoprotectant_23\NN\0|an|against (l_prep) against_24\IN\0|loss (l_pobj) loss_29\NN\13252973|frequency|hearing|caused
D009569_D006316 NONE no_4\NNP\7204911| (r_intj) ester_13\NN\14727670|no|inhibitor|arginine|methyl|(|name|) (r_appos) oxide_2\NN\14818238|the|nitric|(|ester (r_nsubj) act_20\VB\6479665|oxide|may|as|,|but|needed (l_prep) as_21\IN\14622893|otoprotectant (l_pobj) otoprotectant_23\NN\0|an|against (l_prep) against_24\IN\0|loss (l_pobj) loss_29\NN\13252973|frequency|hearing|caused
D019331_D006316 NONE ester_13\NN\14727670|no|inhibitor|arginine|methyl|(|name|) (r_appos) oxide_2\NN\14818238|the|nitric|(|ester (r_nsubj) act_20\VB\6479665|oxide|may|as|,|but|needed (l_prep) as_21\IN\14622893|otoprotectant (l_pobj) otoprotectant_23\NN\0|an|against (l_prep) against_24\IN\0|loss (l_pobj) loss_29\NN\13252973|frequency|hearing|caused
D019331_D006316 NONE name_17\NN\6284225|l|- (r_appos) ester_13\NN\14727670|no|inhibitor|arginine|methyl|(|name|) (r_appos) oxide_2\NN\14818238|the|nitric|(|ester (r_nsubj) act_20\VB\6479665|oxide|may|as|,|but|needed (l_prep) as_21\IN\14622893|otoprotectant (l_pobj) otoprotectant_23\NN\0|an|against (l_prep) against_24\IN\0|loss (l_pobj) loss_29\NN\13252973|frequency|hearing|caused
D005839_D006316 NONE gentamicin_32\NN\2716866| (r_pobj) by_31\IN\0|gentamicin (r_agent) caused_30\VBN\1617192|by (r_acl) loss_29\NN\13252973|frequency|hearing|caused
D009569_D006311 NONE no_17\DT\7204911| (r_pobj) of_16\IN\0|no (r_prep) production_15\NN\30358|the|of (r_dobj) involves_13\VBZ\2676054|as|mechanism|production (r_conj) is_2\VBZ\0|ototoxicity|problem|and|,|involves (l_nsubj) ototoxicity_1\NN\0|their
D009569_D006311 NONE no_17\DT\7204911| (r_pobj) of_16\IN\0|no (r_prep) production_15\NN\30358|the|of (r_dobj) involves_13\VBZ\2676054|as|mechanism|production (l_nsubj) mechanism_12\NN\13446390|their|ototoxic (l_compound) ototoxic_11\JJ\0|
D009569_D006311 NONE no_26\DT\7204911| (r_det) inhibitors_27\NNS\20090|no (r_pobj) of_25\IN\0|inhibitors (r_prep) use_24\NN\407535|the|of|for (r_dobj) assess_22\VB\5220461|to|use (r_xcomp) need_20\VBP\13920835|is|,|we|assess|. (l_ccomp) is_2\VBZ\0|ototoxicity|problem|and|,|involves (l_nsubj) ototoxicity_1\NN\0|their
D009569_D006311 NONE no_26\DT\7204911| (r_det) inhibitors_27\NNS\20090|no (r_pobj) of_25\IN\0|inhibitors (r_prep) use_24\NN\407535|the|of|for (r_dobj) assess_22\VB\5220461|to|use (r_xcomp) need_20\VBP\13920835|is|,|we|assess|. (l_ccomp) is_2\VBZ\0|ototoxicity|problem|and|,|involves (l_conj) involves_13\VBZ\2676054|as|mechanism|production (l_nsubj) mechanism_12\NN\13446390|their|ototoxic (l_compound) ototoxic_11\JJ\0|
D009569_D006319 NONE no_17\DT\7204911| (r_pobj) of_16\IN\0|no (r_prep) production_15\NN\30358|the|of (r_dobj) involves_13\VBZ\2676054|as|mechanism|production (r_conj) is_2\VBZ\0|ototoxicity|problem|and|,|involves (r_ccomp) need_20\VBP\13920835|is|,|we|assess|. (l_xcomp) assess_22\VB\5220461|to|use (l_dobj) use_24\NN\407535|the|of|for (l_prep) for_28\IN\0|prevention (l_pobj) prevention_30\NN\1073995|the|of (l_prep) of_31\IN\0|loss (l_pobj) loss_37\NN\13252973|induced|hearing
D009569_D006319 NONE no_26\DT\7204911| (r_det) inhibitors_27\NNS\20090|no (r_pobj) of_25\IN\0|inhibitors (r_prep) use_24\NN\407535|the|of|for (l_prep) for_28\IN\0|prevention (l_pobj) prevention_30\NN\1073995|the|of (l_prep) of_31\IN\0|loss (l_pobj) loss_37\NN\13252973|induced|hearing
D000617_D006311 NONE aminoglycoside_32\NN\0| (r_npadvmod) induced_34\VBN\1627355|aminoglycoside|- (r_amod) loss_37\NN\13252973|induced|hearing (r_pobj) of_31\IN\0|loss (r_prep) prevention_30\NN\1073995|the|of (r_pobj) for_28\IN\0|prevention (r_prep) use_24\NN\407535|the|of|for (r_dobj) assess_22\VB\5220461|to|use (r_xcomp) need_20\VBP\13920835|is|,|we|assess|. (l_ccomp) is_2\VBZ\0|ototoxicity|problem|and|,|involves (l_nsubj) ototoxicity_1\NN\0|their
D000617_D006311 NONE aminoglycoside_32\NN\0| (r_npadvmod) induced_34\VBN\1627355|aminoglycoside|- (r_amod) loss_37\NN\13252973|induced|hearing (r_pobj) of_31\IN\0|loss (r_prep) prevention_30\NN\1073995|the|of (r_pobj) for_28\IN\0|prevention (r_prep) use_24\NN\407535|the|of|for (r_dobj) assess_22\VB\5220461|to|use (r_xcomp) need_20\VBP\13920835|is|,|we|assess|. (l_ccomp) is_2\VBZ\0|ototoxicity|problem|and|,|involves (l_conj) involves_13\VBZ\2676054|as|mechanism|production (l_nsubj) mechanism_12\NN\13446390|their|ototoxic (l_compound) ototoxic_11\JJ\0|
D000617_D006319 NONE aminoglycoside_32\NN\0| (r_npadvmod) induced_34\VBN\1627355|aminoglycoside|- (r_amod) loss_37\NN\13252973|induced|hearing
D019331_D034381 NONE name_2\NN\6284225|l|- (r_nsubj) reduced_3\VBN\441445|name|loss|in|,|but|gave|. (l_dobj) loss_8\NN\13252973|induced|hearing
D005839_D034381 CID gentamicin_4\NN\2716866| (r_npadvmod) induced_6\VBN\1627355|gentamicin|- (r_amod) loss_8\NN\13252973|induced|hearing
16680561
D003891_D009325 CID desipramine_8\NN\4482543| (r_pobj) with_7\IN\0|desipramine (r_prep) treatment_6\NN\654885|with (r_dobj) following_5\VBG\8180190|treatment (r_acl) events_4\NNS\23100|adverse|following|alone (r_dobj) reported_2\VBD\831651|subjects|events (r_ccomp) reported_35\VBN\831651|reported|,|frequent|nausea|have|been|for|. (l_nsubjpass) nausea_29\NN\14299637|(|and|headache|)
D003891_D009325 CID desipramine_13\NN\4482543| (r_dobj) receiving_12\VBG\2210855|when|desipramine|with|% (r_pcomp) than_10\IN\0|receiving (r_prep) alone_9\RB\0|than (r_amod) events_4\NNS\23100|adverse|following|alone (r_dobj) reported_2\VBD\831651|subjects|events (r_ccomp) reported_35\VBN\831651|reported|,|frequent|nausea|have|been|for|. (l_nsubjpass) nausea_29\NN\14299637|(|and|headache|)
D003891_D009325 CID desipramine_41\NN\4482543|either|or|cinacalcet (r_pobj) with_39\IN\0|desipramine (r_prep) treated_38\VBN\2376958|with (r_acl) patients_37\NNS\9898892|treated (r_pobj) for_36\IN\0|patients (r_prep) reported_35\VBN\831651|reported|,|frequent|nausea|have|been|for|. (l_nsubjpass) nausea_29\NN\14299637|(|and|headache|)
D003891_D006261 CID desipramine_8\NN\4482543| (r_pobj) with_7\IN\0|desipramine (r_prep) treatment_6\NN\654885|with (r_dobj) following_5\VBG\8180190|treatment (r_acl) events_4\NNS\23100|adverse|following|alone (r_dobj) reported_2\VBD\831651|subjects|events (r_ccomp) reported_35\VBN\831651|reported|,|frequent|nausea|have|been|for|. (l_nsubjpass) nausea_29\NN\14299637|(|and|headache|) (l_conj) headache_31\NN\5829480|
D003891_D006261 CID desipramine_13\NN\4482543| (r_dobj) receiving_12\VBG\2210855|when|desipramine|with|% (r_pcomp) than_10\IN\0|receiving (r_prep) alone_9\RB\0|than (r_amod) events_4\NNS\23100|adverse|following|alone (r_dobj) reported_2\VBD\831651|subjects|events (r_ccomp) reported_35\VBN\831651|reported|,|frequent|nausea|have|been|for|. (l_nsubjpass) nausea_29\NN\14299637|(|and|headache|) (l_conj) headache_31\NN\5829480|
D003891_D006261 CID desipramine_41\NN\4482543|either|or|cinacalcet (r_pobj) with_39\IN\0|desipramine (r_prep) treated_38\VBN\2376958|with (r_acl) patients_37\NNS\9898892|treated (r_pobj) for_36\IN\0|patients (r_prep) reported_35\VBN\831651|reported|,|frequent|nausea|have|been|for|. (l_nsubjpass) nausea_29\NN\14299637|(|and|headache|) (l_conj) headache_31\NN\5829480|
C476217_D009325 CID cinacalcet_15\NN\0| (r_pobj) with_14\IN\0|cinacalcet (r_prep) receiving_12\VBG\2210855|when|desipramine|with|% (r_pcomp) than_10\IN\0|receiving (r_prep) alone_9\RB\0|than (r_amod) events_4\NNS\23100|adverse|following|alone (r_dobj) reported_2\VBD\831651|subjects|events (r_ccomp) reported_35\VBN\831651|reported|,|frequent|nausea|have|been|for|. (l_nsubjpass) nausea_29\NN\14299637|(|and|headache|)
C476217_D009325 CID cinacalcet_43\NN\0| (r_conj) desipramine_41\NN\4482543|either|or|cinacalcet (r_pobj) with_39\IN\0|desipramine (r_prep) treated_38\VBN\2376958|with (r_acl) patients_37\NNS\9898892|treated (r_pobj) for_36\IN\0|patients (r_prep) reported_35\VBN\831651|reported|,|frequent|nausea|have|been|for|. (l_nsubjpass) nausea_29\NN\14299637|(|and|headache|)
C476217_D006261 CID cinacalcet_15\NN\0| (r_pobj) with_14\IN\0|cinacalcet (r_prep) receiving_12\VBG\2210855|when|desipramine|with|% (r_pcomp) than_10\IN\0|receiving (r_prep) alone_9\RB\0|than (r_amod) events_4\NNS\23100|adverse|following|alone (r_dobj) reported_2\VBD\831651|subjects|events (r_ccomp) reported_35\VBN\831651|reported|,|frequent|nausea|have|been|for|. (l_nsubjpass) nausea_29\NN\14299637|(|and|headache|) (l_conj) headache_31\NN\5829480|
C476217_D006261 CID cinacalcet_43\NN\0| (r_conj) desipramine_41\NN\4482543|either|or|cinacalcet (r_pobj) with_39\IN\0|desipramine (r_prep) treated_38\VBN\2376958|with (r_acl) patients_37\NNS\9898892|treated (r_pobj) for_36\IN\0|patients (r_prep) reported_35\VBN\831651|reported|,|frequent|nausea|have|been|for|. (l_nsubjpass) nausea_29\NN\14299637|(|and|headache|) (l_conj) headache_31\NN\5829480|
435349
D013390_D005207 CID suxamethonium_0\JJ\0| (r_compound) rate_2\NN\13815152|suxamethonium|infusion|and|observed|. (l_conj) observed_4\JJ\2163746|fasciculations (l_dobj) fasciculations_5\NNS\14361664|
D013390_D013746 NONE sch_20\NNP\0| (r_nsubjpass) exceeded_24\VBN\0|when|sch|mg|was (r_advcl) was_7\VBD\0|either|when|there|response|exceeded (l_attr) response_10\NN\11410625|no|muscular|to (l_prep) to_11\IN\0|stimulation (l_pobj) stimulation_13\NN\242808|tetanic|of|or (l_compound) tetanic_12\JJ\0|
16181582
D014635_D001927 CID valproate_0\NNP\0| (r_npadvmod) induced_2\VBN\1627355|valproate|- (r_amod) encephalopathy_3\NN\14084880|induced|.
D014635_D001927 CID valproate_0\NNP\0| (r_npadvmod) induced_2\VBN\1627355|valproate|- (r_amod) encephalopathy_3\NN\14084880|induced
D014635_D001927 CID valproate_3\NN\0| (r_npadvmod) induced_5\VBN\1627355|valproate|- (r_amod) encephalopathy_6\NN\14084880|induced
D014635_D004827 NONE valproate_0\NNP\0| (r_npadvmod) induced_2\VBN\1627355|valproate|- (r_amod) encephalopathy_3\NN\14084880|induced (r_nsubj) is_4\VBZ\0|encephalopathy|syndrome|. (l_attr) syndrome_7\NN\5870365|a|rare|manifest (l_relcl) manifest_10\VB\6479665|that|may|in (l_prep) in_11\RP\13603305|individuals (l_pobj) individuals_15\NNS\7347|normal|epileptic (l_amod) epileptic_14\JJ\10595647|
1728522
D019980_D006099 CID acid_9\NN\14818238|amoxicillin (r_pobj) of_5\IN\0|acid (r_prep) combination_4\NN\7951464|of (r_pobj) due_2\JJ\5174653|to|combination (r_prep) hepatitis_1\NN\14127211|granulomatous|due|.
D019980_D006099 CID acid_11\NN\14818238| (r_npadvmod) induced_13\VBN\1627355|acid|- (r_amod) hepatitis_14\NN\14127211|clavulanic|induced (r_pobj) with_7\IN\0|hepatitis (r_prep) patient_6\NN\9898892|a|with (r_pobj) of_4\IN\0|patient (r_prep) case_3\NN\7283608|the|of|with (l_prep) with_15\IN\0|granulomas (l_pobj) granulomas_18\NNS\14235200|histologic|multiple
D019980_D056486 CID acid_9\NN\14818238|amoxicillin (r_pobj) of_5\IN\0|acid (r_prep) combination_4\NN\7951464|of (r_pobj) due_2\JJ\5174653|to|combination (r_prep) hepatitis_1\NN\14127211|granulomatous|due|.
D019980_D056486 CID acid_11\NN\14818238| (r_npadvmod) induced_13\VBN\1627355|acid|- (r_amod) hepatitis_14\NN\14127211|clavulanic|induced
16574712
D018817_D003072 CID mdma_0\NN\3054098| (r_compound) users_2\NNS\7846|mdma|polydrug (r_nsubj) show_3\VBP\429048|users|impairments|. (l_dobj) impairments_9\NNS\7296428|specific|central|executive|coupled (l_acl) coupled_10\VBN\1295275|with (l_prep) with_11\IN\0|processes (l_pobj) processes_17\NNS\407535|impaired|social|judgement
D018817_D008569 NONE mdma_12\NNP\3054098|(|3,4-methylenedioxymethamphetamine|ecstasy (r_pobj) of_11\IN\0|mdma (r_prep) users_10\NNS\7846|of (r_pobj) in_9\IN\13603305|users (r_prep) reported_8\VBN\831651|in|deficits|have|been|in|. (l_nsubjpass) deficits_5\NNS\5113133|working|memory
D018817_D008569 NONE 3,4-methylenedioxymethamphetamine_14\CD\0| (r_intj) mdma_12\NNP\3054098|(|3,4-methylenedioxymethamphetamine|ecstasy (r_pobj) of_11\IN\0|mdma (r_prep) users_10\NNS\7846|of (r_pobj) in_9\IN\13603305|users (r_prep) reported_8\VBN\831651|in|deficits|have|been|in|. (l_nsubjpass) deficits_5\NNS\5113133|working|memory
D018817_D008569 NONE ecstasy_16\NN\13985818|,|) (r_appos) mdma_12\NNP\3054098|(|3,4-methylenedioxymethamphetamine|ecstasy (r_pobj) of_11\IN\0|mdma (r_prep) users_10\NNS\7846|of (r_pobj) in_9\IN\13603305|users (r_prep) reported_8\VBN\831651|in|deficits|have|been|in|. (l_nsubjpass) deficits_5\NNS\5113133|working|memory
20196116
D000995_D017114 CID antituberculosis_0\NNP\0| (r_nsubj) induced_3\VBN\1627355|antituberculosis|therapy|-|failure|profile|. (l_dobj) failure_6\NN\66216|acute|liver|:
D000995_D017114 CID antituberculosis_0\NN\0| (r_compound) therapy_1\NN\657604|antituberculosis|(|failure (l_appos) failure_6\NN\66216|att)-associated|acute|liver|(|alf|)
D000995_D017114 CID antituberculosis_0\NN\0| (r_compound) therapy_1\NN\657604|antituberculosis|(|failure (l_appos) failure_6\NN\66216|att)-associated|acute|liver|(|alf|) (l_appos) alf_10\NNP\0|att|-
D000995_D017114 CID antituberculosis_0\NN\0| (r_compound) therapy_1\NN\657604|antituberculosis|(|failure (r_nsubj) is_12\VBZ\0|therapy|alf|. (l_attr) alf_18\NNP\0|the|commonest|induced|in
D001663_D001927 NONE bilirubin_11\NN\14756039|serum|(|dl|)|,|time (l_appos) time_21\NN\7308889|prothrombin|prolongation|,|and|encephalopathy (l_conj) encephalopathy_37\NN\14084880|grade|iv|at
18208574
D006493_D013927 CID heparin_12\NN\2718259| (r_npadvmod) induced_14\VBN\1627355|heparin|- (r_amod) thrombocytopenia_15\NN\14189204|induced (r_pobj) with_11\IN\0|thrombocytopenia (r_prep) patients_10\NNS\9898892|with (r_pobj) in_9\IN\13603305|patients (r_prep) thrombosis_8\NN\14100769|in
D006493_D013927 CID heparin_12\NN\2718259| (r_npadvmod) induced_14\VBN\1627355|heparin|- (r_amod) thrombocytopenia_15\NN\14189204|a|step|induced|assay (l_appos) assay_20\NN\5733583|(|hit|)|antigen|with (l_prep) with_21\IN\0|thrombosis (l_pobj) thrombosis_22\NN\14100769|
D006493_D013927 CID heparin_33\JJ\2718259| (r_compound) concentration_34\NN\4916342|a|high|heparin (r_pobj) of_30\IN\0|concentration (r_prep) characteristics_29\NNS\5849040|inhibition|of (r_dobj) utilizes_26\VBZ\0|correlate|;|assay|characteristics|. (l_advcl) correlate_1\VB\5857459|to|density (l_dobj) density_3\NN\4941325|optical|and|inhibition|of (l_prep) of_7\IN\0|thrombocytopenia (l_pobj) thrombocytopenia_15\NN\14189204|a|step|induced|assay (l_appos) assay_20\NN\5733583|(|hit|)|antigen|with (l_prep) with_21\IN\0|thrombosis (l_pobj) thrombosis_22\NN\14100769|
D006493_D013921 CID heparin_12\NN\2718259| (r_npadvmod) induced_14\VBN\1627355|heparin|- (r_amod) thrombocytopenia_15\NN\14189204|induced
D006493_D013921 CID heparin_12\NN\2718259| (r_npadvmod) induced_14\VBN\1627355|heparin|- (r_amod) thrombocytopenia_15\NN\14189204|a|step|induced|assay
D006493_D013921 CID heparin_12\NN\2718259| (r_npadvmod) induced_14\VBN\1627355|heparin|- (r_amod) thrombocytopenia_15\NN\14189204|a|step|induced|assay (l_appos) assay_20\NN\5733583|(|hit|)|antigen|with (l_nmod) hit_17\NN\36762|
D006493_D013921 CID heparin_33\JJ\2718259| (r_compound) concentration_34\NN\4916342|a|high|heparin (r_pobj) of_30\IN\0|concentration (r_prep) characteristics_29\NNS\5849040|inhibition|of (r_dobj) utilizes_26\VBZ\0|correlate|;|assay|characteristics|. (l_advcl) correlate_1\VB\5857459|to|density (l_dobj) density_3\NN\4941325|optical|and|inhibition|of (l_prep) of_7\IN\0|thrombocytopenia (l_pobj) thrombocytopenia_15\NN\14189204|a|step|induced|assay
D006493_D013921 CID heparin_33\JJ\2718259| (r_compound) concentration_34\NN\4916342|a|high|heparin (r_pobj) of_30\IN\0|concentration (r_prep) characteristics_29\NNS\5849040|inhibition|of (r_dobj) utilizes_26\VBZ\0|correlate|;|assay|characteristics|. (l_advcl) correlate_1\VB\5857459|to|density (l_dobj) density_3\NN\4941325|optical|and|inhibition|of (l_prep) of_7\IN\0|thrombocytopenia (l_pobj) thrombocytopenia_15\NN\14189204|a|step|induced|assay (l_appos) assay_20\NN\5733583|(|hit|)|antigen|with (l_nmod) hit_17\NN\36762|
D006493_D013921 CID heparin_21\NN\2718259|,|had|] (r_pobj) to_20\IN\0|heparin (r_prep) exposure_19\NN\5042871|to (r_pobj) after_18\IN\0|exposure (r_prep) patients_0\NNS\9898892|with|after (l_prep) with_1\IN\0|decrease (l_pobj) decrease_6\NN\7296428|%|in|or|thrombocytopenia|) (l_conj) thrombocytopenia_11\NNP\14189204|10(9)/l
D006493_D013921 CID heparin_48\NN\2718259| (r_pobj) of_47\IN\0|heparin (r_prep) concentration_46\NN\4916342|high|of (r_pobj) with_44\IN\0|concentration (r_prep) inhibition_43\NN\1068773|50|with (r_dobj) had_24\VBD\0|who|assay|inhibition (r_relcl) heparin_21\NN\2718259|,|had|] (r_pobj) to_20\IN\0|heparin (r_prep) exposure_19\NN\5042871|to (r_pobj) after_18\IN\0|exposure (r_prep) patients_0\NNS\9898892|with|after (l_prep) with_1\IN\0|decrease (l_pobj) decrease_6\NN\7296428|%|in|or|thrombocytopenia|) (l_conj) thrombocytopenia_11\NNP\14189204|10(9)/l
16787750
D014635_D001927 CID acid_1\NN\14818238|valproic (r_nsubj) induced_2\VBD\1627355|acid|encephalopathy--19|cases|from|to|. (l_advmod) encephalopathy--19_3\NNP\0|
D014635_D001927 CID vpa_18\NNP\0| (r_compound) therapy_20\NN\657604|vpa|- (r_pobj) to_17\IN\0|therapy (r_prep) associated_16\VBN\628491|to|in (r_acl) effect_15\NN\34213|2003|-a|side|associated (r_pobj) to_10\IN\0|effect (r_prep) induced_2\VBD\1627355|acid|encephalopathy--19|cases|from|to|. (l_advmod) encephalopathy--19_3\NNP\0|
D014635_D001927 CID vpa_17\NNP\0| (r_npadvmod) induced_19\VBN\1627355|vpa|- (r_amod) hepatotoxicity_20\NN\0|,|induced|and|encephalopathy (l_conj) encephalopathy_25\NN\14084880|induced
D014635_D001927 CID vpa_22\NNP\0| (r_npadvmod) induced_24\VBN\1627355|vpa|- (r_compound) encephalopathy_25\NN\14084880|induced
D014635_D001927 CID vpa_4\NNP\0| (r_npadvmod) induced_6\VBN\1627355|vpa|- (r_amod) encephalopathy_7\NN\14084880|induced
D014635_D001927 CID vpa_9\NNP\0| (r_pobj) of_8\IN\0|vpa (r_prep) effect_7\NN\34213|causative|of|in (l_prep) in_10\IN\13603305|patients (l_pobj) patients_11\NNS\9898892|with (l_prep) with_12\IN\0|encephalopathy (l_pobj) encephalopathy_13\JJ\14084880|
D014635_D001927 CID vpa_5\NNP\0| (r_npadvmod) associated_7\VBN\628491|vpa|- (r_amod) encephalopathy_8\NN\14084880|associated|in
D014635_D010195 CID vpa_17\NNP\0| (r_npadvmod) induced_19\VBN\1627355|vpa|- (r_amod) hepatotoxicity_20\NN\0|,|induced|and|encephalopathy (r_npadvmod) occur_4\VB\0|complications|may|in|hepatotoxicity|. (l_prep) in_5\IN\13603305|patients (l_pobj) patients_7\NNS\9898892|some|,|including (l_prep) including_9\VBG\0|pancreatitis (l_pobj) pancreatitis_11\NN\14336539|haemorrhagic|,|suppression
D014635_D010195 CID vpa_22\NNP\0| (r_npadvmod) induced_24\VBN\1627355|vpa|- (r_compound) encephalopathy_25\NN\14084880|induced (r_conj) hepatotoxicity_20\NN\0|,|induced|and|encephalopathy (r_npadvmod) occur_4\VB\0|complications|may|in|hepatotoxicity|. (l_prep) in_5\IN\13603305|patients (l_pobj) patients_7\NNS\9898892|some|,|including (l_prep) including_9\VBG\0|pancreatitis (l_pobj) pancreatitis_11\NN\14336539|haemorrhagic|,|suppression
D014635_D001855 CID vpa_17\NNP\0| (r_npadvmod) induced_19\VBN\1627355|vpa|- (r_amod) hepatotoxicity_20\NN\0|,|induced|and|encephalopathy (r_npadvmod) occur_4\VB\0|complications|may|in|hepatotoxicity|. (l_prep) in_5\IN\13603305|patients (l_pobj) patients_7\NNS\9898892|some|,|including (l_prep) including_9\VBG\0|pancreatitis (l_pobj) pancreatitis_11\NN\14336539|haemorrhagic|,|suppression (l_conj) suppression_15\NN\13489037|bone|marrow
D014635_D001855 CID vpa_22\NNP\0| (r_npadvmod) induced_24\VBN\1627355|vpa|- (r_compound) encephalopathy_25\NN\14084880|induced (r_conj) hepatotoxicity_20\NN\0|,|induced|and|encephalopathy (r_npadvmod) occur_4\VB\0|complications|may|in|hepatotoxicity|. (l_prep) in_5\IN\13603305|patients (l_pobj) patients_7\NNS\9898892|some|,|including (l_prep) including_9\VBG\0|pancreatitis (l_pobj) pancreatitis_11\NN\14336539|haemorrhagic|,|suppression (l_conj) suppression_15\NN\13489037|bone|marrow
D014635_D056486 CID vpa_17\NNP\0| (r_npadvmod) induced_19\VBN\1627355|vpa|- (r_amod) hepatotoxicity_20\NN\0|,|induced|and|encephalopathy
D014635_D056486 CID vpa_22\NNP\0| (r_npadvmod) induced_24\VBN\1627355|vpa|- (r_compound) encephalopathy_25\NN\14084880|induced (r_conj) hepatotoxicity_20\NN\0|,|induced|and|encephalopathy
D014635_D003244 CID vpa_4\NNP\0| (r_npadvmod) induced_6\VBN\1627355|vpa|- (r_amod) encephalopathy_7\NN\14084880|induced (r_pobj) of_3\IN\0|encephalopathy (r_prep) signs_2\NNS\6643763|the|typical|of (r_nsubj) are_8\VBP\13600404|signs|consciousness|,|marked|. (l_attr) consciousness_10\NN\5669934|impaired
D014635_D012640 NONE vpa_4\NNP\0| (r_npadvmod) induced_6\VBN\1627355|vpa|- (r_amod) encephalopathy_7\NN\14084880|induced (r_pobj) of_3\IN\0|encephalopathy (r_prep) signs_2\NNS\6643763|the|typical|of (r_nsubj) are_8\VBP\13600404|signs|consciousness|,|marked|. (l_advcl) marked_13\VBD\1296462|sometimes|slowing (l_ccomp) slowing_16\VBG\7296428|background|,|frequency (l_dobj) frequency_20\NN\15286249|increased|seizure|,|with (l_compound) seizure_19\NN\14081375|
D014635_D022124 NONE vpa_4\NNP\0| (r_npadvmod) induced_6\VBN\1627355|vpa|- (r_amod) encephalopathy_7\NN\14084880|induced (r_pobj) of_3\IN\0|encephalopathy (r_prep) signs_2\NNS\6643763|the|typical|of (r_nsubj) are_8\VBP\13600404|signs|consciousness|,|marked|. (l_advcl) marked_13\VBD\1296462|sometimes|slowing (l_ccomp) slowing_16\VBG\7296428|background|,|frequency (l_dobj) frequency_20\NN\15286249|increased|seizure|,|with (l_prep) with_22\IN\0|or|without (l_conj) without_24\IN\0|hyperammonemia (l_pobj) hyperammonemia_25\NN\0|
9862868
D004997_D002780 CID estradiol_9\NNP\14749794| (r_nmod) treatment_13\NN\654885|estradiol|(|ee|)|and|extrahepatic (r_nmod) cholestasis_16\NN\14052403|treatment|by (r_dobj) used_1\VBD\0|we|models|cholestasis|determine|. (l_dobj) models_3\NNS\5888929|rat|of (l_prep) of_4\IN\0|cholestasis (l_pobj) cholestasis_6\NN\14052403|intrahepatic|by
D004997_D002780 CID ee_11\NNP\6125041| (r_nmod) treatment_13\NN\654885|estradiol|(|ee|)|and|extrahepatic (r_nmod) cholestasis_16\NN\14052403|treatment|by (r_dobj) used_1\VBD\0|we|models|cholestasis|determine|. (l_dobj) models_3\NNS\5888929|rat|of (l_prep) of_4\IN\0|cholestasis (l_pobj) cholestasis_6\NN\14052403|intrahepatic|by
D004997_D001651 NONE estradiol_9\NNP\14749794| (r_nmod) treatment_13\NN\654885|estradiol|(|ee|)|and|extrahepatic (r_nmod) cholestasis_16\NN\14052403|treatment|by
D004997_D001651 NONE ee_11\NNP\6125041| (r_nmod) treatment_13\NN\654885|estradiol|(|ee|)|and|extrahepatic (r_nmod) cholestasis_16\NN\14052403|treatment|by
18308784
C035054_D007859 NONE rg1_1\NNP\0|ginsenoside (r_nsubj) restores_2\VBZ\1631072|rg1|impairment|. (l_dobj) impairment_4\NN\7296428|the|of|induced (l_prep) of_5\IN\0|learning (l_pobj) learning_6\VBG\5701944|
C035054_D007859 NONE rg1_0\NNP\0|,|ameliorate|. (l_advcl) ameliorate_11\VB\126264|as|,|could|impairment (l_dobj) impairment_14\NN\7296428|spatial|learning
C035054_D007859 NONE rg1_11\NN\0| (r_pobj) of_10\IN\0|rg1 (r_prep) effect_9\NN\34213|the|of|on (l_prep) on_12\IN\0|impairment (l_pobj) impairment_14\NN\7296428|learning|by
D009020_D007859 CID morphine_10\NN\2707683| (r_compound) administration_11\NN\1133281|chronic|morphine|in (r_pobj) by_8\IN\0|administration (r_agent) induced_7\VBN\1627355|by (r_acl) impairment_4\NN\7296428|the|of|induced (l_prep) of_5\IN\0|learning (l_pobj) learning_6\VBG\5701944|
D009020_D007859 CID morphine_17\NN\2707683| (r_compound) administration_18\NN\1133281|chronic|morphine|and|mechanism (r_pobj) by_15\IN\0|administration (r_prep) impairment_14\NN\7296428|learning|by
D036145_D007859 NONE ginsenoside_4\NN\0|a|extracted (r_pobj) as_2\IN\14622893|ginsenoside (r_prep) ameliorate_11\VB\126264|as|,|could|impairment (l_dobj) impairment_14\NN\7296428|spatial|learning
16867021
D006632_D002375 NONE histamine_10\NN\14739004| (r_nmod) ligands_12\NNS\20090|histamine|h(3)-receptor|on (l_prep) on_13\IN\0|catalepsy (l_pobj) catalepsy_17\NN\14023236|induced|,
D001058_D002375 NONE apomorphine_19\NN\3786417| (r_npadvmod) induced_21\VBN\1627355|apomorphine|- (r_amod) behavior_23\NN\407535|induced|climbing|and|activities (r_dobj) study_6\VB\635850|to|effect|behavior (l_dobj) effect_8\NN\34213|the|of (l_prep) of_9\IN\0|ligands (l_pobj) ligands_12\NNS\20090|histamine|h(3)-receptor|on (l_prep) on_13\IN\0|catalepsy (l_pobj) catalepsy_17\NN\14023236|induced|,
D001058_D002375 NONE apomorphine_12\NN\3786417|(|mg/kg|)|and|amphetamine (r_nsubjpass) used_26\VBN\0|while|apomorphine|were|for (r_advcl) induced_2\VBN\1627355|catalepsy|was|by|,|used|. (l_nsubjpass) catalepsy_0\NNP\14023236|
D001058_D002375 NONE apomorphine_21\NN\3786417| (r_dobj) reducing_20\VBG\13447361|apomorphine (r_conj) reducing_14\VBG\13447361|hyperactivity|and|reducing (r_conj) potentiating_8\VBG\229605|catalepsy|,|reducing (l_dobj) catalepsy_12\NN\14023236|induced
D000661_D002375 NONE amphetamine_25\NN\3248958| (r_npadvmod) induced_27\VBN\1627355|amphetamine|- (r_amod) activities_29\NNS\30358|induced|locomotor|in (r_conj) behavior_23\NN\407535|induced|climbing|and|activities (r_dobj) study_6\VB\635850|to|effect|behavior (l_dobj) effect_8\NN\34213|the|of (l_prep) of_9\IN\0|ligands (l_pobj) ligands_12\NNS\20090|histamine|h(3)-receptor|on (l_prep) on_13\IN\0|catalepsy (l_pobj) catalepsy_17\NN\14023236|induced|,
D000661_D002375 NONE amphetamine_19\NN\3248958|(|mg/kg|) (r_conj) apomorphine_12\NN\3786417|(|mg/kg|)|and|amphetamine (r_nsubjpass) used_26\VBN\0|while|apomorphine|were|for (r_advcl) induced_2\VBN\1627355|catalepsy|was|by|,|used|. (l_nsubjpass) catalepsy_0\NNP\14023236|
D000661_D002375 NONE amphetamine_15\NN\3248958| (r_npadvmod) induced_17\VBN\1627355|amphetamine|- (r_amod) hyperactivity_18\NN\14052403|induced (r_dobj) reducing_14\VBG\13447361|hyperactivity|and|reducing (r_conj) potentiating_8\VBG\229605|catalepsy|,|reducing (l_dobj) catalepsy_12\NN\14023236|induced
D006220_D002375 CID haloperidol_4\NN\3713736|(|mg/kg|) (r_pobj) by_3\IN\0|haloperidol (r_agent) induced_2\VBN\1627355|catalepsy|was|by|,|used|. (l_nsubjpass) catalepsy_0\NNP\14023236|
D006220_D002375 CID haloperidol_4\NN\3713736| (r_pobj) to_3\IN\0|haloperidol (r_prep) prior_2\RB\10675876|to (r_advmod) resulted_5\VBD\2633881|1|h|prior|in|. (l_prep) in_6\IN\13603305|increase (l_pobj) increase_11\NN\13576355|a|dependent|in|(|p|) (l_prep) in_12\IN\13603305|catalepsy (l_pobj) catalepsy_14\NN\14023236|the|times
D006220_D002375 CID haloperidol_9\NN\3713736| (r_npadvmod) induced_11\VBN\1627355|haloperidol|- (r_amod) catalepsy_12\NN\14023236|induced
C069357_D002375 NONE methylhistamine_3\NN\0|r)-alpha|-|ramh|microg (r_nsubj) cause_27\VB\7323922|(|methylhistamine|,|se|did|not|catalepsy|. (l_dobj) catalepsy_28\NN\14023236|
C069357_D002375 NONE ramh_5\NNP\0|(|) (r_appos) methylhistamine_3\NN\0|r)-alpha|-|ramh|microg (r_nsubj) cause_27\VB\7323922|(|methylhistamine|,|se|did|not|catalepsy|. (l_dobj) catalepsy_28\NN\14023236|
C052075_D002375 CID thioperamide_13\JJ\0|(|thp|) (r_conj) microg_9\NN\0|(|5|i.c.v.|)|and|thioperamide|(|mg/kg|) (r_parataxis) methylhistamine_3\NN\0|r)-alpha|-|ramh|microg (r_nsubj) cause_27\VB\7323922|(|methylhistamine|,|se|did|not|catalepsy|. (l_dobj) catalepsy_28\NN\14023236|
C052075_D002375 CID thp_15\NNP\0| (r_appos) thioperamide_13\JJ\0|(|thp|) (r_conj) microg_9\NN\0|(|5|i.c.v.|)|and|thioperamide|(|mg/kg|) (r_parataxis) methylhistamine_3\NN\0|r)-alpha|-|ramh|microg (r_nsubj) cause_27\VB\7323922|(|methylhistamine|,|se|did|not|catalepsy|. (l_dobj) catalepsy_28\NN\14023236|
C052075_D002375 CID thp_0\NNP\0| (r_nsubj) exhibited_1\VBD\2632167|thp|profile|climbing|. (l_dobj) profile_6\NN\6999802|an|like|by (l_prep) by_7\IN\0|potentiating (l_pcomp) potentiating_8\VBG\229605|catalepsy|,|reducing (l_dobj) catalepsy_12\NN\14023236|induced
D000661_D006948 CID amphetamine_1\NN\3248958| (r_npadvmod) induced_3\VBN\1627355|amphetamine|- (r_amod) hyperactivity_4\NN\14052403|induced
D000661_D006948 CID amphetamine_15\NN\3248958| (r_npadvmod) induced_17\VBN\1627355|amphetamine|- (r_amod) hyperactivity_18\NN\14052403|induced
C052075_D006948 NONE thp_6\NNP\0| (r_nmod) time_16\NN\7308889|thp|mg/kg|i.p.|)|reduced|locomotor (r_npadvmod) traveled_19\VBD\0|on|,|time|,|distance|and|speed|. (l_prep) on_0\IN\0|hyperactivity (l_pobj) hyperactivity_4\NN\14052403|induced
C052075_D006948 NONE thp_0\NNP\0| (r_nsubj) exhibited_1\VBD\2632167|thp|profile|climbing|. (l_dobj) profile_6\NN\6999802|an|like|by (l_prep) by_7\IN\0|potentiating (l_pcomp) potentiating_8\VBG\229605|catalepsy|,|reducing (l_conj) reducing_14\VBG\13447361|hyperactivity|and|reducing (l_dobj) hyperactivity_18\NN\14052403|induced
D006220_D006948 NONE haloperidol_9\NN\3713736| (r_npadvmod) induced_11\VBN\1627355|haloperidol|- (r_amod) catalepsy_12\NN\14023236|induced (r_dobj) potentiating_8\VBG\229605|catalepsy|,|reducing (l_conj) reducing_14\VBG\13447361|hyperactivity|and|reducing (l_dobj) hyperactivity_18\NN\14052403|induced
D001058_D006948 NONE apomorphine_21\NN\3786417| (r_dobj) reducing_20\VBG\13447361|apomorphine (r_conj) reducing_14\VBG\13447361|hyperactivity|and|reducing (l_dobj) hyperactivity_18\NN\14052403|induced
9698967
D008619_D006973 CID mepivacaine_43\NN\0| (r_amod) mg_45\NN\13717155|mepivacaine|850 (r_pobj) with_42\IN\0|mg|containing (r_prep) block_41\NN\21939|axillary|with (r_pobj) of_39\IN\0|block (r_prep) performance_38\NN\6619065|of (r_pobj) after_37\IN\0|performance (r_prep) min_36\NN\15154774|12|after (r_appos) group_28\NN\2137|asa|classification|ii|,|male|min|,|for (r_appos) observed_21\VBN\2163746|increase|was|in|,|group|. (l_nsubjpass) increase_1\NN\13576355|an|in|,|accompanied|, (l_prep) in_2\IN\13603305|pressure (l_pobj) pressure_4\NN\11419404|blood
D008619_D001281 CID mepivacaine_43\NN\0| (r_amod) mg_45\NN\13717155|mepivacaine|850 (r_pobj) with_42\IN\0|mg|containing (r_prep) block_41\NN\21939|axillary|with (r_pobj) of_39\IN\0|block (r_prep) performance_38\NN\6619065|of (r_pobj) after_37\IN\0|performance (r_prep) min_36\NN\15154774|12|after (r_appos) group_28\NN\2137|asa|classification|ii|,|male|min|,|for (r_appos) observed_21\VBN\2163746|increase|was|in|,|group|. (l_nsubjpass) increase_1\NN\13576355|an|in|,|accompanied|, (l_acl) accompanied_6\VBN\0|by (l_agent) by_7\IN\0|fibrillation (l_pobj) fibrillation_9\NN\14361664|atrial|,|agitation
D008619_D011595 NONE mepivacaine_43\NN\0| (r_amod) mg_45\NN\13717155|mepivacaine|850 (r_pobj) with_42\IN\0|mg|containing (r_prep) block_41\NN\21939|axillary|with (r_pobj) of_39\IN\0|block (r_prep) performance_38\NN\6619065|of (r_pobj) after_37\IN\0|performance (r_prep) min_36\NN\15154774|12|after (r_appos) group_28\NN\2137|asa|classification|ii|,|male|min|,|for (r_appos) observed_21\VBN\2163746|increase|was|in|,|group|. (l_nsubjpass) increase_1\NN\13576355|an|in|,|accompanied|, (l_acl) accompanied_6\VBN\0|by (l_agent) by_7\IN\0|fibrillation (l_pobj) fibrillation_9\NN\14361664|atrial|,|agitation (l_conj) agitation_11\NN\14373582|,|shouts
D008619_D019954 NONE mepivacaine_43\NN\0| (r_amod) mg_45\NN\13717155|mepivacaine|850 (r_pobj) with_42\IN\0|mg|containing (r_prep) block_41\NN\21939|axillary|with (r_pobj) of_39\IN\0|block (r_prep) performance_38\NN\6619065|of (r_pobj) after_37\IN\0|performance (r_prep) min_36\NN\15154774|12|after (r_appos) group_28\NN\2137|asa|classification|ii|,|male|min|,|for (r_appos) observed_21\VBN\2163746|increase|was|in|,|group|. (l_nsubjpass) increase_1\NN\13576355|an|in|,|accompanied|, (l_acl) accompanied_6\VBN\0|by (l_agent) by_7\IN\0|fibrillation (l_pobj) fibrillation_9\NN\14361664|atrial|,|agitation (l_conj) agitation_11\NN\14373582|,|shouts (l_conj) shouts_14\NNS\7109847|incomprehensible|and|loss|of
D008619_D014474 NONE mepivacaine_43\NN\0| (r_amod) mg_45\NN\13717155|mepivacaine|850 (r_pobj) with_42\IN\0|mg|containing (r_prep) block_41\NN\21939|axillary|with (r_pobj) of_39\IN\0|block (r_prep) performance_38\NN\6619065|of (r_pobj) after_37\IN\0|performance (r_prep) min_36\NN\15154774|12|after (r_appos) group_28\NN\2137|asa|classification|ii|,|male|min|,|for (r_appos) observed_21\VBN\2163746|increase|was|in|,|group|. (l_nsubjpass) increase_1\NN\13576355|an|in|,|accompanied|, (l_acl) accompanied_6\VBN\0|by (l_agent) by_7\IN\0|fibrillation (l_pobj) fibrillation_9\NN\14361664|atrial|,|agitation (l_conj) agitation_11\NN\14373582|,|shouts (l_conj) shouts_14\NNS\7109847|incomprehensible|and|loss|of (l_prep) of_17\IN\0|consciousness (l_pobj) consciousness_18\NN\5669934|
D008619_D004387 NONE mepivacaine_43\NN\0| (r_amod) mg_45\NN\13717155|mepivacaine|850 (r_pobj) with_42\IN\0|mg|containing (r_prep) block_41\NN\21939|axillary|with (r_pobj) of_39\IN\0|block (r_prep) performance_38\NN\6619065|of (r_pobj) after_37\IN\0|performance (r_prep) min_36\NN\15154774|12|after (r_appos) group_28\NN\2137|asa|classification|ii|,|male|min|,|for (l_prep) for_51\IN\0|correction (l_pobj) correction_52\NN\248977|of (l_prep) of_53\IN\0|contracture (l_pobj) contracture_56\NN\369802|dupuytren
D004837_D006973 CID adrenaline_47\NN\14807929|mg (r_dobj) containing_46\VBG\2632940|adrenaline (r_pcomp) with_42\IN\0|mg|containing (r_prep) block_41\NN\21939|axillary|with (r_pobj) of_39\IN\0|block (r_prep) performance_38\NN\6619065|of (r_pobj) after_37\IN\0|performance (r_prep) min_36\NN\15154774|12|after (r_appos) group_28\NN\2137|asa|classification|ii|,|male|min|,|for (r_appos) observed_21\VBN\2163746|increase|was|in|,|group|. (l_nsubjpass) increase_1\NN\13576355|an|in|,|accompanied|, (l_prep) in_2\IN\13603305|pressure (l_pobj) pressure_4\NN\11419404|blood
D004837_D001281 CID adrenaline_47\NN\14807929|mg (r_dobj) containing_46\VBG\2632940|adrenaline (r_pcomp) with_42\IN\0|mg|containing (r_prep) block_41\NN\21939|axillary|with (r_pobj) of_39\IN\0|block (r_prep) performance_38\NN\6619065|of (r_pobj) after_37\IN\0|performance (r_prep) min_36\NN\15154774|12|after (r_appos) group_28\NN\2137|asa|classification|ii|,|male|min|,|for (r_appos) observed_21\VBN\2163746|increase|was|in|,|group|. (l_nsubjpass) increase_1\NN\13576355|an|in|,|accompanied|, (l_acl) accompanied_6\VBN\0|by (l_agent) by_7\IN\0|fibrillation (l_pobj) fibrillation_9\NN\14361664|atrial|,|agitation
D004837_D011595 NONE adrenaline_47\NN\14807929|mg (r_dobj) containing_46\VBG\2632940|adrenaline (r_pcomp) with_42\IN\0|mg|containing (r_prep) block_41\NN\21939|axillary|with (r_pobj) of_39\IN\0|block (r_prep) performance_38\NN\6619065|of (r_pobj) after_37\IN\0|performance (r_prep) min_36\NN\15154774|12|after (r_appos) group_28\NN\2137|asa|classification|ii|,|male|min|,|for (r_appos) observed_21\VBN\2163746|increase|was|in|,|group|. (l_nsubjpass) increase_1\NN\13576355|an|in|,|accompanied|, (l_acl) accompanied_6\VBN\0|by (l_agent) by_7\IN\0|fibrillation (l_pobj) fibrillation_9\NN\14361664|atrial|,|agitation (l_conj) agitation_11\NN\14373582|,|shouts
D004837_D019954 NONE adrenaline_47\NN\14807929|mg (r_dobj) containing_46\VBG\2632940|adrenaline (r_pcomp) with_42\IN\0|mg|containing (r_prep) block_41\NN\21939|axillary|with (r_pobj) of_39\IN\0|block (r_prep) performance_38\NN\6619065|of (r_pobj) after_37\IN\0|performance (r_prep) min_36\NN\15154774|12|after (r_appos) group_28\NN\2137|asa|classification|ii|,|male|min|,|for (r_appos) observed_21\VBN\2163746|increase|was|in|,|group|. (l_nsubjpass) increase_1\NN\13576355|an|in|,|accompanied|, (l_acl) accompanied_6\VBN\0|by (l_agent) by_7\IN\0|fibrillation (l_pobj) fibrillation_9\NN\14361664|atrial|,|agitation (l_conj) agitation_11\NN\14373582|,|shouts (l_conj) shouts_14\NNS\7109847|incomprehensible|and|loss|of
D004837_D014474 NONE adrenaline_47\NN\14807929|mg (r_dobj) containing_46\VBG\2632940|adrenaline (r_pcomp) with_42\IN\0|mg|containing (r_prep) block_41\NN\21939|axillary|with (r_pobj) of_39\IN\0|block (r_prep) performance_38\NN\6619065|of (r_pobj) after_37\IN\0|performance (r_prep) min_36\NN\15154774|12|after (r_appos) group_28\NN\2137|asa|classification|ii|,|male|min|,|for (r_appos) observed_21\VBN\2163746|increase|was|in|,|group|. (l_nsubjpass) increase_1\NN\13576355|an|in|,|accompanied|, (l_acl) accompanied_6\VBN\0|by (l_agent) by_7\IN\0|fibrillation (l_pobj) fibrillation_9\NN\14361664|atrial|,|agitation (l_conj) agitation_11\NN\14373582|,|shouts (l_conj) shouts_14\NNS\7109847|incomprehensible|and|loss|of (l_prep) of_17\IN\0|consciousness (l_pobj) consciousness_18\NN\5669934|
D004837_D004387 NONE adrenaline_47\NN\14807929|mg (r_dobj) containing_46\VBG\2632940|adrenaline (r_pcomp) with_42\IN\0|mg|containing (r_prep) block_41\NN\21939|axillary|with (r_pobj) of_39\IN\0|block (r_prep) performance_38\NN\6619065|of (r_pobj) after_37\IN\0|performance (r_prep) min_36\NN\15154774|12|after (r_appos) group_28\NN\2137|asa|classification|ii|,|male|min|,|for (l_prep) for_51\IN\0|correction (l_pobj) correction_52\NN\248977|of (l_prep) of_53\IN\0|contracture (l_pobj) contracture_56\NN\369802|dupuytren
8919272
D014635_D001927 CID valproate_11\NN\0|features|to|. (l_nsubj) features_1\NNS\5849040|morphological|of|after (l_prep) of_2\IN\0|encephalopathy (l_pobj) encephalopathy_3\NN\14084880|
D014635_D001927 CID valproate_10\NN\0|application|polfa|at|to|disorders|. (l_dobj) disorders_43\NNS\14034177|revealed|neurological|indicating (l_acl) indicating_44\VBG\952524|damage (l_dobj) damage_46\NN\7296428|cerebellum|encephalopathy (l_appos) encephalopathy_50\JJ\14084880|(|"|valproate|"|)
D014635_D001927 CID valproate_49\NNP\0| (r_amod) encephalopathy_50\JJ\14084880|(|"|valproate|"|)
D014635_D001927 CID valproate_15\NNP\0| (r_amod) encephalopathy_16\NNP\14084880|valproate
D014635_D009422 NONE valproate_10\NN\0|application|polfa|at|to|disorders|. (l_dobj) disorders_43\NNS\14034177|revealed|neurological|indicating
D014635_D009422 NONE valproate_49\NNP\0| (r_amod) encephalopathy_50\JJ\14084880|(|"|valproate|"|) (r_appos) damage_46\NN\7296428|cerebellum|encephalopathy (r_dobj) indicating_44\VBG\952524|damage (r_acl) disorders_43\NNS\14034177|revealed|neurological|indicating
D014635_D002526 NONE valproate_10\NN\0|application|polfa|at|to|disorders|. (l_dobj) disorders_43\NNS\14034177|revealed|neurological|indicating (l_acl) indicating_44\VBG\952524|damage (l_dobj) damage_46\NN\7296428|cerebellum|encephalopathy
D014635_D002526 NONE valproate_49\NNP\0| (r_amod) encephalopathy_50\JJ\14084880|(|"|valproate|"|) (r_appos) damage_46\NN\7296428|cerebellum|encephalopathy
D014635_D056486 NONE valproate_15\NNP\0| (r_amod) encephalopathy_16\NNP\14084880|valproate (r_pobj) of_14\IN\0|encephalopathy (r_prep) development_13\NN\248977|the|of (r_pobj) upon_11\IN\0|development (r_prep) hyperammonemia_9\NN\0|influence|mainly|,|upon (l_nsubj) influence_2\NN\5190804|the|possible|of|, (l_prep) of_3\IN\0|damage (l_pobj) damage_6\NN\7296428|the|hepatic
D014635_D022124 NONE valproate_15\NNP\0| (r_amod) encephalopathy_16\NNP\14084880|valproate (r_pobj) of_14\IN\0|encephalopathy (r_prep) development_13\NN\248977|the|of (r_pobj) upon_11\IN\0|development (r_prep) hyperammonemia_9\NN\0|influence|mainly|,|upon
17615423
D019821_D012206 CID simvastatin_11\NN\3676175|,|amiodarone (r_pobj) of_10\IN\0|simvastatin (r_prep) use_9\NN\407535|concomitant|of (r_pobj) to_7\IN\0|use (r_prep) secondary_6\JJ\8426461|to (r_amod) failure_5\NN\66216|acute|renal|secondary (r_conj) rhabdomyolysis_1\NN\0|severe|and|failure|.
D019821_D012206 CID simvastatin_9\NN\3676175|,|amiodarone (l_conj) amiodarone_11\NN\2715941|,|and|atazanavir (l_conj) atazanavir_14\NNS\0|resulting (l_acl) resulting_15\VBG\2633881|in (l_prep) in_16\IN\13603305|rhabdomyolysis (l_pobj) rhabdomyolysis_17\NN\0|and|failure
D019821_D012206 CID simvastatin_14\NN\3676175| (r_amod) metabolism_15\NN\13526110|simvastatin (r_dobj) inhibit_13\VBP\2510337|that|metabolism (r_relcl) drugs_11\NNS\14778436|concomitant|inhibit (r_pobj) of_9\IN\0|drugs (r_prep) presence_8\NN\13954253|the|of (r_pobj) in_6\IN\13603305|presence (r_prep) increased_5\VBN\169651|risk|is|in|. (l_nsubjpass) risk_1\NN\14541044|the|of (l_prep) of_2\IN\0|rhabdomyolysis (l_pobj) rhabdomyolysis_3\NN\0|
D019821_D058186 CID simvastatin_11\NN\3676175|,|amiodarone (r_pobj) of_10\IN\0|simvastatin (r_prep) use_9\NN\407535|concomitant|of (r_pobj) to_7\IN\0|use (r_prep) secondary_6\JJ\8426461|to (r_amod) failure_5\NN\66216|acute|renal|secondary
D019821_D058186 CID simvastatin_9\NN\3676175|,|amiodarone (l_conj) amiodarone_11\NN\2715941|,|and|atazanavir (l_conj) atazanavir_14\NNS\0|resulting (l_acl) resulting_15\VBG\2633881|in (l_prep) in_16\IN\13603305|rhabdomyolysis (l_pobj) rhabdomyolysis_17\NN\0|and|failure (l_conj) failure_21\NN\66216|acute|renal
D000638_D012206 CID amiodarone_13\NN\2715941|,|and|atazanavir (r_conj) simvastatin_11\NN\3676175|,|amiodarone (r_pobj) of_10\IN\0|simvastatin (r_prep) use_9\NN\407535|concomitant|of (r_pobj) to_7\IN\0|use (r_prep) secondary_6\JJ\8426461|to (r_amod) failure_5\NN\66216|acute|renal|secondary (r_conj) rhabdomyolysis_1\NN\0|severe|and|failure|.
D000638_D012206 CID amiodarone_11\NN\2715941|,|and|atazanavir (l_conj) atazanavir_14\NNS\0|resulting (l_acl) resulting_15\VBG\2633881|in (l_prep) in_16\IN\13603305|rhabdomyolysis (l_pobj) rhabdomyolysis_17\NN\0|and|failure
D000638_D058186 CID amiodarone_13\NN\2715941|,|and|atazanavir (r_conj) simvastatin_11\NN\3676175|,|amiodarone (r_pobj) of_10\IN\0|simvastatin (r_prep) use_9\NN\407535|concomitant|of (r_pobj) to_7\IN\0|use (r_prep) secondary_6\JJ\8426461|to (r_amod) failure_5\NN\66216|acute|renal|secondary
D000638_D058186 CID amiodarone_11\NN\2715941|,|and|atazanavir (l_conj) atazanavir_14\NNS\0|resulting (l_acl) resulting_15\VBG\2633881|in (l_prep) in_16\IN\13603305|rhabdomyolysis (l_pobj) rhabdomyolysis_17\NN\0|and|failure (l_conj) failure_21\NN\66216|acute|renal
C413408_D012206 CID atazanavir_16\NNS\0| (r_conj) amiodarone_13\NN\2715941|,|and|atazanavir (r_conj) simvastatin_11\NN\3676175|,|amiodarone (r_pobj) of_10\IN\0|simvastatin (r_prep) use_9\NN\407535|concomitant|of (r_pobj) to_7\IN\0|use (r_prep) secondary_6\JJ\8426461|to (r_amod) failure_5\NN\66216|acute|renal|secondary (r_conj) rhabdomyolysis_1\NN\0|severe|and|failure|.
C413408_D012206 CID atazanavir_14\NNS\0|resulting (l_acl) resulting_15\VBG\2633881|in (l_prep) in_16\IN\13603305|rhabdomyolysis (l_pobj) rhabdomyolysis_17\NN\0|and|failure
C413408_D058186 CID atazanavir_16\NNS\0| (r_conj) amiodarone_13\NN\2715941|,|and|atazanavir (r_conj) simvastatin_11\NN\3676175|,|amiodarone (r_pobj) of_10\IN\0|simvastatin (r_prep) use_9\NN\407535|concomitant|of (r_pobj) to_7\IN\0|use (r_prep) secondary_6\JJ\8426461|to (r_amod) failure_5\NN\66216|acute|renal|secondary
C413408_D058186 CID atazanavir_14\NNS\0|resulting (l_acl) resulting_15\VBG\2633881|in (l_prep) in_16\IN\13603305|rhabdomyolysis (l_pobj) rhabdomyolysis_17\NN\0|and|failure (l_conj) failure_21\NN\66216|acute|renal
D019821_D015658 NONE simvastatin_0\NNP\3676175|,|amiodarone (r_nmod) medications_11\NNS\3247620|simvastatin|patient|human|virus (l_compound) virus_10\NN\9312843|immunodeficiency
D000638_D015658 NONE amiodarone_2\NN\2715941|,|and (r_conj) simvastatin_0\NNP\3676175|,|amiodarone (r_nmod) medications_11\NNS\3247620|simvastatin|patient|human|virus (l_compound) virus_10\NN\9312843|immunodeficiency
9855119
D016559_D005922 NONE fk506_28\NN\0| (r_compound) nephropathy_29\NN\14573196|type|chronic|fk506|(|n|)|,|and|nephropathy (r_conj) findings_17\NNS\7951464|,|normal|n|,|nephropathy (r_conj) nephropathy_9\NN\14573196|,|recurrent|iga|n|findings|.
D016559_D005922 NONE fk506_40\NN\0|type (r_compound) nephropathy_41\NN\14573196|fk506|(|n|) (r_conj) nephropathy_29\NN\14573196|type|chronic|fk506|(|n|)|,|and|nephropathy (r_conj) findings_17\NNS\7951464|,|normal|n|,|nephropathy (r_conj) nephropathy_9\NN\14573196|,|recurrent|iga|n|findings|.
D016559_D007674 NONE fk506_28\NN\0| (r_compound) nephropathy_29\NN\14573196|type|chronic|fk506|(|n|)|,|and|nephropathy
D016559_D007674 NONE fk506_28\NN\0| (r_compound) nephropathy_29\NN\14573196|type|chronic|fk506|(|n|)|,|and|nephropathy (l_conj) nephropathy_41\NN\14573196|fk506|(|n|)
D016559_D007674 NONE fk506_40\NN\0|type (r_compound) nephropathy_41\NN\14573196|fk506|(|n|) (r_conj) nephropathy_29\NN\14573196|type|chronic|fk506|(|n|)|,|and|nephropathy
D016559_D007674 NONE fk506_40\NN\0|type (r_compound) nephropathy_41\NN\14573196|fk506|(|n|)
D016559_D007674 NONE fk506_18\NN\0| (r_compound) nephropathy_19\NN\14573196|type|chronic|fk506
D016559_D007674 NONE fk506_1\NNP\0|chronic (r_compound) nephropathy_2\NN\14573196|fk506
D016559_D007674 NONE fk506_12\NN\0| (r_compound) nephropathy_13\NN\14573196|fk506
D016559_D007674 NONE fk506_12\NN\0| (r_compound) nephropathy_13\NN\14573196|fk506 (r_compound) group_14\NN\2137|the|type|chronic|nephropathy|,|included|, (r_pobj) in_6\IN\13603305|group (r_prep) patients_5\NNS\9898892|in (r_pobj) of_4\IN\0|patients (r_prep) levels_3\NNS\4916342|the|serum|creatinine|of (r_nsubj) were_22\VBD\0|levels|higher|. (l_acomp) higher_24\JJR\0|statistically|than (l_prep) than_25\IN\0|those (l_pobj) those_26\DT\0|in (l_prep) in_27\IN\13603305|group (l_pobj) group_34\NN\2137|the|type|fk506-nephropathy|(|p|) (l_compound) fk506-nephropathy_33\NNP\0|chronic
D016559_D007674 NONE fk506-nephropathy_33\NNP\0|chronic (r_compound) group_34\NN\2137|the|type|fk506-nephropathy|(|p|) (r_pobj) in_27\IN\13603305|group (r_prep) those_26\DT\0|in (r_pobj) than_25\IN\0|those (r_prep) higher_24\JJR\0|statistically|than (r_acomp) were_22\VBD\0|levels|higher|. (l_nsubj) levels_3\NNS\4916342|the|serum|creatinine|of (l_prep) of_4\IN\0|patients (l_pobj) patients_5\NNS\9898892|in (l_prep) in_6\IN\13603305|group (l_pobj) group_14\NN\2137|the|type|chronic|nephropathy|,|included|, (l_compound) nephropathy_13\NN\14573196|fk506
D016559_D007674 NONE fk506-nephropathy_33\NNP\0|chronic
D016559_D007674 NONE fk506_5\NNP\0| (r_compound) nephropathy_6\NN\14573196|chronic|fk506
D016559_D007674 NONE fk506_5\NNP\0| (r_compound) nephropathy_6\NN\14573196|chronic|fk506 (r_nsubj) consists_7\VBZ\2603699|that|nephropathy|primarily|of|, (r_ccomp) demonstrates_2\VBZ\2137132|study|consists|and|suggests|. (l_conj) suggests_21\VBZ\1010118|is (l_ccomp) is_29\VBZ\0|that|nephropathy|condition (l_nsubj) nephropathy_28\NN\14573196|type|chronic|fk506
D016559_D007674 NONE fk506_27\NN\0| (r_compound) nephropathy_28\NN\14573196|type|chronic|fk506 (r_nsubj) is_29\VBZ\0|that|nephropathy|condition (r_ccomp) suggests_21\VBZ\1010118|is (r_conj) demonstrates_2\VBZ\2137132|study|consists|and|suggests|. (l_ccomp) consists_7\VBZ\2603699|that|nephropathy|primarily|of|, (l_nsubj) nephropathy_6\NN\14573196|chronic|fk506
D016559_D007674 NONE fk506_27\NN\0| (r_compound) nephropathy_28\NN\14573196|type|chronic|fk506
D016559_D005923 CID fk506_1\NNP\0|chronic (r_compound) nephropathy_2\NN\14573196|fk506 (r_nsubj) consisted_3\VBD\2603699|nephropathy|of|, (r_ccomp) angiodegeneration_17\NN\0|consisted|arteriolopathy|(|of|;|biopsies|. (l_appos) biopsies_24\NNS\5739043|20|)|,|glomerulosclerosis (l_conj) glomerulosclerosis_29\NN\0|focal|segmental|(|biopsies|)|and|form
D016559_D005355 NONE fk506_1\NNP\0|chronic (r_compound) nephropathy_2\NN\14573196|fk506 (r_nsubj) consisted_3\VBD\2603699|nephropathy|of|, (r_ccomp) angiodegeneration_17\NN\0|consisted|arteriolopathy|(|of|;|biopsies|. (l_appos) biopsies_24\NNS\5739043|20|)|,|glomerulosclerosis (l_conj) glomerulosclerosis_29\NN\0|focal|segmental|(|biopsies|)|and|form (l_conj) form_37\NN\6286395|the|striped|of (l_prep) of_38\IN\0|fibrosis (l_pobj) fibrosis_40\NN\14204950|interstitial|(|biopsies|)
D003404_D007674 NONE creatinine_2\NN\0| (r_compound) levels_3\NNS\4916342|the|serum|creatinine|of (l_prep) of_4\IN\0|patients (l_pobj) patients_5\NNS\9898892|in (l_prep) in_6\IN\13603305|group (l_pobj) group_14\NN\2137|the|type|chronic|nephropathy|,|included|, (l_compound) nephropathy_13\NN\14573196|fk506
D003404_D007674 NONE creatinine_2\NN\0| (r_compound) levels_3\NNS\4916342|the|serum|creatinine|of (r_nsubj) were_22\VBD\0|levels|higher|. (l_acomp) higher_24\JJR\0|statistically|than (l_prep) than_25\IN\0|those (l_pobj) those_26\DT\0|in (l_prep) in_27\IN\13603305|group (l_pobj) group_34\NN\2137|the|type|fk506-nephropathy|(|p|) (l_compound) fk506-nephropathy_33\NNP\0|chronic
8955532
D001920_D006973 NONE bradykinin_4\NN\0|receptors|in (l_prep) in_7\IN\13603305|disruption (l_pobj) disruption_8\NN\1066163|of|during (l_prep) during_15\IN\0|hypertension (l_pobj) hypertension_17\NN\14057371|acute
D001920_D006973 NONE bradykinin_15\NN\0| (r_pobj) of_14\IN\0|bradykinin (r_prep) release_13\NN\3748886|synthesis|/|of (r_pobj) of_10\IN\0|release (r_prep) role_9\NN\719494|the|of (r_dobj) determine_7\VB\0|to|role|activate (l_xcomp) activate_17\VB\1641914|to|receptors|in (l_prep) in_20\IN\13603305|disruption (l_pobj) disruption_21\NN\1066163|of|during (l_prep) during_28\IN\0|hypertension (l_pobj) hypertension_30\NN\14057371|acute
D001920_D006973 NONE bradykinin_23\NN\0| (r_pobj) of_22\IN\0|bradykinin (r_prep) release_21\NN\3748886|the|synthesis|/|of (r_pobj) to_17\IN\0|release (r_prep) related_16\VBN\628491|is|not|to|activate (l_auxpass) is_14\VBZ\0|that|disruption (l_nsubj) disruption_4\NN\1066163|of|during (l_prep) during_11\IN\0|hypertension (l_pobj) hypertension_13\NN\14057371|acute
D003911_D006973 NONE dextran_15\NN\0|labeled (r_pobj) of_11\IN\0|dextran (r_prep) clearance_10\NN\5089947|of|before (l_prep) before_16\IN\0|and|during (l_conj) during_18\IN\0|hypertension (l_pobj) hypertension_23\NN\14057371|induced|acute|in
D010656_D006973 CID phenylephrine_19\NN\2682038| (r_npadvmod) induced_21\VBN\1627355|phenylephrine|- (r_amod) hypertension_23\NN\14057371|induced|acute|in
C065679_D006973 NONE hoe-140_30\NNP\0| (r_conj) vehicle_28\NN\3100490|and|hoe-140|microm (r_pobj) with_27\IN\0|vehicle (r_prep) treated_26\VBN\2376958|with (r_acl) rats_25\NNS\2329401|treated (r_pobj) in_24\IN\13603305|rats (r_prep) hypertension_23\NN\14057371|induced|acute|in
8638206
D001279_D010243 CID atracurium_6\NN\0| (r_pobj) of_5\IN\0|atracurium (r_prep) use_4\NN\407535|prolonged|of|in (r_pobj) after_2\IN\0|use (r_prep) paralysis_1\NN\14557898|persistent|after|.
D001279_D010243 CID besylate_1\NN\0|atracurium|,|nmba|, (r_nsubjpass) associated_22\VBN\628491|besylate|has|also|been|with|,|but|used (l_prep) with_23\IN\0|paralysis (l_pobj) paralysis_25\NN\14557898|persistent
D001279_D010243 CID atracurium_5\NN\0| (r_npadvmod) related_7\VBN\628491|atracurium|- (r_amod) paralysis_8\NN\14557898|related|persisting
D014673_D010243 CID bromide_21\NN\14904359|vecuronium (r_pobj) as_19\IN\14622893|such|bromide (r_prep) nmbas_17\NNS\0|based|as (r_dobj) involved_13\VBN\2676054|reports|have|often|nmbas|,|used|. (l_nsubj) reports_0\NNS\6470073|of|after (l_prep) of_1\IN\0|paralysis (l_pobj) paralysis_3\NN\14557898|persistent
-1_D010243 NONE benzylisoquinolinium_7\NN\0| (r_amod) nmba_8\NNP\0|a|acting|benzylisoquinolinium|eliminated (r_appos) besylate_1\NN\0|atracurium|,|nmba|, (r_nsubjpass) associated_22\VBN\628491|besylate|has|also|been|with|,|but|used (l_prep) with_23\IN\0|paralysis (l_pobj) paralysis_25\NN\14557898|persistent
8953972
D004837_D013345 CID epinephrine_8\NN\14807929| (r_pobj) of_7\IN\0|epinephrine (r_prep) use_6\NN\407535|prehospital|of (r_pobj) with_4\IN\0|use (r_prep) associated_3\VBN\628491|with (r_acl) bleeding_2\NN\14285662|fatal|intracranial|associated|.
D004837_D012128 NONE epinephrine_26\NN\14807929|subcutaneous (r_dobj) administer_24\VB\2436349|to|epinephrine (r_xcomp) led_16\VBD\3202760|onset|paramedics|administer|. (l_nsubj) onset_2\NN\7325190|the|sudden|of (l_prep) of_3\IN\0|distress (l_pobj) distress_5\NN\7494363|respiratory|,|rash
D004837_D005076 NONE epinephrine_26\NN\14807929|subcutaneous (r_dobj) administer_24\VB\2436349|to|epinephrine (r_xcomp) led_16\VBD\3202760|onset|paramedics|administer|. (l_nsubj) onset_2\NN\7325190|the|sudden|of (l_prep) of_3\IN\0|distress (l_pobj) distress_5\NN\7494363|respiratory|,|rash (l_conj) rash_7\JJ\14321469|,|and|history
D004837_D006323 CID epinephrine_0\NN\14807929| (r_nsubj) has_1\VBZ\13888491|epinephrine|role (l_dobj) role_4\NN\719494|a|proven|in (l_prep) in_5\IN\13603305|arrest (l_pobj) arrest_7\NN\88481|cardiac|in
D004837_D004342 NONE epinephrine_0\NN\14807929| (r_nsubj) has_1\VBZ\13888491|epinephrine|role (r_ccomp) use_14\NN\407535|has|;|however|,|by (l_prep) by_15\IN\0|paramedics (l_pobj) paramedics_16\NNS\10398624|in (l_prep) in_17\IN\13603305|patients (l_pobj) patients_18\NNS\9898892|with (l_prep) with_19\IN\0|reaction (l_pobj) reaction_22\NN\13446390|suspected|allergic|and|hypertension
D004837_D006973 NONE epinephrine_0\NN\14807929| (r_nsubj) has_1\VBZ\13888491|epinephrine|role (r_ccomp) use_14\NN\407535|has|;|however|,|by (l_prep) by_15\IN\0|paramedics (l_pobj) paramedics_16\NNS\10398624|in (l_prep) in_17\IN\13603305|patients (l_pobj) patients_18\NNS\9898892|with (l_prep) with_19\IN\0|reaction (l_pobj) reaction_22\NN\13446390|suspected|allergic|and|hypertension (l_conj) hypertension_25\NN\14057371|severe
2334618
D009020_D001049 NONE morphine_17\NN\2707683| (r_pobj) of_16\IN\0|morphine (r_prep) infusion_15\NN\14589223|a|continuous|i.v.|of (r_dobj) receiving_11\VBG\2210855|infusion (r_acl) patients_10\NNS\9898892|five|receiving|mean|and|patients (r_pobj) between_8\IN\0|patients (r_prep) compared_7\VBN\644583|incidence|was|between|. (l_nsubjpass) incidence_1\NN\13821570|the|of (l_prep) of_2\IN\0|apnoea (l_pobj) apnoea_5\NN\0|postoperative|respiratory
D002045_D001049 NONE bupivacaine_34\NN\0|% (r_pobj) of_31\IN\0|bupivacaine (r_prep) infusion_30\NN\14589223|a|continuous|extradural|of (r_dobj) receiving_26\VBG\2210855|infusion (r_acl) patients_25\NNS\9898892|five|receiving|mean|in (r_conj) patients_10\NNS\9898892|five|receiving|mean|and|patients (r_pobj) between_8\IN\0|patients (r_prep) compared_7\VBN\644583|incidence|was|between|. (l_nsubjpass) incidence_1\NN\13821570|the|of (l_prep) of_2\IN\0|apnoea (l_pobj) apnoea_5\NN\0|postoperative|respiratory
D009020_D020181 CID morphine_25\NN\2707683| (r_compound) infusion_26\NN\14589223|a|morphine (r_dobj) had_23\VBD\0|who|infusion (r_relcl) patients_21\NNS\9898892|had (r_pobj) in_20\IN\13603305|patients (r_prep) occurred_17\VBD\0|obstructive|frequently|in|. (l_nsubj) obstructive_1\JJ\0|both|(|p (l_appos) p_3\NN\14622893|0.05|)|and|apnoea (l_conj) apnoea_10\NN\0|central|(|p|)
D009020_D020182 CID morphine_25\NN\2707683| (r_compound) infusion_26\NN\14589223|a|morphine (r_dobj) had_23\VBD\0|who|infusion (r_relcl) patients_21\NNS\9898892|had (r_pobj) in_20\IN\13603305|patients (r_prep) occurred_17\VBD\0|obstructive|frequently|in|. (l_nsubj) obstructive_1\JJ\0|both|(|p (l_appos) p_3\NN\14622893|0.05|)|and|apnoea (l_conj) apnoea_10\NN\0|central|(|p|)
D009020_D013610 NONE morphine_26\NN\2707683| (r_compound) infusion_27\NN\14589223|morphine (r_compound) group_28\NN\2137|the|infusion (r_pobj) in_24\IN\13603305|group (r_prep) beats_17\NNS\8289449|ventricular|ectopic|(|p|)|in (r_conj) tachyarrhythmias_7\NNS\0|(|p|)|and|beats
D009020_D018879 CID morphine_26\NN\2707683| (r_compound) infusion_27\NN\14589223|morphine (r_compound) group_28\NN\2137|the|infusion (r_pobj) in_24\IN\13603305|group (r_prep) beats_17\NNS\8289449|ventricular|ectopic|(|p|)|in
3997294
D000638_D010996 CID amiodarone_9\NN\2715941| (r_compound) therapy_10\NN\657604|amiodarone (r_pobj) during_8\IN\0|therapy (r_prep) effusion_5\NN\6880249|pleural|and|neuropathy|during
D000638_D010490 CID amiodarone_9\NN\2715941| (r_compound) therapy_10\NN\657604|amiodarone (r_pobj) during_8\IN\0|therapy (r_prep) effusion_5\NN\6880249|pleural|and|neuropathy|during
D000638_D009422 NONE amiodarone_9\NN\2715941| (r_compound) therapy_10\NN\657604|amiodarone (r_pobj) during_8\IN\0|therapy (r_prep) effusion_5\NN\6880249|pleural|and|neuropathy|during (l_conj) neuropathy_7\NN\14204950|
D000638_D002318 NONE amiodarone_11\NN\2715941|(|dose|,|for (r_pobj) with_10\IN\0|amiodarone (r_prep) treated_9\VBN\2376958|patient|was|with|. (l_nsubjpass) patient_1\NN\9898892|a|with|and|pacemaker (l_prep) with_2\IN\0|disease (l_pobj) disease_4\NN\14061805|sinuatrial
D000638_D013617 NONE amiodarone_11\NN\2715941|(|dose|,|for (l_prep) for_28\IN\0|control (l_pobj) control_29\NN\5190804|of (l_prep) of_30\IN\0|tachyarrhythmias (l_pobj) tachyarrhythmias_32\NNS\0|supraventricular
D000638_D011014 CID amiodarone_14\NN\2715941| (r_compound) pneumonitis_15\NN\14336539|amiodarone
D000638_D011014 CID amiodarone_20\NN\2715941| (r_pobj) of_19\IN\0|amiodarone (r_prep) withdrawal_18\NN\7206096|immediate|of|,|and|prompt (r_dobj) indicates_7\VBZ\952524|review|need|,|withdrawal|. (l_dobj) need_9\NN\13920835|the|for (l_prep) for_10\IN\0|diagnosis (l_pobj) diagnosis_12\NN\152018|early|of (l_prep) of_13\IN\0|pneumonitis (l_pobj) pneumonitis_15\NN\14336539|amiodarone
D013256_D011014 NONE steroid_26\NN\14727670| (r_compound) therapy_27\NN\657604|continued|steroid (r_conj) prompt_23\JJ\7011209|but|therapy|ensure (r_conj) withdrawal_18\NN\7206096|immediate|of|,|and|prompt (r_dobj) indicates_7\VBZ\952524|review|need|,|withdrawal|. (l_dobj) need_9\NN\13920835|the|for (l_prep) for_10\IN\0|diagnosis (l_pobj) diagnosis_12\NN\152018|early|of (l_prep) of_13\IN\0|pneumonitis (l_pobj) pneumonitis_15\NN\14336539|amiodarone
9869257
C087567_D000647 NONE pg-9_8\NNP\0|mg/kg|, (r_nsubj) administered_18\VBN\2436349|in|,|pg-9|before|,|prevented|. (l_conj) prevented_26\VBN\0|amnesia (l_dobj) amnesia_27\NN\5669934|induced
C087567_D000647 NONE pg-9_6\NNP\0|20 (r_nmod) microg_11\NN\0|pg-9|per|,|i.c.v.|) (r_nsubj) was_17\VBD\0|in|,|microg|also|able|,|demonstrating|. (l_acomp) able_19\JJ\0|prevent (l_xcomp) prevent_21\VB\0|to|amnesia (l_dobj) amnesia_25\NN\5669934|induced
D012601_D000647 CID scopolamine_36\NN\14712692|both|the|non|selective|antimuscarinic|drug|and|antagonist (r_pobj) by_29\IN\0|scopolamine (r_agent) induced_28\VBN\1627355|by (r_acl) amnesia_27\NN\5669934|induced
C098725_D000647 CID s-(-)-et-126_41\NNP\0| (r_appos) antagonist_40\NN\7846|the|m1-selective|s-(-)-et-126 (r_conj) scopolamine_36\NN\14712692|both|the|non|selective|antimuscarinic|drug|and|antagonist (r_pobj) by_29\IN\0|scopolamine (r_agent) induced_28\VBN\1627355|by (r_acl) amnesia_27\NN\5669934|induced
10526274
C056507_D002289 NONE gemcitabine_0\NNP\0|plus|vinorelbine (l_conj) vinorelbine_2\NN\0|in (l_prep) in_3\IN\13603305|patients (l_pobj) patients_8\NNS\9898892|nonsmall|carcinoma (l_compound) carcinoma_7\NN\14239918|lung
C056507_D002289 NONE gem_12\NNP\2743547|and|vnb (r_pobj) of_11\IN\0|gem (r_prep) combination_10\NN\7951464|the|of|in (l_prep) in_15\IN\13603305|patients (l_pobj) patients_17\NNS\9898892|elderly|with (l_prep) with_18\IN\0|nsclc (l_pobj) nsclc_20\NNP\0|advanced|or|those
C030852_D002289 NONE vinorelbine_2\NN\0|in (l_prep) in_3\IN\13603305|patients (l_pobj) patients_8\NNS\9898892|nonsmall|carcinoma (l_compound) carcinoma_7\NN\14239918|lung
C030852_D002289 NONE vnb_14\NNP\0| (r_conj) gem_12\NNP\2743547|and|vnb (r_pobj) of_11\IN\0|gem (r_prep) combination_10\NN\7951464|the|of|in (l_prep) in_15\IN\13603305|patients (l_pobj) patients_17\NNS\9898892|elderly|with (l_prep) with_18\IN\0|nsclc (l_pobj) nsclc_20\NNP\0|advanced|or|those
D002945_D002289 NONE cisplatin_20\NN\0| (r_dobj) receive_19\VB\2210855|who|can|not|cisplatin (r_relcl) years_11\NNS\15144371|70|or|older|or|patients|receive (r_npadvmod) age_9\NN\4916342|gemcitabine|years|. (l_nsubj) gemcitabine_0\NNP\0|plus|vinorelbine (l_conj) vinorelbine_2\NN\0|in (l_prep) in_3\IN\13603305|patients (l_pobj) patients_8\NNS\9898892|nonsmall|carcinoma (l_compound) carcinoma_7\NN\14239918|lung
D002945_D002289 NONE cisplatin_28\NN\0| (r_dobj) receiving_27\VBG\2210855|cisplatin (r_pcomp) to_26\IN\0|receiving (r_prep) contraindication_25\NN\5819149|some|to (r_pobj) with_23\IN\0|contraindication (r_prep) those_22\DT\0|with (r_conj) nsclc_20\NNP\0|advanced|or|those
D002945_D002289 NONE cisplatin_33\NN\0| (r_dobj) receiving_32\VBG\2210855|cisplatin (r_pcomp) to_31\IN\0|receiving (r_prep) contraindication_30\NN\5819149|some|to (r_dobj) had_28\VBD\0|who|contraindication (r_conj) were_21\VBD\0|11|age|but|had (r_conj) /=_16\NFP\0|years|and|were (r_punct) included_8\VBN\0|patients|were|,|were|/=|. (l_nsubjpass) patients_3\NNS\9898892|nine|with (l_prep) with_4\IN\0|nsclc (l_pobj) nsclc_6\NNP\0|advanced
C056507_D064420 NONE gem_1\NNP\2743547| (r_nsubj) obtain_4\VB\2210855|(|gem|)|may|rate|,|with|. (l_prep) with_17\IN\0|toxicity (l_pobj) toxicity_19\NN\13576101|acceptable|and|improvement|in
C056507_D064420 NONE gem_12\NNP\2743547|and|vnb (r_pobj) of_11\IN\0|gem (r_prep) combination_10\NN\7951464|the|of|in (r_pobj) of_8\IN\0|combination (r_prep) efficacy_5\NN\5199286|the|and|toxicity|of (l_conj) toxicity_7\NN\13576101|
C030852_D064420 NONE vnb_14\NNP\0| (r_conj) gem_12\NNP\2743547|and|vnb (r_pobj) of_11\IN\0|gem (r_prep) combination_10\NN\7951464|the|of|in (r_pobj) of_8\IN\0|combination (r_prep) efficacy_5\NN\5199286|the|and|toxicity|of (l_conj) toxicity_7\NN\13576101|
D002945_D064420 NONE cisplatin_28\NN\0| (r_dobj) receiving_27\VBG\2210855|cisplatin (r_pcomp) to_26\IN\0|receiving (r_prep) contraindication_25\NN\5819149|some|to (r_pobj) with_23\IN\0|contraindication (r_prep) those_22\DT\0|with (r_conj) nsclc_20\NNP\0|advanced|or|those (r_pobj) with_18\IN\0|nsclc (r_prep) patients_17\NNS\9898892|elderly|with (r_pobj) in_15\IN\13603305|patients (r_prep) combination_10\NN\7951464|the|of|in (r_pobj) of_8\IN\0|combination (r_prep) efficacy_5\NN\5199286|the|and|toxicity|of (l_conj) toxicity_7\NN\13576101|
20098969
D008694_D001145 NONE methamphetamine_0\NN\2704153| (r_nsubj) is_1\VBZ\0|methamphetamine|stimulant|. (l_attr) stimulant_7\NN\5816287|a|addictive|,|powerful|increases (l_relcl) increases_9\VBZ\13576355|that|wakefulness|and|produce (l_conj) produce_16\VB\7555863|can|effects (l_dobj) effects_18\NNS\13245626|other|as (l_prep) as_20\IN\14622893|such|dysrhythmias (l_pobj) dysrhythmias_22\NNS\0|cardiac|,|hypertension
D008694_D006973 NONE methamphetamine_0\NN\2704153| (r_nsubj) is_1\VBZ\0|methamphetamine|stimulant|. (l_attr) stimulant_7\NN\5816287|a|addictive|,|powerful|increases (l_relcl) increases_9\VBZ\13576355|that|wakefulness|and|produce (l_conj) produce_16\VB\7555863|can|effects (l_dobj) effects_18\NNS\13245626|other|as (l_prep) as_20\IN\14622893|such|dysrhythmias (l_pobj) dysrhythmias_22\NNS\0|cardiac|,|hypertension (l_conj) hypertension_24\NN\14057371|,|hallucinations
D008694_D006212 NONE methamphetamine_0\NN\2704153| (r_nsubj) is_1\VBZ\0|methamphetamine|stimulant|. (l_attr) stimulant_7\NN\5816287|a|addictive|,|powerful|increases (l_relcl) increases_9\VBZ\13576355|that|wakefulness|and|produce (l_conj) produce_16\VB\7555863|can|effects (l_dobj) effects_18\NNS\13245626|other|as (l_prep) as_20\IN\14622893|such|dysrhythmias (l_pobj) dysrhythmias_22\NNS\0|cardiac|,|hypertension (l_conj) hypertension_24\NN\14057371|,|hallucinations (l_conj) hallucinations_26\NNS\14376855|,|and|behavior
D008694_D001523 NONE methamphetamine_0\NN\2704153| (r_nsubj) is_1\VBZ\0|methamphetamine|stimulant|. (l_attr) stimulant_7\NN\5816287|a|addictive|,|powerful|increases (l_relcl) increases_9\VBZ\13576355|that|wakefulness|and|produce (l_conj) produce_16\VB\7555863|can|effects (l_dobj) effects_18\NNS\13245626|other|as (l_prep) as_20\IN\14622893|such|dysrhythmias (l_pobj) dysrhythmias_22\NNS\0|cardiac|,|hypertension (l_conj) hypertension_24\NN\14057371|,|hallucinations (l_conj) hallucinations_26\NNS\14376855|,|and|behavior (l_conj) behavior_30\NN\407535|violent
D008694_D014987 NONE methamphetamine_3\NN\2704153| (r_dobj) abusing_2\VBG\2514187|methamphetamine (r_acl) patients_1\NNS\9898892|dental|abusing (r_nsubj) present_5\VB\28270|patients|can|with|. (l_prep) with_6\IN\0|hygiene (l_pobj) hygiene_9\NN\14494893|poor|oral|,|xerostomia (l_conj) xerostomia_11\NN\14536438|,|caries
D008694_D003731 CID methamphetamine_3\NN\2704153| (r_dobj) abusing_2\VBG\2514187|methamphetamine (r_acl) patients_1\NNS\9898892|dental|abusing (r_nsubj) present_5\VB\28270|patients|can|with|. (l_prep) with_6\IN\0|hygiene (l_pobj) hygiene_9\NN\14494893|poor|oral|,|xerostomia (l_conj) xerostomia_11\NN\14536438|,|caries (l_conj) caries_14\NNS\13456715|rampant|(|mouth|,|and|wear
D008694_D003731 CID methamphetamine_5\NN\2704153| (r_pobj) of_4\IN\0|methamphetamine (r_prep) use_3\NN\407535|her|of|for (r_dobj) reported_1\VBD\831651|she|use|and|experienced|. (l_conj) experienced_12\VBN\2108377|had|not|episodes|started (l_dobj) episodes_16\NNS\7283608|any|major|carious
D008694_-1 NONE methamphetamine_3\NN\2704153| (r_dobj) abusing_2\VBG\2514187|methamphetamine (r_acl) patients_1\NNS\9898892|dental|abusing (r_nsubj) present_5\VB\28270|patients|can|with|. (l_prep) with_6\IN\0|hygiene (l_pobj) hygiene_9\NN\14494893|poor|oral|,|xerostomia (l_conj) xerostomia_11\NN\14536438|,|caries (l_conj) caries_14\NNS\13456715|rampant|(|mouth|,|and|wear (l_appos) mouth_18\NN\5610008|"|meth|"|)
D008694_-1 NONE methamphetamines_23\NNS\2704153| (r_dobj) abusing_22\VBG\2514187|who|may|be|methamphetamines (r_relcl) patients_18\NNS\9898892|abusing (r_dobj) manage_17\VBP\2524171|patients (r_conj) recognize_15\VBP\686447|practitioners|and|manage (r_ccomp) help_12\VB\407535|to|recognize (r_advcl) presented_10\VBN\2137132|case|was|help|. (l_nsubjpass) case_2\NN\7283608|this|clinical|showing (l_acl) showing_3\VBG\6887726|manifestations (l_dobj) manifestations_5\NNS\7321772|oral|of (l_prep) of_6\IN\0|mouth (l_pobj) mouth_8\NN\5610008|meth
D008694_D057085 NONE methamphetamine_3\NN\2704153| (r_dobj) abusing_2\VBG\2514187|methamphetamine (r_acl) patients_1\NNS\9898892|dental|abusing (r_nsubj) present_5\VB\28270|patients|can|with|. (l_prep) with_6\IN\0|hygiene (l_pobj) hygiene_9\NN\14494893|poor|oral|,|xerostomia (l_conj) xerostomia_11\NN\14536438|,|caries (l_conj) caries_14\NNS\13456715|rampant|(|mouth|,|and|wear (l_conj) wear_25\NN\14561618|excessive|tooth
3425586
D003622_D000743 CID dapsone_0\NN\2716205| (r_npadvmod) associated_2\VBN\628491|dapsone|- (r_amod) anemia_6\NN\14189204|associated|heinz|body|hemolytic|in|.
D003622_D000743 CID dapsone_23\NN\2716205|day|) (r_pobj) of_22\IN\0|dapsone (r_prep) dose_21\NN\3740161|a|of|associated (r_dobj) taking_19\VBG\37396|while|dose (r_advcl) developed_12\VBD\1753788|woman|anemia|taking|. (l_dobj) anemia_17\NN\14189204|a|heinz|body|hemolytic
D003622_D000743 CID dapsone_21\NN\2716205| (r_nsubj) cause_24\VB\7323922|since|dapsone|does|not|anemia|at (l_dobj) anemia_26\NN\14189204|hemolytic
D003622_D007918 NONE dapsone_23\NN\2716205|day|) (r_pobj) of_22\IN\0|dapsone (r_prep) dose_21\NN\3740161|a|of|associated (r_dobj) taking_19\VBG\37396|while|dose (r_advcl) developed_12\VBD\1753788|woman|anemia|taking|. (l_nsubj) woman_2\NN\9605289|a|cambodian|with|leprosy (l_conj) leprosy_11\NN\14127211|
D003622_D006461 NONE dapsone_23\NN\2716205|day|) (r_pobj) of_22\IN\0|dapsone (r_prep) dose_21\NN\3740161|a|of|associated (l_acl) associated_32\VBN\628491|not|usually|with (l_prep) with_33\IN\0|hemolysis (l_pobj) hemolysis_35\NN\13509528|clinical
354896
D008012_D006323 CID lidocaine_0\NN\3681148| (r_npadvmod) induced_2\VBN\1627355|lidocaine|- (r_amod) asystole_4\NN\14204950|induced|cardiac|.
D008012_D003866 NONE lidocaine_8\NN\3681148| (r_pobj) of_7\IN\0|lidocaine (r_prep) bolus_6\NN\13899404|a|single|50-mg|of|in (r_pobj) of_2\IN\0|bolus (r_prep) administration_1\NN\1133281|intravenous|of (r_nsubj) resulted_15\VBD\2633881|administration|in|. (l_prep) in_16\IN\13603305|depression (l_pobj) depression_18\NN\14373582|profound|of
D008012_D001919 NONE lidocaine_29\NN\3681148| (r_pobj) to_28\IN\0|lidocaine (r_prep) idiosyncrasy_27\NN\4763925|a|true|to (r_dobj) represented_24\VBD\2664769|,|thus|,|this|probably|idiosyncrasy|. (r_conj) had_2\VBD\0|patient|conditions|;|and|represented (l_dobj) conditions_6\NNS\14512817|no|apparent|associated|predisposed (l_relcl) predisposed_10\VBN\680841|which|might|have|him|to (l_prep) to_12\IN\0|development (l_pobj) development_14\NN\248977|the|of (l_prep) of_15\IN\0|bradyarrhythmias (l_pobj) bradyarrhythmias_16\NNS\0|
2670794
D000809_D011665 NONE angiotensin_5\NN\4522421|converting (l_acl) converting_6\VBG\126264|enzyme|on (l_prep) on_11\IN\0|insufficiency (l_pobj) insufficiency_15\NN\14462946|pulmonary
D000809_D011665 NONE angiotensin_11\NN\4522421|converting (r_pobj) of_10\IN\0|angiotensin (r_prep) inhibitor_9\NN\20090|an|of (r_appos) injection_0\NN\320852|of|(|mg/kg|)|,|inhibitor|, (r_nsubj) reduced_18\VBD\441445|injection|insufficiency|. (l_dobj) insufficiency_23\NN\14462946|pulmonary|in
D000809_D051437 NONE angiotensin_5\NN\4522421|converting (l_acl) converting_6\VBG\126264|enzyme|on (l_prep) on_11\IN\0|insufficiency (l_pobj) insufficiency_15\NN\14462946|pulmonary
D000809_D051437 NONE angiotensin_11\NN\4522421|converting (r_pobj) of_10\IN\0|angiotensin (r_prep) inhibitor_9\NN\20090|an|of (r_appos) injection_0\NN\320852|of|(|mg/kg|)|,|inhibitor|, (r_nsubj) reduced_18\VBD\441445|injection|insufficiency|. (l_dobj) insufficiency_23\NN\14462946|pulmonary|in
D000809_D004211 NONE angiotensin_5\NN\4522421|converting (r_pobj) of_4\IN\0|angiotensin (r_prep) inhibitor_3\NN\20090|an|of (r_pobj) of_1\IN\0|inhibitor (r_prep) effects_0\NNS\13245626|of|due|. (l_amod) due_16\IN\5174653|to|coagulation (l_pobj) coagulation_19\NN\13518963|intravascular|in
D002216_D011665 NONE captopril_9\NNP\2673637| (r_appos) enzyme_7\NN\14723628|(|captopril|) (r_dobj) converting_6\VBG\126264|enzyme|on (l_prep) on_11\IN\0|insufficiency (l_pobj) insufficiency_15\NN\14462946|pulmonary
D002216_D011665 NONE captopril_2\NNP\2673637| (r_pobj) of_1\IN\0|captopril (r_prep) injection_0\NN\320852|of|(|mg/kg|)|,|inhibitor|, (r_nsubj) reduced_18\VBD\441445|injection|insufficiency|. (l_dobj) insufficiency_23\NN\14462946|pulmonary|in
D002216_D051437 NONE captopril_9\NNP\2673637| (r_appos) enzyme_7\NN\14723628|(|captopril|) (r_dobj) converting_6\VBG\126264|enzyme|on (l_prep) on_11\IN\0|insufficiency (l_pobj) insufficiency_15\NN\14462946|pulmonary
D002216_D051437 NONE captopril_2\NNP\2673637| (r_pobj) of_1\IN\0|captopril (r_prep) injection_0\NN\320852|of|(|mg/kg|)|,|inhibitor|, (r_nsubj) reduced_18\VBD\441445|injection|insufficiency|. (l_dobj) insufficiency_23\NN\14462946|pulmonary|in
D002216_D004211 NONE captopril_9\NNP\2673637| (r_appos) enzyme_7\NN\14723628|(|captopril|) (r_dobj) converting_6\VBG\126264|enzyme|on (r_acl) angiotensin_5\NN\4522421|converting (r_pobj) of_4\IN\0|angiotensin (r_prep) inhibitor_3\NN\20090|an|of (r_pobj) of_1\IN\0|inhibitor (r_prep) effects_0\NNS\13245626|of|due|. (l_amod) due_16\IN\5174653|to|coagulation (l_pobj) coagulation_19\NN\13518963|intravascular|in
D014148_D004211 CID acid_14\NN\14818238|tranexamic|amca (r_conj) thrombin_11\NN\14735953|and|acid (r_pobj) of_10\IN\0|thrombin (r_prep) injection_9\NN\320852|of|in (r_pobj) by_8\IN\0|injection (r_prep) induction_0\NN\7450842|of|by (l_prep) of_1\IN\0|coagulation (l_pobj) coagulation_3\NN\13518963|intravascular|and|inhibition
D014148_D004211 CID amca_16\NNP\0|(|) (r_appos) acid_14\NN\14818238|tranexamic|amca (r_conj) thrombin_11\NN\14735953|and|acid (r_pobj) of_10\IN\0|thrombin (r_prep) injection_9\NN\320852|of|in (r_pobj) by_8\IN\0|injection (r_prep) induction_0\NN\7450842|of|by (l_prep) of_1\IN\0|coagulation (l_pobj) coagulation_3\NN\13518963|intravascular|and|inhibition
D014148_D011665 NONE acid_14\NN\14818238|tranexamic|amca (r_conj) thrombin_11\NN\14735953|and|acid (r_pobj) of_10\IN\0|thrombin (r_prep) injection_9\NN\320852|of|in (r_pobj) by_8\IN\0|injection (r_prep) induction_0\NN\7450842|of|by (r_nsubj) gives_21\VBZ\5020358|induction|rise|resembling|. (l_dobj) rise_22\NN\7324673|to (l_prep) to_23\IN\0|insufficiency (l_pobj) insufficiency_27\NN\14462946|pulmonary
D014148_D011665 NONE amca_16\NNP\0|(|) (r_appos) acid_14\NN\14818238|tranexamic|amca (r_conj) thrombin_11\NN\14735953|and|acid (r_pobj) of_10\IN\0|thrombin (r_prep) injection_9\NN\320852|of|in (r_pobj) by_8\IN\0|injection (r_prep) induction_0\NN\7450842|of|by (r_nsubj) gives_21\VBZ\5020358|induction|rise|resembling|. (l_dobj) rise_22\NN\7324673|to (l_prep) to_23\IN\0|insufficiency (l_pobj) insufficiency_27\NN\14462946|pulmonary
D014148_D051437 NONE acid_14\NN\14818238|tranexamic|amca (r_conj) thrombin_11\NN\14735953|and|acid (r_pobj) of_10\IN\0|thrombin (r_prep) injection_9\NN\320852|of|in (r_pobj) by_8\IN\0|injection (r_prep) induction_0\NN\7450842|of|by (r_nsubj) gives_21\VBZ\5020358|induction|rise|resembling|. (l_dobj) rise_22\NN\7324673|to (l_prep) to_23\IN\0|insufficiency (l_pobj) insufficiency_27\NN\14462946|pulmonary
D014148_D051437 NONE amca_16\NNP\0|(|) (r_appos) acid_14\NN\14818238|tranexamic|amca (r_conj) thrombin_11\NN\14735953|and|acid (r_pobj) of_10\IN\0|thrombin (r_prep) injection_9\NN\320852|of|in (r_pobj) by_8\IN\0|injection (r_prep) induction_0\NN\7450842|of|by (r_nsubj) gives_21\VBZ\5020358|induction|rise|resembling|. (l_dobj) rise_22\NN\7324673|to (l_prep) to_23\IN\0|insufficiency (l_pobj) insufficiency_27\NN\14462946|pulmonary
D014148_D014947 NONE acid_14\NN\14818238|tranexamic|amca (r_conj) thrombin_11\NN\14735953|and|acid (r_pobj) of_10\IN\0|thrombin (r_prep) injection_9\NN\320852|of|in (r_pobj) by_8\IN\0|injection (r_prep) induction_0\NN\7450842|of|by (r_nsubj) gives_21\VBZ\5020358|induction|rise|resembling|. (l_advcl) resembling_28\VBG\2657219|occurring (l_ccomp) occurring_30\VBG\0|that|after (l_prep) after_31\IN\0|trauma (l_pobj) trauma_32\NN\14052046|or|sepsis|in
D014148_D014947 NONE amca_16\NNP\0|(|) (r_appos) acid_14\NN\14818238|tranexamic|amca (r_conj) thrombin_11\NN\14735953|and|acid (r_pobj) of_10\IN\0|thrombin (r_prep) injection_9\NN\320852|of|in (r_pobj) by_8\IN\0|injection (r_prep) induction_0\NN\7450842|of|by (r_nsubj) gives_21\VBZ\5020358|induction|rise|resembling|. (l_advcl) resembling_28\VBG\2657219|occurring (l_ccomp) occurring_30\VBG\0|that|after (l_prep) after_31\IN\0|trauma (l_pobj) trauma_32\NN\14052046|or|sepsis|in
D014148_D018805 NONE acid_14\NN\14818238|tranexamic|amca (r_conj) thrombin_11\NN\14735953|and|acid (r_pobj) of_10\IN\0|thrombin (r_prep) injection_9\NN\320852|of|in (r_pobj) by_8\IN\0|injection (r_prep) induction_0\NN\7450842|of|by (r_nsubj) gives_21\VBZ\5020358|induction|rise|resembling|. (l_advcl) resembling_28\VBG\2657219|occurring (l_ccomp) occurring_30\VBG\0|that|after (l_prep) after_31\IN\0|trauma (l_pobj) trauma_32\NN\14052046|or|sepsis|in (l_conj) sepsis_34\NN\14174549|
D014148_D018805 NONE amca_16\NNP\0|(|) (r_appos) acid_14\NN\14818238|tranexamic|amca (r_conj) thrombin_11\NN\14735953|and|acid (r_pobj) of_10\IN\0|thrombin (r_prep) injection_9\NN\320852|of|in (r_pobj) by_8\IN\0|injection (r_prep) induction_0\NN\7450842|of|by (r_nsubj) gives_21\VBZ\5020358|induction|rise|resembling|. (l_advcl) resembling_28\VBG\2657219|occurring (l_ccomp) occurring_30\VBG\0|that|after (l_prep) after_31\IN\0|trauma (l_pobj) trauma_32\NN\14052046|or|sepsis|in (l_conj) sepsis_34\NN\14174549|
D014508_D007674 NONE urea_9\NN\14727670|serum (r_pobj) in_7\IN\13603305|urea|and|in (r_prep) increase_6\NN\13576355|an|in (r_pobj) by_4\IN\0|increase (r_agent) reflected_3\VBN\923793|as|by (r_advcl) damage_1\NN\7296428|renal|reflected
D002216_D007674 NONE captopril_17\NNP\2673637| (r_pobj) by_16\IN\0|captopril (r_agent) prevented_15\VBN\0|damage|was|by|. (l_nsubjpass) damage_1\NN\7296428|renal|reflected
D002216_D007674 NONE captopril_0\NNP\2673637| (r_nsubj) reduce_8\VB\441445|captopril|may|,|by|,|increase|,|diminishing|. (l_advcl) diminishing_26\VBG\169651|thereby|aggregation|,|with (l_prep) with_36\IN\0|result (l_pobj) result_38\NN\34213|the|deposited (l_acl) deposited_44\VBN\1340439|that|fibrin|will|be|and|produced (l_conj) produced_52\VBN\1617192|damage|will|be (l_nsubjpass) damage_49\NN\7296428|less|kidney
9931093
D016559_D006973 CID 506-induced_3\JJ\0|mechanisms (r_nummod) hypertension_4\NN\14057371|506-induced|in|.
D016559_D006973 CID 506_5\CD\0| (r_nummod) fk_4\NNP\0|506 (r_pobj) of_3\IN\0|fk (r_prep) utility_2\NN\8186047|the|clinical|of (r_nsubjpass) complicated_7\VBN\126264|utility|is|by|. (l_agent) by_8\IN\0|hypertension (l_pobj) hypertension_10\NN\14057371|substantial|and|nephrotoxicity
D016559_D006973 CID 506-induced_6\JJ\0| (r_compound) hypertension_7\NN\14057371|fk|506-induced
D016559_D006973 CID 506_16\CD\0| (r_nummod) fk_15\NNP\0|506 (r_pobj) of_14\IN\0|fk (r_prep) effects_13\NNS\13245626|the|chronic|of|on (r_dobj) studied_10\VBD\0|clarify|,|we|effects|expression (l_advcl) clarify_1\VB\939277|to|mechanisms (l_dobj) mechanisms_3\NNS\13446390|the|of (l_prep) of_4\IN\0|hypertension (l_pobj) hypertension_7\NN\14057371|fk|506-induced
D016559_D006973 CID 506-induced_17\JJ\0| (r_nummod) fk_16\NNP\0|506-induced (r_poss) hypertension_18\NN\14057371|fk|in
D016559_D006973 CID 506-induced_4\JJ\0| (r_nummod) hypertension_5\NN\14057371|fk|506-induced|in
D016559_D007674 NONE 506_5\CD\0| (r_nummod) fk_4\NNP\0|506 (r_pobj) of_3\IN\0|fk (r_prep) utility_2\NN\8186047|the|clinical|of (r_nsubjpass) complicated_7\VBN\126264|utility|is|by|. (l_agent) by_8\IN\0|hypertension (l_pobj) hypertension_10\NN\14057371|substantial|and|nephrotoxicity (l_conj) nephrotoxicity_12\NN\0|
D009569_D006973 NONE oxide_44\NN\14818238| (r_compound) synthase_45\NN\0|,|the|endothelial|nitric|oxide|(|activity|. (r_conj) expression_27\NN\4679549|,|the|of|et-1|and|converting|synthase (r_dobj) studied_10\VBD\0|clarify|,|we|effects|expression (l_advcl) clarify_1\VB\939277|to|mechanisms (l_dobj) mechanisms_3\NNS\13446390|the|of (l_prep) of_4\IN\0|hypertension (l_pobj) hypertension_7\NN\14057371|fk|506-induced
C079574_D006973 NONE 139317_14\CD\0| (r_nummod) fr_13\NNP\14625458|139317|on (l_prep) on_15\IN\0|hypertension (l_pobj) hypertension_18\NN\14057371|fk|in
1919871
D001241_D007681 CID aspirin_20\NN\2707683|and|paracetamol|in (r_pobj) with_19\IN\0|aspirin (r_prep) treatment_18\NN\654885|continuous|term|with (r_pobj) during_13\IN\0|treatment (r_prep) developed_12\VBN\1753788|during (r_acl) ability_11\NN\4723816|a|decreased|urinary|concentrating|developed (r_conj) necrosis_2\NN\11444117|renal|papillary|(|rpn|)|and|ability|.
D001241_D007681 CID aspirin_20\NN\2707683|and|paracetamol|in (r_pobj) with_19\IN\0|aspirin (r_prep) treatment_18\NN\654885|continuous|term|with (r_pobj) during_13\IN\0|treatment (r_prep) developed_12\VBN\1753788|during (r_acl) ability_11\NN\4723816|a|decreased|urinary|concentrating|developed (r_conj) necrosis_2\NN\11444117|renal|papillary|(|rpn|)|and|ability|. (l_appos) rpn_4\NNP\0|
D000082_D007681 CID paracetamol_22\JJ\0| (r_conj) aspirin_20\NN\2707683|and|paracetamol|in (r_pobj) with_19\IN\0|aspirin (r_prep) treatment_18\NN\654885|continuous|term|with (r_pobj) during_13\IN\0|treatment (r_prep) developed_12\VBN\1753788|during (r_acl) ability_11\NN\4723816|a|decreased|urinary|concentrating|developed (r_conj) necrosis_2\NN\11444117|renal|papillary|(|rpn|)|and|ability|.
D000082_D007681 CID paracetamol_22\JJ\0| (r_conj) aspirin_20\NN\2707683|and|paracetamol|in (r_pobj) with_19\IN\0|aspirin (r_prep) treatment_18\NN\654885|continuous|term|with (r_pobj) during_13\IN\0|treatment (r_prep) developed_12\VBN\1753788|during (r_acl) ability_11\NN\4723816|a|decreased|urinary|concentrating|developed (r_conj) necrosis_2\NN\11444117|renal|papillary|(|rpn|)|and|ability|. (l_appos) rpn_4\NNP\0|
18996674
D004837_D011317 NONE epinephrine_1\NN\14807929|intracavernous|:|treatment|. (l_appos) treatment_6\NN\654885|a|invasive|for (l_prep) for_7\IN\0|priapism (l_pobj) priapism_8\NN\14204950|in
D003042_D011317 CID cocaine_9\NN\3492717| (r_compound) user_10\NN\7846|an|admitted|frequent|cocaine (r_appos) man_4\NN\9605289|a|old|,|user|, (r_nsubj) presented_12\VBN\2137132|man|to|on|. (l_prep) on_20\IN\0|occasions (l_pobj) occasions_23\NNS\5983801|two|separate|with (l_prep) with_24\IN\0|history (l_pobj) history_26\NN\15120823|a|of|after (l_prep) of_27\IN\0|priapism (l_pobj) priapism_28\NN\14204950|
D003042_D011317 CID cocaine_30\NN\3492717| (r_compound) use_31\NN\407535|cocaine (r_pobj) after_29\IN\0|use (r_prep) history_26\NN\15120823|a|of|after (l_prep) of_27\IN\0|priapism (l_pobj) priapism_28\NN\14204950|
8386779
D017693_D004414 NONE bicarbonate_1\NN\14798450|sodium (r_nsubj) alleviates_2\VBZ\205885|bicarbonate|pain|induced|. (l_dobj) pain_4\NN\14299637|penile
D017693_D004414 NONE bicarbonate_43\NN\14798450|sodium|to (r_pobj) of_41\IN\0|bicarbonate (r_prep) addition_40\NN\3081021|the|of (r_pobj) without_38\IN\0|addition (r_conj) with_36\IN\0|or|without (r_prep) injections_35\NNS\320852|intracorporeal|with (r_pobj) following_33\VBG\8180190|injections (r_prep) comparing_27\VBG\635850|incidence|following (r_acl) study_26\NN\635850|a|randomized|comparing (r_dobj) performed_23\VBD\0|in|,|we|study|medications. (l_prep) in_0\IN\13603305|attempt (l_pobj) attempt_2\NN\407535|an|determine (l_acl) determine_4\VB\0|to|be (l_ccomp) be_13\VB\14625458|whether|pain|could|due (l_nsubj) pain_7\NN\14299637|penile|associated
D017693_D004414 NONE bicarbonate_43\NN\14798450|sodium|to (r_pobj) of_41\IN\0|bicarbonate (r_prep) addition_40\NN\3081021|the|of (r_pobj) without_38\IN\0|addition (r_conj) with_36\IN\0|or|without (r_prep) injections_35\NNS\320852|intracorporeal|with (r_pobj) following_33\VBG\8180190|injections (r_prep) comparing_27\VBG\635850|incidence|following (l_dobj) incidence_29\NN\13821570|the|of (l_prep) of_30\IN\0|pain (l_pobj) pain_32\NN\14299637|penile
D017693_D004414 NONE bicarbonate_6\NN\14798450|sodium (r_pobj) without_4\IN\0|bicarbonate (r_prep) patients_3\NNS\9898892|the|19|without|added (r_pobj) of_0\IN\0|patients (r_prep) complained_16\VBD\0|of|of|due|,|complained|. (l_prep) of_17\IN\0|pain (l_pobj) pain_19\NN\14299637|penile
D017693_D004414 NONE bicarbonate_6\NN\14798450|sodium (r_pobj) without_4\IN\0|bicarbonate (r_prep) patients_3\NNS\9898892|the|19|without|added (r_pobj) of_0\IN\0|patients (r_prep) complained_16\VBD\0|of|of|due|,|complained|. (l_advcl) complained_40\VBD\0|while|1|of (l_prep) of_41\IN\0|pain (l_pobj) pain_43\NN\14299637|penile
D017693_D004414 NONE bicarbonate_39\NN\14798450|sodium (r_dobj) received_37\VBD\2210855|who|bicarbonate (r_relcl) men_31\NNS\8208016|the|19|(|%|)|received (r_pobj) of_28\IN\0|men (r_prep) 1_27\CD\13741022|only|of (r_nsubj) complained_40\VBD\0|while|1|of (r_advcl) complained_16\VBD\0|of|of|due|,|complained|. (l_prep) of_17\IN\0|pain (l_pobj) pain_19\NN\14299637|penile
D017693_D004414 NONE bicarbonate_39\NN\14798450|sodium (r_dobj) received_37\VBD\2210855|who|bicarbonate (r_relcl) men_31\NNS\8208016|the|19|(|%|)|received (r_pobj) of_28\IN\0|men (r_prep) 1_27\CD\13741022|only|of (r_nsubj) complained_40\VBD\0|while|1|of (l_prep) of_41\IN\0|pain (l_pobj) pain_43\NN\14299637|penile
D017693_D007172 NONE bicarbonate_1\NN\14798450|sodium (r_nsubj) alleviates_2\VBZ\205885|bicarbonate|pain|induced|. (l_advcl) induced_5\VBN\1627355|by (l_agent) by_6\IN\0|injections (l_pobj) injections_8\NNS\320852|intracavernous|for (l_prep) for_9\IN\0|dysfunction (l_pobj) dysfunction_11\NN\14204950|erectile
D010208_D007172 NONE papaverine_25\NN\3800001|6|mg.|,|micrograms (r_appos) drugs_21\NNS\14778436|3|:|papaverine (r_pobj) of_19\IN\0|drugs (r_prep) combination_18\NN\7951464|a|of (r_pobj) of_16\IN\0|combination (r_prep) ml._15\NN\0|0.2|of (r_dobj) received_13\VBD\2210855|total|ml.|. (l_nsubj) total_1\NN\3553|a|of (l_prep) of_2\IN\0|patients (l_pobj) patients_5\NNS\9898892|38|consecutive|presented (l_relcl) presented_7\VBD\2137132|who|to|with (l_prep) with_11\IN\0|impotence (l_pobj) impotence_12\NN\4723816|
3187073
D005472_D002637 CID 5-fu_6\CD\0| (r_compound) treatment_7\NN\654885|5-fu (r_pobj) on_5\IN\0|treatment (r_prep) patients_4\NNS\9898892|on (r_nsubj) be_9\VB\14625458|that|patients|should|under|and|discontinued (l_conj) discontinued_19\VBN\0|that|treatment|should|be|observed (l_advcl) observed_26\VBN\2163746|if|pain|is (l_nsubjpass) pain_22\NN\14299637|chest|or|tachyarrhythmia
D005472_D013610 NONE 5-fu_6\CD\0| (r_compound) treatment_7\NN\654885|5-fu (r_pobj) on_5\IN\0|treatment (r_prep) patients_4\NNS\9898892|on (r_nsubj) be_9\VB\14625458|that|patients|should|under|and|discontinued (l_conj) discontinued_19\VBN\0|that|treatment|should|be|observed (l_advcl) observed_26\VBN\2163746|if|pain|is (l_nsubjpass) pain_22\NN\14299637|chest|or|tachyarrhythmia (l_conj) tachyarrhythmia_24\NN\0|
16274958
D017255_D055154 CID acitretin_3\NN\0| (r_conj) dysphonia_1\NN\14400677|recurrent|and|acitretin|.
D017255_D055154 CID acitretin_15\NN\0| (r_pobj) by_14\IN\0|acitretin (r_agent) treated_13\VBN\2376958|while|she|was|by (r_advcl) report_1\VBP\6470073|we|case|treated|. (l_dobj) case_3\NN\7283608|the|of (l_prep) of_4\IN\0|woman (l_pobj) woman_6\NN\9605289|a|complaining (l_acl) complaining_7\VBG\0|of (l_prep) of_8\IN\0|dysphonia (l_pobj) dysphonia_9\NN\14400677|
D017255_D055154 CID acitretin_10\NN\0| (r_advmod) induced_12\VBN\1627355|acitretin|- (r_amod) dysphonia_13\NN\14400677|induced
1732369
D004280_D009369 NONE dobutamine_0\NNP\0| (r_nsubj) stress_1\VBP\7083732|dobutamine|echocardiography|:|indicator|. (l_appos) indicator_6\NN\6636259|a|sensitive|of (l_prep) of_7\IN\0|function (l_pobj) function_10\NN\13783581|diminished|myocardial|in (l_prep) in_11\IN\13603305|survivors (l_pobj) survivors_19\NNS\9630641|asymptomatic|treated|term|of (l_prep) of_20\IN\0|cancer (l_pobj) cancer_22\NN\14239425|childhood
D004280_D009369 NONE dobutamine_21\NN\0| (r_compound) infusion_22\NN\14589223|dobutamine (r_dobj) using_20\VBG\418025|infusion|differentiate (l_xcomp) differentiate_24\VB\618878|to|survivors (l_dobj) survivors_29\NNS\9630641|asymptomatic|term|of|treated (l_prep) of_30\IN\0|cancer (l_pobj) cancer_32\NN\14239425|childhood
D004317_D009369 NONE doxorubicin_13\NN\2716866| (r_npadvmod) treated_15\VBN\2376958|doxorubicin|- (r_amod) survivors_19\NNS\9630641|asymptomatic|treated|term|of (l_prep) of_20\IN\0|cancer (l_pobj) cancer_22\NN\14239425|childhood
D004317_D009369 NONE doxorubicin_13\NN\2716866| (r_pobj) due_11\IN\5174653|to|doxorubicin (r_amod) damage_10\NN\7296428|cardiac|due (r_pobj) for_8\IN\0|damage (r_prep) test_7\NN\5798043|a|sensitive|echocardiographic|screening|for (r_dobj) develop_1\VB\1753788|to|test (r_advcl) performed_19\VBN\0|develop|,|study|was|using|. (l_xcomp) using_20\VBG\418025|infusion|differentiate (l_xcomp) differentiate_24\VB\618878|to|survivors (l_dobj) survivors_29\NNS\9630641|asymptomatic|term|of|treated (l_prep) of_30\IN\0|cancer (l_pobj) cancer_32\NN\14239425|childhood
D004317_D009369 NONE doxorubicin_35\NN\2716866| (r_pobj) with_34\IN\0|doxorubicin (r_prep) treated_33\VBN\2376958|with|from (r_acl) survivors_29\NNS\9630641|asymptomatic|term|of|treated (l_prep) of_30\IN\0|cancer (l_pobj) cancer_32\NN\14239425|childhood
D004317_D009202 CID doxorubicin_0\NNP\2716866| (r_nsubj) is_1\VBZ\0|doxorubicin|agent|. (l_attr) agent_6\NN\7347|an|effective|anticancer|chemotherapeutic|known (l_acl) known_7\VBN\0|cause (l_xcomp) cause_9\VB\7323922|to|cardiomyopathy (l_dobj) cardiomyopathy_13\NN\14103288|acute
D004317_D006331 NONE doxorubicin_13\NN\2716866| (r_pobj) due_11\IN\5174653|to|doxorubicin (r_amod) damage_10\NN\7296428|cardiac|due
D004317_D006331 NONE doxorubicin_35\NN\2716866| (r_pobj) with_34\IN\0|doxorubicin (r_prep) treated_33\VBN\2376958|with|from (r_acl) survivors_29\NNS\9630641|asymptomatic|term|of|treated (r_dobj) differentiate_24\VB\618878|to|survivors (r_xcomp) using_20\VBG\418025|infusion|differentiate (r_xcomp) performed_19\VBN\0|develop|,|study|was|using|. (l_advcl) develop_1\VB\1753788|to|test (l_dobj) test_7\NN\5798043|a|sensitive|echocardiographic|screening|for (l_prep) for_8\IN\0|damage (l_pobj) damage_10\NN\7296428|cardiac|due
D004280_D006331 NONE dobutamine_21\NN\0| (r_compound) infusion_22\NN\14589223|dobutamine (r_dobj) using_20\VBG\418025|infusion|differentiate (r_xcomp) performed_19\VBN\0|develop|,|study|was|using|. (l_advcl) develop_1\VB\1753788|to|test (l_dobj) test_7\NN\5798043|a|sensitive|echocardiographic|screening|for (l_prep) for_8\IN\0|damage (l_pobj) damage_10\NN\7296428|cardiac|due
11166519
D003042_D012640 CID cocaine_1\NN\3492717| (r_npadvmod) induced_3\VBN\1627355|cocaine|- (r_amod) seizures_4\NNS\14081375|acute|induced|:|sensitivity|.
D003042_D012640 CID cocaine_22\NN\3492717| (r_pobj) of_21\IN\0|cocaine (r_prep) injection_20\NN\320852|a|single|of (r_pobj) by_17\IN\0|injection (r_agent) induced_16\VBN\1627355|by (r_acl) seizures_15\NNS\14081375|behavioral|induced
D003042_D012640 CID cocaine_14\NN\3492717| (r_npadvmod) induced_16\VBN\1627355|cocaine|- (r_amod) seizures_17\NNS\14081375|induced
9625142
D002443_D056486 CID ceftriaxone_11\NN\2996840| (r_pobj) by_10\IN\0|ceftriaxone (r_prep) induced_9\VBN\1627355|hepatitis|by|. (l_nsubj) hepatitis_1\NNP\14127211|acute|,|anemia
D002443_D056486 CID ceftriaxone_12\NN\2996840|oral (r_dobj) ingesting_10\VBG\0|ceftriaxone (r_pcomp) after_9\IN\0|shortly|ingesting (r_prep) developed_5\VBD\1753788|man|hepatitis|after|. (l_dobj) hepatitis_7\NN\14127211|acute
D002443_D000744 CID ceftriaxone_11\NN\2996840| (r_pobj) by_10\IN\0|ceftriaxone (r_prep) induced_9\VBN\1627355|hepatitis|by|. (l_nsubj) hepatitis_1\NNP\14127211|acute|,|anemia (l_appos) anemia_5\NN\14189204|autoimmune|hemolytic|,|and|erythroblastocytopenia
D002443_-1 NONE ceftriaxone_11\NN\2996840| (r_pobj) by_10\IN\0|ceftriaxone (r_prep) induced_9\VBN\1627355|hepatitis|by|. (l_nsubj) hepatitis_1\NNP\14127211|acute|,|anemia (l_appos) anemia_5\NN\14189204|autoimmune|hemolytic|,|and|erythroblastocytopenia (l_conj) erythroblastocytopenia_8\NN\0|
D047090_D000744 NONE lactam_11\NN\0|beta (r_compound) antibiotic_12\NN\2716205|the|lactam (r_dobj) withholding_8\VBG\360757|antibiotic (r_pcomp) after_7\IN\0|withholding (r_prep) returned_4\VBD\1835496|although|transaminases|gradually|to|after (r_advcl) was_15\VBD\0|returned|,|there|increase|. (l_attr) increase_18\NN\13576355|a|gradual|in|and|decrease (l_conj) decrease_24\NN\7296428|a|in (l_prep) in_25\IN\13603305|concentration (l_pobj) concentration_27\NN\4916342|hemoglobin|caused (l_acl) caused_28\VBN\1617192|by (l_agent) by_29\IN\0|anemia (l_pobj) anemia_33\NN\14189204|an|autoimmune|hemolytic|and|erythroblastocytopenia
D047090_-1 NONE lactam_11\NN\0|beta (r_compound) antibiotic_12\NN\2716205|the|lactam (r_dobj) withholding_8\VBG\360757|antibiotic (r_pcomp) after_7\IN\0|withholding (r_prep) returned_4\VBD\1835496|although|transaminases|gradually|to|after (r_advcl) was_15\VBD\0|returned|,|there|increase|. (l_attr) increase_18\NN\13576355|a|gradual|in|and|decrease (l_conj) decrease_24\NN\7296428|a|in (l_prep) in_25\IN\13603305|concentration (l_pobj) concentration_27\NN\4916342|hemoglobin|caused (l_acl) caused_28\VBN\1617192|by (l_agent) by_29\IN\0|anemia (l_pobj) anemia_33\NN\14189204|an|autoimmune|hemolytic|and|erythroblastocytopenia (l_conj) erythroblastocytopenia_35\NN\0|
D001663_D000744 NONE bilirubin_21\NN\14756039|serum (r_pobj) in_19\IN\13603305|bilirubin (r_prep) increase_18\NN\13576355|a|gradual|in|and|decrease (l_conj) decrease_24\NN\7296428|a|in (l_prep) in_25\IN\13603305|concentration (l_pobj) concentration_27\NN\4916342|hemoglobin|caused (l_acl) caused_28\VBN\1617192|by (l_agent) by_29\IN\0|anemia (l_pobj) anemia_33\NN\14189204|an|autoimmune|hemolytic|and|erythroblastocytopenia
D001663_-1 NONE bilirubin_21\NN\14756039|serum (r_pobj) in_19\IN\13603305|bilirubin (r_prep) increase_18\NN\13576355|a|gradual|in|and|decrease (l_conj) decrease_24\NN\7296428|a|in (l_prep) in_25\IN\13603305|concentration (l_pobj) concentration_27\NN\4916342|hemoglobin|caused (l_acl) caused_28\VBN\1617192|by (l_agent) by_29\IN\0|anemia (l_pobj) anemia_33\NN\14189204|an|autoimmune|hemolytic|and|erythroblastocytopenia (l_conj) erythroblastocytopenia_35\NN\0|
9284778
-1_D008107 NONE hydrochlorofluorocarbons_6\NNS\14603497|used (r_pobj) by_5\IN\0|hydrochlorofluorocarbons (r_agent) caused_4\VBN\1617192|by (r_acl) epidemic_0\NN\7435273|of|caused|. (l_prep) of_1\IN\0|disease (l_pobj) disease_3\NN\14061805|liver
D010126_D008107 NONE ozone_9\NN\14877585| (r_npadvmod) sparing_11\VBG\2725714|ozone|- (r_amod) substitutes_12\NNS\5695554|sparing|of (r_pobj) as_8\IN\14622893|substitutes (r_prep) used_7\VBN\0|as (r_acl) hydrochlorofluorocarbons_6\NNS\14603497|used (r_pobj) by_5\IN\0|hydrochlorofluorocarbons (r_agent) caused_4\VBN\1617192|by (r_acl) epidemic_0\NN\7435273|of|caused|. (l_prep) of_1\IN\0|disease (l_pobj) disease_3\NN\14061805|liver
D017402_D008107 NONE chlorofluorocarbons_14\NNS\14871968| (r_pobj) of_13\IN\0|chlorofluorocarbons (r_prep) substitutes_12\NNS\5695554|sparing|of (r_pobj) as_8\IN\14622893|substitutes (r_prep) used_7\VBN\0|as (r_acl) hydrochlorofluorocarbons_6\NNS\14603497|used (r_pobj) by_5\IN\0|hydrochlorofluorocarbons (r_agent) caused_4\VBN\1617192|by (r_acl) epidemic_0\NN\7435273|of|caused|. (l_prep) of_1\IN\0|disease (l_pobj) disease_3\NN\14061805|liver
C067411_D008107 CID 1,1-dichloro-2,2,2-trifluoroethane_21\CD\0|(|hcfc (r_pobj) of_20\IN\0|1,1-dichloro-2,2,2-trifluoroethane (r_prep) mixture_19\NN\19613|a|of (r_pobj) to_17\IN\0|mixture (r_prep) exposure_16\NN\5042871|accidental|to (r_dobj) repeated_14\VBN\952524|who|had|had|exposure (r_relcl) workers_10\NNS\7846|nine|industrial|repeated (r_pobj) in_7\IN\13603305|workers (r_prep) epidemic_3\NN\7435273|an|of|in (l_prep) of_4\IN\0|disease (l_pobj) disease_6\NN\14061805|liver
C067411_D008107 CID 123_24\CD\0| (r_nummod) hcfc_23\NNP\14603497|123|)|and|1-chloro-1,2,2,2-tetrafluoroethane|(|hcfc|) (r_appos) 1,1-dichloro-2,2,2-trifluoroethane_21\CD\0|(|hcfc (r_pobj) of_20\IN\0|1,1-dichloro-2,2,2-trifluoroethane (r_prep) mixture_19\NN\19613|a|of (r_pobj) to_17\IN\0|mixture (r_prep) exposure_16\NN\5042871|accidental|to (r_dobj) repeated_14\VBN\952524|who|had|had|exposure (r_relcl) workers_10\NNS\7846|nine|industrial|repeated (r_pobj) in_7\IN\13603305|workers (r_prep) epidemic_3\NN\7435273|an|of|in (l_prep) of_4\IN\0|disease (l_pobj) disease_6\NN\14061805|liver
C067411_D008107 CID 124_8\CD\0| (r_conj) hcfcs_5\NNS\14603497|123|and|124 (r_nsubj) result_10\VB\34213|whether|hcfcs|can|in (l_prep) in_11\IN\13603305|disease (l_pobj) disease_14\NN\14061805|serious|liver
C072959_D008107 CID 1-chloro-1,2,2,2-tetrafluoroethane_27\NN\0| (r_conj) hcfc_23\NNP\14603497|123|)|and|1-chloro-1,2,2,2-tetrafluoroethane|(|hcfc|) (r_appos) 1,1-dichloro-2,2,2-trifluoroethane_21\CD\0|(|hcfc (r_pobj) of_20\IN\0|1,1-dichloro-2,2,2-trifluoroethane (r_prep) mixture_19\NN\19613|a|of (r_pobj) to_17\IN\0|mixture (r_prep) exposure_16\NN\5042871|accidental|to (r_dobj) repeated_14\VBN\952524|who|had|had|exposure (r_relcl) workers_10\NNS\7846|nine|industrial|repeated (r_pobj) in_7\IN\13603305|workers (r_prep) epidemic_3\NN\7435273|an|of|in (l_prep) of_4\IN\0|disease (l_pobj) disease_6\NN\14061805|liver
C072959_D008107 CID 124_30\CD\0| (r_nummod) hcfc_29\NNP\14603497|124 (r_appos) hcfc_23\NNP\14603497|123|)|and|1-chloro-1,2,2,2-tetrafluoroethane|(|hcfc|) (r_appos) 1,1-dichloro-2,2,2-trifluoroethane_21\CD\0|(|hcfc (r_pobj) of_20\IN\0|1,1-dichloro-2,2,2-trifluoroethane (r_prep) mixture_19\NN\19613|a|of (r_pobj) to_17\IN\0|mixture (r_prep) exposure_16\NN\5042871|accidental|to (r_dobj) repeated_14\VBN\952524|who|had|had|exposure (r_relcl) workers_10\NNS\7846|nine|industrial|repeated (r_pobj) in_7\IN\13603305|workers (r_prep) epidemic_3\NN\7435273|an|of|in (l_prep) of_4\IN\0|disease (l_pobj) disease_6\NN\14061805|liver
C072959_D008107 CID 124_8\CD\0| (r_conj) hcfcs_5\NNS\14603497|123|and|124 (r_nsubj) result_10\VB\34213|whether|hcfcs|can|in (l_prep) in_11\IN\13603305|disease (l_pobj) disease_14\NN\14061805|serious|liver
D006221_D056486 NONE 1-bromo-1-chloro-2,2,2-trifluoroethane_9\CD\0|halothane (r_pobj) as_8\IN\14622893|1-bromo-1-chloro-2,2,2-trifluoroethane (r_prep) way_7\NN\4916342|the|same|as (r_pobj) in_4\IN\13603305|way (r_prep) metabolised_3\VBN\0|compounds|are|in|form|. (l_advcl) form_14\VB\6286395|to|intermediates (l_dobj) intermediates_18\NNS\14806838|reactive|halide|,|implicated (l_relcl) implicated_23\VBN\2677097|which|have|been|in (l_prep) in_24\IN\13603305|hepatotoxicity (l_pobj) hepatotoxicity_26\NN\0|the|of
D006221_D056486 NONE halothane_11\NN\3570838|(|) (r_appos) 1-bromo-1-chloro-2,2,2-trifluoroethane_9\CD\0|halothane (r_pobj) as_8\IN\14622893|1-bromo-1-chloro-2,2,2-trifluoroethane (r_prep) way_7\NN\4916342|the|same|as (r_pobj) in_4\IN\13603305|way (r_prep) metabolised_3\VBN\0|compounds|are|in|form|. (l_advcl) form_14\VB\6286395|to|intermediates (l_dobj) intermediates_18\NNS\14806838|reactive|halide|,|implicated (l_relcl) implicated_23\VBN\2677097|which|have|been|in (l_prep) in_24\IN\13603305|hepatotoxicity (l_pobj) hepatotoxicity_26\NN\0|the|of
D006221_D056486 NONE halothane_28\NN\3570838| (r_pobj) of_27\IN\0|halothane (r_prep) hepatotoxicity_26\NN\0|the|of
D014269_D056486 NONE trifluoroacetyl_16\NNS\0| (r_compound) halide_17\NN\15010703|trifluoroacetyl (r_compound) intermediates_18\NNS\14806838|reactive|halide|,|implicated (l_relcl) implicated_23\VBN\2677097|which|have|been|in (l_prep) in_24\IN\13603305|hepatotoxicity (l_pobj) hepatotoxicity_26\NN\0|the|of
D014269_D056486 NONE trifluoroacetyl_17\NN\0| (r_npadvmod) altered_19\VBN\0|trifluoroacetyl|- (r_amod) proteins_21\NNS\14944888|altered|liver (r_nsubjpass) involved_23\VBN\2676054|that|proteins|are (r_ccomp) suggest_15\VBP\1010118|known|,|results|involved|. (l_advcl) known_11\VBN\0|although|mechanism|is|not (l_nsubjpass) mechanism_3\NN\13446390|the|exact|of (l_prep) of_4\IN\0|hepatotoxicity (l_pobj) hepatotoxicity_5\NN\0|of
C067411_D056486 NONE 124_9\CD\0| (r_conj) hcfcs_6\NNS\14603497|123|and|124 (r_pobj) to_5\IN\0|hcfcs (r_prep) exposure_1\NN\5042871|repeated|of|to (r_nsubj) result_11\VB\34213|exposure|can|in|. (l_prep) in_12\IN\13603305|injury (l_pobj) injury_15\NN\14052046|serious|liver|in
C072959_D056486 NONE 124_9\CD\0| (r_conj) hcfcs_6\NNS\14603497|123|and|124 (r_pobj) to_5\IN\0|hcfcs (r_prep) exposure_1\NN\5042871|repeated|of|to (r_nsubj) result_11\VB\34213|exposure|can|in|. (l_prep) in_12\IN\13603305|injury (l_pobj) injury_15\NN\14052046|serious|liver|in
7292072
D003891_D017180 CID desipramine_4\JJ\4482543| (r_amod) toxicity_5\NN\13576101|desipramine (r_pobj) in_3\IN\13603305|toxicity (r_prep) tachycardia_2\NN\14110674|variant|ventricular|in|.
D003891_D017180 CID desipramine_10\NN\4482543| (r_amod) toxicity_11\NN\13576101|desipramine (r_pobj) by_9\IN\0|toxicity (r_agent) induced_8\VBN\1627355|by (r_acl) tachycardia_7\NN\14110674|variant|ventricular|induced
D003891_D064420 NONE desipramine_4\JJ\4482543| (r_amod) toxicity_5\NN\13576101|desipramine
D003891_D064420 NONE desipramine_10\NN\4482543| (r_amod) toxicity_11\NN\13576101|desipramine
12905102
D003024_D003693 CID clozapine_2\NN\3713736| (r_amod) treatment_3\NN\654885|clozapine (r_pobj) during_1\IN\0|treatment (r_prep) delirium_0\NN\14391660|during|:|factors|.
D003024_D003693 CID clozapine_7\NN\3713736| (r_compound) treatment_8\NN\654885|clozapine (r_pobj) during_6\IN\0|treatment (r_prep) factors_3\NNS\7326557|incidence|for|during (l_prep) for_4\IN\0|delirium (l_pobj) delirium_5\NN\14391660|
D003024_D003693 CID clozapine_13\NN\3713736|(|1995|) (r_pobj) with_12\IN\0|clozapine (r_prep) treated_11\VBN\2376958|with (r_acl) inpatients_10\NNS\10405694|all|adult|psychiatric|treated (r_dobj) identify_6\VB\699815|to|inpatients (r_xcomp) used_1\VBD\0|we|records|identify|,|reviewed|. (l_conj) reviewed_20\VBD\644583|records|score|,|and|tested (l_advcl) score_25\VB\5736149|to|incidence (l_dobj) incidence_26\NN\13821570|and|severity|of (l_prep) of_29\IN\0|delirium (l_pobj) delirium_30\NN\14391660|
D003024_D003693 CID clozapine_7\NN\3713736| (r_npadvmod) treated_9\VBN\2376958|clozapine|- (r_amod) inpatients_10\NNS\10405694|treated (r_pobj) of_6\IN\0|inpatients (r_prep) %_5\NN\0|10|of (r_pobj) in_3\IN\13603305|% (r_prep) found_2\VBN\13279262|delirium|was|in|,|in|. (l_nsubjpass) delirium_0\NNP\14391660|
D003024_D001523 NONE clozapine_13\NN\3713736|(|1995|) (r_pobj) with_12\IN\0|clozapine (r_prep) treated_11\VBN\2376958|with (r_acl) inpatients_10\NNS\10405694|all|adult|psychiatric|treated (l_amod) psychiatric_9\JJ\0|
10091617
D012642_D007024 CID selegiline_0\NNP\0| (r_advmod) induced_2\VBN\1627355|selegiline|-|hypotension|:|study|. (l_dobj) hypotension_4\NN\14057371|postural|in
D012642_D007024 CID selegiline_7\NN\0| (r_pobj) with_6\IN\0|selegiline (r_prep) therapy_5\NN\657604|with|and|dopa (r_nsubjpass) associated_13\VBN\628491|that|therapy|was|with (l_prep) with_14\IN\0|hypotension (l_pobj) hypotension_18\NN\14057371|selective|systolic|orthostatic|abolished
D012642_D007024 CID selegiline_25\NN\0| (r_pobj) of_24\IN\0|selegiline (r_prep) withdrawal_23\NN\7206096|of (r_pobj) by_22\IN\0|withdrawal (r_agent) abolished_21\VBN\0|which|was|by (r_relcl) hypotension_18\NN\14057371|selective|systolic|orthostatic|abolished
D012642_D007024 CID selegiline_29\NN\0| (r_dobj) stopping_28\VBG\3323703|selegiline|in (l_prep) in_30\IN\13603305|expectation (l_pobj) expectation_32\NN\5941423|the|shed (l_acl) shed_36\VB\3859280|that|this|might|light|on (l_prep) on_38\IN\0|mechanisms (l_pobj) mechanisms_40\NNS\13446390|the|causes (l_relcl) causes_45\VBZ\7323922|by|drug|hypotension (l_dobj) hypotension_47\NN\14057371|orthostatic
D012642_D007024 CID selegiline_18\NN\0| (r_pobj) on_17\IN\0|selegiline (r_prep) marked_10\VBN\1296462|which|was|in|on (r_relcl) hypotension_7\NN\14057371|systolic|orthostatic|marked|,|lost
D012642_D007024 CID selegiline_9\NN\0| (r_pobj) of_8\IN\0|selegiline (r_prep) withdrawal_7\NN\7206096|of (r_pobj) after_6\IN\0|days|withdrawal (r_prep) ameliorated_3\VBN\126264|hypotension|was|after|and|abolished|. (l_nsubjpass) hypotension_1\NN\14057371|orthostatic
D012642_D007024 CID selegiline_1\NN\0| (r_dobj) stopping_0\VBG\3323703|selegiline (r_csubj) reduced_4\VBD\441445|stopping|also|significantly|pressures|. (l_dobj) pressures_11\NNS\11419404|the|supine|systolic|blood|consistent
D012642_D007024 CID selegiline_7\NN\0|that|in (r_nsubjpass) associated_15\VBN\628491|selegiline|is|with (l_prep) with_16\IN\0|hypotension (l_pobj) hypotension_19\NN\14057371|selective|orthostatic
D012642_D010300 NONE selegiline_0\NNP\0| (r_advmod) induced_2\VBN\1627355|selegiline|-|hypotension|:|study|. (l_dobj) hypotension_4\NN\14057371|postural|in (l_prep) in_5\IN\13603305|disease (l_pobj) disease_8\NN\14061805|parkinson
D012642_D010300 NONE selegiline_30\NN\0|mg|per (r_dobj) receive_27\VB\2210855|to|selegiline (r_xcomp) randomized_25\VBN\278117|receive (r_acl) mortality_15\NN\5054863|an|increased|in|randomized (r_dobj) found_12\VBD\13279262|trial|mortality|and|compared (l_nsubj) trial_11\NN\786195|group|(|ukpdrg|) (l_nmod) group_7\NNP\2137|parkinson|disease|research (l_compound) disease_5\NNP\14061805|
D012642_D010300 NONE selegiline_30\NN\0|mg|per (r_dobj) receive_27\VB\2210855|to|selegiline (r_xcomp) randomized_25\VBN\278117|receive (r_acl) mortality_15\NN\5054863|an|increased|in|randomized (l_prep) in_16\IN\13603305|patients (l_pobj) patients_17\NNS\9898892|with (l_prep) with_18\IN\0|disease (l_pobj) disease_21\NN\14061805|parkinson|(|pd|)
D012642_D010300 NONE selegiline_30\NN\0|mg|per (r_dobj) receive_27\VB\2210855|to|selegiline (r_xcomp) randomized_25\VBN\278117|receive (r_acl) mortality_15\NN\5054863|an|increased|in|randomized (l_prep) in_16\IN\13603305|patients (l_pobj) patients_17\NNS\9898892|with (l_prep) with_18\IN\0|disease (l_pobj) disease_21\NN\14061805|parkinson|(|pd|) (l_appos) pd_23\NNP\14625458|
D012642_D010300 NONE selegiline_17\RB\0| (r_dobj) receiving_16\VBG\2210855|selegiline (r_acl) patients_15\NNS\9898892|pd|receiving (l_compound) pd_14\NNP\14625458|
D012642_D010300 NONE selegiline_18\NN\0| (r_pobj) on_17\IN\0|selegiline (r_prep) marked_10\VBN\1296462|which|was|in|on (l_prep) in_11\IN\13603305|patients (l_pobj) patients_16\NNS\9898892|20|pd (l_compound) pd_15\NNP\14625458|
D007980_D010300 NONE dopa_36\NN\14601829|l|- (r_nsubj) compared_37\VBN\644583|dopa|with|. (r_conj) found_12\VBD\13279262|trial|mortality|and|compared (l_nsubj) trial_11\NN\786195|group|(|ukpdrg|) (l_nmod) group_7\NNP\2137|parkinson|disease|research (l_compound) disease_5\NNP\14061805|
D007980_D010300 NONE dopa_36\NN\14601829|l|- (r_nsubj) compared_37\VBN\644583|dopa|with|. (r_conj) found_12\VBD\13279262|trial|mortality|and|compared (l_dobj) mortality_15\NN\5054863|an|increased|in|randomized (l_prep) in_16\IN\13603305|patients (l_pobj) patients_17\NNS\9898892|with (l_prep) with_18\IN\0|disease (l_pobj) disease_21\NN\14061805|parkinson|(|pd|)
D007980_D010300 NONE dopa_36\NN\14601829|l|- (r_nsubj) compared_37\VBN\644583|dopa|with|. (r_conj) found_12\VBD\13279262|trial|mortality|and|compared (l_dobj) mortality_15\NN\5054863|an|increased|in|randomized (l_prep) in_16\IN\13603305|patients (l_pobj) patients_17\NNS\9898892|with (l_prep) with_18\IN\0|disease (l_pobj) disease_21\NN\14061805|parkinson|(|pd|) (l_appos) pd_23\NNP\14625458|
D007980_D010300 NONE dopa_43\NN\14601829|l|- (r_dobj) taking_40\VBG\37396|dopa|alone (r_acl) those_39\DT\0|taking (r_pobj) with_38\IN\0|those (r_prep) compared_37\VBN\644583|dopa|with|. (r_conj) found_12\VBD\13279262|trial|mortality|and|compared (l_nsubj) trial_11\NN\786195|group|(|ukpdrg|) (l_nmod) group_7\NNP\2137|parkinson|disease|research (l_compound) disease_5\NNP\14061805|
D007980_D010300 NONE dopa_43\NN\14601829|l|- (r_dobj) taking_40\VBG\37396|dopa|alone (r_acl) those_39\DT\0|taking (r_pobj) with_38\IN\0|those (r_prep) compared_37\VBN\644583|dopa|with|. (r_conj) found_12\VBD\13279262|trial|mortality|and|compared (l_dobj) mortality_15\NN\5054863|an|increased|in|randomized (l_prep) in_16\IN\13603305|patients (l_pobj) patients_17\NNS\9898892|with (l_prep) with_18\IN\0|disease (l_pobj) disease_21\NN\14061805|parkinson|(|pd|)
D007980_D010300 NONE dopa_43\NN\14601829|l|- (r_dobj) taking_40\VBG\37396|dopa|alone (r_acl) those_39\DT\0|taking (r_pobj) with_38\IN\0|those (r_prep) compared_37\VBN\644583|dopa|with|. (r_conj) found_12\VBD\13279262|trial|mortality|and|compared (l_dobj) mortality_15\NN\5054863|an|increased|in|randomized (l_prep) in_16\IN\13603305|patients (l_pobj) patients_17\NNS\9898892|with (l_prep) with_18\IN\0|disease (l_pobj) disease_21\NN\14061805|parkinson|(|pd|) (l_appos) pd_23\NNP\14625458|
D007980_D007024 NONE dopa_11\NNP\14601829|l|- (r_conj) therapy_5\NN\657604|with|and|dopa (r_nsubjpass) associated_13\VBN\628491|that|therapy|was|with (l_prep) with_14\IN\0|hypotension (l_pobj) hypotension_18\NN\14057371|selective|systolic|orthostatic|abolished
D007980_D007024 NONE dopa_13\NNP\14601829|l|- (r_pobj) with_10\IN\0|dopa (r_prep) combination_9\NN\7951464|with (r_pobj) in_8\IN\13603305|combination (r_prep) selegiline_7\NN\0|that|in (r_nsubjpass) associated_15\VBN\628491|selegiline|is|with (l_prep) with_16\IN\0|hypotension (l_pobj) hypotension_19\NN\14057371|selective|orthostatic
3560095
D005480_D001171 NONE flurbiprofen_0\NNP\3828465|in|. (l_prep) in_1\IN\13603305|treatment (l_pobj) treatment_3\NN\654885|the|of (l_prep) of_4\IN\0|arthritis (l_pobj) arthritis_7\NN\14171682|juvenile|rheumatoid
D005480_D001171 NONE flurbiprofen_13\JJ\3828465| (r_pobj) with_12\IN\0|flurbiprofen (r_prep) treated_11\VBN\2376958|who|were|with|at|day (r_relcl) arthritis_7\NN\14171682|juvenile|rheumatoid|,|treated
D005480_D001168 NONE flurbiprofen_13\JJ\3828465| (r_pobj) with_12\IN\0|flurbiprofen (r_prep) treated_11\VBN\2376958|who|were|with|at|day (r_relcl) arthritis_7\NN\14171682|juvenile|rheumatoid|,|treated (r_pobj) with_4\IN\0|arthritis (r_prep) patients_3\NNS\9898892|four|with|, (r_nsubj) had_26\VBD\0|patients|decreases|. (l_dobj) decreases_29\NNS\7296428|significant|from|in|after (l_prep) in_32\IN\13603305|indices (l_pobj) indices_35\NNS\13850304|6|arthritis (l_compound) arthritis_34\NN\14171682|
20722491
D005472_D009369 NONE 5-fu_1\CD\0|(|) (r_nsubj) been_5\VBN\0|5-fu|,|have|mainstay|. (l_attr) mainstay_7\NN\10677713|the|of|for (l_prep) of_8\IN\0|treatment (l_pobj) treatment_9\NN\654885|for (l_prep) for_10\IN\0|tumors (l_pobj) tumors_13\NNS\14234074|several|solid|,|including|,
D005472_D015179 NONE 5-fu_1\CD\0|(|) (r_nsubj) been_5\VBN\0|5-fu|,|have|mainstay|. (l_attr) mainstay_7\NN\10677713|the|of|for (l_prep) of_8\IN\0|treatment (l_pobj) treatment_9\NN\654885|for (l_prep) for_10\IN\0|tumors (l_pobj) tumors_13\NNS\14234074|several|solid|,|including|, (l_prep) including_15\VBG\0|colorectal (l_pobj) colorectal_16\NN\0|,|breast (l_conj) breast_18\NN\5225090|and|cancers (l_conj) cancers_23\NNS\14239425|head
D005472_D001943 NONE 5-fu_1\CD\0|(|) (r_nsubj) been_5\VBN\0|5-fu|,|have|mainstay|. (l_attr) mainstay_7\NN\10677713|the|of|for (l_prep) of_8\IN\0|treatment (l_pobj) treatment_9\NN\654885|for (l_prep) for_10\IN\0|tumors (l_pobj) tumors_13\NNS\14234074|several|solid|,|including|, (l_prep) including_15\VBG\0|colorectal (l_pobj) colorectal_16\NN\0|,|breast (l_conj) breast_18\NN\5225090|and|cancers (l_conj) cancers_23\NNS\14239425|head
D005472_D006258 NONE 5-fu_1\CD\0|(|) (r_nsubj) been_5\VBN\0|5-fu|,|have|mainstay|. (l_attr) mainstay_7\NN\10677713|the|of|for (l_prep) of_8\IN\0|treatment (l_pobj) treatment_9\NN\654885|for (l_prep) for_10\IN\0|tumors (l_pobj) tumors_13\NNS\14234074|several|solid|,|including|, (l_prep) including_15\VBG\0|colorectal (l_pobj) colorectal_16\NN\0|,|breast (l_conj) breast_18\NN\5225090|and|cancers (l_conj) cancers_23\NNS\14239425|head
C110904_D007674 NONE capecitabine_10\NN\0| (r_pobj) of_9\IN\0|capecitabine (r_prep) safety_8\NN\13920835|the|of|in (l_prep) in_11\IN\13603305|populations (l_pobj) populations_13\NNS\7942152|special|as (l_prep) as_15\IN\14622893|such|patients (l_pobj) patients_16\NNS\9898892|with (l_prep) with_17\IN\0|disease (l_pobj) disease_24\NN\14061805|age|renal
C110904_D007674 NONE capecitabine_0\NNP\0| (r_nsubj) has_1\VBZ\13888491|capecitabine|profile|and|given|. (l_conj) given_11\VBN\5892096|can|be|safely|to (l_prep) to_13\IN\0|patients (l_pobj) patients_14\NNS\9898892|with (l_prep) with_15\IN\0|dysfunctions (l_pobj) dysfunctions_22\NNS\14204950|age
C110904_D003967 CID capecitabine_7\NN\0| (r_pobj) of_6\IN\0|capecitabine (r_prep) effects_5\NNS\13245626|the|reported|toxic|of (r_nsubj) are_8\VBP\13600404|effects|diarrhea|. (l_attr) diarrhea_9\NN\14299637|,|nausea
C110904_D009325 CID capecitabine_7\NN\0| (r_pobj) of_6\IN\0|capecitabine (r_prep) effects_5\NNS\13245626|the|reported|toxic|of (r_nsubj) are_8\VBP\13600404|effects|diarrhea|. (l_attr) diarrhea_9\NN\14299637|,|nausea (l_appos) nausea_11\NN\14299637|,|vomiting
C110904_D014839 CID capecitabine_7\NN\0| (r_pobj) of_6\IN\0|capecitabine (r_prep) effects_5\NNS\13245626|the|reported|toxic|of (r_nsubj) are_8\VBP\13600404|effects|diarrhea|. (l_attr) diarrhea_9\NN\14299637|,|nausea (l_appos) nausea_11\NN\14299637|,|vomiting (l_conj) vomiting_13\NN\116687|,|stomatitis
C110904_D013280 CID capecitabine_7\NN\0| (r_pobj) of_6\IN\0|capecitabine (r_prep) effects_5\NNS\13245626|the|reported|toxic|of (r_nsubj) are_8\VBP\13600404|effects|diarrhea|. (l_attr) diarrhea_9\NN\14299637|,|nausea (l_appos) nausea_11\NN\14299637|,|vomiting (l_conj) vomiting_13\NN\116687|,|stomatitis (l_conj) stomatitis_15\JJ\14336539|and|syndrome
C110904_D060831 CID capecitabine_7\NN\0| (r_pobj) of_6\IN\0|capecitabine (r_prep) effects_5\NNS\13245626|the|reported|toxic|of (r_nsubj) are_8\VBP\13600404|effects|diarrhea|. (l_attr) diarrhea_9\NN\14299637|,|nausea (l_appos) nausea_11\NN\14299637|,|vomiting (l_conj) vomiting_13\NN\116687|,|stomatitis (l_conj) stomatitis_15\JJ\14336539|and|syndrome (l_conj) syndrome_20\NN\5870365|foot
C110904_D008107 NONE capecitabine_0\NNP\0| (r_nsubj) has_1\VBZ\13888491|capecitabine|profile|and|given|. (l_conj) given_11\VBN\5892096|can|be|safely|to (l_prep) to_13\IN\0|patients (l_pobj) patients_14\NNS\9898892|with (l_prep) with_15\IN\0|dysfunctions (l_pobj) dysfunctions_22\NNS\14204950|age
12921865
D013256_D012640 NONE steroids_4\NNS\14727670|neuroactive|against (l_prep) against_5\IN\0|seizures (l_pobj) seizures_9\NNS\14081375|cocaine|kindled|-
D013256_D012640 NONE steroid_13\NN\14727670|two|endogenous|one|synthetic|neuroactive|modulate (l_relcl) modulate_16\VBP\1724459|that|positively|acid (l_dobj) acid_21\NN\14818238|the|aminobutyric|(|gaba(a|)|)|receptor (l_appos) receptor_26\NN\5225602|against (l_prep) against_27\IN\0|increase (l_pobj) increase_29\NN\13576355|the|in (l_prep) in_30\IN\13603305|sensitivity (l_pobj) sensitivity_31\NN\5651971|to (l_prep) to_32\IN\0|effects (l_pobj) effects_35\NNS\13245626|the|convulsant|of (l_prep) of_36\IN\0|cocaine (l_pobj) cocaine_37\NN\3492717|engendered (l_acl) engendered_38\VBN\1645601|by (l_agent) by_39\IN\0|administration (l_pobj) administration_42\NN\1133281|repeated|cocaine|(|kindling|) (l_appos) kindling_45\NN\15101361|seizure (l_compound) seizure_44\NN\14081375|
D003042_D012640 CID cocaine_6\NN\3492717| (r_compound) seizures_9\NNS\14081375|cocaine|kindled|-
D003042_D012640 CID cocaine_37\NN\3492717|engendered (l_acl) engendered_38\VBN\1645601|by (l_agent) by_39\IN\0|administration (l_pobj) administration_42\NN\1133281|repeated|cocaine|(|kindling|) (l_appos) kindling_45\NN\15101361|seizure (l_compound) seizure_44\NN\14081375|
D003042_D012640 CID cocaine_41\NN\3492717| (r_compound) administration_42\NN\1133281|repeated|cocaine|(|kindling|) (l_appos) kindling_45\NN\15101361|seizure (l_compound) seizure_44\NN\14081375|
D003042_D012640 CID cocaine_53\NN\3492717| (r_npadvmod) kindled_55\VBN\2764245|cocaine|- (r_amod) seizures_56\NNS\14081375|kindled|in
D003042_D012640 CID cocaine_10\NN\3492717|mg/kg (r_pobj) of_7\IN\0|cocaine (r_prep) administration_6\NN\1133281|daily|of (r_pobj) by_4\IN\0|administration (r_agent) induced_3\VBN\1627355|kindled|were|by|for|. (l_csubjpass) kindled_0\VBN\2764245|seizures (l_dobj) seizures_1\NNS\14081375|
D013256_D009422 NONE steroids_1\NNS\14727670|neuroactive (r_nsubj) demonstrate_2\VBP\2137132|steroids|actions|. (l_dobj) actions_4\NNS\30358|pharmacological|have (l_relcl) have_6\VBP\7846|that|relevance (l_dobj) relevance_7\NN\13791389|for (l_prep) for_8\IN\0|host (l_pobj) host_10\NN\9605289|a|of (l_prep) of_11\IN\0|disorders (l_pobj) disorders_15\NNS\14034177|neurological
D013256_D001523 NONE steroids_1\NNS\14727670|neuroactive (r_nsubj) demonstrate_2\VBP\2137132|steroids|actions|. (l_dobj) actions_4\NNS\30358|pharmacological|have (l_relcl) have_6\VBP\7846|that|relevance (l_dobj) relevance_7\NN\13791389|for (l_prep) for_8\IN\0|host (l_pobj) host_10\NN\9605289|a|of (l_prep) of_11\IN\0|disorders (l_pobj) disorders_15\NNS\14034177|neurological
D005680_D012640 NONE acid_21\NN\14818238|the|aminobutyric|(|gaba(a|)|)|receptor (l_appos) receptor_26\NN\5225602|against (l_prep) against_27\IN\0|increase (l_pobj) increase_29\NN\13576355|the|in (l_prep) in_30\IN\13603305|sensitivity (l_pobj) sensitivity_31\NN\5651971|to (l_prep) to_32\IN\0|effects (l_pobj) effects_35\NNS\13245626|the|convulsant|of (l_prep) of_36\IN\0|cocaine (l_pobj) cocaine_37\NN\3492717|engendered (l_acl) engendered_38\VBN\1645601|by (l_agent) by_39\IN\0|administration (l_pobj) administration_42\NN\1133281|repeated|cocaine|(|kindling|) (l_appos) kindling_45\NN\15101361|seizure (l_compound) seizure_44\NN\14081375|
D005680_D012640 NONE gaba(a_23\NNP\0| (r_appos) acid_21\NN\14818238|the|aminobutyric|(|gaba(a|)|)|receptor (l_appos) receptor_26\NN\5225602|against (l_prep) against_27\IN\0|increase (l_pobj) increase_29\NN\13576355|the|in (l_prep) in_30\IN\13603305|sensitivity (l_pobj) sensitivity_31\NN\5651971|to (l_prep) to_32\IN\0|effects (l_pobj) effects_35\NNS\13245626|the|convulsant|of (l_prep) of_36\IN\0|cocaine (l_pobj) cocaine_37\NN\3492717|engendered (l_acl) engendered_38\VBN\1645601|by (l_agent) by_39\IN\0|administration (l_pobj) administration_42\NN\1133281|repeated|cocaine|(|kindling|) (l_appos) kindling_45\NN\15101361|seizure (l_compound) seizure_44\NN\14081375|
D005680_D012640 NONE gaba(a_4\NN\0| (r_nmod) modulators_6\NNS\0|these|positive|gaba(a|) (r_pobj) of_1\IN\0|modulators (r_prep) all_0\DT\0|of (r_nsubj) suppressed_7\VBD\2510337|all|expression|,|inhibited|. (l_dobj) expression_9\NN\4679549|the|of (l_prep) of_10\IN\0|seizures (l_pobj) seizures_12\NNS\14081375|kindled
D011280_D012640 NONE allopregnanolone_0\NN\0|(|3alpha|)|,|pregnanolone (r_nsubjpass) tested_34\VBN\670261|allopregnanolone|were|for|. (l_prep) for_35\IN\0|ability (l_pobj) ability_37\NN\4723816|their|suppress (l_acl) suppress_39\VB\2510337|to|expression (l_dobj) expression_41\NN\4679549|the|(|effect (l_appos) effect_44\NN\34213|anticonvulsant|)|and|development (l_conj) development_47\NN\248977|(|effect|)|of (l_prep) of_52\IN\0|seizures (l_pobj) seizures_56\NNS\14081375|kindled|in
D011280_D012640 NONE pregnan-20-one_6\NNP\0|hydroxy-5alpha|- (r_advmod) 3alpha_2\CD\0|pregnan-20-one (r_appos) allopregnanolone_0\NN\0|(|3alpha|)|,|pregnanolone (r_nsubjpass) tested_34\VBN\670261|allopregnanolone|were|for|. (l_prep) for_35\IN\0|ability (l_pobj) ability_37\NN\4723816|their|suppress (l_acl) suppress_39\VB\2510337|to|expression (l_dobj) expression_41\NN\4679549|the|(|effect (l_appos) effect_44\NN\34213|anticonvulsant|)|and|development (l_conj) development_47\NN\248977|(|effect|)|of (l_prep) of_52\IN\0|seizures (l_pobj) seizures_56\NNS\14081375|kindled|in
D011280_D012640 NONE pregnanolone_9\NN\0|pregnan-20-one|and|ganaxolone (r_appos) allopregnanolone_0\NN\0|(|3alpha|)|,|pregnanolone (r_nsubjpass) tested_34\VBN\670261|allopregnanolone|were|for|. (l_prep) for_35\IN\0|ability (l_pobj) ability_37\NN\4723816|their|suppress (l_acl) suppress_39\VB\2510337|to|expression (l_dobj) expression_41\NN\4679549|the|(|effect (l_appos) effect_44\NN\34213|anticonvulsant|)|and|development (l_conj) development_47\NN\248977|(|effect|)|of (l_prep) of_52\IN\0|seizures (l_pobj) seizures_56\NNS\14081375|kindled|in
D011280_D012640 NONE pregnan-20-one_15\NNP\0|(|3alpha|-|hydroxy-5beta|-|) (r_parataxis) pregnanolone_9\NN\0|pregnan-20-one|and|ganaxolone (r_appos) allopregnanolone_0\NN\0|(|3alpha|)|,|pregnanolone (r_nsubjpass) tested_34\VBN\670261|allopregnanolone|were|for|. (l_prep) for_35\IN\0|ability (l_pobj) ability_37\NN\4723816|their|suppress (l_acl) suppress_39\VB\2510337|to|expression (l_dobj) expression_41\NN\4679549|the|(|effect (l_appos) effect_44\NN\34213|anticonvulsant|)|and|development (l_conj) development_47\NN\248977|(|effect|)|of (l_prep) of_52\IN\0|seizures (l_pobj) seizures_56\NNS\14081375|kindled|in
D011280_D012640 NONE allopregnanolone_24\NN\0|3alpha (r_pobj) of_23\IN\0|allopregnanolone (r_prep) derivative_22\NN\5802185|a|synthetic|of (r_appos) ganaxolone_18\NN\0|(|derivative|) (r_conj) pregnanolone_9\NN\0|pregnan-20-one|and|ganaxolone (r_appos) allopregnanolone_0\NN\0|(|3alpha|)|,|pregnanolone (r_nsubjpass) tested_34\VBN\670261|allopregnanolone|were|for|. (l_prep) for_35\IN\0|ability (l_pobj) ability_37\NN\4723816|their|suppress (l_acl) suppress_39\VB\2510337|to|expression (l_dobj) expression_41\NN\4679549|the|(|effect (l_appos) effect_44\NN\34213|anticonvulsant|)|and|development (l_conj) development_47\NN\248977|(|effect|)|of (l_prep) of_52\IN\0|seizures (l_pobj) seizures_56\NNS\14081375|kindled|in
D011280_D012640 NONE allopregnanolone_16\NN\0|only|and|ganaxolone (r_nsubj) inhibited_19\VBD\2510337|whereas|allopregnanolone|development (r_advcl) suppressed_7\VBD\2510337|all|expression|,|inhibited|. (l_dobj) expression_9\NN\4679549|the|of (l_prep) of_10\IN\0|seizures (l_pobj) seizures_12\NNS\14081375|kindled
C105051_D012640 NONE ganaxolone_18\NN\0|(|derivative|) (r_conj) pregnanolone_9\NN\0|pregnan-20-one|and|ganaxolone (r_appos) allopregnanolone_0\NN\0|(|3alpha|)|,|pregnanolone (r_nsubjpass) tested_34\VBN\670261|allopregnanolone|were|for|. (l_prep) for_35\IN\0|ability (l_pobj) ability_37\NN\4723816|their|suppress (l_acl) suppress_39\VB\2510337|to|expression (l_dobj) expression_41\NN\4679549|the|(|effect (l_appos) effect_44\NN\34213|anticonvulsant|)|and|development (l_conj) development_47\NN\248977|(|effect|)|of (l_prep) of_52\IN\0|seizures (l_pobj) seizures_56\NNS\14081375|kindled|in
C105051_D012640 NONE pregnan-20-one_31\NNP\0|methyl-5alpha|- (r_appos) 3alpha_25\CD\0|pregnan-20-one (r_appos) allopregnanolone_24\NN\0|3alpha (r_pobj) of_23\IN\0|allopregnanolone (r_prep) derivative_22\NN\5802185|a|synthetic|of (r_appos) ganaxolone_18\NN\0|(|derivative|) (r_conj) pregnanolone_9\NN\0|pregnan-20-one|and|ganaxolone (r_appos) allopregnanolone_0\NN\0|(|3alpha|)|,|pregnanolone (r_nsubjpass) tested_34\VBN\670261|allopregnanolone|were|for|. (l_prep) for_35\IN\0|ability (l_pobj) ability_37\NN\4723816|their|suppress (l_acl) suppress_39\VB\2510337|to|expression (l_dobj) expression_41\NN\4679549|the|(|effect (l_appos) effect_44\NN\34213|anticonvulsant|)|and|development (l_conj) development_47\NN\248977|(|effect|)|of (l_prep) of_52\IN\0|seizures (l_pobj) seizures_56\NNS\14081375|kindled|in
C105051_D012640 NONE ganaxolone_18\NN\0| (r_conj) allopregnanolone_16\NN\0|only|and|ganaxolone (r_nsubj) inhibited_19\VBD\2510337|whereas|allopregnanolone|development (r_advcl) suppressed_7\VBD\2510337|all|expression|,|inhibited|. (l_dobj) expression_9\NN\4679549|the|of (l_prep) of_10\IN\0|seizures (l_pobj) seizures_12\NNS\14081375|kindled
16167916
D020849_D054556 CID raloxifene_11\NN\0| (r_compound) treatment_12\NN\654885|raloxifene (r_pobj) to_10\IN\0|treatment (r_pcomp) due_9\IN\5174653|to (r_amod) thromboembolism_8\NN\14100769|venous|due
220563
C023470_D010523 CID maleate_1\NN\2718811|perhexiline|and|neuropathy|. (l_conj) neuropathy_4\NN\14204950|peripheral
C023470_D010523 CID maleate_12\NN\2718811|perhexiline|,|drug|( (r_pobj) with_10\IN\0|maleate|and|in (r_prep) complication_7\NN\1073995|a|of|with|for (r_pobj) as_5\IN\14622893|complication (r_prep) noted_4\VBN\1009240|neuropathy|has|been|as|. (l_nsubjpass) neuropathy_1\NN\14204950|peripheral
C023470_D000787 NONE maleate_12\NN\2718811|perhexiline|,|drug|( (r_pobj) with_10\IN\0|maleate|and|in (r_prep) complication_7\NN\1073995|a|of|with|for (l_prep) for_30\IN\0|treatment (l_pobj) treatment_33\NN\654885|the|prophylactic|of (l_prep) of_34\IN\0|pectoris (l_pobj) pectoris_36\NN\0|angina
12084448
D007069_D001927 CID ifosfamide_0\NNP\0| (r_compound) encephalopathy_1\NN\14084880|ifosfamide|presenting|.
D007069_D020820 NONE ifosfamide_0\NNP\0| (r_compound) encephalopathy_1\NN\14084880|ifosfamide|presenting|. (l_acl) presenting_2\VBG\2137132|with (l_prep) with_3\IN\0|asterixis (l_pobj) asterixis_4\NNS\0|
D007069_D020820 NONE ifosfamide_3\NN\0| (r_pobj) of_2\IN\0|ifosfamide (r_prep) administration_1\NN\1133281|the|of (r_nsubjpass) discontinued_5\VBN\0|administration|was|and|resolved (l_conj) resolved_12\VBD\352826|within|asterixis|completely|. (l_nsubj) asterixis_11\NNS\0|the
D007069_D020820 NONE ifosfamide_12\JJ\0| (r_pobj) of_11\IN\0|ifosfamide (r_prep) infusion_10\NN\14589223|of (r_pobj) during_9\IN\0|infusion (r_prep) presence_6\NN\13954253|the|of|during|,|findings|following (l_prep) of_7\IN\0|asterixis (l_pobj) asterixis_8\NNS\0|
D007069_D020820 NONE ifx_41\NNP\0| (r_pobj) of_40\IN\0|ifx (r_prep) use_39\NN\407535|the|of (r_pobj) with_37\IN\0|use (r_prep) associated_36\VBN\628491|that|myoclonus|is|with (r_ccomp) suggest_31\VBP\1010118|in|,|presence|associated|. (l_nsubj) presence_6\NN\13954253|the|of|during|,|findings|following (l_prep) of_7\IN\0|asterixis (l_pobj) asterixis_8\NNS\0|
D007069_D009207 CID ifosfamide_27\NN\0| (r_pobj) of_26\IN\0|ifosfamide (r_prep) infusion_25\NN\14589223|the|of|for (r_pobj) after_23\IN\0|infusion (r_prep) disabling_14\VBG\126264|myoclonus|after (l_dobj) myoclonus_16\NN\14360459|negative|of
D007069_D009207 CID ifosfamide_12\JJ\0| (r_pobj) of_11\IN\0|ifosfamide (r_prep) infusion_10\NN\14589223|of (r_pobj) during_9\IN\0|infusion (r_prep) presence_6\NN\13954253|the|of|during|,|findings|following (r_nsubj) suggest_31\VBP\1010118|in|,|presence|associated|. (l_ccomp) associated_36\VBN\628491|that|myoclonus|is|with (l_nsubjpass) myoclonus_34\NN\14360459|negative
D007069_D009207 CID ifx_41\NNP\0| (r_pobj) of_40\IN\0|ifx (r_prep) use_39\NN\407535|the|of (r_pobj) with_37\IN\0|use (r_prep) associated_36\VBN\628491|that|myoclonus|is|with (l_nsubjpass) myoclonus_34\NN\14360459|negative
D007069_D010954 NONE ifosfamide_27\NN\0| (r_pobj) of_26\IN\0|ifosfamide (r_prep) infusion_25\NN\14589223|the|of|for (l_prep) for_28\IN\0|plasmacytoma (l_pobj) plasmacytoma_29\NN\14235200|
12063090
D004177_D003248 NONE metamizol_0\NNP\0| (r_nsubj) potentiates_1\VBZ\229605|metamizol|antinociception|. (l_dobj) antinociception_3\NN\0|morphine|but|constipation (l_conj) constipation_6\NN\14299637|not|after
D004177_D003248 NONE metamizol_20\NN\0|mg/kg|s.c. (r_pobj) with_16\IN\0|metamizol (r_prep) effects_7\NNS\13245626|the|antinociceptive|of|with|in (l_amod) antinociceptive_4\NN\0|and|constipating (l_conj) constipating_6\JJ\440786|
D004177_D003248 NONE metamizol_20\NN\0|that (r_nsubj) potentiate_23\VB\229605|metamizol|did|not|constipation (l_dobj) constipation_27\NN\14299637|induced
D009020_D003248 CID morphine_2\NN\2707683| (r_compound) antinociception_3\NN\0|morphine|but|constipation (l_conj) constipation_6\NN\14299637|not|after
D009020_D003248 CID morphine_15\NN\2707683|mg/kg|s.c. (r_pobj) of_11\IN\0|morphine (r_prep) combination_10\NN\7951464|the|of (r_pobj) of_8\IN\0|combination (r_prep) effects_7\NNS\13245626|the|antinociceptive|of|with|in (l_amod) antinociceptive_4\NN\0|and|constipating (l_conj) constipating_6\JJ\440786|
D009020_D003248 CID morphine_4\NN\2707683| (r_nsubj) inhibited_5\VBD\2510337|in|,|morphine|transit|after|,|respectively|,|suggesting|. (l_advcl) suggesting_23\VBG\1010118|develop (l_ccomp) develop_28\VB\1753788|that|tolerance|did|not|to (l_prep) to_29\IN\0|effects (l_pobj) effects_32\NNS\13245626|the|constipating (l_amod) constipating_31\JJ\440786|
D009020_D003248 CID morphine_10\NN\2707683| (r_pobj) by_9\IN\0|morphine (r_agent) produced_8\VBN\1617192|by|regardless (r_acl) that_7\DT\0|produced (r_pobj) to_6\IN\0|that (r_prep) similar_5\JJ\0|to (r_amod) transit_4\NN\4365484|intestinal|similar (r_dobj) inhibited_2\VBD\2510337|combination|transit|,|suggesting|. (l_advcl) suggesting_18\VBG\1010118|potentiate (l_ccomp) potentiate_23\VB\229605|metamizol|did|not|constipation (l_dobj) constipation_27\NN\14299637|induced
D009020_D003248 CID morphine_24\NN\2707683| (r_npadvmod) induced_26\VBN\1627355|morphine|- (r_amod) constipation_27\NN\14299637|induced
D002606_D010146 NONE charcoal_25\NN\14633206| (r_compound) meal_26\NN\7570720|charcoal (r_compound) test_27\NN\5798043|the|meal (r_nsubjpass) used_29\VBN\0|test|was|evaluate|. (r_conj) assessed_8\VBN\670261|on|,|effects|were|using|,|model|used (l_conj) model_21\NN\5888929|induced|impairment|,|and (l_amod) induced_18\VBN\1627355|pain|- (l_npadvmod) pain_16\NN\14299637|
D009020_D059350 NONE morphine_7\NN\2707683|and|metamizol|in (r_pobj) between_6\IN\0|morphine (r_prep) interaction_5\NN\37396|a|significant|between (r_dobj) show_2\VBP\429048|findings|interaction|,|suggesting|. (l_advcl) suggesting_15\VBG\1010118|be (l_ccomp) be_20\VB\14625458|that|combination|could|useful (l_acomp) useful_21\JJ\0|for (l_prep) for_22\IN\0|treatment (l_pobj) treatment_24\NN\654885|the|of (l_prep) of_25\IN\0|pain (l_pobj) pain_27\NN\14299637|chronic
D004177_D059350 NONE metamizol_9\NN\0| (r_conj) morphine_7\NN\2707683|and|metamizol|in (r_pobj) between_6\IN\0|morphine (r_prep) interaction_5\NN\37396|a|significant|between (r_dobj) show_2\VBP\429048|findings|interaction|,|suggesting|. (l_advcl) suggesting_15\VBG\1010118|be (l_ccomp) be_20\VB\14625458|that|combination|could|useful (l_acomp) useful_21\JJ\0|for (l_prep) for_22\IN\0|treatment (l_pobj) treatment_24\NN\654885|the|of (l_prep) of_25\IN\0|pain (l_pobj) pain_27\NN\14299637|chronic
15957009
C507242_D008569 NONE ro4368554_5\NN\0| (r_nsubj) restores_6\VBZ\1631072|antagonist|ro4368554|performance|in|. (l_prep) in_9\IN\13603305|models (l_pobj) models_13\NNS\5888929|cholinergic|of|in (l_prep) of_14\IN\0|deficiency (l_pobj) deficiency_16\NN\14449126|memory
C507242_D008569 NONE ro4368554_2\NNP\0|(|3|mg/kg|,|intraperitoneally|and|metrifonate|p.o. (r_nsubj) reversed_24\VBD\109660|both|,|ro4368554|deficits|)|. (l_dobj) deficits_26\NNS\5113133|memory|induced
C507242_D008569 NONE ro4368554_4\NN\0| (r_nsubj) improve_7\VB\126264|although|ro4368554|did|not|deficit (r_advcl) reversed_16\VBD\109660|in|,|improve|,|it|cholinergic|,|suggesting|. (l_dobj) cholinergic_18\JJ\0|a|and|deficit (l_conj) deficit_23\NN\5113133|a|serotonergic|memory
C507242_D008569 NONE ro4368554_39\NN\0| (r_pobj) by_38\IN\0|ro4368554 (r_prep) facilitation_34\NN\13920835|the|of|by (r_pobj) in_32\IN\13603305|facilitation (r_prep) involved_31\VBN\2676054|that|mechanisms|may|be|in|and|antagonists (r_ccomp) suggesting_25\VBG\1010118|involved (r_advcl) reversed_16\VBD\109660|in|,|improve|,|it|cholinergic|,|suggesting|. (l_dobj) cholinergic_18\JJ\0|a|and|deficit (l_conj) deficit_23\NN\5113133|a|serotonergic|memory
D014236_D008569 NONE metrifonate_15\NN\0|(|mg/kg|, (r_conj) ro4368554_2\NNP\0|(|3|mg/kg|,|intraperitoneally|and|metrifonate|p.o. (r_nsubj) reversed_24\VBD\109660|both|,|ro4368554|deficits|)|. (l_dobj) deficits_26\NNS\5113133|memory|induced
D012601_D008569 CID scopolamine_29\NN\14712692|and|depletion|(|mg/kg|,|i.p.|,|and|mg/kg (r_pobj) by_28\IN\0|scopolamine (r_agent) induced_27\VBN\1627355|by (r_acl) deficits_26\NNS\5113133|memory|induced
D014364_D008569 NONE trp_31\NNP\0| (r_compound) depletion_32\NN\351638|trp (r_conj) scopolamine_29\NN\14712692|and|depletion|(|mg/kg|,|i.p.|,|and|mg/kg (r_pobj) by_28\IN\0|scopolamine (r_agent) induced_27\VBN\1627355|by (r_acl) deficits_26\NNS\5113133|memory|induced
D012701_D008569 NONE 5-ht(6_45\CD\0| (r_compound) antagonists_48\NNS\7846|,|possibly|,|other|5-ht(6|receptor (r_conj) involved_31\VBN\2676054|that|mechanisms|may|be|in|and|antagonists (r_ccomp) suggesting_25\VBG\1010118|involved (r_advcl) reversed_16\VBD\109660|in|,|improve|,|it|cholinergic|,|suggesting|. (l_dobj) cholinergic_18\JJ\0|a|and|deficit (l_conj) deficit_23\NN\5113133|a|serotonergic|memory
9401499
D013988_D000741 CID ticlopidine_0\NNP\0| (r_npadvmod) induced_2\VBN\1627355|ticlopidine|- (r_amod) anemia_4\NN\14189204|induced|aplastic|:|report|.
D013988_D000741 CID ticlopidine_8\NN\0| (r_npadvmod) induced_10\VBN\1627355|ticlopidine|- (r_amod) anemia_12\NN\14189204|induced|aplastic
D013988_D000741 CID ticlopidine_2\NN\0| (r_npadvmod) induced_4\VBN\1627355|ticlopidine|- (r_amod) anemia_6\NN\14189204|induced|aplastic|with
D013988_D000380 CID ticlopidine_9\NN\0| (r_pobj) of_8\IN\0|ticlopidine (r_prep) initiation_7\NN\7450842|of (r_pobj) after_6\IN\0|weeks|initiation (r_prep) occurred_1\VBD\0|agranulocytosis|after|, (l_nsubj) agranulocytosis_0\NN\14189204|
1833784
D004298_D006948 NONE dopamine_8\NN\14807737|d2 (r_conj) d1_5\NN\0|and|dopamine (r_nmod) receptors_9\NNS\5225602|d1 (r_pobj) of_4\IN\0|receptors (r_prep) involvement_3\NN\1080366|an|of|in (l_prep) in_10\IN\13603305|mediating (l_pcomp) mediating_11\VBG\761713|hyperactivity (l_dobj) hyperactivity_15\NN\14052403|induced|in
D009538_D006948 CID nicotine_12\NN\14712692| (r_npadvmod) induced_14\VBN\1627355|nicotine|- (r_amod) hyperactivity_15\NN\14052403|induced|in
D009538_D006948 CID nicotine_0\NNP\14712692|mg/kg (r_nsubj) caused_5\VBD\1617192|nicotine|increase|,|but|had|. (l_dobj) increase_8\NN\13576355|a|significant|in|habituated (l_prep) in_9\IN\13603305|activity (l_pobj) activity_11\NN\30358|locomotor|in
D009538_D006948 CID nicotine_0\NN\14712692| (r_npadvmod) induced_2\VBN\1627355|nicotine|- (r_amod) hyperactivity_3\NN\14052403|induced
D009538_D006948 CID nicotine_7\NN\14712692| (r_npadvmod) induced_9\VBN\1627355|nicotine|- (r_amod) hyperactivity_10\NN\14052403|enhanced|induced
D009538_D006948 CID nicotine_5\NN\14712692| (r_compound) injection_6\NN\320852|acute|nicotine (r_nsubj) induces_7\VBZ\1627355|that|injection|hyperactivity (l_dobj) hyperactivity_10\NN\14052403|a|pronounced|in
C534628_D006948 NONE 23390_12\CD\0| (r_nummod) sch_11\NNP\0|23390 (r_appos) antagonist_10\NN\7846|the|selective|d1|sch (r_pobj) by_6\IN\0|antagonist (r_agent) blocked_5\VBN\1476483|hyperactivity|was|by (l_nsubjpass) hyperactivity_3\NN\14052403|induced
D020891_D006948 NONE raclopride_18\NN\0|blocked|,|antagonist|and|fluphenazine|. (l_ccomp) blocked_5\VBN\1476483|hyperactivity|was|by (l_nsubjpass) hyperactivity_3\NN\14052403|induced
D005476_D006948 NONE fluphenazine_23\NN\3713736|the|d1/d2|antagonist (r_conj) raclopride_18\NN\0|blocked|,|antagonist|and|fluphenazine|. (l_ccomp) blocked_5\VBN\1476483|hyperactivity|was|by (l_nsubjpass) hyperactivity_3\NN\14052403|induced
-1_D006948 NONE phno_5\NNP\0| (r_npadvmod) enhanced_6\VBN\227165|phno (r_amod) hyperactivity_10\NN\14052403|enhanced|induced
D015647_D006948 NONE 38393_17\CD\0| (r_nummod) skf_16\NNP\0|38393 (r_appos) agonist_15\NN\0|the|d1|skf (r_nsubj) had_18\VBD\0|whereas|agonist|effect (r_advcl) pretreatment_0\NN\0|with|,|had|. (l_prep) with_1\IN\0|agonist (l_pobj) agonist_4\NN\0|the|d2|hyperactivity (l_appos) hyperactivity_10\NN\14052403|enhanced|induced
3750012
D010396_D009157 CID penicillamine_4\NN\3740161|and|therapy (r_pobj) by_3\IN\0|penicillamine (r_agent) caused_2\VBN\1617192|by (r_acl) gravis_1\NN\0|myasthenia|caused|.
D010396_D009157 CID penicillamine_16\NN\3740161|and|therapy (r_pobj) after_15\IN\0|penicillamine (r_prep) had_7\VBD\0|who|gravis|after (l_dobj) gravis_14\NN\0|reversible|myasthenia
D010396_D001172 NONE penicillamine_4\NN\3740161|and|therapy (l_conj) therapy_7\NN\657604|chloroquine|for (l_prep) for_8\IN\0|arthritis (l_pobj) arthritis_10\NN\14171682|rheumatoid
D010396_D001172 NONE penicillamine_16\NN\3740161|and|therapy (l_conj) therapy_19\NN\657604|chloroquine|for (l_prep) for_20\IN\0|arthritis (l_pobj) arthritis_22\NN\14171682|rheumatoid
D002738_D009157 CID chloroquine_6\NN\2721948| (r_amod) therapy_7\NN\657604|chloroquine|for (r_conj) penicillamine_4\NN\3740161|and|therapy (r_pobj) by_3\IN\0|penicillamine (r_agent) caused_2\VBN\1617192|by (r_acl) gravis_1\NN\0|myasthenia|caused|.
D002738_D009157 CID chloroquine_18\NN\2721948| (r_compound) therapy_19\NN\657604|chloroquine|for (r_conj) penicillamine_16\NN\3740161|and|therapy (r_pobj) after_15\IN\0|penicillamine (r_prep) had_7\VBD\0|who|gravis|after (l_dobj) gravis_14\NN\0|reversible|myasthenia
D002738_D001172 NONE chloroquine_6\NN\2721948| (r_amod) therapy_7\NN\657604|chloroquine|for (l_prep) for_8\IN\0|arthritis (l_pobj) arthritis_10\NN\14171682|rheumatoid
D002738_D001172 NONE chloroquine_18\NN\2721948| (r_compound) therapy_19\NN\657604|chloroquine|for (l_prep) for_20\IN\0|arthritis (l_pobj) arthritis_22\NN\14171682|rheumatoid
18703024
D006220_D002375 CID haloperidol_3\NN\3713736| (r_npadvmod) induced_5\VBN\1627355|haloperidol|- (r_amod) catalepsy_6\NN\14023236|induced|or|locomotion
D016291_D002375 NONE mk-801-induced_8\JJ\0| (r_compound) locomotion_9\NN\4773351|mk-801-induced (r_conj) catalepsy_6\NN\14023236|induced|or|locomotion
11426838
-1_D012640 NONE bd1018_10\NN\0|,|bd1063 (r_pobj) with_9\IN\0|bd1018 (r_punct) attenuated_17\VBD\224901|treatment|with|significantly (r_amod) convulsions_21\NNS\14081375|attenuated|induced|and|lethality
-1_D012640 NONE lr132_15\NNS\0| (r_conj) bd1063_12\NNP\0|,|or|lr132 (r_conj) bd1018_10\NN\0|,|bd1063 (r_pobj) with_9\IN\0|bd1018 (r_punct) attenuated_17\VBD\224901|treatment|with|significantly (r_amod) convulsions_21\NNS\14081375|attenuated|induced|and|lethality
C093337_D012640 NONE bd1063_12\NNP\0|,|or|lr132 (r_conj) bd1018_10\NN\0|,|bd1063 (r_pobj) with_9\IN\0|bd1018 (r_punct) attenuated_17\VBD\224901|treatment|with|significantly (r_amod) convulsions_21\NNS\14081375|attenuated|induced|and|lethality
D003042_D012640 CID cocaine_18\NN\3492717| (r_npadvmod) induced_20\VBN\1627355|cocaine|- (r_amod) convulsions_21\NNS\14081375|attenuated|induced|and|lethality
D003042_D012640 CID cocaine_9\NN\3492717|anti|- (r_compound) effects_10\NNS\13245626|the|cocaine|of (r_nsubjpass) shown_29\VBN\2137132|that|effects|was|also|attenuate (l_xcomp) attenuate_32\VB\224901|to|significantly|effects (l_dobj) effects_38\NNS\13245626|the|convulsive|stimulatory|of (l_amod) convulsive_34\JJ\0|and|locomotor
D003042_D012640 CID cocaine_40\NN\3492717| (r_pobj) of_39\IN\0|cocaine (r_prep) effects_38\NNS\13245626|the|convulsive|stimulatory|of (l_amod) convulsive_34\JJ\0|and|locomotor
C050232_D064420 NONE tolylguanidine_22\NN\0|di|o|-|( (r_nmod) dtg_24\NNP\0|the|agonist|tolylguanidine|)|and|bd1031 (r_appos) antagonists_9\NNS\7846|the|putative|,|dtg (r_pobj) by_6\IN\0|antagonists (r_agent) provided_5\VBN\2199590|by (r_acl) protection_4\NN\407535|the|provided (r_pobj) to_2\IN\0|protection (r_prep) contrast_1\NN\13854649|to (r_pobj) in_0\IN\13603305|contrast (r_prep) worsened_37\VBD\146138|in|each|toxicity|. (l_dobj) toxicity_40\NN\13576101|the|behavioral|of
C050232_D064420 NONE dtg_24\NNP\0|the|agonist|tolylguanidine|)|and|bd1031 (r_appos) antagonists_9\NNS\7846|the|putative|,|dtg (r_pobj) by_6\IN\0|antagonists (r_agent) provided_5\VBN\2199590|by (r_acl) protection_4\NN\407535|the|provided (r_pobj) to_2\IN\0|protection (r_prep) contrast_1\NN\13854649|to (r_pobj) in_0\IN\13603305|contrast (r_prep) worsened_37\VBD\146138|in|each|toxicity|. (l_dobj) toxicity_40\NN\13576101|the|behavioral|of
-1_D064420 NONE bd1031_32\NN\0|the|novel|agonist|3r-1-[2-(3,4-dichlorophenyl)ethyl]-1,4-diazabicyclo[4.3.0]nonane (r_conj) dtg_24\NNP\0|the|agonist|tolylguanidine|)|and|bd1031 (r_appos) antagonists_9\NNS\7846|the|putative|,|dtg (r_pobj) by_6\IN\0|antagonists (r_agent) provided_5\VBN\2199590|by (r_acl) protection_4\NN\407535|the|provided (r_pobj) to_2\IN\0|protection (r_prep) contrast_1\NN\13854649|to (r_pobj) in_0\IN\13603305|contrast (r_prep) worsened_37\VBD\146138|in|each|toxicity|. (l_dobj) toxicity_40\NN\13576101|the|behavioral|of
-1_D064420 NONE 3r-1-[2-(3,4-dichlorophenyl)ethyl]-1,4-diazabicyclo[4.3.0]nonane_34\NN\0|(|) (r_appos) bd1031_32\NN\0|the|novel|agonist|3r-1-[2-(3,4-dichlorophenyl)ethyl]-1,4-diazabicyclo[4.3.0]nonane (r_conj) dtg_24\NNP\0|the|agonist|tolylguanidine|)|and|bd1031 (r_appos) antagonists_9\NNS\7846|the|putative|,|dtg (r_pobj) by_6\IN\0|antagonists (r_agent) provided_5\VBN\2199590|by (r_acl) protection_4\NN\407535|the|provided (r_pobj) to_2\IN\0|protection (r_prep) contrast_1\NN\13854649|to (r_pobj) in_0\IN\13603305|contrast (r_prep) worsened_37\VBD\146138|in|each|toxicity|. (l_dobj) toxicity_40\NN\13576101|the|behavioral|of
D003042_D064420 NONE cocaine_42\NN\3492717| (r_pobj) of_41\IN\0|cocaine (r_prep) toxicity_40\NN\13576101|the|behavioral|of
D009838_D012640 NONE oligodeoxynucleotide_23\NN\0|an|antisense|against (r_appos) receptors_19\NNS\5225602|sigma|,|oligodeoxynucleotide (r_pobj) of_17\IN\0|receptors (r_prep) antagonism_16\NN\24720|of (r_dobj) involved_15\VBD\2676054|antagonism (r_acl) ligands_14\NNS\20090|the|novel|involved (r_pobj) of_11\IN\0|ligands (r_prep) effects_10\NNS\13245626|the|cocaine|of (r_nsubjpass) shown_29\VBN\2137132|that|effects|was|also|attenuate (l_xcomp) attenuate_32\VB\224901|to|significantly|effects (l_dobj) effects_38\NNS\13245626|the|convulsive|stimulatory|of (l_amod) convulsive_34\JJ\0|and|locomotor
2924746
D002220_D064420 NONE carbamazepine_1\NN\0|chronic (r_compound) treatment_2\NN\654885|carbamazepine|in|:|efficacy|. (l_appos) efficacy_7\NN\5199286|,|toxicity (l_conj) toxicity_9\NN\13576101|,|and|effect
D005492_D064420 NONE folate_17\JJ\15090742| (r_compound) concentrations_18\NNS\4916342|tissue|folate (r_conj) plasma_14\NN\5398023|and|concentrations (r_pobj) on_13\IN\0|plasma (r_prep) effect_12\NN\34213|on (r_conj) toxicity_9\NN\13576101|,|and|effect
D019946_D012640 NONE glycol_13\NN\14766364|propylene (r_appos) vehicle_10\NN\3100490|a|common|,|glycol (r_nsubjpass) found_22\VBN\13279262|in|,|vehicle|,|by|,|was|exhibit|. (l_xcomp) exhibit_24\VB\6733939|to|properties (l_dobj) properties_26\NNS\32613|protective|against (l_prep) against_27\IN\0|seizures (l_pobj) seizures_29\NNS\14081375|induced|and|gain
D019946_D015430 NONE glycol_13\NN\14766364|propylene (r_appos) vehicle_10\NN\3100490|a|common|,|glycol (r_nsubjpass) found_22\VBN\13279262|in|,|vehicle|,|by|,|was|exhibit|. (l_xcomp) exhibit_24\VB\6733939|to|properties (l_dobj) properties_26\NNS\32613|protective|against (l_prep) against_27\IN\0|seizures (l_pobj) seizures_29\NNS\14081375|induced|and|gain (l_conj) gain_33\NN\13576355|inhibited|weight
D005481_D012640 CID ether_4\NN\14840755|hexafluorodiethyl|hfde (r_pobj) by_2\IN\0|ether (r_prep) induced_1\VBN\1627355|seizures|by|found|. (l_nsubj) seizures_0\NNS\14081375|
D005481_D012640 CID ether_4\NN\14840755|hexafluorodiethyl|hfde (r_pobj) by_2\IN\0|ether (r_prep) induced_1\VBN\1627355|seizures|by|found|. (l_conj) found_10\VBN\13279262|were|also|be (l_xcomp) be_12\VB\14625458|to|measure|than (l_prep) than_21\IN\0|seizures (l_pobj) seizures_22\NNS\14081375|induced
D005481_D012640 CID hfde_6\NNP\0|(|) (r_appos) ether_4\NN\14840755|hexafluorodiethyl|hfde (r_pobj) by_2\IN\0|ether (r_prep) induced_1\VBN\1627355|seizures|by|found|. (l_nsubj) seizures_0\NNS\14081375|
D005481_D012640 CID hfde_6\NNP\0|(|) (r_appos) ether_4\NN\14840755|hexafluorodiethyl|hfde (r_pobj) by_2\IN\0|ether (r_prep) induced_1\VBN\1627355|seizures|by|found|. (l_conj) found_10\VBN\13279262|were|also|be (l_xcomp) be_12\VB\14625458|to|measure|than (l_prep) than_21\IN\0|seizures (l_pobj) seizures_22\NNS\14081375|induced
D005481_D012640 CID hfde_21\NNP\0| (r_npadvmod) induced_23\VBN\1627355|hfde|- (r_amod) seizures_24\NNS\14081375|induced
D002220_D012640 NONE cbz_20\NN\0| (r_pobj) by_19\IN\0|cbz (r_prep) protection_18\NN\407535|by (r_pobj) of_17\IN\0|protection (r_prep) measure_16\NN\168237|a|sensitive|of (r_attr) be_12\VB\14625458|to|measure|than (r_xcomp) found_10\VBN\13279262|were|also|be (r_conj) induced_1\VBN\1627355|seizures|by|found|. (l_nsubj) seizures_0\NNS\14081375|
D002220_D012640 NONE cbz_20\NN\0| (r_pobj) by_19\IN\0|cbz (r_prep) protection_18\NN\407535|by (r_pobj) of_17\IN\0|protection (r_prep) measure_16\NN\168237|a|sensitive|of (r_attr) be_12\VB\14625458|to|measure|than (l_prep) than_21\IN\0|seizures (l_pobj) seizures_22\NNS\14081375|induced
D002220_D012640 NONE cbz_3\NNP\0| (r_pobj) of_2\IN\0|cbz (r_prep) administration_1\NN\1133281|oral|of|as|h (r_nsubj) was_17\VBD\0|administration|protective|and|was|. (l_acomp) protective_19\JJ\0|continuously|against (l_prep) against_20\IN\0|seizures (l_pobj) seizures_24\NNS\14081375|induced
D002220_D015430 NONE cbz_3\NNP\0| (r_pobj) of_2\IN\0|cbz (r_prep) administration_1\NN\1133281|oral|of|as|h (r_nsubj) was_17\VBD\0|administration|protective|and|was|. (l_conj) was_26\VBD\0|toxic|measured (l_advcl) measured_30\VBN\697589|as|by|over (l_agent) by_31\IN\0|gain (l_pobj) gain_33\NN\13576355|weight
D005481_D015430 NONE hfde_21\NNP\0| (r_npadvmod) induced_23\VBN\1627355|hfde|- (r_amod) seizures_24\NNS\14081375|induced (r_pobj) against_20\IN\0|seizures (r_prep) protective_19\JJ\0|continuously|against (r_acomp) was_17\VBD\0|administration|protective|and|was|. (l_conj) was_26\VBD\0|toxic|measured (l_advcl) measured_30\VBN\697589|as|by|over (l_agent) by_31\IN\0|gain (l_pobj) gain_33\NN\13576355|weight
15188772
D004837_D018487 NONE epinephrine_12\NN\14807929| (r_amod) overdose_13\NN\84738|accidental|iatrogenic|epinephrine (r_pobj) due_8\IN\5174653|to|overdose (r_prep) dysfunction_7\NN\14204950|severe|left|ventricular|systolic|due|.
D004837_D018487 NONE epinephrine_15\NN\14807929| (r_pobj) of_14\IN\0|epinephrine (r_prep) mg_13\NN\13717155|8|of (r_nsubj) developed_16\VBN\1753788|woman|mg|markers|. (l_dobj) markers_44\NNS\21939|stunning|elevated|biochemical|of (l_amod) stunning_18\JJ\269140|myocardial|characterized (l_relcl) characterized_21\VBN\609683|that|was|by|left|,|and (l_conj) left_32\VBD\8621598|dysfunction (l_dobj) dysfunction_37\NN\14204950|ventricular|systolic
D004837_D062787 NONE epinephrine_12\NN\14807929| (r_amod) overdose_13\NN\84738|accidental|iatrogenic|epinephrine
D002395_D009202 NONE catecholamine_0\NN\5407119| (r_npadvmod) induced_2\VBN\1627355|catecholamine|- (r_amod) cardiomyopathy_3\NN\14103288|induced|due
D002395_D009202 NONE catecholamines_10\NNS\5407119|endogenous (r_pobj) of_8\IN\0|catecholamines (r_prep) excess_7\NN\5119367|chronic|of (r_pobj) due_4\IN\5174653|to|excess (r_prep) cardiomyopathy_3\NN\14103288|induced|due
D004837_D017682 CID epinephrine_15\NN\14807929| (r_pobj) of_14\IN\0|epinephrine (r_prep) mg_13\NN\13717155|8|of (r_nsubj) developed_16\VBN\1753788|woman|mg|markers|. (l_dobj) markers_44\NNS\21939|stunning|elevated|biochemical|of (l_amod) stunning_18\JJ\269140|myocardial|characterized
D004837_D009202 NONE epinephrine_15\NN\14807929| (r_pobj) of_14\IN\0|epinephrine (r_prep) mg_13\NN\13717155|8|of (r_nsubj) developed_16\VBN\1753788|woman|mg|markers|. (l_dobj) markers_44\NNS\21939|stunning|elevated|biochemical|of (l_prep) of_45\IN\0|necrosis (l_pobj) necrosis_47\NN\11444117|myocardial
19631624
D018817_D007859 CID ecstasy_5\NN\13985818| (r_compound) users_6\NNS\7846|ecstasy (r_pobj) in_4\IN\13603305|users (r_prep) deficits_3\NNS\5113133|learning|in|and|correlates
D018817_D007859 CID ecstasy_6\NN\13985818| (r_compound) users_7\NNS\7846|ecstasy (r_nsubj) display_8\VBP\6879180|that|users|impairments (l_dobj) impairments_9\NNS\7296428|in (l_prep) in_10\IN\13603305|performance (l_pobj) performance_14\NN\6619065|learning (l_nmod) learning_11\NN\5701944|and|memory (l_conj) memory_13\NN\5926676|
D018817_D008569 CID ecstasy_5\NN\13985818| (r_compound) users_6\NNS\7846|ecstasy (r_pobj) in_4\IN\13603305|users (r_prep) deficits_3\NNS\5113133|learning|in|and|correlates
D018817_D008569 CID ecstasy_6\NN\13985818| (r_compound) users_7\NNS\7846|ecstasy (r_nsubj) display_8\VBP\6879180|that|users|impairments (l_dobj) impairments_9\NNS\7296428|in (l_prep) in_10\IN\13603305|performance (l_pobj) performance_14\NN\6619065|learning (l_nmod) learning_11\NN\5701944|and|memory (l_conj) memory_13\NN\5926676|
D002188_D007859 NONE cannabis_12\NN\13112664| (r_compound) users_13\NNS\7846|cannabis (r_pobj) in_11\IN\13603305|users (r_prep) hypoactivity_10\NN\0|frontocortical|in (r_conj) hyperactivity_7\NN\14052403|parahippocampal|and|hypoactivity (r_appos) deficits_0\NNS\5113133|in|:|hyperactivity|. (l_prep) in_1\IN\13603305|learning (l_pobj) learning_2\NN\5701944|and|memory (l_conj) memory_4\NN\5926676|
D002188_D008569 NONE cannabis_12\NN\13112664| (r_compound) users_13\NNS\7846|cannabis (r_pobj) in_11\IN\13603305|users (r_prep) hypoactivity_10\NN\0|frontocortical|in (r_conj) hyperactivity_7\NN\14052403|parahippocampal|and|hypoactivity (r_appos) deficits_0\NNS\5113133|in|:|hyperactivity|. (l_prep) in_1\IN\13603305|learning (l_pobj) learning_2\NN\5701944|and|memory (l_conj) memory_4\NN\5926676|
D002188_D006948 NONE cannabis_12\NN\13112664| (r_compound) users_13\NNS\7846|cannabis (r_pobj) in_11\IN\13603305|users (r_prep) hypoactivity_10\NN\0|frontocortical|in (r_conj) hyperactivity_7\NN\14052403|parahippocampal|and|hypoactivity
D018817_D006948 NONE ecstasy_13\NN\13985818| (r_npadvmod) specific_15\JJ\5817396|ecstasy|- (r_amod) hyperactivity_16\NN\14052403|specific|in
D018817_D020258 NONE ecstasy_1\NN\13985818| (r_npadvmod) specific_3\JJ\5817396|ecstasy|- (r_amod) effects_4\NNS\13245626|these|specific (r_nsubjpass) related_7\VBN\628491|effects|may|be|to|. (l_prep) to_8\IN\0|vulnerability (l_pobj) vulnerability_10\NN\14540765|the|of|to (l_prep) to_16\IN\0|effects (l_pobj) effects_19\NNS\13245626|the|neurotoxic|of (l_amod) neurotoxic_18\JJ\0|
D018817_D020258 NONE ecstasy_21\NN\13985818| (r_pobj) of_20\IN\0|ecstasy (r_prep) effects_19\NNS\13245626|the|neurotoxic|of (l_amod) neurotoxic_18\JJ\0|
11147747
D018490_D014549 CID antidepressants_1\NNS\3740161|serotonergic|and|incontinence|. (l_conj) incontinence_4\NN\13473097|urinary
D018490_D014549 CID antidepressants_8\NNS\3740161|serotonergic (r_pobj) to_6\IN\0|antidepressants (r_prep) secondary_5\JJ\8426461|to (r_amod) incontinence_4\NN\13473097|secondary
C047426_D014549 CID venlafaxine_10\NN\0| (r_dobj) taking_9\VBG\37396|while|venlafaxine (r_advcl) experienced_6\VBD\2108377|who|incontinence|taking (l_dobj) incontinence_7\NN\13473097|
C047426_D014549 CID venlafaxine_35\NNP\0| (r_pobj) on_34\IN\0|venlafaxine (r_prep) developed_30\VBD\1753788|who|effect|on (r_relcl) third_28\NN\13732295|a|developed (r_conj) paroxetine_20\NN\0|the|selective|serotonin|inhibitors|and|sertraline|,|as|third (r_pobj) to_14\IN\0|paroxetine (r_prep) developed_11\VBD\1753788|who|secondary|to (l_dobj) secondary_13\JJ\8426461|incontinence (l_compound) incontinence_12\NN\13473097|
D012701_D014549 NONE serotonin_17\NN\14807737| (r_compound) paroxetine_20\NN\0|the|selective|serotonin|inhibitors|and|sertraline|,|as|third (r_pobj) to_14\IN\0|paroxetine (r_prep) developed_11\VBD\1753788|who|secondary|to (l_dobj) secondary_13\JJ\8426461|incontinence (l_compound) incontinence_12\NN\13473097|
D017374_D014549 CID paroxetine_20\NN\0|the|selective|serotonin|inhibitors|and|sertraline|,|as|third (r_pobj) to_14\IN\0|paroxetine (r_prep) developed_11\VBD\1753788|who|secondary|to (l_dobj) secondary_13\JJ\8426461|incontinence (l_compound) incontinence_12\NN\13473097|
D020280_D014549 CID sertraline_22\NN\4169152| (r_conj) paroxetine_20\NN\0|the|selective|serotonin|inhibitors|and|sertraline|,|as|third (r_pobj) to_14\IN\0|paroxetine (r_prep) developed_11\VBD\1753788|who|secondary|to (l_dobj) secondary_13\JJ\8426461|incontinence (l_compound) incontinence_12\NN\13473097|
D016651_D014549 CID carbonate_12\NN\15010703|lithium|and|blockers (r_dobj) taking_10\VBG\37396|patients|were|also|carbonate (r_relcl) cases_5\NNS\7283608|the|3|taking (r_pobj) of_2\IN\0|cases (r_prep) 2_1\CD\13741022|of (r_pobj) in_0\IN\13603305|2 (r_prep) contributed_23\VBN\126264|in|,|both|could|have|to|. (l_prep) to_24\IN\0|incontinence (l_pobj) incontinence_26\NN\13473097|the
19300402
D001920_D006930 NONE bradykinin_0\NN\0| (r_compound) antagonists_2\NNS\7846|bradykinin|receptors|and|inhibitors|in|and|streptozotocin (r_nsubj) induced_12\VBD\1627355|antagonists|hyperalgesia|. (l_dobj) hyperalgesia_13\NN\0|in
D001920_D006930 NONE bradykinin_9\NN\0| (r_compound) receptors_10\NNS\5225602|bradykinin (r_pobj) of_8\IN\0|receptors (r_prep) inhibition_7\NN\1068773|of|and|synthase|but (r_nsubj) reduces_21\VBZ\441445|that|inhibition|activity|hyperalgesia (l_dobj) hyperalgesia_23\NN\0|diabetic
D001920_D006930 NONE bradykinin_19\NN\0| (r_conj) activation_15\NN\13561719|neuronal|no|synthase|as|bradykinin (r_conj) synthase_10\NN\0|inducible|no|and|activation (r_pobj) of_7\IN\0|synthase (r_prep) products_6\NNS\3076708|both|of (r_nsubjpass) involved_21\VBN\2676054|that|products|are|in (l_prep) in_22\IN\13603305|hyperalgesia (l_pobj) hyperalgesia_23\NN\0|produced
D001920_D006930 NONE bradykinin_14\NN\0| (r_pobj) of_13\IN\0|bradykinin (r_prep) activity_12\NN\30358|pronociceptive|of (r_pobj) in_10\IN\13603305|activity (r_prep) participates_9\VBZ\2367363|in|,|synthase|in|,|induced|seemed (l_prep) in_0\IN\13603305|hyperalgesia (l_pobj) hyperalgesia_4\NN\0|induced
D001920_D006930 NONE bradykinin_14\NN\0| (r_pobj) of_13\IN\0|bradykinin (r_prep) activity_12\NN\30358|pronociceptive|of (r_pobj) in_10\IN\13603305|activity (r_prep) participates_9\VBZ\2367363|in|,|synthase|in|,|induced|seemed (l_advcl) induced_20\VBN\1627355|whereas|in|-|hyperalgesia (l_dobj) hyperalgesia_21\NN\0|
D001920_D006930 NONE bradykinin_22\NN\0| (r_nsubj) seemed_23\VBD\2604760|bradykinin|activate|. (r_conj) participates_9\VBZ\2367363|in|,|synthase|in|,|induced|seemed (l_prep) in_0\IN\13603305|hyperalgesia (l_pobj) hyperalgesia_4\NN\0|induced
D001920_D006930 NONE bradykinin_22\NN\0| (r_nsubj) seemed_23\VBD\2604760|bradykinin|activate|. (r_conj) participates_9\VBZ\2367363|in|,|synthase|in|,|induced|seemed (l_advcl) induced_20\VBN\1627355|whereas|in|-|hyperalgesia (l_dobj) hyperalgesia_21\NN\0|
D001920_D003929 NONE bradykinin_0\NN\0| (r_compound) antagonists_2\NNS\7846|bradykinin|receptors|and|inhibitors|in|and|streptozotocin (r_nsubj) induced_12\VBD\1627355|antagonists|hyperalgesia|. (l_dobj) hyperalgesia_13\NN\0|in (l_prep) in_14\IN\13603305|chemotherapy (l_pobj) chemotherapy_15\NN\661091|and|model (l_conj) model_20\NN\5888929|diabetic|rat (l_compound) rat_19\NN\2329401|neuropathy (l_compound) neuropathy_18\NN\14204950|
D009569_D006930 NONE oxide_5\NN\14818238| (r_compound) synthase_6\NN\0|nitric|oxide (r_compound) inhibitors_7\NNS\20090|synthase (r_conj) antagonists_2\NNS\7846|bradykinin|receptors|and|inhibitors|in|and|streptozotocin (r_nsubj) induced_12\VBD\1627355|antagonists|hyperalgesia|. (l_dobj) hyperalgesia_13\NN\0|in
D009569_D006930 NONE no_13\DT\7204911| (r_det) synthase_14\NN\0|inducible|no (r_conj) inhibition_7\NN\1068773|of|and|synthase|but (r_nsubj) reduces_21\VBZ\441445|that|inhibition|activity|hyperalgesia (l_dobj) hyperalgesia_23\NN\0|diabetic
D009569_D006930 NONE no_18\DT\7204911| (r_det) activity_20\NN\30358|not|neuronal|no|synthase (r_nsubj) reduces_21\VBZ\441445|that|inhibition|activity|hyperalgesia (l_dobj) hyperalgesia_23\NN\0|diabetic
D009569_D006930 NONE no_9\DT\7204911| (r_compound) synthase_10\NN\0|inducible|no|and|activation (r_pobj) of_7\IN\0|synthase (r_prep) products_6\NNS\3076708|both|of (r_nsubjpass) involved_21\VBN\2676054|that|products|are|in (l_prep) in_22\IN\13603305|hyperalgesia (l_pobj) hyperalgesia_23\NN\0|produced
D009569_D006930 NONE no_13\DT\7204911| (r_det) activation_15\NN\13561719|neuronal|no|synthase|as|bradykinin (r_conj) synthase_10\NN\0|inducible|no|and|activation (r_pobj) of_7\IN\0|synthase (r_prep) products_6\NNS\3076708|both|of (r_nsubjpass) involved_21\VBN\2676054|that|products|are|in (l_prep) in_22\IN\13603305|hyperalgesia (l_pobj) hyperalgesia_23\NN\0|produced
D009569_D006930 NONE no_7\DT\7204911| (r_compound) synthase_8\NN\0|inducible|no (r_nsubj) participates_9\VBZ\2367363|in|,|synthase|in|,|induced|seemed (l_prep) in_0\IN\13603305|hyperalgesia (l_pobj) hyperalgesia_4\NN\0|induced
D009569_D006930 NONE no_7\DT\7204911| (r_compound) synthase_8\NN\0|inducible|no (r_nsubj) participates_9\VBZ\2367363|in|,|synthase|in|,|induced|seemed (l_advcl) induced_20\VBN\1627355|whereas|in|-|hyperalgesia (l_dobj) hyperalgesia_21\NN\0|
D009569_D006930 NONE no_27\DT\7204911| (r_det) pathway_29\NN\5483677|neuronal|no|synthase (r_dobj) activate_25\VB\1641914|to|pathway (r_xcomp) seemed_23\VBD\2604760|bradykinin|activate|. (r_conj) participates_9\VBZ\2367363|in|,|synthase|in|,|induced|seemed (l_prep) in_0\IN\13603305|hyperalgesia (l_pobj) hyperalgesia_4\NN\0|induced
D009569_D006930 NONE no_27\DT\7204911| (r_det) pathway_29\NN\5483677|neuronal|no|synthase (r_dobj) activate_25\VB\1641914|to|pathway (r_xcomp) seemed_23\VBD\2604760|bradykinin|activate|. (r_conj) participates_9\VBZ\2367363|in|,|synthase|in|,|induced|seemed (l_advcl) induced_20\VBN\1627355|whereas|in|-|hyperalgesia (l_dobj) hyperalgesia_21\NN\0|
D009569_D003929 NONE oxide_5\NN\14818238| (r_compound) synthase_6\NN\0|nitric|oxide (r_compound) inhibitors_7\NNS\20090|synthase (r_conj) antagonists_2\NNS\7846|bradykinin|receptors|and|inhibitors|in|and|streptozotocin (r_nsubj) induced_12\VBD\1627355|antagonists|hyperalgesia|. (l_dobj) hyperalgesia_13\NN\0|in (l_prep) in_14\IN\13603305|chemotherapy (l_pobj) chemotherapy_15\NN\661091|and|model (l_conj) model_20\NN\5888929|diabetic|rat (l_compound) rat_19\NN\2329401|neuropathy (l_compound) neuropathy_18\NN\14204950|
D014750_D006930 CID vincristine_9\NN\3917455| (r_pobj) in_8\IN\13603305|vincristine (r_prep) antagonists_2\NNS\7846|bradykinin|receptors|and|inhibitors|in|and|streptozotocin (r_nsubj) induced_12\VBD\1627355|antagonists|hyperalgesia|. (l_dobj) hyperalgesia_13\NN\0|in
D014750_D006930 CID vincristine_26\NN\3917455| (r_pobj) by_25\IN\0|vincristine (r_agent) produced_24\VBN\1617192|by (r_acl) hyperalgesia_23\NN\0|produced
D014750_D006930 CID vincristine_18\NN\3917455| (r_pobj) in_17\IN\13603305|vincristine (r_prep) induced_20\VBN\1627355|whereas|in|-|hyperalgesia (r_advcl) participates_9\VBZ\2367363|in|,|synthase|in|,|induced|seemed (l_prep) in_0\IN\13603305|hyperalgesia (l_pobj) hyperalgesia_4\NN\0|induced
D014750_D006930 CID vincristine_18\NN\3917455| (r_pobj) in_17\IN\13603305|vincristine (r_prep) induced_20\VBN\1627355|whereas|in|-|hyperalgesia (l_dobj) hyperalgesia_21\NN\0|
D014750_D003929 NONE vincristine_9\NN\3917455| (r_pobj) in_8\IN\13603305|vincristine (r_prep) antagonists_2\NNS\7846|bradykinin|receptors|and|inhibitors|in|and|streptozotocin (r_nsubj) induced_12\VBD\1627355|antagonists|hyperalgesia|. (l_dobj) hyperalgesia_13\NN\0|in (l_prep) in_14\IN\13603305|chemotherapy (l_pobj) chemotherapy_15\NN\661091|and|model (l_conj) model_20\NN\5888929|diabetic|rat (l_compound) rat_19\NN\2329401|neuropathy (l_compound) neuropathy_18\NN\14204950|
D013311_D006930 CID streptozotocin_11\NNS\0| (r_conj) antagonists_2\NNS\7846|bradykinin|receptors|and|inhibitors|in|and|streptozotocin (r_nsubj) induced_12\VBD\1627355|antagonists|hyperalgesia|. (l_dobj) hyperalgesia_13\NN\0|in
D013311_D006930 CID streptozotocin_1\JJ\0| (r_npadvmod) induced_3\VBN\1627355|streptozotocin|- (r_amod) hyperalgesia_4\NN\0|induced
D013311_D006930 CID streptozotocin_1\JJ\0| (r_npadvmod) induced_3\VBN\1627355|streptozotocin|- (r_amod) hyperalgesia_4\NN\0|induced (r_pobj) in_0\IN\13603305|hyperalgesia (r_prep) participates_9\VBZ\2367363|in|,|synthase|in|,|induced|seemed (l_advcl) induced_20\VBN\1627355|whereas|in|-|hyperalgesia (l_dobj) hyperalgesia_21\NN\0|
D013311_D003929 CID streptozotocin_11\NNS\0| (r_conj) antagonists_2\NNS\7846|bradykinin|receptors|and|inhibitors|in|and|streptozotocin (r_nsubj) induced_12\VBD\1627355|antagonists|hyperalgesia|. (l_dobj) hyperalgesia_13\NN\0|in (l_prep) in_14\IN\13603305|chemotherapy (l_pobj) chemotherapy_15\NN\661091|and|model (l_conj) model_20\NN\5888929|diabetic|rat (l_compound) rat_19\NN\2329401|neuropathy (l_compound) neuropathy_18\NN\14204950|
D001920_D009437 NONE bradykinin_8\NN\0|antagonists (r_pobj) of_7\IN\0|bradykinin (r_prep) doses_6\NNS\3740161|small|of (r_pobj) of_4\IN\0|doses (r_prep) administration_3\NN\1133281|concomitant|of (r_nsubj) be_16\VB\14625458|therefore|,|administration|can|effective|,|in|. (l_acomp) effective_17\JJ\0|in (l_prep) in_18\IN\13603305|alleviation (l_pobj) alleviation_19\NN\7492516|of (l_prep) of_20\IN\0|pain (l_pobj) pain_22\NN\14299637|neuropathic
D009569_D009437 NONE no_12\DT\7204911| (r_det) inhibitors_14\NNS\20090|no|synthase (r_conj) antagonists_10\NNS\7846|receptor|and|inhibitors (r_dobj) bradykinin_8\NN\0|antagonists (r_pobj) of_7\IN\0|bradykinin (r_prep) doses_6\NNS\3740161|small|of (r_pobj) of_4\IN\0|doses (r_prep) administration_3\NN\1133281|concomitant|of (r_nsubj) be_16\VB\14625458|therefore|,|administration|can|effective|,|in|. (l_acomp) effective_17\JJ\0|in (l_prep) in_18\IN\13603305|alleviation (l_pobj) alleviation_19\NN\7492516|of (l_prep) of_20\IN\0|pain (l_pobj) pain_22\NN\14299637|neuropathic
21029050
D013390_D001049 CID succinylcholine_9\NN\3800001|for (r_pobj) after_8\IN\0|succinylcholine (r_prep) mutations_2\NNS\4475|gene|in|after|. (l_prep) in_3\IN\13603305|patients (l_pobj) patients_4\NNS\9898892|with (l_prep) with_5\IN\0|apnea (l_pobj) apnea_7\NN\14299637|prolonged
D013390_D001049 CID succinylcholine_11\NN\3800001| (r_pobj) of_10\IN\0|succinylcholine (r_prep) action_9\NN\30358|of (r_pobj) of_8\IN\0|action (r_prep) duration_7\NN\15113229|a|prolonged|of (r_pobj) with_4\IN\0|duration (r_prep) patients_3\NNS\9898892|13|with (r_pobj) of_1\IN\0|patients (r_prep) eleven_0\CD\13745420|of (r_nsubj) had_12\VBD\0|eleven|mutations|,|indicating|. (l_advcl) indicating_17\VBG\952524|is (l_ccomp) is_20\VBZ\0|that|this|reason (l_attr) reason_23\NN\9178821|the|possible|for (l_prep) for_24\IN\0|period (l_pobj) period_27\NN\13575869|a|prolonged|of (l_prep) of_28\IN\0|apnea (l_pobj) apnea_29\NN\14299637|
10737864
D003000_D001919 CID clonidine_14\NN\2721160|that (r_pobj) given_12\VBN\5892096|clonidine (r_prep) induces_15\VBZ\1627355|given|withdrawal (l_dobj) withdrawal_17\NN\7206096|sympathetic|and|bradycardia (l_conj) bradycardia_19\NNP\14110674|
D003000_D001919 CID clonidine_24\NN\2721160|'s (r_poss) effects_27\NNS\13245626|clonidine|developmental|on (r_nsubj) mirror_35\VB\4069276|that|effects|would|other (r_ccomp) hypothesized_22\VBD\719734|exhibits|,|we|mirror|. (l_ccomp) exhibits_5\VBZ\6733939|given|pattern|,|and|induces (l_conj) induces_15\VBZ\1627355|given|withdrawal (l_dobj) withdrawal_17\NN\7206096|sympathetic|and|bradycardia (l_conj) bradycardia_19\NNP\14110674|
D003000_D001919 CID clonidine_19\NN\2721160| (r_npadvmod) induced_21\VBN\1627355|clonidine|- (r_amod) bradycardia_22\NN\14110674|induced
18544179
D005283_D009325 NONE fentanyl_1\NN\2707683| (r_dobj) omitting_0\VBG\471711|fentanyl (r_csubj) reduces_2\VBZ\441445|omitting|nausea|,|without|,|after|. (l_dobj) nausea_3\NN\14299637|and|vomiting
D005283_D009325 NONE fentanyl_2\NN\2707683| (r_pobj) of_1\IN\0|fentanyl (r_prep) omission_0\NN\70965|of (r_nsubj) reduce_5\VB\441445|omission|did|not|incidence|,|but|reduce|. (l_conj) reduce_17\VB\441445|did|incidence|and/or|moderate|prior|,|to (l_conj) moderate_23\JJ\9605289|to (l_prep) to_24\TO\0|nausea (l_pobj) nausea_26\NN\14299637|severe
D005283_D009325 NONE fentanyl_37\NN\2707683|and (r_nmod) dexamethasone_41\NN\2721538|fentanyl|fentanyl|- (r_pobj) with_36\IN\0|dexamethasone (r_prep) %_35\NN\0|17|with (r_conj) %_32\NN\0|20|and|% (r_pobj) from_30\IN\0|% (r_prep) discharge_29\NN\7283608|from|,|respectively (r_pobj) to_28\IN\0|discharge (r_prep) prior_27\RB\10675876|to (r_advmod) reduce_17\VB\441445|did|incidence|and/or|moderate|prior|,|to (l_conj) moderate_23\JJ\9605289|to (l_prep) to_24\TO\0|nausea (l_pobj) nausea_26\NN\14299637|severe
D005283_D009325 NONE fentanyl_39\NN\2707683| (r_compound) dexamethasone_41\NN\2721538|fentanyl|fentanyl|- (r_pobj) with_36\IN\0|dexamethasone (r_prep) %_35\NN\0|17|with (r_conj) %_32\NN\0|20|and|% (r_pobj) from_30\IN\0|% (r_prep) discharge_29\NN\7283608|from|,|respectively (r_pobj) to_28\IN\0|discharge (r_prep) prior_27\RB\10675876|to (r_advmod) reduce_17\VB\441445|did|incidence|and/or|moderate|prior|,|to (l_conj) moderate_23\JJ\9605289|to (l_prep) to_24\TO\0|nausea (l_pobj) nausea_26\NN\14299637|severe
D005283_D009325 NONE fentanyl_3\NN\2707683|two (r_compound) groups_4\NNS\2137|the|fentanyl (r_dobj) combining_0\VBG\7373277|groups (r_csubj) revealed_5\VBD\2137132|combining|benefits|,|reducing|(|p|decreased|. (l_advcl) reducing_15\VBG\13447361|nausea|prior (l_dobj) nausea_17\NN\14299637|postoperative|and|vomiting (l_conj) vomiting_19\NN\116687|and|nausea (l_conj) nausea_21\NN\14299637|
D005283_D009325 NONE fentanyl_3\NN\2707683|two (r_compound) groups_4\NNS\2137|the|fentanyl (r_dobj) combining_0\VBG\7373277|groups (r_csubj) revealed_5\VBD\2137132|combining|benefits|,|reducing|(|p|decreased|. (l_advcl) decreased_57\VBN\169651|while|nausea|was|from|(|p|) (l_nsubjpass) nausea_50\NN\14299637|in|h
D005283_D014839 NONE fentanyl_1\NN\2707683| (r_dobj) omitting_0\VBG\471711|fentanyl (r_csubj) reduces_2\VBZ\441445|omitting|nausea|,|without|,|after|. (l_dobj) nausea_3\NN\14299637|and|vomiting (l_conj) vomiting_5\NN\116687|
D005283_D014839 NONE fentanyl_2\NN\2707683| (r_pobj) of_1\IN\0|fentanyl (r_prep) omission_0\NN\70965|of (r_nsubj) reduce_5\VB\441445|omission|did|not|incidence|,|but|reduce|. (l_conj) reduce_17\VB\441445|did|incidence|and/or|moderate|prior|,|to (l_dobj) incidence_19\NN\13821570|the|of (l_prep) of_20\IN\0|vomiting (l_pobj) vomiting_21\NN\116687|
D005283_D014839 NONE fentanyl_37\NN\2707683|and (r_nmod) dexamethasone_41\NN\2721538|fentanyl|fentanyl|- (r_pobj) with_36\IN\0|dexamethasone (r_prep) %_35\NN\0|17|with (r_conj) %_32\NN\0|20|and|% (r_pobj) from_30\IN\0|% (r_prep) discharge_29\NN\7283608|from|,|respectively (r_pobj) to_28\IN\0|discharge (r_prep) prior_27\RB\10675876|to (r_advmod) reduce_17\VB\441445|did|incidence|and/or|moderate|prior|,|to (l_dobj) incidence_19\NN\13821570|the|of (l_prep) of_20\IN\0|vomiting (l_pobj) vomiting_21\NN\116687|
D005283_D014839 NONE fentanyl_39\NN\2707683| (r_compound) dexamethasone_41\NN\2721538|fentanyl|fentanyl|- (r_pobj) with_36\IN\0|dexamethasone (r_prep) %_35\NN\0|17|with (r_conj) %_32\NN\0|20|and|% (r_pobj) from_30\IN\0|% (r_prep) discharge_29\NN\7283608|from|,|respectively (r_pobj) to_28\IN\0|discharge (r_prep) prior_27\RB\10675876|to (r_advmod) reduce_17\VB\441445|did|incidence|and/or|moderate|prior|,|to (l_dobj) incidence_19\NN\13821570|the|of (l_prep) of_20\IN\0|vomiting (l_pobj) vomiting_21\NN\116687|
D005283_D010146 NONE fentanyl_1\NN\2707683| (r_dobj) omitting_0\VBG\471711|fentanyl (r_csubj) reduces_2\VBZ\441445|omitting|nausea|,|without|,|after|. (l_prep) without_7\IN\0|increasing (l_pcomp) increasing_8\VBG\169651|pain (l_dobj) pain_9\NN\14299637|
D005283_D010146 NONE fentanyl_11\NN\2707683| (r_pobj) of_10\IN\0|fentanyl (r_prep) omission_9\NN\70965|the|of (r_pobj) by_7\IN\0|omission (r_prep) unaffected_6\JJ\0|by (r_acomp) were_5\VBD\0|severity|unaffected|. (l_nsubj) severity_1\NN\5036394|pain|and|requirements (l_compound) pain_0\NN\14299637|
C009250_D009325 NONE sevoflurane_12\NN\0|for (r_pobj) after_11\IN\0|sevoflurane (r_prep) reduces_2\VBZ\441445|omitting|nausea|,|without|,|after|. (l_dobj) nausea_3\NN\14299637|and|vomiting
C009250_D014839 NONE sevoflurane_12\NN\0|for (r_pobj) after_11\IN\0|sevoflurane (r_prep) reduces_2\VBZ\441445|omitting|nausea|,|without|,|after|. (l_dobj) nausea_3\NN\14299637|and|vomiting (l_conj) vomiting_5\NN\116687|
C009250_D010146 NONE sevoflurane_12\NN\0|for (r_pobj) after_11\IN\0|sevoflurane (r_prep) reduces_2\VBZ\441445|omitting|nausea|,|without|,|after|. (l_prep) without_7\IN\0|increasing (l_pcomp) increasing_8\VBG\169651|pain (l_dobj) pain_9\NN\14299637|
C009250_D010146 NONE sevoflurane_23\NN\0| (r_compound) anaesthesia_24\NN\14034177|sevoflurane|in (r_pobj) after_22\IN\0|anaesthesia (r_prep) h_21\NN\14622893|the|first|24|after (r_pobj) in_17\IN\13603305|h (r_prep) examined_5\VBD\0|study|incidence|in|. (l_dobj) incidence_7\NN\13821570|the|and|severity|of (l_prep) of_10\IN\0|nausea (l_pobj) nausea_12\NN\14299637|postoperative|and|vomiting (l_conj) vomiting_14\NN\116687|and|pain (l_conj) pain_16\NN\14299637|
C009250_D020250 NONE sevoflurane_9\NN\0|, (r_pobj) with_8\IN\0|sevoflurane (r_prep) advantages_1\NNS\5154517|of|with (r_pobj) despite_0\IN\7501545|advantages (r_prep) occurs_15\VBZ\0|despite|nausea|frequently|. (l_nsubj) nausea_12\NN\14299637|postoperative|and|vomiting (l_conj) vomiting_14\NN\116687|
C009250_D020250 NONE sevoflurane_23\NN\0| (r_compound) anaesthesia_24\NN\14034177|sevoflurane|in (r_pobj) after_22\IN\0|anaesthesia (r_prep) h_21\NN\14622893|the|first|24|after (r_pobj) in_17\IN\13603305|h (r_prep) examined_5\VBD\0|study|incidence|in|. (l_dobj) incidence_7\NN\13821570|the|and|severity|of (l_prep) of_10\IN\0|nausea (l_pobj) nausea_12\NN\14299637|postoperative|and|vomiting (l_conj) vomiting_14\NN\116687|and|pain
C009250_D020250 NONE sevoflurane_31\NN\0|to|in (r_relcl) supplement_29\NN\6365467|an|unnecessary|sevoflurane (r_attr) be_23\VB\14625458|to|supplement (r_xcomp) appears_21\VBZ\2604760|exacerbated|,|it|be|. (l_advcl) exacerbated_2\VBD\126264|as|fentanyl|nausea|and|had (l_dobj) nausea_4\NN\14299637|postoperative|and|vomiting (l_conj) vomiting_6\VBG\116687|without
D005283_D020250 CID fentanyl_2\NN\2707683| (r_pobj) of_1\IN\0|fentanyl (r_prep) omission_0\NN\70965|of (r_nsubj) reduce_5\VB\441445|omission|did|not|incidence|,|but|reduce|. (l_dobj) incidence_8\NN\13821570|the|overall|of (l_prep) of_9\IN\0|nausea (l_pobj) nausea_11\NN\14299637|postoperative|and|vomiting (l_conj) vomiting_13\NN\116687|
D005283_D020250 CID fentanyl_37\NN\2707683|and (r_nmod) dexamethasone_41\NN\2721538|fentanyl|fentanyl|- (r_pobj) with_36\IN\0|dexamethasone (r_prep) %_35\NN\0|17|with (r_conj) %_32\NN\0|20|and|% (r_pobj) from_30\IN\0|% (r_prep) discharge_29\NN\7283608|from|,|respectively (r_pobj) to_28\IN\0|discharge (r_prep) prior_27\RB\10675876|to (r_advmod) reduce_17\VB\441445|did|incidence|and/or|moderate|prior|,|to (r_conj) reduce_5\VB\441445|omission|did|not|incidence|,|but|reduce|. (l_dobj) incidence_8\NN\13821570|the|overall|of (l_prep) of_9\IN\0|nausea (l_pobj) nausea_11\NN\14299637|postoperative|and|vomiting (l_conj) vomiting_13\NN\116687|
D005283_D020250 CID fentanyl_39\NN\2707683| (r_compound) dexamethasone_41\NN\2721538|fentanyl|fentanyl|- (r_pobj) with_36\IN\0|dexamethasone (r_prep) %_35\NN\0|17|with (r_conj) %_32\NN\0|20|and|% (r_pobj) from_30\IN\0|% (r_prep) discharge_29\NN\7283608|from|,|respectively (r_pobj) to_28\IN\0|discharge (r_prep) prior_27\RB\10675876|to (r_advmod) reduce_17\VB\441445|did|incidence|and/or|moderate|prior|,|to (r_conj) reduce_5\VB\441445|omission|did|not|incidence|,|but|reduce|. (l_dobj) incidence_8\NN\13821570|the|overall|of (l_prep) of_9\IN\0|nausea (l_pobj) nausea_11\NN\14299637|postoperative|and|vomiting (l_conj) vomiting_13\NN\116687|
D005283_D020250 CID fentanyl_3\NN\2707683|two (r_compound) groups_4\NNS\2137|the|fentanyl (r_dobj) combining_0\VBG\7373277|groups (r_csubj) revealed_5\VBD\2137132|combining|benefits|,|reducing|(|p|decreased|. (l_advcl) reducing_15\VBG\13447361|nausea|prior (l_dobj) nausea_17\NN\14299637|postoperative|and|vomiting (l_conj) vomiting_19\NN\116687|and|nausea
D005283_D020250 CID fentanyl_1\NN\2707683| (r_nsubj) exacerbated_2\VBD\126264|as|fentanyl|nausea|and|had (l_dobj) nausea_4\NN\14299637|postoperative|and|vomiting (l_conj) vomiting_6\VBG\116687|without
D003907_D020250 NONE dexamethasone_41\NN\2721538|fentanyl|fentanyl|- (r_pobj) with_36\IN\0|dexamethasone (r_prep) %_35\NN\0|17|with (r_conj) %_32\NN\0|20|and|% (r_pobj) from_30\IN\0|% (r_prep) discharge_29\NN\7283608|from|,|respectively (r_pobj) to_28\IN\0|discharge (r_prep) prior_27\RB\10675876|to (r_advmod) reduce_17\VB\441445|did|incidence|and/or|moderate|prior|,|to (r_conj) reduce_5\VB\441445|omission|did|not|incidence|,|but|reduce|. (l_dobj) incidence_8\NN\13821570|the|overall|of (l_prep) of_9\IN\0|nausea (l_pobj) nausea_11\NN\14299637|postoperative|and|vomiting (l_conj) vomiting_13\NN\116687|
D003907_D020250 NONE dexamethasone_0\NNP\2721538| (r_nsubj) had_1\VBD\0|dexamethasone|effect|. (l_dobj) effect_4\NN\34213|no|significant|on (l_prep) on_5\IN\0|incidence (l_pobj) incidence_7\NN\13821570|the|or|severity|of (l_prep) of_10\IN\0|nausea (l_pobj) nausea_12\NN\14299637|postoperative|and|vomiting (l_conj) vomiting_14\NN\116687|
D003907_D014839 NONE dexamethasone_41\NN\2721538|fentanyl|fentanyl|- (r_pobj) with_36\IN\0|dexamethasone (r_prep) %_35\NN\0|17|with (r_conj) %_32\NN\0|20|and|% (r_pobj) from_30\IN\0|% (r_prep) discharge_29\NN\7283608|from|,|respectively (r_pobj) to_28\IN\0|discharge (r_prep) prior_27\RB\10675876|to (r_advmod) reduce_17\VB\441445|did|incidence|and/or|moderate|prior|,|to (l_dobj) incidence_19\NN\13821570|the|of (l_prep) of_20\IN\0|vomiting (l_pobj) vomiting_21\NN\116687|
D003907_D009325 NONE dexamethasone_41\NN\2721538|fentanyl|fentanyl|- (r_pobj) with_36\IN\0|dexamethasone (r_prep) %_35\NN\0|17|with (r_conj) %_32\NN\0|20|and|% (r_pobj) from_30\IN\0|% (r_prep) discharge_29\NN\7283608|from|,|respectively (r_pobj) to_28\IN\0|discharge (r_prep) prior_27\RB\10675876|to (r_advmod) reduce_17\VB\441445|did|incidence|and/or|moderate|prior|,|to (l_conj) moderate_23\JJ\9605289|to (l_prep) to_24\TO\0|nausea (l_pobj) nausea_26\NN\14299637|severe
D005283_D012131 CID fentanyl_0\NNP\2707683| (r_nsubj) reduce_2\VB\441445|fentanyl|did|movement|but|had|. (l_conj) had_7\VBD\0|effect|and|depression (l_conj) depression_16\NN\14373582|increased|respiratory|,|hypotension
D005283_D007022 CID fentanyl_0\NNP\2707683| (r_nsubj) reduce_2\VB\441445|fentanyl|did|movement|but|had|. (l_conj) had_7\VBD\0|effect|and|depression (l_conj) depression_16\NN\14373582|increased|respiratory|,|hypotension (l_conj) hypotension_18\NN\14057371|and|bradycardia
D005283_D001919 CID fentanyl_0\NNP\2707683| (r_nsubj) reduce_2\VB\441445|fentanyl|did|movement|but|had|. (l_conj) had_7\VBD\0|effect|and|depression (l_conj) depression_16\NN\14373582|increased|respiratory|,|hypotension (l_conj) hypotension_18\NN\14057371|and|bradycardia (l_conj) bradycardia_20\NN\14110674|
C009250_D012131 NONE sevoflurane_9\NN\0| (r_npadvmod) sparing_11\VBG\2725714|sevoflurane|- (r_amod) effect_12\NN\34213|no|sparing (r_dobj) had_7\VBD\0|effect|and|depression (l_conj) depression_16\NN\14373582|increased|respiratory|,|hypotension
C009250_D007022 NONE sevoflurane_9\NN\0| (r_npadvmod) sparing_11\VBG\2725714|sevoflurane|- (r_amod) effect_12\NN\34213|no|sparing (r_dobj) had_7\VBD\0|effect|and|depression (l_conj) depression_16\NN\14373582|increased|respiratory|,|hypotension (l_conj) hypotension_18\NN\14057371|and|bradycardia
C009250_D001919 NONE sevoflurane_9\NN\0| (r_npadvmod) sparing_11\VBG\2725714|sevoflurane|- (r_amod) effect_12\NN\34213|no|sparing (r_dobj) had_7\VBD\0|effect|and|depression (l_conj) depression_16\NN\14373582|increased|respiratory|,|hypotension (l_conj) hypotension_18\NN\14057371|and|bradycardia (l_conj) bradycardia_20\NN\14110674|
D005283_D010149 NONE fentanyl_1\NN\2707683| (r_nsubj) exacerbated_2\VBD\126264|as|fentanyl|nausea|and|had (l_dobj) nausea_4\NN\14299637|postoperative|and|vomiting (l_conj) vomiting_6\VBG\116687|without (l_prep) without_7\IN\0|improvement (l_pobj) improvement_9\NN\7359599|an|in (l_prep) in_10\IN\13603305|pain (l_pobj) pain_12\NN\14299637|postoperative
C009250_D010149 NONE sevoflurane_31\NN\0|to|in (r_relcl) supplement_29\NN\6365467|an|unnecessary|sevoflurane (r_attr) be_23\VB\14625458|to|supplement (r_xcomp) appears_21\VBZ\2604760|exacerbated|,|it|be|. (l_advcl) exacerbated_2\VBD\126264|as|fentanyl|nausea|and|had (l_dobj) nausea_4\NN\14299637|postoperative|and|vomiting (l_conj) vomiting_6\VBG\116687|without (l_prep) without_7\IN\0|improvement (l_pobj) improvement_9\NN\7359599|an|in (l_prep) in_10\IN\13603305|pain (l_pobj) pain_12\NN\14299637|postoperative
11672959
D012460_D003872 CID sulphasalazine_27\NN\0|oral|for (r_pobj) of_25\IN\0|sulphasalazine (r_prep) course_24\NN\883297|a|of (r_pobj) of_22\IN\0|course (r_prep) day_21\NN\15154774|the|17th|of (r_pobj) on_18\IN\0|day (r_prep) beginning_17\VBG\7283608|on (r_advcl) developed_5\VBD\1753788|lady|constellation|,|beginning|. (l_dobj) constellation_7\NN\5728678|a|of (l_prep) of_8\IN\0|dermatitis (l_pobj) dermatitis_9\NN\14226056|,|fever
D012460_D005334 CID sulphasalazine_27\NN\0|oral|for (r_pobj) of_25\IN\0|sulphasalazine (r_prep) course_24\NN\883297|a|of (r_pobj) of_22\IN\0|course (r_prep) day_21\NN\15154774|the|17th|of (r_pobj) on_18\IN\0|day (r_prep) beginning_17\VBG\7283608|on (r_advcl) developed_5\VBD\1753788|lady|constellation|,|beginning|. (l_dobj) constellation_7\NN\5728678|a|of (l_prep) of_8\IN\0|dermatitis (l_pobj) dermatitis_9\NN\14226056|,|fever (l_conj) fever_11\NN\14299637|,|lymphadenopathy
D012460_D008206 CID sulphasalazine_27\NN\0|oral|for (r_pobj) of_25\IN\0|sulphasalazine (r_prep) course_24\NN\883297|a|of (r_pobj) of_22\IN\0|course (r_prep) day_21\NN\15154774|the|17th|of (r_pobj) on_18\IN\0|day (r_prep) beginning_17\VBG\7283608|on (r_advcl) developed_5\VBD\1753788|lady|constellation|,|beginning|. (l_dobj) constellation_7\NN\5728678|a|of (l_prep) of_8\IN\0|dermatitis (l_pobj) dermatitis_9\NN\14226056|,|fever (l_conj) fever_11\NN\14299637|,|lymphadenopathy (l_conj) lymphadenopathy_13\NN\14204950|and|hepatitis
D012460_D056486 CID sulphasalazine_27\NN\0|oral|for (r_pobj) of_25\IN\0|sulphasalazine (r_prep) course_24\NN\883297|a|of (r_pobj) of_22\IN\0|course (r_prep) day_21\NN\15154774|the|17th|of (r_pobj) on_18\IN\0|day (r_prep) beginning_17\VBG\7283608|on (r_advcl) developed_5\VBD\1753788|lady|constellation|,|beginning|. (l_dobj) constellation_7\NN\5728678|a|of (l_prep) of_8\IN\0|dermatitis (l_pobj) dermatitis_9\NN\14226056|,|fever (l_conj) fever_11\NN\14299637|,|lymphadenopathy (l_conj) lymphadenopathy_13\NN\14204950|and|hepatitis (l_conj) hepatitis_15\NN\14127211|
D012460_D001172 NONE sulphasalazine_27\NN\0|oral|for (l_prep) for_28\IN\0|arthritis (l_pobj) arthritis_33\NN\14171682|negative|rheumatoid
15649445
D012110_D004409 CID reserpine_1\NN\2721160|acute|and|subchronic (r_nsubj) change_6\VBP\7283608|reserpine|haloperidol|treatments|uptake|and|elicit|. (l_conj) elicit_12\VBP\1617192|dyskinesia (l_dobj) dyskinesia_14\NN\14084880|orofacial|in
D012110_D004409 CID reserpine-_0\NNP\0|and|dyskinesia (l_conj) dyskinesia_6\NN\14084880|induced|orofacial
D012110_D004409 CID reserpine-_0\NNP\0|and|dyskinesia (r_nsubj) are_7\VBP\13600404|reserpine-|models|. (l_attr) models_10\NNS\5888929|putative|animal|of|related (l_prep) of_11\IN\0|dyskinesia (l_pobj) dyskinesia_13\JJ\14084880|tardive|td
D012110_D004409 CID reserpine-_0\NNP\0|and|dyskinesia (r_nsubj) are_7\VBP\13600404|reserpine-|models|. (l_attr) models_10\NNS\5888929|putative|animal|of|related (l_prep) of_11\IN\0|dyskinesia (l_pobj) dyskinesia_13\JJ\14084880|tardive|td (l_appos) td_15\NN\0|(|)
D012110_D004409 CID reserpine_12\NN\2721160|acute|and|administration|to (r_pobj) by_10\IN\0|reserpine (r_prep) induced_7\VBD\1627355|in|,|authors|dyskinesia|by|. (l_dobj) dyskinesia_9\NN\14084880|orofacial
D006220_D004409 CID haloperidol_4\NN\3713736| (r_compound) change_6\VBP\7283608|reserpine|haloperidol|treatments|uptake|and|elicit|. (l_conj) elicit_12\VBP\1617192|dyskinesia (l_dobj) dyskinesia_14\NN\14084880|orofacial|in
D006220_D004409 CID haloperidol_2\NN\3713736| (r_npadvmod) induced_4\VBN\1627355|haloperidol|- (r_amod) dyskinesia_6\NN\14084880|induced|orofacial
D006220_D004409 CID haloperidol_2\NN\3713736| (r_npadvmod) induced_4\VBN\1627355|haloperidol|- (r_amod) dyskinesia_6\NN\14084880|induced|orofacial (r_conj) reserpine-_0\NNP\0|and|dyskinesia (r_nsubj) are_7\VBP\13600404|reserpine-|models|. (l_attr) models_10\NNS\5888929|putative|animal|of|related (l_prep) of_11\IN\0|dyskinesia (l_pobj) dyskinesia_13\JJ\14084880|tardive|td
D006220_D004409 CID haloperidol_2\NN\3713736| (r_npadvmod) induced_4\VBN\1627355|haloperidol|- (r_amod) dyskinesia_6\NN\14084880|induced|orofacial (r_conj) reserpine-_0\NNP\0|and|dyskinesia (r_nsubj) are_7\VBP\13600404|reserpine-|models|. (l_attr) models_10\NNS\5888929|putative|animal|of|related (l_prep) of_11\IN\0|dyskinesia (l_pobj) dyskinesia_13\JJ\14084880|tardive|td (l_appos) td_15\NN\0|(|)
D006220_D004409 CID haloperidol_15\NN\3713736| (r_compound) administration_16\NN\1133281|subchronic|haloperidol (r_conj) reserpine_12\NN\2721160|acute|and|administration|to (r_pobj) by_10\IN\0|reserpine (r_prep) induced_7\VBD\1627355|in|,|authors|dyskinesia|by|. (l_dobj) dyskinesia_9\NN\14084880|orofacial
D018698_D004409 NONE glutamate_9\NN\15010703|brain (r_compound) uptake_10\NN\13440063|synaptosomal|glutamate (r_dobj) change_6\VBP\7283608|reserpine|haloperidol|treatments|uptake|and|elicit|. (l_conj) elicit_12\VBP\1617192|dyskinesia (l_dobj) dyskinesia_14\NN\14084880|orofacial|in
D018698_D004409 NONE glutamate_5\NN\15010703| (r_compound) uptake_6\NN\13440063|glutamate (r_pobj) in_4\IN\13603305|uptake (r_prep) decrease_3\NN\7296428|a|in (r_nsubj) correlates_7\VBZ\5857459|importantly|,|decrease|negatively|with|. (l_prep) with_9\IN\0|increase (l_pobj) increase_11\NN\13576355|an|in (l_prep) in_12\IN\13603305|incidence (l_pobj) incidence_14\NN\13821570|the|of (l_prep) of_15\IN\0|diskinesia (l_pobj) diskinesia_17\NN\0|orofacial
12707296
D001120_D006973 NONE arginine_2\NN\14605787|l|- (r_compound) transport_3\NN\3575240|arginine|in|with|. (l_prep) with_6\IN\0|hypertension (l_pobj) hypertension_10\NN\14057371|induced
D001120_D006973 NONE arginine_4\NN\14605787| (r_compound) nitric_6\NN\0|l|-|arginine|- (r_compound) system_8\NN\3575240|a|deficient|nitric|oxide (r_nsubjpass) implicated_10\VBN\2677097|system|is|in|. (l_prep) in_11\IN\13603305|hypertension (l_pobj) hypertension_15\NN\14057371|induced
D001120_D006973 NONE arginine_19\NN\14605787|l|- (r_compound) system_21\NN\3575240|the|arginine|transport (r_pobj) in_15\IN\13603305|system (r_prep) abnormalities_14\NNS\14034177|in (r_pobj) with_13\IN\0|abnormalities (r_prep) associated_12\VBN\628491|that|increases|are|not|with (l_nsubjpass) increases_6\NNS\13576355|induced|in (l_prep) in_7\IN\13603305|pressure (l_pobj) pressure_9\NN\11419404|blood
D006854_D006973 NONE cortisol_7\NN\14751417| (r_npadvmod) induced_9\VBN\1627355|cortisol|- (r_amod) hypertension_10\NN\14057371|induced
D006854_D006973 NONE cortisol_12\NN\14751417| (r_npadvmod) induced_14\VBN\1627355|cortisol|- (r_amod) hypertension_15\NN\14057371|induced
D006854_D006973 NONE cortisol_3\NN\14751417| (r_npadvmod) induced_5\VBN\1627355|cortisol|- (r_amod) increases_6\NNS\13576355|induced|in (l_prep) in_7\IN\13603305|pressure (l_pobj) pressure_9\NN\11419404|blood
D009569_D006973 NONE oxide_7\NN\14818238| (r_compound) system_8\NN\3575240|a|deficient|nitric|oxide (r_nsubjpass) implicated_10\VBN\2677097|system|is|in|. (l_prep) in_11\IN\13603305|hypertension (l_pobj) hypertension_15\NN\14057371|induced
6466532
D006024_D001919 NONE glycopyrrolate_3\NN\0|i.v.|and|atropine|in (l_prep) in_6\IN\13603305|prevention (l_pobj) prevention_8\NN\1073995|the|of (l_prep) of_9\IN\0|bradycardia (l_pobj) bradycardia_10\NN\14110674|and|arrhythmias|following
D006024_D001919 NONE glycopyrrolate_5\NN\0|kg-1 (r_pobj) of_4\IN\0|glycopyrrolate (r_prep) administration_3\NN\1133281|of (r_pobj) of_2\IN\0|administration (r_prep) effectiveness_1\NN\5190804|the|of|before|,|prevent (l_acl) prevent_27\VB\0|to|arrhythmia|following (l_dobj) arrhythmia_28\NN\14103288|and|bradycardia (l_conj) bradycardia_30\NNP\14110674|
D006024_D001145 NONE glycopyrrolate_3\NN\0|i.v.|and|atropine|in (l_prep) in_6\IN\13603305|prevention (l_pobj) prevention_8\NN\1073995|the|of (l_prep) of_9\IN\0|bradycardia (l_pobj) bradycardia_10\NN\14110674|and|arrhythmias|following (l_conj) arrhythmias_12\NNS\14103288|
D006024_D001145 NONE glycopyrrolate_5\NN\0|kg-1 (r_pobj) of_4\IN\0|glycopyrrolate (r_prep) administration_3\NN\1133281|of (r_pobj) of_2\IN\0|administration (r_prep) effectiveness_1\NN\5190804|the|of|before|,|prevent (l_acl) prevent_27\VB\0|to|arrhythmia|following (l_dobj) arrhythmia_28\NN\14103288|and|bradycardia
D001285_D001919 NONE atropine_5\NN\14712692| (r_conj) glycopyrrolate_3\NN\0|i.v.|and|atropine|in (l_prep) in_6\IN\13603305|prevention (l_pobj) prevention_8\NN\1073995|the|of (l_prep) of_9\IN\0|bradycardia (l_pobj) bradycardia_10\NN\14110674|and|arrhythmias|following
D001285_D001919 NONE atropine_12\NN\14712692|micrograms (r_conj) kg-1_10\NNS\0|micrograms|and|atropine (r_dobj) glycopyrrolate_5\NN\0|kg-1 (r_pobj) of_4\IN\0|glycopyrrolate (r_prep) administration_3\NN\1133281|of (r_pobj) of_2\IN\0|administration (r_prep) effectiveness_1\NN\5190804|the|of|before|,|prevent (l_acl) prevent_27\VB\0|to|arrhythmia|following (l_dobj) arrhythmia_28\NN\14103288|and|bradycardia (l_conj) bradycardia_30\NNP\14110674|
D001285_D001145 NONE atropine_5\NN\14712692| (r_conj) glycopyrrolate_3\NN\0|i.v.|and|atropine|in (l_prep) in_6\IN\13603305|prevention (l_pobj) prevention_8\NN\1073995|the|of (l_prep) of_9\IN\0|bradycardia (l_pobj) bradycardia_10\NN\14110674|and|arrhythmias|following (l_conj) arrhythmias_12\NNS\14103288|
D001285_D001145 NONE atropine_12\NN\14712692|micrograms (r_conj) kg-1_10\NNS\0|micrograms|and|atropine (r_dobj) glycopyrrolate_5\NN\0|kg-1 (r_pobj) of_4\IN\0|glycopyrrolate (r_prep) administration_3\NN\1133281|of (r_pobj) of_2\IN\0|administration (r_prep) effectiveness_1\NN\5190804|the|of|before|,|prevent (l_acl) prevent_27\VB\0|to|arrhythmia|following (l_dobj) arrhythmia_28\NN\14103288|and|bradycardia
D013390_D001919 CID suxamethonium_17\NN\0|in (r_pobj) of_16\IN\0|suxamethonium (r_prep) doses_15\NNS\3740161|repeated|of (r_pobj) following_13\VBG\8180190|doses (r_prep) bradycardia_10\NN\14110674|and|arrhythmias|following
D013390_D001919 CID suxamethonium_35\NN\0|in (r_pobj) of_34\IN\0|suxamethonium (r_prep) doses_33\NNS\3740161|repeated|of (r_pobj) following_31\VBG\8180190|doses (r_prep) prevent_27\VB\0|to|arrhythmia|following (l_dobj) arrhythmia_28\NN\14103288|and|bradycardia (l_conj) bradycardia_30\NNP\14110674|
D013390_D001145 NONE suxamethonium_17\NN\0|in (r_pobj) of_16\IN\0|suxamethonium (r_prep) doses_15\NNS\3740161|repeated|of (r_pobj) following_13\VBG\8180190|doses (r_prep) bradycardia_10\NN\14110674|and|arrhythmias|following (l_conj) arrhythmias_12\NNS\14103288|
D013390_D001145 NONE suxamethonium_35\NN\0|in (r_pobj) of_34\IN\0|suxamethonium (r_prep) doses_33\NNS\3740161|repeated|of (r_pobj) following_31\VBG\8180190|doses (r_prep) prevent_27\VB\0|to|arrhythmia|following (l_dobj) arrhythmia_28\NN\14103288|and|bradycardia
9672936
D008614_D012640 CID pethidine_0\NNP\0| (r_npadvmod) associated_2\VBN\628491|pethidine|- (r_amod) seizure_3\NN\14081375|associated|in|.
D008614_D012640 CID pethidine_9\NN\0| (r_dobj) receiving_8\VBG\2210855|pethidine|for (r_acl) adolescent_7\JJ\9622049|a|healthy|receiving (r_pobj) in_4\IN\13603305|adolescent (r_prep) seizure_3\NN\14081375|associated|in|.
D008614_D010149 NONE pethidine_0\NNP\0| (r_npadvmod) associated_2\VBN\628491|pethidine|- (r_amod) seizure_3\NN\14081375|associated|in|. (l_prep) in_4\IN\13603305|adolescent (l_pobj) adolescent_7\JJ\9622049|a|healthy|receiving (l_acl) receiving_8\VBG\2210855|pethidine|for (l_prep) for_10\IN\0|control (l_pobj) control_13\NN\5190804|postoperative|pain (l_compound) pain_12\NN\14299637|
D008614_D010149 NONE pethidine_9\NN\0| (r_dobj) receiving_8\VBG\2210855|pethidine|for (l_prep) for_10\IN\0|control (l_pobj) control_13\NN\5190804|postoperative|pain (l_compound) pain_12\NN\14299637|
D008614_D010149 NONE pethidine_11\NN\0| (r_pobj) of_10\IN\0|pethidine (r_prep) doses_9\NNS\3740161|a|healthy|old|received|standard|intermittent|of|via (r_nsubj) pump_21\NN\3736970|doses|for|. (l_prep) for_22\IN\0|management (l_pobj) management_23\NN\1123598|of (l_prep) of_24\IN\0|control (l_pobj) control_27\NN\5190804|postoperative|pain (l_compound) pain_26\NN\14299637|
10579464
C121249_D006948 NONE nra0160_0\NNP\0|and|clozapine (r_nsubj) antagonized_3\VBN\1787955|nra0160|hyperactivity|. (l_dobj) hyperactivity_5\NN\14052403|locomotor|induced
D003024_D006948 NONE clozapine_2\NN\3713736| (r_conj) nra0160_0\NNP\0|and|clozapine (r_nsubj) antagonized_3\VBN\1787955|nra0160|hyperactivity|. (l_dobj) hyperactivity_5\NN\14052403|locomotor|induced
D008694_D006948 CID methamphetamine_8\NN\2704153|(|map|) (r_pobj) by_7\IN\0|methamphetamine (r_agent) induced_6\VBN\1627355|by|in (r_acl) hyperactivity_5\NN\14052403|locomotor|induced
D008694_D006948 CID map_10\NNP\4076846| (r_appos) methamphetamine_8\NN\2704153|(|map|) (r_pobj) by_7\IN\0|methamphetamine (r_agent) induced_6\VBN\1627355|by|in (r_acl) hyperactivity_5\NN\14052403|locomotor|induced
C121249_D002375 CID nra0160_0\NNP\0|and|clozapine (r_nsubj) induced_4\VBN\1627355|nra0160|significantly|catalepsy|in|,|exceed|. (l_dobj) catalepsy_5\NN\14023236|
D003024_D002375 CID clozapine_2\NN\3713736| (r_conj) nra0160_0\NNP\0|and|clozapine (r_nsubj) induced_4\VBN\1627355|nra0160|significantly|catalepsy|in|,|exceed|. (l_dobj) catalepsy_5\NN\14023236|
14568327
D007980_D004409 CID levodopa_2\NN\14604959| (r_npadvmod) induced_4\VBN\1627355|levodopa|- (r_amod) dyskinesias_5\NNS\14084880|induced|in
D007980_D004409 CID levodopa_0\NNP\14604959| (r_npadvmod) induced_2\VBN\1627355|levodopa|- (r_amod) dyskinesias_3\NNS\14084880|induced|(|lids|)
D007980_D004409 CID levodopa_0\NNP\14604959| (r_npadvmod) induced_2\VBN\1627355|levodopa|- (r_amod) dyskinesias_3\NNS\14084880|induced|(|lids|) (l_appos) lids_5\NNPS\5313679|
D007980_D004409 CID levodopa_34\NN\14604959| (r_compound) therapy_35\NN\657604|levodopa (r_pobj) of_33\IN\0|therapy (r_prep) duration_32\NN\15113229|of (r_conj) response_29\NN\11410625|to|and|duration (r_conj) severity_26\NN\5036394|rate|,|symptom|,|and|response (r_nsubjpass) involved_38\VBN\2676054|to|severity|may|be|in (l_prep) in_39\IN\13603305|development (l_pobj) development_41\NN\248977|the|of (l_prep) of_42\IN\0|lids (l_pobj) lids_43\NNS\5313679|
D007980_D004409 CID levodopa_22\NN\14604959| (r_compound) therapy_23\NN\657604|levodopa (r_pobj) of_21\IN\0|therapy (r_prep) initiation_20\NN\7450842|of (r_pobj) to_19\IN\0|initiation (r_prep) prior_18\RB\10675876|to (r_advmod) developed_24\VBD\1753788|monkeys|prior|dyskinesia|days|. (l_dobj) dyskinesia_25\RB\14084880|
D007980_D004409 CID levodopa_33\JJ\14604959| (r_compound) administration_34\NN\1133281|daily|levodopa (r_pobj) of_31\IN\0|administration (r_prep) days_30\NNS\15140892|11|of (r_npadvmod) developed_24\VBD\1753788|monkeys|prior|dyskinesia|days|. (l_dobj) dyskinesia_25\RB\14084880|
D007980_D004409 CID levodopa_22\NN\14604959| (r_compound) therapy_23\NN\657604|levodopa (r_pobj) of_21\IN\0|therapy (r_prep) initiation_20\NN\7450842|of (r_pobj) to_19\IN\0|initiation (r_prep) prior_18\RB\10675876|to (r_advmod) progression_13\NN\8457976|in|,|monkeys|,|slow|symptom|and/or|duration|prior (r_nsubj) were_24\VBD\0|progression|resistant|developed|. (l_acomp) resistant_26\JJ\0|more|to (l_prep) to_27\IN\0|developing (l_pcomp) developing_28\VBG\13541167|lids (l_dobj) lids_29\NNS\5313679|
D007980_D004409 CID levodopa_22\NN\14604959| (r_compound) therapy_23\NN\657604|levodopa (r_pobj) of_21\IN\0|therapy (r_prep) initiation_20\NN\7450842|of (r_pobj) to_19\IN\0|initiation (r_prep) prior_18\RB\10675876|to (r_advmod) progression_13\NN\8457976|in|,|monkeys|,|slow|symptom|and/or|duration|prior (r_nsubj) were_24\VBD\0|progression|resistant|developed|. (l_parataxis) developed_34\VBD\1753788|(|e.g.|,|dyskinesia|sooner|) (l_nsubj) dyskinesia_33\NN\14084880|
D007980_D004409 CID levodopa_42\JJ\14604959| (r_compound) administration_43\NN\1133281|chronic|levodopa (r_pobj) of_40\IN\0|administration (r_prep) days_39\NNS\15140892|146|of (r_pobj) than_37\IN\0|days (r_prep) sooner_36\RBR\9738708|no|than (r_advmod) developed_34\VBD\1753788|(|e.g.|,|dyskinesia|sooner|) (r_parataxis) were_24\VBD\0|progression|resistant|developed|. (l_acomp) resistant_26\JJ\0|more|to (l_prep) to_27\IN\0|developing (l_pcomp) developing_28\VBG\13541167|lids (l_dobj) lids_29\NNS\5313679|
D007980_D004409 CID levodopa_42\JJ\14604959| (r_compound) administration_43\NN\1133281|chronic|levodopa (r_pobj) of_40\IN\0|administration (r_prep) days_39\NNS\15140892|146|of (r_pobj) than_37\IN\0|days (r_prep) sooner_36\RBR\9738708|no|than (r_advmod) developed_34\VBD\1753788|(|e.g.|,|dyskinesia|sooner|) (l_nsubj) dyskinesia_33\NN\14084880|
D007980_D004409 CID levodopa_24\VB\14604959| (r_pobj) to_23\IN\0|levodopa (r_prep) prior_22\RB\10675876|to (r_advmod) develop_9\VB\1753788|to|lids|with|prior (l_dobj) lids_10\NNS\5313679|in
D007980_D004409 CID levodopa_24\VB\14604959| (r_pobj) to_23\IN\0|levodopa (r_prep) prior_22\RB\10675876|to (r_advmod) develop_9\VB\1753788|to|lids|with|prior (r_acl) propensity_7\NN\7498854|the|develop (r_pobj) in_5\IN\13603305|propensity (r_prep) differences_4\NNS\4723816|distinct|in (r_dobj) suggest_2\VBP\1010118|data|differences|and|demonstrate|. (l_conj) demonstrate_26\VB\2137132|value (l_dobj) value_28\NN\5856066|the|of|for (l_prep) for_32\IN\0|studying (l_pcomp) studying_34\VBG\5808794|further|pathophysiology (l_dobj) pathophysiology_36\NN\0|the|of (l_prep) of_37\IN\0|lids (l_pobj) lids_38\NNS\5313679|
D007980_D010300 NONE levodopa_2\NN\14604959| (r_npadvmod) induced_4\VBN\1627355|levodopa|- (r_amod) dyskinesias_5\NNS\14084880|induced|in (l_prep) in_6\IN\13603305|monkeys (l_pobj) monkeys_8\NNS\2469914|parkinsonian (l_amod) parkinsonian_7\JJ\0|
D007980_D010300 NONE levodopa_0\NNP\14604959| (r_npadvmod) induced_2\VBN\1627355|levodopa|- (r_amod) dyskinesias_3\NNS\14084880|induced|(|lids|) (r_nsubj) present_7\VBP\28270|dyskinesias|problem|. (l_dobj) problem_10\NN\14408086|a|major|for (l_prep) for_11\IN\0|management (l_pobj) management_16\NN\1123598|the|term|of (l_prep) of_17\IN\0|patients (l_pobj) patients_24\NNS\9898892|disease|(|pd|) (l_nmod) disease_20\NN\14061805|parkinson
D007980_D010300 NONE levodopa_0\NNP\14604959| (r_npadvmod) induced_2\VBN\1627355|levodopa|- (r_amod) dyskinesias_3\NNS\14084880|induced|(|lids|) (r_nsubj) present_7\VBP\28270|dyskinesias|problem|. (l_dobj) problem_10\NN\14408086|a|major|for (l_prep) for_11\IN\0|management (l_pobj) management_16\NN\1123598|the|term|of (l_prep) of_17\IN\0|patients (l_pobj) patients_24\NNS\9898892|disease|(|pd|) (l_nmod) pd_22\NNP\14625458|
D015632_D010302 CID mptp_7\NNP\0| (r_npadvmod) induced_9\VBN\1627355|mptp|- (r_amod) parkinsonism_10\NN\14085708|induced
D015632_D004409 NONE mptp_7\NNP\0| (r_npadvmod) induced_9\VBN\1627355|mptp|- (r_amod) parkinsonism_10\NN\14085708|induced (r_pobj) of_6\IN\0|parkinsonism (r_prep) types_5\NNS\5839024|different|of (r_pobj) with_3\IN\0|types (r_prep) using_0\VBG\418025|monkeys|with (r_advcl) evaluated_15\VBD\670261|using|,|study|degree|. (l_dobj) degree_17\NN\4916342|the|involved (l_relcl) involved_38\VBN\2676054|to|severity|may|be|in (l_prep) in_39\IN\13603305|development (l_pobj) development_41\NN\248977|the|of (l_prep) of_42\IN\0|lids (l_pobj) lids_43\NNS\5313679|
D015632_D004409 NONE mptp_8\NNP\0|) (r_compound) exposure_9\NN\5042871|acute|mptp|,|onset (r_pobj) with_1\IN\0|exposure (r_prep) monkeys_0\NNS\2469914|with (r_nsubj) developed_24\VBD\1753788|monkeys|prior|dyskinesia|days|. (l_dobj) dyskinesia_25\RB\14084880|
D015632_D004409 NONE mptp_8\NNP\0| (r_compound) exposure_9\NN\5042871|term|mptp (r_pobj) with_4\IN\0|exposure (r_prep) monkeys_3\NNS\2469914|with (r_nsubj) progression_13\NN\8457976|in|,|monkeys|,|slow|symptom|and/or|duration|prior (r_nsubj) were_24\VBD\0|progression|resistant|developed|. (l_acomp) resistant_26\JJ\0|more|to (l_prep) to_27\IN\0|developing (l_pcomp) developing_28\VBG\13541167|lids (l_dobj) lids_29\NNS\5313679|
D015632_D004409 NONE mptp_8\NNP\0| (r_compound) exposure_9\NN\5042871|term|mptp (r_pobj) with_4\IN\0|exposure (r_prep) monkeys_3\NNS\2469914|with (r_nsubj) progression_13\NN\8457976|in|,|monkeys|,|slow|symptom|and/or|duration|prior (r_nsubj) were_24\VBD\0|progression|resistant|developed|. (l_parataxis) developed_34\VBD\1753788|(|e.g.|,|dyskinesia|sooner|) (l_nsubj) dyskinesia_33\NN\14084880|
D007980_D010302 NONE levodopa_34\NN\14604959| (r_compound) therapy_35\NN\657604|levodopa (r_pobj) of_33\IN\0|therapy (r_prep) duration_32\NN\15113229|of (r_conj) response_29\NN\11410625|to|and|duration (r_conj) severity_26\NN\5036394|rate|,|symptom|,|and|response (r_nsubjpass) involved_38\VBN\2676054|to|severity|may|be|in (r_relcl) degree_17\NN\4916342|the|involved (r_dobj) evaluated_15\VBD\670261|using|,|study|degree|. (l_advcl) using_0\VBG\418025|monkeys|with (l_prep) with_3\IN\0|types (l_pobj) types_5\NNS\5839024|different|of (l_prep) of_6\IN\0|parkinsonism (l_pobj) parkinsonism_10\NN\14085708|induced
869641
D007980_D001919 NONE dopa_9\NN\14601829|l|- (r_pobj) by_6\IN\0|dopa (r_prep) mediation_0\NN\7148192|of|by|via|. (l_prep) of_1\IN\0|bradycardia (l_pobj) bradycardia_5\NNP\14110674|enhanced|reflex|vagal
D007980_D001919 NONE dopa_15\NNP\14601829|l|-|,|dihydroxyphenylserine (r_pobj) by_12\IN\0|dopa (r_agent) enhanced_11\VBN\227165|in|,|bradycardia|was|significantly|by|had|. (l_nsubjpass) bradycardia_4\NN\14110674|reflex|caused
D007980_D001919 NONE dopa_28\NNP\14601829|l|- (r_pobj) of_25\IN\0|dopa (r_prep) effect_24\NN\34213|bradycardia|of (l_amod) bradycardia_19\NN\14110674|or|enhancing
D007980_D001919 NONE dopa_4\NNP\14601829|l|- (r_nsubj) restored_5\VBD\1631072|however|,|dopa|bradycardia|. (l_dobj) bradycardia_7\NN\14110674|the|caused
D007980_D001919 NONE dopa_6\NNP\14601829|l|- (r_nsubj) enhances_7\VBZ\227165|that|dopa|bradycardia|through (l_dobj) bradycardia_9\NN\14110674|reflex
D004298_D001919 NONE dopamine_12\NN\14807737| (r_compound) formation_13\NN\7938773|central|dopamine|in (r_pobj) via_10\IN\0|formation (r_prep) mediation_0\NN\7148192|of|by|via|. (l_prep) of_1\IN\0|bradycardia (l_pobj) bradycardia_5\NNP\14110674|enhanced|reflex|vagal
D004298_D001919 NONE dopamine_3\NN\14807737| (r_compound) oxidase_7\NN\14732946|dopamine|-|beta|- (r_compound) inhibitor_8\NN\20090|a|oxidase (r_nsubj) have_12\VB\7846|fla-63|,|inhibitor|,|did|not|effect|. (l_dobj) effect_14\NN\34213|any|on (l_prep) on_15\IN\0|hypotension (l_pobj) hypotension_17\NN\14057371|the|,|effect (l_appos) effect_24\NN\34213|bradycardia|of (l_amod) bradycardia_19\NN\14110674|or|enhancing
D009638_D001919 CID norepinephrine_8\NN\14807929|injected (r_pobj) by_6\IN\0|norepinephrine (r_agent) caused_5\VBN\1617192|by (r_acl) bradycardia_4\NN\14110674|reflex|caused
D009638_D001919 CID norepinephrine_35\NN\14807929| (r_pobj) to_34\IN\0|norepinephrine (r_prep) responses_33\NNS\11410625|reflex|to (r_conj) rate_30\NN\13815152|heart|or|responses (r_conj) pressure_27\NN\11419404|blood|,|rate (r_pobj) on_25\IN\0|pressure (r_prep) effect_24\NN\34213|no|on (r_dobj) had_22\VBD\0|effect (r_conj) enhanced_11\VBN\227165|in|,|bradycardia|was|significantly|by|had|. (l_nsubjpass) bradycardia_4\NN\14110674|reflex|caused
D009638_D001919 CID norepinephrine_10\NN\14807929| (r_pobj) by_9\IN\0|norepinephrine (r_agent) caused_8\VBN\1617192|by|in (r_acl) bradycardia_7\NN\14110674|the|caused
D009638_D001919 CID norepinephrine_18\NN\14807929| (r_pobj) to_17\IN\0|norepinephrine (r_prep) bradycardia_16\NN\14110674|the|reflex|to
D015103_D001919 NONE dihydroxyphenylserine_21\NN\0|threo|- (r_conj) dopa_15\NNP\14601829|l|-|,|dihydroxyphenylserine (r_pobj) by_12\IN\0|dopa (r_agent) enhanced_11\VBN\227165|in|,|bradycardia|was|significantly|by|had|. (l_nsubjpass) bradycardia_4\NN\14110674|reflex|caused
D005406_D007022 NONE fla-63_0\NN\0| (r_mark) have_12\VB\7846|fla-63|,|inhibitor|,|did|not|effect|. (l_dobj) effect_14\NN\34213|any|on (l_prep) on_15\IN\0|hypotension (l_pobj) hypotension_17\NN\14057371|the|,|effect
D005406_D001919 NONE fla-63_0\NN\0| (r_mark) have_12\VB\7846|fla-63|,|inhibitor|,|did|not|effect|. (l_dobj) effect_14\NN\34213|any|on (l_prep) on_15\IN\0|hypotension (l_pobj) hypotension_17\NN\14057371|the|,|effect (l_appos) effect_24\NN\34213|bradycardia|of (l_amod) bradycardia_19\NN\14110674|or|enhancing
D004298_D007022 NONE dopamine_3\NN\14807737| (r_compound) oxidase_7\NN\14732946|dopamine|-|beta|- (r_compound) inhibitor_8\NN\20090|a|oxidase (r_nsubj) have_12\VB\7846|fla-63|,|inhibitor|,|did|not|effect|. (l_dobj) effect_14\NN\34213|any|on (l_prep) on_15\IN\0|hypotension (l_pobj) hypotension_17\NN\14057371|the|,|effect
D007980_D007022 NONE dopa_28\NNP\14601829|l|- (r_pobj) of_25\IN\0|dopa (r_prep) effect_24\NN\34213|bradycardia|of (r_appos) hypotension_17\NN\14057371|the|,|effect
D006916_D001919 NONE 5-htp_0\NNP\0|i.v.|) (r_nsubj) decreased_6\VBD\169651|5-htp|pressure|and|decreased|. (l_conj) decreased_13\VBD\169651|bradycardia (l_dobj) bradycardia_16\NN\14110674|the|reflex|to
3412544
D000082_D014523 NONE paracetamol_1\JJ\0| (r_nsubj) cause_2\VB\7323922|does|paracetamol|cancer|? (l_dobj) cancer_4\NN\14239425|urothelial|or|necrosis
D000082_D007681 NONE paracetamol_1\JJ\0| (r_nsubj) cause_2\VB\7323922|does|paracetamol|cancer|? (l_dobj) cancer_4\NN\14239425|urothelial|or|necrosis (l_conj) necrosis_8\NN\11444117|renal|papillary
D000082_D007681 NONE paracetamol_24\NNP\0| (r_conj) phenacetin_22\JJ\2707683|either|or|paracetamol (r_pobj) of_20\IN\0|phenacetin (r_prep) consumption_19\NN\13440063|of (r_pobj) with_18\IN\0|consumption (r_prep) associated_17\VBN\628491|with (r_acl) pelvis_12\NN\5578911|the|renal|,|ureter|associated (r_pobj) of_9\IN\0|pelvis (r_prep) necrosis_6\NN\11444117|renal|papillary|or|cancer|of
D000082_D007681 NONE paracetamol_12\JJ\0| (r_compound) consumption_13\NN\13440063|paracetamol (r_pobj) from_11\IN\0|consumption (r_prep) risk_10\NN\14541044|an|increased|from|for|or|any (l_prep) for_14\IN\0|necrosis (l_pobj) necrosis_17\NN\11444117|renal|papillary
D010615_D007681 CID phenacetin_22\JJ\2707683|either|or|paracetamol (r_pobj) of_20\IN\0|phenacetin (r_prep) consumption_19\NN\13440063|of (r_pobj) with_18\IN\0|consumption (r_prep) associated_17\VBN\628491|with (r_acl) pelvis_12\NN\5578911|the|renal|,|ureter|associated (r_pobj) of_9\IN\0|pelvis (r_prep) necrosis_6\NN\11444117|renal|papillary|or|cancer|of
D010615_D007681 CID phenacetin_13\NN\2707683| (r_pobj) of_12\IN\0|phenacetin (r_prep) consumption_11\NN\13440063|of|,|increased (r_pobj) by_10\IN\0|consumption (r_agent) increased_7\VBN\169651|risk|was|20-fold|by|. (l_nsubjpass) risk_1\NN\14541044|the|of (l_prep) of_2\IN\0|necrosis (l_pobj) necrosis_5\NN\11444117|renal|papillary
D010615_D007680 CID phenacetin_13\NN\2707683| (r_pobj) of_12\IN\0|phenacetin (r_prep) consumption_11\NN\13440063|of|,|increased (l_relcl) increased_17\VBD\169651|which|also|risk|but|for (l_dobj) risk_19\NN\14541044|the|for (l_prep) for_20\IN\0|cancer (l_pobj) cancer_21\NN\14239425|of (l_prep) of_22\IN\0|pelvis (l_pobj) pelvis_25\NN\5578911|the|renal|and|bladder (l_conj) bladder_27\NN\5515670|
D010615_D007680 NONE phenacetin_22\JJ\2707683|either|or|paracetamol (r_pobj) of_20\IN\0|phenacetin (r_prep) consumption_19\NN\13440063|of (r_pobj) with_18\IN\0|consumption (r_prep) associated_17\VBN\628491|with (r_acl) pelvis_12\NN\5578911|the|renal|,|ureter|associated (l_conj) ureter_14\NN\5250659|or|bladder (l_conj) bladder_16\NN\5515670|
D010615_D014516 NONE phenacetin_22\JJ\2707683|either|or|paracetamol (r_pobj) of_20\IN\0|phenacetin (r_prep) consumption_19\NN\13440063|of (r_pobj) with_18\IN\0|consumption (r_prep) associated_17\VBN\628491|with (r_acl) pelvis_12\NN\5578911|the|renal|,|ureter|associated (l_conj) ureter_14\NN\5250659|or|bladder (l_conj) bladder_16\NN\5515670|
D010615_D014516 NONE phenacetin_13\NN\2707683| (r_pobj) of_12\IN\0|phenacetin (r_prep) consumption_11\NN\13440063|of|,|increased (l_relcl) increased_17\VBD\169651|which|also|risk|but|for (l_conj) for_30\IN\0|not|cancer (l_pobj) cancer_32\NN\14239425|ureteric
D010615_D001749 CID phenacetin_13\NN\2707683| (r_pobj) of_12\IN\0|phenacetin (r_prep) consumption_11\NN\13440063|of|,|increased (l_relcl) increased_17\VBD\169651|which|also|risk|but|for (l_dobj) risk_19\NN\14541044|the|for (l_prep) for_20\IN\0|cancer (l_pobj) cancer_21\NN\14239425|of (l_prep) of_22\IN\0|pelvis (l_pobj) pelvis_25\NN\5578911|the|renal|and|bladder (l_conj) bladder_27\NN\5515670|
D010615_D001749 NONE phenacetin_22\JJ\2707683|either|or|paracetamol (r_pobj) of_20\IN\0|phenacetin (r_prep) consumption_19\NN\13440063|of (r_pobj) with_18\IN\0|consumption (r_prep) associated_17\VBN\628491|with (r_acl) pelvis_12\NN\5578911|the|renal|,|ureter|associated (l_conj) ureter_14\NN\5250659|or|bladder (l_conj) bladder_16\NN\5515670|
D000082_D007680 NONE paracetamol_24\NNP\0| (r_conj) phenacetin_22\JJ\2707683|either|or|paracetamol (r_pobj) of_20\IN\0|phenacetin (r_prep) consumption_19\NN\13440063|of (r_pobj) with_18\IN\0|consumption (r_prep) associated_17\VBN\628491|with (r_acl) pelvis_12\NN\5578911|the|renal|,|ureter|associated (l_conj) ureter_14\NN\5250659|or|bladder (l_conj) bladder_16\NN\5515670|
D000082_D014516 NONE paracetamol_24\NNP\0| (r_conj) phenacetin_22\JJ\2707683|either|or|paracetamol (r_pobj) of_20\IN\0|phenacetin (r_prep) consumption_19\NN\13440063|of (r_pobj) with_18\IN\0|consumption (r_prep) associated_17\VBN\628491|with (r_acl) pelvis_12\NN\5578911|the|renal|,|ureter|associated (l_conj) ureter_14\NN\5250659|or|bladder (l_conj) bladder_16\NN\5515670|
D000082_D014516 NONE paracetamol_12\JJ\0| (r_compound) consumption_13\NN\13440063|paracetamol (r_pobj) from_11\IN\0|consumption (r_prep) risk_10\NN\14541044|an|increased|from|for|or|any (r_dobj) substantiate_7\VB\0|to|risk (r_xcomp) unable_5\JJ\0|substantiate (r_acomp) were_4\VBD\0|by|,|we|unable|was|. (l_advcl) was_25\VBD\0|although|there|suggestion (l_attr) suggestion_27\NN\5833840|a|of (l_prep) of_28\IN\0|association (l_pobj) association_30\NN\8008335|an|with (l_prep) with_31\IN\0|cancer (l_pobj) cancer_32\NN\14239425|of (l_prep) of_33\IN\0|ureter (l_pobj) ureter_35\NN\5250659|the
D000082_D001749 NONE paracetamol_24\NNP\0| (r_conj) phenacetin_22\JJ\2707683|either|or|paracetamol (r_pobj) of_20\IN\0|phenacetin (r_prep) consumption_19\NN\13440063|of (r_pobj) with_18\IN\0|consumption (r_prep) associated_17\VBN\628491|with (r_acl) pelvis_12\NN\5578911|the|renal|,|ureter|associated (l_conj) ureter_14\NN\5250659|or|bladder (l_conj) bladder_16\NN\5515670|
D000082_D009369 NONE paracetamol_12\JJ\0| (r_compound) consumption_13\NN\13440063|paracetamol (r_pobj) from_11\IN\0|consumption (r_prep) risk_10\NN\14541044|an|increased|from|for|or|any (l_conj) any_19\DT\0|of (l_prep) of_20\IN\0|cancers (l_pobj) cancers_22\NNS\14239425|these
11961407
D014443_D009401 NONE tyrosine_2\NN\14601829| (r_compound) phosphatase_3\NN\14732946|glepp1|receptor|tyrosine|ptpro|in|. (l_prep) in_7\IN\13603305|nephrosis (l_pobj) nephrosis_10\NN\14304060|rat|pan
D011692_D009401 CID pan_9\NNP\3101986| (r_compound) nephrosis_10\NN\14304060|rat|pan
D011692_D009401 CID aminonucleoside_1\JJ\0| (r_amod) nephrosis_2\NN\14304060|puromycin|aminonucleoside
D011692_D009401 CID aminonucleoside_11\NN\0|pan (r_advmod) induced_4\VBN\1627355|nephrosis|was|by|aminonucleoside|. (l_nsubjpass) nephrosis_2\NN\14304060|puromycin|aminonucleoside
D011692_D009401 CID pan_13\NNP\3101986|(|,|mg/100|bw|) (r_appos) aminonucleoside_11\NN\0|pan (r_advmod) induced_4\VBN\1627355|nephrosis|was|by|aminonucleoside|. (l_nsubjpass) nephrosis_2\NN\14304060|puromycin|aminonucleoside
D011692_D011507 CID pan_21\NNP\3101986| (r_compound) injection_22\NN\320852|pan (r_pobj) after_20\IN\0|injection (r_prep) days_19\NNS\15140892|5|80|after (r_npadvmod) analyzed_2\VBN\0|tissues|were|at|days|include|. (l_advcl) include_26\VB\0|so|as|to|phase (l_dobj) phase_30\NN\15113229|both|the|acute|of|associated|(|days (l_prep) of_31\IN\0|proteinuria (l_pobj) proteinuria_32\NN\14299637|
D011692_D011507 CID pan_21\NNP\3101986| (r_compound) injection_22\NN\320852|pan (r_pobj) after_20\IN\0|injection (r_prep) days_19\NNS\15140892|5|80|after (r_npadvmod) analyzed_2\VBN\0|tissues|were|at|days|include|. (l_advcl) include_26\VB\0|so|as|to|phase (l_dobj) phase_30\NN\15113229|both|the|acute|of|associated|(|days (l_appos) days_39\NNS\15140892|5|)|and|phase (l_conj) phase_47\NN\15113229|the|chronic|of|associated (l_prep) of_48\IN\0|proteinuria (l_pobj) proteinuria_49\NN\14299637|
D011692_D005921 NONE pan_21\NNP\3101986| (r_compound) injection_22\NN\320852|pan (r_pobj) after_20\IN\0|injection (r_prep) days_19\NNS\15140892|5|80|after (r_npadvmod) analyzed_2\VBN\0|tissues|were|at|days|include|. (l_advcl) include_26\VB\0|so|as|to|phase (l_dobj) phase_30\NN\15113229|both|the|acute|of|associated|(|days (l_appos) days_39\NNS\15140892|5|)|and|phase (l_conj) phase_47\NN\15113229|the|chronic|of|associated (l_acl) associated_50\VBN\628491|with (l_prep) with_51\IN\0|glomerulosclerosis (l_pobj) glomerulosclerosis_52\NN\0|(|days|)
3800626
D010423_D009408 CID pentazocine_8\NN\2707683| (r_advmod) induced_10\VBN\1627355|pentazocine|- (r_amod) myopathy_12\NNS\14204950|induced|fibrous (r_pobj) due_6\IN\5174653|to|myopathy (r_prep) neuropathy_1\NN\14204950|compression|of|due|. (l_prep) of_2\IN\0|nerve (l_pobj) nerve_5\NN\5475681|the|radial
D010423_D009408 CID pentazocine_10\NN\2707683| (r_npadvmod) induced_12\VBN\1627355|pentazocine|- (r_compound) myopathy_13\NN\14204950|induced (r_pobj) by_9\IN\0|myopathy (r_agent) affected_8\VBN\126264|by (r_acl) muscle_7\NN\5289601|fibrotic|affected (r_pobj) due_4\IN\5174653|to|muscle (r_amod) neuropathy_3\NN\14204950|compression|due
D010423_D020425 CID pentazocine_8\NN\2707683| (r_advmod) induced_10\VBN\1627355|pentazocine|- (r_amod) myopathy_12\NNS\14204950|induced|fibrous (r_pobj) due_6\IN\5174653|to|myopathy (r_prep) neuropathy_1\NN\14204950|compression|of|due|. (l_prep) of_2\IN\0|nerve (l_pobj) nerve_5\NN\5475681|the|radial
D010423_D005355 CID pentazocine_8\NN\2707683| (r_advmod) induced_10\VBN\1627355|pentazocine|- (r_amod) myopathy_12\NNS\14204950|induced|fibrous
D010423_D005355 CID pentazocine_13\NN\2707683| (r_compound) injection_14\NN\320852|repeated|pentazocine (r_pobj) of_11\IN\0|injection (r_prep) effect_10\NN\34213|a|common|,|known|side|of (r_attr) is_2\VBZ\0|myopathy|effect|. (l_nsubj) myopathy_1\NN\14204950|fibrous
D010423_D005355 CID pentazocine_8\NN\2707683| (r_advmod) induced_10\VBN\1627355|pentazocine|- (r_amod) myopathy_12\NNS\14204950|documented|induced|fibrous|of
D010423_D005355 CID pentazocine_8\NN\2707683| (r_advmod) induced_10\VBN\1627355|pentazocine|- (r_amod) myopathy_12\NNS\14204950|documented|induced|fibrous|of (r_pobj) with_6\IN\0|myopathy (r_prep) woman_5\NN\9605289|a|old|with|bilaterally|and|history (r_pobj) in_0\IN\13603305|woman (r_prep) showed_32\VBD\2137132|in|,|examination|lesion|,|in|. (l_prep) in_51\IN\13603305|addition (l_pobj) addition_52\NN\3081021|to (l_prep) to_53\IN\0|myopathy (l_pobj) myopathy_56\NN\14204950|the|fibrous
D010423_D009135 CID pentazocine_8\NN\2707683| (r_advmod) induced_10\VBN\1627355|pentazocine|- (r_amod) myopathy_12\NNS\14204950|induced|fibrous
D010423_D009135 CID pentazocine_13\NN\2707683| (r_compound) injection_14\NN\320852|repeated|pentazocine (r_pobj) of_11\IN\0|injection (r_prep) effect_10\NN\34213|a|common|,|known|side|of (r_attr) is_2\VBZ\0|myopathy|effect|. (l_nsubj) myopathy_1\NN\14204950|fibrous
D010423_D009135 CID pentazocine_10\NN\2707683| (r_npadvmod) induced_12\VBN\1627355|pentazocine|- (r_compound) myopathy_13\NN\14204950|induced
D010423_D009135 CID pentazocine_8\NN\2707683| (r_advmod) induced_10\VBN\1627355|pentazocine|- (r_amod) myopathy_12\NNS\14204950|documented|induced|fibrous|of
D010423_D009135 CID pentazocine_8\NN\2707683| (r_advmod) induced_10\VBN\1627355|pentazocine|- (r_amod) myopathy_12\NNS\14204950|documented|induced|fibrous|of (r_pobj) with_6\IN\0|myopathy (r_prep) woman_5\NN\9605289|a|old|with|bilaterally|and|history (r_pobj) in_0\IN\13603305|woman (r_prep) showed_32\VBD\2137132|in|,|examination|lesion|,|in|. (l_prep) in_51\IN\13603305|addition (l_pobj) addition_52\NN\3081021|to (l_prep) to_53\IN\0|myopathy (l_pobj) myopathy_56\NN\14204950|the|fibrous
19387625
D002211_D010146 NONE capsaicin_7\NN\15032661| (r_npadvmod) induced_9\VBN\1627355|capsaicin|- (r_amod) hyperalgesia_11\NN\0|induced|secondary (r_pobj) in_6\IN\13603305|hyperalgesia (r_prep) intensity_5\NN\5090441|perceived|pain|in (l_compound) pain_4\NN\14299637|
D002211_D010146 NONE capsaicin_16\NN\15032661| (r_npadvmod) induced_18\VBN\1627355|capsaicin|- (r_amod) hyperalgesia_20\NN\0|induced|secondary (r_pobj) in_15\IN\13603305|hyperalgesia (r_prep) attention_14\NN\5701944|in (r_pobj) by_13\IN\0|attention (r_agent) affected_12\VBN\126264|that|how|ratings|are|by (l_nsubjpass) ratings_10\NNS\5733583|intensity (l_compound) intensity_9\NN\5090441|pain (l_compound) pain_8\NN\14299637|
D002211_D010146 NONE capsaicin_7\NN\15032661| (r_compound) treatment_8\NN\654885|capsaicin|and|modulation (r_pobj) between_6\IN\0|treatment (r_prep) interaction_5\NN\37396|no|between (r_dobj) showing_3\VBG\6887726|interaction (r_csubj) suggest_12\VBP\1010118|findings|,|showing|affect|. (l_ccomp) affect_22\VB\26192|that|hyperalgesia|might|pain|through (l_dobj) pain_24\NN\14299637|mechanical
D002211_D010146 NONE capsaicin_14\NN\15032661| (r_npadvmod) induced_16\VBN\1627355|capsaicin|- (r_amod) hyperalgesia_18\NN\0|induced|secondary|and|attention (r_nsubj) affect_22\VB\26192|that|hyperalgesia|might|pain|through (l_dobj) pain_24\NN\14299637|mechanical
D002211_D006930 CID capsaicin_7\NN\15032661| (r_npadvmod) induced_9\VBN\1627355|capsaicin|- (r_amod) hyperalgesia_11\NN\0|induced|secondary
D002211_D006930 CID capsaicin_16\NN\15032661| (r_npadvmod) induced_18\VBN\1627355|capsaicin|- (r_amod) hyperalgesia_20\NN\0|induced|secondary
D002211_D006930 CID capsaicin_20\NN\15032661| (r_npadvmod) untreated_22\VBN\0|capsaicin|- (r_amod) condition_25\NN\24720|untreated|,|control (r_pobj) of_19\IN\0|condition (r_prep) that_18\DT\0|of (r_pobj) to_17\IN\0|that (r_prep) similar_16\JJ\0|very|to (r_acomp) is_14\VBZ\0|that|magnitude|similar (l_nsubj) magnitude_7\NN\4916342|the|of (l_prep) of_8\IN\0|modulation (l_pobj) modulation_10\NN\7044917|attentional|in (l_prep) in_11\IN\13603305|hyperalgesia (l_pobj) hyperalgesia_13\NN\0|secondary
D002211_D006930 CID capsaicin_7\NN\15032661| (r_compound) treatment_8\NN\654885|capsaicin|and|modulation (r_pobj) between_6\IN\0|treatment (r_prep) interaction_5\NN\37396|no|between (r_dobj) showing_3\VBG\6887726|interaction (r_csubj) suggest_12\VBP\1010118|findings|,|showing|affect|. (l_ccomp) affect_22\VB\26192|that|hyperalgesia|might|pain|through (l_nsubj) hyperalgesia_18\NN\0|induced|secondary|and|attention
D002211_D006930 CID capsaicin_14\NN\15032661| (r_npadvmod) induced_16\VBN\1627355|capsaicin|- (r_amod) hyperalgesia_18\NN\0|induced|secondary|and|attention
26094
D008750_D003866 CID dopa_13\NN\14601829|methyl (r_pobj) in_11\IN\13603305|dopa (r_prep) occurring_10\VBG\0|in (r_acl) depressions_9\NNS\14373582|occurring
D008750_D001523 NONE dopa_13\NN\14601829|methyl (r_pobj) in_11\IN\13603305|dopa (r_prep) occurring_10\VBG\0|in (r_acl) depressions_9\NNS\14373582|occurring (r_pobj) of_8\IN\0|depressions (r_prep) number_7\NN\5107765|a|significant|of|treated (l_acl) treated_14\VBD\2376958|patients (l_dobj) patients_15\NNS\9898892|with (l_prep) with_16\IN\0|histories (l_pobj) histories_18\NNS\15120823|psychiatric (l_amod) psychiatric_17\JJ\0|
10365197
D003042_D019964 CID cocaine_0\NN\3492717| (r_npadvmod) induced_2\VBN\1627355|cocaine|- (r_amod) disorder_4\NN\14034177|induced|mood|:|rates|.
D003042_D019964 CID cocaine_14\NN\3492717| (r_npadvmod) dependent_16\JJ\9627906|cocaine|- (r_amod) sample_17\NN\5820620|an|outpatient|dependent (r_pobj) in_11\IN\13603305|sample (r_prep) rates_7\NNS\13308999|prevalence|and|symptoms|in (r_appos) disorder_4\NN\14034177|induced|mood|:|rates|.
D003042_D019964 CID cocaine_1\NN\3492717| (r_npadvmod) dependent_3\JJ\9627906|cocaine|- (r_amod) outpatients_4\NNS\10405694|243|dependent|with|,|disorders (l_prep) with_5\IN\0|disorder (l_pobj) disorder_10\NN\14034177|induced|mood|(|cimd|)
D003042_D019964 CID cocaine_1\NN\3492717| (r_npadvmod) dependent_3\JJ\9627906|cocaine|- (r_amod) outpatients_4\NNS\10405694|243|dependent|with|,|disorders (l_conj) disorders_17\NNS\14034177|other|mood|,|or|disorder
D003042_D019964 CID cocaine_1\NN\3492717| (r_npadvmod) dependent_3\JJ\9627906|cocaine|- (r_amod) outpatients_4\NNS\10405694|243|dependent|with|,|disorders (l_conj) disorders_17\NNS\14034177|other|mood|,|or|disorder (l_conj) disorder_22\NN\14034177|no|mood
D003042_D019964 CID cocaine_6\NN\3492717| (r_npadvmod) induced_8\VBN\1627355|cocaine|- (r_amod) disorder_10\NN\14034177|induced|mood|(|cimd|)
D003042_D019964 CID cocaine_6\NN\3492717| (r_npadvmod) induced_8\VBN\1627355|cocaine|- (r_amod) disorder_10\NN\14034177|induced|mood|(|cimd|) (r_pobj) with_5\IN\0|disorder (r_prep) outpatients_4\NNS\10405694|243|dependent|with|,|disorders (l_conj) disorders_17\NNS\14034177|other|mood|,|or|disorder
D003042_D019964 CID cocaine_6\NN\3492717| (r_npadvmod) induced_8\VBN\1627355|cocaine|- (r_amod) disorder_10\NN\14034177|induced|mood|(|cimd|) (r_pobj) with_5\IN\0|disorder (r_prep) outpatients_4\NNS\10405694|243|dependent|with|,|disorders (l_conj) disorders_17\NNS\14034177|other|mood|,|or|disorder (l_conj) disorder_22\NN\14034177|no|mood
D003042_D001523 NONE cocaine_0\NN\3492717| (r_npadvmod) induced_2\VBN\1627355|cocaine|- (r_amod) disorder_4\NN\14034177|induced|mood|:|rates|. (l_appos) rates_7\NNS\13308999|prevalence|and|symptoms|in (l_conj) symptoms_10\NNS\5823932|psychiatric (l_amod) psychiatric_9\JJ\0|
D003042_D001523 NONE cocaine_14\NN\3492717| (r_npadvmod) dependent_16\JJ\9627906|cocaine|- (r_amod) sample_17\NN\5820620|an|outpatient|dependent (r_pobj) in_11\IN\13603305|sample (r_prep) rates_7\NNS\13308999|prevalence|and|symptoms|in (l_conj) symptoms_10\NNS\5823932|psychiatric (l_amod) psychiatric_9\JJ\0|
D003042_D001523 NONE cocaine_1\NN\3492717| (r_npadvmod) dependent_3\JJ\9627906|cocaine|- (r_amod) outpatients_4\NNS\10405694|243|dependent|with|,|disorders (r_nsubjpass) compared_24\VBN\644583|outpatients|were|on|. (l_prep) on_25\IN\0|measures (l_pobj) measures_26\NNS\168237|of (l_prep) of_27\IN\0|symptoms (l_pobj) symptoms_29\NNS\5823932|psychiatric (l_amod) psychiatric_28\JJ\0|
D003042_D001523 NONE cocaine_6\NN\3492717| (r_npadvmod) induced_8\VBN\1627355|cocaine|- (r_amod) disorder_10\NN\14034177|induced|mood|(|cimd|) (r_pobj) with_5\IN\0|disorder (r_prep) outpatients_4\NNS\10405694|243|dependent|with|,|disorders (r_nsubjpass) compared_24\VBN\644583|outpatients|were|on|. (l_prep) on_25\IN\0|measures (l_pobj) measures_26\NNS\168237|of (l_prep) of_27\IN\0|symptoms (l_pobj) symptoms_29\NNS\5823932|psychiatric (l_amod) psychiatric_28\JJ\0|
D003042_D019970 NONE cocaine_1\NN\3492717| (r_npadvmod) dependent_3\JJ\9627906|cocaine|- (r_amod) outpatients_4\NNS\10405694|243|dependent|with|,|disorders (l_prep) with_5\IN\0|disorder (l_pobj) disorder_10\NN\14034177|induced|mood|(|cimd|) (l_appos) cimd_12\NNP\0|
D003042_D019970 NONE cocaine_6\NN\3492717| (r_npadvmod) induced_8\VBN\1627355|cocaine|- (r_amod) disorder_10\NN\14034177|induced|mood|(|cimd|) (l_appos) cimd_12\NNP\0|
7881871
D011692_D007674 CID aminonucleoside_7\NN\0| (r_advmod) induced_9\VBN\1627355|aminonucleoside|- (r_amod) nephropathy_10\NN\14573196|puromycin|induced
D011692_D007674 CID aminonucleoside_12\NN\0| (r_nmod) nephropathy_15\NN\14573196|puromycin|aminonucleoside|(|pan)-induced
D011692_D007674 CID pan)-induced_14\JJ\0| (r_amod) nephropathy_15\NN\14573196|puromycin|aminonucleoside|(|pan)-induced
D011692_D007674 CID pan_14\NNP\3101986| (r_compound) nephropathy_15\NN\14573196|pan
D010100_D007674 NONE oxygen_1\NN\14622893| (r_compound) species_2\NNS\7992450|reactive|oxygen (r_nsubjpass) implicated_5\VBN\2677097|species|have|been|in|,|with|. (l_prep) in_6\IN\13603305|pathogenesis (l_pobj) pathogenesis_8\NN\13533470|the|of (l_prep) of_9\IN\0|nephropathy (l_pobj) nephropathy_15\NN\14573196|puromycin|aminonucleoside|(|pan)-induced
D010100_D011507 NONE oxygen_1\NN\14622893| (r_compound) species_2\NNS\7992450|reactive|oxygen (r_nsubjpass) implicated_5\VBN\2677097|species|have|been|in|,|with|. (l_prep) with_17\IN\0|reducing (l_pcomp) reducing_20\VBG\13447361|antioxidants|significantly|proteinuria (l_dobj) proteinuria_22\NN\14299637|the
D011692_D011507 CID aminonucleoside_12\NN\0| (r_nmod) nephropathy_15\NN\14573196|puromycin|aminonucleoside|(|pan)-induced (r_pobj) of_9\IN\0|nephropathy (r_prep) pathogenesis_8\NN\13533470|the|of (r_pobj) in_6\IN\13603305|pathogenesis (r_prep) implicated_5\VBN\2677097|species|have|been|in|,|with|. (l_prep) with_17\IN\0|reducing (l_pcomp) reducing_20\VBG\13447361|antioxidants|significantly|proteinuria (l_dobj) proteinuria_22\NN\14299637|the
D011692_D011507 CID pan)-induced_14\JJ\0| (r_amod) nephropathy_15\NN\14573196|puromycin|aminonucleoside|(|pan)-induced (r_pobj) of_9\IN\0|nephropathy (r_prep) pathogenesis_8\NN\13533470|the|of (r_pobj) in_6\IN\13603305|pathogenesis (r_prep) implicated_5\VBN\2677097|species|have|been|in|,|with|. (l_prep) with_17\IN\0|reducing (l_pcomp) reducing_20\VBG\13447361|antioxidants|significantly|proteinuria (l_dobj) proteinuria_22\NN\14299637|the
D011692_D011507 CID pan_14\NNP\3101986| (r_compound) nephropathy_15\NN\14573196|pan (r_pobj) in_13\IN\13603305|nephropathy (r_prep) injury_12\NN\14052046|the|proteinuric|in
1009330
C004658_D003556 NONE choloroaniline_10\NN\0|p|- (r_appos) product_7\NN\3076708|the|degradation|choloroaniline (r_nsubj) is_11\VBZ\0|that|product|not|factor (l_attr) factor_15\NN\7326557|a|significant|in (l_prep) in_16\IN\13603305|cystitis (l_pobj) cystitis_22\NN\14566129|associated|erosive
C010882_D003556 CID digluconate_19\NN\0|chlorhexidine|- (r_npadvmod) associated_20\VBN\628491|digluconate (r_amod) cystitis_22\NN\14566129|associated|erosive
D007612_D003556 CID kanamycin_4\NN\2716866| (r_compound) colistin_6\NN\0|kanamycin|-|and|iodine (r_nmod) irrigations_11\NNS\1057200|colistin (r_pobj) of_3\IN\0|irrigations (r_prep) percentage_2\NN\13815742|a|high|of (r_nsubjpass) associated_13\VBN\628491|percentage|were|with|and|suggested|. (l_prep) with_14\IN\0|cystitis (l_pobj) cystitis_16\NN\14566129|erosive
D003091_D003556 CID colistin_6\NN\0|kanamycin|-|and|iodine (r_nmod) irrigations_11\NNS\1057200|colistin (r_pobj) of_3\IN\0|irrigations (r_prep) percentage_2\NN\13815742|a|high|of (r_nsubjpass) associated_13\VBN\628491|percentage|were|with|and|suggested|. (l_prep) with_14\IN\0|cystitis (l_pobj) cystitis_16\NN\14566129|erosive
D011206_D003556 CID iodine_10\NN\14622893|povidone|- (r_conj) colistin_6\NN\0|kanamycin|-|and|iodine (r_nmod) irrigations_11\NNS\1057200|colistin (r_pobj) of_3\IN\0|irrigations (r_prep) percentage_2\NN\13815742|a|high|of (r_nsubjpass) associated_13\VBN\628491|percentage|were|with|and|suggested|. (l_prep) with_14\IN\0|cystitis (l_pobj) cystitis_16\NN\14566129|erosive
C005253_D003556 NONE picloxydine_0\NNP\0| (r_compound) irrigations_1\NNS\1057200|picloxydine (r_nsubj) appeared_2\VBD\2604760|irrigations|have|but|have (l_xcomp) have_4\VB\7846|to|incidence (l_dobj) incidence_7\NN\13821570|a|lower|of (l_prep) of_8\IN\0|cystitis (l_pobj) cystitis_10\NN\14566129|erosive
19729346
D010098_D010146 NONE oxycodone_18\NN\0|release (r_pobj) of_14\IN\0|oxycodone (r_prep) dose_13\NN\3740161|a|single|10-mg|of|in (r_pobj) of_9\IN\0|dose (r_prep) effects_8\NNS\13245626|the|objective|neurocognitive|of (r_dobj) measured_2\VBD\697589|study|effects|)|,|and|years|adults|. (l_dobj) adults_39\NNS\7846|suffering (l_relcl) suffering_43\VBG\14322699|who|were|not|from (l_prep) from_44\IN\0|pain (l_pobj) pain_49\NN\14299637|chronic|daily
D010098_D059350 NONE oxycodone_30\NN\0|release (r_pobj) of_26\IN\0|oxycodone (r_prep) dose_25\NN\3740161|a|10-mg|of (r_pobj) to_22\IN\0|dose (r_prep) response_21\NN\11410625|to (r_pobj) in_20\IN\13603305|response (r_prep) changes_19\NNS\7283608|in (r_dobj) suffering_11\VBG\14322699|who|are|not|from|changes (l_prep) from_12\IN\0|pain (l_pobj) pain_14\NN\14299637|chronic|,|neurocognitive
12202650
D002211_D063806 NONE capsaicin_0\NN\15032661| (r_npadvmod) induced_2\VBN\1627355|capsaicin|- (r_amod) pain_4\NN\14299637|induced|muscle
D002211_D010146 CID capsaicin_0\NNS\15032661|g (r_nsubjpass) injected_7\VBN\81072|capsaicin|was|into|induce|. (l_advcl) induce_13\VB\1627355|to|pain|in (l_dobj) pain_14\NN\14299637|
18439803
C108761_D012640 NONE n-(2-propylpentanoyl)urea_3\NNP\0| (r_pobj) of_2\IN\0|n-(2-propylpentanoyl)urea (r_prep) effects_1\NNS\13245626|acute|of|on|in|. (l_prep) in_9\IN\13603305|seizure (l_pobj) seizure_13\NN\14081375|induced|in
C108761_D012640 NONE vpu_0\NNS\0| (r_nsubj) was_1\VBD\0|vpu|potent|,|exhibiting|. (l_advcl) exhibiting_7\VBG\2632167|dose|was (l_dobj) dose_11\NN\3740161|the|median|effective|ed(50|)|of (l_prep) of_16\IN\0|mg/kg (l_pobj) mg/kg_18\NNS\0|49|in (l_prep) in_19\IN\13603305|protecting (l_pcomp) protecting_20\VBG\1127795|rats|against (l_prep) against_22\IN\0|seizure (l_pobj) seizure_26\NN\14081375|induced
C108761_D012640 NONE vpu_5\NNPS\0|and|vpa (r_nsubj) protect_9\VB\1127795|that|vpu|could|animals (l_dobj) animals_11\NNS\4475|the|against (l_prep) against_12\IN\0|seizure (l_pobj) seizure_16\NN\14081375|induced
C108761_D012640 NONE vpu_8\NNP\0| (r_nsubj) reduce_11\VB\441445|that|vpu|could|drastically|increases (r_relcl) finding_6\NN\43195|the|reduce (r_appos) vpa_3\NNP\0|,|finding (r_pobj) like_2\IN\5839024|vpa (r_prep) account_21\VB\6647206|therefore|,|like|should|,|for|. (l_prep) for_27\IN\0|partly|,|activity (l_pobj) activity_30\NN\30358|its|anticonvulsant|observed (l_acl) observed_31\VBN\2163746|in (l_prep) in_32\IN\13603305|seizure (l_pobj) seizure_36\NN\14081375|induced|in
D000596_D012640 NONE acid_7\NN\14818238|amino (r_compound) neurotransmitters_8\NNS\14807410|hippocampal|acid (r_pobj) on_4\IN\0|neurotransmitters (r_prep) effects_1\NNS\13245626|acute|of|on|in|. (l_prep) in_9\IN\13603305|seizure (l_pobj) seizure_13\NN\14081375|induced|in
D000596_D012640 NONE acid_26\NN\14818238|amino (r_compound) neurotransmitters_27\NNS\14807410|inhibitory|acid (r_pobj) of_23\IN\0|neurotransmitters (r_prep) reduction_22\NN\351485|the|of (r_nsubj) was_28\VBD\0|that|reduction|minor|and|offset (r_ccomp) suggested_19\VBN\1010118|based|it|is|was|. (l_prep) based_0\VBN\0|on (l_prep) on_1\IN\0|finding (l_pobj) finding_3\NN\43195|the|protect (l_acl) protect_9\VB\1127795|that|vpu|could|animals (l_dobj) animals_11\NNS\4475|the|against (l_prep) against_12\IN\0|seizure (l_pobj) seizure_16\NN\14081375|induced
D010862_D012640 CID pilocarpine_10\NN\14712692| (r_npadvmod) induced_12\VBN\1627355|pilocarpine|- (r_amod) seizure_13\NN\14081375|induced|in
D010862_D012640 CID pilocarpine_23\NN\14712692| (r_npadvmod) induced_25\VBN\1627355|pilocarpine|- (r_amod) seizure_26\NN\14081375|induced
D010862_D012640 CID pilocarpine_13\NN\14712692| (r_npadvmod) induced_15\VBN\1627355|pilocarpine|- (r_amod) seizure_16\NN\14081375|induced
D010862_D012640 CID pilocarpine_12\NN\14712692| (r_npadvmod) induced_14\VBN\1627355|pilocarpine|- (r_amod) increases_15\NNS\13576355|induced|in (r_dobj) reduce_11\VB\441445|that|vpu|could|drastically|increases (r_relcl) finding_6\NN\43195|the|reduce (r_appos) vpa_3\NNP\0|,|finding (r_pobj) like_2\IN\5839024|vpa (r_prep) account_21\VB\6647206|therefore|,|like|should|,|for|. (l_prep) for_27\IN\0|partly|,|activity (l_pobj) activity_30\NN\30358|its|anticonvulsant|observed (l_acl) observed_31\VBN\2163746|in (l_prep) in_32\IN\13603305|seizure (l_pobj) seizure_36\NN\14081375|induced|in
D010862_D012640 CID pilocarpine_33\NN\14712692| (r_npadvmod) induced_35\VBN\1627355|pilocarpine|- (r_amod) seizure_36\NN\14081375|induced|in
D014635_D012640 NONE vpa_5\NNP\0| (r_pobj) than_4\IN\0|vpa (r_prep) potent_3\JJ\0|more|than (r_acomp) was_1\VBD\0|vpu|potent|,|exhibiting|. (l_advcl) exhibiting_7\VBG\2632167|dose|was (l_dobj) dose_11\NN\3740161|the|median|effective|ed(50|)|of (l_prep) of_16\IN\0|mg/kg (l_pobj) mg/kg_18\NNS\0|49|in (l_prep) in_19\IN\13603305|protecting (l_pcomp) protecting_20\VBG\1127795|rats|against (l_prep) against_22\IN\0|seizure (l_pobj) seizure_26\NN\14081375|induced
D014635_D012640 NONE vpa_32\NNP\0| (r_pobj) for_31\IN\0|vpa (r_prep) value_30\NN\5856066|the|corresponding|for (r_nsubj) was_33\VBD\0|whereas|value|mg/kg (r_advcl) exhibiting_7\VBG\2632167|dose|was (l_dobj) dose_11\NN\3740161|the|median|effective|ed(50|)|of (l_prep) of_16\IN\0|mg/kg (l_pobj) mg/kg_18\NNS\0|49|in (l_prep) in_19\IN\13603305|protecting (l_pcomp) protecting_20\VBG\1127795|rats|against (l_prep) against_22\IN\0|seizure (l_pobj) seizure_26\NN\14081375|induced
D014635_D012640 NONE vpa_7\NNP\0| (r_conj) vpu_5\NNPS\0|and|vpa (r_nsubj) protect_9\VB\1127795|that|vpu|could|animals (l_dobj) animals_11\NNS\4475|the|against (l_prep) against_12\IN\0|seizure (l_pobj) seizure_16\NN\14081375|induced
D014635_D012640 NONE vpa_3\NNP\0|,|finding (r_pobj) like_2\IN\5839024|vpa (r_prep) account_21\VB\6647206|therefore|,|like|should|,|for|. (l_prep) for_27\IN\0|partly|,|activity (l_pobj) activity_30\NN\30358|its|anticonvulsant|observed (l_acl) observed_31\VBN\2163746|in (l_prep) in_32\IN\13603305|seizure (l_pobj) seizure_36\NN\14081375|induced|in
D018698_D012640 NONE glutamate_38\NN\15010703|and|aspartate (r_pobj) of_37\IN\0|glutamate (r_prep) reduction_36\NN\351485|a|pronounced|of (r_pobj) by_33\IN\0|reduction (r_agent) offset_32\VBN\15180528|by (r_conj) was_28\VBD\0|that|reduction|minor|and|offset (r_ccomp) suggested_19\VBN\1010118|based|it|is|was|. (l_prep) based_0\VBN\0|on (l_prep) on_1\IN\0|finding (l_pobj) finding_3\NN\43195|the|protect (l_acl) protect_9\VB\1127795|that|vpu|could|animals (l_dobj) animals_11\NNS\4475|the|against (l_prep) against_12\IN\0|seizure (l_pobj) seizure_16\NN\14081375|induced
D018698_D012640 NONE glutamate_17\NN\15010703|and|aspartate (r_pobj) in_16\IN\13603305|glutamate (r_prep) increases_15\NNS\13576355|induced|in (r_dobj) reduce_11\VB\441445|that|vpu|could|drastically|increases (r_relcl) finding_6\NN\43195|the|reduce (r_appos) vpa_3\NNP\0|,|finding (r_pobj) like_2\IN\5839024|vpa (r_prep) account_21\VB\6647206|therefore|,|like|should|,|for|. (l_prep) for_27\IN\0|partly|,|activity (l_pobj) activity_30\NN\30358|its|anticonvulsant|observed (l_acl) observed_31\VBN\2163746|in (l_prep) in_32\IN\13603305|seizure (l_pobj) seizure_36\NN\14081375|induced|in
D001224_D012640 NONE aspartate_40\NN\0| (r_conj) glutamate_38\NN\15010703|and|aspartate (r_pobj) of_37\IN\0|glutamate (r_prep) reduction_36\NN\351485|a|pronounced|of (r_pobj) by_33\IN\0|reduction (r_agent) offset_32\VBN\15180528|by (r_conj) was_28\VBD\0|that|reduction|minor|and|offset (r_ccomp) suggested_19\VBN\1010118|based|it|is|was|. (l_prep) based_0\VBN\0|on (l_prep) on_1\IN\0|finding (l_pobj) finding_3\NN\43195|the|protect (l_acl) protect_9\VB\1127795|that|vpu|could|animals (l_dobj) animals_11\NNS\4475|the|against (l_prep) against_12\IN\0|seizure (l_pobj) seizure_16\NN\14081375|induced
D001224_D012640 NONE aspartate_19\NN\0| (r_conj) glutamate_17\NN\15010703|and|aspartate (r_pobj) in_16\IN\13603305|glutamate (r_prep) increases_15\NNS\13576355|induced|in (r_dobj) reduce_11\VB\441445|that|vpu|could|drastically|increases (r_relcl) finding_6\NN\43195|the|reduce (r_appos) vpa_3\NNP\0|,|finding (r_pobj) like_2\IN\5839024|vpa (r_prep) account_21\VB\6647206|therefore|,|like|should|,|for|. (l_prep) for_27\IN\0|partly|,|activity (l_pobj) activity_30\NN\30358|its|anticonvulsant|observed (l_acl) observed_31\VBN\2163746|in (l_prep) in_32\IN\13603305|seizure (l_pobj) seizure_36\NN\14081375|induced|in
8590259
C016986_D015814 CID apraclonidine_8\NN\0| (r_npadvmod) treated_10\VBN\2376958|apraclonidine|- (r_amod) eyes_11\NNS\5945642|treated (r_pobj) for_7\IN\0|eyes (r_prep) significant_6\JJ\0|statistically|for|throughout|and|significant (r_acomp) were_4\VBD\0|effects|significant|. (l_nsubj) effects_3\NNS\13245626|the|ocular|hypotensive (l_amod) hypotensive_2\JJ\10405694|
C016986_D015814 CID apraclonidine_31\NN\0|% (r_pobj) of_28\IN\0|apraclonidine (r_prep) administration_27\NN\1133281|topical|of (r_pobj) after_25\IN\0|administration (r_prep) hours_24\NNS\15118228|three|after (r_pobj) from_22\IN\0|hours (r_prep) significant_18\JJ\0|also|statistically|for|from (r_conj) significant_6\JJ\0|statistically|for|throughout|and|significant (r_acomp) were_4\VBD\0|effects|significant|. (l_nsubj) effects_3\NNS\13245626|the|ocular|hypotensive (l_amod) hypotensive_2\JJ\10405694|
12596116
D015282_D000860 NONE octreotide_0\NNP\0| (r_npadvmod) induced_2\VBN\1627355|octreotide|-|hypoxemia|. (l_dobj) hypoxemia_3\NN\0|and|hypertension|in
D015282_D006976 CID octreotide_0\NNP\0| (r_npadvmod) induced_2\VBN\1627355|octreotide|-|hypoxemia|. (l_dobj) hypoxemia_3\NN\0|and|hypertension|in (l_conj) hypertension_6\NN\14057371|pulmonary
D015282_D006976 CID octreotide_10\NN\0| (r_advmod) developed_2\VBD\1753788|hypertension|after|octreotide|,|enhance|. (l_nsubj) hypertension_1\NN\14057371|pulmonary
D015282_D005402 NONE octreotide_10\NN\0| (r_advmod) developed_2\VBD\1753788|hypertension|after|octreotide|,|enhance|. (l_advcl) enhance_13\VB\227165|to|resolution (l_dobj) resolution_14\NN\6470073|of (l_prep) of_15\IN\0|fistula (l_pobj) fistula_17\NN\14253124|the
2304736
D011224_D014550 CID prazosin_0\NN\2698769| (r_npadvmod) induced_2\VBN\1627355|prazosin|- (r_amod) incontinence_4\NN\13473097|induced|stress|.
D011224_D014550 CID prazosin_8\NN\2698769|,|drug|, (r_pobj) due_6\IN\5174653|to|prazosin (r_amod) case_1\NN\7283608|a|of|due (l_prep) of_2\IN\0|incontinence (l_pobj) incontinence_5\NN\13473097|genuine|stress
D011224_D014550 CID prazosin_8\NN\2698769| (r_dobj) taking_7\VBG\37396|while|prazosin (r_advcl) present_2\VBP\28270|who|with|taking (l_prep) with_3\IN\0|incontinence (l_pobj) incontinence_5\NN\13473097|stress
D011224_D014549 NONE prazosin_8\NN\2698769| (r_dobj) taking_7\VBG\37396|while|prazosin (r_advcl) present_2\VBP\28270|who|with|taking (r_relcl) patients_0\NNS\9898892|present (r_nsubj) change_10\VB\7283608|patients|should|medication|before|,|resolve|. (l_advcl) resolve_22\VB\4616059|because|incontinence|may|spontaneously|with (l_nsubj) incontinence_20\NN\13473097|their
18821488
C080436_D064420 NONE 8-aminoquinoline_8\JJ\0| (r_compound) 8-[(4-amino_9\CD\0|8-aminoquinoline (r_compound) l_11\NN\13616054|8-[(4-amino|- (r_compound) methylbutyl)amino]-_13\NN\0|l|- (r_punct) wr242511_18\NNP\0|the|methylbutyl)amino]-|hexyloxy)-6-methoxy-4-methylquinoline|( (r_pobj) of_6\IN\0|wr242511 (r_prep) administration_5\NN\1133281|of (r_pobj) following_4\VBG\8180190|administration (r_prep) toxicity_0\NN\13576101|in|following|)|.
C068820_D064420 NONE hexyloxy)-6-methoxy-4-methylquinoline_16\NNP\0|5-(l|- (r_nmod) wr242511_18\NNP\0|the|methylbutyl)amino]-|hexyloxy)-6-methoxy-4-methylquinoline|( (r_pobj) of_6\IN\0|wr242511 (r_prep) administration_5\NN\1133281|of (r_pobj) following_4\VBG\8180190|administration (r_prep) toxicity_0\NN\13576101|in|following|)|.
C068820_D064420 NONE wr242511_18\NNP\0|the|methylbutyl)amino]-|hexyloxy)-6-methoxy-4-methylquinoline|( (r_pobj) of_6\IN\0|wr242511 (r_prep) administration_5\NN\1133281|of (r_pobj) following_4\VBG\8180190|administration (r_prep) toxicity_0\NN\13576101|in|following|)|.
C068820_D064420 NONE wr242511_4\NNP\0| (r_nsubjpass) pursued_8\VBN\10192926|that|wr242511|should|not|be|as|dissociated (l_advcl) dissociated_27\VBN\2431320|unless|characteristics|can|be|successfully|from (l_prep) from_28\IN\0|those (l_pobj) those_29\DT\0|producing (l_acl) producing_30\VBG\1617192|toxicity (l_dobj) toxicity_32\NN\13576101|undesirable
C068820_D008708 NONE wr242511_4\NNP\0|,|produced|, (l_relcl) produced_7\VBD\1617192|which|methemoglobinemia|in (l_dobj) methemoglobinemia_9\NN\0|significant|in
C068820_D006456 CID wr242511_11\NNP\0|(|3.5|) (r_pobj) of_10\IN\0|wr242511 (r_prep) postinjection_9\NN\0|minutes|of (r_dobj) noted_5\VBN\1009240|furthermore|,|hemoglobinuria|was|postinjection|,|and|occurred (l_nsubjpass) hemoglobinuria_3\NN\14299637|transient
C068820_D011041 NONE wr242511_4\NNP\0| (r_nsubjpass) pursued_8\VBN\10192926|that|wr242511|should|not|be|as|dissociated (l_prep) as_9\IN\14622893|pretreatment (l_pobj) pretreatment_11\NN\0|a|for (l_prep) for_12\IN\0|poisoning (l_pobj) poisoning_14\NN\14034177|cn
8319760
D019808_D009401 NONE 753_1\CD\0| (r_nummod) dup_0\NN\0|753 (r_nsubj) prevents_2\VBZ\0|dup|development|. (l_dobj) development_4\NN\248977|the|of (l_prep) of_5\IN\0|puromycin|nephrosis (l_pobj) nephrosis_10\NN\14304060|induced
D011692_D009401 NONE aminonucleoside_7\NN\0| (r_advmod) induced_9\VBN\1627355|aminonucleoside|- (r_amod) nephrosis_10\NN\14304060|induced
D011692_D009401 NONE aminonucleoside_17\NN\0| (r_advmod) induced_19\VBN\1627355|aminonucleoside|- (r_amod) nephrosis_20\NN\14304060|induced
D001806_D009404 NONE urea_17\NN\14727670|nitrogen (r_pobj) in_14\IN\13603305|urea (r_prep) increase_13\NN\13576355|in (r_conj) hypercholesterolemia_11\NN\14299637|and|increase (r_conj) hypoalbuminemia_9\NN\0|,|hypercholesterolemia (r_conj) proteinuria_7\NN\14299637|,|hypoalbuminemia (r_pobj) as_6\IN\14622893|such|proteinuria (r_prep) syndromes_4\NNS\5870365|nephrotic|as
D001806_D011507 NONE urea_17\NN\14727670|nitrogen (r_pobj) in_14\IN\13603305|urea (r_prep) increase_13\NN\13576355|in (r_conj) hypercholesterolemia_11\NN\14299637|and|increase (r_conj) hypoalbuminemia_9\NN\0|,|hypercholesterolemia (r_conj) proteinuria_7\NN\14299637|,|hypoalbuminemia
D001806_D034141 NONE urea_17\NN\14727670|nitrogen (r_pobj) in_14\IN\13603305|urea (r_prep) increase_13\NN\13576355|in (r_conj) hypercholesterolemia_11\NN\14299637|and|increase (r_conj) hypoalbuminemia_9\NN\0|,|hypercholesterolemia
D001806_D006937 NONE urea_17\NN\14727670|nitrogen (r_pobj) in_14\IN\13603305|urea (r_prep) increase_13\NN\13576355|in (r_conj) hypercholesterolemia_11\NN\14299637|and|increase
D011692_D009404 CID aminonucleoside_26\NN\0| (r_advmod) induced_19\VBN\1627355|appearance|,|in|by|aminonucleoside (l_nsubj) appearance_1\NN\4723816|the|of (l_prep) of_2\IN\0|syndromes (l_pobj) syndromes_4\NNS\5870365|nephrotic|as
D011692_D011507 CID aminonucleoside_26\NN\0| (r_advmod) induced_19\VBN\1627355|appearance|,|in|by|aminonucleoside (l_nsubj) appearance_1\NN\4723816|the|of (l_prep) of_2\IN\0|syndromes (l_pobj) syndromes_4\NNS\5870365|nephrotic|as (l_prep) as_6\IN\14622893|such|proteinuria (l_pobj) proteinuria_7\NN\14299637|,|hypoalbuminemia
D011692_D034141 CID aminonucleoside_26\NN\0| (r_advmod) induced_19\VBN\1627355|appearance|,|in|by|aminonucleoside (l_nsubj) appearance_1\NN\4723816|the|of (l_prep) of_2\IN\0|syndromes (l_pobj) syndromes_4\NNS\5870365|nephrotic|as (l_prep) as_6\IN\14622893|such|proteinuria (l_pobj) proteinuria_7\NN\14299637|,|hypoalbuminemia (l_conj) hypoalbuminemia_9\NN\0|,|hypercholesterolemia
D011692_D006937 CID aminonucleoside_26\NN\0| (r_advmod) induced_19\VBN\1627355|appearance|,|in|by|aminonucleoside (l_nsubj) appearance_1\NN\4723816|the|of (l_prep) of_2\IN\0|syndromes (l_pobj) syndromes_4\NNS\5870365|nephrotic|as (l_prep) as_6\IN\14622893|such|proteinuria (l_pobj) proteinuria_7\NN\14299637|,|hypoalbuminemia (l_conj) hypoalbuminemia_9\NN\0|,|hypercholesterolemia (l_conj) hypercholesterolemia_11\NN\14299637|and|increase
D019808_D009404 NONE 753_35\CD\0| (r_nummod) dup_34\NN\0|753 (r_nmod) losartan_37\NN\0|dup|( (r_pobj) of_33\IN\0|losartan (r_prep) administration_32\NN\1133281|oral|of (r_pobj) by_30\IN\0|administration (r_agent) inhibited_29\VBN\2510337|induced|was|markedly|by|)|,|antagonist|. (l_ccomp) induced_19\VBN\1627355|appearance|,|in|by|aminonucleoside (l_nsubj) appearance_1\NN\4723816|the|of (l_prep) of_2\IN\0|syndromes (l_pobj) syndromes_4\NNS\5870365|nephrotic|as
D019808_D009404 NONE losartan_37\NN\0|dup|( (r_pobj) of_33\IN\0|losartan (r_prep) administration_32\NN\1133281|oral|of (r_pobj) by_30\IN\0|administration (r_agent) inhibited_29\VBN\2510337|induced|was|markedly|by|)|,|antagonist|. (l_ccomp) induced_19\VBN\1627355|appearance|,|in|by|aminonucleoside (l_nsubj) appearance_1\NN\4723816|the|of (l_prep) of_2\IN\0|syndromes (l_pobj) syndromes_4\NNS\5870365|nephrotic|as
D019808_D011507 NONE 753_35\CD\0| (r_nummod) dup_34\NN\0|753 (r_nmod) losartan_37\NN\0|dup|( (r_pobj) of_33\IN\0|losartan (r_prep) administration_32\NN\1133281|oral|of (r_pobj) by_30\IN\0|administration (r_agent) inhibited_29\VBN\2510337|induced|was|markedly|by|)|,|antagonist|. (l_ccomp) induced_19\VBN\1627355|appearance|,|in|by|aminonucleoside (l_nsubj) appearance_1\NN\4723816|the|of (l_prep) of_2\IN\0|syndromes (l_pobj) syndromes_4\NNS\5870365|nephrotic|as (l_prep) as_6\IN\14622893|such|proteinuria (l_pobj) proteinuria_7\NN\14299637|,|hypoalbuminemia
D019808_D011507 NONE losartan_37\NN\0|dup|( (r_pobj) of_33\IN\0|losartan (r_prep) administration_32\NN\1133281|oral|of (r_pobj) by_30\IN\0|administration (r_agent) inhibited_29\VBN\2510337|induced|was|markedly|by|)|,|antagonist|. (l_ccomp) induced_19\VBN\1627355|appearance|,|in|by|aminonucleoside (l_nsubj) appearance_1\NN\4723816|the|of (l_prep) of_2\IN\0|syndromes (l_pobj) syndromes_4\NNS\5870365|nephrotic|as (l_prep) as_6\IN\14622893|such|proteinuria (l_pobj) proteinuria_7\NN\14299637|,|hypoalbuminemia
D019808_D034141 NONE 753_35\CD\0| (r_nummod) dup_34\NN\0|753 (r_nmod) losartan_37\NN\0|dup|( (r_pobj) of_33\IN\0|losartan (r_prep) administration_32\NN\1133281|oral|of (r_pobj) by_30\IN\0|administration (r_agent) inhibited_29\VBN\2510337|induced|was|markedly|by|)|,|antagonist|. (l_ccomp) induced_19\VBN\1627355|appearance|,|in|by|aminonucleoside (l_nsubj) appearance_1\NN\4723816|the|of (l_prep) of_2\IN\0|syndromes (l_pobj) syndromes_4\NNS\5870365|nephrotic|as (l_prep) as_6\IN\14622893|such|proteinuria (l_pobj) proteinuria_7\NN\14299637|,|hypoalbuminemia (l_conj) hypoalbuminemia_9\NN\0|,|hypercholesterolemia
D019808_D034141 NONE losartan_37\NN\0|dup|( (r_pobj) of_33\IN\0|losartan (r_prep) administration_32\NN\1133281|oral|of (r_pobj) by_30\IN\0|administration (r_agent) inhibited_29\VBN\2510337|induced|was|markedly|by|)|,|antagonist|. (l_ccomp) induced_19\VBN\1627355|appearance|,|in|by|aminonucleoside (l_nsubj) appearance_1\NN\4723816|the|of (l_prep) of_2\IN\0|syndromes (l_pobj) syndromes_4\NNS\5870365|nephrotic|as (l_prep) as_6\IN\14622893|such|proteinuria (l_pobj) proteinuria_7\NN\14299637|,|hypoalbuminemia (l_conj) hypoalbuminemia_9\NN\0|,|hypercholesterolemia
D019808_D006937 NONE 753_35\CD\0| (r_nummod) dup_34\NN\0|753 (r_nmod) losartan_37\NN\0|dup|( (r_pobj) of_33\IN\0|losartan (r_prep) administration_32\NN\1133281|oral|of (r_pobj) by_30\IN\0|administration (r_agent) inhibited_29\VBN\2510337|induced|was|markedly|by|)|,|antagonist|. (l_ccomp) induced_19\VBN\1627355|appearance|,|in|by|aminonucleoside (l_nsubj) appearance_1\NN\4723816|the|of (l_prep) of_2\IN\0|syndromes (l_pobj) syndromes_4\NNS\5870365|nephrotic|as (l_prep) as_6\IN\14622893|such|proteinuria (l_pobj) proteinuria_7\NN\14299637|,|hypoalbuminemia (l_conj) hypoalbuminemia_9\NN\0|,|hypercholesterolemia (l_conj) hypercholesterolemia_11\NN\14299637|and|increase
D019808_D006937 NONE losartan_37\NN\0|dup|( (r_pobj) of_33\IN\0|losartan (r_prep) administration_32\NN\1133281|oral|of (r_pobj) by_30\IN\0|administration (r_agent) inhibited_29\VBN\2510337|induced|was|markedly|by|)|,|antagonist|. (l_ccomp) induced_19\VBN\1627355|appearance|,|in|by|aminonucleoside (l_nsubj) appearance_1\NN\4723816|the|of (l_prep) of_2\IN\0|syndromes (l_pobj) syndromes_4\NNS\5870365|nephrotic|as (l_prep) as_6\IN\14622893|such|proteinuria (l_pobj) proteinuria_7\NN\14299637|,|hypoalbuminemia (l_conj) hypoalbuminemia_9\NN\0|,|hypercholesterolemia (l_conj) hypercholesterolemia_11\NN\14299637|and|increase
D000804_D009404 NONE ii_43\NNP\13741022| (r_compound) antagonist_45\NN\7846|a|angiotensin|ii|receptor|,|at (r_appos) inhibited_29\VBN\2510337|induced|was|markedly|by|)|,|antagonist|. (l_ccomp) induced_19\VBN\1627355|appearance|,|in|by|aminonucleoside (l_nsubj) appearance_1\NN\4723816|the|of (l_prep) of_2\IN\0|syndromes (l_pobj) syndromes_4\NNS\5870365|nephrotic|as
D000804_D011507 NONE ii_43\NNP\13741022| (r_compound) antagonist_45\NN\7846|a|angiotensin|ii|receptor|,|at (r_appos) inhibited_29\VBN\2510337|induced|was|markedly|by|)|,|antagonist|. (l_ccomp) induced_19\VBN\1627355|appearance|,|in|by|aminonucleoside (l_nsubj) appearance_1\NN\4723816|the|of (l_prep) of_2\IN\0|syndromes (l_pobj) syndromes_4\NNS\5870365|nephrotic|as (l_prep) as_6\IN\14622893|such|proteinuria (l_pobj) proteinuria_7\NN\14299637|,|hypoalbuminemia
D000804_D034141 NONE ii_43\NNP\13741022| (r_compound) antagonist_45\NN\7846|a|angiotensin|ii|receptor|,|at (r_appos) inhibited_29\VBN\2510337|induced|was|markedly|by|)|,|antagonist|. (l_ccomp) induced_19\VBN\1627355|appearance|,|in|by|aminonucleoside (l_nsubj) appearance_1\NN\4723816|the|of (l_prep) of_2\IN\0|syndromes (l_pobj) syndromes_4\NNS\5870365|nephrotic|as (l_prep) as_6\IN\14622893|such|proteinuria (l_pobj) proteinuria_7\NN\14299637|,|hypoalbuminemia (l_conj) hypoalbuminemia_9\NN\0|,|hypercholesterolemia
D000804_D006937 NONE ii_43\NNP\13741022| (r_compound) antagonist_45\NN\7846|a|angiotensin|ii|receptor|,|at (r_appos) inhibited_29\VBN\2510337|induced|was|markedly|by|)|,|antagonist|. (l_ccomp) induced_19\VBN\1627355|appearance|,|in|by|aminonucleoside (l_nsubj) appearance_1\NN\4723816|the|of (l_prep) of_2\IN\0|syndromes (l_pobj) syndromes_4\NNS\5870365|nephrotic|as (l_prep) as_6\IN\14622893|such|proteinuria (l_pobj) proteinuria_7\NN\14299637|,|hypoalbuminemia (l_conj) hypoalbuminemia_9\NN\0|,|hypercholesterolemia (l_conj) hypercholesterolemia_11\NN\14299637|and|increase
D000809_D009401 NONE angiotensin_10\NN\4522421|renin|- (r_compound) system_11\NN\3575240|the|angiotensin|in (l_prep) in_12\IN\13603305|development (l_pobj) development_14\NN\248977|the|of (l_prep) of_15\IN\0|puromycin|nephrosis (l_pobj) nephrosis_20\NN\14304060|induced
12820454
D016729_D000740 CID acetate_6\NN\15010703|cab|[|leuprolide|(|a|)|mg|,|intramuscularly|,|days (r_dobj) received_2\VBD\2210855|patients|acetate|and|evaluated|. (l_conj) evaluated_32\VBN\670261|were|for|by (l_prep) for_33\IN\0|anemia (l_pobj) anemia_34\NN\14189204|
D016729_D000740 CID a_10\NNP\13649268|lhrh|- (r_appos) acetate_6\NN\15010703|cab|[|leuprolide|(|a|)|mg|,|intramuscularly|,|days (r_dobj) received_2\VBD\2210855|patients|acetate|and|evaluated|. (l_conj) evaluated_32\VBN\670261|were|for|by (l_prep) for_33\IN\0|anemia (l_pobj) anemia_34\NN\14189204|
D005485_D000740 CID flutamide_23\NN\0| (r_nmod) tid_25\NN\0|mg|flutamide|,|,|per (r_conj) days_19\NNS\15140892|every|28|plus|tid (r_appos) acetate_6\NN\15010703|cab|[|leuprolide|(|a|)|mg|,|intramuscularly|,|days (r_dobj) received_2\VBD\2210855|patients|acetate|and|evaluated|. (l_conj) evaluated_32\VBN\670261|were|for|by (l_prep) for_33\IN\0|anemia (l_pobj) anemia_34\NN\14189204|
19767176
C020972_D013226 NONE dithiocarbamate_1\NN\0|pyrrolidine (r_nsubj) protects_2\VBZ\1127795|dithiocarbamate|cortex|. (l_dobj) cortex_5\NN\5462674|the|piriform|in (l_prep) in_6\IN\13603305|model (l_pobj) model_11\NN\5888929|the|pilocarpine|status|epilepticus (l_amod) epilepticus_10\NN\0|
C020972_D013226 NONE pdtc_3\NNP\0| (r_pobj) of_2\IN\0|pdtc (r_prep) effect_1\NN\34213|the|of|on (l_prep) on_4\IN\0|loss (l_pobj) loss_10\NN\13252973|status|associated|cell|in (l_amod) associated_8\VBN\628491|epilepticus|- (l_npadvmod) epilepticus_6\NN\0|
C020972_D013226 NONE pdtc_4\NNP\0|mg/kg (r_pobj) with_1\IN\0|pdtc (r_prep) treatment_0\NN\654885|with|before (r_nsubj) increased_11\VBD\169651|treatment|epilepticus|significantly|rate|to|. (l_advmod) epilepticus_9\NN\0|
C020972_D013226 NONE pdtc_4\NNP\0| (r_nmod) dose_8\NN\3740161|mg/kg|pdtc|(|low|- (r_pobj) of_1\IN\0|dose (r_prep) administration_0\NN\1133281|of|) (r_nsubj) exert_12\VB\1158872|administration|did|not|effects|. (l_dobj) effects_14\NNS\13245626|major|on (l_prep) on_15\IN\0|development (l_pobj) development_17\NN\248977|the|of (l_prep) of_18\IN\0|epilepticus (l_pobj) epilepticus_21\NN\0|status|or|rate
C020972_D013226 NONE pdtc_16\NNP\0| (r_npadvmod) treated_18\VBN\2376958|pdtc|- (r_amod) rats_19\NNS\2329401|treated (r_conj) vehicle-_14\NN\0|and|rats (r_pobj) in_13\IN\13603305|vehicle- (r_prep) identified_12\VBN\699815|decrease|was|in|following|. (l_prep) following_20\VBG\8180190|epilepticus (l_pobj) epilepticus_22\NN\0|status
D010862_D013226 CID pilocarpine_8\NN\14712692| (r_amod) model_11\NN\5888929|the|pilocarpine|status|epilepticus (l_amod) epilepticus_10\NN\0|
D010862_D013226 CID pilocarpine_23\NN\14712692| (r_compound) model_24\NN\5888929|the|rat|fractionated|pilocarpine (r_pobj) in_19\IN\13603305|model (r_prep) evaluated_18\VBN\670261|effect|was|in|. (l_nsubjpass) effect_1\NN\34213|the|of|on (l_prep) on_4\IN\0|loss (l_pobj) loss_10\NN\13252973|status|associated|cell|in (l_amod) associated_8\VBN\628491|epilepticus|- (l_npadvmod) epilepticus_6\NN\0|
D010100_D009410 NONE oxygen_5\NN\14622893| (r_compound) species_6\NNS\7992450|reactive|oxygen (r_pobj) of_3\IN\0|species (r_prep) production_2\NN\30358|of|as|activation (r_nsubjpass) implicated_17\VBN\2677097|both|,|production|have|been|in|. (l_prep) in_18\IN\13603305|damage (l_pobj) damage_21\NN\7296428|severe|neuronal|in
D010100_D009410 NONE oxygen_9\NN\14622893| (r_compound) species_10\NNS\7992450|reactive|oxygen|and|activation|of (r_pobj) of_7\IN\0|species (r_prep) generation_6\NN\7942152|the|of (r_nsubj) plays_17\VBZ\7007684|that|generation|role|compared (l_dobj) role_21\NN\719494|a|central|in (l_prep) in_22\IN\13603305|damage (l_pobj) damage_27\NN\7296428|associated|neuronal|in
C020972_D009410 NONE pdtc_10\NNP\0|antioxidant (r_conj) inhibitor_7\NN\20090|the|kappab|and|pdtc (r_nsubj) protected_11\VBD\1127795|in|,|inhibitor|cortex|,|affect|. (l_advcl) affect_20\VB\26192|whereas|it|did|not|loss (l_dobj) loss_23\NN\13252973|hilar|neuronal
D010100_D012640 NONE oxygen_9\NN\14622893| (r_compound) species_10\NNS\7992450|reactive|oxygen|and|activation|of (r_pobj) of_7\IN\0|species (r_prep) generation_6\NN\7942152|the|of (r_nsubj) plays_17\VBZ\7007684|that|generation|role|compared (l_dobj) role_21\NN\719494|a|central|in (l_prep) in_22\IN\13603305|damage (l_pobj) damage_27\NN\7296428|associated|neuronal|in (l_amod) associated_25\VBN\628491|seizure|- (l_npadvmod) seizure_23\NN\14081375|
2312209
D007548_D009203 CID dinitrate_7\NN\0|isosorbide (r_pobj) of_5\IN\0|dinitrate (r_prep) administration_4\NN\1133281|sublingual|of (r_dobj) following_2\VBG\8180190|administration (r_prep) infarction_1\NN\14204950|myocardial|following|.
D007548_D009203 CID dinitrate_22\NN\0|isosorbide (r_pobj) of_20\IN\0|dinitrate (r_prep) administration_19\NN\1133281|the|of (r_pobj) following_17\VBG\8180190|administration (r_prep) suffered_8\VBD\2110220|necrosis|infarction|following|sublingually|. (l_dobj) infarction_12\NN\14204950|a|recurrent|myocardial|of
D007548_D009336 NONE dinitrate_22\NN\0|isosorbide (r_pobj) of_20\IN\0|dinitrate (r_prep) administration_19\NN\1133281|the|of (r_pobj) following_17\VBG\8180190|administration (r_prep) suffered_8\VBD\2110220|necrosis|infarction|following|sublingually|. (l_nsubj) necrosis_7\NN\11444117|a|old|with|healed|septal
2476560
D001556_D012532 NONE lindane_12\NN\14919948|(|hexachloride|)|treatment (r_dobj) consider_11\VBP\689344|initiated|;|most|lindane|. (l_ccomp) initiated_5\VBN\1617192|treatment|is|usually|by (l_nsubjpass) treatment_0\NN\654885|for (l_prep) for_1\IN\0|scabies (l_pobj) scabies_2\NNS\14174549|
D001556_D012532 NONE hexachloride_16\NN\0|gamma|benzene (r_appos) lindane_12\NN\14919948|(|hexachloride|)|treatment (r_dobj) consider_11\VBP\689344|initiated|;|most|lindane|. (l_ccomp) initiated_5\VBN\1617192|treatment|is|usually|by (l_nsubjpass) treatment_0\NN\654885|for (l_prep) for_1\IN\0|scabies (l_pobj) scabies_2\NNS\14174549|
D001556_D002493 CID lindane_4\NN\14919948|that (r_dobj) accumulating_2\VBG\2281093|evidence|is|lindane (r_csubj) be_6\VB\14625458|accumulating|can|toxic|and|associated|. (l_acomp) toxic_7\JJ\0|to (l_prep) to_8\IN\0|system (l_pobj) system_12\NN\3575240|the|central|nervous
D001556_D000741 CID lindane_4\NN\14919948|that (r_dobj) accumulating_2\VBG\2281093|evidence|is|lindane (r_csubj) be_6\VB\14625458|accumulating|can|toxic|and|associated|. (l_conj) associated_16\VBN\628491|may|be|with (l_prep) with_17\IN\0|anaemia (l_pobj) anaemia_19\NN\14299637|aplastic
10835440
D009553_D020521 NONE nimodipine_3\NN\0|intravenous|on (r_pobj) of_1\IN\0|nimodipine (r_prep) effect_0\NN\34213|of|after|. (l_prep) after_9\IN\0|stroke (l_pobj) stroke_11\NN\556313|acute
D009553_D020521 NONE nimodipine_2\NNP\0| (r_compound) trial_6\NN\786195|the|intravenous|nimodipine|west|european|stroke|(|inwest|) (l_compound) stroke_5\NNP\556313|
D009553_D020521 NONE nimodipine_2\NNP\0| (r_compound) trial_6\NN\786195|the|intravenous|nimodipine|west|european|stroke|(|inwest|) (r_nsubj) found_10\VBD\13279262|trial|correlation|. (l_dobj) correlation_12\NN\13841213|a|between (l_prep) between_13\IN\0|reduction (l_pobj) reduction_17\NN\351485|induced|in|and|outcome (l_conj) outcome_27\NN\7291312|an|unfavorable|in (l_prep) in_28\IN\13603305|stroke (l_pobj) stroke_30\NN\556313|acute
D009553_D020521 NONE nimodipine_14\NN\0| (r_npadvmod) induced_16\VBN\1627355|nimodipine|- (r_amod) reduction_17\NN\351485|induced|in|and|outcome (r_pobj) between_13\IN\0|reduction (r_prep) correlation_12\NN\13841213|a|between (r_dobj) found_10\VBD\13279262|trial|correlation|. (l_nsubj) trial_6\NN\786195|the|intravenous|nimodipine|west|european|stroke|(|inwest|) (l_compound) stroke_5\NNP\556313|
D009553_D020521 NONE nimodipine_14\NN\0| (r_npadvmod) induced_16\VBN\1627355|nimodipine|- (r_amod) reduction_17\NN\351485|induced|in|and|outcome (l_conj) outcome_27\NN\7291312|an|unfavorable|in (l_prep) in_28\IN\13603305|stroke (l_pobj) stroke_30\NN\556313|acute
D009553_D020521 NONE nimodipine_15\NN\0|dose (r_pobj) of_11\IN\0|nimodipine (r_prep) administration_10\NN\1133281|the|intravenous|of (r_pobj) after_7\IN\0|administration (r_prep) worsening_6\VBG\13457378|neurological|after|after (l_prep) after_16\IN\0|stroke (l_pobj) stroke_18\NN\556313|acute
D009553_D007022 CID nimodipine_2\NNP\0| (r_compound) trial_6\NN\786195|the|intravenous|nimodipine|west|european|stroke|(|inwest|) (r_nsubj) found_10\VBD\13279262|trial|correlation|. (l_dobj) correlation_12\NN\13841213|a|between (l_prep) between_13\IN\0|reduction (l_pobj) reduction_17\NN\351485|induced|in|and|outcome (l_prep) in_18\IN\13603305|pressure (l_pobj) pressure_20\NN\11419404|blood|(|bp|)
D009553_D007022 CID nimodipine_14\NN\0| (r_npadvmod) induced_16\VBN\1627355|nimodipine|- (r_amod) reduction_17\NN\351485|induced|in|and|outcome (l_prep) in_18\IN\13603305|pressure (l_pobj) pressure_20\NN\11419404|blood|(|bp|)
D009553_D007022 CID nimodipine_0\NNP\0| (r_compound) treatment_1\NN\654885|nimodipine (r_nsubj) resulted_2\VBD\2633881|treatment|in|. (l_prep) in_3\IN\13603305|reduction (l_pobj) reduction_7\NN\351485|a|significant|in (l_prep) in_8\IN\13603305|bp (l_pobj) bp_10\NNP\0|systolic|sbp|and|bp
D009553_D002544 NONE nimodipine_34\NN\0|(|dose|)|n=101|or|nimodipine (r_parataxis) h_28\NN\14622893|1|mg|/|nimodipine (r_appos) receive_19\VB\2210855|to|placebo|,|h (r_advcl) allocated_17\VBN\2228698|methods|were|consecutively|receive|. (l_nsubjpass) methods_0\NNS\5616786|:|patients (l_appos) patients_2\NNS\9898892|with|(|within|) (l_prep) with_3\IN\0|diagnosis (l_pobj) diagnosis_6\NN\152018|a|clinical|of (l_prep) of_7\IN\0|stroke (l_pobj) stroke_9\NN\556313|ischemic
D009553_D002544 NONE nimodipine_49\NN\0|h|(|dose|)|n=94 (r_conj) nimodipine_34\NN\0|(|dose|)|n=101|or|nimodipine (r_parataxis) h_28\NN\14622893|1|mg|/|nimodipine (r_appos) receive_19\VB\2210855|to|placebo|,|h (r_advcl) allocated_17\VBN\2228698|methods|were|consecutively|receive|. (l_nsubjpass) methods_0\NNS\5616786|:|patients (l_appos) patients_2\NNS\9898892|with|(|within|) (l_prep) with_3\IN\0|diagnosis (l_pobj) diagnosis_6\NN\152018|a|clinical|of (l_prep) of_7\IN\0|stroke (l_pobj) stroke_9\NN\556313|ischemic
10406016
C007789_D002543 NONE fucoidan_2\JJ\0| (r_compound) treatment_3\NN\654885|fucoidan|on (l_prep) on_4\IN\0|hemorrhage (l_pobj) hemorrhage_9\NN\14285662|induced|intracerebral|in
C007789_D002543 NONE fucoidan_5\RB\0|the|sulfated|polysaccharide|,|reported|, (r_dobj) tested_1\VBD\670261|we|fucoidan|in|. (l_prep) in_17\IN\13603305|model (l_pobj) model_20\NN\5888929|a|rat|of|induced (l_prep) of_21\IN\0|hemorrhage (l_pobj) hemorrhage_23\NN\14285662|intracerebral
C007789_D001925 NONE fucoidan_5\RB\0|the|sulfated|polysaccharide|,|reported|, (l_relcl) reported_10\VBN\831651|which|has|been|reduce (l_xcomp) reduce_12\VB\441445|to|damage (l_dobj) damage_15\NN\7296428|inflammatory|brain
C007789_D020141 CID fucoidan_0\NNP\0| (r_npadvmod) treated_2\VBN\2376958|fucoidan|- (r_amod) rats_3\NNS\2329401|treated (r_nsubj) exhibited_4\VBD\2632167|rats|evidence|,|had|. (l_dobj) evidence_5\NN\5816287|of (l_prep) of_6\IN\0|clotting (l_pobj) clotting_9\NN\13518963|impaired|blood|and|hemodilution
C007789_D020141 CID fucoidan_0\NNP\0| (r_npadvmod) treated_2\VBN\2376958|fucoidan|- (r_amod) rats_3\NNS\2329401|treated (r_nsubj) exhibited_4\VBD\2632167|rats|evidence|,|had|. (l_dobj) evidence_5\NN\5816287|of (l_prep) of_6\IN\0|clotting (l_pobj) clotting_9\NN\13518963|impaired|blood|and|hemodilution (l_conj) hemodilution_11\NN\0|
C007789_D006406 NONE fucoidan_0\NNP\0| (r_npadvmod) treated_2\VBN\2376958|fucoidan|- (r_amod) rats_3\NNS\2329401|treated (r_nsubj) exhibited_4\VBD\2632167|rats|evidence|,|had|. (l_conj) had_13\VBD\0|hematomas|,|and|tended (l_dobj) hematomas_15\NNS\14317720|larger
C007789_D006406 NONE fucoidan_0\NNP\0| (r_npadvmod) treated_2\VBN\2376958|fucoidan|- (r_amod) rats_3\NNS\2329401|treated (r_nsubj) exhibited_4\VBD\2632167|rats|evidence|,|had|. (l_conj) had_13\VBD\0|hematomas|,|and|tended (l_conj) tended_18\VBD\2604760|have (l_xcomp) have_20\VB\7846|to|inflammation|after (l_dobj) inflammation_22\NN\14299637|less|in (l_prep) in_23\IN\13603305|vicinity (l_pobj) vicinity_25\NN\8648322|the|of (l_prep) of_26\IN\0|hematoma (l_pobj) hematoma_28\NN\14317720|the
C007789_D007249 NONE fucoidan_0\NNP\0| (r_npadvmod) treated_2\VBN\2376958|fucoidan|- (r_amod) rats_3\NNS\2329401|treated (r_nsubj) exhibited_4\VBD\2632167|rats|evidence|,|had|. (l_conj) had_13\VBD\0|hematomas|,|and|tended (l_conj) tended_18\VBD\2604760|have (l_xcomp) have_20\VB\7846|to|inflammation|after (l_dobj) inflammation_22\NN\14299637|less|in
19356053
D020123_D011507 CID sirolimus_7\NN\0| (r_pobj) of_6\IN\0|sirolimus (r_prep) administration_5\NN\1133281|the|of (r_pobj) following_3\VBG\8180190|administration|to (r_prep) proteinuria_2\NN\14299637|significant|following|.
D020123_D011507 CID sirolimus_16\NN\0| (r_pobj) of_15\IN\0|sirolimus (r_prep) use_14\NN\407535|the|of (r_pobj) with_12\IN\0|use (r_prep) linked_11\VBN\628491|with (r_acl) proteinuria_10\NN\14299637|significant|linked
D020123_D011507 CID sirolimus_11\NN\0| (r_compound) use_12\NN\407535|sirolimus (r_pobj) with_10\IN\0|use (r_prep) associated_9\VBN\628491|with (r_acl) proteinuria_8\NN\14299637|substantial|associated
D020123_D011507 CID sirolimus_12\NN\0| (r_compound) therapy_13\NN\657604|sirolimus|and|proteinuria (l_conj) proteinuria_15\NN\14299637|
D020123_D011507 CID sirolimus_12\NN\0| (r_compound) therapy_13\NN\657604|sirolimus|and|proteinuria (r_pobj) of_11\IN\0|therapy (r_prep) commencement_10\NN\15180528|the|of (r_pobj) between_8\IN\0|commencement (r_prep) association_7\NN\8008335|the|close|temporal|between (r_nsubj) implicated_16\VBN\2677097|in|,|association|sirolimus|as|. (l_prep) as_18\IN\14622893|etiology (l_pobj) etiology_22\NN\7326557|the|likely|of (l_prep) of_23\IN\0|proteinuria (l_pobj) proteinuria_25\NN\14299637|the
D020123_D011507 CID sirolimus_17\NN\0| (r_dobj) implicated_16\VBN\2677097|in|,|association|sirolimus|as|. (l_nsubj) association_7\NN\8008335|the|close|temporal|between (l_prep) between_8\IN\0|commencement (l_pobj) commencement_10\NN\15180528|the|of (l_prep) of_11\IN\0|therapy (l_pobj) therapy_13\NN\657604|sirolimus|and|proteinuria (l_conj) proteinuria_15\NN\14299637|
D020123_D011507 CID sirolimus_17\NN\0| (r_dobj) implicated_16\VBN\2677097|in|,|association|sirolimus|as|. (l_prep) as_18\IN\14622893|etiology (l_pobj) etiology_22\NN\7326557|the|likely|of (l_prep) of_23\IN\0|proteinuria (l_pobj) proteinuria_25\NN\14299637|the
D020123_D011507 CID sirolimus_16\NN\0| (r_pobj) of_15\IN\0|sirolimus (r_prep) initiation_14\NN\7450842|the|of|and|development (l_conj) development_19\NN\248977|the|of (l_prep) of_20\IN\0|proteinuria (l_pobj) proteinuria_24\NN\14299637|range
D020123_D011507 CID sirolimus_5\NN\0| (r_compound) therapy_6\NN\657604|sirolimus (r_pobj) with_4\IN\0|therapy (r_prep) correlated_1\VBD\2657219|proteinuria|strongly|with|compared|. (l_nsubj) proteinuria_0\NNP\14299637|
D020123_D011507 CID sirolimus_6\NN\0| (r_pobj) of_5\IN\0|sirolimus (r_prep) discontinuation_4\NN\209943|of (r_nsubj) resulted_7\VBD\2633881|in|,|discontinuation|in|,|but|resolution|. (l_conj) resolution_14\NN\6470073|not|,|of (l_prep) of_16\IN\0|proteinuria (l_pobj) proteinuria_17\NN\14299637|
D020123_D011507 CID sirolimus_0\NNP\0| (r_nsubj) induces_1\VBZ\1627355|sirolimus|or|aggravates|. (l_conj) aggravates_3\VBZ\126264|proteinuria|in (l_dobj) proteinuria_7\NN\14299637|existing
D020123_D011507 CID sirolimus_10\NN\0| (r_nsubjpass) withdrawn_12\VBN\1835496|when|sirolimus|is (r_advcl) resolve_7\VB\4616059|does|not|,|withdrawn (r_conj) improve_2\VB\126264|proteinuria|may|,|but|resolve|. (l_nsubj) proteinuria_0\NNP\14299637|
D020123_D007674 NONE sirolimus_0\NNP\0| (r_nsubj) is_1\VBZ\0|sirolimus|agent|,|and|have|. (l_conj) have_13\VB\7846|may|nephrotoxicity (l_dobj) nephrotoxicity_15\NN\0|less|than
D003404_D011507 NONE creatinine_22\NN\0| (r_compound) ratios_23\NNS\13815152|creatinine|,|estimate (r_conj) measurement_16\NN\407535|turbidometric|or|protein|ratios (r_pobj) by_14\IN\0|measurement (r_agent) assessed_9\VBN\670261|in|,|magnitude|was|on|by|. (l_nsubjpass) magnitude_5\NN\4916342|the|of (l_prep) of_6\IN\0|proteinuria (l_pobj) proteinuria_7\NN\14299637|
D003404_D011507 NONE creatinine_22\NN\0| (r_compound) ratios_23\NNS\13815152|creatinine|,|estimate (l_appos) estimate_26\NN\5802185|an|of|day (l_prep) of_27\IN\0|grams (l_pobj) grams_28\NNS\13717155|of (l_prep) of_29\IN\0|proteinuria (l_pobj) proteinuria_30\NN\14299637|
D020123_D009404 NONE sirolimus_16\NN\0| (r_pobj) of_15\IN\0|sirolimus (r_prep) initiation_14\NN\7450842|the|of|and|development (l_conj) development_19\NN\248977|the|of (l_prep) of_20\IN\0|proteinuria (l_pobj) proteinuria_24\NN\14299637|range (l_compound) range_23\NN\5123416|nephrotic|- (l_amod) nephrotic_21\JJ\0|
17042910
C065179_D006973 NONE atorvastatin_5\NN\3676175| (r_pobj) of_4\IN\0|atorvastatin (r_prep) effects_3\NNS\13245626|oxidant|of|in|. (l_prep) in_6\IN\13603305|hypertension (l_pobj) hypertension_10\NN\14057371|induced|in
C065179_D006973 NONE atorvastatin_0\NNP\3676175|ato|) (r_nsubj) possesses_4\VBZ\8209687|atorvastatin|properties|. (l_dobj) properties_6\NNS\32613|pleiotropic|reported (l_relcl) reported_10\VBN\831651|that|have|been|improve (l_xcomp) improve_12\VB\126264|to|function|through (l_prep) through_15\IN\0|availability (l_pobj) availability_17\NN\4718563|increased|of (l_prep) of_18\IN\0|production (l_pobj) production_23\NN\30358|no|reduced|o2-|in (l_prep) in_24\IN\13603305|forms (l_pobj) forms_26\NNS\6286395|various|of (l_prep) of_27\IN\0|hypertension (l_pobj) hypertension_28\NN\14057371|
C065179_D006973 NONE ato_2\NNP\0|( (r_appos) atorvastatin_0\NNP\3676175|ato|) (r_nsubj) possesses_4\VBZ\8209687|atorvastatin|properties|. (l_dobj) properties_6\NNS\32613|pleiotropic|reported (l_relcl) reported_10\VBN\831651|that|have|been|improve (l_xcomp) improve_12\VB\126264|to|function|through (l_prep) through_15\IN\0|availability (l_pobj) availability_17\NN\4718563|increased|of (l_prep) of_18\IN\0|production (l_pobj) production_23\NN\30358|no|reduced|o2-|in (l_prep) in_24\IN\13603305|forms (l_pobj) forms_26\NNS\6286395|various|of (l_prep) of_27\IN\0|hypertension (l_pobj) hypertension_28\NN\14057371|
D003907_D006973 CID dexamethasone_7\NN\2721538| (r_npadvmod) induced_9\VBN\1627355|dexamethasone|- (r_amod) hypertension_10\NN\14057371|induced|in
D003907_D006973 CID dexamethasone_0\NNP\2721538|characterized|production (l_parataxis) characterized_5\VBN\609683|(|hypertension|is|by|and|increased (l_nsubjpass) hypertension_3\NN\14057371|dex)-induced
D003907_D006973 CID dex)-induced_2\JJ\0| (r_amod) hypertension_3\NN\14057371|dex)-induced
D009569_D006973 NONE oxide_12\NN\14818238|nitric (r_nmod) deficiency_16\NN\14449126|oxide|(|no|) (r_pobj) with_10\IN\0|deficiency (r_prep) associated_9\VBN\628491|with (r_acl) dysfunction_8\NN\14204950|endothelial|associated (r_pobj) by_6\IN\0|dysfunction (r_agent) characterized_5\VBN\609683|(|hypertension|is|by|and|increased (l_nsubjpass) hypertension_3\NN\14057371|dex)-induced
D009569_D006973 NONE no_14\NNP\7204911| (r_intj) deficiency_16\NN\14449126|oxide|(|no|) (r_pobj) with_10\IN\0|deficiency (r_prep) associated_9\VBN\628491|with (r_acl) dysfunction_8\NN\14204950|endothelial|associated (r_pobj) by_6\IN\0|dysfunction (r_agent) characterized_5\VBN\609683|(|hypertension|is|by|and|increased (l_nsubjpass) hypertension_3\NN\14057371|dex)-induced
D009569_D006973 NONE no_19\DT\7204911|and (r_amod) production_23\NN\30358|no|reduced|o2-|in (l_prep) in_24\IN\13603305|forms (l_pobj) forms_26\NNS\6286395|various|of (l_prep) of_27\IN\0|hypertension (l_pobj) hypertension_28\NN\14057371|
D013481_D006973 NONE superoxide_19\NN\14971519| (r_advmod) increased_18\VBN\169651|superoxide (r_conj) characterized_5\VBN\609683|(|hypertension|is|by|and|increased (l_nsubjpass) hypertension_3\NN\14057371|dex)-induced
D013481_D006973 NONE o2-_21\NNPS\0| (r_nmod) production_23\NN\30358|(|o2-|)|. (r_appos) dexamethasone_0\NNP\2721538|characterized|production (l_parataxis) characterized_5\VBN\609683|(|hypertension|is|by|and|increased (l_nsubjpass) hypertension_3\NN\14057371|dex)-induced
D013481_D006973 NONE o2-_22\JJ\0| (r_compound) production_23\NN\30358|no|reduced|o2-|in (l_prep) in_24\IN\13603305|forms (l_pobj) forms_26\NNS\6286395|various|of (l_prep) of_27\IN\0|hypertension (l_pobj) hypertension_28\NN\14057371|
17600377
C524754_D003072 NONE coumarate_7\NN\0|maltolyl|p|- (r_appos) compound_2\NN\5869584|a|novel|,|coumarate|, (r_nsubj) attenuates_9\VBZ\224901|compound|deficits|and|shows|. (l_dobj) deficits_11\NNS\5113133|cognitive
C524754_D003072 NONE coumarate_11\NN\0|p|- (r_nsubj) improve_13\VB\126264|whether|coumarate|could|decline (l_dobj) decline_15\NN\13458571|cognitive|in
C524754_D003072 NONE coumarate_3\NN\0|maltolyl|p|- (r_nsubjpass) found_5\VBN\13279262|coumarate|was|attenuate|beta|. (l_xcomp) attenuate_7\VB\224901|to|deficits (l_dobj) deficits_9\NNS\5113133|cognitive|in|using|observed
C524754_D003072 NONE coumarate_17\NN\0|p|- (r_nsubj) is_18\VBZ\0|that|maltolyl|coumarate|candidate (l_attr) candidate_22\NN\10450303|a|effective|against|characterized (l_relcl) characterized_29\VBN\609683|that|is|by (l_agent) by_30\IN\0|death (l_pobj) death_34\NN\7296428|spread|neuronal|and|decline (l_conj) decline_37\NN\13458571|progressive|of (l_prep) of_38\IN\0|function (l_pobj) function_40\NN\13783581|cognitive
C524754_D003704 NONE coumarate_7\NN\0|maltolyl|p|- (r_appos) compound_2\NN\5869584|a|novel|,|coumarate|, (r_nsubj) attenuates_9\VBZ\224901|compound|deficits|and|shows|. (l_conj) shows_13\VBZ\429048|effects (l_dobj) effects_15\NNS\13245626|neuroprotective|in (l_prep) in_16\IN\13603305|vitro (l_amod) vitro_17\FW\0|and|in (l_conj) in_19\IN\13603305|models (l_pobj) models_22\NNS\5888929|dementia (l_compound) dementia_21\NN\14395018|vivo
D012601_D003072 CID scopolamine_17\NN\14712692| (r_npadvmod) injected_19\VBN\81072|scopolamine|- (r_amod) rats_20\NNS\2329401|injected (r_pobj) in_16\IN\13603305|rats|and|in (r_prep) decline_15\NN\13458571|cognitive|in
C544092_D003072 NONE beta_24\NN\6828818|amyloid (r_pobj) in_22\IN\13603305|beta (r_conj) in_16\IN\13603305|rats|and|in (r_prep) decline_15\NN\13458571|cognitive|in
C544092_D003072 NONE 42)-infused_34\VBN\0|peptide(1|- (r_amod) rats_35\NNS\2329401|42)-infused (r_dobj) beta_31\NN\6828818|amyloid|rats (r_advcl) found_5\VBN\13279262|coumarate|was|attenuate|beta|. (l_xcomp) attenuate_7\VB\224901|to|deficits (l_dobj) deficits_9\NNS\5113133|cognitive|in|using|observed
C524754_D000544 NONE coumarate_17\NN\0|p|- (r_nsubj) is_18\VBZ\0|that|maltolyl|coumarate|candidate (l_attr) candidate_22\NN\10450303|a|effective|against|characterized (l_prep) against_23\IN\0|disease (l_pobj) disease_26\NN\14061805|alzheimer
C524754_D009410 NONE coumarate_17\NN\0|p|- (r_nsubj) is_18\VBZ\0|that|maltolyl|coumarate|candidate (l_attr) candidate_22\NN\10450303|a|effective|against|characterized (l_relcl) characterized_29\VBN\609683|that|is|by (l_agent) by_30\IN\0|death (l_pobj) death_34\NN\7296428|spread|neuronal|and|decline
6747681
D002330_D005910 NONE bcnu_3\NNP\0| (r_compound) chemotherapy_4\NN\661091|arterial|bcnu|for|. (l_prep) for_5\IN\0|treatment (l_pobj) treatment_6\NN\654885|of (l_prep) of_7\IN\0|gliomas (l_pobj) gliomas_9\NNS\14236743|malignant|of
D002330_D005910 NONE bcnu_7\NNP\0| (r_nmod) 1,3-bis-(2-chloroethyl)-1-nitrosourea_9\NN\0|bcnu|(|) (r_pobj) of_6\IN\0|1,3-bis-(2-chloroethyl)-1-nitrosourea (r_prep) clearance_5\NN\5089947|the|rapid|systemic|of (r_pobj) because_0\IN\0|of|clearance (r_prep) provide_17\VB\2199590|because|,|administration|should|advantage|. (l_dobj) advantage_20\NN\5154517|a|substantial|over (l_prep) over_21\IN\5867413|administration (l_pobj) administration_23\NN\1133281|intravenous|for (l_prep) for_24\IN\0|treatment (l_pobj) treatment_26\NN\654885|the|of (l_prep) of_27\IN\0|gliomas (l_pobj) gliomas_29\NNS\14236743|malignant
D002330_D005910 NONE 1,3-bis-(2-chloroethyl)-1-nitrosourea_9\NN\0|bcnu|(|) (r_pobj) of_6\IN\0|1,3-bis-(2-chloroethyl)-1-nitrosourea (r_prep) clearance_5\NN\5089947|the|rapid|systemic|of (r_pobj) because_0\IN\0|of|clearance (r_prep) provide_17\VB\2199590|because|,|administration|should|advantage|. (l_dobj) advantage_20\NN\5154517|a|substantial|over (l_prep) over_21\IN\5867413|administration (l_pobj) administration_23\NN\1133281|intravenous|for (l_prep) for_24\IN\0|treatment (l_pobj) treatment_26\NN\654885|the|of (l_prep) of_27\IN\0|gliomas (l_pobj) gliomas_29\NNS\14236743|malignant
D002330_D001254 NONE bcnu_29\NNP\0| (r_compound) therapy_30\NN\657604|arterial|bcnu (r_pobj) of_25\IN\0|therapy (r_prep) courses_24\NNS\883297|eight|of (r_dobj) received_20\VBD\2210855|patients|courses|. (l_nsubj) patients_3\NNS\9898892|four|with|to (l_prep) to_8\IN\0|astrocytomas (l_pobj) astrocytomas_10\NN\0|iv|,|failed|,
D000431_D014786 NONE ethanol_11\NN\14708720| (r_compound) diluent_12\NN\14778436|the|ethanol (r_pobj) of_9\IN\0|diluent (r_prep) concentration_8\NN\4916342|the|of (r_nsubjpass) lowered_14\VBN\1850315|after|concentration|was (r_advcl) decreased_5\VBD\169651|frequency|lowered|. (l_nsubj) frequency_1\NN\15286249|the|of (l_prep) of_2\IN\0|loss (l_pobj) loss_4\NN\13252973|visual
4027862
D003891_D003693 CID desipramine_0\NN\4482543| (r_npadvmod) induced_2\VBN\1627355|desipramine|- (r_amod) delirium_3\NN\14391660|induced|at|.
D003891_D003693 CID desipramine_7\NNP\4482543| (r_nsubj) developed_8\VBD\1753788|patient|desipramine|delirium|was|. (l_dobj) delirium_10\NN\14391660|a
18768591
D004317_D009404 CID doxorubicin_8\NN\2716866| (r_npadvmod) induced_10\VBN\1627355|doxorubicin|- (r_amod) syndrome_12\NN\5870365|induced|nephrotic
D004317_D009404 CID doxorubicin_0\NNP\2716866| (r_compound) treatment_1\NN\654885|doxorubicin (r_nsubj) resulted_2\VBD\2633881|treatment|in|)|and|15/44|. (l_conj) 15/44_21\CD\0|of (l_prep) of_22\IN\0|mice (l_pobj) mice_25\NNS\2329401|sgk1(-/-|)|leading (l_acl) leading_26\VBG\4339291|to (l_prep) to_27\IN\0|syndrome (l_pobj) syndrome_30\NN\5870365|severe|nephrotic|with
D004317_D007674 NONE doxorubicin_0\NNP\2716866| (r_npadvmod) induced_2\VBN\1627355|doxorubicin|- (r_amod) nephropathy_3\NN\14573196|induced
D004317_D016055 NONE doxorubicin_0\NNP\2716866| (r_npadvmod) induced_2\VBN\1627355|doxorubicin|- (r_amod) nephropathy_3\NN\14573196|induced (r_nsubj) leads_4\VBZ\5155821|nephropathy|to|. (l_prep) to_5\IN\0|channel (l_pobj) channel_8\NN\6251781|epithelial|sodium|retention (l_appos) retention_12\NN\809465|(|enac)-dependent|volume|and|fibrosis
D004317_D005355 NONE doxorubicin_0\NNP\2716866| (r_npadvmod) induced_2\VBN\1627355|doxorubicin|- (r_amod) nephropathy_3\NN\14573196|induced (r_nsubj) leads_4\VBZ\5155821|nephropathy|to|. (l_prep) to_5\IN\0|channel (l_pobj) channel_8\NN\6251781|epithelial|sodium|retention (l_appos) retention_12\NN\809465|(|enac)-dependent|volume|and|fibrosis (l_conj) fibrosis_15\NN\14204950|renal
D012964_D007674 NONE sodium_7\NN\14625458| (r_compound) channel_8\NN\6251781|epithelial|sodium|retention (r_pobj) to_5\IN\0|channel (r_prep) leads_4\VBZ\5155821|nephropathy|to|. (l_nsubj) nephropathy_3\NN\14573196|induced
D012964_D016055 NONE sodium_7\NN\14625458| (r_compound) channel_8\NN\6251781|epithelial|sodium|retention (l_appos) retention_12\NN\809465|(|enac)-dependent|volume|and|fibrosis
D012964_D005355 NONE sodium_7\NN\14625458| (r_compound) channel_8\NN\6251781|epithelial|sodium|retention (l_appos) retention_12\NN\809465|(|enac)-dependent|volume|and|fibrosis (l_conj) fibrosis_15\NN\14204950|renal
D000450_D005355 NONE aldosterone_1\NN\14751863| (r_npadvmod) sensitive_3\JJ\10488309|aldosterone|- (r_amod) sgk1_10\NNP\0|the|sensitive|kinase (r_nsubjpass) shown_13\VBN\2137132|sgk1|has|been|participate|. (l_xcomp) participate_15\VB\2367363|to|in|and|mediate (l_conj) mediate_23\VB\761713|to|fibrosis (l_dobj) fibrosis_25\NN\14204950|renal|following
D004317_D011507 CID doxorubicin_0\NNP\2716866| (r_compound) treatment_1\NN\654885|doxorubicin (r_nsubj) resulted_2\VBD\2633881|treatment|in|)|and|15/44|. (l_prep) in_3\IN\13603305|proteinuria (l_pobj) proteinuria_5\NN\14299637|heavy|(|crea|)|in
D004317_D001201 CID doxorubicin_0\NNP\2716866| (r_compound) treatment_1\NN\654885|doxorubicin (r_nsubj) resulted_2\VBD\2633881|treatment|in|)|and|15/44|. (l_conj) 15/44_21\CD\0|of (l_prep) of_22\IN\0|mice (l_pobj) mice_25\NNS\2329401|sgk1(-/-|)|leading (l_acl) leading_26\VBG\4339291|to (l_prep) to_27\IN\0|syndrome (l_pobj) syndrome_30\NN\5870365|severe|nephrotic|with (l_prep) with_31\IN\0|ascites (l_pobj) ascites_32\NNS\14204950|,|lipidemia
D004317_D006949 CID doxorubicin_0\NNP\2716866| (r_compound) treatment_1\NN\654885|doxorubicin (r_nsubj) resulted_2\VBD\2633881|treatment|in|)|and|15/44|. (l_conj) 15/44_21\CD\0|of (l_prep) of_22\IN\0|mice (l_pobj) mice_25\NNS\2329401|sgk1(-/-|)|leading (l_acl) leading_26\VBG\4339291|to (l_prep) to_27\IN\0|syndrome (l_pobj) syndrome_30\NN\5870365|severe|nephrotic|with (l_prep) with_31\IN\0|ascites (l_pobj) ascites_32\NNS\14204950|,|lipidemia (l_conj) lipidemia_34\NN\14299637|,|and|hypoalbuminemia
D004317_D034141 CID doxorubicin_0\NNP\2716866| (r_compound) treatment_1\NN\654885|doxorubicin (r_nsubj) resulted_2\VBD\2633881|treatment|in|)|and|15/44|. (l_conj) 15/44_21\CD\0|of (l_prep) of_22\IN\0|mice (l_pobj) mice_25\NNS\2329401|sgk1(-/-|)|leading (l_acl) leading_26\VBG\4339291|to (l_prep) to_27\IN\0|syndrome (l_pobj) syndrome_30\NN\5870365|severe|nephrotic|with (l_prep) with_31\IN\0|ascites (l_pobj) ascites_32\NNS\14204950|,|lipidemia (l_conj) lipidemia_34\NN\14299637|,|and|hypoalbuminemia (l_conj) hypoalbuminemia_37\VB\0|in
D000450_D009404 NONE aldosterone_1\NN\14751863| (r_compound) levels_2\NNS\4916342|plasma|aldosterone (r_nsubj) increased_3\VBD\169651|levels|in|and|followed|. (l_prep) in_4\IN\13603305|mice (l_pobj) mice_6\NNS\2329401|nephrotic|of (l_amod) nephrotic_5\JJ\0|
D014508_D009404 NONE urea_8\NN\14727670| (r_compound) concentrations_9\NNS\4916342|serum|urea (r_nsubj) increased_10\VBD\169651|during|,|concentrations|faster|in|than|) (l_prep) during_0\IN\0|course (l_pobj) course_2\NN\883297|the|of (l_prep) of_3\IN\0|syndrome (l_pobj) syndrome_5\NN\5870365|nephrotic
12584269
D020123_D007674 CID srl_5\NN\0| (r_nsubj) seems_6\VBZ\2604760|srl|act|,|is|. (r_conj) are_1\VBP\13600404|these|nephrotoxic|,|but|seems (l_acomp) nephrotoxic_2\JJ\0|
D020123_D007674 CID srl_5\NN\0| (r_nsubj) seems_6\VBZ\2604760|srl|act|,|is|. (l_xcomp) act_8\VB\6479665|to|differently|displaying (l_advcl) displaying_10\VBG\2137132|effects (l_dobj) effects_14\NNS\13245626|only|minor|nephrotoxic (l_amod) nephrotoxic_13\JJ\0|
D020123_D007674 CID srl_7\NN\0| (r_nsubjpass) combined_9\VBN\2630189|where|srl|was|with (l_prep) with_10\IN\0|indications (l_pobj) indications_14\NNS\33020|a|calcineurin|inhibitor|of (l_prep) of_15\IN\0|effect (l_pobj) effect_19\NN\34213|a|synergistic|nephrotoxic (l_amod) nephrotoxic_18\JJ\0|
D020123_D007674 CID srl_11\NNP\0| (r_conj) csa_9\NNP\0|plus|srl (r_pobj) of_8\IN\0|csa (r_prep) effect_7\NN\34213|a|synergistic|nephrotoxic|of (l_amod) nephrotoxic_6\JJ\0|
D020123_D007674 CID srl_16\NNP\0| (r_conj) fk506_14\NNP\0|plus|srl (r_nsubjpass) tolerated_19\VBN\802318|whereas|fk506|was|better (r_advcl) demonstrated_3\VBD\2137132|study|effect|,|tolerated|. (l_dobj) effect_7\NN\34213|a|synergistic|nephrotoxic|of (l_amod) nephrotoxic_6\JJ\0|
D016559_D005355 NONE fk506_1\NNP\0|the|plus (r_nmod) combination_4\NN\7951464|fk506|srl (r_nsubj) showed_5\VBD\2137132|combination|degree|compared|. (l_dobj) degree_10\NN\4916342|only|a|higher|of (l_prep) of_11\IN\0|fibrosis (l_pobj) fibrosis_12\NN\14204950|
D020123_D005355 NONE srl_3\NNP\0| (r_compound) combination_4\NN\7951464|fk506|srl (r_nsubj) showed_5\VBD\2137132|combination|degree|compared|. (l_dobj) degree_10\NN\4916342|only|a|higher|of (l_prep) of_11\IN\0|fibrosis (l_pobj) fibrosis_12\NN\14204950|
D016572_D007674 CID csa_9\NNP\0|plus|srl (r_pobj) of_8\IN\0|csa (r_prep) effect_7\NN\34213|a|synergistic|nephrotoxic|of (l_amod) nephrotoxic_6\JJ\0|
D016559_D007674 CID fk506_14\NNP\0|plus|srl (r_nsubjpass) tolerated_19\VBN\802318|whereas|fk506|was|better (r_advcl) demonstrated_3\VBD\2137132|study|effect|,|tolerated|. (l_dobj) effect_7\NN\34213|a|synergistic|nephrotoxic|of (l_amod) nephrotoxic_6\JJ\0|
8669433
D000082_D007676 NONE acetaminophen_3\NN\2707683| (r_pobj) of_2\IN\0|acetaminophen (r_prep) use_1\NN\407535|habitual|of|as|:|comparison|. (l_prep) as_4\IN\14622893|factor (l_pobj) factor_7\NN\7326557|a|risk|for (l_prep) for_8\IN\0|failure (l_pobj) failure_11\NN\66216|chronic|renal
D000082_D007676 NONE acetaminophen_27\NN\2707683| (r_pobj) of_26\IN\0|acetaminophen (r_prep) use_25\NN\407535|habitual|of (r_nsubjpass) associated_30\VBN\628491|that|use|is|also|with|,|with (l_prep) with_31\IN\0|failure (l_pobj) failure_34\NN\66216|chronic|renal|and|esrd
D000082_D007676 NONE acetaminophen_27\NN\2707683| (r_pobj) of_26\IN\0|acetaminophen (r_prep) use_25\NN\407535|habitual|of (r_nsubjpass) associated_30\VBN\628491|that|use|is|also|with|,|with (l_prep) with_31\IN\0|failure (l_pobj) failure_34\NN\66216|chronic|renal|and|esrd (l_conj) esrd_36\NNP\0|
D000082_D007676 NONE acetaminophen_7\RB\2707683| (r_conj) phenacetin_5\NN\2707683|both|and|acetaminophen (r_nsubj) contribute_9\VB\126264|that|phenacetin|may|to|,|with (l_prep) to_10\IN\0|burden (l_pobj) burden_12\NN\5832264|the|of (l_prep) of_13\IN\0|esrd (l_pobj) esrd_14\NNP\0|
D000082_D007676 NONE acetaminophen_6\NN\2707683| (r_pobj) of_5\IN\0|acetaminophen (r_prep) use_4\NN\407535|habitual|of|alone (r_nsubj) increases_8\VBZ\13576355|that|use|risk (l_dobj) risk_10\NN\14541044|the|of (l_prep) of_11\IN\0|esrd (l_pobj) esrd_12\NNP\0|
D010615_D007676 CID phenacetin_16\NN\2707683| (r_pobj) with_15\IN\0|phenacetin (r_prep) comparison_14\NN\635850|a|with (r_appos) use_1\NN\407535|habitual|of|as|:|comparison|. (l_prep) as_4\IN\14622893|factor (l_pobj) factor_7\NN\7326557|a|risk|for (l_prep) for_8\IN\0|failure (l_pobj) failure_11\NN\66216|chronic|renal
D010615_D007676 CID phenacetin_14\NN\2707683| (r_pobj) of_13\IN\0|phenacetin (r_prep) use_12\NN\407535|habitual|of (r_nsubjpass) associated_16\VBN\628491|that|use|is|with|,|with (l_prep) with_17\IN\0|development (l_pobj) development_19\NN\248977|the|of (l_prep) of_20\IN\0|failure (l_pobj) failure_23\NN\66216|chronic|renal|and|disease
D010615_D007676 CID phenacetin_14\NN\2707683| (r_pobj) of_13\IN\0|phenacetin (r_prep) use_12\NN\407535|habitual|of (r_nsubjpass) associated_16\VBN\628491|that|use|is|with|,|with (l_prep) with_17\IN\0|development (l_pobj) development_19\NN\248977|the|of (l_prep) of_20\IN\0|failure (l_pobj) failure_23\NN\66216|chronic|renal|and|disease (l_conj) disease_29\NN\14061805|stage|renal|(|esrd|)
D010615_D007676 CID phenacetin_14\NN\2707683| (r_pobj) of_13\IN\0|phenacetin (r_prep) use_12\NN\407535|habitual|of (r_nsubjpass) associated_16\VBN\628491|that|use|is|with|,|with (l_prep) with_17\IN\0|development (l_pobj) development_19\NN\248977|the|of (l_prep) of_20\IN\0|failure (l_pobj) failure_23\NN\66216|chronic|renal|and|disease (l_conj) disease_29\NN\14061805|stage|renal|(|esrd|) (l_appos) esrd_31\NNP\0|
D010615_D007676 CID phenacetin_5\NN\2707683|both|and|acetaminophen (r_nsubj) contribute_9\VB\126264|that|phenacetin|may|to|,|with (l_prep) to_10\IN\0|burden (l_pobj) burden_12\NN\5832264|the|of (l_prep) of_13\IN\0|esrd (l_pobj) esrd_14\NNP\0|
234669
D000628_D014693 CID aminophylline_2\NN\2905612|on (r_pobj) of_1\IN\0|aminophylline (r_prep) effects_0\NNS\13245626|of|for|. (l_prep) for_6\IN\0|initiating (l_pcomp) initiating_7\VBG\1617192|fibrillation|during (l_dobj) fibrillation_9\NN\14361664|ventricular
D000628_D014693 CID aminophylline_3\NN\2905612|on (l_prep) on_4\IN\0|threshold (l_pobj) threshold_8\NN\15265518|the|fibrillation|during (l_compound) fibrillation_7\NN\14361664|ventricular
D000628_D014693 CID aminophylline_4\NN\2905612| (r_pobj) of_3\IN\0|aminophylline (r_prep) infusion_2\NN\14589223|the|of (r_pobj) during_0\IN\0|infusion (r_prep) reduced_11\VBN\441445|during|,|threshold|was|by|kept|. (l_nsubjpass) threshold_9\NN\15265518|the|ventricular|fibrillation (l_compound) fibrillation_8\NN\14361664|
D000628_D014693 CID aminophylline_30\NN\2905612| (r_pobj) of_29\IN\0|aminophylline (r_prep) infusion_28\NN\14589223|of (r_nsubj) resulted_31\VBD\2633881|produced|pc02|,|infusion|in|. (l_prep) in_32\IN\13603305|decrease (l_pobj) decrease_36\NN\7296428|an|greater|in (l_prep) in_37\IN\13603305|threshold (l_pobj) threshold_40\NN\15265518|fibrillation|to (l_compound) fibrillation_39\NN\14361664|ventricular
D000628_D012131 NONE aminophylline_2\NN\2905612|on (r_pobj) of_1\IN\0|aminophylline (r_prep) effects_0\NNS\13245626|of|for|. (l_prep) for_6\IN\0|initiating (l_pcomp) initiating_7\VBG\1617192|fibrillation|during (l_prep) during_10\IN\0|failure (l_pobj) failure_12\NN\66216|respiratory
D000628_D012131 NONE aminophylline_3\NN\2905612|on (r_pobj) of_2\IN\0|aminophylline (r_prep) effects_1\NNS\13245626|the|of|and|during (l_conj) during_16\IN\0|failure (l_pobj) failure_18\NN\66216|respiratory
D000628_D012131 NONE aminophylline_30\NN\2905612| (r_pobj) of_29\IN\0|aminophylline (r_prep) infusion_28\NN\14589223|of (r_nsubj) resulted_31\VBD\2633881|produced|pc02|,|infusion|in|. (l_advcl) produced_4\VBN\1617192|when|failure|was|by (l_nsubjpass) failure_2\NN\66216|respiratory
D000628_D012131 NONE aminophylline_24\NN\2905612|particularly (r_appos) agents_21\NNS\7347|pharmacologic|,|aminophylline|, (r_nsubj) play_27\VB\7007684|that|contribute|,|agents|may|role (l_advcl) contribute_8\VB\126264|although|factors|may|to (l_prep) to_9\IN\0|incidence (l_pobj) incidence_12\NN\13821570|the|increased|of (l_prep) of_13\IN\0|arrhythmias (l_pobj) arrhythmias_15\NNS\14103288|ventricular|in (l_prep) in_16\IN\13603305|failure (l_pobj) failure_18\NN\66216|respiratory
D010100_D014693 NONE oxygen_26\NN\14622893|(|po2 (r_pobj) of_25\IN\0|oxygen (r_prep) pressures_24\NNS\11419404|ph|of (r_nsubjpass) kept_37\VBN\0|when|pressures|were|within (r_advcl) reduced_11\VBN\441445|during|,|threshold|was|by|kept|. (l_nsubjpass) threshold_9\NN\15265518|the|ventricular|fibrillation (l_compound) fibrillation_8\NN\14361664|
C093415_D014693 NONE po2_28\NNP\0|)|and|dioxide (r_appos) oxygen_26\NN\14622893|(|po2 (r_pobj) of_25\IN\0|oxygen (r_prep) pressures_24\NNS\11419404|ph|of (r_nsubjpass) kept_37\VBN\0|when|pressures|were|within (r_advcl) reduced_11\VBN\441445|during|,|threshold|was|by|kept|. (l_nsubjpass) threshold_9\NN\15265518|the|ventricular|fibrillation (l_compound) fibrillation_8\NN\14361664|
D002245_D014693 NONE dioxide_32\NN\14971519|carbon|co2 (r_conj) po2_28\NNP\0|)|and|dioxide (r_appos) oxygen_26\NN\14622893|(|po2 (r_pobj) of_25\IN\0|oxygen (r_prep) pressures_24\NNS\11419404|ph|of (r_nsubjpass) kept_37\VBN\0|when|pressures|were|within (r_advcl) reduced_11\VBN\441445|during|,|threshold|was|by|kept|. (l_nsubjpass) threshold_9\NN\15265518|the|ventricular|fibrillation (l_compound) fibrillation_8\NN\14361664|
D002245_D014693 NONE co2_34\NNP\14836127|(|) (r_appos) dioxide_32\NN\14971519|carbon|co2 (r_conj) po2_28\NNP\0|)|and|dioxide (r_appos) oxygen_26\NN\14622893|(|po2 (r_pobj) of_25\IN\0|oxygen (r_prep) pressures_24\NNS\11419404|ph|of (r_nsubjpass) kept_37\VBN\0|when|pressures|were|within (r_advcl) reduced_11\VBN\441445|during|,|threshold|was|by|kept|. (l_nsubjpass) threshold_9\NN\15265518|the|ventricular|fibrillation (l_compound) fibrillation_8\NN\14361664|
D000628_D007040 NONE aminophylline_30\NN\2905612| (r_pobj) of_29\IN\0|aminophylline (r_prep) infusion_28\NN\14589223|of (r_nsubj) resulted_31\VBD\2633881|produced|pc02|,|infusion|in|. (l_advcl) produced_4\VBN\1617192|when|failure|was|by (l_agent) by_5\IN\0|hypoventilation (l_pobj) hypoventilation_6\NN\0|(|ph|;
D000628_D001145 NONE aminophylline_24\NN\2905612|particularly (r_appos) agents_21\NNS\7347|pharmacologic|,|aminophylline|, (r_nsubj) play_27\VB\7007684|that|contribute|,|agents|may|role (l_advcl) contribute_8\VB\126264|although|factors|may|to (l_prep) to_9\IN\0|incidence (l_pobj) incidence_12\NN\13821570|the|increased|of (l_prep) of_13\IN\0|arrhythmias (l_pobj) arrhythmias_15\NNS\14103288|ventricular|in
11263551
D016572_D010146 CID cyclosporine-_3\NN\0|or (r_nmod) levels_7\NNS\4916342|cyclosporine-|trough (r_pobj) of_2\IN\0|levels (r_prep) reduction_1\NN\351485|the|of|and|administration (r_nsubj) led_15\VBD\3202760|reduction|to|. (l_prep) to_16\IN\0|relief (l_pobj) relief_17\NN\7492516|of (l_prep) of_18\IN\0|pain (l_pobj) pain_19\NN\14299637|
D016572_D010146 CID cyclosporine_18\NN\0|or|tacrolimus (r_pobj) of_17\IN\0|cyclosporine (r_prep) effect_16\NN\34213|a|rare|side|of (r_attr) is_10\VBZ\0|syndrome|effect|and|diagnosed|. (l_nsubj) syndrome_6\NNP\5870365|the|inhibitor|pain|(|cips|) (l_compound) pain_5\NNP\14299637|induced
D016559_D010146 CID tacrolimus_5\VB\0| (r_compound) trough_6\NN\9366017|tacrolimus (r_compound) levels_7\NNS\4916342|cyclosporine-|trough (r_pobj) of_2\IN\0|levels (r_prep) reduction_1\NN\351485|the|of|and|administration (r_nsubj) led_15\VBD\3202760|reduction|to|. (l_prep) to_16\IN\0|relief (l_pobj) relief_17\NN\7492516|of (l_prep) of_18\IN\0|pain (l_pobj) pain_19\NN\14299637|
D016559_D010146 CID tacrolimus_20\NN\0| (r_conj) cyclosporine_18\NN\0|or|tacrolimus (r_pobj) of_17\IN\0|cyclosporine (r_prep) effect_16\NN\34213|a|rare|side|of (r_attr) is_10\VBZ\0|syndrome|effect|and|diagnosed|. (l_nsubj) syndrome_6\NNP\5870365|the|inhibitor|pain|(|cips|) (l_compound) pain_5\NNP\14299637|induced
D002118_D010146 NONE calcium_12\NN\14625458| (r_compound) channel_13\NN\6251781|calcium (r_compound) blockers_14\NNS\10101634|channel (r_pobj) of_11\IN\0|blockers (r_prep) administration_10\NN\1133281|the|of (r_conj) reduction_1\NN\351485|the|of|and|administration (r_nsubj) led_15\VBD\3202760|reduction|to|. (l_prep) to_16\IN\0|relief (l_pobj) relief_17\NN\7492516|of (l_prep) of_18\IN\0|pain (l_pobj) pain_19\NN\14299637|
D016572_-1 NONE cyclosporine_18\NN\0|or|tacrolimus (r_pobj) of_17\IN\0|cyclosporine (r_prep) effect_16\NN\34213|a|rare|side|of (r_attr) is_10\VBZ\0|syndrome|effect|and|diagnosed|. (l_nsubj) syndrome_6\NNP\5870365|the|inhibitor|pain|(|cips|) (l_appos) cips_8\NNP\0|
D016559_-1 NONE tacrolimus_20\NN\0| (r_conj) cyclosporine_18\NN\0|or|tacrolimus (r_pobj) of_17\IN\0|cyclosporine (r_prep) effect_16\NN\34213|a|rare|side|of (r_attr) is_10\VBZ\0|syndrome|effect|and|diagnosed|. (l_nsubj) syndrome_6\NNP\5870365|the|inhibitor|pain|(|cips|) (l_appos) cips_8\NNP\0|
6503301
D003606_D006504 CID dacarbazine_6\NN\0| (r_compound) therapy_7\NN\657604|dacarbazine|(|dtic|)|for (r_pobj) after_5\IN\0|therapy (r_prep) disease_4\NN\14061805|occlusive|liver|after|.
D003606_D006504 CID dtic_9\NNP\8337324| (r_appos) therapy_7\NN\657604|dacarbazine|(|dtic|)|for (r_pobj) after_5\IN\0|therapy (r_prep) disease_4\NN\14061805|occlusive|liver|after|.
D003606_D006504 CID dacarbazine_14\NN\0| (r_nmod) therapy_18\NN\657604|dacarbazine|(|dtic|)|for (r_nsubjpass) reported_22\VBN\831651|case|after|therapy|is|. (l_nsubjpass) case_1\NN\7283608|a|of (l_prep) of_2\IN\0|disease (l_pobj) disease_6\NN\14061805|occlusive|of|with (l_prep) of_7\IN\0|liver (l_pobj) liver_9\NN\5298729|the
D003606_D006504 CID dtic_16\NNP\8337324| (r_nmod) therapy_18\NN\657604|dacarbazine|(|dtic|)|for (r_nsubjpass) reported_22\VBN\831651|case|after|therapy|is|. (l_nsubjpass) case_1\NN\7283608|a|of (l_prep) of_2\IN\0|disease (l_pobj) disease_6\NN\14061805|occlusive|of|with (l_prep) of_7\IN\0|liver (l_pobj) liver_9\NN\5298729|the
D003606_D008545 NONE dacarbazine_6\NN\0| (r_compound) therapy_7\NN\657604|dacarbazine|(|dtic|)|for (l_prep) for_11\IN\0|melanoma (l_pobj) melanoma_12\NN\14252320|
D003606_D008545 NONE dtic_9\NNP\8337324| (r_appos) therapy_7\NN\657604|dacarbazine|(|dtic|)|for (l_prep) for_11\IN\0|melanoma (l_pobj) melanoma_12\NN\14252320|
D003606_D008545 NONE dacarbazine_14\NN\0| (r_nmod) therapy_18\NN\657604|dacarbazine|(|dtic|)|for (l_prep) for_19\IN\0|melanoma (l_pobj) melanoma_20\NN\14252320|
D003606_D008545 NONE dtic_16\NNP\8337324| (r_nmod) therapy_18\NN\657604|dacarbazine|(|dtic|)|for (l_prep) for_19\IN\0|melanoma (l_pobj) melanoma_20\NN\14252320|
15458908
D020849_D010024 NONE raloxifene_4\NNP\0| (r_compound) evaluation_5\NNP\874067|raloxifene|,|trial|, (r_pobj) of_3\IN\0|evaluation (r_prep) outcomes_2\NNPS\7291312|the|multiple|of (r_nsubj) enrolled_17\VBD\2471690|outcomes|women|with|. (l_prep) with_21\IN\0|osteoporosis (l_pobj) osteoporosis_22\NN\14204950|
D020849_D054556 CID raloxifene_11\NN\0| (r_nsubjpass) associated_13\VBN\628491|:|during|,|raloxifene|was|with|. (l_prep) with_14\IN\0|risk (l_pobj) risk_17\NN\14541044|an|increased|for (l_prep) for_18\IN\0|thromboembolism (l_pobj) thromboembolism_20\NN\14100769|venous|(|risk|;|interval
D020849_D054556 CID raloxifene_0\NNP\0| (r_nsubjpass) associated_2\VBN\628491|raloxifene|was|with|,|but|was (l_prep) with_3\IN\0|risk (l_pobj) risk_6\NN\14541044|an|increased|for (l_prep) for_7\IN\0|thromboembolism (l_pobj) thromboembolism_9\NN\14100769|venous
D020849_D002386 NONE raloxifene_0\NNP\0| (r_nsubj) increase_3\VB\13576355|raloxifene|did|not|risk|,|disease|. (l_dobj) risk_4\NN\14541044|for (l_prep) for_5\IN\0|cataracts (l_pobj) cataracts_6\NNS\14252864|(|ci|)
D020849_D002386 NONE raloxifene_0\NNP\0| (r_nsubjpass) associated_2\VBN\628491|raloxifene|was|with|,|but|was (l_conj) was_13\VBD\0|there|risk|. (l_attr) risk_16\NN\14541044|no|increased|for (l_prep) for_17\IN\0|cataracts (l_pobj) cataracts_18\NNS\14252864|,|disease
D020849_D005705 NONE raloxifene_0\NNP\0| (r_nsubj) increase_3\VB\13576355|raloxifene|did|not|risk|,|disease|. (l_dep) disease_20\NN\14061805|gallbladder|(|rr|;|ci
D020849_D005705 NONE raloxifene_0\NNP\0| (r_nsubjpass) associated_2\VBN\628491|raloxifene|was|with|,|but|was (l_conj) was_13\VBD\0|there|risk|. (l_attr) risk_16\NN\14541044|no|increased|for (l_prep) for_17\IN\0|cataracts (l_pobj) cataracts_18\NNS\14252864|,|disease (l_conj) disease_21\NN\14061805|gallbladder|,|hyperplasia
D020849_D004714 NONE raloxifene_0\NNP\0| (r_nsubj) increase_3\VB\13576355|raloxifene|did|not|risk|,|disease|. (l_dep) disease_20\NN\14061805|gallbladder|(|rr|;|ci (l_appos) ci_27\NNP\13635336|%|1.3|)|,|hyperplasia (l_appos) hyperplasia_34\NN\14365950|endometrial|(|%
D020849_D004714 NONE raloxifene_0\NNP\0| (r_nsubjpass) associated_2\VBN\628491|raloxifene|was|with|,|but|was (l_conj) was_13\VBD\0|there|risk|. (l_attr) risk_16\NN\14541044|no|increased|for (l_prep) for_17\IN\0|cataracts (l_pobj) cataracts_18\NNS\14252864|,|disease (l_conj) disease_21\NN\14061805|gallbladder|,|hyperplasia (l_conj) hyperplasia_24\NN\14365950|endometrial|,|or|cancer
D020849_D016889 NONE raloxifene_0\NNP\0| (r_nsubj) increase_3\VB\13576355|raloxifene|did|not|risk|,|disease|. (l_dep) disease_20\NN\14061805|gallbladder|(|rr|;|ci (l_appos) ci_27\NNP\13635336|%|1.3|)|,|hyperplasia (l_appos) hyperplasia_34\NN\14365950|endometrial|(|% (l_appos) %_40\NN\0|rr|;|95|0.4|,|or|cancer|;|% (l_conj) cancer_49\NN\14239425|endometrial|(|rr
D020849_D016889 NONE raloxifene_0\NNP\0| (r_nsubjpass) associated_2\VBN\628491|raloxifene|was|with|,|but|was (l_conj) was_13\VBD\0|there|risk|. (l_attr) risk_16\NN\14541044|no|increased|for (l_prep) for_17\IN\0|cataracts (l_pobj) cataracts_18\NNS\14252864|,|disease (l_conj) disease_21\NN\14061805|gallbladder|,|hyperplasia (l_conj) hyperplasia_24\NN\14365950|endometrial|,|or|cancer (l_conj) cancer_28\NN\14239425|endometrial
227508
D003000_D006973 NONE clonidine_17\NN\2721160|intravenous (r_pobj) by_15\IN\0|clonidine (r_agent) produced_14\VBN\1617192|by (r_acl) pressure_10\NN\11419404|blood|and|rate|produced (r_pobj) in_8\IN\13603305|pressure (r_prep) decrease_7\NN\7296428|the|in (r_dobj) rats_5\NNS\2329401|in|,|hypertensive|decrease|,|inhibited|. (l_amod) hypertensive_4\JJ\10405694|spontaneously
D003000_D006973 NONE clonidine_7\NN\2721160|10(-8|to (r_preconj) in_0\IN\13603305|membranes|clonidine (l_pobj) membranes_2\NNS\4188643|brain|from (l_prep) from_3\IN\0|rats (l_pobj) rats_6\NNS\2329401|hypertensive (l_amod) hypertensive_5\JJ\10405694|spontaneously
D003000_D006973 NONE clonidine_42\NN\2721160| (r_npadvmod) suppressible_44\NN\0|clonidine|- (r_amod) binding_45\NN\4688246|suppressible|of (r_dobj) influence_41\VB\5190804|naloxone|did|not|binding|)|. (r_conj) influence_18\VB\5190804|in|,|did|not|binding|,|and|influence (l_prep) in_0\IN\13603305|membranes|clonidine (l_pobj) membranes_2\NNS\4188643|brain|from (l_prep) from_3\IN\0|rats (l_pobj) rats_6\NNS\2329401|hypertensive (l_amod) hypertensive_5\JJ\10405694|spontaneously
-1_D006973 NONE nalozone_31\NN\0| (r_pobj) by_30\IN\0|nalozone (r_agent) reversed_29\VBN\109660|by (r_conj) inhibited_27\VBN\2510337|micrograms|,|was|or|reversed|,|mg/kg (r_conj) rats_5\NNS\2329401|in|,|hypertensive|decrease|,|inhibited|. (l_amod) hypertensive_4\JJ\10405694|spontaneously
-1_D006973 NONE 3h]-naloxone_23\CD\0|[|(|nm|) (r_pobj) of_21\IN\0|3h]-naloxone (r_prep) binding_20\NN\4688246|stereoselective|of (r_dobj) influence_18\VB\5190804|in|,|did|not|binding|,|and|influence (l_prep) in_0\IN\13603305|membranes|clonidine (l_pobj) membranes_2\NNS\4188643|brain|from (l_prep) from_3\IN\0|rats (l_pobj) rats_6\NNS\2329401|hypertensive (l_amod) hypertensive_5\JJ\10405694|spontaneously
-1_D006973 NONE 3h]-dihydroergocryptine_48\CD\0|[ (r_nummod) nm_51\NNP\13649268|3h]-dihydroergocryptine|(|1 (r_pobj) of_46\IN\0|nm (r_prep) binding_45\NN\4688246|suppressible|of (r_dobj) influence_41\VB\5190804|naloxone|did|not|binding|)|. (r_conj) influence_18\VB\5190804|in|,|did|not|binding|,|and|influence (l_prep) in_0\IN\13603305|membranes|clonidine (l_pobj) membranes_2\NNS\4188643|brain|from (l_prep) from_3\IN\0|rats (l_pobj) rats_6\NNS\2329401|hypertensive (l_amod) hypertensive_5\JJ\10405694|spontaneously
D008750_D007022 CID methyldopa_8\NN\2721160|mg/kg|alpha|- (r_pobj) of_3\IN\0|methyldopa (r_prep) effect_2\NN\34213|the|hypotensive|of (l_amod) hypotensive_1\JJ\10405694|
D009270_D007022 NONE naloxone_14\NN\3808977| (r_pobj) by_13\IN\0|naloxone (r_agent) reversed_12\VBN\109660|effect|was|also|partially|by|. (l_nsubjpass) effect_2\NN\34213|the|hypotensive|of (l_amod) hypotensive_1\JJ\10405694|
D009270_D006973 NONE naloxone_30\NN\3808977|10(-8|to|, (r_nsubj) influence_41\VB\5190804|naloxone|did|not|binding|)|. (r_conj) influence_18\VB\5190804|in|,|did|not|binding|,|and|influence (l_prep) in_0\IN\13603305|membranes|clonidine (l_pobj) membranes_2\NNS\4188643|brain|from (l_prep) from_3\IN\0|rats (l_pobj) rats_6\NNS\2329401|hypertensive (l_amod) hypertensive_5\JJ\10405694|spontaneously
6286738
D002762_D064420 NONE d3_1\NN\0|vitamin (r_compound) toxicity_2\NN\13576101|d3|in|.
D002762_D064420 NONE d3_3\NNP\0|vitamin (r_compound) toxicity_4\NN\13576101|d3
D002762_D064420 NONE d3_3\NNP\0|vitamin (r_compound) toxicity_4\NN\13576101|d3 (r_pobj) of_1\IN\0|toxicity (r_prep) signs_0\NNS\6643763|of (r_nsubjpass) observed_7\VBN\2163746|signs|were|not|in (r_ccomp) developed_18\VBN\1753788|observed|;|however|,|cows|commonly|signs|died|. (l_dobj) signs_20\NNS\6643763|severe|of (l_prep) of_21\IN\0|toxicity (l_pobj) toxicity_24\NN\13576101|d3|and|cows
D002762_D064420 NONE d3_23\NNP\0|vitamin (r_compound) toxicity_24\NN\13576101|d3|and|cows (r_pobj) of_21\IN\0|toxicity (r_prep) signs_20\NNS\6643763|severe|of (r_dobj) developed_18\VBN\1753788|observed|;|however|,|cows|commonly|signs|died|. (l_ccomp) observed_7\VBN\2163746|signs|were|not|in (l_nsubjpass) signs_0\NNS\6643763|of (l_prep) of_1\IN\0|toxicity (l_pobj) toxicity_4\NN\13576101|d3
D002762_D064420 NONE d3_23\NNP\0|vitamin (r_compound) toxicity_24\NN\13576101|d3|and|cows
D002762_D064420 NONE d3_7\NN\0|vitamin (r_pobj) of_5\IN\0|d3 (r_prep) toxicity_4\NN\13576101|the|extreme|of|in|and|margin
D002762_D064420 NONE d3_22\NNP\0|vitamin|prevent (r_pobj) of_20\IN\0|d3 (r_prep) doses_19\NNS\3740161|of (r_pobj) between_18\IN\0|doses (r_prep) safety_17\NN\13920835|between (r_pobj) of_16\IN\0|safety (r_prep) margin_15\NN\13903079|the|low|of (r_conj) toxicity_4\NN\13576101|the|extreme|of|in|and|margin
D002762_D064420 NONE d3_38\NNP\0|vitamin (r_nsubjpass) used_42\VBN\0|that|d3|can|not|be|prevent|injected (r_ccomp) concluded_35\VBD\628491|because|,|we|used|. (l_prep) because_0\IN\0|of|toxicity (l_pobj) toxicity_4\NN\13576101|the|extreme|of|in|and|margin
D002762_D006934 CID d3_5\NNP\0|vitamin (r_pobj) of_3\IN\0|d3 (r_prep) doses_2\NNS\3740161|large|parenteral|of|(|d3|) (r_nsubjpass) associated_18\VBN\628491|doses|were|with|. (l_prep) with_19\IN\0|hypercalcemia (l_pobj) hypercalcemia_21\NN\14299637|prolonged|,|hyperphosphatemia
D002762_D006934 CID d3_15\NNP\0|17.5|x|iu|vitamin (r_appos) doses_2\NNS\3740161|large|parenteral|of|(|d3|) (r_nsubjpass) associated_18\VBN\628491|doses|were|with|. (l_prep) with_19\IN\0|hypercalcemia (l_pobj) hypercalcemia_21\NN\14299637|prolonged|,|hyperphosphatemia
D002762_D006934 CID d3_30\NNP\0|vitamin|and|metabolites (r_pobj) of_28\IN\0|d3 (r_prep) increases_27\NNS\13576355|large|of (r_conj) hyperphosphatemia_23\NN\0|,|and|increases (r_conj) hypercalcemia_21\NN\14299637|prolonged|,|hyperphosphatemia
D002762_D054559 CID d3_5\NNP\0|vitamin (r_pobj) of_3\IN\0|d3 (r_prep) doses_2\NNS\3740161|large|parenteral|of|(|d3|) (r_nsubjpass) associated_18\VBN\628491|doses|were|with|. (l_prep) with_19\IN\0|hypercalcemia (l_pobj) hypercalcemia_21\NN\14299637|prolonged|,|hyperphosphatemia (l_conj) hyperphosphatemia_23\NN\0|,|and|increases
D002762_D054559 CID d3_15\NNP\0|17.5|x|iu|vitamin (r_appos) doses_2\NNS\3740161|large|parenteral|of|(|d3|) (r_nsubjpass) associated_18\VBN\628491|doses|were|with|. (l_prep) with_19\IN\0|hypercalcemia (l_pobj) hypercalcemia_21\NN\14299637|prolonged|,|hyperphosphatemia (l_conj) hyperphosphatemia_23\NN\0|,|and|increases
D002762_D054559 CID d3_30\NNP\0|vitamin|and|metabolites (r_pobj) of_28\IN\0|d3 (r_prep) increases_27\NNS\13576355|large|of (r_conj) hyperphosphatemia_23\NN\0|,|and|increases
D002762_D010319 NONE d3_7\NNP\0|vitamin (r_pobj) with_5\IN\0|d3 (r_prep) treated_4\VBN\2376958|with (r_acl) cows_3\NNS\2402010|the|treated (r_pobj) of_1\IN\0|cows (r_prep) none_0\NN\15228378|of (r_nsubj) showed_8\VBD\2137132|none|signs|during (l_dobj) signs_9\NNS\6643763|of (l_prep) of_10\IN\0|fever (l_pobj) fever_12\NN\14299637|milk
D002762_D010319 NONE d3_7\NNP\0|vitamin (r_pobj) with_5\IN\0|d3 (r_prep) treated_4\VBN\2376958|with (r_acl) cows_3\NNS\2402010|the|treated (r_pobj) of_1\IN\0|cows (r_prep) none_0\NN\15228378|of (r_nsubj) showed_8\VBD\2137132|none|signs|during (r_ccomp) developed_26\VBD\1753788|showed|;|however|,|%|signs|during|. (l_dobj) signs_28\NNS\6643763|clinical|of (l_prep) of_29\IN\0|fever (l_pobj) fever_31\NN\14299637|milk
D002762_D010319 NONE d3_7\NN\0|vitamin (r_pobj) of_5\IN\0|d3 (r_prep) toxicity_4\NN\13576101|the|extreme|of|in|and|margin (l_conj) margin_15\NN\13903079|the|low|of (l_prep) of_16\IN\0|safety (l_pobj) safety_17\NN\13920835|between (l_prep) between_18\IN\0|doses (l_pobj) doses_19\NNS\3740161|of (l_prep) of_20\IN\0|d3 (l_pobj) d3_22\NNP\0|vitamin|prevent (l_relcl) prevent_24\VBP\0|that|fever (l_dobj) fever_26\NN\14299637|milk|and|doses|induce
D002762_D010319 NONE d3_7\NN\0|vitamin (r_pobj) of_5\IN\0|d3 (r_prep) toxicity_4\NN\13576101|the|extreme|of|in|and|margin (l_conj) margin_15\NN\13903079|the|low|of (l_prep) of_16\IN\0|safety (l_pobj) safety_17\NN\13920835|between (l_prep) between_18\IN\0|doses (l_pobj) doses_19\NNS\3740161|of (l_prep) of_20\IN\0|d3 (l_pobj) d3_22\NNP\0|vitamin|prevent (l_relcl) prevent_24\VBP\0|that|fever (l_dobj) fever_26\NN\14299637|milk|and|doses|induce (l_relcl) induce_30\VBP\1627355|that|fever (l_dobj) fever_32\NN\14299637|milk
D002762_D010319 NONE d3_7\NN\0|vitamin (r_pobj) of_5\IN\0|d3 (r_prep) toxicity_4\NN\13576101|the|extreme|of|in|and|margin (r_pobj) because_0\IN\0|of|toxicity (r_prep) concluded_35\VBD\628491|because|,|we|used|. (l_ccomp) used_42\VBN\0|that|d3|can|not|be|prevent|injected (l_xcomp) prevent_45\VB\0|practically|to|fever (l_dobj) fever_47\NN\14299637|milk
D002762_D010319 NONE d3_22\NNP\0|vitamin|prevent (l_relcl) prevent_24\VBP\0|that|fever (l_dobj) fever_26\NN\14299637|milk|and|doses|induce
D002762_D010319 NONE d3_22\NNP\0|vitamin|prevent (l_relcl) prevent_24\VBP\0|that|fever (l_dobj) fever_26\NN\14299637|milk|and|doses|induce (l_relcl) induce_30\VBP\1627355|that|fever (l_dobj) fever_32\NN\14299637|milk
D002762_D010319 NONE d3_22\NNP\0|vitamin|prevent (r_pobj) of_20\IN\0|d3 (r_prep) doses_19\NNS\3740161|of (r_pobj) between_18\IN\0|doses (r_prep) safety_17\NN\13920835|between (r_pobj) of_16\IN\0|safety (r_prep) margin_15\NN\13903079|the|low|of (r_conj) toxicity_4\NN\13576101|the|extreme|of|in|and|margin (r_pobj) because_0\IN\0|of|toxicity (r_prep) concluded_35\VBD\628491|because|,|we|used|. (l_ccomp) used_42\VBN\0|that|d3|can|not|be|prevent|injected (l_xcomp) prevent_45\VB\0|practically|to|fever (l_dobj) fever_47\NN\14299637|milk
D002762_D010319 NONE d3_38\NNP\0|vitamin (r_nsubjpass) used_42\VBN\0|that|d3|can|not|be|prevent|injected (r_ccomp) concluded_35\VBD\628491|because|,|we|used|. (l_prep) because_0\IN\0|of|toxicity (l_pobj) toxicity_4\NN\13576101|the|extreme|of|in|and|margin (l_conj) margin_15\NN\13903079|the|low|of (l_prep) of_16\IN\0|safety (l_pobj) safety_17\NN\13920835|between (l_prep) between_18\IN\0|doses (l_pobj) doses_19\NNS\3740161|of (l_prep) of_20\IN\0|d3 (l_pobj) d3_22\NNP\0|vitamin|prevent (l_relcl) prevent_24\VBP\0|that|fever (l_dobj) fever_26\NN\14299637|milk|and|doses|induce
D002762_D010319 NONE d3_38\NNP\0|vitamin (r_nsubjpass) used_42\VBN\0|that|d3|can|not|be|prevent|injected (r_ccomp) concluded_35\VBD\628491|because|,|we|used|. (l_prep) because_0\IN\0|of|toxicity (l_pobj) toxicity_4\NN\13576101|the|extreme|of|in|and|margin (l_conj) margin_15\NN\13903079|the|low|of (l_prep) of_16\IN\0|safety (l_pobj) safety_17\NN\13920835|between (l_prep) between_18\IN\0|doses (l_pobj) doses_19\NNS\3740161|of (l_prep) of_20\IN\0|d3 (l_pobj) d3_22\NNP\0|vitamin|prevent (l_relcl) prevent_24\VBP\0|that|fever (l_dobj) fever_26\NN\14299637|milk|and|doses|induce (l_relcl) induce_30\VBP\1627355|that|fever (l_dobj) fever_32\NN\14299637|milk
D002762_D010319 NONE d3_38\NNP\0|vitamin (r_nsubjpass) used_42\VBN\0|that|d3|can|not|be|prevent|injected (l_xcomp) prevent_45\VB\0|practically|to|fever (l_dobj) fever_47\NN\14299637|milk
11135224
D017239_D002289 NONE paclitaxel_0\NNP\0|,|cisplatin|. (l_conj) cisplatin_2\NN\0|,|and|chemotherapy (l_conj) chemotherapy_7\NN\661091|combination|within (l_prep) within_8\IN\0|approach (l_pobj) approach_12\NN\940842|a|multidisciplinary|therapeutic|in (l_prep) in_13\IN\13603305|carcinoma (l_pobj) carcinoma_18\NN\14239918|metastatic|nonsmall|lung
D017239_D002289 NONE paclitaxel_18\NN\0|a|,|cisplatin|combination (r_pobj) of_16\IN\0|paclitaxel (r_prep) toxicity_15\NN\13576101|of (r_conj) rate_12\NN\13815152|response|,|and|toxicity (r_conj) feasibility_9\NN\5152150|the|,|rate (r_dobj) determine_7\VB\0|to|feasibility|treat (l_xcomp) treat_26\VB\7570720|to|nsclc (l_dobj) nsclc_28\NN\0|metastatic
D017239_D002289 NONE paclitaxel_30\NN\0| (r_pobj) of_29\IN\0|paclitaxel (r_prep) combination_28\NN\7951464|a|of|(|m(2|) (r_pobj) with_26\IN\0|combination (r_prep) treated_25\VBN\2376958|patients|were|with|given|)|on|,|cisplatin|)|given|)|on|,|and|gemcitabine|given|. (l_nsubjpass) patients_7\NNS\9898892|five|consecutive|naive|with (l_prep) with_8\IN\0|nsclc (l_pobj) nsclc_11\NNP\0|iv|and|status
D017239_D002289 NONE paclitaxel_3\NN\0|,|cisplatin (r_pobj) of_2\IN\0|paclitaxel (r_prep) combination_1\NN\7951464|the|of|,|and|gemcitabine (r_nsubjpass) tolerated_11\VBN\802318|combination|is|well|and|shows|. (l_conj) shows_13\VBZ\429048|activity|in (l_prep) in_16\IN\13603305|nsclc (l_pobj) nsclc_18\NNP\0|metastatic
D002945_D002289 NONE cisplatin_2\NN\0|,|and|chemotherapy (l_conj) chemotherapy_7\NN\661091|combination|within (l_prep) within_8\IN\0|approach (l_pobj) approach_12\NN\940842|a|multidisciplinary|therapeutic|in (l_prep) in_13\IN\13603305|carcinoma (l_pobj) carcinoma_18\NN\14239918|metastatic|nonsmall|lung
D002945_D002289 NONE cisplatin_0\NN\0| (r_npadvmod) based_2\VBN\0|cisplatin|- (r_amod) combinations_4\NNS\7951464|based|chemotherapy (r_nsubj) improve_5\VBP\126264|combinations|quality|. (l_dobj) quality_6\NN\24264|of|in (l_prep) in_11\IN\13603305|carcinoma (l_pobj) carcinoma_16\NN\14239918|advanced|nonsmall|lung|(|nsclc|)
D002945_D002289 NONE cisplatin_0\NN\0| (r_npadvmod) based_2\VBN\0|cisplatin|- (r_amod) combinations_4\NNS\7951464|based|chemotherapy (r_nsubj) improve_5\VBP\126264|combinations|quality|. (l_dobj) quality_6\NN\24264|of|in (l_prep) in_11\IN\13603305|carcinoma (l_pobj) carcinoma_16\NN\14239918|advanced|nonsmall|lung|(|nsclc|) (l_appos) nsclc_18\NNP\0|
D002945_D002289 NONE cisplatin_20\NN\0|,|and (r_conj) paclitaxel_18\NN\0|a|,|cisplatin|combination (r_pobj) of_16\IN\0|paclitaxel (r_prep) toxicity_15\NN\13576101|of (r_conj) rate_12\NN\13815152|response|,|and|toxicity (r_conj) feasibility_9\NN\5152150|the|,|rate (r_dobj) determine_7\VB\0|to|feasibility|treat (l_xcomp) treat_26\VB\7570720|to|nsclc (l_dobj) nsclc_28\NN\0|metastatic
D002945_D002289 NONE cisplatin_47\NN\0| (r_conj) treated_25\VBN\2376958|patients|were|with|given|)|on|,|cisplatin|)|given|)|on|,|and|gemcitabine|given|. (l_nsubjpass) patients_7\NNS\9898892|five|consecutive|naive|with (l_prep) with_8\IN\0|nsclc (l_pobj) nsclc_11\NNP\0|iv|and|status
D002945_D002289 NONE cisplatin_5\NN\0| (r_conj) paclitaxel_3\NN\0|,|cisplatin (r_pobj) of_2\IN\0|paclitaxel (r_prep) combination_1\NN\7951464|the|of|,|and|gemcitabine (r_nsubjpass) tolerated_11\VBN\802318|combination|is|well|and|shows|. (l_conj) shows_13\VBZ\429048|activity|in (l_prep) in_16\IN\13603305|nsclc (l_pobj) nsclc_18\NNP\0|metastatic
C056507_D002289 NONE gemcitabine_5\NN\0| (r_compound) combination_6\NN\7951464|gemcitabine (r_compound) chemotherapy_7\NN\661091|combination|within (l_prep) within_8\IN\0|approach (l_pobj) approach_12\NN\940842|a|multidisciplinary|therapeutic|in (l_prep) in_13\IN\13603305|carcinoma (l_pobj) carcinoma_18\NN\14239918|metastatic|nonsmall|lung
C056507_D002289 NONE gemcitabine_23\NN\0| (r_compound) combination_24\NN\7951464|gemcitabine (r_conj) paclitaxel_18\NN\0|a|,|cisplatin|combination (r_pobj) of_16\IN\0|paclitaxel (r_prep) toxicity_15\NN\13576101|of (r_conj) rate_12\NN\13815152|response|,|and|toxicity (r_conj) feasibility_9\NN\5152150|the|,|rate (r_dobj) determine_7\VB\0|to|feasibility|treat (l_xcomp) treat_26\VB\7570720|to|nsclc (l_dobj) nsclc_28\NN\0|metastatic
C056507_D002289 NONE gemcitabine_65\NN\0|) (r_conj) treated_25\VBN\2376958|patients|were|with|given|)|on|,|cisplatin|)|given|)|on|,|and|gemcitabine|given|. (l_nsubjpass) patients_7\NNS\9898892|five|consecutive|naive|with (l_prep) with_8\IN\0|nsclc (l_pobj) nsclc_11\NNP\0|iv|and|status
C056507_D002289 NONE gemcitabine_8\NN\0| (r_conj) combination_1\NN\7951464|the|of|,|and|gemcitabine (r_nsubjpass) tolerated_11\VBN\802318|combination|is|well|and|shows|. (l_conj) shows_13\VBZ\429048|activity|in (l_prep) in_16\IN\13603305|nsclc (l_pobj) nsclc_18\NNP\0|metastatic
D017239_D064420 NONE paclitaxel_18\NN\0|a|,|cisplatin|combination (r_pobj) of_16\IN\0|paclitaxel (r_prep) toxicity_15\NN\13576101|of
D002945_D064420 NONE cisplatin_20\NN\0|,|and (r_conj) paclitaxel_18\NN\0|a|,|cisplatin|combination (r_pobj) of_16\IN\0|paclitaxel (r_prep) toxicity_15\NN\13576101|of
C056507_D064420 NONE gemcitabine_23\NN\0| (r_compound) combination_24\NN\7951464|gemcitabine (r_conj) paclitaxel_18\NN\0|a|,|cisplatin|combination (r_pobj) of_16\IN\0|paclitaxel (r_prep) toxicity_15\NN\13576101|of
17343925
D012906_D034381 CID smoking_3\NN\831191|during|on (r_pobj) of_2\IN\0|smoking (r_prep) influence_1\NN\5190804|the|of (r_nsubjpass) estimated_13\VBN\637259|influence|has|not|been|,|associated|. (l_advcl) associated_20\VBN\628491|although|smoking|has|been|positively|with (l_prep) with_21\IN\0|hearing (l_pcomp) hearing_22\VBG\1184814|loss (l_dobj) loss_23\NN\13252973|in
D012906_D034381 CID smoking_16\NN\831191| (r_nsubjpass) associated_20\VBN\628491|although|smoking|has|been|positively|with (l_prep) with_21\IN\0|hearing (l_pcomp) hearing_22\VBG\1184814|loss (l_dobj) loss_23\NN\13252973|in
6518066
D008094_D004437 CID lithium_1\NN\14625458|maternal|and|anomaly|. (l_conj) anomaly_6\NN\14501726|ebstein|:|evaluation
D008094_D006331 NONE lithium_9\NN\14625458| (r_pobj) to_8\IN\0|lithium (r_prep) exposed_7\VBN\2110927|screening|to|during (r_csubj) provide_13\VB\2199590|exposed|can|assessment|. (l_dobj) assessment_18\NN\5732756|accurate|,|noninvasive|of (l_prep) of_19\IN\0|presence (l_pobj) presence_21\NN\13954253|the|or|absence|of (l_prep) of_24\IN\0|malformations (l_pobj) malformations_29\NNS\14213199|induced|cardiac
D008094_D006331 NONE lithium_25\NN\14625458| (r_npadvmod) induced_27\VBN\1627355|lithium|- (r_amod) malformations_29\NNS\14213199|induced|cardiac
18442015
D014700_D006471 NONE verapamil_3\NN\2938514| (r_pobj) of_2\IN\0|verapamil (r_prep) effect_1\NN\34213|protective|of|on|. (l_prep) on_4\IN\0|ulcers (l_pobj) ulcers_7\NNS\14211294|gastric|hemorrhagic|in (l_amod) hemorrhagic_6\JJ\0|
D014700_D006471 NONE verapamil_15\NN\2938514|daily|intragastric (r_pobj) by_12\IN\0|verapamil (r_agent) ameliorated_11\VBN\126264|dependently|by (r_acomp) were_7\VBD\0|ulcer|ameliorated|. (l_nsubj) ulcer_2\NN\14211294|this|hemorrhagic|and|parameters (l_amod) hemorrhagic_1\JJ\0|
D014700_D006471 NONE verapamil_28\NN\2938514| (r_pobj) by_27\IN\0|verapamil (r_agent) ameliorated_26\VBN\126264|that|could|be|by|in (r_relcl) generation_16\NN\7942152|produce|,|lpo|,|release|ameliorated|. (l_ccomp) produce_2\VB\7555863|atherosclerosis|could|ulcer|via (l_dobj) ulcer_5\NN\14211294|gastric|hemorrhagic (l_amod) hemorrhagic_4\JJ\0|
D014700_D014456 NONE verapamil_3\NN\2938514| (r_pobj) of_2\IN\0|verapamil (r_prep) effect_1\NN\34213|protective|of|on|. (l_prep) on_4\IN\0|ulcers (l_pobj) ulcers_7\NNS\14211294|gastric|hemorrhagic|in
D014700_D014456 NONE verapamil_6\NN\2938514| (r_pobj) of_5\IN\0|verapamil (r_prep) effect_4\NN\34213|the|protective|of|on (l_prep) on_7\IN\0|model (l_pobj) model_10\NN\5888929|this|ulcer (l_compound) ulcer_9\NN\14211294|
D014700_D014456 NONE verapamil_15\NN\2938514|daily|intragastric (r_pobj) by_12\IN\0|verapamil (r_agent) ameliorated_11\VBN\126264|dependently|by (r_acomp) were_7\VBD\0|ulcer|ameliorated|. (l_nsubj) ulcer_2\NN\14211294|this|hemorrhagic|and|parameters
D014700_D014456 NONE verapamil_28\NN\2938514| (r_pobj) by_27\IN\0|verapamil (r_agent) ameliorated_26\VBN\126264|that|could|be|by|in (r_relcl) generation_16\NN\7942152|produce|,|lpo|,|release|ameliorated|. (l_ccomp) produce_2\VB\7555863|atherosclerosis|could|ulcer|via (l_dobj) ulcer_5\NN\14211294|gastric|hemorrhagic
D014700_D050197 NONE verapamil_3\NN\2938514| (r_pobj) of_2\IN\0|verapamil (r_prep) effect_1\NN\34213|protective|of|on|. (l_prep) on_4\IN\0|ulcers (l_pobj) ulcers_7\NNS\14211294|gastric|hemorrhagic|in (l_prep) in_8\IN\13603305|rats (l_pobj) rats_11\NNS\2329401|severe|atherosclerotic (l_amod) atherosclerotic_10\JJ\0|
D014700_D050197 NONE verapamil_28\NN\2938514| (r_pobj) by_27\IN\0|verapamil (r_agent) ameliorated_26\VBN\126264|that|could|be|by|in (r_relcl) generation_16\NN\7942152|produce|,|lpo|,|release|ameliorated|. (l_ccomp) produce_2\VB\7555863|atherosclerosis|could|ulcer|via (l_nsubj) atherosclerosis_0\NN\14108324|
D006632_D006471 NONE histamine_19\NN\14739004|cell (r_compound) release_20\NN\3748886|mast|histamine|,|peroxide (l_conj) peroxide_23\NN\14780040|lipid|permeability (l_appos) permeability_31\NN\4940146|generation|microvascular|in (l_prep) in_32\IN\13603305|modulating (l_pcomp) modulating_33\VBG\1724459|hemorrhage (l_dobj) hemorrhage_35\NN\14285662|gastric|and|ulcer|in
D006632_D006471 NONE histamine_6\NN\14739004| (r_pobj) of_5\IN\0|histamine (r_prep) correlation_4\NN\13841213|a|positive|of|to (l_prep) to_7\IN\0|hemorrhage|and|to (l_pobj) hemorrhage_9\NN\14285662|gastric
D006632_D006471 NONE histamine_18\NN\14739004| (r_compound) release_19\NN\3748886|histamine|and|permeability (r_conj) generation_16\NN\7942152|produce|,|lpo|,|release|ameliorated|. (l_ccomp) produce_2\VB\7555863|atherosclerosis|could|ulcer|via (l_dobj) ulcer_5\NN\14211294|gastric|hemorrhagic (l_amod) hemorrhagic_4\JJ\0|
D006632_D014456 NONE histamine_19\NN\14739004|cell (r_compound) release_20\NN\3748886|mast|histamine|,|peroxide (l_conj) peroxide_23\NN\14780040|lipid|permeability (l_appos) permeability_31\NN\4940146|generation|microvascular|in (l_prep) in_32\IN\13603305|modulating (l_pcomp) modulating_33\VBG\1724459|hemorrhage (l_dobj) hemorrhage_35\NN\14285662|gastric|and|ulcer|in (l_conj) ulcer_37\NN\14211294|
D006632_D014456 NONE histamine_10\NN\14739004| (r_compound) concentration_11\NN\4916342|histamine|,|permeability (l_conj) permeability_14\NN\4940146|microvascular|,|content (l_conj) content_18\NN\7951464|luminal|hemoglobin|and|areas (l_conj) areas_21\NNS\8630985|ulcer (l_compound) ulcer_20\NN\14211294|
D006632_D014456 NONE histamine_16\NN\14739004| (r_compound) release_17\NN\3748886|histamine|,|generation (r_conj) diffusion_14\NN\13518963|gastric|acid|back|-|,|release (r_pobj) including_9\VBG\0|diffusion (r_prep) factors_7\NNS\7326557|increased|ulcerogenic|,|including (r_pobj) with_4\IN\0|factors (r_prep) accompanied_3\VBN\0|ulcers|with (l_nsubj) ulcers_2\NNS\14211294|severe|gastric
D006632_D014456 NONE histamine_6\NN\14739004| (r_pobj) of_5\IN\0|histamine (r_prep) correlation_4\NN\13841213|a|positive|of|to (l_prep) to_7\IN\0|hemorrhage|and|to (l_conj) to_11\IN\0|ulcer (l_pobj) ulcer_12\NN\14211294|
D006632_D014456 NONE histamine_18\NN\14739004| (r_compound) release_19\NN\3748886|histamine|and|permeability (r_conj) generation_16\NN\7942152|produce|,|lpo|,|release|ameliorated|. (l_ccomp) produce_2\VB\7555863|atherosclerosis|could|ulcer|via (l_dobj) ulcer_5\NN\14211294|gastric|hemorrhagic
D006632_D050197 NONE histamine_19\NN\14739004|cell (r_compound) release_20\NN\3748886|mast|histamine|,|peroxide (l_conj) peroxide_23\NN\14780040|lipid|permeability (l_appos) permeability_31\NN\4940146|generation|microvascular|in (l_prep) in_32\IN\13603305|modulating (l_pcomp) modulating_33\VBG\1724459|hemorrhage (l_dobj) hemorrhage_35\NN\14285662|gastric|and|ulcer|in (l_prep) in_38\IN\13603305|rats (l_pobj) rats_39\NNS\2329401|with (l_prep) with_40\IN\0|atherosclerosis (l_pobj) atherosclerosis_41\NN\14108324|
D006632_D050197 NONE histamine_6\NN\14739004| (r_pobj) of_5\IN\0|histamine (r_prep) correlation_4\NN\13841213|a|positive|of|to (r_nsubjpass) found_14\VBN\13279262|moreover|,|correlation|was|in|. (l_prep) in_15\IN\13603305|rats (l_pobj) rats_18\NNS\2329401|those|atherosclerotic (l_amod) atherosclerotic_17\JJ\0|
D006632_D050197 NONE histamine_18\NN\14739004| (r_compound) release_19\NN\3748886|histamine|and|permeability (r_conj) generation_16\NN\7942152|produce|,|lpo|,|release|ameliorated|. (l_ccomp) produce_2\VB\7555863|atherosclerosis|could|ulcer|via (l_nsubj) atherosclerosis_0\NN\14108324|
D004872_D006471 CID d2_47\NN\0|vitamin|and|cholesterol (r_pobj) of_45\IN\0|d2 (r_prep) coadministration_44\NN\0|of (r_pobj) by_43\IN\0|coadministration (r_prep) induced_42\VBN\1627355|,|release|by (l_nsubj) release_20\NN\3748886|mast|histamine|,|peroxide (l_conj) peroxide_23\NN\14780040|lipid|permeability (l_appos) permeability_31\NN\4940146|generation|microvascular|in (l_prep) in_32\IN\13603305|modulating (l_pcomp) modulating_33\VBG\1724459|hemorrhage (l_dobj) hemorrhage_35\NN\14285662|gastric|and|ulcer|in
D004872_D014456 CID d2_47\NN\0|vitamin|and|cholesterol (r_pobj) of_45\IN\0|d2 (r_prep) coadministration_44\NN\0|of (r_pobj) by_43\IN\0|coadministration (r_prep) induced_42\VBN\1627355|,|release|by (l_nsubj) release_20\NN\3748886|mast|histamine|,|peroxide (l_conj) peroxide_23\NN\14780040|lipid|permeability (l_appos) permeability_31\NN\4940146|generation|microvascular|in (l_prep) in_32\IN\13603305|modulating (l_pcomp) modulating_33\VBG\1724459|hemorrhage (l_dobj) hemorrhage_35\NN\14285662|gastric|and|ulcer|in (l_conj) ulcer_37\NN\14211294|
D004872_D050197 CID d2_47\NN\0|vitamin|and|cholesterol (r_pobj) of_45\IN\0|d2 (r_prep) coadministration_44\NN\0|of (r_pobj) by_43\IN\0|coadministration (r_prep) induced_42\VBN\1627355|,|release|by (l_nsubj) release_20\NN\3748886|mast|histamine|,|peroxide (l_conj) peroxide_23\NN\14780040|lipid|permeability (l_appos) permeability_31\NN\4940146|generation|microvascular|in (l_prep) in_32\IN\13603305|modulating (l_pcomp) modulating_33\VBG\1724459|hemorrhage (l_dobj) hemorrhage_35\NN\14285662|gastric|and|ulcer|in (l_prep) in_38\IN\13603305|rats (l_pobj) rats_39\NNS\2329401|with (l_prep) with_40\IN\0|atherosclerosis (l_pobj) atherosclerosis_41\NN\14108324|
D004872_D050197 CID d2_21\NN\0|vitamin|and|cholesterol (r_dobj) containing_19\VBG\2632940|kg|d2|induce (l_advcl) induce_25\VB\1627355|to|atherosclerosis (l_dobj) atherosclerosis_26\NN\14108324|
D002784_D006471 CID cholesterol_49\NN\15058310| (r_conj) d2_47\NN\0|vitamin|and|cholesterol (r_pobj) of_45\IN\0|d2 (r_prep) coadministration_44\NN\0|of (r_pobj) by_43\IN\0|coadministration (r_prep) induced_42\VBN\1627355|,|release|by (l_nsubj) release_20\NN\3748886|mast|histamine|,|peroxide (l_conj) peroxide_23\NN\14780040|lipid|permeability (l_appos) permeability_31\NN\4940146|generation|microvascular|in (l_prep) in_32\IN\13603305|modulating (l_pcomp) modulating_33\VBG\1724459|hemorrhage (l_dobj) hemorrhage_35\NN\14285662|gastric|and|ulcer|in
D002784_D014456 CID cholesterol_49\NN\15058310| (r_conj) d2_47\NN\0|vitamin|and|cholesterol (r_pobj) of_45\IN\0|d2 (r_prep) coadministration_44\NN\0|of (r_pobj) by_43\IN\0|coadministration (r_prep) induced_42\VBN\1627355|,|release|by (l_nsubj) release_20\NN\3748886|mast|histamine|,|peroxide (l_conj) peroxide_23\NN\14780040|lipid|permeability (l_appos) permeability_31\NN\4940146|generation|microvascular|in (l_prep) in_32\IN\13603305|modulating (l_pcomp) modulating_33\VBG\1724459|hemorrhage (l_dobj) hemorrhage_35\NN\14285662|gastric|and|ulcer|in (l_conj) ulcer_37\NN\14211294|
D002784_D050197 CID cholesterol_49\NN\15058310| (r_conj) d2_47\NN\0|vitamin|and|cholesterol (r_pobj) of_45\IN\0|d2 (r_prep) coadministration_44\NN\0|of (r_pobj) by_43\IN\0|coadministration (r_prep) induced_42\VBN\1627355|,|release|by (l_nsubj) release_20\NN\3748886|mast|histamine|,|peroxide (l_conj) peroxide_23\NN\14780040|lipid|permeability (l_appos) permeability_31\NN\4940146|generation|microvascular|in (l_prep) in_32\IN\13603305|modulating (l_pcomp) modulating_33\VBG\1724459|hemorrhage (l_dobj) hemorrhage_35\NN\14285662|gastric|and|ulcer|in (l_prep) in_38\IN\13603305|rats (l_pobj) rats_39\NNS\2329401|with (l_prep) with_40\IN\0|atherosclerosis (l_pobj) atherosclerosis_41\NN\14108324|
D002784_D050197 CID cholesterol_23\NN\15058310| (r_conj) d2_21\NN\0|vitamin|and|cholesterol (r_dobj) containing_19\VBG\2632940|kg|d2|induce (l_advcl) induce_25\VB\1627355|to|atherosclerosis (l_dobj) atherosclerosis_26\NN\14108324|
D002784_D050197 CID cholesterol_10\NN\15058310|total|and|concentration (r_conj) calcium_7\NN\14625458|serum|,|cholesterol (r_pobj) as_5\IN\14622893|such|calcium (r_prep) parameters_2\NNS\5858936|elevated|atherosclerotic|,|as (l_amod) atherosclerotic_1\JJ\0|
D002784_D050197 CID cholesterol_10\NN\15058310|total|and|concentration (r_conj) calcium_7\NN\14625458|serum|,|cholesterol (r_pobj) as_5\IN\14622893|such|calcium (r_prep) parameters_2\NNS\5858936|elevated|atherosclerotic|,|as (r_nsubjpass) obtained_18\VBN\2210855|parameters|were|in|. (l_prep) in_19\IN\13603305|rats (l_pobj) rats_21\NNS\2329401|atherosclerotic (l_amod) atherosclerotic_20\JJ\0|
D010634_D014456 NONE luminal_16\JJ\2792049| (r_amod) content_18\NN\7951464|luminal|hemoglobin|and|areas (l_conj) areas_21\NNS\8630985|ulcer (l_compound) ulcer_20\NN\14211294|
D010634_D014456 NONE luminal_22\JJ\2792049| (r_amod) content_24\NN\7951464|luminal|hemoglobin (r_conj) generation_20\NN\7942152|lpo|and|content (r_conj) release_17\NN\3748886|histamine|,|generation (r_conj) diffusion_14\NN\13518963|gastric|acid|back|-|,|release (r_pobj) including_9\VBG\0|diffusion (r_prep) factors_7\NNS\7326557|increased|ulcerogenic|,|including (r_pobj) with_4\IN\0|factors (r_prep) accompanied_3\VBN\0|ulcers|with (l_nsubj) ulcers_2\NNS\14211294|severe|gastric
D002118_D050197 NONE calcium_7\NN\14625458|serum|,|cholesterol (r_pobj) as_5\IN\14622893|such|calcium (r_prep) parameters_2\NNS\5858936|elevated|atherosclerotic|,|as (l_amod) atherosclerotic_1\JJ\0|
D002118_D050197 NONE calcium_7\NN\14625458|serum|,|cholesterol (r_pobj) as_5\IN\14622893|such|calcium (r_prep) parameters_2\NNS\5858936|elevated|atherosclerotic|,|as (r_nsubjpass) obtained_18\VBN\2210855|parameters|were|in|. (l_prep) in_19\IN\13603305|rats (l_pobj) rats_21\NNS\2329401|atherosclerotic (l_amod) atherosclerotic_20\JJ\0|
17931375
D006493_D003288 CID heparin_10\JJ\2718259| (r_compound) injection_11\NN\320852|subcutaneous|heparin|on (l_prep) on_12\IN\0|bruising (l_pobj) bruising_13\VBG\69879|and|pain
D006493_D003288 CID heparin_24\NN\2718259| (r_pobj) of_23\IN\0|heparin (r_prep) injection_22\NN\320852|the|subcutaneous|of (r_pobj) of_19\IN\0|injection (r_prep) administration_18\NN\1133281|the|of (r_pobj) following_16\VBG\8180190|administration (r_prep) effect_8\NN\34213|the|of|following (l_prep) of_9\IN\0|duration (l_pobj) duration_11\NN\15113229|injection|on (l_prep) on_12\IN\0|bruising (l_pobj) bruising_13\VBG\69879|and|pain
D006493_D003288 CID heparin_13\NN\2718259| (r_pobj) of_12\IN\0|heparin (r_prep) injection_11\NN\320852|the|subcutaneous|of (r_pobj) following_8\VBG\8180190|injection (r_prep) prevent_4\VB\0|to|bruising|following (l_dobj) bruising_5\NN\69879|and|pain
D006493_D003288 CID heparin_13\NN\2718259| (r_pobj) of_12\IN\0|heparin (r_prep) injection_11\NN\320852|the|subcutaneous|of (r_pobj) following_8\VBG\8180190|injection (r_prep) prevent_4\VB\0|to|bruising|following (r_acl) methods_2\NNS\5616786|different|prevent (r_nsubjpass) studied_17\VBN\0|although|methods|have|been|widely|and|described (r_advcl) documented_35\JJ\1000214|studied|,|effect|is|little|. (l_nsubjpass) effect_22\NN\34213|the|of (l_prep) of_23\IN\0|duration (l_pobj) duration_25\NN\15113229|injection|on (l_prep) on_26\IN\0|occurrence (l_pobj) occurrence_28\NN\29378|the|of (l_prep) of_29\IN\0|bruising (l_pobj) bruising_30\VBG\69879|and|pain
D006493_D003288 CID heparin_6\NN\2718259|the (r_pobj) on_4\IN\0|heparin|areas (r_prep) bruising_3\NN\69879|the|on
D006493_D003288 CID heparin_18\NN\2718259| (r_pobj) of_17\IN\0|heparin (r_prep) administration_16\NN\1133281|the|subcutaneous|of (r_pobj) following_13\VBG\8180190|administration (r_prep) had_6\VBD\0|that|duration|effect|following (l_dobj) effect_8\NN\34213|an|on (l_prep) on_9\IN\0|bruising (l_pobj) bruising_10\VBG\69879|and|pain
D006493_D010146 CID heparin_10\JJ\2718259| (r_compound) injection_11\NN\320852|subcutaneous|heparin|on (l_prep) on_12\IN\0|bruising (l_pobj) bruising_13\VBG\69879|and|pain (l_conj) pain_15\NN\14299637|
D006493_D010146 CID heparin_24\NN\2718259| (r_pobj) of_23\IN\0|heparin (r_prep) injection_22\NN\320852|the|subcutaneous|of (r_pobj) of_19\IN\0|injection (r_prep) administration_18\NN\1133281|the|of (r_pobj) following_16\VBG\8180190|administration (r_prep) effect_8\NN\34213|the|of|following (l_prep) of_9\IN\0|duration (l_pobj) duration_11\NN\15113229|injection|on (l_prep) on_12\IN\0|bruising (l_pobj) bruising_13\VBG\69879|and|pain (l_conj) pain_15\NN\14299637|
D006493_D010146 CID heparin_13\NN\2718259| (r_pobj) of_12\IN\0|heparin (r_prep) injection_11\NN\320852|the|subcutaneous|of (r_pobj) following_8\VBG\8180190|injection (r_prep) prevent_4\VB\0|to|bruising|following (l_dobj) bruising_5\NN\69879|and|pain (l_conj) pain_7\NN\14299637|
D006493_D010146 CID heparin_13\NN\2718259| (r_pobj) of_12\IN\0|heparin (r_prep) injection_11\NN\320852|the|subcutaneous|of (r_pobj) following_8\VBG\8180190|injection (r_prep) prevent_4\VB\0|to|bruising|following (r_acl) methods_2\NNS\5616786|different|prevent (r_nsubjpass) studied_17\VBN\0|although|methods|have|been|widely|and|described (r_advcl) documented_35\JJ\1000214|studied|,|effect|is|little|. (l_nsubjpass) effect_22\NN\34213|the|of (l_prep) of_23\IN\0|duration (l_pobj) duration_25\NN\15113229|injection|on (l_prep) on_26\IN\0|occurrence (l_pobj) occurrence_28\NN\29378|the|of (l_prep) of_29\IN\0|bruising (l_pobj) bruising_30\VBG\69879|and|pain (l_conj) pain_32\NN\14299637|
D006493_D010146 CID heparin_18\NN\2718259| (r_pobj) of_17\IN\0|heparin (r_prep) administration_16\NN\1133281|the|subcutaneous|of (r_pobj) following_13\VBG\8180190|administration (r_prep) had_6\VBD\0|that|duration|effect|following (l_dobj) effect_8\NN\34213|an|on (l_prep) on_9\IN\0|bruising (l_pobj) bruising_10\VBG\69879|and|pain (l_conj) pain_12\NN\14299637|
12907309
C121465_D020258 NONE mpep_3\NNP\0| (r_pobj) of_2\IN\0|mpep (r_prep) action_1\NN\30358|neuroprotective|of|,|antagonist|,|in (l_prep) in_10\IN\13603305|neurotoxicity (l_pobj) neurotoxicity_15\NN\0|induced|dopaminergic
C121465_D005334 NONE mpep_3\NNP\0| (r_pobj) of_2\IN\0|mpep (r_prep) action_1\NN\30358|neuroprotective|of|,|antagonist|,|in (r_nsubjpass) associated_17\VBN\628491|action|is|with|. (l_prep) with_18\IN\0|decrease (l_pobj) decrease_20\NN\7296428|a|in (l_prep) in_21\IN\13603305|outflow (l_pobj) outflow_23\NN\7407777|dopamine|and|inhibition|in (l_conj) inhibition_25\NN\1068773|of (l_prep) of_26\IN\0|hyperthermia (l_pobj) hyperthermia_27\NN\14034177|
C121465_D005334 NONE mpep_3\NNP\0| (r_pobj) by_2\IN\0|mpep (r_agent) rendered_1\VBN\120316|by (r_acl) neuroprotection_0\NNP\0|rendered (r_nsubjpass) associated_6\VBN\628491|neuroprotection|may|be|with|,|and|with|. (l_conj) with_29\IN\0|decrease (l_pobj) decrease_31\NN\7296428|a|in (l_prep) in_32\IN\13603305|hyperthermia (l_pobj) hyperthermia_33\NN\14034177|
D008694_D020258 NONE methamphetamine_11\NN\2704153| (r_npadvmod) induced_13\VBN\1627355|methamphetamine|- (r_amod) neurotoxicity_15\NN\0|induced|dopaminergic
D008694_D005334 CID methamphetamine_11\NN\2704153| (r_npadvmod) induced_13\VBN\1627355|methamphetamine|- (r_amod) neurotoxicity_15\NN\0|induced|dopaminergic (r_pobj) in_10\IN\13603305|neurotoxicity (r_prep) action_1\NN\30358|neuroprotective|of|,|antagonist|,|in (r_nsubjpass) associated_17\VBN\628491|action|is|with|. (l_prep) with_18\IN\0|decrease (l_pobj) decrease_20\NN\7296428|a|in (l_prep) in_21\IN\13603305|outflow (l_pobj) outflow_23\NN\7407777|dopamine|and|inhibition|in (l_conj) inhibition_25\NN\1068773|of (l_prep) of_26\IN\0|hyperthermia (l_pobj) hyperthermia_27\NN\14034177|
D008694_D005334 CID methamphetamine_12\NN\2704153| (r_npadvmod) induced_14\VBN\1627355|methamphetamine|- (r_amod) efflux_16\NN\13482330|the|induced|dopamine|in (r_pobj) of_10\IN\0|efflux (r_prep) reduction_9\NN\351485|the|of|due (r_pobj) with_7\IN\0|reduction (r_prep) associated_6\VBN\628491|neuroprotection|may|be|with|,|and|with|. (l_conj) with_29\IN\0|decrease (l_pobj) decrease_31\NN\7296428|a|in (l_prep) in_32\IN\13603305|hyperthermia (l_pobj) hyperthermia_33\NN\14034177|
D004298_D020258 NONE dopamine_22\NN\14807737| (r_compound) outflow_23\NN\7407777|dopamine|and|inhibition|in (r_pobj) in_21\IN\13603305|outflow (r_prep) decrease_20\NN\7296428|a|in (r_pobj) with_18\IN\0|decrease (r_prep) associated_17\VBN\628491|action|is|with|. (l_nsubjpass) action_1\NN\30358|neuroprotective|of|,|antagonist|,|in (l_prep) in_10\IN\13603305|neurotoxicity (l_pobj) neurotoxicity_15\NN\0|induced|dopaminergic
D004298_D005334 NONE dopamine_22\NN\14807737| (r_compound) outflow_23\NN\7407777|dopamine|and|inhibition|in (l_conj) inhibition_25\NN\1068773|of (l_prep) of_26\IN\0|hyperthermia (l_pobj) hyperthermia_27\NN\14034177|
D004298_D005334 NONE dopamine_15\NN\14807737| (r_compound) efflux_16\NN\13482330|the|induced|dopamine|in (r_pobj) of_10\IN\0|efflux (r_prep) reduction_9\NN\351485|the|of|due (r_pobj) with_7\IN\0|reduction (r_prep) associated_6\VBN\628491|neuroprotection|may|be|with|,|and|with|. (l_conj) with_29\IN\0|decrease (l_pobj) decrease_31\NN\7296428|a|in (l_prep) in_32\IN\13603305|hyperthermia (l_pobj) hyperthermia_33\NN\14034177|
C121465_D064420 NONE mpep_12\NNP\0| (r_pobj) by_11\IN\0|mpep (r_prep) blockade_8\NN\952963|the|of|by (r_nsubj) protect_14\VB\1127795|that|blockade|may|neurones (l_dobj) neurones_16\NNS\0|dopaminergic|against (l_prep) against_17\IN\0|toxicity (l_pobj) toxicity_21\NN\13576101|induced
D008694_D064420 NONE methamphetamine_18\NN\2704153| (r_npadvmod) induced_20\VBN\1627355|methamphetamine|- (r_amod) toxicity_21\NN\13576101|induced
8423889
D005473_D009069 CID fluoxetine_5\NN\4169152| (r_amod) medication_6\NN\3247620|fluoxetine (r_pobj) after_4\IN\0|medication (r_prep) increase_0\NNP\13576355|of|after|. (l_prep) of_1\IN\0|disability (l_pobj) disability_3\NN\14547369|parkinson
D005473_D009069 CID fluoxetine_21\NN\4169152|the|antidepressant (r_pobj) to_18\IN\0|fluoxetine (r_prep) exposure_17\NN\5042871|to (r_pobj) after_16\IN\0|exposure (r_prep) amount_4\NN\13329641|the|increased|of|in|after (l_prep) of_5\IN\0|disability (l_pobj) disability_7\NN\14547369|motor
D000928_D009069 NONE antidepressant_20\JJ\3740161| (r_amod) fluoxetine_21\NN\4169152|the|antidepressant (r_pobj) to_18\IN\0|fluoxetine (r_prep) exposure_17\NN\5042871|to (r_pobj) after_16\IN\0|exposure (r_prep) amount_4\NN\13329641|the|increased|of|in|after (l_prep) of_5\IN\0|disability (l_pobj) disability_7\NN\14547369|motor
D000928_D010300 NONE antidepressant_20\JJ\3740161| (r_amod) fluoxetine_21\NN\4169152|the|antidepressant (r_pobj) to_18\IN\0|fluoxetine (r_prep) exposure_17\NN\5042871|to (r_pobj) after_16\IN\0|exposure (r_prep) amount_4\NN\13329641|the|increased|of|in|after (l_prep) in_8\IN\13603305|patients (l_pobj) patients_10\NNS\9898892|four|with (l_prep) with_11\IN\0|disease (l_pobj) disease_15\NN\14061805|parkinson
D005473_D010300 NONE fluoxetine_21\NN\4169152|the|antidepressant (r_pobj) to_18\IN\0|fluoxetine (r_prep) exposure_17\NN\5042871|to (r_pobj) after_16\IN\0|exposure (r_prep) amount_4\NN\13329641|the|increased|of|in|after (l_prep) in_8\IN\13603305|patients (l_pobj) patients_10\NNS\9898892|four|with (l_prep) with_11\IN\0|disease (l_pobj) disease_15\NN\14061805|parkinson
D005473_D010300 NONE fluoxetine_11\NN\4169152| (r_pobj) of_10\IN\0|fluoxetine (r_prep) capacity_9\NN\5202497|a|relevant|antagonistic|of|in (l_prep) in_12\IN\13603305|patients (l_pobj) patients_16\NNS\9898892|parkinson|disease (l_compound) disease_15\NN\14061805|
D004298_D010300 NONE dopamine_6\NN\14807737| (r_npadvmod) antagonistic_8\JJ\0|dopamine|- (r_amod) capacity_9\NN\5202497|a|relevant|antagonistic|of|in (l_prep) in_12\IN\13603305|patients (l_pobj) patients_16\NNS\9898892|parkinson|disease (l_compound) disease_15\NN\14061805|
3076126
D008148_D009135 NONE lovastatin_23\NN\3676175| (r_pobj) with_22\IN\0|lovastatin (r_prep) reported_21\VBN\831651|in|,|has|been|rarely|with|,|in|. (r_conj) associated_2\VBN\628491|in|,|and|reported (r_acl) myopathy_0\NNP\14204950|,|associated
D008148_D009212 CID lovastatin_23\NN\3676175| (r_pobj) with_22\IN\0|lovastatin (r_prep) reported_21\VBN\831651|in|,|has|been|rarely|with|,|in|. (r_conj) associated_2\VBN\628491|in|,|and|reported (l_prep) in_3\IN\13603305|cases (l_pobj) cases_5\NNS\7283608|some|with (l_prep) with_6\IN\0|myoglobinuria (l_pobj) myoglobinuria_7\NNS\14299637|
D008148_D051437 CID lovastatin_23\NN\3676175| (r_pobj) with_22\IN\0|lovastatin (r_prep) reported_21\VBN\831651|in|,|has|been|rarely|with|,|in|. (l_prep) in_10\IN\13603305|cases (l_pobj) cases_12\NNS\7283608|2|with (l_prep) with_13\IN\0|failure (l_pobj) failure_16\NN\66216|transient|renal
D016572_D009135 CID cyclosporin_31\NN\0|,|gemfibrozil (r_pobj) with_30\IN\0|cyclosporin (r_prep) treated_29\VBN\2376958|concomitantly|with (r_acl) patients_27\NNS\9898892|treated (r_pobj) in_26\IN\13603305|especially|patients (r_prep) reported_21\VBN\831651|in|,|has|been|rarely|with|,|in|. (r_conj) associated_2\VBN\628491|in|,|and|reported (r_acl) myopathy_0\NNP\14204950|,|associated
D016572_D009212 NONE cyclosporin_31\NN\0|,|gemfibrozil (r_pobj) with_30\IN\0|cyclosporin (r_prep) treated_29\VBN\2376958|concomitantly|with (r_acl) patients_27\NNS\9898892|treated (r_pobj) in_26\IN\13603305|especially|patients (r_prep) reported_21\VBN\831651|in|,|has|been|rarely|with|,|in|. (r_conj) associated_2\VBN\628491|in|,|and|reported (l_prep) in_3\IN\13603305|cases (l_pobj) cases_5\NNS\7283608|some|with (l_prep) with_6\IN\0|myoglobinuria (l_pobj) myoglobinuria_7\NNS\14299637|
D016572_D051437 NONE cyclosporin_31\NN\0|,|gemfibrozil (r_pobj) with_30\IN\0|cyclosporin (r_prep) treated_29\VBN\2376958|concomitantly|with (r_acl) patients_27\NNS\9898892|treated (r_pobj) in_26\IN\13603305|especially|patients (r_prep) reported_21\VBN\831651|in|,|has|been|rarely|with|,|in|. (l_prep) in_10\IN\13603305|cases (l_pobj) cases_12\NNS\7283608|2|with (l_prep) with_13\IN\0|failure (l_pobj) failure_16\NN\66216|transient|renal
D015248_D009135 CID gemfibrozil_33\NN\3740161|or|niacin (r_conj) cyclosporin_31\NN\0|,|gemfibrozil (r_pobj) with_30\IN\0|cyclosporin (r_prep) treated_29\VBN\2376958|concomitantly|with (r_acl) patients_27\NNS\9898892|treated (r_pobj) in_26\IN\13603305|especially|patients (r_prep) reported_21\VBN\831651|in|,|has|been|rarely|with|,|in|. (r_conj) associated_2\VBN\628491|in|,|and|reported (r_acl) myopathy_0\NNP\14204950|,|associated
D015248_D009212 NONE gemfibrozil_33\NN\3740161|or|niacin (r_conj) cyclosporin_31\NN\0|,|gemfibrozil (r_pobj) with_30\IN\0|cyclosporin (r_prep) treated_29\VBN\2376958|concomitantly|with (r_acl) patients_27\NNS\9898892|treated (r_pobj) in_26\IN\13603305|especially|patients (r_prep) reported_21\VBN\831651|in|,|has|been|rarely|with|,|in|. (r_conj) associated_2\VBN\628491|in|,|and|reported (l_prep) in_3\IN\13603305|cases (l_pobj) cases_5\NNS\7283608|some|with (l_prep) with_6\IN\0|myoglobinuria (l_pobj) myoglobinuria_7\NNS\14299637|
D015248_D051437 NONE gemfibrozil_33\NN\3740161|or|niacin (r_conj) cyclosporin_31\NN\0|,|gemfibrozil (r_pobj) with_30\IN\0|cyclosporin (r_prep) treated_29\VBN\2376958|concomitantly|with (r_acl) patients_27\NNS\9898892|treated (r_pobj) in_26\IN\13603305|especially|patients (r_prep) reported_21\VBN\831651|in|,|has|been|rarely|with|,|in|. (l_prep) in_10\IN\13603305|cases (l_pobj) cases_12\NNS\7283608|2|with (l_prep) with_13\IN\0|failure (l_pobj) failure_16\NN\66216|transient|renal
D009525_D009135 CID niacin_35\NN\15090742| (r_conj) gemfibrozil_33\NN\3740161|or|niacin (r_conj) cyclosporin_31\NN\0|,|gemfibrozil (r_pobj) with_30\IN\0|cyclosporin (r_prep) treated_29\VBN\2376958|concomitantly|with (r_acl) patients_27\NNS\9898892|treated (r_pobj) in_26\IN\13603305|especially|patients (r_prep) reported_21\VBN\831651|in|,|has|been|rarely|with|,|in|. (r_conj) associated_2\VBN\628491|in|,|and|reported (r_acl) myopathy_0\NNP\14204950|,|associated
D009525_D009212 NONE niacin_35\NN\15090742| (r_conj) gemfibrozil_33\NN\3740161|or|niacin (r_conj) cyclosporin_31\NN\0|,|gemfibrozil (r_pobj) with_30\IN\0|cyclosporin (r_prep) treated_29\VBN\2376958|concomitantly|with (r_acl) patients_27\NNS\9898892|treated (r_pobj) in_26\IN\13603305|especially|patients (r_prep) reported_21\VBN\831651|in|,|has|been|rarely|with|,|in|. (r_conj) associated_2\VBN\628491|in|,|and|reported (l_prep) in_3\IN\13603305|cases (l_pobj) cases_5\NNS\7283608|some|with (l_prep) with_6\IN\0|myoglobinuria (l_pobj) myoglobinuria_7\NNS\14299637|
D009525_D051437 NONE niacin_35\NN\15090742| (r_conj) gemfibrozil_33\NN\3740161|or|niacin (r_conj) cyclosporin_31\NN\0|,|gemfibrozil (r_pobj) with_30\IN\0|cyclosporin (r_prep) treated_29\VBN\2376958|concomitantly|with (r_acl) patients_27\NNS\9898892|treated (r_pobj) in_26\IN\13603305|especially|patients (r_prep) reported_21\VBN\831651|in|,|has|been|rarely|with|,|in|. (l_prep) in_10\IN\13603305|cases (l_pobj) cases_12\NNS\7283608|2|with (l_prep) with_13\IN\0|failure (l_pobj) failure_16\NN\66216|transient|renal
2054792
D004317_D005334 NONE adriamycin_2\NNS\0| (r_pobj) of_1\IN\0|adriamycin (r_prep) effect_0\NN\34213|of|combined|. (l_acl) combined_3\VBN\2630189|with|on (l_prep) with_4\IN\0|hyperthermia (l_pobj) hyperthermia_7\NN\14034177|body
D004317_D005334 NONE adriamycin_3\NNP\0| (r_npadvmod) mediated_5\VBN\761713|adriamycin|- (r_amod) activity_7\NN\30358|mediated|antitumor|and|toxicities (l_conj) toxicities_11\NNS\13576101|normal|tissue|by (l_prep) by_12\IN\0|hyperthermia (l_pobj) hyperthermia_15\NN\14034177|whole|body
D004317_D005334 NONE adriamycin_13\NNP\0| (r_npadvmod) mediated_15\VBN\761713|adriamycin|- (r_amod) activity_17\NN\30358|both|mediated|antitumor|and|effects (r_dobj) enhanced_11\VBD\227165|hyperthermia|activity|. (l_nsubj) hyperthermia_2\NN\14034177|whole|body|(|min|)
D004317_D005334 NONE adriamycin_7\NNP\0| (r_npadvmod) mediated_9\VBN\761713|adriamycin|- (r_amod) effect_11\NN\34213|mediated|antitumor (r_dobj) enhances_6\VBZ\227165|while|hyperthermia|effect (l_nsubj) hyperthermia_5\NN\14034177|body
D004317_D009369 NONE adriamycin_2\NNS\0| (r_pobj) of_1\IN\0|adriamycin (r_prep) effect_0\NN\34213|of|combined|. (l_acl) combined_3\VBN\2630189|with|on (l_prep) on_8\IN\0|tumor (l_pobj) tumor_9\NN\14234074|and|tissues
D004317_D064420 NONE adriamycin_3\NNP\0| (r_npadvmod) mediated_5\VBN\761713|adriamycin|- (r_amod) activity_7\NN\30358|mediated|antitumor|and|toxicities (l_conj) toxicities_11\NNS\13576101|normal|tissue|by
D004317_D064420 NONE adriamycin_7\NNP\0| (r_npadvmod) mediated_9\VBN\761713|adriamycin|- (r_amod) effect_11\NN\34213|mediated|antitumor (r_dobj) enhances_6\VBZ\227165|while|hyperthermia|effect (r_advcl) increased_18\VBN\169651|thus|,|enhances|,|toxicity|is|also|,|and|eroded (l_nsubjpass) toxicity_15\NN\13576101|normal|tissue
322550
D009599_D007022 CID nitroprusside_8\RB\0| (r_advmod) induced_10\VBN\1627355|nitroprusside|- (r_amod) hypotension_11\NN\14057371|induced
D009599_D007022 CID nitroprusside_1\JJ\0| (r_amod) infusion_2\NN\14589223|nitroprusside (r_nsubj) produced_3\VBD\1617192|before|infusion|decrease|and|increased|. (l_dobj) decrease_6\NN\7296428|a|further|in (l_prep) in_7\IN\13603305|pressure (l_pobj) pressure_10\NN\11419404|arterial|blood
D009599_D007022 CID nitroprusside_0\NNP\0| (r_nsubj) caused_1\VBD\1617192|nitroprusside|decreases|,|but|change|. (l_dobj) decreases_3\NNS\7296428|significant|in (l_prep) in_4\IN\13603305|pressure (l_pobj) pressure_7\NN\11419404|arterial|blood|and|resistance
D009599_D007022 NONE nitroprusside_1\JJ\0| (r_amod) levels_4\NNS\4916342|nitroprusside|infusion|low|of (r_pobj) during_0\IN\0|levels (r_prep) alter_10\VB\0|during|do|not|markedly|dynamics|,|but|levels|produce|. (l_conj) produce_31\VBP\7555863|,|decreasing|,|decreases (l_dobj) decreases_33\NNS\7296428|marked|in (l_prep) in_34\IN\13603305|pressure (l_pobj) pressure_37\NN\11419404|arterial|blood|and|output (l_conj) output_40\NN\4007894|cardiac
D009599_D002303 NONE nitroprusside_1\JJ\0| (r_amod) infusion_2\NN\14589223|nitroprusside (r_nsubj) produced_3\VBD\1617192|before|infusion|decrease|and|increased|. (l_conj) increased_13\VBN\169651|significantly|rate|and|decreased (l_conj) decreased_17\VBD\169651|output (l_dobj) output_19\NN\4007894|cardiac|and|qt
D009599_D002303 NONE nitroprusside_1\JJ\0| (r_amod) levels_4\NNS\4916342|nitroprusside|infusion|low|of (r_pobj) during_0\IN\0|levels (r_prep) alter_10\VB\0|during|do|not|markedly|dynamics|,|but|levels|produce|. (l_conj) produce_31\VBP\7555863|,|decreasing|,|decreases (l_dobj) decreases_33\NNS\7296428|marked|in (l_prep) in_34\IN\13603305|pressure (l_pobj) pressure_37\NN\11419404|arterial|blood|and|output (l_conj) output_40\NN\4007894|cardiac
D014867_D007022 NONE h2o_22\NNP\14618834|cm (r_punct) levels_16\NNS\4916342|high|of|h2o|) (r_conj) alter_10\VB\0|during|do|not|markedly|dynamics|,|but|levels|produce|. (l_conj) produce_31\VBP\7555863|,|decreasing|,|decreases (l_dobj) decreases_33\NNS\7296428|marked|in (l_prep) in_34\IN\13603305|pressure (l_pobj) pressure_37\NN\11419404|arterial|blood|and|output (l_conj) output_40\NN\4007894|cardiac
D014867_D002303 NONE h2o_22\NNP\14618834|cm (r_punct) levels_16\NNS\4916342|high|of|h2o|) (r_conj) alter_10\VB\0|during|do|not|markedly|dynamics|,|but|levels|produce|. (l_conj) produce_31\VBP\7555863|,|decreasing|,|decreases (l_dobj) decreases_33\NNS\7296428|marked|in (l_prep) in_34\IN\13603305|pressure (l_pobj) pressure_37\NN\11419404|arterial|blood|and|output (l_conj) output_40\NN\4007894|cardiac
12639165
D013988_D002779 CID ticlopidine_0\NNP\0| (r_npadvmod) induced_2\VBN\1627355|ticlopidine|- (r_amod) hepatitis_4\NN\14127211|induced|cholestatic|.
D013988_D002779 CID ticlopidine_5\NN\0| (r_npadvmod) induced_7\VBN\1627355|ticlopidine|- (r_amod) hepatitis_9\NN\14127211|induced|cholestatic
D013988_D002779 CID ticlopidine_8\NN\0| (r_advmod) receiving_7\VBG\2210855|ticlopidine|following (r_pcomp) after_6\IN\0|receiving (r_prep) developed_2\VBD\1753788|patients|hepatitis|after|,|with|. (l_dobj) hepatitis_5\NN\14127211|prolonged|cholestatic
D013988_D002779 CID ticlopidine_10\NN\0| (r_advmod) complication_5\NN\1073995|a|rare|of|ticlopidine (r_attr) is_2\VBZ\0|hepatitis|complication (l_nsubj) hepatitis_1\NN\14127211|cholestatic
D013988_D002779 CID ticlopidine_7\NN\0| (r_pobj) with_6\IN\0|ticlopidine (r_prep) treatment_5\NN\654885|with (r_pobj) following_4\VBG\8180190|treatment (r_prep) developed_2\VBD\1753788|patients|jaundice|following|and|showed|. (l_conj) showed_9\VBD\2137132|characteristics (l_dobj) characteristics_14\NNS\5849040|the|clinical|of|,|resolved (l_prep) of_15\IN\0|hepatitis (l_pobj) hepatitis_17\NN\14127211|cholestatic
D013988_D002779 CID ticlopidine_4\NN\0| (r_npadvmod) induced_6\VBN\1627355|ticlopidine|- (r_amod) cholestasis_7\NN\14052403|this|induced
D013988_D002779 CID ticlopidine_8\NN\0| (r_pobj) of_7\IN\0|ticlopidine (r_prep) effect_6\NN\34213|a|rare|adverse|of|be (r_attr) is_2\VBZ\0|hepatitis|effect|. (l_nsubj) hepatitis_1\NN\14127211|cholestatic
D013988_D056486 CID ticlopidine_0\NNP\0| (r_npadvmod) induced_2\VBN\1627355|ticlopidine|- (r_amod) hepatitis_4\NN\14127211|induced|cholestatic|.
D013988_D056486 CID ticlopidine_5\NN\0| (r_npadvmod) induced_7\VBN\1627355|ticlopidine|- (r_amod) hepatitis_9\NN\14127211|induced|cholestatic
D013988_D056486 CID ticlopidine_8\NN\0| (r_advmod) receiving_7\VBG\2210855|ticlopidine|following (r_pcomp) after_6\IN\0|receiving (r_prep) developed_2\VBD\1753788|patients|hepatitis|after|,|with|. (l_dobj) hepatitis_5\NN\14127211|prolonged|cholestatic
D013988_D056486 CID ticlopidine_10\NN\0| (r_advmod) complication_5\NN\1073995|a|rare|of|ticlopidine (r_attr) is_2\VBZ\0|hepatitis|complication (l_nsubj) hepatitis_1\NN\14127211|cholestatic
D013988_D056486 CID ticlopidine_7\NN\0| (r_pobj) with_6\IN\0|ticlopidine (r_prep) treatment_5\NN\654885|with (r_pobj) following_4\VBG\8180190|treatment (r_prep) developed_2\VBD\1753788|patients|jaundice|following|and|showed|. (l_conj) showed_9\VBD\2137132|characteristics (l_dobj) characteristics_14\NNS\5849040|the|clinical|of|,|resolved (l_prep) of_15\IN\0|hepatitis (l_pobj) hepatitis_17\NN\14127211|cholestatic
D013988_D056486 CID ticlopidine_8\NN\0| (r_pobj) of_7\IN\0|ticlopidine (r_prep) effect_6\NN\34213|a|rare|adverse|of|be (r_attr) is_2\VBZ\0|hepatitis|effect|. (l_nsubj) hepatitis_1\NN\14127211|cholestatic
D013988_D007565 CID ticlopidine_7\NN\0| (r_pobj) with_6\IN\0|ticlopidine (r_prep) treatment_5\NN\654885|with (r_pobj) following_4\VBG\8180190|treatment (r_prep) developed_2\VBD\1753788|patients|jaundice|following|and|showed|. (l_dobj) jaundice_3\NN\14299637|
809711
D010656_D009203 NONE phenylephrine_2\NN\2682038|of (l_prep) of_3\IN\0|effects (l_pobj) effects_6\NNS\13245626|the|beneficial|of|in (l_prep) in_10\IN\13603305|patients (l_pobj) patients_11\NNS\9898892|with (l_prep) with_12\IN\0|infarction (l_pobj) infarction_15\NN\14204950|acute|myocardial
D010656_D009203 NONE phenylephrine_6\NN\2682038|to (r_pobj) of_5\IN\0|phenylephrine (r_prep) addition_4\NN\3081021|of (r_nsubj) is_9\VBZ\0|that|addition|not|beneficial (l_acomp) beneficial_11\JJ\0|in (l_prep) in_12\IN\13603305|treatment (l_pobj) treatment_14\NN\654885|the|of (l_prep) of_15\IN\0|patients (l_pobj) patients_16\NNS\9898892|with (l_prep) with_17\IN\0|infarction (l_pobj) infarction_20\NN\14204950|acute|myocardial
D005996_D009203 NONE nitroglycerin_9\NN\15015501|intravenous (r_pobj) of_7\IN\0|nitroglycerin (r_prep) effects_6\NNS\13245626|the|beneficial|of|in (l_prep) in_10\IN\13603305|patients (l_pobj) patients_11\NNS\9898892|with (l_prep) with_12\IN\0|infarction (l_pobj) infarction_15\NN\14204950|acute|myocardial
D005996_D009203 NONE nitroglycerin_0\NNP\15015501| (r_nsubjpass) shown_3\VBN\2137132|nitroglycerin|has|been|reduce (l_xcomp) reduce_5\VB\441445|to|elevation|during (l_prep) during_10\IN\0|infarction (l_pobj) infarction_13\NN\14204950|acute|myocardial
D005996_D009203 NONE nitroglycerin_25\NN\15015501| (r_npadvmod) induced_27\VBN\1627355|nitroglycerin|- (r_amod) hypotension_28\NN\14057371|induced (r_dobj) reverse_24\VBP\13854649|that|hypotension (r_relcl) agents_22\NNS\7347|reverse (r_pobj) by_21\IN\0|agents (r_agent) potentiated_17\VBN\229605|shown|,|effect|in|by|. (l_ccomp) shown_3\VBN\2137132|nitroglycerin|has|been|reduce (l_xcomp) reduce_5\VB\441445|to|elevation|during (l_prep) during_10\IN\0|infarction (l_pobj) infarction_13\NN\14204950|acute|myocardial
D005996_D009203 NONE nitroglycerin_9\NN\15015501|intravenous|,|sufficient (r_dobj) received_7\VBD\2210855|patients|nitroglycerin|+/- (l_nsubj) patients_1\NNS\9898892|ten|with (l_prep) with_2\IN\0|infarctions (l_pobj) infarctions_6\NNS\14204950|acute|transmural|myocardial
D005996_D009203 NONE nitroglycerin_8\NN\15015501| (r_pobj) to_7\IN\0|nitroglycerin (r_prep) phenylephrine_6\NN\2682038|to (r_pobj) of_5\IN\0|phenylephrine (r_prep) addition_4\NN\3081021|of (r_nsubj) is_9\VBZ\0|that|addition|not|beneficial (l_acomp) beneficial_11\JJ\0|in (l_prep) in_12\IN\13603305|treatment (l_pobj) treatment_14\NN\654885|the|of (l_prep) of_15\IN\0|patients (l_pobj) patients_16\NNS\9898892|with (l_prep) with_17\IN\0|infarction (l_pobj) infarction_20\NN\14204950|acute|myocardial
D005996_D007022 CID nitroglycerin_0\NNP\15015501| (r_nsubjpass) shown_3\VBN\2137132|nitroglycerin|has|been|reduce (r_ccomp) potentiated_17\VBN\229605|shown|,|effect|in|by|. (l_agent) by_21\IN\0|agents (l_pobj) agents_22\NNS\7347|reverse (l_relcl) reverse_24\VBP\13854649|that|hypotension (l_dobj) hypotension_28\NN\14057371|induced
D005996_D007022 CID nitroglycerin_25\NN\15015501| (r_npadvmod) induced_27\VBN\1627355|nitroglycerin|- (r_amod) hypotension_28\NN\14057371|induced
16858720
D014859_D002543 CID warfarin_4\NN\2718259|- (r_pobj) by_3\IN\0|warfarin (r_agent) induced_2\VBN\1627355|by|influence (r_acl) haemorrhage_1\NN\14285662|cerebral|induced|.
D014859_D002543 CID warfarin_9\RB\2718259| (r_npadvmod) induced_11\VBN\1627355|warfarin|- (r_amod) haemorrhages_13\NNS\14285662|induced|cerebral
D014859_D002543 CID warfarin_16\JJ\2718259|and|interactions (r_pobj) due_14\IN\5174653|to|warfarin (r_prep) evaluate_1\VB\670261|to|frequency|due|. (l_dobj) frequency_3\NN\15286249|the|,|severity|of (l_prep) of_8\IN\0|haemorrhages (l_pobj) haemorrhages_13\NNS\14285662|induced|cerebral
D014859_D002543 CID warfarin_18\JJ\2718259| (r_compound) drug_20\NN\14778436|warfarin|- (r_compound) interactions_21\NNS\37396|drug|in (r_conj) warfarin_16\JJ\2718259|and|interactions (r_pobj) due_14\IN\5174653|to|warfarin (r_prep) evaluate_1\VB\670261|to|frequency|due|. (l_dobj) frequency_3\NN\15286249|the|,|severity|of (l_prep) of_8\IN\0|haemorrhages (l_pobj) haemorrhages_13\NNS\14285662|induced|cerebral
D014859_D002543 CID warfarin_8\JJ\2718259|and|drug (r_nmod) interactions_13\NNS\37396|warfarin (r_nsubj) caused_16\VBN\1617192|whether|interactions|could|have|haemorrhage (l_dobj) haemorrhage_19\NN\14285662|the|cerebral
D014859_D002543 CID warfarin_10\JJ\2718259| (r_compound) drug_12\NN\14778436|warfarin|- (r_conj) warfarin_8\JJ\2718259|and|drug (r_nmod) interactions_13\NNS\37396|warfarin (r_nsubj) caused_16\VBN\1617192|whether|interactions|could|have|haemorrhage (l_dobj) haemorrhage_19\NN\14285662|the|cerebral
D014859_D002543 CID warfarin_17\JJ\2718259| (r_compound) treatment_18\NN\654885|warfarin (r_pobj) to_16\IN\0|treatment (r_prep) related_15\VBN\628491|to (r_amod) as_14\IN\14622893|related (r_prep) assessed_13\VBN\670261|among|were|as|. (l_prep) among_0\IN\0|patients (l_pobj) patients_2\NNS\9898892|593|with (l_prep) with_3\IN\0|haemorrhage (l_pobj) haemorrhage_5\NN\14285662|cerebral|,|%|)
D014859_D002543 CID warfarin_0\NNP\2718259| (r_npadvmod) induced_2\VBN\1627355|warfarin|- (r_amod) haemorrhages_4\NNS\14285662|induced|cerebral
D014859_D002543 CID warfarin_4\RB\2718259| (r_npadvmod) related_6\VBN\628491|warfarin|- (r_amod) haemorrhages_8\NNS\14285662|related|cerebral
D014859_D002543 CID warfarin_26\NN\2718259| (r_pobj) with_25\IN\0|warfarin (r_prep) interact_24\VB\2367363|to|with (r_xcomp) known_22\VBN\0|interact (r_acl) drugs_21\NNS\14778436|known (r_dobj) prescribing_20\VBG\748282|when|drugs (r_advcl) taken_18\VBN\2367363|if|caution|had|been|prescribing (r_advcl) prevented_12\VBN\0|proportion|might|have|been|taken|. (l_nsubjpass) proportion_2\NN\13824815|a|significant|of (l_prep) of_3\IN\0|haemorrhages (l_pobj) haemorrhages_8\NNS\14285662|related|cerebral
D014859_D006470 NONE warfarin_1\JJ\2718259| (r_compound) drug_3\NN\14778436|warfarin|- (r_compound) interaction_4\NN\37396|a|drug (r_nsubj) contributed_7\VBN\126264|interaction|could|have|to|in|considered|. (l_prep) to_8\IN\0|haemorrhage (l_pobj) haemorrhage_10\NN\14285662|the
D014859_D006470 NONE warfarin_1\JJ\2718259| (r_compound) drug_3\NN\14778436|warfarin|- (r_compound) interaction_4\NN\37396|a|drug (r_nsubj) contributed_7\VBN\126264|interaction|could|have|to|in|considered|. (l_conj) considered_34\VBN\689344|complication|was|being (l_nsubjpass) complication_32\NN\1073995|the|bleeding (l_amod) bleeding_31\VBG\14285662|
D014859_D006470 NONE warfarin_19\JJ\2718259| (r_compound) patients_20\NNS\9898892|the|warfarin (r_pobj) of_17\IN\0|patients (r_prep) %_15\NN\0|24|(|41|)|of (r_pobj) in_11\IN\13603305|%|and|in (r_prep) contributed_7\VBN\126264|interaction|could|have|to|in|considered|. (l_prep) to_8\IN\0|haemorrhage (l_pobj) haemorrhage_10\NN\14285662|the
D014859_D006470 NONE warfarin_19\JJ\2718259| (r_compound) patients_20\NNS\9898892|the|warfarin (r_pobj) of_17\IN\0|patients (r_prep) %_15\NN\0|24|(|41|)|of (r_pobj) in_11\IN\13603305|%|and|in (r_prep) contributed_7\VBN\126264|interaction|could|have|to|in|considered|. (l_conj) considered_34\VBN\689344|complication|was|being (l_nsubjpass) complication_32\NN\1073995|the|bleeding (l_amod) bleeding_31\VBG\14285662|
20633755
D013390_D001049 CID suxamethonium_0\NNS\0| (r_nsubj) induced_1\VBD\1627355|suxamethonium|apnea|. (l_dobj) apnea_3\NN\14299637|prolonged|in
D013390_D001049 CID suxamethonium_0\JJ\0| (r_nsubj) causes_1\VBZ\7323922|suxamethonium|apnea|. (l_dobj) apnea_3\NN\14299637|prolonged|in
D009943_D001049 CID poisons_17\NNS\20090|organophosphorus|(|op|) (r_pobj) by_12\IN\0|poisons (r_agent) deactivated_11\VBN\1097743|in|enzyme|gets|by (r_relcl) patients_5\NNS\9898892|deactivated (r_pobj) in_4\IN\13603305|patients (r_prep) apnea_3\NN\14299637|prolonged|in
D009943_D001049 CID compound_14\NN\5869584|op (r_pobj) by_12\IN\0|compound (r_prep) attempt_11\NN\407535|suicidal|by (r_pobj) about_9\IN\0|attempt (r_prep) information_8\NN\6598915|the|about (r_nsubjpass) concealed_16\VBN\0|because|information|was|from (r_advcl) ensued_5\VBD\2633881|apnea|concealed|. (l_nsubj) apnea_1\NN\14299637|prolonged|in
7858459
D005472_D003221 CID 5-fluorouracil_10\CD\0| (r_punct) of_9\IN\0|5-fluorouracil (r_prep) infusion_8\NN\14589223|a|dose|of|and|acid (r_pobj) by_3\IN\0|infusion (r_agent) induced_2\VBN\1627355|confusion|by|. (l_nsubj) confusion_1\NN\13972797|acute
D005472_D003221 CID 5-fluorouracil_35\CD\0| (r_punct) of_34\IN\0|5-fluorouracil (r_prep) dose_29\NN\3740161|the|first|day|of|and (r_nmod) infusion_39\NN\14589223|dose|folinic|acid (r_pobj) during_26\IN\0|infusion (r_prep) lasting_21\VBG\2704349|for|during (r_advcl) lapsed_15\VBD\124442|then|into|,|lasting (r_conj) developed_1\VBD\1753788|he|symptoms|,|and|lapsed|. (l_dobj) symptoms_4\NNS\5823932|acute|neurologic|of (l_prep) of_5\IN\0|confusion (l_pobj) confusion_7\NN\13972797|mental|,|disorientation
D005472_D003221 CID 5-fluorouracil_35\CD\0| (r_punct) of_34\IN\0|5-fluorouracil (r_prep) dose_29\NN\3740161|the|first|day|of|and (r_nmod) infusion_39\NN\14589223|dose|folinic|acid (r_pobj) during_26\IN\0|infusion (r_prep) lasting_21\VBG\2704349|for|during (r_advcl) lapsed_15\VBD\124442|then|into|,|lasting (r_conj) developed_1\VBD\1753788|he|symptoms|,|and|lapsed|. (l_dobj) symptoms_4\NNS\5823932|acute|neurologic|of (l_prep) of_5\IN\0|confusion (l_pobj) confusion_7\NN\13972797|mental|,|disorientation (l_conj) disorientation_9\NN\5896733|and|irritability
D002955_D003221 CID acid_13\NN\14818238|folinic (r_conj) infusion_8\NN\14589223|a|dose|of|and|acid (r_pobj) by_3\IN\0|infusion (r_agent) induced_2\VBN\1627355|confusion|by|. (l_nsubj) confusion_1\NN\13972797|acute
D002955_D003221 CID acid_38\NN\14818238| (r_compound) infusion_39\NN\14589223|dose|folinic|acid (r_pobj) during_26\IN\0|infusion (r_prep) lasting_21\VBG\2704349|for|during (r_advcl) lapsed_15\VBD\124442|then|into|,|lasting (r_conj) developed_1\VBD\1753788|he|symptoms|,|and|lapsed|. (l_dobj) symptoms_4\NNS\5823932|acute|neurologic|of (l_prep) of_5\IN\0|confusion (l_pobj) confusion_7\NN\13972797|mental|,|disorientation
D002955_D003221 CID acid_38\NN\14818238| (r_compound) infusion_39\NN\14589223|dose|folinic|acid (r_pobj) during_26\IN\0|infusion (r_prep) lasting_21\VBG\2704349|for|during (r_advcl) lapsed_15\VBD\124442|then|into|,|lasting (r_conj) developed_1\VBD\1753788|he|symptoms|,|and|lapsed|. (l_dobj) symptoms_4\NNS\5823932|acute|neurologic|of (l_prep) of_5\IN\0|confusion (l_pobj) confusion_7\NN\13972797|mental|,|disorientation (l_conj) disorientation_9\NN\5896733|and|irritability
D002945_D013274 NONE cisplatinum_11\NN\0|,|etoposide|hours (l_appos) hours_24\NNS\15118228|m2/24|)|and|acid (l_conj) acid_28\NN\14818238|folinic|for (l_prep) for_29\IN\0|adenocarcinoma (l_pobj) adenocarcinoma_33\NN\14242337|an|inoperable|gastric
D005047_D013274 NONE etoposide_13\NN\0| (r_conj) cisplatinum_11\NN\0|,|etoposide|hours (l_appos) hours_24\NNS\15118228|m2/24|)|and|acid (l_conj) acid_28\NN\14818238|folinic|for (l_prep) for_29\IN\0|adenocarcinoma (l_pobj) adenocarcinoma_33\NN\14242337|an|inoperable|gastric
D005472_D013274 NONE 5-fluorouracil_18\CD\0| (r_punct) m2/24_23\NN\0|,|dose|5-fluorouracil|(|mg|/ (r_compound) hours_24\NNS\15118228|m2/24|)|and|acid (l_conj) acid_28\NN\14818238|folinic|for (l_prep) for_29\IN\0|adenocarcinoma (l_pobj) adenocarcinoma_33\NN\14242337|an|inoperable|gastric
D002955_D013274 NONE acid_28\NN\14818238|folinic|for (l_prep) for_29\IN\0|adenocarcinoma (l_pobj) adenocarcinoma_33\NN\14242337|an|inoperable|gastric
D005472_D001523 NONE 5-fluorouracil_35\CD\0| (r_punct) of_34\IN\0|5-fluorouracil (r_prep) dose_29\NN\3740161|the|first|day|of|and (r_nmod) infusion_39\NN\14589223|dose|folinic|acid (r_pobj) during_26\IN\0|infusion (r_prep) lasting_21\VBG\2704349|for|during (r_advcl) lapsed_15\VBD\124442|then|into|,|lasting (r_conj) developed_1\VBD\1753788|he|symptoms|,|and|lapsed|. (l_dobj) symptoms_4\NNS\5823932|acute|neurologic|of (l_prep) of_5\IN\0|confusion (l_pobj) confusion_7\NN\13972797|mental|,|disorientation (l_conj) disorientation_9\NN\5896733|and|irritability (l_conj) irritability_11\NN\7552087|
D005472_D003128 CID 5-fluorouracil_35\CD\0| (r_punct) of_34\IN\0|5-fluorouracil (r_prep) dose_29\NN\3740161|the|first|day|of|and (r_nmod) infusion_39\NN\14589223|dose|folinic|acid (r_pobj) during_26\IN\0|infusion (r_prep) lasting_21\VBG\2704349|for|during (r_advcl) lapsed_15\VBD\124442|then|into|,|lasting (l_prep) into_16\IN\0|coma (l_pobj) coma_19\NN\5678932|a|deep
D002955_D001523 NONE acid_38\NN\14818238| (r_compound) infusion_39\NN\14589223|dose|folinic|acid (r_pobj) during_26\IN\0|infusion (r_prep) lasting_21\VBG\2704349|for|during (r_advcl) lapsed_15\VBD\124442|then|into|,|lasting (r_conj) developed_1\VBD\1753788|he|symptoms|,|and|lapsed|. (l_dobj) symptoms_4\NNS\5823932|acute|neurologic|of (l_prep) of_5\IN\0|confusion (l_pobj) confusion_7\NN\13972797|mental|,|disorientation (l_conj) disorientation_9\NN\5896733|and|irritability (l_conj) irritability_11\NN\7552087|
D002955_D003128 CID acid_38\NN\14818238| (r_compound) infusion_39\NN\14589223|dose|folinic|acid (r_pobj) during_26\IN\0|infusion (r_prep) lasting_21\VBG\2704349|for|during (r_advcl) lapsed_15\VBD\124442|then|into|,|lasting (l_prep) into_16\IN\0|coma (l_pobj) coma_19\NN\5678932|a|deep
D002955_D020258 NONE acid_2\NN\14818238|folinic (r_nsubj) was_3\VBD\0|because|acid|unlikely (r_advcl) suspected_21\VBN\916909|was|,|neurotoxicity|5-fluorouracil|was|highly|. (l_nsubjpass) neurotoxicity_12\NN\0|due
D005472_D020258 NONE 5-fluorouracil_18\CD\0| (r_punct) suspected_21\VBN\916909|was|,|neurotoxicity|5-fluorouracil|was|highly|. (l_nsubjpass) neurotoxicity_12\NN\0|due
D005472_D020258 NONE 5-fluorouracil_3\CD\0| (r_punct) neurotoxicity_4\NN\0|5-fluorouracil
D005463_D020258 NONE fluoroacetate_14\NN\0|and|fluorocitrate (r_pobj) by_13\IN\0|fluoroacetate (r_prep) blockade_12\NN\952963|a|krebs|cycle|by|,|deficiency (r_pobj) to_8\IN\0|blockade (r_prep) due_7\JJ\5174653|to (r_acomp) be_6\VB\14625458|pathogenesis|may|due|. (l_nsubj) pathogenesis_1\NN\13533470|the|of (l_prep) of_2\IN\0|neurotoxicity (l_pobj) neurotoxicity_4\NN\0|5-fluorouracil
C007744_D020258 NONE fluorocitrate_16\NN\0| (r_conj) fluoroacetate_14\NN\0|and|fluorocitrate (r_pobj) by_13\IN\0|fluoroacetate (r_prep) blockade_12\NN\952963|a|krebs|cycle|by|,|deficiency (r_pobj) to_8\IN\0|blockade (r_prep) due_7\JJ\5174653|to (r_acomp) be_6\VB\14625458|pathogenesis|may|due|. (l_nsubj) pathogenesis_1\NN\13533470|the|of (l_prep) of_2\IN\0|neurotoxicity (l_pobj) neurotoxicity_4\NN\0|5-fluorouracil
D013831_D020258 NONE thiamine_18\NN\15090742| (r_compound) deficiency_19\NN\14449126|thiamine|,|or|deficiency (r_conj) blockade_12\NN\952963|a|krebs|cycle|by|,|deficiency (r_pobj) to_8\IN\0|blockade (r_prep) due_7\JJ\5174653|to (r_acomp) be_6\VB\14625458|pathogenesis|may|due|. (l_nsubj) pathogenesis_1\NN\13533470|the|of (l_prep) of_2\IN\0|neurotoxicity (l_pobj) neurotoxicity_4\NN\0|5-fluorouracil
C007419_D020258 NONE dihydrouracil_22\VBN\0| (r_compound) dehydrogenase_23\NN\0|dihydrouracil (r_compound) deficiency_24\NN\14449126|dehydrogenase (r_conj) deficiency_19\NN\14449126|thiamine|,|or|deficiency (r_conj) blockade_12\NN\952963|a|krebs|cycle|by|,|deficiency (r_pobj) to_8\IN\0|blockade (r_prep) due_7\JJ\5174653|to (r_acomp) be_6\VB\14625458|pathogenesis|may|due|. (l_nsubj) pathogenesis_1\NN\13533470|the|of (l_prep) of_2\IN\0|neurotoxicity (l_pobj) neurotoxicity_4\NN\0|5-fluorouracil
D005472_D009369 NONE 5-fluorouracil_3\CD\0| (r_punct) folinic_5\JJ\0|5-fluorouracil|/ (r_amod) therapy_8\NN\657604|dose|folinic|infusion (r_nsubj) become_11\VBN\146138|therapy|has|recently|regimen|. (l_attr) regimen_14\NN\5898568|a|popular|for (l_prep) for_15\IN\0|cancers (l_pobj) cancers_17\NNS\14239425|various
D002955_D009369 NONE acid_6\NN\14818238| (r_compound) infusion_7\NN\14589223|acid (r_compound) therapy_8\NN\657604|dose|folinic|infusion (r_nsubj) become_11\VBN\146138|therapy|has|recently|regimen|. (l_attr) regimen_14\NN\5898568|a|popular|for (l_prep) for_15\IN\0|cancers (l_pobj) cancers_17\NNS\14239425|various
9249847
D014700_D013611 CID verapamil_7\NN\2938514|and (r_nmod) ablation_10\NN\671351|verapamil|catheter|in|and|cardiomyopathy (r_pobj) after_6\IN\0|ablation (r_prep) induced_1\VBD\1627355|iatrogenically|tachycardia|after|. (l_dobj) tachycardia_5\NN\14110674|intractable|atrioventricular|reentrant
D014700_D013611 CID verapamil_10\NN\2938514|or (r_nmod) block_14\NN\21939|verapamil|unidirectional|antegrade|of (r_pobj) after_9\IN\0|block (r_prep) beats_8\NNS\8289449|junctional|escape|after|after (r_pobj) by_5\IN\0|beats (r_agent) caused_4\VBN\1617192|by (r_acl) qrs_0\UH\0|without|,|caused|, (r_nsubj) established_22\VBD\2426171|qrs|attack|. (l_dobj) attack_25\NN\955060|frequent|avrt (l_compound) avrt_24\NN\0|
D014700_D014927 NONE verapamil_7\NN\2938514|and (r_nmod) ablation_10\NN\671351|verapamil|catheter|in|and|cardiomyopathy (l_prep) in_11\IN\13603305|patient (l_pobj) patient_13\NN\9898892|a|with (l_prep) with_14\IN\0|syndrome (l_pobj) syndrome_20\NN\5870365|white
D014700_D002311 NONE verapamil_7\NN\2938514|and (r_nmod) ablation_10\NN\671351|verapamil|catheter|in|and|cardiomyopathy (l_conj) cardiomyopathy_24\NN\14103288|idiopathic|dilated
20080983
C048833_D012893 NONE modafinil_15\NN\0|dosed|on|sleepiness (l_conj) sleepiness_20\NN\14015731|daytime|in
C048833_D012893 NONE modafinil_0\NNP\0| (r_nsubjpass) associated_2\VBN\628491|modafinil|was|with|,|measured|. (l_advcl) measured_10\VBN\697589|as|by|,|and|decrease (l_conj) decrease_22\NN\7296428|a|significant|in (l_prep) in_23\IN\13603305|sleepiness (l_pobj) sleepiness_26\NN\14015731|subjective|daytime
C048833_D012893 NONE modafinil_3\NN\0|dosed (r_nsubj) promotes_4\VBZ\2556126|modafinil|sleep|,|normalizes|. (l_conj) normalizes_8\VBZ\109660|architecture|,|and|decreases (l_conj) decreases_13\VBZ\7296428|sleepiness (l_dobj) sleepiness_15\NN\14015731|daytime|in
D003042_D012893 CID cocaine_23\NN\3492717| (r_compound) users_24\NNS\7846|chronic|cocaine (r_pobj) in_21\IN\13603305|users (r_prep) sleepiness_20\NN\14015731|daytime|in
D003042_D012893 CID cocaine_18\NN\3492717| (r_compound) users_19\NNS\7846|abstinent|cocaine (r_pobj) in_16\IN\13603305|users (r_prep) sleepiness_15\NN\14015731|daytime|in
11198499
C023754_D007022 CID tizanidine_5\NN\0| (r_pobj) of_4\IN\0|tizanidine (r_prep) initiation_3\NN\7450842|the|of|in (r_dobj) following_1\VBG\8180190|initiation (r_acl) hypotension_0\NN\14057371|following|.
C023754_D007022 CID tizanidine_29\NN\0|,|agonist|, (r_pobj) of_28\IN\0|tizanidine (r_prep) addition_27\NN\3081021|the|of|for (r_pobj) following_25\VBG\8180190|addition (r_prep) developed_23\VBD\1753788|who|hypotension|following (l_dobj) hypotension_24\NN\14057371|
C023754_D006973 NONE tizanidine_5\NN\0| (r_pobj) of_4\IN\0|tizanidine (r_prep) initiation_3\NN\7450842|the|of|in (l_prep) in_6\IN\13603305|patient (l_pobj) patient_8\NN\9898892|a|treated (l_acl) treated_9\VBN\2376958|with (l_prep) with_10\IN\0|angiotensin (l_pobj) angiotensin_12\NN\4522421|an|converting (l_acl) converting_13\VBG\126264|inhibitor|for (l_prep) for_16\IN\0|hypertension (l_pobj) hypertension_18\NN\14057371|chronic
C023754_D006973 NONE tizanidine_29\NN\0|,|agonist|, (r_pobj) of_28\IN\0|tizanidine (r_prep) addition_27\NN\3081021|the|of|for (r_pobj) following_25\VBG\8180190|addition (r_prep) developed_23\VBD\1753788|who|hypotension|following (r_relcl) hypertension_21\NN\14057371|developed
C023754_D006973 NONE tizanidine_4\NN\0|and|agents (r_pobj) of_3\IN\0|tizanidine (r_prep) interaction_2\NN\37396|the|possible|of (r_nsubjpass) kept_11\VBN\0|interaction|should|be|in|prescribing|. (l_advcl) prescribing_15\VBG\748282|when|therapy|treat (l_xcomp) treat_18\VB\7570720|to|hypertension (l_dobj) hypertension_20\NN\14057371|either|or|spasticity|in
D000809_D007022 NONE angiotensin_12\NN\4522421|an|converting (r_pobj) with_10\IN\0|angiotensin (r_prep) treated_9\VBN\2376958|with (r_acl) patient_8\NN\9898892|a|treated (r_pobj) in_6\IN\13603305|patient (r_prep) initiation_3\NN\7450842|the|of|in (r_dobj) following_1\VBG\8180190|initiation (r_acl) hypotension_0\NN\14057371|following|.
D000809_D007022 NONE angiotensin_4\NN\4522421|converting (r_pobj) with_3\IN\0|angiotensin (r_prep) treated_2\VBN\2376958|adults|chronically|with (r_csubj) have_9\VB\7846|treated|may|ability|. (l_dobj) ability_12\NN\4723816|a|limited|respond (l_acl) respond_14\VB\2367363|to|to|blocked (l_prep) to_15\IN\0|hypotension (l_pobj) hypotension_16\NN\14057371|
D000809_D007022 NONE angiotensin_14\NN\4522421|an|converting (r_appos) lisinopril_11\NN\2673637|,|angiotensin (r_pobj) with_10\IN\0|lisinopril (r_prep) treated_9\VBN\2376958|chronically|with (r_acl) boy_7\NN\9624168|a|old|treated|, (r_dobj) present_2\VBP\28270|authors|boy|control|. (l_advcl) control_20\VB\5190804|to|hypertension (l_dobj) hypertension_21\NN\14057371|developed (l_relcl) developed_23\VBD\1753788|who|hypotension|following (l_dobj) hypotension_24\NN\14057371|
D000809_D006973 NONE angiotensin_12\NN\4522421|an|converting (l_acl) converting_13\VBG\126264|inhibitor|for (l_prep) for_16\IN\0|hypertension (l_pobj) hypertension_18\NN\14057371|chronic
D000809_D006973 NONE angiotensin_14\NN\4522421|an|converting (r_appos) lisinopril_11\NN\2673637|,|angiotensin (r_pobj) with_10\IN\0|lisinopril (r_prep) treated_9\VBN\2376958|chronically|with (r_acl) boy_7\NN\9624168|a|old|treated|, (r_dobj) present_2\VBP\28270|authors|boy|control|. (l_advcl) control_20\VB\5190804|to|hypertension (l_dobj) hypertension_21\NN\14057371|developed
D017706_D006973 NONE lisinopril_11\NN\2673637|,|angiotensin (r_pobj) with_10\IN\0|lisinopril (r_prep) treated_9\VBN\2376958|chronically|with (r_acl) boy_7\NN\9624168|a|old|treated|, (r_dobj) present_2\VBP\28270|authors|boy|control|. (l_advcl) control_20\VB\5190804|to|hypertension (l_dobj) hypertension_21\NN\14057371|developed
D017706_D007022 CID lisinopril_11\NN\2673637|,|angiotensin (r_pobj) with_10\IN\0|lisinopril (r_prep) treated_9\VBN\2376958|chronically|with (r_acl) boy_7\NN\9624168|a|old|treated|, (r_dobj) present_2\VBP\28270|authors|boy|control|. (l_advcl) control_20\VB\5190804|to|hypertension (l_dobj) hypertension_21\NN\14057371|developed (l_relcl) developed_23\VBD\1753788|who|hypotension|following (l_dobj) hypotension_24\NN\14057371|
D017706_D009128 NONE lisinopril_11\NN\2673637|,|angiotensin (r_pobj) with_10\IN\0|lisinopril (r_prep) treated_9\VBN\2376958|chronically|with (r_acl) boy_7\NN\9624168|a|old|treated|, (r_dobj) present_2\VBP\28270|authors|boy|control|. (l_advcl) control_20\VB\5190804|to|hypertension (l_dobj) hypertension_21\NN\14057371|developed (l_relcl) developed_23\VBD\1753788|who|hypotension|following (l_prep) following_25\VBG\8180190|addition (l_pobj) addition_27\NN\3081021|the|of|for (l_prep) for_35\IN\0|treatment (l_pobj) treatment_37\NN\654885|the|of (l_prep) of_38\IN\0|spasticity (l_pobj) spasticity_39\NN\4770535|
D000809_D009128 NONE angiotensin_14\NN\4522421|an|converting (r_appos) lisinopril_11\NN\2673637|,|angiotensin (r_pobj) with_10\IN\0|lisinopril (r_prep) treated_9\VBN\2376958|chronically|with (r_acl) boy_7\NN\9624168|a|old|treated|, (r_dobj) present_2\VBP\28270|authors|boy|control|. (l_advcl) control_20\VB\5190804|to|hypertension (l_dobj) hypertension_21\NN\14057371|developed (l_relcl) developed_23\VBD\1753788|who|hypotension|following (l_prep) following_25\VBG\8180190|addition (l_pobj) addition_27\NN\3081021|the|of|for (l_prep) for_35\IN\0|treatment (l_pobj) treatment_37\NN\654885|the|of (l_prep) of_38\IN\0|spasticity (l_pobj) spasticity_39\NN\4770535|
C023754_D009128 NONE tizanidine_29\NN\0|,|agonist|, (r_pobj) of_28\IN\0|tizanidine (r_prep) addition_27\NN\3081021|the|of|for (l_prep) for_35\IN\0|treatment (l_pobj) treatment_37\NN\654885|the|of (l_prep) of_38\IN\0|spasticity (l_pobj) spasticity_39\NN\4770535|
C023754_D009128 NONE tizanidine_4\NN\0|and|agents (r_pobj) of_3\IN\0|tizanidine (r_prep) interaction_2\NN\37396|the|possible|of (r_nsubjpass) kept_11\VBN\0|interaction|should|be|in|prescribing|. (l_advcl) prescribing_15\VBG\748282|when|therapy|treat (l_xcomp) treat_18\VB\7570720|to|hypertension (l_dobj) hypertension_20\NN\14057371|either|or|spasticity|in (l_conj) spasticity_22\NN\4770535|
20588063
D011692_D009401 CID aminonucleoside_17\JJ\0| (r_amod) nephrosis_18\NN\14304060|puromycin|aminonucleoside
D011692_D009401 CID aminonucleoside_2\JJ\0| (r_amod) nephrosis_3\NN\14304060|aminonucleoside
3015567
D009599_D007022 CID nitroprusside_0\NNP\0| (r_npadvmod) induced_2\VBN\1627355|nitroprusside|- (r_amod) hypotension_3\NN\14057371|induced
D009599_D007022 CID nitroprusside_7\RB\0| (r_advmod) induced_9\VBN\1627355|nitroprusside|- (r_amod) hypotension_10\NN\14057371|induced
D003345_D007022 NONE corticosterone_18\NN\14752057|plasma (r_compound) level_19\NN\4916342|a|corticosterone|between (r_pobj) at_15\IN\14622893|level (r_prep) occurs_14\VBZ\0|at (r_conj) observed_12\VBN\2163746|suppression|is|and|occurs|. (l_nsubjpass) suppression_0\NN\13489037|of|secretion (l_appos) secretion_3\NN\13526110|in (l_prep) in_4\IN\13603305|response (l_pobj) response_5\NN\11410625|to (l_prep) to_6\IN\0|hypotension (l_pobj) hypotension_10\NN\14057371|induced
7449470
D004317_D066126 NONE doxorubicin_3\NN\2716866| (r_compound) cardiotoxicity_4\NN\0|late|,|late|doxorubicin|.
D004317_D066126 NONE adriamycin_11\NNS\0| (r_pobj) of_10\IN\0|adriamycin (r_prep) use_9\NN\407535|the|of|as (r_dobj) limits_7\VBZ\5123416|which|use (r_relcl) complication_5\NN\1073995|a|major|limits (r_attr) is_2\VBZ\0|toxicity|complication|. (l_nsubj) toxicity_1\NN\13576101|cardiac
8739323
D008466_D007674 NONE nitrogranulogen_8\NN\0|ng|,|methotrexate (r_pobj) as_7\IN\14622893|such|nitrogranulogen (r_prep) drugs_5\NNS\14778436|anticancer|as (r_pobj) of_3\IN\0|drugs (r_prep) action_2\NN\30358|the|nephrotoxic|of|5-fu|administered|mtx (l_amod) nephrotoxic_1\JJ\0|
D008466_D007674 NONE ng_10\NNP\13717155|(|) (r_appos) nitrogranulogen_8\NN\0|ng|,|methotrexate (r_pobj) as_7\IN\14622893|such|nitrogranulogen (r_prep) drugs_5\NNS\14778436|anticancer|as (r_pobj) of_3\IN\0|drugs (r_prep) action_2\NN\30358|the|nephrotoxic|of|5-fu|administered|mtx (l_amod) nephrotoxic_1\JJ\0|
D008727_D007674 NONE methotrexate_13\NNP\2722166|mtx|, (r_conj) nitrogranulogen_8\NN\0|ng|,|methotrexate (r_pobj) as_7\IN\14622893|such|nitrogranulogen (r_prep) drugs_5\NNS\14778436|anticancer|as (r_pobj) of_3\IN\0|drugs (r_prep) action_2\NN\30358|the|nephrotoxic|of|5-fu|administered|mtx (l_amod) nephrotoxic_1\JJ\0|
D008727_D007674 NONE mtx_15\NNP\0|(|) (r_appos) methotrexate_13\NNP\2722166|mtx|, (r_conj) nitrogranulogen_8\NN\0|ng|,|methotrexate (r_pobj) as_7\IN\14622893|such|nitrogranulogen (r_prep) drugs_5\NNS\14778436|anticancer|as (r_pobj) of_3\IN\0|drugs (r_prep) action_2\NN\30358|the|nephrotoxic|of|5-fu|administered|mtx (l_amod) nephrotoxic_1\JJ\0|
D008727_D007674 NONE mtx_33\NNP\0|[|+|5-fu (r_appos) action_2\NN\30358|the|nephrotoxic|of|5-fu|administered|mtx (l_amod) nephrotoxic_1\JJ\0|
D008727_D007674 NONE mtx_6\NNP\0| (r_pobj) of_5\IN\0|mtx (r_prep) nephrotoxicity_4\NN\0|that|of|+
D005472_D007674 NONE 5-fluorouracil_18\CD\0| (r_punct) 5-fu_20\CD\0|5-fluorouracil|(|)|and|cyclophosphamide (r_appos) action_2\NN\30358|the|nephrotoxic|of|5-fu|administered|mtx (l_amod) nephrotoxic_1\JJ\0|
D005472_D007674 NONE 5-fu_20\CD\0|5-fluorouracil|(|)|and|cyclophosphamide (r_appos) action_2\NN\30358|the|nephrotoxic|of|5-fu|administered|mtx (l_amod) nephrotoxic_1\JJ\0|
D005472_D007674 NONE 5-fu_35\CD\0|+|cy (r_conj) mtx_33\NNP\0|[|+|5-fu (r_appos) action_2\NN\30358|the|nephrotoxic|of|5-fu|administered|mtx (l_amod) nephrotoxic_1\JJ\0|
D005472_D007674 NONE 5-fu_8\CD\0|+|cy|administered (r_nsubj) is_13\VBZ\0|5-fu|lower (r_ccomp) indicate_2\VBP\952524|studies|nephrotoxicity|is|. (l_dobj) nephrotoxicity_4\NN\0|that|of|+
D003520_D007674 NONE cyclophosphamide_23\NN\0|cy (r_conj) 5-fu_20\CD\0|5-fluorouracil|(|)|and|cyclophosphamide (r_appos) action_2\NN\30358|the|nephrotoxic|of|5-fu|administered|mtx (l_amod) nephrotoxic_1\JJ\0|
D003520_D007674 NONE cy_25\NNP\0|(|) (r_appos) cyclophosphamide_23\NN\0|cy (r_conj) 5-fu_20\CD\0|5-fluorouracil|(|)|and|cyclophosphamide (r_appos) action_2\NN\30358|the|nephrotoxic|of|5-fu|administered|mtx (l_amod) nephrotoxic_1\JJ\0|
D003520_D007674 NONE cy_37\NNP\0|cmf|] (r_conj) 5-fu_35\CD\0|+|cy (r_conj) mtx_33\NNP\0|[|+|5-fu (r_appos) action_2\NN\30358|the|nephrotoxic|of|5-fu|administered|mtx (l_amod) nephrotoxic_1\JJ\0|
D003520_D007674 NONE cy_10\NNP\0| (r_conj) 5-fu_8\CD\0|+|cy|administered (r_nsubj) is_13\VBZ\0|5-fu|lower (r_ccomp) indicate_2\VBP\952524|studies|nephrotoxicity|is|. (l_dobj) nephrotoxicity_4\NN\0|that|of|+
D003520_D006470 CID cy_0\NNP\0| (r_nsubj) caused_1\VBD\1617192|cy|cystitis|in|,|but|cause (l_dobj) cystitis_3\NN\14566129|hemorrhagic
D003520_D003556 CID cy_0\NNP\0| (r_nsubj) caused_1\VBD\1617192|cy|cystitis|in|,|but|cause (l_dobj) cystitis_3\NN\14566129|hemorrhagic
D005472_D006470 NONE 5-fu_20\CD\0|and|mtx (r_pobj) with_19\IN\0|5-fu (r_prep) combined_18\VBN\2630189|when|with (r_advcl) cause_14\VB\7323922|it|did|not|complication|combined|. (r_conj) caused_1\VBD\1617192|cy|cystitis|in|,|but|cause (l_dobj) cystitis_3\NN\14566129|hemorrhagic
D005472_D003556 NONE 5-fu_20\CD\0|and|mtx (r_pobj) with_19\IN\0|5-fu (r_prep) combined_18\VBN\2630189|when|with (r_advcl) cause_14\VB\7323922|it|did|not|complication|combined|. (r_conj) caused_1\VBD\1617192|cy|cystitis|in|,|but|cause (l_dobj) cystitis_3\NN\14566129|hemorrhagic
D008727_D006470 NONE mtx_22\NNP\0| (r_conj) 5-fu_20\CD\0|and|mtx (r_pobj) with_19\IN\0|5-fu (r_prep) combined_18\VBN\2630189|when|with (r_advcl) cause_14\VB\7323922|it|did|not|complication|combined|. (r_conj) caused_1\VBD\1617192|cy|cystitis|in|,|but|cause (l_dobj) cystitis_3\NN\14566129|hemorrhagic
D008727_D003556 NONE mtx_22\NNP\0| (r_conj) 5-fu_20\CD\0|and|mtx (r_pobj) with_19\IN\0|5-fu (r_prep) combined_18\VBN\2630189|when|with (r_advcl) cause_14\VB\7323922|it|did|not|complication|combined|. (r_conj) caused_1\VBD\1617192|cy|cystitis|in|,|but|cause (l_dobj) cystitis_3\NN\14566129|hemorrhagic
7930386
D002997_D012893 CID clomipramine_0\NNP\4482543| (r_npadvmod) induced_2\VBN\1627355|clomipramine|- (r_amod) disturbance_4\NN\407535|induced|sleep
D002997_D012893 CID clomipramine_15\NN\4482543| (r_compound) administration_16\NN\1133281|clomipramine (r_pobj) by_14\IN\0|administration (r_agent) induced_13\VBN\1627355|by (r_conj) examine_6\VB\0|to|role|,|induced|,|on (l_dobj) role_8\NN\719494|the|of (l_prep) of_9\IN\0|disturbance (l_pobj) disturbance_11\NN\407535|sleep
3564823
D008012_D013035 NONE lidocaine_7\NN\3681148| (r_pobj) by_6\IN\0|lidocaine (r_prep) relieved_5\VBN\205885|spasm|by|. (l_nsubj) spasm_4\NN\14299637|induced|arterial
D013874_D002545 NONE pentothal_12\NNS\2792049|sodium (r_nsubjpass) infused_15\VBN\606335|following|,|pentothal|was|intravenously|minimize|. (l_advcl) minimize_17\VB\441445|to|ischaemia (l_dobj) ischaemia_19\NN\14195315|cerebral
D008012_D020301 NONE lidocaine_11\NN\3681148| (r_nsubjpass) given_13\VBN\5892096|precluded|,|lidocaine|was|,|with|,|counteract|. (l_advcl) counteract_24\VB\2367363|to|vasospasm (l_dobj) vasospasm_26\NN\0|the
7053303
D002927_D003704 CID cimetidine_10\NN\14778019|(|with|hr|)|in (r_pobj) due_8\IN\5174653|possibly|to|cimetidine (r_amod) case_4\NN\7283608|one|of|due (l_prep) of_5\IN\0|dementia (l_pobj) dementia_6\NN\14395018|
D002927_D003704 CID cimetidine_40\JJ\14778019| (r_compound) levels_41\NNS\4916342|cimetidine (r_dobj) had_39\VBD\0|who|levels|above (r_relcl) disease_37\NN\14061805|liver|had (r_pobj) without_33\IN\0|disease (r_prep) patients_32\NNS\9898892|13|without (r_pobj) of_30\IN\0|patients (r_prep) group_29\NN\2137|a|of (r_pobj) in_27\IN\13603305|group (r_prep) cimetidine_10\NN\14778019|(|with|hr|)|in (r_pobj) due_8\IN\5174653|possibly|to|cimetidine (r_amod) case_4\NN\7283608|one|of|due (l_prep) of_5\IN\0|dementia (l_pobj) dementia_6\NN\14395018|
D002927_D003704 CID cimetidine_3\NN\14778019| (r_compound) levels_4\NNS\4916342|high|cimetidine|alone (r_nsubj) induce_9\VB\1627355|thus|,|levels|do|not|always|dementia|. (l_dobj) dementia_10\NN\14395018|
D002927_D008107 NONE cimetidine_10\NN\14778019|(|with|hr|)|in (l_prep) in_27\IN\13603305|group (l_pobj) group_29\NN\2137|a|of (l_prep) of_30\IN\0|patients (l_pobj) patients_32\NNS\9898892|13|without (l_prep) without_33\IN\0|disease (l_pobj) disease_37\NN\14061805|liver|had
D002927_D008107 NONE cimetidine_40\JJ\14778019| (r_compound) levels_41\NNS\4916342|cimetidine (r_dobj) had_39\VBD\0|who|levels|above (r_relcl) disease_37\NN\14061805|liver|had
D002927_D007674 NONE cimetidine_10\NN\14778019|(|with|hr|)|in (l_prep) in_27\IN\13603305|group (l_pobj) group_29\NN\2137|a|of (l_prep) of_30\IN\0|patients (l_pobj) patients_32\NNS\9898892|13|without (l_prep) without_33\IN\0|disease (l_pobj) disease_37\NN\14061805|liver|had
D002927_D007674 NONE cimetidine_40\JJ\14778019| (r_compound) levels_41\NNS\4916342|cimetidine (r_dobj) had_39\VBD\0|who|levels|above (r_relcl) disease_37\NN\14061805|liver|had
19657887
D000431_D005483 CID alcohol_9\NN\7881800| (r_pobj) of_8\IN\0|alcohol (r_prep) ingestion_7\NN\13440063|the|of (r_pobj) after_5\IN\0|ingestion (r_prep) hour_4\NN\15154774|1|after (r_pobj) in_0\IN\13603305|hour (r_prep) developed_12\VBD\1753788|in|,|he|malaise|. (l_dobj) malaise_13\NN\14446652|with (l_prep) with_14\IN\0|flushing (l_pobj) flushing_15\NN\281101|of (l_prep) of_16\IN\0|face (l_pobj) face_18\NN\5225090|the|,|tachycardia
D000431_D013610 CID alcohol_9\NN\7881800| (r_pobj) of_8\IN\0|alcohol (r_prep) ingestion_7\NN\13440063|the|of (r_pobj) after_5\IN\0|ingestion (r_prep) hour_4\NN\15154774|1|after (r_pobj) in_0\IN\13603305|hour (r_prep) developed_12\VBD\1753788|in|,|he|malaise|. (l_dobj) malaise_13\NN\14446652|with (l_prep) with_14\IN\0|flushing (l_pobj) flushing_15\NN\281101|of (l_prep) of_16\IN\0|face (l_pobj) face_18\NN\5225090|the|,|tachycardia (l_conj) tachycardia_20\NN\14110674|,|and|dyspnea
D000431_D004417 CID alcohol_9\NN\7881800| (r_pobj) of_8\IN\0|alcohol (r_prep) ingestion_7\NN\13440063|the|of (r_pobj) after_5\IN\0|ingestion (r_prep) hour_4\NN\15154774|1|after (r_pobj) in_0\IN\13603305|hour (r_prep) developed_12\VBD\1753788|in|,|he|malaise|. (l_dobj) malaise_13\NN\14446652|with (l_prep) with_14\IN\0|flushing (l_pobj) flushing_15\NN\281101|of (l_prep) of_16\IN\0|face (l_pobj) face_18\NN\5225090|the|,|tachycardia (l_conj) tachycardia_20\NN\14110674|,|and|dyspnea (l_conj) dyspnea_23\NN\14299637|
D004221_D005483 NONE disulfiram_7\NN\3740161| (r_npadvmod) like_9\JJ\5839024|disulfiram|- (r_amod) syndrome_10\NN\5870365|like|with (l_prep) with_11\IN\0|flushing (l_pcomp) flushing_12\NN\281101|,|tachycardia|after
D004221_D013610 NONE disulfiram_7\NN\3740161| (r_npadvmod) like_9\JJ\5839024|disulfiram|- (r_amod) syndrome_10\NN\5870365|like|with (l_prep) with_11\IN\0|flushing (l_pcomp) flushing_12\NN\281101|,|tachycardia|after (l_conj) tachycardia_14\NN\14110674|,|and|hypotension
D004221_D007022 NONE disulfiram_7\NN\3740161| (r_npadvmod) like_9\JJ\5839024|disulfiram|- (r_amod) syndrome_10\NN\5870365|like|with (l_prep) with_11\IN\0|flushing (l_pcomp) flushing_12\NN\281101|,|tachycardia|after (l_conj) tachycardia_14\NN\14110674|,|and|hypotension (l_conj) hypotension_18\NN\14057371|arterial
11250767
D011441_D014657 NONE propylthiouracil_0\NNP\14727670| (r_npadvmod) induced_2\VBN\1627355|propylthiouracil|- (r_amod) vasculitis_11\NN\14336539|induced|staining|antineutrophil|cytoplasmic|positive|in|.
D011441_D014657 NONE propylthiouracil_5\NN\14727670| (r_npadvmod) induced_7\VBN\1627355|propylthiouracil|- (r_amod) vasculitis_8\NN\14336539|induced|manifesting
D011441_D014657 NONE uracil_20\NN\14964590| (r_compound) therapy_21\NN\657604|propylthio-|uracil (r_pobj) with_18\IN\0|therapy (r_prep) associated_17\VBN\628491|with (r_acl) vasculitis_16\NN\14336539|mpo|positive|associated
D011441_D014657 NONE uracil_14\NN\14964590| (r_compound) therapy_15\NN\657604|uracil (r_appos) propylthio-_13\VB\0|therapy (r_pobj) to_12\IN\0|propylthio- (r_prep) attributable_11\JJ\0|to (r_amod) manifestation_5\NN\7321772|the|initial|of|attributable (l_prep) of_6\IN\0|vasculitis (l_pobj) vasculitis_10\NN\14336539|induced
D011441_D010493 CID propylthiouracil_0\NNP\14727670| (r_npadvmod) induced_2\VBN\1627355|propylthiouracil|- (r_amod) vasculitis_11\NN\14336539|induced|staining|antineutrophil|cytoplasmic|positive|in|. (l_prep) in_12\IN\13603305|conjunction (l_pobj) conjunction_13\NN\5048123|with (l_prep) with_14\IN\0|pericarditis (l_pobj) pericarditis_15\NN\14338942|
D011441_D010493 CID propylthiouracil_5\NN\14727670| (r_npadvmod) induced_7\VBN\1627355|propylthiouracil|- (r_amod) vasculitis_8\NN\14336539|induced|manifesting (l_acl) manifesting_9\VBG\1015244|with (l_prep) with_10\IN\0|pericarditis (l_pobj) pericarditis_11\NN\14338942|
D011441_D010493 CID propylthiouracil_13\NN\14727670|developed (l_relcl) developed_25\VBD\1753788|in|syndrome (l_nsubj) syndrome_17\NN\5870365|a|of (l_prep) of_18\IN\0|pericarditis (l_pobj) pericarditis_19\NN\14338942|,|fever
D011441_D010493 CID uracil_20\NN\14964590| (r_compound) therapy_21\NN\657604|propylthio-|uracil (r_pobj) with_18\IN\0|therapy (r_prep) associated_17\VBN\628491|with (r_acl) vasculitis_16\NN\14336539|mpo|positive|associated (r_pobj) in_9\IN\13603305|vasculitis (r_prep) reports_6\NNS\6470073|no|prior|of|in (l_prep) of_7\IN\0|pericarditis (l_pobj) pericarditis_8\NN\14338942|
D011441_D010493 CID uracil_14\NN\14964590| (r_compound) therapy_15\NN\657604|uracil (r_appos) propylthio-_13\VB\0|therapy (r_pobj) to_12\IN\0|propylthio- (r_prep) attributable_11\JJ\0|to (r_amod) manifestation_5\NN\7321772|the|initial|of|attributable (r_attr) be_2\VB\14625458|pericarditis|may|manifestation|. (l_nsubj) pericarditis_0\NNP\14338942|
D011441_D006980 NONE propylthiouracil_13\NN\14727670|developed (r_pobj) with_12\IN\0|propylthiouracil (r_prep) treated_11\VBN\2376958|with (r_acl) report_5\NN\6470073|the|first|case|of|treated (l_prep) of_6\IN\0|woman (l_pobj) woman_8\NN\9605289|a|with (l_prep) with_9\IN\0|hyperthyroidism (l_pobj) hyperthyroidism_10\NN\14059928|
D011441_D005334 CID propylthiouracil_13\NN\14727670|developed (l_relcl) developed_25\VBD\1753788|in|syndrome (l_nsubj) syndrome_17\NN\5870365|a|of (l_prep) of_18\IN\0|pericarditis (l_pobj) pericarditis_19\NN\14338942|,|fever (l_conj) fever_21\NN\14299637|,|and|glomerulonephritis
D011441_D005921 CID propylthiouracil_13\NN\14727670|developed (l_relcl) developed_25\VBD\1753788|in|syndrome (l_nsubj) syndrome_17\NN\5870365|a|of (l_prep) of_18\IN\0|pericarditis (l_pobj) pericarditis_19\NN\14338942|,|fever (l_conj) fever_21\NN\14299637|,|and|glomerulonephritis (l_conj) glomerulonephritis_24\NN\14113798|
17242861
D010862_D012640 NONE pilocarpine_4\NN\14712692| (r_npadvmod) induced_6\VBN\1627355|pilocarpine|- (r_amod) seizures_7\NNS\14081375|induced|,|model|,
D010862_D012640 NONE pilocarpine_4\NN\14712692| (r_npadvmod) induced_6\VBN\1627355|pilocarpine|- (r_amod) seizures_7\NNS\14081375|induced|,|model|, (r_pobj) to_3\IN\0|seizures (r_prep) susceptibility_2\NN\13920835|to (r_pobj) for_1\IN\0|susceptibility (r_prep) qtls_0\NNS\0|for (r_nsubjpass) reported_19\VBN\831651|qtls|have|not|been|,|and|used (l_conj) used_27\VBN\0|css|have|not|previously|been|localize|. (l_xcomp) localize_29\VB\2694933|to|genes (l_dobj) genes_32\NNS\8459252|susceptibility (l_compound) susceptibility_31\NN\13920835|seizure (l_compound) seizure_30\NN\14081375|
D010862_D012640 NONE pilocarpine_9\NN\14712692| (r_npadvmod) induced_11\VBN\1627355|pilocarpine|- (r_amod) seizures_12\NNS\14081375|induced
D010862_D012640 NONE pilocarpine_23\NN\14712692| (r_npadvmod) induced_25\VBN\1627355|pilocarpine|- (r_amod) seizures_26\NNS\14081375|induced
D010862_D004833 CID pilocarpine_4\NN\14712692| (r_npadvmod) induced_6\VBN\1627355|pilocarpine|- (r_amod) seizures_7\NNS\14081375|induced|,|model|, (l_appos) model_10\NN\5888929|a|of (l_prep) of_11\IN\0|epilepsy (l_pobj) epilepsy_14\NN\14085708|temporal|lobe
19803309
D013390_D009224 NONE suxamethonium_29\NN\0|intravenous (r_pobj) of_27\IN\0|suxamethonium (r_prep) dose_26\NN\3740161|a|standard|of|for (r_pobj) following_23\VBG\8180190|dose (r_prep) threatening_20\VBG\2603699|life|spasm|following (r_ccomp) developed_18\VBD\1753788|who|threatening (r_relcl) primigravida_15\NN\10144838|a|old|healthy|,|developed (r_pobj) in_8\IN\13603305|primigravida (r_prep) case_4\NN\7283608|an|undiagnosed|of|in (l_prep) of_5\IN\0|congenita (l_pobj) congenita_7\NN\0|myotonia
D013390_D014313 CID suxamethonium_29\NN\0|intravenous (r_pobj) of_27\IN\0|suxamethonium (r_prep) dose_26\NN\3740161|a|standard|of|for (r_pobj) following_23\VBG\8180190|dose (r_prep) threatening_20\VBG\2603699|life|spasm|following (l_dobj) spasm_22\NN\14299637|masseter
19356307
D012601_D003704 NONE scopolamine_9\NN\14712692| (r_pobj) by_8\IN\0|scopolamine (r_agent) induced_7\VBN\1627355|components|by|. (l_nsubj) components_0\NNS\5867413|of (l_prep) of_1\IN\0|dementia (l_pobj) dementia_6\NN\14395018|attenuate
C008281_D003704 NONE limonene_8\NN\15068635|s|-|and|perillyl (r_nmod) alcohol_13\NN\7881800|limonene (r_pobj) of_5\IN\0|alcohol (r_prep) effects_4\NNS\13245626|the|dementia|of (l_compound) dementia_3\NN\14395018|anti|-
C032208_D003704 NONE alcohol_13\NN\7881800|limonene (r_pobj) of_5\IN\0|alcohol (r_prep) effects_4\NNS\13245626|the|dementia|of (l_compound) dementia_3\NN\14395018|anti|-
D012601_D008569 CID scopolamine_12\NN\14712692| (r_pobj) by_11\IN\0|scopolamine (r_agent) impaired_10\VBN\258857|by
D012601_D008569 CID scopolamine_12\NN\14712692| (r_pobj) by_11\IN\0|scopolamine (r_agent) impaired_10\VBN\258857|by (r_amod) memory_9\NN\5926676|impaired (r_dobj) improve_8\VB\126264|to|memory (r_acl) ability_6\NN\4723816|strong|improve (r_dobj) showed_4\VBD\2137132|oils|ability (r_ccomp) relieved_20\VBD\205885|showed|;|however|,|alcohol|deficit|only|,|and|improve|. (l_dobj) deficit_22\NN\5113133|the|of|in (l_prep) of_23\IN\0|memory (l_pobj) memory_25\NN\5926676|associative
C032208_D008569 NONE alcohol_19\NN\7881800|perillyl (r_nsubj) relieved_20\VBD\205885|showed|;|however|,|alcohol|deficit|only|,|and|improve|. (l_ccomp) showed_4\VBD\2137132|oils|ability (l_dobj) ability_6\NN\4723816|strong|improve (l_acl) improve_8\VB\126264|to|memory (l_dobj) memory_9\NN\5926676|impaired (l_amod) impaired_10\VBN\258857|by
C032208_D008569 NONE alcohol_19\NN\7881800|perillyl (r_nsubj) relieved_20\VBD\205885|showed|;|however|,|alcohol|deficit|only|,|and|improve|. (l_dobj) deficit_22\NN\5113133|the|of|in (l_prep) of_23\IN\0|memory (l_pobj) memory_25\NN\5926676|associative
10706004
D012964_D006973 NONE sodium_2\NN\14625458|and|atp (r_nmod) affinities_5\NNS\11426530|sodium|of (r_pobj) of_1\IN\0|affinities (r_prep) changes_0\NNS\7283608|of|during|. (l_prep) during_13\IN\0|and|after (l_conj) after_15\IN\0|hypertension (l_pobj) hypertension_19\NN\14057371|nitric|deficient
D012964_D006973 NONE na_10\UH\14625458| (r_nmod) k)-atpase_12\NNP\0|the|cardiac|(|na|, (r_pobj) of_6\IN\0|k)-atpase (r_prep) affinities_5\NNS\11426530|sodium|of (r_pobj) of_1\IN\0|affinities (r_prep) changes_0\NNS\7283608|of|during|. (l_prep) during_13\IN\0|and|after (l_conj) after_15\IN\0|hypertension (l_pobj) hypertension_19\NN\14057371|nitric|deficient
D012964_D006973 NONE sodium_9\NN\14625458| (r_compound) level_10\NN\4916342|intracellular|sodium (r_pobj) of_7\IN\0|level (r_prep) elevation_6\NN\7445480|of (r_nsubjpass) documented_12\VBN\1000214|in|,|elevation|was|in|. (l_prep) in_0\IN\13603305|models (l_pobj) models_2\NNS\5888929|several|of (l_prep) of_3\IN\0|hypertension (l_pobj) hypertension_4\NN\14057371|
D012964_D006973 NONE na+_11\NNP\0| (r_pobj) of_10\IN\0|na+ (r_prep) transport_9\NN\3575240|transmembraneous|of (r_pobj) in_7\IN\13603305|transport (r_prep) disturbances_6\NNS\407535|in (r_pobj) of_5\IN\0|disturbances (r_prep) basis_4\NN\13790712|the|molecular|of (r_dobj) assess_1\VB\5220461|to|basis (r_advcl) studied_14\VBD\0|assess|,|we|response|induced|. (l_dobj) response_16\NN\11410625|the|of (l_prep) of_17\IN\0|k)-atpase (l_pobj) k)-atpase_22\NNP\0|cardiac|(|na|,|to (l_prep) to_23\IN\0|hypertension (l_pobj) hypertension_27\NN\14057371|deficient
D012964_D006973 NONE na_20\UH\14625458| (r_nmod) k)-atpase_22\NNP\0|cardiac|(|na|,|to (l_prep) to_23\IN\0|hypertension (l_pobj) hypertension_27\NN\14057371|deficient
D012964_D006973 NONE na_9\NNP\14625458| (r_npadvmod) increased_12\VBD\169651|(|na|,|k)-atpase|,|due|, (r_parataxis) activity_6\NN\30358|after|,|the|of|increased|revealed|. (l_prep) after_0\IN\0|recovery (l_pobj) recovery_1\NN\7357388|from (l_prep) from_2\IN\0|hypertension (l_pobj) hypertension_3\NN\14057371|
D012964_D006973 NONE na+-extrusion_12\NN\0|depressed (r_pobj) by_10\IN\0|na+-extrusion (r_agent) accompanied_9\VBN\0|by|from|as (r_acl) hypertension_8\NN\14057371|a|reversible|accompanied
D012964_D006973 NONE na+-binding_21\NN\0| (r_compound) properties_22\NNS\32613|deteriorated|na+-binding|of (r_pobj) of_19\IN\0|properties (r_prep) consequence_18\NN\34213|a|of (r_pobj) as_16\IN\14622893|consequence (r_prep) accompanied_9\VBN\0|by|from|as (r_acl) hypertension_8\NN\14057371|a|reversible|accompanied
D012964_D006973 NONE na_26\UH\14625458| (r_nmod) k)-atpase_28\NNP\0|the|(|na|, (r_pobj) of_23\IN\0|k)-atpase (r_prep) properties_22\NNS\32613|deteriorated|na+-binding|of (r_pobj) of_19\IN\0|properties (r_prep) consequence_18\NN\34213|a|of (r_pobj) as_16\IN\14622893|consequence (r_prep) accompanied_9\VBN\0|by|from|as (r_acl) hypertension_8\NN\14057371|a|reversible|accompanied
D000255_D006973 NONE atp_4\NNP\14964590| (r_conj) sodium_2\NN\14625458|and|atp (r_nmod) affinities_5\NNS\11426530|sodium|of (r_pobj) of_1\IN\0|affinities (r_prep) changes_0\NNS\7283608|of|during|. (l_prep) during_13\IN\0|and|after (l_conj) after_15\IN\0|hypertension (l_pobj) hypertension_19\NN\14057371|nitric|deficient
D000255_D006973 NONE atp_20\NNP\14964590| (r_npadvmod) binding_22\VBG\4688246|atp|- (r_amod) site_23\NN\8673395|the|binding (r_pobj) of_18\IN\0|site (r_prep) affinity_17\NN\11426530|higher|of (r_pobj) due_14\IN\5174653|to|affinity (r_prep) increased_12\VBD\169651|(|na|,|k)-atpase|,|due|, (r_parataxis) activity_6\NN\30358|after|,|the|of|increased|revealed|. (l_prep) after_0\IN\0|recovery (l_pobj) recovery_1\NN\7357388|from (l_prep) from_2\IN\0|hypertension (l_pobj) hypertension_3\NN\14057371|
D000255_D006973 NONE atp_33\NNP\14964590| (r_pobj) for_32\IN\0|atp (r_prep) value_31\NN\5856066|the|lowered|km|for (r_pobj) from_27\IN\0|value (r_prep) revealed_26\VBN\2137132|as|from (r_advcl) activity_6\NN\30358|after|,|the|of|increased|revealed|. (l_prep) after_0\IN\0|recovery (l_pobj) recovery_1\NN\7357388|from (l_prep) from_2\IN\0|hypertension (l_pobj) hypertension_3\NN\14057371|
D011188_D006973 NONE k)-atpase_12\NNP\0|the|cardiac|(|na|, (r_pobj) of_6\IN\0|k)-atpase (r_prep) affinities_5\NNS\11426530|sodium|of (r_pobj) of_1\IN\0|affinities (r_prep) changes_0\NNS\7283608|of|during|. (l_prep) during_13\IN\0|and|after (l_conj) after_15\IN\0|hypertension (l_pobj) hypertension_19\NN\14057371|nitric|deficient
D011188_D006973 NONE k)-atpase_22\NNP\0|cardiac|(|na|,|to (l_prep) to_23\IN\0|hypertension (l_pobj) hypertension_27\NN\14057371|deficient
D011188_D006973 NONE k)-atpase_11\NNP\0| (r_nsubj) increased_12\VBD\169651|(|na|,|k)-atpase|,|due|, (r_parataxis) activity_6\NN\30358|after|,|the|of|increased|revealed|. (l_prep) after_0\IN\0|recovery (l_pobj) recovery_1\NN\7357388|from (l_prep) from_2\IN\0|hypertension (l_pobj) hypertension_3\NN\14057371|
D011188_D006973 NONE k)-atpase_28\NNP\0|the|(|na|, (r_pobj) of_23\IN\0|k)-atpase (r_prep) properties_22\NNS\32613|deteriorated|na+-binding|of (r_pobj) of_19\IN\0|properties (r_prep) consequence_18\NN\34213|a|of (r_pobj) as_16\IN\14622893|consequence (r_prep) accompanied_9\VBN\0|by|from|as (r_acl) hypertension_8\NN\14057371|a|reversible|accompanied
D009569_D006973 CID oxide_17\NN\14818238| (r_npadvmod) deficient_18\JJ\0|oxide (r_amod) hypertension_19\NN\14057371|nitric|deficient
D009569_D006973 CID no_2\DT\7204911| (r_det) synthesis_3\NN\13446390|no (r_pobj) of_1\IN\0|synthesis (r_prep) inhibition_0\NN\1068773|of (r_nsubj) induces_4\VBZ\1627355|inhibition|hypertension|. (l_dobj) hypertension_6\NN\14057371|sustained
D009569_D006973 CID no_24\JJ\7204911| (r_npadvmod) deficient_26\JJ\0|no|- (r_amod) hypertension_27\NN\14057371|deficient
D009569_D006973 CID no_32\JJ\7204911| (r_compound) synthase_34\NN\0|no|- (r_compound) inhibition_35\NN\1068773|synthase|with (r_pobj) by_31\IN\0|inhibition (r_prep) rats_30\NNS\2329401|by (r_pobj) in_29\IN\13603305|rats (r_prep) induced_28\VBN\1627355|in|for (r_advcl) studied_14\VBD\0|assess|,|we|response|induced|. (l_dobj) response_16\NN\11410625|the|of (l_prep) of_17\IN\0|k)-atpase (l_pobj) k)-atpase_22\NNP\0|cardiac|(|na|,|to (l_prep) to_23\IN\0|hypertension (l_pobj) hypertension_27\NN\14057371|deficient
D009569_D006973 CID no_2\JJ\7204911| (r_compound) synthase_4\NN\0|no|- (r_pobj) of_1\IN\0|synthase (r_prep) inhibition_0\NN\1068773|of (r_nsubj) induced_5\VBD\1627355|inhibition|hypertension|. (l_dobj) hypertension_8\NN\14057371|a|reversible|accompanied
D019331_D006973 NONE ester_49\NN\14727670|arginine|methyl|name|) (r_appos) kg_40\NNS\13717155|40|mg|/|/|day|ester (r_pobj) with_36\IN\0|kg (r_prep) inhibition_35\NN\1068773|synthase|with (r_pobj) by_31\IN\0|inhibition (r_prep) rats_30\NNS\2329401|by (r_pobj) in_29\IN\13603305|rats (r_prep) induced_28\VBN\1627355|in|for (r_advcl) studied_14\VBD\0|assess|,|we|response|induced|. (l_dobj) response_16\NN\11410625|the|of (l_prep) of_17\IN\0|k)-atpase (l_pobj) k)-atpase_22\NNP\0|cardiac|(|na|,|to (l_prep) to_23\IN\0|hypertension (l_pobj) hypertension_27\NN\14057371|deficient
D019331_D006973 NONE name_53\NNP\6284225|(|l|- (r_appos) ester_49\NN\14727670|arginine|methyl|name|) (r_appos) kg_40\NNS\13717155|40|mg|/|/|day|ester (r_pobj) with_36\IN\0|kg (r_prep) inhibition_35\NN\1068773|synthase|with (r_pobj) by_31\IN\0|inhibition (r_prep) rats_30\NNS\2329401|by (r_pobj) in_29\IN\13603305|rats (r_prep) induced_28\VBN\1627355|in|for (r_advcl) studied_14\VBD\0|assess|,|we|response|induced|. (l_dobj) response_16\NN\11410625|the|of (l_prep) of_17\IN\0|k)-atpase (l_pobj) k)-atpase_22\NNP\0|cardiac|(|na|,|to (l_prep) to_23\IN\0|hypertension (l_pobj) hypertension_27\NN\14057371|deficient
D009569_D003866 NONE no_2\JJ\7204911| (r_compound) synthase_4\NN\0|no|- (r_pobj) of_1\IN\0|synthase (r_prep) inhibition_0\NN\1068773|of (r_nsubj) induced_5\VBD\1627355|inhibition|hypertension|. (l_dobj) hypertension_8\NN\14057371|a|reversible|accompanied (l_acl) accompanied_9\VBN\0|by|from|as (l_agent) by_10\IN\0|na+-extrusion (l_pobj) na+-extrusion_12\NN\0|depressed (l_amod) depressed_11\JJ\1819147|
D012964_D003866 NONE na+-extrusion_12\NN\0|depressed (l_amod) depressed_11\JJ\1819147|
D012964_D003866 NONE na+-binding_21\NN\0| (r_compound) properties_22\NNS\32613|deteriorated|na+-binding|of (r_pobj) of_19\IN\0|properties (r_prep) consequence_18\NN\34213|a|of (r_pobj) as_16\IN\14622893|consequence (r_prep) accompanied_9\VBN\0|by|from|as (l_agent) by_10\IN\0|na+-extrusion (l_pobj) na+-extrusion_12\NN\0|depressed (l_amod) depressed_11\JJ\1819147|
D012964_D003866 NONE na_26\UH\14625458| (r_nmod) k)-atpase_28\NNP\0|the|(|na|, (r_pobj) of_23\IN\0|k)-atpase (r_prep) properties_22\NNS\32613|deteriorated|na+-binding|of (r_pobj) of_19\IN\0|properties (r_prep) consequence_18\NN\34213|a|of (r_pobj) as_16\IN\14622893|consequence (r_prep) accompanied_9\VBN\0|by|from|as (l_agent) by_10\IN\0|na+-extrusion (l_pobj) na+-extrusion_12\NN\0|depressed (l_amod) depressed_11\JJ\1819147|
D011188_D003866 NONE k)-atpase_28\NNP\0|the|(|na|, (r_pobj) of_23\IN\0|k)-atpase (r_prep) properties_22\NNS\32613|deteriorated|na+-binding|of (r_pobj) of_19\IN\0|properties (r_prep) consequence_18\NN\34213|a|of (r_pobj) as_16\IN\14622893|consequence (r_prep) accompanied_9\VBN\0|by|from|as (l_agent) by_10\IN\0|na+-extrusion (l_pobj) na+-extrusion_12\NN\0|depressed (l_amod) depressed_11\JJ\1819147|
3437726
D013034_D064420 NONE sparteine_11\NN\0| (r_nmod) debrisoquine_13\JJ\0|sparteine|/ (r_compound) polymorphism_14\NN\11418750|debrisoquine|in|,|constitutes|, (r_pobj) of_10\IN\0|polymorphism (r_prep) phenotype_9\NN\4933544|the|metabolizer|of (r_pobj) to_4\IN\0|phenotype (r_prep) belonging_3\VBG\7526757|to (r_acl) patients_2\NNS\9898892|belonging (r_nsubj) experience_29\VB\5984287|therefore|,|patients|may|reactions|treated|. (l_dobj) reactions_32\NNS\13446390|adverse|drug
D003647_D064420 NONE debrisoquine_13\JJ\0|sparteine|/ (r_compound) polymorphism_14\NN\11418750|debrisoquine|in|,|constitutes|, (r_pobj) of_10\IN\0|polymorphism (r_prep) phenotype_9\NN\4933544|the|metabolizer|of (r_pobj) to_4\IN\0|phenotype (r_prep) belonging_3\VBG\7526757|to (r_acl) patients_2\NNS\9898892|belonging (r_nsubj) experience_29\VB\5984287|therefore|,|patients|may|reactions|treated|. (l_dobj) reactions_32\NNS\13446390|adverse|drug
9293063
D003613_D001650 CID danazol_12\NN\0| (r_pobj) with_11\IN\0|danazol (r_prep) treatment_10\NN\654885|term|with (r_pobj) with_6\IN\0|treatment (r_prep) association_5\NN\8008335|with (r_pobj) in_4\IN\13603305|association (r_prep) occurring_3\VBG\0|in (r_acl) hamartoma_2\NN\14234074|duct|occurring|.
D003613_D001650 CID danazol_20\NN\0| (r_compound) treatment_21\NN\654885|term|danazol (r_pobj) on_16\IN\0|treatment (r_prep) been_15\VBN\0|who|had|on (r_relcl) patient_12\NN\9898892|a|been (r_pobj) in_10\IN\13603305|patient (r_prep) developed_9\VBD\1753788|which|in (r_relcl) hamartoma_7\NN\14234074|duct|developed
D003613_D006222 CID danazol_12\NN\0| (r_pobj) with_11\IN\0|danazol (r_prep) treatment_10\NN\654885|term|with (r_pobj) with_6\IN\0|treatment (r_prep) association_5\NN\8008335|with (r_pobj) in_4\IN\13603305|association (r_prep) occurring_3\VBG\0|in (r_acl) hamartoma_2\NN\14234074|duct|occurring|.
D003613_D006222 CID danazol_20\NN\0| (r_compound) treatment_21\NN\654885|term|danazol (r_pobj) on_16\IN\0|treatment (r_prep) been_15\VBN\0|who|had|on (r_relcl) patient_12\NN\9898892|a|been (r_pobj) in_10\IN\13603305|patient (r_prep) developed_9\VBD\1753788|which|in (r_relcl) hamartoma_7\NN\14234074|duct|developed
3371379
D014700_D020258 CID verapamil_0\NNP\2938514| (r_npadvmod) induced_2\VBN\1627355|verapamil|-|neurotoxicity|. (l_dobj) neurotoxicity_4\NN\0|carbamazepine
D014700_D020258 CID verapamil_11\NN\2938514| (r_pobj) with_10\IN\0|verapamil (r_prep) treatment_9\NN\654885|combined|with (r_pobj) after_7\IN\0|treatment (r_prep) signs_3\NNS\6643763|of|after (l_prep) of_4\IN\0|neurotoxicity (l_pobj) neurotoxicity_6\NN\0|carbamazepine
D002220_D020258 CID carbamazepine_3\NN\0| (r_compound) neurotoxicity_4\NN\0|carbamazepine
D002220_D020258 CID carbamazepine_5\JJ\0| (r_compound) neurotoxicity_6\NN\0|carbamazepine
D002118_D020258 NONE calcium_19\NN\14625458| (r_compound) entry_20\NN\6502378|calcium (r_compound) blocker_21\NN\10101634|the|entry (r_pobj) of_17\IN\0|blocker (r_prep) discontinuation_16\NN\209943|of (r_pobj) after_15\IN\0|discontinuation (r_prep) recovery_14\NN\7357388|complete|after (r_dobj) showed_12\VBD\2137132|patients|recovery|. (l_nsubj) patients_1\NNS\9898892|two|with (l_prep) with_2\IN\0|signs (l_pobj) signs_3\NNS\6643763|of|after (l_prep) of_4\IN\0|neurotoxicity (l_pobj) neurotoxicity_6\NN\0|carbamazepine
7083920
D000638_D006327 CID amiodarone_13\NN\2715941| (r_compound) treatment_14\NN\654885|amiodarone|for (r_pobj) under_12\IN\0|treatment (r_prep) occurring_11\VBG\0|under|in|without (r_acl) block_10\NN\21939|a|reversible|hisian|occurring
D000638_D013617 NONE amiodarone_13\NN\2715941| (r_compound) treatment_14\NN\654885|amiodarone|for (l_prep) for_15\IN\0|tachycardia (l_pobj) tachycardia_17\NNS\14110674|atrial
D000638_D006345 NONE amiodarone_13\NN\2715941| (r_compound) treatment_14\NN\654885|amiodarone|for (r_pobj) under_12\IN\0|treatment (r_prep) occurring_11\VBG\0|under|in|without (l_prep) without_21\IN\0|abnormalities (l_pobj) abnormalities_25\NNS\14034177|clear|intraventricular|conduction
D000638_D001282 NONE amiodarone_3\NN\2715941| (r_compound) discontinuation_4\NN\209943|amiodarone (r_pobj) after_2\IN\0|days|discontinuation (r_prep) showed_9\VBD\2137132|after|,|electrograms|flutter|. (l_dobj) flutter_11\NN\331950|atrial|without
230316
D006912_D020258 NONE hydroxyquinolines_3\NNS\0|halogenated (r_pobj) of_1\IN\0|hydroxyquinolines (r_prep) neurotoxicity_0\NN\0|of|:|analysis
D006912_D020258 NONE hydroxyquinolines_13\NNS\0|halogenated|reported (r_pobj) to_11\IN\0|hydroxyquinolines (r_prep) reactions_10\NNS\13446390|possible|neurotoxic|to (l_amod) neurotoxic_9\JJ\0|
D007464_D009422 NONE clioquinol_25\NN\2720201| (r_pobj) of_24\IN\0|clioquinol (r_prep) dose_23\NN\3740161|a|high|of|over (r_pobj) of_20\IN\0|dose (r_prep) ingestion_19\NN\13440063|the|of (r_pobj) to_17\IN\0|ingestion (r_prep) related_16\VBN\628491|usually|to (r_acl) encephalopathy_14\NN\14084880|an|acute|reversible|related (r_pobj) of_10\IN\0|encephalopathy (r_prep) consisted_9\VBD\2603699|disturbance|of (l_nsubj) disturbance_8\NN\407535|the|neurological
D007464_D001927 CID clioquinol_25\NN\2720201| (r_pobj) of_24\IN\0|clioquinol (r_prep) dose_23\NN\3740161|a|high|of|over (r_pobj) of_20\IN\0|dose (r_prep) ingestion_19\NN\13440063|the|of (r_pobj) to_17\IN\0|ingestion (r_prep) related_16\VBN\628491|usually|to (r_acl) encephalopathy_14\NN\14084880|an|acute|reversible|related
D007464_C538178 NONE clioquinol_13\NN\2720201|as (l_prep) as_14\IN\14622893|treatment (l_pobj) treatment_15\NN\654885|for (l_prep) for_16\IN\0|enteropathica (l_pobj) enteropathica_18\NN\0|acrodermatitis
11875660
D001374_D009436 NONE 5-azacytidine_6\NN\0| (r_pobj) by_5\IN\0|5-azacytidine (r_agent) induced_4\VBN\1627355|by|at (r_acl) exencephaly_3\NNS\0|the|induced
603022
D005702_D062787 NONE hydrobromide_1\RB\0|galanthamine|,|drug|, (r_nsubjpass) used_16\VBN\0|hydrobromide|was|in|. (l_prep) in_17\IN\13603305|patient (l_pobj) patient_19\JJ\9898892|a|demonstrating (l_acl) demonstrating_20\NN\2137132|effects (l_dobj) effects_22\NNS\13245626|central|of (l_prep) of_23\IN\0|overdosage (l_pobj) overdosage_28\NN\0|scopolamine|(|hyoscine|)
D012601_D062787 CID scopolamine_24\NN\14712692| (r_nmod) overdosage_28\NN\0|scopolamine|(|hyoscine|)
D012601_D062787 CID hyoscine_26\NN\14712692| (r_nmod) overdosage_28\NN\0|scopolamine|(|hyoscine|)
20880751
D007980_D004409 CID levodopa_0\NNP\14604959| (r_npadvmod) induced_2\VBN\1627355|levodopa|-|dyskinesias|:|filling|. (l_dobj) dyskinesias_3\NNS\14084880|in
D007980_D004409 CID levodopa_17\NN\14604959| (r_npadvmod) induced_19\VBN\1627355|levodopa|- (r_amod) dyskinesias_20\NNS\14084880|underlying|induced
D007980_D004409 CID levodopa_41\NN\14604959| (r_npadvmod) induced_43\VBN\1627355|levodopa|- (r_amod) dyskinesias_44\NNS\14084880|induced
D007980_D010300 NONE levodopa_0\NNP\14604959| (r_npadvmod) induced_2\VBN\1627355|levodopa|-|dyskinesias|:|filling|. (l_dobj) dyskinesias_3\NNS\14084880|in (l_prep) in_4\IN\13603305|patients (l_pobj) patients_5\NNS\9898892|with (l_prep) with_6\IN\0|disease (l_pobj) disease_9\NN\14061805|parkinson
D007980_D010300 NONE levodopa_0\NNP\14604959| (r_nsubj) is_1\VBZ\0|levodopa|drug|. (l_attr) drug_5\NN\14778436|the|effective|for (l_prep) for_6\IN\0|treatment (l_pobj) treatment_8\NN\654885|the|of (l_prep) of_9\IN\0|disease (l_pobj) disease_12\NN\14061805|parkinson
D004298_D004409 NONE dopamine_9\NN\14807737| (r_compound) precursor_10\NN\14580897|this|dopamine (r_pobj) of_7\IN\0|precursor (r_prep) use_6\NN\407535|the|term|of (r_nsubjpass) complicated_12\VBN\126264|however|,|use|is|by|. (l_agent) by_13\IN\0|fluctuations (l_pobj) fluctuations_16\NNS\7345593|disabling|and|dyskinesias (l_conj) dyskinesias_18\NNS\14084880|
D004298_D004409 NONE dopamine_21\NN\14807737| (r_compound) subtypes_23\NNS\0|dopamine|receptor|,|receptors (l_conj) receptors_29\NNS\5225602|ionotropic|glutamate|,|and|systems (l_conj) systems_36\NNS\3575240|dopaminergic|neurotransmitter|in (l_prep) in_37\IN\13603305|pathophysiology (l_pobj) pathophysiology_39\NN\0|the|of (l_prep) of_40\IN\0|dyskinesias (l_pobj) dyskinesias_44\NNS\14084880|induced
D018698_D004409 NONE glutamate_28\NN\15010703| (r_compound) receptors_29\NNS\5225602|ionotropic|glutamate|,|and|systems (l_conj) systems_36\NNS\3575240|dopaminergic|neurotransmitter|in (l_prep) in_37\IN\13603305|pathophysiology (l_pobj) pathophysiology_39\NN\0|the|of (l_prep) of_40\IN\0|dyskinesias (l_pobj) dyskinesias_44\NNS\14084880|induced
6861444
D009638_D006973 CID noradrenaline_3\NN\14807929| (r_pobj) of_2\IN\0|noradrenaline (r_prep) infusion_1\NN\14589223|intrarenal|of (r_nsubj) caused_4\VBD\1617192|infusion|hypertension|at|. (l_dobj) hypertension_5\NN\14057371|
D009638_D006973 CID noradrenaline_8\NN\14807929| (r_amod) infusion_9\NN\14589223|chronic|intrarenal|noradrenaline (r_pobj) after_5\IN\0|infusion (r_prep) hypertension_4\NN\14057371|after
D009638_D006973 CID noradrenaline_18\NN\14807929| (r_dobj) circulating_17\VBG\1835496|noradrenaline (r_pcomp) of_16\IN\0|circulating (r_prep) levels_15\NNS\4916342|higher|of (r_pobj) by_12\IN\0|levels|and|by (r_agent) produced_11\VBN\1617192|that|hypertension|is|by (l_nsubjpass) hypertension_4\NN\14057371|after
3192036
18186898
D019259_D006509 NONE lamivudine_0\NNP\3834836| (r_nsubjpass) added_2\VBN\156601|lamivudine|was|because|. (l_prep) because_3\IN\0|of|infection (l_pobj) infection_9\NN\14052046|de|b|during
D016559_D000138 NONE tacrolimus_1\NN\0| (r_nsubjpass) suspected_3\VBN\916909|although|tacrolimus|was|be|and|replaced (l_xcomp) be_5\VB\14625458|to|cause (l_attr) cause_7\NN\7323922|the|of (l_prep) of_8\IN\0|acidosis (l_pobj) acidosis_14\NN\14204950|transplant|renal
D016559_D000138 NONE tacrolimus_1\NN\0| (r_nsubjpass) suspected_3\VBN\916909|although|tacrolimus|was|be|and|replaced (l_conj) replaced_17\VBN\1631072|was|by (l_agent) by_18\IN\0|sirolimus (l_pobj) sirolimus_19\NN\0|,|acidosis (l_conj) acidosis_21\NN\14204950|,|and|got
D020123_D000138 NONE sirolimus_19\NN\0|,|acidosis (r_pobj) by_18\IN\0|sirolimus (r_agent) replaced_17\VBN\1631072|was|by (r_conj) suspected_3\VBN\916909|although|tacrolimus|was|be|and|replaced (l_xcomp) be_5\VB\14625458|to|cause (l_attr) cause_7\NN\7323922|the|of (l_prep) of_8\IN\0|acidosis (l_pobj) acidosis_14\NN\14204950|transplant|renal
D020123_D000138 NONE sirolimus_19\NN\0|,|acidosis (l_conj) acidosis_21\NN\14204950|,|and|got
D016559_D005198 CID tacrolimus_20\NN\0| (r_pobj) by_19\IN\0|tacrolimus (r_agent) triggered_18\VBN\1641914|which|is|by|and|augmented (r_relcl) dysfunction_15\NN\14204950|mitochondrial|triggered (r_pobj) from_13\IN\0|dysfunction (r_prep) resulted_12\VBN\2633881|that|dysfunction|may|have|from (l_nsubj) dysfunction_7\NN\14204950|patient|tubular|and|myopathy
D016559_D009135 CID tacrolimus_20\NN\0| (r_pobj) by_19\IN\0|tacrolimus (r_agent) triggered_18\VBN\1641914|which|is|by|and|augmented (r_relcl) dysfunction_15\NN\14204950|mitochondrial|triggered (r_pobj) from_13\IN\0|dysfunction (r_prep) resulted_12\VBN\2633881|that|dysfunction|may|have|from (l_nsubj) dysfunction_7\NN\14204950|patient|tubular|and|myopathy (l_conj) myopathy_9\NNS\14204950|
D016559_D028361 NONE tacrolimus_20\NN\0| (r_pobj) by_19\IN\0|tacrolimus (r_agent) triggered_18\VBN\1641914|which|is|by|and|augmented (r_relcl) dysfunction_15\NN\14204950|mitochondrial|triggered
D019259_D005198 CID lamivudine_24\NN\3834836| (r_pobj) by_23\IN\0|lamivudine (r_agent) augmented_22\VBN\153263|by (r_conj) triggered_18\VBN\1641914|which|is|by|and|augmented (r_relcl) dysfunction_15\NN\14204950|mitochondrial|triggered (r_pobj) from_13\IN\0|dysfunction (r_prep) resulted_12\VBN\2633881|that|dysfunction|may|have|from (l_nsubj) dysfunction_7\NN\14204950|patient|tubular|and|myopathy
D019259_D009135 CID lamivudine_24\NN\3834836| (r_pobj) by_23\IN\0|lamivudine (r_agent) augmented_22\VBN\153263|by (r_conj) triggered_18\VBN\1641914|which|is|by|and|augmented (r_relcl) dysfunction_15\NN\14204950|mitochondrial|triggered (r_pobj) from_13\IN\0|dysfunction (r_prep) resulted_12\VBN\2633881|that|dysfunction|may|have|from (l_nsubj) dysfunction_7\NN\14204950|patient|tubular|and|myopathy (l_conj) myopathy_9\NNS\14204950|
D019259_D028361 NONE lamivudine_24\NN\3834836| (r_pobj) by_23\IN\0|lamivudine (r_agent) augmented_22\VBN\153263|by (r_conj) triggered_18\VBN\1641914|which|is|by|and|augmented (r_relcl) dysfunction_15\NN\14204950|mitochondrial|triggered
3125768
D015760_D009127 CID alfentanil_4\NN\0| (r_npadvmod) induced_6\VBN\1627355|alfentanil|- (r_amod) rigidity_7\NN\5023233|induced
D015760_D009127 CID alfentanil_8\NN\0| (r_npadvmod) induced_10\VBN\1627355|alfentanil|- (r_amod) rigidity_11\NN\5023233|induced|in
D015760_D009127 CID alfentanil_9\NN\0|when (r_advcl) prevented_7\VBN\0|that|rigidity|should|be|alfentanil|,|and|,|used (l_nsubjpass) rigidity_4\NN\5023233|
C032943_D009127 NONE metocurine_10\NN\0| (r_pobj) with_9\IN\0|metocurine (r_prep) abolished_8\VBN\0|when|rigidity|was|with (l_nsubjpass) rigidity_6\NN\5023233|
12615818
D017373_D054556 CID acetate_9\NN\15010703|in (r_oprd) prescribed_7\VBD\748282|cyproterone|acetate (r_acl) women_6\NNS\9605289|prescribed (r_pobj) in_5\IN\13603305|women (r_prep) thromboembolism_4\NN\14100769|venous|in
D017373_D054556 CID cpa_15\NNP\9761403| (r_nmod) ee_17\NNP\6125041|cpa|/ (r_pobj) with_14\IN\0|ee (r_prep) associated_13\VBN\628491|with (r_acl) thromboembolism_9\NN\14100769|venous|(|vte|)|associated
D017373_D054556 CID cpa_15\NNP\9761403| (r_nmod) ee_17\NNP\6125041|cpa|/ (r_pobj) with_14\IN\0|ee (r_prep) associated_13\VBN\628491|with (r_acl) thromboembolism_9\NN\14100769|venous|(|vte|)|associated (l_appos) vte_11\NNP\0|
D017373_D054556 CID cpa_42\NNP\9761403| (r_nmod) ee_44\NNP\6125041|cpa|/ (r_pobj) with_41\IN\0|ee (r_prep) associated_40\VBN\628491|with (r_acl) vte_39\NNP\0|associated
D017373_D054556 CID cpa_13\NNP\9761403| (r_nmod) ee_15\NNP\6125041|cpa|/ (r_pobj) of_12\IN\0|ee (r_prep) use_11\NN\407535|the|of|in (r_pobj) with_9\IN\0|use (r_prep) associated_8\VBN\628491|with|confounding (r_acl) risk_5\NN\14541044|an|increased|of|associated (l_prep) of_6\IN\0|vte (l_pobj) vte_7\NNP\0|
D004997_D054556 CID estradiol_14\NN\14749794|:|analysis (r_appos) risk_1\NN\14541044|the|of|estradiol|. (l_prep) of_2\IN\0|thromboembolism (l_pobj) thromboembolism_4\NN\14100769|venous|in
D004997_D054556 CID ee_17\NNP\6125041|cpa|/ (r_pobj) with_14\IN\0|ee (r_prep) associated_13\VBN\628491|with (r_acl) thromboembolism_9\NN\14100769|venous|(|vte|)|associated
D004997_D054556 CID ee_17\NNP\6125041|cpa|/ (r_pobj) with_14\IN\0|ee (r_prep) associated_13\VBN\628491|with (r_acl) thromboembolism_9\NN\14100769|venous|(|vte|)|associated (l_appos) vte_11\NNP\0|
D004997_D054556 CID ee_44\NNP\6125041|cpa|/ (r_pobj) with_41\IN\0|ee (r_prep) associated_40\VBN\628491|with (r_acl) vte_39\NNP\0|associated
D004997_D054556 CID ee_15\NNP\6125041|cpa|/ (r_pobj) of_12\IN\0|ee (r_prep) use_11\NN\407535|the|of|in (r_pobj) with_9\IN\0|use (r_prep) associated_8\VBN\628491|with|confounding (r_acl) risk_5\NN\14541044|an|increased|of|associated (l_prep) of_6\IN\0|vte (l_pobj) vte_7\NNP\0|
D017373_D000152 NONE acetate_1\NN\15010703|cyproterone|combined (r_nsubjpass) licensed_12\VBN\803325|acetate|estradiol|is|in|for|and|is|. (l_prep) for_16\IN\0|treatment (l_pobj) treatment_18\NN\654885|the|of (l_prep) of_19\IN\0|women (l_pobj) women_20\NNS\9605289|with (l_prep) with_21\IN\0|acne (l_pobj) acne_22\NN\14171682|and|hirsutism
D017373_D000152 NONE cpa_7\NNP\9761403| (r_nmod) ee_9\NNP\6125041|cpa|/ (r_appos) estradiol_5\NN\14749794|(|ee|) (r_nsubjpass) licensed_12\VBN\803325|acetate|estradiol|is|in|for|and|is|. (l_prep) for_16\IN\0|treatment (l_pobj) treatment_18\NN\654885|the|of (l_prep) of_19\IN\0|women (l_pobj) women_20\NNS\9605289|with (l_prep) with_21\IN\0|acne (l_pobj) acne_22\NN\14171682|and|hirsutism
D017373_D000152 NONE cpa_42\NNP\9761403| (r_nmod) ee_44\NNP\6125041|cpa|/ (r_pobj) with_41\IN\0|ee (r_prep) associated_40\VBN\628491|with (r_acl) vte_39\NNP\0|associated (r_pobj) of_38\IN\0|vte (r_prep) risk_37\NN\14541044|the|of (r_dobj) estimate_35\VB\5802185|to|risk (r_advcl) conducted_7\VBD\2436349|using|we|analysis|years|estimate|. (l_npadvmod) years_27\NNS\15144371|15|with (l_prep) with_28\IN\0|acne (l_pobj) acne_29\NN\14171682|,|hirsutism
D017373_D000152 NONE cpa_13\NNP\9761403| (r_nmod) ee_15\NNP\6125041|cpa|/ (r_pobj) of_12\IN\0|ee (r_prep) use_11\NN\407535|the|of|in (l_prep) in_16\IN\13603305|women (l_pobj) women_17\NNS\9605289|with (l_prep) with_18\IN\0|acne (l_pobj) acne_19\NN\14171682|,|hirsutism
D017373_D006628 NONE acetate_1\NN\15010703|cyproterone|combined (r_nsubjpass) licensed_12\VBN\803325|acetate|estradiol|is|in|for|and|is|. (l_prep) for_16\IN\0|treatment (l_pobj) treatment_18\NN\654885|the|of (l_prep) of_19\IN\0|women (l_pobj) women_20\NNS\9605289|with (l_prep) with_21\IN\0|acne (l_pobj) acne_22\NN\14171682|and|hirsutism (l_conj) hirsutism_24\NN\4683453|
D017373_D006628 NONE cpa_7\NNP\9761403| (r_nmod) ee_9\NNP\6125041|cpa|/ (r_appos) estradiol_5\NN\14749794|(|ee|) (r_nsubjpass) licensed_12\VBN\803325|acetate|estradiol|is|in|for|and|is|. (l_prep) for_16\IN\0|treatment (l_pobj) treatment_18\NN\654885|the|of (l_prep) of_19\IN\0|women (l_pobj) women_20\NNS\9605289|with (l_prep) with_21\IN\0|acne (l_pobj) acne_22\NN\14171682|and|hirsutism (l_conj) hirsutism_24\NN\4683453|
D017373_D006628 NONE cpa_42\NNP\9761403| (r_nmod) ee_44\NNP\6125041|cpa|/ (r_pobj) with_41\IN\0|ee (r_prep) associated_40\VBN\628491|with (r_acl) vte_39\NNP\0|associated (r_pobj) of_38\IN\0|vte (r_prep) risk_37\NN\14541044|the|of (r_dobj) estimate_35\VB\5802185|to|risk (r_advcl) conducted_7\VBD\2436349|using|we|analysis|years|estimate|. (l_npadvmod) years_27\NNS\15144371|15|with (l_prep) with_28\IN\0|acne (l_pobj) acne_29\NN\14171682|,|hirsutism (l_conj) hirsutism_31\NN\4683453|or|pcos
D017373_D006628 NONE cpa_13\NNP\9761403| (r_nmod) ee_15\NNP\6125041|cpa|/ (r_pobj) of_12\IN\0|ee (r_prep) use_11\NN\407535|the|of|in (l_prep) in_16\IN\13603305|women (l_pobj) women_17\NNS\9605289|with (l_prep) with_18\IN\0|acne (l_pobj) acne_19\NN\14171682|,|hirsutism (l_conj) hirsutism_21\NN\4683453|or|pcos
D017373_D011085 NONE acetate_1\NN\15010703|cyproterone|combined (r_nsubjpass) licensed_12\VBN\803325|acetate|estradiol|is|in|for|and|is|. (l_conj) is_26\VBZ\0|also|option (l_attr) option_30\NN\6480506|a|treatment|for (l_prep) for_31\IN\0|syndrome (l_pobj) syndrome_34\NN\5870365|polycystic|ovary|(|pcos|)
D017373_D011085 NONE acetate_1\NN\15010703|cyproterone|combined (r_nsubjpass) licensed_12\VBN\803325|acetate|estradiol|is|in|for|and|is|. (l_conj) is_26\VBZ\0|also|option (l_attr) option_30\NN\6480506|a|treatment|for (l_prep) for_31\IN\0|syndrome (l_pobj) syndrome_34\NN\5870365|polycystic|ovary|(|pcos|) (l_appos) pcos_36\NNP\0|
D017373_D011085 NONE cpa_7\NNP\9761403| (r_nmod) ee_9\NNP\6125041|cpa|/ (r_appos) estradiol_5\NN\14749794|(|ee|) (r_nsubjpass) licensed_12\VBN\803325|acetate|estradiol|is|in|for|and|is|. (l_conj) is_26\VBZ\0|also|option (l_attr) option_30\NN\6480506|a|treatment|for (l_prep) for_31\IN\0|syndrome (l_pobj) syndrome_34\NN\5870365|polycystic|ovary|(|pcos|)
D017373_D011085 NONE cpa_7\NNP\9761403| (r_nmod) ee_9\NNP\6125041|cpa|/ (r_appos) estradiol_5\NN\14749794|(|ee|) (r_nsubjpass) licensed_12\VBN\803325|acetate|estradiol|is|in|for|and|is|. (l_conj) is_26\VBZ\0|also|option (l_attr) option_30\NN\6480506|a|treatment|for (l_prep) for_31\IN\0|syndrome (l_pobj) syndrome_34\NN\5870365|polycystic|ovary|(|pcos|) (l_appos) pcos_36\NNP\0|
D017373_D011085 NONE cpa_42\NNP\9761403| (r_nmod) ee_44\NNP\6125041|cpa|/ (r_pobj) with_41\IN\0|ee (r_prep) associated_40\VBN\628491|with (r_acl) vte_39\NNP\0|associated (r_pobj) of_38\IN\0|vte (r_prep) risk_37\NN\14541044|the|of (r_dobj) estimate_35\VB\5802185|to|risk (r_advcl) conducted_7\VBD\2436349|using|we|analysis|years|estimate|. (l_npadvmod) years_27\NNS\15144371|15|with (l_prep) with_28\IN\0|acne (l_pobj) acne_29\NN\14171682|,|hirsutism (l_conj) hirsutism_31\NN\4683453|or|pcos (l_conj) pcos_33\NNP\0|
D017373_D011085 NONE cpa_13\NNP\9761403| (r_nmod) ee_15\NNP\6125041|cpa|/ (r_pobj) of_12\IN\0|ee (r_prep) use_11\NN\407535|the|of|in (l_prep) in_16\IN\13603305|women (l_pobj) women_17\NNS\9605289|with (l_prep) with_18\IN\0|acne (l_pobj) acne_19\NN\14171682|,|hirsutism (l_conj) hirsutism_21\NN\4683453|or|pcos (l_conj) pcos_23\NNP\0|
D004997_D000152 NONE estradiol_5\NN\14749794|(|ee|) (r_nsubjpass) licensed_12\VBN\803325|acetate|estradiol|is|in|for|and|is|. (l_prep) for_16\IN\0|treatment (l_pobj) treatment_18\NN\654885|the|of (l_prep) of_19\IN\0|women (l_pobj) women_20\NNS\9605289|with (l_prep) with_21\IN\0|acne (l_pobj) acne_22\NN\14171682|and|hirsutism
D004997_D000152 NONE ee_9\NNP\6125041|cpa|/ (r_appos) estradiol_5\NN\14749794|(|ee|) (r_nsubjpass) licensed_12\VBN\803325|acetate|estradiol|is|in|for|and|is|. (l_prep) for_16\IN\0|treatment (l_pobj) treatment_18\NN\654885|the|of (l_prep) of_19\IN\0|women (l_pobj) women_20\NNS\9605289|with (l_prep) with_21\IN\0|acne (l_pobj) acne_22\NN\14171682|and|hirsutism
D004997_D000152 NONE ee_44\NNP\6125041|cpa|/ (r_pobj) with_41\IN\0|ee (r_prep) associated_40\VBN\628491|with (r_acl) vte_39\NNP\0|associated (r_pobj) of_38\IN\0|vte (r_prep) risk_37\NN\14541044|the|of (r_dobj) estimate_35\VB\5802185|to|risk (r_advcl) conducted_7\VBD\2436349|using|we|analysis|years|estimate|. (l_npadvmod) years_27\NNS\15144371|15|with (l_prep) with_28\IN\0|acne (l_pobj) acne_29\NN\14171682|,|hirsutism
D004997_D000152 NONE ee_15\NNP\6125041|cpa|/ (r_pobj) of_12\IN\0|ee (r_prep) use_11\NN\407535|the|of|in (l_prep) in_16\IN\13603305|women (l_pobj) women_17\NNS\9605289|with (l_prep) with_18\IN\0|acne (l_pobj) acne_19\NN\14171682|,|hirsutism
D004997_D006628 NONE estradiol_5\NN\14749794|(|ee|) (r_nsubjpass) licensed_12\VBN\803325|acetate|estradiol|is|in|for|and|is|. (l_prep) for_16\IN\0|treatment (l_pobj) treatment_18\NN\654885|the|of (l_prep) of_19\IN\0|women (l_pobj) women_20\NNS\9605289|with (l_prep) with_21\IN\0|acne (l_pobj) acne_22\NN\14171682|and|hirsutism (l_conj) hirsutism_24\NN\4683453|
D004997_D006628 NONE ee_9\NNP\6125041|cpa|/ (r_appos) estradiol_5\NN\14749794|(|ee|) (r_nsubjpass) licensed_12\VBN\803325|acetate|estradiol|is|in|for|and|is|. (l_prep) for_16\IN\0|treatment (l_pobj) treatment_18\NN\654885|the|of (l_prep) of_19\IN\0|women (l_pobj) women_20\NNS\9605289|with (l_prep) with_21\IN\0|acne (l_pobj) acne_22\NN\14171682|and|hirsutism (l_conj) hirsutism_24\NN\4683453|
D004997_D006628 NONE ee_44\NNP\6125041|cpa|/ (r_pobj) with_41\IN\0|ee (r_prep) associated_40\VBN\628491|with (r_acl) vte_39\NNP\0|associated (r_pobj) of_38\IN\0|vte (r_prep) risk_37\NN\14541044|the|of (r_dobj) estimate_35\VB\5802185|to|risk (r_advcl) conducted_7\VBD\2436349|using|we|analysis|years|estimate|. (l_npadvmod) years_27\NNS\15144371|15|with (l_prep) with_28\IN\0|acne (l_pobj) acne_29\NN\14171682|,|hirsutism (l_conj) hirsutism_31\NN\4683453|or|pcos
D004997_D006628 NONE ee_15\NNP\6125041|cpa|/ (r_pobj) of_12\IN\0|ee (r_prep) use_11\NN\407535|the|of|in (l_prep) in_16\IN\13603305|women (l_pobj) women_17\NNS\9605289|with (l_prep) with_18\IN\0|acne (l_pobj) acne_19\NN\14171682|,|hirsutism (l_conj) hirsutism_21\NN\4683453|or|pcos
D004997_D011085 NONE estradiol_5\NN\14749794|(|ee|) (r_nsubjpass) licensed_12\VBN\803325|acetate|estradiol|is|in|for|and|is|. (l_conj) is_26\VBZ\0|also|option (l_attr) option_30\NN\6480506|a|treatment|for (l_prep) for_31\IN\0|syndrome (l_pobj) syndrome_34\NN\5870365|polycystic|ovary|(|pcos|)
D004997_D011085 NONE estradiol_5\NN\14749794|(|ee|) (r_nsubjpass) licensed_12\VBN\803325|acetate|estradiol|is|in|for|and|is|. (l_conj) is_26\VBZ\0|also|option (l_attr) option_30\NN\6480506|a|treatment|for (l_prep) for_31\IN\0|syndrome (l_pobj) syndrome_34\NN\5870365|polycystic|ovary|(|pcos|) (l_appos) pcos_36\NNP\0|
D004997_D011085 NONE ee_9\NNP\6125041|cpa|/ (r_appos) estradiol_5\NN\14749794|(|ee|) (r_nsubjpass) licensed_12\VBN\803325|acetate|estradiol|is|in|for|and|is|. (l_conj) is_26\VBZ\0|also|option (l_attr) option_30\NN\6480506|a|treatment|for (l_prep) for_31\IN\0|syndrome (l_pobj) syndrome_34\NN\5870365|polycystic|ovary|(|pcos|)
D004997_D011085 NONE ee_9\NNP\6125041|cpa|/ (r_appos) estradiol_5\NN\14749794|(|ee|) (r_nsubjpass) licensed_12\VBN\803325|acetate|estradiol|is|in|for|and|is|. (l_conj) is_26\VBZ\0|also|option (l_attr) option_30\NN\6480506|a|treatment|for (l_prep) for_31\IN\0|syndrome (l_pobj) syndrome_34\NN\5870365|polycystic|ovary|(|pcos|) (l_appos) pcos_36\NNP\0|
D004997_D011085 NONE ee_44\NNP\6125041|cpa|/ (r_pobj) with_41\IN\0|ee (r_prep) associated_40\VBN\628491|with (r_acl) vte_39\NNP\0|associated (r_pobj) of_38\IN\0|vte (r_prep) risk_37\NN\14541044|the|of (r_dobj) estimate_35\VB\5802185|to|risk (r_advcl) conducted_7\VBD\2436349|using|we|analysis|years|estimate|. (l_npadvmod) years_27\NNS\15144371|15|with (l_prep) with_28\IN\0|acne (l_pobj) acne_29\NN\14171682|,|hirsutism (l_conj) hirsutism_31\NN\4683453|or|pcos (l_conj) pcos_33\NNP\0|
D004997_D011085 NONE ee_15\NNP\6125041|cpa|/ (r_pobj) of_12\IN\0|ee (r_prep) use_11\NN\407535|the|of|in (l_prep) in_16\IN\13603305|women (l_pobj) women_17\NNS\9605289|with (l_prep) with_18\IN\0|acne (l_pobj) acne_19\NN\14171682|,|hirsutism (l_conj) hirsutism_21\NN\4683453|or|pcos (l_conj) pcos_23\NNP\0|
D003276_D054556 NONE contraceptives_23\NNS\3183080|conventional|combined|oral|(|cocs|) (r_pobj) with_19\IN\0|contraceptives (r_prep) compared_18\VBN\644583|with (r_prep) demonstrated_3\VBN\2137132|studies|have|risk|compared|. (l_dobj) risk_6\NN\14541044|an|increased|of (l_prep) of_7\IN\0|thromboembolism (l_pobj) thromboembolism_9\NN\14100769|venous|(|vte|)|associated
D003276_D054556 NONE contraceptives_23\NNS\3183080|conventional|combined|oral|(|cocs|) (r_pobj) with_19\IN\0|contraceptives (r_prep) compared_18\VBN\644583|with (r_prep) demonstrated_3\VBN\2137132|studies|have|risk|compared|. (l_dobj) risk_6\NN\14541044|an|increased|of (l_prep) of_7\IN\0|thromboembolism (l_pobj) thromboembolism_9\NN\14100769|venous|(|vte|)|associated (l_appos) vte_11\NNP\0|
2008831
D008755_D000788 NONE methylergonovine_6\NN\0| (r_pobj) of_5\IN\0|methylergonovine (r_prep) administration_4\NN\1133281|direct|intracoronary|of|in (l_prep) in_7\IN\13603305|patients (l_pobj) patients_8\NNS\9898892|with (l_prep) with_9\IN\0|and|without (l_conj) without_11\IN\0|angina (l_pobj) angina_13\NN\14171682|variant
D008755_D000788 NONE methylergonovine_6\NN\0| (r_pobj) of_5\IN\0|methylergonovine (r_prep) administration_4\NN\1133281|intracoronary|of (r_pobj) of_2\IN\0|administration (r_prep) effects_1\NNS\13245626|the|of (r_nsubjpass) studied_8\VBN\0|effects|were|in|without|. (l_prep) in_9\IN\13603305|patients (l_pobj) patients_11\NNS\9898892|21|with (l_prep) with_12\IN\0|angina (l_pobj) angina_14\NN\14171682|variant|and|patients
D008755_D000788 NONE methylergonovine_19\NN\0| (r_pobj) of_18\IN\0|methylergonovine (r_prep) dose_17\NN\3740161|a|low|of (r_pobj) of_13\IN\0|dose (r_prep) injection_12\NN\320852|an|intracoronary|of (r_dobj) use_9\VBP\407535|which|injection (r_relcl) tests_6\NNS\5798043|spasm|provocation|,|use|, (r_nsubj) have_21\VBP\7846|that|tests|sensitivity|and|be (l_dobj) sensitivity_24\NN\5651971|a|high|in (l_prep) in_25\IN\13603305|angina (l_pobj) angina_27\NN\14171682|variant
D008755_D002637 NONE methylergonovine_6\NN\0| (r_pobj) of_5\IN\0|methylergonovine (r_prep) administration_4\NN\1133281|intracoronary|of (r_pobj) of_2\IN\0|administration (r_prep) effects_1\NNS\13245626|the|of (r_nsubjpass) studied_8\VBN\0|effects|were|in|without|. (l_prep) in_9\IN\13603305|patients (l_pobj) patients_11\NNS\9898892|21|with (l_prep) with_12\IN\0|angina (l_pobj) angina_14\NN\14171682|variant|and|patients (l_conj) patients_17\NNS\9898892|22|with (l_prep) with_18\IN\0|pain|and|in (l_pobj) pain_21\NN\14299637|atypical|chest
D008755_D000787 NONE methylergonovine_6\NN\0| (r_pobj) of_5\IN\0|methylergonovine (r_prep) administration_4\NN\1133281|intracoronary|of (r_pobj) of_2\IN\0|administration (r_prep) effects_1\NNS\13245626|the|of (r_nsubjpass) studied_8\VBN\0|effects|were|in|without|. (l_prep) without_25\IN\0|angina (l_pobj) angina_26\NN\14171682|pectoris (l_appos) pectoris_27\NN\0|group
D008755_D013035 NONE methylergonovine_19\NN\0| (r_pobj) of_18\IN\0|methylergonovine (r_prep) dose_17\NN\3740161|a|low|of (r_pobj) of_13\IN\0|dose (r_prep) injection_12\NN\320852|an|intracoronary|of (r_dobj) use_9\VBP\407535|which|injection (r_relcl) tests_6\NNS\5798043|spasm|provocation|,|use|, (l_compound) spasm_4\NN\14299637|
3780846
D009020_D009127 CID morphine_14\NN\2707683| (r_pobj) by_13\IN\0|morphine (r_agent) produced_12\VBN\1617192|by|in (r_acl) rigidity_11\NN\5023233|the|muscular|produced
D009020_D009127 CID morphine_10\NN\2707683| (r_pobj) by_9\IN\0|morphine (r_agent) produced_8\VBN\1617192|by (r_acl) rigidity_7\NN\5023233|the|muscular|produced
D009020_D009127 CID morphine_9\NN\2707683| (r_pobj) of_8\IN\0|morphine (r_prep) dose_7\NN\3740161|a|test|of|(|mg/kg|) (r_dobj) given_4\VBN\5892096|controls|dose (r_csubj) showed_15\VBD\2137132|given|rigidity|. (l_dobj) rigidity_18\NN\5023233|a|pronounced|recorded
D009020_D009127 CID morphine_6\NN\2707683| (r_pobj) with_5\IN\0|morphine (r_prep) treated_1\VBD\2376958|rats|for|with|and|withdrawn|h|showed|showed|. (l_conj) showed_27\VBD\2137132|half|rigidity|after (l_dobj) rigidity_29\NN\5023233|a
D009020_D009127 CID morphine_35\NN\2707683| (r_pobj) of_34\IN\0|morphine (r_prep) dose_33\NN\3740161|the|test|of|was|group (r_pobj) after_30\IN\0|dose (r_prep) showed_27\VBD\2137132|half|rigidity|after (l_dobj) rigidity_29\NN\5023233|a
D009020_D009127 CID morphine_16\NN\2707683| (r_pobj) of_15\IN\0|morphine (r_prep) action_14\NN\30358|an|of|in (r_pobj) to_12\IN\0|action (r_prep) due_11\JJ\5174653|to (r_acomp) be_10\VB\14625458|to|due (r_xcomp) assumed_8\VBN\719734|which|is|be (r_relcl) rigidity_4\NN\5023233|,|assumed|,
D009020_D018476 CID morphine_6\NN\2707683| (r_pobj) with_5\IN\0|morphine (r_prep) treated_1\VBD\2376958|rats|for|with|and|withdrawn|h|showed|showed|. (l_conj) showed_27\VBD\2137132|half|rigidity|after (l_prep) after_30\IN\0|dose (l_pobj) dose_33\NN\3740161|the|test|of|was|group (l_relcl) was_37\VBD\0|that|not|less|and|were (l_conj) were_46\VBD\0|akinetic (l_acomp) akinetic_47\JJ\0|
D009020_D018476 CID morphine_35\NN\2707683| (r_pobj) of_34\IN\0|morphine (r_prep) dose_33\NN\3740161|the|test|of|was|group (l_relcl) was_37\VBD\0|that|not|less|and|were (l_conj) were_46\VBD\0|akinetic (l_acomp) akinetic_47\JJ\0|
D006220_D009127 CID haloperidol_7\NN\3713736|(|mg/kg|i.p.|) (r_nsubjpass) used_14\VBN\0|in|,|haloperidol|was|in|. (l_prep) in_15\IN\13603305|order (l_pobj) order_16\NN\7168131|block (l_acl) block_18\VB\21939|to|activation|and|estimate (l_conj) estimate_24\VB\5802185|to|degree (l_dobj) degree_27\NN\4916342|the|real|of (l_prep) of_28\IN\0|tolerance (l_pobj) tolerance_30\NN\5032565|the|to (l_prep) to_31\IN\0|rigidity (l_pobj) rigidity_33\NN\5023233|the|without
D006220_D009127 CID haloperidol_0\NNP\3713736| (r_nsubj) enhanced_1\VBD\227165|haloperidol|rigidity|. (l_dobj) rigidity_3\NN\5023233|the|in
2887062
D004967_D015175 CID estrogen_8\NN\14745635| (r_npadvmod) induced_10\VBN\1627355|estrogen|- (r_amod) prolactinomas_12\NNS\0|induced|rat|after
D004967_D015175 CID estrogen_21\NN\14745635| (r_npadvmod) induced_23\VBN\1627355|estrogen|- (r_amod) cells_26\NNS\3080309|induced|rat|prolactinoma|h|and (r_pobj) to_20\IN\0|cells (r_prep) applied_19\VBN\0|clarify|analyses|were|to|h|. (l_advcl) clarify_1\VB\939277|to|effects (l_dobj) effects_3\NNS\13245626|the|of|on (l_prep) on_6\IN\0|cells (l_pobj) cells_8\NNS\3080309|prolactinoma|in (l_compound) prolactinoma_7\NN\0|
D004967_D015175 CID estrogen_21\NN\14745635| (r_npadvmod) induced_23\VBN\1627355|estrogen|- (r_amod) cells_26\NNS\3080309|induced|rat|prolactinoma|h|and (l_compound) prolactinoma_25\NN\0|
D001971_D015175 NONE bromocriptine_14\NN\0| (r_amod) treatment_15\NN\654885|bromocriptine (r_pobj) after_13\IN\0|treatment (r_prep) prolactinomas_12\NNS\0|induced|rat|after
D001971_D015175 NONE bromocriptine_5\NN\0| (r_pobj) of_4\IN\0|bromocriptine (r_prep) effects_3\NNS\13245626|the|of|on (l_prep) on_6\IN\0|cells (l_pobj) cells_8\NNS\3080309|prolactinoma|in (l_compound) prolactinoma_7\NN\0|
D001971_D015175 NONE bromocriptine_5\NN\0| (r_pobj) of_4\IN\0|bromocriptine (r_prep) effects_3\NNS\13245626|the|of|on (r_dobj) clarify_1\VB\939277|to|effects (r_advcl) applied_19\VBN\0|clarify|analyses|were|to|h|. (l_prep) to_20\IN\0|cells (l_pobj) cells_26\NNS\3080309|induced|rat|prolactinoma|h|and (l_compound) prolactinoma_25\NN\0|
D001971_D015175 NONE bromocriptine_35\NN\0| (r_pobj) of_34\IN\0|bromocriptine (r_prep) injection_33\NN\320852|of (r_pobj) after_32\IN\0|injection (r_prep) h_31\NN\14622893|6|after|mg/kg (r_conj) applied_19\VBN\0|clarify|analyses|were|to|h|. (l_advcl) clarify_1\VB\939277|to|effects (l_dobj) effects_3\NNS\13245626|the|of|on (l_prep) on_6\IN\0|cells (l_pobj) cells_8\NNS\3080309|prolactinoma|in (l_compound) prolactinoma_7\NN\0|
D001971_D015175 NONE bromocriptine_35\NN\0| (r_pobj) of_34\IN\0|bromocriptine (r_prep) injection_33\NN\320852|of (r_pobj) after_32\IN\0|injection (r_prep) h_31\NN\14622893|6|after|mg/kg (r_conj) applied_19\VBN\0|clarify|analyses|were|to|h|. (l_prep) to_20\IN\0|cells (l_pobj) cells_26\NNS\3080309|induced|rat|prolactinoma|h|and (l_compound) prolactinoma_25\NN\0|
D001971_D000236 NONE bromocriptine_15\JJ\0| (r_amod) treatment_16\NN\654885|bromocriptine|of (l_prep) of_17\IN\0|cells (l_pobj) cells_20\NNS\3080309|the|adenoma (l_compound) adenoma_19\NN\14236226|
11532387
D018967_D013375 CID risperidone_9\NN\0| (r_pobj) of_8\IN\0|risperidone (r_prep) reduction_7\NN\351485|dose|of (r_pobj) during_5\IN\0|reduction (r_prep) syndrome_4\NN\5870365|emergent|rabbit|during|.
D018967_D013375 CID risperidone_21\NN\0|,|antagonist (r_pobj) of_20\IN\0|risperidone (r_prep) profile_19\NN\6999802|the|pharmacological|of (r_pobj) to_16\IN\0|profile (r_prep) related_15\VBN\628491|mechanism|may|have|been|to|,|suggesting|. (l_nsubjpass) mechanism_2\NN\13446390|the|underlying|of|in (l_prep) of_3\IN\0|rs (l_pobj) rs_7\NN\13635336|emergent
D018967_D001480 CID risperidone_9\NN\0| (r_pobj) of_8\IN\0|risperidone (r_prep) reduction_7\NN\351485|dose|of (r_pobj) during_5\IN\0|reduction (r_prep) syndrome_4\NN\5870365|emergent|rabbit|during|.
D018967_D001480 CID risperidone_8\NN\0| (r_pobj) of_7\IN\0|risperidone (r_prep) reduction_6\NN\351485|dose|of (r_pobj) during_4\IN\0|reduction (r_prep) developed_2\VBN\1753788|patient|rs|during|. (l_dobj) rs_3\NN\13635336|
D018967_D001480 CID risperidone_21\NN\0|,|antagonist (r_pobj) of_20\IN\0|risperidone (r_prep) profile_19\NN\6999802|the|pharmacological|of (r_pobj) to_16\IN\0|profile (r_prep) related_15\VBN\628491|mechanism|may|have|been|to|,|suggesting|. (l_nsubjpass) mechanism_2\NN\13446390|the|underlying|of|in (l_prep) of_3\IN\0|rs (l_pobj) rs_7\NN\13635336|emergent
D018967_D001480 CID risperidone_21\NN\0|,|antagonist (r_pobj) of_20\IN\0|risperidone (r_prep) profile_19\NN\6999802|the|pharmacological|of (r_pobj) to_16\IN\0|profile (r_prep) related_15\VBN\628491|mechanism|may|have|been|to|,|suggesting|. (l_advcl) suggesting_29\VBG\1010118|influence (l_dobj) influence_32\NN\5190804|the|pathophysiologic|of|in (l_prep) in_37\IN\13603305|development (l_pobj) development_39\NN\248977|the|of (l_prep) of_40\IN\0|rs (l_pobj) rs_41\NN\13635336|
D012701_D013375 NONE serotonin_24\NN\14807737| (r_compound) dopamine_26\NN\14807737|serotonin|- (r_compound) antagonist_27\NN\7846|a|dopamine (r_appos) risperidone_21\NN\0|,|antagonist (r_pobj) of_20\IN\0|risperidone (r_prep) profile_19\NN\6999802|the|pharmacological|of (r_pobj) to_16\IN\0|profile (r_prep) related_15\VBN\628491|mechanism|may|have|been|to|,|suggesting|. (l_nsubjpass) mechanism_2\NN\13446390|the|underlying|of|in (l_prep) of_3\IN\0|rs (l_pobj) rs_7\NN\13635336|emergent
D012701_D013375 NONE serotonin_35\NN\14807737| (r_compound) system_36\NN\3575240|the|serotonin (r_pobj) of_33\IN\0|system (r_prep) influence_32\NN\5190804|the|pathophysiologic|of|in (r_dobj) suggesting_29\VBG\1010118|influence (r_advcl) related_15\VBN\628491|mechanism|may|have|been|to|,|suggesting|. (l_nsubjpass) mechanism_2\NN\13446390|the|underlying|of|in (l_prep) of_3\IN\0|rs (l_pobj) rs_7\NN\13635336|emergent
D012701_D001480 NONE serotonin_24\NN\14807737| (r_compound) dopamine_26\NN\14807737|serotonin|- (r_compound) antagonist_27\NN\7846|a|dopamine (r_appos) risperidone_21\NN\0|,|antagonist (r_pobj) of_20\IN\0|risperidone (r_prep) profile_19\NN\6999802|the|pharmacological|of (r_pobj) to_16\IN\0|profile (r_prep) related_15\VBN\628491|mechanism|may|have|been|to|,|suggesting|. (l_nsubjpass) mechanism_2\NN\13446390|the|underlying|of|in (l_prep) of_3\IN\0|rs (l_pobj) rs_7\NN\13635336|emergent
D012701_D001480 NONE serotonin_24\NN\14807737| (r_compound) dopamine_26\NN\14807737|serotonin|- (r_compound) antagonist_27\NN\7846|a|dopamine (r_appos) risperidone_21\NN\0|,|antagonist (r_pobj) of_20\IN\0|risperidone (r_prep) profile_19\NN\6999802|the|pharmacological|of (r_pobj) to_16\IN\0|profile (r_prep) related_15\VBN\628491|mechanism|may|have|been|to|,|suggesting|. (l_advcl) suggesting_29\VBG\1010118|influence (l_dobj) influence_32\NN\5190804|the|pathophysiologic|of|in (l_prep) in_37\IN\13603305|development (l_pobj) development_39\NN\248977|the|of (l_prep) of_40\IN\0|rs (l_pobj) rs_41\NN\13635336|
D012701_D001480 NONE serotonin_35\NN\14807737| (r_compound) system_36\NN\3575240|the|serotonin (r_pobj) of_33\IN\0|system (r_prep) influence_32\NN\5190804|the|pathophysiologic|of|in (r_dobj) suggesting_29\VBG\1010118|influence (r_advcl) related_15\VBN\628491|mechanism|may|have|been|to|,|suggesting|. (l_nsubjpass) mechanism_2\NN\13446390|the|underlying|of|in (l_prep) of_3\IN\0|rs (l_pobj) rs_7\NN\13635336|emergent
D012701_D001480 NONE serotonin_35\NN\14807737| (r_compound) system_36\NN\3575240|the|serotonin (r_pobj) of_33\IN\0|system (r_prep) influence_32\NN\5190804|the|pathophysiologic|of|in (l_prep) in_37\IN\13603305|development (l_pobj) development_39\NN\248977|the|of (l_prep) of_40\IN\0|rs (l_pobj) rs_41\NN\13635336|
D004298_D013375 NONE dopamine_26\NN\14807737|serotonin|- (r_compound) antagonist_27\NN\7846|a|dopamine (r_appos) risperidone_21\NN\0|,|antagonist (r_pobj) of_20\IN\0|risperidone (r_prep) profile_19\NN\6999802|the|pharmacological|of (r_pobj) to_16\IN\0|profile (r_prep) related_15\VBN\628491|mechanism|may|have|been|to|,|suggesting|. (l_nsubjpass) mechanism_2\NN\13446390|the|underlying|of|in (l_prep) of_3\IN\0|rs (l_pobj) rs_7\NN\13635336|emergent
D004298_D001480 NONE dopamine_26\NN\14807737|serotonin|- (r_compound) antagonist_27\NN\7846|a|dopamine (r_appos) risperidone_21\NN\0|,|antagonist (r_pobj) of_20\IN\0|risperidone (r_prep) profile_19\NN\6999802|the|pharmacological|of (r_pobj) to_16\IN\0|profile (r_prep) related_15\VBN\628491|mechanism|may|have|been|to|,|suggesting|. (l_nsubjpass) mechanism_2\NN\13446390|the|underlying|of|in (l_prep) of_3\IN\0|rs (l_pobj) rs_7\NN\13635336|emergent
D004298_D001480 NONE dopamine_26\NN\14807737|serotonin|- (r_compound) antagonist_27\NN\7846|a|dopamine (r_appos) risperidone_21\NN\0|,|antagonist (r_pobj) of_20\IN\0|risperidone (r_prep) profile_19\NN\6999802|the|pharmacological|of (r_pobj) to_16\IN\0|profile (r_prep) related_15\VBN\628491|mechanism|may|have|been|to|,|suggesting|. (l_advcl) suggesting_29\VBG\1010118|influence (l_dobj) influence_32\NN\5190804|the|pathophysiologic|of|in (l_prep) in_37\IN\13603305|development (l_pobj) development_39\NN\248977|the|of (l_prep) of_40\IN\0|rs (l_pobj) rs_41\NN\13635336|
16005948
-1_D062787 NONE gnc92h2_6\NNP\0|the|anticocaine|monoclonal|antibody (r_pobj) of_1\IN\0|gnc92h2 (r_prep) evaluation_0\NN\874067|of|as|. (l_prep) as_7\IN\14622893|immunotherapy (l_pobj) immunotherapy_9\NN\661091|an|for (l_prep) for_10\IN\0|overdose (l_pobj) overdose_12\NN\84738|cocaine
-1_D062787 NONE gnc92h2_7\NNP\0|the|anticocaine|antibody (r_pobj) of_3\IN\0|gnc92h2 (r_prep) potential_2\NN\14481929|the|therapeutic|of (r_nsubjpass) examined_9\VBN\0|potential|was|using|. (l_advcl) using_10\VBG\418025|model (l_dobj) model_12\NN\5888929|a|of (l_prep) of_13\IN\0|overdose (l_pobj) overdose_15\NN\84738|cocaine
-1_D062787 NONE gnc92h2_7\NNP\0| (r_pobj) of_6\IN\0|gnc92h2 (r_prep) potential_5\NN\14481929|the|important|of|as (l_prep) as_8\IN\14622893|tool (l_pobj) tool_11\NN\3563967|a|therapeutic|against (l_prep) against_12\IN\0|overdose (l_pobj) overdose_14\NN\84738|cocaine
D003042_D062787 NONE cocaine_4\NN\3492717| (r_pobj) of_3\IN\0|cocaine (r_prep) use_2\NN\407535|the|illicit|of (r_nsubj) continues_5\VBZ\2367363|use|in (l_prep) in_6\IN\13603305|proportions (l_pobj) proportions_8\NNS\13824815|epidemic|and|treatment (l_conj) treatment_10\NN\654885|for (l_prep) for_11\IN\0|overdose (l_pobj) overdose_13\NN\84738|cocaine
D003042_D064420 NONE cocaine_3\NN\3492717| (r_compound) toxicity_4\NN\13576101|cocaine
D003042_D012640 CID cocaine_3\NN\3492717| (r_compound) toxicity_4\NN\13576101|cocaine (r_pobj) of_2\IN\0|toxicity (r_prep) blockade_1\NN\952963|significant|of (r_nsubjpass) observed_6\VBN\2163746|blockade|was|with|. (l_prep) with_7\IN\0|dose (l_pobj) dose_10\NN\3740161|the|higher|of|mg/kg|)|,|reduced|,|seizures (l_appos) seizures_28\NNS\14081375|up|by
D003042_D003643 NONE cocaine_3\NN\3492717| (r_compound) toxicity_4\NN\13576101|cocaine (r_pobj) of_2\IN\0|toxicity (r_prep) blockade_1\NN\952963|significant|of (r_nsubjpass) observed_6\VBN\2163746|blockade|was|with|. (l_prep) with_7\IN\0|dose (l_pobj) dose_10\NN\3740161|the|higher|of|mg/kg|)|,|reduced|,|seizures (l_appos) seizures_28\NNS\14081375|up|by (l_prt) up_29\IN\153263|to (l_prep) to_30\TO\0|% (l_pobj) %_32\NN\0|77|and|death (l_conj) death_34\NN\7296428|
D003042_D003643 NONE cocaine_8\NN\3492717|post|- (r_compound) injection_9\NN\320852|even|cocaine (r_dobj) prevented_3\VBD\0|importantly|,|gnc92h2|death|injection|. (l_dobj) death_4\NN\7296428|
-1_D064420 NONE gnc92h2_12\NNP\0| (r_pobj) of_11\IN\0|gnc92h2 (r_prep) dose_10\NN\3740161|the|higher|of|mg/kg|)|,|reduced|,|seizures (r_pobj) with_7\IN\0|dose (r_prep) observed_6\VBN\2163746|blockade|was|with|. (l_nsubjpass) blockade_1\NN\952963|significant|of (l_prep) of_2\IN\0|toxicity (l_pobj) toxicity_4\NN\13576101|cocaine
-1_D012640 NONE gnc92h2_12\NNP\0| (r_pobj) of_11\IN\0|gnc92h2 (r_prep) dose_10\NN\3740161|the|higher|of|mg/kg|)|,|reduced|,|seizures (l_appos) seizures_28\NNS\14081375|up|by
-1_D003643 NONE gnc92h2_12\NNP\0| (r_pobj) of_11\IN\0|gnc92h2 (r_prep) dose_10\NN\3740161|the|higher|of|mg/kg|)|,|reduced|,|seizures (l_appos) seizures_28\NNS\14081375|up|by (l_prt) up_29\IN\153263|to (l_prep) to_30\TO\0|% (l_pobj) %_32\NN\0|77|and|death (l_conj) death_34\NN\7296428|
-1_D003643 NONE gnc92h2_2\NNP\0| (r_nsubj) prevented_3\VBD\0|importantly|,|gnc92h2|death|injection|. (l_dobj) death_4\NN\7296428|
1867351
D015767_D008288 NONE mefloquine_10\NN\2721948| (r_pobj) with_9\IN\0|mefloquine (r_prep) treatment_8\NN\654885|with (r_conj) prophylaxis_6\NN\1077350|malaria|and|treatment (l_compound) malaria_5\NN\14178913|
11027905
D007649_D009369 NONE ketamine_4\NN\3054098|intravenous|in (l_prep) in_5\IN\13603305|patients (l_pobj) patients_7\NNS\9898892|cancer|on (l_compound) cancer_6\NN\14239425|
D007649_D009369 NONE ketamine_7\NN\3054098| (r_pobj) of_6\IN\0|ketamine (r_prep) doses_5\NNS\3740161|subhypnotic|of|(|0.25|) (r_pobj) of_3\IN\0|doses (r_prep) bolus_2\NN\13899404|a|slow|of (r_nsubjpass) given_16\VBN\5892096|bolus|was|to|. (l_dative) to_17\IN\0|patients (l_pobj) patients_20\NNS\9898892|10|cancer|was (l_compound) cancer_19\NN\14239425|
D009020_D009369 NONE morphine_9\NN\2707683| (r_compound) therapy_10\NN\657604|morphine (r_pobj) on_8\IN\0|therapy (r_prep) patients_7\NNS\9898892|cancer|on (l_compound) cancer_6\NN\14239425|
D009020_D009369 NONE morphine_26\NN\2707683| (r_pobj) by_25\IN\0|morphine (r_prep) unrelieved_24\JJ\0|by (r_acomp) was_23\VBD\0|pain|unrelieved|in (r_relcl) patients_20\NNS\9898892|10|cancer|was (l_compound) cancer_19\NN\14239425|
D009020_D010146 NONE morphine_4\NN\2707683| (r_pobj) to_3\IN\0|morphine (r_prep) responsive_2\JJ\0|not|to (r_amod) pain_0\NN\14299637|responsive
D009020_D010146 NONE morphine_26\NN\2707683| (r_pobj) by_25\IN\0|morphine (r_prep) unrelieved_24\JJ\0|by (r_acomp) was_23\VBD\0|pain|unrelieved|in (l_nsubj) pain_22\NN\14299637|whose
D009020_D010146 NONE morphine_3\NN\2707683| (r_compound) analgesia_4\NN\14034177|morphine|in (l_prep) in_5\IN\13603305|syndromes (l_pobj) syndromes_8\NNS\5870365|difficult|pain|,|as (l_compound) pain_7\NN\14299637|
D016202_D010146 NONE aspartate_13\NNP\0|methyl|-|d|- (r_nmod) antagonists_17\NNS\7846|aspartate|(|nmda|)|,|as (r_nsubj) be_24\VB\14625458|that|antagonists|,|may|effective (l_acomp) effective_25\JJ\0|in (l_prep) in_26\IN\13603305|improving (l_pcomp) improving_27\VBG\126264|analgesia (l_dobj) analgesia_29\NN\14034177|opioid|in (l_prep) in_30\IN\13603305|syndromes (l_pobj) syndromes_33\NNS\5870365|difficult|pain|,|as (l_compound) pain_32\NN\14299637|
D016202_D010146 NONE nmda_15\NNP\0| (r_nmod) antagonists_17\NNS\7846|aspartate|(|nmda|)|,|as (r_nsubj) be_24\VB\14625458|that|antagonists|,|may|effective (l_acomp) effective_25\JJ\0|in (l_prep) in_26\IN\13603305|improving (l_pcomp) improving_27\VBG\126264|analgesia (l_dobj) analgesia_29\NN\14034177|opioid|in (l_prep) in_30\IN\13603305|syndromes (l_pobj) syndromes_33\NNS\5870365|difficult|pain|,|as (l_compound) pain_32\NN\14299637|
D016202_D009437 NONE aspartate_13\NNP\0|methyl|-|d|- (r_nmod) antagonists_17\NNS\7846|aspartate|(|nmda|)|,|as (r_nsubj) be_24\VB\14625458|that|antagonists|,|may|effective (l_acomp) effective_25\JJ\0|in (l_prep) in_26\IN\13603305|improving (l_pcomp) improving_27\VBG\126264|analgesia (l_dobj) analgesia_29\NN\14034177|opioid|in (l_prep) in_30\IN\13603305|syndromes (l_pobj) syndromes_33\NNS\5870365|difficult|pain|,|as (l_prep) as_36\IN\14622893|such|pain (l_pobj) pain_38\NN\14299637|neuropathic
D016202_D009437 NONE nmda_15\NNP\0| (r_nmod) antagonists_17\NNS\7846|aspartate|(|nmda|)|,|as (r_nsubj) be_24\VB\14625458|that|antagonists|,|may|effective (l_acomp) effective_25\JJ\0|in (l_prep) in_26\IN\13603305|improving (l_pcomp) improving_27\VBG\126264|analgesia (l_dobj) analgesia_29\NN\14034177|opioid|in (l_prep) in_30\IN\13603305|syndromes (l_pobj) syndromes_33\NNS\5870365|difficult|pain|,|as (l_prep) as_36\IN\14622893|such|pain (l_pobj) pain_38\NN\14299637|neuropathic
D007649_D010146 NONE ketamine_21\NN\3054098| (r_pobj) as_20\IN\14622893|such|ketamine (r_prep) antagonists_17\NNS\7846|aspartate|(|nmda|)|,|as (r_nsubj) be_24\VB\14625458|that|antagonists|,|may|effective (l_acomp) effective_25\JJ\0|in (l_prep) in_26\IN\13603305|improving (l_pcomp) improving_27\VBG\126264|analgesia (l_dobj) analgesia_29\NN\14034177|opioid|in (l_prep) in_30\IN\13603305|syndromes (l_pobj) syndromes_33\NNS\5870365|difficult|pain|,|as (l_compound) pain_32\NN\14299637|
D007649_D010146 NONE ketamine_7\NN\3054098| (r_pobj) of_6\IN\0|ketamine (r_prep) doses_5\NNS\3740161|subhypnotic|of|(|0.25|) (r_pobj) of_3\IN\0|doses (r_prep) bolus_2\NN\13899404|a|slow|of (r_nsubjpass) given_16\VBN\5892096|bolus|was|to|. (l_dative) to_17\IN\0|patients (l_pobj) patients_20\NNS\9898892|10|cancer|was (l_relcl) was_23\VBD\0|pain|unrelieved|in (l_nsubj) pain_22\NN\14299637|whose
D007649_D010146 NONE ketamine_0\NN\3054098|,|but|solution (r_nsubj) reduced_8\VBD\441445|ketamine|significantly|intensity|in|. (l_dobj) intensity_11\NN\5090441|the|pain (l_compound) pain_10\NN\14299637|
D007649_D010146 NONE ketamine_0\NNP\3054098| (r_nsubj) improve_2\VB\126264|ketamine|can|analgesia|. (l_dobj) analgesia_4\NN\14034177|morphine|in (l_prep) in_5\IN\13603305|syndromes (l_pobj) syndromes_8\NNS\5870365|difficult|pain|,|as (l_compound) pain_7\NN\14299637|
D007649_D009437 NONE ketamine_21\NN\3054098| (r_pobj) as_20\IN\14622893|such|ketamine (r_prep) antagonists_17\NNS\7846|aspartate|(|nmda|)|,|as (r_nsubj) be_24\VB\14625458|that|antagonists|,|may|effective (l_acomp) effective_25\JJ\0|in (l_prep) in_26\IN\13603305|improving (l_pcomp) improving_27\VBG\126264|analgesia (l_dobj) analgesia_29\NN\14034177|opioid|in (l_prep) in_30\IN\13603305|syndromes (l_pobj) syndromes_33\NNS\5870365|difficult|pain|,|as (l_prep) as_36\IN\14622893|such|pain (l_pobj) pain_38\NN\14299637|neuropathic
D007649_D009437 NONE ketamine_0\NNP\3054098| (r_nsubj) improve_2\VB\126264|ketamine|can|analgesia|. (l_dobj) analgesia_4\NN\14034177|morphine|in (l_prep) in_5\IN\13603305|syndromes (l_pobj) syndromes_8\NNS\5870365|difficult|pain|,|as (l_prep) as_11\IN\14622893|such|pain (l_pobj) pain_13\NN\14299637|neuropathic
D009020_D009437 NONE morphine_3\NN\2707683| (r_compound) analgesia_4\NN\14034177|morphine|in (l_prep) in_5\IN\13603305|syndromes (l_pobj) syndromes_8\NNS\5870365|difficult|pain|,|as (l_prep) as_11\IN\14622893|such|pain (l_pobj) pain_13\NN\14299637|neuropathic
8558192
C030852_C562729 NONE vinorelbine_4\NN\0| (r_pobj) of_3\IN\0|vinorelbine (r_prep) trial_2\NN\786195|ii|of|in|. (l_prep) in_5\IN\13603305|carcinoma (l_pobj) carcinoma_10\NN\14239918|metastatic|esophageal
C030852_C562729 NONE vinorelbine_9\NN\0|(|vnb|) (r_pobj) of_8\IN\0|vinorelbine (r_prep) effects_7\NNS\13245626|toxic|of (r_conj) rate_4\NN\13815152|the|response|and|effects|administered (l_acl) administered_13\VBN\2436349|as (l_prep) as_14\IN\14622893|agent (l_pobj) agent_17\NN\7347|a|single|in (l_prep) in_18\IN\13603305|carcinoma (l_pobj) carcinoma_23\NN\14239918|metastatic|esophageal
C030852_C562729 NONE vnb_11\NNP\0| (r_appos) vinorelbine_9\NN\0|(|vnb|) (r_pobj) of_8\IN\0|vinorelbine (r_prep) effects_7\NNS\13245626|toxic|of (r_conj) rate_4\NN\13815152|the|response|and|effects|administered (l_acl) administered_13\VBN\2436349|as (l_prep) as_14\IN\14622893|agent (l_pobj) agent_17\NN\7347|a|single|in (l_prep) in_18\IN\13603305|carcinoma (l_pobj) carcinoma_23\NN\14239918|metastatic|esophageal
C030852_C562729 NONE vnb_4\NNP\0| (r_nsubj) is_5\VBZ\0|that|vnb|agent (l_attr) agent_8\NN\7347|an|active|in (l_prep) in_9\IN\13603305|carcinoma (l_pobj) carcinoma_14\NN\14239918|metastatic|cell
D002945_D064420 NONE cisplatin_9\NN\0| (r_npadvmod) based_11\VBN\0|cisplatin|- (r_amod) chemotherapy_12\NN\661091|based (r_pobj) with_8\IN\0|chemotherapy (r_prep) pretreated_7\VBN\0|patients|with (r_csubj) were_13\VBD\0|pretreated|assessable|. (l_acomp) assessable_14\JJ\0|for (l_prep) for_15\IN\0|toxicity (l_pobj) toxicity_16\NN\13576101|and|response
C030852_D064420 NONE vnb_0\NNP\0| (r_nsubjpass) tolerated_3\VBN\802318|vnb|was|well|and|occurred (l_conj) occurred_13\VBD\0|instances|toxicity|. (l_nsubj) toxicity_12\NN\13576101|nonhematologic
C030852_D064420 NONE vnb_12\NNP\0| (r_pobj) of_11\IN\0|vnb (r_prep) evaluation_10\NN\874067|further|of|in (r_nsubjpass) warranted_17\VBN\1012073|given|,|evaluation|is|. (l_prep) given_0\VBN\5892096|profile (l_pobj) profile_4\NN\6999802|its|tolerance|and|toxicity (l_conj) toxicity_7\NN\13576101|low
1639466
D002118_D009400 NONE calcium_4\NN\14625458| (r_compound) channel_5\NN\6251781|the|calcium (r_pobj) of_2\IN\0|channel (r_prep) effect_1\NN\34213|adverse|of|nitrendipine|. (l_appos) nitrendipine_7\NN\0|blocker|on (l_prep) on_8\IN\0|nephrosclerosis (l_pobj) nephrosclerosis_9\NN\14113228|in
D002118_D006978 NONE calcium_4\NN\14625458| (r_compound) channel_5\NN\6251781|the|calcium (r_pobj) of_2\IN\0|channel (r_prep) effect_1\NN\34213|adverse|of|nitrendipine|. (l_appos) nitrendipine_7\NN\0|blocker|on (l_prep) on_8\IN\0|nephrosclerosis (l_pobj) nephrosclerosis_9\NN\14113228|in (l_prep) in_10\IN\13603305|rats (l_pobj) rats_11\NNS\2329401|with (l_prep) with_12\IN\0|hypertension (l_pobj) hypertension_14\NN\14057371|renovascular
D002118_D006978 NONE calcium_8\NN\14625458| (r_compound) channel_9\NN\6251781|the|calcium|nitrendipine (r_pobj) with_6\IN\0|channel (r_prep) treatment_5\NN\654885|a|6-week|with (r_pobj) of_2\IN\0|treatment (r_prep) effect_1\NN\34213|the|of (r_nsubjpass) studied_35\VBN\0|effect|was|in|. (l_prep) in_36\IN\13603305|rats (l_pobj) rats_37\NNS\2329401|with (l_prep) with_38\IN\0|kidney (l_pobj) kidney_41\NN\5333259|two|-|,|hypertension (l_appos) hypertension_46\NN\14057371|one|renovascular
D009568_D009400 CID nitrendipine_7\NN\0|blocker|on (l_prep) on_8\IN\0|nephrosclerosis (l_pobj) nephrosclerosis_9\NN\14113228|in
D009568_D006978 NONE nitrendipine_7\NN\0|blocker|on (l_prep) on_8\IN\0|nephrosclerosis (l_pobj) nephrosclerosis_9\NN\14113228|in (l_prep) in_10\IN\13603305|rats (l_pobj) rats_11\NNS\2329401|with (l_prep) with_12\IN\0|hypertension (l_pobj) hypertension_14\NN\14057371|renovascular
D009568_D006978 NONE nitrendipine_11\NN\0|blocker|or|angiotensin (r_appos) channel_9\NN\6251781|the|calcium|nitrendipine (r_pobj) with_6\IN\0|channel (r_prep) treatment_5\NN\654885|a|6-week|with (r_pobj) of_2\IN\0|treatment (r_prep) effect_1\NN\34213|the|of (r_nsubjpass) studied_35\VBN\0|effect|was|in|. (l_prep) in_36\IN\13603305|rats (l_pobj) rats_37\NNS\2329401|with (l_prep) with_38\IN\0|kidney (l_pobj) kidney_41\NN\5333259|two|-|,|hypertension (l_appos) hypertension_46\NN\14057371|one|renovascular
D002118_D000419 NONE calcium_8\NN\14625458| (r_compound) channel_9\NN\6251781|the|calcium|nitrendipine (l_appos) nitrendipine_11\NN\0|blocker|or|angiotensin (l_conj) angiotensin_14\NN\4522421|the|converting (l_acl) converting_15\VBG\126264|enalapril|on (l_prep) on_19\IN\0|pressure (l_pobj) pressure_21\NN\11419404|blood|,|albuminuria (l_conj) albuminuria_23\NN\14299637|,|hemodynamics
D009568_D000419 CID nitrendipine_11\NN\0|blocker|or|angiotensin (l_conj) angiotensin_14\NN\4522421|the|converting (l_acl) converting_15\VBG\126264|enalapril|on (l_prep) on_19\IN\0|pressure (l_pobj) pressure_21\NN\11419404|blood|,|albuminuria (l_conj) albuminuria_23\NN\14299637|,|hemodynamics
D009568_D000419 CID nitrendipine_5\NN\0| (r_npadvmod) treated_7\VBN\2376958|nitrendipine|- (r_amod) albuminuria_9\NN\14299637|the|treated|group
D000809_D000419 NONE angiotensin_14\NN\4522421|the|converting (l_acl) converting_15\VBG\126264|enalapril|on (l_prep) on_19\IN\0|pressure (l_pobj) pressure_21\NN\11419404|blood|,|albuminuria (l_conj) albuminuria_23\NN\14299637|,|hemodynamics
D000809_D006978 NONE angiotensin_14\NN\4522421|the|converting (r_conj) nitrendipine_11\NN\0|blocker|or|angiotensin (r_appos) channel_9\NN\6251781|the|calcium|nitrendipine (r_pobj) with_6\IN\0|channel (r_prep) treatment_5\NN\654885|a|6-week|with (r_pobj) of_2\IN\0|treatment (r_prep) effect_1\NN\34213|the|of (r_nsubjpass) studied_35\VBN\0|effect|was|in|. (l_prep) in_36\IN\13603305|rats (l_pobj) rats_37\NNS\2329401|with (l_prep) with_38\IN\0|kidney (l_pobj) kidney_41\NN\5333259|two|-|,|hypertension (l_appos) hypertension_46\NN\14057371|one|renovascular
D004656_D000419 NONE enalapril_18\NN\2673637|inhibitor (r_dobj) converting_15\VBG\126264|enalapril|on (l_prep) on_19\IN\0|pressure (l_pobj) pressure_21\NN\11419404|blood|,|albuminuria (l_conj) albuminuria_23\NN\14299637|,|hemodynamics
D004656_D006978 NONE enalapril_18\NN\2673637|inhibitor (r_dobj) converting_15\VBG\126264|enalapril|on (r_acl) angiotensin_14\NN\4522421|the|converting (r_conj) nitrendipine_11\NN\0|blocker|or|angiotensin (r_appos) channel_9\NN\6251781|the|calcium|nitrendipine (r_pobj) with_6\IN\0|channel (r_prep) treatment_5\NN\654885|a|6-week|with (r_pobj) of_2\IN\0|treatment (r_prep) effect_1\NN\34213|the|of (r_nsubjpass) studied_35\VBN\0|effect|was|in|. (l_prep) in_36\IN\13603305|rats (l_pobj) rats_37\NNS\2329401|with (l_prep) with_38\IN\0|kidney (l_pobj) kidney_41\NN\5333259|two|-|,|hypertension (l_appos) hypertension_46\NN\14057371|one|renovascular
D004656_D006973 NONE enalapril_33\NN\2673637| (r_npadvmod) treated_35\VBN\2376958|enalapril|- (r_amod) 8)_39\CD\0|treated|(|n|=|,|or|treated (r_appos) controls_27\NNS\5190804|untreated|hypertensive|(|8)|8) (r_appos) groups_23\NNS\2137|three|:|controls (r_pobj) to_21\IN\0|groups (r_prep) assigned_20\VBN\2475922|after|were|randomly|to|. (l_prep) after_2\IN\0|weeks|clipping (l_pobj) clipping_3\VBG\6400510|of (l_prep) of_4\IN\0|artery (l_pobj) artery_7\NN\5417975|one|renal|,|rats|(|hg|) (l_appos) rats_10\NNS\2329401|hypertensive (l_amod) hypertensive_9\JJ\10405694|
D004656_D006973 NONE enalapril_33\NN\2673637| (r_npadvmod) treated_35\VBN\2376958|enalapril|- (r_amod) 8)_39\CD\0|treated|(|n|=|,|or|treated (r_appos) controls_27\NNS\5190804|untreated|hypertensive|(|8)|8) (l_amod) hypertensive_26\JJ\10405694|
D004656_D006973 NONE enalapril_25\NN\2673637| (r_npadvmod) treated_27\VBN\2376958|enalapril|- (r_amod) group_28\NN\2137|the|treated (r_pobj) in_23\IN\13603305|group (r_prep) lower_22\JJR\2831724|in|(|+/-|compared (l_prep) compared_37\VBN\644583|with (l_prep) with_38\IN\0|controls (l_pobj) controls_41\NNS\5190804|the|hypertensive|(|+/-|) (l_amod) hypertensive_40\JJ\10405694|
D009568_D006973 NONE nitrendipine_42\NN\0| (r_advmod) treated_44\VBN\2376958|nitrendipine|-|n (r_conj) 8)_39\CD\0|treated|(|n|=|,|or|treated (r_appos) controls_27\NNS\5190804|untreated|hypertensive|(|8)|8) (r_appos) groups_23\NNS\2137|three|:|controls (r_pobj) to_21\IN\0|groups (r_prep) assigned_20\VBN\2475922|after|were|randomly|to|. (l_prep) after_2\IN\0|weeks|clipping (l_pobj) clipping_3\VBG\6400510|of (l_prep) of_4\IN\0|artery (l_pobj) artery_7\NN\5417975|one|renal|,|rats|(|hg|) (l_appos) rats_10\NNS\2329401|hypertensive (l_amod) hypertensive_9\JJ\10405694|
D009568_D006973 NONE nitrendipine_42\NN\0| (r_advmod) treated_44\VBN\2376958|nitrendipine|-|n (r_conj) 8)_39\CD\0|treated|(|n|=|,|or|treated (r_appos) controls_27\NNS\5190804|untreated|hypertensive|(|8)|8) (l_amod) hypertensive_26\JJ\10405694|
D009568_D006973 NONE nitrendipine_5\NN\0| (r_npadvmod) treated_7\VBN\2376958|nitrendipine|- (r_amod) albuminuria_9\NN\14299637|the|treated|group (r_pobj) in_3\IN\13603305|albuminuria (r_prep) increased_10\VBD\169651|in|,|in|from|progressively|to|compared|. (l_prep) compared_20\VBN\644583|with (l_prep) with_21\IN\0|hr (l_pobj) hr_26\NN\15154774|mg/24|in (l_prep) in_27\IN\13603305|controls (l_pobj) controls_30\NNS\5190804|the|hypertensive (l_amod) hypertensive_29\JJ\10405694|
D009568_D006973 NONE nitrendipine_9\NN\0| (r_npadvmod) treated_11\VBN\2376958|nitrendipine|- (r_amod) group_12\NN\2137|the|treated (r_pobj) in_7\IN\13603305|group (r_prep) increased_6\VBN\169651|furthermore|,|index|was|significantly|in|compared|. (l_prep) compared_13\VBN\644583|with (l_prep) with_14\IN\0|controls (l_pobj) controls_17\NNS\5190804|the|hypertensive|(|0.38|) (l_amod) hypertensive_16\JJ\10405694|
D009568_D006973 NONE nitrendipine_9\NN\0| (r_npadvmod) treated_11\VBN\2376958|nitrendipine|- (r_amod) group_12\NN\2137|the|treated|(|+/-|) (r_pobj) in_7\IN\13603305|group (r_prep) was_5\VBD\0|in|,|size|higher|in|but|lower|. (l_conj) lower_22\JJR\2831724|in|(|+/-|compared (l_prep) compared_37\VBN\644583|with (l_prep) with_38\IN\0|controls (l_pobj) controls_41\NNS\5190804|the|hypertensive|(|+/-|) (l_amod) hypertensive_40\JJ\10405694|
D004656_D005921 NONE enalapril_14\JJ\2673637| (r_compound) treatment_15\NN\654885|enalapril (r_pobj) after_13\IN\0|treatment (r_prep) change_12\VB\7283608|excretion|did|not|after|. (l_nsubj) excretion_7\NN\13466586|albumin|and|glomerulosclerosis (l_conj) glomerulosclerosis_9\NN\0|
D009568_D005921 NONE nitrendipine_9\NN\0| (r_npadvmod) treated_11\VBN\2376958|nitrendipine|- (r_amod) group_12\NN\2137|the|treated (r_pobj) in_7\IN\13603305|group (r_prep) increased_6\VBN\169651|furthermore|,|index|was|significantly|in|compared|. (l_nsubjpass) index_3\NN\13850304|glomerulosclerosis (l_compound) glomerulosclerosis_2\NN\0|
7977601
16330766
C040029_D009437 NONE gabapentin_11\NN\2718469|,|drug (l_appos) drug_14\NN\14778436|a|effective (l_amod) effective_15\JJ\0|in (l_prep) in_16\IN\13603305|patients (l_pobj) patients_19\NNS\9898892|neuropathic|pain (l_compound) pain_18\NN\14299637|
C040029_D006930 NONE gabapentin_15\NN\2718469| (r_npadvmod) induced_17\VBN\1627355|gabapentin|- (r_amod) modulation_18\NN\7044917|the|induced|of|in (l_prep) in_22\IN\13603305|response (l_pobj) response_23\NN\11410625|to (l_prep) to_24\IN\0|stimulation (l_pobj) stimulation_27\NN\242808|nociceptive|mechanical|of (l_prep) of_28\IN\0|skin (l_pobj) skin_30\NN\5237755|normal|and|hyperalgesia (l_conj) hyperalgesia_36\NN\0|induced|secondary
D002211_D006930 CID capsaicin_32\NN\15032661| (r_npadvmod) induced_34\VBN\1627355|capsaicin|- (r_amod) hyperalgesia_36\NN\0|induced|secondary
11206082
C036150_D012640 CID carboline_10\NN\0|beta|- (r_npadvmod) induced_12\VBN\1627355|carboline|- (r_amod) seizures_13\NNS\14081375|induced
C036150_D012640 CID carboline-3-carboxylate_32\NN\0|methyl|beta|-|ccm|)|,|agonist (r_pobj) of_28\IN\0|carboline-3-carboxylate (r_prep) injection_27\NN\320852|a|single|i.p.|of (r_pobj) by_23\IN\0|injection (r_agent) induced_22\VBN\1627355|by (r_acl) seizures_21\NNS\14081375|induced
C036150_D012640 CID ccm_36\NNP\0|(|beta|- (r_appos) carboline-3-carboxylate_32\NN\0|methyl|beta|-|ccm|)|,|agonist (r_pobj) of_28\IN\0|carboline-3-carboxylate (r_prep) injection_27\NN\320852|a|single|i.p.|of (r_pobj) by_23\IN\0|injection (r_agent) induced_22\VBN\1627355|by (r_acl) seizures_21\NNS\14081375|induced
D005680_D012640 NONE gaba(a_24\NNP\0| (r_nmod) ligands_27\NNS\20090|other|gaba(a|)|receptor (r_pobj) of_22\IN\0|ligands (r_prep) effects_21\NNS\13245626|various|pharmacological|of (r_pobj) to_18\IN\0|effects (r_prep) sensitive_17\JJ\10488309|differentially|to (r_acomp) are_14\VBP\13600404|lines|also|sensitive|. (l_nsubj) lines_2\NNS\8426461|two|mouse|selected (l_acl) selected_3\VBN\697589|for (l_prep) for_4\IN\0|sensitivities (l_pobj) sensitivities_6\NNS\5651971|differential|to (l_prep) to_7\IN\0|seizures (l_pobj) seizures_13\NNS\14081375|induced
D005680_D012640 NONE gaba(a_44\NNP\0| (r_nmod) site_48\NN\8673395|the|gaba(a|receptor|benzodiazepine (r_pobj) of_42\IN\0|site (r_prep) agonist_41\NN\0|an|inverse|of (r_appos) carboline-3-carboxylate_32\NN\0|methyl|beta|-|ccm|)|,|agonist (r_pobj) of_28\IN\0|carboline-3-carboxylate (r_prep) injection_27\NN\320852|a|single|i.p.|of (r_pobj) by_23\IN\0|injection (r_agent) induced_22\VBN\1627355|by (r_acl) seizures_21\NNS\14081375|induced
D001569_D012640 NONE benzodiazepine_47\NN\3771443| (r_amod) site_48\NN\8673395|the|gaba(a|receptor|benzodiazepine (r_pobj) of_42\IN\0|site (r_prep) agonist_41\NN\0|an|inverse|of (r_appos) carboline-3-carboxylate_32\NN\0|methyl|beta|-|ccm|)|,|agonist (r_pobj) of_28\IN\0|carboline-3-carboxylate (r_prep) injection_27\NN\320852|a|single|i.p.|of (r_pobj) by_23\IN\0|injection (r_agent) induced_22\VBN\1627355|by (r_acl) seizures_21\NNS\14081375|induced
D003975_D012640 NONE diazepam_2\NN\2830852| (r_npadvmod) induced_4\VBN\1627355|diazepam|- (r_amod) anxiolysis_5\NN\0|induced (r_dobj) measured_1\VBD\697589|we|anxiolysis|with|,|sedation|. (l_dobj) sedation_17\NN\14034177|induced|by (l_prep) by_18\IN\0|recording (l_pcomp) recording_19\VBG\6791372|states (l_dobj) states_22\NNS\8491826|the|vigilance|,|and|seizures (l_conj) seizures_30\NNS\14081375|picrotoxin-|after
D003975_D012640 NONE diazepam_14\NN\2830852| (r_npadvmod) induced_16\VBN\1627355|diazepam|- (r_amod) sedation_17\NN\14034177|induced|by (l_prep) by_18\IN\0|recording (l_pcomp) recording_19\VBG\6791372|states (l_dobj) states_22\NNS\8491826|the|vigilance|,|and|seizures (l_conj) seizures_30\NNS\14081375|picrotoxin-|after
D010852_D012640 CID picrotoxin-_25\NN\0|and|induced (r_amod) seizures_30\NNS\14081375|picrotoxin-|after
D010433_D012640 CID pentylenetetrazol_27\NN\3740161| (r_npadvmod) induced_29\VBN\1627355|pentylenetetrazol|- (r_conj) picrotoxin-_25\NN\0|and|induced (r_amod) seizures_30\NNS\14081375|picrotoxin-|after
20067456
D016642_D012735 NONE bupropion_5\NN\0|the|adjunctive|on (l_prep) on_6\IN\0|dysfunction (l_pobj) dysfunction_9\NN\14204950|male|sexual|induced
D016642_D012735 NONE bupropion_8\NN\0|adjunctive|sr|on (l_prep) on_15\IN\0|dysfunction (l_pobj) dysfunction_18\NN\14204950|male|sexual|(|sd|)
D016642_D012735 NONE bupropion_8\NN\0|adjunctive|sr|on (l_prep) on_15\IN\0|dysfunction (l_pobj) dysfunction_18\NN\14204950|male|sexual|(|sd|) (l_appos) sd_20\NN\0|
D016642_D012735 NONE bupropion_8\NN\0|adjunctive|sr|on (r_pobj) of_6\IN\0|bupropion (r_prep) safety_3\NN\13920835|the|and|efficacy|of (r_dobj) determine_1\VB\0|to|safety (r_csubj) induced_22\VBN\1627355|determine|by|,|is|. (l_advcl) is_35\VBZ\0|as|sd|effect|have (l_nsubj) sd_34\NN\0|
D016642_D012735 NONE bupropion_0\NN\0| (r_nsubj) is_1\VBZ\0|bupropion|treatment|. (l_attr) treatment_4\NN\654885|an|effective|for|induced (l_prep) for_5\IN\0|sd (l_pobj) sd_7\NN\0|male
D017367_D012735 NONE inhibitor_16\NN\20090|a|selective|serotonin|reuptake|:|study (r_pobj) by_11\IN\0|inhibitor (r_agent) induced_10\VBN\1627355|by (r_acl) dysfunction_9\NN\14204950|male|sexual|induced
D017367_D012735 NONE inhibitor_28\NN\20090|a|selective|serotonin|reuptake|(|ssri|) (r_pobj) by_23\IN\0|inhibitor (r_agent) induced_22\VBN\1627355|determine|by|,|is|. (l_csubj) determine_1\VB\0|to|safety (l_dobj) safety_3\NN\13920835|the|and|efficacy|of (l_prep) of_6\IN\0|bupropion (l_pobj) bupropion_8\NN\0|adjunctive|sr|on (l_prep) on_15\IN\0|dysfunction (l_pobj) dysfunction_18\NN\14204950|male|sexual|(|sd|)
D017367_D012735 NONE inhibitor_28\NN\20090|a|selective|serotonin|reuptake|(|ssri|) (r_pobj) by_23\IN\0|inhibitor (r_agent) induced_22\VBN\1627355|determine|by|,|is|. (l_csubj) determine_1\VB\0|to|safety (l_dobj) safety_3\NN\13920835|the|and|efficacy|of (l_prep) of_6\IN\0|bupropion (l_pobj) bupropion_8\NN\0|adjunctive|sr|on (l_prep) on_15\IN\0|dysfunction (l_pobj) dysfunction_18\NN\14204950|male|sexual|(|sd|) (l_appos) sd_20\NN\0|
D017367_D012735 NONE inhibitor_28\NN\20090|a|selective|serotonin|reuptake|(|ssri|) (r_pobj) by_23\IN\0|inhibitor (r_agent) induced_22\VBN\1627355|determine|by|,|is|. (l_advcl) is_35\VBZ\0|as|sd|effect|have (l_nsubj) sd_34\NN\0|
D017367_D012735 NONE ssri_30\NNP\2718811| (r_appos) inhibitor_28\NN\20090|a|selective|serotonin|reuptake|(|ssri|) (r_pobj) by_23\IN\0|inhibitor (r_agent) induced_22\VBN\1627355|determine|by|,|is|. (l_csubj) determine_1\VB\0|to|safety (l_dobj) safety_3\NN\13920835|the|and|efficacy|of (l_prep) of_6\IN\0|bupropion (l_pobj) bupropion_8\NN\0|adjunctive|sr|on (l_prep) on_15\IN\0|dysfunction (l_pobj) dysfunction_18\NN\14204950|male|sexual|(|sd|)
D017367_D012735 NONE ssri_30\NNP\2718811| (r_appos) inhibitor_28\NN\20090|a|selective|serotonin|reuptake|(|ssri|) (r_pobj) by_23\IN\0|inhibitor (r_agent) induced_22\VBN\1627355|determine|by|,|is|. (l_csubj) determine_1\VB\0|to|safety (l_dobj) safety_3\NN\13920835|the|and|efficacy|of (l_prep) of_6\IN\0|bupropion (l_pobj) bupropion_8\NN\0|adjunctive|sr|on (l_prep) on_15\IN\0|dysfunction (l_pobj) dysfunction_18\NN\14204950|male|sexual|(|sd|) (l_appos) sd_20\NN\0|
D017367_D012735 NONE ssri_30\NNP\2718811| (r_appos) inhibitor_28\NN\20090|a|selective|serotonin|reuptake|(|ssri|) (r_pobj) by_23\IN\0|inhibitor (r_agent) induced_22\VBN\1627355|determine|by|,|is|. (l_advcl) is_35\VBZ\0|as|sd|effect|have (l_nsubj) sd_34\NN\0|
D017367_D012735 NONE ssris_42\NNS\2718811|and|treatments (r_pobj) of_41\IN\0|ssris (r_prep) effect_40\NN\34213|a|common|side|-|of (r_attr) is_35\VBZ\0|as|sd|effect|have (r_advcl) induced_22\VBN\1627355|determine|by|,|is|. (l_csubj) determine_1\VB\0|to|safety (l_dobj) safety_3\NN\13920835|the|and|efficacy|of (l_prep) of_6\IN\0|bupropion (l_pobj) bupropion_8\NN\0|adjunctive|sr|on (l_prep) on_15\IN\0|dysfunction (l_pobj) dysfunction_18\NN\14204950|male|sexual|(|sd|)
D017367_D012735 NONE ssris_42\NNS\2718811|and|treatments (r_pobj) of_41\IN\0|ssris (r_prep) effect_40\NN\34213|a|common|side|-|of (r_attr) is_35\VBZ\0|as|sd|effect|have (r_advcl) induced_22\VBN\1627355|determine|by|,|is|. (l_csubj) determine_1\VB\0|to|safety (l_dobj) safety_3\NN\13920835|the|and|efficacy|of (l_prep) of_6\IN\0|bupropion (l_pobj) bupropion_8\NN\0|adjunctive|sr|on (l_prep) on_15\IN\0|dysfunction (l_pobj) dysfunction_18\NN\14204950|male|sexual|(|sd|) (l_appos) sd_20\NN\0|
D017367_D012735 NONE ssris_42\NNS\2718811|and|treatments (r_pobj) of_41\IN\0|ssris (r_prep) effect_40\NN\34213|a|common|side|-|of (r_attr) is_35\VBZ\0|as|sd|effect|have (l_nsubj) sd_34\NN\0|
D017367_D012735 NONE ssri_21\NNP\2718811| (r_pobj) of_20\IN\0|ssri (r_prep) type_19\NN\5839024|of (r_appos) sd_17\NN\0|,|type
D017367_D012735 NONE ssris_10\NNS\2718811| (r_pobj) by_9\IN\0|ssris (r_agent) induced_8\VBN\1627355|by (r_acl) treatment_4\NN\654885|an|effective|for|induced (l_prep) for_5\IN\0|sd (l_pobj) sd_7\NN\0|male
2632720
D007654_D006973 CID ketoconazole_7\JJ\0| (r_compound) treatment_8\NN\654885|prolonged|ketoconazole (r_pobj) of_5\IN\0|treatment (r_prep) complication_4\NN\1073995|a|of (r_pobj) as_2\IN\14622893|complication (r_prep) hypertension_1\NN\14057371|arterial|as|.
D007654_D006973 CID ketoconazole_16\JJ\0| (r_pobj) with_15\IN\0|ketoconazole (r_prep) basis_14\NN\13790712|a|term|with (r_pobj) on_9\IN\0|basis (r_prep) treated_8\VBN\2376958|patients|on|developed|. (l_advcl) developed_17\VBN\1753788|hypertension (l_dobj) hypertension_19\NN\14057371|sustained
D007654_D006973 CID ketoconazole_14\JJ\0| (r_compound) therapy_15\NN\657604|ketoconazole|,|yet|monitoring (r_dobj) following_13\VBG\8180190|therapy (r_prep) achieved_12\VBN\2524171|in|levels|had|been|following|demonstrated|. (l_conj) demonstrated_22\VBD\2137132|hypertension (l_dobj) hypertension_23\NN\14057371|31|patient
D007654_D006973 CID ketoconazole_12\NN\0| (r_pobj) of_11\IN\0|ketoconazole (r_prep) doses_10\NNS\3740161|high|of (r_pobj) with_8\IN\0|doses (r_prep) treatment_7\NN\654885|term|with (r_nsubj) induce_14\VB\1627355|that|treatment|may|blockade (l_dobj) blockade_16\NN\952963|enzyme|leading (l_acl) leading_17\VBG\4339291|to (l_prep) to_18\IN\0|hypertension (l_pobj) hypertension_22\NN\14057371|related
D007654_D003480 NONE ketoconazole_16\JJ\0| (r_pobj) with_15\IN\0|ketoconazole (r_prep) basis_14\NN\13790712|a|term|with (r_pobj) on_9\IN\0|basis (r_prep) treated_8\VBN\2376958|patients|on|developed|. (l_nsubj) patients_3\NNS\9898892|14|with (l_prep) with_4\IN\0|syndrome (l_pobj) syndrome_7\NN\5870365|cushing
D006854_D006973 NONE cortisol_8\NN\14751417|free (r_compound) levels_9\NNS\4916342|plasma|urinary|cortisol (r_nsubjpass) achieved_12\VBN\2524171|in|levels|had|been|following|demonstrated|. (l_conj) demonstrated_22\VBD\2137132|hypertension (l_dobj) hypertension_23\NN\14057371|31|patient
1664218
D000677_D002289 NONE amsacrine_5\NN\0| (r_compound) analogue_6\NN\4743605|the|amsacrine (r_pobj) of_3\IN\0|analogue (r_prep) study_2\NN\635850|ii|of|nsc|in|. (l_prep) in_12\IN\13603305|cancer (l_pobj) cancer_18\NN\14239425|small|lung
C042315_D002289 NONE ci-921_7\NNP\0| (r_punct) (_8\-LRB-\0|ci-921 (r_punct) nsc_9\NNP\8123696|(|343499|) (r_appos) study_2\NN\635850|ii|of|nsc|in|. (l_prep) in_12\IN\13603305|cancer (l_pobj) cancer_18\NN\14239425|small|lung
C042315_D002289 NONE 343499_10\CD\0| (r_nummod) nsc_9\NNP\8123696|(|343499|) (r_appos) study_2\NN\635850|ii|of|nsc|in|. (l_prep) in_12\IN\13603305|cancer (l_pobj) cancer_18\NN\14239425|small|lung
6386793
D004308_D003866 NONE hydrochloride_12\NN\14817592|dothiepin (r_pobj) of_10\IN\0|hydrochloride (r_prep) efficacy_7\NN\5199286|the|and|safety|of (r_pobj) of_5\IN\0|efficacy (r_prep) study_4\NN\635850|a|blind|of|in|. (l_prep) in_13\IN\13603305|treatment (l_pobj) treatment_15\NN\654885|the|of (l_prep) of_16\IN\0|disorder (l_pobj) disorder_19\NN\14034177|major|depressive
D004308_D003866 NONE dothiepin_10\JJ\0|and|amitriptyline (r_nsubjpass) compared_14\VBN\644583|in|,|dothiepin|were|to|. (l_prep) to_15\IN\0|placebo (l_pobj) placebo_16\NN\3740161|in (l_prep) in_17\IN\13603305|treatment (l_pobj) treatment_19\NN\654885|the|of (l_prep) of_20\IN\0|outpatients (l_pobj) outpatients_23\NNS\10405694|33|depressed (l_amod) depressed_22\JJ\1819147|
D004308_D003866 NONE dothiepin_0\JJ\0|and|amitriptyline (r_nsubj) were_3\VBD\0|dothiepin|effective|,|and|were (l_acomp) effective_5\JJ\0|equally|in (l_prep) in_6\IN\13603305|alleviating (l_pcomp) alleviating_7\VBG\205885|symptoms (l_dobj) symptoms_9\NNS\5823932|the|of (l_prep) of_10\IN\0|illness (l_pobj) illness_12\NN\14052046|depressive
D004308_D003866 NONE dothiepin_0\NNP\0| (r_nsubjpass) found_3\VBN\13279262|dothiepin|thus|was|be|. (l_xcomp) be_5\VB\14625458|to|drug (l_attr) drug_9\NN\14778436|an|effective|antidepressant|associated (l_acl) associated_10\VBN\628491|with (l_prep) with_11\IN\0|effects (l_pobj) effects_14\NNS\13245626|fewer|side|than (l_prep) than_15\IN\0|amitriptyline (l_pobj) amitriptyline_16\NN\4482543|in (l_prep) in_17\IN\13603305|treatment (l_pobj) treatment_19\NN\654885|the|of (l_prep) of_20\IN\0|outpatients (l_pobj) outpatients_22\NNS\10405694|depressed (l_amod) depressed_21\JJ\1819147|
D000639_D003866 NONE amitriptyline_12\NN\4482543| (r_conj) dothiepin_10\JJ\0|and|amitriptyline (r_nsubjpass) compared_14\VBN\644583|in|,|dothiepin|were|to|. (l_prep) to_15\IN\0|placebo (l_pobj) placebo_16\NN\3740161|in (l_prep) in_17\IN\13603305|treatment (l_pobj) treatment_19\NN\654885|the|of (l_prep) of_20\IN\0|outpatients (l_pobj) outpatients_23\NNS\10405694|33|depressed (l_amod) depressed_22\JJ\1819147|
D000639_D003866 NONE amitriptyline_2\NN\4482543| (r_conj) dothiepin_0\JJ\0|and|amitriptyline (r_nsubj) were_3\VBD\0|dothiepin|effective|,|and|were (l_acomp) effective_5\JJ\0|equally|in (l_prep) in_6\IN\13603305|alleviating (l_pcomp) alleviating_7\VBG\205885|symptoms (l_dobj) symptoms_9\NNS\5823932|the|of (l_prep) of_10\IN\0|illness (l_pobj) illness_12\NN\14052046|depressive
D000639_D003866 NONE amitriptyline_16\NN\4482543|in (l_prep) in_17\IN\13603305|treatment (l_pobj) treatment_19\NN\654885|the|of (l_prep) of_20\IN\0|outpatients (l_pobj) outpatients_22\NNS\10405694|depressed (l_amod) depressed_21\JJ\1819147|
D004308_D014786 NONE dothiepin_24\JJ\0| (r_pobj) with_23\IN\0|dothiepin (r_prep) less_22\JJR\14187378|significantly|with|than (r_acomp) were_20\VBD\0|incidence|less|. (l_nsubj) incidence_2\NN\13821570|the|overall|of (l_prep) of_3\IN\0|effects (l_pobj) effects_5\NNS\13245626|side|and|frequency (l_conj) frequency_8\NN\15286249|the|and|severity|of (l_prep) of_11\IN\0|vision (l_pobj) vision_13\NN\5767733|blurred|,|mouth
D004308_D014987 NONE dothiepin_24\JJ\0| (r_pobj) with_23\IN\0|dothiepin (r_prep) less_22\JJR\14187378|significantly|with|than (r_acomp) were_20\VBD\0|incidence|less|. (l_nsubj) incidence_2\NN\13821570|the|overall|of (l_prep) of_3\IN\0|effects (l_pobj) effects_5\NNS\13245626|side|and|frequency (l_conj) frequency_8\NN\15286249|the|and|severity|of (l_prep) of_11\IN\0|vision (l_pobj) vision_13\NN\5767733|blurred|,|mouth (l_conj) mouth_16\NN\5610008|dry|,|and|drowsiness
D000639_D014786 CID amitriptyline_27\NN\4482543| (r_pobj) with_26\IN\0|amitriptyline (r_prep) than_25\IN\0|with (r_prep) less_22\JJR\14187378|significantly|with|than (r_acomp) were_20\VBD\0|incidence|less|. (l_nsubj) incidence_2\NN\13821570|the|overall|of (l_prep) of_3\IN\0|effects (l_pobj) effects_5\NNS\13245626|side|and|frequency (l_conj) frequency_8\NN\15286249|the|and|severity|of (l_prep) of_11\IN\0|vision (l_pobj) vision_13\NN\5767733|blurred|,|mouth
D000639_D014987 CID amitriptyline_27\NN\4482543| (r_pobj) with_26\IN\0|amitriptyline (r_prep) than_25\IN\0|with (r_prep) less_22\JJR\14187378|significantly|with|than (r_acomp) were_20\VBD\0|incidence|less|. (l_nsubj) incidence_2\NN\13821570|the|overall|of (l_prep) of_3\IN\0|effects (l_pobj) effects_5\NNS\13245626|side|and|frequency (l_conj) frequency_8\NN\15286249|the|and|severity|of (l_prep) of_11\IN\0|vision (l_pobj) vision_13\NN\5767733|blurred|,|mouth (l_conj) mouth_16\NN\5610008|dry|,|and|drowsiness
D000928_D003866 NONE antidepressant_8\NN\3740161| (r_amod) drug_9\NN\14778436|an|effective|antidepressant|associated (l_acl) associated_10\VBN\628491|with (l_prep) with_11\IN\0|effects (l_pobj) effects_14\NNS\13245626|fewer|side|than (l_prep) than_15\IN\0|amitriptyline (l_pobj) amitriptyline_16\NN\4482543|in (l_prep) in_17\IN\13603305|treatment (l_pobj) treatment_19\NN\654885|the|of (l_prep) of_20\IN\0|outpatients (l_pobj) outpatients_22\NNS\10405694|depressed (l_amod) depressed_21\JJ\1819147|
6103707
D005445_D010146 CID flunitrazepam_7\NN\0| (r_pobj) of_6\IN\0|flunitrazepam (r_prep) injection_5\NN\320852|i.m.|of (r_pobj) on_3\IN\0|injection (r_prep) pain_2\NN\14299637|on
17244258
D003520_D003556 CID cyclophosphamide_9\NN\0| (r_npadvmod) induced_11\VBN\1627355|cyclophosphamide|- (r_amod) cystitis_12\NN\14566129|induced|in
D003520_D003556 CID cyclophosphamide_1\NN\0| (r_npadvmod) induced_3\VBN\1627355|cyclophosphamide|- (r_amod) cystitis_4\NN\14566129|induced|in
3173179
D014700_D009203 CID verapamil_0\NNP\2938514| (r_compound) withdrawal_1\NN\7206096|verapamil|as|. (l_prep) as_2\IN\14622893|cause (l_pobj) cause_5\NN\7323922|a|possible|of (l_prep) of_6\IN\0|infarction (l_pobj) infarction_8\NN\14204950|myocardial|in|with
D014700_D009203 CID verapamil_18\NN\2938514| (r_pobj) of_17\IN\0|verapamil (r_prep) withdrawal_16\NN\7206096|the|of|in (r_conj) introduction_11\NN\235435|the|of|and|withdrawal (r_pobj) with_9\IN\0|introduction (r_prep) coincided_8\VBD\2604477|in|infarction|with (l_nsubj) infarction_7\NN\14204950|myocardial
D014700_D006973 NONE verapamil_0\NNP\2938514| (r_compound) withdrawal_1\NN\7206096|verapamil|as|. (l_prep) as_2\IN\14622893|cause (l_pobj) cause_5\NN\7323922|a|possible|of (l_prep) of_6\IN\0|infarction (l_pobj) infarction_8\NN\14204950|myocardial|in|with (l_prep) in_9\IN\13603305|woman (l_pobj) woman_12\NN\9605289|a|hypertensive (l_amod) hypertensive_11\JJ\10405694|
D014700_D006973 NONE verapamil_18\NN\2938514| (r_pobj) of_17\IN\0|verapamil (r_prep) withdrawal_16\NN\7206096|the|of|in (l_prep) in_19\IN\13603305|woman (l_pobj) woman_23\NN\9605289|a|asymptomatic|with (l_prep) with_24\IN\0|hypertension (l_pobj) hypertension_26\NN\14057371|severe
D002216_D009203 NONE captopril_13\NN\2673637| (r_pobj) of_12\IN\0|captopril (r_prep) introduction_11\NN\235435|the|of|and|withdrawal (r_pobj) with_9\IN\0|introduction (r_prep) coincided_8\VBD\2604477|in|infarction|with (l_nsubj) infarction_7\NN\14204950|myocardial
D002216_D006973 NONE captopril_13\NN\2673637| (r_pobj) of_12\IN\0|captopril (r_prep) introduction_11\NN\235435|the|of|and|withdrawal (l_conj) withdrawal_16\NN\7206096|the|of|in (l_prep) in_19\IN\13603305|woman (l_pobj) woman_23\NN\9605289|a|asymptomatic|with (l_prep) with_24\IN\0|hypertension (l_pobj) hypertension_26\NN\14057371|severe
8170551
D000086_D053040 NONE acetazolamide_0\RB\0| (r_npadvmod) induced_2\VBN\1627355|acetazolamide|- (r_amod) nephrolithiasis_3\NN\14115914|induced|:|implications|.
D000086_D053040 NONE acetazolamide_5\NN\0| (r_pobj) of_4\IN\0|acetazolamide (r_prep) complication_3\NN\1073995|a|of (r_attr) is_1\VBZ\0|nephrolithiasis|complication|but|preclude|. (l_nsubj) nephrolithiasis_0\NNP\14115914|
D000086_D009468 NONE acetazolamide_0\RB\0| (r_npadvmod) induced_2\VBN\1627355|acetazolamide|- (r_amod) nephrolithiasis_3\NN\14115914|induced|:|implications|. (l_appos) implications_5\NNS\5774614|for (l_prep) for_6\IN\0|treatment (l_pobj) treatment_7\NN\654885|of (l_prep) of_8\IN\0|disorders (l_pobj) disorders_10\NNS\14034177|neuromuscular
D000086_D007669 CID acetazolamide_3\NN\0|% (r_pobj) on_2\IN\0|acetazolamide (r_prep) patients_1\NNS\9898892|three|on (r_nsubj) developed_8\VBN\1753788|patients|calculi|. (l_dobj) calculi_10\NNS\9416076|renal
19759529
D004298_D012559 NONE dopamine_8\NN\14807737| (r_compound) neurotransmission_9\NN\0|dopamine (r_pobj) in_7\IN\13603305|neurotransmission (r_prep) dysfunction_6\NN\14204950|in (r_pobj) with_5\IN\0|dysfunction (r_prep) associated_4\VBN\628491|schizophrenia|has|been|initially|with|. (l_nsubjpass) schizophrenia_0\NNP\14398067|
D018698_D012559 NONE glutamate_8\NN\15010703| (r_nmod) receptor_19\NN\5225602|the|glutamate|methyl|(|nmda|) (r_pobj) of_6\IN\0|receptor (r_prep) antagonists_5\NNS\7846|of (r_nsubj) produce_20\VBP\7555863|that|antagonists|symptoms (l_dobj) symptoms_24\NNS\5823932|like|in (l_amod) like_23\JJ\5839024|schizophrenic|- (l_npadvmod) schizophrenic_21\JJ\10490141|
D016202_D012559 NONE aspartate_15\NNP\0|d|- (r_appos) methyl_11\NN\14617189|n|-|aspartate (r_nmod) receptor_19\NN\5225602|the|glutamate|methyl|(|nmda|) (r_pobj) of_6\IN\0|receptor (r_prep) antagonists_5\NNS\7846|of (r_nsubj) produce_20\VBP\7555863|that|antagonists|symptoms (l_dobj) symptoms_24\NNS\5823932|like|in (l_amod) like_23\JJ\5839024|schizophrenic|- (l_npadvmod) schizophrenic_21\JJ\10490141|
D016202_D012559 NONE nmda_17\NNP\0| (r_nmod) receptor_19\NN\5225602|the|glutamate|methyl|(|nmda|) (r_pobj) of_6\IN\0|receptor (r_prep) antagonists_5\NNS\7846|of (r_nsubj) produce_20\VBP\7555863|that|antagonists|symptoms (l_dobj) symptoms_24\NNS\5823932|like|in (l_amod) like_23\JJ\5839024|schizophrenic|- (l_npadvmod) schizophrenic_21\JJ\10490141|
D016202_D012559 NONE nmda_41\NNP\0| (r_compound) receptor_42\NN\5225602|its|nmda (r_pobj) via_39\IN\0|receptor (r_prep) dysfunctioning_34\NN\0|a|of|via (r_pobj) of_32\IN\0|dysfunctioning (r_prep) idea_31\NN\5809192|the|of (r_pobj) to_29\IN\0|idea (r_prep) led_28\VBN\3202760|however|,|observation|has|to|. (l_nsubj) observation_3\NN\996969|the|produce (l_relcl) produce_20\VBP\7555863|that|antagonists|symptoms (l_dobj) symptoms_24\NNS\5823932|like|in (l_amod) like_23\JJ\5839024|schizophrenic|- (l_npadvmod) schizophrenic_21\JJ\10490141|
-1_D006948 NONE ssr103800_12\NNP\0| (r_pobj) of_11\IN\0|ssr103800 (r_prep) properties_10\NNS\32613|the|potential|like|of|involving (r_dobj) investigating_4\VBG\575741|properties|,|with (l_prep) with_14\IN\0|focus (l_pobj) focus_17\NN\5704266|a|particular|on|, (l_prep) on_18\IN\0|models (l_pobj) models_19\NNS\5888929|of (l_prep) of_20\IN\0|hyperactivity (l_pobj) hyperactivity_21\NN\14052403|
-1_D006948 NONE ssr103800_3\NNP\0| (r_nmod) hyperactivity_12\NN\14052403|ssr103800|(|mg/kg|p.o.|)|blocked|induced
-1_D006948 NONE ssr103800_3\NNP\0| (r_nmod) hyperactivity_12\NN\14052403|ssr103800|(|mg/kg|p.o.|)|blocked|induced (r_punct) that_2\IN\0|hyperactivity (r_dobj) showed_1\VBD\2137132|results|that|and|reversed|. (l_conj) reversed_26\VBD\109660|partially|hyperactivity (l_dobj) hyperactivity_28\NN\14052403|spontaneous|of
-1_D006948 NONE ssr103800_3\NNP\0| (r_nsubj) failed_4\VBD\0|in|,|ssr103800|affect|or|observed|) (l_xcomp) affect_6\VB\26192|to|hyperactivity (l_dobj) hyperactivity_7\NN\14052403|induced
D000661_D006948 CID amphetamine_30\NN\3248958|(|ie|,|and|) (r_appos) challenge_26\NN\13927383|either|drug|amphetamine|or|mice (r_dobj) involving_23\VBG\2676054|challenge (r_prep) properties_10\NNS\32613|the|potential|like|of|involving (r_dobj) investigating_4\VBG\575741|properties|,|with (l_prep) with_14\IN\0|focus (l_pobj) focus_17\NN\5704266|a|particular|on|, (l_prep) on_18\IN\0|models (l_pobj) models_19\NNS\5888929|of (l_prep) of_20\IN\0|hyperactivity (l_pobj) hyperactivity_21\NN\14052403|
D000661_D006948 CID amphetamine_10\NN\3248958| (r_pobj) by_9\IN\0|amphetamine (r_agent) induced_8\VBN\1627355|by (r_acl) hyperactivity_7\NN\14052403|induced
D016291_D006948 CID mk-801_32\NNP\0| (r_punct) )_33\-RRB-\0|mk-801 (r_punct) amphetamine_30\NN\3248958|(|ie|,|and|) (r_appos) challenge_26\NN\13927383|either|drug|amphetamine|or|mice (r_dobj) involving_23\VBG\2676054|challenge (r_prep) properties_10\NNS\32613|the|potential|like|of|involving (r_dobj) investigating_4\VBG\575741|properties|,|with (l_prep) with_14\IN\0|focus (l_pobj) focus_17\NN\5704266|a|particular|on|, (l_prep) on_18\IN\0|models (l_pobj) models_19\NNS\5888929|of (l_prep) of_20\IN\0|hyperactivity (l_pobj) hyperactivity_21\NN\14052403|
D016291_D006948 CID mk-801_23\NNP\0| (r_punct) and_24\CC\0|mk-801 (r_cc) showed_1\VBD\2137132|results|that|and|reversed|. (l_dobj) that_2\IN\0|hyperactivity (l_punct) hyperactivity_12\NN\14052403|ssr103800|(|mg/kg|p.o.|)|blocked|induced
D016291_D006948 CID mk-801_23\NNP\0| (r_punct) and_24\CC\0|mk-801 (r_cc) showed_1\VBD\2137132|results|that|and|reversed|. (l_conj) reversed_26\VBD\109660|partially|hyperactivity (l_dobj) hyperactivity_28\NN\14052403|spontaneous|of
D016202_D006948 NONE nmda_40\NNP\0| (r_compound) nr1(neo-/-_41\NNP\0|(|ie|,|nmda|)|and|dat(-/- (r_appos) mice_36\NNS\2329401|transgenic|nr1(neo-/-|) (r_conj) challenge_26\NN\13927383|either|drug|amphetamine|or|mice (r_dobj) involving_23\VBG\2676054|challenge (r_prep) properties_10\NNS\32613|the|potential|like|of|involving (r_dobj) investigating_4\VBG\575741|properties|,|with (l_prep) with_14\IN\0|focus (l_pobj) focus_17\NN\5704266|a|particular|on|, (l_prep) on_18\IN\0|models (l_pobj) models_19\NNS\5888929|of (l_prep) of_20\IN\0|hyperactivity (l_pobj) hyperactivity_21\NN\14052403|
D016202_D006948 NONE nmda_19\NNP\0| (r_compound) antagonist_21\NN\7846|the|competitive|nmda|receptor|, (r_pobj) by_14\IN\0|antagonist (r_agent) induced_13\VBN\1627355|by (r_acl) hyperactivity_12\NN\14052403|ssr103800|(|mg/kg|p.o.|)|blocked|induced
D016202_D006948 NONE nmda_19\NNP\0| (r_compound) antagonist_21\NN\7846|the|competitive|nmda|receptor|, (r_pobj) by_14\IN\0|antagonist (r_agent) induced_13\VBN\1627355|by (r_acl) hyperactivity_12\NN\14052403|ssr103800|(|mg/kg|p.o.|)|blocked|induced (r_punct) that_2\IN\0|hyperactivity (r_dobj) showed_1\VBD\2137132|results|that|and|reversed|. (l_conj) reversed_26\VBD\109660|partially|hyperactivity (l_dobj) hyperactivity_28\NN\14052403|spontaneous|of
D016202_D006948 NONE nmda_30\NNP\0| (r_nmod) mice_33\NNS\2329401|nmda|nr1(neo-/-|) (r_pobj) of_29\IN\0|mice (r_prep) hyperactivity_28\NN\14052403|spontaneous|of (r_dobj) reversed_26\VBD\109660|partially|hyperactivity (r_conj) showed_1\VBD\2137132|results|that|and|reversed|. (l_dobj) that_2\IN\0|hyperactivity (l_punct) hyperactivity_12\NN\14052403|ssr103800|(|mg/kg|p.o.|)|blocked|induced
D016202_D006948 NONE nmda_30\NNP\0| (r_nmod) mice_33\NNS\2329401|nmda|nr1(neo-/-|) (r_pobj) of_29\IN\0|mice (r_prep) hyperactivity_28\NN\14052403|spontaneous|of
D004298_D006948 NONE dopamine_15\NN\14807737| (r_compound) transporter_16\NN\4490091|dopamine|(|dat(-/-|) (r_pobj) in_14\IN\13603305|transporter (r_prep) observed_13\VBN\2163746|naturally|in (r_conj) failed_4\VBD\0|in|,|ssr103800|affect|or|observed|) (l_xcomp) affect_6\VB\26192|to|hyperactivity (l_dobj) hyperactivity_7\NN\14052403|induced
D006220_D006948 NONE haloperidol_5\NN\3713736|importantly|,|both|classical|(|)|and|atypical (r_nmod) antipsychotics_16\NNS\4470232|haloperidol|clozapine (r_nsubj) were_17\VBD\0|antipsychotics|effective|. (l_acomp) effective_18\JJ\0|in (l_prep) in_19\IN\13603305|models (l_pobj) models_22\NNS\5888929|all|these|of (l_prep) of_23\IN\0|hyperactivity (l_pobj) hyperactivity_24\NN\14052403|
C076029_D006948 NONE olanzapine_10\NN\0| (r_nmod) clozapine_12\NN\3713736|(|olanzapine|,|and|aripiprazole|) (r_nmod) antipsychotics_16\NNS\4470232|haloperidol|clozapine (r_nsubj) were_17\VBD\0|antipsychotics|effective|. (l_acomp) effective_18\JJ\0|in (l_prep) in_19\IN\13603305|models (l_pobj) models_22\NNS\5888929|all|these|of (l_prep) of_23\IN\0|hyperactivity (l_pobj) hyperactivity_24\NN\14052403|
D003024_D006948 NONE clozapine_12\NN\3713736|(|olanzapine|,|and|aripiprazole|) (r_nmod) antipsychotics_16\NNS\4470232|haloperidol|clozapine (r_nsubj) were_17\VBD\0|antipsychotics|effective|. (l_acomp) effective_18\JJ\0|in (l_prep) in_19\IN\13603305|models (l_pobj) models_22\NNS\5888929|all|these|of (l_prep) of_23\IN\0|hyperactivity (l_pobj) hyperactivity_24\NN\14052403|
C094645_D006948 NONE aripiprazole_14\NN\0| (r_conj) clozapine_12\NN\3713736|(|olanzapine|,|and|aripiprazole|) (r_nmod) antipsychotics_16\NNS\4470232|haloperidol|clozapine (r_nsubj) were_17\VBD\0|antipsychotics|effective|. (l_acomp) effective_18\JJ\0|in (l_prep) in_19\IN\13603305|models (l_pobj) models_22\NNS\5888929|all|these|of (l_prep) of_23\IN\0|hyperactivity (l_pobj) hyperactivity_24\NN\14052403|
-1_D002375 NONE ssr103800_6\NNP\0| (r_nsubj) produce_9\VB\7555863|however|,|unlike|,|ssr103800|did|not|catalepsy|retention|up|together (l_dobj) catalepsy_10\NN\14023236|
9653867
D013974_D013971 CID thyroxine_0\NNP\5413241| (r_compound) abuse_1\NN\418025|thyroxine|:|case|. (l_appos) case_5\NN\7283608|an|unusual|of (l_prep) of_6\IN\0|thyrotoxicosis (l_pobj) thyrotoxicosis_7\NN\14059928|in
D013974_D013971 CID thyroxine_28\NN\5413241| (r_compound) abuse_29\NN\418025|thyroxine (r_nsubjpass) considered_32\VBN\689344|that|remains|,|abuse|should|be|and|explored (l_advcl) remains_25\VBZ\2684|when|cause|obscure (l_nsubj) cause_22\NN\7323922|a|for (l_prep) for_23\IN\0|thyrotoxicosis (l_pobj) thyrotoxicosis_24\NN\14059928|
D013974_D001068 NONE thyroxine_28\NN\5413241| (r_compound) abuse_29\NN\418025|thyroxine (r_nsubjpass) considered_32\VBN\689344|that|remains|,|abuse|should|be|and|explored (r_ccomp) reminds_17\VBZ\0|us|considered (r_conj) illustrates_3\VBZ\955601|in|it|derangements|and|reminds|. (l_dobj) derangements_5\NNS\14395018|the|of (l_prep) of_6\IN\0|function (l_pobj) function_8\NN\13783581|thyroid|seen (l_acl) seen_9\VBN\2106506|in|with (l_prep) with_13\IN\0|eating (l_pcomp) eating_14\VBG\838098|disorders (l_dobj) disorders_15\NNS\14034177|
10807237
D003042_D000783 NONE cocaine_12\NN\3492717| (r_npadvmod) related_14\VBN\628491|cocaine|- (r_amod) aneurysms_15\NNS\14057371|related
D003042_D000783 NONE cocaine_25\NN\3492717| (r_npadvmod) related_27\VBN\628491|cocaine|- (r_amod) aneurysms_28\NNS\14057371|related
D003042_D000783 NONE cocaine_0\NN\3492717| (r_compound) use_1\NN\407535|cocaine (r_nsubj) predisposed_2\VBN\680841|use|rupture|at|. (l_prep) at_5\IN\14622893|age|and|in (l_conj) in_11\IN\13603305|aneurysms (l_pobj) aneurysms_14\NNS\14057371|smaller
D003042_D017542 CID cocaine_0\NN\3492717| (r_compound) use_1\NN\407535|cocaine (r_nsubj) predisposed_2\VBN\680841|use|rupture|at|. (l_dobj) rupture_4\NN\14285662|aneurysmal
7269015
D002066_D006470 CID busulfan_0\NNS\0| (r_npadvmod) induced_2\VBN\1627355|busulfan|- (r_amod) cystitis_4\NN\14566129|induced|hemorrhagic|.
D002066_D006470 CID busulfan_4\NNS\0| (r_npadvmod) induced_6\VBN\1627355|busulfan|- (r_amod) cystitis_8\NN\14566129|a|induced|hemorrhage
D002066_D003556 CID busulfan_0\NNS\0| (r_npadvmod) induced_2\VBN\1627355|busulfan|- (r_amod) cystitis_4\NN\14566129|induced|hemorrhagic|.
D002066_D003556 CID busulfan_4\NNS\0| (r_npadvmod) induced_6\VBN\1627355|busulfan|- (r_amod) cystitis_8\NN\14566129|a|induced|hemorrhage
D002066_D003556 CID busulfan_7\NNS\0| (r_amod) cystitis_8\NN\14566129|busulfan|and|cystitis
D002066_D003556 CID busulfan_7\NNS\0| (r_amod) cystitis_8\NN\14566129|busulfan|and|cystitis (l_conj) cystitis_16\NN\14566129|radiation
D003520_D003556 NONE cyclophosphamide_13\NN\0| (r_npadvmod) induced_15\VBN\1627355|cyclophosphamide|- (r_conj) radiation_11\NN\11452218|both|and|induced (r_nmod) cystitis_16\NN\14566129|radiation (r_conj) cystitis_8\NN\14566129|busulfan|and|cystitis
D003520_D003556 NONE cyclophosphamide_13\NN\0| (r_npadvmod) induced_15\VBN\1627355|cyclophosphamide|- (r_conj) radiation_11\NN\11452218|both|and|induced (r_nmod) cystitis_16\NN\14566129|radiation
D002066_D002277 NONE busulfan_7\NNS\0| (r_pobj) of_6\IN\0|busulfan (r_prep) tendency_5\NN\6193203|the|known|of (r_pobj) of_2\IN\0|tendency (r_prep) view_1\NN\6208021|of (r_pobj) in_0\IN\13603305|view|induce (l_advcl) induce_9\VB\1627355|to|atypia (l_dobj) atypia_11\NN\0|cellular|and|carcinoma|in (l_conj) carcinoma_13\NN\14239918|
15737522
D002443_D001660 CID ceftriaxone_0\NN\2996840| (r_npadvmod) associated_2\VBN\628491|ceftriaxone|- (r_amod) pseudolithiasis_4\NN\0|associated|biliary|in|.
D002443_D001660 CID ceftriaxone_5\NN\2996840| (r_nsubj) leads_6\VBZ\5155821|that|ceftriaxone|pseudolithiasis (l_xcomp) pseudolithiasis_8\NN\0|to|in
D002443_D001660 CID ceftriaxone_19\CD\2996840| (r_compound) treatment_20\NN\654885|ceftriaxone|,|had (r_dobj) receiving_18\VBG\2210855|treatment (r_acl) patients_17\NNS\9898892|paediatric|surgical|receiving (r_pobj) in_14\IN\13603305|patients (r_prep) pseudolithiasis_13\NN\0|in
11587867
D014750_D001927 NONE vincristin_6\NN\0| (r_compound) administration_7\NN\1133281|accidental|intrathecal|vincristin|:|report (r_pobj) due_2\IN\5174653|to|administration (r_prep) myeloencephalopathy_1\NN\0|fatal|due|.
D014750_D054198 NONE vincristine_9\NN\3917455| (r_compound) instillation_10\NN\320852|accidental|intrathecal|vincristine|in (l_prep) in_11\IN\13603305|girl (l_pobj) girl_15\NN\10787470|a|5-year|old|with (l_prep) with_16\IN\0|leucemia (l_pobj) leucemia_20\NN\0|recurrent|acute|lymphoblastic|and|man
D014750_D054198 NONE vincristine_9\NN\3917455| (r_compound) instillation_10\NN\320852|accidental|intrathecal|vincristine|in (l_prep) in_11\IN\13603305|girl (l_pobj) girl_15\NN\10787470|a|5-year|old|with (l_prep) with_16\IN\0|leucemia (l_pobj) leucemia_20\NN\0|recurrent|acute|lymphoblastic|and|man (l_conj) man_25\NN\9605289|a|57-year|old|with (l_prep) with_26\IN\0|lymphoma (l_pobj) lymphoma_28\NN\14239918|lymphoblastic
D014750_D003711 CID vincristine_28\NN\3917455| (r_pobj) to_27\IN\0|vincristine (r_prep) exposed_26\VBN\2110927|to (r_acl) areas_25\NNS\8630985|exposed (r_pobj) in_24\IN\13603305|areas (r_prep) transformation_23\NN\7296428|pseudocystic|in|,|accompanied (r_conj) degeneration_14\NN\29677|of|as|transformation (l_prep) of_15\IN\0|myelin (l_pobj) myelin_16\NN\14864360|and|axons (l_conj) axons_18\NNS\5464104|
D014750_D009410 CID vincristine_28\NN\3917455| (r_pobj) to_27\IN\0|vincristine (r_prep) exposed_26\VBN\2110927|to (r_acl) areas_25\NNS\8630985|exposed (r_pobj) in_24\IN\13603305|areas (r_prep) transformation_23\NN\7296428|pseudocystic|in|,|accompanied (r_conj) degeneration_14\NN\29677|of|as|transformation (l_prep) of_15\IN\0|myelin (l_pobj) myelin_16\NN\14864360|and|axons (l_conj) axons_18\NNS\5464104|
D014750_-1 NONE vincristine_28\NN\3917455| (r_pobj) to_27\IN\0|vincristine (r_prep) exposed_26\VBN\2110927|to (r_acl) areas_25\NNS\8630985|exposed (r_pobj) in_24\IN\13603305|areas (r_prep) transformation_23\NN\7296428|pseudocystic|in|,|accompanied
3031535
D013759_D002375 CID 9-tetrahydrocannabinol_7\NN\0|delta (r_pobj) by_5\IN\0|9-tetrahydrocannabinol (r_agent) induced_4\VBN\1627355|involvement|by|. (l_nsubj) involvement_1\NN\1080366|noradrenergic|in (l_prep) in_2\IN\13603305|catalepsy (l_pobj) catalepsy_3\NN\14023236|
D013759_D002375 CID thc_17\NNP\4017137| (r_pobj) by_16\IN\0|thc (r_agent) induced_15\VBN\1627355|by (r_acl) manifestation_12\NN\7321772|the|of|induced (l_prep) of_13\IN\0|catalepsy (l_pobj) catalepsy_14\NN\14023236|
D013759_D002375 CID thc_17\NNP\4017137| (r_pobj) by_16\IN\0|thc (r_agent) induced_15\VBN\1627355|by (r_acl) manifestation_12\NN\7321772|the|of|induced (r_pobj) in_10\IN\13603305|manifestation (r_prep) role_9\NN\719494|an|important|in (r_dobj) have_6\VBP\7846|that|neurons|role|,|are (l_advcl) are_22\VBP\13600404|whereas|neurons|important|in|induced (l_prep) in_24\IN\13603305|catalepsy (l_pobj) catalepsy_25\NN\14023236|
D006220_D002375 CID haloperidol_28\NN\3713736| (r_pobj) by_27\IN\0|haloperidol (r_agent) induced_26\VBN\1627355|by (r_advcl) are_22\VBP\13600404|whereas|neurons|important|in|induced (r_advcl) have_6\VBP\7846|that|neurons|role|,|are (l_dobj) role_9\NN\719494|an|important|in (l_prep) in_10\IN\13603305|manifestation (l_pobj) manifestation_12\NN\7321772|the|of|induced (l_prep) of_13\IN\0|catalepsy (l_pobj) catalepsy_14\NN\14023236|
D006220_D002375 CID haloperidol_28\NN\3713736| (r_pobj) by_27\IN\0|haloperidol (r_agent) induced_26\VBN\1627355|by (r_advcl) are_22\VBP\13600404|whereas|neurons|important|in|induced (l_prep) in_24\IN\13603305|catalepsy (l_pobj) catalepsy_25\NN\14023236|
8682684
D000082_D007022 CID acetaminophen_0\NNP\2707683| (r_npadvmod) induced_2\VBN\1627355|acetaminophen|- (r_amod) hypotension_3\NN\14057371|induced|.
D000082_D007022 CID acetaminophen_2\RB\2707683| (r_nsubjpass) demonstrated_5\VBN\2137132|however|,|acetaminophen|has|been|produce|. (l_xcomp) produce_7\VB\7555863|to|symptoms (l_dobj) symptoms_8\NNS\5823932|of|,|including|,|in (l_prep) including_12\VBG\0|hypotension (l_pobj) hypotension_13\NN\14057371|
D000082_D007022 CID acetaminophen_18\NN\2707683| (r_pobj) of_17\IN\0|acetaminophen (r_prep) administration_16\NN\1133281|of (r_pobj) after_15\IN\0|administration (r_prep) developed_14\VBN\1753788|in|episodes|reproducibly|after (l_nsubj) episodes_10\NNS\7283608|transient|of (l_prep) of_11\IN\0|hypotension (l_pobj) hypotension_12\NN\14057371|
D000082_D007022 CID acetaminophen_9\NN\2707683| (r_dobj) consider_8\VB\689344|for|clinicians|to|acetaminophen|in (l_prep) in_10\IN\13603305|patients (l_pobj) patients_11\NNS\9898892|with (l_prep) with_12\IN\0|hypotension (l_pobj) hypotension_13\NN\14057371|of
D000082_D002318 NONE acetaminophen_3\NN\2707683| (r_pobj) for_2\IN\0|acetaminophen (r_prep) potential_1\NN\14481929|the|for|produce (l_acl) produce_5\VB\7555863|to|toxicities (l_dobj) toxicities_7\NNS\13576101|cardiovascular
D000082_D000707 NONE acetaminophen_2\RB\2707683| (r_nsubjpass) demonstrated_5\VBN\2137132|however|,|acetaminophen|has|been|produce|. (l_xcomp) produce_7\VB\7555863|to|symptoms (l_dobj) symptoms_8\NNS\5823932|of|,|including|,|in (l_prep) of_9\IN\0|anaphylaxis (l_pobj) anaphylaxis_10\NN\14533203|
D000082_D016638 NONE acetaminophen_18\NN\2707683| (r_pobj) of_17\IN\0|acetaminophen (r_prep) administration_16\NN\1133281|of (r_pobj) after_15\IN\0|administration (r_prep) developed_14\VBN\1753788|in|episodes|reproducibly|after (r_relcl) patients_6\NNS\9898892|two|ill|developed (l_amod) ill_5\JJ\14052403|critically
1616457
D010424_D000647 CID pentobarbital_7\NN\2792049| (r_pobj) by_6\IN\0|pentobarbital (r_agent) caused_5\VBN\1617192|by (r_acl) amnesia_4\NN\5669934|caused
D010424_D000647 CID pentobarbital_15\NN\2792049| (r_nmod) ip_20\NNP\5999797|pentobarbital|(|mg/kg|, (r_pobj) by_14\IN\0|ip (r_agent) produced_13\VBN\1617192|by (r_acl) amnesia_12\NN\5669934|produced
15863244
C106876_D064420 NONE dfu_17\NNP\0|and|study (r_appos) inhibitors_11\NNS\20090|selective|cyclooxygenase-2|in|--|dfu (r_pobj) of_4\IN\0|inhibitors (r_prep) toxicity_3\NN\13576101|developmental|of
C106876_D064420 NONE dfu_22\NNP\0|selective|( (r_conj) toxicity_10\NN\13576101|the|developmental|of|dfu
C106876_D064420 NONE phenyl-2(5h)-furanon_26\XX\0|was|;|5,5-dimethyl-3-(3-fluorophenyl)-4-(4-methylsulphonyl|)|) (l_ccomp) was_5\VBD\0|aim|evaluate (l_xcomp) evaluate_7\VB\670261|to|toxicity (l_dobj) toxicity_10\NN\13576101|the|developmental|of|dfu
C106876_D064420 NONE dfu_10\NNP\0| (r_nmod) toxicity_12\NN\13576101|the|dfu|developmental|observed
D010894_D064420 NONE piroxicam_19\NN\3828465| (r_compound) study_20\NN\635850|piroxicam (r_conj) dfu_17\NNP\0|and|study (r_appos) inhibitors_11\NNS\20090|selective|cyclooxygenase-2|in|--|dfu (r_pobj) of_4\IN\0|inhibitors (r_prep) toxicity_3\NN\13576101|developmental|of
D010894_D064420 NONE piroxicam_17\NN\3828465|the|selective|(|)|and (r_pobj) of_11\IN\0|piroxicam (r_prep) toxicity_10\NN\13576101|the|developmental|of|dfu
D010894_D064420 NONE piroxicam_24\NN\3828465| (r_pobj) of_23\IN\0|piroxicam (r_prep) dose_22\NN\3740161|the|highest|of (r_pobj) with_19\IN\0|dose (r_prep) treated_18\VBN\2376958|with (r_acl) rats_17\NNS\2329401|treated (r_pobj) in_16\IN\13603305|rats (r_prep) found_15\VBN\13279262|toxicity|were|in|. (l_nsubjpass) toxicity_1\NN\13576101|maternal|,|retardation
D010894_D006345 NONE piroxicam_23\NN\3828465|, (r_nmod) inhibitor_31\NN\20090|piroxicam|selective|cox-2|based (r_pobj) to_22\IN\0|inhibitor (r_prep) exposed_21\VBN\2110927|to (r_acl) fetuses_20\NNS\1471682|rat|exposed (r_pobj) for_18\IN\0|fetuses (r_prep) performed_17\VBN\0|analysis|was|for|. (l_nsubjpass) analysis_3\NN\633864|the|pooled|statistical|for (l_prep) for_4\IN\0|defects (l_pobj) defects_15\NNS\14462666|vsd|(|md|)
D010894_D009436 NONE piroxicam_23\NN\3828465|, (r_nmod) inhibitor_31\NN\20090|piroxicam|selective|cox-2|based (r_pobj) to_22\IN\0|inhibitor (r_prep) exposed_21\VBN\2110927|to (r_acl) fetuses_20\NNS\1471682|rat|exposed (r_pobj) for_18\IN\0|fetuses (r_prep) performed_17\VBN\0|analysis|was|for|. (l_nsubjpass) analysis_3\NN\633864|the|pooled|statistical|for (l_prep) for_4\IN\0|defects (l_pobj) defects_15\NNS\14462666|vsd|(|md|)
D010894_D005317 CID piroxicam_24\NN\3828465| (r_pobj) of_23\IN\0|piroxicam (r_prep) dose_22\NN\3740161|the|highest|of (r_pobj) with_19\IN\0|dose (r_prep) treated_18\VBN\2376958|with (r_acl) rats_17\NNS\2329401|treated (r_pobj) in_16\IN\13603305|rats (r_prep) found_15\VBN\13279262|toxicity|were|in|. (l_nsubjpass) toxicity_1\NN\13576101|maternal|,|retardation (l_appos) retardation_5\NN\7296428|intrauterine|growth|,|and|increase
D010894_D009139 CID piroxicam_24\NN\3828465| (r_pobj) of_23\IN\0|piroxicam (r_prep) dose_22\NN\3740161|the|highest|of (r_pobj) with_19\IN\0|dose (r_prep) treated_18\VBN\2376958|with (r_acl) rats_17\NNS\2329401|treated (r_pobj) in_16\IN\13603305|rats (r_prep) found_15\VBN\13279262|toxicity|were|in|. (l_nsubjpass) toxicity_1\NN\13576101|maternal|,|retardation (l_appos) retardation_5\NN\7296428|intrauterine|growth|,|and|increase (l_conj) increase_8\NN\13576355|of (l_prep) of_9\IN\0|variations (l_pobj) variations_13\NNS\7296428|external
2266990
D008454_D020388 NONE mazindol_7\NN\0|in (l_prep) in_8\IN\13603305|dystrophy (l_pobj) dystrophy_10\NN\14151139|duchenne
D008454_D020388 NONE mazindol_7\NN\0| (r_pobj) of_6\IN\0|mazindol (r_prep) trial_5\NN\786195|a|12-month|controlled|of|,|inhibitor|, (r_dobj) conducted_1\VBD\2436349|we|trial|in|. (l_prep) in_16\IN\13603305|boys (l_pobj) boys_18\NNS\9624168|83|with (l_prep) with_19\IN\0|dystrophy (l_pobj) dystrophy_21\NN\14151139|duchenne
D008454_D020388 NONE mazindol_0\JJ\0| (r_compound) doses_1\NNS\3740161|mazindol (r_nsubj) slow_3\VBP\151689|doses|not|progression|. (l_dobj) progression_5\NN\8457976|the|of (l_prep) of_6\IN\0|weakness (l_pobj) weakness_7\NN\14462666|in (l_prep) in_8\IN\13603305|dystrophy (l_pobj) dystrophy_10\NN\14151139|duchenne
D008454_D001068 CID mazindol_4\NN\0| (r_pobj) to_3\IN\0|mazindol (r_prep) attributable_2\JJ\0|to (r_amod) effects_1\NNS\13245626|side|attributable (r_nsubj) included_5\VBN\0|effects|appetite (l_dobj) appetite_7\NN\7485475|decreased|(|%|)|,|mouth|,|change
D008454_D001068 CID mazindol_35\NN\0| (r_amod) dosage_36\NN\13576355|mazindol (r_nsubjpass) reduced_38\VBN\441445|included|;|dosage|was|in|. (l_ccomp) included_5\VBN\0|effects|appetite (l_dobj) appetite_7\NN\7485475|decreased|(|%|)|,|mouth|,|change
D008454_D014987 CID mazindol_4\NN\0| (r_pobj) to_3\IN\0|mazindol (r_prep) attributable_2\JJ\0|to (r_amod) effects_1\NNS\13245626|side|attributable (r_nsubj) included_5\VBN\0|effects|appetite (l_dobj) appetite_7\NN\7485475|decreased|(|%|)|,|mouth|,|change (l_appos) mouth_14\NN\5610008|dry|(|%|)
D008454_D014987 CID mazindol_35\NN\0| (r_amod) dosage_36\NN\13576355|mazindol (r_nsubjpass) reduced_38\VBN\441445|included|;|dosage|was|in|. (l_ccomp) included_5\VBN\0|effects|appetite (l_dobj) appetite_7\NN\7485475|decreased|(|%|)|,|mouth|,|change (l_appos) mouth_14\NN\5610008|dry|(|%|)
D008454_D012817 CID mazindol_4\NN\0| (r_pobj) to_3\IN\0|mazindol (r_prep) attributable_2\JJ\0|to (r_amod) effects_1\NNS\13245626|side|attributable (r_nsubj) included_5\VBN\0|effects|appetite (l_dobj) appetite_7\NN\7485475|decreased|(|%|)|,|mouth|,|change (l_appos) change_21\NN\7283608|behavioral|(|%|)|,|and|symptoms (l_conj) symptoms_29\NNS\5823932|gastrointestinal|(|%|)
D008454_D012817 CID mazindol_35\NN\0| (r_amod) dosage_36\NN\13576355|mazindol (r_nsubjpass) reduced_38\VBN\441445|included|;|dosage|was|in|. (l_ccomp) included_5\VBN\0|effects|appetite (l_dobj) appetite_7\NN\7485475|decreased|(|%|)|,|mouth|,|change (l_appos) change_21\NN\7283608|behavioral|(|%|)|,|and|symptoms (l_conj) symptoms_29\NNS\5823932|gastrointestinal|(|%|)
D008454_D018908 NONE mazindol_0\JJ\0| (r_compound) doses_1\NNS\3740161|mazindol (r_nsubj) slow_3\VBP\151689|doses|not|progression|. (l_dobj) progression_5\NN\8457976|the|of (l_prep) of_6\IN\0|weakness (l_pobj) weakness_7\NN\14462666|in
16428221
D008774_D020293 CID methylphenidate_4\NN\4320126| (r_compound) intake_5\NN\13440063|oral|methylphenidate|in (r_dobj) following_2\VBG\8180190|intake (r_prep) vasculitis_1\NNS\14336539|cerebral|following|:|report|.
D008774_D020293 CID methylphenidate_20\NN\4320126| (r_compound) intake_21\NN\13440063|methylphenidate|in (r_pobj) after_19\IN\0|intake (r_prep) reported_18\VBN\831651|in|stroke|has|been|after|. (r_conj) documented_8\VBN\1000214|vasculitis|is|well|,|and|reported (l_nsubjpass) vasculitis_1\NN\14336539|cerebral|associated
D008774_D019969 NONE methylphenidate_20\NN\4320126| (r_compound) intake_21\NN\13440063|methylphenidate|in (r_pobj) after_19\IN\0|intake (r_prep) reported_18\VBN\831651|in|stroke|has|been|after|. (r_conj) documented_8\VBN\1000214|vasculitis|is|well|,|and|reported (l_nsubjpass) vasculitis_1\NN\14336539|cerebral|associated (l_acl) associated_2\VBN\628491|with (l_prep) with_3\IN\0|abuse (l_pobj) abuse_5\NN\418025|amphetamine
D008774_D002544 NONE methylphenidate_20\NN\4320126| (r_compound) intake_21\NN\13440063|methylphenidate|in (r_pobj) after_19\IN\0|intake (r_prep) reported_18\VBN\831651|in|stroke|has|been|after|. (l_nsubjpass) stroke_15\NN\556313|ischaemic
D008774_D002544 NONE methylphenidate_14\NN\4320126| (r_pobj) with_13\IN\0|methylphenidate (r_prep) treated_12\VBN\2376958|who|was|with|due|and|suffered (l_conj) suffered_19\VBD\2110220|from (l_prep) from_20\IN\0|strokes (l_pobj) strokes_23\NNS\556313|multiple|ischaemic
D008774_D006948 NONE methylphenidate_14\NN\4320126| (r_pobj) with_13\IN\0|methylphenidate (r_prep) treated_12\VBN\2376958|who|was|with|due|and|suffered (l_prep) due_15\IN\5174653|to|hyperactivity (l_pobj) hyperactivity_17\NN\14052403|
D008774_D014657 NONE methylphenidate_3\NN\4320126|vasculitis (l_dobj) vasculitis_5\NN\14336539|mediated
D008774_D014657 NONE methylphenidate_18\NN\4320126| (r_compound) therapy_19\NN\657604|methylphenidate (r_pobj) of_17\IN\0|therapy (r_prep) history_16\NN\15120823|a|of (r_conj) symptoms_13\NNS\5823932|neurological|and|history (r_pobj) with_11\IN\0|symptoms (r_prep) patients_10\NNS\9898892|with (r_pobj) in_9\IN\13603305|patients (r_prep) considered_8\VBN\689344|that|methylphenidate|should|be|in (l_nsubjpass) methylphenidate_3\NN\4320126|vasculitis (l_dobj) vasculitis_5\NN\14336539|mediated
3985451
D014859_D006470 NONE warfarin_0\NNP\2718259| (r_npadvmod) induced_2\VBN\1627355|warfarin|- (r_amod) hemorrhage_4\NN\14285662|induced|iliopsoas|with|.
D014859_D020428 CID warfarin_0\NNP\2718259| (r_npadvmod) induced_2\VBN\1627355|warfarin|- (r_amod) hemorrhage_4\NN\14285662|induced|iliopsoas|with|. (l_prep) with_5\IN\0|palsy (l_pobj) palsy_9\JJ\14557898|subsequent|femoral|nerve
D014859_D020428 CID warfarin_12\RB\2718259| (r_npadvmod) induced_14\VBN\1627355|warfarin|- (r_amod) neuropathy_16\NN\14204950|induced|peripheral (r_pobj) of_11\IN\0|neuropathy (r_prep) form_10\NN\6286395|the|common|of (r_dobj) represents_6\VBZ\2664769|palsy|form (l_nsubj) palsy_5\JJ\14557898|induced|femoral|nerve
D014859_D009135 CID warfarin_12\NN\2718259| (r_compound) therapy_13\NN\657604|chronic|warfarin (r_pobj) on_10\IN\0|therapy (r_prep) man_9\NN\9605289|a|old|on|sustained (l_relcl) sustained_15\VBD\2679899|who|tear|and|developed (l_dobj) tear_19\NN\13771404|a|muscle
D014859_D010146 NONE warfarin_12\NN\2718259| (r_compound) therapy_13\NN\657604|chronic|warfarin (r_pobj) on_10\IN\0|therapy (r_prep) man_9\NN\9605289|a|old|on|sustained (l_relcl) sustained_15\VBD\2679899|who|tear|and|developed (l_conj) developed_21\VBD\1753788|pain (l_dobj) pain_23\NN\14299637|increasing|and|contracture
D014859_D010146 NONE warfarin_12\RB\2718259| (r_npadvmod) induced_14\VBN\1627355|warfarin|- (r_amod) neuropathy_16\NN\14204950|induced|peripheral (r_pobj) of_11\IN\0|neuropathy (r_prep) form_10\NN\6286395|the|common|of (r_dobj) represents_6\VBZ\2664769|palsy|form (r_ccomp) characterized_20\VBN\609683|represents|;|it|is|by|. (l_agent) by_21\IN\0|pain (l_pobj) pain_23\NN\14299637|severe|in|,|degrees
D014859_D003286 NONE warfarin_12\NN\2718259| (r_compound) therapy_13\NN\657604|chronic|warfarin (r_pobj) on_10\IN\0|therapy (r_prep) man_9\NN\9605289|a|old|on|sustained (l_relcl) sustained_15\VBD\2679899|who|tear|and|developed (l_conj) developed_21\VBD\1753788|pain (l_dobj) pain_23\NN\14299637|increasing|and|contracture (l_conj) contracture_27\NN\369802|a|flexure|of
D014859_D003286 NONE warfarin_12\RB\2718259| (r_npadvmod) induced_14\VBN\1627355|warfarin|- (r_amod) neuropathy_16\NN\14204950|induced|peripheral (r_pobj) of_11\IN\0|neuropathy (r_prep) form_10\NN\6286395|the|common|of (r_dobj) represents_6\VBZ\2664769|palsy|form (r_ccomp) characterized_20\VBN\609683|represents|;|it|is|by|. (l_agent) by_21\IN\0|pain (l_pobj) pain_23\NN\14299637|severe|in|,|degrees (l_conj) degrees_30\NNS\4916342|varying|of|,|and|contracture (l_conj) contracture_39\NN\369802|flexure|of
D014859_D010523 NONE warfarin_12\RB\2718259| (r_npadvmod) induced_14\VBN\1627355|warfarin|- (r_amod) neuropathy_16\NN\14204950|induced|peripheral
D014859_D015417 NONE warfarin_12\RB\2718259| (r_npadvmod) induced_14\VBN\1627355|warfarin|- (r_amod) neuropathy_16\NN\14204950|induced|peripheral (r_pobj) of_11\IN\0|neuropathy (r_prep) form_10\NN\6286395|the|common|of (r_dobj) represents_6\VBZ\2664769|palsy|form (r_ccomp) characterized_20\VBN\609683|represents|;|it|is|by|. (l_agent) by_21\IN\0|pain (l_pobj) pain_23\NN\14299637|severe|in|,|degrees (l_conj) degrees_30\NNS\4916342|varying|of|,|and|contracture (l_prep) of_31\IN\0|impairment (l_pobj) impairment_35\NN\7296428|motor
1468485
D010100_D006470 NONE oxygen_1\NN\14622893| (r_compound) therapy_2\NN\657604|hyperbaric|oxygen|for|. (l_prep) for_3\IN\0|control (l_pobj) control_4\NN\5190804|of (l_prep) of_5\IN\0|cystitis (l_pobj) cystitis_11\NN\14566129|intractable|induced|hemorrhagic
D010100_D003556 NONE oxygen_1\NN\14622893| (r_compound) therapy_2\NN\657604|hyperbaric|oxygen|for|. (l_prep) for_3\IN\0|control (l_pobj) control_4\NN\5190804|of (l_prep) of_5\IN\0|cystitis (l_pobj) cystitis_11\NN\14566129|intractable|induced|hemorrhagic
D003520_D006470 CID cyclophosphamide_7\NN\0| (r_npadvmod) induced_9\VBN\1627355|cyclophosphamide|- (r_amod) cystitis_11\NN\14566129|intractable|induced|hemorrhagic
D003520_D006470 CID cyclophosphamide_10\NN\0| (r_compound) therapy_11\NN\657604|cyclophosphamide|for (r_pobj) due_8\IN\5174653|to|therapy (r_prep) report_1\VBP\6470073|we|case|due|. (l_dobj) case_3\NN\7283608|a|of (l_prep) of_4\IN\0|cystitis (l_pobj) cystitis_7\NN\14566129|intractable|hemorrhagic
D003520_D006470 CID cyclophosphamide_16\NN\0| (r_pobj) of_15\IN\0|cyclophosphamide (r_prep) treatment_14\NN\654885|the|of (r_pobj) in_12\IN\13603305|treatment (r_prep) alternative_11\NN\5788149|a|safe|in (r_dobj) offer_8\VB\7160883|in|,|form|can|alternative|cystitis|. (l_dobj) cystitis_20\NN\14566129|induced|hemorrhagic
D003520_D003556 CID cyclophosphamide_7\NN\0| (r_npadvmod) induced_9\VBN\1627355|cyclophosphamide|- (r_amod) cystitis_11\NN\14566129|intractable|induced|hemorrhagic
D003520_D003556 CID cyclophosphamide_10\NN\0| (r_compound) therapy_11\NN\657604|cyclophosphamide|for (r_pobj) due_8\IN\5174653|to|therapy (r_prep) report_1\VBP\6470073|we|case|due|. (l_dobj) case_3\NN\7283608|a|of (l_prep) of_4\IN\0|cystitis (l_pobj) cystitis_7\NN\14566129|intractable|hemorrhagic
D003520_D003556 CID cyclophosphamide_16\NN\0| (r_pobj) of_15\IN\0|cyclophosphamide (r_prep) treatment_14\NN\654885|the|of (r_pobj) in_12\IN\13603305|treatment (r_prep) alternative_11\NN\5788149|a|safe|in (r_dobj) offer_8\VB\7160883|in|,|form|can|alternative|cystitis|. (l_dobj) cystitis_20\NN\14566129|induced|hemorrhagic
D003520_D014890 NONE cyclophosphamide_10\NN\0| (r_compound) therapy_11\NN\657604|cyclophosphamide|for (l_prep) for_12\IN\0|granulomatosis (l_pobj) granulomatosis_15\NN\0|wegener
D015237_D006470 NONE alpha_14\NN\6828818|prostaglandin|f2 (r_pobj) of_11\IN\0|alpha (r_prep) saline_8\NN\14849367|physiological|and|instillation|of (r_pobj) with_6\IN\0|saline (r_prep) irrigation_5\NN\1057200|bladder|with (r_pobj) including_3\VBG\0|irrigation (r_prep) treatment_1\NN\654885|conservative|,|including|, (r_nsubj) failed_16\VBD\0|treatment|control|. (l_xcomp) control_19\VB\5190804|to|totally|hemorrhage (l_dobj) hemorrhage_20\NN\14285662|
2445283
D012254_D006478 NONE ribavirin_5\NN\2725367| (r_pobj) of_4\IN\0|ribavirin (r_prep) effect_3\NN\34213|antiviral|of (r_conj) tolerance_0\NN\5032565|and|effect|in|. (l_prep) in_6\IN\13603305|patients (l_pobj) patients_7\NNS\9898892|with (l_prep) with_8\IN\0|fever (l_pobj) fever_11\NN\14299637|argentine|hemorrhagic
D012254_D006478 NONE ribavirin_5\NN\2725367| (r_pobj) of_4\IN\0|ribavirin (r_prep) effect_3\NN\34213|antiviral|of (r_conj) tolerance_0\NN\5032565|and|effect (r_nsubjpass) studied_7\VBN\0|tolerance|was|in|. (l_prep) in_8\IN\13603305|patients (l_pobj) patients_10\NNS\9898892|6|with (l_prep) with_11\IN\0|fever (l_pobj) fever_14\NN\14299637|argentine|hemorrhagic|(|ahf|)|of
D012254_D006478 NONE ribavirin_5\NN\2725367| (r_pobj) of_4\IN\0|ribavirin (r_prep) effect_3\NN\34213|antiviral|of (r_conj) tolerance_0\NN\5032565|and|effect (r_nsubjpass) studied_7\VBN\0|tolerance|was|in|. (l_prep) in_8\IN\13603305|patients (l_pobj) patients_10\NNS\9898892|6|with (l_prep) with_11\IN\0|fever (l_pobj) fever_14\NN\14299637|argentine|hemorrhagic|(|ahf|)|of (l_appos) ahf_16\NNP\0|
D012254_D006478 NONE ribavirin_7\NN\2725367| (r_nsubj) has_8\VBZ\13888491|that|ribavirin|effect|,|and|managed (l_dobj) effect_11\NN\34213|an|antiviral|in (l_prep) in_12\IN\13603305|cases (l_pobj) cases_14\NNS\7283608|advanced|of (l_prep) of_15\IN\0|ahf (l_pobj) ahf_16\NNP\0|
D012254_D006478 NONE ribavirin_5\RB\2725367| (r_pobj) of_4\IN\0|ribavirin (r_prep) effect_3\NN\34213|the|possible|beneficial|of|during (l_prep) during_6\IN\0|days (l_pobj) days_9\NNS\15140892|the|initial|of (l_prep) of_10\IN\0|ahf (l_pobj) ahf_11\NNP\0|
D012254_D014766 NONE ribavirin_2\RB\2725367| (r_pobj) of_1\IN\0|ribavirin (r_prep) administration_0\NN\1133281|of (r_nsubj) resulted_3\VBD\2633881|administration|in|. (l_prep) in_4\IN\13603305|neutralization (l_pobj) neutralization_6\NN\231567|a|of|and|drop (l_prep) of_7\IN\0|viremia (l_pobj) viremia_8\NN\14204950|
D012254_D000740 CID ribavirin_7\NN\2725367| (r_nsubj) has_8\VBZ\13888491|that|ribavirin|effect|,|and|managed (l_conj) managed_31\VBN\2524171|anemia|can|be|easily|. (l_nsubjpass) anemia_20\NN\14189204|that|,|observed|,
20084309
D008874_D020521 NONE mz_38\NNP\0| (r_compound) dose_39\NN\3740161|the|mz (r_conj) mr_34\NNP\6339416|)|and|dose (r_appos) regurgitation_32\NN\7406350|mitral|(|mr (r_conj) duration_26\NN\15113229|of|,|regurgitation (r_dobj) test_7\VB\5798043|to|influence|duration (l_dobj) influence_9\NN\5190804|the|of (l_prep) of_10\IN\0|variables (l_pobj) variables_13\NNS\2452|the|clinical|:|age|, (l_appos) age_15\NN\4916342|,|sex (l_conj) sex_17\NN\13440063|,|stroke (l_conj) stroke_19\UH\556313|,|mp
D008874_D009202 NONE mz_38\NNP\0| (r_compound) dose_39\NN\3740161|the|mz (r_conj) mr_34\NNP\6339416|)|and|dose (r_appos) regurgitation_32\NN\7406350|mitral|(|mr (r_conj) duration_26\NN\15113229|of|,|regurgitation (r_dobj) test_7\VB\5798043|to|influence|duration (l_dobj) influence_9\NN\5190804|the|of (l_prep) of_10\IN\0|variables (l_pobj) variables_13\NNS\2452|the|clinical|:|age|, (l_appos) age_15\NN\4916342|,|sex (l_conj) sex_17\NN\13440063|,|stroke (l_conj) stroke_19\UH\556313|,|mp (l_conj) mp_23\NNP\10249459|myocardiopathy|(|) (l_amod) myocardiopathy_21\NN\14103288|
D008874_D009202 NONE mz_38\NNP\0| (r_compound) dose_39\NN\3740161|the|mz (r_conj) mr_34\NNP\6339416|)|and|dose (r_appos) regurgitation_32\NN\7406350|mitral|(|mr (r_conj) duration_26\NN\15113229|of|,|regurgitation (r_dobj) test_7\VB\5798043|to|influence|duration (l_dobj) influence_9\NN\5190804|the|of (l_prep) of_10\IN\0|variables (l_pobj) variables_13\NNS\2452|the|clinical|:|age|, (l_appos) age_15\NN\4916342|,|sex (l_conj) sex_17\NN\13440063|,|stroke (l_conj) stroke_19\UH\556313|,|mp (l_conj) mp_23\NNP\10249459|myocardiopathy|(|)
D008874_D009202 NONE mz_17\NNP\0| (r_pobj) of_16\IN\0|mz (r_prep) doses_15\NNS\3740161|high|of (r_appos) mp_8\NNP\10249459|severe|mr|,|(|%|doses|associated
D008874_D008944 NONE mz_38\NNP\0| (r_compound) dose_39\NN\3740161|the|mz (r_conj) mr_34\NNP\6339416|)|and|dose (r_appos) regurgitation_32\NN\7406350|mitral|(|mr
D008874_D008944 NONE mz_38\NNP\0| (r_compound) dose_39\NN\3740161|the|mz (r_conj) mr_34\NNP\6339416|)|and|dose
D008874_D008944 NONE mz_17\NNP\0| (r_pobj) of_16\IN\0|mz (r_prep) doses_15\NNS\3740161|high|of (r_appos) mp_8\NNP\10249459|severe|mr|,|(|%|doses|associated (l_nmod) mr_6\NNP\6339416|
D008874_D000860 CID mz_42\NNP\0| (r_compound) use_43\NN\407535|mz (r_pobj) by_41\IN\0|use (r_agent) caused_40\VBN\1617192|by (r_acl) hypoxia_39\NN\14035298|caused (r_pobj) due_37\JJ\5174653|to|hypoxia (r_prep) presented_20\VBD\2137132|was|;|patients|hypoxia|due|due|. (l_dobj) hypoxia_22\NN\14035298|transient
D008874_D000860 CID mz_42\NNP\0| (r_compound) use_43\NN\407535|mz (r_pobj) by_41\IN\0|use (r_agent) caused_40\VBN\1617192|by (r_acl) hypoxia_39\NN\14035298|caused
D008874_D000402 NONE mz_42\NNP\0| (r_compound) use_43\NN\407535|mz (r_pobj) by_41\IN\0|use (r_agent) caused_40\VBN\1617192|by (r_acl) hypoxia_39\NN\14035298|caused (r_pobj) due_37\JJ\5174653|to|hypoxia (r_prep) presented_20\VBD\2137132|was|;|patients|hypoxia|due|due|. (l_prep) due_23\IN\5174653|to|obstruction (l_pobj) obstruction_27\NN\4341686|upper|airway|by
17439425
D019820_D006973 NONE xanthine_2\NN\14727670| (r_compound) oxidase_3\NN\14732946|xanthine (r_pobj) of_1\IN\0|oxidase (r_prep) role_0\NN\719494|of|in|. (l_prep) in_4\IN\13603305|hypertension (l_pobj) hypertension_8\NN\14057371|induced|in
D019820_D006973 NONE xanthine_5\NN\14727670| (r_compound) oxidase_6\NN\14732946|xanthine|xo|,|implicated|, (r_pobj) of_4\IN\0|oxidase (r_prep) role_3\NN\719494|the|of|in (l_prep) in_22\IN\13603305|hypertension (l_pobj) hypertension_26\NN\14057371|induced|ht
D019820_D006973 NONE xanthine_5\NN\14727670| (r_compound) oxidase_6\NN\14732946|xanthine|xo|,|implicated|, (r_pobj) of_4\IN\0|oxidase (r_prep) role_3\NN\719494|the|of|in (l_prep) in_22\IN\13603305|hypertension (l_pobj) hypertension_26\NN\14057371|induced|ht (l_appos) ht_30\NNP\0|(|dex|-|)
D003907_D006973 CID dexamethasone_5\NN\2721538| (r_npadvmod) induced_7\VBN\1627355|dexamethasone|- (r_amod) hypertension_8\NN\14057371|induced|in
D003907_D006973 CID dexamethasone_23\NN\2721538| (r_npadvmod) induced_25\VBN\1627355|dexamethasone|- (r_amod) hypertension_26\NN\14057371|induced|ht
D003907_D006973 CID dexamethasone_23\NN\2721538| (r_npadvmod) induced_25\VBN\1627355|dexamethasone|- (r_amod) hypertension_26\NN\14057371|induced|ht (l_appos) ht_30\NNP\0|(|dex|-|)
D003907_D006973 CID dex_28\NN\0| (r_compound) ht_30\NNP\0|(|dex|-|) (r_appos) hypertension_26\NN\14057371|induced|ht
D003907_D006973 CID dex_28\NN\0| (r_compound) ht_30\NNP\0|(|dex|-|)
D003907_D006973 CID dex_0\NNP\0| (r_nsubj) increased_1\VBD\169651|dex|sbp|+/-|mmhg|;|p|. (l_dobj) sbp_2\NNP\0|
D003907_D006973 CID dex_4\NN\0| (r_compound) ht_6\NNP\0|dex|-
D009569_D006973 NONE oxide_16\NN\14818238| (r_compound) redox_18\NN\13447361|oxide|- (r_compound) imbalance_19\NN\13934274|nitric|redox (r_pobj) with_14\IN\0|imbalance (r_prep) associated_13\VBN\628491|hypertension|is|with|. (l_nsubjpass) hypertension_3\NN\14057371|induced|ht|in
D009569_D006973 NONE oxide_16\NN\14818238| (r_compound) redox_18\NN\13447361|oxide|- (r_compound) imbalance_19\NN\13934274|nitric|redox (r_pobj) with_14\IN\0|imbalance (r_prep) associated_13\VBN\628491|hypertension|is|with|. (l_nsubjpass) hypertension_3\NN\14057371|induced|ht|in (l_appos) ht_7\NNP\0|(|gc|-|)
D003907_D015431 CID dex_0\NNP\0| (r_nsubj) increased_1\VBD\169651|dex|sbp|+/-|mmhg|;|p|. (l_dep) p_13\NN\14622893|0.001|)|and|decreased (l_conj) decreased_18\VBN\169651|thymus (l_dobj) thymus_19\NN\11579418|(|p|)|and|bodyweights (l_conj) bodyweights_26\NNS\0|(|p
D000493_D006973 NONE allopurinol_0\NNP\3740161| (r_nsubj) prevent_3\VB\0|allopurinol|did|not|ht|. (l_dobj) ht_6\NNP\0|dex|-
D000493_D006973 NONE allopurinol_8\NN\3740161| (r_nsubj) failed_9\VBD\0|that|allopurinol|prevent (r_acl) findings_6\NNS\7951464|our|previous|failed (r_pobj) with_3\IN\0|together|findings (r_prep) induced_14\VBN\1627355|this|,|with|hypertension (l_dobj) hypertension_15\NN\14057371|
D000493_D006973 NONE allopurinol_8\NN\3740161| (r_nsubj) failed_9\VBD\0|that|allopurinol|prevent (r_acl) findings_6\NNS\7951464|our|previous|failed (r_pobj) with_3\IN\0|together|findings (r_prep) induced_14\VBN\1627355|this|,|with|hypertension (r_ccomp) suggests_17\VBZ\1010118|induced|,|is|. (l_ccomp) is_21\VBZ\0|that|activity|not|determinant (l_attr) determinant_25\NN\5686481|a|major|of|in (l_prep) of_26\IN\0|ht (l_pobj) ht_29\NNP\0|gc|-
18329269
D006220_D002375 CID haloperidol_36\NN\3713736| (r_npadvmod) induced_38\VBN\1627355|haloperidol|- (r_amod) model_40\NN\5888929|rat|induced|catalepsy|for (l_compound) catalepsy_39\NN\14023236|
D006220_D010300 NONE haloperidol_36\NN\3713736| (r_npadvmod) induced_38\VBN\1627355|haloperidol|- (r_amod) model_40\NN\5888929|rat|induced|catalepsy|for (l_prep) for_41\IN\0|disease (l_pobj) disease_44\NN\14061805|parkinson
1436384
D000661_D020258 CID amphetamine_2\NN\3248958| (r_npadvmod) induced_4\VBN\1627355|amphetamine|- (r_amod) neurotoxicity_5\NN\0|induced|toward
D000661_D020258 CID amphetamine_10\NN\3248958|and (r_nmod) compounds_13\NNS\5869584|amphetamine|related|toward (r_pobj) of_9\IN\0|compounds (r_prep) effect_8\NN\34213|the|neurotoxic|of (l_amod) neurotoxic_7\JJ\0|
D004298_D020258 NONE dopamine_8\NN\14807737| (r_compound) neurons_9\NNS\5430628|striatal|dopamine|in (r_pobj) toward_6\IN\0|neurons (r_prep) neurotoxicity_5\NN\0|induced|toward
D004298_D020258 NONE dopamine_16\NN\14807737| (r_compound) neurons_17\NNS\5430628|nigrostriatal|dopamine (r_pobj) toward_14\IN\0|neurons (r_prep) compounds_13\NNS\5869584|amphetamine|related|toward (r_pobj) of_9\IN\0|compounds (r_prep) effect_8\NN\34213|the|neurotoxic|of (l_amod) neurotoxic_7\JJ\0|
C070935_D020258 NONE ly274614_13\NNP\0|,|antagonist (r_pobj) by_12\IN\0|ly274614 (r_prep) rodents_11\NNS\1886756|by (r_pobj) in_10\IN\13603305|rodents (r_prep) neurons_9\NNS\5430628|striatal|dopamine|in (r_pobj) toward_6\IN\0|neurons (r_prep) neurotoxicity_5\NN\0|induced|toward
C070935_D020258 NONE ly274614_23\NNP\0| (r_nsubj) is_24\VBZ\0|that|ly274614|antagonist (r_conj) involves_18\VBZ\2676054|that|effect|receptors|and|is (l_nsubj) effect_8\NN\34213|the|neurotoxic|of (l_amod) neurotoxic_7\JJ\0|
D000596_D020258 NONE acid_18\NN\14818238|amino (r_compound) antagonist_19\NN\7846|an|excitatory|acid (r_appos) ly274614_13\NNP\0|,|antagonist (r_pobj) by_12\IN\0|ly274614 (r_prep) rodents_11\NNS\1886756|by (r_pobj) in_10\IN\13603305|rodents (r_prep) neurons_9\NNS\5430628|striatal|dopamine|in (r_pobj) toward_6\IN\0|neurons (r_prep) neurotoxicity_5\NN\0|induced|toward
D016202_D020258 NONE nmda_19\NNP\0| (r_compound) receptors_20\NNS\5225602|nmda (r_dobj) involves_18\VBZ\2676054|that|effect|receptors|and|is (l_nsubj) effect_8\NN\34213|the|neurotoxic|of (l_amod) neurotoxic_7\JJ\0|
D016202_D020258 NONE nmda_26\NNP\0| (r_compound) antagonist_28\NN\7846|an|nmda|receptor|with (r_attr) is_24\VBZ\0|that|ly274614|antagonist (r_conj) involves_18\VBZ\2676054|that|effect|receptors|and|is (l_nsubj) effect_8\NN\34213|the|neurotoxic|of (l_amod) neurotoxic_7\JJ\0|
18020536
D001569_D004244 CID bzds_4\NNP\0| (r_nmod) rds_6\NNS\0|bzds|/ (r_pobj) of_3\IN\0|rds (r_prep) use_2\NN\407535|of (r_nsubjpass) associated_8\VBN\628491|however|,|use|was|with|,|inability|. (l_prep) with_9\IN\0|dizziness (l_pobj) dizziness_10\NN\14299637|
D001569_D007319 CID bzds_4\NNP\0| (r_nmod) rds_6\NNS\0|bzds|/ (r_pobj) of_3\IN\0|rds (r_prep) use_2\NN\407535|of (r_nsubjpass) associated_8\VBN\628491|however|,|use|was|with|,|inability|. (l_npadvmod) inability_12\NN\23271|sleep (l_acl) sleep_14\VB\14034177|to|after
D001569_D005221 CID bzds_4\NNP\0| (r_nmod) rds_6\NNS\0|bzds|/ (r_pobj) of_3\IN\0|rds (r_prep) use_2\NN\407535|of (r_nsubjpass) associated_8\VBN\628491|however|,|use|was|with|,|inability|. (l_npadvmod) inability_12\NN\23271|sleep (l_acl) sleep_14\VB\14034177|to|after (l_prep) after_15\IN\0|awaking|and|with (l_pcomp) awaking_16\VBG\146138|at|in|during (l_prep) at_17\IN\14622893|night (l_pobj) night_18\NN\15113229|and|tiredness (l_conj) tiredness_20\NN\14015731|
D001569_D003866 CID bzds_4\NNP\0| (r_nmod) rds_6\NNS\0|bzds|/ (r_pobj) of_3\IN\0|rds (r_prep) use_2\NN\407535|of (r_nsubjpass) associated_8\VBN\628491|however|,|use|was|with|,|inability|. (l_npadvmod) inability_12\NN\23271|sleep (l_acl) sleep_14\VB\14034177|to|after (l_prep) after_15\IN\0|awaking|and|with (l_conj) with_31\IN\0|symptoms (l_pobj) symptoms_34\NNS\5823932|stronger|depressive|measured
7453952
D008094_D003919 CID lithium_3\NN\14625458| (r_npadvmod) induced_5\VBN\1627355|lithium|- (r_amod) syndrome_11\NN\5870365|the|induced|like|by|in
D008094_D003919 CID lithium_9\NN\14625458| (r_npadvmod) induced_11\VBN\1627355|lithium|- (r_amod) syndrome_17\NN\5870365|the|induced|like|by
D008094_D003919 CID lithium_30\NN\14625458| (r_compound) concentration_31\NN\4916342|the|lithium|in|and|elevation (r_pobj) between_28\IN\0|concentration (r_prep) ratio_27\NN\13815152|the|between (r_pobj) of_25\IN\0|ratio (r_prep) reduction_24\NN\351485|a|of (r_pobj) by_22\IN\0|reduction (r_agent) accompanied_21\VBN\0|in|,|attenuation|was|by|. (l_nsubjpass) attenuation_6\NN\7427337|the|of (l_prep) of_7\IN\0|syndrome (l_pobj) syndrome_17\NN\5870365|the|induced|like|by
D000584_D003919 NONE amiloride_13\NN\0| (r_pobj) by_12\IN\0|amiloride (r_prep) syndrome_11\NN\5870365|the|induced|like|by|in
D000584_D003919 NONE amiloride_19\NN\0| (r_pobj) by_18\IN\0|amiloride (r_prep) syndrome_17\NN\5870365|the|induced|like|by
D000584_D059606 NONE amiloride_3\NN\0| (r_pobj) of_2\IN\0|amiloride (r_prep) effect_1\NN\34213|the|of|on (l_prep) on_4\IN\0|polydipsia|and|on (l_pobj) polydipsia_8\NN\14040660|induced|and|polyuria
D000584_D059606 NONE amiloride_5\NN\0| (r_compound) administration_6\NN\1133281|acute|amiloride|to (l_prep) to_7\IN\0|patients (l_pobj) patients_11\NNS\9898892|treated|suffering (l_acl) suffering_12\VBG\14322699|from (l_prep) from_13\IN\0|polydipsia (l_pobj) polydipsia_14\NN\14040660|and|polyuria
D000584_D059606 NONE amiloride_23\JJ\0| (r_compound) supplementation_24\NN\5108947|prolonged|amiloride (r_nsubj) result_26\VB\34213|supplementation|would|in|and|be (r_conj) relieve_18\VB\205885|that|administration|might|patients|but|result (l_nsubj) administration_6\NN\1133281|acute|amiloride|to (l_prep) to_7\IN\0|patients (l_pobj) patients_11\NNS\9898892|treated|suffering (l_acl) suffering_12\VBG\14322699|from (l_prep) from_13\IN\0|polydipsia (l_pobj) polydipsia_14\NN\14040660|and|polyuria
D000584_D011141 NONE amiloride_3\NN\0| (r_pobj) of_2\IN\0|amiloride (r_prep) effect_1\NN\34213|the|of|on (l_prep) on_4\IN\0|polydipsia|and|on (l_pobj) polydipsia_8\NN\14040660|induced|and|polyuria (l_conj) polyuria_10\NN\14113228|
D000584_D011141 NONE amiloride_5\NN\0| (r_compound) administration_6\NN\1133281|acute|amiloride|to (l_prep) to_7\IN\0|patients (l_pobj) patients_11\NNS\9898892|treated|suffering (l_acl) suffering_12\VBG\14322699|from (l_prep) from_13\IN\0|polydipsia (l_pobj) polydipsia_14\NN\14040660|and|polyuria (l_conj) polyuria_16\NN\14113228|
D000584_D011141 NONE amiloride_23\JJ\0| (r_compound) supplementation_24\NN\5108947|prolonged|amiloride (r_nsubj) result_26\VB\34213|supplementation|would|in|and|be (r_conj) relieve_18\VB\205885|that|administration|might|patients|but|result (l_nsubj) administration_6\NN\1133281|acute|amiloride|to (l_prep) to_7\IN\0|patients (l_pobj) patients_11\NNS\9898892|treated|suffering (l_acl) suffering_12\VBG\14322699|from (l_prep) from_13\IN\0|polydipsia (l_pobj) polydipsia_14\NN\14040660|and|polyuria (l_conj) polyuria_16\NN\14113228|
D008094_D059606 NONE lithium_5\NN\14625458| (r_npadvmod) induced_7\VBN\1627355|lithium|- (r_amod) polydipsia_8\NN\14040660|induced|and|polyuria
D008094_D059606 NONE lithium_14\NN\14625458| (r_compound) concentration_15\NN\4916342|the|lithium|in (r_pobj) on_12\IN\0|concentration (r_conj) on_4\IN\0|polydipsia|and|on (l_pobj) polydipsia_8\NN\14040660|induced|and|polyuria
D008094_D059606 NONE lithium_8\NN\14625458| (r_npadvmod) treated_10\VBN\2376958|lithium|- (r_amod) patients_11\NNS\9898892|treated|suffering (l_acl) suffering_12\VBG\14322699|from (l_prep) from_13\IN\0|polydipsia (l_pobj) polydipsia_14\NN\14040660|and|polyuria
D008094_D059606 NONE lithium_29\NN\14625458| (r_compound) levels_30\NNS\4916342|elevated|lithium (r_pobj) in_27\IN\13603305|levels (r_prep) result_26\VB\34213|supplementation|would|in|and|be (r_conj) relieve_18\VB\205885|that|administration|might|patients|but|result (l_nsubj) administration_6\NN\1133281|acute|amiloride|to (l_prep) to_7\IN\0|patients (l_pobj) patients_11\NNS\9898892|treated|suffering (l_acl) suffering_12\VBG\14322699|from (l_prep) from_13\IN\0|polydipsia (l_pobj) polydipsia_14\NN\14040660|and|polyuria
D008094_D011141 NONE lithium_5\NN\14625458| (r_npadvmod) induced_7\VBN\1627355|lithium|- (r_amod) polydipsia_8\NN\14040660|induced|and|polyuria (l_conj) polyuria_10\NN\14113228|
D008094_D011141 NONE lithium_14\NN\14625458| (r_compound) concentration_15\NN\4916342|the|lithium|in (r_pobj) on_12\IN\0|concentration (r_conj) on_4\IN\0|polydipsia|and|on (l_pobj) polydipsia_8\NN\14040660|induced|and|polyuria (l_conj) polyuria_10\NN\14113228|
D008094_D011141 NONE lithium_8\NN\14625458| (r_npadvmod) treated_10\VBN\2376958|lithium|- (r_amod) patients_11\NNS\9898892|treated|suffering (l_acl) suffering_12\VBG\14322699|from (l_prep) from_13\IN\0|polydipsia (l_pobj) polydipsia_14\NN\14040660|and|polyuria (l_conj) polyuria_16\NN\14113228|
D008094_D011141 NONE lithium_29\NN\14625458| (r_compound) levels_30\NNS\4916342|elevated|lithium (r_pobj) in_27\IN\13603305|levels (r_prep) result_26\VB\34213|supplementation|would|in|and|be (r_conj) relieve_18\VB\205885|that|administration|might|patients|but|result (l_nsubj) administration_6\NN\1133281|acute|amiloride|to (l_prep) to_7\IN\0|patients (l_pobj) patients_11\NNS\9898892|treated|suffering (l_acl) suffering_12\VBG\14322699|from (l_prep) from_13\IN\0|polydipsia (l_pobj) polydipsia_14\NN\14040660|and|polyuria (l_conj) polyuria_16\NN\14113228|
D018021_D059606 NONE licl_37\NNP\0| (r_pobj) with_36\IN\0|licl (r_prep) treated_35\VBN\2376958|chronically|with (r_conj) investigated_30\VBN\644583|effect|was|in|,|treated|. (l_nsubjpass) effect_1\NN\34213|the|of|on (l_prep) on_4\IN\0|polydipsia|and|on (l_pobj) polydipsia_8\NN\14040660|induced|and|polyuria
D018021_D011141 NONE licl_37\NNP\0| (r_pobj) with_36\IN\0|licl (r_prep) treated_35\VBN\2376958|chronically|with (r_conj) investigated_30\VBN\644583|effect|was|in|,|treated|. (l_nsubjpass) effect_1\NN\34213|the|of|on (l_prep) on_4\IN\0|polydipsia|and|on (l_pobj) polydipsia_8\NN\14040660|induced|and|polyuria (l_conj) polyuria_10\NN\14113228|
D011188_D003919 NONE potassium_48\NN\14625458|plasma (r_compound) level_49\NN\4916342|the|potassium (r_pobj) in_45\IN\13603305|level (r_prep) elevation_44\NN\7445480|an|in (r_conj) concentration_31\NN\4916342|the|lithium|in|and|elevation (r_pobj) between_28\IN\0|concentration (r_prep) ratio_27\NN\13815152|the|between (r_pobj) of_25\IN\0|ratio (r_prep) reduction_24\NN\351485|a|of (r_pobj) by_22\IN\0|reduction (r_agent) accompanied_21\VBN\0|in|,|attenuation|was|by|. (l_nsubjpass) attenuation_6\NN\7427337|the|of (l_prep) of_7\IN\0|syndrome (l_pobj) syndrome_17\NN\5870365|the|induced|like|by
10193204
C009438_D013927 NONE tetrandrine_2\NN\0|and|fangchinoline (r_pobj) of_1\IN\0|tetrandrine (r_prep) effects_0\NNS\13245626|of|on|. (l_prep) on_5\IN\0|thrombosis (l_pobj) thrombosis_7\NN\14100769|experimental|in
C009438_D013927 NONE tet_10\NNP\15157225|and|fan (r_pobj) of_9\IN\0|tet (r_prep) effects_8\NNS\13245626|the|of|on (l_prep) on_13\IN\0|thrombosis (l_pobj) thrombosis_16\NN\14100769|the|experimental|induced
C009438_D013927 NONE tet_15\NNP\15157225|and|fan (r_pobj) of_14\IN\0|tet (r_prep) administration_7\NN\1133281|the|(|mg/kg|i.p.|)|of (r_nsubj) showed_20\VBD\2137132|in|,|administration|inhibition|,|acetylsalicylic|. (l_dobj) inhibition_22\NN\1068773|the|of|by|,|respectively (l_prep) of_23\IN\0|thrombosis (l_pobj) thrombosis_24\NN\14100769|
C009438_D001791 NONE tetrandrine_2\NN\0|and|fangchinoline (r_pobj) of_1\IN\0|tetrandrine (r_prep) effects_0\NNS\13245626|of|on|. (l_prep) on_5\IN\0|thrombosis (l_pobj) thrombosis_7\NN\14100769|experimental|in (l_prep) in_8\IN\13603305|mice (l_pobj) mice_9\NNS\2329401|and|aggregation (l_conj) aggregation_13\NN\31264|platelet
C009438_D001791 NONE tet_10\NNP\15157225|and|fan (r_pobj) of_9\IN\0|tet (r_prep) effects_8\NNS\13245626|the|of|on (r_dobj) investigate_6\VB\644583|to|effects (r_advcl) undertaken_4\VBN\1641914|study|was|investigate|,|and|in (l_conj) in_34\IN\13603305|aggregation|vitro|. (l_nsubj) aggregation_30\NN\31264|platelet|and|coagulation
C009438_D001791 NONE tet_14\NNP\15157225|and|fan (r_nsubj) showed_17\VBD\2137132|in|,|tet|dose|dependently|. (l_prep) in_0\IN\13603305|aggregations (l_pobj) aggregations_5\NNS\31264|the|vitro|platelet|induced
C060802_D013927 NONE fangchinoline_4\NN\0| (r_conj) tetrandrine_2\NN\0|and|fangchinoline (r_pobj) of_1\IN\0|tetrandrine (r_prep) effects_0\NNS\13245626|of|on|. (l_prep) on_5\IN\0|thrombosis (l_pobj) thrombosis_7\NN\14100769|experimental|in
C060802_D013927 NONE fan_12\NNP\3183080| (r_conj) tet_10\NNP\15157225|and|fan (r_pobj) of_9\IN\0|tet (r_prep) effects_8\NNS\13245626|the|of|on (l_prep) on_13\IN\0|thrombosis (l_pobj) thrombosis_16\NN\14100769|the|experimental|induced
C060802_D013927 NONE fan_17\NNP\3183080|in (r_conj) tet_15\NNP\15157225|and|fan (r_pobj) of_14\IN\0|tet (r_prep) administration_7\NN\1133281|the|(|mg/kg|i.p.|)|of (r_nsubj) showed_20\VBD\2137132|in|,|administration|inhibition|,|acetylsalicylic|. (l_dobj) inhibition_22\NN\1068773|the|of|by|,|respectively (l_prep) of_23\IN\0|thrombosis (l_pobj) thrombosis_24\NN\14100769|
C060802_D001791 NONE fangchinoline_4\NN\0| (r_conj) tetrandrine_2\NN\0|and|fangchinoline (r_pobj) of_1\IN\0|tetrandrine (r_prep) effects_0\NNS\13245626|of|on|. (l_prep) on_5\IN\0|thrombosis (l_pobj) thrombosis_7\NN\14100769|experimental|in (l_prep) in_8\IN\13603305|mice (l_pobj) mice_9\NNS\2329401|and|aggregation (l_conj) aggregation_13\NN\31264|platelet
C060802_D001791 NONE fan_12\NNP\3183080| (r_conj) tet_10\NNP\15157225|and|fan (r_pobj) of_9\IN\0|tet (r_prep) effects_8\NNS\13245626|the|of|on (r_dobj) investigate_6\VB\644583|to|effects (r_advcl) undertaken_4\VBN\1641914|study|was|investigate|,|and|in (l_conj) in_34\IN\13603305|aggregation|vitro|. (l_nsubj) aggregation_30\NN\31264|platelet|and|coagulation
C060802_D001791 NONE fan_16\NNP\3183080| (r_conj) tet_14\NNP\15157225|and|fan (r_nsubj) showed_17\VBD\2137132|in|,|tet|dose|dependently|. (l_prep) in_0\IN\13603305|aggregations (l_pobj) aggregations_5\NNS\31264|the|vitro|platelet|induced
C009438_D001778 NONE tet_10\NNP\15157225|and|fan (r_pobj) of_9\IN\0|tet (r_prep) effects_8\NNS\13245626|the|of|on (r_dobj) investigate_6\VB\644583|to|effects (r_advcl) undertaken_4\VBN\1641914|study|was|investigate|,|and|in (l_conj) in_34\IN\13603305|aggregation|vitro|. (l_nsubj) aggregation_30\NN\31264|platelet|and|coagulation (l_conj) coagulation_33\NN\13518963|blood
C060802_D001778 NONE fan_12\NNP\3183080| (r_conj) tet_10\NNP\15157225|and|fan (r_pobj) of_9\IN\0|tet (r_prep) effects_8\NNS\13245626|the|of|on (r_dobj) investigate_6\VB\644583|to|effects (r_advcl) undertaken_4\VBN\1641914|study|was|investigate|,|and|in (l_conj) in_34\IN\13603305|aggregation|vitro|. (l_nsubj) aggregation_30\NN\31264|platelet|and|coagulation (l_conj) coagulation_33\NN\13518963|blood
D004837_D013927 CID epinephrine_21\NN\14807929|ep (r_conj) collagen_19\NN\15026716|plus|epinephrine (r_pobj) by_18\IN\0|collagen (r_agent) induced_17\VBN\1627355|by|in (r_acl) thrombosis_16\NN\14100769|the|experimental|induced
D004837_D013927 CID ep_23\NN\0|(|) (r_appos) epinephrine_21\NN\14807929|ep (r_conj) collagen_19\NN\15026716|plus|epinephrine (r_pobj) by_18\IN\0|collagen (r_agent) induced_17\VBN\1627355|by|in (r_acl) thrombosis_16\NN\14100769|the|experimental|induced
D004837_D001791 NONE epinephrine_21\NN\14807929|ep (r_conj) collagen_19\NN\15026716|plus|epinephrine (r_pobj) by_18\IN\0|collagen (r_agent) induced_17\VBN\1627355|by|in (r_acl) thrombosis_16\NN\14100769|the|experimental|induced (r_pobj) on_13\IN\0|thrombosis (r_prep) effects_8\NNS\13245626|the|of|on (r_dobj) investigate_6\VB\644583|to|effects (r_advcl) undertaken_4\VBN\1641914|study|was|investigate|,|and|in (l_conj) in_34\IN\13603305|aggregation|vitro|. (l_nsubj) aggregation_30\NN\31264|platelet|and|coagulation
D004837_D001791 NONE ep_23\NN\0|(|) (r_appos) epinephrine_21\NN\14807929|ep (r_conj) collagen_19\NN\15026716|plus|epinephrine (r_pobj) by_18\IN\0|collagen (r_agent) induced_17\VBN\1627355|by|in (r_acl) thrombosis_16\NN\14100769|the|experimental|induced (r_pobj) on_13\IN\0|thrombosis (r_prep) effects_8\NNS\13245626|the|of|on (r_dobj) investigate_6\VB\644583|to|effects (r_advcl) undertaken_4\VBN\1641914|study|was|investigate|,|and|in (l_conj) in_34\IN\13603305|aggregation|vitro|. (l_nsubj) aggregation_30\NN\31264|platelet|and|coagulation
D004837_D001778 NONE epinephrine_21\NN\14807929|ep (r_conj) collagen_19\NN\15026716|plus|epinephrine (r_pobj) by_18\IN\0|collagen (r_agent) induced_17\VBN\1627355|by|in (r_acl) thrombosis_16\NN\14100769|the|experimental|induced (r_pobj) on_13\IN\0|thrombosis (r_prep) effects_8\NNS\13245626|the|of|on (r_dobj) investigate_6\VB\644583|to|effects (r_advcl) undertaken_4\VBN\1641914|study|was|investigate|,|and|in (l_conj) in_34\IN\13603305|aggregation|vitro|. (l_nsubj) aggregation_30\NN\31264|platelet|and|coagulation (l_conj) coagulation_33\NN\13518963|blood
D004837_D001778 NONE ep_23\NN\0|(|) (r_appos) epinephrine_21\NN\14807929|ep (r_conj) collagen_19\NN\15026716|plus|epinephrine (r_pobj) by_18\IN\0|collagen (r_agent) induced_17\VBN\1627355|by|in (r_acl) thrombosis_16\NN\14100769|the|experimental|induced (r_pobj) on_13\IN\0|thrombosis (r_prep) effects_8\NNS\13245626|the|of|on (r_dobj) investigate_6\VB\644583|to|effects (r_advcl) undertaken_4\VBN\1641914|study|was|investigate|,|and|in (l_conj) in_34\IN\13603305|aggregation|vitro|. (l_nsubj) aggregation_30\NN\31264|platelet|and|coagulation (l_conj) coagulation_33\NN\13518963|blood
D001241_D013927 NONE acid_36\NN\14818238|asa (r_dobj) acetylsalicylic_35\JJ\0|while|acid|mg/kg|,|control|,|showed (r_advcl) showed_20\VBD\2137132|in|,|administration|inhibition|,|acetylsalicylic|. (l_dobj) inhibition_22\NN\1068773|the|of|by|,|respectively (l_prep) of_23\IN\0|thrombosis (l_pobj) thrombosis_24\NN\14100769|
D001241_D013927 NONE asa_38\NNP\0|(|, (r_appos) acid_36\NN\14818238|asa (r_dobj) acetylsalicylic_35\JJ\0|while|acid|mg/kg|,|control|,|showed (r_advcl) showed_20\VBD\2137132|in|,|administration|inhibition|,|acetylsalicylic|. (l_dobj) inhibition_22\NN\1068773|the|of|by|,|respectively (l_prep) of_23\IN\0|thrombosis (l_pobj) thrombosis_24\NN\14100769|
1549199
D007980_D064420 NONE levodopa_9\NN\14604959| (r_compound) therapy_10\NN\657604|levodopa (r_pobj) for_8\IN\0|therapy (r_prep) dose_7\NN\3740161|for (r_dobj) starting_6\NN\457382|dose (r_acl) correct_5\JJ\138508|no|single|starting (r_attr) is_2\VBZ\0|while|there|correct (r_advcl) started_16\VBN\0|is|,|individuals|can|be|on|,|following|. (l_prep) following_27\VBG\8180190|rule (l_pobj) rule_30\NN\5835747|the|general|attempt (l_relcl) attempt_33\VB\407535|not|to|titrate (l_xcomp) titrate_35\VB\489837|to|levodopa (l_dobj) levodopa_38\NN\14604959|carbidopa|-|to|,|"|lead (l_relcl) lead_49\VB\5155821|which|can|to (l_prep) to_50\IN\0|toxicity (l_pobj) toxicity_51\NN\13576101|
D007980_D064420 NONE levodopa_38\NN\14604959|carbidopa|-|to|,|"|lead (l_relcl) lead_49\VB\5155821|which|can|to (l_prep) to_50\IN\0|toxicity (l_pobj) toxicity_51\NN\13576101|
D002230_D064420 NONE carbidopa_36\NN\0| (r_compound) levodopa_38\NN\14604959|carbidopa|-|to|,|"|lead (l_relcl) lead_49\VB\5155821|which|can|to (l_prep) to_50\IN\0|toxicity (l_pobj) toxicity_51\NN\13576101|
D007980_D005767 CID levodopa_13\RB\14604959| (r_npadvmod) induced_15\VBN\1627355|levodopa|- (r_amod) psychosis_16\NN\14380140|induced|,|disturbances (r_conj) hypotension_11\NN\14057371|orthostatic|,|psychosis (r_conj) disorders_8\NNS\14034177|gastrointestinal|,|hypotension
D007980_D007024 CID levodopa_13\RB\14604959| (r_npadvmod) induced_15\VBN\1627355|levodopa|- (r_amod) psychosis_16\NN\14380140|induced|,|disturbances (r_conj) hypotension_11\NN\14057371|orthostatic|,|psychosis
D007980_D011618 NONE levodopa_13\RB\14604959| (r_npadvmod) induced_15\VBN\1627355|levodopa|- (r_amod) psychosis_16\NN\14380140|induced|,|disturbances
D007980_D012893 NONE levodopa_13\RB\14604959| (r_npadvmod) induced_15\VBN\1627355|levodopa|- (r_amod) psychosis_16\NN\14380140|induced|,|disturbances (l_conj) disturbances_19\NNS\407535|sleep|or|parasomnias
D007980_D020447 CID levodopa_13\RB\14604959| (r_npadvmod) induced_15\VBN\1627355|levodopa|- (r_amod) psychosis_16\NN\14380140|induced|,|disturbances (l_conj) disturbances_19\NNS\407535|sleep|or|parasomnias (l_conj) parasomnias_21\NNS\0|,|or|interactions
11773892
D016572_D007674 CID cyclosporine_3\VBP\0|and|tacrolimus (r_appos) inhibitors_2\NNS\20090|the|calcineurin|cyclosporine (r_nsubjpass) known_8\VBN\0|inhibitors|are|both|be|. (l_xcomp) be_10\VB\14625458|to|nephrotoxic (l_acomp) nephrotoxic_11\JJ\0|
D016559_D007674 CID tacrolimus_5\NN\0| (r_conj) cyclosporine_3\VBP\0|and|tacrolimus (r_appos) inhibitors_2\NNS\20090|the|calcineurin|cyclosporine (r_nsubjpass) known_8\VBN\0|inhibitors|are|both|be|. (l_xcomp) be_10\VB\14625458|to|nephrotoxic (l_acomp) nephrotoxic_11\JJ\0|
D003404_D007676 NONE creatinine_20\NN\0|sustained|serum (r_conj) crf_16\NNP\0|,|creatinine (r_conj) controls_7\NNS\5190804|,|crf|;|crf (l_conj) crf_10\NNP\0|no|or|esrd
D003404_D007676 NONE creatinine_20\NN\0|sustained|serum (r_conj) crf_16\NNP\0|,|creatinine (r_conj) controls_7\NNS\5190804|,|crf|;|crf (l_conj) crf_10\NNP\0|no|or|esrd (l_conj) esrd_12\NNP\0|,|n=748
D003404_D007676 NONE creatinine_20\NN\0|sustained|serum (r_conj) crf_16\NNP\0|,|creatinine
D003404_D007676 NONE creatinine_20\NN\0|sustained|serum (r_conj) crf_16\NNP\0|,|creatinine (r_conj) controls_7\NNS\5190804|,|crf|;|crf (r_appos) groups_5\NNS\2137|three|:|controls|>|;|and|n=45 (l_conj) n=45_32\JJ\0|esrd|. (l_nmod) esrd_30\NNS\0|,
D003404_D007676 NONE creatinine_13\NN\0|serum (r_compound) levels_14\NNS\4916342|higher|preoperative|creatinine|,|percentage|,|requirement (r_dobj) had_9\VBD\0|compared|,|patients|levels|. (l_nsubj) patients_8\NNS\9898892|crf|esrd (l_nmod) crf_5\NNP\0|and
D003404_D007676 NONE creatinine_13\NN\0|serum (r_compound) levels_14\NNS\4916342|higher|preoperative|creatinine|,|percentage|,|requirement (r_dobj) had_9\VBD\0|compared|,|patients|levels|. (l_nsubj) patients_8\NNS\9898892|crf|esrd (l_compound) esrd_7\NNP\0|
D003404_D007676 NONE creatinine_42\NN\0|a|higher|1-year|serum (r_conj) requirement_27\NN\1129920|higher|percentage|for|in|,|and|creatinine (r_appos) levels_14\NNS\4916342|higher|preoperative|creatinine|,|percentage|,|requirement (r_dobj) had_9\VBD\0|compared|,|patients|levels|. (l_nsubj) patients_8\NNS\9898892|crf|esrd (l_nmod) crf_5\NNP\0|and
D003404_D007676 NONE creatinine_42\NN\0|a|higher|1-year|serum (r_conj) requirement_27\NN\1129920|higher|percentage|for|in|,|and|creatinine (r_appos) levels_14\NNS\4916342|higher|preoperative|creatinine|,|percentage|,|requirement (r_dobj) had_9\VBD\0|compared|,|patients|levels|. (l_nsubj) patients_8\NNS\9898892|crf|esrd (l_compound) esrd_7\NNP\0|
D003404_D007676 NONE creatinine_16\NN\0|serum (r_pobj) of_14\IN\0|creatinine (r_prep) increase_13\NN\13576355|an|of|compared|,|and (r_nsubj) were_31\VBD\0|that|increase|postoperatively|factors|respectively (l_attr) factors_34\NNS\7326557|independent|risk|for|with (l_prep) for_35\IN\0|development (l_pobj) development_37\NN\248977|the|of (l_prep) of_38\IN\0|crf (l_pobj) crf_39\NNP\0|or|esrd
D003404_D007676 NONE creatinine_16\NN\0|serum (r_pobj) of_14\IN\0|creatinine (r_prep) increase_13\NN\13576355|an|of|compared|,|and (r_nsubj) were_31\VBD\0|that|increase|postoperatively|factors|respectively (l_attr) factors_34\NNS\7326557|independent|risk|for|with (l_prep) for_35\IN\0|development (l_pobj) development_37\NN\248977|the|of (l_prep) of_38\IN\0|crf (l_pobj) crf_39\NNP\0|or|esrd (l_conj) esrd_41\NNP\0|
D003404_D007676 NONE creatinine_11\NN\0|a|higher|preoperative (r_dobj) have_4\VBP\7846|patients|creatinine|and|are|. (l_nsubj) patients_0\NNS\9898892|develop (l_relcl) develop_2\VBP\1753788|who|esrd (l_dobj) esrd_3\NNS\0|
D003404_D007676 NONE creatinine_6\NN\0|serum (r_pobj) of_4\IN\0|creatinine (r_prep) increase_3\NN\13576355|an|of|at|postoperatively (r_nsubj) is_11\VBZ\0|however|,|increase|predictive|. (l_acomp) predictive_13\JJ\0|more|of (l_prep) of_14\IN\0|development (l_pobj) development_16\NN\248977|the|of (l_prep) of_17\IN\0|crf (l_pobj) crf_18\NNP\0|or|esrd
D003404_D007676 NONE creatinine_6\NN\0|serum (r_pobj) of_4\IN\0|creatinine (r_prep) increase_3\NN\13576355|an|of|at|postoperatively (r_nsubj) is_11\VBZ\0|however|,|increase|predictive|. (l_acomp) predictive_13\JJ\0|more|of (l_prep) of_14\IN\0|development (l_pobj) development_16\NN\248977|the|of (l_prep) of_17\IN\0|crf (l_pobj) crf_18\NNP\0|or|esrd (l_conj) esrd_20\NNP\0|
D003404_D006530 NONE creatinine_13\NN\0|serum (r_compound) levels_14\NNS\4916342|higher|preoperative|creatinine|,|percentage|,|requirement (l_appos) percentage_18\NN\13815742|a|greater|of (l_prep) of_19\IN\0|patients (l_pobj) patients_20\NNS\9898892|with (l_prep) with_21\IN\0|syndrome (l_pobj) syndrome_23\NN\5870365|hepatorenal
D003404_D006530 NONE creatinine_42\NN\0|a|higher|1-year|serum (r_conj) requirement_27\NN\1129920|higher|percentage|for|in|,|and|creatinine (r_appos) levels_14\NNS\4916342|higher|preoperative|creatinine|,|percentage|,|requirement (l_appos) percentage_18\NN\13815742|a|greater|of (l_prep) of_19\IN\0|patients (l_pobj) patients_20\NNS\9898892|with (l_prep) with_21\IN\0|syndrome (l_pobj) syndrome_23\NN\5870365|hepatorenal
D003404_D006530 NONE creatinine_11\NN\0|a|higher|preoperative (r_dobj) have_4\VBP\7846|patients|creatinine|and|are|. (l_conj) are_13\VBP\13600404|likely (l_acomp) likely_15\JJ\0|more|have (l_xcomp) have_17\VB\7846|to|syndrome (l_dobj) syndrome_19\NN\5870365|hepatorenal
2375138
D008874_D006323 CID midazolam_2\RB\2830852| (r_npadvmod) associated_4\VBN\628491|midazolam|- (r_amod) arrest_6\NN\88481|possible|intramuscular|associated|cardiorespiratory|and|death|.
D008874_D006323 CID midazolam_17\NN\2830852| (r_pobj) of_16\IN\0|midazolam (r_prep) administration_15\NN\1133281|intramuscular|of (r_pobj) with_13\IN\0|administration (r_prep) associated_12\VBN\628491|with (r_acl) case_6\NN\7283608|the|first|published|of|associated (l_prep) of_7\IN\0|arrest (l_pobj) arrest_9\NN\88481|cardiorespiratory|and|death
D008874_D003643 NONE midazolam_2\RB\2830852| (r_npadvmod) associated_4\VBN\628491|midazolam|- (r_amod) arrest_6\NN\88481|possible|intramuscular|associated|cardiorespiratory|and|death|. (l_conj) death_8\NN\7296428|
D008874_D003643 NONE midazolam_17\NN\2830852| (r_pobj) of_16\IN\0|midazolam (r_prep) administration_15\NN\1133281|intramuscular|of (r_pobj) with_13\IN\0|administration (r_prep) associated_12\VBN\628491|with (r_acl) case_6\NN\7283608|the|first|published|of|associated (l_prep) of_7\IN\0|arrest (l_pobj) arrest_9\NN\88481|cardiorespiratory|and|death (l_conj) death_11\NN\7296428|
9406968
D014667_D003919 NONE vasopressin_5\NN\5407119| (r_compound) gene_6\NN\8459252|vasopressin|in (l_prep) in_7\IN\13603305|nuclei (l_pobj) nuclei_12\NNS\5445668|the|paraventricular|of (l_prep) of_13\IN\0|rat (l_pobj) rat_20\NN\2329401|the|diabetes|insipidus (l_compound) insipidus_19\NN\0|
D008094_D003919 NONE lithium_15\NN\14625458| (r_npadvmod) induced_17\VBN\1627355|lithium|- (r_amod) diabetes_18\NN\14075199|induced (r_compound) rat_20\NN\2329401|the|diabetes|insipidus (l_compound) insipidus_19\NN\0|
D008094_D003919 NONE li_35\NNP\14625458| (r_npadvmod) induced_37\VBN\1627355|li|- (r_amod) diabetes_38\NN\14075199|induced (r_compound) rat_40\NN\2329401|the|diabetes|insipidus (l_compound) insipidus_39\NN\0|
D001127_D011141 NONE vasopressin_4\NN\5407119|arginine (r_pobj) of_2\IN\0|vasopressin (r_prep) expression_1\NN\4679549|the|of (r_nsubjpass) investigated_22\VBN\644583|expression|gene|was|in|polyuria|using|. (l_parataxis) polyuria_29\NN\14113228|(|li)-induced|,
D001127_D011141 NONE avp_6\NNP\0| (r_nmod) gene_8\NN\8459252|(|avp|)|in (r_nsubjpass) investigated_22\VBN\644583|expression|gene|was|in|polyuria|using|. (l_parataxis) polyuria_29\NN\14113228|(|li)-induced|,
D008094_D011141 NONE lithium_26\NN\14625458| (r_pobj) with_25\IN\0|lithium (r_prep) rats_24\NNS\2329401|with (r_pobj) in_23\IN\13603305|rats (r_prep) investigated_22\VBN\644583|expression|gene|was|in|polyuria|using|. (l_parataxis) polyuria_29\NN\14113228|(|li)-induced|,
D008094_D011141 NONE li)-induced_28\JJ\0| (r_amod) polyuria_29\NN\14113228|(|li)-induced|,
D018021_D011141 CID licl_9\NNP\0|(|kg|) (r_dobj) contained_8\VBD\2632940|that|licl|for (r_relcl) diet_6\NN\7560652|a|contained (r_dobj) consuming_4\VBG\1168468|diet (r_acl) rats_3\NNS\2329401|the|male|wistar|consuming (r_nsubj) developed_19\VBN\1753788|rats|polyuria|. (l_dobj) polyuria_21\NN\14113228|marked
D001127_D003681 NONE avp_19\NNP\0|plasma|and (r_pobj) of_17\IN\0|avp (r_prep) elevation_16\NN\7445480|the|of|upregulation (r_pobj) to_14\IN\0|elevation (r_prep) contribute_13\VB\126264|that|dehydration|may|to (l_nsubj) dehydration_4\NN\14536438|and/or|activation
D001127_D003681 NONE avp_24\NNP\0| (r_compound) expression_26\NN\4679549|avp|gene|in (r_pobj) of_23\IN\0|expression (r_prep) upregulation_22\NN\0|the|of (r_conj) elevation_16\NN\7445480|the|of|upregulation (r_pobj) to_14\IN\0|elevation (r_prep) contribute_13\VB\126264|that|dehydration|may|to (l_nsubj) dehydration_4\NN\14536438|and/or|activation
D001127_D003919 NONE avp_19\NNP\0|plasma|and (r_pobj) of_17\IN\0|avp (r_prep) elevation_16\NN\7445480|the|of|upregulation (l_conj) upregulation_22\NN\0|the|of (l_prep) of_23\IN\0|expression (l_pobj) expression_26\NN\4679549|avp|gene|in (l_prep) in_27\IN\13603305|pvn (l_pobj) pvn_29\NN\0|the|and|son (l_conj) son_32\NN\10285938|the|of (l_prep) of_33\IN\0|rat (l_pobj) rat_40\NN\2329401|the|diabetes|insipidus (l_compound) insipidus_39\NN\0|
D001127_D003919 NONE avp_24\NNP\0| (r_compound) expression_26\NN\4679549|avp|gene|in (l_prep) in_27\IN\13603305|pvn (l_pobj) pvn_29\NN\0|the|and|son (l_conj) son_32\NN\10285938|the|of (l_prep) of_33\IN\0|rat (l_pobj) rat_40\NN\2329401|the|diabetes|insipidus (l_compound) insipidus_39\NN\0|
D008094_D003681 NONE li_35\NNP\14625458| (r_npadvmod) induced_37\VBN\1627355|li|- (r_amod) diabetes_38\NN\14075199|induced (r_compound) rat_40\NN\2329401|the|diabetes|insipidus (r_pobj) of_33\IN\0|rat (r_prep) son_32\NN\10285938|the|of (r_conj) pvn_29\NN\0|the|and|son (r_pobj) in_27\IN\13603305|pvn (r_prep) expression_26\NN\4679549|avp|gene|in (r_pobj) of_23\IN\0|expression (r_prep) upregulation_22\NN\0|the|of (r_conj) elevation_16\NN\7445480|the|of|upregulation (r_pobj) to_14\IN\0|elevation (r_prep) contribute_13\VB\126264|that|dehydration|may|to (l_nsubj) dehydration_4\NN\14536438|and/or|activation
4071154
D007213_D051437 NONE indomethacin_0\NNP\3828465| (r_npadvmod) induced_2\VBN\1627355|indomethacin|- (r_amod) insufficiency_4\NN\14462946|induced|renal|:|recurrence|.
D007213_D051437 NONE indomethacin_24\NN\3828465|therapy (r_advcl) reported_2\VBN\831651|we|have|case|indomethacin|. (l_dobj) case_4\NN\7283608|a|of|in (l_prep) of_5\IN\0|failure (l_pobj) failure_9\NN\66216|acute|oliguric|renal|with
D007213_D006947 CID indomethacin_24\NN\3828465|therapy (r_advcl) reported_2\VBN\831651|we|have|case|indomethacin|. (l_dobj) case_4\NN\7283608|a|of|in (l_prep) of_5\IN\0|failure (l_pobj) failure_9\NN\66216|acute|oliguric|renal|with (l_prep) with_10\IN\0|hyperkalemia (l_pobj) hyperkalemia_11\NN\14299637|
D007213_D005355 CID indomethacin_24\NN\3828465|therapy (r_advcl) reported_2\VBN\831651|we|have|case|indomethacin|. (l_dobj) case_4\NN\7283608|a|of|in (l_prep) in_12\IN\13603305|patient (l_pobj) patient_14\NN\9898892|a|with (l_prep) with_15\IN\0|cirrhosis (l_pobj) cirrhosis_16\NN\14116321|,|ascites
D007213_D001201 CID indomethacin_24\NN\3828465|therapy (r_advcl) reported_2\VBN\831651|we|have|case|indomethacin|. (l_dobj) case_4\NN\7283608|a|of|in (l_prep) in_12\IN\13603305|patient (l_pobj) patient_14\NN\9898892|a|with (l_prep) with_15\IN\0|cirrhosis (l_pobj) cirrhosis_16\NN\14116321|,|ascites (l_conj) ascites_18\NNS\14204950|,|and|pulmonale
D007213_D011660 CID indomethacin_24\NN\3828465|therapy (r_advcl) reported_2\VBN\831651|we|have|case|indomethacin|. (l_dobj) case_4\NN\7283608|a|of|in (l_prep) in_12\IN\13603305|patient (l_pobj) patient_14\NN\9898892|a|with (l_prep) with_15\IN\0|cirrhosis (l_pobj) cirrhosis_16\NN\14116321|,|ascites (l_conj) ascites_18\NNS\14204950|,|and|pulmonale (l_conj) pulmonale_22\NN\0|cor|after
D007213_D009846 CID indomethacin_18\NN\3828465| (r_pobj) of_17\IN\0|indomethacin (r_prep) dose_16\NN\3740161|a|single|of (r_pobj) to_13\IN\0|exposure|dose (r_punct) caused_19\VBD\1617192|to|recurrence (l_dobj) recurrence_20\NN\7342049|of (l_prep) of_21\IN\0|oliguria (l_pobj) oliguria_24\NN\14299637|acute|reversible
9660111
D014299_D007035 NONE tri_4\NNP\0|(|given|) (r_nsubj) antagonize_11\VB\1787955|in|tri|does|not|hypothermia|in|and|potentiate|. (l_dobj) hypothermia_14\VBN\14034177|the|reserpine
D012110_D007035 CID reserpine_13\NN\2721160| (r_compound) hypothermia_14\VBN\14034177|the|reserpine
D006916_D007035 NONE 5-hydroxytryptophan_22\JJ\0| (r_poss) head_23\NN\5225090|the|5-hydroxytryptophan (r_compound) twitches_24\NNS\14360459|head|in (r_dobj) potentiate_20\VB\229605|does|not|twitches (r_conj) antagonize_11\VB\1787955|in|tri|does|not|hypothermia|in|and|potentiate|. (l_dobj) hypothermia_14\VBN\14034177|the|reserpine
D014299_D006948 CID tri_0\NNP\0|given (r_nsubj) increases_5\VBZ\13576355|tri|hyperactivity|. (l_dobj) hyperactivity_8\NN\14052403|the|locomotor|induced
D003913_D006948 CID amphetamine_13\NN\3248958|d|-|,|quinpirole (r_pobj) by_10\IN\0|amphetamine (r_agent) induced_9\VBN\1627355|by (r_acl) hyperactivity_8\NN\14052403|the|locomotor|induced
D019257_D006948 CID quinpirole_15\NN\0|and|(|+|dipropyloaminotetralin (r_conj) amphetamine_13\NN\3248958|d|-|,|quinpirole (r_pobj) by_10\IN\0|amphetamine (r_agent) induced_9\VBN\1627355|by (r_acl) hyperactivity_8\NN\14052403|the|locomotor|induced
D004298_D006948 NONE dopamine_24\NN\14807737| (r_compound) d2_25\NN\0|dopamine|and|effects (r_appos) dipropyloaminotetralin_22\NN\0|)|-7-hydroxy|-|(|d2|) (r_conj) quinpirole_15\NN\0|and|(|+|dipropyloaminotetralin (r_conj) amphetamine_13\NN\3248958|d|-|,|quinpirole (r_pobj) by_10\IN\0|amphetamine (r_agent) induced_9\VBN\1627355|by (r_acl) hyperactivity_8\NN\14052403|the|locomotor|induced
D010656_D010554 NONE phenylephrine_7\NN\2682038|given|evaluated (l_acl) evaluated_15\VBN\670261|in|as|aggressiveness (l_conj) aggressiveness_25\NN\4835724|the|evoked
D003000_D010554 NONE clonidine_28\NN\2721160| (r_pobj) by_27\IN\0|clonidine (r_agent) evoked_26\VBN\1617192|by|in (r_acl) aggressiveness_25\NN\4835724|the|evoked
17879945
D019438_D050197 CID ritonavir_5\VBZ\4013993| (r_compound) treatment_6\NN\654885|ritonavir (r_nsubj) increases_7\VBZ\13576355|that|treatment|formation|to (l_dobj) formation_10\NN\7938773|atherosclerotic|lesion|in (l_compound) lesion_9\NN\14204950|
7802851
D000525_D016584 NONE alprazolam_3\NN\2830852|and|placebo (r_pobj) of_2\IN\0|alprazolam (r_prep) efficacy_1\NN\5199286|the|of|in|,|and|effect (l_prep) in_6\IN\13603305|disorder (l_pobj) disorder_8\NN\14034177|panic|with
D000525_D016584 NONE alprazolam_20\NN\2830852|to|or|placebo (r_xcomp) randomised_18\VBN\278117|in|were|alprazolam|. (l_prep) in_0\IN\13603305|london (l_pobj) london_1\NNP\0|and|patients (l_conj) patients_5\NNS\9898892|toronto|154|met (l_relcl) met_7\VBD\0|who|criteria (l_dobj) criteria_11\NNS\13577171|iii|for (l_prep) for_12\IN\0|disorder (l_pobj) disorder_14\NN\14034177|panic|with
D000525_D000379 NONE alprazolam_3\NN\2830852|and|placebo (r_pobj) of_2\IN\0|alprazolam (r_prep) efficacy_1\NN\5199286|the|of|in|,|and|effect (l_prep) in_6\IN\13603305|disorder (l_pobj) disorder_8\NN\14034177|panic|with (l_prep) with_9\IN\0|agoraphobia (l_pobj) agoraphobia_10\NNP\14381416|
D000525_D000379 NONE alprazolam_20\NN\2830852|to|or|placebo (r_xcomp) randomised_18\VBN\278117|in|were|alprazolam|. (l_prep) in_0\IN\13603305|london (l_pobj) london_1\NNP\0|and|patients (l_conj) patients_5\NNS\9898892|toronto|154|met (l_relcl) met_7\VBD\0|who|criteria (l_dobj) criteria_11\NNS\13577171|iii|for (l_prep) for_12\IN\0|disorder (l_pobj) disorder_14\NN\14034177|panic|with (l_prep) with_15\IN\0|agoraphobia (l_pobj) agoraphobia_16\NNP\14381416|
D000525_D003866 CID alprazolam_5\NN\2830852| (r_compound) patients_6\NNS\9898892|alprazolam (r_nsubj) developed_7\VBD\1753788|compared|,|patients|reactions|. (l_dobj) reactions_10\NNS\13446390|adverse|(|%|)|of|;|and|effects (l_prep) of_18\IN\0|depression (l_pobj) depression_19\NN\14373582|,|enuresis
D000525_D004775 CID alprazolam_5\NN\2830852| (r_compound) patients_6\NNS\9898892|alprazolam (r_nsubj) developed_7\VBD\1753788|compared|,|patients|reactions|. (l_dobj) reactions_10\NNS\13446390|adverse|(|%|)|of|;|and|effects (l_prep) of_18\IN\0|depression (l_pobj) depression_19\NN\14373582|,|enuresis (l_conj) enuresis_21\NN\13496972|,|disinhibition
D000525_D001523 NONE alprazolam_5\NN\2830852| (r_compound) patients_6\NNS\9898892|alprazolam (r_nsubj) developed_7\VBD\1753788|compared|,|patients|reactions|. (l_dobj) reactions_10\NNS\13446390|adverse|(|%|)|of|;|and|effects (l_prep) of_18\IN\0|depression (l_pobj) depression_19\NN\14373582|,|enuresis (l_conj) enuresis_21\NN\13496972|,|disinhibition (l_conj) disinhibition_23\NN\0|and|aggression (l_conj) aggression_25\NN\4657876|
D000525_D001523 NONE alprazolam_5\NN\2830852| (r_compound) patients_6\NNS\9898892|alprazolam (r_nsubj) developed_7\VBD\1753788|compared|,|patients|reactions|. (l_dobj) reactions_10\NNS\13446390|adverse|(|%|)|of|;|and|effects (l_conj) effects_31\NNS\13245626|more|side|-|,|sedation (l_appos) sedation_34\NN\14034177|particularly|,|irritability (l_conj) irritability_36\NN\7552087|,|memory
D000525_D008569 CID alprazolam_5\NN\2830852| (r_compound) patients_6\NNS\9898892|alprazolam (r_nsubj) developed_7\VBD\1753788|compared|,|patients|reactions|. (l_dobj) reactions_10\NNS\13446390|adverse|(|%|)|of|;|and|effects (l_conj) effects_31\NNS\13245626|more|side|-|,|sedation (l_appos) sedation_34\NN\14034177|particularly|,|irritability (l_conj) irritability_36\NN\7552087|,|memory (l_conj) memory_39\NN\5926676|impaired|,|loss
D000525_D015431 CID alprazolam_5\NN\2830852| (r_compound) patients_6\NNS\9898892|alprazolam (r_nsubj) developed_7\VBD\1753788|compared|,|patients|reactions|. (l_dobj) reactions_10\NNS\13446390|adverse|(|%|)|of|;|and|effects (l_conj) effects_31\NNS\13245626|more|side|-|,|sedation (l_appos) sedation_34\NN\14034177|particularly|,|irritability (l_conj) irritability_36\NN\7552087|,|memory (l_conj) memory_39\NN\5926676|impaired|,|loss (l_conj) loss_42\NN\13252973|weight|and|ataxia
D000525_D001259 CID alprazolam_5\NN\2830852| (r_compound) patients_6\NNS\9898892|alprazolam (r_nsubj) developed_7\VBD\1753788|compared|,|patients|reactions|. (l_dobj) reactions_10\NNS\13446390|adverse|(|%|)|of|;|and|effects (l_conj) effects_31\NNS\13245626|more|side|-|,|sedation (l_appos) sedation_34\NN\14034177|particularly|,|irritability (l_conj) irritability_36\NN\7552087|,|memory (l_conj) memory_39\NN\5926676|impaired|,|loss (l_conj) loss_42\NN\13252973|weight|and|ataxia (l_conj) ataxia_44\NN\14084880|
15572383
D004317_D007674 NONE adriamycin_12\NNS\0| (r_advmod) induced_14\VBN\1627355|adriamycin|- (r_amod) damage_16\NN\7296428|induced|renal
D004317_D007674 NONE adriamycin_23\NNS\0| (r_pobj) of_22\IN\0|adriamycin (r_prep) injection_21\NN\320852|a|single|of|in (r_pobj) by_18\IN\0|injection (r_agent) induced_17\VBN\1627355|by (r_acl) severity_13\NN\5036394|the|of|induced (l_prep) of_14\IN\0|damage (l_pobj) damage_16\NN\7296428|renal
D004317_D007674 NONE adriamycin_3\NNS\0|anticipated|,|proteinuria|. (l_pobj) proteinuria_7\NN\14299637|elicited|nephrotic|range|,|damage (l_conj) damage_11\NN\7296428|renal|interstitial|and|glomerulosclerosis
D004317_D007674 NONE adriamycin_10\NNS\0| (r_advmod) induced_12\VBN\1627355|adriamycin|- (r_amod) damage_14\NN\7296428|induced|renal|in
D004317_D011507 CID adriamycin_10\NNS\0|[|intravenously (r_pobj) by_9\IN\0|adriamycin (r_agent) induced_8\VBN\1627355|after|,|proteinuria|was|by|. (l_nsubjpass) proteinuria_6\NN\14299637|
D004317_D011507 CID adriamycin_3\NNS\0|anticipated|,|proteinuria|. (l_pobj) proteinuria_7\NN\14299637|elicited|nephrotic|range|,|damage
D004317_D011507 CID adriamycin_12\NNS\0|after|0.62|,|actin (r_advcl) correlated_4\VBD\2657219|ace|positively|with|adriamycin (l_prep) with_5\IN\0|rise (l_pobj) rise_8\NN\7324673|the|relative|in (l_prep) in_9\IN\13603305|proteinuria (l_pobj) proteinuria_10\NN\14299637|
D004317_D009404 NONE adriamycin_3\NNS\0|anticipated|,|proteinuria|. (l_pobj) proteinuria_7\NN\14299637|elicited|nephrotic|range|,|damage (l_amod) nephrotic_5\JJ\0|
D004317_D005923 NONE adriamycin_3\NNS\0|anticipated|,|proteinuria|. (l_pobj) proteinuria_7\NN\14299637|elicited|nephrotic|range|,|damage (l_conj) damage_11\NN\7296428|renal|interstitial|and|glomerulosclerosis (l_conj) glomerulosclerosis_15\NN\0|mild|focal
10342929
D000806_D000799 CID inhibitors_4\NNS\20090|ace|:|common (r_pobj) to_2\IN\0|inhibitors (r_pcomp) due_1\IN\5174653|to (r_prep) angioedema_0\NNP\14316714|due|.
D000806_D000799 CID inhibitor_13\NN\20090| (r_compound) treatment_14\NN\654885|ace|)|inhibitor (r_nsubj) is_15\VBZ\0|incidence|(|treatment|patients|. (l_nsubj) incidence_2\NN\13821570|the|estimated|of|during (l_prep) of_3\IN\0|angioedema (l_pobj) angioedema_4\NN\14316714|
9245658
D009538_D002318 CID nicotine_3\NN\14712692| (r_pobj) of_2\IN\0|nicotine (r_prep) role_1\NN\719494|the|of|in|. (l_prep) in_4\IN\13603305|disease (l_pobj) disease_9\NN\14061805|related|cardiovascular
D009538_D002318 CID nicotine_0\NNP\14712692| (r_nsubj) activates_1\VBZ\1641914|nicotine|system|and|contribute (l_conj) contribute_11\VB\126264|in|could|to|. (l_prep) to_12\IN\0|disease (l_pobj) disease_14\NN\14061805|cardiovascular
D009538_D050197 CID nicotine_7\NN\14712692| (r_nsubj) play_9\VB\7007684|that|nicotine|could|role|, (l_dobj) role_11\NN\719494|a|in (l_prep) in_12\IN\13603305|accelerating (l_pcomp) accelerating_13\VBG\226566|atherosclerosis (l_dobj) atherosclerosis_14\NN\14108324|
D009538_D013927 NONE nicotine_0\NN\14712692| (r_nsubj) appear_3\VB\2604760|nicotine|does|not|enhance|. (l_xcomp) enhance_5\VB\227165|to|thrombosis (l_dobj) thrombosis_6\NN\14100769|among
2440413
D001556_D012640 NONE hexachlorocyclohexane_5\NN\0|gamma|-|lindane (r_pobj) of_2\IN\0|hexachlorocyclohexane (r_prep) effects_1\NNS\13245626|differential|of|on|. (l_prep) on_9\IN\0|seizures (l_pobj) seizures_13\NNS\14081375|induced
D001556_D012640 NONE lindane_7\NN\14919948|(|) (r_appos) hexachlorocyclohexane_5\NN\0|gamma|-|lindane (r_pobj) of_2\IN\0|hexachlorocyclohexane (r_prep) effects_1\NNS\13245626|differential|of|on|. (l_prep) on_9\IN\0|seizures (l_pobj) seizures_13\NNS\14081375|induced
D001556_D012640 NONE hexachlorocyclohexane_2\NN\0|gamma|-|(|hch|)|,|ingredient|, (r_nsubjpass) shown_19\VBN\2137132|hexachlorocyclohexane|has|been|decrease|) (l_xcomp) decrease_21\VB\7296428|to|threshold|to (l_dobj) threshold_23\NN\15265518|seizure (l_compound) seizure_22\NN\14081375|
D001556_D012640 NONE hch_6\NNP\0|gamma|- (r_appos) hexachlorocyclohexane_2\NN\0|gamma|-|(|hch|)|,|ingredient|, (r_nsubjpass) shown_19\VBN\2137132|hexachlorocyclohexane|has|been|decrease|) (l_xcomp) decrease_21\VB\7296428|to|threshold|to (l_dobj) threshold_23\NN\15265518|seizure (l_compound) seizure_22\NN\14081375|
D001556_D012640 NONE lindane_15\NN\14919948|the|insecticide (r_pobj) of_12\IN\0|lindane (r_prep) ingredient_11\NN\3081021|the|active|of (r_appos) hexachlorocyclohexane_2\NN\0|gamma|-|(|hch|)|,|ingredient|, (r_nsubjpass) shown_19\VBN\2137132|hexachlorocyclohexane|has|been|decrease|) (l_xcomp) decrease_21\VB\7296428|to|threshold|to (l_dobj) threshold_23\NN\15265518|seizure (l_compound) seizure_22\NN\14081375|
D001556_D012640 NONE hch_7\NNP\0|gamma|- (r_pobj) to_4\IN\0|hch (r_prep) exposure_3\NN\5042871|to (r_pobj) after_2\IN\0|exposure (r_prep) h_1\NN\14622893|3|after|and|increase (l_conj) increase_10\VB\13576355|conversely|threshold|to (l_prep) to_12\IN\0|seizures (l_pobj) seizures_16\NNS\14081375|induced
D001556_D012640 NONE hch_24\NNP\0|gamma|-|al (r_pobj) to_21\IN\0|hch (r_prep) exposure_20\NN\5042871|to (r_pobj) after_19\IN\0|exposure (r_prep) h_18\NN\14622893|h|24|after|)|. (l_dep) h_1\NN\14622893|3|after|and|increase (l_conj) increase_10\VB\13576355|conversely|threshold|to (l_prep) to_12\IN\0|seizures (l_pobj) seizures_16\NNS\14081375|induced
D001556_D012640 NONE hch_30\NNP\0|mg/kg|gamma|- (r_pobj) of_25\IN\0|hch (r_prep) administration_24\NN\1133281|intraperitoneal|of (r_pobj) after_22\IN\0|administration (r_prep) tested_15\VBN\670261|in|,|severity|was|in|h|after|. (l_nsubjpass) severity_5\NN\5036394|the|of (l_prep) of_6\IN\0|response (l_pobj) response_7\NN\11410625|to (l_prep) to_8\IN\0|agents (l_pobj) agents_13\NNS\7347|other|inducing (l_amod) inducing_12\VBG\42311|seizure|- (l_npadvmod) seizure_10\NN\14081375|
D001556_D012640 NONE hch_8\NNP\0|gamma|- (r_pobj) of_5\IN\0|hch (r_prep) administration_4\NN\1133281|the|of (r_pobj) after_2\IN\0|administration (r_prep) increased_18\VBN\169651|hour|after|,|activity|was (l_nsubjpass) activity_11\NN\30358|the|of (l_prep) of_12\IN\0|agents (l_pobj) agents_16\NNS\7347|inducing (l_amod) inducing_15\VBG\42311|seizure|- (l_npadvmod) seizure_13\NN\14081375|
D001556_D012640 NONE hch_31\NNP\0|- (r_appos) h_27\NN\14622893|24|after|hch (r_dep) observed_36\VBN\2163746|increased|,|regardless|,|while|h|response|was|. (l_advcl) increased_18\VBN\169651|hour|after|,|activity|was (l_nsubjpass) activity_11\NN\30358|the|of (l_prep) of_12\IN\0|agents (l_pobj) agents_16\NNS\7347|inducing (l_amod) inducing_15\VBG\42311|seizure|- (l_npadvmod) seizure_13\NN\14081375|
D001556_D012640 NONE hch_22\NNP\0|gamma|- (r_pobj) after_19\IN\0|hch (r_prep) h_18\NN\14622893|24|after (r_npadvmod) occur_8\VB\0|that|tolerance|may|to|h|,|decreased (l_prep) to_9\IN\0|activity (l_pobj) activity_11\NN\30358|seizure|induced (l_compound) seizure_10\NN\14081375|
D001556_D012640 NONE hch_22\NNP\0|gamma|- (r_pobj) after_19\IN\0|hch (r_prep) h_18\NN\14622893|24|after (r_npadvmod) occur_8\VB\0|that|tolerance|may|to|h|,|decreased (l_advcl) decreased_36\VBN\169651|since|response|is (l_nsubjpass) response_26\NN\11410625|the|to (l_prep) to_27\IN\0|agents (l_pobj) agents_34\NNS\7347|only|these|two|inducing (l_amod) inducing_33\VBG\42311|seizure|- (l_npadvmod) seizure_31\NN\14081375|
D001556_D012640 NONE hch_20\NNP\0|gamma|- (r_nsubj) be_22\VB\14625458|that|site|hch|may|channel (l_nsubj) site_7\NN\8673395|the|responsible|h (l_amod) responsible_8\JJ\0|for (l_prep) for_9\IN\0|decrease (l_pobj) decrease_11\NN\7296428|the|in (l_prep) in_12\IN\13603305|activity (l_pobj) activity_14\NN\30358|seizure (l_compound) seizure_13\NN\14081375|
D010433_D012640 CID ptz_27\NNP\0|pentylenetrazol|( (r_pobj) to_24\TO\0|ptz (r_prep) decrease_21\VB\7296428|to|threshold|to (l_dobj) threshold_23\NN\15265518|seizure (l_compound) seizure_22\NN\14081375|
D010433_D012640 CID ptz_13\NNP\0| (r_npadvmod) induced_15\VBN\1627355|ptz|- (r_amod) seizures_16\NNS\14081375|induced
D010433_D012640 CID ptz_4\NNP\0|and|picrotoxin|ptx (r_pobj) due_2\IN\5174653|to|ptz (r_amod) activity_1\NN\30358|seizure|due (l_compound) seizure_0\NN\14081375|
D010433_D012640 CID ptz_4\NNP\0|and|picrotoxin|ptx (r_pobj) due_2\IN\5174653|to|ptz (r_amod) activity_1\NN\30358|seizure|due (r_nsubjpass) decreased_12\VBN\169651|activity|was|significantly (r_ccomp) was_46\VBD\0|decreased|;|however|,|activity|not|different|. (l_nsubj) activity_17\NN\30358|seizure|due (l_compound) seizure_16\NN\14081375|
D010433_D012640 CID ptz_14\NNP\0|and|ptx (r_pobj) by_13\IN\0|ptz (r_agent) induced_12\VBN\1627355|by (r_acl) activity_11\NN\30358|seizure|induced (l_compound) seizure_10\NN\14081375|
D010433_D012640 CID ptz_14\NNP\0|and|ptx (r_pobj) by_13\IN\0|ptz (r_agent) induced_12\VBN\1627355|by (r_acl) activity_11\NN\30358|seizure|induced (r_pobj) to_9\IN\0|activity (r_prep) occur_8\VB\0|that|tolerance|may|to|h|,|decreased (l_advcl) decreased_36\VBN\169651|since|response|is (l_nsubjpass) response_26\NN\11410625|the|to (l_prep) to_27\IN\0|agents (l_pobj) agents_34\NNS\7347|only|these|two|inducing (l_amod) inducing_33\VBG\42311|seizure|- (l_npadvmod) seizure_31\NN\14081375|
D010852_D012640 CID picrotoxin_6\NN\0| (r_conj) ptz_4\NNP\0|and|picrotoxin|ptx (r_pobj) due_2\IN\5174653|to|ptz (r_amod) activity_1\NN\30358|seizure|due (l_compound) seizure_0\NN\14081375|
D010852_D012640 CID picrotoxin_6\NN\0| (r_conj) ptz_4\NNP\0|and|picrotoxin|ptx (r_pobj) due_2\IN\5174653|to|ptz (r_amod) activity_1\NN\30358|seizure|due (r_nsubjpass) decreased_12\VBN\169651|activity|was|significantly (r_ccomp) was_46\VBD\0|decreased|;|however|,|activity|not|different|. (l_nsubj) activity_17\NN\30358|seizure|due (l_compound) seizure_16\NN\14081375|
D010852_D012640 CID ptx_8\NNP\0|(|) (r_appos) ptz_4\NNP\0|and|picrotoxin|ptx (r_pobj) due_2\IN\5174653|to|ptz (r_amod) activity_1\NN\30358|seizure|due (l_compound) seizure_0\NN\14081375|
D010852_D012640 CID ptx_8\NNP\0|(|) (r_appos) ptz_4\NNP\0|and|picrotoxin|ptx (r_pobj) due_2\IN\5174653|to|ptz (r_amod) activity_1\NN\30358|seizure|due (r_nsubjpass) decreased_12\VBN\169651|activity|was|significantly (r_ccomp) was_46\VBD\0|decreased|;|however|,|activity|not|different|. (l_nsubj) activity_17\NN\30358|seizure|due (l_compound) seizure_16\NN\14081375|
D010852_D012640 CID ptx_16\NNP\0| (r_conj) ptz_14\NNP\0|and|ptx (r_pobj) by_13\IN\0|ptz (r_agent) induced_12\VBN\1627355|by (r_acl) activity_11\NN\30358|seizure|induced (l_compound) seizure_10\NN\14081375|
D010852_D012640 CID ptx_16\NNP\0| (r_conj) ptz_14\NNP\0|and|ptx (r_pobj) by_13\IN\0|ptz (r_agent) induced_12\VBN\1627355|by (r_acl) activity_11\NN\30358|seizure|induced (r_pobj) to_9\IN\0|activity (r_prep) occur_8\VB\0|that|tolerance|may|to|h|,|decreased (l_advcl) decreased_36\VBN\169651|since|response|is (l_nsubjpass) response_26\NN\11410625|the|to (l_prep) to_27\IN\0|agents (l_pobj) agents_34\NNS\7347|only|these|two|inducing (l_amod) inducing_33\VBG\42311|seizure|- (l_npadvmod) seizure_31\NN\14081375|
D015097_D012640 CID acid_21\NN\14818238|3-mercaptopropionic|mpa|,|bicuculline|bcc|,|carboline-3-carboxylate|(|str|) (r_pobj) to_19\IN\0|acid (r_pcomp) due_18\IN\5174653|to (r_prep) activity_17\NN\30358|seizure|due (r_nsubj) was_46\VBD\0|decreased|;|however|,|activity|not|different|. (l_ccomp) decreased_12\VBN\169651|activity|was|significantly (l_nsubjpass) activity_1\NN\30358|seizure|due (l_compound) seizure_0\NN\14081375|
D015097_D012640 CID acid_21\NN\14818238|3-mercaptopropionic|mpa|,|bicuculline|bcc|,|carboline-3-carboxylate|(|str|) (r_pobj) to_19\IN\0|acid (r_pcomp) due_18\IN\5174653|to (r_prep) activity_17\NN\30358|seizure|due (l_compound) seizure_16\NN\14081375|
D015097_D012640 CID mpa_23\NNP\0|(|) (r_appos) acid_21\NN\14818238|3-mercaptopropionic|mpa|,|bicuculline|bcc|,|carboline-3-carboxylate|(|str|) (r_pobj) to_19\IN\0|acid (r_pcomp) due_18\IN\5174653|to (r_prep) activity_17\NN\30358|seizure|due (r_nsubj) was_46\VBD\0|decreased|;|however|,|activity|not|different|. (l_ccomp) decreased_12\VBN\169651|activity|was|significantly (l_nsubjpass) activity_1\NN\30358|seizure|due (l_compound) seizure_0\NN\14081375|
D015097_D012640 CID mpa_23\NNP\0|(|) (r_appos) acid_21\NN\14818238|3-mercaptopropionic|mpa|,|bicuculline|bcc|,|carboline-3-carboxylate|(|str|) (r_pobj) to_19\IN\0|acid (r_pcomp) due_18\IN\5174653|to (r_prep) activity_17\NN\30358|seizure|due (l_compound) seizure_16\NN\14081375|
D001640_D012640 CID bicuculline_26\NN\0| (r_conj) acid_21\NN\14818238|3-mercaptopropionic|mpa|,|bicuculline|bcc|,|carboline-3-carboxylate|(|str|) (r_pobj) to_19\IN\0|acid (r_pcomp) due_18\IN\5174653|to (r_prep) activity_17\NN\30358|seizure|due (r_nsubj) was_46\VBD\0|decreased|;|however|,|activity|not|different|. (l_ccomp) decreased_12\VBN\169651|activity|was|significantly (l_nsubjpass) activity_1\NN\30358|seizure|due (l_compound) seizure_0\NN\14081375|
D001640_D012640 CID bicuculline_26\NN\0| (r_conj) acid_21\NN\14818238|3-mercaptopropionic|mpa|,|bicuculline|bcc|,|carboline-3-carboxylate|(|str|) (r_pobj) to_19\IN\0|acid (r_pcomp) due_18\IN\5174653|to (r_prep) activity_17\NN\30358|seizure|due (l_compound) seizure_16\NN\14081375|
D001640_D012640 CID bcc_28\NNP\0|(|) (r_appos) acid_21\NN\14818238|3-mercaptopropionic|mpa|,|bicuculline|bcc|,|carboline-3-carboxylate|(|str|) (r_pobj) to_19\IN\0|acid (r_pcomp) due_18\IN\5174653|to (r_prep) activity_17\NN\30358|seizure|due (r_nsubj) was_46\VBD\0|decreased|;|however|,|activity|not|different|. (l_ccomp) decreased_12\VBN\169651|activity|was|significantly (l_nsubjpass) activity_1\NN\30358|seizure|due (l_compound) seizure_0\NN\14081375|
D001640_D012640 CID bcc_28\NNP\0|(|) (r_appos) acid_21\NN\14818238|3-mercaptopropionic|mpa|,|bicuculline|bcc|,|carboline-3-carboxylate|(|str|) (r_pobj) to_19\IN\0|acid (r_pcomp) due_18\IN\5174653|to (r_prep) activity_17\NN\30358|seizure|due (l_compound) seizure_16\NN\14081375|
C034818_D012640 CID carboline-3-carboxylate_36\NNP\0|methyl|6,7-dimethoxy-4-ethyl|-|b|-|(|dmcm|)|,|or|strychnine (r_conj) acid_21\NN\14818238|3-mercaptopropionic|mpa|,|bicuculline|bcc|,|carboline-3-carboxylate|(|str|) (r_pobj) to_19\IN\0|acid (r_pcomp) due_18\IN\5174653|to (r_prep) activity_17\NN\30358|seizure|due (r_nsubj) was_46\VBD\0|decreased|;|however|,|activity|not|different|. (l_ccomp) decreased_12\VBN\169651|activity|was|significantly (l_nsubjpass) activity_1\NN\30358|seizure|due (l_compound) seizure_0\NN\14081375|
C034818_D012640 CID carboline-3-carboxylate_36\NNP\0|methyl|6,7-dimethoxy-4-ethyl|-|b|-|(|dmcm|)|,|or|strychnine (r_conj) acid_21\NN\14818238|3-mercaptopropionic|mpa|,|bicuculline|bcc|,|carboline-3-carboxylate|(|str|) (r_pobj) to_19\IN\0|acid (r_pcomp) due_18\IN\5174653|to (r_prep) activity_17\NN\30358|seizure|due (l_compound) seizure_16\NN\14081375|
C034818_D012640 CID dmcm_38\NNP\0| (r_appos) carboline-3-carboxylate_36\NNP\0|methyl|6,7-dimethoxy-4-ethyl|-|b|-|(|dmcm|)|,|or|strychnine (r_conj) acid_21\NN\14818238|3-mercaptopropionic|mpa|,|bicuculline|bcc|,|carboline-3-carboxylate|(|str|) (r_pobj) to_19\IN\0|acid (r_pcomp) due_18\IN\5174653|to (r_prep) activity_17\NN\30358|seizure|due (r_nsubj) was_46\VBD\0|decreased|;|however|,|activity|not|different|. (l_ccomp) decreased_12\VBN\169651|activity|was|significantly (l_nsubjpass) activity_1\NN\30358|seizure|due (l_compound) seizure_0\NN\14081375|
C034818_D012640 CID dmcm_38\NNP\0| (r_appos) carboline-3-carboxylate_36\NNP\0|methyl|6,7-dimethoxy-4-ethyl|-|b|-|(|dmcm|)|,|or|strychnine (r_conj) acid_21\NN\14818238|3-mercaptopropionic|mpa|,|bicuculline|bcc|,|carboline-3-carboxylate|(|str|) (r_pobj) to_19\IN\0|acid (r_pcomp) due_18\IN\5174653|to (r_prep) activity_17\NN\30358|seizure|due (l_compound) seizure_16\NN\14081375|
D013331_D012640 CID strychnine_42\NN\14712692| (r_conj) carboline-3-carboxylate_36\NNP\0|methyl|6,7-dimethoxy-4-ethyl|-|b|-|(|dmcm|)|,|or|strychnine (r_conj) acid_21\NN\14818238|3-mercaptopropionic|mpa|,|bicuculline|bcc|,|carboline-3-carboxylate|(|str|) (r_pobj) to_19\IN\0|acid (r_pcomp) due_18\IN\5174653|to (r_prep) activity_17\NN\30358|seizure|due (r_nsubj) was_46\VBD\0|decreased|;|however|,|activity|not|different|. (l_ccomp) decreased_12\VBN\169651|activity|was|significantly (l_nsubjpass) activity_1\NN\30358|seizure|due (l_compound) seizure_0\NN\14081375|
D013331_D012640 CID strychnine_42\NN\14712692| (r_conj) carboline-3-carboxylate_36\NNP\0|methyl|6,7-dimethoxy-4-ethyl|-|b|-|(|dmcm|)|,|or|strychnine (r_conj) acid_21\NN\14818238|3-mercaptopropionic|mpa|,|bicuculline|bcc|,|carboline-3-carboxylate|(|str|) (r_pobj) to_19\IN\0|acid (r_pcomp) due_18\IN\5174653|to (r_prep) activity_17\NN\30358|seizure|due (l_compound) seizure_16\NN\14081375|
D013331_D012640 CID str_44\NNP\0| (r_appos) acid_21\NN\14818238|3-mercaptopropionic|mpa|,|bicuculline|bcc|,|carboline-3-carboxylate|(|str|) (r_pobj) to_19\IN\0|acid (r_pcomp) due_18\IN\5174653|to (r_prep) activity_17\NN\30358|seizure|due (r_nsubj) was_46\VBD\0|decreased|;|however|,|activity|not|different|. (l_ccomp) decreased_12\VBN\169651|activity|was|significantly (l_nsubjpass) activity_1\NN\30358|seizure|due (l_compound) seizure_0\NN\14081375|
D013331_D012640 CID str_44\NNP\0| (r_appos) acid_21\NN\14818238|3-mercaptopropionic|mpa|,|bicuculline|bcc|,|carboline-3-carboxylate|(|str|) (r_pobj) to_19\IN\0|acid (r_pcomp) due_18\IN\5174653|to (r_prep) activity_17\NN\30358|seizure|due (l_compound) seizure_16\NN\14081375|
D005680_D012640 NONE gaba_24\NNP\14601829| (r_compound) a_26\NNP\13649268|gaba|- (r_nmod) channel_31\NN\6251781|the|a|linked|chloride (r_attr) be_22\VB\14625458|that|site|hch|may|channel (l_nsubj) site_7\NN\8673395|the|responsible|h (l_amod) responsible_8\JJ\0|for (l_prep) for_9\IN\0|decrease (l_pobj) decrease_11\NN\7296428|the|in (l_prep) in_12\IN\13603305|activity (l_pobj) activity_14\NN\30358|seizure (l_compound) seizure_13\NN\14081375|
18417364
D009538_D009759 CID nicotine_0\NN\14712692| (r_npadvmod) induced_2\VBN\1627355|nicotine|- (r_amod) nystagmus_3\NN\337486|induced
D009538_D009759 CID nicotine_3\NN\14712692| (r_npadvmod) induced_5\VBN\1627355|nicotine|- (r_amod) nystagmus_6\NN\337486|induced|(|nin|)
D009538_D009759 CID nicotine_3\NN\14712692| (r_npadvmod) induced_5\VBN\1627355|nicotine|- (r_amod) nystagmus_6\NN\337486|induced|(|nin|) (l_appos) nin_8\NNP\0|
D010100_D009759 NONE oxygen_4\NN\14622893|blood (r_nmod) levels_12\NNS\4916342|oxygen|dependent|(|bold|)|activity|in (r_pobj) with_2\IN\0|levels (r_prep) correlated_1\VBD\2657219|nin|with|. (l_nsubj) nin_0\NNP\0|
2559236
D004317_D007674 NONE adriamycin_9\NNS\0| (r_npadvmod) induced_11\VBN\1627355|adriamycin|- (r_amod) nephropathy_12\NN\14573196|induced
D004317_D007674 NONE adriamycin_24\JJ\0| (r_amod) nephrosis_25\NN\14304060|adriamycin (r_pobj) in_23\IN\13603305|nephrosis (r_prep) injury_22\NN\14052046|renal|in
D004656_D009401 NONE enalapril_10\NN\2673637|(|cei|) (r_appos) inhibitor_6\NN\20090|enzyme|enalapril (r_pobj) of_2\IN\0|inhibitor (r_prep) effect_1\NN\34213|the|of (r_nsubjpass) assessed_12\VBN\670261|effect|was|in|with|. (l_prep) with_18\IN\0|nephrosis (l_pobj) nephrosis_21\NN\14304060|established|adriamycin
D004656_D009401 NONE enalapril_17\NN\2673637| (r_pobj) of_16\IN\0|enalapril (r_prep) effect_15\NN\34213|the|of|on (l_prep) on_18\IN\0|progression (l_pobj) progression_19\NN\8457976|of (l_prep) of_20\IN\0|injury (l_pobj) injury_22\NN\14052046|renal|in (l_prep) in_23\IN\13603305|nephrosis (l_pobj) nephrosis_25\NN\14304060|adriamycin
D004317_D009401 CID adriamycin_20\NNS\0| (r_amod) nephrosis_21\NN\14304060|established|adriamycin
D004317_D009401 CID adriamycin_24\JJ\0| (r_amod) nephrosis_25\NN\14304060|adriamycin
D004317_D000419 CID adriamycin_7\NNS\0| (r_pobj) of_6\IN\0|adriamycin (r_prep) dose_5\NN\3740161|a|single|of|and (r_dobj) given_2\VBN\5892096|rats|were|dose|divided|. (l_advcl) divided_12\VBD\140123|later|into (l_prep) into_13\IN\0|groups (l_pobj) groups_15\NNS\2137|four|matched (l_acl) matched_16\VBN\2664769|for (l_prep) for_17\IN\0|albuminuria (l_pobj) albuminuria_18\NN\14299637|,|pressure
D004656_D000419 NONE enalapril_7\DT\2673637| (r_nsubj) reduced_8\JJ\441445|that|enalapril|pressure|2|vs. (l_prep) vs._16\IN\0|hg (l_pobj) hg_21\NNP\14625458|mm|,|group|,|p|)|and|pressure (l_conj) pressure_36\NN\11419404|glomerular|capillary|(|+/-|(|+/-|)|or|gfr (l_appos) +/-_39\SYM\0|54|1|vs.|without (l_prep) without_53\IN\0|reducing (l_pcomp) reducing_54\VBG\13447361|albuminuria (l_dobj) albuminuria_55\NN\14299637|
D004656_D000419 NONE enalapril_1\NN\2673637|chronic (r_compound) treatment_2\NN\654885|enalapril (r_nsubj) reduced_3\VBN\441445|treatment (r_amod) pressure_5\NN\11419404|reduced|blood|without|. (l_prep) without_6\IN\0|reducing (l_pcomp) reducing_7\VBG\13447361|albuminuria|in (l_dobj) albuminuria_8\NN\14299637|
D004656_D007674 NONE enalapril_17\NN\2673637| (r_pobj) of_16\IN\0|enalapril (r_prep) effect_15\NN\34213|the|of|on (l_prep) on_18\IN\0|progression (l_pobj) progression_19\NN\8457976|of (l_prep) of_20\IN\0|injury (l_pobj) injury_22\NN\14052046|renal|in
12464714
C093622_D008881 NONE rizatriptan_7\JJ\0| (r_pobj) for_6\IN\0|rizatriptan (r_prep) preference_5\NN\7497473|for (r_conj) efficacy_3\NN\5199286|and|preference (r_pobj) of_2\IN\0|efficacy (r_prep) comparison_1\NN\635850|crossover|of|caffeine|. (l_conj) caffeine_13\NN\14712692|mg|ergotamine|/|in (l_prep) in_14\IN\13603305|migraine (l_pobj) migraine_15\NN\14326607|
C093622_D008881 NONE rizatriptan_0\NNP\0| (r_nsubj) is_1\VBZ\0|rizatriptan|agonist|. (l_attr) agonist_7\NN\0|a|selective|receptor|with (l_prep) with_8\IN\0|absorption (l_pobj) absorption_11\NN\13558490|rapid|oral|and|onset (l_conj) onset_14\NN\7325190|early|of|in (l_prep) in_17\IN\13603305|treatment (l_pobj) treatment_20\NN\654885|the|acute|of (l_prep) of_21\IN\0|migraine (l_pobj) migraine_22\NN\14326607|
C093622_D008881 NONE rizatriptan_12\JJ\0|1|tablet (r_pobj) for_10\IN\0|rizatriptan (r_prep) preference_9\NN\7497473|the|for (r_dobj) assessed_7\VBD\670261|study|preference|tablets|in|. (l_prep) in_26\IN\13603305|patients (l_pobj) patients_28\NNS\9898892|439|treating (l_acl) treating_29\VBG\2376958|attack (l_dobj) attack_33\NN\955060|a|single|migraine|with (l_compound) migraine_32\JJ\14326607|
D004878_D008881 NONE ergotamine_11\NN\14712692| (r_nmod) caffeine_13\NN\14712692|mg|ergotamine|/|in (l_prep) in_14\IN\13603305|migraine (l_pobj) migraine_15\NN\14326607|
D004878_D008881 NONE ergotamine_18\NN\14712692|2|caffeine (r_pobj) to_16\IN\0|ergotamine (r_prep) tablet_15\NN\4233405|mg|to (r_amod) rizatriptan_12\JJ\0|1|tablet (r_pobj) for_10\IN\0|rizatriptan (r_prep) preference_9\NN\7497473|the|for (r_dobj) assessed_7\VBD\670261|study|preference|tablets|in|. (l_prep) in_26\IN\13603305|patients (l_pobj) patients_28\NNS\9898892|439|treating (l_acl) treating_29\VBG\2376958|attack (l_dobj) attack_33\NN\955060|a|single|migraine|with (l_compound) migraine_32\JJ\14326607|
D002110_D008881 NONE caffeine_13\NN\14712692|mg|ergotamine|/|in (l_prep) in_14\IN\13603305|migraine (l_pobj) migraine_15\NN\14326607|
D002110_D008881 NONE caffeine_22\NN\14712692|1|mg|/ (r_appos) ergotamine_18\NN\14712692|2|caffeine (r_pobj) to_16\IN\0|ergotamine (r_prep) tablet_15\NN\4233405|mg|to (r_amod) rizatriptan_12\JJ\0|1|tablet (r_pobj) for_10\IN\0|rizatriptan (r_prep) preference_9\NN\7497473|the|for (r_dobj) assessed_7\VBD\670261|study|preference|tablets|in|. (l_prep) in_26\IN\13603305|patients (l_pobj) patients_28\NNS\9898892|439|treating (l_acl) treating_29\VBG\2376958|attack (l_dobj) attack_33\NN\955060|a|single|migraine|with (l_compound) migraine_32\JJ\14326607|
D012701_D008881 NONE 5-ht(1b/1d_4\CD\0| (r_nummod) receptor_6\NN\5225602|5-ht(1b/1d|) (r_compound) agonist_7\NN\0|a|selective|receptor|with (l_prep) with_8\IN\0|absorption (l_pobj) absorption_11\NN\13558490|rapid|oral|and|onset (l_conj) onset_14\NN\7325190|early|of|in (l_prep) in_17\IN\13603305|treatment (l_pobj) treatment_20\NN\654885|the|acute|of (l_prep) of_21\IN\0|migraine (l_pobj) migraine_22\NN\14326607|
C093622_D006261 NONE rizatriptan_19\JJ\0|and|% (r_dobj) preferring_18\VBG\1777210|rizatriptan (r_acl) patients_17\NNS\9898892|preferring (r_pobj) of_16\IN\0|patients (r_prep) %_15\NN\0|67.3|of (r_pobj) by_13\IN\0|% (r_agent) cited_12\VBN\730052|by (r_acl) reason_8\NN\9178821|the|important|for|,|cited (r_attr) was_4\VBD\0|relief|reason|. (l_nsubj) relief_1\NN\7492516|faster|of (l_prep) of_2\IN\0|headache (l_pobj) headache_3\NN\5829480|
D004878_D006261 NONE ergotamine_27\NN\14712692| (r_nmod) caffeine_29\NN\14712692|ergotamine|/ (r_dobj) preferred_26\VBD\1777210|who|caffeine (r_relcl) patients_24\NNS\9898892|preferred (r_pobj) of_23\IN\0|patients (r_prep) %_22\NN\0|54.2|of (r_conj) rizatriptan_19\JJ\0|and|% (r_dobj) preferring_18\VBG\1777210|rizatriptan (r_acl) patients_17\NNS\9898892|preferring (r_pobj) of_16\IN\0|patients (r_prep) %_15\NN\0|67.3|of (r_pobj) by_13\IN\0|% (r_agent) cited_12\VBN\730052|by (r_acl) reason_8\NN\9178821|the|important|for|,|cited (r_attr) was_4\VBD\0|relief|reason|. (l_nsubj) relief_1\NN\7492516|faster|of (l_prep) of_2\IN\0|headache (l_pobj) headache_3\NN\5829480|
D002110_D006261 NONE caffeine_29\NN\14712692|ergotamine|/ (r_dobj) preferred_26\VBD\1777210|who|caffeine (r_relcl) patients_24\NNS\9898892|preferred (r_pobj) of_23\IN\0|patients (r_prep) %_22\NN\0|54.2|of (r_conj) rizatriptan_19\JJ\0|and|% (r_dobj) preferring_18\VBG\1777210|rizatriptan (r_acl) patients_17\NNS\9898892|preferring (r_pobj) of_16\IN\0|patients (r_prep) %_15\NN\0|67.3|of (r_pobj) by_13\IN\0|% (r_agent) cited_12\VBN\730052|by (r_acl) reason_8\NN\9178821|the|important|for|,|cited (r_attr) was_4\VBD\0|relief|reason|. (l_nsubj) relief_1\NN\7492516|faster|of (l_prep) of_2\IN\0|headache (l_pobj) headache_3\NN\5829480|
C093622_D010146 NONE rizatriptan_12\NN\0| (r_pobj) after_11\IN\0|rizatriptan (r_prep) h_10\NN\14622893|2|after (r_npadvmod) were_6\VBD\0|percent|free|h|,|compared|,|being|. (l_acomp) free_8\JJ\7942152|pain (l_npadvmod) pain_7\NN\14299637|
C093622_D010146 NONE rizatriptan_31\JJ\0| (r_nsubj) being_32\VBG\24720|rizatriptan|superior|within (r_advcl) were_6\VBD\0|percent|free|h|,|compared|,|being|. (l_acomp) free_8\JJ\7942152|pain (l_npadvmod) pain_7\NN\14299637|
C093622_D010146 NONE rizatriptan_6\NN\0| (r_dobj) taking_5\VBG\37396|rizatriptan (r_acl) patients_4\NNS\9898892|taking (r_pobj) of_3\IN\0|patients (r_prep) %_2\NN\0|36|of (r_nsubj) were_7\VBD\0|%|free|at|and|had|,|compared|. (l_acomp) free_9\JJ\7942152|pain (l_npadvmod) pain_8\NN\14299637|
D004878_D010146 NONE ergotamine_20\NN\14712692| (r_nmod) caffeine_22\NN\14712692|ergotamine|/|0.001 (r_pobj) with_19\IN\0|caffeine (r_prep) treated_18\VBN\2376958|with (r_acl) %_17\NN\0|24.3|treated (r_pobj) with_15\IN\0|% (r_prep) compared_14\VBN\644583|with (r_prep) were_6\VBD\0|percent|free|h|,|compared|,|being|. (l_acomp) free_8\JJ\7942152|pain (l_npadvmod) pain_7\NN\14299637|
D004878_D010146 NONE ergotamine_33\NNP\14712692| (r_nmod) caffeine_35\NN\14712692|ergotamine|/|0.001 (r_pobj) on_32\IN\0|caffeine (r_prep) patients_31\NNS\9898892|on (r_pobj) of_30\IN\0|patients (r_prep) %_29\NN\0|20|of (r_pobj) to_27\IN\0|% (r_prep) compared_26\VBN\644583|to (r_prep) were_7\VBD\0|%|free|at|and|had|,|compared|. (l_acomp) free_9\JJ\7942152|pain (l_npadvmod) pain_8\NN\14299637|
D002110_D010146 NONE caffeine_22\NN\14712692|ergotamine|/|0.001 (r_pobj) with_19\IN\0|caffeine (r_prep) treated_18\VBN\2376958|with (r_acl) %_17\NN\0|24.3|treated (r_pobj) with_15\IN\0|% (r_prep) compared_14\VBN\644583|with (r_prep) were_6\VBD\0|percent|free|h|,|compared|,|being|. (l_acomp) free_8\JJ\7942152|pain (l_npadvmod) pain_7\NN\14299637|
D002110_D010146 NONE caffeine_35\NN\14712692|ergotamine|/|0.001 (r_pobj) on_32\IN\0|caffeine (r_prep) patients_31\NNS\9898892|on (r_pobj) of_30\IN\0|patients (r_prep) %_29\NN\0|20|of (r_pobj) to_27\IN\0|% (r_prep) compared_26\VBN\644583|to (r_prep) were_7\VBD\0|%|free|at|and|had|,|compared|. (l_acomp) free_9\JJ\7942152|pain (l_npadvmod) pain_8\NN\14299637|
C093622_D009325 CID rizatriptan_0\NNP\0| (r_nsubj) was_1\VBD\0|rizatriptan|also|superior|h|. (l_acomp) superior_3\JJ\9623038|to (l_prep) to_4\IN\0|caffeine (l_pobj) caffeine_7\NN\14712692|ergotamine|/|in (l_prep) in_8\IN\13603305|proportions (l_pobj) proportions_10\NNS\13824815|the|of (l_prep) of_11\IN\0|patients (l_pobj) patients_12\NNS\9898892|with (l_prep) with_13\IN\0|nausea (l_pobj) nausea_15\NN\14299637|no|,|vomiting
C093622_D009325 CID rizatriptan_17\NN\0|and|caffeine (r_pobj) after_16\IN\0|rizatriptan (r_prep) >_7\XX\0|incidence|or|%|after (r_appos) events_4\NNS\23100|the|common|adverse|(|>|,|nausea (l_appos) nausea_34\NN\14299637|(|4.2|)|and|somnolence
C093622_D014839 NONE rizatriptan_0\NNP\0| (r_nsubj) was_1\VBD\0|rizatriptan|also|superior|h|. (l_acomp) superior_3\JJ\9623038|to (l_prep) to_4\IN\0|caffeine (l_pobj) caffeine_7\NN\14712692|ergotamine|/|in (l_prep) in_8\IN\13603305|proportions (l_pobj) proportions_10\NNS\13824815|the|of (l_prep) of_11\IN\0|patients (l_pobj) patients_12\NNS\9898892|with (l_prep) with_13\IN\0|nausea (l_pobj) nausea_15\NN\14299637|no|,|vomiting (l_conj) vomiting_17\VBG\116687|,|phonophobia|and|for
C093622_D012001 NONE rizatriptan_0\NNP\0| (r_nsubj) was_1\VBD\0|rizatriptan|also|superior|h|. (l_acomp) superior_3\JJ\9623038|to (l_prep) to_4\IN\0|caffeine (l_pobj) caffeine_7\NN\14712692|ergotamine|/|in (l_prep) in_8\IN\13603305|proportions (l_pobj) proportions_10\NNS\13824815|the|of (l_prep) of_11\IN\0|patients (l_pobj) patients_12\NNS\9898892|with (l_prep) with_13\IN\0|nausea (l_pobj) nausea_15\NN\14299637|no|,|vomiting (l_conj) vomiting_17\VBG\116687|,|phonophobia|and|for (l_conj) phonophobia_19\NNS\14382238|or|photophobia
C093622_D020795 NONE rizatriptan_0\NNP\0| (r_nsubj) was_1\VBD\0|rizatriptan|also|superior|h|. (l_acomp) superior_3\JJ\9623038|to (l_prep) to_4\IN\0|caffeine (l_pobj) caffeine_7\NN\14712692|ergotamine|/|in (l_prep) in_8\IN\13603305|proportions (l_pobj) proportions_10\NNS\13824815|the|of (l_prep) of_11\IN\0|patients (l_pobj) patients_12\NNS\9898892|with (l_prep) with_13\IN\0|nausea (l_pobj) nausea_15\NN\14299637|no|,|vomiting (l_conj) vomiting_17\VBG\116687|,|phonophobia|and|for (l_conj) phonophobia_19\NNS\14382238|or|photophobia (l_conj) photophobia_21\NNS\14382238|
D004878_D009325 NONE ergotamine_5\NN\14712692| (r_nmod) caffeine_7\NN\14712692|ergotamine|/|in (l_prep) in_8\IN\13603305|proportions (l_pobj) proportions_10\NNS\13824815|the|of (l_prep) of_11\IN\0|patients (l_pobj) patients_12\NNS\9898892|with (l_prep) with_13\IN\0|nausea (l_pobj) nausea_15\NN\14299637|no|,|vomiting
D004878_D009325 NONE ergotamine_19\NNP\14712692| (r_nmod) caffeine_21\NN\14712692|ergotamine|/ (r_conj) rizatriptan_17\NN\0|and|caffeine (r_pobj) after_16\IN\0|rizatriptan (r_prep) >_7\XX\0|incidence|or|%|after (r_appos) events_4\NNS\23100|the|common|adverse|(|>|,|nausea (l_appos) nausea_34\NN\14299637|(|4.2|)|and|somnolence
D004878_D014839 NONE ergotamine_5\NN\14712692| (r_nmod) caffeine_7\NN\14712692|ergotamine|/|in (l_prep) in_8\IN\13603305|proportions (l_pobj) proportions_10\NNS\13824815|the|of (l_prep) of_11\IN\0|patients (l_pobj) patients_12\NNS\9898892|with (l_prep) with_13\IN\0|nausea (l_pobj) nausea_15\NN\14299637|no|,|vomiting (l_conj) vomiting_17\VBG\116687|,|phonophobia|and|for
D004878_D012001 NONE ergotamine_5\NN\14712692| (r_nmod) caffeine_7\NN\14712692|ergotamine|/|in (l_prep) in_8\IN\13603305|proportions (l_pobj) proportions_10\NNS\13824815|the|of (l_prep) of_11\IN\0|patients (l_pobj) patients_12\NNS\9898892|with (l_prep) with_13\IN\0|nausea (l_pobj) nausea_15\NN\14299637|no|,|vomiting (l_conj) vomiting_17\VBG\116687|,|phonophobia|and|for (l_conj) phonophobia_19\NNS\14382238|or|photophobia
D004878_D020795 NONE ergotamine_5\NN\14712692| (r_nmod) caffeine_7\NN\14712692|ergotamine|/|in (l_prep) in_8\IN\13603305|proportions (l_pobj) proportions_10\NNS\13824815|the|of (l_prep) of_11\IN\0|patients (l_pobj) patients_12\NNS\9898892|with (l_prep) with_13\IN\0|nausea (l_pobj) nausea_15\NN\14299637|no|,|vomiting (l_conj) vomiting_17\VBG\116687|,|phonophobia|and|for (l_conj) phonophobia_19\NNS\14382238|or|photophobia (l_conj) photophobia_21\NNS\14382238|
D002110_D009325 NONE caffeine_7\NN\14712692|ergotamine|/|in (l_prep) in_8\IN\13603305|proportions (l_pobj) proportions_10\NNS\13824815|the|of (l_prep) of_11\IN\0|patients (l_pobj) patients_12\NNS\9898892|with (l_prep) with_13\IN\0|nausea (l_pobj) nausea_15\NN\14299637|no|,|vomiting
D002110_D009325 NONE caffeine_21\NN\14712692|ergotamine|/ (r_conj) rizatriptan_17\NN\0|and|caffeine (r_pobj) after_16\IN\0|rizatriptan (r_prep) >_7\XX\0|incidence|or|%|after (r_appos) events_4\NNS\23100|the|common|adverse|(|>|,|nausea (l_appos) nausea_34\NN\14299637|(|4.2|)|and|somnolence
D002110_D014839 NONE caffeine_7\NN\14712692|ergotamine|/|in (l_prep) in_8\IN\13603305|proportions (l_pobj) proportions_10\NNS\13824815|the|of (l_prep) of_11\IN\0|patients (l_pobj) patients_12\NNS\9898892|with (l_prep) with_13\IN\0|nausea (l_pobj) nausea_15\NN\14299637|no|,|vomiting (l_conj) vomiting_17\VBG\116687|,|phonophobia|and|for
D002110_D012001 NONE caffeine_7\NN\14712692|ergotamine|/|in (l_prep) in_8\IN\13603305|proportions (l_pobj) proportions_10\NNS\13824815|the|of (l_prep) of_11\IN\0|patients (l_pobj) patients_12\NNS\9898892|with (l_prep) with_13\IN\0|nausea (l_pobj) nausea_15\NN\14299637|no|,|vomiting (l_conj) vomiting_17\VBG\116687|,|phonophobia|and|for (l_conj) phonophobia_19\NNS\14382238|or|photophobia
D002110_D020795 NONE caffeine_7\NN\14712692|ergotamine|/|in (l_prep) in_8\IN\13603305|proportions (l_pobj) proportions_10\NNS\13824815|the|of (l_prep) of_11\IN\0|patients (l_pobj) patients_12\NNS\9898892|with (l_prep) with_13\IN\0|nausea (l_pobj) nausea_15\NN\14299637|no|,|vomiting (l_conj) vomiting_17\VBG\116687|,|phonophobia|and|for (l_conj) phonophobia_19\NNS\14382238|or|photophobia (l_conj) photophobia_21\NNS\14382238|
C093622_D004244 CID rizatriptan_17\NN\0|and|caffeine (r_pobj) after_16\IN\0|rizatriptan (r_prep) >_7\XX\0|incidence|or|%|after (r_appos) events_4\NNS\23100|the|common|adverse|(|>|,|nausea (r_nsubj) were_25\VBD\0|events|respectively|,|dizziness|,|. (l_attr) dizziness_26\NN\14299637|(|6.7|)
C093622_D006970 NONE rizatriptan_17\NN\0|and|caffeine (r_pobj) after_16\IN\0|rizatriptan (r_prep) >_7\XX\0|incidence|or|%|after (r_appos) events_4\NNS\23100|the|common|adverse|(|>|,|nausea (l_appos) nausea_34\NN\14299637|(|4.2|)|and|somnolence (l_conj) somnolence_42\NN\14015731|(|5.5|)
D004878_D004244 NONE ergotamine_19\NNP\14712692| (r_nmod) caffeine_21\NN\14712692|ergotamine|/ (r_conj) rizatriptan_17\NN\0|and|caffeine (r_pobj) after_16\IN\0|rizatriptan (r_prep) >_7\XX\0|incidence|or|%|after (r_appos) events_4\NNS\23100|the|common|adverse|(|>|,|nausea (r_nsubj) were_25\VBD\0|events|respectively|,|dizziness|,|. (l_attr) dizziness_26\NN\14299637|(|6.7|)
D004878_D006970 NONE ergotamine_19\NNP\14712692| (r_nmod) caffeine_21\NN\14712692|ergotamine|/ (r_conj) rizatriptan_17\NN\0|and|caffeine (r_pobj) after_16\IN\0|rizatriptan (r_prep) >_7\XX\0|incidence|or|%|after (r_appos) events_4\NNS\23100|the|common|adverse|(|>|,|nausea (l_appos) nausea_34\NN\14299637|(|4.2|)|and|somnolence (l_conj) somnolence_42\NN\14015731|(|5.5|)
D002110_D004244 NONE caffeine_21\NN\14712692|ergotamine|/ (r_conj) rizatriptan_17\NN\0|and|caffeine (r_pobj) after_16\IN\0|rizatriptan (r_prep) >_7\XX\0|incidence|or|%|after (r_appos) events_4\NNS\23100|the|common|adverse|(|>|,|nausea (r_nsubj) were_25\VBD\0|events|respectively|,|dizziness|,|. (l_attr) dizziness_26\NN\14299637|(|6.7|)
D002110_D006970 NONE caffeine_21\NN\14712692|ergotamine|/ (r_conj) rizatriptan_17\NN\0|and|caffeine (r_pobj) after_16\IN\0|rizatriptan (r_prep) >_7\XX\0|incidence|or|%|after (r_appos) events_4\NNS\23100|the|common|adverse|(|>|,|nausea (l_appos) nausea_34\NN\14299637|(|4.2|)|and|somnolence (l_conj) somnolence_42\NN\14015731|(|5.5|)
3827439
D000666_D058186 CID amphotericin_6\JJ\2716866| (r_pobj) from_5\IN\0|amphotericin (r_prep) failure_4\NN\66216|recurrent|reversible|acute|renal|from|.
D000666_D058186 CID b_18\NNP\1355326|amphotericin (r_pobj) of_16\IN\0|b (r_prep) administration_15\NN\1133281|the|of (r_dobj) following_13\VBG\8180190|immediately|administration|on (r_acl) failure_11\NN\66216|acute|renal|following
D000666_D058186 CID amphotericin_3\JJ\2716866| (r_advmod) propose_1\VBP\1010118|we|that|amphotericin|activate|. (l_conj) activate_15\VB\1641914|,|in|,|may|feedback|,|contributing (l_advcl) contributing_20\VBG\126264|thereby|to (l_prep) to_21\IN\0|failure (l_pobj) failure_24\NN\66216|acute|renal
D000666_D005355 NONE b_18\NNP\1355326|amphotericin (r_pobj) of_16\IN\0|b (r_prep) administration_15\NN\1133281|the|of (r_dobj) following_13\VBG\8180190|immediately|administration|on (r_acl) failure_11\NN\66216|acute|renal|following (r_dobj) developed_8\VBD\1753788|patient|failure|. (l_nsubj) patient_1\NN\9898892|a|with|and|disseminated (l_prep) with_2\IN\0|cirrhosis (l_pobj) cirrhosis_4\NN\14116321|cryptogenic
D000666_D013174 NONE b_18\NNP\1355326|amphotericin (r_pobj) of_16\IN\0|b (r_prep) administration_15\NN\1133281|the|of (r_dobj) following_13\VBG\8180190|immediately|administration|on (r_acl) failure_11\NN\66216|acute|renal|following (r_dobj) developed_8\VBD\1753788|patient|failure|. (l_nsubj) patient_1\NN\9898892|a|with|and|disseminated (l_conj) disseminated_6\VBN\954608|sporotrichosis (l_dobj) sporotrichosis_7\NN\14176895|
20003049
C031942_D013921 NONE argatroban_4\NN\0|elevation|in|. (l_prep) in_5\IN\13603305|patient (l_pobj) patient_9\NN\9898892|a|transplant|with (l_prep) with_10\IN\0|history (l_pobj) history_13\NN\15120823|a|suspected|of (l_prep) of_14\IN\0|thrombocytopenia (l_pobj) thrombocytopenia_18\NN\14189204|induced|with
C031942_D013921 NONE argatroban_20\NN\0|for (r_oprd) administered_19\VBN\2436349|in|,|patient|was|argatroban|during|. (l_nsubjpass) patient_11\JJ\9898892|a|old|ill|with (l_prep) with_12\IN\0|history (l_pobj) history_15\NN\15120823|a|suspected|of (l_prep) of_16\IN\0|hitt (l_pobj) hitt_17\NNP\0|
C031942_D013927 NONE argatroban_4\NN\0|elevation|in|. (l_prep) in_5\IN\13603305|patient (l_pobj) patient_9\NN\9898892|a|transplant|with (l_prep) with_10\IN\0|history (l_pobj) history_13\NN\15120823|a|suspected|of (l_prep) of_14\IN\0|thrombocytopenia (l_pobj) thrombocytopenia_18\NN\14189204|induced|with (l_prep) with_19\IN\0|thrombosis (l_pobj) thrombosis_20\NN\14100769|
C031942_D013927 NONE argatroban_20\NN\0|for (r_oprd) administered_19\VBN\2436349|in|,|patient|was|argatroban|during|. (l_nsubjpass) patient_11\JJ\9898892|a|old|ill|with (l_prep) with_12\IN\0|history (l_pobj) history_15\NN\15120823|a|suspected|of (l_prep) of_16\IN\0|hitt (l_pobj) hitt_17\NNP\0|
D006493_D013921 NONE heparin_15\NN\2718259| (r_npadvmod) induced_17\VBN\1627355|heparin|- (r_amod) thrombocytopenia_18\NN\14189204|induced|with
D006493_D013921 NONE heparin_18\NN\2718259| (r_npadvmod) induced_20\VBN\1627355|heparin|- (r_amod) thrombocytopenia_21\NN\14189204|induced|(|hit
D006493_D013921 NONE heparin_18\NN\2718259| (r_npadvmod) induced_20\VBN\1627355|heparin|- (r_amod) thrombocytopenia_21\NN\14189204|induced|(|hit (l_appos) hit_23\NNP\36762|)
D006493_D013921 NONE heparin_18\NN\2718259| (r_npadvmod) induced_20\VBN\1627355|heparin|- (r_amod) thrombocytopenia_21\NN\14189204|induced|(|hit (r_pobj) of_17\IN\0|thrombocytopenia (r_prep) history_16\NN\15120823|a|of (r_pobj) with_14\IN\0|history (r_prep) patients_13\NNS\9898892|with (r_pobj) for_12\IN\0|patients (r_prep) anticoagulation_11\NN\657604|for (r_pobj) of_10\IN\0|anticoagulation (r_prep) method_9\NN\5616786|an|alternative|of (r_dobj) provide_6\VBP\2199590|inhibitors|method|or|hit|. (l_conj) hit_26\VB\36762|with|undergoing
D006493_D013921 NONE heparin_18\NN\2718259| (r_npadvmod) induced_20\VBN\1627355|heparin|- (r_amod) thrombocytopenia_21\NN\14189204|induced|(|hit (r_pobj) of_17\IN\0|thrombocytopenia (r_prep) history_16\NN\15120823|a|of (r_pobj) with_14\IN\0|history (r_prep) patients_13\NNS\9898892|with (r_pobj) for_12\IN\0|patients (r_prep) anticoagulation_11\NN\657604|for (r_pobj) of_10\IN\0|anticoagulation (r_prep) method_9\NN\5616786|an|alternative|of (r_dobj) provide_6\VBP\2199590|inhibitors|method|or|hit|. (l_conj) hit_26\VB\36762|with|undergoing (l_prep) with_27\IN\0|thrombosis (l_pobj) thrombosis_28\NN\14100769|hitt (l_appos) hitt_30\NNP\0|(|)
D006493_D013927 NONE heparin_15\NN\2718259| (r_npadvmod) induced_17\VBN\1627355|heparin|- (r_amod) thrombocytopenia_18\NN\14189204|induced|with (l_prep) with_19\IN\0|thrombosis (l_pobj) thrombosis_20\NN\14100769|
D006493_D013927 NONE heparin_18\NN\2718259| (r_npadvmod) induced_20\VBN\1627355|heparin|- (r_amod) thrombocytopenia_21\NN\14189204|induced|(|hit (r_pobj) of_17\IN\0|thrombocytopenia (r_prep) history_16\NN\15120823|a|of (r_pobj) with_14\IN\0|history (r_prep) patients_13\NNS\9898892|with (r_pobj) for_12\IN\0|patients (r_prep) anticoagulation_11\NN\657604|for (r_pobj) of_10\IN\0|anticoagulation (r_prep) method_9\NN\5616786|an|alternative|of (r_dobj) provide_6\VBP\2199590|inhibitors|method|or|hit|. (l_conj) hit_26\VB\36762|with|undergoing (l_prep) with_27\IN\0|thrombosis (l_pobj) thrombosis_28\NN\14100769|hitt
D006493_D013927 NONE heparin_18\NN\2718259| (r_npadvmod) induced_20\VBN\1627355|heparin|- (r_amod) thrombocytopenia_21\NN\14189204|induced|(|hit (r_pobj) of_17\IN\0|thrombocytopenia (r_prep) history_16\NN\15120823|a|of (r_pobj) with_14\IN\0|history (r_prep) patients_13\NNS\9898892|with (r_pobj) for_12\IN\0|patients (r_prep) anticoagulation_11\NN\657604|for (r_pobj) of_10\IN\0|anticoagulation (r_prep) method_9\NN\5616786|an|alternative|of (r_dobj) provide_6\VBP\2199590|inhibitors|method|or|hit|. (l_conj) hit_26\VB\36762|with|undergoing (l_prep) with_27\IN\0|thrombosis (l_pobj) thrombosis_28\NN\14100769|hitt (l_appos) hitt_30\NNP\0|(|)
C031942_D016638 NONE argatroban_20\NN\0|for (r_oprd) administered_19\VBN\2436349|in|,|patient|was|argatroban|during|. (l_nsubjpass) patient_11\JJ\9898892|a|old|ill|with (l_amod) ill_10\JJ\14052403|critically
C031942_D008107 NONE argatroban_4\NN\0| (r_pobj) of_3\IN\0|argatroban (r_prep) concentrations_2\NNS\4916342|high|of (r_nsubjpass) measured_6\VBN\697589|concentrations|were|in|,|and|observed|is|. (l_conj) is_42\VBZ\0|minutes|) (l_attr) minutes_46\NNS\6502378|39|51|[|minutes|] (l_appos) minutes_52\NNS\6502378|<|=|181|with (l_prep) with_53\IN\0|impairment (l_pobj) impairment_55\NN\7296428|hepatic
C031942_D008107 NONE argatroban_25\JJ\0| (r_amod) life_27\NN\13954253|argatroban|half|t(1/2 (r_npadvmod) plasma_24\NN\5398023|a|prolonged|life|)|of (r_nsubjpass) observed_36\VBN\2163746|plasma|was|published (r_conj) measured_6\VBN\697589|concentrations|were|in|,|and|observed|is|. (l_conj) is_42\VBZ\0|minutes|) (l_attr) minutes_46\NNS\6502378|39|51|[|minutes|] (l_appos) minutes_52\NNS\6502378|<|=|181|with (l_prep) with_53\IN\0|impairment (l_pobj) impairment_55\NN\7296428|hepatic
C031942_D001778 NONE argatroban_3\JJ\0| (r_amod) concentration_4\NN\4916342|correlation|argatroban|versus (r_nsubj) suggest_14\VBP\1010118|concentration|contributed|. (l_ccomp) contributed_24\VBN\126264|that|levels|may|have|to (l_prep) to_25\IN\0|coagulopathy (l_pobj) coagulopathy_30\NN\0|patient|extended
C031942_D001778 NONE argatroban_21\NN\0| (r_amod) levels_18\NNS\4916342|prolonged|elevated|of|argatroban (r_nsubj) contributed_24\VBN\126264|that|levels|may|have|to (l_prep) to_25\IN\0|coagulopathy (l_pobj) coagulopathy_30\NN\0|patient|extended
C031942_D001778 NONE argatroban_8\JJ\0| (r_amod) concentration_9\NN\4916342|argatroban|in (r_dobj) measure_6\VB\168237|to|plasma|concentration|and|extended (l_conj) extended_16\VBN\153263|coagulopathy (l_dobj) coagulopathy_17\NN\0|
7265370
D014223_D053040 CID triamterene_0\JJ\0| (r_compound) nephrolithiasis_1\JJ\14115914|triamterene
D014223_D053040 CID triamterene_3\JJ\0| (r_compound) nephrolithiasis_4\NN\14115914|triamterene
D014223_D053040 CID triamterene_2\JJ\0| (r_compound) nephrolithiasis_3\NN\14115914|triamterene
C020743_D053040 NONE dyazide_3\RB\0| (r_compound) therapy_4\NN\657604|dyazide (r_dobj) complicating_2\VBG\126264|nephrolithiasis|therapy|. (l_nsubj) nephrolithiasis_1\JJ\14115914|triamterene
C020743_D053040 NONE triamterene_16\JJ\0|hydrochlorothiazide|- (r_compound) therapy_17\NN\657604|triamterene (r_pobj) of_13\IN\0|therapy (r_prep) years_12\NNS\15144371|4|of|for (r_pobj) after_10\IN\0|years (r_prep) reported_6\VBN\831651|case|is|in|after|. (l_nsubjpass) case_1\NN\7283608|a|of (l_prep) of_2\IN\0|nephrolithiasis (l_pobj) nephrolithiasis_4\NN\14115914|triamterene
D014223_D006973 NONE triamterene_3\JJ\0| (r_compound) nephrolithiasis_4\NN\14115914|triamterene (r_pobj) of_2\IN\0|nephrolithiasis (r_prep) case_1\NN\7283608|a|of (r_nsubjpass) reported_6\VBN\831651|case|is|in|after|. (l_prep) after_10\IN\0|years (l_pobj) years_12\NNS\15144371|4|of|for (l_prep) for_18\IN\0|hypertension (l_pobj) hypertension_19\NN\14057371|
C020743_D006973 NONE triamterene_16\JJ\0|hydrochlorothiazide|- (r_compound) therapy_17\NN\657604|triamterene (r_pobj) of_13\IN\0|therapy (r_prep) years_12\NNS\15144371|4|of|for (l_prep) for_18\IN\0|hypertension (l_pobj) hypertension_19\NN\14057371|
9522152
D002045_D009461 NONE bupivacaine_11\NN\0|%|hyperbaric|for (r_pobj) of_7\IN\0|bupivacaine (r_prep) injection_6\NN\320852|intrathecal|of (r_dobj) following_4\VBG\8180190|injection (r_acl) deficit_3\NN\5113133|a|transient|neurological|following|.
D002045_D009461 NONE bupivacaine_21\NN\0|%|hyperbaric (r_pobj) with_14\IN\0|bupivacaine (r_prep) anaesthesia_13\NN\14034177|unilateral|spinal|with (r_pobj) after_10\IN\0|anaesthesia (r_prep) occurred_9\VBD\0|that|after (r_relcl) deficit_7\NN\5113133|transient|neurological|occurred
10901305
D007649_D050723 NONE ketamine_0\NN\3054098|sedation|. (l_dobj) sedation_1\NN\14034177|for (l_prep) for_2\IN\0|reduction (l_pobj) reduction_4\NN\351485|the|of (l_prep) of_5\IN\0|fractures (l_pobj) fractures_8\NNS\14285662|children|in
D007649_D050723 NONE ketamine_14\NN\3054098|for (l_prep) for_15\IN\0|sedation (l_pobj) sedation_16\NN\14034177|in (l_prep) in_17\IN\13603305|treatment (l_pobj) treatment_19\NN\654885|the|of (l_prep) of_20\IN\0|fractures (l_pobj) fractures_23\NNS\14285662|children|in
D007649_D050723 NONE ketamine_7\NN\3054098|to (l_prep) to_8\IN\0|manipulation (l_pobj) manipulation_9\NN\157081|of (l_prep) of_10\IN\0|fracture (l_pobj) fracture_12\NN\14285662|the|or|dislocation
D007649_D050723 NONE ketamine_0\NNP\3054098| (r_nsubj) provided_7\VBD\2199590|ketamine|reliably|quickly|sedation|. (l_dobj) sedation_9\NN\14034177|adequate|facilitate (l_acl) facilitate_12\VB\2547586|to|effectively|reduction (l_dobj) reduction_14\NN\351485|the|of (l_prep) of_15\IN\0|fractures (l_pobj) fractures_18\NNS\14285662|children|in
D007649_D004204 NONE ketamine_7\NN\3054098|to (l_prep) to_8\IN\0|manipulation (l_pobj) manipulation_9\NN\157081|of (l_prep) of_10\IN\0|fracture (l_pobj) fracture_12\NN\14285662|the|or|dislocation (l_conj) dislocation_14\NN\7367812|
8231633
D002118_D064420 NONE calcium_2\NN\14625458| (r_compound) channel_3\NN\6251781|calcium (r_compound) blockers_4\NNS\10101634|channel|on (l_prep) on_5\IN\0|toxicity (l_pobj) toxicity_9\NN\13576101|induced
D002118_D064420 NONE calcium_11\NN\14625458| (r_compound) channel_12\NN\6251781|calcium (r_compound) blockers_13\NNS\10101634|channel|on (l_prep) on_14\IN\0|toxicity (l_pobj) toxicity_19\NN\13576101|induced|acute
D002045_D064420 NONE bupivacaine_6\NN\0| (r_npadvmod) induced_8\VBN\1627355|bupivacaine|- (r_amod) toxicity_9\NN\13576101|induced
D002045_D064420 NONE bupivacaine_15\NN\0| (r_npadvmod) induced_17\VBN\1627355|bupivacaine|- (r_amod) toxicity_19\NN\13576101|induced|acute
D002045_D012640 CID bupivacaine_4\NN\0| (r_pobj) of_3\IN\0|bupivacaine (r_prep) activity_2\NN\30358|the|convulsant|of (r_nsubj) was_5\VBD\0|activity (r_auxpass) modified_8\VBN\109660|was|not|significantly|but|decreased (l_conj) decreased_13\VBD\169651|blockers|time (l_dobj) time_15\NN\7308889|the|of|obtain (l_relcl) obtain_19\VB\2210855|to|convulsions (l_dobj) convulsions_23\NNS\14081375|induced
D002045_D012640 CID bupivacaine_20\NN\0| (r_npadvmod) induced_22\VBN\1627355|bupivacaine|- (r_amod) convulsions_23\NNS\14081375|induced
D002118_D012640 NONE calcium_10\NN\14625458| (r_compound) channel_11\NN\6251781|calcium (r_compound) blockers_12\NNS\10101634|channel (r_nsubj) decreased_13\VBD\169651|blockers|time (l_dobj) time_15\NN\7308889|the|of|obtain (l_relcl) obtain_19\VB\2210855|to|convulsions (l_dobj) convulsions_23\NNS\14081375|induced
D015764_D012640 NONE bepridil_31\NN\0| (r_pcomp) with_30\IN\0|bepridil (r_prep) pronounced_29\VBN\0|less|with (r_acomp) was_27\VBD\0|modified|;|effect|pronounced|. (l_ccomp) modified_8\VBN\109660|was|not|significantly|but|decreased (l_conj) decreased_13\VBD\169651|blockers|time (l_dobj) time_15\NN\7308889|the|of|obtain (l_relcl) obtain_19\VB\2210855|to|convulsions (l_dobj) convulsions_23\NNS\14081375|induced
6666578
D010396_D001018 CID penicillamine_2\NN\3740161|d|- (r_compound) induced_4\VBN\1627355|penicillamine|-|angiopathy|in|. (l_advmod) angiopathy_5\NN\14204950|
14659530
D009569_D008881 NONE no_0\RB\7204911| (r_intj) induced_2\VBN\1627355|no|- (r_amod) attack_4\NN\955060|induced|migraine|:|increase|. (l_compound) migraine_3\JJ\14326607|
D015740_D008881 NONE peptide_14\NN\14724264|plasma|calcitonin|related|concentration (r_pobj) in_8\IN\13603305|peptide (r_prep) increase_7\NN\13576355|strong|in (r_appos) attack_4\NN\955060|induced|migraine|:|increase|. (l_compound) migraine_3\JJ\14326607|
D015740_D008881 NONE cgrp_16\NN\0| (r_nmod) concentration_18\NN\4916342|(|cgrp|)|and|correlation (r_appos) peptide_14\NN\14724264|plasma|calcitonin|related|concentration (r_pobj) in_8\IN\13603305|peptide (r_prep) increase_7\NN\13576355|strong|in (r_appos) attack_4\NN\955060|induced|migraine|:|increase|. (l_compound) migraine_3\JJ\14326607|
D015740_D008881 NONE peptide_17\NN\14724264|the|plasma|calcitonin|related (r_nmod) content_30\NN\7951464|peptide|concentration|serotonin|5-ht|) (r_pobj) in_10\IN\13603305|content (r_prep) changes_9\NNS\7283608|in|during (r_dobj) investigate_8\VB\644583|to|changes|and|attack (l_conj) attack_40\NN\955060|the|delayed|genuine|migraine|provoked (l_compound) migraine_39\JJ\14326607|
D015740_D008881 NONE cgrp_19\NN\0| (r_nmod) concentration_21\NN\4916342|(|cgrp|)|and (r_nmod) content_30\NN\7951464|peptide|concentration|serotonin|5-ht|) (r_pobj) in_10\IN\13603305|content (r_prep) changes_9\NNS\7283608|in|during (r_dobj) investigate_8\VB\644583|to|changes|and|attack (l_conj) attack_40\NN\955060|the|delayed|genuine|migraine|provoked (l_compound) migraine_39\JJ\14326607|
D015740_D008881 NONE cgrp_1\NN\0| (r_compound) concentration_2\NN\4916342|plasma|cgrp (r_nsubj) increased_3\VBD\169651|concentration|significantly|p<0.01|during|and|returned|. (l_prep) during_8\IN\0|attack (l_pobj) attack_11\NN\955060|the|migraine (l_compound) migraine_10\JJ\14326607|
D015740_D008881 NONE cgrp_1\NN\0| (r_compound) concentration_2\NN\4916342|plasma|cgrp (r_nsubj) increased_3\VBD\169651|concentration|significantly|p<0.01|during|and|returned|. (l_conj) returned_13\VBD\1835496|to|after (l_prep) after_16\IN\0|cessation (l_pobj) cessation_18\NN\7365849|the|of (l_prep) of_19\IN\0|migraine (l_pobj) migraine_21\NN\14326607|the
D015740_D008881 NONE cgrp_3\NNP\0| (r_compound) concentrations_4\NNS\4916342|plasma|cgrp (r_nsubj) failed_5\VBD\0|however|,|concentrations|change|. (l_xcomp) change_7\VB\7283608|to|during (l_prep) during_8\IN\0|headache|and|in (l_conj) in_12\IN\13603305|subjects (l_pobj) subjects_14\NNS\6598915|the|with (l_prep) with_15\IN\0|attack (l_pobj) attack_18\NN\955060|no|migraine (l_compound) migraine_17\JJ\14326607|
D015740_D008881 NONE cgrp_1\NNP\0| (r_compound) concentration_2\NN\4916342|basal|cgrp (r_nsubj) was_3\VBD\0|concentration|higher|and|platelet|. (l_conj) platelet_7\NN\5432736|tended (l_ccomp) tended_10\VBD\2604760|content|be (l_xcomp) be_12\VB\14625458|to|lower|in (l_prep) in_14\IN\13603305|subjects (l_pobj) subjects_15\NNS\6598915|experienced (l_relcl) experienced_17\VBD\2108377|who|attack (l_dobj) attack_20\NN\955060|a|migraine (l_compound) migraine_19\JJ\14326607|
D015740_D008881 NONE cgrp_7\NN\0| (r_compound) concentration_8\NN\4916342|plasma|cgrp (r_nsubj) correlates_9\VBZ\5857459|that|concentration|with (l_prep) with_10\IN\0|timing (l_pobj) timing_12\NN\5044673|the|and|severity|of (l_prep) of_15\IN\0|headache (l_pobj) headache_18\NN\5829480|a|migraine (l_compound) migraine_17\JJ\14326607|
D015740_D008881 NONE cgrp_7\NN\0| (r_compound) concentration_8\NN\4916342|plasma|cgrp (r_nsubj) correlates_9\VBZ\5857459|that|concentration|with (r_acl) fact_4\NN\5816287|the|correlates (r_nsubj) suggests_19\VBZ\1010118|in|,|fact|relationship|. (l_dobj) relationship_22\NN\31921|a|direct|between (l_prep) between_23\IN\0|cgrp (l_pobj) cgrp_24\NN\0|and|migraine (l_conj) migraine_26\NN\14326607|
D015740_D008881 NONE cgrp_24\NN\0|and|migraine (r_pobj) between_23\IN\0|cgrp (r_prep) relationship_22\NN\31921|a|direct|between (r_dobj) suggests_19\VBZ\1010118|in|,|fact|relationship|. (l_nsubj) fact_4\NN\5816287|the|correlates (l_acl) correlates_9\VBZ\5857459|that|concentration|with (l_prep) with_10\IN\0|timing (l_pobj) timing_12\NN\5044673|the|and|severity|of (l_prep) of_15\IN\0|headache (l_pobj) headache_18\NN\5829480|a|migraine (l_compound) migraine_17\JJ\14326607|
D015740_D008881 NONE cgrp_24\NN\0|and|migraine (l_conj) migraine_26\NN\14326607|
D015740_D008881 NONE cgrp_21\NN\0| (r_compound) release_22\NN\3748886|the|concomitant|cgrp|in (r_conj) headache_17\NN\5829480|the|and|release (r_dobj) counteract_15\VB\2367363|provoke|,|it|may|even|headache|. (l_ccomp) provoke_9\VB\1617192|in|,|release|does|not|migraine (l_dobj) migraine_10\NN\14326607|
D012701_D008881 NONE serotonin_24\NN\14807737|platelet (r_compound) release_25\NN\3748886|serotonin (r_pobj) with_22\IN\0|release (r_prep) correlation_21\NN\13841213|negative|with (r_conj) concentration_18\NN\4916342|(|cgrp|)|and|correlation (r_appos) peptide_14\NN\14724264|plasma|calcitonin|related|concentration (r_pobj) in_8\IN\13603305|peptide (r_prep) increase_7\NN\13576355|strong|in (r_appos) attack_4\NN\955060|induced|migraine|:|increase|. (l_compound) migraine_3\JJ\14326607|
D012701_D008881 NONE serotonin_24\NN\14807737|platelet (r_nmod) content_30\NN\7951464|peptide|concentration|serotonin|5-ht|) (r_pobj) in_10\IN\13603305|content (r_prep) changes_9\NNS\7283608|in|during (r_dobj) investigate_8\VB\644583|to|changes|and|attack (l_conj) attack_40\NN\955060|the|delayed|genuine|migraine|provoked (l_compound) migraine_39\JJ\14326607|
D012701_D008881 NONE 5-hydroxytriptamine_26\NN\0|( (r_punct) ,_27\,\0|5-hydroxytriptamine (r_punct) 5-ht_28\CD\0|, (r_nmod) content_30\NN\7951464|peptide|concentration|serotonin|5-ht|) (r_pobj) in_10\IN\13603305|content (r_prep) changes_9\NNS\7283608|in|during (r_dobj) investigate_8\VB\644583|to|changes|and|attack (l_conj) attack_40\NN\955060|the|delayed|genuine|migraine|provoked (l_compound) migraine_39\JJ\14326607|
D012701_D008881 NONE 5-ht_28\CD\0|, (r_nmod) content_30\NN\7951464|peptide|concentration|serotonin|5-ht|) (r_pobj) in_10\IN\13603305|content (r_prep) changes_9\NNS\7283608|in|during (r_dobj) investigate_8\VB\644583|to|changes|and|attack (l_conj) attack_40\NN\955060|the|delayed|genuine|migraine|provoked (l_compound) migraine_39\JJ\14326607|
D012701_D008881 NONE 5-ht_8\CD\0| (r_nummod) content_9\NN\7951464|5-ht (r_nsubj) tended_10\VBD\2604760|content|be (l_xcomp) be_12\VB\14625458|to|lower|in (l_prep) in_14\IN\13603305|subjects (l_pobj) subjects_15\NNS\6598915|experienced (l_relcl) experienced_17\VBD\2108377|who|attack (l_dobj) attack_20\NN\955060|a|migraine (l_compound) migraine_19\JJ\14326607|
D012701_D008881 NONE serotonin_1\NN\14807737|platelet (r_compound) content_2\NN\7951464|serotonin (r_nsubj) decreased_3\VBD\169651|content|significantly|p<0.01|after|but|observed (l_prep) after_8\IN\0|nitroglycerin (l_pobj) nitroglycerin_9\NN\15015501|in (l_prep) in_10\IN\13603305|subjects (l_pobj) subjects_11\NNS\6598915|with (l_prep) with_12\IN\0|attack (l_pobj) attack_15\NN\955060|no|migraine (l_compound) migraine_14\JJ\14326607|
D012701_D008881 NONE serotonin_1\NN\14807737|platelet (r_compound) content_2\NN\7951464|serotonin (r_nsubj) decreased_3\VBD\169651|content|significantly|p<0.01|after|but|observed (l_conj) observed_21\VBN\2163746|change|was|in|. (l_prep) in_22\IN\13603305|patients (l_pobj) patients_23\NNS\9898892|with (l_prep) with_24\IN\0|attack (l_pobj) attack_26\NN\955060|migraine (l_compound) migraine_25\JJ\14326607|
D012701_D008881 NONE serotonin_3\NN\14807737| (r_compound) release_4\NN\3748886|serotonin|from (r_nsubj) provoke_9\VB\1617192|in|,|release|does|not|migraine (l_dobj) migraine_10\NN\14326607|
D015740_D006261 NONE peptide_17\NN\14724264|the|plasma|calcitonin|related (r_nmod) content_30\NN\7951464|peptide|concentration|serotonin|5-ht|) (r_pobj) in_10\IN\13603305|content (r_prep) changes_9\NNS\7283608|in|during (l_prep) during_31\IN\0|headache (l_pobj) headache_34\NN\5829480|the|immediate
D015740_D006261 NONE cgrp_19\NN\0| (r_nmod) concentration_21\NN\4916342|(|cgrp|)|and (r_nmod) content_30\NN\7951464|peptide|concentration|serotonin|5-ht|) (r_pobj) in_10\IN\13603305|content (r_prep) changes_9\NNS\7283608|in|during (l_prep) during_31\IN\0|headache (l_pobj) headache_34\NN\5829480|the|immediate
D015740_D006261 NONE cgrp_3\NNP\0| (r_compound) concentrations_4\NNS\4916342|plasma|cgrp (r_nsubj) failed_5\VBD\0|however|,|concentrations|change|. (l_xcomp) change_7\VB\7283608|to|during (l_prep) during_8\IN\0|headache|and|in (l_pobj) headache_10\NN\5829480|immediate
D015740_D006261 NONE cgrp_7\NN\0| (r_compound) concentration_8\NN\4916342|plasma|cgrp (r_nsubj) correlates_9\VBZ\5857459|that|concentration|with (l_prep) with_10\IN\0|timing (l_pobj) timing_12\NN\5044673|the|and|severity|of (l_prep) of_15\IN\0|headache (l_pobj) headache_18\NN\5829480|a|migraine
D015740_D006261 NONE cgrp_24\NN\0|and|migraine (r_pobj) between_23\IN\0|cgrp (r_prep) relationship_22\NN\31921|a|direct|between (r_dobj) suggests_19\VBZ\1010118|in|,|fact|relationship|. (l_nsubj) fact_4\NN\5816287|the|correlates (l_acl) correlates_9\VBZ\5857459|that|concentration|with (l_prep) with_10\IN\0|timing (l_pobj) timing_12\NN\5044673|the|and|severity|of (l_prep) of_15\IN\0|headache (l_pobj) headache_18\NN\5829480|a|migraine
D015740_D006261 NONE cgrp_21\NN\0| (r_compound) release_22\NN\3748886|the|concomitant|cgrp|in (r_conj) headache_17\NN\5829480|the|and|release
D012701_D006261 NONE serotonin_24\NN\14807737|platelet (r_nmod) content_30\NN\7951464|peptide|concentration|serotonin|5-ht|) (r_pobj) in_10\IN\13603305|content (r_prep) changes_9\NNS\7283608|in|during (l_prep) during_31\IN\0|headache (l_pobj) headache_34\NN\5829480|the|immediate
D012701_D006261 NONE 5-hydroxytriptamine_26\NN\0|( (r_punct) ,_27\,\0|5-hydroxytriptamine (r_punct) 5-ht_28\CD\0|, (r_nmod) content_30\NN\7951464|peptide|concentration|serotonin|5-ht|) (r_pobj) in_10\IN\13603305|content (r_prep) changes_9\NNS\7283608|in|during (l_prep) during_31\IN\0|headache (l_pobj) headache_34\NN\5829480|the|immediate
D012701_D006261 NONE 5-ht_28\CD\0|, (r_nmod) content_30\NN\7951464|peptide|concentration|serotonin|5-ht|) (r_pobj) in_10\IN\13603305|content (r_prep) changes_9\NNS\7283608|in|during (l_prep) during_31\IN\0|headache (l_pobj) headache_34\NN\5829480|the|immediate
D012701_D006261 NONE serotonin_3\NN\14807737| (r_compound) release_4\NN\3748886|serotonin|from (r_nsubj) provoke_9\VB\1617192|in|,|release|does|not|migraine (r_ccomp) counteract_15\VB\2367363|provoke|,|it|may|even|headache|. (l_dobj) headache_17\NN\5829480|the|and|release
D005996_D006261 NONE nitroglycerin_43\NN\15015501| (r_pobj) by_42\IN\0|nitroglycerin (r_agent) provoked_41\VBN\1617192|by (r_acl) attack_40\NN\955060|the|delayed|genuine|migraine|provoked (r_conj) investigate_8\VB\644583|to|changes|and|attack (l_dobj) changes_9\NNS\7283608|in|during (l_prep) during_31\IN\0|headache (l_pobj) headache_34\NN\5829480|the|immediate
D005996_D008881 NONE nitroglycerin_43\NN\15015501| (r_pobj) by_42\IN\0|nitroglycerin (r_agent) provoked_41\VBN\1617192|by (r_acl) attack_40\NN\955060|the|delayed|genuine|migraine|provoked (l_compound) migraine_39\JJ\14326607|
D005996_D008881 NONE nitroglycerin_16\NN\15015501| (r_compound) application_17\NN\947128|the|nitroglycerin (r_pobj) after_14\IN\0|application (r_conj) before_12\RB\0|min|and|after (r_advmod) collected_2\VBN\2281093|blood|was|from|times|before|,|and|min (l_conj) min_23\NN\15154774|60|after|;|subjects|. (l_prep) after_24\IN\0|beginning (l_pobj) beginning_26\NN\7283608|the|of (l_prep) of_27\IN\0|attack (l_pobj) attack_30\NN\955060|the|migraine|mean (l_compound) migraine_29\JJ\14326607|
D005996_D008881 NONE nitroglycerin_9\NN\15015501|in (l_prep) in_10\IN\13603305|subjects (l_pobj) subjects_11\NNS\6598915|with (l_prep) with_12\IN\0|attack (l_pobj) attack_15\NN\955060|no|migraine (l_compound) migraine_14\JJ\14326607|
D005996_D008881 NONE nitroglycerin_9\NN\15015501|in (r_pobj) after_8\IN\0|nitroglycerin (r_prep) decreased_3\VBD\169651|content|significantly|p<0.01|after|but|observed (l_conj) observed_21\VBN\2163746|change|was|in|. (l_prep) in_22\IN\13603305|patients (l_pobj) patients_23\NNS\9898892|with (l_prep) with_24\IN\0|attack (l_pobj) attack_26\NN\955060|migraine (l_compound) migraine_25\JJ\14326607|
17241784
D019821_D009135 CID statin_12\NN\3740161| (r_compound) therapy_13\NN\657604|statin (r_pobj) with_11\IN\0|therapy (r_prep) associated_10\VBD\628491|with (r_acl) myopathy_1\NNS\14204950|progressive|with|associated|.
D019821_D009135 CID statins_0\NNS\3740161| (r_nsubj) cause_2\VB\7323922|statins|can|necrotizing|myopathy|. (l_ccomp) myopathy_5\NN\14204950|and|hyperckaemia
D019821_D009135 CID statins_9\NNS\3740161| (r_nsubj) induce_11\VB\1627355|whereby|statins|may|myopathy (l_dobj) myopathy_13\NN\14204950|a
D019821_D009135 CID statins_4\NNS\3740161| (r_nsubj) initiate_6\VB\9632274|that|statins|may|myopathy (l_dobj) myopathy_11\NN\14204950|an|mediated|persists
D019821_D009135 CID statins_13\NNS\3740161|of (r_pobj) by_12\IN\0|statins (r_prep) induction_11\NN\7450842|the|by (r_dobj) involve_9\VB\2676054|may|induction (r_conj) is_5\VBZ\0|mechanism|uncertain|but|involve|. (l_nsubj) mechanism_1\NN\13446390|the|of (l_prep) of_2\IN\0|myopathy (l_pobj) myopathy_4\NN\14204950|this
D019821_-1 NONE statins_0\NNS\3740161| (r_nsubj) cause_2\VB\7323922|statins|can|necrotizing|myopathy|. (l_ccomp) myopathy_5\NN\14204950|and|hyperckaemia (l_conj) hyperckaemia_7\NN\0|
15602202
D017963_D009395 CID azithromycin_6\PRP\2716205| (r_pobj) by_5\IN\0|azithromycin (r_prep) induced_4\VBN\1627355|nephritis|by|. (l_nsubj) nephritis_3\NN\14113228|recurrent|acute|interstitial
D017963_D009395 CID azithromycin_10\RB\2716205| (r_advmod) induced_12\VBN\1627355|azithromycin|- (r_amod) nephritis_16\NN\14113228|induced|,|acute|interstitial
7444978
D013307_D020258 NONE streptomycin_11\NNS\2716866| (r_pobj) of_10\IN\0|streptomycin (r_prep) effects_9\NNS\13245626|neurotoxic|of (l_amod) neurotoxic_8\JJ\0|
D013307_D004409 CID streptomycin_48\NNS\2716866|than (r_pobj) to_47\IN\0|streptomycin (r_prep) sensitive_46\JJ\10488309|more|to (r_acomp) is_44\VBZ\0|that|cochlea|sensitive (r_ccomp) indicating_40\VBG\952524|is (r_advcl) occurred_23\VBD\0|occurred|;|within|sensitivities|from|,|indicating|. (l_ccomp) occurred_4\VBD\0|movements|in (l_nsubj) movements_1\NNS\191142|abnormal|and|deafness
D013307_D004409 CID streptomycin_48\NNS\2716866|than (l_prep) than_49\IN\0|site (l_pobj) site_51\NN\8673395|the|(|vestibular|)|responsible (l_amod) responsible_57\JJ\0|for (l_prep) for_58\IN\0|dyskinesias (l_pobj) dyskinesias_60\NNS\14084880|the
D013307_D003638 CID streptomycin_48\NNS\2716866|than (r_pobj) to_47\IN\0|streptomycin (r_prep) sensitive_46\JJ\10488309|more|to (r_acomp) is_44\VBZ\0|that|cochlea|sensitive (r_ccomp) indicating_40\VBG\952524|is (r_advcl) occurred_23\VBD\0|occurred|;|within|sensitivities|from|,|indicating|. (l_ccomp) occurred_4\VBD\0|movements|in (l_nsubj) movements_1\NNS\191142|abnormal|and|deafness (l_conj) deafness_3\NN\14550797|
8437969
D002927_D054138 CID cimetidine_7\NN\14778019|infusion (r_pobj) with_3\IN\0|cimetidine (r_prep) associated_2\VBN\628491|with (r_acl) arrest_1\NN\88481|sinus|associated|.
D002927_D054138 CID cimetidine_27\NN\14778019|infusion (r_dobj) receiving_23\VBG\2210855|while|cimetidine|hour (r_advcl) recurrent_14\JJ\0|developed|,|episodes|receiving (l_appos) episodes_17\NNS\7283608|brief|of (l_prep) of_18\IN\0|arrest (l_pobj) arrest_21\NN\88481|apparent|sinus
D002927_D054138 CID cimetidine_14\NN\14778019|infusion (r_pobj) with_10\IN\0|cimetidine (r_prep) associated_9\VBN\628491|with (r_acl) case_5\NN\7283608|the|first|reported|of|associated (l_prep) of_6\IN\0|arrest (l_pobj) arrest_8\NN\88481|sinus
D002927_D001919 CID cimetidine_7\NN\14778019| (r_pobj) of_6\IN\0|cimetidine (r_prep) infusions_5\NNS\14589223|intermittent|intravenous|of (r_pobj) of_2\IN\0|infusions (r_prep) administration_1\NN\1133281|the|of (r_nsubjpass) associated_10\VBN\628491|administration|is|infrequently|with|. (l_prep) with_11\IN\0|development (l_pobj) development_13\NN\248977|the|of (l_prep) of_14\IN\0|bradyarrhythmias (l_pobj) bradyarrhythmias_15\NNS\0|
D002927_D007938 NONE cimetidine_27\NN\14778019|infusion (r_dobj) receiving_23\VBG\2210855|while|cimetidine|hour (r_advcl) recurrent_14\JJ\0|developed|,|episodes|receiving (r_appos) man_4\NN\9605289|a|old|with|and|history|recurrent|. (l_prep) with_5\IN\0|leukemia (l_pobj) leukemia_6\NN\14239918|
D002927_D006331 NONE cimetidine_27\NN\14778019|infusion (r_dobj) receiving_23\VBG\2210855|while|cimetidine|hour (r_advcl) recurrent_14\JJ\0|developed|,|episodes|receiving (r_appos) man_4\NN\9605289|a|old|with|and|history|recurrent|. (l_conj) history_9\NN\15120823|no|of (l_prep) of_10\IN\0|disease (l_pobj) disease_12\NN\14061805|cardiac
D002927_D001145 NONE cimetidine_6\NN\14778019| (r_compound) administration_7\NN\1133281|cimetidine (r_pobj) to_5\IN\0|administration (r_prep) related_4\VBN\628491|arrhythmias|were|temporally|to (l_nsubjpass) arrhythmias_1\NNS\14103288|the
D011899_D001145 NONE ranitidine_18\NN\14778019| (r_compound) treatment_19\NN\654885|ranitidine (r_pobj) during_17\IN\0|treatment (r_prep) recur_16\VB\339934|did|not|during (r_conj) disappeared_9\VBD\0|related|,|after|,|and|recur|. (l_ccomp) related_4\VBN\628491|arrhythmias|were|temporally|to (l_nsubjpass) arrhythmias_1\NNS\14103288|the
19843802
D004837_D006973 CID epinephrine_5\NN\14807929| (r_pobj) of_4\IN\0|epinephrine (r_prep) bolus_3\NN\13899404|a|of|injected (r_nsubj) provoked_11\VBD\1617192|however|,|bolus|crisis|. (l_dobj) crisis_14\NN\14411243|a|hypertensive (l_amod) hypertensive_13\JJ\10405694|
17344566
D019821_D003161 CID simvastatin_0\NNP\3676175| (r_npadvmod) induced_2\VBN\1627355|simvastatin|- (r_amod) syndrome_6\NN\5870365|induced|compartment|and|myonecrosis|associated|.
D019821_D003161 CID simvastatin_9\NN\3676175| (r_conj) thyroxine_7\NN\5413241|a|old|taking|and|simvastatin (r_nsubj) presented_10\VBD\2137132|thyroxine|with|. (l_prep) with_11\IN\0|syndrome (l_pobj) syndrome_15\NN\5870365|compartment|and|myonecrosis
D019821_D009135 NONE simvastatin_0\NNP\3676175| (r_npadvmod) induced_2\VBN\1627355|simvastatin|- (r_amod) syndrome_6\NN\5870365|induced|compartment|and|myonecrosis|associated|. (l_conj) myonecrosis_8\NN\11486708|
D019821_D009135 NONE simvastatin_9\NN\3676175| (r_conj) thyroxine_7\NN\5413241|a|old|taking|and|simvastatin (r_nsubj) presented_10\VBD\2137132|thyroxine|with|. (l_prep) with_11\IN\0|syndrome (l_pobj) syndrome_15\NN\5870365|compartment|and|myonecrosis (l_conj) myonecrosis_17\NN\11486708|
D019821_D007037 NONE simvastatin_0\NNP\3676175| (r_npadvmod) induced_2\VBN\1627355|simvastatin|- (r_amod) syndrome_6\NN\5870365|induced|compartment|and|myonecrosis|associated|. (l_acl) associated_9\VBN\628491|with (l_prep) with_10\IN\0|hypothyroidism (l_pobj) hypothyroidism_11\NN\14059928|
D019821_D007037 NONE simvastatin_9\NN\3676175| (r_conj) thyroxine_7\NN\5413241|a|old|taking|and|simvastatin (l_compound) taking_6\VBG\37396|male (l_nsubj) male_5\NN\15388|hypothyroid (l_amod) hypothyroid_4\JJ\0|
D013974_D007037 NONE thyroxine_7\NN\5413241|a|old|taking|and|simvastatin (l_compound) taking_6\VBG\37396|male (l_nsubj) male_5\NN\15388|hypothyroid (l_amod) hypothyroid_4\JJ\0|
D013974_D003161 NONE thyroxine_7\NN\5413241|a|old|taking|and|simvastatin (r_nsubj) presented_10\VBD\2137132|thyroxine|with|. (l_prep) with_11\IN\0|syndrome (l_pobj) syndrome_15\NN\5870365|compartment|and|myonecrosis
D013974_D009135 NONE thyroxine_7\NN\5413241|a|old|taking|and|simvastatin (r_nsubj) presented_10\VBD\2137132|thyroxine|with|. (l_prep) with_11\IN\0|syndrome (l_pobj) syndrome_15\NN\5870365|compartment|and|myonecrosis (l_conj) myonecrosis_17\NN\11486708|
3173180
D008795_D006463 CID metronidazole_7\NN\2723292| (r_pobj) with_6\IN\0|metronidazole (r_prep) treatment_5\NN\654885|with (r_pobj) after_4\IN\0|treatment (r_prep) syndrome_3\NN\5870365|uraemic|after|.
D008795_D006463 CID metronidazole_19\NN\2723292| (r_pobj) with_18\IN\0|metronidazole (r_prep) treatment_17\NN\654885|with (r_pobj) after_16\IN\0|treatment (r_prep) developed_10\VBD\1753788|who|syndrome|after (l_dobj) syndrome_15\NN\5870365|the|uraemic
D008795_D006463 CID metronidazole_4\NN\2723292| (r_pobj) of_3\IN\0|metronidazole (r_prep) involvement_2\NN\1080366|the|of|in (l_prep) in_5\IN\13603305|aetiology (l_pobj) aetiology_7\NN\7326557|the|of (l_prep) of_8\IN\0|syndrome (l_pobj) syndrome_13\NN\5870365|the|uraemic
D008795_D006463 CID metronidazole_4\NN\2723292| (r_pobj) of_3\IN\0|metronidazole (r_prep) involvement_2\NN\1080366|the|of|in (r_nsubjpass) established_16\VBN\2426171|while|involvement|is|not|firmly (r_advcl) suggest_43\VBP\1010118|established|,|action|link|. (l_nsubj) action_20\NN\30358|the|of|in|evidence (l_conj) evidence_33\NN\5816287|the|reported|of (l_prep) of_34\IN\0|changes (l_pobj) changes_36\NNS\7283608|oxidation|in (l_prep) in_37\IN\13603305|syndrome (l_pobj) syndrome_42\NN\5870365|the|uraemic
D008795_D006463 CID metronidazole_4\NN\2723292| (r_pobj) of_3\IN\0|metronidazole (r_prep) involvement_2\NN\1080366|the|of|in (r_nsubjpass) established_16\VBN\2426171|while|involvement|is|not|firmly (r_advcl) suggest_43\VBP\1010118|established|,|action|link|. (l_dobj) link_46\NN\13792579|a|possible|between (l_prep) between_47\IN\0|treatment (l_pobj) treatment_49\NN\654885|metronidazole|and|cases (l_conj) cases_52\NNS\7283608|some|of (l_prep) of_53\IN\0|syndrome (l_pobj) syndrome_58\NN\5870365|the|uraemic
D008795_D006463 CID metronidazole_48\NN\2723292| (r_amod) treatment_49\NN\654885|metronidazole|and|cases (r_pobj) between_47\IN\0|treatment (r_prep) link_46\NN\13792579|a|possible|between (r_dobj) suggest_43\VBP\1010118|established|,|action|link|. (l_advcl) established_16\VBN\2426171|while|involvement|is|not|firmly (l_nsubjpass) involvement_2\NN\1080366|the|of|in (l_prep) in_5\IN\13603305|aetiology (l_pobj) aetiology_7\NN\7326557|the|of (l_prep) of_8\IN\0|syndrome (l_pobj) syndrome_13\NN\5870365|the|uraemic
D008795_D006463 CID metronidazole_48\NN\2723292| (r_amod) treatment_49\NN\654885|metronidazole|and|cases (r_pobj) between_47\IN\0|treatment (r_prep) link_46\NN\13792579|a|possible|between (r_dobj) suggest_43\VBP\1010118|established|,|action|link|. (l_nsubj) action_20\NN\30358|the|of|in|evidence (l_conj) evidence_33\NN\5816287|the|reported|of (l_prep) of_34\IN\0|changes (l_pobj) changes_36\NNS\7283608|oxidation|in (l_prep) in_37\IN\13603305|syndrome (l_pobj) syndrome_42\NN\5870365|the|uraemic
D008795_D006463 CID metronidazole_48\NN\2723292| (r_amod) treatment_49\NN\654885|metronidazole|and|cases (l_conj) cases_52\NNS\7283608|some|of (l_prep) of_53\IN\0|syndrome (l_pobj) syndrome_58\NN\5870365|the|uraemic
20621845
D002122_D017545 CID cacl2-induced_14\VBN\0| (r_amod) aneurysm_17\NN\14057371|cacl2-induced|thoracic|aortic|in
D002122_D017545 CID chloride_18\NN\14818238|calcium|injury (r_pobj) by_16\IN\0|chloride (r_prep) establish_5\VB\2426171|to|model|by|and|explore (l_dobj) model_8\NN\5888929|a|rat|of (l_prep) of_9\IN\0|aneurysm (l_pobj) aneurysm_12\NN\14057371|thoracic|aortic|(|taa|)
D002122_D017545 CID chloride_18\NN\14818238|calcium|injury (r_pobj) by_16\IN\0|chloride (r_prep) establish_5\VB\2426171|to|model|by|and|explore (l_dobj) model_8\NN\5888929|a|rat|of (l_prep) of_9\IN\0|aneurysm (l_pobj) aneurysm_12\NN\14057371|thoracic|aortic|(|taa|) (l_appos) taa_14\NNP\0|
D002122_D017545 CID chloride_18\NN\14818238|calcium|injury (r_pobj) by_16\IN\0|chloride (r_prep) establish_5\VB\2426171|to|model|by|and|explore (r_xcomp) designed_3\VBN\1631534|study|was|establish|,|metalloproteinases|. (l_conj) metalloproteinases_39\NNS\0|matrix|(|mmps|)|and|inhibitors (l_conj) inhibitors_46\NNS\20090|their|endogenous|(|timps|)|in (l_prep) in_50\IN\13603305|formation (l_pobj) formation_52\NN\7938773|taa (l_compound) taa_51\NNP\0|
D002122_D017545 CID cacl(2))-induced_20\VBN\0| (r_amod) injury_22\NN\14052046|(|cacl(2))-induced|arterial (r_appos) chloride_18\NN\14818238|calcium|injury (r_pobj) by_16\IN\0|chloride (r_prep) establish_5\VB\2426171|to|model|by|and|explore (l_dobj) model_8\NN\5888929|a|rat|of (l_prep) of_9\IN\0|aneurysm (l_pobj) aneurysm_12\NN\14057371|thoracic|aortic|(|taa|)
D002122_D017545 CID cacl(2))-induced_20\VBN\0| (r_amod) injury_22\NN\14052046|(|cacl(2))-induced|arterial (r_appos) chloride_18\NN\14818238|calcium|injury (r_pobj) by_16\IN\0|chloride (r_prep) establish_5\VB\2426171|to|model|by|and|explore (l_dobj) model_8\NN\5888929|a|rat|of (l_prep) of_9\IN\0|aneurysm (l_pobj) aneurysm_12\NN\14057371|thoracic|aortic|(|taa|) (l_appos) taa_14\NNP\0|
D002122_D017545 CID cacl(2))-induced_20\VBN\0| (r_amod) injury_22\NN\14052046|(|cacl(2))-induced|arterial (r_appos) chloride_18\NN\14818238|calcium|injury (r_pobj) by_16\IN\0|chloride (r_prep) establish_5\VB\2426171|to|model|by|and|explore (r_xcomp) designed_3\VBN\1631534|study|was|establish|,|metalloproteinases|. (l_conj) metalloproteinases_39\NNS\0|matrix|(|mmps|)|and|inhibitors (l_conj) inhibitors_46\NNS\20090|their|endogenous|(|timps|)|in (l_prep) in_50\IN\13603305|formation (l_pobj) formation_52\NN\7938773|taa (l_compound) taa_51\NNP\0|
D002122_D017545 CID )_9\-RRB-\0| (r_punct) establishes_2\VBZ\2426171|study|model|by|) (l_dobj) model_5\NN\5888929|a|taa (l_compound) taa_4\NNP\0|
D002122_D014652 NONE chloride_18\NN\14818238|calcium|injury (l_appos) injury_22\NN\14052046|(|cacl(2))-induced|arterial
D002122_D014652 NONE cacl(2))-induced_20\VBN\0| (r_amod) injury_22\NN\14052046|(|cacl(2))-induced|arterial
567256
D004054_D006394 CID diethylstilbestrol_6\NN\14749794| (r_pobj) with_5\IN\0|diethylstilbestrol (r_prep) associated_4\VBN\628491|with (r_acl) liver_3\NN\5298729|the|associated
D004054_D006394 CID diethylstilbestrol_25\NN\14749794| (r_pobj) with_24\IN\0|diethylstilbestrol (r_prep) liver_23\NN\5298729|the|with (r_pobj) of_21\IN\0|liver (r_prep) adenocarcinoma_20\NN\14242337|a|differentiated|of (r_pobj) for_15\IN\0|adenocarcinoma (r_prep) treated_14\VBN\2376958|who|had|been|for|for (r_relcl) man_10\NN\9605289|a|old|treated (r_pobj) in_5\IN\13603305|man (r_prep) occurred_4\VBD\0|angiosarcoma|in|. (l_nsubj) angiosarcoma_0\NNP\14239425|of (l_prep) of_1\IN\0|liver (l_pobj) liver_3\NN\5298729|the
D004054_D008113 CID diethylstilbestrol_6\NN\14749794| (r_pobj) with_5\IN\0|diethylstilbestrol (r_prep) associated_4\VBN\628491|with (r_acl) liver_3\NN\5298729|the|associated
D004054_D008113 CID diethylstilbestrol_25\NN\14749794| (r_pobj) with_24\IN\0|diethylstilbestrol (r_prep) liver_23\NN\5298729|the|with (r_pobj) of_21\IN\0|liver (r_prep) adenocarcinoma_20\NN\14242337|a|differentiated|of (r_pobj) for_15\IN\0|adenocarcinoma (r_prep) treated_14\VBN\2376958|who|had|been|for|for (r_relcl) man_10\NN\9605289|a|old|treated (r_pobj) in_5\IN\13603305|man (r_prep) occurred_4\VBD\0|angiosarcoma|in|. (l_nsubj) angiosarcoma_0\NNP\14239425|of (l_prep) of_1\IN\0|liver (l_pobj) liver_3\NN\5298729|the
D004054_D008113 NONE diethylstilbestrol_25\NN\14749794| (r_pobj) with_24\IN\0|diethylstilbestrol (r_prep) liver_23\NN\5298729|the|with
D004054_D000230 NONE diethylstilbestrol_25\NN\14749794| (r_pobj) with_24\IN\0|diethylstilbestrol (r_prep) liver_23\NN\5298729|the|with
2870085
C047847_D013610 NONE flestolol_0\NNP\0| (r_nsubj) produced_1\VBD\1617192|flestolol|attenuation|. (l_dobj) attenuation_6\NN\7427337|a|dependent|of (l_prep) of_7\IN\0|tachycardia (l_pobj) tachycardia_11\NN\14110674|induced
D007545_D013610 CID isoproterenol_8\NN\3740161| (r_npadvmod) induced_10\VBN\1627355|isoproterenol|- (r_amod) tachycardia_11\NN\14110674|induced
C047847_D013617 NONE flestolol_0\NNP\0| (r_nsubj) reduced_2\VBD\441445|flestolol|effectively|rate|in|. (l_prep) in_5\IN\13603305|patients (l_pobj) patients_6\NNS\9898892|with (l_prep) with_7\IN\0|tachyarrhythmia (l_pobj) tachyarrhythmia_9\NN\0|supraventricular
C047847_D000789 NONE flestolol_6\NN\0| (r_compound) infusion_7\NN\14589223|flestolol (r_nsubjpass) found_9\VBN\13279262|in|,|infusion|was|be|. (l_prep) in_0\IN\13603305|patients (l_pobj) patients_1\NNS\9898892|with (l_prep) with_2\IN\0|angina (l_pobj) angina_4\NN\14171682|unstable
C047847_D002637 NONE flestolol_6\NN\0| (r_compound) infusion_7\NN\14589223|flestolol (r_nsubjpass) found_9\VBN\13279262|in|,|infusion|was|be|. (l_xcomp) be_11\VB\14625458|to|safe (l_acomp) safe_12\JJ\4340750|and|effective (l_conj) effective_14\JJ\0|in (l_prep) in_15\IN\13603305|controlling (l_pcomp) controlling_16\VBG\0|pain (l_dobj) pain_18\NN\14299637|chest
17020434
D014859_D020521 NONE warfarin_12\NN\2718259| (r_nsubj) reduces_13\VBZ\441445|that|warfarin|risk|by|,|and|reduces (l_dobj) risk_15\NN\14541044|the|of (l_prep) of_16\IN\0|stroke (l_pobj) stroke_17\NN\556313|
D014859_D020521 NONE warfarin_8\VB\2718259| (r_nsubj) is_9\VBZ\0|overall|,|in|,|warfarin|superior|,|with|. (l_acomp) superior_10\JJ\9623038|to (l_prep) to_11\IN\0|aspirin (l_pobj) aspirin_12\NN\2707683|in (l_prep) in_13\IN\13603305|preventing (l_pcomp) preventing_14\VBG\0|strokes (l_dobj) strokes_15\NNS\556313|
D001241_D020521 NONE aspirin_24\NN\2707683|alone (r_nsubj) reduces_26\VBZ\441445|that|aspirin|risk|by (r_conj) reduces_13\VBZ\441445|that|warfarin|risk|by|,|and|reduces (l_dobj) risk_15\NN\14541044|the|of (l_prep) of_16\IN\0|stroke (l_pobj) stroke_17\NN\556313|
D001241_D020521 NONE aspirin_12\NN\2707683|in (l_prep) in_13\IN\13603305|preventing (l_pcomp) preventing_14\VBG\0|strokes (l_dobj) strokes_15\NNS\556313|
C426686_D004617 NONE ximelagatran_0\NN\0|,|inhibitor|, (r_nsubjpass) found_9\VBN\13279262|ximelagatran|was|be|,|but|withdrawn|. (l_xcomp) be_11\VB\14625458|to|efficient (l_acomp) efficient_13\JJ\0|as|as|in (l_prep) in_19\IN\13603305|prevention (l_pobj) prevention_21\NN\1073995|the|of (l_prep) of_22\IN\0|events (l_pobj) events_24\NNS\23100|embolic
C426686_D056486 CID ximelagatran_0\NN\0|,|inhibitor|, (r_nsubjpass) found_9\VBN\13279262|ximelagatran|was|be|,|but|withdrawn|. (l_conj) withdrawn_30\VBN\1835496|has|been|recently|because (l_prep) because_31\IN\0|of|tests (l_pobj) tests_36\NNS\5798043|abnormal|function (l_compound) function_35\NN\13783581|liver
D014812_D004617 NONE k_16\NNP\13608598|vitamin (r_compound) drugs_18\NNS\14778436|k|antagonist (r_pobj) as_14\IN\14622893|drugs (r_prep) efficient_13\JJ\0|as|as|in (l_prep) in_19\IN\13603305|prevention (l_pobj) prevention_21\NN\1073995|the|of (l_prep) of_22\IN\0|events (l_pobj) events_24\NNS\23100|embolic
D014812_D056486 NONE k_16\NNP\13608598|vitamin (r_compound) drugs_18\NNS\14778436|k|antagonist (r_pobj) as_14\IN\14622893|drugs (r_prep) efficient_13\JJ\0|as|as|in (r_acomp) be_11\VB\14625458|to|efficient (r_xcomp) found_9\VBN\13279262|ximelagatran|was|be|,|but|withdrawn|. (l_conj) withdrawn_30\VBN\1835496|has|been|recently|because (l_prep) because_31\IN\0|of|tests (l_pobj) tests_36\NNS\5798043|abnormal|function (l_compound) function_35\NN\13783581|liver
C055162_D001281 NONE clopidogrel_7\NNP\0|fibrillation (l_compound) fibrillation_6\NNP\14361664|
C055162_D001281 NONE clopidogrel_28\JJ\0|plus|aspirin (r_dobj) platelet_25\NN\5432736|to|therapy|clopidogrel|)|in (r_xcomp) superior_23\JJ\9623038|platelet (r_acomp) is_22\VBZ\0|that|warfarin|superior (r_ccomp) demonstrated_19\VBN\2137132|trial|has|is|. (l_nsubj) trial_8\NN\786195|the|w|(|atrial|clopidogrel|with|)|study (l_compound) clopidogrel_7\NNP\0|fibrillation (l_compound) fibrillation_6\NNP\14361664|
C055162_D004617 NONE clopidogrel_7\NNP\0|fibrillation (r_compound) trial_8\NN\786195|the|w|(|atrial|clopidogrel|with|)|study (r_nsubj) demonstrated_19\VBN\2137132|trial|has|is|. (l_ccomp) is_22\VBZ\0|that|warfarin|superior (l_acomp) superior_23\JJ\9623038|platelet (l_xcomp) platelet_25\NN\5432736|to|therapy|clopidogrel|)|in (l_prep) in_32\IN\13603305|prevention|events (l_pobj) events_37\NNS\23100|af|embolic
C055162_D004617 NONE clopidogrel_28\JJ\0|plus|aspirin (r_dobj) platelet_25\NN\5432736|to|therapy|clopidogrel|)|in (l_prep) in_32\IN\13603305|prevention|events (l_pobj) events_37\NNS\23100|af|embolic
C081309_D001281 NONE irbesartan_10\NNP\0|for (r_pobj) with_9\IN\0|irbesartan (r_prep) trial_8\NN\786195|the|w|(|atrial|clopidogrel|with|)|study (l_compound) clopidogrel_7\NNP\0|fibrillation (l_compound) fibrillation_6\NNP\14361664|
C081309_D004617 NONE irbesartan_10\NNP\0|for (r_pobj) with_9\IN\0|irbesartan (r_prep) trial_8\NN\786195|the|w|(|atrial|clopidogrel|with|)|study (r_nsubj) demonstrated_19\VBN\2137132|trial|has|is|. (l_ccomp) is_22\VBZ\0|that|warfarin|superior (l_acomp) superior_23\JJ\9623038|platelet (l_xcomp) platelet_25\NN\5432736|to|therapy|clopidogrel|)|in (l_prep) in_32\IN\13603305|prevention|events (l_pobj) events_37\NNS\23100|af|embolic
D014859_D001281 NONE warfarin_21\NN\2718259| (r_nsubj) is_22\VBZ\0|that|warfarin|superior (r_ccomp) demonstrated_19\VBN\2137132|trial|has|is|. (l_nsubj) trial_8\NN\786195|the|w|(|atrial|clopidogrel|with|)|study (l_compound) clopidogrel_7\NNP\0|fibrillation (l_compound) fibrillation_6\NNP\14361664|
D014859_D004617 NONE warfarin_21\NN\2718259| (r_nsubj) is_22\VBZ\0|that|warfarin|superior (l_acomp) superior_23\JJ\9623038|platelet (l_xcomp) platelet_25\NN\5432736|to|therapy|clopidogrel|)|in (l_prep) in_32\IN\13603305|prevention|events (l_pobj) events_37\NNS\23100|af|embolic
D001241_D001281 NONE aspirin_30\NN\2707683| (r_conj) clopidogrel_28\JJ\0|plus|aspirin (r_dobj) platelet_25\NN\5432736|to|therapy|clopidogrel|)|in (r_xcomp) superior_23\JJ\9623038|platelet (r_acomp) is_22\VBZ\0|that|warfarin|superior (r_ccomp) demonstrated_19\VBN\2137132|trial|has|is|. (l_nsubj) trial_8\NN\786195|the|w|(|atrial|clopidogrel|with|)|study (l_compound) clopidogrel_7\NNP\0|fibrillation (l_compound) fibrillation_6\NNP\14361664|
D001241_D004617 NONE aspirin_30\NN\2707683| (r_conj) clopidogrel_28\JJ\0|plus|aspirin (r_dobj) platelet_25\NN\5432736|to|therapy|clopidogrel|)|in (l_prep) in_32\IN\13603305|prevention|events (l_pobj) events_37\NNS\23100|af|embolic
C479958_D001281 NONE idraparinux_0\NNP\0|,|inhibitor|, (r_nsubjpass) evaluated_9\VBN\670261|idraparinux|is|being|in|. (l_prep) in_10\IN\13603305|patients (l_pobj) patients_11\NNS\9898892|with (l_prep) with_12\IN\0|fibrillation (l_pobj) fibrillation_14\NN\14361664|atrial
D000809_D001281 NONE angiotensin_0\NN\4522421| (r_npadvmod) converting_2\VBG\126264|angiotensin|- (r_amod) inhibitors_4\NNS\20090|converting|enzyme|and|drugs (r_nsubj) hold_12\VBP\812274|inhibitors|promise|. (l_dobj) promise_13\NN\6684383|in (l_prep) in_14\IN\13603305|fibrillation (l_pobj) fibrillation_16\NN\14361664|atrial|through
D000809_D020257 NONE angiotensin_0\NN\4522421| (r_npadvmod) converting_2\VBG\126264|angiotensin|- (r_amod) inhibitors_4\NNS\20090|converting|enzyme|and|drugs (r_nsubj) hold_12\VBP\812274|inhibitors|promise|. (l_dobj) promise_13\NN\6684383|in (l_prep) in_14\IN\13603305|fibrillation (l_pobj) fibrillation_16\NN\14361664|atrial|through (l_prep) through_17\IN\0|remodelling (l_pobj) remodelling_19\NN\0|cardiac
D000804_D001281 NONE ii_7\CD\13741022| (r_nummod) drugs_11\NNS\14778436|angiotensin|ii|blocking (r_conj) inhibitors_4\NNS\20090|converting|enzyme|and|drugs (r_nsubj) hold_12\VBP\812274|inhibitors|promise|. (l_dobj) promise_13\NN\6684383|in (l_prep) in_14\IN\13603305|fibrillation (l_pobj) fibrillation_16\NN\14361664|atrial|through
D000804_D020257 NONE ii_7\CD\13741022| (r_nummod) drugs_11\NNS\14778436|angiotensin|ii|blocking (r_conj) inhibitors_4\NNS\20090|converting|enzyme|and|drugs (r_nsubj) hold_12\VBP\812274|inhibitors|promise|. (l_dobj) promise_13\NN\6684383|in (l_prep) in_14\IN\13603305|fibrillation (l_pobj) fibrillation_16\NN\14361664|atrial|through (l_prep) through_17\IN\0|remodelling (l_pobj) remodelling_19\NN\0|cardiac
3970039
D000477_D015470 CID agents_4\NNS\7347|alkylating (r_pobj) with_2\IN\0|agents (r_prep) treated_1\VBN\2376958|patients|with (r_csubj) have_5\VBP\7846|treated|risk|,|and|associated (l_dobj) risk_8\NN\14541044|an|increased|of (l_prep) of_9\IN\0|development (l_pobj) development_10\NN\248977|of (l_prep) of_11\IN\0|leukemia (l_pobj) leukemia_14\NN\14239918|acute|nonlymphocytic
D000477_D015470 CID agents_19\NNS\7347|both|alkylating|and|azathioprine (r_nsubjpass) associated_23\VBN\628491|agents|are|with|. (r_conj) have_5\VBP\7846|treated|risk|,|and|associated (l_dobj) risk_8\NN\14541044|an|increased|of (l_prep) of_9\IN\0|development (l_pobj) development_10\NN\248977|of (l_prep) of_11\IN\0|leukemia (l_pobj) leukemia_14\NN\14239918|acute|nonlymphocytic
D000477_D008228 CID agents_4\NNS\7347|alkylating (r_pobj) with_2\IN\0|agents (r_prep) treated_1\VBN\2376958|patients|with (r_csubj) have_5\VBP\7846|treated|risk|,|and|associated (l_conj) associated_23\VBN\628491|agents|are|with|. (l_prep) with_24\IN\0|development (l_pobj) development_26\NN\248977|the|of (l_prep) of_27\IN\0|lymphoma (l_pobj) lymphoma_32\NN\14239918|hodgkin
D000477_D008228 CID agents_19\NNS\7347|both|alkylating|and|azathioprine (r_nsubjpass) associated_23\VBN\628491|agents|are|with|. (l_prep) with_24\IN\0|development (l_pobj) development_26\NN\248977|the|of (l_prep) of_27\IN\0|lymphoma (l_pobj) lymphoma_32\NN\14239918|hodgkin
D001379_D015470 NONE azathioprine_21\NN\3740161| (r_conj) agents_19\NNS\7347|both|alkylating|and|azathioprine (r_nsubjpass) associated_23\VBN\628491|agents|are|with|. (r_conj) have_5\VBP\7846|treated|risk|,|and|associated (l_dobj) risk_8\NN\14541044|an|increased|of (l_prep) of_9\IN\0|development (l_pobj) development_10\NN\248977|of (l_prep) of_11\IN\0|leukemia (l_pobj) leukemia_14\NN\14239918|acute|nonlymphocytic
D001379_D008228 CID azathioprine_21\NN\3740161| (r_conj) agents_19\NNS\7347|both|alkylating|and|azathioprine (r_nsubjpass) associated_23\VBN\628491|agents|are|with|. (l_prep) with_24\IN\0|development (l_pobj) development_26\NN\248977|the|of (l_prep) of_27\IN\0|lymphoma (l_pobj) lymphoma_32\NN\14239918|hodgkin
D003520_D001749 CID cyclophosphamide_0\NNP\0| (r_compound) therapy_1\NN\657604|cyclophosphamide (r_nsubj) increases_2\VBZ\13576355|therapy|risk|. (l_dobj) risk_4\NN\14541044|the|of (l_prep) of_5\IN\0|carcinoma (l_pobj) carcinoma_6\NN\14239918|of (l_prep) of_7\IN\0|bladder (l_pobj) bladder_9\NN\5515670|the
D003520_D002277 CID cyclophosphamide_0\NNP\0| (r_compound) therapy_1\NN\657604|cyclophosphamide (r_nsubj) increases_2\VBZ\13576355|therapy|risk|. (l_dobj) risk_4\NN\14541044|the|of (l_prep) of_5\IN\0|carcinoma (l_pobj) carcinoma_6\NN\14239918|of (l_prep) of_7\IN\0|bladder (l_pobj) bladder_9\NN\5515670|the
D001379_D001172 NONE azathioprine_15\NN\3740161|and|cyclophosphamide (r_pobj) with_14\IN\0|azathioprine (r_prep) treated_13\VBN\2376958|with (r_acl) studies_7\NNS\635850|several|term|of|treated|and (l_prep) of_8\IN\0|patients (l_pobj) patients_9\NNS\9898892|with (l_prep) with_10\IN\0|arthritis (l_pobj) arthritis_12\NN\14171682|rheumatoid
D001379_D009369 NONE azathioprine_15\NN\3740161|and|cyclophosphamide (r_pobj) with_14\IN\0|azathioprine (r_prep) treated_13\VBN\2376958|with (r_acl) studies_7\NNS\635850|several|term|of|treated|and (r_attr) been_2\VBN\0|there|have|studies|increased|. (l_conj) increased_29\VBN\169651|incidence|is|not (l_nsubjpass) incidence_20\NN\13821570|the|of (l_prep) of_21\IN\0|most (l_pobj) most_22\JJS\0|of (l_prep) of_23\IN\0|cancers (l_pobj) cancers_26\NNS\14239425|the|common
D003520_D001172 NONE cyclophosphamide_17\NN\0| (r_conj) azathioprine_15\NN\3740161|and|cyclophosphamide (r_pobj) with_14\IN\0|azathioprine (r_prep) treated_13\VBN\2376958|with (r_acl) studies_7\NNS\635850|several|term|of|treated|and (l_prep) of_8\IN\0|patients (l_pobj) patients_9\NNS\9898892|with (l_prep) with_10\IN\0|arthritis (l_pobj) arthritis_12\NN\14171682|rheumatoid
D003520_D009369 NONE cyclophosphamide_17\NN\0| (r_conj) azathioprine_15\NN\3740161|and|cyclophosphamide (r_pobj) with_14\IN\0|azathioprine (r_prep) treated_13\VBN\2376958|with (r_acl) studies_7\NNS\635850|several|term|of|treated|and (r_attr) been_2\VBN\0|there|have|studies|increased|. (l_conj) increased_29\VBN\169651|incidence|is|not (l_nsubjpass) incidence_20\NN\13821570|the|of (l_prep) of_21\IN\0|most (l_pobj) most_22\JJS\0|of (l_prep) of_23\IN\0|cancers (l_pobj) cancers_26\NNS\14239425|the|common
D000477_D009369 NONE agents_31\NNS\7347|particularly|alkylating (r_appos) drugs_27\NNS\14778436|immunosuppressive|,|agents|, (r_pobj) of_25\IN\0|drugs (r_prep) use_24\NN\407535|the|of|in (r_nsubjpass) reserved_41\VBN\2213690|is|,|use|should|be|for|. (r_conj) collected_14\VBN\2281093|data|are|still|being|,|and|reserved (l_nsubjpass) data_0\NNS\7951464|on (l_prep) on_1\IN\0|risk (l_pobj) risk_5\NN\14541044|the|possible|increased|of (l_prep) of_6\IN\0|malignancy (l_pobj) malignancy_7\NN\14070360|in
D000477_D001172 NONE agents_31\NNS\7347|particularly|alkylating (r_appos) drugs_27\NNS\14778436|immunosuppressive|,|agents|, (r_pobj) of_25\IN\0|drugs (r_prep) use_24\NN\407535|the|of|in (r_nsubjpass) reserved_41\VBN\2213690|is|,|use|should|be|for|. (r_conj) collected_14\VBN\2281093|data|are|still|being|,|and|reserved (l_nsubjpass) data_0\NNS\7951464|on (l_prep) on_1\IN\0|risk (l_pobj) risk_5\NN\14541044|the|possible|increased|of (l_prep) of_6\IN\0|malignancy (l_pobj) malignancy_7\NN\14070360|in (l_prep) in_8\IN\13603305|arthritis (l_pobj) arthritis_10\NN\14171682|rheumatoid
D000477_D001172 NONE agents_31\NNS\7347|particularly|alkylating (r_appos) drugs_27\NNS\14778436|immunosuppressive|,|agents|, (r_pobj) of_25\IN\0|drugs (r_prep) use_24\NN\407535|the|of|in (l_prep) in_33\IN\13603305|treatment (l_pobj) treatment_35\NN\654885|the|of (l_prep) of_36\IN\0|arthritis (l_pobj) arthritis_38\NN\14171682|rheumatoid
7516729
D014700_D001919 CID verapamil_6\NN\2938514| (r_pobj) by_5\IN\0|verapamil (r_agent) induced_4\VBN\1627355|by (r_acl) bradycardia_3\NNS\14110674|dependent|induced
18081909
C026098_D001927 CID levetiracetam_3\NN\0| (r_pcomp) by_2\IN\0|levetiracetam (r_prep) induced_1\VBN\1627355|encephalopathy|by|added|. (l_nsubj) encephalopathy_0\JJ\14084880|
C026098_D001927 CID levetiracetam_7\FW\0| (r_amod) encephalopathy_10\JJ\14084880|a|levetiracetam|(|lev)-induced
C026098_D001927 CID lev)-induced_9\VBN\0| (r_amod) encephalopathy_10\JJ\14084880|a|levetiracetam|(|lev)-induced
D014635_D001927 CID valproate_6\VB\0|to (r_xcomp) added_4\VBN\156601|valproate (r_conj) induced_1\VBN\1627355|encephalopathy|by|added|. (l_nsubj) encephalopathy_0\JJ\14084880|
C026098_C562694 NONE lev_15\NNP\13685678|mg (r_pobj) with_14\IN\0|lev (r_prep) treated_13\VBN\2376958|man|was|with|)|added|. (l_nsubjpass) man_4\NN\9605289|a|old|suffering (l_acl) suffering_5\VBG\14322699|from|with (l_prep) from_6\IN\0|epilepsy (l_pobj) epilepsy_8\NN\14085708|idiopathic
C026098_D012640 NONE lev_15\NNP\13685678|mg (r_pobj) with_14\IN\0|lev (r_prep) treated_13\VBN\2376958|man|was|with|)|added|. (l_nsubjpass) man_4\NN\9605289|a|old|suffering (l_acl) suffering_5\VBG\14322699|from|with (l_prep) with_9\IN\0|seizures (l_pobj) seizures_11\NNS\14081375|generalized
C026098_D012640 NONE lev_3\NNP\13685678|,|eeg (r_pobj) of_2\IN\0|lev (r_prep) discontinuation_1\NN\209943|of (r_pobj) following_0\VBG\8180190|discontinuation|improved (l_preconj) improved_9\VBN\126264|and|decreased (l_conj) decreased_13\VBD\169651|frequency|. (l_nsubj) frequency_12\NN\15286249|seizure (l_compound) seizure_11\NN\14081375|
D014635_C562694 NONE valproate_22\VB\0|to|(|vpa|)|(|mg|) (r_xcomp) added_20\VBN\156601|valproate (r_conj) treated_13\VBN\2376958|man|was|with|)|added|. (l_nsubjpass) man_4\NN\9605289|a|old|suffering (l_acl) suffering_5\VBG\14322699|from|with (l_prep) from_6\IN\0|epilepsy (l_pobj) epilepsy_8\NN\14085708|idiopathic
D014635_C562694 NONE vpa_24\NNP\0| (r_dobj) valproate_22\VB\0|to|(|vpa|)|(|mg|) (r_xcomp) added_20\VBN\156601|valproate (r_conj) treated_13\VBN\2376958|man|was|with|)|added|. (l_nsubjpass) man_4\NN\9605289|a|old|suffering (l_acl) suffering_5\VBG\14322699|from|with (l_prep) from_6\IN\0|epilepsy (l_pobj) epilepsy_8\NN\14085708|idiopathic
D014635_D012640 NONE valproate_22\VB\0|to|(|vpa|)|(|mg|) (r_xcomp) added_20\VBN\156601|valproate (r_conj) treated_13\VBN\2376958|man|was|with|)|added|. (l_nsubjpass) man_4\NN\9605289|a|old|suffering (l_acl) suffering_5\VBG\14322699|from|with (l_prep) with_9\IN\0|seizures (l_pobj) seizures_11\NNS\14081375|generalized
D014635_D012640 NONE vpa_24\NNP\0| (r_dobj) valproate_22\VB\0|to|(|vpa|)|(|mg|) (r_xcomp) added_20\VBN\156601|valproate (r_conj) treated_13\VBN\2376958|man|was|with|)|added|. (l_nsubjpass) man_4\NN\9605289|a|old|suffering (l_acl) suffering_5\VBG\14322699|from|with (l_prep) with_9\IN\0|seizures (l_pobj) seizures_11\NNS\14081375|generalized
2515254
D005996_D008881 CID nitroglycerin_11\NN\15015501|(|patients (r_pobj) of_10\IN\0|nitroglycerin (r_prep) application_9\NN\947128|a|one|sided|frontotemporal|of (r_dobj) received_4\VBD\2210855|patients|application|. (l_nsubj) patients_3\NNS\9898892|twenty|common|migraine (l_compound) migraine_2\NN\14326607|
D005996_D008881 CID nitroglycerin_7\NN\15015501| (r_pobj) by_6\IN\0|nitroglycerin (r_agent) induced_5\VBN\1627355|attacks|were|by|in|. (l_nsubjpass) attacks_3\NNS\955060|early|onset|migraine (l_compound) migraine_2\NN\14326607|
D005996_D008881 CID nitroglycerin_13\NN\15015501|frontotemporal (r_pobj) with_11\IN\0|nitroglycerin (r_prep) attack_10\NN\955060|an|early|onset|with (r_dobj) developed_6\VBD\1753788|who|attack (r_relcl) patients_3\NNS\9898892|20|migraine|,|developed|, (l_compound) migraine_2\NN\14326607|
D005996_D008881 CID nitroglycerin_7\NN\15015501| (r_pobj) of_6\IN\0|nitroglycerin (r_prep) effect_5\NN\34213|the|inducing|of (l_amod) inducing_4\VBG\42311|migraine|- (l_npadvmod) migraine_2\NN\14326607|
D005996_D008881 CID nitroglycerin_7\NN\15015501| (r_pobj) of_6\IN\0|nitroglycerin (r_prep) effect_5\NN\34213|the|inducing|of (r_nsubj) seems_8\VBZ\2604760|thus|effect|depend|,|suggesting|. (l_advcl) suggesting_21\VBG\1010118|is (l_ccomp) is_26\VBZ\0|that|region|of (l_prep) of_27\IN\0|importance (l_pobj) importance_29\NN\5138488|crucial|in (l_prep) in_30\IN\13603305|development (l_pobj) development_32\NN\248977|the|of (l_prep) of_33\IN\0|crisis (l_pobj) crisis_36\NN\14411243|a|migraine (l_compound) migraine_35\JJ\14326607|
D005996_D010146 NONE nitroglycerin_7\NN\15015501| (r_pobj) of_6\IN\0|nitroglycerin (r_prep) effect_5\NN\34213|the|inducing|of (r_nsubj) seems_8\VBZ\2604760|thus|effect|depend|,|suggesting|. (l_xcomp) depend_10\VB\2604760|to|on (l_prep) on_11\IN\0|stimulation (l_pobj) stimulation_13\NN\242808|direct|of (l_prep) of_14\IN\0|site (l_pobj) site_17\NN\8673395|the|habitual|of (l_prep) of_18\IN\0|pain (l_pobj) pain_19\NN\14299637|
18752389
C492458_D017093 NONE ezetimibe_2\NN\0|simvastatin|- (r_npadvmod) induced_4\VBN\1627355|ezetimibe|- (r_amod) failure_6\NN\66216|induced|hepatic|necessitating|.
C492458_D017093 NONE ezetimibe_13\NN\0|simvastatin|- (r_npadvmod) induced_15\VBN\1627355|ezetimibe|- (r_amod) failure_17\NN\66216|induced|liver|resulted
C108606_D056486 NONE ezetimibe_10\NN\0|or|agent (r_pobj) with_9\IN\0|ezetimibe (r_prep) published_8\VBN\1621555|however|,|events|have|not|been|widely|with|. (l_nsubjpass) events_3\NNS\23100|hepatotoxic (l_amod) hepatotoxic_2\JJ\0|
C108606_D056486 NONE ezetimibe_0\NNP\0| (r_nsubj) undergoes_1\VBZ\109660|ezetimibe|glucuronidation|and|inhibited|. (l_conj) inhibited_19\VBN\2510337|may|have|glucuronidation|,|resulting (l_advcl) resulting_27\VBG\2633881|in (l_prep) in_28\IN\13603305|exposure (l_pobj) exposure_31\NN\5042871|increased|simvastatin|and|hepatotoxicity (l_conj) hepatotoxicity_34\NN\0|subsequent
C108606_D056486 NONE ezetimibe_17\NN\0| (r_compound) inhibition_18\NN\1068773|ezetimibe|of (r_pobj) by_16\IN\0|inhibition (r_prep) exposure_15\NN\5042871|the|increased|simvastatin|by (r_attr) is_11\VBZ\0|that|mechanism|exposure (l_nsubj) mechanism_4\NN\13446390|the|of (l_prep) of_5\IN\0|hepatotoxicity (l_pobj) hepatotoxicity_10\NN\0|the|induced
C492458_D056486 CID ezetimibe_17\NN\0|simvastatin|- (r_appos) agent_14\NN\7347|the|combination|ezetimibe (r_conj) ezetimibe_10\NN\0|or|agent (r_pobj) with_9\IN\0|ezetimibe (r_prep) published_8\VBN\1621555|however|,|events|have|not|been|widely|with|. (l_nsubjpass) events_3\NNS\23100|hepatotoxic (l_amod) hepatotoxic_2\JJ\0|
C492458_D056486 CID simvastatinezetimibe_0\NNP\0|and|escitalopram|(|taking|) (r_nsubjpass) discontinued_12\VBN\0|simvastatinezetimibe|were|,|and|excluded (l_conj) excluded_21\VBN\471711|causes|were|. (l_nsubjpass) causes_17\NNS\7323922|other|potential|of (l_prep) of_18\IN\0|hepatotoxicity (l_pobj) hepatotoxicity_19\NN\0|
C492458_D056486 CID simvastatinezetimibe_7\NN\0| (r_npadvmod) induced_9\VBN\1627355|simvastatinezetimibe|- (r_amod) hepatotoxicity_10\NN\0|the|induced
C492458_D056486 CID ezetimibe_10\NN\0|simvastatin|-|in (r_pobj) with_7\IN\0|ezetimibe (r_prep) hepatotoxicity_6\NN\0|potential|with
D019821_D017114 NONE simvastatin_21\NN\3676175| (r_nmod) day_25\NN\15154774|simvastatin|40|mg|/ (r_pobj) from_20\IN\0|day (r_prep) conversion_19\NN\7359599|from (r_pobj) after_18\IN\0|weeks|conversion (r_prep) necessitating_13\VBG\0|transplantation|after|simvastatin (r_acl) failure_12\NN\66216|fulminant|hepatic|necessitating
C492458_D017114 CID mg_33\NN\13717155|40 (r_nummod) day_35\NN\15154774|mg|/ (r_npadvmod) ezetimibe_31\NN\0|10|mg|-|day (r_dobj) simvastatin_27\NN\3676175|to|ezetimibe (r_advcl) necessitating_13\VBG\0|transplantation|after|simvastatin (r_acl) failure_12\NN\66216|fulminant|hepatic|necessitating
D019821_D056486 NONE simvastatin_9\NN\3676175| (r_pobj) with_8\IN\0|simvastatin (r_prep) maintained_7\VBN\0|panel|had|been|with|for|. (l_prep) for_10\IN\0|months (l_pobj) months_12\NNS\15113229|18|before (l_prep) before_13\IN\0|conversion (l_pobj) conversion_15\NN\7359599|the|without (l_prep) without_16\IN\0|evidence (l_pobj) evidence_17\NN\5816287|of (l_prep) of_18\IN\0|hepatotoxicity (l_pobj) hepatotoxicity_19\NN\0|
D019821_D056486 NONE simvastatin_30\NN\3676175| (r_amod) exposure_31\NN\5042871|increased|simvastatin|and|hepatotoxicity (l_conj) hepatotoxicity_34\NN\0|subsequent
D019821_D056486 NONE simvastatin_14\NN\3676175| (r_amod) exposure_15\NN\5042871|the|increased|simvastatin|by (r_attr) is_11\VBZ\0|that|mechanism|exposure (l_nsubj) mechanism_4\NN\13446390|the|of (l_prep) of_5\IN\0|hepatotoxicity (l_pobj) hepatotoxicity_10\NN\0|the|induced
C492458_D003866 NONE simvastatinezetimibe_0\NNP\0|and|escitalopram|(|taking|) (l_relcl) taking_7\VBG\37396|which|she|was|for (l_prep) for_8\IN\0|depression (l_pobj) depression_9\NN\14373582|
D015283_D003866 NONE escitalopram_2\NNP\0| (r_conj) simvastatinezetimibe_0\NNP\0|and|escitalopram|(|taking|) (l_relcl) taking_7\VBG\37396|which|she|was|for (l_prep) for_8\IN\0|depression (l_pobj) depression_9\NN\14373582|
D015283_D056486 NONE escitalopram_2\NNP\0| (r_conj) simvastatinezetimibe_0\NNP\0|and|escitalopram|(|taking|) (r_nsubjpass) discontinued_12\VBN\0|simvastatinezetimibe|were|,|and|excluded (l_conj) excluded_21\VBN\471711|causes|were|. (l_nsubjpass) causes_17\NNS\7323922|other|potential|of (l_prep) of_18\IN\0|hepatotoxicity (l_pobj) hepatotoxicity_19\NN\0|
D014530_D056486 NONE diphosphate_6\NN\0|uridine (r_compound) glucoronosyltransferases_7\NNS\0|diphosphate|ugt|in (r_pobj) by_4\IN\0|glucoronosyltransferases (r_prep) glucuronidation_3\NN\0|extensive|by (r_dobj) undergoes_1\VBZ\109660|ezetimibe|glucuronidation|and|inhibited|. (l_conj) inhibited_19\VBN\2510337|may|have|glucuronidation|,|resulting (l_advcl) resulting_27\VBG\2633881|in (l_prep) in_28\IN\13603305|exposure (l_pobj) exposure_31\NN\5042871|increased|simvastatin|and|hepatotoxicity (l_conj) hepatotoxicity_34\NN\0|subsequent
C532833_D056486 NONE acid_25\NN\14818238|simvastatin|hydroxy (r_pobj) of_22\IN\0|acid (r_prep) glucuronidation_21\NN\0|the|of (r_dobj) inhibited_19\VBN\2510337|may|have|glucuronidation|,|resulting (l_advcl) resulting_27\VBG\2633881|in (l_prep) in_28\IN\13603305|exposure (l_pobj) exposure_31\NN\5042871|increased|simvastatin|and|hepatotoxicity (l_conj) hepatotoxicity_34\NN\0|subsequent
10743446
D007649_D006930 NONE ketamine_5\NN\3054098|administered|and|lidocaine|on (l_prep) on_8\IN\0|hyperalgesia (l_pobj) hyperalgesia_12\NN\0|dynamic
D007649_D006930 NONE ketamine_9\NN\3054098|and|lidocaine (r_pobj) of_8\IN\0|ketamine (r_prep) administration_7\NN\1133281|systemic|of|on (l_prep) on_12\IN\0|hyperalgesia (l_pobj) hyperalgesia_27\NN\0|pain|evoked|(|static|)
D007649_D006930 NONE ketamine_0\NN\3054098| (r_nsubj) reduced_1\VBD\441445|ketamine|area|significantly|and|tended (l_dobj) area_4\NN\8630985|both|the|of (l_prep) of_5\IN\0|hyperalgesia (l_pobj) hyperalgesia_13\NN\0|evoked
D007649_D006930 NONE ketamine_4\NN\3054098|and|lidocaine (r_pobj) of_3\IN\0|ketamine (r_prep) effects_2\NNS\13245626|the|differential|of|on (l_prep) on_7\IN\0|hyperalgesia (l_pobj) hyperalgesia_11\NN\0|static
D007649_D006930 NONE ketamine_4\NN\3054098|and|lidocaine (r_pobj) of_3\IN\0|ketamine (r_prep) effects_2\NNS\13245626|the|differential|of|on (r_nsubj) suggest_12\VBP\1010118|effects|mediated|. (l_ccomp) mediated_20\VBN\761713|that|types|are|by|and|have (l_nsubjpass) types_16\NNS\5839024|the|two|of (l_prep) of_17\IN\0|hyperalgesia (l_pobj) hyperalgesia_18\NN\0|
D008012_D006930 NONE lidocaine_7\NN\3681148| (r_conj) ketamine_5\NN\3054098|administered|and|lidocaine|on (l_prep) on_8\IN\0|hyperalgesia (l_pobj) hyperalgesia_12\NN\0|dynamic
D008012_D006930 NONE lidocaine_11\NN\3681148| (r_conj) ketamine_9\NN\3054098|and|lidocaine (r_pobj) of_8\IN\0|ketamine (r_prep) administration_7\NN\1133281|systemic|of|on (l_prep) on_12\IN\0|hyperalgesia (l_pobj) hyperalgesia_27\NN\0|pain|evoked|(|static|)
D008012_D006930 NONE lidocaine_0\NN\3681148| (r_nsubj) reduced_1\VBD\441445|lidocaine|area|significantly|. (l_dobj) area_3\NN\8630985|the|of (l_prep) of_4\IN\0|hyperalgesia (l_pobj) hyperalgesia_8\NN\0|evoked
D008012_D006930 NONE lidocaine_6\NN\3681148| (r_conj) ketamine_4\NN\3054098|and|lidocaine (r_pobj) of_3\IN\0|ketamine (r_prep) effects_2\NNS\13245626|the|differential|of|on (l_prep) on_7\IN\0|hyperalgesia (l_pobj) hyperalgesia_11\NN\0|static
D008012_D006930 NONE lidocaine_6\NN\3681148| (r_conj) ketamine_4\NN\3054098|and|lidocaine (r_pobj) of_3\IN\0|ketamine (r_prep) effects_2\NNS\13245626|the|differential|of|on (r_nsubj) suggest_12\VBP\1010118|effects|mediated|. (l_ccomp) mediated_20\VBN\761713|that|types|are|by|and|have (l_nsubjpass) types_16\NNS\5839024|the|two|of (l_prep) of_17\IN\0|hyperalgesia (l_pobj) hyperalgesia_18\NN\0|
D002211_D006930 CID capsaicin_16\NN\15032661|intradermal|in (r_pobj) by_14\IN\0|capsaicin (r_agent) induced_13\VBN\1627355|by (r_acl) effects_1\NNS\13245626|differential|of|induced|. (l_prep) of_2\IN\0|ketamine (l_pobj) ketamine_5\NN\3054098|administered|and|lidocaine|on (l_prep) on_8\IN\0|hyperalgesia (l_pobj) hyperalgesia_12\NN\0|dynamic
D002211_D006930 CID capsaicin_30\NN\15032661| (r_pobj) by_29\IN\0|capsaicin (r_agent) induced_28\VBN\1627355|by (r_acl) effect_4\NN\34213|the|of|induced (l_prep) of_5\IN\0|administration (l_pobj) administration_7\NN\1133281|systemic|of|on (l_prep) on_12\IN\0|hyperalgesia (l_pobj) hyperalgesia_27\NN\0|pain|evoked|(|static|)
D007649_D010146 NONE ketamine_9\NN\3054098|and|lidocaine (r_pobj) of_8\IN\0|ketamine (r_prep) administration_7\NN\1133281|systemic|of|on (l_prep) on_12\IN\0|hyperalgesia (l_pobj) hyperalgesia_27\NN\0|pain|evoked|(|static|) (l_nmod) pain_19\NN\14299637|evoked|(|dynamic|)|and
D007649_D010146 NONE ketamine_0\NN\3054098| (r_nsubj) reduced_1\VBD\441445|ketamine|area|significantly|and|tended (l_conj) tended_17\VBD\2604760|it|reduce|. (l_xcomp) reduce_19\VB\441445|to|pain (l_dobj) pain_23\NN\14299637|evoked
D008012_D010146 NONE lidocaine_11\NN\3681148| (r_conj) ketamine_9\NN\3054098|and|lidocaine (r_pobj) of_8\IN\0|ketamine (r_prep) administration_7\NN\1133281|systemic|of|on (l_prep) on_12\IN\0|hyperalgesia (l_pobj) hyperalgesia_27\NN\0|pain|evoked|(|static|) (l_nmod) pain_19\NN\14299637|evoked|(|dynamic|)|and
D002211_D010146 CID capsaicin_30\NN\15032661| (r_pobj) by_29\IN\0|capsaicin (r_agent) induced_28\VBN\1627355|by (r_acl) effect_4\NN\34213|the|of|induced (l_prep) of_5\IN\0|administration (l_pobj) administration_7\NN\1133281|systemic|of|on (l_prep) on_12\IN\0|hyperalgesia (l_pobj) hyperalgesia_27\NN\0|pain|evoked|(|static|) (l_nmod) pain_19\NN\14299637|evoked|(|dynamic|)|and
16938416
D013739_D050197 CID testosterone_3\NN\14747587|dose (r_nsubjpass) associated_5\VBN\628491|testosterone|is|with|. (l_prep) with_6\IN\0|atherosclerosis (l_pobj) atherosclerosis_7\NN\14108324|in
D013739_D050197 CID testosterone_32\NN\14747587|estrogen|- (r_compound) therapy_33\NN\657604|reported|administered|dose|testosterone|esters|)|and|atherosclerosis (l_conj) atherosclerosis_42\NN\14108324|aortic
D013739_D050197 CID testosterone_7\NN\14747587| (r_compound) therapy_8\NN\657604|dose|testosterone (r_nsubj) affect_11\VB\26192|that|therapy|may|adversely|atherosclerosis|and|indicate (l_dobj) atherosclerosis_12\NN\14108324|in
D004967_D050197 NONE estrogen_30\NN\14745635| (r_compound) testosterone_32\NN\14747587|estrogen|- (r_compound) therapy_33\NN\657604|reported|administered|dose|testosterone|esters|)|and|atherosclerosis (l_conj) atherosclerosis_42\NN\14108324|aortic
C032109_D050197 NONE esters_38\NNS\14727670|estradiol- (r_appos) therapy_33\NN\657604|reported|administered|dose|testosterone|esters|)|and|atherosclerosis (l_conj) atherosclerosis_42\NN\14108324|aortic
D002784_D003920 NONE cholesterol_9\NN\15058310| (r_compound) level_10\NN\4916342|cholesterol|,|pressure (r_conj) diabetes_7\NNS\14075199|,|level
D000431_D003920 NONE alcohol_17\NN\7881800| (r_compound) use_18\NN\407535|alcohol (r_conj) pressure_14\NN\11419404|systolic|blood|,|or|use (r_conj) level_10\NN\4916342|cholesterol|,|pressure (r_conj) diabetes_7\NNS\14075199|,|level
3496378
D014217_D002779 CID troleandomycin_3\NN\0| (r_npadvmod) induced_5\VBN\1627355|troleandomycin|- (r_amod) hepatitis_7\NN\14127211|induced|acute (r_pobj) after_2\IN\0|hepatitis (r_prep) cholestasis_1\NN\14052403|prolonged|after|.
D014217_D002779 CID troleandomycin_9\NN\0| (r_npadvmod) induced_11\VBN\1627355|in|troleandomycin|- (r_relcl) patient_6\NN\9898892|a|induced (r_pobj) of_4\IN\0|patient (r_prep) case_3\NN\7283608|the|of (r_dobj) report_1\VBP\6470073|we|case|followed|. (l_ccomp) followed_14\VBN\1835496|hepatitis|was|by (l_agent) by_15\IN\0|cholestasis (l_pobj) cholestasis_18\NN\14052403|prolonged|anicteric
D014217_D002779 CID troleandomycin_8\NN\0| (r_npadvmod) induced_10\VBN\1627355|troleandomycin|- (r_amod) hepatitis_12\NN\14127211|induced|acute (r_dobj) follow_7\VB\1835496|that|cholestasis|can|hepatitis (l_nsubj) cholestasis_5\NN\14052403|prolonged
D014217_D056486 CID troleandomycin_3\NN\0| (r_npadvmod) induced_5\VBN\1627355|troleandomycin|- (r_amod) hepatitis_7\NN\14127211|induced|acute
D014217_D056486 CID troleandomycin_9\NN\0| (r_npadvmod) induced_11\VBN\1627355|in|troleandomycin|- (r_relcl) patient_6\NN\9898892|a|induced (r_pobj) of_4\IN\0|patient (r_prep) case_3\NN\7283608|the|of (r_dobj) report_1\VBP\6470073|we|case|followed|. (l_ccomp) followed_14\VBN\1835496|hepatitis|was|by (l_nsubjpass) hepatitis_12\NN\14127211|
D014217_D056486 CID troleandomycin_8\NN\0| (r_npadvmod) induced_10\VBN\1627355|troleandomycin|- (r_amod) hepatitis_12\NN\14127211|induced|acute
D014217_D007565 CID troleandomycin_5\NN\0| (r_pobj) of_4\IN\0|troleandomycin (r_prep) administration_3\NN\1133281|of (r_pobj) after_2\IN\0|administration (r_prep) occurred_1\VBD\0|jaundice|after|for|and|associated|. (l_nsubj) jaundice_0\NN\14299637|
D014217_D004802 CID troleandomycin_5\NN\0| (r_pobj) of_4\IN\0|troleandomycin (r_prep) administration_3\NN\1133281|of (r_pobj) after_2\IN\0|administration (r_prep) occurred_1\VBD\0|jaundice|after|for|and|associated|. (l_conj) associated_11\VBN\628491|was|with (l_prep) with_12\IN\0|hypereosinophilia (l_pobj) hypereosinophilia_13\NNS\0|
7199841
C004616_D010243 CID ce_11\NN\14625458|2-chloroprocaine|- (r_nmod) %_15\NN\0|ce|seven|35 (r_pobj) of_8\IN\0|% (r_prep) injection_7\NN\320852|subarachnoid|of (r_dobj) received_5\VBD\2210855|that|injection (r_relcl) animals_3\NNS\4475|the|20|received|) (r_pobj) of_0\IN\0|animals (r_prep) paralysis_21\NN\14557898|of|developed|limb|.
D002045_D010243 NONE bupivacaine_6\NN\0| (r_dobj) received_5\VBD\2210855|that|bupivacaine (r_relcl) animals_3\NNS\4475|the|received (r_pobj) of_1\IN\0|animals (r_prep) none_0\NN\15228378|of|,|saline (r_nsubj) titrated_14\VBN\489837|none|to|. (l_prep) to_15\IN\0|paralysis (l_pobj) paralysis_23\NN\14557898|a|ph|3.0|developed|limb
C004616_D013118 CID ce_12\NNP\14625458|2-chloroprocaine|- (r_dobj) received_9\VBD\2210855|that|ce (r_relcl) animals_7\NNS\4475|the|received (r_pobj) of_5\IN\0|animals (r_prep) cords_4\NNS\4489008|the|15|spinal|of (r_pobj) of_0\IN\0|cords (r_prep) 13_14\CD\13745420|of (r_nsubj) showed_15\VBD\2137132|,|13|necrosis (l_dobj) necrosis_17\NN\11444117|subpial
8387218
D016049_D064420 NONE didanosine_5\NN\2725367|ddi|in (r_pobj) of_4\IN\0|didanosine (r_prep) use_1\NN\407535|the|and|toxicity|of|) (l_conj) toxicity_3\NN\13576101|
D016049_D064420 NONE ddi_7\NN\2725367|(|) (r_appos) didanosine_5\NN\2725367|ddi|in (r_pobj) of_4\IN\0|didanosine (r_prep) use_1\NN\407535|the|and|toxicity|of|) (l_conj) toxicity_3\NN\13576101|
D016049_D015658 NONE didanosine_5\NN\2725367|ddi|in (l_prep) in_9\IN\13603305|individuals (l_pobj) individuals_14\NNS\7347|hiv|positive|intolerant|azt (l_amod) positive_13\JJ\6321702|antibody|-
D016049_D015658 NONE ddi_7\NN\2725367|(|) (r_appos) didanosine_5\NN\2725367|ddi|in (l_prep) in_9\IN\13603305|individuals (l_pobj) individuals_14\NNS\7347|hiv|positive|intolerant|azt (l_amod) positive_13\JJ\6321702|antibody|-
D015215_D064420 NONE zidovudine_17\NNP\3834836| (r_pobj) to_16\IN\0|zidovudine (r_prep) intolerant_15\JJ\0|to (r_amod) individuals_14\NNS\7347|hiv|positive|intolerant|azt (r_pobj) in_9\IN\13603305|individuals (r_prep) didanosine_5\NN\2725367|ddi|in (r_pobj) of_4\IN\0|didanosine (r_prep) use_1\NN\407535|the|and|toxicity|of|) (l_conj) toxicity_3\NN\13576101|
D015215_D064420 NONE azt_19\NNP\3834836|( (r_appos) individuals_14\NNS\7347|hiv|positive|intolerant|azt (r_pobj) in_9\IN\13603305|individuals (r_prep) didanosine_5\NN\2725367|ddi|in (r_pobj) of_4\IN\0|didanosine (r_prep) use_1\NN\407535|the|and|toxicity|of|) (l_conj) toxicity_3\NN\13576101|
D015215_D015658 NONE zidovudine_17\NNP\3834836| (r_pobj) to_16\IN\0|zidovudine (r_prep) intolerant_15\JJ\0|to (r_amod) individuals_14\NNS\7347|hiv|positive|intolerant|azt (l_amod) positive_13\JJ\6321702|antibody|-
D015215_D015658 NONE azt_19\NNP\3834836|( (r_appos) individuals_14\NNS\7347|hiv|positive|intolerant|azt (l_amod) positive_13\JJ\6321702|antibody|-
D016049_D018149 CID didanosine_24\NN\2725367| (r_dobj) ceasing_23\VBG\0|didanosine (r_pcomp) on_22\IN\0|ceasing (r_prep) returned_19\VBN\1835496|to|on (r_conj) require_16\VB\0|,|did|not|treatment|and|returned|. (r_conj) developed_2\VBD\1753788|patients|curves|but|were|require (l_dobj) curves_5\VBZ\13863771|tolerance|characteristic
D016049_D003920 NONE didanosine_24\NN\2725367| (r_dobj) ceasing_23\VBG\0|didanosine (r_pcomp) on_22\IN\0|ceasing (r_prep) returned_19\VBN\1835496|to|on (r_conj) require_16\VB\0|,|did|not|treatment|and|returned|. (r_conj) developed_2\VBD\1753788|patients|curves|but|were|require (l_dobj) curves_5\VBZ\13863771|tolerance|characteristic (l_amod) characteristic_6\JJ\5849040|of (l_prep) of_7\IN\0|diabetes (l_pobj) diabetes_8\NNS\14075199|
6888657
D004967_D010911 NONE estrogen_2\NN\14745635| (r_npadvmod) induced_4\VBN\1627355|estrogen|- (r_amod) tumors_6\NNS\14234074|induced|adenohypophyseal|in
D004054_D010911 CID diethylstilbestrol_12\NN\14749794| (r_pobj) with_11\IN\0|diethylstilbestrol (r_prep) treatment_10\NN\654885|chronic|with (r_pobj) by_8\IN\0|treatment (r_agent) induced_3\VBN\1627355|tumors|were|in|by|implanted|. (l_nsubjpass) tumors_1\NNS\14234074|pituitary
D004054_D010911 CID des_14\NNP\14749794| (r_npadvmod) implanted_21\VBN\1421622|(|des|,|subcutaneously|in (r_parataxis) induced_3\VBN\1627355|tumors|were|in|by|implanted|. (l_nsubjpass) tumors_1\NNS\14234074|pituitary
D004054_D009369 NONE des_12\NNP\14749794| (r_npadvmod) induced_14\VBN\1627355|des|- (r_amod) tumor_15\NN\14234074|the|induced
8092427
D000658_D004342 CID amoxicillin_4\NNP\3910033| (r_pobj) to_3\IN\0|amoxicillin (r_prep) reactions_2\NNS\13446390|immediate|allergic|to|.
D000658_D004342 CID amoxicillin_39\NNP\3910033|ax (r_pobj) to_38\IN\0|amoxicillin (r_prep) responses_37\NNS\11410625|selective|immediate|allergic|to (r_dobj) had_33\VBD\0|responses|or|were (r_conj) used_22\VBN\0|history|,|with|,|rast|was|establish|had|. (l_xcomp) establish_24\VB\2426171|to|allergic (l_ccomp) allergic_27\JJ\0|whether|patients|to
D000658_D004342 CID amoxicillin_39\NNP\3910033|ax (r_pobj) to_38\IN\0|amoxicillin (r_prep) responses_37\NNS\11410625|selective|immediate|allergic|to (l_amod) allergic_36\JJ\0|
D000658_D004342 CID ax_41\NN\3265032|(|) (r_appos) amoxicillin_39\NNP\3910033|ax (r_pobj) to_38\IN\0|amoxicillin (r_prep) responses_37\NNS\11410625|selective|immediate|allergic|to (r_dobj) had_33\VBD\0|responses|or|were (r_conj) used_22\VBN\0|history|,|with|,|rast|was|establish|had|. (l_xcomp) establish_24\VB\2426171|to|allergic (l_ccomp) allergic_27\JJ\0|whether|patients|to
D000658_D004342 CID ax_41\NN\3265032|(|) (r_appos) amoxicillin_39\NNP\3910033|ax (r_pobj) to_38\IN\0|amoxicillin (r_prep) responses_37\NNS\11410625|selective|immediate|allergic|to (l_amod) allergic_36\JJ\0|
D000658_D004342 CID ax_11\NNP\3265032| (r_compound) allergy_12\NN\14533203|immediate|ax|with
D000658_D004342 CID ax_3\NN\3265032| (r_pobj) with_2\IN\0|ax (r_prep) tests_1\NNS\5798043|challenge|with (r_nsubjpass) performed_5\VBN\0|tests|were|in|establish|and|were (l_advcl) establish_14\VB\2426171|to|diagnosis|, (l_dobj) diagnosis_16\NN\152018|the|of (l_prep) of_17\IN\0|reaction (l_pobj) reaction_20\NN\13446390|immediate|allergic|to
D000658_D004342 CID ax_22\NN\3265032| (r_pobj) to_21\IN\0|ax (r_prep) reaction_20\NN\13446390|immediate|allergic|to
D000658_D004342 CID ax_38\NN\3265032| (r_pobj) for_37\IN\0|ax (r_prep) rast_36\NNP\0|for (r_conj) test_34\NN\5798043|both|skin|and|rast (r_appos) %_30\NN\0|28|)|test (r_nsubj) were_39\VBD\0|in|(|%|negative|. (r_conj) performed_5\VBN\0|tests|were|in|establish|and|were (l_advcl) establish_14\VB\2426171|to|diagnosis|, (l_dobj) diagnosis_16\NN\152018|the|of (l_prep) of_17\IN\0|reaction (l_pobj) reaction_20\NN\13446390|immediate|allergic|to
D000658_D004342 CID ax_6\NN\3265032| (r_npadvmod) allergic_8\JJ\0|ax|-
D047090_D004342 NONE lactam_12\NN\0|beta|- (r_amod) antibiotics_13\NNS\2716205|lactam (r_pobj) to_9\IN\0|antibiotics (r_prep) reactions_8\NNS\13446390|suspected|allergic|to
D047090_D004342 NONE lactam_31\NN\0|beta|- (r_amod) antibiotics_32\NNS\2716205|lactam (r_pobj) to_28\IN\0|antibiotics (r_prep) allergic_27\JJ\0|whether|patients|to
D047090_D004342 NONE lactam_31\NN\0|beta|- (r_amod) antibiotics_32\NNS\2716205|lactam (r_pobj) to_28\IN\0|antibiotics (r_prep) allergic_27\JJ\0|whether|patients|to (r_ccomp) establish_24\VB\2426171|to|allergic (r_xcomp) used_22\VBN\0|history|,|with|,|rast|was|establish|had|. (l_conj) had_33\VBD\0|responses|or|were (l_dobj) responses_37\NNS\11410625|selective|immediate|allergic|to (l_amod) allergic_36\JJ\0|
D047090_D004342 NONE lactam_12\NN\0|beta|- (r_amod) antibiotics_13\NNS\2716205|lactam (r_pobj) to_9\IN\0|antibiotics (r_prep) allergic_8\JJ\0|to
D010406_D004342 NONE penicillin_50\NN\2716866| (r_compound) derivatives_51\NNS\5802185|other|penicillin (r_pobj) with_48\IN\0|derivatives (r_prep) reacting_47\VBG\2367363|cross|-|with (r_acomp) were_44\VBD\0|reacting (r_conj) had_33\VBD\0|responses|or|were (r_conj) used_22\VBN\0|history|,|with|,|rast|was|establish|had|. (l_xcomp) establish_24\VB\2426171|to|allergic (l_ccomp) allergic_27\JJ\0|whether|patients|to
D010406_D004342 NONE penicillin_50\NN\2716866| (r_compound) derivatives_51\NNS\5802185|other|penicillin (r_pobj) with_48\IN\0|derivatives (r_prep) reacting_47\VBG\2367363|cross|-|with (r_acomp) were_44\VBD\0|reacting (r_conj) had_33\VBD\0|responses|or|were (l_dobj) responses_37\NNS\11410625|selective|immediate|allergic|to (l_amod) allergic_36\JJ\0|
D010400_D004342 NONE pg_17\NNP\0| (r_pobj) of_16\IN\0|pg (r_prep) tolerance_15\NN\5032565|good|of (r_pobj) with_13\IN\0|tolerance (r_prep) allergy_12\NN\14533203|immediate|ax|with
D010400_D004342 NONE pg_13\NNP\0| (r_dobj) tolerated_12\VBN\802318|who|have|pg (r_relcl) patients_9\NNS\9898892|allergic|tolerated (l_amod) allergic_8\JJ\0|ax|-
-1_D007645 NONE bpo_8\NNP\0| (r_pobj) to_7\IN\0|bpo (r_prep) negative_6\JJ\7204401|to (r_amod) test_5\NN\5798043|skin|negative (r_attr) were_3\VBD\0|patients|test (r_ccomp) were_17\VBD\0|were|;|49|also|negative|,|and|44|. (l_acomp) negative_19\JJ\7204401|to (l_prep) to_20\IN\0|mdm (l_pobj) mdm_21\NNP\0|
D010400_D007645 NONE pg_32\NNP\0| (r_pobj) to_31\IN\0|pg (r_prep) 44_24\CD\0|of|%|)|to (r_conj) were_17\VBD\0|were|;|49|also|negative|,|and|44|. (l_acomp) negative_19\JJ\7204401|to (l_prep) to_20\IN\0|mdm (l_pobj) mdm_21\NNP\0|
2505783
C004656_D006470 CID chloroacetaldehyde_7\NN\0|caa (r_nsubj) is_11\VBZ\0|that|chloroacetaldehyde|metabolite (l_attr) metabolite_14\NN\20090|an|important|of|,|carried (l_relcl) carried_23\VBN\1850315|study|was|out|in (l_prep) in_25\IN\13603305|order (l_pobj) order_26\NN\7168131|elucidate (l_acl) elucidate_28\VB\939277|to|role|in (l_prep) in_33\IN\13603305|development (l_pobj) development_35\NN\248977|the|of (l_prep) of_36\IN\0|cystitis (l_pobj) cystitis_38\NN\14566129|hemorrhagic
C004656_D006470 CID caa_9\NNP\0|(|) (r_appos) chloroacetaldehyde_7\NN\0|caa (r_nsubj) is_11\VBZ\0|that|chloroacetaldehyde|metabolite (l_attr) metabolite_14\NN\20090|an|important|of|,|carried (l_relcl) carried_23\VBN\1850315|study|was|out|in (l_prep) in_25\IN\13603305|order (l_pobj) order_26\NN\7168131|elucidate (l_acl) elucidate_28\VB\939277|to|role|in (l_prep) in_33\IN\13603305|development (l_pobj) development_35\NN\248977|the|of (l_prep) of_36\IN\0|cystitis (l_pobj) cystitis_38\NN\14566129|hemorrhagic
C004656_D006470 CID caa_32\NNP\0| (r_pobj) of_31\IN\0|caa (r_prep) role_30\NN\719494|the|of (r_dobj) elucidate_28\VB\939277|to|role|in (l_prep) in_33\IN\13603305|development (l_pobj) development_35\NN\248977|the|of (l_prep) of_36\IN\0|cystitis (l_pobj) cystitis_38\NN\14566129|hemorrhagic
C004656_D003556 CID chloroacetaldehyde_7\NN\0|caa (r_nsubj) is_11\VBZ\0|that|chloroacetaldehyde|metabolite (l_attr) metabolite_14\NN\20090|an|important|of|,|carried (l_relcl) carried_23\VBN\1850315|study|was|out|in (l_prep) in_25\IN\13603305|order (l_pobj) order_26\NN\7168131|elucidate (l_acl) elucidate_28\VB\939277|to|role|in (l_prep) in_33\IN\13603305|development (l_pobj) development_35\NN\248977|the|of (l_prep) of_36\IN\0|cystitis (l_pobj) cystitis_38\NN\14566129|hemorrhagic
C004656_D003556 CID caa_9\NNP\0|(|) (r_appos) chloroacetaldehyde_7\NN\0|caa (r_nsubj) is_11\VBZ\0|that|chloroacetaldehyde|metabolite (l_attr) metabolite_14\NN\20090|an|important|of|,|carried (l_relcl) carried_23\VBN\1850315|study|was|out|in (l_prep) in_25\IN\13603305|order (l_pobj) order_26\NN\7168131|elucidate (l_acl) elucidate_28\VB\939277|to|role|in (l_prep) in_33\IN\13603305|development (l_pobj) development_35\NN\248977|the|of (l_prep) of_36\IN\0|cystitis (l_pobj) cystitis_38\NN\14566129|hemorrhagic
C004656_D003556 CID caa_32\NNP\0| (r_pobj) of_31\IN\0|caa (r_prep) role_30\NN\719494|the|of (r_dobj) elucidate_28\VB\939277|to|role|in (l_prep) in_33\IN\13603305|development (l_pobj) development_35\NN\248977|the|of (l_prep) of_36\IN\0|cystitis (l_pobj) cystitis_38\NN\14566129|hemorrhagic
C004656_D001745 NONE caa_4\NNP\0| (r_nsubj) contribute_10\VB\126264|that|caa|after|administration|does|not|to (l_prep) to_11\IN\0|damage (l_pobj) damage_13\NN\7296428|bladder
12617329
D006170_D007674 NONE arabic_6\JJ\6986894|gum (r_pobj) with_4\IN\0|arabic (r_prep) treatment_3\NN\654885|with|on (l_prep) on_7\IN\0|nephrotoxicity (l_pobj) nephrotoxicity_9\NN\0|gentamicin|in
D006170_D007674 NONE arabic_14\JJ\6986894|gum (r_pobj) with_12\IN\0|arabic (r_prep) rats_11\NNS\2329401|with (r_pobj) of_10\IN\0|rats (r_prep) treatment_9\NN\654885|of|on (l_prep) on_15\IN\0|failure (l_pobj) failure_18\NN\66216|acute|renal|induced (l_acl) induced_19\VBN\1627355|by (l_agent) by_20\IN\0|nephrotoxicity (l_pobj) nephrotoxicity_25\NN\0|gentamicin|(|gm|)
D006170_D007674 NONE arabic_6\JJ\6986894| (r_amod) treatment_7\NN\654885|gum|arabic (r_nsubj) induced_9\VBN\1627355|that|treatment|has|amelioration (l_dobj) amelioration_12\NN\248977|a|modest|of (l_prep) of_13\IN\0|some (l_pobj) some_14\DT\0|of (l_prep) of_15\IN\0|indices (l_pobj) indices_20\NNS\13850304|the|histological|of (l_prep) of_21\IN\0|nephrotoxicity (l_pobj) nephrotoxicity_23\NN\0|gm
D005839_D007674 NONE gentamicin_8\NN\2716866| (r_amod) nephrotoxicity_9\NN\0|gentamicin|in
D005839_D007674 NONE gentamicin_21\NN\2716866| (r_nmod) nephrotoxicity_25\NN\0|gentamicin|(|gm|)
D005839_D007674 NONE gm_23\NNP\13717155| (r_nmod) nephrotoxicity_25\NN\0|gentamicin|(|gm|)
D005839_D007674 NONE gm_22\NNP\13717155| (r_compound) nephrotoxicity_23\NN\0|gm
D006170_D058186 CID arabic_14\JJ\6986894|gum (r_pobj) with_12\IN\0|arabic (r_prep) rats_11\NNS\2329401|with (r_pobj) of_10\IN\0|rats (r_prep) treatment_9\NN\654885|of|on (l_prep) on_15\IN\0|failure (l_pobj) failure_18\NN\66216|acute|renal|induced
D005839_D058186 CID gentamicin_21\NN\2716866| (r_nmod) nephrotoxicity_25\NN\0|gentamicin|(|gm|) (r_pobj) by_20\IN\0|nephrotoxicity (r_agent) induced_19\VBN\1627355|by (r_acl) failure_18\NN\66216|acute|renal|induced
D005839_D058186 CID gm_23\NNP\13717155| (r_nmod) nephrotoxicity_25\NN\0|gentamicin|(|gm|) (r_pobj) by_20\IN\0|nephrotoxicity (r_agent) induced_19\VBN\1627355|by (r_acl) failure_18\NN\66216|acute|renal|induced
D003404_D007674 NONE creatinine_8\NN\0|and|urea (r_pobj) of_7\IN\0|creatinine (r_prep) concentrations_6\NNS\4916342|the|of|in (r_dobj) measuring_4\VBG\407535|concentrations|and|glutathione (r_pcomp) by_3\IN\0|measuring|and|by (r_prep) assessed_2\VBN\670261|nephrotoxicity|was|by|. (l_nsubjpass) nephrotoxicity_0\NN\0|
D014508_D007674 NONE urea_10\NN\14727670| (r_conj) creatinine_8\NN\0|and|urea (r_pobj) of_7\IN\0|creatinine (r_prep) concentrations_6\NNS\4916342|the|of|in (r_dobj) measuring_4\VBG\407535|concentrations|and|glutathione (r_pcomp) by_3\IN\0|measuring|and|by (r_prep) assessed_2\VBN\670261|nephrotoxicity|was|by|. (l_nsubjpass) nephrotoxicity_0\NN\0|
D005978_D007674 NONE glutathione_16\NN\0|reduced|gsh|in|, (r_conj) measuring_4\VBG\407535|concentrations|and|glutathione (r_pcomp) by_3\IN\0|measuring|and|by (r_prep) assessed_2\VBN\670261|nephrotoxicity|was|by|. (l_nsubjpass) nephrotoxicity_0\NN\0|
D005978_D007674 NONE gsh_18\NNP\0|(|) (r_appos) glutathione_16\NN\0|reduced|gsh|in|, (r_conj) measuring_4\VBG\407535|concentrations|and|glutathione (r_pcomp) by_3\IN\0|measuring|and|by (r_prep) assessed_2\VBN\670261|nephrotoxicity|was|by|. (l_nsubjpass) nephrotoxicity_0\NN\0|
D005839_D007683 NONE gm_1\NNP\13717155| (r_npadvmod) induced_3\VBN\1627355|gm|- (r_amod) necrosis_6\NN\11444117|the|induced|proximal|tubular
D005839_D007683 NONE gm_16\NNP\13717155| (r_dobj) given_15\VBN\5892096|gm|with|than (r_acl) rats_14\NNS\2329401|given (r_pobj) in_13\IN\13603305|rats (r_prep) severe_12\JJ\0|less|in (r_acomp) be_9\VB\14625458|to|severe (r_xcomp) appeared_7\VBD\2604760|necrosis|be|. (l_nsubj) necrosis_6\NN\11444117|the|induced|proximal|tubular
D005839_D007683 NONE gm_25\NNP\13717155|and|cellulose (r_pobj) given_24\VBN\5892096|gm (r_acl) those_23\DT\0|given (r_pobj) in_22\IN\13603305|those (r_prep) than_21\IN\0|in (r_prep) given_15\VBN\5892096|gm|with|than (r_acl) rats_14\NNS\2329401|given (r_pobj) in_13\IN\13603305|rats (r_prep) severe_12\JJ\0|less|in (r_acomp) be_9\VB\14625458|to|severe (r_xcomp) appeared_7\VBD\2604760|necrosis|be|. (l_nsubj) necrosis_6\NN\11444117|the|induced|proximal|tubular
D006170_D007683 NONE arabic_20\JJ\6986894|gum (r_pobj) with_18\IN\0|together|arabic (r_prep) given_15\VBN\5892096|gm|with|than (r_acl) rats_14\NNS\2329401|given (r_pobj) in_13\IN\13603305|rats (r_prep) severe_12\JJ\0|less|in (r_acomp) be_9\VB\14625458|to|severe (r_xcomp) appeared_7\VBD\2604760|necrosis|be|. (l_nsubj) necrosis_6\NN\11444117|the|induced|proximal|tubular
17491223
D004280_D017202 CID dobutamine_14\NN\0| (r_npadvmod) induced_16\VBN\1627355|dobutamine|- (r_amod) ischemia_18\NN\14195315|induced|myocardial
D004280_D017202 CID dobutamine_8\NN\0| (r_npadvmod) induced_10\VBN\1627355|dobutamine|- (r_amod) ischemia_12\NN\14195315|induced|myocardial
D004280_D017202 CID dobutamine_37\NN\0| (r_npadvmod) induced_39\VBN\1627355|dobutamine|- (r_amod) ischemia_41\NN\14195315|induced|myocardial
D004280_D007511 NONE dobutamine_37\NN\0| (r_npadvmod) induced_39\VBN\1627355|dobutamine|- (r_amod) ischemia_41\NN\14195315|induced|myocardial (r_dobj) detecting_36\VBG\635012|ischemia|,|using (r_pcomp) for_35\IN\0|detecting (r_prep) assess_3\VB\5220461|to|value|,|compared|,|for|computed (l_conj) computed_51\VBD\632627|tomography|assess (l_advcl) assess_60\VB\5220461|to|presence (l_dobj) presence_62\NN\13954253|the|or|absence|of (l_prep) of_65\IN\0|ischemia (l_pobj) ischemia_66\NN\14195315|
D017256_D017202 NONE sestamibi_46\NNP\0|tc99m|- (r_nmod) emission_50\NN\44455|sestamibi|photon (r_dobj) using_43\VBG\418025|emission (r_conj) detecting_36\VBG\635012|ischemia|,|using (l_dobj) ischemia_41\NN\14195315|induced|myocardial
D017256_D007511 NONE sestamibi_46\NNP\0|tc99m|- (r_nmod) emission_50\NN\44455|sestamibi|photon (r_dobj) using_43\VBG\418025|emission (r_conj) detecting_36\VBG\635012|ischemia|,|using (r_pcomp) for_35\IN\0|detecting (r_prep) assess_3\VB\5220461|to|value|,|compared|,|for|computed (l_conj) computed_51\VBD\632627|tomography|assess (l_advcl) assess_60\VB\5220461|to|presence (l_dobj) presence_62\NN\13954253|the|or|absence|of (l_prep) of_65\IN\0|ischemia (l_pobj) ischemia_66\NN\14195315|
2348231
D010431_D006940 NONE pentoxifylline_0\NNP\3247620|(|trental|) (r_nsubj) inhibit_6\VB\2510337|pentoxifylline|does|not|hyperemia|. (l_dobj) hyperemia_11\NN\14320394|induced|coronary|:|implications
D010431_D006940 NONE trental_2\NNP\3247620| (r_appos) pentoxifylline_0\NNP\3247620|(|trental|) (r_nsubj) inhibit_6\VB\2510337|pentoxifylline|does|not|hyperemia|. (l_dobj) hyperemia_11\NN\14320394|induced|coronary|:|implications
D010431_D006940 NONE pentoxifylline_1\NN\3247620|whether (r_nsubj) inhibits_2\VBZ\2510337|pentoxifylline|hyperemia|and|stopped (l_dobj) hyperemia_7\NN\14320394|induced|coronary|like
D010431_D006940 NONE pentoxifylline_3\NN\3247620| (r_pobj) of_2\IN\0|pentoxifylline (r_prep) dose_1\NN\3740161|neither|of (r_nsubj) decreased_5\VBD\169651|dose|significantly|hyperemia|,|peak|less|)|. (l_dobj) hyperemia_10\NN\14320394|the|induced
D010431_D006940 NONE pentoxyifylline_3\NN\0| (r_nsubj) inhibit_6\VB\2510337|that|pentoxyifylline|does|not|hyperemia|at (l_dobj) hyperemia_11\NN\14320394|induced|coronary
D004176_D006940 CID dipyridamole_7\NN\0| (r_npadvmod) induced_9\VBN\1627355|dipyridamole|- (r_amod) hyperemia_11\NN\14320394|induced|coronary|:|implications
D004176_D006940 CID dipyridamole_15\JJ\0| (r_npadvmod) thallium-201_17\NN\0|dipyridamole|- (r_nmod) imaging_19\NN\5765159|thallium-201|myocardial (r_pobj) for_14\IN\0|imaging (r_prep) implications_13\NNS\5774614|for (r_appos) hyperemia_11\NN\14320394|induced|coronary|:|implications
D004176_D006940 CID dipyridamole_3\NN\0| (r_dep) induced_5\VBN\1627355|dipyridamole|- (r_amod) hyperemia_7\NN\14320394|induced|coronary|like
D004176_D006940 CID dipyridamole_20\NN\0| (r_compound) thallium-201_22\NN\0|dipyridamole|- (r_compound) imaging_23\NN\5765159|thallium-201 (r_pobj) to_19\IN\0|imaging (r_prep) prior_18\RB\10675876|to (r_advmod) stopped_17\VBN\0|should|be|prior (r_conj) inhibits_2\VBZ\2510337|pentoxifylline|hyperemia|and|stopped (l_dobj) hyperemia_7\NN\14320394|induced|coronary|like
D004176_D006940 CID dipyridamole_7\NN\0| (r_npadvmod) induced_9\VBN\1627355|dipyridamole|- (r_amod) hyperemia_10\NN\14320394|the|induced
D004176_D006940 CID dipyridamole_7\NN\0| (r_npadvmod) induced_9\VBN\1627355|dipyridamole|- (r_amod) hyperemia_11\NN\14320394|induced|coronary
D013793_D006940 NONE thallium-201_17\NN\0|dipyridamole|- (r_nmod) imaging_19\NN\5765159|thallium-201|myocardial (r_pobj) for_14\IN\0|imaging (r_prep) implications_13\NNS\5774614|for (r_appos) hyperemia_11\NN\14320394|induced|coronary|:|implications
D013793_D006940 NONE thallium-201_22\NN\0|dipyridamole|- (r_compound) imaging_23\NN\5765159|thallium-201 (r_pobj) to_19\IN\0|imaging (r_prep) prior_18\RB\10675876|to (r_advmod) stopped_17\VBN\0|should|be|prior (r_conj) inhibits_2\VBZ\2510337|pentoxifylline|hyperemia|and|stopped (l_dobj) hyperemia_7\NN\14320394|induced|coronary|like
D010431_D007383 CID pentoxifylline_6\NN\3247620| (r_dobj) taking_5\VBG\37396|many|are|pentoxifylline|(|trental|)|,|derivative|. (l_conj) derivative_13\NN\5802185|a|methylxanthine|improve (l_relcl) improve_16\VB\126264|which|may|claudication (l_dobj) claudication_18\NN\14548913|intermittent
D010431_D007383 CID trental_8\NNP\3247620| (r_npadvmod) taking_5\VBG\37396|many|are|pentoxifylline|(|trental|)|,|derivative|. (l_conj) derivative_13\NN\5802185|a|methylxanthine|improve (l_relcl) improve_16\VB\126264|which|may|claudication (l_dobj) claudication_18\NN\14548913|intermittent
C008514_D007383 NONE methylxanthine_12\NN\0| (r_compound) derivative_13\NN\5802185|a|methylxanthine|improve (l_relcl) improve_16\VB\126264|which|may|claudication (l_dobj) claudication_18\NN\14548913|intermittent
C008514_D006940 NONE methylxanthines_10\NNS\0|other|as (r_pobj) like_8\IN\5839024|methylxanthines (r_prep) hyperemia_7\NN\14320394|induced|coronary|like
D013806_D006940 NONE theophylline_13\NN\2905612| (r_pobj) as_12\IN\14622893|such|theophylline (r_prep) methylxanthines_10\NNS\0|other|as (r_pobj) like_8\IN\5839024|methylxanthines (r_prep) hyperemia_7\NN\14320394|induced|coronary|like
D013806_D006940 NONE theophylline_21\NN\2905612| (r_pobj) after_20\IN\0|theophylline (r_prep) was_17\VBD\0|flow|lower|after (r_ccomp) peak_13\JJ\13758296|while|was (r_advcl) decreased_5\VBD\169651|dose|significantly|hyperemia|,|peak|less|)|. (l_dobj) hyperemia_10\NN\14320394|the|induced
19473225
D018698_D010523 NONE glutamate_3\NN\15010703| (r_compound) supplementation_4\NN\5108947|term|glutamate (r_nsubj) failed_5\VBD\0|supplementation|protect|. (l_xcomp) protect_7\VB\1127795|to|against (l_prep) against_8\IN\0|neurotoxicity (l_pobj) neurotoxicity_10\NN\0|peripheral|of
D018698_D010523 NONE glutamate_18\NN\15010703|and|glutamine (r_nsubjpass) claimed_27\VBN\1011725|although|glutamate|were|ameliorate (r_advcl) is_3\VBZ\0|neuropathy|still|factor|,|claimed|. (l_nsubj) neuropathy_2\NN\14204950|toxic|peripheral
D018698_D010523 NONE glutamine_25\NN\14601829|its|related|acid (r_conj) glutamate_18\NN\15010703|and|glutamine (r_nsubjpass) claimed_27\VBN\1011725|although|glutamate|were|ameliorate (r_advcl) is_3\VBZ\0|neuropathy|still|factor|,|claimed|. (l_nsubj) neuropathy_2\NN\14204950|toxic|peripheral
D018698_D010523 NONE glutamate_9\NN\15010703| (r_compound) supplementation_10\NN\5108947|glutamate|for (l_prep) for_11\IN\0|preventing (l_pcomp) preventing_12\VBG\0|neuropathy|in (l_dobj) neuropathy_17\NN\14204950|induced|peripheral
D018698_D010523 NONE glutamate_8\NN\15010703| (r_compound) supplementation_9\NN\5108947|glutamate|at (r_nsubj) fails_14\VBZ\0|that|supplementation|protect (l_xcomp) protect_16\VB\1127795|to|against (l_prep) against_17\IN\0|neurotoxicity (l_pobj) neurotoxicity_19\NN\0|peripheral|of
D017239_D010523 CID paclitaxel_12\NN\0| (r_pobj) of_11\IN\0|paclitaxel (r_prep) neurotoxicity_10\NN\0|peripheral|of
D017239_D010523 CID paclitaxel_12\NN\0| (r_pobj) with_11\IN\0|paclitaxel (r_prep) chemotherapy_10\NN\661091|with|pac (r_pobj) for_9\IN\0|chemotherapy (r_prep) factor_8\NN\7326557|a|significant|limiting|for (r_attr) is_3\VBZ\0|neuropathy|still|factor|,|claimed|. (l_nsubj) neuropathy_2\NN\14204950|toxic|peripheral
D017239_D010523 CID pac_14\NNP\8324514|(|) (r_appos) chemotherapy_10\NN\661091|with|pac (r_pobj) for_9\IN\0|chemotherapy (r_prep) factor_8\NN\7326557|a|significant|limiting|for (r_attr) is_3\VBZ\0|neuropathy|still|factor|,|claimed|. (l_nsubj) neuropathy_2\NN\14204950|toxic|peripheral
D017239_D010523 CID pac_30\NNP\8324514| (r_compound) neurotoxicity_31\NN\0|pac (r_dobj) ameliorate_29\VB\126264|to|neurotoxicity (r_xcomp) claimed_27\VBN\1011725|although|glutamate|were|ameliorate (r_advcl) is_3\VBZ\0|neuropathy|still|factor|,|claimed|. (l_nsubj) neuropathy_2\NN\14204950|toxic|peripheral
D017239_D010523 CID pac_13\NNP\8324514| (r_npadvmod) induced_15\VBN\1627355|pac|- (r_amod) neuropathy_17\NN\14204950|induced|peripheral
D017239_D010523 CID pac_21\NNP\8324514| (r_pobj) of_20\IN\0|pac (r_prep) neurotoxicity_19\NN\0|peripheral|of
D017239_D020258 NONE paclitaxel_12\NN\0| (r_pobj) with_11\IN\0|paclitaxel (r_prep) chemotherapy_10\NN\661091|with|pac (r_pobj) for_9\IN\0|chemotherapy (r_prep) factor_8\NN\7326557|a|significant|limiting|for (r_attr) is_3\VBZ\0|neuropathy|still|factor|,|claimed|. (l_advcl) claimed_27\VBN\1011725|although|glutamate|were|ameliorate (l_xcomp) ameliorate_29\VB\126264|to|neurotoxicity (l_dobj) neurotoxicity_31\NN\0|pac
D017239_D020258 NONE pac_14\NNP\8324514|(|) (r_appos) chemotherapy_10\NN\661091|with|pac (r_pobj) for_9\IN\0|chemotherapy (r_prep) factor_8\NN\7326557|a|significant|limiting|for (r_attr) is_3\VBZ\0|neuropathy|still|factor|,|claimed|. (l_advcl) claimed_27\VBN\1011725|although|glutamate|were|ameliorate (l_xcomp) ameliorate_29\VB\126264|to|neurotoxicity (l_dobj) neurotoxicity_31\NN\0|pac
D017239_D020258 NONE pac_30\NNP\8324514| (r_compound) neurotoxicity_31\NN\0|pac
D018698_D020258 NONE glutamate_18\NN\15010703|and|glutamine (r_nsubjpass) claimed_27\VBN\1011725|although|glutamate|were|ameliorate (l_xcomp) ameliorate_29\VB\126264|to|neurotoxicity (l_dobj) neurotoxicity_31\NN\0|pac
D018698_D020258 NONE glutamine_25\NN\14601829|its|related|acid (r_conj) glutamate_18\NN\15010703|and|glutamine (r_nsubjpass) claimed_27\VBN\1011725|although|glutamate|were|ameliorate (l_xcomp) ameliorate_29\VB\126264|to|neurotoxicity (l_dobj) neurotoxicity_31\NN\0|pac
D000596_D010523 NONE acid_24\NN\14818238|amino (r_compound) glutamine_25\NN\14601829|its|related|acid (r_conj) glutamate_18\NN\15010703|and|glutamine (r_nsubjpass) claimed_27\VBN\1011725|although|glutamate|were|ameliorate (r_advcl) is_3\VBZ\0|neuropathy|still|factor|,|claimed|. (l_nsubj) neuropathy_2\NN\14204950|toxic|peripheral
D000596_D020258 NONE acid_24\NN\14818238|amino (r_compound) glutamine_25\NN\14601829|its|related|acid (r_conj) glutamate_18\NN\15010703|and|glutamine (r_nsubjpass) claimed_27\VBN\1011725|although|glutamate|were|ameliorate (l_xcomp) ameliorate_29\VB\126264|to|neurotoxicity (l_dobj) neurotoxicity_31\NN\0|pac
D017239_D010051 NONE pac_16\NNP\8324514| (r_npadvmod) containing_18\VBG\2632940|pac|- (r_amod) regimen_19\NN\5898568|the|same|containing (r_pobj) of_13\IN\0|regimen (r_prep) cycles_12\NNS\15269513|six|of (r_pobj) following_10\VBG\8180190|cycles (r_prep) analysis_9\NN\633864|following (r_pobj) for_8\IN\0|analysis (r_prep) available_7\JJ\0|for (r_acomp) were_6\VBD\0|patients|available (l_nsubj) patients_5\NNS\9898892|three|ovarian|cancer (l_compound) cancer_4\NN\14239425|
D018698_D010051 NONE glutamate_26\NN\15010703|along (r_pobj) by_25\IN\0|glutamate (r_agent) supplemented_24\VBN\182406|were|:|23|had|been|by|,|at|,|and|received|. (l_ccomp) were_6\VBD\0|patients|available (l_nsubj) patients_5\NNS\9898892|three|ovarian|cancer (l_compound) cancer_4\NN\14239425|
8690168
D006497_D003928 NONE sulphate_3\NN\15010703| (r_npadvmod) associated_5\VBN\628491|sulphate|- (r_amod) sites_7\NNS\8673395|heparan|associated|anionic|in (l_prep) in_8\IN\13603305|membrane (l_pobj) membrane_12\NN\4188643|the|glomerular|basement|of (l_prep) of_13\IN\0|rats (l_pobj) rats_14\NNS\2329401|with (l_prep) with_15\IN\0|nephropathy (l_pobj) nephropathy_20\NN\14573196|induced|diabetic
D013311_D003928 CID streptozotocin_16\NNS\0| (r_npadvmod) induced_18\VBN\1627355|streptozotocin|- (r_amod) nephropathy_20\NN\14573196|induced|diabetic
D006497_D003920 NONE sulphate_1\NN\15010703| (r_npadvmod) associated_3\VBN\628491|sulphate|- (r_amod) sites_5\NNS\8673395|heparan|associated|anionic|in (r_nsubjpass) studied_12\VBN\0|sites|were|in|after|,|employing|. (l_prep) after_17\IN\0|months|induction (l_pobj) induction_18\NN\7450842|of|by (l_prep) of_19\IN\0|diabetes (l_pobj) diabetes_20\NNS\14075199|
D006497_D003920 NONE sulphate_18\NN\15010703| (r_compound) charge_19\NN\972621|sulphate (r_compound) density_22\NN\4941325|a|reduced|heparan|charge|barrier|/ (r_nsubjpass) found_24\VBN\13279262|that|in|density|is|at (l_prep) in_3\IN\13603305|rats (l_pobj) rats_7\NNS\2329401|diabetic|with (l_amod) diabetic_6\JJ\10595647|streptozotocin|-
D013311_D003920 NONE streptozotocin_22\NNS\0| (r_pobj) by_21\IN\0|streptozotocin|and|in (r_prep) induction_18\NN\7450842|of|by (l_prep) of_19\IN\0|diabetes (l_pobj) diabetes_20\NNS\14075199|
D013311_D003920 NONE streptozotocin_4\JJ\0| (r_amod) diabetic_6\JJ\10595647|streptozotocin|-
C015445_D003920 NONE blue_38\JJ\4959672|the|cationic|dye|cuprolinic (r_dobj) employing_33\VBG\0|blue (r_advcl) studied_12\VBN\0|sites|were|in|after|,|employing|. (l_prep) after_17\IN\0|months|induction (l_pobj) induction_18\NN\7450842|of|by (l_prep) of_19\IN\0|diabetes (l_pobj) diabetes_20\NNS\14075199|
7468724
D013726_D002318 CID terbutaline_4\JJ\0| (r_compound) treatment_5\NN\654885|terbutaline|for (r_pobj) with_3\IN\0|treatment (r_prep) associated_2\VBN\628491|with (r_acl) complications_1\NNS\1073995|cardiovascular|associated|.
D013726_D002318 CID terbutaline_11\NN\0|for (r_pobj) with_10\IN\0|terbutaline (r_prep) treated_9\VBN\2376958|with (r_acl) patients_8\NNS\9898892|160|treated (r_pobj) in_4\IN\13603305|patients (r_prep) occurred_3\VBD\0|complications|in|. (l_nsubj) complications_2\NNS\1073995|severe|cardiovascular
D013726_D007752 NONE terbutaline_4\JJ\0| (r_compound) treatment_5\NN\654885|terbutaline|for (l_prep) for_6\IN\0|labor (l_pobj) labor_8\NN\7974025|preterm
D013726_D007752 NONE terbutaline_11\NN\0|for (l_prep) for_12\IN\0|labor (l_pobj) labor_14\NN\7974025|preterm
11007689
D016572_D057049 CID cyclosporine_0\NN\0|and|microangiopathy|. (l_conj) microangiopathy_6\NN\0|associated|thrombotic
D016572_D057049 CID cyclosporine_13\NN\0| (r_pobj) of_12\IN\0|cyclosporine (r_prep) use_11\NN\407535|the|of (r_pobj) with_9\IN\0|use (r_prep) associated_8\VBN\628491|with (r_acl) microangiopathy_4\NN\0|thrombotic|tma|associated
D016572_D057049 CID cyclosporine_13\NN\0| (r_pobj) of_12\IN\0|cyclosporine (r_prep) use_11\NN\407535|the|of (r_pobj) with_9\IN\0|use (r_prep) associated_8\VBN\628491|with (r_acl) microangiopathy_4\NN\0|thrombotic|tma|associated (l_appos) tma_6\NNP\0|(|)
D016572_D057049 CID cyclosporine_20\NN\0| (r_npadvmod) induced_22\VBN\1627355|cyclosporine|- (r_amod) tma_23\NNP\0|induced
D016572_D057049 CID cyclosporine_16\NN\0|and|tacrolimus (r_pobj) to_15\IN\0|cyclosporine (r_prep) exposed_13\VBN\2110927|sequentially|to (r_acl) patients_12\NNS\9898892|exposed (r_pobj) in_11\IN\13603305|patients (r_prep) recurrence_8\NN\7342049|the|of|in (l_prep) of_9\IN\0|tma (l_pobj) tma_10\NNP\0|
D016572_D057049 CID cyclosporine_13\NN\0| (r_npadvmod) induced_15\VBN\1627355|cyclosporine|- (r_amod) tma_16\NNP\0|induced|responded
D016572_D057049 CID cyclosporine_23\NN\0| (r_pobj) of_22\IN\0|cyclosporine (r_prep) withdrawal_21\NN\7206096|the|of|in (r_pobj) to_19\IN\0|withdrawal (r_prep) responded_18\VBD\2367363|that|to (r_relcl) tma_16\NNP\0|induced|responded
D016572_D057049 CID cyclosporine_5\NN\0| (r_pobj) from_4\IN\0|cyclosporine (r_prep) switched_3\VBN\138508|who|are|from|to (r_relcl) patients_0\NNS\9898892|switched (r_nsubjpass) monitored_14\VBN\2169352|patients|should|be|closely|for|. (l_prep) for_15\IN\0|signs (l_pobj) signs_17\NNS\6643763|the|and|symptoms|of (l_prep) of_20\IN\0|tma (l_pobj) tma_22\NNP\0|recurrent
D016559_D057049 CID tacrolimus_2\NN\0| (r_npadvmod) associated_4\VBN\628491|tacrolimus|- (r_amod) microangiopathy_6\NN\0|associated|thrombotic
D016559_D057049 CID tacrolimus_6\NN\0| (r_pobj) to_5\IN\0|tacrolimus (r_prep) switching_4\VBG\191142|to (r_nsubjpass) reported_9\VBN\831651|as|,|switching|has|been|be|. (l_xcomp) be_11\VB\14625458|to|option (l_attr) option_15\NN\6480506|a|viable|therapeutic|in (l_prep) in_16\IN\13603305|setting (l_pobj) setting_18\NN\8567235|the|of (l_prep) of_19\IN\0|tma (l_pobj) tma_23\NNP\0|induced
D016559_D057049 CID tacrolimus_6\NN\0|in (r_pobj) of_5\IN\0|tacrolimus (r_prep) application_4\NN\947128|the|widespread|of (r_pobj) with_0\IN\0|application (r_prep) recognized_18\VBN\686447|with|,|tma|has|also|been|. (l_nsubjpass) tma_14\NNP\0|associated
D016559_D057049 CID tacrolimus_11\NN\0| (r_npadvmod) associated_13\VBN\628491|tacrolimus|- (r_amod) tma_14\NNP\0|associated
D016559_D057049 CID tacrolimus_18\NN\0| (r_conj) cyclosporine_16\NN\0|and|tacrolimus (r_pobj) to_15\IN\0|cyclosporine (r_prep) exposed_13\VBN\2110927|sequentially|to (r_acl) patients_12\NNS\9898892|exposed (r_pobj) in_11\IN\13603305|patients (r_prep) recurrence_8\NN\7342049|the|of|in (l_prep) of_9\IN\0|tma (l_pobj) tma_10\NNP\0|
D016559_D057049 CID tacrolimus_2\NN\0|as (r_pobj) of_1\IN\0|tacrolimus (r_prep) introduction_0\NN\235435|of (r_nsubj) resulted_8\VBD\2633881|introduction|in|. (l_prep) in_9\IN\13603305|recurrence (l_pobj) recurrence_11\NN\7342049|the|of|and|loss (l_prep) of_12\IN\0|tma (l_pobj) tma_13\NNP\0|
D016559_D057049 CID tacrolimus_7\NN\0|or|versa (r_pobj) to_6\IN\0|tacrolimus (r_prep) switched_3\VBN\138508|who|are|from|to (r_relcl) patients_0\NNS\9898892|switched (r_nsubjpass) monitored_14\VBN\2169352|patients|should|be|closely|for|. (l_prep) for_15\IN\0|signs (l_pobj) signs_17\NNS\6643763|the|and|symptoms|of (l_prep) of_20\IN\0|tma (l_pobj) tma_22\NNP\0|recurrent
15632880
D013148_D051437 CID spironolactone_0\NNP\2721160| (r_npadvmod) induced_2\VBN\1627355|spironolactone|-|insufficiency|. (l_dobj) insufficiency_4\NN\14462946|renal|and|hyperkalemia|in
D013148_D051437 CID spironolactone_9\NN\2721160|in (r_pobj) of_8\IN\0|spironolactone (r_prep) use_7\NN\407535|the|of (r_dobj) evaluating_5\VBG\670261|use (r_acl) trial_4\NN\786195|a|previous|randomized|controlled|evaluating (r_nsubj) reported_14\VBD\831651|trial|risk|. (l_dobj) risk_17\NN\14541044|a|low|of (l_prep) of_18\IN\0|hyperkalemia (l_pobj) hyperkalemia_19\NN\14299637|(|%|)|and|insufficiency (l_conj) insufficiency_26\NN\14462946|renal|(|%|)
D013148_D051437 CID spironolactone_21\NN\2721160| (r_pobj) with_20\IN\0|spironolactone (r_prep) treated_19\VBN\2376958|with (r_acl) patients_18\NNS\9898892|failure|treated (r_pobj) in_15\IN\13603305|patients (r_prep) insufficiency_14\NN\14462946|renal|in
D013148_D051437 CID spironolactone_13\NN\2721160| (r_pobj) of_12\IN\0|spironolactone (r_prep) discontinuation_11\NN\209943|of (r_dobj) required_10\VBD\0|seven|discontinuation|due|. (l_prep) due_14\IN\5174653|to|hyperkalemia (l_pobj) hyperkalemia_16\NN\14299637|(|n|)|or|failure (l_conj) failure_24\NN\66216|renal|(|34|)
D013148_D051437 CID spironolactone_0\NNP\2721160| (r_npadvmod) induced_2\VBN\1627355|spironolactone|- (r_amod) hyperkalemia_3\NN\14299637|induced|and (r_nmod) insufficiency_6\NN\14462946|hyperkalemia|renal
D013148_D006947 CID spironolactone_0\NNP\2721160| (r_npadvmod) induced_2\VBN\1627355|spironolactone|-|insufficiency|. (l_dobj) insufficiency_4\NN\14462946|renal|and|hyperkalemia|in (l_conj) hyperkalemia_6\NN\14299637|
D013148_D006947 CID spironolactone_9\NN\2721160|in (r_pobj) of_8\IN\0|spironolactone (r_prep) use_7\NN\407535|the|of (r_dobj) evaluating_5\VBG\670261|use (r_acl) trial_4\NN\786195|a|previous|randomized|controlled|evaluating (r_nsubj) reported_14\VBD\831651|trial|risk|. (l_dobj) risk_17\NN\14541044|a|low|of (l_prep) of_18\IN\0|hyperkalemia (l_pobj) hyperkalemia_19\NN\14299637|(|%|)|and|insufficiency
D013148_D006947 CID spironolactone_21\NN\2721160| (r_pobj) with_20\IN\0|spironolactone (r_prep) treated_19\VBN\2376958|with (r_acl) patients_18\NNS\9898892|failure|treated (r_pobj) in_15\IN\13603305|patients (r_prep) insufficiency_14\NN\14462946|renal|in (r_conj) hyperkalemia_11\NN\14299637|and|insufficiency
D013148_D006947 CID spironolactone_13\NN\2721160| (r_pobj) of_12\IN\0|spironolactone (r_prep) discontinuation_11\NN\209943|of (r_dobj) required_10\VBD\0|seven|discontinuation|due|. (l_prep) due_14\IN\5174653|to|hyperkalemia (l_pobj) hyperkalemia_16\NN\14299637|(|n|)|or|failure
D013148_D006947 CID spironolactone_0\NNP\2721160| (r_npadvmod) induced_2\VBN\1627355|spironolactone|- (r_amod) hyperkalemia_3\NN\14299637|induced|and
D013148_D006333 NONE spironolactone_0\NNP\2721160| (r_npadvmod) induced_2\VBN\1627355|spironolactone|-|insufficiency|. (l_dobj) insufficiency_4\NN\14462946|renal|and|hyperkalemia|in (l_prep) in_7\IN\13603305|patients (l_pobj) patients_8\NNS\9898892|with (l_prep) with_9\IN\0|failure (l_pobj) failure_11\NN\66216|heart
D013148_D006333 NONE spironolactone_9\NN\2721160|in (l_prep) in_10\IN\13603305|patients (l_pobj) patients_13\NNS\9898892|failure (l_compound) failure_12\NN\66216|heart
D013148_D006333 NONE spironolactone_11\NN\2721160| (r_pobj) of_10\IN\0|spironolactone (r_prep) benefits_9\NNS\13278375|the|of (r_nsubjpass) reported_13\VBN\831651|since|benefits|were (r_advcl) changed_6\VBN\0|because|treatments|have|reported (l_nsubj) treatments_1\NNS\654885|for (l_prep) for_2\IN\0|failure (l_pobj) failure_4\NN\66216|heart
D013148_D006333 NONE spironolactone_21\NN\2721160| (r_pobj) with_20\IN\0|spironolactone (r_prep) treated_19\VBN\2376958|with (r_acl) patients_18\NNS\9898892|failure|treated (l_compound) failure_17\NN\66216|heart
D013148_D006333 NONE spironolactone_12\NN\2721160|in (r_pobj) with_11\IN\0|spironolactone (r_prep) treated_10\VBN\2376958|with (r_acl) patients_9\NNS\9898892|failure|treated (l_compound) failure_8\NN\66216|heart
D011188_D006947 NONE k(+_7\NNP\0|(|) (r_appos) hyperkalemia_5\NN\14299637|k(+
D011188_D006947 NONE potassium_17\NN\14625458|serum (r_compound) levels_18\NNS\4916342|higher|baseline|potassium|and|doses (r_dobj) had_13\VBD\0|levels|,|and|were (r_conj) were_4\VBD\0|patients|older|,|had|. (l_nsubj) patients_0\NNS\9898892|developed (l_relcl) developed_2\VBD\1753788|who|hyperkalemia (l_dobj) hyperkalemia_3\NN\14299637|
D011188_D006947 NONE potassium_22\NN\14625458| (r_compound) supplement_23\NN\6365467|potassium (r_compound) doses_24\NNS\3740161|lower|baseline|supplement (r_conj) levels_18\NNS\4916342|higher|baseline|potassium|and|doses (r_dobj) had_13\VBD\0|levels|,|and|were (r_conj) were_4\VBD\0|patients|older|,|had|. (l_nsubj) patients_0\NNS\9898892|developed (l_relcl) developed_2\VBD\1753788|who|hyperkalemia (l_dobj) hyperkalemia_3\NN\14299637|
D011188_D051437 NONE k(+_7\NNP\0|(|) (r_appos) hyperkalemia_5\NN\14299637|k(+ (r_dobj) developed_4\VBD\1753788|who|hyperkalemia (r_relcl) patients_2\NNS\9898892|developed (r_attr) were_1\VBD\0|cases|patients|( (l_nsubj) cases_0\NNS\7283608|l (l_appos) l_13\NN\13616054|>|meq|/|)|or|insufficiency (l_conj) insufficiency_17\NN\14462946|renal
D011188_D003920 NONE potassium_17\NN\14625458|serum (r_compound) levels_18\NNS\4916342|higher|baseline|potassium|and|doses (r_dobj) had_13\VBD\0|levels|,|and|were (r_conj) were_4\VBD\0|patients|older|,|had|. (l_acomp) older_5\JJR\0|and|likely (l_conj) likely_8\JJ\0|more|have (l_xcomp) have_10\VB\7846|to|diabetes (l_dobj) diabetes_11\NNS\14075199|
D011188_D003920 NONE potassium_22\NN\14625458| (r_compound) supplement_23\NN\6365467|potassium (r_compound) doses_24\NNS\3740161|lower|baseline|supplement (r_conj) levels_18\NNS\4916342|higher|baseline|potassium|and|doses (r_dobj) had_13\VBD\0|levels|,|and|were (r_conj) were_4\VBD\0|patients|older|,|had|. (l_acomp) older_5\JJR\0|and|likely (l_conj) likely_8\JJ\0|more|have (l_xcomp) have_10\VB\7846|to|diabetes (l_dobj) diabetes_11\NNS\14075199|
D003404_D051437 NONE creatinine_14\NN\0|higher|serum (r_conj) weight_9\NN\5009170|lower|baseline|body|and|creatinine (r_dobj) had_5\VBD\0|patients|weight|,|required|. (l_nsubj) patients_0\NNS\9898892|developed (l_relcl) developed_2\VBD\1753788|who|insufficiency (l_dobj) insufficiency_4\NN\14462946|renal
D049971_D051437 NONE thiazide_31\NN\3214670| (r_amod) diuretics_32\NNS\3247620|thiazide|than (r_pobj) with_30\IN\0|diuretics (r_prep) treated_29\VBN\2376958|to|be|with (r_xcomp) likely_26\JJ\0|more|treated (r_acomp) were_24\VBD\0|likely (r_conj) required_16\VBD\0|doses|,|and|were (r_conj) had_5\VBD\0|patients|weight|,|required|. (l_nsubj) patients_0\NNS\9898892|developed (l_relcl) developed_2\VBD\1753788|who|insufficiency (l_dobj) insufficiency_4\NN\14462946|renal
20528871
C104457_D015458 NONE nelarabine_3\NN\0|,|etoposide|in (l_prep) in_9\IN\13603305|leukaemia (l_pobj) leukaemia_18\NN\14239918|relapsed|/|refractory|lymphoblastic|and|lymphoma (l_conj) lymphoma_20\NN\14239918|
C104457_D015458 NONE nelarabine_6\JJ\0|arag (r_pobj) of_5\IN\0|nelarabine (r_prep) d_4\SYM\15089472|5|of (r_pobj) of_2\IN\0|d (r_prep) combination_1\NN\7951464|a|of (r_nsubjpass) used_28\VBN\0|combination|was|as|in|. (l_prep) in_32\IN\13603305|children (l_pobj) children_34\NNS\9622049|seven|with (l_prep) with_35\IN\0|leukaemia (l_pobj) leukaemia_42\NN\14239918|refractory|cell|or|lymphoma (l_conj) lymphoma_44\NN\14239918|
C104457_D015458 NONE arag_8\NNP\0|(|)|with (r_appos) nelarabine_6\JJ\0|arag (r_pobj) of_5\IN\0|nelarabine (r_prep) d_4\SYM\15089472|5|of (r_pobj) of_2\IN\0|d (r_prep) combination_1\NN\7951464|a|of (r_nsubjpass) used_28\VBN\0|combination|was|as|in|. (l_prep) in_32\IN\13603305|children (l_pobj) children_34\NNS\9622049|seven|with (l_prep) with_35\IN\0|leukaemia (l_pobj) leukaemia_42\NN\14239918|refractory|cell|or|lymphoma (l_conj) lymphoma_44\NN\14239918|
C104457_D016399 NONE nelarabine_3\NN\0|,|etoposide|in (l_prep) in_9\IN\13603305|leukaemia (l_pobj) leukaemia_18\NN\14239918|relapsed|/|refractory|lymphoblastic|and|lymphoma (l_conj) lymphoma_20\NN\14239918|
C104457_D016399 NONE nelarabine_6\JJ\0|arag (r_pobj) of_5\IN\0|nelarabine (r_prep) d_4\SYM\15089472|5|of (r_pobj) of_2\IN\0|d (r_prep) combination_1\NN\7951464|a|of (r_nsubjpass) used_28\VBN\0|combination|was|as|in|. (l_prep) in_32\IN\13603305|children (l_pobj) children_34\NNS\9622049|seven|with (l_prep) with_35\IN\0|leukaemia (l_pobj) leukaemia_42\NN\14239918|refractory|cell|or|lymphoma (l_conj) lymphoma_44\NN\14239918|
C104457_D016399 NONE arag_8\NNP\0|(|)|with (r_appos) nelarabine_6\JJ\0|arag (r_pobj) of_5\IN\0|nelarabine (r_prep) d_4\SYM\15089472|5|of (r_pobj) of_2\IN\0|d (r_prep) combination_1\NN\7951464|a|of (r_nsubjpass) used_28\VBN\0|combination|was|as|in|. (l_prep) in_32\IN\13603305|children (l_pobj) children_34\NNS\9622049|seven|with (l_prep) with_35\IN\0|leukaemia (l_pobj) leukaemia_42\NN\14239918|refractory|cell|or|lymphoma (l_conj) lymphoma_44\NN\14239918|
D005047_D015458 NONE etoposide_5\RB\0|,|and|cyclophosphamide (r_conj) nelarabine_3\NN\0|,|etoposide|in (l_prep) in_9\IN\13603305|leukaemia (l_pobj) leukaemia_18\NN\14239918|relapsed|/|refractory|lymphoblastic|and|lymphoma (l_conj) lymphoma_20\NN\14239918|
D005047_D015458 NONE etoposide_14\NN\0| (r_pobj) of_13\IN\0|etoposide (r_prep) d_12\SYM\15089472|5|of|vp (r_pobj) with_10\IN\0|d (r_prep) arag_8\NNP\0|(|)|with (r_appos) nelarabine_6\JJ\0|arag (r_pobj) of_5\IN\0|nelarabine (r_prep) d_4\SYM\15089472|5|of (r_pobj) of_2\IN\0|d (r_prep) combination_1\NN\7951464|a|of (r_nsubjpass) used_28\VBN\0|combination|was|as|in|. (l_prep) in_32\IN\13603305|children (l_pobj) children_34\NNS\9622049|seven|with (l_prep) with_35\IN\0|leukaemia (l_pobj) leukaemia_42\NN\14239918|refractory|cell|or|lymphoma (l_conj) lymphoma_44\NN\14239918|
D005047_D015458 NONE vp_16\NNP\0|(|)|and|cyclophosphamide|cpm|and|chemotherapy (r_appos) d_12\SYM\15089472|5|of|vp (r_pobj) with_10\IN\0|d (r_prep) arag_8\NNP\0|(|)|with (r_appos) nelarabine_6\JJ\0|arag (r_pobj) of_5\IN\0|nelarabine (r_prep) d_4\SYM\15089472|5|of (r_pobj) of_2\IN\0|d (r_prep) combination_1\NN\7951464|a|of (r_nsubjpass) used_28\VBN\0|combination|was|as|in|. (l_prep) in_32\IN\13603305|children (l_pobj) children_34\NNS\9622049|seven|with (l_prep) with_35\IN\0|leukaemia (l_pobj) leukaemia_42\NN\14239918|refractory|cell|or|lymphoma (l_conj) lymphoma_44\NN\14239918|
D005047_D016399 NONE etoposide_5\RB\0|,|and|cyclophosphamide (r_conj) nelarabine_3\NN\0|,|etoposide|in (l_prep) in_9\IN\13603305|leukaemia (l_pobj) leukaemia_18\NN\14239918|relapsed|/|refractory|lymphoblastic|and|lymphoma (l_conj) lymphoma_20\NN\14239918|
D005047_D016399 NONE etoposide_14\NN\0| (r_pobj) of_13\IN\0|etoposide (r_prep) d_12\SYM\15089472|5|of|vp (r_pobj) with_10\IN\0|d (r_prep) arag_8\NNP\0|(|)|with (r_appos) nelarabine_6\JJ\0|arag (r_pobj) of_5\IN\0|nelarabine (r_prep) d_4\SYM\15089472|5|of (r_pobj) of_2\IN\0|d (r_prep) combination_1\NN\7951464|a|of (r_nsubjpass) used_28\VBN\0|combination|was|as|in|. (l_prep) in_32\IN\13603305|children (l_pobj) children_34\NNS\9622049|seven|with (l_prep) with_35\IN\0|leukaemia (l_pobj) leukaemia_42\NN\14239918|refractory|cell|or|lymphoma (l_conj) lymphoma_44\NN\14239918|
D005047_D016399 NONE vp_16\NNP\0|(|)|and|cyclophosphamide|cpm|and|chemotherapy (r_appos) d_12\SYM\15089472|5|of|vp (r_pobj) with_10\IN\0|d (r_prep) arag_8\NNP\0|(|)|with (r_appos) nelarabine_6\JJ\0|arag (r_pobj) of_5\IN\0|nelarabine (r_prep) d_4\SYM\15089472|5|of (r_pobj) of_2\IN\0|d (r_prep) combination_1\NN\7951464|a|of (r_nsubjpass) used_28\VBN\0|combination|was|as|in|. (l_prep) in_32\IN\13603305|children (l_pobj) children_34\NNS\9622049|seven|with (l_prep) with_35\IN\0|leukaemia (l_pobj) leukaemia_42\NN\14239918|refractory|cell|or|lymphoma (l_conj) lymphoma_44\NN\14239918|
D003520_D015458 NONE cyclophosphamide_8\NN\0| (r_conj) etoposide_5\RB\0|,|and|cyclophosphamide (r_conj) nelarabine_3\NN\0|,|etoposide|in (l_prep) in_9\IN\13603305|leukaemia (l_pobj) leukaemia_18\NN\14239918|relapsed|/|refractory|lymphoblastic|and|lymphoma (l_conj) lymphoma_20\NN\14239918|
D003520_D015458 NONE cyclophosphamide_19\NN\0| (r_conj) vp_16\NNP\0|(|)|and|cyclophosphamide|cpm|and|chemotherapy (r_appos) d_12\SYM\15089472|5|of|vp (r_pobj) with_10\IN\0|d (r_prep) arag_8\NNP\0|(|)|with (r_appos) nelarabine_6\JJ\0|arag (r_pobj) of_5\IN\0|nelarabine (r_prep) d_4\SYM\15089472|5|of (r_pobj) of_2\IN\0|d (r_prep) combination_1\NN\7951464|a|of (r_nsubjpass) used_28\VBN\0|combination|was|as|in|. (l_prep) in_32\IN\13603305|children (l_pobj) children_34\NNS\9622049|seven|with (l_prep) with_35\IN\0|leukaemia (l_pobj) leukaemia_42\NN\14239918|refractory|cell|or|lymphoma (l_conj) lymphoma_44\NN\14239918|
D003520_D015458 NONE cpm_21\NNP\0|(|) (r_appos) vp_16\NNP\0|(|)|and|cyclophosphamide|cpm|and|chemotherapy (r_appos) d_12\SYM\15089472|5|of|vp (r_pobj) with_10\IN\0|d (r_prep) arag_8\NNP\0|(|)|with (r_appos) nelarabine_6\JJ\0|arag (r_pobj) of_5\IN\0|nelarabine (r_prep) d_4\SYM\15089472|5|of (r_pobj) of_2\IN\0|d (r_prep) combination_1\NN\7951464|a|of (r_nsubjpass) used_28\VBN\0|combination|was|as|in|. (l_prep) in_32\IN\13603305|children (l_pobj) children_34\NNS\9622049|seven|with (l_prep) with_35\IN\0|leukaemia (l_pobj) leukaemia_42\NN\14239918|refractory|cell|or|lymphoma (l_conj) lymphoma_44\NN\14239918|
D003520_D016399 NONE cyclophosphamide_8\NN\0| (r_conj) etoposide_5\RB\0|,|and|cyclophosphamide (r_conj) nelarabine_3\NN\0|,|etoposide|in (l_prep) in_9\IN\13603305|leukaemia (l_pobj) leukaemia_18\NN\14239918|relapsed|/|refractory|lymphoblastic|and|lymphoma (l_conj) lymphoma_20\NN\14239918|
D003520_D016399 NONE cyclophosphamide_19\NN\0| (r_conj) vp_16\NNP\0|(|)|and|cyclophosphamide|cpm|and|chemotherapy (r_appos) d_12\SYM\15089472|5|of|vp (r_pobj) with_10\IN\0|d (r_prep) arag_8\NNP\0|(|)|with (r_appos) nelarabine_6\JJ\0|arag (r_pobj) of_5\IN\0|nelarabine (r_prep) d_4\SYM\15089472|5|of (r_pobj) of_2\IN\0|d (r_prep) combination_1\NN\7951464|a|of (r_nsubjpass) used_28\VBN\0|combination|was|as|in|. (l_prep) in_32\IN\13603305|children (l_pobj) children_34\NNS\9622049|seven|with (l_prep) with_35\IN\0|leukaemia (l_pobj) leukaemia_42\NN\14239918|refractory|cell|or|lymphoma (l_conj) lymphoma_44\NN\14239918|
D003520_D016399 NONE cpm_21\NNP\0|(|) (r_appos) vp_16\NNP\0|(|)|and|cyclophosphamide|cpm|and|chemotherapy (r_appos) d_12\SYM\15089472|5|of|vp (r_pobj) with_10\IN\0|d (r_prep) arag_8\NNP\0|(|)|with (r_appos) nelarabine_6\JJ\0|arag (r_pobj) of_5\IN\0|nelarabine (r_prep) d_4\SYM\15089472|5|of (r_pobj) of_2\IN\0|d (r_prep) combination_1\NN\7951464|a|of (r_nsubjpass) used_28\VBN\0|combination|was|as|in|. (l_prep) in_32\IN\13603305|children (l_pobj) children_34\NNS\9622049|seven|with (l_prep) with_35\IN\0|leukaemia (l_pobj) leukaemia_42\NN\14239918|refractory|cell|or|lymphoma (l_conj) lymphoma_44\NN\14239918|
C104457_D009422 CID arag_8\NNP\0|the (r_pobj) to_6\IN\0|arag (r_prep) attributable_5\JJ\0|to (r_amod) effects_4\NNS\13245626|the|common|side|attributable (r_nsubj) included_9\VBD\0|effects|neuropathy|. (l_dobj) neuropathy_17\NN\14204950|grade|sensory|and|pain
C104457_D009422 CID arag_7\NN\0| (r_dobj) giving_6\VBG\1085793|arag|as (r_pcomp) of_5\IN\0|giving (r_prep) safety_4\NN\13920835|the|of (r_dobj) supports_2\VBZ\407535|experience|safety|,|monitored|. (l_advcl) monitored_24\VBN\2169352|although|toxicity|must|be|closely (l_nsubjpass) toxicity_20\NN\13576101|neurological
C104457_D059352 CID arag_8\NNP\0|the (r_pobj) to_6\IN\0|arag (r_prep) attributable_5\JJ\0|to (r_amod) effects_4\NNS\13245626|the|common|side|attributable (r_nsubj) included_9\VBD\0|effects|neuropathy|. (l_dobj) neuropathy_17\NN\14204950|grade|sensory|and|pain (l_conj) pain_20\NN\14299637|musculoskeletal
C104457_D006402 CID arag_8\NNP\0|alone (r_pobj) than_7\IN\0|arag (r_prep) combination_6\NN\7951464|the|than (r_pobj) for_4\IN\0|combination (r_prep) greater_3\JJR\0|for (r_acomp) was_2\VBD\0|toxicity|greater|,|was|. (l_nsubj) toxicity_1\NN\13576101|haematological
D005047_D009422 NONE etoposide_14\NN\0|and|cyclophosphamide (r_pobj) with_13\IN\0|etoposide (r_prep) synchrony_12\NN\13844690|with (r_pobj) in_11\IN\13603305|synchrony (r_prep) therapy_10\NN\657604|salvage|in (r_pobj) as_8\IN\14622893|therapy (r_prep) giving_6\VBG\1085793|arag|as (r_pcomp) of_5\IN\0|giving (r_prep) safety_4\NN\13920835|the|of (r_dobj) supports_2\VBZ\407535|experience|safety|,|monitored|. (l_advcl) monitored_24\VBN\2169352|although|toxicity|must|be|closely (l_nsubjpass) toxicity_20\NN\13576101|neurological
D003520_D009422 NONE cyclophosphamide_16\NN\0| (r_conj) etoposide_14\NN\0|and|cyclophosphamide (r_pobj) with_13\IN\0|etoposide (r_prep) synchrony_12\NN\13844690|with (r_pobj) in_11\IN\13603305|synchrony (r_prep) therapy_10\NN\657604|salvage|in (r_pobj) as_8\IN\14622893|therapy (r_prep) giving_6\VBG\1085793|arag|as (r_pcomp) of_5\IN\0|giving (r_prep) safety_4\NN\13920835|the|of (r_dobj) supports_2\VBZ\407535|experience|safety|,|monitored|. (l_advcl) monitored_24\VBN\2169352|although|toxicity|must|be|closely (l_nsubjpass) toxicity_20\NN\13576101|neurological
17175308
D020123_D011507 CID sirolimus_4\VB\0| (r_pobj) to_3\TO\0|sirolimus (r_prep) conversion_2\NN\7359599|to|in (r_pobj) after_1\IN\0|conversion (r_prep) proteinuria_0\NNP\14299637|after|.
D020123_D011507 CID sirolimus_11\NN\0| (r_compound) therapy_12\NN\657604|sirolimus (r_pobj) of_10\IN\0|therapy (r_prep) consequence_9\NN\34213|a|of (r_pobj) as_7\IN\14622893|consequence (r_prep) reported_6\VBN\831651|recently|,|proteinuria|has|been|as|,|remained|. (l_nsubjpass) proteinuria_3\NN\14299637|
D020123_D011507 CID srl_18\NN\0| (r_compound) conversion_19\NN\7359599|srl (r_pobj) after_17\IN\0|conversion (r_prep) displayed_14\VBD\2137132|proteinuria|after (l_dobj) proteinuria_16\NN\14299637|increased
D020123_D011507 CID srl_8\NN\0| (r_pobj) of_7\IN\0|srl (r_prep) use_6\NN\407535|the|of|as (r_pobj) after_4\IN\0|use (r_prep) was_2\VBD\0|proteinuria|common|after|. (l_nsubj) proteinuria_1\NN\14299637|heavy
D020123_D051436 NONE srl_13\NNP\0| (r_pobj) with_12\IN\0|srl (r_prep) treated_11\VBN\2376958|cohort|was|with|as|,|due|) (l_prep) due_18\IN\5174653|to|nephropathy (l_pobj) nephropathy_22\NN\14573196|chronic|allograft|(|can|(|n
D020123_D007674 NONE srl_13\NNP\0| (r_pobj) with_12\IN\0|srl (r_prep) treated_11\VBN\2376958|cohort|was|with|as|,|due|) (l_prep) due_18\IN\5174653|to|nephropathy (l_pobj) nephropathy_22\NN\14573196|chronic|allograft|(|can|(|n (l_advmod) can_24\VB\3094503|)
2265898
C009265_D004827 CID carbidopa_6\NN\0|epilepsy|/|administration|in|. (l_nsubj) epilepsy_1\NN\14085708|serial|caused
C009265_D007676 NONE levodopa_38\JJ\14604959|/ (r_compound) preparation_39\NN\407535|a|carbidopa|levodopa (r_dobj) receiving_34\VBG\2210855|had|;|both|had|been|preparation|;|and|had|. (l_ccomp) had_11\VBD\0|presented|:|patients|failure|,|on|but|begun (l_dobj) failure_14\NN\66216|chronic|renal
C009265_D001523 NONE levodopa_38\JJ\14604959|/ (r_compound) preparation_39\NN\407535|a|carbidopa|levodopa (r_dobj) receiving_34\VBG\2210855|had|;|both|had|been|preparation|;|and|had|. (l_conj) had_43\VBD\0|both|onset (l_dobj) onset_45\NN\7325190|the|of (l_prep) of_46\IN\0|seizures (l_pobj) seizures_50\NNS\14081375|hallucinosis|,|were (l_nmod) hallucinosis_47\NN\14373582|and|recurrent
C009265_D012640 NONE levodopa_38\JJ\14604959|/ (r_compound) preparation_39\NN\407535|a|carbidopa|levodopa (r_dobj) receiving_34\VBG\2210855|had|;|both|had|been|preparation|;|and|had|. (l_conj) had_43\VBD\0|both|onset (l_dobj) onset_45\NN\7325190|the|of (l_prep) of_46\IN\0|seizures (l_pobj) seizures_50\NNS\14081375|hallucinosis|,|were
18503483
D016559_D020968 CID tacrolimus_2\NN\0| (r_npadvmod) associated_4\VBN\628491|tacrolimus|- (r_amod) neuritis_6\NN\14336539|associated|brachial
C107135_D020968 NONE everolimus_10\NN\0| (r_pobj) to_9\TO\0|everolimus (r_prep) conversion_8\NN\7359599|to|in (r_pobj) after_7\IN\0|conversion (r_prep) recovery_0\NN\7357388|of|after|--|report|. (l_prep) of_1\IN\0|neuritis (l_pobj) neuritis_6\NN\14336539|associated|brachial
3629586
D015790_D006402 NONE cefonicid_4\NN\0|and|cefazedone (r_pobj) of_3\IN\0|cefonicid (r_prep) effects_2\NNS\13245626|the|hematologic|of|:|model|. (l_appos) model_13\NN\5888929|a|potential|of (l_prep) of_14\IN\0|hematotoxicity (l_pobj) hematotoxicity_16\NN\0|cephalosporin|in
D015790_D006402 NONE cefonicid_23\NN\0|400|mg/kg|or|cefazedone (r_dobj) receiving_18\VBG\2210855|cefonicid (r_acl) dogs_17\NNS\2083346|receiving (r_pobj) of_16\IN\0|dogs (r_prep) %_15\NN\0|50|of (r_pobj) in_12\IN\13603305|% (r_prep) occurred_11\VBD\0|in (r_conj) was_3\VBD\0|anemia|compromising|and|occurred|. (l_attr) compromising_6\NN\1035530|the|most|of (l_prep) of_7\IN\0|cytopenias (l_pobj) cytopenias_9\NNS\14189204|the
D015790_D006402 NONE cefonicid_16\NN\0| (r_amod) dogs_21\NNS\2083346|cefonicid|(|cefazedone)-treated (r_nsubj) showed_22\VBD\2137132|reproduced|;|dogs|period|compared|. (l_ccomp) reproduced_10\VBN\1621555|upon|,|syndrome|was|in (l_nsubjpass) syndrome_8\NN\5870365|the|hematologic
D015790_D006402 NONE cefonicid_9\NN\0|or|cefazedone (r_pobj) of_8\IN\0|cefonicid (r_prep) doses_7\NNS\3740161|high|of (r_pobj) of_5\IN\0|doses (r_prep) administration_4\NN\1133281|the|of|to (r_nsubj) induce_15\VB\1627355|that|administration|can|hematotoxicity|and|provides (l_dobj) hematotoxicity_16\NN\0|similar
D015790_D006402 NONE cefonicid_9\NN\0|or|cefazedone (r_pobj) of_8\IN\0|cefonicid (r_prep) doses_7\NNS\3740161|high|of (r_pobj) of_5\IN\0|doses (r_prep) administration_4\NN\1133281|the|of|to (r_nsubj) induce_15\VB\1627355|that|administration|can|hematotoxicity|and|provides (l_dobj) hematotoxicity_16\NN\0|similar (l_amod) similar_17\JJ\0|to (l_prep) to_18\IN\0|dyscrasias (l_pobj) dyscrasias_24\NNS\14052046|the|induced|blood|described
C021341_D006402 NONE cefazedone_6\NN\0|in (r_conj) cefonicid_4\NN\0|and|cefazedone (r_pobj) of_3\IN\0|cefonicid (r_prep) effects_2\NNS\13245626|the|hematologic|of|:|model|. (l_appos) model_13\NN\5888929|a|potential|of (l_prep) of_14\IN\0|hematotoxicity (l_pobj) hematotoxicity_16\NN\0|cephalosporin|in
C021341_D006402 NONE cefazedone_29\NN\0|540|840|mg/kg (r_conj) cefonicid_23\NN\0|400|mg/kg|or|cefazedone (r_dobj) receiving_18\VBG\2210855|cefonicid (r_acl) dogs_17\NNS\2083346|receiving (r_pobj) of_16\IN\0|dogs (r_prep) %_15\NN\0|50|of (r_pobj) in_12\IN\13603305|% (r_prep) occurred_11\VBD\0|in (r_conj) was_3\VBD\0|anemia|compromising|and|occurred|. (l_attr) compromising_6\NN\1035530|the|most|of (l_prep) of_7\IN\0|cytopenias (l_pobj) cytopenias_9\NNS\14189204|the
C021341_D006402 NONE cefazedone)-treated_20\VBN\0|but|not (r_amod) dogs_21\NNS\2083346|cefonicid|(|cefazedone)-treated (r_nsubj) showed_22\VBD\2137132|reproduced|;|dogs|period|compared|. (l_ccomp) reproduced_10\VBN\1621555|upon|,|syndrome|was|in (l_nsubjpass) syndrome_8\NN\5870365|the|hematologic
C021341_D006402 NONE cefazedone_11\NN\0| (r_conj) cefonicid_9\NN\0|or|cefazedone (r_pobj) of_8\IN\0|cefonicid (r_prep) doses_7\NNS\3740161|high|of (r_pobj) of_5\IN\0|doses (r_prep) administration_4\NN\1133281|the|of|to (r_nsubj) induce_15\VB\1627355|that|administration|can|hematotoxicity|and|provides (l_dobj) hematotoxicity_16\NN\0|similar
C021341_D006402 NONE cefazedone_11\NN\0| (r_conj) cefonicid_9\NN\0|or|cefazedone (r_pobj) of_8\IN\0|cefonicid (r_prep) doses_7\NNS\3740161|high|of (r_pobj) of_5\IN\0|doses (r_prep) administration_4\NN\1133281|the|of|to (r_nsubj) induce_15\VB\1627355|that|administration|can|hematotoxicity|and|provides (l_dobj) hematotoxicity_16\NN\0|similar (l_amod) similar_17\JJ\0|to (l_prep) to_18\IN\0|dyscrasias (l_pobj) dyscrasias_24\NNS\14052046|the|induced|blood|described
D002511_D006402 NONE cephalosporin_15\JJ\2716866| (r_amod) hematotoxicity_16\NN\0|cephalosporin|in
D002511_D006402 NONE cephalosporin_0\JJ\2716866| (r_amod) antibiotics_1\NNS\2716205|cephalosporin (r_nsubj) cause_2\VBP\7323922|antibiotics|variety|characterized|. (l_dobj) variety_4\NN\7951464|a|of|, (l_prep) of_5\IN\0|disturbances (l_pobj) disturbances_7\NNS\407535|hematologic|in
D002511_D006402 NONE cephalosporin_4\NN\2716866|either (r_pobj) with_2\IN\0|cephalosporin (r_prep) rechallenge_1\VB\0|with (r_pobj) upon_0\IN\0|rechallenge (r_prep) reproduced_10\VBN\1621555|upon|,|syndrome|was|in (l_nsubjpass) syndrome_8\NN\5870365|the|hematologic
D002511_D006402 NONE cephalosporin_20\NN\2716866| (r_advmod) induced_22\VBN\1627355|cephalosporin|- (r_amod) dyscrasias_24\NNS\14052046|the|induced|blood|described (r_pobj) to_18\IN\0|dyscrasias (r_prep) similar_17\JJ\0|to (r_amod) hematotoxicity_16\NN\0|similar
D002511_D006402 NONE cephalosporin_20\NN\2716866| (r_advmod) induced_22\VBN\1627355|cephalosporin|- (r_amod) dyscrasias_24\NNS\14052046|the|induced|blood|described
D015790_D064420 NONE cefonicid_10\NN\0|or|cefazedone (r_pobj) of_9\IN\0|cefonicid (r_prep) administration_8\NN\1133281|the|intravenous|of|to (r_nsubj) caused_16\VBD\1617192|in|,|administration|incidence|thrombocytopenia|. (l_prep) in_0\IN\13603305|studies (l_pobj) studies_4\NNS\635850|four|subacute|toxicity (l_compound) toxicity_3\NN\13576101|
D015790_D000740 CID cefonicid_10\NN\0|or|cefazedone (r_pobj) of_9\IN\0|cefonicid (r_prep) administration_8\NN\1133281|the|intravenous|of|to (r_nsubj) caused_16\VBD\1617192|in|,|administration|incidence|thrombocytopenia|. (l_dobj) incidence_21\NN\13821570|a|dependent|of (l_prep) of_22\IN\0|anemia (l_pobj) anemia_23\NN\14189204|,|neutropenia
D015790_D000740 CID cefonicid_23\NN\0|400|mg/kg|or|cefazedone (r_dobj) receiving_18\VBG\2210855|cefonicid (r_acl) dogs_17\NNS\2083346|receiving (r_pobj) of_16\IN\0|dogs (r_prep) %_15\NN\0|50|of (r_pobj) in_12\IN\13603305|% (r_prep) occurred_11\VBD\0|in (r_conj) was_3\VBD\0|anemia|compromising|and|occurred|. (l_nsubj) anemia_2\NN\14189204|a|nonregenerative
D015790_D009503 CID cefonicid_10\NN\0|or|cefazedone (r_pobj) of_9\IN\0|cefonicid (r_prep) administration_8\NN\1133281|the|intravenous|of|to (r_nsubj) caused_16\VBD\1617192|in|,|administration|incidence|thrombocytopenia|. (l_dobj) incidence_21\NN\13821570|a|dependent|of (l_prep) of_22\IN\0|anemia (l_pobj) anemia_23\NN\14189204|,|neutropenia (l_conj) neutropenia_25\NN\14196405|,|and
D015790_D013921 CID cefonicid_10\NN\0|or|cefazedone (r_pobj) of_9\IN\0|cefonicid (r_prep) administration_8\NN\1133281|the|intravenous|of|to (r_nsubj) caused_16\VBD\1617192|in|,|administration|incidence|thrombocytopenia|. (l_ccomp) thrombocytopenia_28\NN\14189204|after
C021341_D064420 NONE cefazedone_12\NN\0| (r_conj) cefonicid_10\NN\0|or|cefazedone (r_pobj) of_9\IN\0|cefonicid (r_prep) administration_8\NN\1133281|the|intravenous|of|to (r_nsubj) caused_16\VBD\1617192|in|,|administration|incidence|thrombocytopenia|. (l_prep) in_0\IN\13603305|studies (l_pobj) studies_4\NNS\635850|four|subacute|toxicity (l_compound) toxicity_3\NN\13576101|
C021341_D000740 CID cefazedone_12\NN\0| (r_conj) cefonicid_10\NN\0|or|cefazedone (r_pobj) of_9\IN\0|cefonicid (r_prep) administration_8\NN\1133281|the|intravenous|of|to (r_nsubj) caused_16\VBD\1617192|in|,|administration|incidence|thrombocytopenia|. (l_dobj) incidence_21\NN\13821570|a|dependent|of (l_prep) of_22\IN\0|anemia (l_pobj) anemia_23\NN\14189204|,|neutropenia
C021341_D000740 CID cefazedone_29\NN\0|540|840|mg/kg (r_conj) cefonicid_23\NN\0|400|mg/kg|or|cefazedone (r_dobj) receiving_18\VBG\2210855|cefonicid (r_acl) dogs_17\NNS\2083346|receiving (r_pobj) of_16\IN\0|dogs (r_prep) %_15\NN\0|50|of (r_pobj) in_12\IN\13603305|% (r_prep) occurred_11\VBD\0|in (r_conj) was_3\VBD\0|anemia|compromising|and|occurred|. (l_nsubj) anemia_2\NN\14189204|a|nonregenerative
C021341_D009503 CID cefazedone_12\NN\0| (r_conj) cefonicid_10\NN\0|or|cefazedone (r_pobj) of_9\IN\0|cefonicid (r_prep) administration_8\NN\1133281|the|intravenous|of|to (r_nsubj) caused_16\VBD\1617192|in|,|administration|incidence|thrombocytopenia|. (l_dobj) incidence_21\NN\13821570|a|dependent|of (l_prep) of_22\IN\0|anemia (l_pobj) anemia_23\NN\14189204|,|neutropenia (l_conj) neutropenia_25\NN\14196405|,|and
C021341_D013921 CID cefazedone_12\NN\0| (r_conj) cefonicid_10\NN\0|or|cefazedone (r_pobj) of_9\IN\0|cefonicid (r_prep) administration_8\NN\1133281|the|intravenous|of|to (r_nsubj) caused_16\VBD\1617192|in|,|administration|incidence|thrombocytopenia|. (l_ccomp) thrombocytopenia_28\NN\14189204|after
11706060
D019344_D009202 NONE lactate_8\NN\14850483|plasma (r_dobj) elevates_6\VBZ\2391803|lactate|in (r_conj) causes_3\VBZ\7323922|combined|therapy|cardiomyopathy|and|elevates|. (l_advmod) cardiomyopathy_4\NN\14103288|
D019344_D009202 NONE lactate_18\NN\14850483|elevated|plasma|(|la|)|in (r_pobj) in_15\IN\13603305|lactate (r_conj) in_9\IN\13603305|cm|and|in (l_pobj) cm_12\NNP\13649268|cardiomyopathy|(|) (l_amod) cardiomyopathy_10\NN\14103288|
D019344_D009202 NONE lactate_18\NN\14850483|elevated|plasma|(|la|)|in (r_pobj) in_15\IN\13603305|lactate (r_conj) in_9\IN\13603305|cm|and|in (l_pobj) cm_12\NNP\13649268|cardiomyopathy|(|)
D019344_D009202 NONE la_20\NNP\14625458| (r_appos) lactate_18\NN\14850483|elevated|plasma|(|la|)|in (r_pobj) in_15\IN\13603305|lactate (r_conj) in_9\IN\13603305|cm|and|in (l_pobj) cm_12\NNP\13649268|cardiomyopathy|(|) (l_amod) cardiomyopathy_10\NN\14103288|
D019344_D009202 NONE la_20\NNP\14625458| (r_appos) lactate_18\NN\14850483|elevated|plasma|(|la|)|in (r_pobj) in_15\IN\13603305|lactate (r_conj) in_9\IN\13603305|cm|and|in (l_pobj) cm_12\NNP\13649268|cardiomyopathy|(|)
D019344_D009202 NONE la_41\NNP\14625458|plasma (r_pobj) of_39\IN\0|la (r_prep) determination_38\NN\43195|of (r_conj) underwent_7\VBD\109660|at|,|mice|echocardiography|,|and|determination|. (l_dobj) echocardiography_8\RB\177127|,|quantitation (l_appos) quantitation_10\NN\0|of|encoding (l_prep) of_11\IN\0|abundance (l_pobj) abundance_12\NN\5108740|of (l_prep) of_13\IN\0|markers (l_pobj) markers_15\NNS\21939|molecular|of (l_prep) of_16\IN\0|cm (l_pobj) cm_17\NNP\13649268|
D019344_D009202 NONE la_10\NNP\14625458|elevated|in (r_pobj) with_8\IN\0|la (r_prep) cm_7\NNP\13649268|mitochondrial|with
D019344_D000163 NONE lactate_8\NN\14850483|plasma (r_dobj) elevates_6\VBZ\2391803|lactate|in (l_prep) in_9\IN\13603305|mice (l_pobj) mice_12\NNS\2329401|transgenic|aids (l_compound) aids_11\NNP\13974317|
D019344_D000163 NONE lactate_18\NN\14850483|elevated|plasma|(|la|)|in (l_prep) in_22\IN\13603305|aids (l_pobj) aids_23\NNP\13974317|
D019344_D000163 NONE la_20\NNP\14625458| (r_appos) lactate_18\NN\14850483|elevated|plasma|(|la|)|in (l_prep) in_22\IN\13603305|aids (l_pobj) aids_23\NNP\13974317|
D019344_D000163 NONE la_10\NNP\14625458|elevated|in (l_prep) in_11\IN\13603305|mice (l_pobj) mice_14\NNS\2329401|transgenic (l_compound) transgenic_13\JJ\0|aids (l_compound) aids_12\NNP\13974317|
D019344_D028361 NONE lactate_18\NN\14850483|elevated|plasma|(|la|)|in (r_pobj) in_15\IN\13603305|lactate (r_conj) in_9\IN\13603305|cm|and|in (r_prep) implicated_8\VBN\2677097|therapy|is|in|through|. (l_prep) through_24\IN\0|mechanisms (l_pobj) mechanisms_25\NNS\13446390|of (l_prep) of_26\IN\0|dysfunction (l_pobj) dysfunction_28\NN\14204950|mitochondrial
D019344_D028361 NONE la_20\NNP\14625458| (r_appos) lactate_18\NN\14850483|elevated|plasma|(|la|)|in (r_pobj) in_15\IN\13603305|lactate (r_conj) in_9\IN\13603305|cm|and|in (r_prep) implicated_8\VBN\2677097|therapy|is|in|through|. (l_prep) through_24\IN\0|mechanisms (l_pobj) mechanisms_25\NNS\13446390|of (l_prep) of_26\IN\0|dysfunction (l_pobj) dysfunction_28\NN\14204950|mitochondrial
D015215_D000163 NONE zidovudine_41\NN\3834836| (r_nmod) lamivudine_43\NN\3834836|zidovudine|,|,|and|indinavir (r_pobj) of_40\IN\0|lamivudine (r_prep) combination_39\NN\7951464|the|haart|of (r_pobj) with_36\IN\0|combination (r_prep) treated_35\VBN\2376958|determine|,|mice|were|with|. (l_nsubjpass) mice_15\NNS\2329401|old|hemizygous|transgenic|aids|pol (l_compound) aids_14\NNP\13974317|
D019259_D000163 NONE lamivudine_43\NN\3834836|zidovudine|,|,|and|indinavir (r_pobj) of_40\IN\0|lamivudine (r_prep) combination_39\NN\7951464|the|haart|of (r_pobj) with_36\IN\0|combination (r_prep) treated_35\VBN\2376958|determine|,|mice|were|with|. (l_nsubjpass) mice_15\NNS\2329401|old|hemizygous|transgenic|aids|pol (l_compound) aids_14\NNP\13974317|
D019469_D000163 NONE indinavir_46\NNS\4013993|or|control|for (r_conj) lamivudine_43\NN\3834836|zidovudine|,|,|and|indinavir (r_pobj) of_40\IN\0|lamivudine (r_prep) combination_39\NN\7951464|the|haart|of (r_pobj) with_36\IN\0|combination (r_prep) treated_35\VBN\2376958|determine|,|mice|were|with|. (l_nsubjpass) mice_15\NNS\2329401|old|hemizygous|transgenic|aids|pol (l_compound) aids_14\NNP\13974317|
D002118_D009202 NONE calcium_30\NN\14625458| (r_compound) atpase_31\NNP\0|sarcoplasmic|calcium|[|serca2|]|) (r_conj) encoding_21\VBG\614489|(|ventricular|mrna|factor|and|atpase (r_parataxis) quantitation_10\NN\0|of|encoding (l_prep) of_11\IN\0|abundance (l_pobj) abundance_12\NN\5108740|of (l_prep) of_13\IN\0|markers (l_pobj) markers_15\NNS\21939|molecular|of (l_prep) of_16\IN\0|cm (l_pobj) cm_17\NNP\13649268|
9754849
D008691_D002819 CID methadone_7\NN\3808564| (r_pobj) to_6\IN\0|methadone (r_prep) adjustment_5\NN\7357388|rapid|to (r_pobj) with_3\IN\0|adjustment (r_prep) associated_2\VBN\628491|with (r_acl) movements_1\NNS\191142|choreoathetoid|associated|.
D008691_D002819 CID methadone_24\NN\3808564|the|selective|opioid|agonist (r_pobj) to_16\IN\0|methadone (r_prep) adjustment_15\NN\7357388|rapid|to|in (r_pobj) by_13\IN\0|adjustment (r_agent) induced_12\VBN\1627355|both|transiently|by (r_xcomp) choreoathetoid_8\JJ\0|movements|induced (l_dobj) movements_9\NNS\191142|
D003042_D002819 CID cocaine_12\NN\3492717|but|opiates (r_pobj) with_11\IN\0|cocaine (r_prep) intoxications_10\NNS\14034177|with (r_pobj) during_9\IN\0|intoxications (r_prep) be_5\VB\14625458|to|abnormalities|during (r_xcomp) known_3\VBN\0|hyperkinesias|are|be|. (l_nsubjpass) hyperkinesias_1\NNS\0|choreatiform
D003042_D002819 CID cocaine_32\NN\3492717| (r_conj) heroine_30\NN\5929008|and|cocaine (r_dobj) abusing_29\VBG\2514187|previously|heroine (r_acl) inpatient_27\NN\10405694|an|abusing (r_pobj) in_25\IN\13603305|inpatient (r_prep) adjustment_15\NN\7357388|rapid|to|in (r_pobj) by_13\IN\0|adjustment (r_agent) induced_12\VBN\1627355|both|transiently|by (r_xcomp) choreoathetoid_8\JJ\0|movements|induced (l_dobj) movements_9\NNS\191142|
D003042_D006948 CID cocaine_12\NN\3492717|but|opiates (r_pobj) with_11\IN\0|cocaine (r_prep) intoxications_10\NNS\14034177|with (r_pobj) during_9\IN\0|intoxications (r_prep) be_5\VB\14625458|to|abnormalities|during (r_xcomp) known_3\VBN\0|hyperkinesias|are|be|. (l_nsubjpass) hyperkinesias_1\NNS\0|choreatiform
D003042_D020820 NONE cocaine_12\NN\3492717|but|opiates (r_pobj) with_11\IN\0|cocaine (r_prep) intoxications_10\NNS\14034177|with (r_pobj) during_9\IN\0|intoxications (r_prep) be_5\VB\14625458|to|abnormalities|during (l_attr) abnormalities_8\NNS\14034177|occasional|movement
D003932_D002819 NONE heroine_30\NN\5929008|and|cocaine (r_dobj) abusing_29\VBG\2514187|previously|heroine (r_acl) inpatient_27\NN\10405694|an|abusing (r_pobj) in_25\IN\13603305|inpatient (r_prep) adjustment_15\NN\7357388|rapid|to|in (r_pobj) by_13\IN\0|adjustment (r_agent) induced_12\VBN\1627355|both|transiently|by (r_xcomp) choreoathetoid_8\JJ\0|movements|induced (l_dobj) movements_9\NNS\191142|
18004067
D000431_D017114 NONE alcohol_8\NN\7881800| (r_compound) consumption_9\NN\13440063|regular|alcohol|ingesting (r_pobj) with_6\IN\0|consumption (r_prep) patients_5\NNS\9898892|two|with (r_pobj) in_3\IN\13603305|patients (r_prep) failure_2\NN\66216|acute|liver|in|.
D000082_D017114 NONE paracetamol_11\NN\0| (r_dobj) ingesting_10\VBG\0|paracetamol|at (r_acl) consumption_9\NN\13440063|regular|alcohol|ingesting (r_pobj) with_6\IN\0|consumption (r_prep) patients_5\NNS\9898892|two|with (r_pobj) in_3\IN\13603305|patients (r_prep) failure_2\NN\66216|acute|liver|in|.
D000431_D056486 NONE alcohol_4\NN\7881800| (r_pobj) of_3\IN\0|alcohol (r_prep) role_2\NN\719494|the|possible|of|in (l_prep) in_5\IN\13603305|development (l_pobj) development_7\NN\248977|the|of (l_prep) of_8\IN\0|hepatotoxicity (l_pobj) hepatotoxicity_9\NN\0|associated
D000082_D056486 CID paracetamol_15\JJ\0|(|acetaminophen|) (r_pobj) of_14\IN\0|paracetamol (r_prep) doses_13\NNS\3740161|therapeutic|of (r_pobj) with_11\IN\0|doses (r_prep) associated_10\VBN\628491|with (r_acl) hepatotoxicity_9\NN\0|associated
D000082_D056486 CID acetaminophen_17\NN\2707683| (r_appos) paracetamol_15\JJ\0|(|acetaminophen|) (r_pobj) of_14\IN\0|paracetamol (r_prep) doses_13\NNS\3740161|therapeutic|of (r_pobj) with_11\IN\0|doses (r_prep) associated_10\VBN\628491|with (r_acl) hepatotoxicity_9\NN\0|associated
D000082_D056486 CID paracetamol_15\NN\0| (r_pobj) of_14\IN\0|paracetamol (r_prep) doses_13\NNS\3740161|therapeutic|of (r_pobj) with_11\IN\0|doses (r_prep) treated_10\VBN\2376958|with (r_acl) patients_9\NNS\9898892|treated (r_pobj) in_8\IN\13603305|patients (r_prep) development_5\NN\248977|the|of|in (l_prep) of_6\IN\0|hepatotoxicity (l_pobj) hepatotoxicity_7\NN\0|
D000431_D017093 NONE alcohol_9\NN\7881800| (r_pobj) of_8\IN\0|alcohol (r_prep) consumers_7\NNS\10741590|regular|of (r_attr) were_5\VBD\0|who|consumers|and|developed (l_conj) developed_12\VBD\1753788|who|failure|within|and|stopping (l_dobj) failure_14\NN\66216|liver
D000431_D017093 NONE alcohol_24\NN\7881800| (r_compound) consumption_25\NN\13440063|alcohol (r_dobj) stopping_23\VBG\3323703|consumption|treated (r_conj) developed_12\VBD\1753788|who|failure|within|and|stopping (l_dobj) failure_14\NN\66216|liver
D000431_D017093 NONE alcohol_10\NN\7881800| (r_pobj) of_9\IN\0|alcohol (r_prep) consumption_8\NN\13440063|e.g.|regular|of (r_appos) factors_4\NNS\7326557|risk|,|consumption (r_pobj) with_2\IN\0|factors (r_prep) patients_1\NNS\9898892|with (r_pobj) in_0\IN\13603305|patients (r_prep) is_14\VBZ\0|in|,|failure|possible|ingested|. (l_nsubj) failure_13\NN\66216|liver
D000082_D017093 CID paracetamol_32\JJ\0|g (r_advmod) 4_30\CD\13741022|paracetamol (r_nummod) day_34\NN\15154774|4|/ (r_pobj) with_29\IN\0|day (r_prep) treated_28\VBN\2376958|while|being|with (r_advcl) stopping_23\VBG\3323703|consumption|treated (r_conj) developed_12\VBD\1753788|who|failure|within|and|stopping (l_dobj) failure_14\NN\66216|liver
9495837
C087567_D000647 NONE /-)-pg-9_2\.\0|mg|kg-1|) (r_nsubj) was_11\VBD\0|(|+|/-)-pg-9|able|. (l_acomp) able_12\JJ\0|prevent (l_xcomp) prevent_14\VB\0|to|amnesia (l_dobj) amnesia_15\NN\5669934|induced
C087567_D000647 NONE /-)-pg-9_5\NFP\0|for|, (r_conj) of_2\IN\0|(|+|/-)-pg-9 (r_prep) profiles_1\NNS\6999802|affinity|of|determined|deferens (r_nsubj) shown_44\VBN\2137132|profiles|,|have|ratio|+|/-)-pg-9|. (l_dobj) ratio_48\NN\13815152|an|m4/m1|selectivity|of|be (l_relcl) be_53\VB\14625458|that|might|responsible (l_acomp) responsible_54\JJ\0|for (l_prep) for_55\IN\0|antinociception (l_pobj) antinociception_57\NN\0|the|and|effect|induced (l_conj) effect_63\NN\34213|the|amnesic (l_amod) amnesic_62\JJ\10158756|anti|-
C087567_D000647 NONE /-)-pg-9_68\NFP\0|through (r_punct) shown_44\VBN\2137132|profiles|,|have|ratio|+|/-)-pg-9|. (l_dobj) ratio_48\NN\13815152|an|m4/m1|selectivity|of|be (l_relcl) be_53\VB\14625458|that|might|responsible (l_acomp) responsible_54\JJ\0|for (l_prep) for_55\IN\0|antinociception (l_pobj) antinociception_57\NN\0|the|and|effect|induced (l_conj) effect_63\NN\34213|the|amnesic (l_amod) amnesic_62\JJ\10158756|anti|-
D012601_D000647 CID scopolamine_18\NN\14712692|(|kg-1|in (r_pobj) by_17\IN\0|scopolamine (r_agent) induced_16\VBN\1627355|by (r_acl) amnesia_15\NN\5669934|induced
D004025_D000647 CID dicyclomine_26\NN\0|(|kg-1|) (r_conj) kg-1_22\NNP\0|mg|i.p.|)|and|dicyclomine (r_appos) scopolamine_18\NN\14712692|(|kg-1|in (r_pobj) by_17\IN\0|scopolamine (r_agent) induced_16\VBN\1627355|by (r_acl) amnesia_15\NN\5669934|induced
D000109_D000647 NONE acetylcholine_73\NN\14807558| (r_amod) levels_75\NNS\4916342|acetylcholine|extracellular (r_pobj) in_72\IN\13603305|levels (r_prep) increase_71\NN\13576355|an|in (r_pobj) through_69\IN\0|increase (r_prep) /-)-pg-9_68\NFP\0|through (r_punct) shown_44\VBN\2137132|profiles|,|have|ratio|+|/-)-pg-9|. (l_dobj) ratio_48\NN\13815152|an|m4/m1|selectivity|of|be (l_relcl) be_53\VB\14625458|that|might|responsible (l_acomp) responsible_54\JJ\0|for (l_prep) for_55\IN\0|antinociception (l_pobj) antinociception_57\NN\0|the|and|effect|induced (l_conj) effect_63\NN\34213|the|amnesic (l_amod) amnesic_62\JJ\10158756|anti|-
16403073
D007654_D016171 CID ketoconazole_0\NNP\0| (r_nsubj) induced_1\VBD\1627355|ketoconazole|pointes|without|. (l_dobj) pointes_4\FW\831651|torsades|de
D007654_D016171 CID ketoconazole_24\RB\0| (r_dobj) taking_23\VBG\37396|ketoconazole|for (r_pcomp) after_22\IN\0|taking (r_prep) torsades_16\NNS\0|pointes|after (l_dobj) pointes_18\FW\831651|de|(|tdp|)
D007654_D016171 CID ketoconazole_24\RB\0| (r_dobj) taking_23\VBG\37396|ketoconazole|for (r_pcomp) after_22\IN\0|taking (r_prep) torsades_16\NNS\0|pointes|after (l_dobj) pointes_18\FW\831651|de|(|tdp|) (l_appos) tdp_20\NN\0|
D007654_D016171 CID ketoconazole_13\RB\0|alone (r_nsubj) prolong_16\VB\317700|that|by|,|ketoconazole|may|interval|and|induce (l_conj) induce_20\VB\1627355|tdp. (l_dobj) tdp._21\NN\0|
D007654_D003324 NONE ketoconazole_24\RB\0| (r_dobj) taking_23\VBG\37396|ketoconazole|for (r_pcomp) after_22\IN\0|taking (r_prep) torsades_16\NNS\0|pointes|after (r_conj) developed_9\VBD\1753788|who|interval|and|torsades (r_relcl) woman_3\NN\9605289|a|with|developed (l_prep) with_4\IN\0|disease (l_pobj) disease_7\NN\14061805|coronary|artery
D007654_D008133 CID ketoconazole_24\RB\0| (r_dobj) taking_23\VBG\37396|ketoconazole|for (r_pcomp) after_22\IN\0|taking (r_prep) torsades_16\NNS\0|pointes|after (r_conj) developed_9\VBD\1753788|who|interval|and|torsades (l_dobj) interval_14\NN\33615|a|prolonged|qt
D007654_D008133 CID ketoconazole_5\JJ\0| (r_nsubjpass) administered_7\VBN\2436349|when|ketoconazole|is|to (l_prep) to_8\IN\0|patients (l_pobj) patients_9\NNS\9898892|with (l_prep) with_10\IN\0|factors (l_pobj) factors_12\NNS\7326557|risk|for (l_prep) for_13\IN\0|syndrome (l_pobj) syndrome_17\NN\5870365|acquired|long|qt
D007654_D009181 NONE ketoconazole_24\RB\0| (r_dobj) taking_23\VBG\37396|ketoconazole|for (l_prep) for_25\IN\0|treatment (l_pobj) treatment_26\NN\654885|of (l_prep) of_27\IN\0|infection (l_pobj) infection_29\NN\14052046|fungal
12757899
D004958_D012640 NONE estradiol_0\NN\14749794| (r_nsubj) reduces_1\VBZ\441445|estradiol|injury|but|in|. (l_dobj) injury_6\NN\14052046|induced|hippocampal|in (l_amod) induced_4\VBN\1627355|seizure|- (l_npadvmod) seizure_2\NN\14081375|
D004958_D012640 NONE estradiol_7\NN\14749794| (r_pobj) of_6\IN\0|estradiol (r_prep) effects_5\NNS\13245626|the|of|on (l_prep) on_8\IN\0|threshold (l_pobj) threshold_10\NN\15265518|seizure|and|damage (l_compound) seizure_9\NN\14081375|
D004958_D001930 NONE estradiol_0\NN\14749794| (r_nsubj) reduces_1\VBZ\441445|estradiol|injury|but|in|. (l_dobj) injury_6\NN\14052046|induced|hippocampal|in
D007608_D001930 NONE acid_10\NN\14818238| (r_npadvmod) induced_12\VBN\1627355|acid|- (r_amod) status_13\NN\24720|kainic|induced|se (r_pobj) by_8\IN\0|status (r_agent) induced_7\VBN\1627355|by (r_advcl) protect_1\VBP\1127795|estrogens|rats|induced|)|. (l_dobj) rats_3\NNS\2329401|ovariectomized|from (l_prep) from_4\IN\0|injury (l_pobj) injury_6\NN\14052046|hippocampal
D007608_D013226 NONE acid_10\NN\14818238| (r_npadvmod) induced_12\VBN\1627355|acid|- (r_amod) status_13\NN\24720|kainic|induced|se (l_appos) se_16\NNP\14724645|epilepticus|( (l_amod) epilepticus_14\NN\0|
D007608_D013226 NONE acid_10\NN\14818238| (r_npadvmod) induced_12\VBN\1627355|acid|- (r_amod) status_13\NN\24720|kainic|induced|se (l_appos) se_16\NNP\14724645|epilepticus|(
D004958_D013226 NONE estradiol_7\NN\14749794|17beta|- (r_pobj) of_4\IN\0|estradiol (r_prep) effects_3\NNS\13245626|the|of|in|and|rats (l_conj) rats_14\NNS\2329401|ovariectomized|female|subjected (l_acl) subjected_15\VBN\137313|to (l_prep) to_16\IN\0|se (l_pobj) se_22\NNP\14724645|induced
D008094_D013226 CID lithium_17\NN\14625458| (r_compound) pilocarpine_19\NN\14712692|lithium|- (r_npadvmod) induced_21\VBN\1627355|pilocarpine|- (r_amod) se_22\NNP\14724645|induced
D010862_D013226 CID pilocarpine_19\NN\14712692|lithium|- (r_npadvmod) induced_21\VBN\1627355|pilocarpine|- (r_amod) se_22\NNP\14724645|induced
D012834_D013226 NONE silver_3\NN\14821043| (r_npadvmod) stained_5\VBN\283090|silver|- (r_amod) ca3_6\NN\0|stained|and|neurons (r_pobj) of_2\IN\0|ca3 (r_prep) extent_1\NN\13939892|the|of (r_nsubjpass) evaluated_12\VBN\670261|extent|was|after|. (l_prep) after_15\IN\0|days|se (l_pobj) se_16\NNP\14724645|
15275829
D000109_D012640 NONE acetylcholine_5\NN\14807558| (r_compound) subunits_7\NNS\13604718|alpha3|nicotinic|acetylcholine|receptor (r_nsubj) are_8\VBP\13600404|subunits|necessary|for|. (l_prep) for_10\IN\0|seizures (l_pobj) seizures_14\NNS\14081375|induced|and|hypolocomotion
D000109_D012640 NONE acetylcholine_5\NN\14807558| (r_compound) receptors_6\NNS\5225602|nicotinic|acetylcholine|(|nachrs|) (r_pobj) to_3\IN\0|receptors (r_prep) binding_0\NN\4688246|of|to (r_nsubj) elicits_10\VBZ\1617192|binding|series|. (l_dobj) series_12\NN\8456993|a|of (l_prep) of_13\IN\0|behaviors (l_pobj) behaviors_17\NNS\407535|dependent|go (l_relcl) go_19\VBP\15291801|that|from|,|to (l_prep) to_29\IN\0|seizures (l_pobj) seizures_30\NNS\14081375|and|death
D000109_D006948 NONE acetylcholine_5\NN\14807558| (r_compound) subunits_7\NNS\13604718|alpha3|nicotinic|acetylcholine|receptor (r_nsubj) are_8\VBP\13600404|subunits|necessary|for|. (l_prep) for_10\IN\0|seizures (l_pobj) seizures_14\NNS\14081375|induced|and|hypolocomotion (l_conj) hypolocomotion_16\NN\0|in
D009538_D012640 CID nicotine_11\NN\14712692| (r_npadvmod) induced_13\VBN\1627355|nicotine|- (r_amod) seizures_14\NNS\14081375|induced|and|hypolocomotion
D009538_D012640 CID nicotine_2\NN\14712692| (r_pobj) of_1\IN\0|nicotine (r_prep) binding_0\NN\4688246|of|to (r_nsubj) elicits_10\VBZ\1617192|binding|series|. (l_dobj) series_12\NN\8456993|a|of (l_prep) of_13\IN\0|behaviors (l_pobj) behaviors_17\NNS\407535|dependent|go (l_relcl) go_19\VBP\15291801|that|from|,|to (l_prep) to_29\IN\0|seizures (l_pobj) seizures_30\NNS\14081375|and|death
D009538_D012640 CID nicotine_9\NN\14712692| (r_npadvmod) induced_11\VBN\1627355|nicotine|- (r_amod) seizures_12\NNS\14081375|induced
D009538_D012640 CID nicotine_10\NN\14712692| (r_pobj) of_9\IN\0|nicotine (r_prep) effects_8\NNS\13245626|the|of|at (r_pobj) to_6\IN\0|effects (r_prep) sensitive_5\JJ\10488309|less|to (r_acomp) were_3\VBD\0|mice|sensitive|,|measured|. (l_advcl) measured_16\VBN\697589|as|,|and|at|measured (l_conj) measured_30\VBN\697589|as (l_prep) as_31\IN\14622893|sensitivity (l_pobj) sensitivity_32\NN\5651971|to (l_prep) to_33\IN\0|seizures (l_pobj) seizures_37\NNS\14081375|induced
D009538_D012640 CID nicotine_34\NN\14712692| (r_npadvmod) induced_36\VBN\1627355|nicotine|- (r_amod) seizures_37\NNS\14081375|induced
D009538_D012640 CID nicotine_7\NN\14712692| (r_npadvmod) induced_9\VBN\1627355|nicotine|- (r_amod) seizures_10\NNS\14081375|induced
D009538_D012640 CID nicotine_15\NN\14712692| (r_npadvmod) induced_17\VBN\1627355|nicotine|- (r_amod) seizures_18\NNS\14081375|induced|and|hypolocomotion
D009538_D006948 NONE nicotine_11\NN\14712692| (r_npadvmod) induced_13\VBN\1627355|nicotine|- (r_amod) seizures_14\NNS\14081375|induced|and|hypolocomotion (l_conj) hypolocomotion_16\NN\0|in
D009538_D006948 NONE nicotine_9\NN\14712692| (r_npadvmod) induced_11\VBN\1627355|nicotine|- (r_amod) seizures_12\NNS\14081375|induced (r_pobj) in_8\IN\13603305|seizures (r_prep) subunits_7\NNS\13604718|the|beta4|in|and|hypolocomotion (l_conj) hypolocomotion_14\NN\0|in
D009538_D006948 NONE nicotine_15\NN\14712692| (r_npadvmod) induced_17\VBN\1627355|nicotine|- (r_amod) seizures_18\NNS\14081375|induced|and|hypolocomotion (l_conj) hypolocomotion_20\NN\0|
D009538_D014202 NONE nicotine_2\NN\14712692| (r_pobj) of_1\IN\0|nicotine (r_prep) binding_0\NN\4688246|of|to (r_nsubj) elicits_10\VBZ\1617192|binding|series|. (l_dobj) series_12\NN\8456993|a|of (l_prep) of_13\IN\0|behaviors (l_pobj) behaviors_17\NNS\407535|dependent|go (l_relcl) go_19\VBP\15291801|that|from|,|to (l_prep) from_20\IN\0|exploration (l_pobj) exploration_22\NN\309647|altered|,|sedation (l_conj) sedation_24\NN\14034177|,|and|tremors (l_conj) tremors_27\NNS\345926|
D009538_D003643 NONE nicotine_2\NN\14712692| (r_pobj) of_1\IN\0|nicotine (r_prep) binding_0\NN\4688246|of|to (r_nsubj) elicits_10\VBZ\1617192|binding|series|. (l_dobj) series_12\NN\8456993|a|of (l_prep) of_13\IN\0|behaviors (l_pobj) behaviors_17\NNS\407535|dependent|go (l_relcl) go_19\VBP\15291801|that|from|,|to (l_prep) to_29\IN\0|seizures (l_pobj) seizures_30\NNS\14081375|and|death (l_conj) death_32\NN\7296428|
D000109_D014202 NONE acetylcholine_5\NN\14807558| (r_compound) receptors_6\NNS\5225602|nicotinic|acetylcholine|(|nachrs|) (r_pobj) to_3\IN\0|receptors (r_prep) binding_0\NN\4688246|of|to (r_nsubj) elicits_10\VBZ\1617192|binding|series|. (l_dobj) series_12\NN\8456993|a|of (l_prep) of_13\IN\0|behaviors (l_pobj) behaviors_17\NNS\407535|dependent|go (l_relcl) go_19\VBP\15291801|that|from|,|to (l_prep) from_20\IN\0|exploration (l_pobj) exploration_22\NN\309647|altered|,|sedation (l_conj) sedation_24\NN\14034177|,|and|tremors (l_conj) tremors_27\NNS\345926|
D000109_D003643 NONE acetylcholine_5\NN\14807558| (r_compound) receptors_6\NNS\5225602|nicotinic|acetylcholine|(|nachrs|) (r_pobj) to_3\IN\0|receptors (r_prep) binding_0\NN\4688246|of|to (r_nsubj) elicits_10\VBZ\1617192|binding|series|. (l_dobj) series_12\NN\8456993|a|of (l_prep) of_13\IN\0|behaviors (l_pobj) behaviors_17\NNS\407535|dependent|go (l_relcl) go_19\VBP\15291801|that|from|,|to (l_prep) to_29\IN\0|seizures (l_pobj) seizures_30\NNS\14081375|and|death (l_conj) death_32\NN\7296428|
3676049
D007530_D007022 CID isoflurane_6\RB\3570838| (r_npadvmod) induced_8\VBN\1627355|isoflurane|- (r_amod) hypotension_9\NN\14057371|induced|in
D007530_D007022 CID isoflurane_12\RB\3570838| (r_npadvmod) induced_14\VBN\1627355|isoflurane|- (r_amod) hypotension_15\NN\14057371|induced|in
D007530_D007022 CID isoflurane_19\NN\3570838| (r_pobj) of_18\IN\0|isoflurane (r_prep) dose_17\NN\3740161|the|of (r_dobj) increasing_15\VBG\169651|dose (r_pcomp) by_14\IN\0|increasing (r_prep) induced_13\VBN\1627355|hypotension|was|by|,|and|maintained|. (l_nsubjpass) hypotension_1\NN\14057371|controlled|to
D007530_D002532 NONE isoflurane_6\RB\3570838| (r_npadvmod) induced_8\VBN\1627355|isoflurane|- (r_amod) hypotension_9\NN\14057371|induced|in (l_prep) in_10\IN\13603305|patients (l_pobj) patients_11\NNS\9898892|subjected (l_acl) subjected_12\VBN\137313|to|for (l_prep) for_15\IN\0|aneurysms (l_pobj) aneurysms_17\NNS\14057371|cerebral
D007530_D002532 NONE isoflurane_12\RB\3570838| (r_npadvmod) induced_14\VBN\1627355|isoflurane|- (r_amod) hypotension_15\NN\14057371|induced|in (l_prep) in_16\IN\13603305|patients (l_pobj) patients_18\NNS\9898892|10|subjected (l_acl) subjected_19\VBN\137313|to (l_prep) to_20\IN\0|craniotomy (l_pobj) craniotomy_21\NN\671351|for (l_prep) for_22\IN\0|clipping (l_pobj) clipping_23\NN\6400510|of (l_prep) of_24\IN\0|aneurysm (l_pobj) aneurysm_27\NN\14057371|a|cerebral
D010100_D007022 NONE oxygen_8\NN\14622893| (r_pobj) for_7\IN\0|oxygen (r_prep) rate_6\NN\13815152|cerebral|metabolic|for (r_conj) flow_2\NN\7311115|cerebral|blood|and|rate (r_nsubjpass) measured_10\VBN\697589|flow|were|during|. (l_prep) during_11\IN\0|hypotension (l_pobj) hypotension_15\NN\14057371|induced|in
D010100_D002532 NONE oxygen_8\NN\14622893| (r_pobj) for_7\IN\0|oxygen (r_prep) rate_6\NN\13815152|cerebral|metabolic|for (r_conj) flow_2\NN\7311115|cerebral|blood|and|rate (r_nsubjpass) measured_10\VBN\697589|flow|were|during|. (l_prep) during_11\IN\0|hypotension (l_pobj) hypotension_15\NN\14057371|induced|in (l_prep) in_16\IN\13603305|patients (l_pobj) patients_18\NNS\9898892|10|subjected (l_acl) subjected_19\VBN\137313|to (l_prep) to_20\IN\0|craniotomy (l_pobj) craniotomy_21\NN\671351|for (l_prep) for_22\IN\0|clipping (l_pobj) clipping_23\NN\6400510|of (l_prep) of_24\IN\0|aneurysm (l_pobj) aneurysm_27\NN\14057371|a|cerebral
D014978_D013345 NONE xenon-133_24\.\0| (r_punct) measured_4\VBN\697589|flow|were|after|by|xenon-133 (l_prep) after_9\IN\0|days|haemorrhage (l_pobj) haemorrhage_12\NN\14285662|the|subarachnoid
D008628_D007022 NONE hg_11\NNP\14625458|mm (r_pobj) of_6\IN\0|hg (r_prep) map_5\NNP\4076846|an|average|of (r_pobj) to_2\IN\0|map (r_prep) hypotension_1\NN\14057371|controlled|to
D007530_D000783 NONE isoflurane_7\JJ\3570838| (r_amod) concentration_8\NN\4916342|the|isoflurane (r_nsubjpass) reduced_10\VBN\441445|after|concentration|was|to|. (l_prep) after_0\IN\0|clipping (l_pobj) clipping_2\NN\6400510|the|of (l_prep) of_3\IN\0|aneurysm (l_pobj) aneurysm_5\NN\14057371|the
12536034
D002220_D004832 CID carbamazepine_13\NN\0|and|vigabatrin (r_pobj) of_12\IN\0|carbamazepine (r_prep) administration_11\NN\1133281|of (r_pobj) after_10\IN\0|administration (r_prep) present_2\VBP\28270|authors|patients|after|. (l_dobj) patients_4\NNS\9898892|three|with (l_prep) with_5\IN\0|epilepsy (l_pobj) epilepsy_9\NN\14085708|absence
D020888_D004832 CID vigabatrin_15\NN\0| (r_conj) carbamazepine_13\NN\0|and|vigabatrin (r_pobj) of_12\IN\0|carbamazepine (r_prep) administration_11\NN\1133281|of (r_pobj) after_10\IN\0|administration (r_prep) present_2\VBP\28270|authors|patients|after|. (l_dobj) patients_4\NNS\9898892|three|with (l_prep) with_5\IN\0|epilepsy (l_pobj) epilepsy_9\NN\14085708|absence
D005680_D004832 NONE acid_4\NN\14818238| (r_npadvmod) transmitted_6\VBN\2232190|acid|- (r_amod) circuitry_8\NN\3278248|transmitted|thalamocortical (r_compound) accounts_9\VBZ\6647206|the|aminobutyric|circuitry|for|. (l_prep) for_10\IN\0|part (l_pobj) part_13\NN\31921|a|major|of (l_prep) of_14\IN\0|neurophysiology (l_pobj) neurophysiology_17\NN\6081833|the|underlying|of (l_prep) of_18\IN\0|epilepsy (l_pobj) epilepsy_21\NN\14085708|the|absence
19308880
D014635_D003221 CID acid_10\NN\14818238|valproic (r_pobj) with_8\IN\0|acid (r_prep) reaction_7\NN\13446390|a|serious|adverse|drug|with (r_appos) confusion_0\NN\13972797|,|reaction|:|review|.
D014635_D003221 CID acid_10\NN\14818238|valproic (r_pobj) with_8\IN\0|acid (r_prep) observed_7\VBD\2163746|frequently|with (r_acl) reaction_5\NN\13446390|an|adverse|drug|observed (r_attr) is_1\VBZ\0|confusion|reaction|. (l_nsubj) confusion_0\NN\13972797|
D014635_D003221 CID acid_17\NN\14818238|valproic (r_pobj) with_15\IN\0|acid (r_prep) reported_12\VBN\831651|since|with (r_acl) confusion_11\NN\13972797|reported
D014635_D003221 CID acid_9\NN\14818238|valproic|:|women (r_pobj) with_7\IN\0|acid (r_prep) reported_6\VBN\831651|:|cases|were|with|. (l_nsubjpass) cases_2\NNS\7283608|272|of (l_prep) of_3\IN\0|confusion (l_pobj) confusion_4\NN\13972797|
D014635_D003221 CID acid_10\NN\14818238|valproic (r_compound) exposure_11\NN\5042871|acid|(|%|) (r_pobj) following_8\VBG\8180190|exposure (r_prep) weeks_7\NNS\15113229|the|two|first|following (r_pobj) during_3\IN\0|weeks (r_prep) occurred_2\VBD\0|confusion|mostly|during|. (l_nsubj) confusion_0\NN\13972797|
D014635_D003221 CID acid_7\NN\14818238|valproic (r_pobj) with_5\IN\0|acid (r_prep) confusion_4\NN\13972797|with
20477932
D003042_D008569 CID cocaine_0\NN\3492717| (r_nsubj) causes_1\VBZ\7323922|cocaine|memory|. (l_dobj) memory_2\NN\5926676|and|learning|:|involvement (l_conj) learning_4\VBG\5701944|impairments (l_dobj) impairments_5\NNS\7296428|in
D003042_D007859 CID cocaine_0\NN\3492717| (r_nsubj) causes_1\VBZ\7323922|cocaine|memory|. (l_dobj) memory_2\NN\5926676|and|learning|:|involvement (l_conj) learning_4\VBG\5701944|impairments (l_dobj) impairments_5\NNS\7296428|in
C052342_D008569 NONE topiramate_22\NN\0| (r_pobj) by_21\IN\0|topiramate (r_prep) prevention_20\NN\1073995|by (r_conj) involvement_9\NN\1080366|of|,|and|prevention (r_appos) memory_2\NN\5926676|and|learning|:|involvement (l_conj) learning_4\VBG\5701944|impairments (l_dobj) impairments_5\NNS\7296428|in
C052342_D007859 NONE topiramate_22\NN\0| (r_pobj) by_21\IN\0|topiramate (r_prep) prevention_20\NN\1073995|by (r_conj) involvement_9\NN\1080366|of|,|and|prevention (r_appos) memory_2\NN\5926676|and|learning|:|involvement (l_conj) learning_4\VBG\5701944|impairments (l_dobj) impairments_5\NNS\7296428|in
D003042_D064420 NONE cocaine_6\NN\3492717| (r_compound) toxicity_7\NN\13576101|cocaine|including
D003042_D064420 NONE cocaine_24\NN\3492717| (r_conj) brain_22\NN\5462674|the|and|cocaine (r_nmod) behaviour_27\NN\14006945|brain|induced|- (r_pobj) in_20\IN\13603305|behaviour (r_prep) status_19\NN\24720|oxidative|in (r_pobj) between_17\IN\0|status (r_prep) association_16\NN\8008335|the|between (r_conj) increase_10\NN\13576355|an|in|but|association (r_pobj) including_8\VBG\0|increase (r_prep) toxicity_7\NN\13576101|cocaine|including
D009569_D019970 NONE oxide_9\NN\14818238| (r_compound) synthase_10\NN\0|neuronal|nitric|oxide|(|activity|,|therapy (l_conj) therapy_31\NN\657604|a|proposed|for (l_prep) for_32\IN\0|addiction (l_pobj) addiction_34\NN\14034177|cocaine
C052342_D019970 NONE topiramate_26\NN\0| (r_pobj) of_25\IN\0|topiramate (r_prep) effect_24\NN\34213|the|of (r_conj) learning_17\NN\5701944|spatial|and|memory|as|effect (r_conj) activity_14\NN\30358|nnos|)|,|learning (r_conj) synthase_10\NN\0|neuronal|nitric|oxide|(|activity|,|therapy (l_conj) therapy_31\NN\657604|a|proposed|for (l_prep) for_32\IN\0|addiction (l_pobj) addiction_34\NN\14034177|cocaine
D003042_D019970 NONE cocaine_43\NN\3492717| (r_compound) administration_44\NN\1133281|cocaine (r_pobj) of_42\IN\0|administration (r_prep) model_41\NN\5888929|an|experimental|of|in (r_pobj) in_38\IN\13603305|model (r_prep) evaluated_37\VBN\670261|therefore|activity|were|in|. (l_nsubjpass) activity_2\NN\30358|nfkappab|,|stress|, (l_appos) stress_5\NN\7083732|oxidative|,|synthase (l_conj) synthase_10\NN\0|neuronal|nitric|oxide|(|activity|,|therapy (l_conj) therapy_31\NN\657604|a|proposed|for (l_prep) for_32\IN\0|addiction (l_pobj) addiction_34\NN\14034177|cocaine
84204
D002927_D003221 CID cimetidine_7\NN\14778019| (r_npadvmod) associated_9\VBN\628491|cimetidine|- (r_amod) confusion_11\NN\13972797|associated|mental
D002927_D003221 CID cimetidine_3\NN\14778019| (r_npadvmod) associated_5\VBN\628491|cimetidine|- (r_amod) confusion_7\NN\13972797|associated|mental
D002927_D051437 NONE cimetidine_19\FW\14778019|concentrations (r_conj) dysfunction_8\NN\14204950|both|renal|(|p|)|,|as|cimetidine
D002927_D008107 NONE cimetidine_19\FW\14778019|concentrations (r_conj) dysfunction_8\NN\14204950|both|renal|(|p|)|,|as|cimetidine
8372922
2673163
D003042_D020521 NONE cocaine_3\NN\3492717| (r_compound) use_4\NN\407535|cocaine (r_pobj) with_2\IN\0|use (r_prep) associated_1\VBN\628491|with (r_acl) stroke_0\NN\556313|associated|.
D003042_D020521 NONE cocaine_6\NN\3492717| (r_compound) use_7\NN\407535|cocaine (r_nsubjpass) related_9\VBN\628491|in|use|was|to|and|review (l_prep) to_10\IN\0|stroke (l_pobj) stroke_11\NN\556313|
D003042_D020521 NONE cocaine_2\NN\3492717| (r_compound) use_3\NN\407535|cocaine|by (r_dobj) followed_1\VBD\1835496|stroke|use|. (l_nsubj) stroke_0\NN\556313|
D003042_D020521 NONE cocaine_14\NN\3492717| (r_compound) use_15\NN\407535|cocaine (r_pobj) to_13\IN\0|use (r_prep) related_12\VBN\628491|to (r_acl) stroke_11\NN\556313|related
D003042_D020521 NONE cocaine_14\NN\3492717| (r_compound) use_15\NN\407535|cocaine (r_pobj) to_13\IN\0|use (r_prep) related_12\VBN\628491|to (r_acl) stroke_11\NN\556313|related (r_pobj) of_10\IN\0|stroke (r_prep) incidence_9\NN\13821570|the|apparent|of (r_nsubj) increasing_17\VBG\169651|that|incidence|is (r_ccomp) indicate_2\VBP\952524|data|increasing (r_ccomp) occurs_26\VBZ\0|indicate|;|(|stroke|primarily|in (l_nsubj) stroke_25\NN\556313|2|)|associated
D003042_D020521 NONE cocaine_14\NN\3492717| (r_compound) use_15\NN\407535|cocaine (r_pobj) to_13\IN\0|use (r_prep) related_12\VBN\628491|to (r_acl) stroke_11\NN\556313|related (r_pobj) of_10\IN\0|stroke (r_prep) incidence_9\NN\13821570|the|apparent|of (r_nsubj) increasing_17\VBG\169651|that|incidence|is (r_ccomp) indicate_2\VBP\952524|data|increasing (r_ccomp) occurs_26\VBZ\0|indicate|;|(|stroke|primarily|in (r_ccomp) follow_37\VB\1835496|occurs|;|stroke|may|route (l_nsubj) stroke_35\NN\556313|3
D003042_D020521 NONE cocaine_14\NN\3492717| (r_compound) use_15\NN\407535|cocaine (r_pobj) to_13\IN\0|use (r_prep) related_12\VBN\628491|to (r_acl) stroke_11\NN\556313|related (r_pobj) of_10\IN\0|stroke (r_prep) incidence_9\NN\13821570|the|apparent|of (r_nsubj) increasing_17\VBG\169651|that|incidence|is (r_ccomp) indicate_2\VBP\952524|data|increasing (r_ccomp) occurs_26\VBZ\0|indicate|;|(|stroke|primarily|in (r_ccomp) follow_37\VB\1835496|occurs|;|stroke|may|route (r_ccomp) exceeds_76\VBZ\0|follow|;|frequency|that|. (l_nsubj) frequency_72\NN\15286249|stroke|the|of (l_nmod) stroke_47\NN\556313|4|associated|;|and|5
D003042_D020521 NONE cocaine_14\NN\3492717| (r_compound) use_15\NN\407535|cocaine (r_pobj) to_13\IN\0|use (r_prep) related_12\VBN\628491|to (r_acl) stroke_11\NN\556313|related (r_pobj) of_10\IN\0|stroke (r_prep) incidence_9\NN\13821570|the|apparent|of (r_nsubj) increasing_17\VBG\169651|that|incidence|is (r_ccomp) indicate_2\VBP\952524|data|increasing (r_ccomp) occurs_26\VBZ\0|indicate|;|(|stroke|primarily|in (r_ccomp) follow_37\VB\1835496|occurs|;|stroke|may|route (r_ccomp) exceeds_76\VBZ\0|follow|;|frequency|that|. (l_nsubj) frequency_72\NN\15286249|stroke|the|of (l_nmod) stroke_47\NN\556313|4|associated|;|and|5 (l_conj) 5_63\CD\13741022|(|)|in|, (l_prep) in_65\IN\13603305|stroke (l_pobj) stroke_69\NN\556313|associated
D003042_D020521 NONE cocaine_22\NN\3492717| (r_npadvmod) associated_24\VBN\628491|cocaine|- (r_amod) stroke_25\NN\556313|2|)|associated (r_nsubj) occurs_26\VBZ\0|indicate|;|(|stroke|primarily|in (l_ccomp) indicate_2\VBP\952524|data|increasing (l_ccomp) increasing_17\VBG\169651|that|incidence|is (l_nsubj) incidence_9\NN\13821570|the|apparent|of (l_prep) of_10\IN\0|stroke (l_pobj) stroke_11\NN\556313|related
D003042_D020521 NONE cocaine_22\NN\3492717| (r_npadvmod) associated_24\VBN\628491|cocaine|- (r_amod) stroke_25\NN\556313|2|)|associated
D003042_D020521 NONE cocaine_22\NN\3492717| (r_npadvmod) associated_24\VBN\628491|cocaine|- (r_amod) stroke_25\NN\556313|2|)|associated (r_nsubj) occurs_26\VBZ\0|indicate|;|(|stroke|primarily|in (r_ccomp) follow_37\VB\1835496|occurs|;|stroke|may|route (l_nsubj) stroke_35\NN\556313|3
D003042_D020521 NONE cocaine_22\NN\3492717| (r_npadvmod) associated_24\VBN\628491|cocaine|- (r_amod) stroke_25\NN\556313|2|)|associated (r_nsubj) occurs_26\VBZ\0|indicate|;|(|stroke|primarily|in (r_ccomp) follow_37\VB\1835496|occurs|;|stroke|may|route (r_ccomp) exceeds_76\VBZ\0|follow|;|frequency|that|. (l_nsubj) frequency_72\NN\15286249|stroke|the|of (l_nmod) stroke_47\NN\556313|4|associated|;|and|5
D003042_D020521 NONE cocaine_22\NN\3492717| (r_npadvmod) associated_24\VBN\628491|cocaine|- (r_amod) stroke_25\NN\556313|2|)|associated (r_nsubj) occurs_26\VBZ\0|indicate|;|(|stroke|primarily|in (r_ccomp) follow_37\VB\1835496|occurs|;|stroke|may|route (r_ccomp) exceeds_76\VBZ\0|follow|;|frequency|that|. (l_nsubj) frequency_72\NN\15286249|stroke|the|of (l_nmod) stroke_47\NN\556313|4|associated|;|and|5 (l_conj) 5_63\CD\13741022|(|)|in|, (l_prep) in_65\IN\13603305|stroke (l_pobj) stroke_69\NN\556313|associated
D003042_D020521 NONE cocaine_41\NN\3492717| (r_compound) administration_42\NN\1133281|cocaine (r_pobj) of_40\IN\0|administration (r_prep) route_39\NN\8593262|any|of (r_dobj) follow_37\VB\1835496|occurs|;|stroke|may|route (l_ccomp) occurs_26\VBZ\0|indicate|;|(|stroke|primarily|in (l_ccomp) indicate_2\VBP\952524|data|increasing (l_ccomp) increasing_17\VBG\169651|that|incidence|is (l_nsubj) incidence_9\NN\13821570|the|apparent|of (l_prep) of_10\IN\0|stroke (l_pobj) stroke_11\NN\556313|related
D003042_D020521 NONE cocaine_41\NN\3492717| (r_compound) administration_42\NN\1133281|cocaine (r_pobj) of_40\IN\0|administration (r_prep) route_39\NN\8593262|any|of (r_dobj) follow_37\VB\1835496|occurs|;|stroke|may|route (l_ccomp) occurs_26\VBZ\0|indicate|;|(|stroke|primarily|in (l_nsubj) stroke_25\NN\556313|2|)|associated
D003042_D020521 NONE cocaine_41\NN\3492717| (r_compound) administration_42\NN\1133281|cocaine (r_pobj) of_40\IN\0|administration (r_prep) route_39\NN\8593262|any|of (r_dobj) follow_37\VB\1835496|occurs|;|stroke|may|route (l_nsubj) stroke_35\NN\556313|3
D003042_D020521 NONE cocaine_41\NN\3492717| (r_compound) administration_42\NN\1133281|cocaine (r_pobj) of_40\IN\0|administration (r_prep) route_39\NN\8593262|any|of (r_dobj) follow_37\VB\1835496|occurs|;|stroke|may|route (r_ccomp) exceeds_76\VBZ\0|follow|;|frequency|that|. (l_nsubj) frequency_72\NN\15286249|stroke|the|of (l_nmod) stroke_47\NN\556313|4|associated|;|and|5
D003042_D020521 NONE cocaine_41\NN\3492717| (r_compound) administration_42\NN\1133281|cocaine (r_pobj) of_40\IN\0|administration (r_prep) route_39\NN\8593262|any|of (r_dobj) follow_37\VB\1835496|occurs|;|stroke|may|route (r_ccomp) exceeds_76\VBZ\0|follow|;|frequency|that|. (l_nsubj) frequency_72\NN\15286249|stroke|the|of (l_nmod) stroke_47\NN\556313|4|associated|;|and|5 (l_conj) 5_63\CD\13741022|(|)|in|, (l_prep) in_65\IN\13603305|stroke (l_pobj) stroke_69\NN\556313|associated
D003042_D020521 NONE cocaine_49\NN\3492717| (r_compound) use_50\NN\407535|cocaine (r_nsubjpass) associated_53\VBN\628491|after|use|is|frequently|with (r_advcl) stroke_47\NN\556313|4|associated|;|and|5 (r_nmod) frequency_72\NN\15286249|stroke|the|of (r_nsubj) exceeds_76\VBZ\0|follow|;|frequency|that|. (l_ccomp) follow_37\VB\1835496|occurs|;|stroke|may|route (l_ccomp) occurs_26\VBZ\0|indicate|;|(|stroke|primarily|in (l_ccomp) indicate_2\VBP\952524|data|increasing (l_ccomp) increasing_17\VBG\169651|that|incidence|is (l_nsubj) incidence_9\NN\13821570|the|apparent|of (l_prep) of_10\IN\0|stroke (l_pobj) stroke_11\NN\556313|related
D003042_D020521 NONE cocaine_49\NN\3492717| (r_compound) use_50\NN\407535|cocaine (r_nsubjpass) associated_53\VBN\628491|after|use|is|frequently|with (r_advcl) stroke_47\NN\556313|4|associated|;|and|5 (r_nmod) frequency_72\NN\15286249|stroke|the|of (r_nsubj) exceeds_76\VBZ\0|follow|;|frequency|that|. (l_ccomp) follow_37\VB\1835496|occurs|;|stroke|may|route (l_ccomp) occurs_26\VBZ\0|indicate|;|(|stroke|primarily|in (l_nsubj) stroke_25\NN\556313|2|)|associated
D003042_D020521 NONE cocaine_49\NN\3492717| (r_compound) use_50\NN\407535|cocaine (r_nsubjpass) associated_53\VBN\628491|after|use|is|frequently|with (r_advcl) stroke_47\NN\556313|4|associated|;|and|5 (r_nmod) frequency_72\NN\15286249|stroke|the|of (r_nsubj) exceeds_76\VBZ\0|follow|;|frequency|that|. (l_ccomp) follow_37\VB\1835496|occurs|;|stroke|may|route (l_nsubj) stroke_35\NN\556313|3
D003042_D020521 NONE cocaine_49\NN\3492717| (r_compound) use_50\NN\407535|cocaine (r_nsubjpass) associated_53\VBN\628491|after|use|is|frequently|with (r_advcl) stroke_47\NN\556313|4|associated|;|and|5
D003042_D020521 NONE cocaine_49\NN\3492717| (r_compound) use_50\NN\407535|cocaine (r_nsubjpass) associated_53\VBN\628491|after|use|is|frequently|with (r_advcl) stroke_47\NN\556313|4|associated|;|and|5 (l_conj) 5_63\CD\13741022|(|)|in|, (l_prep) in_65\IN\13603305|stroke (l_pobj) stroke_69\NN\556313|associated
D003042_D020521 NONE cocaine_66\NN\3492717| (r_npadvmod) associated_68\VBN\628491|cocaine|- (r_amod) stroke_69\NN\556313|associated (r_pobj) in_65\IN\13603305|stroke (r_prep) 5_63\CD\13741022|(|)|in|, (r_conj) stroke_47\NN\556313|4|associated|;|and|5 (r_nmod) frequency_72\NN\15286249|stroke|the|of (r_nsubj) exceeds_76\VBZ\0|follow|;|frequency|that|. (l_ccomp) follow_37\VB\1835496|occurs|;|stroke|may|route (l_ccomp) occurs_26\VBZ\0|indicate|;|(|stroke|primarily|in (l_ccomp) indicate_2\VBP\952524|data|increasing (l_ccomp) increasing_17\VBG\169651|that|incidence|is (l_nsubj) incidence_9\NN\13821570|the|apparent|of (l_prep) of_10\IN\0|stroke (l_pobj) stroke_11\NN\556313|related
D003042_D020521 NONE cocaine_66\NN\3492717| (r_npadvmod) associated_68\VBN\628491|cocaine|- (r_amod) stroke_69\NN\556313|associated (r_pobj) in_65\IN\13603305|stroke (r_prep) 5_63\CD\13741022|(|)|in|, (r_conj) stroke_47\NN\556313|4|associated|;|and|5 (r_nmod) frequency_72\NN\15286249|stroke|the|of (r_nsubj) exceeds_76\VBZ\0|follow|;|frequency|that|. (l_ccomp) follow_37\VB\1835496|occurs|;|stroke|may|route (l_ccomp) occurs_26\VBZ\0|indicate|;|(|stroke|primarily|in (l_nsubj) stroke_25\NN\556313|2|)|associated
D003042_D020521 NONE cocaine_66\NN\3492717| (r_npadvmod) associated_68\VBN\628491|cocaine|- (r_amod) stroke_69\NN\556313|associated (r_pobj) in_65\IN\13603305|stroke (r_prep) 5_63\CD\13741022|(|)|in|, (r_conj) stroke_47\NN\556313|4|associated|;|and|5 (r_nmod) frequency_72\NN\15286249|stroke|the|of (r_nsubj) exceeds_76\VBZ\0|follow|;|frequency|that|. (l_ccomp) follow_37\VB\1835496|occurs|;|stroke|may|route (l_nsubj) stroke_35\NN\556313|3
D003042_D020521 NONE cocaine_66\NN\3492717| (r_npadvmod) associated_68\VBN\628491|cocaine|- (r_amod) stroke_69\NN\556313|associated (r_pobj) in_65\IN\13603305|stroke (r_prep) 5_63\CD\13741022|(|)|in|, (r_conj) stroke_47\NN\556313|4|associated|;|and|5
D003042_D020521 NONE cocaine_66\NN\3492717| (r_npadvmod) associated_68\VBN\628491|cocaine|- (r_amod) stroke_69\NN\556313|associated
D003042_D002532 NONE cocaine_14\NN\3492717| (r_compound) use_15\NN\407535|cocaine (r_pobj) to_13\IN\0|use (r_prep) related_12\VBN\628491|to (r_acl) stroke_11\NN\556313|related (r_pobj) of_10\IN\0|stroke (r_prep) incidence_9\NN\13821570|the|apparent|of (r_nsubj) increasing_17\VBG\169651|that|incidence|is (r_ccomp) indicate_2\VBP\952524|data|increasing (r_ccomp) occurs_26\VBZ\0|indicate|;|(|stroke|primarily|in (r_ccomp) follow_37\VB\1835496|occurs|;|stroke|may|route (r_ccomp) exceeds_76\VBZ\0|follow|;|frequency|that|. (l_nsubj) frequency_72\NN\15286249|stroke|the|of (l_nmod) stroke_47\NN\556313|4|associated|;|and|5 (l_advcl) associated_53\VBN\628491|after|use|is|frequently|with (l_prep) with_54\IN\0|aneurysms (l_pobj) aneurysms_56\NNS\14057371|intracranial|and|malformations
D003042_D002532 NONE cocaine_22\NN\3492717| (r_npadvmod) associated_24\VBN\628491|cocaine|- (r_amod) stroke_25\NN\556313|2|)|associated (r_nsubj) occurs_26\VBZ\0|indicate|;|(|stroke|primarily|in (r_ccomp) follow_37\VB\1835496|occurs|;|stroke|may|route (r_ccomp) exceeds_76\VBZ\0|follow|;|frequency|that|. (l_nsubj) frequency_72\NN\15286249|stroke|the|of (l_nmod) stroke_47\NN\556313|4|associated|;|and|5 (l_advcl) associated_53\VBN\628491|after|use|is|frequently|with (l_prep) with_54\IN\0|aneurysms (l_pobj) aneurysms_56\NNS\14057371|intracranial|and|malformations
D003042_D002532 NONE cocaine_41\NN\3492717| (r_compound) administration_42\NN\1133281|cocaine (r_pobj) of_40\IN\0|administration (r_prep) route_39\NN\8593262|any|of (r_dobj) follow_37\VB\1835496|occurs|;|stroke|may|route (r_ccomp) exceeds_76\VBZ\0|follow|;|frequency|that|. (l_nsubj) frequency_72\NN\15286249|stroke|the|of (l_nmod) stroke_47\NN\556313|4|associated|;|and|5 (l_advcl) associated_53\VBN\628491|after|use|is|frequently|with (l_prep) with_54\IN\0|aneurysms (l_pobj) aneurysms_56\NNS\14057371|intracranial|and|malformations
D003042_D002532 NONE cocaine_49\NN\3492717| (r_compound) use_50\NN\407535|cocaine (r_nsubjpass) associated_53\VBN\628491|after|use|is|frequently|with (l_prep) with_54\IN\0|aneurysms (l_pobj) aneurysms_56\NNS\14057371|intracranial|and|malformations
D003042_D002532 NONE cocaine_66\NN\3492717| (r_npadvmod) associated_68\VBN\628491|cocaine|- (r_amod) stroke_69\NN\556313|associated (r_pobj) in_65\IN\13603305|stroke (r_prep) 5_63\CD\13741022|(|)|in|, (r_conj) stroke_47\NN\556313|4|associated|;|and|5 (l_advcl) associated_53\VBN\628491|after|use|is|frequently|with (l_prep) with_54\IN\0|aneurysms (l_pobj) aneurysms_56\NNS\14057371|intracranial|and|malformations
D003042_D001165 NONE cocaine_14\NN\3492717| (r_compound) use_15\NN\407535|cocaine (r_pobj) to_13\IN\0|use (r_prep) related_12\VBN\628491|to (r_acl) stroke_11\NN\556313|related (r_pobj) of_10\IN\0|stroke (r_prep) incidence_9\NN\13821570|the|apparent|of (r_nsubj) increasing_17\VBG\169651|that|incidence|is (r_ccomp) indicate_2\VBP\952524|data|increasing (r_ccomp) occurs_26\VBZ\0|indicate|;|(|stroke|primarily|in (r_ccomp) follow_37\VB\1835496|occurs|;|stroke|may|route (r_ccomp) exceeds_76\VBZ\0|follow|;|frequency|that|. (l_nsubj) frequency_72\NN\15286249|stroke|the|of (l_nmod) stroke_47\NN\556313|4|associated|;|and|5 (l_advcl) associated_53\VBN\628491|after|use|is|frequently|with (l_prep) with_54\IN\0|aneurysms (l_pobj) aneurysms_56\NNS\14057371|intracranial|and|malformations (l_conj) malformations_59\NNS\14213199|arteriovenous
D003042_D001165 NONE cocaine_22\NN\3492717| (r_npadvmod) associated_24\VBN\628491|cocaine|- (r_amod) stroke_25\NN\556313|2|)|associated (r_nsubj) occurs_26\VBZ\0|indicate|;|(|stroke|primarily|in (r_ccomp) follow_37\VB\1835496|occurs|;|stroke|may|route (r_ccomp) exceeds_76\VBZ\0|follow|;|frequency|that|. (l_nsubj) frequency_72\NN\15286249|stroke|the|of (l_nmod) stroke_47\NN\556313|4|associated|;|and|5 (l_advcl) associated_53\VBN\628491|after|use|is|frequently|with (l_prep) with_54\IN\0|aneurysms (l_pobj) aneurysms_56\NNS\14057371|intracranial|and|malformations (l_conj) malformations_59\NNS\14213199|arteriovenous
D003042_D001165 NONE cocaine_41\NN\3492717| (r_compound) administration_42\NN\1133281|cocaine (r_pobj) of_40\IN\0|administration (r_prep) route_39\NN\8593262|any|of (r_dobj) follow_37\VB\1835496|occurs|;|stroke|may|route (r_ccomp) exceeds_76\VBZ\0|follow|;|frequency|that|. (l_nsubj) frequency_72\NN\15286249|stroke|the|of (l_nmod) stroke_47\NN\556313|4|associated|;|and|5 (l_advcl) associated_53\VBN\628491|after|use|is|frequently|with (l_prep) with_54\IN\0|aneurysms (l_pobj) aneurysms_56\NNS\14057371|intracranial|and|malformations (l_conj) malformations_59\NNS\14213199|arteriovenous
D003042_D001165 NONE cocaine_49\NN\3492717| (r_compound) use_50\NN\407535|cocaine (r_nsubjpass) associated_53\VBN\628491|after|use|is|frequently|with (l_prep) with_54\IN\0|aneurysms (l_pobj) aneurysms_56\NNS\14057371|intracranial|and|malformations (l_conj) malformations_59\NNS\14213199|arteriovenous
D003042_D001165 NONE cocaine_66\NN\3492717| (r_npadvmod) associated_68\VBN\628491|cocaine|- (r_amod) stroke_69\NN\556313|associated (r_pobj) in_65\IN\13603305|stroke (r_prep) 5_63\CD\13741022|(|)|in|, (r_conj) stroke_47\NN\556313|4|associated|;|and|5 (l_advcl) associated_53\VBN\628491|after|use|is|frequently|with (l_prep) with_54\IN\0|aneurysms (l_pobj) aneurysms_56\NNS\14057371|intracranial|and|malformations (l_conj) malformations_59\NNS\14213199|arteriovenous
D003042_D020300 NONE cocaine_14\NN\3492717| (r_compound) use_15\NN\407535|cocaine (r_pobj) to_13\IN\0|use (r_prep) related_12\VBN\628491|to (r_acl) stroke_11\NN\556313|related (r_pobj) of_10\IN\0|stroke (r_prep) incidence_9\NN\13821570|the|apparent|of (r_nsubj) increasing_17\VBG\169651|that|incidence|is (r_ccomp) indicate_2\VBP\952524|data|increasing (r_ccomp) occurs_26\VBZ\0|indicate|;|(|stroke|primarily|in (r_ccomp) follow_37\VB\1835496|occurs|;|stroke|may|route (r_ccomp) exceeds_76\VBZ\0|follow|;|frequency|that|. (l_nsubj) frequency_72\NN\15286249|stroke|the|of (l_prep) of_73\IN\0|hemorrhage (l_pobj) hemorrhage_75\NN\14285662|intracranial
D003042_D020300 NONE cocaine_22\NN\3492717| (r_npadvmod) associated_24\VBN\628491|cocaine|- (r_amod) stroke_25\NN\556313|2|)|associated (r_nsubj) occurs_26\VBZ\0|indicate|;|(|stroke|primarily|in (r_ccomp) follow_37\VB\1835496|occurs|;|stroke|may|route (r_ccomp) exceeds_76\VBZ\0|follow|;|frequency|that|. (l_nsubj) frequency_72\NN\15286249|stroke|the|of (l_prep) of_73\IN\0|hemorrhage (l_pobj) hemorrhage_75\NN\14285662|intracranial
D003042_D020300 NONE cocaine_41\NN\3492717| (r_compound) administration_42\NN\1133281|cocaine (r_pobj) of_40\IN\0|administration (r_prep) route_39\NN\8593262|any|of (r_dobj) follow_37\VB\1835496|occurs|;|stroke|may|route (r_ccomp) exceeds_76\VBZ\0|follow|;|frequency|that|. (l_nsubj) frequency_72\NN\15286249|stroke|the|of (l_prep) of_73\IN\0|hemorrhage (l_pobj) hemorrhage_75\NN\14285662|intracranial
D003042_D020300 NONE cocaine_49\NN\3492717| (r_compound) use_50\NN\407535|cocaine (r_nsubjpass) associated_53\VBN\628491|after|use|is|frequently|with (r_advcl) stroke_47\NN\556313|4|associated|;|and|5 (r_nmod) frequency_72\NN\15286249|stroke|the|of (l_prep) of_73\IN\0|hemorrhage (l_pobj) hemorrhage_75\NN\14285662|intracranial
D003042_D020300 NONE cocaine_66\NN\3492717| (r_npadvmod) associated_68\VBN\628491|cocaine|- (r_amod) stroke_69\NN\556313|associated (r_pobj) in_65\IN\13603305|stroke (r_prep) 5_63\CD\13741022|(|)|in|, (r_conj) stroke_47\NN\556313|4|associated|;|and|5 (r_nmod) frequency_72\NN\15286249|stroke|the|of (l_prep) of_73\IN\0|hemorrhage (l_pobj) hemorrhage_75\NN\14285662|intracranial
D003042_D002544 CID cocaine_14\NN\3492717| (r_compound) use_15\NN\407535|cocaine (r_pobj) to_13\IN\0|use (r_prep) related_12\VBN\628491|to (r_acl) stroke_11\NN\556313|related (r_pobj) of_10\IN\0|stroke (r_prep) incidence_9\NN\13821570|the|apparent|of (r_nsubj) increasing_17\VBG\169651|that|incidence|is (r_ccomp) indicate_2\VBP\952524|data|increasing (r_ccomp) occurs_26\VBZ\0|indicate|;|(|stroke|primarily|in (r_ccomp) follow_37\VB\1835496|occurs|;|stroke|may|route (r_ccomp) exceeds_76\VBZ\0|follow|;|frequency|that|. (l_dobj) that_77\DT\0|of (l_prep) of_78\IN\0|infarction (l_pobj) infarction_80\NN\14204950|cerebral
D003042_D002544 CID cocaine_22\NN\3492717| (r_npadvmod) associated_24\VBN\628491|cocaine|- (r_amod) stroke_25\NN\556313|2|)|associated (r_nsubj) occurs_26\VBZ\0|indicate|;|(|stroke|primarily|in (r_ccomp) follow_37\VB\1835496|occurs|;|stroke|may|route (r_ccomp) exceeds_76\VBZ\0|follow|;|frequency|that|. (l_dobj) that_77\DT\0|of (l_prep) of_78\IN\0|infarction (l_pobj) infarction_80\NN\14204950|cerebral
D003042_D002544 CID cocaine_41\NN\3492717| (r_compound) administration_42\NN\1133281|cocaine (r_pobj) of_40\IN\0|administration (r_prep) route_39\NN\8593262|any|of (r_dobj) follow_37\VB\1835496|occurs|;|stroke|may|route (r_ccomp) exceeds_76\VBZ\0|follow|;|frequency|that|. (l_dobj) that_77\DT\0|of (l_prep) of_78\IN\0|infarction (l_pobj) infarction_80\NN\14204950|cerebral
D003042_D002544 CID cocaine_49\NN\3492717| (r_compound) use_50\NN\407535|cocaine (r_nsubjpass) associated_53\VBN\628491|after|use|is|frequently|with (r_advcl) stroke_47\NN\556313|4|associated|;|and|5 (r_nmod) frequency_72\NN\15286249|stroke|the|of (r_nsubj) exceeds_76\VBZ\0|follow|;|frequency|that|. (l_dobj) that_77\DT\0|of (l_prep) of_78\IN\0|infarction (l_pobj) infarction_80\NN\14204950|cerebral
D003042_D002544 CID cocaine_66\NN\3492717| (r_npadvmod) associated_68\VBN\628491|cocaine|- (r_amod) stroke_69\NN\556313|associated (r_pobj) in_65\IN\13603305|stroke (r_prep) 5_63\CD\13741022|(|)|in|, (r_conj) stroke_47\NN\556313|4|associated|;|and|5 (r_nmod) frequency_72\NN\15286249|stroke|the|of (r_nsubj) exceeds_76\VBZ\0|follow|;|frequency|that|. (l_dobj) that_77\DT\0|of (l_prep) of_78\IN\0|infarction (l_pobj) infarction_80\NN\14204950|cerebral
7423039
D004317_D066126 CID adriamycin_3\JJ\0| (r_amod) cardiotoxicity_4\NN\0|adriamycin
D004317_D066126 CID adriamycin_4\NNS\0| (r_pobj) of_3\IN\0|adriamycin (r_prep) effects_2\NNS\13245626|the|cardiotoxic|of (l_amod) cardiotoxic_1\JJ\0|
3070035
D002216_D051437 NONE captopril_2\NN\2673637| (r_npadvmod) induced_4\VBN\1627355|captopril|- (r_amod) insufficiency_6\NN\14462946|induced|renal
D002216_D051437 NONE captopril_4\NN\2673637| (r_npadvmod) induced_6\VBN\1627355|captopril|- (r_amod) failure_8\NN\66216|induced|renal
D002216_D006978 NONE captopril_2\NN\2673637| (r_npadvmod) induced_4\VBN\1627355|captopril|- (r_amod) insufficiency_6\NN\14462946|induced|renal (r_pobj) of_1\IN\0|insufficiency (r_prep) reversibility_0\NN\4733640|of|after|. (l_prep) after_7\IN\0|use (l_pobj) use_9\NN\407535|prolonged|in (l_prep) in_10\IN\13603305|case (l_pobj) case_13\NN\7283608|an|unusual|of (l_prep) of_14\IN\0|hypertension (l_pobj) hypertension_16\NN\14057371|renovascular
D002216_D006973 NONE captopril_27\NN\2673637| (r_pobj) with_26\IN\0|captopril (r_prep) treatment_25\NN\654885|with (r_pobj) following_24\VBG\8180190|treatment (r_prep) deterioration_20\NN\14560612|sudden|of|following (r_dobj) developed_18\VBD\1753788|who|deterioration (r_relcl) kidney_15\NN\5333259|a|solitary|,|developed (r_pobj) to_12\IN\0|kidney (r_prep) artery_11\NN\5417975|an|occluded|renal|to (r_pobj) with_7\IN\0|artery (r_prep) hypertension_6\NN\14057371|severe|with
D002216_D058186 CID captopril_27\NN\2673637| (r_pobj) with_26\IN\0|captopril (r_prep) treatment_25\NN\654885|with (r_pobj) following_24\VBG\8180190|treatment (r_prep) deterioration_20\NN\14560612|sudden|of|following (l_prep) of_21\IN\0|function (l_pobj) function_23\NN\13783581|renal
3865016
D005047_D054218 NONE etoposide_4\NN\0|and|cyclosporin (r_nmod) a_7\NNP\13649268|etoposide (r_pobj) of_3\IN\0|a (r_prep) effect_2\NN\34213|a|synergistic|of (r_nsubjpass) observed_9\VBN\2163746|effect|was|in|in|. (l_prep) in_10\IN\13603305|patient (l_pobj) patient_12\NN\9898892|a|with (l_prep) with_13\IN\0|leukemia (l_pobj) leukemia_18\NN\14239918|acute|lymphocytic
D016572_D054218 NONE a_7\NNP\13649268|etoposide (r_pobj) of_3\IN\0|a (r_prep) effect_2\NN\34213|a|synergistic|of (r_nsubjpass) observed_9\VBN\2163746|effect|was|in|in|. (l_prep) in_10\IN\13603305|patient (l_pobj) patient_12\NN\9898892|a|with (l_prep) with_13\IN\0|leukemia (l_pobj) leukemia_18\NN\14239918|acute|lymphocytic
D005047_D017254 NONE etoposide_4\NN\0|and|cyclosporin (r_nmod) a_7\NNP\13649268|etoposide (r_pobj) of_3\IN\0|a (r_prep) administration_2\NN\1133281|the|concomitant|of (r_nsubj) resulted_8\VBD\2633881|administration|in|. (l_prep) in_9\IN\13603305|eradication (l_pobj) eradication_10\NN\7334490|of (l_prep) of_11\IN\0|infiltration (l_pobj) infiltration_15\NN\975452|hitherto|refractory|leukemic|of
D016572_D017254 NONE a_7\NNP\13649268|etoposide (r_pobj) of_3\IN\0|a (r_prep) administration_2\NN\1133281|the|concomitant|of (r_nsubj) resulted_8\VBD\2633881|administration|in|. (l_prep) in_9\IN\13603305|eradication (l_pobj) eradication_10\NN\7334490|of (l_prep) of_11\IN\0|infiltration (l_pobj) infiltration_15\NN\975452|hitherto|refractory|leukemic|of
17532790
D007980_D004409 CID dopa_12\NNP\14601829| (r_npadvmod) induced_14\VBN\1627355|l|-|dopa|- (r_amod) dyskinesia_15\NN\14084880|induced
D007980_D004409 CID dopa_2\NNP\14601829| (r_npadvmod) induced_4\VBN\1627355|l|-|dopa|- (r_amod) dyskinesia_5\NN\14084880|induced|lid
D007980_D004409 CID dopa_2\NNP\14601829| (r_npadvmod) induced_4\VBN\1627355|l|-|dopa|- (r_amod) dyskinesia_5\NN\14084880|induced|lid (l_appos) lid_7\NNP\5313679|(|)
D007980_D004409 CID dopa_31\NNP\14601829|l|- (r_pobj) with_28\IN\0|dopa (r_prep) treatment_27\NN\654885|a|prolonged|with (r_pobj) after_24\IN\0|treatment (r_prep) arise_15\VBP\2623529|that|in|after (r_relcl) complications_13\NNS\1073995|the|motor|arise (r_pobj) among_10\IN\0|complications (r_prep) is_9\VBZ\0|dyskinesia|among|. (l_nsubj) dyskinesia_5\NN\14084880|induced|lid
D007980_D004409 CID dopa_31\NNP\14601829|l|- (r_pobj) with_28\IN\0|dopa (r_prep) treatment_27\NN\654885|a|prolonged|with (r_pobj) after_24\IN\0|treatment (r_prep) arise_15\VBP\2623529|that|in|after (r_relcl) complications_13\NNS\1073995|the|motor|arise (r_pobj) among_10\IN\0|complications (r_prep) is_9\VBZ\0|dyskinesia|among|. (l_nsubj) dyskinesia_5\NN\14084880|induced|lid (l_appos) lid_7\NNP\5313679|(|)
D007980_D004409 CID dopa_5\NNP\14601829|l|- (r_pobj) with_2\IN\0|dopa (r_prep) treated_1\VBD\2376958|rats|with|allocated|. (l_conj) allocated_7\VBN\2228698|were|to (l_prep) to_8\IN\0|groups (l_pobj) groups_10\NNS\2137|two|based (l_acl) based_11\VBN\0|on (l_prep) on_12\IN\0|presence (l_pobj) presence_14\NN\13954253|the|or|absence (l_conj) absence_16\NN\14449405|of (l_prep) of_17\IN\0|lid (l_pobj) lid_18\NNP\5313679|
D007980_D010300 NONE dopa_2\NNP\14601829| (r_npadvmod) induced_4\VBN\1627355|l|-|dopa|- (r_amod) dyskinesia_5\NN\14084880|induced|lid (r_nsubj) is_9\VBZ\0|dyskinesia|among|. (l_prep) among_10\IN\0|complications (l_pobj) complications_13\NNS\1073995|the|motor|arise (l_relcl) arise_15\VBP\2623529|that|in|after (l_prep) in_16\IN\13603305|patients (l_pobj) patients_23\NNS\9898892|disease|(|pd|) (l_nmod) disease_19\NN\14061805|parkinson
D007980_D010300 NONE dopa_2\NNP\14601829| (r_npadvmod) induced_4\VBN\1627355|l|-|dopa|- (r_amod) dyskinesia_5\NN\14084880|induced|lid (r_nsubj) is_9\VBZ\0|dyskinesia|among|. (l_prep) among_10\IN\0|complications (l_pobj) complications_13\NNS\1073995|the|motor|arise (l_relcl) arise_15\VBP\2623529|that|in|after (l_prep) in_16\IN\13603305|patients (l_pobj) patients_23\NNS\9898892|disease|(|pd|) (l_nmod) pd_21\NNP\14625458|
D007980_D010300 NONE dopa_31\NNP\14601829|l|- (r_pobj) with_28\IN\0|dopa (r_prep) treatment_27\NN\654885|a|prolonged|with (r_pobj) after_24\IN\0|treatment (r_prep) arise_15\VBP\2623529|that|in|after (l_prep) in_16\IN\13603305|patients (l_pobj) patients_23\NNS\9898892|disease|(|pd|) (l_nmod) disease_19\NN\14061805|parkinson
D007980_D010300 NONE dopa_31\NNP\14601829|l|- (r_pobj) with_28\IN\0|dopa (r_prep) treatment_27\NN\654885|a|prolonged|with (r_pobj) after_24\IN\0|treatment (r_prep) arise_15\VBP\2623529|that|in|after (l_prep) in_16\IN\13603305|patients (l_pobj) patients_23\NNS\9898892|disease|(|pd|) (l_nmod) pd_21\NNP\14625458|
D007980_D010300 NONE dopa_34\NNP\14601829|l|-|or|bromocriptine (r_appos) changes_8\NNS\7283608|the|occurring|,|dopa|using (l_acl) occurring_9\VBG\0|at (l_prep) at_10\IN\14622893|level (l_pobj) level_13\NN\4916342|the|protein|in|obtained (l_acl) obtained_17\VBN\2210855|from (l_prep) from_18\IN\0|model (l_pobj) model_25\NN\5888929|the|unilaterally|rat|of|treated (l_prep) of_26\IN\0|pd (l_pobj) pd_27\NNP\14625458|
D016627_D010300 NONE 6-hydroxydopamine_21\CD\0| (r_compound) lesion_23\NN\14204950|6-hydroxydopamine|- (r_compound) rat_24\NN\2329401|lesion (r_compound) model_25\NN\5888929|the|unilaterally|rat|of|treated (l_prep) of_26\IN\0|pd (l_pobj) pd_27\NNP\14625458|
D001971_D010300 NONE bromocriptine_36\NN\0| (r_conj) dopa_34\NNP\14601829|l|-|or|bromocriptine (r_appos) changes_8\NNS\7283608|the|occurring|,|dopa|using (l_acl) occurring_9\VBG\0|at (l_prep) at_10\IN\14622893|level (l_pobj) level_13\NN\4916342|the|protein|in|obtained (l_acl) obtained_17\VBN\2210855|from (l_prep) from_18\IN\0|model (l_pobj) model_25\NN\5888929|the|unilaterally|rat|of|treated (l_prep) of_26\IN\0|pd (l_pobj) pd_27\NNP\14625458|
1085609
D011736_D012640 NONE pyridoxine_1\NN\15090742| (r_nmod) convulsions_3\NNS\14081375|neonatal|pyridoxine|responsive|due|.
D011736_D012640 NONE pyridoxine_9\NN\15090742|intramuscular (r_dobj) administering_7\VBG\2436349|pyridoxine (r_pcomp) of_6\IN\0|administering (r_prep) hours_5\NNS\15118228|4|of (r_pobj) within_3\IN\0|hours (r_prep) ceased_2\VBD\0|fits|within|,|suggesting|. (l_nsubj) fits_1\NNS\7518132|the
D011736_D012640 NONE pyridoxine_15\JJ\15090742| (r_compound) deficiency_16\NN\14449126|pyridoxine|secondary (r_pobj) of_14\IN\0|deficiency (r_prep) aetiology_13\NN\7326557|an|of|isoniazid (r_dobj) suggesting_11\VBG\1010118|aetiology (r_advcl) ceased_2\VBD\0|fits|within|,|suggesting|. (l_nsubj) fits_1\NNS\7518132|the
D007538_D012640 CID isoniazid_6\NN\2716205| (r_amod) therapy_7\NN\657604|isoniazid (r_pobj) due_4\IN\5174653|to|therapy (r_amod) convulsions_3\NNS\14081375|neonatal|pyridoxine|responsive|due|.
D007538_D012640 CID isoniazid_6\NN\2716205| (r_pobj) on_5\IN\0|isoniazid|therapy (r_prep) infant_4\NN\9918248|a|old|on|daily|because (r_nsubjpass) admitted_18\VBN\822367|infant|was|after|. (l_prep) after_19\IN\0|days (l_pobj) days_21\NNS\15140892|4|of (l_prep) of_22\IN\0|fits (l_pobj) fits_24\NNS\7518132|clonic
D007538_D012640 CID isoniazid_19\NN\2716205|to|medication (r_relcl) aetiology_13\NN\7326557|an|of|isoniazid (r_dobj) suggesting_11\VBG\1010118|aetiology (r_advcl) ceased_2\VBD\0|fits|within|,|suggesting|. (l_nsubj) fits_1\NNS\7518132|the
D007538_D014376 NONE isoniazid_6\NN\2716205| (r_pobj) on_5\IN\0|isoniazid|therapy (r_prep) infant_4\NN\9918248|a|old|on|daily|because (l_prep) because_13\IN\0|of|tuberculosis (l_pobj) tuberculosis_16\NN\14127211|maternal
11897407
C067171_D009203 NONE glucarate_2\NN\0|99mtc|-|for|. (l_prep) for_3\IN\0|detection (l_pobj) detection_4\NN\5708432|of (l_prep) of_5\IN\0|infarction (l_pobj) infarction_10\NN\14204950|induced|myocardial|in
C067171_D009203 NONE glucarate_2\NN\0|99mtc|- (r_nsubj) was_3\VBD\0|glucarate|easy|,|stable|and|used|. (l_conj) used_14\VBN\0|was|study (l_xcomp) study_16\VB\635850|to|biodistribution (l_dobj) biodistribution_18\NN\0|its|in (l_prep) in_19\IN\13603305|rats (l_pobj) rats_20\NNS\2329401|with (l_prep) with_21\IN\0|infarction (l_pobj) infarction_27\NN\14204950|induced|acute|myocardial
D007545_D009203 CID isoproterenol_6\NN\3740161| (r_npadvmod) induced_8\VBN\1627355|isoproterenol|- (r_amod) infarction_10\NN\14204950|induced|myocardial|in
D007545_D009203 CID isoproterenol_22\NN\3740161| (r_npadvmod) induced_24\VBN\1627355|isoproterenol|- (r_amod) infarction_27\NN\14204950|induced|acute|myocardial
D007545_D007238 NONE isoproterenol_18\NN\3740161| (r_pobj) with_17\IN\0|isoproterenol (r_prep) obtained_16\VBN\2210855|can|be|easily|with (r_conj) implies_7\VBZ\943837|model|ligation|obtained|. (l_nsubj) model_2\NN\5888929|the|animal|used (l_acl) used_3\VBN\0|produce (l_xcomp) produce_5\VB\7555863|to|infarction (l_dobj) infarction_6\NN\14204950|
D007545_D007238 NONE isoproterenol_12\JJ\3740161| (r_compound) administration_13\NN\1133281|isoproterenol (r_pobj) after_11\IN\0|administration (r_prep) h_10\NN\14622893|18|after (r_npadvmod) developed_6\VBD\1753788|that|rats|infarct|h (l_dobj) infarct_8\NN\14204950|an
D005937_D007238 NONE acid_9\NN\14818238|glucaric (r_pobj) on_7\IN\0|acid (r_prep) based_6\VBN\0|on (r_acl) radiopharmaceutical_5\NN\3920989|a|new|avid|based (l_amod) avid_4\JJ\0|infarct|- (l_npadvmod) infarct_2\NN\14204950|
7919560
D000667_D004892 CID ampicillin_7\NN\3910033| (r_pobj) by_6\IN\0|ampicillin (r_agent) caused_5\VBN\1617192|multiforme|by|. (l_nsubj) multiforme_1\NN\0|erythema|and|myocarditis
D000667_D004892 CID ampicillin_12\NN\3910033| (r_pobj) by_11\IN\0|ampicillin (r_agent) caused_10\VBN\1617192|by (r_acl) case_3\NN\7283608|a|of|caused (l_prep) of_4\IN\0|multiforme (l_pobj) multiforme_6\NNS\0|erythema|and|myocarditis
D000667_D009205 CID ampicillin_7\NN\3910033| (r_pobj) by_6\IN\0|ampicillin (r_agent) caused_5\VBN\1617192|multiforme|by|. (l_nsubj) multiforme_1\NN\0|erythema|and|myocarditis (l_conj) myocarditis_4\NN\14338942|hypersensitivity
D000667_D009205 CID ampicillin_12\NN\3910033| (r_pobj) by_11\IN\0|ampicillin (r_agent) caused_10\VBN\1617192|by (r_acl) case_3\NN\7283608|a|of|caused (l_prep) of_4\IN\0|multiforme (l_pobj) multiforme_6\NNS\0|erythema|and|myocarditis (l_conj) myocarditis_9\NN\14338942|hypersensitivity
D000667_D018805 NONE ampicillin_8\NN\3910033| (r_pobj) with_7\IN\0|ampicillin (r_prep) treated_6\VBN\2376958|boy|was|with|and|gentamicin|. (l_conj) gentamicin_10\NN\2716866|because (l_prep) because_11\IN\0|of|septicemia (l_pobj) septicemia_14\NN\14189204|suspected
D005839_D018805 NONE gentamicin_10\NN\2716866|because (l_prep) because_11\IN\0|of|septicemia (l_pobj) septicemia_14\NN\14189204|suspected
D010406_D009205 NONE penicillins_11\NNS\2716866| (r_pobj) to_10\IN\0|penicillins (r_prep) is_2\VBZ\0|myocarditis|manifestation|to|. (l_nsubj) myocarditis_1\NN\14338942|hypersensitivity
D010406_D004342 NONE penicillins_11\NNS\2716866| (r_pobj) to_10\IN\0|penicillins (r_prep) is_2\VBZ\0|myocarditis|manifestation|to|. (l_attr) manifestation_7\NN\7321772|a|rare|of (l_prep) of_8\IN\0|allergy (l_pobj) allergy_9\NN\14533203|
18809400
D008063_D028361 NONE acid_3\NN\14818238|lipoic (r_nsubj) prevents_4\VBZ\0|acid|damage|. (l_dobj) damage_6\NN\7296428|mitochondrial|and|neurotoxicity|in
D008063_D028361 NONE acid_7\NN\14818238|lipoic (r_nsubj) is_8\VBZ\0|if|acid|neuroprotective|induced|,|plays (l_advcl) plays_18\VBZ\7007684|if|damage|role|,|and|depend (l_nsubj) damage_17\NN\7296428|mitochondrial
D008063_D028361 NONE acid_35\NN\14818238|lipoic (r_pobj) of_31\IN\0|acid (r_prep) effects_30\NNS\13245626|neuroprotective|of (r_nsubj) depend_36\VBP\2604760|if|effects|on (r_conj) plays_18\VBZ\7007684|if|damage|role|,|and|depend (l_nsubj) damage_17\NN\7296428|mitochondrial
D008063_D028361 NONE acid_3\NN\14818238|lipoic (r_nsubj) exerts_4\VBZ\1158872|acid|effects|induced (r_ccomp) rescues_16\VBZ\45907|exerts|:|it|toxicity|and|induces|. (l_dobj) toxicity_19\NN\13576101|the|mitochondrial
D008063_D020258 NONE acid_3\NN\14818238|lipoic (r_nsubj) prevents_4\VBZ\0|acid|damage|. (l_dobj) damage_6\NN\7296428|mitochondrial|and|neurotoxicity|in (l_conj) neurotoxicity_8\NN\0|
D008063_D020258 NONE acid_7\NN\14818238|lipoic (r_nsubj) is_8\VBZ\0|if|acid|neuroprotective|induced|,|plays (l_advcl) induced_12\VBN\1627355|neurotoxicity (l_dobj) neurotoxicity_13\NN\0|
D008063_D020258 NONE acid_35\NN\14818238|lipoic (r_pobj) of_31\IN\0|acid (r_prep) effects_30\NNS\13245626|neuroprotective|of (r_nsubj) depend_36\VBP\2604760|if|effects|on (r_conj) plays_18\VBZ\7007684|if|damage|role|,|and|depend (r_advcl) is_8\VBZ\0|if|acid|neuroprotective|induced|,|plays (l_advcl) induced_12\VBN\1627355|neurotoxicity (l_dobj) neurotoxicity_13\NN\0|
D008063_D020258 NONE acid_3\NN\14818238|lipoic (r_nsubj) exerts_4\VBZ\1158872|acid|effects|induced (l_conj) induced_9\VBN\1627355|neurotoxicity (l_dobj) neurotoxicity_10\NN\0|in
D008063_D009422 NONE acid_3\NN\14818238|lipoic (r_nsubj) prevents_4\VBZ\0|acid|damage|. (l_dobj) damage_6\NN\7296428|mitochondrial|and|neurotoxicity|in (l_prep) in_9\IN\13603305|neuropathy (l_pobj) neuropathy_12\NN\14204950|experimental|chemotherapy
D008063_D009410 NONE acid_7\NN\14818238|lipoic (r_nsubj) is_8\VBZ\0|if|acid|neuroprotective|induced|,|plays (l_advcl) plays_18\VBZ\7007684|if|damage|role|,|and|depend (l_dobj) role_21\NN\719494|a|critical|in (l_prep) in_22\IN\13603305|cascade (l_pobj) cascade_25\NN\9475292|toxic|neurodegenerative
D008063_D009410 NONE acid_35\NN\14818238|lipoic (r_pobj) of_31\IN\0|acid (r_prep) effects_30\NNS\13245626|neuroprotective|of (r_nsubj) depend_36\VBP\2604760|if|effects|on (r_conj) plays_18\VBZ\7007684|if|damage|role|,|and|depend (l_dobj) role_21\NN\719494|a|critical|in (l_prep) in_22\IN\13603305|cascade (l_pobj) cascade_25\NN\9475292|toxic|neurodegenerative
D017239_D010523 CID paclitaxel_32\NN\0|and|cisplatin (r_pobj) to_31\IN\0|paclitaxel (r_prep) neurons_30\NNS\5430628|(|drg|)|sensory|to (r_appos) ganglion_25\NN\5462674|dorsal|root|neurons (r_pobj) of_22\IN\0|ganglion (r_prep) cultures_21\NNS\7966140|primary|of (r_dobj) exposing_19\VBG\2110927|cultures (r_pcomp) by_18\IN\0|exposing (r_prep) mimic_13\VBP\10200365|that|closely|in|by|drugs (r_relcl) model_5\NN\5888929|an|in|vitro|of|mimic (r_dobj) used_1\VBD\0|we|model|induced|. (l_xcomp) induced_8\VBD\1627355|neuropathy (l_dobj) neuropathy_10\NN\14204950|peripheral
D002945_D010523 CID cisplatin_34\NN\0| (r_conj) paclitaxel_32\NN\0|and|cisplatin (r_pobj) to_31\IN\0|paclitaxel (r_prep) neurons_30\NNS\5430628|(|drg|)|sensory|to (r_appos) ganglion_25\NN\5462674|dorsal|root|neurons (r_pobj) of_22\IN\0|ganglion (r_prep) cultures_21\NNS\7966140|primary|of (r_dobj) exposing_19\VBG\2110927|cultures (r_pcomp) by_18\IN\0|exposing (r_prep) mimic_13\VBP\10200365|that|closely|in|by|drugs (r_relcl) model_5\NN\5888929|an|in|vitro|of|mimic (r_dobj) used_1\VBD\0|we|model|induced|. (l_xcomp) induced_8\VBD\1627355|neuropathy (l_dobj) neuropathy_10\NN\14204950|peripheral
D008063_D001480 NONE acid_10\NN\14818238|lipoic (r_pobj) of_6\IN\0|acid (r_prep) efficacy_5\NN\5199286|the|of|in (l_prep) in_11\IN\13603305|preventing (l_pcomp) preventing_12\VBG\0|damage (l_dobj) damage_14\NN\7296428|axonal
D008063_D001480 NONE acid_34\NN\14818238|lipoic (r_conj) agents_29\NNS\7347|toxic|and|acid (r_pobj) to_27\IN\0|agents (r_prep) exposure_26\NN\5042871|to (r_pobj) after_25\IN\0|exposure (r_prep) function_19\NN\13783581|the|and|morphology|of|after (r_conj) apoptosis_16\NN\11486178|and|function (r_conj) investigating_3\VBG\575741|efficacy|and|apoptosis (l_dobj) efficacy_5\NN\5199286|the|of|in (l_prep) in_11\IN\13603305|preventing (l_pcomp) preventing_12\VBG\0|damage (l_dobj) damage_14\NN\7296428|axonal
D002945_D028361 NONE cisplatin_5\NN\0|both|and|paclitaxel (r_nsubj) cause_8\VBP\7323922|that|cisplatin|impairment (l_dobj) impairment_11\NN\7296428|early|mitochondrial|with
D002945_D028361 NONE cisplatin_13\NN\0| (r_conj) in_10\IN\13603305|both|paclitaxel|and|cisplatin (r_prep) event_8\NN\23100|an|early|common|in (r_attr) is_4\VBZ\0|in|toxicity|event|induced|. (l_nsubj) toxicity_3\NN\13576101|mitochondrial
D017239_D028361 NONE paclitaxel_7\NN\0| (r_conj) cisplatin_5\NN\0|both|and|paclitaxel (r_nsubj) cause_8\VBP\7323922|that|cisplatin|impairment (l_dobj) impairment_11\NN\7296428|early|mitochondrial|with
D017239_D028361 NONE paclitaxel_11\NN\0| (r_pobj) in_10\IN\13603305|both|paclitaxel|and|cisplatin (r_prep) event_8\NN\23100|an|early|common|in (r_attr) is_4\VBZ\0|in|toxicity|event|induced|. (l_nsubj) toxicity_3\NN\13576101|mitochondrial
D017239_D020258 NONE paclitaxel_11\NN\0| (r_pobj) in_10\IN\13603305|both|paclitaxel|and|cisplatin (r_prep) event_8\NN\23100|an|early|common|in (r_attr) is_4\VBZ\0|in|toxicity|event|induced|. (l_advcl) induced_14\VBN\1627355|neurotoxicity (l_dobj) neurotoxicity_15\NN\0|
D002945_D020258 NONE cisplatin_13\NN\0| (r_conj) in_10\IN\13603305|both|paclitaxel|and|cisplatin (r_prep) event_8\NN\23100|an|early|common|in (r_attr) is_4\VBZ\0|in|toxicity|event|induced|. (l_advcl) induced_14\VBN\1627355|neurotoxicity (l_dobj) neurotoxicity_15\NN\0|
D008063_D010523 NONE acid_7\NN\14818238|lipoic (r_nsubj) reduce_9\VB\441445|that|acid|might|risk|and|encourage (l_dobj) risk_11\NN\14541044|the|of (l_prep) of_12\IN\0|developing (l_pcomp) developing_13\VBG\13541167|toxicity (l_dobj) toxicity_16\NN\13576101|nerve|in
9746003
D002220_D004832 CID carbamazepine_3\NN\0|and|vigabatrin (l_conj) vigabatrin_5\VBP\0|in (l_prep) in_6\IN\13603305|seizures (l_pobj) seizures_9\NNS\14081375|typical|absence
D002220_D004832 CID carbamazepine_0\NNP\0|and|vigabatrin (r_nsubjpass) contraindicated_4\VBN\872886|carbamazepine|are|in|. (l_prep) in_5\IN\13603305|seizures (l_pobj) seizures_8\NNS\14081375|typical|absence
D020888_D004832 CID vigabatrin_5\VBP\0|in (l_prep) in_6\IN\13603305|seizures (l_pobj) seizures_9\NNS\14081375|typical|absence
D020888_D004832 CID vigabatrin_2\NN\0| (r_conj) carbamazepine_0\NNP\0|and|vigabatrin (r_nsubjpass) contraindicated_4\VBN\872886|carbamazepine|are|in|. (l_prep) in_5\IN\13603305|seizures (l_pobj) seizures_8\NNS\14081375|typical|absence
D002220_D009207 CID carbamazepine_9\NN\0|and|two (l_conj) two_11\CD\13741022|of (l_prep) of_12\IN\0|jerks (l_pobj) jerks_16\NNS\10322238|these|developed|myoclonic|,|resolved
D002220_D009207 CID carbamazepine_23\NN\0| (r_pobj) of_22\IN\0|carbamazepine (r_prep) withdrawal_21\NN\7206096|of (r_pobj) on_20\IN\0|withdrawal (r_prep) resolved_19\VBD\352826|which|on (r_relcl) jerks_16\NNS\10322238|these|developed|myoclonic|,|resolved
8829025
D016559_D006973 CID tacrolimus_5\NNS\0| (r_dobj) receiving_4\VBG\2210855|tacrolimus (r_acl) patients_3\NNS\9898892|receiving (r_pobj) of_2\IN\0|patients (r_prep) groups_1\NNS\2137|two|of (r_nsubjpass) compared_7\VBN\644583|groups|were|over|,|group|. (l_appos) group_16\NN\2137|one|comprising|,|and|other (l_acl) comprising_17\VBG\2604760|patients (l_dobj) patients_19\NNS\9898892|hypertensive|receiving (l_amod) hypertensive_18\JJ\10405694|
D016559_D006973 CID tacrolimus_12\NN\0|in (r_pobj) with_11\IN\0|tacrolimus (r_prep) associated_10\VBN\628491|with (r_acl) nephrotoxicity_9\NN\0|the|associated (r_dobj) reducing_7\VBG\13447361|nephrotoxicity (r_pcomp) on_6\IN\0|reducing (r_prep) impact_3\NN\7339329|the|observed|positive|of|on (r_nsubj) be_18\VB\14625458|impact|should|factor|. (l_attr) factor_21\NN\7326557|an|important|in (l_prep) in_22\IN\13603305|selecting (l_pcomp) selecting_23\VBG\697589|agent|treat (l_xcomp) treat_27\VB\7570720|to|hypertension (l_dobj) hypertension_28\NN\14057371|in
D009543_D006973 NONE nifedipine_23\NN\2938514| (r_dobj) receiving_22\VBG\2210855|who|were|nifedipine (r_relcl) patients_19\NNS\9898892|hypertensive|receiving (l_amod) hypertensive_18\JJ\10405694|
D009543_D006973 NONE nifedipine_33\NN\2938514| (r_dobj) receiving_32\VBG\2210855|not|nifedipine (r_acl) patients_30\NNS\9898892|nonhypertensive|receiving (r_dobj) comprising_28\VBG\2604760|patients (r_acl) other_27\JJ\0|the|comprising (r_conj) group_16\NN\2137|one|comprising|,|and|other (l_acl) comprising_17\VBG\2604760|patients (l_dobj) patients_19\NNS\9898892|hypertensive|receiving (l_amod) hypertensive_18\JJ\10405694|
D009543_D006973 NONE nifedipine_5\NN\2938514| (r_pobj) of_4\IN\0|nifedipine (r_prep) impact_3\NN\7339329|the|observed|positive|of|on (r_nsubj) be_18\VB\14625458|impact|should|factor|. (l_attr) factor_21\NN\7326557|an|important|in (l_prep) in_22\IN\13603305|selecting (l_pcomp) selecting_23\VBG\697589|agent|treat (l_xcomp) treat_27\VB\7570720|to|hypertension (l_dobj) hypertension_28\NN\14057371|in
D009543_D007674 NONE nifedipine_5\NN\2938514| (r_pobj) of_4\IN\0|nifedipine (r_prep) impact_3\NN\7339329|the|observed|positive|of|on (l_prep) on_6\IN\0|reducing (l_pcomp) reducing_7\VBG\13447361|nephrotoxicity (l_dobj) nephrotoxicity_9\NN\0|the|associated
D016559_D007674 NONE tacrolimus_12\NN\0|in (r_pobj) with_11\IN\0|tacrolimus (r_prep) associated_10\VBN\628491|with (r_acl) nephrotoxicity_9\NN\0|the|associated
11334364
D000082_D009336 CID acetaminophen_13\RB\2707683| (r_advmod) induced_15\VBN\1627355|acetaminophen|- (r_amod) nephrotoxicity_16\NN\0|induced|,|toxicity (r_pobj) during_12\IN\0|nephrotoxicity (r_prep) deaths_11\NNS\7296428|associated|apoptotic|cell|during (l_amod) apoptotic_7\JJ\0|and|necrotic (l_conj) necrotic_9\JJ\0|
D000082_D009336 CID aap_9\NNP\0|,|ami (r_appos) drugs_4\NNS\14778436|all|the|,|as|aap (r_nsubj) induced_14\VBD\1627355|interestingly|,|drugs|death|in|. (l_prep) in_17\IN\13603305|addition (l_pobj) addition_18\NN\3081021|to (l_prep) to_19\IN\0|necrosis (l_pobj) necrosis_20\NN\11444117|in|blocked
D000082_D007674 CID acetaminophen_13\RB\2707683| (r_advmod) induced_15\VBN\1627355|acetaminophen|- (r_amod) nephrotoxicity_16\NN\0|induced|,|toxicity
D000082_D007674 CID acetaminophen_16\RB\2707683| (r_advmod) prevent_15\VB\0|to|acetaminophen|toxicity (l_dobj) toxicity_25\NN\13576101|nephrotoxicity|(|ami)-induced|lung|,|and|doxorubicin (l_nmod) nephrotoxicity_19\NN\0|(|aap)-induced|,|amiodarone
D000082_D007674 CID aap)-induced_18\VBN\0| (r_compound) nephrotoxicity_19\NN\0|(|aap)-induced|,|amiodarone
D000082_D008171 NONE acetaminophen_13\RB\2707683| (r_advmod) induced_15\VBN\1627355|acetaminophen|- (r_amod) nephrotoxicity_16\NN\0|induced|,|toxicity (l_conj) toxicity_22\NN\13576101|induced|lung|and|cardiotoxicity
D000082_D008171 NONE acetaminophen_16\RB\2707683| (r_advmod) prevent_15\VB\0|to|acetaminophen|toxicity (l_dobj) toxicity_25\NN\13576101|nephrotoxicity|(|ami)-induced|lung|,|and|doxorubicin
D000082_D008171 NONE aap)-induced_18\VBN\0| (r_compound) nephrotoxicity_19\NN\0|(|aap)-induced|,|amiodarone (r_nmod) toxicity_25\NN\13576101|nephrotoxicity|(|ami)-induced|lung|,|and|doxorubicin
D000082_D066126 NONE acetaminophen_13\RB\2707683| (r_advmod) induced_15\VBN\1627355|acetaminophen|- (r_amod) nephrotoxicity_16\NN\0|induced|,|toxicity (l_conj) toxicity_22\NN\13576101|induced|lung|and|cardiotoxicity (l_conj) cardiotoxicity_27\NN\0|induced|by
D000082_D066126 NONE acetaminophen_16\RB\2707683| (r_advmod) prevent_15\VB\0|to|acetaminophen|toxicity (l_dobj) toxicity_25\NN\13576101|nephrotoxicity|(|ami)-induced|lung|,|and|doxorubicin (l_conj) doxorubicin_28\NN\2716866|cardiotoxicity (l_dobj) cardiotoxicity_31\NN\0|(|dox)-induced|in
D000082_D066126 NONE aap)-induced_18\VBN\0| (r_compound) nephrotoxicity_19\NN\0|(|aap)-induced|,|amiodarone (r_nmod) toxicity_25\NN\13576101|nephrotoxicity|(|ami)-induced|lung|,|and|doxorubicin (l_conj) doxorubicin_28\NN\2716866|cardiotoxicity (l_dobj) cardiotoxicity_31\NN\0|(|dox)-induced|in
D000638_D009336 CID amiodarone_18\NN\2715941| (r_npadvmod) induced_20\VBN\1627355|amiodarone|- (r_amod) toxicity_22\NN\13576101|induced|lung|and|cardiotoxicity (r_conj) nephrotoxicity_16\NN\0|induced|,|toxicity (r_pobj) during_12\IN\0|nephrotoxicity (r_prep) deaths_11\NNS\7296428|associated|apoptotic|cell|during (l_amod) apoptotic_7\JJ\0|and|necrotic (l_conj) necrotic_9\JJ\0|
D000638_D009336 CID ami_11\NNP\0|and|dox (r_conj) aap_9\NNP\0|,|ami (r_appos) drugs_4\NNS\14778436|all|the|,|as|aap (r_nsubj) induced_14\VBD\1627355|interestingly|,|drugs|death|in|. (l_prep) in_17\IN\13603305|addition (l_pobj) addition_18\NN\3081021|to (l_prep) to_19\IN\0|necrosis (l_pobj) necrosis_20\NN\11444117|in|blocked
D000638_D007674 NONE amiodarone_18\NN\2715941| (r_npadvmod) induced_20\VBN\1627355|amiodarone|- (r_amod) toxicity_22\NN\13576101|induced|lung|and|cardiotoxicity (r_conj) nephrotoxicity_16\NN\0|induced|,|toxicity
D000638_D007674 NONE amiodarone_21\NN\2715941| (r_appos) nephrotoxicity_19\NN\0|(|aap)-induced|,|amiodarone
D000638_D007674 NONE ami)-induced_23\JJ\0| (r_amod) toxicity_25\NN\13576101|nephrotoxicity|(|ami)-induced|lung|,|and|doxorubicin (l_nmod) nephrotoxicity_19\NN\0|(|aap)-induced|,|amiodarone
D000638_D008171 CID amiodarone_18\NN\2715941| (r_npadvmod) induced_20\VBN\1627355|amiodarone|- (r_amod) toxicity_22\NN\13576101|induced|lung|and|cardiotoxicity
D000638_D008171 CID amiodarone_21\NN\2715941| (r_appos) nephrotoxicity_19\NN\0|(|aap)-induced|,|amiodarone (r_nmod) toxicity_25\NN\13576101|nephrotoxicity|(|ami)-induced|lung|,|and|doxorubicin
D000638_D008171 CID ami)-induced_23\JJ\0| (r_amod) toxicity_25\NN\13576101|nephrotoxicity|(|ami)-induced|lung|,|and|doxorubicin
D000638_D066126 NONE amiodarone_18\NN\2715941| (r_npadvmod) induced_20\VBN\1627355|amiodarone|- (r_amod) toxicity_22\NN\13576101|induced|lung|and|cardiotoxicity (l_conj) cardiotoxicity_27\NN\0|induced|by
D000638_D066126 NONE amiodarone_21\NN\2715941| (r_appos) nephrotoxicity_19\NN\0|(|aap)-induced|,|amiodarone (r_nmod) toxicity_25\NN\13576101|nephrotoxicity|(|ami)-induced|lung|,|and|doxorubicin (l_conj) doxorubicin_28\NN\2716866|cardiotoxicity (l_dobj) cardiotoxicity_31\NN\0|(|dox)-induced|in
D000638_D066126 NONE ami)-induced_23\JJ\0| (r_amod) toxicity_25\NN\13576101|nephrotoxicity|(|ami)-induced|lung|,|and|doxorubicin (l_conj) doxorubicin_28\NN\2716866|cardiotoxicity (l_dobj) cardiotoxicity_31\NN\0|(|dox)-induced|in
D004317_D009336 CID doxorubicin_24\NN\2716866| (r_npadvmod) induced_26\VBN\1627355|doxorubicin|- (r_amod) cardiotoxicity_27\NN\0|induced|by (r_conj) toxicity_22\NN\13576101|induced|lung|and|cardiotoxicity (r_conj) nephrotoxicity_16\NN\0|induced|,|toxicity (r_pobj) during_12\IN\0|nephrotoxicity (r_prep) deaths_11\NNS\7296428|associated|apoptotic|cell|during (l_amod) apoptotic_7\JJ\0|and|necrotic (l_conj) necrotic_9\JJ\0|
D004317_D009336 CID dox_13\NNP\0| (r_conj) ami_11\NNP\0|and|dox (r_conj) aap_9\NNP\0|,|ami (r_appos) drugs_4\NNS\14778436|all|the|,|as|aap (r_nsubj) induced_14\VBD\1627355|interestingly|,|drugs|death|in|. (l_prep) in_17\IN\13603305|addition (l_pobj) addition_18\NN\3081021|to (l_prep) to_19\IN\0|necrosis (l_pobj) necrosis_20\NN\11444117|in|blocked
D004317_D007674 NONE doxorubicin_24\NN\2716866| (r_npadvmod) induced_26\VBN\1627355|doxorubicin|- (r_amod) cardiotoxicity_27\NN\0|induced|by (r_conj) toxicity_22\NN\13576101|induced|lung|and|cardiotoxicity (r_conj) nephrotoxicity_16\NN\0|induced|,|toxicity
D004317_D007674 NONE doxorubicin_28\NN\2716866|cardiotoxicity (r_conj) toxicity_25\NN\13576101|nephrotoxicity|(|ami)-induced|lung|,|and|doxorubicin (l_nmod) nephrotoxicity_19\NN\0|(|aap)-induced|,|amiodarone
D004317_D007674 NONE dox)-induced_30\JJ\0| (r_amod) cardiotoxicity_31\NN\0|(|dox)-induced|in (r_dobj) doxorubicin_28\NN\2716866|cardiotoxicity (r_conj) toxicity_25\NN\13576101|nephrotoxicity|(|ami)-induced|lung|,|and|doxorubicin (l_nmod) nephrotoxicity_19\NN\0|(|aap)-induced|,|amiodarone
D004317_D008171 NONE doxorubicin_24\NN\2716866| (r_npadvmod) induced_26\VBN\1627355|doxorubicin|- (r_amod) cardiotoxicity_27\NN\0|induced|by (r_conj) toxicity_22\NN\13576101|induced|lung|and|cardiotoxicity
D004317_D008171 NONE doxorubicin_28\NN\2716866|cardiotoxicity (r_conj) toxicity_25\NN\13576101|nephrotoxicity|(|ami)-induced|lung|,|and|doxorubicin
D004317_D008171 NONE dox)-induced_30\JJ\0| (r_amod) cardiotoxicity_31\NN\0|(|dox)-induced|in (r_dobj) doxorubicin_28\NN\2716866|cardiotoxicity (r_conj) toxicity_25\NN\13576101|nephrotoxicity|(|ami)-induced|lung|,|and|doxorubicin
D004317_D066126 CID doxorubicin_24\NN\2716866| (r_npadvmod) induced_26\VBN\1627355|doxorubicin|- (r_amod) cardiotoxicity_27\NN\0|induced|by
D004317_D066126 CID doxorubicin_28\NN\2716866|cardiotoxicity (l_dobj) cardiotoxicity_31\NN\0|(|dox)-induced|in
D004317_D066126 CID dox)-induced_30\JJ\0| (r_amod) cardiotoxicity_31\NN\0|(|dox)-induced|in
C511402_D009336 NONE extract_35\NN\14589223|a|novel|ih636|proanthocyanidin (r_pobj) by_28\IN\0|extract (r_prep) cardiotoxicity_27\NN\0|induced|by (r_conj) toxicity_22\NN\13576101|induced|lung|and|cardiotoxicity (r_conj) nephrotoxicity_16\NN\0|induced|,|toxicity (r_pobj) during_12\IN\0|nephrotoxicity (r_prep) deaths_11\NNS\7296428|associated|apoptotic|cell|during (l_amod) apoptotic_7\JJ\0|and|necrotic (l_conj) necrotic_9\JJ\0|
C511402_D009336 NONE gspe_31\NNP\0| (r_pobj) by_30\IN\0|gspe (r_agent) blocked_29\VBN\1476483|which|was|effectively|by (r_relcl) necrosis_20\NN\11444117|in|blocked
C511402_D007674 NONE extract_35\NN\14589223|a|novel|ih636|proanthocyanidin (r_pobj) by_28\IN\0|extract (r_prep) cardiotoxicity_27\NN\0|induced|by (r_conj) toxicity_22\NN\13576101|induced|lung|and|cardiotoxicity (r_conj) nephrotoxicity_16\NN\0|induced|,|toxicity
C511402_D007674 NONE extract_10\NN\14589223|ih636|proanthocyanidin|(|gspe|) (r_pobj) of_5\IN\0|extract (r_prep) ability_4\NN\4723816|the|of|prevent (l_acl) prevent_15\VB\0|to|acetaminophen|toxicity (l_dobj) toxicity_25\NN\13576101|nephrotoxicity|(|ami)-induced|lung|,|and|doxorubicin (l_nmod) nephrotoxicity_19\NN\0|(|aap)-induced|,|amiodarone
C511402_D007674 NONE gspe_12\NNP\0| (r_appos) extract_10\NN\14589223|ih636|proanthocyanidin|(|gspe|) (r_pobj) of_5\IN\0|extract (r_prep) ability_4\NN\4723816|the|of|prevent (l_acl) prevent_15\VB\0|to|acetaminophen|toxicity (l_dobj) toxicity_25\NN\13576101|nephrotoxicity|(|ami)-induced|lung|,|and|doxorubicin (l_nmod) nephrotoxicity_19\NN\0|(|aap)-induced|,|amiodarone
C511402_D008171 NONE extract_35\NN\14589223|a|novel|ih636|proanthocyanidin (r_pobj) by_28\IN\0|extract (r_prep) cardiotoxicity_27\NN\0|induced|by (r_conj) toxicity_22\NN\13576101|induced|lung|and|cardiotoxicity
C511402_D008171 NONE extract_10\NN\14589223|ih636|proanthocyanidin|(|gspe|) (r_pobj) of_5\IN\0|extract (r_prep) ability_4\NN\4723816|the|of|prevent (l_acl) prevent_15\VB\0|to|acetaminophen|toxicity (l_dobj) toxicity_25\NN\13576101|nephrotoxicity|(|ami)-induced|lung|,|and|doxorubicin
C511402_D008171 NONE gspe_12\NNP\0| (r_appos) extract_10\NN\14589223|ih636|proanthocyanidin|(|gspe|) (r_pobj) of_5\IN\0|extract (r_prep) ability_4\NN\4723816|the|of|prevent (l_acl) prevent_15\VB\0|to|acetaminophen|toxicity (l_dobj) toxicity_25\NN\13576101|nephrotoxicity|(|ami)-induced|lung|,|and|doxorubicin
C511402_D066126 NONE extract_35\NN\14589223|a|novel|ih636|proanthocyanidin (r_pobj) by_28\IN\0|extract (r_prep) cardiotoxicity_27\NN\0|induced|by
C511402_D066126 NONE extract_10\NN\14589223|ih636|proanthocyanidin|(|gspe|) (r_pobj) of_5\IN\0|extract (r_prep) ability_4\NN\4723816|the|of|prevent (l_acl) prevent_15\VB\0|to|acetaminophen|toxicity (l_dobj) toxicity_25\NN\13576101|nephrotoxicity|(|ami)-induced|lung|,|and|doxorubicin (l_conj) doxorubicin_28\NN\2716866|cardiotoxicity (l_dobj) cardiotoxicity_31\NN\0|(|dox)-induced|in
C511402_D066126 NONE gspe_12\NNP\0| (r_appos) extract_10\NN\14589223|ih636|proanthocyanidin|(|gspe|) (r_pobj) of_5\IN\0|extract (r_prep) ability_4\NN\4723816|the|of|prevent (l_acl) prevent_15\VB\0|to|acetaminophen|toxicity (l_dobj) toxicity_25\NN\13576101|nephrotoxicity|(|ami)-induced|lung|,|and|doxorubicin (l_conj) doxorubicin_28\NN\2716866|cardiotoxicity (l_dobj) cardiotoxicity_31\NN\0|(|dox)-induced|in
C511402_D017695 NONE gspe_30\NNP\0| (r_compound) preexposure_31\NN\0|gspe|than (r_pobj) of_29\IN\0|preexposure (r_prep) absence_28\NN\14449405|the|of (r_pobj) in_26\IN\13603305|absence (r_prep) variety_17\NN\7951464|a|of|by|in (r_pobj) with_15\IN\0|variety (r_prep) damage_14\NN\7296428|massive|tissue|with
8643971
D017239_D006258 NONE paclitaxel_7\NN\0| (r_pobj) of_6\IN\0|paclitaxel (r_prep) study_5\NN\635850|ii|of (r_dobj) phase_1\NN\15113229|a|study|plus|cisplatin|. (l_conj) cisplatin_9\NN\0|as (l_prep) as_10\IN\14622893|therapy (l_pobj) therapy_14\NN\657604|line|for|:|results (l_prep) for_15\IN\0|cancers (l_pobj) cancers_19\NNS\14239425|head
D017239_D006258 NONE paclitaxel_13\NN\0|agent|taxol (r_pobj) of_9\IN\0|paclitaxel (r_prep) study_8\NN\635850|an|group|of (r_pobj) of_2\IN\0|study (r_prep) results_1\NNS\34213|preliminary|of (r_nsubj) reported_27\VBD\831651|results|rate|used|. (l_dobj) rate_32\NN\13815152|a|%|response|in|,|and (l_prep) in_33\IN\13603305|patients (l_pobj) patients_34\NNS\9898892|with (l_prep) with_35\IN\0|cancer (l_pobj) cancer_39\NN\14239425|head
D017239_D006258 NONE taxol_15\NNP\0|(|;|company|) (r_appos) paclitaxel_13\NN\0|agent|taxol (r_pobj) of_9\IN\0|paclitaxel (r_prep) study_8\NN\635850|an|group|of (r_pobj) of_2\IN\0|study (r_prep) results_1\NNS\34213|preliminary|of (r_nsubj) reported_27\VBD\831651|results|rate|used|. (l_dobj) rate_32\NN\13815152|a|%|response|in|,|and (l_prep) in_33\IN\13603305|patients (l_pobj) patients_34\NNS\9898892|with (l_prep) with_35\IN\0|cancer (l_pobj) cancer_39\NN\14239425|head
D017239_D006258 NONE paclitaxel_43\NN\0| (r_nmod) combination_46\NN\7951464|the|paclitaxel|cisplatin (r_nsubjpass) used_49\VBN\0|combination|has|been|successfully|and|improved (r_conj) reported_27\VBD\831651|results|rate|used|. (l_dobj) rate_32\NN\13815152|a|%|response|in|,|and (l_prep) in_33\IN\13603305|patients (l_pobj) patients_34\NNS\9898892|with (l_prep) with_35\IN\0|cancer (l_pobj) cancer_39\NN\14239425|head
D017239_D006258 NONE paclitaxel_16\NN\0| (r_compound) doses_17\NNS\3740161|escalating|paclitaxel|combined (l_acl) combined_18\VBN\2630189|with|with (l_prep) with_24\IN\0|support (l_pobj) support_30\NN\407535|granulocyte|factor|in (l_prep) in_31\IN\13603305|patients (l_pobj) patients_32\NNS\9898892|with (l_prep) with_33\IN\0|head (l_pobj) head_38\NN\5225090|untreated|advanced|inoperable|and|carcinoma (l_conj) carcinoma_41\NN\14239918|neck
D017239_D006258 NONE paclitaxel_0\NNP\0| (r_nsubj) is_3\VBZ\0|paclitaxel|cisplatin|regimen|warranted (l_attr) regimen_9\NN\5898568|an|effective|line|for|and (l_prep) for_10\IN\0|head (l_pobj) head_13\NN\5225090|advanced|and|cancer (l_conj) cancer_16\NN\14239425|neck
D002945_D006258 NONE cisplatin_9\NN\0|as (l_prep) as_10\IN\14622893|therapy (l_pobj) therapy_14\NN\657604|line|for|:|results (l_prep) for_15\IN\0|cancers (l_pobj) cancers_19\NNS\14239425|head
D002945_D006258 NONE cisplatin_45\NN\0|/ (r_compound) combination_46\NN\7951464|the|paclitaxel|cisplatin (r_nsubjpass) used_49\VBN\0|combination|has|been|successfully|and|improved (r_conj) reported_27\VBD\831651|results|rate|used|. (l_dobj) rate_32\NN\13815152|a|%|response|in|,|and (l_prep) in_33\IN\13603305|patients (l_pobj) patients_34\NNS\9898892|with (l_prep) with_35\IN\0|cancer (l_pobj) cancer_39\NN\14239425|head
D002945_D006258 NONE cisplatin_23\NN\0|dose (r_pobj) with_19\IN\0|cisplatin (r_prep) combined_18\VBN\2630189|with|with (l_prep) with_24\IN\0|support (l_pobj) support_30\NN\407535|granulocyte|factor|in (l_prep) in_31\IN\13603305|patients (l_pobj) patients_32\NNS\9898892|with (l_prep) with_33\IN\0|head (l_pobj) head_38\NN\5225090|untreated|advanced|inoperable|and|carcinoma (l_conj) carcinoma_41\NN\14239918|neck
D002945_D006258 NONE cisplatin_2\NN\0|/ (r_advmod) is_3\VBZ\0|paclitaxel|cisplatin|regimen|warranted (l_attr) regimen_9\NN\5898568|an|effective|line|for|and (l_prep) for_10\IN\0|head (l_pobj) head_13\NN\5225090|advanced|and|cancer (l_conj) cancer_16\NN\14239425|neck
D017239_D010051 NONE paclitaxel_13\NN\0|agent|taxol (r_pobj) of_9\IN\0|paclitaxel (r_prep) study_8\NN\635850|an|group|of (r_pobj) of_2\IN\0|study (r_prep) results_1\NNS\34213|preliminary|of (r_nsubj) reported_27\VBD\831651|results|rate|used|. (l_conj) used_49\VBN\0|combination|has|been|successfully|and|improved (l_conj) improved_54\VBN\126264|has|significantly|duration (l_dobj) duration_57\NN\15113229|median|response|in (l_prep) in_58\IN\13603305|patients (l_pobj) patients_61\NNS\9898892|ovarian|cancer (l_compound) cancer_60\NN\14239425|
D017239_D010051 NONE taxol_15\NNP\0|(|;|company|) (r_appos) paclitaxel_13\NN\0|agent|taxol (r_pobj) of_9\IN\0|paclitaxel (r_prep) study_8\NN\635850|an|group|of (r_pobj) of_2\IN\0|study (r_prep) results_1\NNS\34213|preliminary|of (r_nsubj) reported_27\VBD\831651|results|rate|used|. (l_conj) used_49\VBN\0|combination|has|been|successfully|and|improved (l_conj) improved_54\VBN\126264|has|significantly|duration (l_dobj) duration_57\NN\15113229|median|response|in (l_prep) in_58\IN\13603305|patients (l_pobj) patients_61\NNS\9898892|ovarian|cancer (l_compound) cancer_60\NN\14239425|
D017239_D010051 NONE paclitaxel_43\NN\0| (r_nmod) combination_46\NN\7951464|the|paclitaxel|cisplatin (r_nsubjpass) used_49\VBN\0|combination|has|been|successfully|and|improved (l_conj) improved_54\VBN\126264|has|significantly|duration (l_dobj) duration_57\NN\15113229|median|response|in (l_prep) in_58\IN\13603305|patients (l_pobj) patients_61\NNS\9898892|ovarian|cancer (l_compound) cancer_60\NN\14239425|
D002945_D010051 NONE cisplatin_45\NN\0|/ (r_compound) combination_46\NN\7951464|the|paclitaxel|cisplatin (r_nsubjpass) used_49\VBN\0|combination|has|been|successfully|and|improved (l_conj) improved_54\VBN\126264|has|significantly|duration (l_dobj) duration_57\NN\15113229|median|response|in (l_prep) in_58\IN\13603305|patients (l_pobj) patients_61\NNS\9898892|ovarian|cancer (l_compound) cancer_60\NN\14239425|
D017239_D064420 NONE paclitaxel_16\NN\0| (r_compound) doses_17\NNS\3740161|escalating|paclitaxel|combined (r_pobj) of_14\IN\0|doses (r_prep) response_11\NN\11410625|the|and|toxicity|of (l_conj) toxicity_13\NN\13576101|
D017239_D064420 NONE paclitaxel_5\NN\0| (r_compound) doses_6\NNS\3740161|escalating|paclitaxel (r_dobj) incorporate_3\VBP\1461328|levels|doses|,|and|permitted (l_conj) permitted_17\VBN\797697|escalations|are|permits|. (l_advcl) permits_20\VBZ\6479665|if|toxicity (l_nsubj) toxicity_19\NN\13576101|
D002945_D064420 NONE cisplatin_23\NN\0|dose (r_pobj) with_19\IN\0|cisplatin (r_prep) combined_18\VBN\2630189|with|with (r_acl) doses_17\NNS\3740161|escalating|paclitaxel|combined (r_pobj) of_14\IN\0|doses (r_prep) response_11\NN\11410625|the|and|toxicity|of (l_conj) toxicity_13\NN\13576101|
20667451
D003474_D003072 NONE curcumin_0\NN\0| (r_nsubj) ameliorates_1\VBZ\126264|curcumin|dysfunction|. (l_dobj) dysfunction_3\NN\14204950|cognitive|and|damage|administered
D003474_D003072 NONE curcumin_14\NN\0| (r_compound) administration_15\NN\1133281|chronic|curcumin (r_pobj) of_12\IN\0|administration (r_prep) effect_11\NN\34213|the|of|on (l_prep) on_16\IN\0|impairment (l_pobj) impairment_23\NN\7296428|phenobarbitone-|cognitive|and|stress
D003474_D003072 NONE curcumin_1\NN\0| (r_compound) administration_2\NN\1133281|concomitant|curcumin (r_nsubj) prevented_3\VBD\0|administration|impairment|and|decreased|. (l_dobj) impairment_6\NN\7296428|the|cognitive
D003474_D003072 NONE curcumin_4\NN\0| (r_nsubj) has_5\VBZ\13888491|that|curcumin|effect (l_dobj) effect_7\NN\34213|beneficial|in (l_prep) in_8\IN\13603305|mitigating (l_pcomp) mitigating_9\VBG\894738|deterioration (l_dobj) deterioration_11\NN\14560612|the|of (l_prep) of_12\IN\0|functions (l_pobj) functions_14\NNS\13783581|cognitive|and|damage
D003474_D003072 NONE curcumin_4\NN\0| (r_nsubjpass) considered_7\VBN\689344|that|curcumin|can|be|as|phenobarbitone (l_advcl) phenobarbitone_16\NN\2792049|to|and|therapy|in (l_prep) in_20\IN\13603305|preventing (l_pcomp) preventing_21\VBG\0|impairment (l_dobj) impairment_23\NN\7296428|cognitive|associated
D010634_D003072 CID phenobarbitone_8\NN\2792049|and|carbamazepine (r_pobj) in_7\IN\13603305|phenobarbitone (r_prep) damage_6\NN\7296428|oxidative|in (r_conj) dysfunction_3\NN\14204950|cognitive|and|damage|administered
D010634_D003072 CID phenobarbitone_4\NN\2792049|and|carbamazepine (r_conj) drugs_2\NNS\14778436|the|antiepileptic|,|phenobarbitone (r_nsubj) are_7\VBP\13600404|drugs|known|. (l_acomp) known_9\JJ\0|well|cause (l_xcomp) cause_11\VB\7323922|to|impairment (l_dobj) impairment_13\NN\7296428|cognitive|on
D010634_D003072 CID phenobarbitone-_17\JJ\0|and|induced (r_nmod) impairment_23\NN\7296428|phenobarbitone-|cognitive|and|stress
D010634_D003072 CID phenobarbitone_3\NN\2792049|and|carbamazepine (r_pobj) of_2\IN\0|phenobarbitone (r_prep) administration_1\NN\1133281|the|of|for (r_nsubj) caused_8\VBD\1617192|administration|impairment|. (l_dobj) impairment_11\NN\7296428|a|significant|of (l_prep) of_12\IN\0|learning|stress (l_pobj) learning_13\NN\5701944|and|memory|as (l_conj) memory_15\NN\5926676|
D010634_D003072 CID phenobarbitone_22\NN\2792049|and|carbamazepine (r_pobj) with_21\IN\0|phenobarbitone (r_prep) treated_20\VBN\2376958|with|without (r_acl) rats_19\NNS\2329401|treated (r_pobj) in_18\IN\13603305|rats (r_prep) damage_17\NN\7296428|oxidative|in (r_conj) functions_14\NNS\13783581|cognitive|and|damage
D010634_D003072 CID phenobarbitone_16\NN\2792049|to|and|therapy|in (l_prep) in_20\IN\13603305|preventing (l_pcomp) preventing_21\VBG\0|impairment (l_dobj) impairment_23\NN\7296428|cognitive|associated
D002220_D003072 CID carbamazepine_10\NN\0| (r_conj) phenobarbitone_8\NN\2792049|and|carbamazepine (r_pobj) in_7\IN\13603305|phenobarbitone (r_prep) damage_6\NN\7296428|oxidative|in (r_conj) dysfunction_3\NN\14204950|cognitive|and|damage|administered
D002220_D003072 CID carbamazepine_6\NN\0| (r_conj) phenobarbitone_4\NN\2792049|and|carbamazepine (r_conj) drugs_2\NNS\14778436|the|antiepileptic|,|phenobarbitone (r_nsubj) are_7\VBP\13600404|drugs|known|. (l_acomp) known_9\JJ\0|well|cause (l_xcomp) cause_11\VB\7323922|to|impairment (l_dobj) impairment_13\NN\7296428|cognitive|on
D002220_D003072 CID carbamazepine_19\NN\0| (r_npadvmod) induced_21\VBN\1627355|carbamazepine|- (r_conj) phenobarbitone-_17\JJ\0|and|induced (r_nmod) impairment_23\NN\7296428|phenobarbitone-|cognitive|and|stress
D002220_D003072 CID carbamazepine_5\NN\0| (r_conj) phenobarbitone_3\NN\2792049|and|carbamazepine (r_pobj) of_2\IN\0|phenobarbitone (r_prep) administration_1\NN\1133281|the|of|for (r_nsubj) caused_8\VBD\1617192|administration|impairment|. (l_dobj) impairment_11\NN\7296428|a|significant|of (l_prep) of_12\IN\0|learning|stress (l_pobj) learning_13\NN\5701944|and|memory|as (l_conj) memory_15\NN\5926676|
D002220_D003072 CID carbamazepine_24\NN\0| (r_conj) phenobarbitone_22\NN\2792049|and|carbamazepine (r_pobj) with_21\IN\0|phenobarbitone (r_prep) treated_20\VBN\2376958|with|without (r_acl) rats_19\NNS\2329401|treated (r_pobj) in_18\IN\13603305|rats (r_prep) damage_17\NN\7296428|oxidative|in (r_conj) functions_14\NNS\13783581|cognitive|and|damage
D002220_D003072 CID carbamazepine_18\NN\0| (r_compound) therapy_19\NN\657604|carbamazepine (r_conj) phenobarbitone_16\NN\2792049|to|and|therapy|in (l_prep) in_20\IN\13603305|preventing (l_pcomp) preventing_21\VBG\0|impairment (l_dobj) impairment_23\NN\7296428|cognitive|associated
7582165
D000305_D004342 NONE corticosteroids_5\NNS\14745635| (r_pobj) to_4\IN\0|corticosteroids (r_prep) reactions_3\NNS\13446390|allergic|to|:|diagnosis|.
D010248_D004342 NONE paramethasone_3\NN\0| (r_pobj) from_2\IN\0|paramethasone (r_prep) different_1\JJ\0|from (r_amod) corticosteroids_0\NNS\14745635|different (r_nsubj) produced_5\VBD\1617192|corticosteroids|also|reactions (l_dobj) reactions_7\NNS\13446390|hypersensitivity|in (l_compound) hypersensitivity_6\NN\14531772|
D010248_D004342 NONE paramethasone_16\NN\0| (r_pobj) by_15\IN\0|paramethasone (r_agent) caused_14\VBN\1617192|by (r_acl) allergy_13\NN\14533203|a|pseudo|-|caused
8421099
D015282_D042882 CID octreotide_12\NN\0| (r_appos) analog_10\NN\4743605|somatostatin|(|octreotide|) (r_pobj) of_8\IN\0|analog (r_prep) effects_7\NNS\13245626|the|term|of|on (l_prep) on_14\IN\0|function (l_pobj) function_16\NN\13783581|gallbladder|and|formation|in (l_conj) formation_19\NN\7938773|gallstone (l_compound) gallstone_18\NN\9230768|
D015282_D042882 CID octreotide_3\NN\0| (r_pobj) with_2\IN\0|octreotide (r_prep) treatment_1\NN\654885|with (r_pobj) during_0\IN\0|treatment (r_prep) developed_7\VBD\1753788|during|,|patients|sludge|had|. (l_conj) had_11\VBD\0|10|gallstones|,|and|developed (l_dobj) gallstones_12\NNS\9230768|
D015282_D042882 CID octreotide_3\NN\0| (r_pobj) of_2\IN\0|octreotide (r_prep) withdrawal_1\NN\7206096|of|in (l_prep) in_4\IN\13603305|patients (l_pobj) patients_6\NNS\9898892|10|without (l_prep) without_7\IN\0|gallstones (l_pobj) gallstones_8\NNS\9230768|
D015282_D042882 CID octreotide_25\NN\0| (r_compound) therapy_26\NN\657604|octreotide|in (r_pobj) during_24\IN\0|therapy (r_prep) formation_15\NN\7938773|the|successive|of|during (l_prep) of_16\IN\0|sludge (l_pobj) sludge_18\NN\14591635|bile|,|gallstones (l_conj) gallstones_20\NNS\9230768|,|and|cholecystitis
D015282_D000172 NONE octreotide_12\NN\0| (r_appos) analog_10\NN\4743605|somatostatin|(|octreotide|) (r_pobj) of_8\IN\0|analog (r_prep) effects_7\NNS\13245626|the|term|of|on (l_prep) on_14\IN\0|function (l_pobj) function_16\NN\13783581|gallbladder|and|formation|in (l_prep) in_20\IN\13603305|patients (l_pobj) patients_23\NNS\9898892|chinese|acromegalic (l_compound) acromegalic_22\JJ\0|
D015282_D000172 NONE octreotide_26\NN\0| (r_appos) analog_25\NN\4743605|the|somatostatin|octreotide (r_pobj) of_22\IN\0|analog (r_prep) injection_21\NN\320852|sc|of (r_pobj) with_19\IN\0|injection (r_prep) treated_18\VBN\2376958|with|in|day|for (r_acl) patients_14\NNS\9898892|20|chinese|with|treated (l_prep) with_15\IN\0|acromegaly (l_pobj) acromegaly_17\NNS\14366759|active
D015282_D000172 NONE octreotide_25\NN\0| (r_compound) therapy_26\NN\657604|octreotide|in (l_prep) in_27\IN\13603305|patients (l_pobj) patients_30\NNS\9898892|chinese|acromegalic (l_compound) acromegalic_29\JJ\0|
D015282_D000172 NONE octreotide_16\NN\0| (r_compound) therapy_17\NN\657604|term|octreotide|of (l_prep) of_18\IN\0|patients (l_pobj) patients_20\NNS\9898892|acromegalic (l_compound) acromegalic_19\JJ\0|
D015282_D041881 CID octreotide_3\NN\0| (r_pobj) with_2\IN\0|octreotide (r_prep) treatment_1\NN\654885|with (r_pobj) during_0\IN\0|treatment (r_prep) developed_7\VBD\1753788|during|,|patients|sludge|had|. (l_conj) had_11\VBD\0|10|gallstones|,|and|developed (l_conj) developed_16\VBD\1753788|1|cholecystitis|requiring (l_dobj) cholecystitis_18\NN\14336539|acute
D015282_D002764 NONE octreotide_25\NN\0| (r_compound) therapy_26\NN\657604|octreotide|in (r_pobj) during_24\IN\0|therapy (r_prep) formation_15\NN\7938773|the|successive|of|during (l_prep) of_16\IN\0|sludge (l_pobj) sludge_18\NN\14591635|bile|,|gallstones (l_conj) gallstones_20\NNS\9230768|,|and|cholecystitis (l_conj) cholecystitis_23\NN\14336539|
2385256
D008274_D009157 CID magnesium_6\NN\14625458| (r_compound) administration_7\NN\1133281|magnesium (r_pobj) after_5\IN\0|administration (r_prep) weakness_4\NN\14462666|after (r_pobj) as_3\IN\14622893|weakness (r_prep) presenting_2\VBG\2137132|as (r_acl) gravis_1\NN\0|myasthenia|presenting|.
D008274_D009157 CID magnesium_3\NN\14625458| (r_compound) administration_4\NN\1133281|magnesium (r_pobj) after_2\IN\0|administration (r_prep) paralysis_1\NN\14557898|after (r_nsubjpass) described_7\VBN\1001294|although|paralysis|has|been|in (l_prep) in_8\IN\13603305|patients (l_pobj) patients_9\NNS\9898892|with (l_prep) with_10\IN\0|gravis (l_pobj) gravis_13\NN\0|known|myasthenia
D008274_D009468 NONE magnesium_17\NN\14625458| (r_compound) administration_18\NN\1133281|parenteral|magnesium|for (r_pobj) after_15\IN\0|administration (r_prep) became_12\VBD\146138|who|quadriplegic|after (r_relcl) disease_10\NN\14061805|neuromuscular|became
D008274_D011782 NONE magnesium_17\NN\14625458| (r_compound) administration_18\NN\1133281|parenteral|magnesium|for (r_pobj) after_15\IN\0|administration (r_prep) became_12\VBD\146138|who|quadriplegic|after (l_acomp) quadriplegic_14\JJ\10158756|virtually
D008274_D011225 NONE magnesium_17\NN\14625458| (r_compound) administration_18\NN\1133281|parenteral|magnesium|for (l_prep) for_19\IN\0|preeclampsia (l_pobj) preeclampsia_20\NN\14191037|
D008274_D010243 NONE magnesium_3\NN\14625458| (r_compound) administration_4\NN\1133281|magnesium (r_pobj) after_2\IN\0|administration (r_prep) paralysis_1\NN\14557898|after
D008274_D020511 NONE magnesium_10\NN\14625458| (r_pobj) of_9\IN\0|magnesium (r_prep) effects_8\NNS\13245626|the|neuromuscular|of (r_pobj) to_5\IN\0|effects (r_prep) sensitive_4\JJ\10488309|unusually|to (r_acomp) are_2\VBP\13600404|who|sensitive (r_relcl) patients_0\NNS\9898892|are (r_nsubjpass) suspected_13\VBN\916909|patients|should|be|of|. (l_prep) of_14\IN\0|having (l_pcomp) having_15\VBG\0|disorder (l_dobj) disorder_18\NN\14034177|an|underlying|of (l_prep) of_19\IN\0|transmission (l_pobj) transmission_21\NN\121166|neuromuscular
7988234
D008790_D000799 CID metoprolol_6\NN\2832168| (r_pobj) of_5\IN\0|metoprolol (r_prep) administration_4\NN\1133281|the|intravenous|of (r_dobj) following_1\VBG\8180190|administration (r_prep) angioedema_0\NNP\14316714|following|.
D008790_D000799 CID metoprolol_12\NN\2832168|intravenous (r_nsubjpass) given_14\VBN\5892096|during|,|metoprolol|was|,|resulting|. (l_advcl) resulting_16\VBG\2633881|in (l_prep) in_17\IN\13603305|angioedema (l_pobj) angioedema_19\NN\14316714|severe
D017706_D000799 CID lisinopril_6\NN\2673637| (r_compound) therapy_7\NN\657604|lisinopril (r_pobj) to_5\IN\0|therapy (r_prep) history_1\NN\15120823|a|of|to (l_prep) of_2\IN\0|angioedema (l_pobj) angioedema_3\NN\14316714|secondary
D013256_D000799 NONE steroids_7\NNS\14727670|intravenous|and|diphenhydramine (r_pobj) with_5\IN\0|steroids (r_prep) resolved_2\VBD\352826|angioedema|after|with|. (l_nsubj) angioedema_1\NN\14316714|the
D004155_D000799 NONE diphenhydramine_9\NN\2720725|hydrochloride (r_conj) steroids_7\NNS\14727670|intravenous|and|diphenhydramine (r_pobj) with_5\IN\0|steroids (r_prep) resolved_2\VBD\352826|angioedema|after|with|. (l_nsubj) angioedema_1\NN\14316714|the
2611118
D004008_D006521 NONE sodium_6\NN\14625458| (r_compound) therapy_7\NN\657604|diclofenac|sodium (r_pobj) with_4\IN\0|therapy (r_prep) associated_3\VBN\628491|with (r_acl) hepatitis_2\NN\14127211|chronic|active|associated|.
D004008_D006521 NONE sodium_13\NN\14625458|diclofenac (r_pobj) with_11\IN\0|sodium (r_prep) therapy_10\NN\657604|months|with|progressed (r_pobj) after_7\IN\0|therapy (r_prep) developed_3\VBD\1753788|patient|hepatitis|after|,|finding|. (l_dobj) hepatitis_6\NN\14127211|chronic|active
D004008_D056486 CID diclofenac_23\NNP\0| (r_pobj) by_22\IN\0|diclofenac (r_agent) induced_21\VBN\1627355|,|commonly|,|hepatitis|by|. (r_conj) recorded_13\VBN\2225492|tolerated|,|abnormalities|have|been|and|induced (l_nsubjpass) abnormalities_7\NNS\14034177|asymptomatic|of (l_prep) of_8\IN\0|function (l_pobj) function_10\NN\13783581|liver
D004008_D056486 CID diclofenac_23\NNP\0| (r_pobj) by_22\IN\0|diclofenac (r_agent) induced_21\VBN\1627355|,|commonly|,|hepatitis|by|. (l_nsubj) hepatitis_20\NN\14127211|severe
10457883
11745184
D002945_D001943 NONE cisplatin_5\NN\0|plus (r_nmod) amifostine_9\NN\0|cisplatin|wr-2721|(|) (r_pobj) of_4\IN\0|amifostine (r_prep) trial_3\NN\786195|a|ii|of|for|:|e8188|. (l_prep) for_11\IN\0|carcinoma (l_pobj) carcinoma_14\NN\14239918|metastatic|breast
D002945_D001943 NONE cisplatin_0\NNP\0| (r_nsubj) has_1\VBZ\13888491|cisplatin|activity|used|. (l_advcl) used_6\VBN\0|when|as (l_prep) as_7\IN\14622893|treatment (l_pobj) treatment_13\NN\654885|second-|line|of (l_prep) of_14\IN\0|carcinoma (l_pobj) carcinoma_17\NN\14239918|metastatic|breast
D002945_D001943 NONE cisplatin_10\NN\0| (r_pobj) with_9\IN\0|cisplatin (r_prep) observed_8\VBN\2163746|although|effect|has|been|with (r_advcl) limited_31\VBN\4019101|observed|,|toxicities|have|use|. (l_dobj) use_33\NN\407535|its|as (l_prep) as_34\IN\14622893|treatment (l_pobj) treatment_36\NN\654885|a|for (l_prep) for_37\IN\0|carcinoma (l_pobj) carcinoma_39\NN\14239918|breast
D002945_D001943 NONE cisplatin_19\NN\0|nephrotoxicity (r_pcomp) with_18\IN\0|cisplatin (r_prep) associated_17\VBN\628491|with (r_acl) toxicities_16\NNS\13576101|the|limiting|associated (r_nsubj) limited_31\VBN\4019101|observed|,|toxicities|have|use|. (l_dobj) use_33\NN\407535|its|as (l_prep) as_34\IN\14622893|treatment (l_pobj) treatment_36\NN\654885|a|for (l_prep) for_37\IN\0|carcinoma (l_pobj) carcinoma_39\NN\14239918|breast
D002945_D001943 NONE cisplatin_8\NN\0|plus|amifostine (r_pobj) of_7\IN\0|cisplatin (r_prep) combination_6\NN\7951464|the|of (r_pobj) of_4\IN\0|combination (r_prep) study_3\NN\635850|a|ii|of (r_nsubjpass) conducted_12\VBN\2436349|study|was|in|,|but|regimen (l_prep) in_13\IN\13603305|patients (l_pobj) patients_14\NNS\9898892|with (l_prep) with_15\IN\0|carcinoma (l_pobj) carcinoma_19\NN\14239918|progressive|metastatic|breast|received
D004999_D001943 NONE wr-2721_7\NNP\0| (r_nmod) amifostine_9\NN\0|cisplatin|wr-2721|(|) (r_pobj) of_4\IN\0|amifostine (r_prep) trial_3\NN\786195|a|ii|of|for|:|e8188|. (l_prep) for_11\IN\0|carcinoma (l_pobj) carcinoma_14\NN\14239918|metastatic|breast
D004999_D001943 NONE amifostine_9\NN\0|cisplatin|wr-2721|(|) (r_pobj) of_4\IN\0|amifostine (r_prep) trial_3\NN\786195|a|ii|of|for|:|e8188|. (l_prep) for_11\IN\0|carcinoma (l_pobj) carcinoma_14\NN\14239918|metastatic|breast
D004999_D001943 NONE amifostine_10\NN\0| (r_conj) cisplatin_8\NN\0|plus|amifostine (r_pobj) of_7\IN\0|cisplatin (r_prep) combination_6\NN\7951464|the|of (r_pobj) of_4\IN\0|combination (r_prep) study_3\NN\635850|a|ii|of (r_nsubjpass) conducted_12\VBN\2436349|study|was|in|,|but|regimen (l_prep) in_13\IN\13603305|patients (l_pobj) patients_14\NNS\9898892|with (l_prep) with_15\IN\0|carcinoma (l_pobj) carcinoma_19\NN\14239918|progressive|metastatic|breast|received
D002945_D064420 NONE cisplatin_10\NN\0| (r_pobj) with_9\IN\0|cisplatin (r_prep) observed_8\VBN\2163746|although|effect|has|been|with (r_advcl) limited_31\VBN\4019101|observed|,|toxicities|have|use|. (l_nsubj) toxicities_16\NNS\13576101|the|limiting|associated
D002945_D064420 NONE cisplatin_19\NN\0|nephrotoxicity (r_pcomp) with_18\IN\0|cisplatin (r_prep) associated_17\VBN\628491|with (r_acl) toxicities_16\NNS\13576101|the|limiting|associated
D002945_D064420 NONE cisplatin_20\VB\0|to|in (r_acl) amifostine_18\NN\0|cisplatin (r_pobj) of_17\IN\0|amifostine (r_prep) addition_16\NN\3081021|the|of (r_pobj) with_14\IN\0|addition (r_prep) observed_13\VBN\2163746|effect|was|with|. (l_nsubjpass) effect_5\NN\34213|neither|a|protective|nor|reduced (l_conj) reduced_7\VBN\441445|toxicity|to (l_dobj) toxicity_8\NN\13576101|
D002945_D007674 CID cisplatin_10\NN\0| (r_pobj) with_9\IN\0|cisplatin (r_prep) observed_8\VBN\2163746|although|effect|has|been|with (r_advcl) limited_31\VBN\4019101|observed|,|toxicities|have|use|. (l_nsubj) toxicities_16\NNS\13576101|the|limiting|associated (l_acl) associated_17\VBN\628491|with (l_prep) with_18\IN\0|cisplatin (l_pcomp) cisplatin_19\NN\0|nephrotoxicity (l_preconj) nephrotoxicity_23\NN\0|(|e.g.|,|,|ototoxicity|)
D002945_D007674 CID cisplatin_19\NN\0|nephrotoxicity (l_preconj) nephrotoxicity_23\NN\0|(|e.g.|,|,|ototoxicity|)
D002945_D007674 CID cisplatin_3\NN\0|and|amifostine (r_pobj) of_2\IN\0|cisplatin (r_prep) trials_1\NNS\786195|early|of (r_nsubj) suggested_7\VBD\1010118|trials|also|reduced|. (l_ccomp) reduced_24\VBN\441445|that|incidence|were (l_nsubjpass) incidence_10\NN\13821570|the|and|severity|of (l_prep) of_13\IN\0|nephrotoxicity (l_pobj) nephrotoxicity_17\NN\0|induced|,|ototoxicity
D002945_D007674 CID cisplatin_14\NN\0| (r_advmod) induced_16\VBN\1627355|cisplatin|- (r_amod) nephrotoxicity_17\NN\0|induced|,|ototoxicity
D002945_D006311 CID cisplatin_10\NN\0| (r_pobj) with_9\IN\0|cisplatin (r_prep) observed_8\VBN\2163746|although|effect|has|been|with (r_advcl) limited_31\VBN\4019101|observed|,|toxicities|have|use|. (l_nsubj) toxicities_16\NNS\13576101|the|limiting|associated (l_acl) associated_17\VBN\628491|with (l_prep) with_18\IN\0|cisplatin (l_pcomp) cisplatin_19\NN\0|nephrotoxicity (l_preconj) nephrotoxicity_23\NN\0|(|e.g.|,|,|ototoxicity|) (l_conj) ototoxicity_25\NN\0|,|and|neurotoxicity
D002945_D006311 CID cisplatin_19\NN\0|nephrotoxicity (l_preconj) nephrotoxicity_23\NN\0|(|e.g.|,|,|ototoxicity|) (l_conj) ototoxicity_25\NN\0|,|and|neurotoxicity
D002945_D006311 CID cisplatin_3\NN\0|and|amifostine (r_pobj) of_2\IN\0|cisplatin (r_prep) trials_1\NNS\786195|early|of (r_nsubj) suggested_7\VBD\1010118|trials|also|reduced|. (l_ccomp) reduced_24\VBN\441445|that|incidence|were (l_nsubjpass) incidence_10\NN\13821570|the|and|severity|of (l_prep) of_13\IN\0|nephrotoxicity (l_pobj) nephrotoxicity_17\NN\0|induced|,|ototoxicity (l_conj) ototoxicity_19\NN\0|,|and|neuropathy
D002945_D006311 CID cisplatin_14\NN\0| (r_advmod) induced_16\VBN\1627355|cisplatin|- (r_amod) nephrotoxicity_17\NN\0|induced|,|ototoxicity (l_conj) ototoxicity_19\NN\0|,|and|neuropathy
D002945_D020258 NONE cisplatin_10\NN\0| (r_pobj) with_9\IN\0|cisplatin (r_prep) observed_8\VBN\2163746|although|effect|has|been|with (r_advcl) limited_31\VBN\4019101|observed|,|toxicities|have|use|. (l_nsubj) toxicities_16\NNS\13576101|the|limiting|associated (l_acl) associated_17\VBN\628491|with (l_prep) with_18\IN\0|cisplatin (l_pcomp) cisplatin_19\NN\0|nephrotoxicity (l_preconj) nephrotoxicity_23\NN\0|(|e.g.|,|,|ototoxicity|) (l_conj) ototoxicity_25\NN\0|,|and|neurotoxicity (l_conj) neurotoxicity_28\NN\0|
D002945_D020258 NONE cisplatin_19\NN\0|nephrotoxicity (l_preconj) nephrotoxicity_23\NN\0|(|e.g.|,|,|ototoxicity|) (l_conj) ototoxicity_25\NN\0|,|and|neurotoxicity (l_conj) neurotoxicity_28\NN\0|
D002945_D009422 CID cisplatin_3\NN\0|and|amifostine (r_pobj) of_2\IN\0|cisplatin (r_prep) trials_1\NNS\786195|early|of (r_nsubj) suggested_7\VBD\1010118|trials|also|reduced|. (l_ccomp) reduced_24\VBN\441445|that|incidence|were (l_nsubjpass) incidence_10\NN\13821570|the|and|severity|of (l_prep) of_13\IN\0|nephrotoxicity (l_pobj) nephrotoxicity_17\NN\0|induced|,|ototoxicity (l_conj) ototoxicity_19\NN\0|,|and|neuropathy (l_conj) neuropathy_22\NN\14204950|
D002945_D009422 CID cisplatin_14\NN\0| (r_advmod) induced_16\VBN\1627355|cisplatin|- (r_amod) nephrotoxicity_17\NN\0|induced|,|ototoxicity (l_conj) ototoxicity_19\NN\0|,|and|neuropathy (l_conj) neuropathy_22\NN\14204950|
D004999_D007674 NONE amifostine_5\NN\0| (r_conj) cisplatin_3\NN\0|and|amifostine (r_pobj) of_2\IN\0|cisplatin (r_prep) trials_1\NNS\786195|early|of (r_nsubj) suggested_7\VBD\1010118|trials|also|reduced|. (l_ccomp) reduced_24\VBN\441445|that|incidence|were (l_nsubjpass) incidence_10\NN\13821570|the|and|severity|of (l_prep) of_13\IN\0|nephrotoxicity (l_pobj) nephrotoxicity_17\NN\0|induced|,|ototoxicity
D004999_D006311 NONE amifostine_5\NN\0| (r_conj) cisplatin_3\NN\0|and|amifostine (r_pobj) of_2\IN\0|cisplatin (r_prep) trials_1\NNS\786195|early|of (r_nsubj) suggested_7\VBD\1010118|trials|also|reduced|. (l_ccomp) reduced_24\VBN\441445|that|incidence|were (l_nsubjpass) incidence_10\NN\13821570|the|and|severity|of (l_prep) of_13\IN\0|nephrotoxicity (l_pobj) nephrotoxicity_17\NN\0|induced|,|ototoxicity (l_conj) ototoxicity_19\NN\0|,|and|neuropathy
D004999_D009422 NONE amifostine_5\NN\0| (r_conj) cisplatin_3\NN\0|and|amifostine (r_pobj) of_2\IN\0|cisplatin (r_prep) trials_1\NNS\786195|early|of (r_nsubj) suggested_7\VBD\1010118|trials|also|reduced|. (l_ccomp) reduced_24\VBN\441445|that|incidence|were (l_nsubjpass) incidence_10\NN\13821570|the|and|severity|of (l_prep) of_13\IN\0|nephrotoxicity (l_pobj) nephrotoxicity_17\NN\0|induced|,|ototoxicity (l_conj) ototoxicity_19\NN\0|,|and|neuropathy (l_conj) neuropathy_22\NN\14204950|
D004999_D009369 NONE amifostine_18\NN\0|cisplatin (r_pobj) of_17\IN\0|amifostine (r_prep) addition_16\NN\3081021|the|of (r_pobj) with_14\IN\0|addition (r_prep) observed_13\VBN\2163746|effect|was|with|. (l_nsubjpass) effect_5\NN\34213|neither|a|protective|nor|reduced (l_amod) protective_4\JJ\0|tumor|- (l_npadvmod) tumor_2\NN\14234074|
D004999_D064420 NONE amifostine_18\NN\0|cisplatin (r_pobj) of_17\IN\0|amifostine (r_prep) addition_16\NN\3081021|the|of (r_pobj) with_14\IN\0|addition (r_prep) observed_13\VBN\2163746|effect|was|with|. (l_nsubjpass) effect_5\NN\34213|neither|a|protective|nor|reduced (l_conj) reduced_7\VBN\441445|toxicity|to (l_dobj) toxicity_8\NN\13576101|
D002945_D009369 NONE cisplatin_20\VB\0|to|in (r_acl) amifostine_18\NN\0|cisplatin (r_pobj) of_17\IN\0|amifostine (r_prep) addition_16\NN\3081021|the|of (r_pobj) with_14\IN\0|addition (r_prep) observed_13\VBN\2163746|effect|was|with|. (l_nsubjpass) effect_5\NN\34213|neither|a|protective|nor|reduced (l_amod) protective_4\JJ\0|tumor|- (l_npadvmod) tumor_2\NN\14234074|
3714122
C005238_D020258 NONE mipafox_7\NN\0| (r_npadvmod) induced_9\VBN\1627355|mipafox|- (r_amod) damage_11\NN\7296428|induced|neuropathic|in (r_conj) inhibition_5\NN\1068773|neurotoxic|esterase|and|damage (l_amod) neurotoxic_3\JJ\0|
C005238_D020258 NONE mipafox_24\NNP\0|n'-diisopropylphosphorodiamidofluoridate|)|,|organophosphate (r_pobj) to_23\IN\0|mipafox (r_prep) exposed_22\VBN\2110927|acutely|to (r_acl) rats_20\NNS\2329401|exposed (r_pobj) in_19\IN\13603305|rats (r_prep) examined_18\VBN\0|correlation|was|in|. (l_nsubjpass) correlation_1\NN\13841213|the|between (l_prep) between_2\IN\0|damage (l_pobj) damage_4\NN\7296428|neuropathic|and|inhibition|of (l_prep) of_7\IN\0|esterase (l_pobj) esterase_9\NN\0|neurotoxic|or|enzyme (l_amod) neurotoxic_8\JJ\0|
C005238_D020258 NONE mipafox_24\NNP\0|n'-diisopropylphosphorodiamidofluoridate|)|,|organophosphate (l_appos) organophosphate_33\NN\14919948|a|neurotoxic (l_amod) neurotoxic_32\JJ\0|
C005238_D020258 NONE n'-diisopropylphosphorodiamidofluoridate_28\NNP\0|(|n|, (r_appos) mipafox_24\NNP\0|n'-diisopropylphosphorodiamidofluoridate|)|,|organophosphate (r_pobj) to_23\IN\0|mipafox (r_prep) exposed_22\VBN\2110927|acutely|to (r_acl) rats_20\NNS\2329401|exposed (r_pobj) in_19\IN\13603305|rats (r_prep) examined_18\VBN\0|correlation|was|in|. (l_nsubjpass) correlation_1\NN\13841213|the|between (l_prep) between_2\IN\0|damage (l_pobj) damage_4\NN\7296428|neuropathic|and|inhibition|of (l_prep) of_7\IN\0|esterase (l_pobj) esterase_9\NN\0|neurotoxic|or|enzyme (l_amod) neurotoxic_8\JJ\0|
C005238_D020258 NONE n'-diisopropylphosphorodiamidofluoridate_28\NNP\0|(|n|, (r_appos) mipafox_24\NNP\0|n'-diisopropylphosphorodiamidofluoridate|)|,|organophosphate (l_appos) organophosphate_33\NN\14919948|a|neurotoxic (l_amod) neurotoxic_32\JJ\0|
C005238_D009422 NONE mipafox_7\NN\0| (r_npadvmod) induced_9\VBN\1627355|mipafox|- (r_amod) damage_11\NN\7296428|induced|neuropathic|in
C005238_D009422 NONE mipafox_24\NNP\0|n'-diisopropylphosphorodiamidofluoridate|)|,|organophosphate (r_pobj) to_23\IN\0|mipafox (r_prep) exposed_22\VBN\2110927|acutely|to (r_acl) rats_20\NNS\2329401|exposed (r_pobj) in_19\IN\13603305|rats (r_prep) examined_18\VBN\0|correlation|was|in|. (l_nsubjpass) correlation_1\NN\13841213|the|between (l_prep) between_2\IN\0|damage (l_pobj) damage_4\NN\7296428|neuropathic|and|inhibition|of
C005238_D009422 NONE mipafox_24\NNP\0|n'-diisopropylphosphorodiamidofluoridate|)|,|organophosphate (r_pobj) to_23\IN\0|mipafox (r_prep) exposed_22\VBN\2110927|acutely|to (r_acl) rats_20\NNS\2329401|exposed (r_pobj) in_19\IN\13603305|rats (r_prep) examined_18\VBN\0|correlation|was|in|. (l_nsubjpass) correlation_1\NN\13841213|the|between (l_prep) between_2\IN\0|damage (l_pobj) damage_4\NN\7296428|neuropathic|and|inhibition|of (l_prep) of_7\IN\0|esterase (l_pobj) esterase_9\NN\0|neurotoxic|or|enzyme (l_conj) enzyme_13\NN\14723628|target|(|nte|) (l_compound) target_12\NN\7258332|neuropathy (l_compound) neuropathy_11\NN\14204950|
C005238_D009422 NONE n'-diisopropylphosphorodiamidofluoridate_28\NNP\0|(|n|, (r_appos) mipafox_24\NNP\0|n'-diisopropylphosphorodiamidofluoridate|)|,|organophosphate (r_pobj) to_23\IN\0|mipafox (r_prep) exposed_22\VBN\2110927|acutely|to (r_acl) rats_20\NNS\2329401|exposed (r_pobj) in_19\IN\13603305|rats (r_prep) examined_18\VBN\0|correlation|was|in|. (l_nsubjpass) correlation_1\NN\13841213|the|between (l_prep) between_2\IN\0|damage (l_pobj) damage_4\NN\7296428|neuropathic|and|inhibition|of
C005238_D009422 NONE n'-diisopropylphosphorodiamidofluoridate_28\NNP\0|(|n|, (r_appos) mipafox_24\NNP\0|n'-diisopropylphosphorodiamidofluoridate|)|,|organophosphate (r_pobj) to_23\IN\0|mipafox (r_prep) exposed_22\VBN\2110927|acutely|to (r_acl) rats_20\NNS\2329401|exposed (r_pobj) in_19\IN\13603305|rats (r_prep) examined_18\VBN\0|correlation|was|in|. (l_nsubjpass) correlation_1\NN\13841213|the|between (l_prep) between_2\IN\0|damage (l_pobj) damage_4\NN\7296428|neuropathic|and|inhibition|of (l_prep) of_7\IN\0|esterase (l_pobj) esterase_9\NN\0|neurotoxic|or|enzyme (l_conj) enzyme_13\NN\14723628|target|(|nte|) (l_compound) target_12\NN\7258332|neuropathy (l_compound) neuropathy_11\NN\14204950|
C005238_D009422 NONE mipafox_18\NNP\0| (r_compound) exposure_19\NN\5042871|mipafox (r_nsubj) predict_21\VB\916909|shortly|after|exposure|can|damage|later (l_dobj) damage_23\NN\7296428|neuropathic|in
D010755_D009422 NONE organophosphate_33\NN\14919948|a|neurotoxic (r_appos) mipafox_24\NNP\0|n'-diisopropylphosphorodiamidofluoridate|)|,|organophosphate (r_pobj) to_23\IN\0|mipafox (r_prep) exposed_22\VBN\2110927|acutely|to (r_acl) rats_20\NNS\2329401|exposed (r_pobj) in_19\IN\13603305|rats (r_prep) examined_18\VBN\0|correlation|was|in|. (l_nsubjpass) correlation_1\NN\13841213|the|between (l_prep) between_2\IN\0|damage (l_pobj) damage_4\NN\7296428|neuropathic|and|inhibition|of
D010755_D009422 NONE organophosphate_33\NN\14919948|a|neurotoxic (r_appos) mipafox_24\NNP\0|n'-diisopropylphosphorodiamidofluoridate|)|,|organophosphate (r_pobj) to_23\IN\0|mipafox (r_prep) exposed_22\VBN\2110927|acutely|to (r_acl) rats_20\NNS\2329401|exposed (r_pobj) in_19\IN\13603305|rats (r_prep) examined_18\VBN\0|correlation|was|in|. (l_nsubjpass) correlation_1\NN\13841213|the|between (l_prep) between_2\IN\0|damage (l_pobj) damage_4\NN\7296428|neuropathic|and|inhibition|of (l_prep) of_7\IN\0|esterase (l_pobj) esterase_9\NN\0|neurotoxic|or|enzyme (l_conj) enzyme_13\NN\14723628|target|(|nte|) (l_compound) target_12\NN\7258332|neuropathy (l_compound) neuropathy_11\NN\14204950|
D010755_D020258 NONE organophosphate_33\NN\14919948|a|neurotoxic (r_appos) mipafox_24\NNP\0|n'-diisopropylphosphorodiamidofluoridate|)|,|organophosphate (r_pobj) to_23\IN\0|mipafox (r_prep) exposed_22\VBN\2110927|acutely|to (r_acl) rats_20\NNS\2329401|exposed (r_pobj) in_19\IN\13603305|rats (r_prep) examined_18\VBN\0|correlation|was|in|. (l_nsubjpass) correlation_1\NN\13841213|the|between (l_prep) between_2\IN\0|damage (l_pobj) damage_4\NN\7296428|neuropathic|and|inhibition|of (l_prep) of_7\IN\0|esterase (l_pobj) esterase_9\NN\0|neurotoxic|or|enzyme (l_amod) neurotoxic_8\JJ\0|
D010755_D020258 NONE organophosphate_33\NN\14919948|a|neurotoxic (l_amod) neurotoxic_32\JJ\0|
C005238_D013118 CID mipafox_5\NNP\0| (r_pobj) of_4\IN\0|mipafox (r_prep) dosages_3\NNS\13576355|of|less|inhibited (r_nsubj) produced_39\VBN\1617192|in|,|dosages|degree|in|. (l_dobj) degree_41\NN\4916342|this|of (l_prep) of_42\IN\0|damage (l_pobj) damage_44\NN\7296428|cord
9195768
D018170_D010292 CID sumatriptan_7\NN\0|subcutaneous (r_pobj) of_5\IN\0|sumatriptan (r_prep) use_4\NN\407535|the|of (r_dobj) following_2\VBG\8180190|use (r_prep) sensations_1\NNS\5708432|atypical|following
6387529
D003975_D016584 NONE diazepam_3\NN\2830852| (r_pobj) of_2\IN\0|diazepam (r_prep) effects_1\NNS\13245626|behavioral|of|and|propranolol|. (l_conj) propranolol_5\NN\0|in (l_prep) in_6\IN\13603305|patients (l_pobj) patients_7\NNS\9898892|with (l_prep) with_8\IN\0|disorder (l_pobj) disorder_10\NN\14034177|panic|and|agoraphobia
D003975_D016584 NONE diazepam_6\NN\2830852| (r_pobj) of_5\IN\0|diazepam (r_prep) doses_4\NNS\3740161|oral|of|(|dose|and (r_pobj) of_2\IN\0|doses (r_prep) effects_1\NNS\13245626|the|of (r_nsubj) propranolol_27\NN\0|effects|dose (r_advcl) investigated_58\VBN\644583|propranolol|dose|were|in|. (l_nsubjpass) dose_37\NN\3740161|a|median|of|for|)|on (l_prep) on_47\IN\0|performance (l_pobj) performance_49\NN\6619065|psychological|of (l_prep) of_50\IN\0|patients (l_pobj) patients_51\NNS\9898892|with (l_prep) with_52\IN\0|disorders (l_pobj) disorders_54\NNS\14034177|panic|and|agoraphobia
D003975_D000379 NONE diazepam_3\NN\2830852| (r_pobj) of_2\IN\0|diazepam (r_prep) effects_1\NNS\13245626|behavioral|of|and|propranolol|. (l_conj) propranolol_5\NN\0|in (l_prep) in_6\IN\13603305|patients (l_pobj) patients_7\NNS\9898892|with (l_prep) with_8\IN\0|disorder (l_pobj) disorder_10\NN\14034177|panic|and|agoraphobia (l_conj) agoraphobia_12\NNP\14381416|
D003975_D000379 NONE diazepam_6\NN\2830852| (r_pobj) of_5\IN\0|diazepam (r_prep) doses_4\NNS\3740161|oral|of|(|dose|and (r_pobj) of_2\IN\0|doses (r_prep) effects_1\NNS\13245626|the|of (r_nsubj) propranolol_27\NN\0|effects|dose (r_advcl) investigated_58\VBN\644583|propranolol|dose|were|in|. (l_nsubjpass) dose_37\NN\3740161|a|median|of|for|)|on (l_prep) on_47\IN\0|performance (l_pobj) performance_49\NN\6619065|psychological|of (l_prep) of_50\IN\0|patients (l_pobj) patients_51\NNS\9898892|with (l_prep) with_52\IN\0|disorders (l_pobj) disorders_54\NNS\14034177|panic|and|agoraphobia (l_conj) agoraphobia_56\NNP\14381416|
D011433_D016584 NONE propranolol_5\NN\0|in (l_prep) in_6\IN\13603305|patients (l_pobj) patients_7\NNS\9898892|with (l_prep) with_8\IN\0|disorder (l_pobj) disorder_10\NN\14034177|panic|and|agoraphobia
D011433_D016584 NONE propranolol_27\NN\0|effects|dose (r_advcl) investigated_58\VBN\644583|propranolol|dose|were|in|. (l_nsubjpass) dose_37\NN\3740161|a|median|of|for|)|on (l_prep) on_47\IN\0|performance (l_pobj) performance_49\NN\6619065|psychological|of (l_prep) of_50\IN\0|patients (l_pobj) patients_51\NNS\9898892|with (l_prep) with_52\IN\0|disorders (l_pobj) disorders_54\NNS\14034177|panic|and|agoraphobia
D011433_D000379 NONE propranolol_5\NN\0|in (l_prep) in_6\IN\13603305|patients (l_pobj) patients_7\NNS\9898892|with (l_prep) with_8\IN\0|disorder (l_pobj) disorder_10\NN\14034177|panic|and|agoraphobia (l_conj) agoraphobia_12\NNP\14381416|
D011433_D000379 NONE propranolol_27\NN\0|effects|dose (r_advcl) investigated_58\VBN\644583|propranolol|dose|were|in|. (l_nsubjpass) dose_37\NN\3740161|a|median|of|for|)|on (l_prep) on_47\IN\0|performance (l_pobj) performance_49\NN\6619065|psychological|of (l_prep) of_50\IN\0|patients (l_pobj) patients_51\NNS\9898892|with (l_prep) with_52\IN\0|disorders (l_pobj) disorders_54\NNS\14034177|panic|and|agoraphobia (l_conj) agoraphobia_56\NNP\14381416|
D003975_D008569 CID diazepam_12\NN\2830852|propranolol (r_pobj) for_11\IN\0|diazepam (r_prep) greater_10\JJR\0|for (r_acomp) was_9\VBD\0|decrease|greater|. (r_conj) impaired_2\VBD\258857|drugs|recall|but|was (l_dobj) recall_5\NN\7185325|immediate|free
D011433_D008569 CID propranolol_14\NN\0|than (r_advcl) diazepam_12\NN\2830852|propranolol (r_pobj) for_11\IN\0|diazepam (r_prep) greater_10\JJR\0|for (r_acomp) was_9\VBD\0|decrease|greater|. (r_conj) impaired_2\VBD\258857|drugs|recall|but|was (l_dobj) recall_5\NN\7185325|immediate|free
9034419
C047426_D012640 CID venlafaxine_4\NNP\0| (r_amod) overdose_5\NN\84738|a|venlafaxine (r_pobj) from_2\IN\0|overdose (r_prep) resulting_1\VBG\2633881|from (r_acl) seizure_0\NN\14081375|resulting|.
C047426_D012640 CID venlafaxine_5\NNP\0|26 (r_pobj) of_3\IN\0|venlafaxine (r_prep) ingestion_2\NN\13440063|the|of|tablets (r_pobj) after_0\IN\0|ingestion (r_prep) experienced_11\VBD\2108377|after|,|patient|seizure|. (l_dobj) seizure_15\NN\14081375|a|witnessed|generalized
C047426_D012640 CID venlafaxine_11\NNP\0| (r_amod) overdose_12\NN\84738|venlafaxine (r_pobj) of_10\IN\0|overdose (r_prep) case_9\NN\7283608|the|first|reported|of|resulted (l_relcl) resulted_14\VBD\2633881|that|in (l_prep) in_15\IN\13603305|seizure (l_pobj) seizure_18\NN\14081375|a|generalized
C047426_D012640 CID venlafaxine_1\NNP\0| (r_amod) overdose_2\NN\84738|the|venlafaxine|in (r_nsubj) resulted_6\VBD\2633881|overdose|in|but|elicited|. (l_prep) in_7\IN\13603305|episode (l_pobj) episode_10\NN\7283608|a|single|of (l_prep) of_11\IN\0|seizure (l_pobj) seizure_13\NN\14081375|generalized
C047426_D062787 CID venlafaxine_4\NNP\0| (r_amod) overdose_5\NN\84738|a|venlafaxine
C047426_D062787 CID venlafaxine_5\NNP\0| (r_amod) overdose_6\NN\84738|venlafaxine
C047426_D062787 CID venlafaxine_12\NN\0| (r_pobj) of_11\IN\0|venlafaxine (r_prep) overdose_10\NN\84738|an|of
C047426_D062787 CID venlafaxine_11\NNP\0| (r_amod) overdose_12\NN\84738|venlafaxine
C047426_D062787 CID venlafaxine_1\NNP\0| (r_amod) overdose_2\NN\84738|the|venlafaxine|in
C047426_D003865 NONE venlafaxine_12\NN\0| (r_pobj) of_11\IN\0|venlafaxine (r_prep) overdose_10\NN\84738|an|of (r_dobj) took_8\VBD\2367363|woman|overdose|in|. (l_nsubj) woman_4\NN\9605289|a|old|with (l_prep) with_5\IN\0|depression (l_pobj) depression_7\NN\14373582|major
14976857
D011405_-1 NONE propafenone_9\NN\0| (r_compound) overdose_10\NN\84738|propafenone|in (r_pobj) by_8\IN\0|overdose (r_agent) induced_7\VBN\1627355|by (r_acl) syndrome_6\NN\5870365|transient|like|induced|.
D011405_D062787 NONE propafenone_9\NN\0| (r_compound) overdose_10\NN\84738|propafenone|in
D011405_D062787 NONE propafenone_26\NN\0| (r_compound) overdose_27\NN\84738|a|propafenone
D011405_D004437 NONE propafenone_9\NN\0| (r_compound) overdose_10\NN\84738|propafenone|in (l_prep) in_11\IN\13603305|woman (l_pobj) woman_14\NN\9605289|a|young|with (l_prep) with_15\IN\0|anomaly (l_pobj) anomaly_18\NN\14501726|ebstein
D011405_D054092 NONE propafenone_26\NN\0| (r_compound) overdose_27\NN\84738|a|propafenone (r_pobj) by_24\IN\0|overdose (r_agent) precipitated_23\VBN\1642924|was|probably|by (r_conj) occurred_9\VBD\0|shunt|in|,|and|precipitated|. (l_nsubj) shunt_1\NN\5248181|this|of|via (l_prep) via_4\IN\0|ovale (l_pobj) ovale_8\NN\0|a|foramen
9522143
D011318_D034381 CID prilocaine_2\NN\0| (r_dobj) given_1\VBN\5892096|prilocaine (r_acl) patients_0\NNS\9898892|given|p (r_nsubj) were_3\VBD\0|patients|likely|. (l_acomp) likely_5\JJ\0|more|develop (l_xcomp) develop_7\VB\1753788|to|hearing (l_xcomp) hearing_8\VBG\1184814|loss (l_dobj) loss_9\NN\13252973|10|than
D011318_D034381 CID prilocaine_12\NN\0|and|db (r_pobj) after_11\IN\0|prilocaine (r_prep) was_7\VBD\0|loss|db|after|. (l_nsubj) loss_3\NN\13252973|the|average|hearing|for
D002045_D034381 CID bupivacaine_19\NN\0|those|given|4 (r_pobj) than_16\IN\0|bupivacaine (r_prep) loss_9\NN\13252973|10|than
D002045_D034381 CID bupivacaine_17\NN\0| (r_pobj) after_16\IN\0|bupivacaine (r_prep) db_15\NN\14622893|15|after (r_conj) prilocaine_12\NN\0|and|db (r_pobj) after_11\IN\0|prilocaine (r_prep) was_7\VBD\0|loss|db|after|. (l_nsubj) loss_3\NN\13252973|the|average|hearing|for
1835291
D009241_D029424 NONE bromide_5\NN\14904359|ipratropium|and|theophylline (r_pobj) of_3\IN\0|bromide (r_prep) effects_2\NNS\13245626|acute|bronchodilating|of|in|. (l_prep) in_8\IN\13603305|disease (l_pobj) disease_12\NN\14061805|chronic|obstructive|pulmonary
D009241_D029424 NONE bromide_9\NN\14904359| (r_compound) aerosol_10\NN\11439690|ipratropium|bromide|(|micrograms|)|and|tablets (r_pobj) of_7\IN\0|aerosol (r_prep) dose_6\NN\3740161|a|single|of|titrated (r_pobj) of_3\IN\0|dose (r_prep) effects_2\NNS\13245626|the|bronchodilator|of (r_nsubjpass) compared_37\VBN\644583|effects|were|in|. (l_prep) in_38\IN\13603305|study (l_pobj) study_48\NN\635850|a|blind|,|controlled|crossover|in (l_prep) in_49\IN\13603305|patients (l_pobj) patients_51\NNS\9898892|21|with (l_prep) with_52\IN\0|disease (l_pobj) disease_58\NN\14061805|stable|,|chronic|obstructive|pulmonary
D009241_D029424 NONE ipratropium_4\NN\0| (r_nsubj) is_5\VBZ\0|that|ipratropium|bronchodilator|in (l_prep) in_13\IN\13603305|patients (l_pobj) patients_14\NNS\9898892|with (l_prep) with_15\IN\0|obstruction (l_pobj) obstruction_18\NN\4341686|chronic|airflow
D013806_D029424 NONE theophylline_7\NN\2905612| (r_conj) bromide_5\NN\14904359|ipratropium|and|theophylline (r_pobj) of_3\IN\0|bromide (r_prep) effects_2\NNS\13245626|acute|bronchodilating|of|in|. (l_prep) in_8\IN\13603305|disease (l_pobj) disease_12\NN\14061805|chronic|obstructive|pulmonary
D013806_D029424 NONE theophylline_19\NN\2905612| (r_amod) tablets_20\NNS\4233405|acting|theophylline (r_conj) aerosol_10\NN\11439690|ipratropium|bromide|(|micrograms|)|and|tablets (r_pobj) of_7\IN\0|aerosol (r_prep) dose_6\NN\3740161|a|single|of|titrated (r_pobj) of_3\IN\0|dose (r_prep) effects_2\NNS\13245626|the|bronchodilator|of (r_nsubjpass) compared_37\VBN\644583|effects|were|in|. (l_prep) in_38\IN\13603305|study (l_pobj) study_48\NN\635850|a|blind|,|controlled|crossover|in (l_prep) in_49\IN\13603305|patients (l_pobj) patients_51\NNS\9898892|21|with (l_prep) with_52\IN\0|disease (l_pobj) disease_58\NN\14061805|stable|,|chronic|obstructive|pulmonary
D013806_D029424 NONE theophylline_12\NN\2905612|oral (r_pobj) than_10\IN\0|theophylline (r_prep) bronchodilator_9\NN\3740161|a|potent|than (r_attr) is_5\VBZ\0|that|ipratropium|bronchodilator|in (l_prep) in_13\IN\13603305|patients (l_pobj) patients_14\NNS\9898892|with (l_prep) with_15\IN\0|obstruction (l_pobj) obstruction_18\NN\4341686|chronic|airflow
D013806_D002318 CID theophylline_9\JJ\2905612| (r_amod) use_10\NN\407535|theophylline (r_pobj) after_8\IN\0|use (r_prep) experienced_7\VBN\2108377|after (r_acl) those_6\DT\0|experienced (r_nsubj) involve_12\VB\2676054|were|,|those|did|systems|. (l_dobj) systems_17\NNS\3575240|the|cardiovascular
D013806_D005767 CID theophylline_9\JJ\2905612| (r_amod) use_10\NN\407535|theophylline (r_pobj) after_8\IN\0|use (r_prep) experienced_7\VBN\2108377|after (r_acl) those_6\DT\0|experienced (r_nsubj) involve_12\VB\2676054|were|,|those|did|systems|. (l_dobj) systems_17\NNS\3575240|the|cardiovascular
6287825
D013831_D010523 CID thiamine_7\NN\15090742|and|riboflavin (r_pobj) of_6\IN\0|thiamine (r_prep) deficiency_5\NN\14449126|nutritional|of (r_pobj) due_2\IN\5174653|to|deficiency (r_prep) neuropathy_1\NNS\14204950|peripheral|due
D013831_D010523 CID thiamine_7\NN\15090742|and|riboflavin (r_pobj) of_6\IN\0|thiamine (r_prep) deficiency_5\NN\14449126|nutritional|of (r_pobj) due_2\IN\5174653|to|deficiency (r_prep) neuropathy_1\NNS\14204950|peripheral|due (r_nsubj) was_10\VBD\0|neuropathy|common|%|and|presented|. (l_conj) presented_17\VBN\2137132|as (l_prep) as_19\IN\14622893|mainly|neuropathy (l_pobj) neuropathy_25\NN\14204950|sensory
D013831_D044342 NONE thiamine_7\NN\15090742|and|riboflavin (r_pobj) of_6\IN\0|thiamine (r_prep) deficiency_5\NN\14449126|nutritional|of
D012256_D010523 CID riboflavin_9\NN\15090742| (r_conj) thiamine_7\NN\15090742|and|riboflavin (r_pobj) of_6\IN\0|thiamine (r_prep) deficiency_5\NN\14449126|nutritional|of (r_pobj) due_2\IN\5174653|to|deficiency (r_prep) neuropathy_1\NNS\14204950|peripheral|due
D012256_D010523 CID riboflavin_9\NN\15090742| (r_conj) thiamine_7\NN\15090742|and|riboflavin (r_pobj) of_6\IN\0|thiamine (r_prep) deficiency_5\NN\14449126|nutritional|of (r_pobj) due_2\IN\5174653|to|deficiency (r_prep) neuropathy_1\NNS\14204950|peripheral|due (r_nsubj) was_10\VBD\0|neuropathy|common|%|and|presented|. (l_conj) presented_17\VBN\2137132|as (l_prep) as_19\IN\14622893|mainly|neuropathy (l_pobj) neuropathy_25\NN\14204950|sensory
D012256_D044342 NONE riboflavin_9\NN\15090742| (r_conj) thiamine_7\NN\15090742|and|riboflavin (r_pobj) of_6\IN\0|thiamine (r_prep) deficiency_5\NN\14449126|nutritional|of
D007538_D009422 NONE isoniazid_0\NNP\2716205| (r_nsubj) was_1\VBD\0|isoniazid|agent|. (l_attr) agent_5\NN\7347|the|frequent|in (l_prep) in_6\IN\13603305|neuropathy (l_pobj) neuropathy_10\NN\14204950|induced
19269743
D002211_D010146 CID capsaicin_9\NN\15032661| (r_npadvmod) induced_11\VBN\1627355|capsaicin|- (r_amod) pain_12\NN\14299637|induced
D002211_D010146 CID capsaicin_21\NN\15032661| (r_pobj) of_20\IN\0|capsaicin (r_prep) doses_19\NNS\3740161|three|of|microg (r_pobj) of_17\IN\0|doses (r_prep) injections_16\NNS\320852|intradermal|of|separated (r_dobj) received_14\VBD\2210855|in|,|volunteers|injections|)|,|given|. (l_prep) in_0\IN\13603305|order (l_pobj) order_1\NN\7168131|address (l_acl) address_3\VB\6355894|to|memory (l_dobj) memory_8\NN\5926676|term|pain (l_compound) pain_7\NN\14299637|
D002211_D010146 CID capsaicin_11\NN\15032661| (r_compound) doses_12\NNS\3740161|capsaicin|(|p<0.001|) (r_pobj) across_10\IN\0|doses (r_prep) discriminate_5\VB\650353|to|reliably|magnitude|across|,|regardless (l_dobj) magnitude_7\NN\4916342|pain|and|duration (l_compound) pain_6\NN\14299637|
15130900
D003520_D001749 CID cyclophosphamide_12\NN\0| (r_pobj) to_11\IN\0|cyclophosphamide (r_prep) risks_8\NNS\14541044|and|relation|to (r_appos) granulomatosis_6\NN\0|wegener|:|risks (r_pobj) in_3\IN\13603305|granulomatosis (r_prep) cancer_2\NN\14239425|urinary|bladder|in|.
D003520_D001749 CID cyclophosphamide_16\NN\0| (r_pobj) to_15\IN\0|cyclophosphamide (r_prep) relation_14\NN\2137|its|to|,|in (r_conj) assess_3\VB\5220461|to|and|characterise|,|and|relation (l_conj) characterise_5\VB\651991|risk (l_dobj) risk_7\NN\14541044|the|of (l_prep) of_8\IN\0|cancer (l_pobj) cancer_10\NN\14239425|bladder
D003520_D001749 CID cyclophosphamide_18\NN\0|and|cancer (l_conj) cancer_21\NN\14239425|bladder
D003520_D001749 CID cyclophosphamide_12\NN\0| (r_pobj) in_11\IN\13603305|cyclophosphamide (r_prep) increment_10\NN\29677|every|10|g|in|(|or (r_pobj) for_6\IN\0|increment (r_prep) doubled_5\VBD\247390|risk|for|. (l_nsubj) risk_1\NN\14541044|the|of (l_prep) of_2\IN\0|cancer (l_pobj) cancer_4\NN\14239425|bladder
D003520_D001749 CID cyclophosphamide_9\NN\0| (r_pobj) between_8\IN\0|cyclophosphamide (r_prep) relationship_7\NN\31921|a|response|between|and|risk (l_conj) risk_12\NN\14541044|the|of|,|risks (l_prep) of_13\IN\0|cancer (l_pobj) cancer_15\NN\14239425|bladder
D003520_D014890 NONE cyclophosphamide_12\NN\0| (r_pobj) to_11\IN\0|cyclophosphamide (r_prep) risks_8\NNS\14541044|and|relation|to (r_appos) granulomatosis_6\NN\0|wegener|:|risks
D003520_D014890 NONE cyclophosphamide_16\NN\0| (r_pobj) to_15\IN\0|cyclophosphamide (r_prep) relation_14\NN\2137|its|to|,|in (l_prep) in_18\IN\13603305|patients (l_pobj) patients_19\NNS\9898892|with (l_prep) with_20\IN\0|granulomatosis (l_pobj) granulomatosis_23\NN\0|wegener
D003520_D014890 NONE cyclophosphamide_9\NN\0| (r_pobj) between_8\IN\0|cyclophosphamide (r_prep) relationship_7\NN\31921|a|response|between|and|risk (l_conj) risk_12\NN\14541044|the|of|,|risks (l_conj) risks_19\NNS\14541044|high|cumulative|in|,|and|possibility (l_conj) possibility_28\NN\5944958|the|of (l_prep) of_29\IN\0|factors (l_pobj) factors_31\NNS\7326557|risk|operating (l_acl) operating_32\VBG\2439501|before (l_prep) before_34\IN\0|even|granulomatosis (l_pobj) granulomatosis_37\NN\0|wegener
17612891
D003024_D009205 CID clozapine_4\NN\3713736| (r_pobj) with_3\IN\0|clozapine (r_prep) associated_2\VBN\628491|with (r_acl) myocarditis_1\NN\14338942|acute|associated|.
D003024_D009205 CID clozapine_10\NN\3713736| (r_pobj) of_9\IN\0|clozapine (r_prep) commencement_8\NN\15180528|the|of (r_pobj) with_6\IN\0|commencement (r_prep) associated_5\VBN\628491|with (r_acl) case_1\NN\7283608|a|of|associated (l_prep) of_2\IN\0|myocarditis (l_pobj) myocarditis_4\NN\14338942|acute
D003024_D009205 CID clozapine_16\NN\3713736| (r_pobj) of_15\IN\0|clozapine (r_prep) commencement_14\NN\15180528|of (r_pobj) after_13\IN\0|commencement (r_prep) developed_7\VBD\1753788|male|onset|after|. (l_dobj) onset_10\NN\7325190|a|sudden|of (l_prep) of_11\IN\0|myocarditis (l_pobj) myocarditis_12\NN\14338942|
D003024_D009205 CID clozapine_11\NN\3713736| (r_pobj) of_10\IN\0|clozapine (r_prep) use_9\NN\407535|the|of (r_pobj) with_7\IN\0|use (r_prep) associated_6\VBN\628491|with (r_acl) complication_5\NN\1073995|an|recognized|associated (r_attr) is_1\VBZ\0|myocarditis|complication|. (l_nsubj) myocarditis_0\NNP\14338942|
D003024_D012559 NONE clozapine_16\NN\3713736| (r_pobj) of_15\IN\0|clozapine (r_prep) commencement_14\NN\15180528|of (r_pobj) after_13\IN\0|commencement (r_prep) developed_7\VBD\1753788|male|onset|after|. (l_nsubj) male_4\NN\15388|a|old|with (l_prep) with_5\IN\0|schizophrenia (l_pobj) schizophrenia_6\NN\14398067|
D003024_D011618 NONE clozapine_2\NN\3713736|that (r_pobj) considering_0\VBG\689344|clozapine (r_csubj) remains_3\VBZ\2684|considering|standard (l_attr) standard_6\NN\13577171|the|gold|in (l_prep) in_7\IN\13603305|treatment (l_pobj) treatment_8\NN\654885|of (l_prep) of_9\IN\0|psychosis (l_pobj) psychosis_11\NN\14380140|resistant
1428568
D013999_D005901 NONE timolol_6\NN\2832168| (r_compound) 0.5%/12h_7\CD\0|timolol (r_pobj) with_5\IN\0|0.5%/12h (r_prep) treated_4\VBN\2376958|patients|chronically|with|,|suffering (l_nsubj) patients_2\NNS\9898892|eight|glaucomatous (l_amod) glaucomatous_1\JJ\0|
D013999_D003866 CID timolol_6\NN\2832168| (r_compound) 0.5%/12h_7\CD\0|timolol (r_pobj) with_5\IN\0|0.5%/12h (r_prep) treated_4\VBN\2376958|patients|chronically|with|,|suffering (l_advcl) suffering_9\VBG\14322699|from|diagnosed (l_prep) from_10\IN\0|depression (l_pobj) depression_11\NN\14373582|
D013999_D003866 CID timolol_15\NN\2832168| (r_compound) treatment_16\NN\654885|timolol (r_pobj) under_14\IN\0|treatment (r_prep) patients_13\NNS\9898892|the|under (r_nsubj) presented_17\VBD\2137132|in|,|patients|values|. (l_dobj) values_20\NNS\5941423|higher|depression|measured|0.001 (l_compound) depression_19\NN\14373582|
D013999_D003866 CID timolol_14\NN\2832168|in (r_pobj) than_13\IN\0|timolol (r_prep) less_7\JJR\14187378|of|than (l_prep) of_8\IN\0|inducer (l_pobj) inducer_12\NN\14778436|a|depression|- (l_compound) depression_10\NN\14373582|
D015784_D003866 NONE betaxolol_4\NN\0| (r_nsubj) be_6\VB\14625458|that|betaxolol|could|less (l_attr) less_7\JJR\14187378|of|than (l_prep) of_8\IN\0|inducer (l_pobj) inducer_12\NN\14778436|a|depression|- (l_compound) depression_10\NN\14373582|
10721819
D007545_D013610 NONE isoproterenol_7\NN\3740161|on (l_prep) on_8\IN\0|tachycardia (l_pobj) tachycardia_12\NN\14110674|induced
D007545_D013610 NONE isoproterenol_10\NN\3740161| (r_pobj) with_9\IN\0|isoproterenol (r_prep) pretreatment_8\NN\0|prolonged|with (r_nsubj) abolish_12\VB\0|whether|pretreatment|could|tachycardia|in (l_dobj) tachycardia_16\NN\14110674|induced
D007545_D013610 NONE isoproterenol_7\JJ\3740161| (r_compound) pretreatment_8\NN\0|isoproterenol (r_pobj) by_6\IN\0|pretreatment (r_prep) unaffected_5\JJ\0|by (r_acomp) was_4\VBD\0|hypotension|unaffected|,|reversed|. (l_advcl) reversed_13\VBN\109660|while|tachycardia|was|to|,|effect (l_nsubjpass) tachycardia_11\NN\14110674|
D007545_D013610 NONE isoproterenol_5\JJ\3740161| (r_compound) pretreatment_6\NN\0|15-day|isoproterenol (r_nsubj) abolished_9\VBD\0|that|pretreatment|not|but|reversed (l_conj) reversed_11\VBD\109660|tachycardia|to|,|effect (l_dobj) tachycardia_15\NN\14110674|induced
D001971_D013610 CID bromocriptine_9\NN\0| (r_npadvmod) induced_11\VBN\1627355|bromocriptine|- (r_amod) tachycardia_12\NN\14110674|induced
D001971_D013610 CID bromocriptine_5\NN\0| (r_npadvmod) induced_7\VBN\1627355|bromocriptine|- (r_amod) tachycardia_8\NN\14110674|induced|,|persisted|,
D001971_D013610 CID bromocriptine_13\NN\0| (r_npadvmod) induced_15\VBN\1627355|bromocriptine|- (r_amod) tachycardia_16\NN\14110674|induced
D001971_D013610 CID bromocriptine_5\NN\0|intravenous|(|kg|) (r_nsubj) induced_12\VBD\1627355|in|,|bromocriptine|hypotension|. (l_dobj) hypotension_14\NN\14057371|significant|and|tachycardia (l_conj) tachycardia_16\NN\14110674|
D001971_D013610 CID bromocriptine_0\NNP\0| (r_npadvmod) induced_2\VBN\1627355|bromocriptine|- (r_amod) hypotension_3\NN\14057371|induced (r_nsubj) was_4\VBD\0|hypotension|unaffected|,|reversed|. (l_advcl) reversed_13\VBN\109660|while|tachycardia|was|to|,|effect (l_nsubjpass) tachycardia_11\NN\14110674|
D001971_D013610 CID bromocriptine_12\NN\0| (r_npadvmod) induced_14\VBN\1627355|bromocriptine|- (r_amod) tachycardia_15\NN\14110674|induced
D001971_D013610 CID bromocriptine_13\NN\0| (r_pobj) of_12\IN\0|bromocriptine (r_prep) tachycardia_11\NN\14110674|the|central|of
D007545_D006332 CID isoproterenol_0\JJ\3740161| (r_compound) pretreatment_1\NN\0|isoproterenol|for (r_nsubj) caused_5\VBD\1617192|pretreatment|hypertrophy|without|. (l_dobj) hypertrophy_7\NN\14365950|cardiac
D001971_D007022 CID bromocriptine_5\NN\0|intravenous|(|kg|) (r_nsubj) induced_12\VBD\1627355|in|,|bromocriptine|hypotension|. (l_dobj) hypotension_14\NN\14057371|significant|and|tachycardia
D001971_D007022 CID bromocriptine_0\NNP\0| (r_npadvmod) induced_2\VBN\1627355|bromocriptine|- (r_amod) hypotension_3\NN\14057371|induced
D001971_D001919 NONE bromocriptine_0\NNP\0| (r_npadvmod) induced_2\VBN\1627355|bromocriptine|- (r_amod) hypotension_3\NN\14057371|induced (r_nsubj) was_4\VBD\0|hypotension|unaffected|,|reversed|. (l_advcl) reversed_13\VBN\109660|while|tachycardia|was|to|,|effect (l_prep) to_14\IN\0|bradycardia (l_pobj) bradycardia_16\NNS\14110674|significant
D001971_D001919 NONE bromocriptine_12\NN\0| (r_npadvmod) induced_14\VBN\1627355|bromocriptine|- (r_amod) tachycardia_15\NN\14110674|induced (r_dobj) reversed_11\VBD\109660|tachycardia|to|,|effect (l_prep) to_16\IN\0|bradycardia (l_pobj) bradycardia_17\NNP\14110674|
D001971_D001919 NONE bromocriptine_13\NN\0| (r_pobj) of_12\IN\0|bromocriptine (r_prep) tachycardia_11\NN\14110674|the|central|of (r_nsubj) appears_14\VBZ\2604760|that|,|in|,|tachycardia|predominate (l_xcomp) predominate_16\VB\0|to|and|mask (l_conj) mask_19\VB\3122748|to|bradycardia (l_dobj) bradycardia_21\NN\14110674|the|of|at
D007545_D007022 NONE isoproterenol_7\JJ\3740161| (r_compound) pretreatment_8\NN\0|isoproterenol (r_pobj) by_6\IN\0|pretreatment (r_prep) unaffected_5\JJ\0|by (r_acomp) was_4\VBD\0|hypotension|unaffected|,|reversed|. (l_nsubj) hypotension_3\NN\14057371|induced
D007545_D001919 CID isoproterenol_7\JJ\3740161| (r_compound) pretreatment_8\NN\0|isoproterenol (r_pobj) by_6\IN\0|pretreatment (r_prep) unaffected_5\JJ\0|by (r_acomp) was_4\VBD\0|hypotension|unaffected|,|reversed|. (l_advcl) reversed_13\VBN\109660|while|tachycardia|was|to|,|effect (l_prep) to_14\IN\0|bradycardia (l_pobj) bradycardia_16\NNS\14110674|significant
D007545_D001919 CID isoproterenol_5\JJ\3740161| (r_compound) pretreatment_6\NN\0|15-day|isoproterenol (r_nsubj) abolished_9\VBD\0|that|pretreatment|not|but|reversed (l_conj) reversed_11\VBD\109660|tachycardia|to|,|effect (l_prep) to_16\IN\0|bradycardia (l_pobj) bradycardia_17\NNP\14110674|
D004294_D007022 NONE domperidone_26\NN\0|i.v. (r_pobj) by_24\IN\0|domperidone (r_agent) reduced_23\VBN\441445|that|was|partly|by (r_relcl) effect_19\NN\34213|an|reduced|mg/kg|) (r_npadvmod) reversed_13\VBN\109660|while|tachycardia|was|to|,|effect (r_advcl) was_4\VBD\0|hypotension|unaffected|,|reversed|. (l_nsubj) hypotension_3\NN\14057371|induced
D004294_D013610 NONE domperidone_26\NN\0|i.v. (r_pobj) by_24\IN\0|domperidone (r_agent) reduced_23\VBN\441445|that|was|partly|by (r_relcl) effect_19\NN\34213|an|reduced|mg/kg|) (r_npadvmod) reversed_13\VBN\109660|while|tachycardia|was|to|,|effect (l_nsubjpass) tachycardia_11\NN\14110674|
D004294_D001919 CID domperidone_26\NN\0|i.v. (r_pobj) by_24\IN\0|domperidone (r_agent) reduced_23\VBN\441445|that|was|partly|by (r_relcl) effect_19\NN\34213|an|reduced|mg/kg|) (r_npadvmod) reversed_13\VBN\109660|while|tachycardia|was|to|,|effect (l_prep) to_14\IN\0|bradycardia (l_pobj) bradycardia_16\NNS\14110674|significant
D004298_D013610 NONE dopamine_27\NN\14807737| (r_compound) d2_28\NN\0|dopamine (r_compound) receptors_29\NNS\5225602|peripheral|d2 (r_pobj) at_25\IN\14622893|receptors (r_prep) bradycardia_21\NN\14110674|the|of|at (r_dobj) mask_19\VB\3122748|to|bradycardia (r_conj) predominate_16\VB\0|to|and|mask (r_xcomp) appears_14\VBZ\2604760|that|,|in|,|tachycardia|predominate (l_nsubj) tachycardia_11\NN\14110674|the|central|of
D004298_D001919 NONE dopamine_27\NN\14807737| (r_compound) d2_28\NN\0|dopamine (r_compound) receptors_29\NNS\5225602|peripheral|d2 (r_pobj) at_25\IN\14622893|receptors (r_prep) bradycardia_21\NN\14110674|the|of|at
17854040
D019259_D006509 NONE lamivudine_3\NN\3834836| (r_compound) resistance_5\NN\37396|lamivudine|-|in (r_pobj) with_2\IN\0|resistance (r_prep) associated_1\VBN\628491|with (r_acl) mutations_0\NNS\4475|associated (r_nsubj) ve_10\VB\0|mutations|na|virus|. (l_dobj) virus_13\NN\9312843|b|(|hbv|)|patients (l_appos) patients_18\NNS\9898892|infected|with (l_amod) infected_17\JJ\2316868|
D019259_D006509 NONE lamivudine_3\NN\3834836| (r_compound) resistance_5\NN\37396|lamivudine|-|in (r_pobj) with_2\IN\0|resistance (r_prep) associated_1\VBN\628491|with (r_acl) mutations_0\NNS\4475|associated (r_nsubj) ve_10\VB\0|mutations|na|virus|. (l_dobj) virus_13\NN\9312843|b|(|hbv|)|patients (l_appos) patients_18\NNS\9898892|infected|with (l_prep) with_19\IN\0|and|without (l_conj) without_21\IN\0|implications (l_pobj) implications_27\NNS\5774614|:|for|patients (l_conj) patients_40\NNS\9898892|infected|african (l_amod) infected_37\VBN\2316868|-
D019259_D006509 NONE lamivudine_7\JJ\3834836| (r_npadvmod) resistant_9\JJ\0|lamivudine|- (r_amod) virus_12\NN\9312843|resistant|b (l_compound) b_11\NN\1355326|hepatitis
D019259_D006509 NONE lamivudine_19\NN\3834836| (r_compound) na_21\NN\14625458|selected|lamivudine|- (r_aux) ve_22\VB\0|na|carriers|with (r_acl) study_4\NN\635850|an|exploratory|investigate|strains|ve (l_acl) investigate_6\VB\644583|to|virus (l_dobj) virus_12\NN\9312843|resistant|b (l_compound) b_11\NN\1355326|hepatitis
D019259_D006509 NONE lamivudine_1\NN\3834836| (r_npadvmod) resistant_3\JJ\0|lamivudine|- (r_amod) strains_4\NNS\7358060|hbv|resistant (r_nsubjpass) detected_6\VBN\2163746|strains|were|in|and|patients|. (l_prep) in_7\IN\13603305|patients (l_pobj) patients_17\NNS\9898892|15|infected|chronic|b (l_compound) b_16\NNP\1355326|hepatitis
D019259_D006509 NONE lamivudine_1\NN\3834836| (r_npadvmod) resistant_3\JJ\0|lamivudine|- (r_amod) strains_4\NNS\7358060|hbv|resistant (r_nsubjpass) detected_6\VBN\2163746|strains|were|in|and|patients|. (l_conj) patients_28\NNS\9898892|20|infected (l_amod) infected_27\VBN\2316868|hiv|-
D019259_D006509 NONE lamivudine_14\NN\3834836| (r_npadvmod) resistant_16\JJ\0|lamivudine|- (r_amod) strains_17\NNS\7358060|hbv|resistant|in (l_prep) in_18\IN\13603305|ve (l_pcomp) ve_22\VB\0|na|patients (l_dobj) patients_29\NNS\9898892|infected (l_amod) infected_28\VBN\2316868|hiv|-
D019259_D006509 NONE lamivudine_22\NN\3834836| (r_npadvmod) containing_24\VBG\2632940|when|lamivudine|-|treatment (r_advcl) emergence_16\NN\7290905|widespread|of|containing (r_pobj) in_14\IN\13603305|emergence (r_prep) result_13\VB\34213|whether|mutations|could|in|applied (l_conj) applied_38\VBN\0|regimens|become|widely|in|,|is (l_advcl) is_45\VBZ\0|as|this|likely (l_acomp) likely_46\JJ\0|have (l_xcomp) have_48\VB\7846|to|implications (l_dobj) implications_50\NNS\5774614|potential|in (l_prep) in_51\IN\13603305|management (l_pobj) management_53\NN\1123598|the|of (l_prep) of_54\IN\0|patients (l_pobj) patients_61\NNS\9898892|infected (l_amod) infected_60\VBN\2316868|hiv|-
D019259_D015658 NONE lamivudine_3\NN\3834836| (r_compound) resistance_5\NN\37396|lamivudine|-|in (r_pobj) with_2\IN\0|resistance (r_prep) associated_1\VBN\628491|with (r_acl) mutations_0\NNS\4475|associated (r_nsubj) ve_10\VB\0|mutations|na|virus|. (l_dobj) virus_13\NN\9312843|b|(|hbv|)|patients (l_appos) patients_18\NNS\9898892|infected|with (l_prep) with_19\IN\0|and|without (l_conj) without_21\IN\0|implications (l_pobj) implications_27\NNS\5774614|:|for|patients (l_punct) :_26\:\0|infection (l_punct) infection_25\NN\14052046|hiv|-
D019259_D015658 NONE lamivudine_3\NN\3834836| (r_compound) resistance_5\NN\37396|lamivudine|-|in (r_pobj) with_2\IN\0|resistance (r_prep) associated_1\VBN\628491|with (r_acl) mutations_0\NNS\4475|associated (r_nsubj) ve_10\VB\0|mutations|na|virus|. (l_dobj) virus_13\NN\9312843|b|(|hbv|)|patients (l_appos) patients_18\NNS\9898892|infected|with (l_prep) with_19\IN\0|and|without (l_conj) without_21\IN\0|implications (l_pobj) implications_27\NNS\5774614|:|for|patients (l_conj) patients_40\NNS\9898892|infected|african (l_amod) infected_37\VBN\2316868|-
D019259_D015658 NONE lamivudine_7\JJ\3834836| (r_npadvmod) resistant_9\JJ\0|lamivudine|- (r_amod) virus_12\NN\9312843|resistant|b (r_dobj) investigate_6\VB\644583|to|virus (r_acl) study_4\NN\635850|an|exploratory|investigate|strains|ve (r_attr) was_1\VBD\0|this|study|. (l_punct) ._41\.\0|in (l_punct) in_37\IN\13603305|infection|patients (l_punct) infection_36\NN\14052046|-
D019259_D015658 NONE lamivudine_19\NN\3834836| (r_compound) na_21\NN\14625458|selected|lamivudine|- (r_aux) ve_22\VB\0|na|carriers|with (r_acl) study_4\NN\635850|an|exploratory|investigate|strains|ve (r_attr) was_1\VBD\0|this|study|. (l_punct) ._41\.\0|in (l_punct) in_37\IN\13603305|infection|patients (l_punct) infection_36\NN\14052046|-
D019259_D015658 NONE lamivudine_1\NN\3834836| (r_npadvmod) resistant_3\JJ\0|lamivudine|- (r_amod) strains_4\NNS\7358060|hbv|resistant (r_nsubjpass) detected_6\VBN\2163746|strains|were|in|and|patients|. (l_conj) patients_28\NNS\9898892|20|infected (l_amod) infected_27\VBN\2316868|hiv|-
D019259_D015658 NONE lamivudine_14\NN\3834836| (r_npadvmod) resistant_16\JJ\0|lamivudine|- (r_amod) strains_17\NNS\7358060|hbv|resistant|in (l_prep) in_18\IN\13603305|ve (l_pcomp) ve_22\VB\0|na|patients (l_dobj) patients_29\NNS\9898892|infected (l_amod) infected_28\VBN\2316868|hiv|-
D019259_D015658 NONE lamivudine_22\NN\3834836| (r_npadvmod) containing_24\VBG\2632940|when|lamivudine|-|treatment (r_advcl) emergence_16\NN\7290905|widespread|of|containing (r_pobj) in_14\IN\13603305|emergence (r_prep) result_13\VB\34213|whether|mutations|could|in|applied (l_conj) applied_38\VBN\0|regimens|become|widely|in|,|is (l_advcl) is_45\VBZ\0|as|this|likely (l_acomp) likely_46\JJ\0|have (l_xcomp) have_48\VB\7846|to|implications (l_dobj) implications_50\NNS\5774614|potential|in (l_prep) in_51\IN\13603305|management (l_pobj) management_53\NN\1123598|the|of (l_prep) of_54\IN\0|patients (l_pobj) patients_61\NNS\9898892|infected (l_amod) infected_60\VBN\2316868|hiv|-
D012964_D006509 NONE na_9\TO\14625458|therapy|- (r_aux) ve_10\VB\0|mutations|na|virus|. (l_dobj) virus_13\NN\9312843|b|(|hbv|)|patients (l_appos) patients_18\NNS\9898892|infected|with (l_amod) infected_17\JJ\2316868|
D012964_D006509 NONE na_9\TO\14625458|therapy|- (r_aux) ve_10\VB\0|mutations|na|virus|. (l_dobj) virus_13\NN\9312843|b|(|hbv|)|patients (l_appos) patients_18\NNS\9898892|infected|with (l_prep) with_19\IN\0|and|without (l_conj) without_21\IN\0|implications (l_pobj) implications_27\NNS\5774614|:|for|patients (l_conj) patients_40\NNS\9898892|infected|african (l_amod) infected_37\VBN\2316868|-
D012964_D006509 NONE na_21\NN\14625458|selected|lamivudine|- (r_aux) ve_22\VB\0|na|carriers|with (r_acl) study_4\NN\635850|an|exploratory|investigate|strains|ve (l_acl) investigate_6\VB\644583|to|virus (l_dobj) virus_12\NN\9312843|resistant|b (l_compound) b_11\NN\1355326|hepatitis
D012964_D006509 NONE na_21\TO\14625458|therapy|- (r_aux) ve_22\VB\0|na|patients (l_dobj) patients_29\NNS\9898892|infected (l_amod) infected_28\VBN\2316868|hiv|-
D012964_D015658 NONE na_9\TO\14625458|therapy|- (r_aux) ve_10\VB\0|mutations|na|virus|. (l_dobj) virus_13\NN\9312843|b|(|hbv|)|patients (l_appos) patients_18\NNS\9898892|infected|with (l_prep) with_19\IN\0|and|without (l_conj) without_21\IN\0|implications (l_pobj) implications_27\NNS\5774614|:|for|patients (l_punct) :_26\:\0|infection (l_punct) infection_25\NN\14052046|hiv|-
D012964_D015658 NONE na_9\TO\14625458|therapy|- (r_aux) ve_10\VB\0|mutations|na|virus|. (l_dobj) virus_13\NN\9312843|b|(|hbv|)|patients (l_appos) patients_18\NNS\9898892|infected|with (l_prep) with_19\IN\0|and|without (l_conj) without_21\IN\0|implications (l_pobj) implications_27\NNS\5774614|:|for|patients (l_conj) patients_40\NNS\9898892|infected|african (l_amod) infected_37\VBN\2316868|-
D012964_D015658 NONE na_21\NN\14625458|selected|lamivudine|- (r_aux) ve_22\VB\0|na|carriers|with (r_acl) study_4\NN\635850|an|exploratory|investigate|strains|ve (r_attr) was_1\VBD\0|this|study|. (l_punct) ._41\.\0|in (l_punct) in_37\IN\13603305|infection|patients (l_punct) infection_36\NN\14052046|-
D012964_D015658 NONE na_21\TO\14625458|therapy|- (r_aux) ve_22\VB\0|na|patients (l_dobj) patients_29\NNS\9898892|infected (l_amod) infected_28\VBN\2316868|hiv|-
9334596
D013739_D007172 NONE testosterone_6\NN\14747587|serum|and|determination (r_pobj) of_4\IN\0|testosterone (r_prep) results_3\NNS\34213|the|of|in (l_prep) in_10\IN\13603305|patients (l_pobj) patients_12\NNS\9898892|1,022|referred (l_acl) referred_13\VBD\730052|because (l_prep) because_14\IN\0|of|dysfunction (l_pobj) dysfunction_17\NN\14204950|erectile
D013739_D007172 NONE testosterone_5\NN\14747587| (r_compound) levels_6\NNS\4916342|the|other|low|testosterone (r_pobj) of_1\IN\0|levels (r_prep) most_0\JJS\0|of (r_nsubj) seemed_7\VBD\2604760|most|result|. (l_xcomp) result_9\VB\34213|to|from|because (l_prep) because_14\IN\0|of|hormone|and|have (l_conj) have_24\VB\7846|to|role (l_dobj) role_28\NN\719494|only|a|small|in (l_prep) in_29\IN\13603305|dysfunction (l_pobj) dysfunction_31\NN\14204950|erectile|(|improvement|)
D013739_D007172 NONE testosterone_6\NN\14747587|low|and|prolactin (r_pobj) of_4\IN\0|testosterone (r_prep) effects_3\NNS\13245626|of|in (l_prep) in_10\IN\13603305|dysfunction (l_pobj) dysfunction_12\NN\14204950|erectile
D013739_D020018 CID testosterone_5\NN\14747587|and|451 (r_pobj) for_4\IN\0|testosterone (r_prep) screened_3\VBN\2533282|patient|was|for|screened|. (l_conj) screened_9\VBN\2533282|were|for|on (l_prep) on_12\IN\0|basis (l_pobj) basis_14\NN\13790712|the|of (l_prep) of_15\IN\0|desire (l_pobj) desire_18\NN\26192|low|sexual|,|gynecomastia
D013739_D020018 CID testosterone_22\NN\14747587|ng./ml (r_conj) gynecomastia_20\NN\14501726|or|testosterone (r_conj) desire_18\NN\26192|low|sexual|,|gynecomastia
D013739_D020018 CID testosterone_1\NN\14747587| (r_dobj) determining_0\VBG\0|testosterone|in (l_prep) in_3\IN\13603305|only|cases (l_pobj) cases_4\NNS\7283608|of (l_prep) of_5\IN\0|desire (l_pobj) desire_8\NN\26192|low|sexual|or|examination
D013739_D020018 CID testosterone_23\NN\14747587|low|,|including (r_pobj) with_21\IN\0|testosterone (r_prep) cases_20\NNS\7283608|the|with (r_pobj) of_18\IN\0|cases (r_prep) %_17\NN\0|40|of (r_dobj) missed_15\VBN\0|determining|would|have|%|. (l_csubj) determining_0\VBG\0|testosterone|in (l_prep) in_3\IN\13603305|only|cases (l_pobj) cases_4\NNS\7283608|of (l_prep) of_5\IN\0|desire (l_pobj) desire_8\NN\26192|low|sexual|or|examination
D013739_D020018 CID testosterone_8\NN\14747587|years (r_nsubjpass) determined_10\VBN\0|that|before|testosterone|be|in|but|measured (l_prep) in_12\IN\13603305|only|cases (l_pobj) cases_13\NNS\7283608|of (l_prep) of_14\IN\0|desire (l_pobj) desire_17\NN\26192|low|sexual|and|examination
D013739_D020018 CID testosterone_14\NN\14747587|ng./ml (r_conj) gynecomastia_12\NN\14501726|and/or|testosterone (r_conj) desire_10\NN\26192|low|sexual|,|gynecomastia
D013739_D006177 NONE testosterone_5\NN\14747587|and|451 (r_pobj) for_4\IN\0|testosterone (r_prep) screened_3\VBN\2533282|patient|was|for|screened|. (l_conj) screened_9\VBN\2533282|were|for|on (l_prep) on_12\IN\0|basis (l_pobj) basis_14\NN\13790712|the|of (l_prep) of_15\IN\0|desire (l_pobj) desire_18\NN\26192|low|sexual|,|gynecomastia (l_conj) gynecomastia_20\NN\14501726|or|testosterone
D013739_D006177 NONE testosterone_22\NN\14747587|ng./ml (r_conj) gynecomastia_20\NN\14501726|or|testosterone
D013739_D006177 NONE testosterone_14\NN\14747587|ng./ml (r_conj) gynecomastia_12\NN\14501726|and/or|testosterone
C004648_D007006 NONE heptylate_5\NN\0|testosterone|or|gonadotropin (l_conj) gonadotropin_9\NN\5407119|human|chorionic|for (l_prep) for_10\IN\0|hypogonadism (l_pobj) hypogonadism_11\NN\14076126|and|bromocriptine
C004648_D006966 NONE heptylate_5\NN\0|testosterone|or|gonadotropin (l_conj) gonadotropin_9\NN\5407119|human|chorionic|for (l_prep) for_10\IN\0|hypogonadism (l_pobj) hypogonadism_11\NN\14076126|and|bromocriptine (l_conj) bromocriptine_13\NN\0|for (l_prep) for_14\IN\0|hyperprolactinemia (l_pobj) hyperprolactinemia_15\NN\0|
D001971_D007006 NONE bromocriptine_13\NN\0|for (r_conj) hypogonadism_11\NN\14076126|and|bromocriptine
D001971_D006966 NONE bromocriptine_13\NN\0|for (l_prep) for_14\IN\0|hyperprolactinemia (l_pobj) hyperprolactinemia_15\NN\0|
D013739_D010911 NONE testosterone_6\NN\14747587| (r_compound) determination_7\NN\43195|testosterone (r_pobj) after_5\IN\0|determination (r_prep) discovered_4\VBN\2163746|tumors|were|after|. (l_nsubjpass) tumors_2\NNS\14234074|two|pituitary
D013739_D007027 NONE testosterone_5\NN\14747587| (r_compound) levels_6\NNS\4916342|the|other|low|testosterone (r_pobj) of_1\IN\0|levels (r_prep) most_0\JJS\0|of (r_nsubj) seemed_7\VBD\2604760|most|result|. (l_xcomp) result_9\VB\34213|to|from|because (l_prep) from_10\IN\0|dysfunction (l_pobj) dysfunction_13\NN\14204950|nonorganic|hypothalamic
1987816
D008094_D011141 CID lithium_0\NN\14625458| (r_npadvmod) induced_2\VBN\1627355|lithium|- (r_amod) polyuria_3\NN\14113228|induced
20619828
D002997_D001008 CID clomipramine_0\NNP\4482543| (r_compound) exposure_1\NN\5042871|clomipramine|in (r_nsubj) produced_5\VBD\1617192|exposure|changes|inflexibility|. (l_dobj) changes_10\NNS\7283608|significant|behavioral|include (l_relcl) include_12\VBP\0|that|anxiety (l_dobj) anxiety_14\NN\14373582|enhanced|(|elevated|)
D002997_-1 NONE clomipramine_0\NNP\4482543| (r_compound) exposure_1\NN\5042871|clomipramine|in (r_nsubj) produced_5\VBD\1617192|exposure|changes|inflexibility|. (l_npadvmod) inflexibility_25\NN\5023741|,|behavioral|(|perseveration|,|impairment
D002997_-1 NONE clomipramine_0\NNP\4482543| (r_compound) exposure_1\NN\5042871|clomipramine|in (r_nsubj) produced_5\VBD\1617192|exposure|changes|inflexibility|. (l_npadvmod) inflexibility_25\NN\5023741|,|behavioral|(|perseveration|,|impairment (l_appos) impairment_41\NN\7296428|working|memory|(|paradigm|,|hoarding (l_conj) hoarding_51\NN\4217882|,|and|dysfunction (l_conj) dysfunction_55\NN\14204950|corticostriatal
D002997_D008569 CID clomipramine_0\NNP\4482543| (r_compound) exposure_1\NN\5042871|clomipramine|in (r_nsubj) produced_5\VBD\1617192|exposure|changes|inflexibility|. (l_npadvmod) inflexibility_25\NN\5023741|,|behavioral|(|perseveration|,|impairment (l_appos) impairment_41\NN\7296428|working|memory|(|paradigm|,|hoarding
D002997_D060845 CID clomipramine_0\NNP\4482543| (r_compound) exposure_1\NN\5042871|clomipramine|in (r_nsubj) produced_5\VBD\1617192|exposure|changes|inflexibility|. (l_npadvmod) inflexibility_25\NN\5023741|,|behavioral|(|perseveration|,|impairment (l_appos) impairment_41\NN\7296428|working|memory|(|paradigm|,|hoarding (l_conj) hoarding_51\NN\4217882|,|and|dysfunction
10704919
D013629_D006461 CID tamoxifen_6\NN\2714883| (r_pobj) by_5\IN\0|tamoxifen (r_agent) induced_4\VBN\1627355|hemolysis|by|related|. (l_nsubj) hemolysis_0\NNP\13509528|of
D013629_D006461 CID tam_0\NNP\2954340| (r_nsubj) induces_1\VBZ\1627355|tam|hemolysis|. (l_dobj) hemolysis_2\NN\13509528|of
D013629_D006461 CID tam_13\NNP\2954340|12.5|microm (r_nsubj) induces_14\VBZ\1627355|tam|hemolysis|. (r_conj) is_4\VBZ\0|extension|variable|,|but|induces (l_nsubj) extension_1\NN\15272029|the|of (l_prep) of_2\IN\0|hemolysis (l_pobj) hemolysis_3\NN\13509528|
D013629_D006461 CID tam_13\NNP\2954340|12.5|microm (r_nsubj) induces_14\VBZ\1627355|tam|hemolysis|. (l_dobj) hemolysis_16\NN\13509528|total|of
D013629_D006461 CID tam_4\NNP\2954340| (r_pobj) of_3\IN\0|tam (r_prep) effect_2\NN\34213|the|hemolytic|of (l_amod) hemolytic_1\JJ\0|
D013629_D006461 CID tam_4\NNP\2954340| (r_pobj) of_3\IN\0|tam (r_prep) effect_2\NN\34213|the|hemolytic|of (r_nsubjpass) prevented_6\VBN\0|effect|is|by|inactivated|indicating|. (l_advcl) indicating_34\VBG\952524|related (l_ccomp) related_42\VBN\628491|that|hemolysis|is|not|to (l_nsubjpass) hemolysis_39\NN\13509528|induced
D013629_D006461 CID tam_36\NNP\2954340| (r_npadvmod) induced_38\VBN\1627355|tam|- (r_amod) hemolysis_39\NN\13509528|induced (r_nsubjpass) related_42\VBN\628491|that|hemolysis|is|not|to (r_ccomp) indicating_34\VBG\952524|related (r_advcl) prevented_6\VBN\0|effect|is|by|inactivated|indicating|. (l_nsubjpass) effect_2\NN\34213|the|hemolytic|of (l_amod) hemolytic_1\JJ\0|
D013629_D006461 CID tam_36\NNP\2954340| (r_npadvmod) induced_38\VBN\1627355|tam|- (r_amod) hemolysis_39\NN\13509528|induced
D013629_D006461 CID tam_17\NNP\2954340| (r_npadvmod) induced_19\VBN\1627355|tam|- (r_amod) hemolysis_20\NN\13509528|induced
D013629_D006461 CID tam_3\NNP\2954340| (r_pobj) by_2\IN\0|tam (r_agent) caused_1\VBN\1617192|by (r_acl) hemolysis_0\NNP\13509528|caused
D013629_D006461 CID tam_3\NNP\2954340| (r_pobj) by_2\IN\0|tam (r_agent) caused_1\VBN\1617192|by (r_acl) hemolysis_0\NNP\13509528|caused (r_nsubjpass) preceded_6\VBN\0|hemolysis|was|not|by|,|excluding|,|according|. (l_prep) excluding_18\VBG\471711|also|mechanism (l_pobj) mechanism_24\NN\13446390|a|osmotic|type|of (l_prep) of_25\IN\0|hemolysis (l_pobj) hemolysis_26\NN\13509528|
D013629_D006461 CID tam_15\NNP\2954340| (r_compound) incorporation_16\NN\1237415|a|decreased|tam|in|and (r_pobj) to_12\IN\0|incorporation (r_prep) related_11\VBN\628491|that|protection|is|to (l_nsubjpass) protection_5\NN\407535|the|from|by (l_prep) from_6\IN\0|hemolysis (l_pobj) hemolysis_7\NN\13509528|
D013629_D006461 CID tam_2\NNP\2954340| (r_npadvmod) induced_4\VBN\1627355|tam|- (r_amod) results_6\NNS\34213|therefore|,|induced|hemolysis|from|,|leading|. (l_compound) hemolysis_5\NN\13509528|
D013629_D001943 NONE tamoxifen_0\NNP\2714883|tam|, (r_nsubj) induces_18\VBZ\1627355|tamoxifen|drug|,|changes|. (l_nsubj) drug_7\NN\14778436|the|antiestrogenic|prescribed (l_acl) prescribed_10\VBN\748282|widely|in (l_prep) in_11\IN\13603305|chemotherapy (l_pobj) chemotherapy_13\NN\661091|the|of (l_prep) of_14\IN\0|cancer (l_pobj) cancer_16\NN\14239425|breast
D013629_D001943 NONE tam_2\NNP\2954340|(|) (r_appos) tamoxifen_0\NNP\2714883|tam|, (r_nsubj) induces_18\VBZ\1627355|tamoxifen|drug|,|changes|. (l_nsubj) drug_7\NN\14778436|the|antiestrogenic|prescribed (l_acl) prescribed_10\VBN\748282|widely|in (l_prep) in_11\IN\13603305|chemotherapy (l_pobj) chemotherapy_13\NN\661091|the|of (l_prep) of_14\IN\0|cancer (l_pobj) cancer_16\NN\14239425|breast
D013629_D000743 CID tamoxifen_0\NNP\2714883|tam|, (r_nsubj) induces_18\VBZ\1627355|tamoxifen|drug|,|changes|. (l_dobj) changes_19\NNS\7283608|in (l_prep) in_20\IN\13603305|shape (l_pobj) shape_23\NN\5062748|normal|discoid|of (l_prep) of_24\IN\0|erythrocytes (l_pobj) erythrocytes_25\NNS\5449268|and|anemia (l_conj) anemia_28\NN\14189204|hemolytic
D013629_D000743 CID tam_2\NNP\2954340|(|) (r_appos) tamoxifen_0\NNP\2714883|tam|, (r_nsubj) induces_18\VBZ\1627355|tamoxifen|drug|,|changes|. (l_dobj) changes_19\NNS\7283608|in (l_prep) in_20\IN\13603305|shape (l_pobj) shape_23\NN\5062748|normal|discoid|of (l_prep) of_24\IN\0|erythrocytes (l_pobj) erythrocytes_25\NNS\5449268|and|anemia (l_conj) anemia_28\NN\14189204|hemolytic
D013629_D000743 CID tam_6\NNP\2954340| (r_pobj) of_5\IN\0|tam (r_prep) effects_4\NNS\13245626|the|of|on (r_dobj) evaluates_2\VBZ\670261|work|effects|,|attempting|. (l_advcl) attempting_12\VBG\2367363|identify (l_xcomp) identify_14\VB\699815|to|mechanisms (l_dobj) mechanisms_17\NNS\13446390|the|underlying|on|and|involvement (l_prep) on_18\IN\0|anemia (l_pobj) anemia_23\NN\14189204|induced|hemolytic
D013629_D000743 CID tam_19\NNP\2954340| (r_npadvmod) induced_21\VBN\1627355|tam|- (r_amod) anemia_23\NN\14189204|induced|hemolytic
D013629_D000743 CID tam_13\NNP\2954340| (r_pobj) by_12\IN\0|tam (r_agent) promoted_11\VBN\2556126|by (r_acl) stability_10\NN\4777852|mechanical|promoted (r_dobj) decreased_8\VBD\169651|stability|,|resulting (l_conj) resulting_15\VBG\2633881|in (l_prep) in_16\IN\13603305|anemia (l_pobj) anemia_18\NN\14189204|hemolytic
D024502_D006461 NONE tocopherol_13\NN\14724645|alpha|-|(|t|) (r_pobj) of_10\IN\0|tocopherol (r_prep) concentrations_9\NNS\4916342|low|of|and|acetate (r_pobj) by_7\IN\0|concentrations (r_agent) prevented_6\VBN\0|effect|is|by|inactivated|indicating|. (l_nsubjpass) effect_2\NN\34213|the|hemolytic|of (l_amod) hemolytic_1\JJ\0|
D024502_D006461 NONE tocopherol_13\NN\14724645|alpha|-|(|t|) (r_pobj) of_10\IN\0|tocopherol (r_prep) concentrations_9\NNS\4916342|low|of|and|acetate (r_pobj) by_7\IN\0|concentrations (r_agent) prevented_6\VBN\0|effect|is|by|inactivated|indicating|. (l_advcl) indicating_34\VBG\952524|related (l_ccomp) related_42\VBN\628491|that|hemolysis|is|not|to (l_nsubjpass) hemolysis_39\NN\13509528|induced
D024502_D006461 NONE t_17\NNP\14999913|alpha|- (r_appos) tocopherol_13\NN\14724645|alpha|-|(|t|) (r_pobj) of_10\IN\0|tocopherol (r_prep) concentrations_9\NNS\4916342|low|of|and|acetate (r_pobj) by_7\IN\0|concentrations (r_agent) prevented_6\VBN\0|effect|is|by|inactivated|indicating|. (l_nsubjpass) effect_2\NN\34213|the|hemolytic|of (l_amod) hemolytic_1\JJ\0|
D024502_D006461 NONE t_17\NNP\14999913|alpha|- (r_appos) tocopherol_13\NN\14724645|alpha|-|(|t|) (r_pobj) of_10\IN\0|tocopherol (r_prep) concentrations_9\NNS\4916342|low|of|and|acetate (r_pobj) by_7\IN\0|concentrations (r_agent) prevented_6\VBN\0|effect|is|by|inactivated|indicating|. (l_advcl) indicating_34\VBG\952524|related (l_ccomp) related_42\VBN\628491|that|hemolysis|is|not|to (l_nsubjpass) hemolysis_39\NN\13509528|induced
D024502_D006461 NONE acetate_23\NN\15010703|tocopherol|(|tac|) (r_conj) concentrations_9\NNS\4916342|low|of|and|acetate (r_pobj) by_7\IN\0|concentrations (r_agent) prevented_6\VBN\0|effect|is|by|inactivated|indicating|. (l_nsubjpass) effect_2\NN\34213|the|hemolytic|of (l_amod) hemolytic_1\JJ\0|
D024502_D006461 NONE acetate_23\NN\15010703|tocopherol|(|tac|) (r_conj) concentrations_9\NNS\4916342|low|of|and|acetate (r_pobj) by_7\IN\0|concentrations (r_agent) prevented_6\VBN\0|effect|is|by|inactivated|indicating|. (l_advcl) indicating_34\VBG\952524|related (l_ccomp) related_42\VBN\628491|that|hemolysis|is|not|to (l_nsubjpass) hemolysis_39\NN\13509528|induced
D024502_D006461 NONE tac_27\NNS\0|alpha|- (r_appos) acetate_23\NN\15010703|tocopherol|(|tac|) (r_conj) concentrations_9\NNS\4916342|low|of|and|acetate (r_pobj) by_7\IN\0|concentrations (r_agent) prevented_6\VBN\0|effect|is|by|inactivated|indicating|. (l_nsubjpass) effect_2\NN\34213|the|hemolytic|of (l_amod) hemolytic_1\JJ\0|
D024502_D006461 NONE tac_27\NNS\0|alpha|- (r_appos) acetate_23\NN\15010703|tocopherol|(|tac|) (r_conj) concentrations_9\NNS\4916342|low|of|and|acetate (r_pobj) by_7\IN\0|concentrations (r_agent) prevented_6\VBN\0|effect|is|by|inactivated|indicating|. (l_advcl) indicating_34\VBG\952524|related (l_ccomp) related_42\VBN\628491|that|hemolysis|is|not|to (l_nsubjpass) hemolysis_39\NN\13509528|induced
D017665_D006461 NONE hydroxyl_32\NN\14621446|functional (r_dobj) inactivated_30\VBN\1097743|(|hydroxyl|) (r_parataxis) prevented_6\VBN\0|effect|is|by|inactivated|indicating|. (l_nsubjpass) effect_2\NN\34213|the|hemolytic|of (l_amod) hemolytic_1\JJ\0|
D017665_D006461 NONE hydroxyl_32\NN\14621446|functional (r_dobj) inactivated_30\VBN\1097743|(|hydroxyl|) (r_parataxis) prevented_6\VBN\0|effect|is|by|inactivated|indicating|. (l_advcl) indicating_34\VBG\952524|related (l_ccomp) related_42\VBN\628491|that|hemolysis|is|not|to (l_nsubjpass) hemolysis_39\NN\13509528|induced
D010100_D006461 NONE oxygen_7\NN\14622893| (r_compound) consumption_8\NN\13440063|oxygen|and|oxidation (r_pobj) of_6\IN\0|consumption (r_prep) absence_5\NN\14449405|of (r_pobj) by_4\IN\0|absence (r_agent) evidenced_3\VBN\1015244|this|was|further|by|determined|. (l_conj) determined_13\VBN\0|in (l_prep) in_14\IN\13603305|parallel (l_pobj) parallel_15\NN\4743605|with (l_prep) with_16\IN\0|hemolysis (l_pobj) hemolysis_20\NN\13509528|induced
D011188_D006461 NONE k(+_11\NNP\0| (r_pobj) of_10\IN\0|k(+ (r_prep) leakage_9\NN\7407777|the|of|)|from (r_pobj) by_7\IN\0|leakage (r_agent) preceded_6\VBN\0|hemolysis|was|not|by|,|excluding|,|according|. (l_nsubjpass) hemolysis_0\NNP\13509528|caused
D011188_D006461 NONE k(+_11\NNP\0| (r_pobj) of_10\IN\0|k(+ (r_prep) leakage_9\NN\7407777|the|of|)|from (r_pobj) by_7\IN\0|leakage (r_agent) preceded_6\VBN\0|hemolysis|was|not|by|,|excluding|,|according|. (l_prep) excluding_18\VBG\471711|also|mechanism (l_pobj) mechanism_24\NN\13446390|a|osmotic|type|of (l_prep) of_25\IN\0|hemolysis (l_pobj) hemolysis_26\NN\13509528|
D024505_D006461 NONE tocopherols_9\NNS\14724645| (r_pobj) by_8\IN\0|tocopherols (r_prep) protection_5\NN\407535|the|from|by (l_prep) from_6\IN\0|hemolysis (l_pobj) hemolysis_7\NN\13509528|
8864707
D010672_D004827 NONE phenytoin_10\NNP\3550533| (r_compound) overdosages_11\NNS\0|phenytoin (r_pobj) after_9\IN\0|overdosages (r_prep) volumetry_2\NN\0|resonance|of|in|after|. (l_prep) in_6\IN\13603305|patients (l_pobj) patients_8\NNS\9898892|epileptic (l_amod) epileptic_7\JJ\10595647|
D010672_D062787 CID phenytoin_10\NNP\3550533| (r_compound) overdosages_11\NNS\0|phenytoin
D010672_D062787 CID phenytoin_3\JJ\3550533| (r_compound) overdosage_4\NN\0|phenytoin
D010672_D062787 CID phenytoin_17\JJ\3550533| (r_compound) medication_18\NN\3247620|phenytoin (r_nsubj) was_19\VBD\0|that|medication|cause (r_ccomp) is_14\VBZ\0|it|unlikely|was (r_conj) result_8\VB\34213|that|overdosage|does|not|necessarily|in|and|is (l_nsubj) overdosage_4\NN\0|phenytoin
D010672_D002526 NONE phenytoin_11\JJ\3550533| (r_compound) medication_12\NN\3247620|phenytoin|and|atrophy (l_conj) atrophy_15\NN\14299637|cerebellar|in
D010672_D002526 NONE phenytoin_3\JJ\3550533| (r_compound) overdosage_4\NN\0|phenytoin (r_nsubj) result_8\VB\34213|that|overdosage|does|not|necessarily|in|and|is (l_prep) in_9\IN\13603305|atrophy (l_pobj) atrophy_11\NN\14299637|cerebellar
D010672_D002526 NONE phenytoin_3\JJ\3550533| (r_compound) overdosage_4\NN\0|phenytoin (r_nsubj) result_8\VB\34213|that|overdosage|does|not|necessarily|in|and|is (l_conj) is_14\VBZ\0|it|unlikely|was (l_ccomp) was_19\VBD\0|that|medication|cause (l_attr) cause_22\NN\7323922|the|only|of (l_prep) of_23\IN\0|atrophy (l_pobj) atrophy_25\NN\14299637|cerebellar|in
D010672_D002526 NONE phenytoin_17\JJ\3550533| (r_compound) medication_18\NN\3247620|phenytoin (r_nsubj) was_19\VBD\0|that|medication|cause (r_ccomp) is_14\VBZ\0|it|unlikely|was (r_conj) result_8\VB\34213|that|overdosage|does|not|necessarily|in|and|is (l_prep) in_9\IN\13603305|atrophy (l_pobj) atrophy_11\NN\14299637|cerebellar
D010672_D002526 NONE phenytoin_17\JJ\3550533| (r_compound) medication_18\NN\3247620|phenytoin (r_nsubj) was_19\VBD\0|that|medication|cause (l_attr) cause_22\NN\7323922|the|only|of (l_prep) of_23\IN\0|atrophy (l_pobj) atrophy_25\NN\14299637|cerebellar|in
D010672_D012640 NONE phenytoin_15\JJ\3550533| (r_compound) levels_17\NNS\4916342|phenytoin|serum|and|volume (r_pobj) of_14\IN\0|levels (r_prep) elevation_13\NN\7445480|of (r_conj) duration_11\NN\15113229|seizure|,|elevation (l_compound) seizure_10\NN\14081375|
14765563
D011803_D020922 NONE quinine_23\NN\2721948| (r_nsubj) is_24\VBZ\0|banned|,|quinine|available|. (l_advcl) banned_8\VBD\2480923|although|administration|use|due (l_dobj) use_10\NN\407535|its|for (l_prep) for_11\IN\0|cramps (l_pobj) cramps_14\NNS\14299637|nocturnal|leg
D011803_D002493 NONE quinine_7\NN\2721948| (r_dobj) containing_6\VBG\2632940|quinine (r_acl) products_5\NNS\3076708|containing (r_nsubj) produce_9\VB\7555863|that|products|may|complications|status|in (l_dobj) complications_11\NNS\1073995|neurological|,|including|,
D011803_D003221 CID quinine_7\NN\2721948| (r_dobj) containing_6\VBG\2632940|quinine (r_acl) products_5\NNS\3076708|containing (r_nsubj) produce_9\VB\7555863|that|products|may|complications|status|in (l_dobj) complications_11\NNS\1073995|neurological|,|including|, (l_prep) including_13\VBG\0|confusion (l_pobj) confusion_14\NN\13972797|
D011803_D012640 CID quinine_7\NN\2721948| (r_dobj) containing_6\VBG\2632940|quinine (r_acl) products_5\NNS\3076708|containing (r_nsubj) produce_9\VB\7555863|that|products|may|complications|status|in (l_dobj) status_18\NN\24720|altered|mental|,|seizures|, (l_conj) seizures_20\NNS\14081375|,|and|coma
D011803_D003128 CID quinine_7\NN\2721948| (r_dobj) containing_6\VBG\2632940|quinine (r_acl) products_5\NNS\3076708|containing (r_nsubj) produce_9\VB\7555863|that|products|may|complications|status|in (l_dobj) status_18\NN\24720|altered|mental|,|seizures|, (l_conj) seizures_20\NNS\14081375|,|and|coma (l_conj) coma_23\NN\5678932|
12369736
D003042_D009069 CID cocaine_14\NN\3492717| (r_npadvmod) induced_16\VBN\1627355|cocaine|- (r_amod) hyperactivity_18\NN\14052403|the|induced|locomotor|in
D003042_D009069 CID cocaine_34\NN\3492717|in (r_pobj) by_33\IN\0|cocaine (r_agent) induced_32\VBN\1627355|by (r_acl) hyperactivity_31\NN\14052403|the|locomotor|induced
D003042_D009069 CID cocaine_18\NN\3492717|, (r_pobj) to_17\IN\0|cocaine (r_prep) prior_16\RB\10675876|to (r_advmod) administered_11\VBN\2436349|gr|shell|prior|attenuated|. (l_conj) attenuated_23\VBD\224901|dependently|hyperactivity (l_dobj) hyperactivity_29\NN\14052403|the|induced|locomotor
D003042_D009069 CID cocaine_4\NN\3492717| (r_nsubj) induced_5\VBN\1627355|that|cocaine (r_ccomp) indicate_2\VBP\952524|findings|induced|modified (l_ccomp) modified_8\VBN\109660|hyperlocomotion|is|by|. (l_nsubjpass) hyperlocomotion_6\NN\0|
C103477_D009069 NONE 55562_1\CD\0| (r_nummod) gr_0\NNP\0|55562|side|, (r_nsubj) administered_11\VBN\2436349|gr|shell|prior|attenuated|. (l_conj) attenuated_23\VBD\224901|dependently|hyperactivity (l_dobj) hyperactivity_29\NN\14052403|the|induced|locomotor
C103477_D009069 NONE 55562_38\CD\0| (r_nummod) gr_37\NNP\0|55562 (r_appos) antagonist_35\NN\7846|the|5-ht1b|receptor|(|gr|) (r_pobj) of_31\IN\0|antagonist (r_prep) effects_30\NNS\13245626|inhibitory|of (r_pobj) in_26\IN\13603305|effects (r_prep) consisting_25\VBG\2603699|in (r_acl) modification_24\NN\191142|core|,|this|consisting|and|agonist|respectively (r_conj) shell_17\NN\2703275|the|accumbens|,|but|modification (r_pobj) into_14\IN\0|shell (r_prep) microinjected_13\VBN\0|into (r_acl) ligands_12\NNS\20090|5-ht1b|receptor|microinjected (r_pobj) by_9\IN\0|ligands (r_agent) modified_8\VBN\109660|hyperlocomotion|is|by|. (l_nsubjpass) hyperlocomotion_6\NN\0|
C065046_D009069 CID 93129_44\CD\0| (r_nummod) cp_43\NNP\0|(|93129|) (r_appos) agonist_41\NN\0|cp|, (r_conj) modification_24\NN\191142|core|,|this|consisting|and|agonist|respectively (r_conj) shell_17\NN\2703275|the|accumbens|,|but|modification (r_pobj) into_14\IN\0|shell (r_prep) microinjected_13\VBN\0|into (r_acl) ligands_12\NNS\20090|5-ht1b|receptor|microinjected (r_pobj) by_9\IN\0|ligands (r_agent) modified_8\VBN\109660|hyperlocomotion|is|by|. (l_nsubjpass) hyperlocomotion_6\NN\0|
17261653
D003000_D001919 CID clonidine_0\NNP\2721160| (r_npadvmod) induced_2\VBN\1627355|clonidine|-|bradycardia|in (l_dobj) bradycardia_3\NN\14110674|
1601297
D003042_D009202 NONE cocaine_8\NN\3492717| (r_compound) abusers_9\NNS\9633969|hospitalized|cocaine (r_pobj) in_5\IN\13603305|abusers (r_prep) injury_4\NN\14052046|myocardial|in
D003042_D009202 NONE cocaine_3\NN\3492717| (r_compound) abusers_4\NNS\9633969|the|cocaine (r_pobj) of_1\IN\0|abusers (r_prep) eleven_0\CD\13745420|of|and|none (r_nsubj) had_10\VBD\0|eleven|evidence|. (l_dobj) evidence_12\NN\5816287|ecg|of (l_prep) of_13\IN\0|injury (l_pobj) injury_16\NN\14052046|significant|myocardial|defined
D003042_D012559 NONE cocaine_7\NN\3492717| (r_npadvmod) abusing_9\VBG\2514187|cocaine|- (r_amod) patients_10\NNS\9898892|99|abusing (r_pobj) of_5\IN\0|patients (r_prep) ecg_3\NNP\7000195|(|)|of (r_appos) electrocardiograms_1\NNS\7000195|the|ecg (r_nsubjpass) compared_12\VBN\644583|electrocardiograms|were|with|. (l_prep) with_13\IN\0|ecgs (l_pobj) ecgs_15\NNS\7000195|the|of (l_prep) of_16\IN\0|controls (l_pobj) controls_19\NNS\5190804|50|schizophrenic (l_amod) schizophrenic_18\JJ\10490141|
D003042_D009203 CID cocaine_3\NN\3492717| (r_compound) abusers_4\NNS\9633969|the|cocaine (r_pobj) of_1\IN\0|abusers (r_prep) eleven_0\CD\13745420|of|and|none (r_nsubj) had_10\VBD\0|eleven|evidence|. (l_dobj) evidence_12\NN\5816287|ecg|of (l_prep) of_13\IN\0|injury (l_pobj) injury_16\NN\14052046|significant|myocardial|defined (l_acl) defined_17\VBN\2604760|as (l_prep) as_18\IN\14622893|infarction (l_pobj) infarction_20\NN\14204950|myocardial|,|ischemia
D003042_D007511 NONE cocaine_3\NN\3492717| (r_compound) abusers_4\NNS\9633969|the|cocaine (r_pobj) of_1\IN\0|abusers (r_prep) eleven_0\CD\13745420|of|and|none (r_nsubj) had_10\VBD\0|eleven|evidence|. (l_dobj) evidence_12\NN\5816287|ecg|of (l_prep) of_13\IN\0|injury (l_pobj) injury_16\NN\14052046|significant|myocardial|defined (l_acl) defined_17\VBN\2604760|as (l_prep) as_18\IN\14622893|infarction (l_pobj) infarction_20\NN\14204950|myocardial|,|ischemia (l_conj) ischemia_22\NN\14195315|,|and|block
D003042_D002037 CID cocaine_3\NN\3492717| (r_compound) abusers_4\NNS\9633969|the|cocaine (r_pobj) of_1\IN\0|abusers (r_prep) eleven_0\CD\13745420|of|and|none (r_nsubj) had_10\VBD\0|eleven|evidence|. (l_dobj) evidence_12\NN\5816287|ecg|of (l_prep) of_13\IN\0|injury (l_pobj) injury_16\NN\14052046|significant|myocardial|defined (l_acl) defined_17\VBN\2604760|as (l_prep) as_18\IN\14622893|infarction (l_pobj) infarction_20\NN\14204950|myocardial|,|ischemia (l_conj) ischemia_22\NN\14195315|,|and|block (l_conj) block_27\NN\21939|bundle|branch
11279304
D018943_D066126 NONE anthracycline_7\NN\0| (r_advmod) induced_9\VBN\1627355|anthracycline|- (r_amod) cardiotoxicity_10\NN\0|induced
D018943_D066126 NONE anthracyclines_0\NNS\0| (r_nsubj) are_1\VBP\13600404|anthracyclines|drugs|,|but|cause (l_conj) cause_9\VBP\7323922|they|frequently|cardiotoxicity|. (l_dobj) cardiotoxicity_13\NN\0|related
D018943_D066126 NONE anthracycline_4\NN\0| (r_amod) therapy_5\NN\657604|conventional|anthracycline (r_pobj) of_2\IN\0|therapy (r_prep) cardiotoxicity_1\NN\0|the|of
D018943_D066126 NONE anthracycline_24\NN\0| (r_advmod) induced_26\VBN\1627355|anthracycline|- (r_amod) cardiotoxicity_27\NN\0|induced|in
D018943_D066126 NONE anthracycline_16\NN\0| (r_advmod) induced_18\VBN\1627355|anthracycline|- (r_compound) cardiotoxicity_19\NN\0|induced
D018943_D006331 NONE anthracycline_4\NN\0| (r_amod) therapy_5\NN\657604|conventional|anthracycline (r_pobj) of_2\IN\0|therapy (r_prep) cardiotoxicity_1\NN\0|the|of (r_nsubj) highlights_6\VBZ\13809920|cardiotoxicity|need|. (l_dobj) need_8\NN\13920835|a|search (l_acl) search_10\VB\407535|to|for (l_prep) for_11\IN\0|methods (l_pobj) methods_12\NNS\5616786|are (l_relcl) are_14\VBP\13600404|that|sensitive (l_acomp) sensitive_16\JJ\10488309|highly|and|capable (l_conj) capable_18\JJ\0|of (l_prep) of_19\IN\0|predicting (l_pcomp) predicting_20\VBG\916909|dysfunction (l_dobj) dysfunction_22\NN\14204950|cardiac
D018943_D015470 NONE anthracycline_24\NN\0| (r_advmod) induced_26\VBN\1627355|anthracycline|- (r_amod) cardiotoxicity_27\NN\0|induced|in (l_prep) in_28\IN\13603305|patients (l_pobj) patients_29\NNS\9898892|with (l_prep) with_30\IN\0|leukemia (l_pobj) leukemia_32\NN\14239918|acute|treated
D003630_D066126 NONE daunorubicin_36\NN\0|a|(|regimen (r_pobj) with_34\IN\0|daunorubicin (r_prep) treated_33\VBN\2376958|with (r_acl) leukemia_32\NN\14239918|acute|treated (r_pobj) with_30\IN\0|leukemia (r_prep) patients_29\NNS\9898892|with (r_pobj) in_28\IN\13603305|patients (r_prep) cardiotoxicity_27\NN\0|induced|in
D003630_D066126 NONE dnr)-containing_38\NN\0| (r_compound) regimen_39\NNS\5898568|dnr)-containing (r_appos) daunorubicin_36\NN\0|a|(|regimen (r_pobj) with_34\IN\0|daunorubicin (r_prep) treated_33\VBN\2376958|with (r_acl) leukemia_32\NN\14239918|acute|treated (r_pobj) with_30\IN\0|leukemia (r_prep) patients_29\NNS\9898892|with (r_pobj) in_28\IN\13603305|patients (r_prep) cardiotoxicity_27\NN\0|induced|in
D003630_D015470 NONE daunorubicin_36\NN\0|a|(|regimen (r_pobj) with_34\IN\0|daunorubicin (r_prep) treated_33\VBN\2376958|with (r_acl) leukemia_32\NN\14239918|acute|treated
D003630_D015470 NONE dnr)-containing_38\NN\0| (r_compound) regimen_39\NNS\5898568|dnr)-containing (r_appos) daunorubicin_36\NN\0|a|(|regimen (r_pobj) with_34\IN\0|daunorubicin (r_prep) treated_33\VBN\2376958|with (r_acl) leukemia_32\NN\14239918|acute|treated
D003630_D015470 NONE dnr_9\NNP\0| (r_npadvmod) containing_11\VBG\2632940|dnr|- (r_amod) regimen_12\NN\5898568|a|containing (r_pobj) with_7\IN\0|regimen (r_prep) treated_6\VBN\2376958|patients|were|with|. (l_nsubjpass) patients_1\NNS\9898892|thirteen|with (l_prep) with_2\IN\0|leukemia (l_pobj) leukemia_4\NN\14239918|acute
D003630_D006333 CID dnr_16\NNP\0| (r_pobj) given_15\VBN\5892096|dnr (r_acl) failure_14\NN\66216|heart|given
3341566
D009599_D006470 NONE nitroprusside_10\RB\0| (r_advmod) induced_12\VBN\1627355|nitroprusside|- (r_amod) hypotension_13\NN\14057371|sodium|induced|in (r_pobj) during_8\IN\0|hypotension (r_prep) than_7\IN\0|during (r_prep) is_3\VBZ\0|variation|greater|during|than|. (l_prep) during_5\IN\0|hemorrhage (l_pobj) hemorrhage_6\NN\14285662|
D009599_D006470 NONE nitroprusside_28\NN\0|n (r_advcl) decreased_4\VBN\169651|pressure|was|to|for|nitroprusside|. (l_prep) for_9\IN\0|minutes (l_pobj) minutes_11\NNS\6502378|30|by (l_prep) by_13\IN\0|either|hemorrhage|or|by (l_pobj) hemorrhage_14\NN\14285662|hem
D009599_D006470 NONE nitroprusside_28\NN\0|n (r_advcl) decreased_4\VBN\169651|pressure|was|to|for|nitroprusside|. (l_prep) for_9\IN\0|minutes (l_pobj) minutes_11\NNS\6502378|30|by (l_prep) by_13\IN\0|either|hemorrhage|or|by (l_pobj) hemorrhage_14\NN\14285662|hem (l_appos) hem_16\NNP\3264542|(|,|n|7|)
D009599_D006470 NONE snp_30\NNP\11493266| (r_dep) n_32\CC\14622893|(|snp|,|7|) (r_npadvmod) nitroprusside_28\NN\0|n (r_advcl) decreased_4\VBN\169651|pressure|was|to|for|nitroprusside|. (l_prep) for_9\IN\0|minutes (l_pobj) minutes_11\NNS\6502378|30|by (l_prep) by_13\IN\0|either|hemorrhage|or|by (l_pobj) hemorrhage_14\NN\14285662|hem
D009599_D006470 NONE snp_30\NNP\11493266| (r_dep) n_32\CC\14622893|(|snp|,|7|) (r_npadvmod) nitroprusside_28\NN\0|n (r_advcl) decreased_4\VBN\169651|pressure|was|to|for|nitroprusside|. (l_prep) for_9\IN\0|minutes (l_pobj) minutes_11\NNS\6502378|30|by (l_prep) by_13\IN\0|either|hemorrhage|or|by (l_pobj) hemorrhage_14\NN\14285662|hem (l_appos) hem_16\NNP\3264542|(|,|n|7|)
D009599_D006470 NONE snp_21\NNP\11493266| (r_compound) group_22\NN\2137|the|snp (r_pobj) in_19\IN\13603305|group (r_prep) that_18\DT\0|in (r_pobj) with_17\IN\0|that (r_prep) compared_16\VBN\644583|with (r_prep) higher_15\RBR\0|compared (r_acomp) was_8\VBD\0|during|output|lower|higher|. (l_prep) during_0\IN\0|hypotension (l_pobj) hypotension_4\NN\14057371|induced (l_amod) induced_3\VBN\1627355|hem|- (l_npadvmod) hem_1\NNP\3264542|
D009599_D006470 NONE snp_17\NNP\11493266| (r_compound) group_18\NN\2137|the|snp (r_pobj) in_15\IN\13603305|group (r_prep) hg_14\NNP\14625458|in (r_appos) mm_13\NN\13649268|+/-|2.0|hg|p (r_pobj) with_9\IN\0|mm (r_prep) compared_8\VBN\644583|with (r_prep) hg_2\NNP\14625458|mm|in|,|compared|. (l_prep) in_3\IN\13603305|group (l_pobj) group_6\NN\2137|the|hem (l_compound) hem_5\NNP\3264542|
D009599_D006470 NONE snp_7\NNP\11493266| (r_compound) groups_8\NNS\2137|hem|snp (l_nmod) hem_5\NNP\3264542|the|and
D009599_D007022 CID nitroprusside_10\RB\0| (r_advmod) induced_12\VBN\1627355|nitroprusside|- (r_amod) hypotension_13\NN\14057371|sodium|induced|in
D009599_D007022 CID snp_21\NNP\11493266| (r_compound) group_22\NN\2137|the|snp (r_pobj) in_19\IN\13603305|group (r_prep) that_18\DT\0|in (r_pobj) with_17\IN\0|that (r_prep) compared_16\VBN\644583|with (r_prep) higher_15\RBR\0|compared (r_acomp) was_8\VBD\0|during|output|lower|higher|. (l_prep) during_0\IN\0|hypotension (l_pobj) hypotension_4\NN\14057371|induced
D009599_D007022 CID snp_7\NNP\11493266| (r_compound) groups_8\NNS\2137|hem|snp (r_pobj) in_3\IN\13603305|groups (r_prep) hg_2\NNP\14625458|mm|in|,|respectively|,|during|p|. (l_prep) during_12\IN\0|hypotension (l_pobj) hypotension_13\NN\14057371|
12695819
D016559_D020258 NONE tacrolimus_7\NN\0| (r_npadvmod) induced_9\VBN\1627355|tacrolimus|- (r_amod) neurotoxicity_10\NN\0|induced|in
D016559_D020258 NONE tacrolimus_15\NN\0| (r_npadvmod) induced_17\VBN\1627355|tacrolimus|- (r_amod) neurotoxicity_18\NN\0|induced
D016559_D009422 NONE tacrolimus_17\NNS\0|developed (l_relcl) developed_19\VBD\1753788|who|complications (l_dobj) complications_21\NNS\1073995|neurologic
1592014
D003042_D012640 CID cocaine_4\NN\3492717| (r_compound) metabolite_5\NN\20090|cocaine (r_amod) benzoylecgonine_6\NN\0|the|metabolite|in (r_pobj) by_2\IN\0|benzoylecgonine (r_agent) induced_1\VBN\1627355|seizures|by|. (l_nsubj) seizures_0\NNS\14081375|
D003042_D012640 CID cocaine_8\NN\3492717| (r_pobj) of_7\IN\0|cocaine (r_prep) t1/2_5\NN\0|(|)|of (r_appos) life_3\NN\13954253|half|-|t1/2 (r_nsubj) is_9\VBZ\0|the|life|short|,|but|occur (l_conj) occur_29\VB\0|some|can|hours|. (l_nsubj) some_14\DT\0|of (l_prep) of_15\IN\0|consequences (l_pobj) consequences_17\NNS\34213|the|of (l_prep) of_18\IN\0|use (l_pobj) use_20\NN\407535|its|,|as|, (l_prep) as_23\IN\14622893|such|seizures (l_pobj) seizures_24\NNS\14081375|and|strokes
D003042_D012640 CID cocaine_9\NN\3492717|, (r_pobj) of_8\IN\0|cocaine (r_prep) metabolite_7\NN\20090|the|major|of|benzoylecgonine|be (r_pobj) of_4\IN\0|metabolite (r_prep) potential_3\NN\14481929|the|of (r_dobj) evaluated_1\VBD\670261|we|potential|,|cause|. (l_advcl) cause_17\VB\7323922|to|seizures (l_dobj) seizures_18\NNS\14081375|
D003042_D012640 CID cocaine_19\NN\3492717| (r_pobj) of_18\IN\0|cocaine (r_prep) amounts_17\NNS\13329641|equimolar|of (r_pobj) by_15\IN\0|amounts (r_agent) induced_14\VBN\1627355|by (r_acl) those_13\DT\0|induced (r_pobj) than_12\IN\0|those (r_prep) latencies_11\NNS\15269513|longer|than (r_dobj) had_8\VBD\0|latencies (r_conj) occurred_4\VBD\0|seizures|frequently|and|had|. (l_nsubj) seizures_3\NNS\14081375|induced
D003042_D012640 CID cocaine_1\NN\3492717| (r_npadvmod) induced_3\VBN\1627355|cocaine|- (r_amod) seizures_4\NNS\14081375|induced
D003042_D012640 CID cocaine_15\NN\3492717| (r_npadvmod) injected_17\VBN\81072|cocaine|- (r_amod) animals_18\NNS\4475|injected (r_pobj) than_14\IN\0|animals (r_prep) activity_13\NN\30358|more|locomotor|than (r_dobj) had_9\VBD\0|rats|activity|without|. (l_nsubj) rats_3\NNS\2329401|injected|have (l_relcl) have_7\VB\7846|that|did|not|seizures (l_dobj) seizures_8\NNS\14081375|
D003042_D012640 CID cocaine_15\NN\3492717| (r_npadvmod) injected_17\VBN\81072|cocaine|- (r_amod) animals_18\NNS\4475|injected (r_pobj) than_14\IN\0|animals (r_prep) activity_13\NN\30358|more|locomotor|than (r_dobj) had_9\VBD\0|rats|activity|without|. (l_prep) without_19\IN\0|seizures (l_pobj) seizures_20\NNS\14081375|
D003042_D012640 CID cocaine-_3\NN\0|and|induced (r_nmod) seizures_8\NNS\14081375|cocaine-
D003042_D012640 CID cocaine-_3\NN\0|and|induced (r_nmod) seizures_8\NNS\14081375|cocaine- (r_nsubj) differ_9\VBP\0|seizures|in (r_relcl) finding_1\NN\43195|the|differ (r_nsubj) suggests_13\VBZ\1010118|finding|mechanism|and|emphasizes|. (l_dobj) mechanism_17\NN\13446390|one|for (l_prep) for_18\IN\0|seizures (l_pobj) seizures_22\NNS\14081375|induced
D003042_D012640 CID cocaine_19\NN\3492717| (r_npadvmod) induced_21\VBN\1627355|cocaine|- (r_amod) seizures_22\NNS\14081375|induced (r_pobj) for_18\IN\0|seizures (r_prep) mechanism_17\NN\13446390|one|for (r_dobj) suggests_13\VBZ\1010118|finding|mechanism|and|emphasizes|. (l_nsubj) finding_1\NN\43195|the|differ (l_relcl) differ_9\VBP\0|seizures|in (l_nsubj) seizures_8\NNS\14081375|cocaine-
D003042_D012640 CID cocaine_19\NN\3492717| (r_npadvmod) induced_21\VBN\1627355|cocaine|- (r_amod) seizures_22\NNS\14081375|induced
D003042_D012640 CID cocaine_29\NN\3492717| (r_compound) metabolite_30\NN\20090|a|cocaine (r_pobj) of_27\IN\0|metabolite (r_prep) importance_26\NN\5138488|the|of (r_dobj) emphasizes_24\VBZ\943837|importance|,|be (r_conj) suggests_13\VBZ\1010118|finding|mechanism|and|emphasizes|. (l_nsubj) finding_1\NN\43195|the|differ (l_relcl) differ_9\VBP\0|seizures|in (l_nsubj) seizures_8\NNS\14081375|cocaine-
D003042_D012640 CID cocaine_29\NN\3492717| (r_compound) metabolite_30\NN\20090|a|cocaine (r_pobj) of_27\IN\0|metabolite (r_prep) importance_26\NN\5138488|the|of (r_dobj) emphasizes_24\VBZ\943837|importance|,|be (r_conj) suggests_13\VBZ\1010118|finding|mechanism|and|emphasizes|. (l_dobj) mechanism_17\NN\13446390|one|for (l_prep) for_18\IN\0|seizures (l_pobj) seizures_22\NNS\14081375|induced
C005618_D012640 CID benzoylecgonine_6\NN\0|the|metabolite|in (r_pobj) by_2\IN\0|benzoylecgonine (r_agent) induced_1\VBN\1627355|seizures|by|. (l_nsubj) seizures_0\NNS\14081375|
C005618_D012640 CID benzoylecgonine_11\NN\0| (r_appos) metabolite_7\NN\20090|the|major|of|benzoylecgonine|be (r_pobj) of_4\IN\0|metabolite (r_prep) potential_3\NN\14481929|the|of (r_dobj) evaluated_1\VBD\670261|we|potential|,|cause|. (l_advcl) cause_17\VB\7323922|to|seizures (l_dobj) seizures_18\NNS\14081375|
C005618_D012640 CID be_13\VB\14625458|(|) (r_appos) metabolite_7\NN\20090|the|major|of|benzoylecgonine|be (r_pobj) of_4\IN\0|metabolite (r_prep) potential_3\NN\14481929|the|of (r_dobj) evaluated_1\VBD\670261|we|potential|,|cause|. (l_advcl) cause_17\VB\7323922|to|seizures (l_dobj) seizures_18\NNS\14081375|
C005618_D012640 CID be_0\VB\14625458| (r_advmod) induced_2\VBN\1627355|be|- (r_amod) seizures_3\NNS\14081375|induced
C005618_D012640 CID be_23\NNP\14625458| (r_pobj) by_22\IN\0|be (r_agent) induced_21\VBN\1627355|by (r_acl) those_20\DT\0|induced (r_nsubj) were_24\VBD\0|characterized|,|those|multiple|,|and|resulted|. (l_advcl) characterized_7\VBN\609683|whereas|seizures|were|best|as|and|resulted (l_nsubjpass) seizures_4\NNS\14081375|induced
C005618_D012640 CID be_0\VB\14625458| (r_advmod) injected_2\VBN\81072|be|- (r_amod) rats_3\NNS\2329401|injected|have (l_relcl) have_7\VB\7846|that|did|not|seizures (l_dobj) seizures_8\NNS\14081375|
C005618_D012640 CID be_0\VB\14625458| (r_advmod) injected_2\VBN\81072|be|- (r_amod) rats_3\NNS\2329401|injected|have (r_nsubj) had_9\VBD\0|rats|activity|without|. (l_prep) without_19\IN\0|seizures (l_pobj) seizures_20\NNS\14081375|
C005618_D012640 CID be_5\VB\14625458| (r_advmod) induced_7\VBN\1627355|be|- (r_conj) cocaine-_3\NN\0|and|induced (r_nmod) seizures_8\NNS\14081375|cocaine-
C005618_D012640 CID be_5\VB\14625458| (r_advmod) induced_7\VBN\1627355|be|- (r_conj) cocaine-_3\NN\0|and|induced (r_nmod) seizures_8\NNS\14081375|cocaine- (r_nsubj) differ_9\VBP\0|seizures|in (r_relcl) finding_1\NN\43195|the|differ (r_nsubj) suggests_13\VBZ\1010118|finding|mechanism|and|emphasizes|. (l_dobj) mechanism_17\NN\13446390|one|for (l_prep) for_18\IN\0|seizures (l_pobj) seizures_22\NNS\14081375|induced
C005618_D012640 CID be_32\VB\14625458| (r_conj) emphasizes_24\VBZ\943837|importance|,|be (r_conj) suggests_13\VBZ\1010118|finding|mechanism|and|emphasizes|. (l_nsubj) finding_1\NN\43195|the|differ (l_relcl) differ_9\VBP\0|seizures|in (l_nsubj) seizures_8\NNS\14081375|cocaine-
C005618_D012640 CID be_32\VB\14625458| (r_conj) emphasizes_24\VBZ\943837|importance|,|be (r_conj) suggests_13\VBZ\1010118|finding|mechanism|and|emphasizes|. (l_dobj) mechanism_17\NN\13446390|one|for (l_prep) for_18\IN\0|seizures (l_pobj) seizures_22\NNS\14081375|induced
D003042_D020521 NONE cocaine_8\NN\3492717| (r_pobj) of_7\IN\0|cocaine (r_prep) t1/2_5\NN\0|(|)|of (r_appos) life_3\NN\13954253|half|-|t1/2 (r_nsubj) is_9\VBZ\0|the|life|short|,|but|occur (l_conj) occur_29\VB\0|some|can|hours|. (l_nsubj) some_14\DT\0|of (l_prep) of_15\IN\0|consequences (l_pobj) consequences_17\NNS\34213|the|of (l_prep) of_18\IN\0|use (l_pobj) use_20\NN\407535|its|,|as|, (l_prep) as_23\IN\14622893|such|seizures (l_pobj) seizures_24\NNS\14081375|and|strokes (l_conj) strokes_26\NNS\556313|
D003042_D003643 NONE cocaine_1\NN\3492717| (r_npadvmod) induced_3\VBN\1627355|cocaine|- (r_amod) seizures_4\NNS\14081375|induced (r_nsubjpass) characterized_7\VBN\609683|whereas|seizures|were|best|as|and|resulted (l_conj) resulted_16\VBD\2633881|in (l_prep) in_17\IN\13603305|death (l_pobj) death_18\NN\7296428|
D003042_D003643 NONE cocaine_1\NN\3492717| (r_npadvmod) induced_3\VBN\1627355|cocaine|- (r_amod) seizures_4\NNS\14081375|induced (r_nsubjpass) characterized_7\VBN\609683|whereas|seizures|were|best|as|and|resulted (r_advcl) were_24\VBD\0|characterized|,|those|multiple|,|and|resulted|. (l_conj) resulted_36\VBD\2633881|rarely|in (l_prep) in_37\IN\13603305|death (l_pobj) death_38\NN\7296428|
C005618_D003643 NONE be_23\NNP\14625458| (r_pobj) by_22\IN\0|be (r_agent) induced_21\VBN\1627355|by (r_acl) those_20\DT\0|induced (r_nsubj) were_24\VBD\0|characterized|,|those|multiple|,|and|resulted|. (l_advcl) characterized_7\VBN\609683|whereas|seizures|were|best|as|and|resulted (l_conj) resulted_16\VBD\2633881|in (l_prep) in_17\IN\13603305|death (l_pobj) death_18\NN\7296428|
C005618_D003643 NONE be_23\NNP\14625458| (r_pobj) by_22\IN\0|be (r_agent) induced_21\VBN\1627355|by (r_acl) those_20\DT\0|induced (r_nsubj) were_24\VBD\0|characterized|,|those|multiple|,|and|resulted|. (l_conj) resulted_36\VBD\2633881|rarely|in (l_prep) in_37\IN\13603305|death (l_pobj) death_38\NN\7296428|
18619688
D004317_D003643 NONE adriamycin_0\NNP\0| (r_advmod) induced_2\VBN\1627355|adriamycin|- (r_amod) death_5\NN\7296428|induced|cardiomyocyte
D004317_D003643 NONE adriamycin_17\NNS\0| (r_pobj) by_16\IN\0|adriamycin (r_agent) induced_15\VBN\1627355|by (r_advcl) plays_3\VBZ\7007684|death|role|in|induced|. (l_nsubj) death_2\NN\7296428|autophagic|cardiomyocyte
D004317_D006333 CID adriamycin_0\NNP\0| (r_advmod) induced_2\VBN\1627355|adriamycin|- (r_amod) death_5\NN\7296428|induced|cardiomyocyte (r_nsubj) plays_6\VBZ\7007684|death|role|in|. (l_prep) in_10\IN\13603305|model (l_pobj) model_13\NN\5888929|a|rat|of (l_prep) of_14\IN\0|failure (l_pobj) failure_16\NN\66216|heart
D004317_D006333 CID adriamycin_7\NNS\0| (r_pobj) by_6\IN\0|adriamycin (r_agent) induced_5\VBN\1627355|by (r_acl) failure_4\NN\66216|mechanisms|underlying|heart|induced
D004317_D006333 CID adriamycin_20\NNS\0| (r_pobj) by_19\IN\0|adriamycin (r_agent) induced_18\VBN\1627355|by (r_acl) progression_14\NN\8457976|the|of|induced (l_prep) of_15\IN\0|failure (l_pobj) failure_17\NN\66216|heart
D004317_D006333 CID adriamycin_20\NNS\0| (r_pobj) by_19\IN\0|adriamycin (r_agent) induced_18\VBN\1627355|by (r_acl) progression_14\NN\8457976|the|of|induced (r_pobj) in_12\IN\13603305|progression (r_prep) involved_11\VBN\2676054|whether|autophagy|was|in (r_ccomp) investigate_7\VB\644583|to|involved|,|develop (l_advcl) develop_26\VB\1753788|so|that|we|can|strategy (l_dobj) strategy_30\NN\5902545|a|novel|treatment|for (l_prep) for_31\IN\0|failure (l_pobj) failure_33\NN\66216|heart
D004317_D006333 CID adriamycin_23\NNS\0| (r_pobj) by_22\IN\0|adriamycin (r_agent) induced_21\VBN\1627355|by (r_acl) model_18\NN\5888929|a|heart|failure|of|induced (l_compound) failure_17\NN\66216|
D004317_D006333 CID adriamycin_17\NNS\0| (r_pobj) by_16\IN\0|adriamycin (r_agent) induced_15\VBN\1627355|by (r_advcl) plays_3\VBZ\7007684|death|role|in|induced|. (l_prep) in_7\IN\13603305|pathogenesis (l_pobj) pathogenesis_9\NN\13533470|the|of (l_prep) of_10\IN\0|failure (l_pobj) failure_12\NN\66216|heart|in
D004317_D006333 CID adriamycin_13\NNS\0| (r_pobj) by_12\IN\0|adriamycin (r_agent) caused_11\VBN\1617192|by|via (r_acl) failure_10\NN\66216|heart|caused
C025946_D006333 NONE 3-methyladenine_2\LS\0|3ma (r_appos) methods_0\NNS\5616786|:|3-methyladenine|, (r_nsubjpass) used_13\VBN\0|methods|inhibitor|was|in|. (l_prep) in_14\IN\13603305|model (l_pobj) model_18\NN\5888929|a|heart|failure|of|induced (l_compound) failure_17\NN\66216|
C025946_D006333 NONE 3ma_4\VBN\0|(|) (r_appos) 3-methyladenine_2\LS\0|3ma (r_appos) methods_0\NNS\5616786|:|3-methyladenine|, (r_nsubjpass) used_13\VBN\0|methods|inhibitor|was|in|. (l_prep) in_14\IN\13603305|model (l_pobj) model_18\NN\5888929|a|heart|failure|of|induced (l_compound) failure_17\NN\66216|
18221780
D016202_D010146 NONE nmda_3\NNP\0| (r_compound) enhancement_5\NN\248977|nmda|antagonist|of (r_pobj) in_2\IN\13603305|enhancement (r_prep) differences_1\NNS\4723816|sex|in|in|:|comparisons|. (l_prep) in_9\IN\13603305|model (l_pobj) model_12\NN\5888929|a|capsaicin|of (l_prep) of_13\IN\0|pain (l_pobj) pain_15\NN\14299637|persistent
D016202_D010146 NONE nmda_9\NNP\0| (r_compound) antagonists_10\NNS\7846|nmda|and|morphine (r_pobj) between_8\IN\0|antagonists (r_prep) interaction_7\NN\37396|a|dimorphic|between|in (l_prep) in_13\IN\13603305|model (l_pobj) model_17\NN\5888929|a|persistent|pain|distinguished (l_compound) pain_16\NN\14299637|
D016202_D059787 NONE nmda_3\NNP\0| (r_compound) enhancement_5\NN\248977|nmda|antagonist|of (r_pobj) in_2\IN\13603305|enhancement (r_prep) differences_1\NNS\4723816|sex|in|in|:|comparisons|. (l_appos) comparisons_17\NNS\635850|to (l_prep) to_18\IN\0|models (l_pobj) models_20\NNS\5888929|two|of (l_prep) of_21\IN\0|pain (l_pobj) pain_23\NN\14299637|acute
D016202_D059787 NONE aspartate_11\NNP\0|d|- (r_nmod) antagonists_15\NNS\7846|methyl|aspartate|(|nmda|) (r_nsubj) enhance_16\VBP\227165|in|antagonists|effects|to|. (l_prep) in_0\IN\13603305|models|, (l_pobj) models_3\NNS\5888929|acute|pain (l_compound) pain_2\NN\14299637|
D016202_D059787 NONE nmda_13\NNP\0| (r_nmod) antagonists_15\NNS\7846|methyl|aspartate|(|nmda|) (r_nsubj) enhance_16\VBP\227165|in|antagonists|effects|to|. (l_prep) in_0\IN\13603305|models|, (l_pobj) models_3\NNS\5888929|acute|pain (l_compound) pain_2\NN\14299637|
D016202_D059787 NONE nmda_9\NNP\0| (r_compound) antagonists_10\NNS\7846|nmda|and|morphine (r_pobj) between_8\IN\0|antagonists (r_prep) interaction_7\NN\37396|a|dimorphic|between|in (l_prep) in_13\IN\13603305|model (l_pobj) model_17\NN\5888929|a|persistent|pain|distinguished (l_relcl) distinguished_21\VBN\618878|that|can|be|from (l_prep) from_22\IN\0|those (l_pobj) those_23\DT\0|observed (l_acl) observed_24\VBN\2163746|in (l_prep) in_25\IN\13603305|models (l_pobj) models_28\NNS\5888929|acute|pain (l_compound) pain_27\NN\14299637|
D009020_D010146 NONE morphine_7\NN\2707683| (r_compound) antihyperalgesia_8\NN\0|morphine (r_pobj) of_6\IN\0|antihyperalgesia (r_prep) enhancement_5\NN\248977|nmda|antagonist|of (r_pobj) in_2\IN\13603305|enhancement (r_prep) differences_1\NNS\4723816|sex|in|in|:|comparisons|. (l_prep) in_9\IN\13603305|model (l_pobj) model_12\NN\5888929|a|capsaicin|of (l_prep) of_13\IN\0|pain (l_pobj) pain_15\NN\14299637|persistent
D009020_D010146 NONE morphine_12\NN\2707683| (r_conj) antagonists_10\NNS\7846|nmda|and|morphine (r_pobj) between_8\IN\0|antagonists (r_prep) interaction_7\NN\37396|a|dimorphic|between|in (l_prep) in_13\IN\13603305|model (l_pobj) model_17\NN\5888929|a|persistent|pain|distinguished (l_compound) pain_16\NN\14299637|
D009020_D059787 NONE morphine_7\NN\2707683| (r_compound) antihyperalgesia_8\NN\0|morphine (r_pobj) of_6\IN\0|antihyperalgesia (r_prep) enhancement_5\NN\248977|nmda|antagonist|of (r_pobj) in_2\IN\13603305|enhancement (r_prep) differences_1\NNS\4723816|sex|in|in|:|comparisons|. (l_appos) comparisons_17\NNS\635850|to (l_prep) to_18\IN\0|models (l_pobj) models_20\NNS\5888929|two|of (l_prep) of_21\IN\0|pain (l_pobj) pain_23\NN\14299637|acute
D009020_D059787 NONE morphine_21\NN\2707683| (r_pobj) of_20\IN\0|morphine (r_prep) effects_19\NNS\13245626|the|antinociceptive|of (r_dobj) enhance_16\VBP\227165|in|antagonists|effects|to|. (l_prep) in_0\IN\13603305|models|, (l_pobj) models_3\NNS\5888929|acute|pain (l_compound) pain_2\NN\14299637|
D009020_D059787 NONE morphine_2\NN\2707683| (r_compound) antinociception_3\NN\0|morphine (r_pobj) of_1\IN\0|antinociception (r_prep) enhancement_0\NN\248977|of|by (r_nsubjpass) seen_7\VBN\2106506|enhancement|was|in|,|with|. (l_prep) in_8\IN\13603305|males (l_pobj) males_10\NNS\15388|both|and|females|in (l_prep) in_13\IN\13603305|models (l_pobj) models_17\NNS\5888929|the|acute|pain (l_compound) pain_16\NN\14299637|
D009020_D059787 NONE morphine_12\NN\2707683| (r_conj) antagonists_10\NNS\7846|nmda|and|morphine (r_pobj) between_8\IN\0|antagonists (r_prep) interaction_7\NN\37396|a|dimorphic|between|in (l_prep) in_13\IN\13603305|model (l_pobj) model_17\NN\5888929|a|persistent|pain|distinguished (l_relcl) distinguished_21\VBN\618878|that|can|be|from (l_prep) from_22\IN\0|those (l_pobj) those_23\DT\0|observed (l_acl) observed_24\VBN\2163746|in (l_prep) in_25\IN\13603305|models (l_pobj) models_28\NNS\5888929|acute|pain (l_compound) pain_27\NN\14299637|
D002211_D010146 NONE capsaicin_11\NN\15032661| (r_compound) model_12\NN\5888929|a|capsaicin|of (l_prep) of_13\IN\0|pain (l_pobj) pain_15\NN\14299637|persistent
D002211_D059787 NONE capsaicin_11\NN\15032661| (r_compound) model_12\NN\5888929|a|capsaicin|of (r_pobj) in_9\IN\13603305|model (r_prep) differences_1\NNS\4723816|sex|in|in|:|comparisons|. (l_appos) comparisons_17\NNS\635850|to (l_prep) to_18\IN\0|models (l_pobj) models_20\NNS\5888929|two|of (l_prep) of_21\IN\0|pain (l_pobj) pain_23\NN\14299637|acute
D002211_D006930 CID capsaicin_11\NN\15032661| (r_pobj) of_10\IN\0|capsaicin (r_prep) administration_9\NN\1133281|of|in (r_pobj) by_8\IN\0|administration (r_agent) induced_7\VBN\1627355|to|,|hyperalgesia|was|by|,|immersed|. (l_nsubjpass) hyperalgesia_5\NN\0|persistent
D003915_D059787 NONE dextromethorphan_5\NNP\0| (r_pobj) by_4\IN\0|dextromethorphan (r_prep) enhancement_0\NN\248977|of|by (r_nsubjpass) seen_7\VBN\2106506|enhancement|was|in|,|with|. (l_prep) in_8\IN\13603305|males (l_pobj) males_10\NNS\15388|both|and|females|in (l_prep) in_13\IN\13603305|models (l_pobj) models_17\NNS\5888929|the|acute|pain (l_compound) pain_16\NN\14299637|
11391224
D003042_D006974 NONE cocaine_23\NN\3492717| (r_npadvmod) related_25\VBN\628491|cocaine|- (r_amod) failure_28\NN\66216|related|acute|renal (r_conj) glomerulonephritis_20\NN\14113798|crescentic|,|and|failure (r_conj) nephritis_17\NN\14113228|schonlein|,|glomerulonephritis (r_conj) nephritis_12\NN\14113228|,|nephritis (r_dobj) lupus_11\NN\14219661|microangiopathy|nephritis (r_conj) included_2\VBD\0|13|cases|,|lupus|. (l_dobj) cases_3\NNS\7283608|of (l_prep) of_4\IN\0|hypertension (l_pobj) hypertension_6\NN\14057371|malignant
D003042_D057049 NONE cocaine_23\NN\3492717| (r_npadvmod) related_25\VBN\628491|cocaine|- (r_amod) failure_28\NN\66216|related|acute|renal (r_conj) glomerulonephritis_20\NN\14113798|crescentic|,|and|failure (r_conj) nephritis_17\NN\14113228|schonlein|,|glomerulonephritis (r_conj) nephritis_12\NN\14113228|,|nephritis (r_dobj) lupus_11\NN\14219661|microangiopathy|nephritis (l_nsubj) microangiopathy_9\NN\0|thrombotic|,
D003042_D008181 NONE cocaine_23\NN\3492717| (r_npadvmod) related_25\VBN\628491|cocaine|- (r_amod) failure_28\NN\66216|related|acute|renal (r_conj) glomerulonephritis_20\NN\14113798|crescentic|,|and|failure (r_conj) nephritis_17\NN\14113228|schonlein|,|glomerulonephritis (r_conj) nephritis_12\NN\14113228|,|nephritis
D003042_D011695 NONE cocaine_23\NN\3492717| (r_npadvmod) related_25\VBN\628491|cocaine|- (r_amod) failure_28\NN\66216|related|acute|renal (r_conj) glomerulonephritis_20\NN\14113798|crescentic|,|and|failure (r_conj) nephritis_17\NN\14113228|schonlein|,|glomerulonephritis
D003042_D005921 NONE cocaine_23\NN\3492717| (r_npadvmod) related_25\VBN\628491|cocaine|- (r_amod) failure_28\NN\66216|related|acute|renal (r_conj) glomerulonephritis_20\NN\14113798|crescentic|,|and|failure
D003042_D058186 CID cocaine_23\NN\3492717| (r_npadvmod) related_25\VBN\628491|cocaine|- (r_amod) failure_28\NN\66216|related|acute|renal
10739826
D003276_D054556 CID contraceptives_5\NNS\3183080|newer|oral|and|risk (l_conj) risk_8\NN\14541044|the|of (l_prep) of_9\IN\0|thromboembolism (l_pobj) thromboembolism_11\NN\14100769|venous
D003276_D054556 CID contraceptives_17\NNS\3183080|newer|oral|oc (r_pobj) with_14\IN\0|contraceptives (r_prep) associated_13\VBN\628491|with (r_acl) thromboembolism_9\NN\14100769|venous|(|vte|)|associated
D003276_D054556 CID contraceptives_17\NNS\3183080|newer|oral|oc (r_pobj) with_14\IN\0|contraceptives (r_prep) associated_13\VBN\628491|with (r_acl) thromboembolism_9\NN\14100769|venous|(|vte|)|associated (l_appos) vte_11\NNP\0|
D003276_D054556 CID oc_19\NNP\0|(|) (r_appos) contraceptives_17\NNS\3183080|newer|oral|oc (r_pobj) with_14\IN\0|contraceptives (r_prep) associated_13\VBN\628491|with (r_acl) thromboembolism_9\NN\14100769|venous|(|vte|)|associated
D003276_D054556 CID oc_19\NNP\0|(|) (r_appos) contraceptives_17\NNS\3183080|newer|oral|oc (r_pobj) with_14\IN\0|contraceptives (r_prep) associated_13\VBN\628491|with (r_acl) thromboembolism_9\NN\14100769|venous|(|vte|)|associated (l_appos) vte_11\NNP\0|
D003276_D054556 CID oc_27\NNP\0| (r_compound) use_28\NN\407535|oc|,|users (r_pobj) of_26\IN\0|use (r_prep) patterns_25\NNS\5726345|of (r_pobj) between_24\IN\0|patterns (r_prep) distinguish_23\VB\618878|studies|did|not|between|. (l_nsubj) studies_2\NNS\635850|the|epidemiological|assessed (l_relcl) assessed_4\VBD\670261|that|risk (l_dobj) risk_6\NN\14541044|the|of (l_prep) of_7\IN\0|thromboembolism (l_pobj) thromboembolism_9\NN\14100769|venous|(|vte|)|associated
D003276_D054556 CID oc_27\NNP\0| (r_compound) use_28\NN\407535|oc|,|users (r_pobj) of_26\IN\0|use (r_prep) patterns_25\NNS\5726345|of (r_pobj) between_24\IN\0|patterns (r_prep) distinguish_23\VB\618878|studies|did|not|between|. (l_nsubj) studies_2\NNS\635850|the|epidemiological|assessed (l_relcl) assessed_4\VBD\670261|that|risk (l_dobj) risk_6\NN\14541044|the|of (l_prep) of_7\IN\0|thromboembolism (l_pobj) thromboembolism_9\NN\14100769|venous|(|vte|)|associated (l_appos) vte_11\NNP\0|
D003276_D054556 CID oc_12\NNP\0|generation (r_pobj) of_9\IN\0|oc (r_prep) users_8\NNS\7846|repeat|of (r_pobj) for_6\IN\0|users (r_prep) ratio_3\NN\13815152|the|adjusted|rate|of|for (l_prep) of_4\IN\0|vte (l_pobj) vte_5\NN\0|
15145918
D004967_D007022 NONE estrogen_3\NN\14745635|of (l_prep) of_4\IN\0|hypotension (l_pobj) hypotension_11\NN\14057371|alpha2-adrenergic|in
D004967_D007022 NONE estrogen_5\NN\14745635| (r_nsubj) modulates_7\VBZ\1724459|that|estrogen|negatively|effect|and|implicates (l_dobj) effect_10\NN\34213|the|hypotensive|of (l_amod) hypotensive_9\JJ\10405694|
D004967_D007022 NONE estrogen_4\NN\14745635| (r_nsubj) downregulates_5\VBZ\0|that|estrogen|alpha2-|but|hypotension|and|highlight (l_conj) hypotension_12\NN\14057371|not|mediated
D004967_D007022 NONE estrogen_27\NN\14745635|methyldopa|- (r_compound) interaction_28\NN\37396|estrogen (r_pobj) in_22\IN\13603305|interaction (r_prep) control_21\NN\5190804|the|cardiac|autonomic|in (r_pobj) for_17\IN\0|control (r_prep) role_16\NN\719494|a|for (r_dobj) highlight_14\VB\13809920|role (r_conj) downregulates_5\VBZ\0|that|estrogen|alpha2-|but|hypotension|and|highlight (l_conj) hypotension_12\NN\14057371|not|mediated
D048288_D007022 NONE i1-imidazoline_7\NNP\0| (r_punct) mediated_10\VBN\761713|i1-imidazoline|receptor|- (r_conj) alpha2-adrenergic_5\JJ\0|and|mediated (r_amod) hypotension_11\NN\14057371|alpha2-adrenergic|in
D003000_D007022 NONE clonidine_12\NN\2721160|agonist (r_pobj) of_11\IN\0|clonidine (r_prep) effect_10\NN\34213|the|hypotensive|of (l_amod) hypotensive_9\JJ\10405694|
C032302_D007022 CID rilmenidine_6\NN\0|or|methyldopa (r_amod) rats_4\NNS\2329401|operated|,|rilmenidine (r_pobj) in_0\IN\13603305|rats (r_prep) elicited_11\VBD\1617192|in|hypotension|. (l_dobj) hypotension_13\NN\14057371|similar|lasted
C032302_D007022 CID rilmenidine_17\JJ\0| (r_amod) hypotension_18\NN\14057371|rilmenidine (r_pobj) on_16\IN\0|hypotension (r_prep) effect_15\NN\34213|no|on (r_pobj) to_13\IN\0|effect (r_prep) contrast_12\NN\13854649|to (r_pobj) in_11\IN\13603305|contrast (r_prep) enhanced_2\VBD\227165|ovx|significantly|response|,|in|. (l_dobj) response_5\NN\11410625|the|hypotensive|to (l_amod) hypotensive_4\JJ\10405694|
C032302_D007022 CID rilmenidine_17\JJ\0| (r_amod) hypotension_18\NN\14057371|rilmenidine
D008750_D007022 CID methyldopa_10\NN\2721160|alpha|- (r_conj) rilmenidine_6\NN\0|or|methyldopa (r_amod) rats_4\NNS\2329401|operated|,|rilmenidine (r_pobj) in_0\IN\13603305|rats (r_prep) elicited_11\VBD\1617192|in|hypotension|. (l_dobj) hypotension_13\NN\14057371|similar|lasted
D008750_D007022 CID methyldopa_9\NN\2721160|alpha|- (r_pobj) to_6\IN\0|methyldopa (r_prep) response_5\NN\11410625|the|hypotensive|to (l_amod) hypotensive_4\JJ\10405694|
D008750_D007022 CID methyldopa_9\NN\2721160|alpha|- (r_pobj) to_6\IN\0|methyldopa (r_prep) response_5\NN\11410625|the|hypotensive|to (r_dobj) enhanced_2\VBD\227165|ovx|significantly|response|,|in|. (l_prep) in_11\IN\13603305|contrast (l_pobj) contrast_12\NN\13854649|to (l_prep) to_13\IN\0|effect (l_pobj) effect_15\NN\34213|no|on (l_prep) on_16\IN\0|hypotension (l_pobj) hypotension_18\NN\14057371|rilmenidine
D008750_D007022 CID methyldopa_4\NN\2721160|alpha|- (r_compound) hypotension_5\NN\14057371|the|enhanced|methyldopa|in
D008750_D007022 CID methyldopa_25\NN\2721160|alpha|- (r_compound) estrogen_27\NN\14745635|methyldopa|- (r_compound) interaction_28\NN\37396|estrogen (r_pobj) in_22\IN\13603305|interaction (r_prep) control_21\NN\5190804|the|cardiac|autonomic|in (r_pobj) for_17\IN\0|control (r_prep) role_16\NN\719494|a|for (r_dobj) highlight_14\VB\13809920|role (r_conj) downregulates_5\VBZ\0|that|estrogen|alpha2-|but|hypotension|and|highlight (l_conj) hypotension_12\NN\14057371|not|mediated
D008750_D001523 NONE methyldopa_4\NN\2721160|alpha|- (r_compound) hypotension_5\NN\14057371|the|enhanced|methyldopa|in (r_nsubjpass) paralleled_10\VBN\2657219|hypotension|was|with|. (l_prep) with_11\IN\0|reduction (l_pobj) reduction_13\NN\351485|further|in|and|activity (l_conj) activity_20\NN\30358|a|reduced|locomotor
20470218
D008727_D056784 NONE methotrexate_32\NN\2722166| (r_compound) toxicity_33\NN\13576101|dose|methotrexate|(|n|2|)|,|syndrome (r_conj) syndrome_6\NN\5870365|posterior|reversible|leukoencephalopathy|(|n|)|,|stroke|,|toxicity (l_compound) leukoencephalopathy_5\JJ\0|
D008727_D020521 NONE methotrexate_32\NN\2722166| (r_compound) toxicity_33\NN\13576101|dose|methotrexate|(|n|2|)|,|syndrome (r_conj) syndrome_6\NN\5870365|posterior|reversible|leukoencephalopathy|(|n|)|,|stroke|,|toxicity (l_conj) stroke_13\NN\556313|(|n|5|)|,|epilepsy
D008727_D004833 NONE methotrexate_32\NN\2722166| (r_compound) toxicity_33\NN\13576101|dose|methotrexate|(|n|2|)|,|syndrome (r_conj) syndrome_6\NN\5870365|posterior|reversible|leukoencephalopathy|(|n|)|,|stroke|,|toxicity (l_conj) stroke_13\NN\556313|(|n|5|)|,|epilepsy (l_conj) epilepsy_22\NN\14085708|temporal|lobe|(|n|)
D008727_D064420 NONE methotrexate_32\NN\2722166| (r_compound) toxicity_33\NN\13576101|dose|methotrexate|(|n|2|)|,|syndrome
D008727_D007177 NONE methotrexate_32\NN\2722166| (r_compound) toxicity_33\NN\13576101|dose|methotrexate|(|n|2|)|,|syndrome (l_conj) syndrome_40\NN\5870365|of|,|and|events (l_prep) of_41\IN\0|secretion (l_pobj) secretion_45\NN\13526110|inappropriate|antidiuretic|hormone|(|n|)
4008111
D000638_D012848 CID amiodarone_0\NN\2715941| (r_npadvmod) induced_2\VBN\1627355|amiodarone|- (r_amod) block_4\NN\21939|induced|sinoatrial|.
D000638_D012848 CID amiodarone_7\NN\2715941| (r_compound) administration_8\NN\1133281|chronic|amiodarone|in (r_pobj) due_4\JJ\5174653|to|administration (r_prep) observed_1\VBD\2163746|we|block|due|,|syndrome|. (l_dobj) block_3\NN\21939|sinoatrial
D000638_D012848 CID amiodarone_5\NN\2715941| (r_pobj) of_4\IN\0|amiodarone (r_prep) dosage_3\NN\13576355|the|of (r_pobj) in_1\IN\13603305|dosage (r_prep) reduction_0\NN\351485|in (r_nsubj) resulted_6\VBD\2633881|reduction|in|. (l_prep) in_7\IN\13603305|disappearance (l_pobj) disappearance_9\NN\42757|the|of|and|persistence (l_prep) of_10\IN\0|block (l_pobj) block_13\NN\21939|the|sinoatrial
D000638_D009202 NONE amiodarone_7\NN\2715941| (r_compound) administration_8\NN\1133281|chronic|amiodarone|in (l_prep) in_9\IN\13603305|boy (l_pobj) boy_14\NN\9624168|a|old|with (l_prep) with_15\IN\0|cardiomyopathy (l_pobj) cardiomyopathy_17\NN\14103288|primary
D000638_D014927 NONE amiodarone_7\NN\2715941| (r_compound) administration_8\NN\1133281|chronic|amiodarone|in (r_pobj) due_4\JJ\5174653|to|administration (r_prep) observed_1\VBD\2163746|we|block|due|,|syndrome|. (l_dobj) syndrome_24\NN\5870365|white|and|tachycardia
D000638_D013617 NONE amiodarone_7\NN\2715941| (r_compound) administration_8\NN\1133281|chronic|amiodarone|in (r_pobj) due_4\JJ\5174653|to|administration (r_prep) observed_1\VBD\2163746|we|block|due|,|syndrome|. (l_dobj) syndrome_24\NN\5870365|white|and|tachycardia (l_conj) tachycardia_27\NN\14110674|supraventricular
D000638_D012804 NONE amiodarone_5\NN\2715941| (r_pobj) of_4\IN\0|amiodarone (r_prep) dosage_3\NN\13576355|the|of (r_pobj) in_1\IN\13603305|dosage (r_prep) reduction_0\NN\351485|in (r_nsubj) resulted_6\VBD\2633881|reduction|in|. (l_prep) in_7\IN\13603305|disappearance (l_pobj) disappearance_9\NN\42757|the|of|and|persistence (l_conj) persistence_16\NN\5053688|the|of (l_prep) of_17\IN\0|bradycardia (l_pobj) bradycardia_20\NNP\14110674|asymptomatic|sinus
9390208
D008942_D001943 NONE mitoxantrone_8\NN\0|and (r_pobj) by_7\IN\0|mitoxantrone (r_prep) cancer_6\NN\14239425|treated|metastatic|breast|by
D008942_D001943 NONE mitoxantrone_20\NN\0| (r_pobj) by_19\IN\0|mitoxantrone (r_prep) treated_8\VBD\2376958|from|,|we|patients|by|,|m2|on|,|with|,|m2|for|. (l_dobj) patients_10\NNS\9898892|13|with (l_prep) with_11\IN\0|cancer (l_pobj) cancer_18\NN\14239425|treated|metastatic|breast
D008942_D064420 NONE mitoxantrone_8\NN\0|and (r_pobj) by_7\IN\0|mitoxantrone (r_prep) cancer_6\NN\14239425|treated|metastatic|breast|by (r_pobj) of_1\IN\0|cancer (r_prep) treatment_0\NN\654885|of|infusion|. (l_conj) infusion_12\NN\14589223|48-hour|continuous|of (l_prep) of_13\IN\0|5-fu (l_pobj) 5-fu_17\CD\0|dose|and|leucovorin|(|mfl|)|:|benefit (l_conj) benefit_26\NN\13278375|low|palliative|and|toxicity (l_conj) toxicity_32\NN\13576101|high|related
D005472_D001943 NONE 5-fu_17\CD\0|dose|and|leucovorin|(|mfl|)|:|benefit (r_pobj) of_13\IN\0|5-fu (r_prep) infusion_12\NN\14589223|48-hour|continuous|of (r_conj) treatment_0\NN\654885|of|infusion|. (l_prep) of_1\IN\0|cancer (l_pobj) cancer_6\NN\14239425|treated|metastatic|breast|by
D005472_D001943 NONE 5-fu_34\CD\0|,|m2 (r_pobj) of_33\IN\0|5-fu (r_prep) infusion_32\NN\14589223|continuous|of (r_conj) day_28\NN\15154774|1|and|infusion (r_pobj) on_27\IN\0|day (r_prep) treated_8\VBD\2376958|from|,|we|patients|by|,|m2|on|,|with|,|m2|for|. (l_dobj) patients_10\NNS\9898892|13|with (l_prep) with_11\IN\0|cancer (l_pobj) cancer_18\NN\14239425|treated|metastatic|breast
D005472_D064420 NONE 5-fu_17\CD\0|dose|and|leucovorin|(|mfl|)|:|benefit (l_conj) benefit_26\NN\13278375|low|palliative|and|toxicity (l_conj) toxicity_32\NN\13576101|high|related
D002955_D001943 NONE leucovorin_19\NN\0| (r_conj) 5-fu_17\CD\0|dose|and|leucovorin|(|mfl|)|:|benefit (r_pobj) of_13\IN\0|5-fu (r_prep) infusion_12\NN\14589223|48-hour|continuous|of (r_conj) treatment_0\NN\654885|of|infusion|. (l_prep) of_1\IN\0|cancer (l_pobj) cancer_6\NN\14239425|treated|metastatic|breast|by
D002955_D001943 NONE leucovorin_43\NN\0| (r_pobj) with_42\IN\0|together|leucovorin (r_prep) treated_8\VBD\2376958|from|,|we|patients|by|,|m2|on|,|with|,|m2|for|. (l_dobj) patients_10\NNS\9898892|13|with (l_prep) with_11\IN\0|cancer (l_pobj) cancer_18\NN\14239425|treated|metastatic|breast
D002955_D064420 NONE leucovorin_19\NN\0| (r_conj) 5-fu_17\CD\0|dose|and|leucovorin|(|mfl|)|:|benefit (l_conj) benefit_26\NN\13278375|low|palliative|and|toxicity (l_conj) toxicity_32\NN\13576101|high|related
C085788_D001943 NONE mfl_21\NNP\0| (r_appos) 5-fu_17\CD\0|dose|and|leucovorin|(|mfl|)|:|benefit (r_pobj) of_13\IN\0|5-fu (r_prep) infusion_12\NN\14589223|48-hour|continuous|of (r_conj) treatment_0\NN\654885|of|infusion|. (l_prep) of_1\IN\0|cancer (l_pobj) cancer_6\NN\14239425|treated|metastatic|breast|by
C085788_D064420 NONE mfl_21\NNP\0| (r_appos) 5-fu_17\CD\0|dose|and|leucovorin|(|mfl|)|:|benefit (l_conj) benefit_26\NN\13278375|low|palliative|and|toxicity (l_conj) toxicity_32\NN\13576101|high|related
C085788_D064420 NONE regimen_2\NN\5898568|the|mfl (r_nsubj) achieves_3\VBZ\2524171|regimen|benefit|and|induces|. (l_conj) induces_8\VBZ\1627355|toxicity|at (l_dobj) toxicity_10\NN\13576101|severe
12443032
D003042_D002637 CID cocaine_0\NN\3492717| (r_nsubj) related_1\VBN\628491|cocaine|pain (l_dobj) pain_3\NN\14299637|chest
D003042_D002637 CID cocaine_6\NN\3492717| (r_pobj) of_5\IN\0|cocaine (r_prep) tendency_4\NN\6193203|the|of|produce (l_acl) produce_8\VB\7555863|to|pain (l_dobj) pain_10\NN\14299637|chest
D003042_D002637 CID cocaine_6\NN\3492717| (r_pobj) of_5\IN\0|cocaine (r_prep) tendency_4\NN\6193203|the|of|produce (r_nsubj) ought_11\MD\0|in|,|tendency|be|. (l_xcomp) be_13\VB\14625458|to|in|faced (l_advcl) faced_22\VBN\2439281|when|with (l_prep) with_23\IN\0|victim (l_pobj) victim_26\NN\9630641|a|young|of|is (l_prep) of_27\IN\0|pain (l_pobj) pain_29\NN\14299637|chest
D003042_D002637 CID cocaine_7\NN\3492717| (r_compound) use_8\NN\407535|cocaine (r_pobj) to_6\IN\0|use (r_prep) related_5\VBN\628491|to (r_acl) mechanism_1\NN\13446390|the|of|related (l_prep) of_2\IN\0|pain (l_pobj) pain_4\NN\14299637|chest
19346865
D008795_D001927 CID metronidazole_5\NN\2723292| (r_npadvmod) induced_7\VBN\1627355|metronidazole|- (r_amod) encephalopathy_8\NN\14084880|induced (r_pobj) in_4\IN\13603305|encephalopathy (r_prep) lesion_3\NN\14204950|reversible|inferior|colliculus|in|:|findings|.
D008795_D001927 CID metronidazole_5\NN\2723292| (r_npadvmod) induced_7\VBN\1627355|metronidazole|- (r_amod) encephalopathy_8\NN\14084880|induced
D008795_D001927 CID metronidazole_9\NN\2723292| (r_npadvmod) induced_11\VBN\1627355|metronidazole|- (r_amod) encephalopathy_12\NN\14084880|induced (r_pobj) in_8\IN\13603305|encephalopathy (r_prep) lesions_7\NNS\14204950|reversible|inferior|colliculus|in
D008795_D001927 CID metronidazole_9\NN\2723292| (r_npadvmod) induced_11\VBN\1627355|metronidazole|- (r_amod) encephalopathy_12\NN\14084880|induced
D008795_D001927 CID metronidazole_20\NN\2723292| (r_npadvmod) induced_22\VBN\1627355|metronidazole|- (r_amod) encephalopathy_23\NN\14084880|induced|(|range|;|years
D008795_D001927 CID metronidazole_11\NN\2723292| (r_npadvmod) induced_13\VBN\1627355|metronidazole|- (r_amod) encephalopathy_14\NN\14084880|induced (r_pobj) for_10\IN\0|encephalopathy (r_prep) characteristic_9\NN\5849040|the|for (r_pobj) as_7\IN\14622893|characteristic (r_prep) considered_6\VBN\689344|lesions|could|be|as|,|next|. (l_nsubjpass) lesions_3\NNS\14204950|reversible|inferior|colliculus
D008795_D001927 CID metronidazole_11\NN\2723292| (r_npadvmod) induced_13\VBN\1627355|metronidazole|- (r_amod) encephalopathy_14\NN\14084880|induced
D008795_D007239 NONE metronidazole_4\NN\2723292| (r_dobj) taking_3\VBG\37396|they|had|been|metronidazole|(|dosage|)|treat|. (l_advcl) treat_23\VB\7570720|to|infection (l_dobj) infection_25\NN\14052046|the|in
3403780
D000082_D003128 NONE paracetamol_0\NN\0| (r_npadvmod) associated_2\VBN\628491|paracetamol|- (r_amod) coma_3\NN\5678932|associated|,|acidosis|.
D000082_D000138 CID paracetamol_0\NN\0| (r_npadvmod) associated_2\VBN\628491|paracetamol|- (r_amod) coma_3\NN\5678932|associated|,|acidosis|. (l_appos) acidosis_6\NN\14204950|metabolic|,|failure
D000082_D000138 CID paracetamol_13\JJ\0| (r_compound) ingestion_14\NN\13440063|paracetamol (r_pobj) following_12\VBG\8180190|ingestion (r_prep) failure_8\NN\66216|acute|renal|and|failure|following (r_nsubjpass) presented_16\VBN\2137132|case|,|failure|is|. (l_nsubjpass) case_1\NN\7283608|a|of (l_prep) of_2\IN\0|acidosis (l_pobj) acidosis_4\NN\14204950|metabolic
D000082_D058186 CID paracetamol_13\JJ\0| (r_compound) ingestion_14\NN\13440063|paracetamol (r_pobj) following_12\VBG\8180190|ingestion (r_prep) failure_8\NN\66216|acute|renal|and|failure|following (l_conj) failure_11\NN\66216|hepatic
D000082_D058186 NONE paracetamol_0\NN\0| (r_npadvmod) associated_2\VBN\628491|paracetamol|- (r_amod) coma_3\NN\5678932|associated|,|acidosis|. (l_appos) acidosis_6\NN\14204950|metabolic|,|failure (l_conj) failure_11\NN\66216|renal
D000082_D017093 NONE paracetamol_0\NN\0| (r_npadvmod) associated_2\VBN\628491|paracetamol|- (r_amod) coma_3\NN\5678932|associated|,|acidosis|. (l_appos) acidosis_6\NN\14204950|metabolic|,|failure (l_conj) failure_11\NN\66216|renal
D000082_D017114 CID paracetamol_13\JJ\0| (r_compound) ingestion_14\NN\13440063|paracetamol (r_pobj) following_12\VBG\8180190|ingestion (r_prep) failure_8\NN\66216|acute|renal|and|failure|following (l_conj) failure_11\NN\66216|hepatic
8701950
D016559_D000743 CID fk506_4\NNP\0|(|therapy (r_dobj) complicating_3\VBG\126264|anemia|fk506|. (l_nsubj) anemia_2\NN\14189204|microangiopathic|hemolytic
D016559_D000743 CID tacrolimus_6\NNP\0|) (r_nmod) therapy_8\NN\657604|tacrolimus (r_appos) fk506_4\NNP\0|(|therapy (r_dobj) complicating_3\VBG\126264|anemia|fk506|. (l_nsubj) anemia_2\NN\14189204|microangiopathic|hemolytic
D016559_D000743 CID fk506_17\NNP\0|( (r_nmod) therapy_21\NN\657604|fk506|tacrolimus (r_pobj) under_16\IN\0|therapy (r_prep) recipients_15\NNS\9764201|2|solid|organ|under (r_pobj) in_11\IN\13603305|recipients (r_prep) episodes_3\NNS\7283608|3|of|in (l_prep) of_4\IN\0|anemia (l_pobj) anemia_7\NN\14189204|microangiopathic|hemolytic|(|maha|)
D016559_D000743 CID fk506_17\NNP\0|( (r_nmod) therapy_21\NN\657604|fk506|tacrolimus (r_pobj) under_16\IN\0|therapy (r_prep) recipients_15\NNS\9764201|2|solid|organ|under (r_pobj) in_11\IN\13603305|recipients (r_prep) episodes_3\NNS\7283608|3|of|in (l_prep) of_4\IN\0|anemia (l_pobj) anemia_7\NN\14189204|microangiopathic|hemolytic|(|maha|) (l_appos) maha_9\NNP\9654687|
D016559_D000743 CID tacrolimus_19\NNP\0|) (r_nmod) therapy_21\NN\657604|fk506|tacrolimus (r_pobj) under_16\IN\0|therapy (r_prep) recipients_15\NNS\9764201|2|solid|organ|under (r_pobj) in_11\IN\13603305|recipients (r_prep) episodes_3\NNS\7283608|3|of|in (l_prep) of_4\IN\0|anemia (l_pobj) anemia_7\NN\14189204|microangiopathic|hemolytic|(|maha|)
D016559_D000743 CID tacrolimus_19\NNP\0|) (r_nmod) therapy_21\NN\657604|fk506|tacrolimus (r_pobj) under_16\IN\0|therapy (r_prep) recipients_15\NNS\9764201|2|solid|organ|under (r_pobj) in_11\IN\13603305|recipients (r_prep) episodes_3\NNS\7283608|3|of|in (l_prep) of_4\IN\0|anemia (l_pobj) anemia_7\NN\14189204|microangiopathic|hemolytic|(|maha|) (l_appos) maha_9\NNP\9654687|
D016559_D000743 CID fk506_6\NNP\0|and|treatment (r_pobj) of_5\IN\0|fk506 (r_prep) discontinuation_4\NN\209943|of|,|replacement (r_nsubj) led_24\VBD\3202760|in|,|discontinuation|to|. (l_prep) to_25\IN\0|resolution (l_pobj) resolution_26\NN\6470073|of (l_prep) of_27\IN\0|maha (l_pobj) maha_28\NNP\9654687|
D016559_D000743 CID fk506_6\NNP\0| (r_pobj) of_5\IN\0|fk506 (r_prep) reintroduction_4\NN\7217349|of (r_nsubj) led_7\VBD\3202760|in|,|reintroduction|to|. (l_prep) to_8\IN\0|recurrence (l_pobj) recurrence_10\NN\7342049|rapid|of (l_prep) of_11\IN\0|maha (l_pobj) maha_12\NNP\9654687|
D016559_D000743 CID fk506-associated_0\VBN\0| (r_amod) maha_1\NNP\9654687|fk506-associated
D016559_D000743 CID fk506_9\NNP\0| (r_nsubj) seem_12\VB\2604760|in|,|fk506|does|not|a|. (l_oprd) a_19\NNP\13649268|react|with|cyclosporin|cya|,|drug (l_appos) drug_28\NN\14778436|an|suppressive|known (l_acl) known_30\VBN\0|already|induce (l_xcomp) induce_32\VB\1627355|to|maha (l_dobj) maha_33\NNP\9654687|
D000305_D000743 NONE corticosteroids_18\NNS\14745635|,|aspirin (r_conj) replacement_16\NN\196485|fresh|plasma|,|corticosteroids (r_appos) discontinuation_4\NN\209943|of|,|replacement (r_nsubj) led_24\VBD\3202760|in|,|discontinuation|to|. (l_prep) to_25\IN\0|resolution (l_pobj) resolution_26\NN\6470073|of (l_prep) of_27\IN\0|maha (l_pobj) maha_28\NNP\9654687|
D001241_D000743 NONE aspirin_20\NN\2707683|,|and|dipyridamole (r_conj) corticosteroids_18\NNS\14745635|,|aspirin (r_conj) replacement_16\NN\196485|fresh|plasma|,|corticosteroids (r_appos) discontinuation_4\NN\209943|of|,|replacement (r_nsubj) led_24\VBD\3202760|in|,|discontinuation|to|. (l_prep) to_25\IN\0|resolution (l_pobj) resolution_26\NN\6470073|of (l_prep) of_27\IN\0|maha (l_pobj) maha_28\NNP\9654687|
D004176_D000743 NONE dipyridamole_23\NN\0| (r_conj) aspirin_20\NN\2707683|,|and|dipyridamole (r_conj) corticosteroids_18\NNS\14745635|,|aspirin (r_conj) replacement_16\NN\196485|fresh|plasma|,|corticosteroids (r_appos) discontinuation_4\NN\209943|of|,|replacement (r_nsubj) led_24\VBD\3202760|in|,|discontinuation|to|. (l_prep) to_25\IN\0|resolution (l_pobj) resolution_26\NN\6470073|of (l_prep) of_27\IN\0|maha (l_pobj) maha_28\NNP\9654687|
D016572_D000743 NONE a_19\NNP\13649268|react|with|cyclosporin|cya|,|drug (l_appos) drug_28\NN\14778436|an|suppressive|known (l_acl) known_30\VBN\0|already|induce (l_xcomp) induce_32\VB\1627355|to|maha (l_dobj) maha_33\NNP\9654687|
D016572_D000743 NONE cya_21\NN\0|(|) (r_appos) a_19\NNP\13649268|react|with|cyclosporin|cya|,|drug (l_appos) drug_28\NN\14778436|an|suppressive|known (l_acl) known_30\VBN\0|already|induce (l_xcomp) induce_32\VB\1627355|to|maha (l_dobj) maha_33\NNP\9654687|
12589964
D004317_D009202 CID doxorubicin_14\NN\2716866| (r_npadvmod) induced_16\VBN\1627355|doxorubicin|- (r_amod) rats_18\NNS\2329401|induced|cardiomyopathy (r_pobj) in_13\IN\13603305|rats (r_prep) damage_12\NN\7296428|myocardial|in
D004317_D009202 CID doxorubicin_14\NN\2716866| (r_npadvmod) induced_16\VBN\1627355|doxorubicin|- (r_amod) rats_18\NNS\2329401|induced|cardiomyopathy (l_amod) cardiomyopathy_17\NN\14103288|
D004317_D009202 CID doxorubicin_20\NN\2716866| (r_pobj) of_19\IN\0|doxorubicin (r_prep) model_18\NN\5888929|a|rat|of|cardiomyopathy (r_pobj) in_15\IN\13603305|model (r_prep) damage_14\NN\7296428|myocardial|in
D004317_D009202 CID doxorubicin_20\NN\2716866| (r_pobj) of_19\IN\0|doxorubicin (r_prep) model_18\NN\5888929|a|rat|of|cardiomyopathy (l_appos) cardiomyopathy_23\NN\14103288|(|dox)-induced
D004317_D009202 CID dox)-induced_22\VBN\0| (r_amod) cardiomyopathy_23\NN\14103288|(|dox)-induced (r_appos) model_18\NN\5888929|a|rat|of|cardiomyopathy (r_pobj) in_15\IN\13603305|model (r_prep) damage_14\NN\7296428|myocardial|in
D004317_D009202 CID dox)-induced_22\VBN\0| (r_amod) cardiomyopathy_23\NN\14103288|(|dox)-induced
D004317_D009202 CID dox_6\NNP\0|in (r_pobj) after_5\IN\0|dox (r_prep) markers_1\NNS\21939|of|after (r_pobj) among_0\IN\0|markers (r_prep) showed_11\VBD\2137132|among|,|ctnt|ability|. (l_dobj) ability_14\NN\4723816|the|greatest|detect (l_acl) detect_16\VB\2163746|to|damage (l_dobj) damage_18\NN\7296428|myocardial|assessed
D004317_D006331 NONE doxorubicin_20\NN\2716866| (r_pobj) of_19\IN\0|doxorubicin (r_prep) model_18\NN\5888929|a|rat|of|cardiomyopathy (r_pobj) in_15\IN\13603305|model (r_prep) damage_14\NN\7296428|myocardial|in (r_pobj) of_12\IN\0|damage (r_prep) diagnosis_11\NN\152018|the|of (r_pobj) for_9\IN\0|diagnosis (r_prep) investigated_1\VBD\644583|we|value|for|,|and|examined (l_conj) examined_27\VBD\0|we|relationship|. (l_dobj) relationship_29\NN\31921|the|between|with (l_prep) with_35\IN\0|development (l_pobj) development_37\NN\248977|the|of (l_prep) of_38\IN\0|disorders (l_pobj) disorders_40\NNS\14034177|cardiac|monitored
D004317_D006331 NONE dox)-induced_22\VBN\0| (r_amod) cardiomyopathy_23\NN\14103288|(|dox)-induced (r_appos) model_18\NN\5888929|a|rat|of|cardiomyopathy (r_pobj) in_15\IN\13603305|model (r_prep) damage_14\NN\7296428|myocardial|in (r_pobj) of_12\IN\0|damage (r_prep) diagnosis_11\NN\152018|the|of (r_pobj) for_9\IN\0|diagnosis (r_prep) investigated_1\VBD\644583|we|value|for|,|and|examined (l_conj) examined_27\VBD\0|we|relationship|. (l_dobj) relationship_29\NN\31921|the|between|with (l_prep) with_35\IN\0|development (l_pobj) development_37\NN\248977|the|of (l_prep) of_38\IN\0|disorders (l_pobj) disorders_40\NNS\14034177|cardiac|monitored
D004317_D064420 NONE dox_3\NNP\0| (r_compound) rats_4\NNS\2329401|the|dox (r_pobj) of_1\IN\0|rats (r_prep) eighteen_0\CD\13745420|of (r_nsubj) died_5\VBD\146138|eighteen|prematurely|of|during|. (l_prep) of_7\IN\0|toxicity (l_pobj) toxicity_9\NN\13576101|general
D004317_D005355 NONE dox_8\NNP\0| (r_pobj) given_7\VBN\5892096|dox (r_prep) rats_6\NNS\2329401|all|given (r_pobj) from_4\IN\0|rats (r_prep) hearts_3\NNS\496167|from (r_pobj) of_2\IN\0|hearts (r_prep) evaluation_1\NN\874067|histological|of (r_nsubj) revealed_9\VBD\2137132|evaluation|degrees|. (l_dobj) degrees_12\NNS\4916342|significant|slight|of (l_prep) of_13\IN\0|fibrosis (l_pobj) fibrosis_17\NN\14204950|perivascular
D004317_D017202 NONE dox_6\NNP\0|in (r_pobj) after_5\IN\0|dox (r_prep) markers_1\NNS\21939|of|after (l_prep) of_2\IN\0|injury (l_pobj) injury_4\NN\14052046|ischemic
D004317_D066126 NONE dox_13\NNP\0| (r_pobj) after_12\IN\0|dox (r_prep) amount_7\NN\13329641|the|of|after|, (r_pobj) between_5\IN\0|amount (r_prep) discrepancy_4\NN\4748836|a|between (r_attr) was_2\VBD\0|although|there|discrepancy|due (r_advcl) is_33\VBZ\0|was|,|it|likely|. (l_acomp) likely_34\JJ\0|indicates (l_ccomp) indicates_41\VBZ\952524|that|ctnt|after|dox|damage|induced|and|be (l_conj) be_55\VB\14625458|that|ctnt|should|marker (l_attr) marker_58\NN\21939|a|useful|for (l_prep) for_59\IN\0|prediction (l_pobj) prediction_61\NN\5772356|the|of (l_prep) of_62\IN\0|cardiotoxicity (l_pobj) cardiotoxicity_65\NN\0|induced|and|for
D004317_D066126 NONE dox_40\NNP\0| (r_nsubj) indicates_41\VBZ\952524|that|ctnt|after|dox|damage|induced|and|be (l_conj) be_55\VB\14625458|that|ctnt|should|marker (l_attr) marker_58\NN\21939|a|useful|for (l_prep) for_59\IN\0|prediction (l_pobj) prediction_61\NN\5772356|the|of (l_prep) of_62\IN\0|cardiotoxicity (l_pobj) cardiotoxicity_65\NN\0|induced|and|for
19037603
D019259_D012216 NONE lamivudine_3\NN\3834836| (r_pobj) of_2\IN\0|lamivudine (r_prep) use_1\NN\407535|prophylactic|of|with|. (l_prep) with_4\IN\0|therapy (l_pobj) therapy_7\NN\657604|chronic|immunosuppressive|for (l_prep) for_8\IN\0|disorders (l_pobj) disorders_10\NNS\14034177|rheumatologic
D019259_D012216 NONE lamivudine_18\NN\3834836| (r_pobj) of_17\IN\0|lamivudine (r_prep) administration_16\NN\1133281|the|prophylactic|of|in (r_pobj) of_13\IN\0|administration (r_prep) effectiveness_12\NN\5190804|the|of (r_pobj) concerning_10\VBG\0|effectiveness (r_prep) report_7\VB\6470073|to|experience|concerning (r_xcomp) was_5\VBD\0|objective|report|patients|. (l_attr) patients_30\NNS\9898892|)|positive|with (l_prep) with_31\IN\0|disease (l_pobj) disease_33\NN\14061805|rheumatologic
D019259_D012216 NONE lamivudine_23\JJ\3834836| (r_compound) therapies_24\NNS\657604|immunosuppressive|lamivudine (r_pobj) on_18\IN\0|therapies (r_prep) were_17\VBD\0|who|on (r_relcl) diseases_14\NNS\14061805|rheumatologic|,|were
D006514_D012216 NONE antigen_24\NN\20090|virus|surface|ag (r_pobj) in_19\IN\13603305|antigen (r_prep) administration_16\NN\1133281|the|prophylactic|of|in (r_pobj) of_13\IN\0|administration (r_prep) effectiveness_12\NN\5190804|the|of (r_pobj) concerning_10\VBG\0|effectiveness (r_prep) report_7\VB\6470073|to|experience|concerning (r_xcomp) was_5\VBD\0|objective|report|patients|. (l_attr) patients_30\NNS\9898892|)|positive|with (l_prep) with_31\IN\0|disease (l_pobj) disease_33\NN\14061805|rheumatologic
D006514_D012216 NONE ag_27\NNP\14821043|(|hbs (r_appos) antigen_24\NN\20090|virus|surface|ag (r_pobj) in_19\IN\13603305|antigen (r_prep) administration_16\NN\1133281|the|prophylactic|of|in (r_pobj) of_13\IN\0|administration (r_prep) effectiveness_12\NN\5190804|the|of (r_pobj) concerning_10\VBG\0|effectiveness (r_prep) report_7\VB\6470073|to|experience|concerning (r_xcomp) was_5\VBD\0|objective|report|patients|. (l_attr) patients_30\NNS\9898892|)|positive|with (l_prep) with_31\IN\0|disease (l_pobj) disease_33\NN\14061805|rheumatologic
D006514_D012216 NONE ag_9\NNP\14821043|11|hbs (r_nmod) patients_11\NNS\9898892|ag|positive|with (l_prep) with_12\IN\0|diseases (l_pobj) diseases_14\NNS\14061805|rheumatologic|,|were
12653683
D012964_D009404 NONE sodium_1\NN\14625458| (r_compound) channel_2\NN\6251781|epithelial|sodium|(|enac|)|subunit|. (l_appos) subunit_6\NN\13604718|mrna (l_appos) mrna_7\NN\14832193|and|expression (l_conj) expression_10\NN\4679549|protein|in (l_prep) in_11\IN\13603305|rats (l_pobj) rats_12\NNS\2329401|with (l_prep) with_13\IN\0|syndrome (l_pobj) syndrome_19\NN\5870365|puromycin|induced|nephrotic
D012964_D009404 NONE sodium_6\NN\14625458|urinary (r_compound) excretion_7\NN\13466586|sodium (r_nsubjpass) decreased_9\VBN\169651|in|,|excretion|is|during|. (l_prep) in_0\IN\13603305|syndrome (l_pobj) syndrome_3\NN\5870365|experimental|nephrotic
D011692_D009404 CID aminonucleoside_15\RB\0| (r_advmod) induced_17\VBN\1627355|aminonucleoside|- (r_amod) syndrome_19\NN\5870365|puromycin|induced|nephrotic
D011692_D009404 CID aminonucleoside_12\NN\0|syndrome (l_pobj) syndrome_16\NN\5870365|pan)-induced|nephrotic
D011692_D009404 CID pan)-induced_14\VBN\0|( (r_amod) syndrome_16\NN\5870365|pan)-induced|nephrotic
D011692_D009404 CID pan_22\NNP\3101986| (r_npadvmod) induced_24\VBN\1627355|pan|- (r_amod) syndrome_26\NN\5870365|induced|nephrotic|in
D012964_D011507 NONE sodium_5\NN\14625458|urinary (r_compound) excretion_6\NN\13466586|sodium|,|concentration (l_conj) concentration_10\NN\4916342|aldosterone|and|proteinuria (l_conj) proteinuria_12\NN\14299637|
D012964_D011507 NONE sodium_4\NN\14625458|urinary (r_compound) excretion_5\NN\13466586|sodium (r_pobj) of_2\IN\0|excretion (r_prep) kinetics_1\NNS\6100236|the|of|and|appearance (l_conj) appearance_8\NN\4723816|the|of (l_prep) of_9\IN\0|proteinuria (l_pobj) proteinuria_10\NN\14299637|
D000450_D011507 NONE aldosterone_9\NN\14751863|plasma (r_compound) concentration_10\NN\4916342|aldosterone|and|proteinuria (l_conj) proteinuria_12\NN\14299637|
D011692_D011507 CID pan_28\NNP\3101986|either|or|vehicle (r_pobj) of_26\IN\0|pan (r_prep) dose_25\NN\3740161|a|single|of (r_pobj) with_22\IN\0|dose (r_prep) treated_21\VBN\2376958|with (r_acl) rats_20\NNS\2329401|male|dawley|treated (r_pobj) in_15\IN\13603305|rats (r_prep) studied_14\VBN\0|courses|were|in|. (l_nsubjpass) courses_2\NNS\883297|the|time|of (l_prep) of_3\IN\0|excretion (l_pobj) excretion_6\NN\13466586|sodium|,|concentration (l_conj) concentration_10\NN\4916342|aldosterone|and|proteinuria (l_conj) proteinuria_12\NN\14299637|
D000450_D009404 NONE aldosterone_38\NN\14751863| (r_pobj) by_37\IN\0|aldosterone (r_prep) regulation_36\NN\6652242|the|by (r_pobj) from_34\IN\0|regulation (r_prep) escape_33\VB\46177|to|from|after (r_xcomp) appears_31\VBZ\2604760|escape (r_conj) increased_11\VBN\169651|in|,|expression|is|in|,|but|appears|. (l_prep) in_12\IN\13603305|phase (l_pobj) phase_16\NN\15113229|the|early|of (l_prep) of_17\IN\0|model (l_pobj) model_20\NN\5888929|the|experimental|of (l_prep) of_21\IN\0|syndrome (l_pobj) syndrome_26\NN\5870365|induced|nephrotic|in
12090760
D015215_D000740 CID azidothymidine_9\RB\0| (r_advmod) induced_11\VBN\1627355|azidothymidine|- (r_amod) anemia_12\NN\14189204|induced
D015215_D000740 CID azidothymidine_0\NNP\0| (r_nsubjpass) reversed_8\VBN\109660|azidothymidine|anemia|can|be|by|and|interleukin|. (l_nsubjpass) anemia_3\NN\14189204|(|azt)-induced|in
D015215_D000740 CID azt)-induced_2\VBN\0| (r_compound) anemia_3\NN\14189204|(|azt)-induced|in
20080419
D010862_D004827 CID pilocarpine_24\NN\14712692| (r_pobj) by_23\IN\0|pilocarpine (r_agent) induced_22\VBN\1627355|by|in (r_acl) model_19\NN\5888929|a|of|induced (l_prep) of_20\IN\0|epilepsy (l_pobj) epilepsy_21\NN\14085708|
11419773
D002110_D001145 NONE caffeine_0\NN\14712692| (r_nsubj) induced_2\VBN\1627355|caffeine|- (r_amod) arrhythmia_4\NN\14103288|induced|cardiac|:|danger|.
D002110_D008945 NONE caffeine_34\NN\14712692| (r_pobj) of_33\IN\0|caffeine (r_prep) concentration_32\NN\4916342|a|high|of (r_dobj) containing_29\VBG\2632940|concentration (r_acl) drink_28\NN\7578363|a|"|energy|"|guarana|health|containing (r_dobj) consuming_20\VBG\1168468|drink (r_pcomp) after_19\IN\0|consuming (r_prep) developed_15\VBD\1753788|who|fibrillation|after (r_relcl) woman_6\NN\9605289|a|old|with|developed (l_prep) with_7\IN\0|prolapse (l_pobj) prolapse_13\NN\14548343|existing|mitral|valve
D002110_D014693 CID caffeine_34\NN\14712692| (r_pobj) of_33\IN\0|caffeine (r_prep) concentration_32\NN\4916342|a|high|of (r_dobj) containing_29\VBG\2632940|concentration (r_acl) drink_28\NN\7578363|a|"|energy|"|guarana|health|containing (r_dobj) consuming_20\VBG\1168468|drink (r_pcomp) after_19\IN\0|consuming (r_prep) developed_15\VBD\1753788|who|fibrillation|after (l_dobj) fibrillation_18\NN\14361664|intractable|ventricular
12627929
C067311_D054556 CID docetaxel_9\NNS\0|and|thalidomide (r_pobj) of_8\IN\0|docetaxel (r_prep) combination_7\NN\7951464|the|of|in (r_pobj) with_5\IN\0|combination (r_prep) thromboembolism_4\NN\14100769|venous|with
C067311_D054556 CID docetaxel_26\NNS\0| (r_pobj) with_25\IN\0|docetaxel (r_prep) treated_24\VBN\2376958|who|were|with|alone (r_relcl) cancer_21\NN\14239425|advanced|independent|prostate|treated (r_pobj) with_15\IN\0|cancer (r_prep) patients_14\NNS\9898892|with (r_pobj) in_13\IN\13603305|patients (r_prep) frequency_6\NN\15286249|the|of|in (l_prep) of_7\IN\0|thromboembolism (l_pobj) thromboembolism_9\NN\14100769|venous|(|vte|)
C067311_D054556 CID docetaxel_26\NNS\0| (r_pobj) with_25\IN\0|docetaxel (r_prep) treated_24\VBN\2376958|who|were|with|alone (r_relcl) cancer_21\NN\14239425|advanced|independent|prostate|treated (r_pobj) with_15\IN\0|cancer (r_prep) patients_14\NNS\9898892|with (r_pobj) in_13\IN\13603305|patients (r_prep) frequency_6\NN\15286249|the|of|in (l_prep) of_7\IN\0|thromboembolism (l_pobj) thromboembolism_9\NN\14100769|venous|(|vte|) (l_appos) vte_11\NNP\0|
C067311_D054556 CID docetaxel_6\NNS\0| (r_dobj) received_5\VBD\2210855|who|docetaxel|alone (r_relcl) patients_3\NNS\9898892|23|received (r_pobj) of_1\IN\0|patients (r_prep) none_0\NN\15228378|of (r_nsubj) developed_8\VBN\1753788|none|vte|,|developed|. (l_dobj) vte_9\NNP\0|
C067311_D054556 CID docetaxel_6\NNS\0| (r_dobj) received_5\VBD\2210855|who|docetaxel|alone (r_relcl) patients_3\NNS\9898892|23|received (r_pobj) of_1\IN\0|patients (r_prep) none_0\NN\15228378|of (r_nsubj) developed_8\VBN\1753788|none|vte|,|developed|. (l_advcl) developed_25\VBD\1753788|whereas|9|vte (l_dobj) vte_26\NNP\0|p=0.025
C067311_D054556 CID docetaxel_22\NNS\0| (r_dobj) received_21\VBD\2210855|who|docetaxel (r_relcl) patients_15\NNS\9898892|47|(|%|)|received (r_pobj) of_13\IN\0|patients (r_prep) 9_12\CD\13741022|of|plus|thalidomide (r_nsubj) developed_25\VBD\1753788|whereas|9|vte (r_advcl) developed_8\VBN\1753788|none|vte|,|developed|. (l_dobj) vte_9\NNP\0|
C067311_D054556 CID docetaxel_22\NNS\0| (r_dobj) received_21\VBD\2210855|who|docetaxel (r_relcl) patients_15\NNS\9898892|47|(|%|)|received (r_pobj) of_13\IN\0|patients (r_prep) 9_12\CD\13741022|of|plus|thalidomide (r_nsubj) developed_25\VBD\1753788|whereas|9|vte (l_dobj) vte_26\NNP\0|p=0.025
C067311_D054556 CID docetaxel_5\NNS\0|to|in (r_relcl) addition_1\NN\3081021|the|of|docetaxel (r_nsubj) increases_13\VBZ\13576355|addition|significantly|frequency|. (l_dobj) frequency_15\NN\15286249|the|of (l_prep) of_16\IN\0|vte (l_pobj) vte_17\NNP\0|
C067311_D011471 NONE docetaxel_9\NNS\0|and|thalidomide (r_pobj) of_8\IN\0|docetaxel (r_prep) combination_7\NN\7951464|the|of|in (l_prep) in_12\IN\13603305|patients (l_pobj) patients_13\NNS\9898892|with (l_prep) with_14\IN\0|cancer (l_pobj) cancer_20\NN\14239425|metastatic|independent|prostate
C067311_D011471 NONE docetaxel_26\NNS\0| (r_pobj) with_25\IN\0|docetaxel (r_prep) treated_24\VBN\2376958|who|were|with|alone (r_relcl) cancer_21\NN\14239425|advanced|independent|prostate|treated
C067311_D011471 NONE docetaxel_5\NNS\0|to|in (l_prep) in_6\IN\13603305|treatment (l_pobj) treatment_8\NN\654885|the|of (l_prep) of_9\IN\0|cancer (l_pobj) cancer_11\NN\14239425|prostate
D013792_D054556 CID thalidomide_11\NN\4166841| (r_conj) docetaxel_9\NNS\0|and|thalidomide (r_pobj) of_8\IN\0|docetaxel (r_prep) combination_7\NN\7951464|the|of|in (r_pobj) with_5\IN\0|combination (r_prep) thromboembolism_4\NN\14100769|venous|with
D013792_D054556 CID thalidomide_32\NN\4166841| (r_pobj) with_31\IN\0|thalidomide (r_prep) combination_30\NN\7951464|with (r_pobj) in_29\IN\13603305|combination (r_conj) alone_27\RB\0|or|in (r_advmod) treated_24\VBN\2376958|who|were|with|alone (r_relcl) cancer_21\NN\14239425|advanced|independent|prostate|treated (r_pobj) with_15\IN\0|cancer (r_prep) patients_14\NNS\9898892|with (r_pobj) in_13\IN\13603305|patients (r_prep) frequency_6\NN\15286249|the|of|in (l_prep) of_7\IN\0|thromboembolism (l_pobj) thromboembolism_9\NN\14100769|venous|(|vte|)
D013792_D054556 CID thalidomide_32\NN\4166841| (r_pobj) with_31\IN\0|thalidomide (r_prep) combination_30\NN\7951464|with (r_pobj) in_29\IN\13603305|combination (r_conj) alone_27\RB\0|or|in (r_advmod) treated_24\VBN\2376958|who|were|with|alone (r_relcl) cancer_21\NN\14239425|advanced|independent|prostate|treated (r_pobj) with_15\IN\0|cancer (r_prep) patients_14\NNS\9898892|with (r_pobj) in_13\IN\13603305|patients (r_prep) frequency_6\NN\15286249|the|of|in (l_prep) of_7\IN\0|thromboembolism (l_pobj) thromboembolism_9\NN\14100769|venous|(|vte|) (l_appos) vte_11\NNP\0|
D013792_D054556 CID thalidomide_24\NN\4166841| (r_conj) 9_12\CD\13741022|of|plus|thalidomide (r_nsubj) developed_25\VBD\1753788|whereas|9|vte (r_advcl) developed_8\VBN\1753788|none|vte|,|developed|. (l_dobj) vte_9\NNP\0|
D013792_D054556 CID thalidomide_24\NN\4166841| (r_conj) 9_12\CD\13741022|of|plus|thalidomide (r_nsubj) developed_25\VBD\1753788|whereas|9|vte (l_dobj) vte_26\NNP\0|p=0.025
D013792_D054556 CID thalidomide_3\NN\4166841| (r_pobj) of_2\IN\0|thalidomide (r_prep) addition_1\NN\3081021|the|of|docetaxel (r_nsubj) increases_13\VBZ\13576355|addition|significantly|frequency|. (l_dobj) frequency_15\NN\15286249|the|of (l_prep) of_16\IN\0|vte (l_pobj) vte_17\NNP\0|
D013792_D011471 NONE thalidomide_11\NN\4166841| (r_conj) docetaxel_9\NNS\0|and|thalidomide (r_pobj) of_8\IN\0|docetaxel (r_prep) combination_7\NN\7951464|the|of|in (l_prep) in_12\IN\13603305|patients (l_pobj) patients_13\NNS\9898892|with (l_prep) with_14\IN\0|cancer (l_pobj) cancer_20\NN\14239425|metastatic|independent|prostate
D013792_D011471 NONE thalidomide_32\NN\4166841| (r_pobj) with_31\IN\0|thalidomide (r_prep) combination_30\NN\7951464|with (r_pobj) in_29\IN\13603305|combination (r_conj) alone_27\RB\0|or|in (r_advmod) treated_24\VBN\2376958|who|were|with|alone (r_relcl) cancer_21\NN\14239425|advanced|independent|prostate|treated
D013792_D011471 NONE thalidomide_3\NN\4166841| (r_pobj) of_2\IN\0|thalidomide (r_prep) addition_1\NN\3081021|the|of|docetaxel (l_relcl) docetaxel_5\NNS\0|to|in (l_prep) in_6\IN\13603305|treatment (l_pobj) treatment_8\NN\654885|the|of (l_prep) of_9\IN\0|cancer (l_pobj) cancer_11\NN\14239425|prostate
11256525
D019808_D001002 CID losartan_4\NN\0| (r_amod) administration_5\NN\1133281|losartan (r_dobj) following_3\VBG\8180190|administration|in (r_prep) anuria_2\NN\14061805|repeated|transient|following|.
D019808_D001002 CID losartan_27\NN\0| (r_amod) administration_28\NN\1133281|losartan (r_pobj) after_26\IN\0|administration (r_prep) developed_20\VBD\1753788|who|episodes|after (l_dobj) episodes_22\NNS\7283608|two|of (l_prep) of_23\IN\0|anuria (l_pobj) anuria_25\NN\14061805|transient
D019808_D001002 CID losartan_9\NN\0| (r_pobj) of_8\IN\0|losartan (r_prep) mg_7\NN\13717155|50|of (r_pobj) of_5\IN\0|mg (r_prep) dose_4\NN\3740161|the|first|of (r_nsubj) resulted_10\VBD\2633881|surprisingly|,|dose|in|. (l_prep) in_11\IN\13603305|anuria (l_pobj) anuria_14\NN\14061805|a|sudden|,|lasted
D019808_D001002 CID losartan_7\NN\0| (r_nsubjpass) prescribed_9\VBN\748282|later|,|by|,|losartan|was|again|and|developed (l_conj) developed_22\VBD\1753788|after|,|patient|episode|. (l_dobj) episode_25\NN\7283608|a|second|of|lasting (l_prep) of_26\IN\0|anuria (l_pobj) anuria_28\NN\14061805|transient
D019808_D006973 NONE losartan_27\NN\0| (r_amod) administration_28\NN\1133281|losartan (r_pobj) after_26\IN\0|administration (r_prep) developed_20\VBD\1753788|who|episodes|after (r_relcl) kidney_14\NN\5333259|a|solitary|and|insufficiency|developed (r_pobj) with_11\IN\0|kidney (r_prep) man_10\NN\9605289|a|old|hypertensive|with (l_amod) hypertensive_9\JJ\10405694|
D019808_D051436 NONE losartan_27\NN\0| (r_amod) administration_28\NN\1133281|losartan (r_pobj) after_26\IN\0|administration (r_prep) developed_20\VBD\1753788|who|episodes|after (r_relcl) kidney_14\NN\5333259|a|solitary|and|insufficiency|developed (l_conj) insufficiency_18\NN\14462946|chronic|renal
D019808_D006331 NONE losartan_5\NN\0|dysfunction (l_compound) dysfunction_4\NN\14204950|severe|systolic
D005665_D001002 NONE furosemide_24\NN\3214670|and|amine (r_nmod) infusion_27\NN\14589223|dose|furosemide (r_pobj) despite_20\IN\7501545|infusion (r_prep) lasted_17\VBD\2704349|which|hours|despite (r_relcl) anuria_14\NN\14061805|a|sudden|,|lasted
D000588_D001002 NONE amine_26\NN\14951377| (r_conj) furosemide_24\NN\3214670|and|amine (r_nmod) infusion_27\NN\14589223|dose|furosemide (r_pobj) despite_20\IN\7501545|infusion (r_prep) lasted_17\VBD\2704349|which|hours|despite (r_relcl) anuria_14\NN\14061805|a|sudden|,|lasted
D000809_D012078 NONE angiotensin_24\NN\4522421|renin|- (r_compound) system_25\NN\3575240|the|angiotensin|(|ras|) (r_pobj) of_20\IN\0|system (r_prep) activation_19\NN\13561719|a|strong|of (r_pobj) in_16\IN\13603305|activation (r_prep) resulted_15\VBD\2633881|in|,|stenosis|certainly|in|. (l_nsubj) stenosis_6\NN\14204950|renal|artery|combined
D000809_D006333 NONE angiotensin_24\NN\4522421|renin|- (r_compound) system_25\NN\3575240|the|angiotensin|(|ras|) (r_pobj) of_20\IN\0|system (r_prep) activation_19\NN\13561719|a|strong|of (r_pobj) in_16\IN\13603305|activation (r_prep) resulted_15\VBD\2633881|in|,|stenosis|certainly|in|. (l_nsubj) stenosis_6\NN\14204950|renal|artery|combined (l_acl) combined_7\VBN\2630189|with (l_prep) with_8\IN\0|failure (l_pobj) failure_10\NN\66216|heart|and|therapy
D000804_D014652 NONE ii_9\NNP\13741022| (r_compound) antagonist_11\NN\7846|ii|receptor (r_compound) losartan_12\NN\0|the|angiotensin|antagonist (r_nsubj) cause_14\VB\7323922|that|losartan|can|complications|and|used (l_dobj) complications_17\NNS\1073995|serious|unexpected|in (l_prep) in_18\IN\13603305|patients (l_pobj) patients_19\NNS\9898892|with (l_prep) with_20\IN\0|disease (l_pobj) disease_22\NN\14061805|renovascular
D019808_D014652 NONE losartan_12\NN\0|the|angiotensin|antagonist (r_nsubj) cause_14\VB\7323922|that|losartan|can|complications|and|used (l_dobj) complications_17\NNS\1073995|serious|unexpected|in (l_prep) in_18\IN\13603305|patients (l_pobj) patients_19\NNS\9898892|with (l_prep) with_20\IN\0|disease (l_pobj) disease_22\NN\14061805|renovascular
3358181
D012312_D014693 CID ritodrine_6\JJ\0| (r_compound) therapy_7\NN\657604|ritodrine (r_pobj) after_5\IN\0|therapy (r_prep) section_4\NN\7020895|cesarean|after (r_pobj) during_2\IN\0|section (r_prep) tachyarrhythmias_1\NNS\0|ventricular|during|:|interaction|.
D012312_D007752 NONE ritodrine_6\RB\0|for (l_prep) for_7\IN\0|labor (l_pobj) labor_9\NN\7974025|preterm
D012312_D007752 NONE ritodrine_19\NN\0| (r_pobj) of_18\IN\0|ritodrine (r_prep) effects_17\NNS\13245626|the|residual|betamimetic|of|and|effects (r_pobj) between_13\IN\0|effects (r_prep) interactions_12\NNS\37396|between (r_dobj) risk_11\VB\14541044|that|patients|may|interactions (l_nsubj) patients_4\NNS\9898892|receiving (l_acl) receiving_5\VBG\2210855|ritodrine (l_dobj) ritodrine_6\RB\0|for (l_prep) for_7\IN\0|labor (l_pobj) labor_9\NN\7974025|preterm
D012312_D002318 NONE ritodrine_15\NN\0| (r_pobj) of_14\IN\0|ritodrine (r_prep) infusion_13\NN\14589223|an|of (r_pobj) of_11\IN\0|infusion (r_prep) cessation_10\NN\7365849|of (r_pobj) after_9\IN\0|even|cessation (r_prep) complications_7\NNS\1073995|serious|cardiovascular|after
D010656_D007022 NONE phenylephrine_22\NN\2682038|treat (l_relcl) treat_24\VB\7570720|to|patients|with (l_dobj) patients_26\NNS\9898892|hypotensive (l_amod) hypotensive_25\JJ\10405694|
D010656_D013610 NONE phenylephrine_22\NN\2682038|treat (l_relcl) treat_24\VB\7570720|to|patients|with (l_prep) with_27\IN\0|tachycardia (l_pobj) tachycardia_28\NNS\14110674|
11581460
D005283_D016055 CID fentanyl_12\NN\2707683| (r_pobj) of_11\IN\0|fentanyl (r_prep) infusion_10\NN\14589223|continuous|intravenous|of (r_pobj) of_7\IN\0|infusion (r_prep) result_6\NN\34213|a|of (r_pobj) as_4\IN\14622893|result (r_prep) retention_1\NN\809465|bladder|of|as (l_prep) of_2\IN\0|urine (l_pobj) urine_3\NN\14853947|
D005283_D009127 NONE fentanyl_5\NN\2707683| (r_compound) administration_6\NN\1133281|fentanyl (r_pobj) of_4\IN\0|administration (r_prep) effects_3\NNS\13245626|various|reported|side|of (r_nsubj) include_7\VBP\0|effects|rigidity|. (l_dobj) rigidity_10\NN\5023233|chest|wall|,|hypotension
D005283_D007022 CID fentanyl_5\NN\2707683| (r_compound) administration_6\NN\1133281|fentanyl (r_pobj) of_4\IN\0|administration (r_prep) effects_3\NNS\13245626|various|reported|side|of (r_nsubj) include_7\VBP\0|effects|rigidity|. (l_dobj) rigidity_10\NN\5023233|chest|wall|,|hypotension (l_conj) hypotension_12\NN\14057371|,|depression
D005283_D012131 CID fentanyl_5\NN\2707683| (r_compound) administration_6\NN\1133281|fentanyl (r_pobj) of_4\IN\0|administration (r_prep) effects_3\NNS\13245626|various|reported|side|of (r_nsubj) include_7\VBP\0|effects|rigidity|. (l_dobj) rigidity_10\NN\5023233|chest|wall|,|hypotension (l_conj) hypotension_12\NN\14057371|,|depression (l_conj) depression_15\NN\14373582|respiratory|,|and|bradycardia
D005283_D001919 CID fentanyl_5\NN\2707683| (r_compound) administration_6\NN\1133281|fentanyl (r_pobj) of_4\IN\0|administration (r_prep) effects_3\NNS\13245626|various|reported|side|of (r_nsubj) include_7\VBP\0|effects|rigidity|. (l_dobj) rigidity_10\NN\5023233|chest|wall|,|hypotension (l_conj) hypotension_12\NN\14057371|,|depression (l_conj) depression_15\NN\14373582|respiratory|,|and|bradycardia (l_conj) bradycardia_18\NN\14110674|
D005283_D001745 CID fentanyl_22\NN\2707683| (r_pobj) of_21\IN\0|fentanyl (r_prep) infusion_20\NN\14589223|continuous|of (r_pobj) of_18\IN\0|infusion (r_prep) result_17\NN\34213|a|of (r_pobj) as_15\IN\14622893|result (r_prep) mimicking_13\VBG\1742886|hydronephrosis|as (r_acl) dilatation_12\NN\14034177|renal|pelvocalyceal|mimicking (r_pobj) to_9\IN\0|dilatation (r_prep) leading_8\VBG\4339291|to (r_acl) cases_3\NNS\7283608|2|of|leading (l_prep) of_4\IN\0|retention (l_pobj) retention_7\NN\809465|urinary|bladder
D005283_D006869 NONE fentanyl_22\NN\2707683| (r_pobj) of_21\IN\0|fentanyl (r_prep) infusion_20\NN\14589223|continuous|of (r_pobj) of_18\IN\0|infusion (r_prep) result_17\NN\34213|a|of (r_pobj) as_15\IN\14622893|result (r_prep) mimicking_13\VBG\1742886|hydronephrosis|as (l_dobj) hydronephrosis_14\NN\14204950|
2396046
D002794_D006528 CID choline_13\NN\15090742| (r_npadvmod) supplemented_15\VBN\182406|choline|- (r_amod) diet_16\NN\7560652|the|plain|supplemented (r_dobj) fed_10\VBD\10373801|nodules|diet|,|developed|fed|. (l_nsubj) nodules_3\NNS\5264913|no|hepatic|preneoplastic|or|carcinomas|developed (l_conj) carcinomas_6\NNS\14239918|hepatocellular
D002794_D006528 CID choline_13\NN\15090742| (r_npadvmod) supplemented_15\VBN\182406|choline|- (r_amod) diet_16\NN\7560652|the|plain|supplemented (r_dobj) fed_10\VBD\10373801|nodules|diet|,|developed|fed|. (l_advcl) developed_26\VBN\1753788|while|nodule|in (l_nsubj) nodule_21\NN\5264913|one|preneoplastic|and|carcinoma (l_conj) carcinoma_25\NN\14239918|one|hepatocellular
D002794_D006528 CID choline_23\NN\15090742| (r_npadvmod) devoid_25\JJ\0|choline|- (r_amod) diet_26\NN\7560652|the|plain|devoid (r_dobj) fed_20\VBD\10373801|in|rats|diet|,|and|%|,|in (r_conj) was_9\VBD\0|incidence|%|,|respectively|,|fed|fed|. (l_nsubj) incidence_1\NN\13821570|the|of (l_prep) of_2\IN\0|nodules|and|of (l_conj) of_6\IN\0|carcinomas (l_pobj) carcinomas_8\NNS\14239918|hepatocellular
D002794_D006528 CID choline_42\NN\15090742| (r_npadvmod) devoid_44\JJ\0|choline|- (r_amod) diet_45\NN\7560652|the|containing|devoid (r_dobj) fed_37\VBD\10373801|diet (r_conj) was_9\VBD\0|incidence|%|,|respectively|,|fed|fed|. (l_nsubj) incidence_1\NN\13821570|the|of (l_prep) of_2\IN\0|nodules|and|of (l_conj) of_6\IN\0|carcinomas (l_pobj) carcinomas_8\NNS\14239918|hepatocellular
D010634_D006528 NONE phenobarbital_35\NN\2792049| (r_dobj) containing_34\VBG\2632940|phenobarbital (r_acl) diet_33\NN\7560652|the|same|containing (r_dobj) fed_30\VBD\10373801|diet (r_conj) fed_10\VBD\10373801|nodules|diet|,|developed|fed|. (l_nsubj) nodules_3\NNS\5264913|no|hepatic|preneoplastic|or|carcinomas|developed (l_conj) carcinomas_6\NNS\14239918|hepatocellular
D010634_D006528 NONE phenobarbital_35\NN\2792049| (r_dobj) containing_34\VBG\2632940|phenobarbital (r_acl) diet_33\NN\7560652|the|same|containing (r_dobj) fed_30\VBD\10373801|diet (r_conj) fed_10\VBD\10373801|nodules|diet|,|developed|fed|. (l_advcl) developed_26\VBN\1753788|while|nodule|in (l_nsubj) nodule_21\NN\5264913|one|preneoplastic|and|carcinoma (l_conj) carcinoma_25\NN\14239918|one|hepatocellular
D010634_D006528 NONE phenobarbital_39\RB\2792049| (r_npadvmod) containing_41\VBG\2632940|phenobarbital|- (r_amod) diet_45\NN\7560652|the|containing|devoid (r_dobj) fed_37\VBD\10373801|diet (r_conj) was_9\VBD\0|incidence|%|,|respectively|,|fed|fed|. (l_nsubj) incidence_1\NN\13821570|the|of (l_prep) of_2\IN\0|nodules|and|of (l_conj) of_6\IN\0|carcinomas (l_pobj) carcinomas_8\NNS\14239918|hepatocellular
18754075
D004164_D011507 NONE bisphosphonate_8\NN\0|oral (r_nmod) administration_12\NN\1133281|bisphosphonate|alendronate|in (r_pobj) after_6\IN\0|administration (r_prep) proteinuria_1\NN\14299637|massive|and|failure|after|.
D004164_D011507 NONE bisphosphonates_11\NNS\0|oral (r_nsubj) aggravate_13\VB\126264|that|intravenous|bisphosphonates|can|proteinuria (l_dobj) proteinuria_14\NN\14299637|and|failure
D004164_D058186 NONE bisphosphonate_8\NN\0|oral (r_nmod) administration_12\NN\1133281|bisphosphonate|alendronate|in (r_pobj) after_6\IN\0|administration (r_prep) proteinuria_1\NN\14299637|massive|and|failure|after|. (l_conj) failure_5\NN\66216|acute|renal
D004164_D058186 NONE bisphosphonate_6\NN\0|the|oral (r_pobj) of_3\IN\0|bisphosphonate (r_prep) days_2\NNS\15140892|14|of (r_pobj) within_0\IN\0|days (r_prep) increased_19\VBD\169651|within|administration|amount|rapidly|up|with|. (l_prep) with_25\IN\0|failure (l_pobj) failure_28\NN\66216|acute|renal
D004164_D058186 NONE bisphosphonates_11\NNS\0|oral (r_nsubj) aggravate_13\VB\126264|that|intravenous|bisphosphonates|can|proteinuria (l_dobj) proteinuria_14\NN\14299637|and|failure (l_conj) failure_18\NN\66216|acute|renal
D004164_D005923 NONE bisphosphonate_8\NN\0|oral (r_nmod) administration_12\NN\1133281|bisphosphonate|alendronate|in (l_prep) in_13\IN\13603305|patient (l_pobj) patient_15\NN\9898892|a|with (l_prep) with_16\IN\0|glomerulosclerosis (l_pobj) glomerulosclerosis_19\NN\0|focal|segmental
D019386_D011507 CID alendronate_10\JJ\3740161|(|) (r_nmod) administration_12\NN\1133281|bisphosphonate|alendronate|in (r_pobj) after_6\IN\0|administration (r_prep) proteinuria_1\NN\14299637|massive|and|failure|after|.
D019386_D058186 CID alendronate_10\JJ\3740161|(|) (r_nmod) administration_12\NN\1133281|bisphosphonate|alendronate|in (r_pobj) after_6\IN\0|administration (r_prep) proteinuria_1\NN\14299637|massive|and|failure|after|. (l_conj) failure_5\NN\66216|acute|renal
D019386_D058186 CID sodium_9\NN\14625458|(|alendronate|) (r_nmod) administration_11\NN\1133281|sodium|, (r_nsubj) increased_19\VBD\169651|within|administration|amount|rapidly|up|with|. (l_prep) with_25\IN\0|failure (l_pobj) failure_28\NN\66216|acute|renal
D019386_D005923 NONE alendronate_10\JJ\3740161|(|) (r_nmod) administration_12\NN\1133281|bisphosphonate|alendronate|in (l_prep) in_13\IN\13603305|patient (l_pobj) patient_15\NN\9898892|a|with (l_prep) with_16\IN\0|glomerulosclerosis (l_pobj) glomerulosclerosis_19\NN\0|focal|segmental
D013256_D009404 NONE steroid_19\NN\14727670| (r_compound) therapy_20\NN\657604|steroid (r_pobj) to_18\IN\0|therapy (r_prep) responding_16\VBG\2367363|man|was|initially|well|to|. (l_nsubj) man_5\NN\9605289|a|old|japanese|with|due (l_prep) with_6\IN\0|syndrome (l_pobj) syndrome_8\NN\5870365|nephrotic
D013256_D005923 NONE steroid_19\NN\14727670| (r_compound) therapy_20\NN\657604|steroid (r_pobj) to_18\IN\0|therapy (r_prep) responding_16\VBG\2367363|man|was|initially|well|to|. (l_nsubj) man_5\NN\9605289|a|old|japanese|with|due (l_amod) due_9\IN\5174653|to|glomerulosclerosis (l_pobj) glomerulosclerosis_13\NN\0|focal|segmental
10683478
D001058_D007035 CID apomorphine_0\NNP\3786417|,|agonist|, (r_nsubjpass) selected_8\VBN\697589|apomorphine|was|due|,|ability|. (l_dobj) ability_17\NN\4723816|its|induce (l_acl) induce_19\VB\1627355|to|hypothermia|,|and|produce (l_dobj) hypothermia_20\NN\14034177|
D001058_D007035 CID apomorphine_11\NN\3786417|to|as (l_prep) as_13\IN\14622893|such|hypothermia (l_pobj) hypothermia_17\NN\14034177|induced
D018491_D007035 NONE agonist_5\NN\0|a|nonselective|dopamine (r_appos) apomorphine_0\NNP\3786417|,|agonist|, (r_nsubjpass) selected_8\VBN\697589|apomorphine|was|due|,|ability|. (l_dobj) ability_17\NN\4723816|its|induce (l_acl) induce_19\VB\1627355|to|hypothermia|,|and|produce (l_dobj) hypothermia_20\NN\14034177|
D004298_D007035 NONE dopamine_28\NN\14807737|to|turnover (r_relcl) changes_26\NNS\7283608|distinct|dopamine (r_dobj) produce_24\VB\7555863|to|changes (r_conj) induce_19\VB\1627355|to|hypothermia|,|and|produce (l_dobj) hypothermia_20\NN\14034177|
D001058_D006948 CID apomorphine_5\NN\3786417| (r_npadvmod) induced_7\VBN\1627355|apomorphine|- (r_amod) hyperactivity_8\NN\14052403|induced
15859940
D016572_D064420 NONE cyclosporine_7\NN\0|,|tacrolimus (r_nmod) toxicity_11\NN\13576101|related|(|cyclosporine|,|status
D016559_D064420 NONE tacrolimus_9\NN\0|) (r_conj) cyclosporine_7\NN\0|,|tacrolimus (r_nmod) toxicity_11\NN\13576101|related|(|cyclosporine|,|status
D016572_D057049 CID cyclosporine_18\NN\0| (r_pobj) to_17\IN\0|mainly|cyclosporine (r_prep) secondary_15\JJ\8426461|to (r_amod) related_13\VBN\628491|drug|,|secondary (r_acomp) was_11\VBD\0|that|cause|related (l_nsubj) cause_7\NN\7323922|the|frequent|of (l_prep) of_8\IN\0|microangiopathy (l_pobj) microangiopathy_10\NN\0|thrombotic
18343374
D002996_D012170 CID clomiphene_6\NN\3329880| (r_npadvmod) induced_8\VBN\1627355|clomiphene|- (r_amod) ovulation_9\NN\13526110|induced (r_pobj) with_5\IN\0|ovulation (r_prep) associated_4\VBN\628491|with (r_acl) occlusion_3\NN\14081375|central|vein|associated|.
D002996_D012170 CID citrate_12\NN\14850483|clomiphene|(|cc|) (r_pobj) with_10\IN\0|citrate (r_prep) associated_9\VBN\628491|with (r_acl) occlusion_8\NN\14081375|central|vein|associated
D002996_D012170 CID cc_14\NN\13616054| (r_appos) citrate_12\NN\14850483|clomiphene|(|cc|) (r_pobj) with_10\IN\0|citrate (r_prep) associated_9\VBN\628491|with (r_acl) occlusion_8\NN\14081375|central|vein|associated
D002996_D012170 CID cc_13\NN\13616054| (r_pobj) with_12\IN\0|cc (r_prep) induction_11\NN\7450842|ovulation|with (r_pobj) after_9\IN\0|induction (r_prep) occlusion_8\NN\14081375|central|vein|after
D002996_D012170 CID cc_18\NN\13616054| (r_pobj) of_17\IN\0|cc (r_prep) courses_16\NNS\883297|eight|of (r_pobj) after_14\IN\0|courses (r_prep) developed_9\VBD\1753788|result(s|:|woman|occlusion|after|. (l_dobj) occlusion_13\NN\14081375|central|vein
D002996_D012170 CID cc_15\NN\13616054| (r_pobj) with_14\IN\0|cc (r_prep) treatment_13\NN\654885|with (r_pobj) after_12\IN\0|treatment (r_prep) occlusion_11\NN\14081375|vein|after
D002996_D013923 NONE cc_10\NN\13616054| (r_pobj) of_9\IN\0|cc (r_prep) complications_8\NNS\1073995|the|thromboembolic|of (l_compound) thromboembolic_7\JJ\0|
D002996_D013923 NONE cc_24\NN\13616054| (r_compound) intake_25\NN\13440063|cc (r_pobj) after_23\IN\0|intake (r_prep) disturbance_22\NN\407535|mild|visual|after (r_nsubj) is_26\VBZ\0|although|disturbance|not|uncommon (r_advcl) include_13\VB\0|search|does|not|complication|,|is|. (l_nsubj) search_1\NN\407535|a|of|on (l_prep) on_5\IN\0|complications (l_pobj) complications_8\NNS\1073995|the|thromboembolic|of (l_compound) thromboembolic_7\JJ\0|
D002996_D014786 CID cc_10\NN\13616054| (r_pobj) of_9\IN\0|cc (r_prep) complications_8\NNS\1073995|the|thromboembolic|of (r_pobj) on_5\IN\0|complications (r_prep) search_1\NN\407535|a|of|on (r_nsubj) include_13\VB\0|search|does|not|complication|,|is|. (l_advcl) is_26\VBZ\0|although|disturbance|not|uncommon (l_nsubj) disturbance_22\NN\407535|mild|visual|after
D002996_D014786 CID cc_24\NN\13616054| (r_compound) intake_25\NN\13440063|cc (r_pobj) after_23\IN\0|intake (r_prep) disturbance_22\NN\407535|mild|visual|after
D002996_D007247 NONE cc_9\NN\13616054| (r_pobj) with_8\IN\0|cc (r_prep) treating_5\VBG\2376958|patients|with (l_dobj) patients_7\NNS\9898892|infertility (l_compound) infertility_6\NN\14034177|
2425813
D011239_D006529 CID prednisolone_14\NN\2721538| (r_pobj) of_13\IN\0|prednisolone (r_prep) administration_12\NN\1133281|the|subcutaneous|of (r_pobj) following_9\VBG\8180190|administration (r_prep) occurred_5\VBD\0|enlargement|in|following|. (l_nsubj) enlargement_1\NN\363260|liver|and|wastage
D011239_D009133 CID prednisolone_14\NN\2721538| (r_pobj) of_13\IN\0|prednisolone (r_prep) administration_12\NN\1133281|the|subcutaneous|of (r_pobj) following_9\VBG\8180190|administration (r_prep) occurred_5\VBD\0|enlargement|in|following|. (l_nsubj) enlargement_1\NN\363260|liver|and|wastage (l_conj) wastage_4\NN\13458571|muscle
18726058
D010208_D020301 NONE hydrochloride_1\NN\14817592|papaverine (r_nsubj) is_2\VBZ\0|hydrochloride|vasodilator|. (l_attr) vasodilator_7\NN\3198383|a|acting|used (l_acl) used_8\VBD\0|manage (l_xcomp) manage_10\VB\2524171|to|vasospasm|during (l_dobj) vasospasm_11\NN\0|
D010208_D020301 NONE papaverine_18\NN\3800001|topical (r_dobj) received_16\VBD\2210855|who|papaverine|for (l_prep) for_19\IN\0|vasospasm (l_pobj) vasospasm_20\NN\0|
D010208_D020301 NONE papaverine_1\NN\3800001|topical (r_nsubjpass) used_3\VBN\0|papaverine|was|as|. (l_prep) as_4\IN\14622893|action (l_pobj) action_8\NN\30358|a|direct|therapeutic|manage (l_acl) manage_10\VB\2524171|to|vasospasm|in (l_dobj) vasospasm_11\NN\0|
D010208_D020301 NONE papaverine_1\NN\3800001|topical|for (l_prep) for_2\IN\0|treatment (l_pobj) treatment_4\NN\654885|the|of (l_prep) of_5\IN\0|vasospasm (l_pobj) vasospasm_6\NN\0|
D010208_D003389 NONE papaverine_13\NN\3800001|topical (r_pobj) with_11\IN\0|papaverine (r_prep) cases_10\NNS\7283608|a|few|with (r_pobj) in_7\IN\13603305|cases (r_prep) described_6\VBN\1001294|dysfunction|has|been|in|. (l_nsubjpass) dysfunction_3\NN\14204950|transient|cranial|nerve
D010208_D003389 NONE papaverine_8\NN\3800001| (r_pobj) from_7\IN\0|papaverine (r_prep) deficits_6\NNS\5113133|potential|nerve|from
11752354
D003276_D009203 CID contraceptives_1\NNS\3183080|oral|and|risk|. (l_conj) risk_4\NN\14541044|the|of (l_prep) of_5\IN\0|infarction (l_pobj) infarction_7\NN\14204950|myocardial
D003276_D009203 CID contraceptives_7\NNS\3183080|oral (r_pobj) of_5\IN\0|contraceptives (r_prep) use_4\NN\407535|the|of|and|risk (l_conj) risk_10\NN\14541044|the|of (l_prep) of_11\IN\0|infarction (l_pobj) infarction_13\NN\14204950|myocardial
D003276_D009203 CID contraceptives_33\NNS\3183080|generation|oral (r_pobj) in_12\IN\13603305|contraceptives (r_prep) included_11\VBN\0|in (r_acl) type_8\NN\5839024|the|of|included (r_pobj) to_6\IN\0|type (r_prep) according_5\VBG\2657219|to (r_prep) investigated_1\VBD\644583|we|association|,|according|identified (l_conj) identified_64\VBD\699815|,|dose|:|in|,|we|and|enrolled|. (l_conj) enrolled_66\VBD\2471690|women|18|through|,|year (l_dobj) women_68\NNS\9605289|248|had (l_relcl) had_77\VBN\0|who|had|infarction (l_dobj) infarction_81\NN\14204950|a|first|myocardial|between
D003276_D009203 CID contraceptives_33\NNS\3183080|generation|oral (r_pobj) in_12\IN\13603305|contraceptives (r_prep) included_11\VBN\0|in (r_acl) type_8\NN\5839024|the|of|included (r_pobj) to_6\IN\0|type (r_prep) according_5\VBG\2657219|to (r_prep) investigated_1\VBD\644583|we|association|,|according|identified (l_conj) identified_64\VBD\699815|,|dose|:|in|,|we|and|enrolled|. (l_conj) enrolled_66\VBD\2471690|women|18|through|,|year (l_dobj) women_68\NNS\9605289|248|had (l_relcl) had_77\VBN\0|who|had|infarction (l_dobj) infarction_81\NN\14204950|a|first|myocardial|between (l_prep) between_82\IN\0|1990 (l_pobj) 1990_83\CD\0|and|1995|and|women (l_conj) women_89\NNS\9605289|925|control|had (l_relcl) had_93\VBN\0|who|had|not|infarction|and|matched (l_dobj) infarction_96\NN\14204950|a|myocardial
D003276_D009203 CID contraceptive_39\NN\3183080|combined|oral (r_pobj) of_36\IN\0|contraceptive (r_prep) type_35\NN\5839024|any|of (r_dobj) used_33\VBD\0|who|type|,|compared (r_relcl) women_31\NNS\9605289|used (r_pobj) among_30\IN\0|women (r_prep) infarction_29\NN\14204950|myocardial|among
D003276_D009203 CID contraceptives_5\NNS\3183080|oral (r_dobj) used_3\VBD\0|who|contraceptives (r_relcl) women_1\NNS\9605289|used (r_pobj) among_0\IN\0|women (r_prep) was_10\VBD\0|among|,|ratio|interval|for|: (r_ccomp) increased_53\VBN\169651|was|risk|was|among|. (l_nsubjpass) risk_48\NN\14541044|the|of (l_prep) of_49\IN\0|infarction (l_pobj) infarction_51\NN\14204950|myocardial
D003276_D009203 CID contraceptives_62\NNS\3183080|generation|oral (r_dobj) used_57\VBD\0|who|contraceptives (r_relcl) women_55\NNS\9605289|used (r_pobj) among_54\IN\0|women (r_prep) increased_53\VBN\169651|was|risk|was|among|. (l_nsubjpass) risk_48\NN\14541044|the|of (l_prep) of_49\IN\0|infarction (l_pobj) infarction_51\NN\14204950|myocardial
D003276_D009203 CID contraceptives_12\NNS\3183080|oral (r_dobj) used_10\VBD\0|who|contraceptives|had (r_relcl) women_8\NNS\9605289|used (r_pobj) among_7\IN\0|women (r_prep) similar_6\JJ\0|among (r_acomp) was_5\VBD\0|risk|similar|. (l_nsubj) risk_1\NN\14541044|the|of (l_prep) of_2\IN\0|infarction (l_pobj) infarction_4\NN\14204950|myocardial
D011372_D009203 NONE progestagen_10\NN\0| (r_pobj) of_9\IN\0|progestagen (r_prep) type_8\NN\5839024|the|of|included (r_pobj) to_6\IN\0|type (r_prep) according_5\VBG\2657219|to (r_prep) investigated_1\VBD\644583|we|association|,|according|identified (l_conj) identified_64\VBD\699815|,|dose|:|in|,|we|and|enrolled|. (l_conj) enrolled_66\VBD\2471690|women|18|through|,|year (l_dobj) women_68\NNS\9605289|248|had (l_relcl) had_77\VBN\0|who|had|infarction (l_dobj) infarction_81\NN\14204950|a|first|myocardial|between
D011372_D009203 NONE progestagen_10\NN\0| (r_pobj) of_9\IN\0|progestagen (r_prep) type_8\NN\5839024|the|of|included (r_pobj) to_6\IN\0|type (r_prep) according_5\VBG\2657219|to (r_prep) investigated_1\VBD\644583|we|association|,|according|identified (l_conj) identified_64\VBD\699815|,|dose|:|in|,|we|and|enrolled|. (l_conj) enrolled_66\VBD\2471690|women|18|through|,|year (l_dobj) women_68\NNS\9605289|248|had (l_relcl) had_77\VBN\0|who|had|infarction (l_dobj) infarction_81\NN\14204950|a|first|myocardial|between (l_prep) between_82\IN\0|1990 (l_pobj) 1990_83\CD\0|and|1995|and|women (l_conj) women_89\NNS\9605289|925|control|had (l_relcl) had_93\VBN\0|who|had|not|infarction|and|matched (l_dobj) infarction_96\NN\14204950|a|myocardial
D017135_D009203 NONE desogestrel_19\NN\0|(|i.e.|,|or|gestodene|)|and|levonorgestrel (r_appos) generation_15\NN\7942152|third|-|desogestrel (r_nmod) contraceptives_33\NNS\3183080|generation|oral (r_pobj) in_12\IN\13603305|contraceptives (r_prep) included_11\VBN\0|in (r_acl) type_8\NN\5839024|the|of|included (r_pobj) to_6\IN\0|type (r_prep) according_5\VBG\2657219|to (r_prep) investigated_1\VBD\644583|we|association|,|according|identified (l_conj) identified_64\VBD\699815|,|dose|:|in|,|we|and|enrolled|. (l_conj) enrolled_66\VBD\2471690|women|18|through|,|year (l_dobj) women_68\NNS\9605289|248|had (l_relcl) had_77\VBN\0|who|had|infarction (l_dobj) infarction_81\NN\14204950|a|first|myocardial|between
D017135_D009203 NONE desogestrel_19\NN\0|(|i.e.|,|or|gestodene|)|and|levonorgestrel (r_appos) generation_15\NN\7942152|third|-|desogestrel (r_nmod) contraceptives_33\NNS\3183080|generation|oral (r_pobj) in_12\IN\13603305|contraceptives (r_prep) included_11\VBN\0|in (r_acl) type_8\NN\5839024|the|of|included (r_pobj) to_6\IN\0|type (r_prep) according_5\VBG\2657219|to (r_prep) investigated_1\VBD\644583|we|association|,|according|identified (l_conj) identified_64\VBD\699815|,|dose|:|in|,|we|and|enrolled|. (l_conj) enrolled_66\VBD\2471690|women|18|through|,|year (l_dobj) women_68\NNS\9605289|248|had (l_relcl) had_77\VBN\0|who|had|infarction (l_dobj) infarction_81\NN\14204950|a|first|myocardial|between (l_prep) between_82\IN\0|1990 (l_pobj) 1990_83\CD\0|and|1995|and|women (l_conj) women_89\NNS\9605289|925|control|had (l_relcl) had_93\VBN\0|who|had|not|infarction|and|matched (l_dobj) infarction_96\NN\14204950|a|myocardial
C033273_D009203 NONE gestodene_21\NN\0| (r_conj) desogestrel_19\NN\0|(|i.e.|,|or|gestodene|)|and|levonorgestrel (r_appos) generation_15\NN\7942152|third|-|desogestrel (r_nmod) contraceptives_33\NNS\3183080|generation|oral (r_pobj) in_12\IN\13603305|contraceptives (r_prep) included_11\VBN\0|in (r_acl) type_8\NN\5839024|the|of|included (r_pobj) to_6\IN\0|type (r_prep) according_5\VBG\2657219|to (r_prep) investigated_1\VBD\644583|we|association|,|according|identified (l_conj) identified_64\VBD\699815|,|dose|:|in|,|we|and|enrolled|. (l_conj) enrolled_66\VBD\2471690|women|18|through|,|year (l_dobj) women_68\NNS\9605289|248|had (l_relcl) had_77\VBN\0|who|had|infarction (l_dobj) infarction_81\NN\14204950|a|first|myocardial|between
C033273_D009203 NONE gestodene_21\NN\0| (r_conj) desogestrel_19\NN\0|(|i.e.|,|or|gestodene|)|and|levonorgestrel (r_appos) generation_15\NN\7942152|third|-|desogestrel (r_nmod) contraceptives_33\NNS\3183080|generation|oral (r_pobj) in_12\IN\13603305|contraceptives (r_prep) included_11\VBN\0|in (r_acl) type_8\NN\5839024|the|of|included (r_pobj) to_6\IN\0|type (r_prep) according_5\VBG\2657219|to (r_prep) investigated_1\VBD\644583|we|association|,|according|identified (l_conj) identified_64\VBD\699815|,|dose|:|in|,|we|and|enrolled|. (l_conj) enrolled_66\VBD\2471690|women|18|through|,|year (l_dobj) women_68\NNS\9605289|248|had (l_relcl) had_77\VBN\0|who|had|infarction (l_dobj) infarction_81\NN\14204950|a|first|myocardial|between (l_prep) between_82\IN\0|1990 (l_pobj) 1990_83\CD\0|and|1995|and|women (l_conj) women_89\NNS\9605289|925|control|had (l_relcl) had_93\VBN\0|who|had|not|infarction|and|matched (l_dobj) infarction_96\NN\14204950|a|myocardial
D016912_D009203 NONE levonorgestrel_30\JJ\0|generation|(|i.e.|,|) (r_conj) desogestrel_19\NN\0|(|i.e.|,|or|gestodene|)|and|levonorgestrel (r_appos) generation_15\NN\7942152|third|-|desogestrel (r_nmod) contraceptives_33\NNS\3183080|generation|oral (r_pobj) in_12\IN\13603305|contraceptives (r_prep) included_11\VBN\0|in (r_acl) type_8\NN\5839024|the|of|included (r_pobj) to_6\IN\0|type (r_prep) according_5\VBG\2657219|to (r_prep) investigated_1\VBD\644583|we|association|,|according|identified (l_conj) identified_64\VBD\699815|,|dose|:|in|,|we|and|enrolled|. (l_conj) enrolled_66\VBD\2471690|women|18|through|,|year (l_dobj) women_68\NNS\9605289|248|had (l_relcl) had_77\VBN\0|who|had|infarction (l_dobj) infarction_81\NN\14204950|a|first|myocardial|between
D016912_D009203 NONE levonorgestrel_30\JJ\0|generation|(|i.e.|,|) (r_conj) desogestrel_19\NN\0|(|i.e.|,|or|gestodene|)|and|levonorgestrel (r_appos) generation_15\NN\7942152|third|-|desogestrel (r_nmod) contraceptives_33\NNS\3183080|generation|oral (r_pobj) in_12\IN\13603305|contraceptives (r_prep) included_11\VBN\0|in (r_acl) type_8\NN\5839024|the|of|included (r_pobj) to_6\IN\0|type (r_prep) according_5\VBG\2657219|to (r_prep) investigated_1\VBD\644583|we|association|,|according|identified (l_conj) identified_64\VBD\699815|,|dose|:|in|,|we|and|enrolled|. (l_conj) enrolled_66\VBD\2471690|women|18|through|,|year (l_dobj) women_68\NNS\9605289|248|had (l_relcl) had_77\VBN\0|who|had|infarction (l_dobj) infarction_81\NN\14204950|a|first|myocardial|between (l_prep) between_82\IN\0|1990 (l_pobj) 1990_83\CD\0|and|1995|and|women (l_conj) women_89\NNS\9605289|925|control|had (l_relcl) had_93\VBN\0|who|had|not|infarction|and|matched (l_dobj) infarction_96\NN\14204950|a|myocardial
D004967_D009203 NONE estrogen_38\NN\14745635| (r_pobj) of_37\IN\0|estrogen (r_prep) dose_36\NN\3740161|the|of|,|and|presence (r_dep) identified_64\VBD\699815|,|dose|:|in|,|we|and|enrolled|. (l_conj) enrolled_66\VBD\2471690|women|18|through|,|year (l_dobj) women_68\NNS\9605289|248|had (l_relcl) had_77\VBN\0|who|had|infarction (l_dobj) infarction_81\NN\14204950|a|first|myocardial|between
D004967_D009203 NONE estrogen_38\NN\14745635| (r_pobj) of_37\IN\0|estrogen (r_prep) dose_36\NN\3740161|the|of|,|and|presence (r_dep) identified_64\VBD\699815|,|dose|:|in|,|we|and|enrolled|. (l_conj) enrolled_66\VBD\2471690|women|18|through|,|year (l_dobj) women_68\NNS\9605289|248|had (l_relcl) had_77\VBN\0|who|had|infarction (l_dobj) infarction_81\NN\14204950|a|first|myocardial|between (l_prep) between_82\IN\0|1990 (l_pobj) 1990_83\CD\0|and|1995|and|women (l_conj) women_89\NNS\9605289|925|control|had (l_relcl) had_93\VBN\0|who|had|not|infarction|and|matched (l_dobj) infarction_96\NN\14204950|a|myocardial
9721172
D007052_D001649 NONE ibuprofen_30\JJ\3828465| (r_compound) use_31\NN\407535|ibuprofen (r_pobj) with_29\IN\0|use (r_prep) associated_28\VBN\628491|child|;|this|was|temporally|with|. (l_nsubjpass) child_3\NN\9622049|a|healthy|developed|described (l_relcl) developed_5\VBD\1753788|who|syndrome (l_dobj) syndrome_15\NN\5870365|acute|,|severe|,|progressive|duct
D007052_D013262 CID ibuprofen_30\JJ\3828465| (r_compound) use_31\NN\407535|ibuprofen (r_pobj) with_29\IN\0|use (r_prep) associated_28\VBN\628491|child|;|this|was|temporally|with|. (l_nsubjpass) child_3\NN\9622049|a|healthy|developed|described (l_relcl) described_23\VBN\1001294|after|syndrome|is (l_nsubjpass) syndrome_21\NN\5870365|johnson
D014580_D002779 NONE acid_4\NN\14818238|ursodeoxycholic|,|prednisone (l_conj) prednisone_6\NN\2721538|,|and|tacrolimus (l_conj) tacrolimus_10\VB\0|then|,|disease (l_conj) disease_14\NN\14061805|her|cholestatic
D014580_D005355 NONE acid_4\NN\14818238|ursodeoxycholic|,|prednisone (r_pobj) with_2\IN\0|acid (r_prep) therapy_1\NN\657604|with (r_pobj) despite_0\IN\7501545|therapy (r_prep) was_15\VBD\0|despite|unrelenting|,|with|. (l_prep) with_18\IN\0|cirrhosis (l_pobj) cirrhosis_19\NN\14116321|shown
D011241_D002779 NONE prednisone_6\NN\2721538|,|and|tacrolimus (l_conj) tacrolimus_10\VB\0|then|,|disease (l_conj) disease_14\NN\14061805|her|cholestatic
D011241_D005355 NONE prednisone_6\NN\2721538|,|and|tacrolimus (r_conj) acid_4\NN\14818238|ursodeoxycholic|,|prednisone (r_pobj) with_2\IN\0|acid (r_prep) therapy_1\NN\657604|with (r_pobj) despite_0\IN\7501545|therapy (r_prep) was_15\VBD\0|despite|unrelenting|,|with|. (l_prep) with_18\IN\0|cirrhosis (l_pobj) cirrhosis_19\NN\14116321|shown
D016559_D002779 NONE tacrolimus_10\VB\0|then|,|disease (l_conj) disease_14\NN\14061805|her|cholestatic
D016559_D005355 NONE tacrolimus_10\VB\0|then|,|disease (r_conj) prednisone_6\NN\2721538|,|and|tacrolimus (r_conj) acid_4\NN\14818238|ursodeoxycholic|,|prednisone (r_pobj) with_2\IN\0|acid (r_prep) therapy_1\NN\657604|with (r_pobj) despite_0\IN\7501545|therapy (r_prep) was_15\VBD\0|despite|unrelenting|,|with|. (l_prep) with_18\IN\0|cirrhosis (l_pobj) cirrhosis_19\NN\14116321|shown
9587734
D013390_D006323 CID suxamethonium_0\NN\0| (r_npadvmod) induced_2\VBN\1627355|suxamethonium|- (r_amod) arrest_4\NN\88481|induced|cardiac|and|death|following|.
D013390_D006323 CID suxamethonium_21\NN\0|in (r_pobj) of_20\IN\0|suxamethonium (r_prep) use_19\NN\407535|the|of (r_pobj) following_17\VBG\8180190|use (r_prep) case_5\NN\7283608|a|of|following (l_prep) of_6\IN\0|arrest (l_pobj) arrest_8\NN\88481|cardiac|and|death
D013390_D006323 CID suxamethonium_5\NN\0|,|arrest (l_appos) arrest_10\NN\88481|bradycardia|cardiac
D013390_D003643 NONE suxamethonium_0\NN\0| (r_npadvmod) induced_2\VBN\1627355|suxamethonium|- (r_amod) arrest_4\NN\88481|induced|cardiac|and|death|following|. (l_conj) death_6\NN\7296428|
D013390_D003643 NONE suxamethonium_21\NN\0|in (r_pobj) of_20\IN\0|suxamethonium (r_prep) use_19\NN\407535|the|of (r_pobj) following_17\VBG\8180190|use (r_prep) case_5\NN\7283608|a|of|following (l_prep) of_6\IN\0|arrest (l_pobj) arrest_8\NN\88481|cardiac|and|death (l_conj) death_11\NN\7296428|subsequent|as
D013390_D003643 NONE suxamethonium_11\NN\0| (r_pobj) to_10\IN\0|suxamethonium (r_prep) hypersensitivity_9\NN\14531772|to (r_pobj) by_8\IN\0|hypersensitivity (r_agent) caused_7\VBN\1617192|that|death|was|by|,|associated (l_nsubjpass) death_5\NN\7296428|her
D013390_D006947 CID suxamethonium_21\NN\0|in (r_pobj) of_20\IN\0|suxamethonium (r_prep) use_19\NN\407535|the|of (r_pobj) following_17\VBG\8180190|use (r_prep) case_5\NN\7283608|a|of|following (l_prep) of_6\IN\0|arrest (l_pobj) arrest_8\NN\88481|cardiac|and|death (l_conj) death_11\NN\7296428|subsequent|as (l_prep) as_12\IN\14622893|result (l_pobj) result_14\NN\34213|a|of (l_prep) of_15\IN\0|hyperkalaemia (l_pobj) hyperkalaemia_16\NN\0|
D013390_D006947 CID suxamethonium_35\NN\0| (r_pobj) of_34\IN\0|suxamethonium (r_prep) administration_33\NN\1133281|the|of (r_pobj) following_31\VBG\8180190|administration (r_prep) signs_15\NNS\6643763|no|of|following (l_prep) of_16\IN\0|damage|or|of (l_conj) of_21\IN\0|any (l_pobj) any_22\DT\0|of (l_prep) of_23\IN\0|conditions (l_pobj) conditions_28\NNS\14512817|the|other|known|predisposing|for (l_prep) for_29\IN\0|hyperkalaemia (l_pobj) hyperkalaemia_30\NN\0|
D013390_D001919 CID suxamethonium_5\NN\0|,|arrest (l_appos) arrest_10\NN\88481|bradycardia|cardiac (l_amod) bradycardia_7\NN\14110674|and
D013390_D004342 CID suxamethonium_11\NN\0| (r_pobj) to_10\IN\0|suxamethonium (r_prep) hypersensitivity_9\NN\14531772|to
3856631
D008727_D008577 NONE methotrexate_10\NNP\2722166|dose|intravenous (r_pobj) with_5\IN\0|methotrexate (r_prep) leukemia_4\NN\14239918|meningeal|with
D008727_D054198 NONE methotrexate_18\NNP\2722166| (r_compound) regimen_19\NN\5898568|a|dose|intravenous|methotrexate|designed (r_pobj) with_12\IN\0|regimen (r_prep) treated_11\VBN\2376958|children|were|with|. (l_nsubjpass) children_1\NNS\9622049|twenty|with|developed (l_prep) with_2\IN\0|leukemia (l_pobj) leukemia_5\NN\14239918|acute|lymphoblastic
D008727_D054198 NONE methotrexate_28\NNP\2722166| (r_compound) concentrations_29\NNS\4916342|csf|methotrexate|of (r_dobj) maintain_26\VB\0|concentrations|without (r_conj) achieve_24\VB\2524171|to|and|maintain (r_xcomp) designed_22\VBN\1631534|that|was|achieve (r_relcl) regimen_19\NN\5898568|a|dose|intravenous|methotrexate|designed (r_pobj) with_12\IN\0|regimen (r_prep) treated_11\VBN\2376958|children|were|with|. (l_nsubjpass) children_1\NNS\9622049|twenty|with|developed (l_prep) with_2\IN\0|leukemia (l_pobj) leukemia_5\NN\14239918|acute|lymphoblastic
D008727_D054198 NONE methotrexate_4\NN\2722166|dose|intravenous (r_nsubj) is_5\VBZ\0|methotrexate|treatment|. (l_attr) treatment_8\NN\654885|an|effective|for (l_prep) for_9\IN\0|induction (l_pobj) induction_11\NN\7450842|the|of|after (l_prep) after_14\IN\0|relapse (l_pobj) relapse_16\NN\66636|meningeal|in (l_prep) in_17\IN\13603305|leukemia (l_pobj) leukemia_20\NN\14239918|acute|lymphoblastic
D008727_D002493 NONE methotrexate_18\NNP\2722166| (r_compound) regimen_19\NN\5898568|a|dose|intravenous|methotrexate|designed (r_pobj) with_12\IN\0|regimen (r_prep) treated_11\VBN\2376958|children|were|with|. (l_nsubjpass) children_1\NNS\9622049|twenty|with|developed (l_relcl) developed_7\VBD\1753788|who|disease (l_dobj) disease_9\NN\14061805|meningeal
D008727_D002493 NONE methotrexate_28\NNP\2722166| (r_compound) concentrations_29\NNS\4916342|csf|methotrexate|of (r_dobj) maintain_26\VB\0|concentrations|without (r_conj) achieve_24\VB\2524171|to|and|maintain (r_xcomp) designed_22\VBN\1631534|that|was|achieve (r_relcl) regimen_19\NN\5898568|a|dose|intravenous|methotrexate|designed (r_pobj) with_12\IN\0|regimen (r_prep) treated_11\VBN\2376958|children|were|with|. (l_nsubjpass) children_1\NNS\9622049|twenty|with|developed (l_relcl) developed_7\VBD\1753788|who|disease (l_dobj) disease_9\NN\14061805|meningeal
D001663_D064420 NONE bilirubin_10\NN\14756039| (r_amod) elevations_11\NNS\7445480|bilirubin (r_conj) transaminase_8\NN\15077571|transient|serum|and|elevations|,|neutropenia (r_attr) were_5\VBD\0|toxicities|transaminase|. (l_nsubj) toxicities_3\NNS\13576101|the|common|encountered
D001663_D009503 NONE bilirubin_10\NN\14756039| (r_amod) elevations_11\NNS\7445480|bilirubin (r_conj) transaminase_8\NN\15077571|transient|serum|and|elevations|,|neutropenia (l_appos) neutropenia_13\NN\14196405|,|and|mucositis
D001663_D052016 NONE bilirubin_10\NN\14756039| (r_amod) elevations_11\NNS\7445480|bilirubin (r_conj) transaminase_8\NN\15077571|transient|serum|and|elevations|,|neutropenia (l_appos) neutropenia_13\NN\14196405|,|and|mucositis (l_conj) mucositis_16\NN\0|
15804801
D017239_D003323 CID paclitaxel_6\NN\0| (r_compound) eluting_8\VBG\1270199|paclitaxel|- (r_amod) stent_9\NN\4493505|a|eluting (r_pobj) of_4\IN\0|stent (r_prep) implantation_3\NN\13526110|of (r_pobj) after_2\IN\0|implantation (r_prep) aneurysm_1\NN\14057371|coronary|after|.
D017239_D003323 CID paclitaxel_22\NN\0| (r_compound) eluting_24\VBG\1270199|paclitaxel|- (r_amod) stent_25\NN\4493505|a|eluting (r_dobj) receiving_20\VBG\2210855|stent (r_pcomp) after_19\IN\0|months|receiving (r_prep) developed_8\VBD\1753788|who|aneurysm|in|after (l_dobj) aneurysm_11\NN\14057371|a|coronary
6634932
C002616_D017180 NONE um-272_0\NNP\0| (r_punct) dimethylpropranolol_6\NNP\0|um-272|(|n|,|n|-|)|,|agent (r_nsubjpass) administered_15\VBN\2436349|dimethylpropranolol|,|was|sublingually|to|. (l_prep) to_17\IN\0|dogs (l_pobj) dogs_18\NNS\2083346|with (l_prep) with_19\IN\0|tachycardias (l_pobj) tachycardias_24\NNS\14110674|induced|ventricular
C002616_D017180 NONE dimethylpropranolol_6\NNP\0|um-272|(|n|,|n|-|)|,|agent (r_nsubjpass) administered_15\VBN\2436349|dimethylpropranolol|,|was|sublingually|to|. (l_prep) to_17\IN\0|dogs (l_pobj) dogs_18\NNS\2083346|with (l_prep) with_19\IN\0|tachycardias (l_pobj) tachycardias_24\NNS\14110674|induced|ventricular
C002616_D017180 NONE um-272_1\NNP\0| (r_punct) converted_2\VBD\126264|sublingual|um-272|tachycardia|sinus|. (l_dobj) tachycardia_4\NN\14110674|ventricular
D010042_D017180 CID ouabain_20\RB\0| (r_npadvmod) induced_22\VBN\1627355|ouabain|- (r_amod) tachycardias_24\NNS\14110674|induced|ventricular
6640832
D004317_D001749 NONE adriamycin_2\NNS\0|in (l_prep) in_3\IN\13603305|carcinoma (l_pobj) carcinoma_6\NN\14239918|superficial|bladder
D004317_D001749 NONE adriamycin_0\NNP\0|ml (r_nsubjpass) administered_7\VBN\2436349|adriamycin|was|intravesically|within|after|. (l_prep) after_12\IN\0|resection (l_pobj) resection_14\NN\671351|transurethral|of (l_prep) of_15\IN\0|tumors (l_pobj) tumors_25\NNS\14234074|t1|(|a|)|bladder
D004317_D002277 NONE adriamycin_2\NNS\0|in (l_prep) in_3\IN\13603305|carcinoma (l_pobj) carcinoma_6\NN\14239918|superficial|bladder
8741744
D009538_D009069 NONE nicotine_29\NN\14712692| (r_pobj) by_28\IN\0|nicotine (r_agent) caused_27\VBN\1617192|by (r_acl) hypoactivity_26\NN\0|the|early|(|min|)|field|locomotor|caused|(|kg(-1|)|,|i.m.|)
D009538_D009069 NONE nicotine_48\NN\14712692| (r_npadvmod) induced_50\VBN\1627355|nicotine|- (r_amod) hyperactivity_51\NN\14052403|the|later|(|min|induced (r_dobj) enhanced_39\VBD\227165|hyperactivity|,|and|raised (r_advcl) blunted_14\VBD\224901|compared|,|lesions|hypoactivity|,|enhanced|. (l_dobj) hypoactivity_26\NN\0|the|early|(|min|)|field|locomotor|caused|(|kg(-1|)|,|i.m.|)
D009538_D006948 CID nicotine_29\NN\14712692| (r_pobj) by_28\IN\0|nicotine (r_agent) caused_27\VBN\1617192|by (r_acl) hypoactivity_26\NN\0|the|early|(|min|)|field|locomotor|caused|(|kg(-1|)|,|i.m.|) (r_dobj) blunted_14\VBD\224901|compared|,|lesions|hypoactivity|,|enhanced|. (l_advcl) enhanced_39\VBD\227165|hyperactivity|,|and|raised (l_dobj) hyperactivity_51\NN\14052403|the|later|(|min|induced
D009538_D006948 CID nicotine_48\NN\14712692| (r_npadvmod) induced_50\VBN\1627355|nicotine|- (r_amod) hyperactivity_51\NN\14052403|the|later|(|min|induced
1147734
D011441_D008107 NONE propylthiouracil_4\NN\14727670| (r_pobj) by_3\IN\0|propylthiouracil (r_agent) caused_2\VBN\1617192|by (r_acl) disease_1\NN\14061805|liver|caused|.
D011441_D006521 CID propylthiouracil_29\NN\14727670| (r_pobj) of_28\IN\0|propylthiouracil (r_prep) administration_27\NN\1133281|the|of (r_pobj) by_25\IN\0|administration (r_agent) caused_24\VBN\1617192|by (r_acl) hepatitis_23\NN\14127211|chronic|active|(|aggressive|)|caused
1720453
D007069_D007674 CID ifosfamide_7\JJ\0| (r_amod) toxicity_9\NN\13576101|ifosfamide|renal|in
D007069_C535700 NONE ifosfamide_7\JJ\0| (r_amod) toxicity_9\NN\13576101|ifosfamide|renal|in (r_pobj) of_6\IN\0|toxicity (r_prep) up_5\NN\153263|term|follow|-|of (r_nsubj) treated_12\VBN\2376958|up|for|:|society|. (l_prep) for_13\IN\0|tumors (l_pobj) tumors_16\NNS\14234074|malignant|mesenchymal
D007069_C535700 NONE ifosfamide_19\JJ\0| (r_compound) protocol_21\NN\6652242|the|same|ifosfamide|chemotherapy|(|society|mmt|) (r_dobj) received_16\VBN\2210855|who|have|protocol (r_relcl) function_2\NN\13783581|the|renal|of|with|in|and|received (l_prep) with_6\IN\0|tumors (l_pobj) tumors_9\NNS\14234074|malignant|mesenchymal
D007069_C535700 NONE ifosfamide_19\JJ\0| (r_compound) protocol_21\NN\6652242|the|same|ifosfamide|chemotherapy|(|society|mmt|) (l_appos) society_24\NNP\7950920|international|of (l_prep) of_25\IN\0|study (l_pobj) study_31\NNP\635850|oncology|malignant|mesenchymal|tumor (l_compound) tumor_30\NNP\14234074|
D007069_C535700 NONE ifosfamide_18\NN\0| (r_pobj) of_17\IN\0|ifosfamide (r_prep) efficacy_16\NN\5199286|the|of|in (l_prep) in_19\IN\13603305|treatment (l_pobj) treatment_21\NN\654885|the|of|in (l_prep) of_22\IN\0|tumors (l_pobj) tumors_24\NNS\14234074|mesenchymal
D003404_D006030 NONE creatinine_22\NN\0| (r_compound) clearance_23\NN\5089947|creatinine|,|reabsorption (r_conj) osmolarity_20\NN\0|,|clearance (r_conj) ph_18\NN\5038959|urinary|,|osmolarity (r_conj) aminoaciduria_15\JJ\14299637|,|ph (r_conj) proteinuria_13\NN\14299637|,|aminoaciduria (r_conj) glucosuria_11\NN\14267841|,|proteinuria
D003404_D011507 NONE creatinine_22\NN\0| (r_compound) clearance_23\NN\5089947|creatinine|,|reabsorption (r_conj) osmolarity_20\NN\0|,|clearance (r_conj) ph_18\NN\5038959|urinary|,|osmolarity (r_conj) aminoaciduria_15\JJ\14299637|,|ph (r_conj) proteinuria_13\NN\14299637|,|aminoaciduria
D003404_D000608 NONE creatinine_22\NN\0| (r_compound) clearance_23\NN\5089947|creatinine|,|reabsorption (r_conj) osmolarity_20\NN\0|,|clearance (r_conj) ph_18\NN\5038959|urinary|,|osmolarity (r_conj) aminoaciduria_15\JJ\14299637|,|ph
D010710_D006030 NONE phosphate_25\NN\15010703| (r_nmod) reabsorption_27\NN\13526110|phosphate|tubular (r_conj) clearance_23\NN\5089947|creatinine|,|reabsorption (r_conj) osmolarity_20\NN\0|,|clearance (r_conj) ph_18\NN\5038959|urinary|,|osmolarity (r_conj) aminoaciduria_15\JJ\14299637|,|ph (r_conj) proteinuria_13\NN\14299637|,|aminoaciduria (r_conj) glucosuria_11\NN\14267841|,|proteinuria
D010710_D011507 NONE phosphate_25\NN\15010703| (r_nmod) reabsorption_27\NN\13526110|phosphate|tubular (r_conj) clearance_23\NN\5089947|creatinine|,|reabsorption (r_conj) osmolarity_20\NN\0|,|clearance (r_conj) ph_18\NN\5038959|urinary|,|osmolarity (r_conj) aminoaciduria_15\JJ\14299637|,|ph (r_conj) proteinuria_13\NN\14299637|,|aminoaciduria
D010710_D000608 NONE phosphate_25\NN\15010703| (r_nmod) reabsorption_27\NN\13526110|phosphate|tubular (r_conj) clearance_23\NN\5089947|creatinine|,|reabsorption (r_conj) osmolarity_20\NN\0|,|clearance (r_conj) ph_18\NN\5038959|urinary|,|osmolarity (r_conj) aminoaciduria_15\JJ\14299637|,|ph
D010710_D064420 NONE phosphate_51\NN\15010703|low (r_compound) reabsorption_52\NN\13526110|phosphate (r_conj) microglobulinuria_48\NN\0|elevated|beta|2|and|reabsorption (r_pobj) with_44\IN\0|microglobulinuria (r_prep) patients_43\NNS\9898892|five|with (r_dobj) included_41\VBD\0|group|patients|. (r_conj) included_13\VBD\0|identified|:|first|patients|;|and|included (l_dobj) patients_15\NNS\9898892|four|(|%|)|developed (l_relcl) developed_25\VBD\1753788|who|toxicity (l_dobj) toxicity_27\NN\13576101|major|resulting
D010710_D005198 NONE phosphate_51\NN\15010703|low (r_compound) reabsorption_52\NN\13526110|phosphate (r_conj) microglobulinuria_48\NN\0|elevated|beta|2|and|reabsorption (r_pobj) with_44\IN\0|microglobulinuria (r_prep) patients_43\NNS\9898892|five|with (r_dobj) included_41\VBD\0|group|patients|. (r_conj) included_13\VBD\0|identified|:|first|patients|;|and|included (l_dobj) patients_15\NNS\9898892|four|(|%|)|developed (l_relcl) developed_25\VBD\1753788|who|toxicity (l_dobj) toxicity_27\NN\13576101|major|resulting (l_acl) resulting_28\VBG\2633881|in (l_prep) in_29\IN\13603305|syndrome (l_pobj) syndrome_32\NN\5870365|fanconi|(|tdfs|)
D010710_D005198 NONE phosphate_51\NN\15010703|low (r_compound) reabsorption_52\NN\13526110|phosphate (r_conj) microglobulinuria_48\NN\0|elevated|beta|2|and|reabsorption (r_pobj) with_44\IN\0|microglobulinuria (r_prep) patients_43\NNS\9898892|five|with (r_dobj) included_41\VBD\0|group|patients|. (r_conj) included_13\VBD\0|identified|:|first|patients|;|and|included (l_dobj) patients_15\NNS\9898892|four|(|%|)|developed (l_relcl) developed_25\VBD\1753788|who|toxicity (l_dobj) toxicity_27\NN\13576101|major|resulting (l_acl) resulting_28\VBG\2633881|in (l_prep) in_29\IN\13603305|syndrome (l_pobj) syndrome_32\NN\5870365|fanconi|(|tdfs|) (l_appos) tdfs_34\NNP\0|
D007069_D064420 NONE ifosfamide_15\NN\0| (r_pobj) of_14\IN\0|ifosfamide (r_prep) m2_13\NN\13357178|60|g|/|of (r_pobj) of_9\IN\0|m2 (r_prep) dose_8\NN\3740161|the|higher|cumulative|of|,|age|,|and|predominance (r_pobj) with_4\IN\0|dose (r_prep) correlated_3\VBN\2657219|toxicity|was|with|. (l_nsubjpass) toxicity_1\NN\13576101|severe
D007069_D009369 NONE ifosfamide_15\NN\0| (r_pobj) of_14\IN\0|ifosfamide (r_prep) m2_13\NN\13357178|60|g|/|of (r_pobj) of_9\IN\0|m2 (r_prep) dose_8\NN\3740161|the|higher|cumulative|of|,|age|,|and|predominance (l_conj) predominance_31\NN\14441825|a|of (l_prep) of_32\IN\0|involvement (l_pobj) involvement_35\NN\1080366|vesicoprostatic|tumor (l_compound) tumor_34\NN\14234074|
7352670
D009599_D006973 NONE nitroprusside_4\NN\0|after|sodium (r_advmod) hypertensive_1\JJ\10405694|rebound|nitroprusside|prevented|.
D009599_D006973 NONE snp_2\NNP\11493266| (r_compound) infusion_3\NN\14589223|the|snp (r_pobj) during_0\IN\0|infusion (r_prep) demonstrated_7\VBD\2137132|during|animals|increase|,|showed|. (l_dobj) increase_10\NN\13576355|a|progressive|in|to (l_prep) in_11\IN\13603305|pressure (l_pobj) pressure_13\NN\11419404|blood
D012504_D006973 NONE saralasin_7\NN\0|in (r_pobj) by_6\IN\0|saralasin (r_agent) prevented_5\VBN\0|by (r_acl) hypertensive_1\JJ\10405694|rebound|nitroprusside|prevented|.
D012504_D006973 NONE saralasin_20\NN\0| (r_npadvmod) treated_22\VBN\2376958|saralasin|- (r_amod) animals_23\NNS\4475|the|treated (r_nsubj) showed_24\VBD\2137132|whereas|animals|change (r_advcl) demonstrated_7\VBD\2137132|during|animals|increase|,|showed|. (l_dobj) increase_10\NN\13576355|a|progressive|in|to (l_prep) in_11\IN\13603305|pressure (l_pobj) pressure_13\NN\11419404|blood
D000809_D007022 NONE angiotensin_6\NN\4522421| (r_compound) system_7\NN\3575240|angiotensin|in (l_prep) in_8\IN\13603305|maintenance (l_pobj) maintenance_10\NN\266806|the|of|during (l_prep) during_14\IN\0|anesthesia (l_pobj) anesthesia_16\NN\14034177|halothane|and|sodium|nitroprusside (l_conj) nitroprusside_19\NN\0|evaluated (l_parataxis) evaluated_24\VBN\670261|(|hypotension|was (l_nsubjpass) hypotension_22\NN\14057371|snp)-induced
D000809_D007022 NONE angiotensin_8\NN\4522421| (r_compound) system_9\NN\3575240|angiotensin|in (l_prep) in_10\IN\13603305|antagonizing (l_pcomp) antagonizing_11\VBG\1787955|effects (l_dobj) effects_15\NNS\13245626|the|combined|hypotensive|of (l_amod) hypotensive_14\JJ\10405694|
D006221_D007022 CID halothane_15\NN\3570838| (r_compound) anesthesia_16\NN\14034177|halothane|and|sodium|nitroprusside (l_conj) nitroprusside_19\NN\0|evaluated (l_parataxis) evaluated_24\VBN\670261|(|hypotension|was (l_nsubjpass) hypotension_22\NN\14057371|snp)-induced
D006221_D007022 CID halothane_17\NN\3570838|and|snp (r_pobj) of_16\IN\0|halothane (r_prep) effects_15\NNS\13245626|the|combined|hypotensive|of (l_amod) hypotensive_14\JJ\10405694|
D009599_D007022 CID nitroprusside_19\NN\0|evaluated (l_parataxis) evaluated_24\VBN\670261|(|hypotension|was (l_nsubjpass) hypotension_22\NN\14057371|snp)-induced
D009599_D007022 CID snp)-induced_21\VBN\0| (r_amod) hypotension_22\NN\14057371|snp)-induced
D009599_D007022 CID snp_19\NNP\11493266| (r_conj) halothane_17\NN\3570838|and|snp (r_pobj) of_16\IN\0|halothane (r_prep) effects_15\NNS\13245626|the|combined|hypotensive|of (l_amod) hypotensive_14\JJ\10405694|
9100294
D002118_D018376 NONE calcium_7\NN\14625458| (r_compound) channel_8\NN\6251781|calcium (r_compound) blockers_9\NNS\10101634|channel (r_pobj) to_6\IN\0|blockers (r_prep) exposed_5\VBN\2110927|to (r_acl) alterations_1\NNS\7283608|cardiovascular|in|exposed|.
D002118_D018376 NONE calcium_7\NN\14625458| (r_compound) channel_8\NN\6251781|new|calcium (r_compound) blocker_9\NN\10101634|a|channel|,|ro (r_nsubj) induced_16\VBD\1627355|that|blocker|,|alterations (l_dobj) alterations_18\NNS\7283608|cardiovascular|in|exposed
D002118_D018376 NONE calcium_10\NN\14625458| (r_compound) channel_11\NN\6251781|calcium (r_compound) blockers_12\NNS\10101634|channel|in (r_nsubj) induce_15\VBP\1627355|that|blockers|malformations (l_dobj) malformations_17\NNS\14213199|cardiovascular|indicating
D002118_D018376 NONE calcium_7\NN\14625458| (r_compound) channel_8\NN\6251781|calcium (r_compound) blockers_9\NNS\10101634|these|channel (r_pobj) of_5\IN\0|blockers (r_prep) one_4\CD\13741022|of (r_dobj) administered_3\VBN\2436349|rats|were|one|during|. (l_prep) during_10\IN\0|period (l_pobj) period_12\NN\13575869|the|of (l_prep) of_13\IN\0|morphogenesis (l_pobj) morphogenesis_15\NN\13489037|cardiac|and|offspring (l_conj) offspring_18\NN\10235549|the|examined (l_acl) examined_19\VBD\0|on (l_prep) on_20\IN\0|day (l_pobj) day_21\NN\15154774|20|of (l_prep) of_23\IN\0|gestation (l_pobj) gestation_24\NN\15116532|for (l_prep) for_25\IN\0|malformations (l_pobj) malformations_27\NNS\14213199|cardiovascular
D002118_D018376 NONE calcium_15\NN\14625458| (r_compound) channel_16\NN\6251781|calcium (r_compound) blockers_17\NNS\10101634|the|four|channel (r_pobj) of_12\IN\0|blockers (r_prep) each_11\DT\0|of (r_pobj) to_10\IN\0|each (r_prep) exposure_9\NN\5042871|to (r_pobj) after_8\IN\0|exposure (r_prep) observed_7\VBN\2163746|incidence|was|after|,|but|was (l_nsubjpass) incidence_2\NN\13821570|a|low|of (l_prep) of_3\IN\0|malformations (l_pobj) malformations_5\NNS\14213199|cardiovascular
D020748_D018376 CID 5967_14\CD\0|- (r_prep) 40_12\CD\13745420|5967 (r_nummod) ro_11\NNP\6894544|40 (r_appos) blocker_9\NN\10101634|a|channel|,|ro (r_nsubj) induced_16\VBD\1627355|that|blocker|,|alterations (l_dobj) alterations_18\NNS\7283608|cardiovascular|in|exposed
D014700_D018376 CID verapamil_27\NN\2938514|and|nifedipine (r_pobj) for_26\IN\0|only|verapamil (r_prep) significant_24\JJ\0|statistically|for (r_acomp) was_22\VBD\0|incidence|significant|. (r_conj) observed_7\VBN\2163746|incidence|was|after|,|but|was (l_nsubjpass) incidence_2\NN\13821570|a|low|of (l_prep) of_3\IN\0|malformations (l_pobj) malformations_5\NNS\14213199|cardiovascular
D009543_D018376 CID nifedipine_29\NN\2938514| (r_conj) verapamil_27\NN\2938514|and|nifedipine (r_pobj) for_26\IN\0|only|verapamil (r_prep) significant_24\JJ\0|statistically|for (r_acomp) was_22\VBD\0|incidence|significant|. (r_conj) observed_7\VBN\2163746|incidence|was|after|,|but|was (l_nsubjpass) incidence_2\NN\13821570|a|low|of (l_prep) of_3\IN\0|malformations (l_pobj) malformations_5\NNS\14213199|cardiovascular
18083142
D009638_D001008 NONE norepinephrine_0\NN\14807929| (r_compound) signaling_1\VBG\33020|norepinephrine|through (r_nsubj) is_7\VBZ\0|signaling|critical|. (l_acomp) critical_8\JJ\0|for (l_prep) for_9\IN\0|expression (l_pobj) expression_10\NN\4679549|of (l_prep) of_11\IN\0|anxiety (l_pobj) anxiety_15\NN\14373582|induced
D009638_D001008 NONE norepinephrine_22\NN\14807929|ne (r_dobj) lack_21\VBP\14449126|which|norepinephrine (r_relcl) mice_18\NNS\2329401|(|dbh|-/-|)|,|lack|, (r_appos) knockout_13\NN\10787470|dopamine|hydroxylase|mice (r_pobj) of_8\IN\0|knockout (r_prep) performance_7\NN\6619065|the|of (r_dobj) evaluated_5\VBD\670261|in|,|we|performance|in|examine|. (l_advcl) examine_36\VB\0|to|contribution (l_dobj) contribution_38\NN\786195|the|of (l_prep) of_39\IN\0|signaling (l_pobj) signaling_41\NN\33020|noradrenergic|to (l_prep) to_42\IN\0|anxiety (l_pobj) anxiety_46\NN\14373582|induced
D009638_D001008 NONE ne_24\NNP\14622893|(|) (r_appos) norepinephrine_22\NN\14807929|ne (r_dobj) lack_21\VBP\14449126|which|norepinephrine (r_relcl) mice_18\NNS\2329401|(|dbh|-/-|)|,|lack|, (r_appos) knockout_13\NN\10787470|dopamine|hydroxylase|mice (r_pobj) of_8\IN\0|knockout (r_prep) performance_7\NN\6619065|the|of (r_dobj) evaluated_5\VBD\670261|in|,|we|performance|in|examine|. (l_advcl) examine_36\VB\0|to|contribution (l_dobj) contribution_38\NN\786195|the|of (l_prep) of_39\IN\0|signaling (l_pobj) signaling_41\NN\33020|noradrenergic|to (l_prep) to_42\IN\0|anxiety (l_pobj) anxiety_46\NN\14373582|induced
D003042_D001008 CID cocaine_12\NN\3492717| (r_npadvmod) induced_14\VBN\1627355|cocaine|- (r_amod) anxiety_15\NN\14373582|induced
D003042_D001008 CID cocaine_4\NN\3492717|'s (r_poss) effects_7\NNS\13245626|underlying|cocaine|rewarding (r_nsubjpass) studied_10\VBN\0|while|mechanisms|effects|have|been|extensively (r_advcl) paid_17\VBN\2199590|studied|,|attention|has|been|to|. (l_dative) to_18\IN\0|states (l_pobj) states_22\NNS\8491826|the|unpleasant|behavioral|induced (l_acl) induced_23\VBN\1627355|by (l_agent) by_24\IN\0|cocaine (l_pobj) cocaine_25\NN\3492717|,|as (l_prep) as_28\IN\14622893|such|anxiety (l_pobj) anxiety_29\NN\14373582|
D003042_D001008 CID cocaine_25\NN\3492717|,|as (l_prep) as_28\IN\14622893|such|anxiety (l_pobj) anxiety_29\NN\14373582|
D003042_D001008 CID cocaine_43\NN\3492717| (r_npadvmod) induced_45\VBN\1627355|cocaine|- (r_amod) anxiety_46\NN\14373582|induced
D003042_D001008 CID cocaine_4\NN\3492717| (r_nsubj) increased_8\VBN\169651|that|cocaine|dependently|behavior|,|measured (l_dobj) behavior_12\NN\407535|like|in (l_amod) like_11\JJ\5839024|anxiety (l_npadvmod) anxiety_9\NN\14373582|-
D003042_D001008 CID cocaine_0\NN\3492717| (r_npadvmod) induced_2\VBN\1627355|cocaine|- (r_amod) anxiety_3\NN\14373582|induced
D003042_D001008 CID cocaine_20\NN\3492717| (r_npadvmod) induced_22\VBN\1627355|cocaine|- (r_amod) behavior_26\NN\407535|blocked|induced|like (l_amod) like_25\JJ\5839024|anxiety|- (l_npadvmod) anxiety_23\NN\14373582|
D003042_D001008 CID cocaine_14\NN\3492717| (r_npadvmod) induced_16\VBN\1627355|cocaine|- (r_amod) anxiety_17\NN\14373582|induced|in
D004298_D001008 NONE dopamine_9\NN\14807737| (r_compound) knockout_13\NN\10787470|dopamine|hydroxylase|mice (r_pobj) of_8\IN\0|knockout (r_prep) performance_7\NN\6619065|the|of (r_dobj) evaluated_5\VBD\670261|in|,|we|performance|in|examine|. (l_advcl) examine_36\VB\0|to|contribution (l_dobj) contribution_38\NN\786195|the|of (l_prep) of_39\IN\0|signaling (l_pobj) signaling_41\NN\33020|noradrenergic|to (l_prep) to_42\IN\0|anxiety (l_pobj) anxiety_46\NN\14373582|induced
D004298_D001008 NONE dopamine_17\NN\14807737| (r_nmod) hydroxylase_20\NN\0|a|dopamine|beta|- (r_nmod) inhibitor_24\NN\20090|hydroxylase|(|dbh|) (r_appos) administration_12\NN\1133281|of|,|inhibitor (r_pobj) following_11\VBG\8180190|administration (r_prep) attenuated_6\VBN\224901|anxiety|was|also|in|following|. (l_nsubjpass) anxiety_3\NN\14373582|induced
D004221_D001008 NONE disulfiram_14\NN\3740161| (r_pobj) of_13\IN\0|disulfiram (r_prep) administration_12\NN\1133281|of|,|inhibitor (r_pobj) following_11\VBG\8180190|administration (r_prep) attenuated_6\VBN\224901|anxiety|was|also|in|following|. (l_nsubjpass) anxiety_3\NN\14373582|induced
D011433_D001008 NONE propranolol_18\NN\0|behavior|in (l_dobj) behavior_26\NN\407535|blocked|induced|like (l_amod) like_25\JJ\5839024|anxiety|- (l_npadvmod) anxiety_23\NN\14373582|
D011224_D001008 NONE prazosin_42\NN\2698769|the|antagonist|and|antagonist (r_nsubj) had_49\VBD\0|while|prazosin|effect (r_advcl) pretreatment_10\NN\0|that|with|,|had (l_prep) with_11\IN\0|antagonist (l_pobj) antagonist_17\NN\7846|the|adrenergic|receptor|propranolol (l_acl) propranolol_18\NN\0|behavior|in (l_dobj) behavior_26\NN\407535|blocked|induced|like (l_amod) like_25\JJ\5839024|anxiety|- (l_npadvmod) anxiety_23\NN\14373582|
D015016_D001008 NONE yohimbine_48\NN\0| (r_appos) antagonist_47\NN\7846|the|alpha(2|)|yohimbine (r_conj) prazosin_42\NN\2698769|the|antagonist|and|antagonist (r_nsubj) had_49\VBD\0|while|prazosin|effect (r_advcl) pretreatment_10\NN\0|that|with|,|had (l_prep) with_11\IN\0|antagonist (l_pobj) antagonist_17\NN\7846|the|adrenergic|receptor|propranolol (l_acl) propranolol_18\NN\0|behavior|in (l_dobj) behavior_26\NN\407535|blocked|induced|like (l_amod) like_25\JJ\5839024|anxiety|- (l_npadvmod) anxiety_23\NN\14373582|
2234245
D003676_D014786 NONE desferrioxamine_8\NN\0| (r_dobj) receiving_7\VBG\2210855|desferrioxamine (r_acl) patients_6\NNS\9898892|hemodialyzed|receiving (r_pobj) in_4\IN\13603305|patients (r_prep) toxicity_3\NN\13576101|ocular|in|.
D003676_D014786 NONE desferrioxamine_10\NN\0| (r_dobj) receiving_9\VBG\2210855|desferrioxamine (r_acl) patients_8\NNS\9898892|41|hemodialyzed|receiving|weekly (r_pobj) during_0\IN\0|period|patients (r_prep) monitored_25\VBN\2169352|during|for|were|for|. (l_prep) for_26\IN\0|detection (l_pobj) detection_27\NN\5708432|of (l_prep) of_28\IN\0|toxicity (l_pobj) toxicity_30\NN\13576101|audiovisual
D003676_D014786 NONE desferrioxamine_15\NN\0| (r_dobj) receiving_14\VBG\2210855|desferrioxamine (r_acl) patients_13\NNS\9898892|hemodialyzed|receiving (r_pobj) in_11\IN\13603305|patients (r_prep) complication_10\NN\1073995|an|infrequent|in (r_attr) is_6\VBZ\0|that|toxicity|not|complication (l_nsubj) toxicity_5\NN\13576101|audiovisual
D003676_D006311 NONE desferrioxamine_8\NN\0| (r_dobj) receiving_7\VBG\2210855|desferrioxamine (r_acl) patients_6\NNS\9898892|hemodialyzed|receiving (r_pobj) in_4\IN\13603305|patients (r_prep) toxicity_3\NN\13576101|ocular|in|.
D003676_D006311 NONE desferrioxamine_10\NN\0| (r_dobj) receiving_9\VBG\2210855|desferrioxamine (r_acl) patients_8\NNS\9898892|41|hemodialyzed|receiving|weekly (r_pobj) during_0\IN\0|period|patients (r_prep) monitored_25\VBN\2169352|during|for|were|for|. (l_prep) for_26\IN\0|detection (l_pobj) detection_27\NN\5708432|of (l_prep) of_28\IN\0|toxicity (l_pobj) toxicity_30\NN\13576101|audiovisual
D003676_D006311 NONE desferrioxamine_15\NN\0| (r_dobj) receiving_14\VBG\2210855|desferrioxamine (r_acl) patients_13\NNS\9898892|hemodialyzed|receiving (r_pobj) in_11\IN\13603305|patients (r_prep) complication_10\NN\1073995|an|infrequent|in (r_attr) is_6\VBZ\0|that|toxicity|not|complication (l_nsubj) toxicity_5\NN\13576101|audiovisual
D003676_D034381 NONE desferrioxamine_0\NNP\0| (r_compound) withdrawal_1\NN\7206096|desferrioxamine (r_nsubj) resulted_2\VBD\2633881|withdrawal|in|,|and|reversal|. (l_conj) reversal_22\NN\199130|a|complete|of (l_prep) of_23\IN\0|hearing (l_pcomp) hearing_24\NN\1184814|loss|in|in (l_dobj) loss_25\NN\13252973|
D003676_D064420 NONE desferrioxamine_10\NN\0| (r_pobj) of_9\IN\0|desferrioxamine (r_prep) doses_8\NNS\3740161|the|higher|of (r_dobj) receiving_5\VBG\2210855|doses (r_acl) patients_4\NNS\9898892|receiving (r_pobj) in_3\IN\13603305|patients (r_prep) appeared_2\VBD\2604760|toxicity|in|or|coincided|. (l_nsubj) toxicity_1\NN\13576101|this
-1_D064420 NONE aluminium_19\NN\14625458| (r_conj) ferritin_17\NN\14728724|or|aluminium (r_nmod) levels_21\NNS\4916342|ferritin|serum (r_pobj) of_16\IN\0|levels (r_prep) normalization_15\NN\1123598|the|of (r_pobj) with_13\IN\0|normalization (r_prep) coincided_12\VBD\2604477|with (r_conj) appeared_2\VBD\2604760|toxicity|in|or|coincided|. (l_nsubj) toxicity_1\NN\13576101|this
18217897
D013792_D008228 NONE thalidomide_0\NNP\4166841| (r_nsubj) limited_2\VBN\4019101|thalidomide|has|activity|in (l_prep) in_7\IN\13603305|lymphomas (l_pobj) lymphomas_15\NNS\14239918|relapsed|indolent|hodgkin|:|trial
D013792_D009369 NONE thalidomide_0\NNP\4166841| (r_nsubj) limited_2\VBN\4019101|thalidomide|has|activity|in (l_prep) in_7\IN\13603305|lymphomas (l_pobj) lymphomas_15\NNS\14239918|relapsed|indolent|hodgkin|:|trial (l_appos) trial_20\NN\786195|a|phase|ii|of (l_prep) of_21\IN\0|cancer (l_pobj) cancer_23\NNP\14239425|the|and|b.
D013792_D007938 NONE thalidomide_0\NNP\4166841| (r_nsubj) limited_2\VBN\4019101|thalidomide|has|activity|in (l_prep) in_7\IN\13603305|lymphomas (l_pobj) lymphomas_15\NNS\14239918|relapsed|indolent|hodgkin|:|trial (l_appos) trial_20\NN\786195|a|phase|ii|of (l_prep) of_21\IN\0|cancer (l_pobj) cancer_23\NNP\14239425|the|and|b. (l_conj) b._27\NNP\0|leukemia|group (l_compound) leukemia_25\NNP\14239918|
D013792_D009101 NONE thalidomide_0\NNP\4166841| (r_nsubj) is_1\VBZ\0|thalidomide|agent|. (l_attr) agent_4\NN\7347|an|immunomodulatory|with (l_prep) with_5\IN\0|activity (l_pobj) activity_7\NN\30358|demonstrated|in (l_prep) in_8\IN\13603305|myeloma (l_pobj) myeloma_10\NN\14239425|multiple|,|lymphoma
D013792_D020522 NONE thalidomide_0\NNP\4166841| (r_nsubj) is_1\VBZ\0|thalidomide|agent|. (l_attr) agent_4\NN\7347|an|immunomodulatory|with (l_prep) with_5\IN\0|activity (l_pobj) activity_7\NN\30358|demonstrated|in (l_prep) in_8\IN\13603305|myeloma (l_pobj) myeloma_10\NN\14239425|multiple|,|lymphoma (l_conj) lymphoma_14\NN\14239918|mantle|cell|and|lymphoma
D013792_D008223 NONE thalidomide_0\NNP\4166841| (r_nsubj) is_1\VBZ\0|thalidomide|agent|. (l_attr) agent_4\NN\7347|an|immunomodulatory|with (l_prep) with_5\IN\0|activity (l_pobj) activity_7\NN\30358|demonstrated|in (l_prep) in_8\IN\13603305|myeloma (l_pobj) myeloma_10\NN\14239425|multiple|,|lymphoma (l_conj) lymphoma_14\NN\14239918|mantle|cell|and|lymphoma (l_conj) lymphoma_17\NN\14239918|lymphoplasmacytic
D013792_D008223 NONE thalidomide_16\NN\4166841| (r_dobj) received_15\VBD\2210855|between|,|patients|thalidomide|daily|with|tolerated|. (l_nsubj) patients_8\NNS\9898892|24|with (l_prep) with_9\IN\0|lymphomas (l_pobj) lymphomas_14\NNS\14239918|relapsed|/|refractory|indolent
D013792_D008223 NONE thalidomide_12\NN\4166841|agent (r_pobj) to_9\IN\0|thalidomide (r_prep) rate_8\NN\13815152|an|important|response|to|in (l_prep) in_13\IN\13603305|lymphomas (l_pobj) lymphomas_15\NNS\14239918|indolent
C467567_D008223 NONE lenalidomide_31\NN\0| (r_appos) agent_29\NN\7347|the|generation|immunomodulatory|,|lenalidomide (r_pobj) with_24\IN\0|agent (r_prep) reported_23\VBN\831651|with (r_acl) level_22\NN\4916342|the|higher|activity|reported (r_pobj) with_18\IN\0|level (r_prep) contrast_17\NN\13854649|with (r_conj) demonstrate_4\VB\2137132|to|rate|and|contrast (l_dobj) rate_8\NN\13815152|an|important|response|to|in (l_prep) in_13\IN\13603305|lymphomas (l_pobj) lymphomas_15\NNS\14239918|indolent
3101906
D007654_D003643 NONE ketoconazole_9\JJ\0| (r_compound) treatment_10\NN\654885|ketoconazole (r_pobj) with_8\IN\0|treatment (r_prep) associated_7\VBN\628491|probably|with (r_acl) deaths_5\NNS\7296428|the|three|associated
D007654_D007565 CID ketoconazole_9\JJ\0| (r_compound) treatment_10\NN\654885|ketoconazole (r_pobj) with_8\IN\0|treatment (r_prep) associated_7\VBN\628491|probably|with (r_acl) deaths_5\NNS\7296428|the|three|associated (r_pobj) of_2\IN\0|deaths (r_prep) two_1\CD\13741022|of (r_pobj) in_0\IN\13603305|two (r_prep) continued_15\VBN\2367363|in|drug|had|been|after|. (l_prep) after_16\IN\0|onset (l_pobj) onset_18\NN\7325190|the|of (l_prep) of_19\IN\0|jaundice (l_pobj) jaundice_20\NN\14299637|and|symptoms
D007654_D056486 CID ketoconazole_9\JJ\0| (r_compound) treatment_10\NN\654885|ketoconazole (r_pobj) with_8\IN\0|treatment (r_prep) associated_7\VBN\628491|probably|with (r_acl) deaths_5\NNS\7296428|the|three|associated (r_pobj) of_2\IN\0|deaths (r_prep) two_1\CD\13741022|of (r_pobj) in_0\IN\13603305|two (r_prep) continued_15\VBN\2367363|in|drug|had|been|after|. (l_prep) after_16\IN\0|onset (l_pobj) onset_18\NN\7325190|the|of (l_prep) of_19\IN\0|jaundice (l_pobj) jaundice_20\NN\14299637|and|symptoms (l_conj) symptoms_23\NNS\5823932|other|of (l_prep) of_24\IN\0|hepatitis (l_pobj) hepatitis_25\NN\14127211|
D007654_D056486 CID ketoconazole_18\NN\0| (r_pobj) with_17\IN\0|ketoconazole (r_prep) treatment_16\NN\654885|term|with (r_pobj) during_13\IN\0|treatment (r_prep) advised_12\VBN\813978|monitoring|is|during|prevent|. (l_nsubjpass) monitoring_3\NN\879759|clinical|at|for (l_prep) for_7\IN\0|evidence (l_pobj) evidence_8\NN\5816287|of (l_prep) of_9\IN\0|hepatitis (l_pobj) hepatitis_10\NN\14127211|
D007654_D056486 CID ketoconazole_18\NN\0| (r_pobj) with_17\IN\0|ketoconazole (r_prep) treatment_16\NN\654885|term|with (r_pobj) during_13\IN\0|treatment (r_prep) advised_12\VBN\813978|monitoring|is|during|prevent|. (l_advcl) prevent_20\VB\0|to|injury (l_dobj) injury_24\NN\14052046|possible|serious|hepatic
2273650
D012601_D000647 CID scopolamine_3\NN\14712692|and|cycloheximide (r_pobj) by_2\IN\0|scopolamine (r_agent) produced_1\VBN\1617192|by (r_acl) amnesia_0\NNP\5669934|produced
D012601_D000647 CID scopolamine_5\NN\14712692|test (r_nsubj) reversed_7\VBD\109660|similarly|scopolamine|partially|amnesia|,|but|failed (l_dobj) amnesia_12\NN\5669934|the|induced
D012601_D000647 CID scopolamine_5\NN\14712692|test (r_nsubj) reversed_7\VBD\109660|similarly|scopolamine|partially|amnesia|,|but|failed (l_conj) failed_23\VBD\0|significantly|cycloheximide|reverse|. (l_xcomp) reverse_25\VB\13854649|to|amnesia (l_dobj) amnesia_30\NN\5669934|the|induced
D012601_D000647 CID scopolamine_9\NN\14712692| (r_npadvmod) induced_11\VBN\1627355|scopolamine|- (r_amod) amnesia_12\NN\5669934|the|induced
D012601_D000647 CID scopolamine_9\NN\14712692| (r_npadvmod) induced_11\VBN\1627355|scopolamine|- (r_amod) amnesia_12\NN\5669934|the|induced (r_dobj) reversed_7\VBD\109660|similarly|scopolamine|partially|amnesia|,|but|failed (l_conj) failed_23\VBD\0|significantly|cycloheximide|reverse|. (l_xcomp) reverse_25\VB\13854649|to|amnesia (l_dobj) amnesia_30\NN\5669934|the|induced
D003513_D000647 CID cycloheximide_5\NN\0| (r_conj) scopolamine_3\NN\14712692|and|cycloheximide (r_pobj) by_2\IN\0|scopolamine (r_agent) produced_1\VBN\1617192|by (r_acl) amnesia_0\NNP\5669934|produced
D003513_D000647 CID cycloheximide_22\NN\0|test (r_nsubj) failed_23\VBD\0|significantly|cycloheximide|reverse|. (r_conj) reversed_7\VBD\109660|similarly|scopolamine|partially|amnesia|,|but|failed (l_dobj) amnesia_12\NN\5669934|the|induced
D003513_D000647 CID cycloheximide_22\NN\0|test (r_nsubj) failed_23\VBD\0|significantly|cycloheximide|reverse|. (l_xcomp) reverse_25\VB\13854649|to|amnesia (l_dobj) amnesia_30\NN\5669934|the|induced
D003513_D000647 CID cycloheximide_27\RB\0| (r_advmod) induced_29\VBN\1627355|cycloheximide|- (r_amod) amnesia_30\NN\5669934|the|induced (r_dobj) reverse_25\VB\13854649|to|amnesia (r_xcomp) failed_23\VBD\0|significantly|cycloheximide|reverse|. (r_conj) reversed_7\VBD\109660|similarly|scopolamine|partially|amnesia|,|but|failed (l_dobj) amnesia_12\NN\5669934|the|induced
D003513_D000647 CID cycloheximide_27\RB\0| (r_advmod) induced_29\VBN\1627355|cycloheximide|- (r_amod) amnesia_30\NN\5669934|the|induced
D009020_D000647 NONE morphine_9\NN\2707683| (r_pobj) by_8\IN\0|morphine (r_agent) reversed_7\VBN\109660|amnesia|were|by|given|,|and|facilitated (l_nsubjpass) amnesia_0\NNP\5669934|produced
D009020_D000647 NONE morphine_27\NN\2707683|test (r_nsubj) facilitated_29\VBD\2547586|morphine|also|retrieval|. (r_conj) reversed_7\VBN\109660|amnesia|were|by|given|,|and|facilitated (l_nsubjpass) amnesia_0\NNP\5669934|produced
D009270_D000647 NONE naloxone_37\NN\3808977| (r_dobj) administered_36\VBN\2436349|naloxone|during (r_acl) retrieval_32\NN\13450862|the|memory|in|administered (r_dobj) facilitated_29\VBD\2547586|morphine|also|retrieval|. (r_conj) reversed_7\VBN\109660|amnesia|were|by|given|,|and|facilitated (l_nsubjpass) amnesia_0\NNP\5669934|produced
6538499
D011092_D064420 NONE 400_4\CD\0|on (r_nummod) glycol_3\NN\14766364|effect|400|adriamycin|. (l_advcl) adriamycin_6\JJ\0|toxicity (l_dobj) toxicity_7\NN\13576101|in
D004317_D064420 NONE adriamycin_6\JJ\0|toxicity (l_dobj) toxicity_7\NN\13576101|in
D004317_D009202 CID adr_8\NNP\0| (r_npadvmod) induced_10\VBN\1627355|adr|- (r_amod) alterations_13\NNS\7283608|induced|cardiac|morphological
D004317_D007939 NONE adr_6\NNP\0| (r_compound) activity_8\NN\30358|the|adr|antitumor|in|tumor (l_prep) in_9\IN\13603305|leukemia|and (l_pobj) leukemia_11\NN\14239918|l1210
D004317_D002286 NONE adr_6\NNP\0| (r_compound) activity_8\NN\30358|the|adr|antitumor|in|tumor (l_relcl) tumor_16\NN\14234074|in|ascites
9351491
D018967_D011618 NONE risperidone_6\NN\0|'s (r_poss) profile_9\NN\6999802|risperidone|pharmacologic (r_nsubj) produce_11\VB\7555863|that|profile|may|efficacy|and|decreased (l_dobj) efficacy_13\NN\5199286|improved|for (l_prep) for_14\IN\0|symptoms (l_pobj) symptoms_17\NNS\5823932|negative|psychotic
D018967_D010302 CID risperidone_10\NN\0|(|%|)|and|haloperidol (r_pobj) with_9\IN\0|risperidone (r_prep) treated_8\VBN\2376958|with (r_acl) subjects_7\NNS\6598915|treated (r_pobj) in_6\IN\13603305|subjects (r_prep) observed_5\VBN\2163746|parkinsonism|was|in|and|observed|. (l_nsubjpass) parkinsonism_3\NN\14085708|induced
D006220_D010302 CID haloperidol_16\NN\3713736|(|%|) (r_conj) risperidone_10\NN\0|(|%|)|and|haloperidol (r_pobj) with_9\IN\0|risperidone (r_prep) treated_8\VBN\2376958|with (r_acl) subjects_7\NNS\6598915|treated (r_pobj) in_6\IN\13603305|subjects (r_prep) observed_5\VBN\2163746|parkinsonism|was|in|and|observed|. (l_nsubjpass) parkinsonism_3\NN\14085708|induced
15120741
D010862_D013226 CID pilocarpine_5\NN\14712692| (r_compound) injection_6\NN\320852|systemic|pilocarpine (r_nsubj) causes_7\VBZ\7323922|similar|,|injection|se|,|but|identified (l_dobj) se_11\NNP\14724645|status|epilepticus|(|)|and|development (l_nmod) epilepticus_9\NN\0|
D010862_D013226 CID pilocarpine_5\NN\14712692| (r_compound) injection_6\NN\320852|systemic|pilocarpine (r_nsubj) causes_7\VBZ\7323922|similar|,|injection|se|,|but|identified (l_dobj) se_11\NNP\14724645|status|epilepticus|(|)|and|development
D010862_D013226 CID pilocarpine_34\NN\14712692| (r_npadvmod) treated_36\VBN\2376958|pilocarpine|- (r_amod) mice_37\NNS\2329401|treated (r_conj) mice_32\NNS\2329401|control|and|mice (r_pobj) from_30\IN\0|mice (r_prep) cells_29\NNS\3080309|granule|from (r_pobj) in_27\IN\13603305|cells (r_prep) spike_26\NN\7307895|a|single|population|in|experience (l_relcl) experience_41\VB\5984287|that|did|not|se (l_dobj) se_42\NNP\14724645|
D010862_D012640 CID pilocarpine_5\NN\14712692| (r_compound) injection_6\NN\320852|systemic|pilocarpine (r_nsubj) causes_7\VBZ\7323922|similar|,|injection|se|,|but|identified (l_dobj) se_11\NNP\14724645|status|epilepticus|(|)|and|development (l_conj) development_16\NN\248977|the|eventual|of (l_prep) of_17\IN\0|seizures (l_pobj) seizures_19\NNS\14081375|spontaneous|and|fiber|sprouting
D008274_D013226 NONE mg(2+)-free_1\JJ\0| (r_pobj) in_0\IN\13603305|mg(2+)-free|bicuculline (r_prep) resulted_21\VBD\2633881|in|,|conditions|,|stimulation|in|. (l_prep) in_22\IN\13603305|spike (l_pobj) spike_26\NN\7307895|a|single|population|in|experience (l_relcl) experience_41\VB\5984287|that|did|not|se (l_dobj) se_42\NNP\14724645|
D001640_D013226 NONE bicuculline_5\NN\0|bathing|containing (r_pobj) in_0\IN\13603305|mg(2+)-free|bicuculline (r_prep) resulted_21\VBD\2633881|in|,|conditions|,|stimulation|in|. (l_prep) in_22\IN\13603305|spike (l_pobj) spike_26\NN\7307895|a|single|population|in|experience (l_relcl) experience_41\VB\5984287|that|did|not|se (l_dobj) se_42\NNP\14724645|
D018698_D013226 NONE glutamate_37\NN\15010703| (r_compound) receptor_38\NN\5225602|glutamate (r_compound) antagonists_39\NNS\7846|ionotropic|receptor (r_pobj) by_35\IN\0|antagonists (r_agent) blocked_34\VBN\1476483|which|were|by (r_relcl) duration_30\NN\15113229|s|,|blocked (r_pobj) of_25\IN\0|duration (r_prep) afterdischarges_24\NNS\0|repetitive|of (r_conj) shifts_21\NNS\7446404|negative|dc|and|afterdischarges (r_pobj) by_18\IN\0|shifts (r_prep) followed_11\VBD\1835496|,|at|,|by (r_advcl) resulted_6\VBD\2633881|in|,|stimulation|in|followed|. (l_prep) in_0\IN\13603305|survivors (l_pobj) survivors_2\NNS\9630641|se (l_compound) se_1\NNP\14724645|
D018698_D013226 NONE glutamate_1\NN\15010703| (r_compound) photostimulation_2\NN\0|focal|glutamate|of|at (r_nsubj) resulted_15\VBD\2633881|photostimulation|in|. (l_prep) in_16\IN\13603305|responses (l_pobj) responses_18\NNS\11410625|population|of (l_prep) of_19\IN\0|duration (l_pobj) duration_24\NN\15113229|s|in|but|groups (l_prep) in_25\IN\13603305|slices (l_pobj) slices_26\NNS\13285176|from (l_prep) from_27\IN\0|survivors (l_pobj) survivors_29\NNS\9630641|se (l_compound) se_28\NNP\14724645|
2578334
D001374_D011230 CID 5-azacytidine_0\RB\0| (r_nsubj) potentiates_1\VBZ\229605|5-azacytidine|initiation|. (l_dobj) initiation_2\NN\7450842|induced (l_acl) induced_3\VBN\1627355|by (l_agent) by_4\IN\0|carcinogens (l_pobj) carcinogens_5\NNS\20090|in
D001374_D011230 CID 5-azacytidine_22\JJ\0| (r_punct) 5-azc_24\CD\0|test|,|5-azacytidine|(|)|mg/kg|,|inhibitor|, (l_advcl) test_1\VB\5798043|to|validity (l_dobj) validity_3\NN\4782878|the|of (l_prep) of_4\IN\0|hypothesis (l_pobj) hypothesis_6\NN\7162194|the|plays (l_acl) plays_11\VBZ\7007684|that|hypomethylation|role|in (l_prep) in_15\IN\13603305|initiation (l_pobj) initiation_17\NN\7450842|the|of (l_prep) of_18\IN\0|process (l_pobj) process_20\NN\407535|carcinogenic
D001374_D011230 CID 5-azc_24\CD\0|test|,|5-azacytidine|(|)|mg/kg|,|inhibitor|, (l_advcl) test_1\VB\5798043|to|validity (l_dobj) validity_3\NN\4782878|the|of (l_prep) of_4\IN\0|hypothesis (l_pobj) hypothesis_6\NN\7162194|the|plays (l_acl) plays_11\VBZ\7007684|that|hypomethylation|role|in (l_prep) in_15\IN\13603305|initiation (l_pobj) initiation_17\NN\7450842|the|of (l_prep) of_18\IN\0|process (l_pobj) process_20\NN\407535|carcinogenic
D001564_D011230 CID benzo[a]-pyrene_53\NN\0|(|mg/kg|) (r_appos) carcinogens_51\NNS\20090|the|three|,|benzo[a]-pyrene|,|nitrosourea (r_pobj) by_48\IN\0|carcinogens (r_agent) induced_47\VBN\1627355|by (r_acl) phase_43\NN\15113229|the|of|induced (r_pobj) during_41\IN\0|phase (r_prep) given_38\VBN\5892096|5-azc|was|to|during|. (l_nsubjpass) 5-azc_24\CD\0|test|,|5-azacytidine|(|)|mg/kg|,|inhibitor|, (l_advcl) test_1\VB\5798043|to|validity (l_dobj) validity_3\NN\4782878|the|of (l_prep) of_4\IN\0|hypothesis (l_pobj) hypothesis_6\NN\7162194|the|plays (l_acl) plays_11\VBZ\7007684|that|hypomethylation|role|in (l_prep) in_15\IN\13603305|initiation (l_pobj) initiation_17\NN\7450842|the|of (l_prep) of_18\IN\0|process (l_pobj) process_20\NN\407535|carcinogenic
D008770_D011230 CID nitrosourea_65\NN\0|methyl|-|n|-|60|1,2-dmh|mg/kg (r_appos) carcinogens_51\NNS\20090|the|three|,|benzo[a]-pyrene|,|nitrosourea (r_pobj) by_48\IN\0|carcinogens (r_agent) induced_47\VBN\1627355|by (r_acl) phase_43\NN\15113229|the|of|induced (r_pobj) during_41\IN\0|phase (r_prep) given_38\VBN\5892096|5-azc|was|to|during|. (l_nsubjpass) 5-azc_24\CD\0|test|,|5-azacytidine|(|)|mg/kg|,|inhibitor|, (l_advcl) test_1\VB\5798043|to|validity (l_dobj) validity_3\NN\4782878|the|of (l_prep) of_4\IN\0|hypothesis (l_pobj) hypothesis_6\NN\7162194|the|plays (l_acl) plays_11\VBZ\7007684|that|hypomethylation|role|in (l_prep) in_15\IN\13603305|initiation (l_pobj) initiation_17\NN\7450842|the|of (l_prep) of_18\IN\0|process (l_pobj) process_20\NN\407535|carcinogenic
D019813_D011230 CID 1,2-dimethylhydrazine_71\CD\0| (r_conj) 60_67\CD\13745420|(|mg/kg|)|and|1,2-dimethylhydrazine (r_appos) nitrosourea_65\NN\0|methyl|-|n|-|60|1,2-dmh|mg/kg (r_appos) carcinogens_51\NNS\20090|the|three|,|benzo[a]-pyrene|,|nitrosourea (r_pobj) by_48\IN\0|carcinogens (r_agent) induced_47\VBN\1627355|by (r_acl) phase_43\NN\15113229|the|of|induced (r_pobj) during_41\IN\0|phase (r_prep) given_38\VBN\5892096|5-azc|was|to|during|. (l_nsubjpass) 5-azc_24\CD\0|test|,|5-azacytidine|(|)|mg/kg|,|inhibitor|, (l_advcl) test_1\VB\5798043|to|validity (l_dobj) validity_3\NN\4782878|the|of (l_prep) of_4\IN\0|hypothesis (l_pobj) hypothesis_6\NN\7162194|the|plays (l_acl) plays_11\VBZ\7007684|that|hypomethylation|role|in (l_prep) in_15\IN\13603305|initiation (l_pobj) initiation_17\NN\7450842|the|of (l_prep) of_18\IN\0|process (l_pobj) process_20\NN\407535|carcinogenic
D019813_D011230 CID 1,2-dmh_73\NNP\0|(|) (r_appos) nitrosourea_65\NN\0|methyl|-|n|-|60|1,2-dmh|mg/kg (r_appos) carcinogens_51\NNS\20090|the|three|,|benzo[a]-pyrene|,|nitrosourea (r_pobj) by_48\IN\0|carcinogens (r_agent) induced_47\VBN\1627355|by (r_acl) phase_43\NN\15113229|the|of|induced (r_pobj) during_41\IN\0|phase (r_prep) given_38\VBN\5892096|5-azc|was|to|during|. (l_nsubjpass) 5-azc_24\CD\0|test|,|5-azacytidine|(|)|mg/kg|,|inhibitor|, (l_advcl) test_1\VB\5798043|to|validity (l_dobj) validity_3\NN\4782878|the|of (l_prep) of_4\IN\0|hypothesis (l_pobj) hypothesis_6\NN\7162194|the|plays (l_acl) plays_11\VBZ\7007684|that|hypomethylation|role|in (l_prep) in_15\IN\13603305|initiation (l_pobj) initiation_17\NN\7450842|the|of (l_prep) of_18\IN\0|process (l_pobj) process_20\NN\407535|carcinogenic
8410052
D019344_D001480 NONE lactate_10\NN\14850483| (r_pobj) of_9\IN\0|lactate (r_prep) infusion_8\NN\14589223|of|at (r_pobj) by_7\IN\0|infusion|or|by (r_agent) produced_6\VBN\1617192|injury|was|by|. (l_nsubjpass) injury_1\NN\14052046|focal|in (l_prep) in_2\IN\13603305|cortex (l_pobj) cortex_4\NN\5462674|the
D010862_D002544 CID pilocarpine_10\NN\14712692| (r_npadvmod) induced_12\VBN\1627355|pilocarpine|- (r_amod) status_13\NN\24720|prolonged|induced (r_pobj) by_8\IN\0|status (r_agent) evoked_7\VBN\1617192|infarcts|were|by|epilepticus|. (l_nsubjpass) infarcts_0\NNS\14204950|in (l_prep) in_1\IN\13603305|reticulata (l_pobj) reticulata_5\NNS\0|substantia|pars
D010862_D013226 CID pilocarpine_10\NN\14712692| (r_npadvmod) induced_12\VBN\1627355|pilocarpine|- (r_amod) status_13\NN\24720|prolonged|induced (r_pobj) by_8\IN\0|status (r_agent) evoked_7\VBN\1617192|infarcts|were|by|epilepticus|. (l_advmod) epilepticus_14\NN\0|
11807648
D014148_D004827 NONE acid_10\NN\14818238|tranexamic (r_dobj) containing_8\VBG\2632940|acid|in (r_acl) sealants_7\NNS\14705533|fibrin|containing (r_pobj) of_5\IN\0|sealants (r_prep) application_4\NN\947128|cortical|of (r_dobj) following_2\VBG\8180190|application (r_prep) seizures_1\NNS\14081375|epileptic|following|.
D014148_D004827 NONE tamca_2\NN\0| (r_nsubjpass) shown_5\VBN\2137132|however|,|tamca|has|been|cause|. (l_xcomp) cause_7\VB\7323922|to|seizures (l_dobj) seizures_9\NNS\14081375|epileptic
D014148_D012640 CID tamca_5\NN\0| (r_nsubj) retains_6\VBZ\2700867|whether|tamca|action|incorporated (l_dobj) action_9\NN\30358|its|convulsive (l_amod) convulsive_8\JJ\0|
D014148_D012640 CID tamca_4\NN\0| (r_appos) findings_0\NNS\7951464|:|fs|tamca (r_nsubj) caused_5\VBD\1617192|findings|activity|. (l_dobj) activity_8\NN\30358|paroxysmal|brain|associated (l_relcl) associated_11\VBN\628491|which|was|with (l_prep) with_12\IN\0|behaviours (l_pobj) behaviours_15\NNS\14006945|distinct|convulsive (l_amod) convulsive_14\JJ\0|
D014148_D012640 CID tamca_10\CD\0| (r_pobj) of_9\IN\0|tamca (r_prep) concentration_8\NN\4916342|increasing|of (r_pobj) with_6\IN\0|concentration (r_prep) increased_5\VBD\169651|degree|with|. (l_nsubj) degree_1\NN\4916342|the|of (l_prep) of_2\IN\0|seizures (l_pobj) seizures_4\NNS\14081375|these
D014148_D012640 CID tamca_0\NN\0| (r_advmod) evoked_1\VBD\1617192|tamca|seizures|evoked|. (l_dobj) seizures_3\NNS\14081375|generalized|in
D014148_D012640 CID tamca_0\NN\0| (r_advmod) evoked_1\VBD\1617192|tamca|seizures|evoked|. (l_advcl) evoked_24\VBD\1617192|while|concentration|)|only|episodes (l_dobj) episodes_26\NNS\7283608|brief|of (l_prep) of_27\IN\0|potentials (l_pobj) potentials_32\NNS\14481929|correlated|convulsive|in (l_amod) convulsive_31\JJ\0|
D014148_D012640 CID tamca_16\NN\0| (r_nmod) ml_21\NNS\13616054|tamca|(|0.5|mg|/ (r_pobj) of_15\IN\0|ml (r_prep) concentration_14\NN\4916342|the|lowest|of (r_nsubj) evoked_24\VBD\1617192|while|concentration|)|only|episodes (r_advcl) evoked_1\VBD\1617192|tamca|seizures|evoked|. (l_dobj) seizures_3\NNS\14081375|generalized|in
D014148_D012640 CID tamca_16\NN\0| (r_nmod) ml_21\NNS\13616054|tamca|(|0.5|mg|/ (r_pobj) of_15\IN\0|ml (r_prep) concentration_14\NN\4916342|the|lowest|of (r_nsubj) evoked_24\VBD\1617192|while|concentration|)|only|episodes (l_dobj) episodes_26\NNS\7283608|brief|of (l_prep) of_27\IN\0|potentials (l_pobj) potentials_32\NNS\14481929|correlated|convulsive|in (l_amod) convulsive_31\JJ\0|
D014148_D012640 CID acid_1\NN\14818238|tranexamic (r_nsubj) retains_2\VBZ\2700867|acid|action|. (l_dobj) action_5\NN\30358|its|convulsive|within (l_amod) convulsive_4\JJ\0|
7234705
D011342_D017180 CID procainamide_0\NNP\0| (r_npadvmod) induced_2\VBN\1627355|procainamide|-|tachycardia|. (l_dobj) tachycardia_5\NN\14110674|polymorphous|ventricular
D011342_D017180 CID procainamide_3\RB\0| (r_advmod) induced_5\VBN\1627355|procainamide|- (r_amod) tachycardia_8\NNS\14110674|induced|polymorphous|ventricular
D011342_D017180 CID procainamide_17\NN\0| (r_pobj) of_16\IN\0|procainamide (r_prep) mg_15\IN\13717155|400|of (r_pobj) of_11\IN\0|mg (r_prep) administration_10\NN\1133281|intravenous|of|for (r_pobj) after_8\IN\0|administration (r_prep) appeared_7\VBD\2604760|in|,|tachycardia|after|. (l_nsubj) tachycardia_6\NN\14110674|polymorphous|ventricular
D011342_D017180 CID procainamide_17\NN\0| (r_pobj) of_16\IN\0|procainamide (r_prep) mg_15\IN\13717155|400|of (r_pobj) of_11\IN\0|mg (r_prep) administration_10\NN\1133281|intravenous|of|for (l_prep) for_18\IN\0|treatment (l_pobj) treatment_20\NN\654885|the|of (l_prep) of_21\IN\0|tachycardia (l_pobj) tachycardia_24\NN\14110674|sustained|ventricular
D011342_D017180 CID procainamide_16\NN\0| (r_amod) therapy_17\NN\657604|procainamide (r_pobj) of_15\IN\0|therapy (r_prep) continuation_14\NN\407535|of (r_pobj) despite_13\IN\7501545|continuation (r_prep) reoccur_24\VB\0|despite|,|tachycardia|did|not|. (l_nsubj) tachycardia_21\NN\14110674|polymorphous|ventricular
D011342_D017180 CID procainamide_5\NN\0| (r_nsubj) produce_7\VB\7555863|that|procainamide|can|syndrome|with (l_prep) with_15\IN\0|tachycardia (l_pobj) tachycardia_18\NN\14110674|polymorphous|ventricular
D011342_D018879 NONE procainamide_6\NN\0| (r_nsubjpass) administered_8\VBN\2436349|in|,|procainamide|was|orally|for|. (l_prep) for_10\IN\0|treatment (l_pobj) treatment_11\NN\654885|of (l_prep) of_12\IN\0|contractions (l_pobj) contractions_16\NNS\358931|chronic|premature|ventricular|or|flutter
D011342_D001282 NONE procainamide_6\NN\0| (r_nsubjpass) administered_8\VBN\2436349|in|,|procainamide|was|orally|for|. (l_prep) for_10\IN\0|treatment (l_pobj) treatment_11\NN\654885|of (l_prep) of_12\IN\0|contractions (l_pobj) contractions_16\NNS\358931|chronic|premature|ventricular|or|flutter (l_conj) flutter_19\NN\331950|atrial
D011342_D008133 NONE procainamide_5\NN\0| (r_nsubj) produce_7\VB\7555863|that|procainamide|can|syndrome|with (l_dobj) syndrome_14\NN\5870365|an|acquired|prolonged|t
15278670
C009250_D012640 NONE sevoflurane_3\NN\0| (r_pobj) of_2\IN\0|sevoflurane (r_prep) effects_1\NNS\13245626|the|of|on|. (l_prep) on_4\IN\0|convulsions (l_pobj) convulsions_8\NNS\14081375|induced
C009250_D012640 NONE sevoflurane_3\NN\0|on (l_prep) on_4\IN\0|convulsions (l_pobj) convulsions_8\NNS\14081375|induced
C009250_D012640 NONE sevoflurane_40\NN\0| (r_pobj) of_39\IN\0|sevoflurane (r_prep) concentration_38\NN\4916342|the|tidal|of (r_nsubj) was_41\VBD\0|when|concentration|% (r_relcl) l(-1_31\NN\0|mg.|)|was (r_pobj) to_26\IN\0|l(-1 (r_prep) increasing_24\VBG\169651|significantly|to (r_advcl) was_8\VBD\0|threshold|+/-|)|with|)|,|increasing|. (l_nsubj) threshold_2\NN\15265518|the|convulsive|(|mean|) (l_amod) convulsive_1\JJ\0|
C009250_D012640 NONE sevoflurane_10\NN\0|and|enflurane (r_pobj) between_9\IN\0|sevoflurane (r_prep) threshold_8\NN\15265518|the|convulsive|between (l_amod) convulsive_7\JJ\0|
C009250_D012640 NONE sevoflurane_12\NN\0|or|enflurane (r_pobj) of_11\IN\0|sevoflurane (r_prep) concentrations_10\NNS\4916342|higher|of (r_nsubjpass) administered_16\VBN\2436349|when|concentrations|were|and|decreased (l_conj) decreased_23\VBD\169651|pressure|significantly|in|,|and|in (l_nsubj) pressure_20\NN\11419404|the|blood|at (l_prep) at_21\IN\14622893|convulsions (l_pobj) convulsions_22\NNS\14081375|
C009250_D012640 NONE sevoflurane_28\NN\0|% (r_pobj) in_25\IN\13603305|sevoflurane (r_prep) decreased_23\VBD\169651|pressure|significantly|in|,|and|in (l_nsubj) pressure_20\NN\11419404|the|blood|at (l_prep) at_21\IN\14622893|convulsions (l_pobj) convulsions_22\NNS\14081375|
C009250_D012640 NONE sevoflurane_4\NN\0| (r_nsubj) reduces_5\VBZ\441445|that|sevoflurane|effect|but|carries (l_dobj) effect_8\NN\34213|the|convulsive|of (l_amod) convulsive_7\JJ\0|
D008012_D012640 CID lidocaine_5\NN\3681148| (r_npadvmod) induced_7\VBN\1627355|lidocaine|- (r_amod) convulsions_8\NNS\14081375|induced
D008012_D012640 CID lidocaine_5\NN\3681148| (r_npadvmod) induced_7\VBN\1627355|lidocaine|- (r_amod) convulsions_8\NNS\14081375|induced
D008012_D012640 CID lidocaine_16\NN\3681148| (r_compound) infusion_17\NN\14589223|lidocaine|(|mg.kg(-1).min(-1|) (r_pobj) with_15\IN\0|infusion (r_prep) was_8\VBD\0|threshold|+/-|)|with|)|,|increasing|. (l_nsubj) threshold_2\NN\15265518|the|convulsive|(|mean|) (l_amod) convulsive_1\JJ\0|
D008012_D012640 CID lidocaine_10\JJ\3681148| (r_compound) toxicity_11\NN\13576101|lidocaine (r_pobj) of_9\IN\0|toxicity (r_prep) effect_8\NN\34213|the|convulsive|of (l_amod) convulsive_7\JJ\0|
D004737_D012640 NONE enflurane_12\NN\3299929| (r_conj) sevoflurane_10\NN\0|and|enflurane (r_pobj) between_9\IN\0|sevoflurane (r_prep) threshold_8\NN\15265518|the|convulsive|between (l_amod) convulsive_7\JJ\0|
D004737_D012640 NONE enflurane_14\NN\3299929| (r_conj) sevoflurane_12\NN\0|or|enflurane (r_pobj) of_11\IN\0|sevoflurane (r_prep) concentrations_10\NNS\4916342|higher|of (r_nsubjpass) administered_16\VBN\2436349|when|concentrations|were|and|decreased (l_conj) decreased_23\VBD\169651|pressure|significantly|in|,|and|in (l_nsubj) pressure_20\NN\11419404|the|blood|at (l_prep) at_21\IN\14622893|convulsions (l_pobj) convulsions_22\NNS\14081375|
D004737_D012640 NONE enflurane_37\NN\3299929|% (r_conj) %_33\NN\0|0.8|and|enflurane (r_pobj) in_31\IN\13603305|% (r_conj) decreased_23\VBD\169651|pressure|significantly|in|,|and|in (l_nsubj) pressure_20\NN\11419404|the|blood|at (l_prep) at_21\IN\14622893|convulsions (l_pobj) convulsions_22\NNS\14081375|
D001030_D012640 NONE apamin_0\NNP\0|ng (r_nsubj) had_5\VBD\0|apamin|tendency|)|but|was (l_dobj) tendency_7\NN\6193203|a|decrease (l_acl) decrease_9\VB\7296428|to|threshold (l_dobj) threshold_12\NN\15265518|the|convulsive|(|+/-|) (l_amod) convulsive_11\JJ\0|
C009250_D064420 NONE sevoflurane_4\NN\0| (r_nsubj) reduces_5\VBZ\441445|that|sevoflurane|effect|but|carries (l_dobj) effect_8\NN\34213|the|convulsive|of (l_prep) of_9\IN\0|toxicity (l_pobj) toxicity_11\NN\13576101|lidocaine
C009250_D003866 NONE sevoflurane_4\NN\0| (r_nsubj) reduces_5\VBZ\441445|that|sevoflurane|effect|but|carries (l_conj) carries_13\VBZ\315986|risk|due (l_prep) due_16\IN\5174653|to (l_pcomp) to_17\IN\0|depression (l_pobj) depression_19\NN\14373582|circulatory
D008012_D064420 NONE lidocaine_10\JJ\3681148| (r_compound) toxicity_11\NN\13576101|lidocaine
D008012_D003866 NONE lidocaine_10\JJ\3681148| (r_compound) toxicity_11\NN\13576101|lidocaine (r_pobj) of_9\IN\0|toxicity (r_prep) effect_8\NN\34213|the|convulsive|of (r_dobj) reduces_5\VBZ\441445|that|sevoflurane|effect|but|carries (l_conj) carries_13\VBZ\315986|risk|due (l_prep) due_16\IN\5174653|to (l_pcomp) to_17\IN\0|depression (l_pobj) depression_19\NN\14373582|circulatory
6209318
D008801_D001145 NONE mexiletine_1\NN\2715941|and|placebo (r_nmod) trial_6\NN\786195|international|mexiletine|antiarrhythmic|coronary|:|report|. (l_appos) report_9\NNP\6470073|i.|on (l_prep) on_10\IN\0|arrhythmia (l_pobj) arrhythmia_11\NN\14103288|and|findings
D008801_D009203 NONE mexiletine_9\NN\2715941| (r_pobj) of_8\IN\0|mexiletine|perlongets (r_prep) form_7\NN\6286395|the|sustained|release|of (r_pobj) of_3\IN\0|form (r_prep) effects_2\NNS\13245626|the|antiarrhythmic|of (r_nsubjpass) evaluated_16\VBN\670261|effects|were|in|. (l_prep) in_17\IN\13603305|trial (l_pobj) trial_23\NN\786195|a|blind|placebo|in (l_prep) in_24\IN\13603305|patients (l_pobj) patients_26\NNS\9898892|630|with (l_prep) with_27\IN\0|infarction (l_pobj) infarction_31\NN\14204950|recent|documented|myocardial
D008801_D009203 NONE perlongets_13\NNP\0|(|mexitil|-|) (r_pobj) of_8\IN\0|mexiletine|perlongets (r_prep) form_7\NN\6286395|the|sustained|release|of (r_pobj) of_3\IN\0|form (r_prep) effects_2\NNS\13245626|the|antiarrhythmic|of (r_nsubjpass) evaluated_16\VBN\670261|effects|were|in|. (l_prep) in_17\IN\13603305|trial (l_pobj) trial_23\NN\786195|a|blind|placebo|in (l_prep) in_24\IN\13603305|patients (l_pobj) patients_26\NNS\9898892|630|with (l_prep) with_27\IN\0|infarction (l_pobj) infarction_31\NN\14204950|recent|documented|myocardial
D008801_D003643 NONE mexiletine_6\NN\2715941| (r_amod) group_7\NN\2137|the|mexiletine|(|%|) (r_pobj) in_4\IN\13603305|group (r_prep) deaths_3\NNS\7296428|more|in|than
D008801_D014202 CID mexiletine_16\NN\2715941| (r_amod) group_17\NN\2137|the|mexiletine (r_pobj) in_14\IN\13603305|group (r_prep) frequent_13\JJ\2556126|more|in|than (r_acomp) were_11\VBD\0|effects|frequent|. (l_nsubj) effects_3\NNS\13245626|recognized|side|,|tremor|, (l_appos) tremor_6\JJ\345926|particularly|and|problems
D008801_D012817 CID mexiletine_16\NN\2715941| (r_amod) group_17\NN\2137|the|mexiletine (r_pobj) in_14\IN\13603305|group (r_prep) frequent_13\JJ\2556126|more|in|than (r_acomp) were_11\VBD\0|effects|frequent|. (l_nsubj) effects_3\NNS\13245626|recognized|side|,|tremor|, (l_appos) tremor_6\JJ\345926|particularly|and|problems (l_conj) problems_9\NNS\14408086|gastrointestinal
2071257
D005997_D000647 NONE phosphorylcholine_8\NN\0|glyceryl|- (r_pobj) of_1\IN\0|phosphorylcholine (r_prep) effect_0\NN\34213|of|on|. (l_prep) on_9\IN\0|amnesia (l_pobj) amnesia_10\NN\5669934|caused
D012601_D000647 NONE scopolamine_13\NN\14712692| (r_pobj) by_12\IN\0|scopolamine (r_agent) caused_11\VBN\1617192|by (r_acl) amnesia_10\NN\5669934|caused
D005997_D008569 NONE glycerylphosphorylcholine_15\NN\0|l|-|alpha|-|gfc (r_pobj) of_10\IN\0|glycerylphosphorylcholine (r_prep) effects_9\NNS\13245626|the|of|on (l_prep) on_23\IN\0|impairment (l_pobj) impairment_25\NN\7296428|memory|induced
D005997_D008569 NONE gfc_21\NNP\0|(|l|-|alpha|-|) (r_appos) glycerylphosphorylcholine_15\NN\0|l|-|alpha|-|gfc (r_pobj) of_10\IN\0|glycerylphosphorylcholine (r_prep) effects_9\NNS\13245626|the|of|on (l_prep) on_23\IN\0|impairment (l_pobj) impairment_25\NN\7296428|memory|induced
D012601_D008569 CID scopolamine_28\NN\14712692|in (r_pobj) by_27\IN\0|scopolamine (r_agent) induced_26\VBN\1627355|by (r_acl) impairment_25\NN\7296428|memory|induced
D012601_D008569 CID scopolamine_20\NN\14712692| (r_pobj) by_19\IN\0|scopolamine (r_agent) induced_18\VBN\1627355|by (r_acl) impairment_13\NN\7296428|of|induced (l_prep) of_14\IN\0|attention (l_pobj) attention_15\NN\5701944|and|memory (l_conj) memory_17\NN\5926676|
17437408
D010862_D012640 CID pilocarpine_11\NN\14712692| (r_npadvmod) induced_13\VBN\1627355|pilocarpine|- (r_amod) seizures_14\NNS\14081375|induced|in
4812392
D001379_D011565 NONE azathioprine_4\NN\3740161| (r_pobj) with_3\IN\0|azathioprine (r_prep) psoriasis_2\NN\14219661|with
D001379_D011565 NONE azathioprine_0\JJ\3740161| (r_det) treatment_1\NN\654885|azathioprine (r_nsubj) benefited_2\VBD\2210855|treatment|%|out|. (l_prep) out_8\IN\66636|of (l_prep) of_9\IN\0|patients (l_pobj) patients_11\NNS\9898892|29|suffering (l_acl) suffering_12\VBG\14322699|from (l_prep) from_13\IN\0|psoriasis (l_pobj) psoriasis_15\NN\14219661|severe
D001379_D056486 NONE azathioprine_9\JJ\3740161| (r_amod) therapy_10\NN\657604|azathioprine (r_nsubjpass) continued_12\VBN\2367363|if|therapy|is|detected (l_advcl) detected_20\VBN\2163746|so|that|damage|may|be|at (l_nsubjpass) damage_17\NN\7296428|structural|liver
1786266
D000928_D001480 NONE antidepressant_3\NN\3740161| (r_compound) use_4\NN\407535|antidepressant|,|and|findings (r_conj) syndrome_1\NN\5870365|rabbit|,|use|.
12523465
C022189_D006212 CID zonisamide_4\NN\0| (r_pobj) with_3\IN\0|zonisamide (r_prep) associated_2\VBN\628491|with (r_acl) hallucinations_1\NNS\14376855|visual|associated|.
C022189_D006212 CID zonisamide_29\NN\0| (r_amod) treatment_30\NN\654885|zonisamide (r_pobj) after_28\IN\0|treatment (r_prep) altered_25\VBD\0|status|after (r_conj) experienced_20\VBD\2108377|who|hallucinations|and|altered (r_relcl) patients_18\NNS\9898892|three|experienced (r_dobj) describe_16\VBP\1001294|reported|,|we|patients|begun|. (l_advcl) reported_6\VBN\831651|although|hallucinations|have|not|been|as (l_nsubjpass) hallucinations_2\NNS\14376855|visual
C022189_D006212 CID zonisamide_29\NN\0| (r_amod) treatment_30\NN\654885|zonisamide (r_pobj) after_28\IN\0|treatment (r_prep) altered_25\VBD\0|status|after (r_conj) experienced_20\VBD\2108377|who|hallucinations|and|altered (l_dobj) hallucinations_23\NNS\14376855|complex|visual
C022189_D012640 NONE zonisamide_0\NNP\0| (r_nsubj) is_1\VBZ\0|zonisamide|drug|. (l_attr) drug_7\NN\14778436|a|spectrum|antiepileptic|used (l_acl) used_8\VBN\0|treat (l_xcomp) treat_10\VB\7570720|to|types (l_dobj) types_12\NNS\5839024|various|of (l_prep) of_13\IN\0|seizures (l_pobj) seizures_14\NNS\14081375|
2355241
D007980_D002543 NONE levodopa_23\NN\14604959| (r_pobj) of_22\IN\0|levodopa (r_prep) effect_21\NN\34213|the|hypotensive|of|and|mechanism (r_dobj) reflect_18\VB\923793|incidence|may|effect|. (l_nsubj) incidence_2\NN\13821570|the|low|of|as (l_prep) of_3\IN\0|haemorrhage (l_pobj) haemorrhage_5\NN\14285662|cerebral
D007980_D003643 NONE levodopa_23\NN\14604959| (r_pobj) of_22\IN\0|levodopa (r_prep) effect_21\NN\34213|the|hypotensive|of|and|mechanism (r_dobj) reflect_18\VB\923793|incidence|may|effect|. (l_nsubj) incidence_2\NN\13821570|the|low|of|as (l_prep) as_6\IN\14622893|cause (l_pobj) cause_8\NN\7323922|a|of|in (l_prep) of_9\IN\0|death (l_pobj) death_10\NN\7296428|
D007980_D010300 NONE levodopa_23\NN\14604959| (r_pobj) of_22\IN\0|levodopa (r_prep) effect_21\NN\34213|the|hypotensive|of|and|mechanism (r_dobj) reflect_18\VB\923793|incidence|may|effect|. (l_nsubj) incidence_2\NN\13821570|the|low|of|as (l_prep) as_6\IN\14622893|cause (l_pobj) cause_8\NN\7323922|a|of|in (l_prep) in_11\IN\13603305|patients (l_pobj) patients_12\NNS\9898892|with (l_prep) with_13\IN\0|disease (l_pobj) disease_16\NN\14061805|parkinson
D007980_D010300 NONE levodopa_23\NN\14604959| (r_pobj) of_22\IN\0|levodopa (r_prep) effect_21\NN\34213|the|hypotensive|of|and|mechanism (l_conj) mechanism_27\NN\13446390|a|hypotensive|due (l_amod) due_28\IN\5174653|to|levels (l_pobj) levels_32\NNS\4916342|reduced|noradrenaline|in (l_prep) in_33\IN\13603305|brain (l_pobj) brain_36\NN\5462674|the|parkinsonian (l_amod) parkinsonian_35\JJ\0|
D007980_D007022 CID levodopa_23\NN\14604959| (r_pobj) of_22\IN\0|levodopa (r_prep) effect_21\NN\34213|the|hypotensive|of|and|mechanism (l_amod) hypotensive_20\JJ\10405694|
D007980_D007022 CID levodopa_23\NN\14604959| (r_pobj) of_22\IN\0|levodopa (r_prep) effect_21\NN\34213|the|hypotensive|of|and|mechanism (l_conj) mechanism_27\NN\13446390|a|hypotensive|due (l_amod) hypotensive_26\JJ\10405694|
D009638_D002543 NONE noradrenaline_31\NN\14807929| (r_amod) levels_32\NNS\4916342|reduced|noradrenaline|in (r_pobj) due_28\IN\5174653|to|levels (r_amod) mechanism_27\NN\13446390|a|hypotensive|due (r_conj) effect_21\NN\34213|the|hypotensive|of|and|mechanism (r_dobj) reflect_18\VB\923793|incidence|may|effect|. (l_nsubj) incidence_2\NN\13821570|the|low|of|as (l_prep) of_3\IN\0|haemorrhage (l_pobj) haemorrhage_5\NN\14285662|cerebral
D009638_D003643 NONE noradrenaline_31\NN\14807929| (r_amod) levels_32\NNS\4916342|reduced|noradrenaline|in (r_pobj) due_28\IN\5174653|to|levels (r_amod) mechanism_27\NN\13446390|a|hypotensive|due (r_conj) effect_21\NN\34213|the|hypotensive|of|and|mechanism (r_dobj) reflect_18\VB\923793|incidence|may|effect|. (l_nsubj) incidence_2\NN\13821570|the|low|of|as (l_prep) as_6\IN\14622893|cause (l_pobj) cause_8\NN\7323922|a|of|in (l_prep) of_9\IN\0|death (l_pobj) death_10\NN\7296428|
D009638_D010300 NONE noradrenaline_31\NN\14807929| (r_amod) levels_32\NNS\4916342|reduced|noradrenaline|in (r_pobj) due_28\IN\5174653|to|levels (r_amod) mechanism_27\NN\13446390|a|hypotensive|due (r_conj) effect_21\NN\34213|the|hypotensive|of|and|mechanism (r_dobj) reflect_18\VB\923793|incidence|may|effect|. (l_nsubj) incidence_2\NN\13821570|the|low|of|as (l_prep) as_6\IN\14622893|cause (l_pobj) cause_8\NN\7323922|a|of|in (l_prep) in_11\IN\13603305|patients (l_pobj) patients_12\NNS\9898892|with (l_prep) with_13\IN\0|disease (l_pobj) disease_16\NN\14061805|parkinson
D009638_D010300 NONE noradrenaline_31\NN\14807929| (r_amod) levels_32\NNS\4916342|reduced|noradrenaline|in (l_prep) in_33\IN\13603305|brain (l_pobj) brain_36\NN\5462674|the|parkinsonian (l_amod) parkinsonian_35\JJ\0|
D009638_D007022 NONE noradrenaline_31\NN\14807929| (r_amod) levels_32\NNS\4916342|reduced|noradrenaline|in (r_pobj) due_28\IN\5174653|to|levels (r_amod) mechanism_27\NN\13446390|a|hypotensive|due (r_conj) effect_21\NN\34213|the|hypotensive|of|and|mechanism (l_amod) hypotensive_20\JJ\10405694|
D009638_D007022 NONE noradrenaline_31\NN\14807929| (r_amod) levels_32\NNS\4916342|reduced|noradrenaline|in (r_pobj) due_28\IN\5174653|to|levels (r_amod) mechanism_27\NN\13446390|a|hypotensive|due (l_amod) hypotensive_26\JJ\10405694|
1378968
D008094_D007676 CID lithium_8\NN\14625458| (r_npadvmod) induced_10\VBN\1627355|lithium|- (r_amod) failure_13\NN\66216|induced|chronic|renal|in
D008094_D007674 NONE lithium_2\NN\14625458| (r_npadvmod) induced_4\VBN\1627355|lithium|- (r_amod) nephropathy_5\NN\14573196|induced
D008094_D007674 NONE li_4\NNP\14625458| (r_npadvmod) induced_6\VBN\1627355|li|- (r_amod) nephropathy_7\NN\14573196|induced|,|reduced|,
D008094_D051437 NONE lithium_2\NN\14625458| (r_npadvmod) induced_4\VBN\1627355|lithium|- (r_amod) nephropathy_5\NN\14573196|induced (r_pobj) with_1\IN\0|nephropathy (r_prep) rats_0\NNS\2329401|with (r_nsubjpass) subjected_7\VBN\137313|rats|were|to|,|in|. (l_prep) in_26\IN\13603305|attempt (l_pobj) attempt_28\NN\407535|an|induce (l_acl) induce_30\VB\1627355|to|hyperfiltration (l_dobj) hyperfiltration_32\NN\0|glomerular|and|progression (l_conj) progression_35\NN\8457976|further|of (l_prep) of_36\IN\0|failure (l_pobj) failure_38\NN\66216|renal
D008094_D051437 NONE lithium_21\NN\14625458| (r_nmod) rats_23\NNS\2329401|lithium|pretreated (r_pobj) in_20\IN\13603305|rats (r_prep) levels_19\NNS\4916342|plasma|creatinine|in (r_dobj) decrease_16\NN\7296428|levels (r_conj) increase_13\VB\13576355|to|gfr|decrease (r_xcomp) tended_11\VBD\2604760|in|increase|. (r_conj) failed_1\VBD\0|hp|accentuante|and|tended (l_xcomp) accentuante_3\NN\0|to|progression (l_dobj) progression_4\NN\8457976|of (l_prep) of_5\IN\0|failure (l_pobj) failure_7\NN\66216|renal
D008094_D011507 CID lithium_0\NN\14625458| (r_nsubj) caused_2\VBD\1617192|lithium|also|proteinuria|in|. (l_dobj) proteinuria_3\NN\14299637|and|hypertension
D008094_D011507 CID li_4\NNP\14625458| (r_npadvmod) induced_6\VBN\1627355|li|- (r_amod) nephropathy_7\NN\14573196|induced|,|reduced|, (r_nsubjpass) associated_19\VBN\628491|that|nephropathy|is|with (l_prep) with_20\IN\0|proteinuria (l_pobj) proteinuria_21\NN\14299637|and|hypertension
D008094_D006973 CID lithium_0\NN\14625458| (r_nsubj) caused_2\VBD\1617192|lithium|also|proteinuria|in|. (l_dobj) proteinuria_3\NN\14299637|and|hypertension (l_conj) hypertension_6\NN\14057371|systolic
D008094_D006973 CID li_4\NNP\14625458| (r_npadvmod) induced_6\VBN\1627355|li|- (r_amod) nephropathy_7\NN\14573196|induced|,|reduced|, (r_nsubjpass) associated_19\VBN\628491|that|nephropathy|is|with (l_prep) with_20\IN\0|proteinuria (l_pobj) proteinuria_21\NN\14299637|and|hypertension (l_conj) hypertension_25\NN\14057371|arterial|systolic
D008094_D005921 NONE lithium_0\NN\14625458| (r_nsubj) caused_2\VBD\1617192|lithium|also|proteinuria|in|. (l_prep) in_7\IN\13603305|absence (l_pobj) absence_8\NN\14449405|of (l_prep) of_9\IN\0|glomerulosclerosis (l_pobj) glomerulosclerosis_10\NN\0|
D003404_D051437 NONE creatinine_18\NN\0| (r_compound) levels_19\NNS\4916342|plasma|creatinine|in (r_dobj) decrease_16\NN\7296428|levels (r_conj) increase_13\VB\13576355|to|gfr|decrease (r_xcomp) tended_11\VBD\2604760|in|increase|. (r_conj) failed_1\VBD\0|hp|accentuante|and|tended (l_xcomp) accentuante_3\NN\0|to|progression (l_dobj) progression_4\NN\8457976|of (l_prep) of_5\IN\0|failure (l_pobj) failure_7\NN\66216|renal
9766615
D003024_D001480 NONE clozapine_40\NN\3713736|primarily (r_appos) threshold_37\NN\15265518|seizure|(|clozapine|) (r_dobj) lowered_35\VBD\1850315|effects|threshold|,|and|agranulocytosis (r_conj) associated_13\VBN\628491|are|in|,|lowered (r_conj) have_4\VBP\7846|agents|risk|,|but|associated|. (l_dobj) risk_7\NN\14541044|a|lower|of (l_prep) of_8\IN\0|eps (l_pobj) eps_9\NNP\0|
D003024_D001480 NONE clozapine_46\NN\3713736|(|only|) (r_appos) agranulocytosis_44\NN\14189204|clozapine (r_conj) lowered_35\VBD\1850315|effects|threshold|,|and|agranulocytosis (r_conj) associated_13\VBN\628491|are|in|,|lowered (r_conj) have_4\VBP\7846|agents|risk|,|but|associated|. (l_dobj) risk_7\NN\14541044|a|lower|of (l_prep) of_8\IN\0|eps (l_pobj) eps_9\NNP\0|
D003024_D015430 NONE clozapine_40\NN\3713736|primarily (r_appos) threshold_37\NN\15265518|seizure|(|clozapine|) (r_dobj) lowered_35\VBD\1850315|effects|threshold|,|and|agranulocytosis (l_nsubj) effects_21\NNS\13245626|cardiovascular|,|effects|, (l_conj) effects_24\NNS\13245626|anticholinergic|,|gain (l_conj) gain_27\NN\13576355|weight|,|dysfunction
D003024_D015430 NONE clozapine_46\NN\3713736|(|only|) (r_appos) agranulocytosis_44\NN\14189204|clozapine (r_conj) lowered_35\VBD\1850315|effects|threshold|,|and|agranulocytosis (l_nsubj) effects_21\NNS\13245626|cardiovascular|,|effects|, (l_conj) effects_24\NNS\13245626|anticholinergic|,|gain (l_conj) gain_27\NN\13576355|weight|,|dysfunction
D003024_D012735 NONE clozapine_40\NN\3713736|primarily (r_appos) threshold_37\NN\15265518|seizure|(|clozapine|) (r_dobj) lowered_35\VBD\1850315|effects|threshold|,|and|agranulocytosis (l_nsubj) effects_21\NNS\13245626|cardiovascular|,|effects|, (l_conj) effects_24\NNS\13245626|anticholinergic|,|gain (l_conj) gain_27\NN\13576355|weight|,|dysfunction (l_conj) dysfunction_30\NN\14204950|sexual|,|effects
D003024_D012735 NONE clozapine_46\NN\3713736|(|only|) (r_appos) agranulocytosis_44\NN\14189204|clozapine (r_conj) lowered_35\VBD\1850315|effects|threshold|,|and|agranulocytosis (l_nsubj) effects_21\NNS\13245626|cardiovascular|,|effects|, (l_conj) effects_24\NNS\13245626|anticholinergic|,|gain (l_conj) gain_27\NN\13576355|weight|,|dysfunction (l_conj) dysfunction_30\NN\14204950|sexual|,|effects
D003024_D012640 NONE clozapine_40\NN\3713736|primarily (r_appos) threshold_37\NN\15265518|seizure|(|clozapine|) (l_compound) seizure_36\NN\14081375|
D003024_D012640 NONE clozapine_46\NN\3713736|(|only|) (r_appos) agranulocytosis_44\NN\14189204|clozapine (r_conj) lowered_35\VBD\1850315|effects|threshold|,|and|agranulocytosis (l_dobj) threshold_37\NN\15265518|seizure|(|clozapine|) (l_compound) seizure_36\NN\14081375|
D003024_D000380 CID clozapine_40\NN\3713736|primarily (r_appos) threshold_37\NN\15265518|seizure|(|clozapine|) (r_dobj) lowered_35\VBD\1850315|effects|threshold|,|and|agranulocytosis (l_conj) agranulocytosis_44\NN\14189204|clozapine
D003024_D000380 CID clozapine_46\NN\3713736|(|only|) (r_appos) agranulocytosis_44\NN\14189204|clozapine
15899738
D003401_D001281 CID creatine_5\NN\14601829| (r_compound) supplementation_7\NN\5108947|creatine|monohydrate (r_pobj) with_4\IN\0|supplementation (r_prep) associated_3\VBN\628491|with (r_acl) fibrillation_2\NN\14361664|lone|atrial|associated|.
D003401_D001145 NONE creatine_5\NN\14601829|to (l_prep) to_6\IN\0|development (l_pobj) development_8\NN\248977|the|of (l_prep) of_9\IN\0|arrhythmia (l_pobj) arrhythmia_10\NN\14103288|
1992636
D009853_D000743 CID omeprazole_7\NN\14778019| (r_pobj) of_6\IN\0|omeprazole (r_prep) use_5\NN\407535|the|of (r_pobj) with_3\IN\0|use (r_prep) associated_2\VBN\628491|with (r_acl) anemia_1\NN\14189204|hemolytic|associated|.
D009853_D000743 CID omeprazole_17\NN\14778019| (r_pobj) of_16\IN\0|omeprazole (r_prep) use_15\NN\407535|the|of (r_pobj) with_13\IN\0|use (r_prep) reaction_12\NN\13446390|a|serious|term|adverse|with (r_pobj) of_5\IN\0|reaction (r_prep) case_4\NN\7283608|the|first|of|:|anemia (l_appos) anemia_20\NN\14189204|hemolytic
D009853_D000743 CID omeprazole_4\NN\14778019| (r_nsubj) caused_5\VBD\1617192|by|omeprazole|is (l_ccomp) is_11\VBZ\0|anemia|uncertain (l_nsubj) anemia_10\NN\14189204|patient|hemolytic
D009853_D053609 CID omeprazole_17\NN\14778019| (r_pobj) with_16\IN\0|omeprazole (r_prep) starting_14\VBG\457382|therapy|with (r_pcomp) after_13\IN\0|days|starting (r_prep) weakness_3\NN\14462666|developed|,|lethargy|after|. (l_conj) lethargy_5\NN\14014621|,|and|shortness
D009853_D004417 CID omeprazole_17\NN\14778019| (r_pobj) with_16\IN\0|omeprazole (r_prep) starting_14\VBG\457382|therapy|with (r_pcomp) after_13\IN\0|days|starting (r_prep) weakness_3\NN\14462666|developed|,|lethargy|after|. (l_conj) lethargy_5\NN\14014621|,|and|shortness (l_conj) shortness_8\NN\5129201|of (l_prep) of_9\IN\0|breath (l_pobj) breath_10\NN\13440063|
2951327
D009638_D013610 NONE norepinephrine_76\NN\14807929| (r_amod) rate_78\NN\13815152|the|norepinephrine|release|( (r_pobj) of_74\IN\0|rate (r_prep) augmentation_73\NN\7356676|no|of (r_conj) tachycardia_70\NN\14110674|no|and|augmentation|min|)
D009638_D007022 NONE norepinephrine_76\NN\14807929| (r_amod) rate_78\NN\13815152|the|norepinephrine|release|( (r_pobj) of_74\IN\0|rate (r_prep) augmentation_73\NN\7356676|no|of (r_conj) tachycardia_70\NN\14110674|no|and|augmentation|min|) (r_conj) +/-_45\NN\0|93|1|p|,|or|%|but|tachycardia (r_appos) was_29\VBD\0|pressure|+/-|,|+/-|observed|. (l_conj) observed_90\VBN\2163746|were|,|is (l_advcl) is_93\VBZ\0|which|in (l_prep) in_94\IN\13603305|contrast (l_pobj) contrast_95\NN\13854649|to (l_prep) to_96\IN\0|hypotension (l_pobj) hypotension_98\NN\14057371|comparable|induced
D006830_D013610 NONE hydralazine_101\NN\2721160|or|nitroglycerin (r_pobj) by_100\IN\0|hydralazine (r_agent) induced_99\VBN\1627355|by (r_acl) hypotension_98\NN\14057371|comparable|induced (r_pobj) to_96\IN\0|hypotension (r_prep) contrast_95\NN\13854649|to (r_pobj) in_94\IN\13603305|contrast (r_prep) is_93\VBZ\0|which|in (r_advcl) observed_90\VBN\2163746|were|,|is (r_conj) was_29\VBD\0|pressure|+/-|,|+/-|observed|. (l_appos) +/-_45\NN\0|93|1|p|,|or|%|but|tachycardia (l_conj) tachycardia_70\NN\14110674|no|and|augmentation|min|)
D006830_D007022 CID hydralazine_101\NN\2721160|or|nitroglycerin (r_pobj) by_100\IN\0|hydralazine (r_agent) induced_99\VBN\1627355|by (r_acl) hypotension_98\NN\14057371|comparable|induced
D005996_D013610 NONE nitroglycerin_103\NN\15015501| (r_conj) hydralazine_101\NN\2721160|or|nitroglycerin (r_pobj) by_100\IN\0|hydralazine (r_agent) induced_99\VBN\1627355|by (r_acl) hypotension_98\NN\14057371|comparable|induced (r_pobj) to_96\IN\0|hypotension (r_prep) contrast_95\NN\13854649|to (r_pobj) in_94\IN\13603305|contrast (r_prep) is_93\VBZ\0|which|in (r_advcl) observed_90\VBN\2163746|were|,|is (r_conj) was_29\VBD\0|pressure|+/-|,|+/-|observed|. (l_appos) +/-_45\NN\0|93|1|p|,|or|%|but|tachycardia (l_conj) tachycardia_70\NN\14110674|no|and|augmentation|min|)
D005996_D007022 CID nitroglycerin_103\NN\15015501| (r_conj) hydralazine_101\NN\2721160|or|nitroglycerin (r_pobj) by_100\IN\0|hydralazine (r_agent) induced_99\VBN\1627355|by (r_acl) hypotension_98\NN\14057371|comparable|induced
10669626
D014859_D061205 CID warfarin_0\NNP\2718259| (r_npadvmod) induced_2\VBN\1627355|warfarin|- (r_amod) calcification_4\NN\13446390|induced|artery
D014859_D061205 CID warfarin_22\NNP\2718259| (r_pobj) of_21\IN\0|warfarin (r_prep) doses_20\NNS\3740161|sufficient|of (r_dobj) given_18\VBN\5892096|doses|inhibit (r_prep) enhance_10\VB\227165|that|treatment|extent|given (l_dobj) extent_12\NN\13939892|the|of (l_prep) of_13\IN\0|calcification (l_pobj) calcification_15\NN\13446390|artery|in
D014859_D061205 CID warfarin_17\NNP\2718259| (r_npadvmod) treated_19\VBN\2376958|warfarin|- (r_amod) rats_20\NNS\2329401|treated (r_pobj) in_16\IN\13603305|rats (r_prep) calcification_15\NN\13446390|artery|in
D014859_D061205 CID warfarin_5\NNP\2718259| (r_pobj) with_4\IN\0|warfarin (r_prep) treatment_0\NN\654885|for|with (r_nsubj) caused_6\VBD\1617192|treatment|calcification|. (l_dobj) calcification_9\NN\13446390|massive|focal|of|in|and|calcification (l_prep) of_10\IN\0|media (l_pobj) media_13\NNS\3575240|the|artery (l_compound) artery_12\NN\5417975|
D014859_D061205 CID warfarin_20\NNP\2718259| (r_compound) treatment_21\NN\654885|warfarin (r_pobj) of_19\IN\0|treatment (r_prep) weeks_18\NNS\15113229|4|of (r_pobj) after_16\IN\0|even|weeks (r_prep) detected_8\VBN\2163746|in|,|calcification|could|be|in|after|. (l_nsubjpass) calcification_5\NN\13446390|no|artery
D014859_D061205 CID warfarin_8\NNP\2718259| (r_npadvmod) induced_10\VBN\1627355|warfarin|- (r_amod) calcification_12\NN\13446390|induced|artery|in
D014859_D061205 CID warfarin_7\NNP\2718259| (r_pobj) with_6\IN\0|warfarin (r_prep) groups_5\NNS\2137|both|dietary|with (r_pobj) of_2\IN\0|groups (r_prep) treatment_1\NN\654885|concurrent|of (r_nsubj) produced_8\VBD\1617192|treatment|calcification|. (l_dobj) calcification_11\NN\13446390|massive|focal|of|in|but|calcification (l_prep) of_12\IN\0|media (l_pobj) media_15\NNS\3575240|the|artery (l_compound) artery_14\NN\5417975|
D014859_D061205 CID warfarin_7\NNP\2718259| (r_pobj) with_6\IN\0|warfarin (r_prep) groups_5\NNS\2137|both|dietary|with (r_pobj) of_2\IN\0|groups (r_prep) treatment_1\NN\654885|concurrent|of (r_nsubj) produced_8\VBD\1617192|treatment|calcification|. (l_dobj) calcification_11\NN\13446390|massive|focal|of|in|but|calcification (l_conj) calcification_27\NN\13446390|no|detectable|artery|in
D014859_D061205 CID warfarin_61\NNP\2718259| (r_npadvmod) induced_63\VBN\1627355|warfarin|- (r_amod) calcification_65\NN\13446390|induced|artery (r_pobj) to_60\IN\0|calcification (r_prep) resistant_59\JJ\0|to (r_acomp) was_58\VBD\0|that|resistant (r_relcl) groups_56\NNS\2137|the|was (r_pobj) of_54\IN\0|groups (r_prep) either_53\DT\0|of (r_pobj) with_52\IN\0|either (r_prep) compared_51\VBN\644583|with|rats (r_prep) rats_50\NNS\2329401|ad|fed|compared (r_appos) relationship_24\NN\31921|a|between|,|with|,|rats (r_attr) was_22\VBD\0|determined|,|there|relationship|. (l_advcl) determined_15\VBN\0|although|explanation|can|not|be|from (l_nsubjpass) explanation_2\NN\6722453|the|for (l_prep) for_3\IN\0|association (l_pobj) association_5\NN\8008335|the|between (l_prep) between_6\IN\0|calcification (l_pobj) calcification_8\NN\13446390|artery|and|status
D014859_D061205 CID warfarin_61\NNP\2718259| (r_npadvmod) induced_63\VBN\1627355|warfarin|- (r_amod) calcification_65\NN\13446390|induced|artery (r_pobj) to_60\IN\0|calcification (r_prep) resistant_59\JJ\0|to (r_acomp) was_58\VBD\0|that|resistant (r_relcl) groups_56\NNS\2137|the|was (r_pobj) of_54\IN\0|groups (r_prep) either_53\DT\0|of (r_pobj) with_52\IN\0|either (r_prep) compared_51\VBN\644583|with|rats (r_prep) rats_50\NNS\2329401|ad|fed|compared (r_appos) relationship_24\NN\31921|a|between|,|with|,|rats (l_prep) between_25\IN\0|phosphate (l_pobj) phosphate_28\NN\15010703|higher|serum|and|susceptibility (l_conj) susceptibility_30\NN\13920835|to (l_prep) to_31\IN\0|calcification (l_pobj) calcification_33\NN\13446390|artery
D014859_D061205 CID warfarin_61\NNP\2718259| (r_npadvmod) induced_63\VBN\1627355|warfarin|- (r_amod) calcification_65\NN\13446390|induced|artery
D014859_D061205 CID warfarin_7\NNP\2718259| (r_npadvmod) induced_9\VBN\1627355|warfarin|- (r_amod) calcification_11\NN\13446390|induced|artery
D014859_D061205 CID warfarin_13\NNP\2718259| (r_conj) d_11\NN\15089472|vitamin|and|warfarin (r_pobj) between_9\IN\0|d (r_prep) synergy_8\NN\13518963|the|possible|between|in (l_prep) in_14\IN\13603305|calcification (l_pobj) calcification_16\NN\13446390|artery
D014859_D061205 CID warfarin_0\NNP\2718259| (r_nsubjpass) known_3\VBN\0|warfarin|are|also|cause|,|but|at|. (l_xcomp) cause_5\VB\7323922|to|calcification (l_dobj) calcification_6\NN\13446390|of (l_prep) of_7\IN\0|media (l_pobj) media_10\NNS\3575240|the|artery (l_compound) artery_9\NN\5417975|
D014859_D061205 CID warfarin_20\NNP\2718259| (r_conj) d_18\NNP\15089472|vitamin|plus|warfarin (r_pobj) with_16\IN\0|d (r_prep) treated_15\VBN\2376958|with (r_acl) rats_14\NNS\2329401|treated (r_pobj) in_13\IN\13603305|rats (r_prep) calcification_12\NN\13446390|artery|in
D014807_D061205 NONE d._11\NNP\0| (r_conj) growth_8\NN\13526110|and|vitamin|d. (r_pobj) by_7\IN\0|growth (r_agent) accelerated_6\VBN\226566|calcification|is|by (l_nsubjpass) calcification_4\NN\13446390|induced|artery
D014807_D061205 NONE d_8\JJ\15089472|vitamin (r_conj) growth_5\NN\13526110|and|d (r_nmod) treatment_9\NN\654885|growth (r_nsubj) enhance_10\VB\227165|that|treatment|extent|given (l_dobj) extent_12\NN\13939892|the|of (l_prep) of_13\IN\0|calcification (l_pobj) calcification_15\NN\13446390|artery|in
D014807_D061205 NONE d_11\NN\15089472|vitamin|and|warfarin (r_pobj) between_9\IN\0|d (r_prep) synergy_8\NN\13518963|the|possible|between|in (l_prep) in_14\IN\13603305|calcification (l_pobj) calcification_16\NN\13446390|artery
D014807_D061205 NONE d_4\NNP\15089472|vitamin (r_pobj) of_2\IN\0|d (r_prep) doses_1\NNS\3740161|high|of (r_nsubjpass) known_6\VBN\0|doses|are|cause|. (l_xcomp) cause_8\VB\7323922|to|calcification|in (l_dobj) calcification_9\NN\13446390|of (l_prep) of_10\IN\0|media (l_pobj) media_13\NNS\3575240|the|artery (l_compound) artery_12\NN\5417975|
D014807_D061205 NONE d_10\NN\15089472|vitamin (r_compound) dose_11\NN\3740161|d|on (l_prep) on_12\IN\0|calcification (l_pobj) calcification_14\NN\13446390|artery
D014807_D061205 NONE d_10\NN\15089472|vitamin (r_compound) dose_11\NN\3740161|d|on (r_pobj) of_8\IN\0|dose (r_prep) effect_7\NN\34213|the|of|and|effect (l_conj) effect_17\NN\34213|the|of (l_prep) of_18\IN\0|dose (l_pobj) dose_21\NN\3740161|d|on (l_prep) on_22\IN\0|elevation (l_pobj) elevation_24\NN\7445480|the|of|,|suggests (l_relcl) suggests_30\VBZ\1010118|which|induce (l_ccomp) induce_35\VB\1627355|that|d|may|calcification|through (l_dobj) calcification_37\NN\13446390|artery
D014807_D061205 NONE d_20\NNP\15089472|vitamin (r_compound) dose_21\NN\3740161|d|on (r_pobj) of_18\IN\0|dose (r_prep) effect_17\NN\34213|the|of (r_conj) effect_7\NN\34213|the|of|and|effect (l_prep) of_8\IN\0|dose (l_pobj) dose_11\NN\3740161|d|on (l_prep) on_12\IN\0|calcification (l_pobj) calcification_14\NN\13446390|artery
D014807_D061205 NONE d_20\NNP\15089472|vitamin (r_compound) dose_21\NN\3740161|d|on (l_prep) on_22\IN\0|elevation (l_pobj) elevation_24\NN\7445480|the|of|,|suggests (l_relcl) suggests_30\VBZ\1010118|which|induce (l_ccomp) induce_35\VB\1627355|that|d|may|calcification|through (l_dobj) calcification_37\NN\13446390|artery
D014807_D061205 NONE d_33\NN\15089472|vitamin (r_nsubj) induce_35\VB\1627355|that|d|may|calcification|through (r_ccomp) suggests_30\VBZ\1010118|which|induce (r_relcl) elevation_24\NN\7445480|the|of|,|suggests (r_pobj) on_22\IN\0|elevation (r_prep) dose_21\NN\3740161|d|on (r_pobj) of_18\IN\0|dose (r_prep) effect_17\NN\34213|the|of (r_conj) effect_7\NN\34213|the|of|and|effect (l_prep) of_8\IN\0|dose (l_pobj) dose_11\NN\3740161|d|on (l_prep) on_12\IN\0|calcification (l_pobj) calcification_14\NN\13446390|artery
D014807_D061205 NONE d_33\NN\15089472|vitamin (r_nsubj) induce_35\VB\1627355|that|d|may|calcification|through (l_dobj) calcification_37\NN\13446390|artery
D014807_D061205 NONE d_18\NNP\15089472|vitamin|plus|warfarin (r_pobj) with_16\IN\0|d (r_prep) treated_15\VBN\2376958|with (r_acl) rats_14\NNS\2329401|treated (r_pobj) in_13\IN\13603305|rats (r_prep) calcification_12\NN\13446390|artery|in
D014807_D002114 NONE d_8\JJ\15089472|vitamin (r_conj) growth_5\NN\13526110|and|d (r_nmod) treatment_9\NN\654885|growth (r_nsubj) enhance_10\VB\227165|that|treatment|extent|given (l_prep) given_18\VBN\5892096|doses|inhibit (l_advcl) inhibit_24\VB\2510337|to|carboxylation (l_dobj) carboxylation_27\NN\0|gamma|-|of (l_prep) of_28\IN\0|protein (l_pobj) protein_31\NN\14944888|matrix|gla|,|inhibitor (l_appos) inhibitor_35\NN\20090|calcification|known (l_compound) calcification_34\NN\13446390|a
D014807_D002114 NONE d_30\NN\15089472| (r_npadvmod) treated_32\VBN\2376958|d|- (r_amod) rats_33\NNS\2329401|vitamin|treated (r_pobj) of_28\IN\0|rats (r_prep) media_27\NNS\3575240|the|of (r_pobj) in_25\IN\13603305|media (r_prep) calcification_24\NN\13446390|in|at
D014807_D002114 NONE d_15\NN\15089472|vitamin|,|synergy (r_pobj) by_13\IN\0|d (r_agent) produced_12\VBN\1617192|by (r_acl) calcium_11\NN\14625458|serum|produced (r_pobj) in_9\IN\13603305|calcium (r_prep) elevation_8\NN\7445480|the|in (r_pobj) on_6\IN\0|elevation (r_prep) effect_5\NN\34213|no|on (r_dobj) had_3\VBD\0|because|treatment|effect (r_advcl) explained_27\VBN\831651|had|is|probably|best|by|. (l_agent) by_28\IN\0|hypothesis (l_pobj) hypothesis_30\NN\7162194|the|inhibits (l_acl) inhibits_33\VBZ\2510337|that|warfarin|activity|as (l_prep) as_40\IN\14622893|inhibitor (l_pobj) inhibitor_43\NN\20090|a|calcification (l_compound) calcification_42\NN\13446390|
D014807_D002114 NONE d_23\NN\15089472|warfarin (r_pobj) between_19\IN\0|d (r_prep) synergy_18\NN\13518963|the|between (r_appos) d_15\NN\15089472|vitamin|,|synergy (r_pobj) by_13\IN\0|d (r_agent) produced_12\VBN\1617192|by (r_acl) calcium_11\NN\14625458|serum|produced (r_pobj) in_9\IN\13603305|calcium (r_prep) elevation_8\NN\7445480|the|in (r_pobj) on_6\IN\0|elevation (r_prep) effect_5\NN\34213|no|on (r_dobj) had_3\VBD\0|because|treatment|effect (r_advcl) explained_27\VBN\831651|had|is|probably|best|by|. (l_agent) by_28\IN\0|hypothesis (l_pobj) hypothesis_30\NN\7162194|the|inhibits (l_acl) inhibits_33\VBZ\2510337|that|warfarin|activity|as (l_prep) as_40\IN\14622893|inhibitor (l_pobj) inhibitor_43\NN\20090|a|calcification (l_compound) calcification_42\NN\13446390|
D014859_D002114 NONE warfarin_22\NNP\2718259| (r_pobj) of_21\IN\0|warfarin (r_prep) doses_20\NNS\3740161|sufficient|of (r_dobj) given_18\VBN\5892096|doses|inhibit (l_advcl) inhibit_24\VB\2510337|to|carboxylation (l_dobj) carboxylation_27\NN\0|gamma|-|of (l_prep) of_28\IN\0|protein (l_pobj) protein_31\NN\14944888|matrix|gla|,|inhibitor (l_appos) inhibitor_35\NN\20090|calcification|known (l_compound) calcification_34\NN\13446390|a
D014859_D002114 NONE warfarin_5\NNP\2718259| (r_pobj) with_4\IN\0|warfarin (r_prep) treatment_0\NN\654885|for|with (r_nsubj) caused_6\VBD\1617192|treatment|calcification|. (l_dobj) calcification_9\NN\13446390|massive|focal|of|in|and|calcification (l_conj) calcification_23\NN\13446390|less|extensive|focal|in
D014859_D002114 NONE warfarin_17\NNP\2718259| (r_compound) administration_18\NN\1133281|concurrent|warfarin (r_nsubj) increased_20\VBD\169651|that|administration|dramatically|extent (l_dobj) extent_22\NN\13939892|the|of (l_prep) of_23\IN\0|calcification (l_pobj) calcification_24\NN\13446390|in|at
D014859_D002114 NONE warfarin_1\NNP\2718259| (r_compound) treatment_2\NN\654885|warfarin (r_nsubj) had_3\VBD\0|because|treatment|effect (r_advcl) explained_27\VBN\831651|had|is|probably|best|by|. (l_agent) by_28\IN\0|hypothesis (l_pobj) hypothesis_30\NN\7162194|the|inhibits (l_acl) inhibits_33\VBZ\2510337|that|warfarin|activity|as (l_prep) as_40\IN\14622893|inhibitor (l_pobj) inhibitor_43\NN\20090|a|calcification (l_compound) calcification_42\NN\13446390|
D014859_D002114 NONE warfarin_20\NNP\2718259|and|vitamin (r_nmod) d_23\NN\15089472|warfarin (r_pobj) between_19\IN\0|d (r_prep) synergy_18\NN\13518963|the|between (r_appos) d_15\NN\15089472|vitamin|,|synergy (r_pobj) by_13\IN\0|d (r_agent) produced_12\VBN\1617192|by (r_acl) calcium_11\NN\14625458|serum|produced (r_pobj) in_9\IN\13603305|calcium (r_prep) elevation_8\NN\7445480|the|in (r_pobj) on_6\IN\0|elevation (r_prep) effect_5\NN\34213|no|on (r_dobj) had_3\VBD\0|because|treatment|effect (r_advcl) explained_27\VBN\831651|had|is|probably|best|by|. (l_agent) by_28\IN\0|hypothesis (l_pobj) hypothesis_30\NN\7162194|the|inhibits (l_acl) inhibits_33\VBZ\2510337|that|warfarin|activity|as (l_prep) as_40\IN\14622893|inhibitor (l_pobj) inhibitor_43\NN\20090|a|calcification (l_compound) calcification_42\NN\13446390|
D014859_D002114 NONE warfarin_32\NNP\2718259| (r_nsubj) inhibits_33\VBZ\2510337|that|warfarin|activity|as (l_prep) as_40\IN\14622893|inhibitor (l_pobj) inhibitor_43\NN\20090|a|calcification (l_compound) calcification_42\NN\13446390|
D010710_D061205 NONE phosphate_28\NN\15010703|higher|serum|and|susceptibility (r_pobj) between_25\IN\0|phosphate (r_prep) relationship_24\NN\31921|a|between|,|with|,|rats (r_attr) was_22\VBD\0|determined|,|there|relationship|. (l_advcl) determined_15\VBN\0|although|explanation|can|not|be|from (l_nsubjpass) explanation_2\NN\6722453|the|for (l_prep) for_3\IN\0|association (l_pobj) association_5\NN\8008335|the|between (l_prep) between_6\IN\0|calcification (l_pobj) calcification_8\NN\13446390|artery|and|status
D010710_D061205 NONE phosphate_28\NN\15010703|higher|serum|and|susceptibility (l_conj) susceptibility_30\NN\13920835|to (l_prep) to_31\IN\0|calcification (l_pobj) calcification_33\NN\13446390|artery
D010710_D061205 NONE phosphate_28\NN\15010703|higher|serum|and|susceptibility (r_pobj) between_25\IN\0|phosphate (r_prep) relationship_24\NN\31921|a|between|,|with|,|rats (l_appos) rats_50\NNS\2329401|ad|fed|compared (l_prep) compared_51\VBN\644583|with|rats (l_prep) with_52\IN\0|either (l_pobj) either_53\DT\0|of (l_prep) of_54\IN\0|groups (l_pobj) groups_56\NNS\2137|the|was (l_relcl) was_58\VBD\0|that|resistant (l_acomp) resistant_59\JJ\0|to (l_prep) to_60\IN\0|calcification (l_pobj) calcification_65\NN\13446390|induced|artery
D010710_D061205 NONE phosphate_42\NN\15010703|serum (r_pobj) of_40\IN\0|phosphate (r_prep) levels_39\NNS\4916342|higher|of|in (r_pobj) with_35\IN\0|levels (r_prep) relationship_24\NN\31921|a|between|,|with|,|rats (r_attr) was_22\VBD\0|determined|,|there|relationship|. (l_advcl) determined_15\VBN\0|although|explanation|can|not|be|from (l_nsubjpass) explanation_2\NN\6722453|the|for (l_prep) for_3\IN\0|association (l_pobj) association_5\NN\8008335|the|between (l_prep) between_6\IN\0|calcification (l_pobj) calcification_8\NN\13446390|artery|and|status
D010710_D061205 NONE phosphate_42\NN\15010703|serum (r_pobj) of_40\IN\0|phosphate (r_prep) levels_39\NNS\4916342|higher|of|in (r_pobj) with_35\IN\0|levels (r_prep) relationship_24\NN\31921|a|between|,|with|,|rats (l_prep) between_25\IN\0|phosphate (l_pobj) phosphate_28\NN\15010703|higher|serum|and|susceptibility (l_conj) susceptibility_30\NN\13920835|to (l_prep) to_31\IN\0|calcification (l_pobj) calcification_33\NN\13446390|artery
D010710_D061205 NONE phosphate_42\NN\15010703|serum (r_pobj) of_40\IN\0|phosphate (r_prep) levels_39\NNS\4916342|higher|of|in (r_pobj) with_35\IN\0|levels (r_prep) relationship_24\NN\31921|a|between|,|with|,|rats (l_appos) rats_50\NNS\2329401|ad|fed|compared (l_prep) compared_51\VBN\644583|with|rats (l_prep) with_52\IN\0|either (l_pobj) either_53\DT\0|of (l_prep) of_54\IN\0|groups (l_pobj) groups_56\NNS\2137|the|was (l_relcl) was_58\VBD\0|that|resistant (l_acomp) resistant_59\JJ\0|to (l_prep) to_60\IN\0|calcification (l_pobj) calcification_65\NN\13446390|induced|artery
D010710_D061205 NONE phosphate_18\NN\15010703|serum (r_compound) levels_19\NNS\4916342|higher|phosphate (r_pobj) to_15\IN\0|levels (r_prep) related_14\VBN\628491|that|susceptibility|could|be|to (l_nsubjpass) susceptibility_5\NN\13920835|increased|to (l_prep) to_6\IN\0|calcification (l_pobj) calcification_11\NN\13446390|induced|artery
D002118_D061205 NONE calcium_27\NN\14625458|serum (r_pobj) of_25\IN\0|calcium (r_prep) elevation_24\NN\7445480|the|of|,|suggests (r_pobj) on_22\IN\0|elevation (r_prep) dose_21\NN\3740161|d|on (r_pobj) of_18\IN\0|dose (r_prep) effect_17\NN\34213|the|of (r_conj) effect_7\NN\34213|the|of|and|effect (l_prep) of_8\IN\0|dose (l_pobj) dose_11\NN\3740161|d|on (l_prep) on_12\IN\0|calcification (l_pobj) calcification_14\NN\13446390|artery
D002118_D061205 NONE calcium_27\NN\14625458|serum (r_pobj) of_25\IN\0|calcium (r_prep) elevation_24\NN\7445480|the|of|,|suggests (l_relcl) suggests_30\VBZ\1010118|which|induce (l_ccomp) induce_35\VB\1627355|that|d|may|calcification|through (l_dobj) calcification_37\NN\13446390|artery
D002118_D061205 NONE calcium_43\NN\14625458|serum (r_pobj) on_41\IN\0|calcium (r_prep) effect_40\NN\34213|its|on (r_pobj) through_38\IN\0|effect (r_prep) induce_35\VB\1627355|that|d|may|calcification|through (r_ccomp) suggests_30\VBZ\1010118|which|induce (r_relcl) elevation_24\NN\7445480|the|of|,|suggests (r_pobj) on_22\IN\0|elevation (r_prep) dose_21\NN\3740161|d|on (r_pobj) of_18\IN\0|dose (r_prep) effect_17\NN\34213|the|of (r_conj) effect_7\NN\34213|the|of|and|effect (l_prep) of_8\IN\0|dose (l_pobj) dose_11\NN\3740161|d|on (l_prep) on_12\IN\0|calcification (l_pobj) calcification_14\NN\13446390|artery
D002118_D061205 NONE calcium_43\NN\14625458|serum (r_pobj) on_41\IN\0|calcium (r_prep) effect_40\NN\34213|its|on (r_pobj) through_38\IN\0|effect (r_prep) induce_35\VB\1627355|that|d|may|calcification|through (l_dobj) calcification_37\NN\13446390|artery
D002118_D002114 NONE calcium_11\NN\14625458|serum|produced (r_pobj) in_9\IN\13603305|calcium (r_prep) elevation_8\NN\7445480|the|in (r_pobj) on_6\IN\0|elevation (r_prep) effect_5\NN\34213|no|on (r_dobj) had_3\VBD\0|because|treatment|effect (r_advcl) explained_27\VBN\831651|had|is|probably|best|by|. (l_agent) by_28\IN\0|hypothesis (l_pobj) hypothesis_30\NN\7162194|the|inhibits (l_acl) inhibits_33\VBZ\2510337|that|warfarin|activity|as (l_prep) as_40\IN\14622893|inhibitor (l_pobj) inhibitor_43\NN\20090|a|calcification (l_compound) calcification_42\NN\13446390|
D015055_D061205 NONE carboxylated_36\JJ\515154|not|gamma|- (r_acomp) was_31\VBD\0|that|protein|indeed|carboxylated (r_ccomp) showed_25\VBD\2137132|analysis|was|. (r_conj) found_7\VBN\13279262|levels|are|at|,|and|showed (l_prep) at_8\IN\14622893|sites (l_pobj) sites_9\NNS\8673395|of (l_prep) of_10\IN\0|calcification (l_pobj) calcification_12\NN\13446390|artery|in
D015055_D002114 NONE carboxyglutamate_8\NN\0|gamma|- (r_compound) residues_9\NNS\20827|the|carboxyglutamate|of (r_nsubjpass) required_16\VBN\0|although|residues|are|apparently|for|as (l_prep) as_20\IN\14622893|inhibitor (l_pobj) inhibitor_23\NN\20090|a|calcification (l_compound) calcification_22\NN\13446390|
D015055_D002114 NONE carboxyglutamate_8\NN\0|gamma|- (r_compound) residues_9\NNS\20827|the|carboxyglutamate|of (r_nsubjpass) required_16\VBN\0|although|residues|are|apparently|for|as (r_advcl) required_28\VBN\0|that|required|,|they|are|not|for (l_prep) for_29\IN\0|accumulation (l_pobj) accumulation_31\NN\13497135|its|at (l_prep) at_32\IN\14622893|sites (l_pobj) sites_34\NNS\8673395|calcification (l_compound) calcification_33\NN\13446390|
17147461
D020123_D011507 CID sirolimus_0\NNP\0| (r_npadvmod) associated_2\VBN\628491|sirolimus|- (r_amod) proteinuria_3\NN\14299637|associated|and|dysfunction|.
D020123_D011507 CID sirolimus_11\NN\0| (r_nsubjpass) associated_13\VBN\628491|that|,|under|,|sirolimus|is|with (l_prep) with_14\IN\0|proteinuria (l_pobj) proteinuria_15\NN\14299637|and|dysfunction
D020123_D011507 CID sirolimus_3\NN\0| (r_npadvmod) associated_5\VBN\628491|sirolimus|- (r_amod) proteinuria_6\NN\14299637|associated
D020123_D011507 CID sirolimus_21\NN\0| (r_pobj) of_20\IN\0|sirolimus (r_prep) effects_19\NNS\13245626|the|molecular|of|on (r_pobj) of_16\IN\0|effects (r_prep) knowledge_15\NN\23100|of (r_pobj) by_14\IN\0|knowledge (r_agent) minimised_13\VBN\831651|occur|,|occurrence|could|be|by|,|use|. (l_dep) use_27\NN\407535|the|of|in|,|monitoring (l_appos) monitoring_36\NN\879759|close|of|,|use|occurs (l_prep) of_37\IN\0|proteinuria (l_pobj) proteinuria_38\NN\14299637|and|function
D020123_D011507 CID sirolimus_21\NN\0| (r_pobj) of_20\IN\0|sirolimus (r_prep) effects_19\NNS\13245626|the|molecular|of|on (r_pobj) of_16\IN\0|effects (r_prep) knowledge_15\NN\23100|of (r_pobj) by_14\IN\0|knowledge (r_agent) minimised_13\VBN\831651|occur|,|occurrence|could|be|by|,|use|. (l_dep) use_27\NN\407535|the|of|in|,|monitoring (l_appos) monitoring_36\NN\879759|close|of|,|use|occurs (l_advcl) occurs_57\VBZ\0|if|proteinuria|and|withdrawal|needed (l_nsubj) proteinuria_56\NN\14299637|
D020123_D011507 CID sirolimus_29\NN\0| (r_pobj) of_28\IN\0|sirolimus (r_prep) use_27\NN\407535|the|of|in|,|monitoring (l_appos) monitoring_36\NN\879759|close|of|,|use|occurs (l_prep) of_37\IN\0|proteinuria (l_pobj) proteinuria_38\NN\14299637|and|function
D020123_D011507 CID sirolimus_29\NN\0| (r_pobj) of_28\IN\0|sirolimus (r_prep) use_27\NN\407535|the|of|in|,|monitoring (l_appos) monitoring_36\NN\879759|close|of|,|use|occurs (l_advcl) occurs_57\VBZ\0|if|proteinuria|and|withdrawal|needed (l_nsubj) proteinuria_56\NN\14299637|
D020123_D007674 CID sirolimus_0\NNP\0| (r_npadvmod) associated_2\VBN\628491|sirolimus|- (r_amod) proteinuria_3\NN\14299637|associated|and|dysfunction|. (l_conj) dysfunction_6\NN\14204950|renal
D020123_D007674 CID sirolimus_0\NNP\0| (r_nsubj) represents_1\VBZ\2664769|sirolimus|advance|. (l_dobj) advance_5\NN\7311115|a|major|therapeutic|in (l_prep) in_6\IN\13603305|prevention (l_pobj) prevention_8\NN\1073995|the|of (l_prep) of_9\IN\0|rejection (l_pobj) rejection_13\NN\30358|acute|allograft|and|nephropathy (l_conj) nephropathy_17\NN\14573196|chronic|allograft
D020123_D007674 CID sirolimus_1\NN\0| (r_nsubj) share_4\VB\13329641|because|sirolimus|does|not|vasomotor|effects (r_advcl) designated_18\VBN\0|share|,|it|has|been|drug|. (l_oprd) drug_24\NN\14778436|a|'|nephrotoxic|' (l_amod) nephrotoxic_23\JJ\0|-
D020123_D058186 NONE sirolimus_11\NN\0| (r_nsubjpass) associated_13\VBN\628491|that|,|under|,|sirolimus|is|with (l_prep) with_14\IN\0|proteinuria (l_pobj) proteinuria_15\NN\14299637|and|dysfunction (l_conj) dysfunction_19\NN\14204950|acute|renal
D020123_D058186 NONE sirolimus_6\NN\0| (r_pobj) with_5\IN\0|sirolimus (r_prep) associated_4\VBN\628491|with (r_acl) dysfunction_3\NN\14204950|the|acute|renal|associated|(|as|)
D000809_D011507 NONE angiotensin_45\NN\4522421| (r_npadvmod) converting_47\VBG\126264|angiotensin|- (r_amod) inhibitors_49\NNS\20090|converting|enzyme|or|blockers (r_pobj) of_44\IN\0|inhibitors (r_prep) use_43\NN\407535|of (r_conj) monitoring_36\NN\879759|close|of|,|use|occurs (l_prep) of_37\IN\0|proteinuria (l_pobj) proteinuria_38\NN\14299637|and|function
D000809_D011507 NONE angiotensin_45\NN\4522421| (r_npadvmod) converting_47\VBG\126264|angiotensin|- (r_amod) inhibitors_49\NNS\20090|converting|enzyme|or|blockers (r_pobj) of_44\IN\0|inhibitors (r_prep) use_43\NN\407535|of (r_conj) monitoring_36\NN\879759|close|of|,|use|occurs (l_advcl) occurs_57\VBZ\0|if|proteinuria|and|withdrawal|needed (l_nsubj) proteinuria_56\NN\14299637|
D000804_D011507 NONE ii_52\CD\13741022| (r_compound) blockers_54\NNS\10101634|angiotensin|ii|receptor (r_conj) inhibitors_49\NNS\20090|converting|enzyme|or|blockers (r_pobj) of_44\IN\0|inhibitors (r_prep) use_43\NN\407535|of (r_conj) monitoring_36\NN\879759|close|of|,|use|occurs (l_prep) of_37\IN\0|proteinuria (l_pobj) proteinuria_38\NN\14299637|and|function
D000804_D011507 NONE ii_52\CD\13741022| (r_compound) blockers_54\NNS\10101634|angiotensin|ii|receptor (r_conj) inhibitors_49\NNS\20090|converting|enzyme|or|blockers (r_pobj) of_44\IN\0|inhibitors (r_prep) use_43\NN\407535|of (r_conj) monitoring_36\NN\879759|close|of|,|use|occurs (l_advcl) occurs_57\VBZ\0|if|proteinuria|and|withdrawal|needed (l_nsubj) proteinuria_56\NN\14299637|
6308277
D002110_D064420 NONE caffeine_2\NN\14712692| (r_compound) toxicity_3\NN\13576101|caffeine
D002110_D064420 NONE caffeine_11\NN\14712692| (r_pobj) of_10\IN\0|caffeine (r_prep) effects_9\NNS\13245626|the|stimulatory|of|on (r_dobj) augment_6\VB\153263|to|effects (r_xcomp) reported_4\VBN\831651|because|salicylates|have|been|augment (r_advcl) focused_18\VBN\628491|reported|,|attention|was|on|. (l_prep) on_19\IN\0|possibility (l_pobj) possibility_21\NN\5944958|the|reduced (l_acl) reduced_33\VBD\441445|that|presence|(|micrograms|toxicity (l_dobj) toxicity_36\NN\13576101|the|cns|of
D002110_D064420 NONE caffeine_38\NN\14712692| (r_pobj) of_37\IN\0|caffeine (r_prep) toxicity_36\NN\13576101|the|cns|of
D000082_D064420 NONE acetaminophen_5\NN\2707683| (r_pobj) by_4\IN\0|acetaminophen (r_prep) reduction_0\NN\351485|in|by|. (l_prep) in_1\IN\13603305|toxicity (l_pobj) toxicity_3\NN\13576101|caffeine
D000082_D064420 NONE acetaminophen_26\NN\2707683| (r_pobj) of_25\IN\0|acetaminophen (r_prep) presence_24\NN\13954253|the|of (r_nsubj) reduced_33\VBD\441445|that|presence|(|micrograms|toxicity (l_dobj) toxicity_36\NN\13576101|the|cns|of
D000082_D012640 NONE acetaminophen_11\NN\2707683|mg/kg (r_pobj) with_10\IN\0|acetaminophen (r_prep) pretreatment_9\NN\0|:|1|with|) (r_nsubj) increased_16\VBD\169651|that|pretreatment|interval|reduced (l_dobj) interval_18\NN\33615|the|between (l_prep) between_19\IN\0|administration (l_pobj) administration_21\NN\1133281|the|of|ip|and|onset (l_conj) onset_33\NN\7325190|the|of|by|;|and|pretreatment (l_prep) of_34\IN\0|convulsions (l_pobj) convulsions_36\NNS\14081375|fatal
D000082_D012640 NONE acetaminophen_11\NN\2707683|mg/kg (r_pobj) with_10\IN\0|acetaminophen (r_prep) pretreatment_9\NN\0|:|1|with|) (r_nsubj) increased_16\VBD\169651|that|pretreatment|interval|reduced (l_conj) reduced_54\VBD\441445|incidence|(|ip|) (l_dobj) incidence_56\NN\13821570|the|of (l_prep) of_57\IN\0|seizures (l_pobj) seizures_59\NNS\14081375|audiogenic|produced
D000082_D012640 NONE acetaminophen_49\NN\2707683|mg/kg (r_pobj) with_48\IN\0|acetaminophen (r_prep) pretreatment_47\NN\0|2|with|) (r_conj) onset_33\NN\7325190|the|of|by|;|and|pretreatment (l_prep) of_34\IN\0|convulsions (l_pobj) convulsions_36\NNS\14081375|fatal
D000082_D012640 NONE acetaminophen_49\NN\2707683|mg/kg (r_pobj) with_48\IN\0|acetaminophen (r_prep) pretreatment_47\NN\0|2|with|) (r_conj) onset_33\NN\7325190|the|of|by|;|and|pretreatment (r_conj) administration_21\NN\1133281|the|of|ip|and|onset (r_pobj) between_19\IN\0|administration (r_prep) interval_18\NN\33615|the|between (r_dobj) increased_16\VBD\169651|that|pretreatment|interval|reduced (l_conj) reduced_54\VBD\441445|incidence|(|ip|) (l_dobj) incidence_56\NN\13821570|the|of (l_prep) of_57\IN\0|seizures (l_pobj) seizures_59\NNS\14081375|audiogenic|produced
D000082_D012640 NONE acetaminophen_21\NN\2707683| (r_pobj) by_20\IN\0|acetaminophen (r_agent) reduced_14\VBN\441445|frequency|was|from|by|. (l_nsubjpass) frequency_1\NN\15286249|the|of|after (l_prep) of_2\IN\0|seizures (l_pobj) seizures_6\NNS\14081375|induced
D000082_D012640 NONE acetaminophen_6\FW\2707683|mg/kg|) (r_nsubj) modify_15\VB\109660|in|,|acetaminophen|did|not|seizures|and|alter|. (l_dobj) seizures_17\NNS\14081375|the|induced
D002110_D012640 CID caffeine_23\NN\14712692| (r_pobj) of_22\IN\0|caffeine (r_prep) administration_21\NN\1133281|the|of|ip|and|onset (l_conj) onset_33\NN\7325190|the|of|by|;|and|pretreatment (l_prep) of_34\IN\0|convulsions (l_pobj) convulsions_36\NNS\14081375|fatal
D002110_D012640 CID caffeine_23\NN\14712692| (r_pobj) of_22\IN\0|caffeine (r_prep) administration_21\NN\1133281|the|of|ip|and|onset (r_pobj) between_19\IN\0|administration (r_prep) interval_18\NN\33615|the|between (r_dobj) increased_16\VBD\169651|that|pretreatment|interval|reduced (l_conj) reduced_54\VBD\441445|incidence|(|ip|) (l_dobj) incidence_56\NN\13821570|the|of (l_prep) of_57\IN\0|seizures (l_pobj) seizures_59\NNS\14081375|audiogenic|produced
D002110_D012640 CID caffeine_65\NN\14712692| (r_pobj) of_64\IN\0|caffeine (r_prep) presence_63\NN\13954253|the|of (r_pobj) in_61\IN\13603305|presence (r_prep) produced_60\VBN\1617192|in (r_acl) seizures_59\NNS\14081375|audiogenic|produced (r_pobj) of_57\IN\0|seizures (r_prep) incidence_56\NN\13821570|the|of (r_dobj) reduced_54\VBD\441445|incidence|(|ip|) (r_conj) increased_16\VBD\169651|that|pretreatment|interval|reduced (l_dobj) interval_18\NN\33615|the|between (l_prep) between_19\IN\0|administration (l_pobj) administration_21\NN\1133281|the|of|ip|and|onset (l_conj) onset_33\NN\7325190|the|of|by|;|and|pretreatment (l_prep) of_34\IN\0|convulsions (l_pobj) convulsions_36\NNS\14081375|fatal
D002110_D012640 CID caffeine_65\NN\14712692| (r_pobj) of_64\IN\0|caffeine (r_prep) presence_63\NN\13954253|the|of (r_pobj) in_61\IN\13603305|presence (r_prep) produced_60\VBN\1617192|in (r_acl) seizures_59\NNS\14081375|audiogenic|produced
D002110_D012640 CID caffeine_12\NN\14712692|12.5 (r_pobj) after_7\IN\0|caffeine (r_prep) frequency_1\NN\15286249|the|of|after (l_prep) of_2\IN\0|seizures (l_pobj) seizures_6\NNS\14081375|induced
D002110_D012640 CID caffeine_4\NN\14712692| (r_pobj) of_3\IN\0|caffeine (r_prep) absence_2\NN\14449405|the|of (r_pobj) in_0\IN\13603305|absence (r_prep) modify_15\VB\109660|in|,|acetaminophen|did|not|seizures|and|alter|. (l_dobj) seizures_17\NNS\14081375|the|induced
D010433_D012640 CID pentylenetetrezol_30\NN\0| (r_pobj) of_29\IN\0|pentylenetetrezol (r_prep) dose_28\NN\3740161|the|convulsant|of|in|tests (r_dobj) alter_25\VB\0|did|not|dose (r_conj) modify_15\VB\109660|in|,|acetaminophen|did|not|seizures|and|alter|. (l_dobj) seizures_17\NNS\14081375|the|induced
19211690
D013739_D006973 NONE testosterone_0\NN\14747587| (r_npadvmod) dependent_2\JJ\9627906|testosterone|- (r_amod) hypertension_3\NN\14057371|dependent|and|upregulation|.
D013739_D006973 NONE testosterone_0\NN\14747587| (r_nsubj) contributes_1\VBZ\126264|testosterone|to|through|. (l_prep) to_2\IN\0|development (l_pobj) development_4\NN\248977|the|of (l_prep) of_5\IN\0|hypertension (l_pobj) hypertension_6\NN\14057371|and|injury|in
D017673_D006973 NONE salt_11\NN\14818238| (r_npadvmod) sensitive_13\JJ\10488309|salt|- (r_amod) rats_14\NNS\2329401|dahl|sensitive (r_pobj) in_9\IN\13603305|rats (r_prep) upregulation_5\NN\0|of|in (r_conj) hypertension_3\NN\14057371|dependent|and|upregulation|.
D013739_D007674 NONE testosterone_24\NN\14747587| (r_pobj) by_23\IN\0|testosterone (r_agent) mediated_22\VBN\761713|by (r_acl) angiotensinogen_21\NN\0|intrarenal|mediated (r_pobj) of_19\IN\0|angiotensinogen (r_prep) upregulation_18\NN\0|induced|of (r_pobj) in_14\IN\13603305|upregulation (r_prep) dimorphism_13\NN\11492833|a|sexual|in|causes (l_relcl) causes_27\VBZ\7323922|that|also|increases (l_dobj) increases_28\NNS\13576355|in (l_prep) in_29\IN\13603305|bp (l_pobj) bp_30\NNP\0|and|injury (l_conj) injury_33\NN\14052046|renal
D013739_D007674 NONE testosterone_0\NN\14747587| (r_compound) replacement_1\NN\196485|testosterone|in (r_nsubj) increased_6\VBD\169651|replacement|bp|. (l_npadvmod) bp_7\NNP\0|,|injury (l_appos) injury_10\NN\14052046|renal|,|and|upregulation
D013739_D007674 NONE testosterone_0\NN\14747587| (r_nsubj) contributes_1\VBZ\126264|testosterone|to|through|. (l_prep) to_2\IN\0|development (l_pobj) development_4\NN\248977|the|of (l_prep) of_5\IN\0|hypertension (l_pobj) hypertension_6\NN\14057371|and|injury|in (l_conj) injury_9\NN\14052046|renal
D000809_D006973 NONE angiotensin_25\NN\4522421|renin|- (r_compound) system_26\NN\3575240|the|intrarenal|angiotensin (r_pobj) of_20\IN\0|system (r_prep) upregulation_19\NN\0|of (r_pobj) through_18\IN\0|possibly|upregulation (r_prep) contributes_1\VBZ\126264|testosterone|to|through|. (l_prep) to_2\IN\0|development (l_pobj) development_4\NN\248977|the|of (l_prep) of_5\IN\0|hypertension (l_pobj) hypertension_6\NN\14057371|and|injury|in
D000809_D007674 NONE angiotensin_25\NN\4522421|renin|- (r_compound) system_26\NN\3575240|the|intrarenal|angiotensin (r_pobj) of_20\IN\0|system (r_prep) upregulation_19\NN\0|of (r_pobj) through_18\IN\0|possibly|upregulation (r_prep) contributes_1\VBZ\126264|testosterone|to|through|. (l_prep) to_2\IN\0|development (l_pobj) development_4\NN\248977|the|of (l_prep) of_5\IN\0|hypertension (l_pobj) hypertension_6\NN\14057371|and|injury|in (l_conj) injury_9\NN\14052046|renal
8302922
D000527_D007022 CID e1_5\NNP\0|prostaglandin|or|trimethaphan (r_pobj) during_3\IN\0|e1 (r_prep) flow_2\NN\7311115|epidural|blood|during (r_nsubj) induced_8\VBD\1627355|flow|hypotension|. (l_dobj) hypotension_9\NN\14057371|
D000527_D007022 CID e1_6\NNP\0| (r_nmod) pge1_8\NNP\0|prostaglandin|e1|(|)|or|trimethaphan (r_pobj) of_4\IN\0|pge1 (r_prep) effect_3\NN\34213|the|of (r_dobj) evaluate_1\VB\670261|to|effect (r_csubj) induced_15\VBN\1627355|evaluate|hypotension|during (l_dobj) hypotension_16\NN\14057371|on
D000527_D007022 CID pge1_8\NNP\0|prostaglandin|e1|(|)|or|trimethaphan (r_pobj) of_4\IN\0|pge1 (r_prep) effect_3\NN\34213|the|of (r_dobj) evaluate_1\VB\670261|to|effect (r_csubj) induced_15\VBN\1627355|evaluate|hypotension|during (l_dobj) hypotension_16\NN\14057371|on
D000527_D007022 CID pge1_2\NNP\0|or|tmp|product (r_dobj) starting_1\VBG\457382|pge1 (r_pcomp) after_0\IN\0|starting (r_prep) decreased_14\VBD\169651|after|significantly|compared|,|and|remained (l_conj) remained_34\VBD\2604760|degree|constant|until|. (l_nsubj) degree_28\NN\4916342|the|of|due (l_prep) of_29\IN\0|hypotension (l_pobj) hypotension_30\NN\14057371|
D000527_D007022 CID pge1_33\NNP\0| (r_pobj) to_32\IN\0|pge1 (r_pcomp) due_31\IN\5174653|to (r_prep) degree_28\NN\4916342|the|of|due (l_prep) of_29\IN\0|hypotension (l_pobj) hypotension_30\NN\14057371|
D000527_D007022 CID pge1_4\NNP\0| (r_nsubj) be_6\VB\14625458|that|pge1|may|preferable|decreased (l_acomp) preferable_7\JJ\0|tmp (l_xcomp) tmp_9\VB\0|to|for (l_prep) for_10\IN\0|anaesthesia (l_pobj) anaesthesia_12\NN\14034177|hypotensive|in (l_amod) hypotensive_11\JJ\10405694|
D014294_D007022 CID trimethaphan_7\RB\0| (r_conj) e1_5\NNP\0|prostaglandin|or|trimethaphan (r_pobj) during_3\IN\0|e1 (r_prep) flow_2\NN\7311115|epidural|blood|during (r_nsubj) induced_8\VBD\1627355|flow|hypotension|. (l_dobj) hypotension_9\NN\14057371|
D014294_D007022 CID trimethaphan_11\NN\0|tmp (r_conj) pge1_8\NNP\0|prostaglandin|e1|(|)|or|trimethaphan (r_pobj) of_4\IN\0|pge1 (r_prep) effect_3\NN\34213|the|of (r_dobj) evaluate_1\VB\670261|to|effect (r_csubj) induced_15\VBN\1627355|evaluate|hypotension|during (l_dobj) hypotension_16\NN\14057371|on
D014294_D007022 CID tmp_13\NNP\0|(|) (r_appos) trimethaphan_11\NN\0|tmp (r_conj) pge1_8\NNP\0|prostaglandin|e1|(|)|or|trimethaphan (r_pobj) of_4\IN\0|pge1 (r_prep) effect_3\NN\34213|the|of (r_dobj) evaluate_1\VB\670261|to|effect (r_csubj) induced_15\VBN\1627355|evaluate|hypotension|during (l_dobj) hypotension_16\NN\14057371|on
D014294_D007022 CID tmp_4\NNP\0|,|map (r_conj) pge1_2\NNP\0|or|tmp|product (r_dobj) starting_1\VBG\457382|pge1 (r_pcomp) after_0\IN\0|starting (r_prep) decreased_14\VBD\169651|after|significantly|compared|,|and|remained (l_conj) remained_34\VBD\2604760|degree|constant|until|. (l_nsubj) degree_28\NN\4916342|the|of|due (l_prep) of_29\IN\0|hypotension (l_pobj) hypotension_30\NN\14057371|
D014294_D007022 CID tmp_9\VB\0|to|for (l_prep) for_10\IN\0|anaesthesia (l_pobj) anaesthesia_12\NN\14034177|hypotensive|in (l_amod) hypotensive_11\JJ\10405694|
D014294_D007022 CID tmp_17\NNP\0| (r_nsubj) decreased_18\VBD\169651|because|tmp|ebf (r_advcl) be_6\VB\14625458|that|pge1|may|preferable|decreased (l_acomp) preferable_7\JJ\0|tmp (l_xcomp) tmp_9\VB\0|to|for (l_prep) for_10\IN\0|anaesthesia (l_pobj) anaesthesia_12\NN\14034177|hypotensive|in (l_amod) hypotensive_11\JJ\10405694|
D007530_D007022 NONE isoflurane_47\JJ\3570838| (r_amod) anaesthesia_48\NN\14034177|isoflurane (r_pobj) under_46\IN\0|anaesthesia (r_prep) fusion_45\NN\7373277|lateral|interbody|under (r_dobj) underwent_40\VBD\109660|who|fusion (r_relcl) patients_38\NNS\9898892|30|underwent (r_pobj) in_36\IN\13603305|patients (r_prep) using_31\VBG\418025|method|in (r_advcl) measured_30\VBN\697589|induced|,|ebf|was|using|. (l_advcl) induced_15\VBN\1627355|evaluate|hypotension|during (l_dobj) hypotension_16\NN\14057371|on
16337777
D010862_D004827 NONE pilocarpine_12\NN\14712692| (r_pobj) by_11\IN\0|pilocarpine (r_agent) induced_10\VBN\1627355|by (r_acl) model_7\NN\5888929|the|experimental|of|induced (l_prep) of_8\IN\0|epilepsy (l_pobj) epilepsy_9\NN\14085708|
D010862_D013226 NONE pilocarpine_49\NN\14712692| (r_amod) model_50\NN\5888929|the|pilocarpine|of (r_pobj) of_47\IN\0|model (r_prep) phase_46\NN\15113229|the|chronic|of (r_pobj) in_43\IN\13603305|phase (r_prep) provoke_18\VB\1617192|to|abnormalities|in (r_xcomp) sufficient_16\JJ\0|provoke (r_acomp) be_15\VB\14625458|whether|generation|would|sufficient (l_nsubj) generation_8\NN\7942152|increased|of|during (l_prep) during_11\IN\0|epilepticus (l_pobj) epilepticus_13\NN\0|status
D010862_D004833 CID pilocarpine_49\NN\14712692| (r_amod) model_50\NN\5888929|the|pilocarpine|of (l_prep) of_51\IN\0|epilepsy (l_pobj) epilepsy_54\NN\14085708|temporal|lobe
2070391
D008012_D010146 CID lidocaine_6\NN\3681148|buffered (r_dobj) using_4\VBG\418025|lidocaine|as (r_acl) reduction_0\NN\351485|in|using|. (l_prep) in_1\IN\13603305|pain (l_pobj) pain_3\NN\14299637|injection
D008012_D010146 CID lidocaine_11\NN\3681148| (r_pobj) of_10\IN\0|lidocaine (r_prep) injection_9\NN\320852|the|of (r_pobj) with_7\IN\0|injection (r_prep) associated_6\VBN\628491|with (r_acl) pain_5\NN\14299637|associated
D008012_D010146 CID lidocaine_14\NN\3681148| (r_pobj) of_13\IN\0|lidocaine (r_prep) ph_12\NN\5038959|the|of (r_dobj) adjust_10\VB\126264|to|ph|into (r_relcl) solution_8\NN\14586258|a|buffering|adjust (r_pobj) of_5\IN\0|solution (r_prep) addition_4\NN\3081021|the|of (r_nsubj) reduce_20\VB\441445|if|addition|would|pain|during (l_dobj) pain_21\NN\14299637|
D008012_D010146 CID lidocaine_13\NN\3681148|standard (r_dobj) receiving_11\VBG\2210855|lidocaine|in|and|lidocaine (r_pcomp) after_10\IN\0|receiving (r_prep) quantify_5\VB\947077|to|severity|after (l_dobj) severity_7\NN\5036394|the|of (l_prep) of_8\IN\0|pain (l_pobj) pain_9\NN\14299637|
D008012_D010146 CID lidocaine_20\NN\3681148|buffered|in (r_conj) receiving_11\VBG\2210855|lidocaine|in|and|lidocaine (r_pcomp) after_10\IN\0|receiving (r_prep) quantify_5\VB\947077|to|severity|after (l_dobj) severity_7\NN\5036394|the|of (l_prep) of_8\IN\0|pain (l_pobj) pain_9\NN\14299637|
D008012_D010146 CID lidocaine_6\NN\3681148|buffered (r_pobj) for_4\IN\0|lidocaine (r_prep) score_3\NN\5736149|the|mean|pain|for (l_compound) pain_2\NN\14299637|
D008012_D010146 CID lidocaine_16\NN\3681148|standard (r_pobj) for_14\IN\0|lidocaine (r_prep) score_13\NN\5736149|the|mean|for|(|+/-|,|p|) (r_pobj) than_10\IN\0|score (r_prep) lower_9\JJR\2831724|significantly|than (r_acomp) was_7\VBD\0|score|lower|. (l_nsubj) score_3\NN\5736149|the|mean|pain|for (l_compound) pain_2\NN\14299637|
D008012_D010146 CID lidocaine_5\NN\3681148|standard (r_pobj) of_3\IN\0|lidocaine (r_prep) adjustment_2\NN\7357388|the|ph|of (r_nsubjpass) accomplished_8\VBN\484166|adjustment|can|be|easily|in|. (l_prep) in_10\IN\13603305|laboratory (l_pobj) laboratory_13\NN\4602044|the|catheterization|before (l_prep) before_14\IN\0|injection (l_pobj) injection_15\NN\320852|and|results|in (l_prep) in_18\IN\13603305|reduction (l_pobj) reduction_20\NN\351485|a|of (l_prep) of_21\IN\0|pain (l_pobj) pain_23\NN\14299637|the|occurring
7834920
D012293_D005921 CID rifampin_6\NN\2716205| (r_amod) therapy_7\NN\657604|intermittent|rifampin|for (r_pobj) with_4\IN\0|therapy (r_prep) associated_3\VBN\628491|with (r_acl) glomerulonephritis_2\NN\14113798|associated
D012293_D005921 CID rifampin_17\NN\2716205| (r_pobj) with_16\IN\0|rifampin (r_prep) treated_15\VBN\2376958|with (r_acl) patient_14\NN\9898892|a|treated (r_pobj) in_12\IN\13603305|patient (r_prep) finding_6\NN\43195|an|unusual|of|in|had (l_prep) of_7\IN\0|glomerulonephritis (l_pobj) glomerulonephritis_11\NN\14113798|proliferative|crescentic
D012293_D005921 CID rifampin_20\NN\2716205| (r_pobj) with_19\IN\0|rifampin (r_prep) treated_18\VBN\2376958|with (r_acl) patient_17\NN\9898892|a|treated (r_pobj) in_15\IN\13603305|patient (r_prep) occurrence_5\NN\29378|the|unusual|of|in (l_prep) of_6\IN\0|glomerulonephritis (l_pobj) glomerulonephritis_9\NN\14113798|progressive|with
D012293_D005921 CID rifampin_20\NN\2716205| (r_pobj) with_19\IN\0|rifampin (r_prep) treated_18\VBN\2376958|with (r_acl) patient_17\NN\9898892|a|treated (r_pobj) in_15\IN\13603305|patient (r_prep) occurrence_5\NN\29378|the|unusual|of|in (l_prep) of_6\IN\0|glomerulonephritis (l_pobj) glomerulonephritis_9\NN\14113798|progressive|with (l_prep) with_10\IN\0|crescents (l_pobj) crescents_11\NNS\13867641|and|glomerulonephritis (l_conj) glomerulonephritis_14\NN\14113798|fibrillar
D012293_D014397 NONE rifampin_6\NN\2716205| (r_amod) therapy_7\NN\657604|intermittent|rifampin|for (l_prep) for_8\IN\0|tuberculosis (l_pobj) tuberculosis_10\NN\14127211|pulmonary
D012293_D014397 NONE rifampin_7\NN\2716205| (r_pobj) of_6\IN\0|rifampin (r_prep) regimen_5\NN\5898568|a|10-month|of (r_dobj) underwent_2\VBD\109660|patient|regimen|and|isoniazid|and|discovered|. (l_conj) isoniazid_9\NN\2716205|for (l_prep) for_10\IN\0|tuberculosis (l_pobj) tuberculosis_12\NN\14127211|pulmonary
D012293_D051437 CID rifampin_7\NN\2716205| (r_pobj) of_6\IN\0|rifampin (r_prep) regimen_5\NN\5898568|a|10-month|of (r_dobj) underwent_2\VBD\109660|patient|regimen|and|isoniazid|and|discovered|. (l_conj) discovered_15\VBN\2163746|was|developed (l_xcomp) developed_18\VBN\1753788|to|have|signs|after (l_dobj) signs_19\NNS\6643763|of (l_prep) of_20\IN\0|failure (l_pobj) failure_23\NN\66216|severe|renal
D007538_D014397 NONE isoniazid_9\NN\2716205|for (l_prep) for_10\IN\0|tuberculosis (l_pobj) tuberculosis_12\NN\14127211|pulmonary
D007538_D051437 NONE isoniazid_9\NN\2716205|for (r_conj) underwent_2\VBD\109660|patient|regimen|and|isoniazid|and|discovered|. (l_conj) discovered_15\VBN\2163746|was|developed (l_xcomp) developed_18\VBN\1753788|to|have|signs|after (l_dobj) signs_19\NNS\6643763|of (l_prep) of_20\IN\0|failure (l_pobj) failure_23\NN\66216|severe|renal
12789195
D008914_D004194 NONE minoxidil_9\NN\4522904| (r_pobj) of_8\IN\0|minoxidil (r_prep) use_7\NN\407535|the|term|of (r_pobj) by_2\IN\0|use (r_agent) induced_1\VBN\1627355|pseudoacromegaly|by|. (l_nsubj) pseudoacromegaly_0\NNS\0|
D008914_D004194 NONE minoxidil_15\NN\4522904| (r_pobj) of_14\IN\0|minoxidil (r_prep) use_13\NN\407535|the|term|of|at (r_pobj) from_8\IN\0|use (r_prep) resulted_7\VBD\2633881|that|from (r_relcl) patient_3\NN\9898892|a|with|resulted (l_prep) with_4\IN\0|pseudoacromegaly (l_pobj) pseudoacromegaly_5\NNS\0|
D008914_D004194 NONE minoxidil_13\JJ\4522904| (r_amod) use_14\NN\407535|minoxidil (r_pobj) of_12\IN\0|use (r_prep) effect_11\NN\34213|a|side|of (r_pobj) as_8\IN\14622893|effect (r_prep) report_5\NN\6470073|the|first|case|of|as (l_prep) of_6\IN\0|pseudoacromegaly (l_pobj) pseudoacromegaly_7\NNS\0|
3693336
D014229_D001714 CID triazolam_0\NNP\2830852| (r_npadvmod) induced_2\VBN\1627355|triazolam|-|episodes|. (l_dobj) episodes_4\NNS\7283608|brief|of|in (l_prep) of_5\IN\0|mania (l_pobj) mania_7\NN\9180259|secondary
D014229_D001714 CID triazolam_3\NN\2830852| (r_pobj) of_2\IN\0|triazolam (r_prep) doses_1\NNS\3740161|large|of (r_nsubj) induced_5\VBD\1627355|doses|repeatedly|episodes|. (l_dobj) episodes_7\NNS\7283608|brief|of|in (l_prep) of_8\IN\0|mania (l_pobj) mania_9\NN\9180259|
D014229_D001714 CID triazolam_10\NN\2830852| (r_pobj) of_9\IN\0|triazolam (r_prep) action_8\NN\30358|of (r_pobj) of_7\IN\0|action (r_prep) duration_6\NN\15113229|the|of (r_pobj) with_4\IN\0|duration (r_prep) coincident_3\JJ\0|with (r_acomp) was_2\VBD\0|excitement|coincident|. (l_nsubj) excitement_1\NN\7527352|manic (l_amod) manic_0\JJ\0|
D014229_D003866 NONE triazolam_0\NNP\2830852| (r_npadvmod) induced_2\VBN\1627355|triazolam|-|episodes|. (l_dobj) episodes_4\NNS\7283608|brief|of|in (l_prep) in_8\IN\13603305|patient (l_pobj) patient_11\NN\9898892|a|depressed (l_amod) depressed_10\JJ\1819147|
D014229_D003866 NONE triazolam_3\NN\2830852| (r_pobj) of_2\IN\0|triazolam (r_prep) doses_1\NNS\3740161|large|of (r_nsubj) induced_5\VBD\1627355|doses|repeatedly|episodes|. (l_dobj) episodes_7\NNS\7283608|brief|of|in (l_prep) in_10\IN\13603305|woman (l_pobj) woman_14\NN\9605289|a|depressed|elderly (l_amod) depressed_12\JJ\1819147|
7862923
D002220_D012559 NONE carbamazepine_0\NNP\0| (r_nsubjpass) switched_2\VBN\138508|carbamazepine|was|to|among|. (l_prep) among_8\IN\0|patients (l_pobj) patients_19\NNS\9898892|six|difficult|schizophrenic|psychotic|using (l_amod) schizophrenic_15\JJ\10490141|or|organic
D002220_D019965 NONE carbamazepine_0\NNP\0| (r_nsubjpass) switched_2\VBN\138508|carbamazepine|was|to|among|. (l_prep) among_8\IN\0|patients (l_pobj) patients_19\NNS\9898892|six|difficult|schizophrenic|psychotic|using (l_amod) psychotic_18\JJ\10595647|
C036006_D012559 NONE oxcarbazepine_7\NN\0|its|analogue (r_pobj) to_3\IN\0|oxcarbazepine (r_prep) switched_2\VBN\138508|carbamazepine|was|to|among|. (l_prep) among_8\IN\0|patients (l_pobj) patients_19\NNS\9898892|six|difficult|schizophrenic|psychotic|using (l_amod) schizophrenic_15\JJ\10490141|or|organic
C036006_D019965 NONE oxcarbazepine_7\NN\0|its|analogue (r_pobj) to_3\IN\0|oxcarbazepine (r_prep) switched_2\VBN\138508|carbamazepine|was|to|among|. (l_prep) among_8\IN\0|patients (l_pobj) patients_19\NNS\9898892|six|difficult|schizophrenic|psychotic|using (l_amod) psychotic_18\JJ\10595647|
D006220_D012559 NONE haloperidol_22\NN\3713736|,|chlorpromazine (r_dobj) using_20\VBG\418025|concomitantly|haloperidol (r_acl) patients_19\NNS\9898892|six|difficult|schizophrenic|psychotic|using (l_amod) schizophrenic_15\JJ\10490141|or|organic
D006220_D019965 NONE haloperidol_22\NN\3713736|,|chlorpromazine (r_dobj) using_20\VBG\418025|concomitantly|haloperidol (r_acl) patients_19\NNS\9898892|six|difficult|schizophrenic|psychotic|using (l_amod) psychotic_18\JJ\10595647|
D002746_D012559 NONE chlorpromazine_24\NN\3713736|or|clozapine (r_conj) haloperidol_22\NN\3713736|,|chlorpromazine (r_dobj) using_20\VBG\418025|concomitantly|haloperidol (r_acl) patients_19\NNS\9898892|six|difficult|schizophrenic|psychotic|using (l_amod) schizophrenic_15\JJ\10490141|or|organic
D002746_D019965 NONE chlorpromazine_24\NN\3713736|or|clozapine (r_conj) haloperidol_22\NN\3713736|,|chlorpromazine (r_dobj) using_20\VBG\418025|concomitantly|haloperidol (r_acl) patients_19\NNS\9898892|six|difficult|schizophrenic|psychotic|using (l_amod) psychotic_18\JJ\10595647|
D003024_D012559 NONE clozapine_26\NN\3713736| (r_conj) chlorpromazine_24\NN\3713736|or|clozapine (r_conj) haloperidol_22\NN\3713736|,|chlorpromazine (r_dobj) using_20\VBG\418025|concomitantly|haloperidol (r_acl) patients_19\NNS\9898892|six|difficult|schizophrenic|psychotic|using (l_amod) schizophrenic_15\JJ\10490141|or|organic
D003024_D019965 NONE clozapine_26\NN\3713736| (r_conj) chlorpromazine_24\NN\3713736|or|clozapine (r_conj) haloperidol_22\NN\3713736|,|chlorpromazine (r_dobj) using_20\VBG\418025|concomitantly|haloperidol (r_acl) patients_19\NNS\9898892|six|difficult|schizophrenic|psychotic|using (l_amod) psychotic_18\JJ\10595647|
15233872
C007145_D009203 NONE crataegus_5\NNP\11585340| (r_pobj) of_4\IN\0|crataegus (r_prep) tincture_3\NN\14984973|of (r_pobj) of_2\IN\0|tincture (r_prep) effect_1\NN\34213|cardioprotective|of|on|. (l_prep) on_6\IN\0|infarction (l_pobj) infarction_11\NN\14204950|induced|myocardial|in
C007145_D009203 NONE tcr_11\NNP\0| (r_pobj) of_10\IN\0|tcr (r_prep) effect_9\NN\34213|the|protective|of|on (l_prep) on_12\IN\0|infarction (l_pobj) infarction_16\NN\14204950|induced|myocardial|in
D007545_D009203 CID isoproterenol_7\NN\3740161| (r_npadvmod) induced_9\VBN\1627355|isoproterenol|- (r_amod) infarction_11\NN\14204950|induced|myocardial|in
19445921
C066201_D009203 NONE a_5\NN\13649268|acid|on (l_prep) on_6\IN\0|infarction (l_pobj) infarction_11\NN\14204950|induced|myocardial|in
C066201_D009203 NONE a_13\NN\13649268|acid (r_pobj) of_10\IN\0|salvianolic|a (r_prep) potential_9\NN\14481929|the|cardioprotective|of|on (l_prep) on_14\IN\0|infarction (l_pobj) infarction_19\NN\14204950|induced|myocardial|in
C066201_D009203 NONE a_9\DT\13649268|acid|possessing (r_appos) salvianolic_7\JJ\0|that|a (r_nsubj) has_13\VBZ\13888491|salvianolic|effect (l_dobj) effect_17\NN\34213|a|significant|protective|against (l_prep) against_18\IN\0|infarction (l_pobj) infarction_23\NN\14204950|induced|myocardial
D007545_D009203 CID isoproterenol_7\NN\3740161| (r_npadvmod) induced_9\VBN\1627355|isoproterenol|- (r_amod) infarction_11\NN\14204950|induced|myocardial|in
D007545_D009203 CID isoproterenol_15\NN\3740161| (r_npadvmod) induced_17\VBN\1627355|isoproterenol|- (r_amod) infarction_19\NN\14204950|induced|myocardial|in
D007545_D009203 CID isoproterenol_19\NN\3740161| (r_npadvmod) induced_21\VBN\1627355|isoproterenol|- (r_amod) infarction_23\NN\14204950|induced|myocardial
D000244_D012131 NONE adp_13\NNP\14964590| (r_nmod) o_15\NNP\14622893|adp|/ (r_conj) ratio_11\NN\13815152|decreased|control|and|o (r_pobj) by_7\IN\0|ratio (r_agent) characterized_6\VBN\609683|by (r_acl) dysfunction_5\NN\14204950|mitochondrial|respiratory|characterized
D007545_D012131 NONE isoproterenol_19\NN\3740161| (r_npadvmod) treated_21\VBN\2376958|isoproterenol|- (r_amod) rats_22\NNS\2329401|treated (r_pobj) in_18\IN\13603305|rats (r_prep) observed_17\VBN\2163746|in|,|dysfunction|was|in|. (l_nsubjpass) dysfunction_5\NN\14204950|mitochondrial|respiratory|characterized
C066201_D006331 NONE a_4\NN\13649268|acid (r_appos) administration_0\NN\1133281|of|a|for|dysfunction|and|improved (l_conj) dysfunction_17\NN\14204950|attenuated|induced|cardiac|and|injury
C066201_D009202 NONE a_4\NN\13649268|acid (r_appos) administration_0\NN\1133281|of|a|for|dysfunction|and|improved (l_conj) dysfunction_17\NN\14204950|attenuated|induced|cardiac|and|injury (l_conj) injury_20\NN\14052046|myocardial
C066201_D009202 NONE a_6\NN\13649268|acid (r_pobj) of_3\IN\0|salvianolic|a (r_prep) role_2\NN\719494|the|protective|of|against (l_prep) against_7\IN\0|damage (l_pobj) damage_12\NN\7296428|induced|myocardial
D007545_D006331 NONE isoproterenol_13\NN\3740161| (r_npadvmod) induced_15\VBN\1627355|isoproterenol|- (r_amod) dysfunction_17\NN\14204950|attenuated|induced|cardiac|and|injury
D007545_D009202 NONE isoproterenol_13\NN\3740161| (r_npadvmod) induced_15\VBN\1627355|isoproterenol|- (r_amod) dysfunction_17\NN\14204950|attenuated|induced|cardiac|and|injury (l_conj) injury_20\NN\14052046|myocardial
D007545_D009202 NONE isoproterenol_8\NN\3740161| (r_npadvmod) induced_10\VBN\1627355|isoproterenol|- (r_amod) damage_12\NN\7296428|induced|myocardial
1527456
D008012_D014012 NONE lignocaine_7\NN\0|lidocaine (r_pobj) of_6\IN\0|lignocaine (r_prep) instillation_5\NN\320852|intratympanic|of (r_pobj) by_3\IN\0|instillation (r_prep) treatment_0\NN\654885|of|by|2|through|. (l_prep) of_1\IN\0|tinnitus (l_pobj) tinnitus_2\NN\14299637|
D008012_D014012 NONE lidocaine_9\NN\3681148|(|) (r_appos) lignocaine_7\NN\0|lidocaine (r_pobj) of_6\IN\0|lignocaine (r_prep) instillation_5\NN\320852|intratympanic|of (r_pobj) by_3\IN\0|instillation (r_prep) treatment_0\NN\654885|of|by|2|through|. (l_prep) of_1\IN\0|tinnitus (l_pobj) tinnitus_2\NN\14299637|
D008012_D014012 NONE lignocaine_12\NN\0|lidocaine (r_pobj) of_11\IN\0|lignocaine (r_prep) instillation_10\NN\320852|intratympanic|of (r_pobj) by_8\IN\0|instillation (r_prep) treating_6\VBG\2376958|ist|by (l_dobj) ist_7\NNP\0|
D008012_D014012 NONE lidocaine_14\NN\3681148|(|) (r_appos) lignocaine_12\NN\0|lidocaine (r_pobj) of_11\IN\0|lignocaine (r_prep) instillation_10\NN\320852|intratympanic|of (r_pobj) by_8\IN\0|instillation (r_prep) treating_6\VBG\2376958|ist|by (l_dobj) ist_7\NNP\0|
9523805
D011318_D009422 CID prilocaine_11\NN\0|and|bupivacaine (r_pobj) with_10\IN\0|prilocaine (r_prep) incidence_9\NN\13821570|a|lower|with|than (r_appos) symptoms_2\NNS\5823932|transient|neurologic|after|:|incidence|.
D011318_D009422 CID prilocaine_11\JJ\0|with (l_prep) with_12\IN\0|lidocaine (l_pobj) lidocaine_13\NN\3681148|and|bupivacaine (l_conj) bupivacaine_15\NN\0|with (l_prep) with_16\IN\0|respect (l_pobj) respect_17\NN\5817845|to (l_prep) to_18\IN\0|duration (l_pobj) duration_19\NN\15113229|of (l_prep) of_20\IN\0|action (l_pobj) action_21\NN\30358|and|risk (l_conj) risk_24\NN\14541044|relative|of (l_prep) of_25\IN\0|tnss (l_pobj) tnss_26\NNS\0|
D011318_D009422 CID prilocaine_15\NN\0|(|p|) (r_dobj) receiving_14\VBG\2210855|prilocaine (r_acl) patients_13\NNS\9898892|30|receiving (r_nsubj) had_21\VBD\0|:|patients|,|patients|them|,|and|had (l_nsubj) patients_4\NNS\9898892|30|receiving (l_acl) receiving_5\VBG\2210855|lidocaine|tnss (l_dobj) tnss_8\NNS\0|experienced
D011318_D009422 CID prilocaine_15\NN\0|(|p|) (r_dobj) receiving_14\VBG\2210855|prilocaine (r_acl) patients_13\NNS\9898892|30|receiving (r_nsubj) had_21\VBD\0|:|patients|,|patients|them|,|and|had (l_conj) had_31\VBD\0|none|tnss|. (l_dobj) tnss_32\NNS\0|
D011318_D009422 CID prilocaine_0\NNP\0| (r_nsubj) be_2\VB\14625458|prilocaine|may|preferable|has|. (l_advcl) has_12\VBZ\13888491|because|it|duration (l_dobj) duration_15\NN\15113229|a|similar|of|but|incidence (l_conj) incidence_21\NN\13821570|a|lower|of (l_prep) of_22\IN\0|tnss (l_pobj) tnss_23\NNS\0|
D002045_D009422 NONE bupivacaine_13\NN\0| (r_conj) prilocaine_11\NN\0|and|bupivacaine (r_pobj) with_10\IN\0|prilocaine (r_prep) incidence_9\NN\13821570|a|lower|with|than (r_appos) symptoms_2\NNS\5823932|transient|neurologic|after|:|incidence|.
D002045_D009422 NONE bupivacaine_19\NN\0| (r_pobj) with_18\IN\0|bupivacaine (r_prep) infrequent_17\JJ\0|with (r_acomp) are_16\VBP\13600404|infrequent (r_conj) follow_11\VBP\1835496|that|symptoms|frequently|anesthesia|but|are (l_nsubj) symptoms_6\NNS\5823932|transient|neurologic|(|tnss|)
D002045_D009422 NONE bupivacaine_19\NN\0| (r_pobj) with_18\IN\0|bupivacaine (r_prep) infrequent_17\JJ\0|with (r_acomp) are_16\VBP\13600404|infrequent (r_conj) follow_11\VBP\1835496|that|symptoms|frequently|anesthesia|but|are (l_nsubj) symptoms_6\NNS\5823932|transient|neurologic|(|tnss|) (l_appos) tnss_8\NNS\0|
D002045_D009422 NONE bupivacaine_15\NN\0|with (l_prep) with_16\IN\0|respect (l_pobj) respect_17\NN\5817845|to (l_prep) to_18\IN\0|duration (l_pobj) duration_19\NN\15113229|of (l_prep) of_20\IN\0|action (l_pobj) action_21\NN\30358|and|risk (l_conj) risk_24\NN\14541044|relative|of (l_prep) of_25\IN\0|tnss (l_pobj) tnss_26\NNS\0|
D002045_D009422 NONE bupivacaine_30\NN\0| (r_dobj) receiving_29\VBG\2210855|bupivacaine (r_acl) patients_28\NNS\9898892|30|receiving (r_pobj) of_26\IN\0|patients (r_prep) none_25\NN\15228378|of (r_nsubj) had_31\VBD\0|none|tnss|. (r_conj) had_21\VBD\0|:|patients|,|patients|them|,|and|had (l_nsubj) patients_4\NNS\9898892|30|receiving (l_acl) receiving_5\VBG\2210855|lidocaine|tnss (l_dobj) tnss_8\NNS\0|experienced
D002045_D009422 NONE bupivacaine_30\NN\0| (r_dobj) receiving_29\VBG\2210855|bupivacaine (r_acl) patients_28\NNS\9898892|30|receiving (r_pobj) of_26\IN\0|patients (r_prep) none_25\NN\15228378|of (r_nsubj) had_31\VBD\0|none|tnss|. (l_dobj) tnss_32\NNS\0|
D008012_D009422 CID lidocaine_16\NN\3681148| (r_pobj) with_15\IN\0|lidocaine (r_prep) than_14\IN\0|with (r_prep) incidence_9\NN\13821570|a|lower|with|than (r_appos) symptoms_2\NNS\5823932|transient|neurologic|after|:|incidence|.
D008012_D009422 CID lidocaine_12\NN\3681148| (r_amod) anesthesia_14\NN\14034177|lidocaine|spinal (r_dobj) follow_11\VBP\1835496|that|symptoms|frequently|anesthesia|but|are (l_nsubj) symptoms_6\NNS\5823932|transient|neurologic|(|tnss|)
D008012_D009422 CID lidocaine_12\NN\3681148| (r_amod) anesthesia_14\NN\14034177|lidocaine|spinal (r_dobj) follow_11\VBP\1835496|that|symptoms|frequently|anesthesia|but|are (l_nsubj) symptoms_6\NNS\5823932|transient|neurologic|(|tnss|) (l_appos) tnss_8\NNS\0|
D008012_D009422 CID lidocaine_13\NN\3681148|and|bupivacaine (l_conj) bupivacaine_15\NN\0|with (l_prep) with_16\IN\0|respect (l_pobj) respect_17\NN\5817845|to (l_prep) to_18\IN\0|duration (l_pobj) duration_19\NN\15113229|of (l_prep) of_20\IN\0|action (l_pobj) action_21\NN\30358|and|risk (l_conj) risk_24\NN\14541044|relative|of (l_prep) of_25\IN\0|tnss (l_pobj) tnss_26\NNS\0|
D008012_D009422 CID lidocaine_6\NN\3681148| (r_dobj) receiving_5\VBG\2210855|lidocaine|tnss (l_dobj) tnss_8\NNS\0|experienced
D008012_D009422 CID lidocaine_6\NN\3681148| (r_dobj) receiving_5\VBG\2210855|lidocaine|tnss (r_acl) patients_4\NNS\9898892|30|receiving (r_nsubj) had_21\VBD\0|:|patients|,|patients|them|,|and|had (l_conj) had_31\VBD\0|none|tnss|. (l_dobj) tnss_32\NNS\0|
D008012_D009422 CID lidocaine_5\NN\3681148|to|for (r_xcomp) preferable_3\JJ\0|lidocaine (r_acomp) be_2\VB\14625458|prilocaine|may|preferable|has|. (l_advcl) has_12\VBZ\13888491|because|it|duration (l_dobj) duration_15\NN\15113229|a|similar|of|but|incidence (l_conj) incidence_21\NN\13821570|a|lower|of (l_prep) of_22\IN\0|tnss (l_pobj) tnss_23\NNS\0|
137340
D009020_D006948 CID morphine_5\NN\2707683| (r_npadvmod) induced_7\VBN\1627355|morphine|- (r_amod) increase_8\NN\13576355|induced|in (l_prep) in_9\IN\13603305|activity (l_pobj) activity_11\NN\30358|locomotor|of
D009020_D006948 CID morphine_7\NN\2707683| (r_npadvmod) induced_9\VBN\1627355|morphine|- (r_amod) increase_10\NN\13576355|the|induced|in (l_prep) in_11\IN\13603305|activity (l_pobj) activity_13\NN\30358|locomotor|of
D009020_D006948 CID morphine_7\NN\2707683| (r_compound) hc1_9\NNP\0|morphine|- (r_pobj) of_6\IN\0|hc1 (r_prep) mg/kg_5\NN\0|10|of (r_pobj) of_3\IN\0|mg/kg (r_prep) administration_2\NN\1133281|the|subcutaneous|of (r_nsubj) produced_10\VBD\1617192|administration|increase|. (l_dobj) increase_13\NN\13576355|a|marked|in (l_prep) in_14\IN\13603305|activity (l_pobj) activity_16\NN\30358|locomotor|in
D009020_D006948 CID morphine_1\NN\2707683| (r_npadvmod) induced_3\VBN\1627355|morphine|- (r_amod) hyperactivity_4\NN\14052403|the|induced
D009020_D006948 CID morphine_26\NN\2707683| (r_pobj) by_25\IN\0|morphine (r_agent) produced_24\VBN\1617192|by (r_acl) hyperactivity_23\NN\14052403|the|produced
D012601_D006948 CID scopolamine_8\NN\14712692| (r_pobj) by_7\IN\0|scopolamine (r_agent) potentiated_6\VBN\229605|hyperactivity|was|by|and|attenuated|. (l_nsubjpass) hyperactivity_4\NN\14052403|the|induced
D010830_D006948 NONE physostigmine_12\NN\14712692| (r_pobj) by_11\IN\0|physostigmine (r_agent) attenuated_10\VBN\224901|by (r_conj) potentiated_6\VBN\229605|hyperactivity|was|by|and|attenuated|. (l_nsubjpass) hyperactivity_4\NN\14052403|the|induced
D019832_D006948 NONE methscopolamine_4\NN\0|both|and|neostigmine|,|penetrate (r_nsubj) had_18\VBD\0|in|,|methscopolamine|,|effect|. (l_dobj) effect_20\NN\34213|no|on (l_prep) on_21\IN\0|hyperactivity (l_pobj) hyperactivity_23\NN\14052403|the|produced
D009388_D006948 NONE neostigmine_6\NN\2718084| (r_conj) methscopolamine_4\NN\0|both|and|neostigmine|,|penetrate (r_nsubj) had_18\VBD\0|in|,|methscopolamine|,|effect|. (l_dobj) effect_20\NN\34213|no|on (l_prep) on_21\IN\0|hyperactivity (l_pobj) hyperactivity_23\NN\14052403|the|produced
D010134_D006948 NONE chlorophenylalamine_9\NN\0|p|-|(|i.p.|,|hr|) (r_pobj) with_6\IN\0|chlorophenylalamine (r_prep) pretreatment_5\NN\0|with (r_nsubj) caused_25\VBD\1617192|on|,|pretreatment|,|depletor|,|change|. (l_dobj) change_28\NN\7283608|no|significant|in (l_prep) in_29\IN\13603305|hyperactivity (l_pobj) hyperactivity_31\NN\14052403|the
D012701_D006948 NONE serotonin_22\NN\14807737| (r_compound) depletor_23\NN\0|a|serotonin (r_nsubj) caused_25\VBD\1617192|on|,|pretreatment|,|depletor|,|change|. (l_dobj) change_28\NN\7283608|no|significant|in (l_prep) in_29\IN\13603305|hyperactivity (l_pobj) hyperactivity_31\NN\14052403|the
18162529
D012313_D006966 NONE acid_5\NN\14818238|ribonucleic (r_compound) levels_6\NNS\4916342|hypothalamic|prolactin|messenger|acid|,|signaling (l_conj) signaling_9\NN\33020|prolactin|,|and|inhibition (l_conj) inhibition_13\NN\1068773|hyperprolactinemic|of (l_amod) hyperprolactinemic_12\JJ\0|
D004958_D006966 NONE estradiol_22\NN\14749794| (r_pobj) on_21\IN\0|estradiol (r_prep) dependent_20\JJ\9627906|on (r_acomp) are_19\VBP\13600404|levels|dependent|. (l_nsubj) levels_6\NNS\4916342|hypothalamic|prolactin|messenger|acid|,|signaling (l_conj) signaling_9\NN\33020|prolactin|,|and|inhibition (l_conj) inhibition_13\NN\1068773|hyperprolactinemic|of (l_amod) hyperprolactinemic_12\JJ\0|
D004958_D006966 NONE estradiol_30\NN\14749794| (r_pobj) of_29\IN\0|estradiol (r_prep) levels_28\NNS\4916342|chronic|low|of (r_pobj) of_25\IN\0|levels (r_prep) presence_24\NN\13954253|the|of (r_pobj) in_22\IN\13603305|only|presence (r_conj) caused_8\VBD\1617192|hyperprolactinemia|frequency|,|but|in|. (l_nsubj) hyperprolactinemia_1\NN\0|chronic|induced
D004967_D006966 NONE estrogen_20\NN\14745635| (r_npadvmod) induced_22\VBN\1627355|estrogen|- (r_amod) surge_24\NN\7405893|the|induced|lh (r_conj) secretion_17\NN\13526110|pulsatile|lh|and|surge (r_appos) parameters_9\NNS\5858936|two|neuroendocrine|necessary|:|secretion (r_dobj) inhibited_6\VBD\2510337|whether|hyperprolactinemia|parameters (l_nsubj) hyperprolactinemia_5\NN\0|chronic
D004298_D006966 NONE dopamine_5\NN\14807737| (r_compound) antagonist_6\NN\7846|dopamine (r_compound) sulpiride_7\NN\0|the|antagonist (r_pobj) by_3\IN\0|sulpiride (r_agent) induced_2\VBN\1627355|by (r_acl) hyperprolactinemia_1\NN\0|chronic|induced
D013469_D006966 CID sulpiride_7\NN\0|the|antagonist (r_pobj) by_3\IN\0|sulpiride (r_agent) induced_2\VBN\1627355|by (r_acl) hyperprolactinemia_1\NN\0|chronic|induced
D013256_D006966 NONE steroid_14\NN\14727670| (r_npadvmod) dependent_16\JJ\9627906|steroid|- (r_amod) manner_17\NN\4916342|a|dependent (r_pobj) in_12\IN\13603305|manner (r_prep) inhibited_8\VBN\2510337|that|frequency|is|by|in (l_agent) by_9\IN\0|hyperprolactinemia (l_pobj) hyperprolactinemia_11\NN\0|chronic
16904497
D013256_D011128 NONE steroid_5\NN\14727670| (r_compound) injection_6\NN\320852|epidural|steroid (r_pobj) after_3\IN\0|injection (r_prep) syndrome_2\NN\5870365|equina|after|:|report|.
D013256_D011843 NONE steroid_11\NN\14727670| (r_compound) injections_12\NNS\320852|epidural|steroid|,|medications (r_conj) therapy_8\NN\657604|physical|,|injections (r_attr) are_6\VBP\13600404|methods|therapy|. (l_nsubj) methods_2\NNS\5616786|conventional|treatment|of (l_prep) of_3\IN\0|radiculopathy (l_pobj) radiculopathy_5\NN\0|lumbusacral
D014221_D011128 NONE triamcinolone_16\NN\14751417|and|bupivacaine (r_pobj) of_15\IN\0|triamcinolone (r_prep) injection_14\NN\320852|epidural|of (r_pobj) by_12\IN\0|injection (r_agent) caused_11\VBN\1617192|possibly|by (r_acl) report_5\NN\6470073|a|of|caused (l_prep) of_6\IN\0|syndrome (l_pobj) syndrome_9\NN\5870365|cauda|equina
D002045_D011128 CID bupivacaine_18\NN\0| (r_conj) triamcinolone_16\NN\14751417|and|bupivacaine (r_pobj) of_15\IN\0|triamcinolone (r_prep) injection_14\NN\320852|epidural|of (r_pobj) by_12\IN\0|injection (r_agent) caused_11\VBN\1617192|possibly|by (r_acl) report_5\NN\6470073|a|of|caused (l_prep) of_6\IN\0|syndrome (l_pobj) syndrome_9\NN\5870365|cauda|equina
D013256_D017116 NONE steroid_16\NN\14727670| (r_compound) injection_17\NN\320852|epidural|steroid (r_pobj) for_14\IN\0|injection (r_prep) scheduled_13\VBN\704690|woman|was|for|. (l_nsubjpass) woman_4\NN\9605289|a|old|with (l_prep) with_5\IN\0|pain (l_pobj) pain_11\NN\14299637|back|leg
D013256_D010146 NONE steroid_16\NN\14727670| (r_compound) injection_17\NN\320852|epidural|steroid (r_pobj) for_14\IN\0|injection (r_prep) scheduled_13\VBN\704690|woman|was|for|. (l_nsubjpass) woman_4\NN\9605289|a|old|with (l_prep) with_5\IN\0|pain (l_pobj) pain_11\NN\14299637|back|leg
D013256_D009422 NONE steroid_10\NN\14727670| (r_compound) injections_11\NNS\320852|epidural|steroid (r_pobj) after_8\IN\0|injections (r_prep) vigilance_4\NN\5650579|continued|for|after (l_prep) for_5\IN\0|deterioration (l_pobj) deterioration_7\NN\14560612|neurologic
19884587
D013449_D000757 CID sulfonamides_0\NNS\2716205| (r_nsubjpass) associated_2\VBN\628491|sulfonamides|were|with (l_prep) with_3\IN\0|aor (l_pobj) aor_9\NNP\0|anencephaly|(|adjusted|or|[|]|3.4 (l_amod) anencephaly_4\NNS\14465048|
D013449_D018636 CID sulfonamides_0\NNS\2716205| (r_nsubjpass) associated_2\VBN\628491|sulfonamides|were|with (r_ccomp) interval_17\NN\33615|associated|;|%|confidence|ci|,|1.3|)|,|syndrome (l_appos) syndrome_30\NN\5870365|hypoplastic|left|heart
D009582_D000853 CID nitrofurantoins_0\NNS\2716205| (r_nsubjpass) associated_2\VBN\628491|nitrofurantoins|were|with|aor|. (l_prep) with_3\IN\0|anophthalmia (l_pobj) anophthalmia_4\NN\0|or|microphthalmos
D009582_D008850 CID nitrofurantoins_0\NNS\2716205| (r_nsubjpass) associated_2\VBN\628491|nitrofurantoins|were|with|aor|. (l_prep) with_3\IN\0|anophthalmia (l_pobj) anophthalmia_4\NN\0|or|microphthalmos (l_conj) microphthalmos_6\NNS\0|
D009582_D018636 CID nitrofurantoins_0\NNS\2716205| (r_nsubjpass) associated_2\VBN\628491|nitrofurantoins|were|with|aor|. (l_appos) aor_8\NNP\0|(|=|3.7|;|ci|,|syndrome|aor|aor (l_appos) syndrome_24\NN\5870365|hypoplastic|left|heart
D009582_D006344 CID nitrofurantoins_0\NNS\2716205| (r_nsubjpass) associated_2\VBN\628491|nitrofurantoins|were|with|aor|. (l_appos) aor_8\NNP\0|(|=|3.7|;|ci|,|syndrome|aor|aor (l_appos) aor_26\NNP\0|(|=|4.2|;|ci|)|,|defects|(|aor|;|ci|)|,|and|lip (l_appos) defects_41\NNS\14462666|atrial|septal
D009582_D002971 CID nitrofurantoins_0\NNS\2716205| (r_nsubjpass) associated_2\VBN\628491|nitrofurantoins|were|with|aor|. (l_appos) aor_8\NNP\0|(|=|3.7|;|ci|,|syndrome|aor|aor (l_appos) aor_26\NNP\0|(|=|4.2|;|ci|)|,|defects|(|aor|;|ci|)|,|and|lip (l_conj) lip_58\NN\5301392|cleft|with
D009582_D002972 CID nitrofurantoins_0\NNS\2716205| (r_nsubjpass) associated_2\VBN\628491|nitrofurantoins|were|with|aor|. (l_appos) aor_8\NNP\0|(|=|3.7|;|ci|,|syndrome|aor|aor (l_appos) aor_26\NNP\0|(|=|4.2|;|ci|)|,|defects|(|aor|;|ci|)|,|and|lip (l_conj) lip_58\NN\5301392|cleft|with (l_prep) with_59\IN\0|palate (l_pobj) palate_61\NN\8660339|cleft
D010406_D000014 NONE penicillins_2\NNS\2716866|,|erythromycins|,|used|, (r_nsubjpass) associated_18\VBN\628491|reassuringly|,|penicillins|were|not|with|. (l_prep) with_19\IN\0|defects (l_pobj) defects_22\NNS\14462666|many|birth
D004917_D000014 NONE erythromycins_4\NNS\2716866|,|and|cephalosporins (r_conj) penicillins_2\NNS\2716866|,|erythromycins|,|used|, (r_nsubjpass) associated_18\VBN\628491|reassuringly|,|penicillins|were|not|with|. (l_prep) with_19\IN\0|defects (l_pobj) defects_22\NNS\14462666|many|birth
D002511_D000014 NONE cephalosporins_7\NNS\2716866| (r_conj) erythromycins_4\NNS\2716866|,|and|cephalosporins (r_conj) penicillins_2\NNS\2716866|,|erythromycins|,|used|, (r_nsubjpass) associated_18\VBN\628491|reassuringly|,|penicillins|were|not|with|. (l_prep) with_19\IN\0|defects (l_pobj) defects_22\NNS\14462666|many|birth
D013449_D000014 CID sulfonamides_0\NNS\2716205|and|nitrofurantoins (r_nsubjpass) associated_4\VBN\628491|sulfonamides|were|with|,|indicating|. (l_prep) with_5\IN\0|defects (l_pobj) defects_8\NNS\14462666|several|birth
D009582_D000014 CID nitrofurantoins_2\NNS\2716205| (r_conj) sulfonamides_0\NNS\2716205|and|nitrofurantoins (r_nsubjpass) associated_4\VBN\628491|sulfonamides|were|with|,|indicating|. (l_prep) with_5\IN\0|defects (l_pobj) defects_8\NNS\14462666|several|birth
7248170
D010634_D006529 CID phenobarbitone_0\NNP\2792049| (r_npadvmod) induced_2\VBN\1627355|phenobarbitone|- (r_amod) enlargement_3\NN\363260|induced|of|:|relationship|. (l_prep) of_4\IN\0|liver (l_pobj) liver_6\NN\5298729|the|in
D010634_D006529 CID phenobarbitone_60\NN\2792049| (r_npadvmod) primed_62\VBN\406243|phenobarbitone|- (r_amod) rat_63\NN\2329401|the|primed (r_pobj) in_58\IN\13603305|rat (r_prep) given_56\VBN\5892096|ascites|tetrachloride|intragastrically|in|increased|. (l_conj) increased_65\VBN\169651|was|from|by (l_prep) by_72\IN\0|giving (l_pcomp) giving_73\VBG\1085793|calibrating|at (l_prep) at_83\IN\14622893|peak (l_pobj) peak_85\NN\13758296|the|of (l_prep) of_86\IN\0|enlargement (l_pobj) enlargement_91\NN\363260|the|induced|of (l_prep) of_92\IN\0|liver (l_pobj) liver_94\NN\5298729|the
D010634_D006529 CID phenobarbitone_88\NN\2792049| (r_npadvmod) induced_90\VBN\1627355|phenobarbitone|- (r_amod) enlargement_91\NN\363260|the|induced|of (l_prep) of_92\IN\0|liver (l_pobj) liver_94\NN\5298729|the
D010634_D005355 NONE phenobarbitone_0\NNP\2792049| (r_npadvmod) induced_2\VBN\1627355|phenobarbitone|- (r_amod) enlargement_3\NN\363260|induced|of|:|relationship|. (l_appos) relationship_12\NN\31921|its|to (l_prep) to_13\TO\0|cirrhosis (l_pobj) cirrhosis_18\NN\14116321|carbon|induced
D002251_D006529 NONE tetrachloride_15\NN\14818238| (r_advmod) induced_17\VBN\1627355|tetrachloride|- (r_amod) cirrhosis_18\NN\14116321|carbon|induced (r_pobj) to_13\TO\0|cirrhosis (r_prep) relationship_12\NN\31921|its|to (r_appos) enlargement_3\NN\363260|induced|of|:|relationship|. (l_prep) of_4\IN\0|liver (l_pobj) liver_6\NN\5298729|the|in
D002251_D006529 NONE tetrachloride_55\NN\14818238| (r_advmod) given_56\VBN\5892096|ascites|tetrachloride|intragastrically|in|increased|. (l_conj) increased_65\VBN\169651|was|from|by (l_prep) by_72\IN\0|giving (l_pcomp) giving_73\VBG\1085793|calibrating|at (l_prep) at_83\IN\14622893|peak (l_pobj) peak_85\NN\13758296|the|of (l_prep) of_86\IN\0|enlargement (l_pobj) enlargement_91\NN\363260|the|induced|of (l_prep) of_92\IN\0|liver (l_pobj) liver_94\NN\5298729|the
D002251_D006529 NONE tetrachloride_82\NN\14818238| (r_advmod) calibrating_77\VBG\296178|the|initial|"|"|dose|tetrachloride (r_dative) giving_73\VBG\1085793|calibrating|at (l_prep) at_83\IN\14622893|peak (l_pobj) peak_85\NN\13758296|the|of (l_prep) of_86\IN\0|enlargement (l_pobj) enlargement_91\NN\363260|the|induced|of (l_prep) of_92\IN\0|liver (l_pobj) liver_94\NN\5298729|the
D002251_D005355 NONE tetrachloride_15\NN\14818238| (r_advmod) induced_17\VBN\1627355|tetrachloride|- (r_amod) cirrhosis_18\NN\14116321|carbon|induced
D002251_D008103 CID tetrachloride_55\NN\14818238| (r_advmod) given_56\VBN\5892096|ascites|tetrachloride|intragastrically|in|increased|. (l_nsubj) ascites_20\VBZ\14204950|yield|greater|,|albumin (l_nsubj) yield_1\NN\913705|the|of (l_prep) of_2\IN\0|cirrhosis (l_pobj) cirrhosis_4\NN\14116321|severe|of (l_prep) of_5\IN\0|liver (l_pobj) liver_7\NN\5298729|the|(|defined|,
D002251_D008103 CID tetrachloride_82\NN\14818238| (r_advmod) calibrating_77\VBG\296178|the|initial|"|"|dose|tetrachloride (r_dative) giving_73\VBG\1085793|calibrating|at (r_pcomp) by_72\IN\0|giving (r_prep) increased_65\VBN\169651|was|from|by (r_conj) given_56\VBN\5892096|ascites|tetrachloride|intragastrically|in|increased|. (l_nsubj) ascites_20\VBZ\14204950|yield|greater|,|albumin (l_nsubj) yield_1\NN\913705|the|of (l_prep) of_2\IN\0|cirrhosis (l_pobj) cirrhosis_4\NN\14116321|severe|of (l_prep) of_5\IN\0|liver (l_pobj) liver_7\NN\5298729|the|(|defined|,
D002251_D001201 NONE tetrachloride_55\NN\14818238| (r_advmod) given_56\VBN\5892096|ascites|tetrachloride|intragastrically|in|increased|. (l_nsubj) ascites_20\VBZ\14204950|yield|greater|,|albumin
D002251_D001201 NONE tetrachloride_82\NN\14818238| (r_advmod) calibrating_77\VBG\296178|the|initial|"|"|dose|tetrachloride (r_dative) giving_73\VBG\1085793|calibrating|at (r_pcomp) by_72\IN\0|giving (r_prep) increased_65\VBN\169651|was|from|by (r_conj) given_56\VBN\5892096|ascites|tetrachloride|intragastrically|in|increased|. (l_nsubj) ascites_20\VBZ\14204950|yield|greater|,|albumin
D002251_D013163 NONE tetrachloride_55\NN\14818238| (r_advmod) given_56\VBN\5892096|ascites|tetrachloride|intragastrically|in|increased|. (l_nsubj) ascites_20\VBZ\14204950|yield|greater|,|albumin (l_conj) albumin_27\NN\14736972|plasma|less|,|splenomegaly (l_conj) splenomegaly_35\JJ\14366759|2|,|and|atrophy|after
D002251_D013163 NONE tetrachloride_82\NN\14818238| (r_advmod) calibrating_77\VBG\296178|the|initial|"|"|dose|tetrachloride (r_dative) giving_73\VBG\1085793|calibrating|at (r_pcomp) by_72\IN\0|giving (r_prep) increased_65\VBN\169651|was|from|by (r_conj) given_56\VBN\5892096|ascites|tetrachloride|intragastrically|in|increased|. (l_nsubj) ascites_20\VBZ\14204950|yield|greater|,|albumin (l_conj) albumin_27\NN\14736972|plasma|less|,|splenomegaly (l_conj) splenomegaly_35\JJ\14366759|2|,|and|atrophy|after
D002251_D001284 NONE tetrachloride_55\NN\14818238| (r_advmod) given_56\VBN\5892096|ascites|tetrachloride|intragastrically|in|increased|. (l_nsubj) ascites_20\VBZ\14204950|yield|greater|,|albumin (l_conj) albumin_27\NN\14736972|plasma|less|,|splenomegaly (l_conj) splenomegaly_35\JJ\14366759|2|,|and|atrophy|after (l_conj) atrophy_44\NN\14299637|testicular|weight|)
D002251_D001284 NONE tetrachloride_82\NN\14818238| (r_advmod) calibrating_77\VBG\296178|the|initial|"|"|dose|tetrachloride (r_dative) giving_73\VBG\1085793|calibrating|at (r_pcomp) by_72\IN\0|giving (r_prep) increased_65\VBN\169651|was|from|by (r_conj) given_56\VBN\5892096|ascites|tetrachloride|intragastrically|in|increased|. (l_nsubj) ascites_20\VBZ\14204950|yield|greater|,|albumin (l_conj) albumin_27\NN\14736972|plasma|less|,|splenomegaly (l_conj) splenomegaly_35\JJ\14366759|2|,|and|atrophy|after (l_conj) atrophy_44\NN\14299637|testicular|weight|)
D010634_D008103 CID phenobarbitone_60\NN\2792049| (r_npadvmod) primed_62\VBN\406243|phenobarbitone|- (r_amod) rat_63\NN\2329401|the|primed (r_pobj) in_58\IN\13603305|rat (r_prep) given_56\VBN\5892096|ascites|tetrachloride|intragastrically|in|increased|. (l_nsubj) ascites_20\VBZ\14204950|yield|greater|,|albumin (l_nsubj) yield_1\NN\913705|the|of (l_prep) of_2\IN\0|cirrhosis (l_pobj) cirrhosis_4\NN\14116321|severe|of (l_prep) of_5\IN\0|liver (l_pobj) liver_7\NN\5298729|the|(|defined|,
D010634_D008103 CID phenobarbitone_88\NN\2792049| (r_npadvmod) induced_90\VBN\1627355|phenobarbitone|- (r_amod) enlargement_91\NN\363260|the|induced|of (r_pobj) of_86\IN\0|enlargement (r_prep) peak_85\NN\13758296|the|of (r_pobj) at_83\IN\14622893|peak (r_prep) giving_73\VBG\1085793|calibrating|at (r_pcomp) by_72\IN\0|giving (r_prep) increased_65\VBN\169651|was|from|by (r_conj) given_56\VBN\5892096|ascites|tetrachloride|intragastrically|in|increased|. (l_nsubj) ascites_20\VBZ\14204950|yield|greater|,|albumin (l_nsubj) yield_1\NN\913705|the|of (l_prep) of_2\IN\0|cirrhosis (l_pobj) cirrhosis_4\NN\14116321|severe|of (l_prep) of_5\IN\0|liver (l_pobj) liver_7\NN\5298729|the|(|defined|,
D010634_D001201 NONE phenobarbitone_60\NN\2792049| (r_npadvmod) primed_62\VBN\406243|phenobarbitone|- (r_amod) rat_63\NN\2329401|the|primed (r_pobj) in_58\IN\13603305|rat (r_prep) given_56\VBN\5892096|ascites|tetrachloride|intragastrically|in|increased|. (l_nsubj) ascites_20\VBZ\14204950|yield|greater|,|albumin
D010634_D001201 NONE phenobarbitone_88\NN\2792049| (r_npadvmod) induced_90\VBN\1627355|phenobarbitone|- (r_amod) enlargement_91\NN\363260|the|induced|of (r_pobj) of_86\IN\0|enlargement (r_prep) peak_85\NN\13758296|the|of (r_pobj) at_83\IN\14622893|peak (r_prep) giving_73\VBG\1085793|calibrating|at (r_pcomp) by_72\IN\0|giving (r_prep) increased_65\VBN\169651|was|from|by (r_conj) given_56\VBN\5892096|ascites|tetrachloride|intragastrically|in|increased|. (l_nsubj) ascites_20\VBZ\14204950|yield|greater|,|albumin
D010634_D013163 NONE phenobarbitone_60\NN\2792049| (r_npadvmod) primed_62\VBN\406243|phenobarbitone|- (r_amod) rat_63\NN\2329401|the|primed (r_pobj) in_58\IN\13603305|rat (r_prep) given_56\VBN\5892096|ascites|tetrachloride|intragastrically|in|increased|. (l_nsubj) ascites_20\VBZ\14204950|yield|greater|,|albumin (l_conj) albumin_27\NN\14736972|plasma|less|,|splenomegaly (l_conj) splenomegaly_35\JJ\14366759|2|,|and|atrophy|after
D010634_D013163 NONE phenobarbitone_88\NN\2792049| (r_npadvmod) induced_90\VBN\1627355|phenobarbitone|- (r_amod) enlargement_91\NN\363260|the|induced|of (r_pobj) of_86\IN\0|enlargement (r_prep) peak_85\NN\13758296|the|of (r_pobj) at_83\IN\14622893|peak (r_prep) giving_73\VBG\1085793|calibrating|at (r_pcomp) by_72\IN\0|giving (r_prep) increased_65\VBN\169651|was|from|by (r_conj) given_56\VBN\5892096|ascites|tetrachloride|intragastrically|in|increased|. (l_nsubj) ascites_20\VBZ\14204950|yield|greater|,|albumin (l_conj) albumin_27\NN\14736972|plasma|less|,|splenomegaly (l_conj) splenomegaly_35\JJ\14366759|2|,|and|atrophy|after
D010634_D001284 NONE phenobarbitone_60\NN\2792049| (r_npadvmod) primed_62\VBN\406243|phenobarbitone|- (r_amod) rat_63\NN\2329401|the|primed (r_pobj) in_58\IN\13603305|rat (r_prep) given_56\VBN\5892096|ascites|tetrachloride|intragastrically|in|increased|. (l_nsubj) ascites_20\VBZ\14204950|yield|greater|,|albumin (l_conj) albumin_27\NN\14736972|plasma|less|,|splenomegaly (l_conj) splenomegaly_35\JJ\14366759|2|,|and|atrophy|after (l_conj) atrophy_44\NN\14299637|testicular|weight|)
D010634_D001284 NONE phenobarbitone_88\NN\2792049| (r_npadvmod) induced_90\VBN\1627355|phenobarbitone|- (r_amod) enlargement_91\NN\363260|the|induced|of (r_pobj) of_86\IN\0|enlargement (r_prep) peak_85\NN\13758296|the|of (r_pobj) at_83\IN\14622893|peak (r_prep) giving_73\VBG\1085793|calibrating|at (r_pcomp) by_72\IN\0|giving (r_prep) increased_65\VBN\169651|was|from|by (r_conj) given_56\VBN\5892096|ascites|tetrachloride|intragastrically|in|increased|. (l_nsubj) ascites_20\VBZ\14204950|yield|greater|,|albumin (l_conj) albumin_27\NN\14736972|plasma|less|,|splenomegaly (l_conj) splenomegaly_35\JJ\14366759|2|,|and|atrophy|after (l_conj) atrophy_44\NN\14299637|testicular|weight|)
3782049
D008972_D012206 CID molindone_6\NN\3713736| (r_compound) administration_7\NN\1133281|molindone (r_pobj) following_5\VBG\8180190|administration (r_prep) rhabdomyolysis_4\NN\0|massive|following
D008972_D012206 CID molindone_18\NN\3713736| (r_compound) administration_19\NN\1133281|molindone (r_pobj) following_17\VBG\8180190|administration (r_prep) rhabdomyolysis_11\NN\0|massive|and|failure|following
D008972_D012559 NONE molindone_18\NN\3713736| (r_compound) administration_19\NN\1133281|molindone (r_pobj) following_17\VBG\8180190|administration (r_prep) rhabdomyolysis_11\NN\0|massive|and|failure|following (r_dobj) illustrate_9\VB\955601|to|rhabdomyolysis (r_xcomp) reported_7\VBN\831651|case|is|illustrate|. (l_nsubjpass) case_1\NN\7283608|the|of (l_prep) of_2\IN\0|patient (l_pobj) patient_5\NN\9898892|a|schizophrenic (l_amod) schizophrenic_4\JJ\10490141|
D008972_D058186 CID molindone_18\NN\3713736| (r_compound) administration_19\NN\1133281|molindone (r_pobj) following_17\VBG\8180190|administration (r_prep) rhabdomyolysis_11\NN\0|massive|and|failure|following (l_conj) failure_16\NN\66216|subsequent|acute|renal
17608141
D008694_D020258 NONE methamphetamine_2\NN\2704153| (r_npadvmod) induced_4\VBN\1627355|attenuation|methamphetamine|-|neurotoxicity|. (l_dobj) neurotoxicity_7\NN\0|nigrostriatal|dopaminergic|in|by
D008694_D020258 NONE methamphetamine_23\NN\2704153| (r_npadvmod) induced_25\VBN\1627355|methamphetamine|- (r_amod) neurotoxicity_28\NN\0|the|induced|nigrostriatal|dopamine
D008694_D020258 NONE methamphetamine_15\NN\2704153| (r_npadvmod) induced_17\VBN\1627355|methamphetamine|- (r_amod) neurotoxicity_20\NN\0|induced|nigrostriatal|dopamine
D008070_D020258 NONE lipopolysaccharide_11\NN\0| (r_compound) pretreatment_12\NN\0|lipopolysaccharide (r_pobj) by_10\IN\0|pretreatment (r_prep) neurotoxicity_7\NN\0|nigrostriatal|dopaminergic|in|by
D008070_D020258 NONE lipopolysaccharide_9\NN\0| (r_pobj) of_8\IN\0|lipopolysaccharide (r_prep) roles_7\NNS\719494|the|of|,|factor (l_appos) factor_17\NN\7326557|a|inflammatory|,|treatment (l_conj) treatment_19\NN\654885|in (l_prep) in_20\IN\13603305|modulating (l_pcomp) modulating_21\VBG\1724459|neurotoxicity (l_dobj) neurotoxicity_28\NN\0|the|induced|nigrostriatal|dopamine
D008070_D020258 NONE lipopolysaccharide_8\NN\0| (r_compound) pretreatment_9\NN\0|systemic|lipopolysaccharide|in (l_prep) in_10\IN\13603305|exerting (l_pcomp) exerting_11\VBG\1158872|protection (l_dobj) protection_13\NN\407535|effective|against (l_prep) against_14\IN\0|neurotoxicity (l_pobj) neurotoxicity_20\NN\0|induced|nigrostriatal|dopamine
D008694_D009422 NONE methamphetamine_10\NN\2704153| (r_npadvmod) induced_12\VBN\1627355|methamphetamine|- (r_amod) damage_15\NN\7296428|induced|dopaminergic|terminal
D004298_D020258 NONE dopamine_27\NN\14807737| (r_compound) neurotoxicity_28\NN\0|the|induced|nigrostriatal|dopamine
D004298_D020258 NONE dopamine_19\NN\14807737| (r_compound) neurotoxicity_20\NN\0|induced|nigrostriatal|dopamine
D008070_D005334 NONE lipopolysaccharide_0\JJ\0| (r_compound) pretreatment_1\NN\0|lipopolysaccharide (r_nsubj) affect_4\VB\26192|pretreatment|did|not|temperature|later|. (l_dobj) temperature_8\NN\13575869|the|basal|body|or|hyperthermia (l_conj) hyperthermia_13\NN\14034177|elicited
D008694_D005334 CID methamphetamine_10\NN\2704153| (r_npadvmod) elicited_12\VBN\1617192|methamphetamine|- (r_amod) hyperthermia_13\NN\14034177|elicited
9088814
D000527_D007022 CID e1-induced_5\JJ\0| (r_amod) hypotension_6\NN\14057371|prolonged|prostaglandin|e1-induced|and|haemodilution|on
D000527_D007022 CID e1_5\NN\0|prolonged|prostaglandin|hypotension (l_appos) hypotension_8\NN\14057371|(|pge1)-induced|and|haemodilution
D000527_D007022 CID pge1)-induced_7\JJ\0| (r_amod) hypotension_8\NN\14057371|(|pge1)-induced|and|haemodilution
D000527_D007022 CID pge1_10\NNP\0| (r_pobj) with_9\IN\0|pge1 (r_prep) induced_8\VBN\1627355|hypotension|was|with|maintain|. (l_nsubjpass) hypotension_1\NN\14057371|controlled|in
D000527_D007022 CID pge1-induced_13\JJ\0| (r_amod) hypotension_14\NN\14057371|pge1-induced|and|haemodilution
D000527_D020141 NONE e1-induced_5\JJ\0| (r_amod) hypotension_6\NN\14057371|prolonged|prostaglandin|e1-induced|and|haemodilution|on (l_conj) haemodilution_8\NN\0|
D000527_D020141 NONE e1_5\NN\0|prolonged|prostaglandin|hypotension (l_appos) hypotension_8\NN\14057371|(|pge1)-induced|and|haemodilution (l_conj) haemodilution_10\NN\0|on
D000527_D020141 NONE pge1)-induced_7\JJ\0| (r_amod) hypotension_8\NN\14057371|(|pge1)-induced|and|haemodilution (l_conj) haemodilution_10\NN\0|on
D000527_D020141 NONE pge1-induced_13\JJ\0| (r_amod) hypotension_14\NN\14057371|pge1-induced|and|haemodilution (l_conj) haemodilution_17\NN\0|moderate
D003911_D020141 NONE dextran_23\NN\0| (r_amod) solution_24\NN\14586258|dextran (r_pobj) of_22\IN\0|solution (r_prep) amount_21\NN\13329641|the|same|of (r_pobj) with_18\IN\0|amount (r_prep) replacing_16\VBG\196485|it|with (r_conj) withdrawing_9\VBG\1835496|ml|and|replacing (r_pcomp) by_8\IN\0|withdrawing (r_prep) produced_7\VBN\1617192|haemodilution|was|by|,|and|were (l_nsubjpass) haemodilution_0\NN\0|in
D001663_D007022 NONE bilirubin_68\NN\14756039|total (r_conj) ldh_65\NNP\0|and|bilirubin (r_conj) sgpt_63\NNP\0|,|ldh (r_appos) sgot_61\NNP\0|,|sgpt (r_nsubj) showed_69\VBD\2137132|sgot|increases|. (r_conj) showed_23\VBD\2137132|showed|,|akbr|decrease|and|at|after|,|and|showed (l_prep) after_42\IN\0|start|and|at|after (l_pobj) start_44\NN\7290905|the|of (l_prep) of_45\IN\0|hypotension (l_pobj) hypotension_46\NN\14057371|
D000527_D008107 CID pge1-induced_13\JJ\0| (r_amod) hypotension_14\NN\14057371|pge1-induced|and|haemodilution (r_pobj) of_12\IN\0|hypotension (r_prep) min_11\NN\15154774|120|of (r_pobj) of_7\IN\0|min (r_prep) combination_6\NN\7951464|a|prolonged|of (r_nsubj) cause_19\VB\7323922|that|combination|would|impairment (l_dobj) impairment_20\NN\7296428|of (l_prep) of_21\IN\0|function (l_pobj) function_23\NN\13783581|hepatic
3615541
D000661_D006948 CID amphetamine_6\NN\3248958| (r_npadvmod) induced_8\VBN\1627355|amphetamine|- (r_amod) hyperactivity_9\NN\14052403|induced
D002116_D006948 NONE calcitonin_12\NN\5413241| (r_compound) injections_13\NNS\320852|intracerebral|calcitonin (r_pobj) by_10\IN\0|injections (r_prep) antagonism_4\NN\24720|the|of|by (l_prep) of_5\IN\0|hyperactivity (l_pobj) hyperactivity_9\NN\14052403|induced
2572625
C084599_D056486 CID clotiazepam_0\NNP\0| (r_npadvmod) induced_2\VBN\1627355|clotiazepam|- (r_amod) hepatitis_4\NN\14127211|induced|acute|.
C084599_D056486 CID clotiazepam_24\NN\0| (r_pobj) of_23\IN\0|clotiazepam (r_prep) administration_22\NN\1133281|of (r_pobj) of_21\IN\0|administration (r_prep) onset_20\NN\7325190|the|of (r_pobj) after_18\IN\0|months|onset (r_prep) developed_8\VBD\1753788|who|hepatitis|with|after (l_dobj) hepatitis_10\NN\14127211|acute
C084599_D056486 CID clotiazepam_9\NN\0|to (r_xcomp) related_7\VBN\628491|chemically|clotiazepam (r_acl) administration_1\NN\1133281|the|of|,|related (r_nsubj) interfere_13\VB\2451370|administration|,|did|not|with|and|induce|. (l_conj) induce_19\VB\1627355|did|not|relapse (l_dobj) relapse_21\NN\66636|any|of (l_prep) of_22\IN\0|hepatitis (l_pobj) hepatitis_23\NN\14127211|
C084599_D056486 CID clotiazepam_4\NN\0| (r_nsubj) induce_6\VB\1627355|that|clotiazepam|can|hepatitis|and|suggests (l_dobj) hepatitis_8\NN\14127211|acute
C084599_D056486 CID clotiazepam_4\NN\0| (r_nsubj) induce_6\VB\1627355|that|clotiazepam|can|hepatitis|and|suggests (l_conj) suggests_10\VBZ\1010118|is (l_ccomp) is_13\VBZ\0|that|there|hepatotoxicity (l_attr) hepatotoxicity_16\NN\0|cross|between
C084599_D056486 CID clotiazepam_18\NN\0|and|benzodiazepines (r_pobj) between_17\IN\0|clotiazepam (r_prep) hepatotoxicity_16\NN\0|cross|between (r_attr) is_13\VBZ\0|that|there|hepatotoxicity (r_ccomp) suggests_10\VBZ\1010118|is (r_conj) induce_6\VB\1627355|that|clotiazepam|can|hepatitis|and|suggests (l_dobj) hepatitis_8\NN\14127211|acute
C084599_D056486 CID clotiazepam_18\NN\0|and|benzodiazepines (r_pobj) between_17\IN\0|clotiazepam (r_prep) hepatotoxicity_16\NN\0|cross|between
C084599_D047508 NONE clotiazepam_24\NN\0| (r_pobj) of_23\IN\0|clotiazepam (r_prep) administration_22\NN\1133281|of (r_pobj) of_21\IN\0|administration (r_prep) onset_20\NN\7325190|the|of (r_pobj) after_18\IN\0|months|onset (r_prep) developed_8\VBD\1753788|who|hepatitis|with|after (l_prep) with_11\IN\0|necrosis (l_pobj) necrosis_14\NN\11444117|extensive|hepatocellular|,
C013295_D056486 NONE thienodiazepine_27\NN\0| (r_amod) derivative_28\NN\5802185|a|thienodiazepine (r_appos) patient_6\NN\9898892|a|developed|,|derivative (l_relcl) developed_8\VBD\1753788|who|hepatitis|with|after (l_dobj) hepatitis_10\NN\14127211|acute
C013295_D047508 NONE thienodiazepine_27\NN\0| (r_amod) derivative_28\NN\5802185|a|thienodiazepine (r_appos) patient_6\NN\9898892|a|developed|,|derivative (l_relcl) developed_8\VBD\1753788|who|hepatitis|with|after (l_prep) with_11\IN\0|necrosis (l_pobj) necrosis_14\NN\11444117|extensive|hepatocellular|,
D001569_D056486 NONE benzodiazepines_4\NNS\3771443|several (r_pobj) of_2\IN\0|benzodiazepines (r_prep) administration_1\NN\1133281|the|of|,|related (r_nsubj) interfere_13\VB\2451370|administration|,|did|not|with|and|induce|. (l_conj) induce_19\VB\1627355|did|not|relapse (l_dobj) relapse_21\NN\66636|any|of (l_prep) of_22\IN\0|hepatitis (l_pobj) hepatitis_23\NN\14127211|
D001569_D056486 NONE benzodiazepines_21\NNS\3771443|several (r_conj) clotiazepam_18\NN\0|and|benzodiazepines (r_pobj) between_17\IN\0|clotiazepam (r_prep) hepatotoxicity_16\NN\0|cross|between (r_attr) is_13\VBZ\0|that|there|hepatotoxicity (r_ccomp) suggests_10\VBZ\1010118|is (r_conj) induce_6\VB\1627355|that|clotiazepam|can|hepatitis|and|suggests (l_dobj) hepatitis_8\NN\14127211|acute
D001569_D056486 NONE benzodiazepines_21\NNS\3771443|several (r_conj) clotiazepam_18\NN\0|and|benzodiazepines (r_pobj) between_17\IN\0|clotiazepam (r_prep) hepatotoxicity_16\NN\0|cross|between
6229975
D013999_D009203 NONE timolol_8\NN\2832168| (r_compound) treatment_9\NN\654885|term|timolol|after (l_prep) after_10\IN\0|infarction (l_pobj) infarction_12\NN\14204950|myocardial
D013999_D009203 NONE timolol_6\NN\2832168| (r_compound) treatment_7\NN\654885|term|timolol|on (r_pobj) of_2\IN\0|treatment (r_prep) effect_1\NN\34213|the|of|after (l_prep) after_11\IN\0|infarction (l_pobj) infarction_13\NN\14204950|myocardial
D013999_D009203 NONE timolol_33\NN\2832168|115|) (r_conj) evaluated_15\VBN\670261|effect|was|by|in|timolol|. (l_nsubjpass) effect_1\NN\34213|the|of|after (l_prep) after_11\IN\0|infarction (l_pobj) infarction_13\NN\14204950|myocardial
D013999_D001919 NONE timolol_6\NN\2832168| (r_npadvmod) induced_8\VBN\1627355|timolol|- (r_amod) bradycardia_9\NN\14110674|induced|and|increase
D013999_D007238 NONE timolol_17\NN\2832168| (r_compound) group_18\NN\2137|the|timolol (r_pobj) in_15\IN\13603305|group (r_prep) remained_13\VBD\2604760|unchanged|in (r_conj) increased_7\VBD\169651|after|,|size|in|and|remained|. (l_punct) ,_4\,\0|infarction (l_punct) infarction_3\NN\14204950|-
891050
D003276_D006463 CID contraceptives_17\NNS\3183080|oral (r_dobj) taking_15\VBG\37396|contraceptives (r_acl) woman_14\NN\9605289|a|taking (r_pobj) in_12\IN\13603305|woman (r_prep) syndrome_8\NN\5870365|the|hemolytic|uremic|(|hus|)|in
D003276_D006463 CID contraceptives_17\NNS\3183080|oral (r_dobj) taking_15\VBG\37396|contraceptives (r_acl) woman_14\NN\9605289|a|taking (r_pobj) in_12\IN\13603305|woman (r_prep) syndrome_8\NN\5870365|the|hemolytic|uremic|(|hus|)|in (l_appos) hus_10\NNP\0|
D006493_D001002 NONE heparin_4\JJ\2718259|,|dipyridamole (r_pobj) with_3\IN\0|heparin (r_prep) treated_2\VBN\2376958|she|was|with|;|and|rose (l_conj) rose_20\VBD\13112664|after|,|output|above|;|and|stopped|. (l_conj) stopped_37\VBN\0|after|,|treatment|was (l_prep) after_28\IN\0|months|onset (l_pobj) onset_30\NN\7325190|the|of (l_prep) of_31\IN\0|anuria (l_pobj) anuria_32\NN\14061805|
D004176_D001002 NONE dipyridamole_6\NN\0|and|hemodialysis (r_conj) heparin_4\JJ\2718259|,|dipyridamole (r_pobj) with_3\IN\0|heparin (r_prep) treated_2\VBN\2376958|she|was|with|;|and|rose (l_conj) rose_20\VBD\13112664|after|,|output|above|;|and|stopped|. (l_conj) stopped_37\VBN\0|after|,|treatment|was (l_prep) after_28\IN\0|months|onset (l_pobj) onset_30\NN\7325190|the|of (l_prep) of_31\IN\0|anuria (l_pobj) anuria_32\NN\14061805|
2894766
D012460_D008180 CID sulfasalazine_0\NNP\0| (r_npadvmod) induced_2\VBN\1627355|sulfasalazine|- (r_amod) erythematosus_4\NN\0|induced|lupus|.
D012460_D008180 CID sulfasalazine_7\RB\0| (r_npadvmod) induced_9\VBN\1627355|sulfasalazine|- (r_amod) lupus_10\NN\14219661|induced|,|manifested
D012460_D008180 CID sulfasalazine_3\NN\0| (r_dobj) use_2\VBP\407535|who|sulfasalazine|treat (r_relcl) physicians_0\NNS\10305802|use (r_nsubj) be_12\VB\14625458|physicians|should|aware|. (l_acomp) aware_13\JJ\0|of (l_prep) of_14\IN\0|signs (l_pobj) signs_16\NNS\6643763|the|of (l_prep) of_17\IN\0|syndrome (l_pobj) syndrome_22\NN\5870365|induced|lupus
D012460_D008180 CID sulfasalazine_18\NN\0| (r_npadvmod) induced_20\VBN\1627355|sulfasalazine|- (r_amod) syndrome_22\NN\5870365|induced|lupus
D012460_D011014 CID sulfasalazine_29\NN\0| (r_compound) therapy_30\NN\657604|term|sulfasalazine (r_dobj) receiving_25\VBG\2210855|who|was|therapy|for (r_relcl) man_21\NN\9605289|a|old|,|receiving (r_pobj) in_16\IN\13603305|man (r_prep) developed_15\VBN\1753788|in (r_acl) autoantibodies_14\NNS\15027189|positive|developed (r_conj) evidence_7\NN\5816287|echocardiographic|of|,|and|autoantibodies (r_appos) effusions_4\NNS\6880249|pneumonitis|,|bilateral|pleural|,|evidence|. (l_dep) pneumonitis_0\NNP\14336539|
D012460_D010996 CID sulfasalazine_29\NN\0| (r_compound) therapy_30\NN\657604|term|sulfasalazine (r_dobj) receiving_25\VBG\2210855|who|was|therapy|for (r_relcl) man_21\NN\9605289|a|old|,|receiving (r_pobj) in_16\IN\13603305|man (r_prep) developed_15\VBN\1753788|in (r_acl) autoantibodies_14\NNS\15027189|positive|developed (r_conj) evidence_7\NN\5816287|echocardiographic|of|,|and|autoantibodies (r_appos) effusions_4\NNS\6880249|pneumonitis|,|bilateral|pleural|,|evidence|.
D012460_D002305 CID sulfasalazine_29\NN\0| (r_compound) therapy_30\NN\657604|term|sulfasalazine (r_dobj) receiving_25\VBG\2210855|who|was|therapy|for (r_relcl) man_21\NN\9605289|a|old|,|receiving (r_pobj) in_16\IN\13603305|man (r_prep) developed_15\VBN\1753788|in (r_acl) autoantibodies_14\NNS\15027189|positive|developed (r_conj) evidence_7\NN\5816287|echocardiographic|of|,|and|autoantibodies (l_prep) of_8\IN\0|tamponade (l_pobj) tamponade_10\NN\14507951|cardiac
D012460_D003093 NONE sulfasalazine_29\NN\0| (r_compound) therapy_30\NN\657604|term|sulfasalazine (r_dobj) receiving_25\VBG\2210855|who|was|therapy|for (l_prep) for_31\IN\0|colitis (l_pobj) colitis_34\NN\14336539|chronic|ulcerative
D012460_D012700 NONE sulfasalazine_7\RB\0| (r_npadvmod) induced_9\VBN\1627355|sulfasalazine|- (r_amod) lupus_10\NN\14219661|induced|,|manifested (l_relcl) manifested_13\VBD\1015244|which|with|in (l_prep) with_14\IN\0|serositis (l_pobj) serositis_15\NN\0|and|involvement
D012460_D015212 NONE sulfasalazine_3\NN\0| (r_dobj) use_2\VBP\407535|who|sulfasalazine|treat (l_xcomp) treat_5\VB\7570720|to|patients (l_dobj) patients_6\NNS\9898892|with (l_prep) with_7\IN\0|disease (l_pobj) disease_10\NN\14061805|inflammatory|bowel
D012460_D015212 NONE sulfasalazine_18\NN\0| (r_npadvmod) induced_20\VBN\1627355|sulfasalazine|- (r_amod) syndrome_22\NN\5870365|induced|lupus (r_pobj) of_17\IN\0|syndrome (r_prep) signs_16\NNS\6643763|the|of (r_pobj) of_14\IN\0|signs (r_prep) aware_13\JJ\0|of (r_acomp) be_12\VB\14625458|physicians|should|aware|. (l_nsubj) physicians_0\NNS\10305802|use (l_relcl) use_2\VBP\407535|who|sulfasalazine|treat (l_xcomp) treat_5\VB\7570720|to|patients (l_dobj) patients_6\NNS\9898892|with (l_prep) with_7\IN\0|disease (l_pobj) disease_10\NN\14061805|inflammatory|bowel
6727060
D008787_D004409 CID metoclopramide_7\NN\0| (r_pobj) by_6\IN\0|metoclopramide (r_agent) caused_5\VBN\1617192|by (r_acl) dyskinesia_4\JJ\14084880|tardive|caused
D008787_D004409 CID metoclopramide_23\RB\0| (r_dobj) took_22\VBD\2367363|after|he|metoclopramide|for|in (r_advcl) appeared_3\VBD\2604760|movements|in|took|. (l_nsubj) movements_2\NNS\191142|abnormal|involuntary
D008787_D004409 CID metoclopramide_2\JJ\0| (r_compound) administration_3\NN\1133281|the|metoclopramide (r_nsubjpass) discontinued_5\VBN\0|when|administration|was (r_advcl) improved_11\VBD\126264|discontinued|,|movements|gradually|to|. (l_nsubj) movements_9\NNS\191142|the|abnormal
D008787_D005767 NONE metoclopramide_23\RB\0| (r_dobj) took_22\VBD\2367363|after|he|metoclopramide|for|in (l_prep) for_24\IN\0|disorder (l_pobj) disorder_26\NN\14034177|gastrointestinal
2696505
D007741_D007022 CID labetalol_4\NN\2721160|and|nitroprusside (l_conj) nitroprusside_6\RB\0|for (l_prep) for_7\IN\0|hypotension (l_pobj) hypotension_9\NN\14057371|induced
D007741_D007022 CID labetalol_5\RB\2721160| (r_npadvmod) induced_7\VBN\1627355|labetalol|- (r_amod) hypotension_8\NN\14057371|induced|and|hypotension
D007741_D007022 CID labetalol_5\RB\2721160| (r_npadvmod) induced_7\VBN\1627355|labetalol|- (r_amod) hypotension_8\NN\14057371|induced|and|hypotension (l_conj) hypotension_13\NN\14057371|induced
D009599_D007022 CID nitroprusside_6\RB\0|for (l_prep) for_7\IN\0|hypotension (l_pobj) hypotension_9\NN\14057371|induced
D009599_D007022 CID nitroprusside_10\RB\0| (r_advmod) induced_12\VBN\1627355|nitroprusside|- (r_amod) hypotension_13\NN\14057371|induced (r_conj) hypotension_8\NN\14057371|induced|and|hypotension
D009599_D007022 CID nitroprusside_10\RB\0| (r_advmod) induced_12\VBN\1627355|nitroprusside|- (r_amod) hypotension_13\NN\14057371|induced
D009599_D016534 CID nitroprusside_31\NN\0| (r_pobj) of_30\IN\0|nitroprusside (r_prep) discontinuation_29\NN\209943|of (r_pobj) after_28\IN\0|discontinuation (r_prep) observed_24\VBN\2163746|associated|;|hypertension|was|in|after|. (l_ccomp) associated_3\VBN\628491|infusion|was|with|increase (l_advcl) increase_13\NN\13576355|in (l_prep) in_14\IN\13603305|rate (l_pobj) rate_16\NN\13815152|heart|and|output (l_conj) output_19\NN\4007894|cardiac
D009599_D006973 NONE nitroprusside_31\NN\0| (r_pobj) of_30\IN\0|nitroprusside (r_prep) discontinuation_29\NN\209943|of (r_pobj) after_28\IN\0|discontinuation (r_prep) observed_24\VBN\2163746|associated|;|hypertension|was|in|after|. (l_nsubjpass) hypertension_22\NN\14057371|rebound
17562951
D007479_D051436 NONE iopamidol_14\NN\0|and|iodixanol (r_pobj) of_13\IN\0|iopamidol (r_prep) comparison_12\NN\635850|a|multicenter|,|randomized|,|blind|of|in (l_prep) in_17\IN\13603305|patients (l_pobj) patients_18\NNS\9898892|with (l_prep) with_19\IN\0|disease (l_pobj) disease_22\NN\14061805|chronic|kidney
C044834_D051436 NONE iodixanol_16\NN\0| (r_conj) iopamidol_14\NN\0|and|iodixanol (r_pobj) of_13\IN\0|iopamidol (r_prep) comparison_12\NN\635850|a|multicenter|,|randomized|,|blind|of|in (l_prep) in_17\IN\13603305|patients (l_pobj) patients_18\NNS\9898892|with (l_prep) with_19\IN\0|disease (l_pobj) disease_22\NN\14061805|chronic|kidney
D000111_D003920 NONE acetylcysteine_16\NN\0|n|- (r_pobj) of_13\IN\0|acetylcysteine (r_prep) use_12\NN\407535|of (r_appos) volume_5\NN\33615|contrast|,|presence|,|use (l_appos) presence_7\NN\13954253|of (l_prep) of_8\IN\0|mellitus (l_pobj) mellitus_10\NN\0|diabetes
D007479_D003920 NONE iopamidol_24\NN\0|and|%|(|patients|) (r_pobj) with_23\IN\0|iopamidol|with (r_prep) were_14\VBD\0|dl|%|with|,|increases (r_conj) increases_6\VBZ\13576355|in|,|scr|>|were|. (l_prep) in_0\IN\13603305|patients (l_pobj) patients_1\NNS\9898892|with (l_prep) with_2\IN\0|diabetes (l_pobj) diabetes_3\NNS\14075199|
D007479_D003920 NONE iopamidol_23\NN\0|or|iodixanol (r_pobj) of_22\IN\0|iopamidol (r_prep) administration_21\NN\1133281|the|intraarterial|of|to|, (r_pobj) after_18\IN\0|administration (r_prep) is_14\VBZ\0|rate|not|different|after|with|. (l_prep) with_32\IN\0|or|without (l_conj) without_34\IN\0|mellitus (l_pobj) mellitus_36\NN\0|diabetes
C044834_D003920 NONE iodixanol_35\NN\0|(|p=0.11|) (r_pobj) with_34\IN\0|iodixanol (r_prep) with_23\IN\0|iopamidol|with (r_prep) were_14\VBD\0|dl|%|with|,|increases (r_conj) increases_6\VBZ\13576355|in|,|scr|>|were|. (l_prep) in_0\IN\13603305|patients (l_pobj) patients_1\NNS\9898892|with (l_prep) with_2\IN\0|diabetes (l_pobj) diabetes_3\NNS\14075199|
C044834_D003920 NONE iodixanol_25\NN\0| (r_conj) iopamidol_23\NN\0|or|iodixanol (r_pobj) of_22\IN\0|iopamidol (r_prep) administration_21\NN\1133281|the|intraarterial|of|to|, (r_pobj) after_18\IN\0|administration (r_prep) is_14\VBZ\0|rate|not|different|after|with|. (l_prep) with_32\IN\0|or|without (l_conj) without_34\IN\0|mellitus (l_pobj) mellitus_36\NN\0|diabetes
D007479_D007674 CID iopamidol_23\NN\0|or|iodixanol (r_pobj) of_22\IN\0|iopamidol (r_prep) administration_21\NN\1133281|the|intraarterial|of|to|, (r_pobj) after_18\IN\0|administration (r_prep) is_14\VBZ\0|rate|not|different|after|with|. (l_nsubj) rate_1\NN\13815152|the|of|,|defined|, (l_prep) of_2\IN\0|nephropathy (l_pobj) nephropathy_6\NN\14573196|induced
C044834_D007674 CID iodixanol_25\NN\0| (r_conj) iopamidol_23\NN\0|or|iodixanol (r_pobj) of_22\IN\0|iopamidol (r_prep) administration_21\NN\1133281|the|intraarterial|of|to|, (r_pobj) after_18\IN\0|administration (r_prep) is_14\VBZ\0|rate|not|different|after|with|. (l_nsubj) rate_1\NN\13815152|the|of|,|defined|, (l_prep) of_2\IN\0|nephropathy (l_pobj) nephropathy_6\NN\14573196|induced
1749407
D003042_D009203 CID cocaine_0\NN\3492717| (r_npadvmod) induced_2\VBN\1627355|cocaine|- (r_amod) infarction_4\NN\14204950|induced|myocardial|:|observations|.
D003042_D009203 CID cocaine_13\NN\3492717| (r_nsubj) result_15\VB\34213|by|cocaine|may|in (l_prep) in_16\IN\13603305|infarction (l_pobj) infarction_19\NN\14204950|acute|myocardial
D003042_D009203 CID cocaine_26\NN\3492717| (r_npadvmod) induced_28\VBN\1627355|cocaine|- (r_amod) increase_29\NN\13576355|induced|in (r_pobj) with_25\IN\0|increase (r_prep) associated_24\VBN\628491|with (r_acl) demand_23\NN\6513366|myocardial|oxygen|associated (r_pobj) in_20\IN\13603305|demand (r_prep) increase_19\NN\13576355|an|in (r_pobj) from_17\IN\0|increase (r_prep) result_16\VB\34213|in|,|infarction|may|from|. (l_nsubj) infarction_14\NN\14204950|acute|myocardial
D010100_D009203 NONE oxygen_22\NN\14622893| (r_compound) demand_23\NN\6513366|myocardial|oxygen|associated (r_pobj) in_20\IN\13603305|demand (r_prep) increase_19\NN\13576355|an|in (r_pobj) from_17\IN\0|increase (r_prep) result_16\VB\34213|in|,|infarction|may|from|. (l_nsubj) infarction_14\NN\14204950|acute|myocardial
D003042_D013035 NONE cocaine_16\NN\3492717| (r_npadvmod) induced_18\VBN\1627355|cocaine|- (r_amod) vasoconstriction_19\NN\1149911|induced (r_pobj) of_15\IN\0|vasoconstriction (r_prep) locus_14\NN\8645963|the|of (r_nsubj) remains_20\VBZ\2684|locus|speculative|. (r_conj) are_8\VBP\13600404|with|,|findings|circumstantial|,|and|remains (l_prep) with_0\IN\0|regard (l_pobj) regard_1\NN\5817845|to (l_prep) to_2\IN\0|spasm (l_pobj) spasm_3\NN\14299637|
D003042_D013927 NONE cocaine_11\NN\3492717| (r_pobj) of_10\IN\0|cocaine (r_prep) effect_9\NN\34213|a|primary|,|thrombotic|of (l_amod) thrombotic_8\JJ\0|
8595686
D013874_D010146 NONE thiopentone_0\NN\0| (r_compound) pretreatment_1\NN\0|thiopentone|for|. (l_prep) for_2\IN\0|pain (l_pobj) pain_5\NN\14299637|propofol|injection|in
D013874_D010146 NONE thiopentone_17\NN\0| (r_nsubj) reduces_19\VBZ\441445|whereas|thiopentone|only|severity (r_advcl) reduces_4\VBZ\441445|that|lidocaine|incidence|reduces (l_dobj) incidence_6\NN\13821570|the|and|severity|of (l_prep) of_9\IN\0|pain (l_pobj) pain_12\NN\14299637|propofol|injection|in
D015742_D010146 CID propofol_3\JJ\0| (r_amod) pain_5\NN\14299637|propofol|injection|in
D015742_D010146 CID propofol_3\JJ\0| (r_amod) pain_5\NN\14299637|propofol|injection|in
D015742_D010146 CID propofol_10\JJ\0| (r_amod) pain_12\NN\14299637|propofol|injection|in
D008012_D010146 NONE lidocaine_3\NN\3681148| (r_nsubj) reduces_4\VBZ\441445|that|lidocaine|incidence|reduces (l_dobj) incidence_6\NN\13821570|the|and|severity|of (l_prep) of_9\IN\0|pain (l_pobj) pain_12\NN\14299637|propofol|injection|in
12198388
D000109_D012640 NONE acetylcholine_4\NN\14807558| (r_compound) release_5\NN\3748886|hippocampal|acetylcholine|and|sensitivity (l_conj) sensitivity_9\NN\5651971|cholinergic|convulsant|in (l_prep) in_10\IN\13603305|lines (l_pobj) lines_22\NNS\8426461|withdrawal|prone|resistant|selected|mouse (l_amod) prone_14\JJ\0|seizure|-|and|withdrawal (l_npadvmod) seizure_12\NN\14081375|
D000109_D012640 NONE acetylcholine_4\NN\14807558| (r_compound) release_5\NN\3748886|hippocampal|acetylcholine|and|sensitivity (l_conj) sensitivity_9\NN\5651971|cholinergic|convulsant|in (l_prep) in_10\IN\13603305|lines (l_pobj) lines_22\NNS\8426461|withdrawal|prone|resistant|selected|mouse (l_amod) resistant_19\JJ\0|seizure|- (l_npadvmod) seizure_17\NN\14081375|
D000109_D012640 NONE ach_1\NNS\0|hippocampal (r_nsubjpass) measured_4\VBN\697589|ach|also|was|during|. (l_prep) during_5\IN\0|testing (l_pobj) testing_6\VBG\639556|for (l_prep) for_7\IN\0|convulsions (l_pobj) convulsions_11\NNS\14081375|induced
D000109_D012640 NONE ach_2\NNS\0|hippocampal (r_nsubjpass) measured_4\VBN\697589|when|ach|was|during (l_prep) during_5\IN\0|testing (l_pobj) testing_6\VBG\639556|for (l_prep) for_7\IN\0|convulsions (l_pobj) convulsions_11\NNS\14081375|induced
D000109_D012640 NONE ach_14\NNS\0|extracellular (r_nsubjpass) elevated_17\JJ\4048568|measured|,|ach|was|significantly|%|in|,|but|elevated|. (l_advcl) measured_4\VBN\697589|when|ach|was|during (l_prep) during_5\IN\0|testing (l_pobj) testing_6\VBG\639556|for (l_prep) for_7\IN\0|convulsions (l_pobj) convulsions_11\NNS\14081375|induced
D000431_D012640 NONE alcohol_6\NN\7881800| (r_compound) na_8\TO\14625458|alcohol|- (r_aux) ve_9\VB\0|na|mice (l_dobj) mice_23\NNS\2329401|prone|(|wsr|) (l_nmod) prone_13\NNP\0|withdrawal|seizure|-|(|wsp|and|resistant (l_compound) seizure_11\NN\14081375|
D000431_D012640 NONE ethanol_18\NN\14708720| (r_compound) withdrawal_19\NN\7206096|ethanol (r_compound) severity_20\NN\5036394|withdrawal (r_pobj) with_17\IN\0|severity (r_prep) associated_16\VBN\628491|that|differences|may|be|with|and|implicate (l_nsubjpass) differences_4\NNS\4723816|in (l_prep) in_5\IN\13603305|activity (l_pobj) activity_7\NN\30358|cholinergic|and|sensitivity (l_conj) sensitivity_10\NN\5651971|postsynaptic|to (l_prep) to_11\IN\0|convulsants (l_pobj) convulsants_13\NNS\0|cholinergic
D000431_D012640 NONE alcohol_26\NN\7881800| (r_compound) withdrawal_27\NN\7206096|alcohol (r_pobj) in_25\IN\13603305|withdrawal (r_prep) mechanisms_24\NNS\13446390|cholinergic|in (r_dobj) implicate_22\VB\2677097|mechanisms (r_conj) associated_16\VBN\628491|that|differences|may|be|with|and|implicate (l_nsubjpass) differences_4\NNS\4723816|in (l_prep) in_5\IN\13603305|activity (l_pobj) activity_7\NN\30358|cholinergic|and|sensitivity (l_conj) sensitivity_10\NN\5651971|postsynaptic|to (l_prep) to_11\IN\0|convulsants (l_pobj) convulsants_13\NNS\0|cholinergic
D009538_D014202 NONE nicotine_3\NN\14712692|,|carbachol (r_dobj) administered_2\VBN\2436349|animals|were|nicotine|,|and|recorded (l_conj) recorded_25\VBN\2225492|latencies|were|and|converted|. (l_nsubjpass) latencies_17\NNS\15269513|the|onset (l_relcl) onset_19\VB\7325190|to|of (l_prep) of_20\IN\0|tremor (l_pobj) tremor_21\NN\345926|and|clonus
D002217_D014202 NONE carbachol_5\NN\0|,|or|neostigmine (r_conj) nicotine_3\NN\14712692|,|carbachol (r_dobj) administered_2\VBN\2436349|animals|were|nicotine|,|and|recorded (l_conj) recorded_25\VBN\2225492|latencies|were|and|converted|. (l_nsubjpass) latencies_17\NNS\15269513|the|onset (l_relcl) onset_19\VB\7325190|to|of (l_prep) of_20\IN\0|tremor (l_pobj) tremor_21\NN\345926|and|clonus
D009388_D014202 NONE neostigmine_8\JJ\2718084|via (r_conj) carbachol_5\NN\0|,|or|neostigmine (r_conj) nicotine_3\NN\14712692|,|carbachol (r_dobj) administered_2\VBN\2436349|animals|were|nicotine|,|and|recorded (l_conj) recorded_25\VBN\2225492|latencies|were|and|converted|. (l_nsubjpass) latencies_17\NNS\15269513|the|onset (l_relcl) onset_19\VB\7325190|to|of (l_prep) of_20\IN\0|tremor (l_pobj) tremor_21\NN\345926|and|clonus
D009538_D012640 CID nicotine_7\NN\14712692|,|carbachol (r_pobj) by_6\IN\0|nicotine (r_agent) induced_5\VBN\1627355|by (r_acl) endpoints_4\NNS\8566028|several|convulsion|induced (l_compound) convulsion_3\NN\14081375|
D002217_D012640 CID carbachol_9\NN\0| (r_conj) nicotine_7\NN\14712692|,|carbachol (r_pobj) by_6\IN\0|nicotine (r_agent) induced_5\VBN\1627355|by (r_acl) endpoints_4\NNS\8566028|several|convulsion|induced (l_compound) convulsion_3\NN\14081375|
D009388_D012640 CID neostigmine_12\NN\2718084| (r_conj) sensitivity_0\NN\5651971|to|,|and|neostigmine (l_prep) to_1\IN\0|endpoints (l_pobj) endpoints_4\NNS\8566028|several|convulsion|induced (l_compound) convulsion_3\NN\14081375|
18791946
D002939_D013921 CID ciprofloxacin_7\NNS\2716866| (r_pobj) with_6\IN\0|ciprofloxacin (r_prep) associated_5\VBN\628491|with (r_acl) thrombocytopenia_1\JJ\14189204|severe|and|anaemia|associated
D002939_D013921 CID ciprofloxacin_5\NNS\2716866| (r_nsubj) precipitate_7\VB\15046900|that|ciprofloxacin|may|thrombocytopenia|,|in (l_dobj) thrombocytopenia_11\JJ\14189204|threatening|and|anaemia
D002939_D000743 CID ciprofloxacin_7\NNS\2716866| (r_pobj) with_6\IN\0|ciprofloxacin (r_prep) associated_5\VBN\628491|with (r_acl) thrombocytopenia_1\JJ\14189204|severe|and|anaemia|associated (l_conj) anaemia_4\NN\14299637|haemolytic
D002939_D000743 CID ciprofloxacin_5\NNS\2716866| (r_nsubj) precipitate_7\VB\15046900|that|ciprofloxacin|may|thrombocytopenia|,|in (l_dobj) thrombocytopenia_11\JJ\14189204|threatening|and|anaemia (l_conj) anaemia_14\NN\14299637|haemolytic
D002939_D015746 CID ciprofloxacin_16\NNS\2716866|oral (r_pobj) of_14\IN\0|ciprofloxacin (r_prep) administration_13\NN\1133281|3-day|of|for (r_pobj) after_11\IN\0|administration (r_prep) reported_5\VBN\831651|man|with|after|. (l_prep) with_6\IN\0|pain (l_pobj) pain_8\NN\14299637|abdominal|and|jaundice
D002939_D007565 CID ciprofloxacin_16\NNS\2716866|oral (r_pobj) of_14\IN\0|ciprofloxacin (r_prep) administration_13\NN\1133281|3-day|of|for (r_pobj) after_11\IN\0|administration (r_prep) reported_5\VBN\831651|man|with|after|. (l_prep) with_6\IN\0|pain (l_pobj) pain_8\NN\14299637|abdominal|and|jaundice (l_conj) jaundice_10\NN\14299637|
D002939_D014552 NONE ciprofloxacin_16\NNS\2716866|oral (r_pobj) of_14\IN\0|ciprofloxacin (r_prep) administration_13\NN\1133281|3-day|of|for (l_prep) for_17\IN\0|suspect (l_pobj) suspect_19\NN\7846|a|of (l_prep) of_20\IN\0|infection (l_pobj) infection_23\NN\14052046|urinary|tract
7890216
D015282_D042882 CID octreotide_7\NN\0| (r_pobj) with_6\IN\0|octreotide (r_prep) associated_5\VBN\628491|with (r_acl) stones_4\NNS\19128|gall|bladder|associated
D015282_D042882 CID octreotide_0\NNP\0|,|treatment (r_nsubj) induces_8\VBZ\1627355|octreotide|,|stones|in|. (l_dobj) stones_11\NNS\19128|gall|bladder
D015282_D042882 CID octreotide_28\NN\0|14 (r_pobj) in_26\IN\13603305|octreotide (r_prep) methods_25\NNS\5616786|direct|in (r_pobj) by_21\IN\0|methods (r_agent) investigated_20\VBN\644583|is|,|this|was|by|treated|. (l_conj) treated_29\VBD\2376958|patients|with (l_prep) with_32\IN\0|stones (l_pobj) stones_34\NNS\19128|gall
D015282_D042882 CID octreotide_3\NN\0| (r_advmod) induced_4\VBN\1627355|in|,|octreotide|stones|are|have (l_dobj) stones_6\NNS\19128|gall
D015282_D042882 CID octreotide_3\NN\0| (r_advmod) induced_4\VBN\1627355|in|,|octreotide|stones|are|have (l_ccomp) are_7\VBP\13600404|generally|small|although|,|in|, (l_prep) in_18\IN\13603305|common (l_pobj) common_19\JJ\8673395|with (l_prep) with_20\IN\0|disease (l_pobj) disease_24\NN\14061805|spontaneous|gall|stone
D015282_D042882 CID octreotide_3\NN\0| (r_advmod) induced_4\VBN\1627355|in|,|octreotide|stones|are|have (l_conj) have_31\VB\7846|at|patients|will|duct|. (l_dobj) duct_35\NN\5248181|a|blocked|cystic|and|stones (l_conj) stones_39\NNS\19128|some|gall|containing
D014580_D042882 NONE acid_13\NN\14818238|ursodeoxycholic (r_pobj) to_10\IN\0|acid (r_prep) response_9\NN\11410625|to (r_appos) composition_0\NN\5075602|of|:|response|. (l_prep) of_1\IN\0|stones (l_pobj) stones_4\NNS\19128|gall|bladder|associated
D015282_D000172 NONE octreotide_0\NNP\0|,|treatment (l_appos) treatment_4\NN\654885|an|effective|for (l_prep) for_5\IN\0|acromegaly (l_pobj) acromegaly_6\NNS\14366759|
D015282_D000172 NONE octreotide_28\NN\0|14 (r_pobj) in_26\IN\13603305|octreotide (r_prep) methods_25\NNS\5616786|direct|in (r_pobj) by_21\IN\0|methods (r_agent) investigated_20\VBN\644583|is|,|this|was|by|treated|. (l_conj) treated_29\VBD\2376958|patients|with (l_dobj) patients_31\NNS\9898892|acromegalic (l_compound) acromegalic_30\JJ\0|
D002784_D042882 NONE cholesterol_21\NN\15058310|%|by (r_conj) %_17\NN\0|71|and|cholesterol (r_dobj) contained_15\VBD\2632940|that|they|% (r_ccomp) showed_12\VBD\2137132|analysis|,|contained|. (l_nsubj) analysis_1\NN\633864|chemical|of (l_prep) of_2\IN\0|stones (l_pobj) stones_4\NNS\19128|gall|retrieved
D002784_D042882 NONE cholesterol_36\NN\15058310| (r_nsubj) rich_37\JJ\7942152|cholesterol (r_acomp) were_35\VBD\0|that|stones|rich (r_ccomp) suggesting_31\VBG\1010118|were (r_advcl) showed_12\VBD\2137132|after|,|five|dissolution|,|suggesting|. (l_dobj) dissolution_29\NN\13518963|either|partial|gall|stone (l_compound) stone_28\NN\19128|
D002784_D042882 NONE cholesterol_14\NN\15058310| (r_conj) multiple_11\JJ\5859630|,|and|cholesterol|rich (r_conj) small_9\JJ\5220461|,|multiple (r_acomp) are_7\VBP\13600404|generally|small|although|,|in|, (r_ccomp) induced_4\VBN\1627355|in|,|octreotide|stones|are|have (l_dobj) stones_6\NNS\19128|gall
D002784_D042882 NONE cholesterol_14\NN\15058310| (r_conj) multiple_11\JJ\5859630|,|and|cholesterol|rich (r_conj) small_9\JJ\5220461|,|multiple (r_acomp) are_7\VBP\13600404|generally|small|although|,|in|, (l_prep) in_18\IN\13603305|common (l_pobj) common_19\JJ\8673395|with (l_prep) with_20\IN\0|disease (l_pobj) disease_24\NN\14061805|spontaneous|gall|stone
D002784_D042882 NONE cholesterol_14\NN\15058310| (r_conj) multiple_11\JJ\5859630|,|and|cholesterol|rich (r_conj) small_9\JJ\5220461|,|multiple (r_acomp) are_7\VBP\13600404|generally|small|although|,|in|, (r_ccomp) induced_4\VBN\1627355|in|,|octreotide|stones|are|have (l_conj) have_31\VB\7846|at|patients|will|duct|. (l_dobj) duct_35\NN\5248181|a|blocked|cystic|and|stones (l_conj) stones_39\NNS\19128|some|gall|containing
D002118_D042882 NONE calcium_41\NN\14625458| (r_dobj) containing_40\VBG\2632940|calcium (r_acl) stones_39\NNS\19128|some|gall|containing (r_conj) duct_35\NN\5248181|a|blocked|cystic|and|stones (r_dobj) have_31\VB\7846|at|patients|will|duct|. (r_conj) induced_4\VBN\1627355|in|,|octreotide|stones|are|have (l_dobj) stones_6\NNS\19128|gall
D002118_D042882 NONE calcium_41\NN\14625458| (r_dobj) containing_40\VBG\2632940|calcium (r_acl) stones_39\NNS\19128|some|gall|containing (r_conj) duct_35\NN\5248181|a|blocked|cystic|and|stones (r_dobj) have_31\VB\7846|at|patients|will|duct|. (r_conj) induced_4\VBN\1627355|in|,|octreotide|stones|are|have (l_ccomp) are_7\VBP\13600404|generally|small|although|,|in|, (l_prep) in_18\IN\13603305|common (l_pobj) common_19\JJ\8673395|with (l_prep) with_20\IN\0|disease (l_pobj) disease_24\NN\14061805|spontaneous|gall|stone
D002118_D042882 NONE calcium_41\NN\14625458| (r_dobj) containing_40\VBG\2632940|calcium (r_acl) stones_39\NNS\19128|some|gall|containing
11679859
D011346_D017109 CID prochlorperazine_3\NN\2719750|by (r_pobj) of_2\IN\0|prochlorperazine (r_prep) administration_1\NN\1133281|intravenous|of (r_nsubj) affect_12\VB\26192|administration|does|not|incidence|. (l_dobj) incidence_14\NN\13821570|the|of (l_prep) of_15\IN\0|akathisia (l_pobj) akathisia_16\NN\0|:|trial
D011346_D017109 CID prochlorperazine_12\NN\2719750|intravenous|as (r_pobj) of_10\IN\0|prochlorperazine (r_prep) administration_9\NN\1133281|of (r_pobj) after_8\IN\0|administration (r_prep) akathisia_7\NN\0|after
D011346_D017109 CID prochlorperazine_10\NN\2719750| (r_nsubjpass) administered_12\VBN\2436349|when|prochlorperazine|was|by (r_advcl) reduction_3\NN\351485|a|%|in|administered (l_prep) in_4\IN\13603305|incidence (l_pobj) incidence_6\NN\13821570|the|of (l_prep) of_7\IN\0|akathisia (l_pobj) akathisia_8\NN\0|
D011346_D006261 NONE prochlorperazine_8\NN\2719750|for (l_prep) for_9\IN\0|headache (l_pobj) headache_10\NN\5829480|,|nausea
D011346_D006261 NONE prochlorperazine_3\NN\2719750| (r_pobj) of_2\IN\0|prochlorperazine (r_prep) efficacy_1\NN\5199286|the|of|in (l_prep) in_4\IN\13603305|treatment (l_pobj) treatment_6\NN\654885|the|of (l_prep) of_7\IN\0|headache (l_pobj) headache_8\NN\5829480|and|nausea
D011346_D009325 NONE prochlorperazine_8\NN\2719750|for (l_prep) for_9\IN\0|headache (l_pobj) headache_10\NN\5829480|,|nausea (l_conj) nausea_12\NN\14299637|,|or|vomiting
D011346_D009325 NONE prochlorperazine_3\NN\2719750| (r_pobj) of_2\IN\0|prochlorperazine (r_prep) efficacy_1\NN\5199286|the|of|in (l_prep) in_4\IN\13603305|treatment (l_pobj) treatment_6\NN\654885|the|of (l_prep) of_7\IN\0|headache (l_pobj) headache_8\NN\5829480|and|nausea (l_conj) nausea_10\NN\14299637|
D011346_D014839 NONE prochlorperazine_8\NN\2719750|for (l_prep) for_9\IN\0|headache (l_pobj) headache_10\NN\5829480|,|nausea (l_conj) nausea_12\NN\14299637|,|or|vomiting (l_conj) vomiting_15\NN\116687|
1967484
D013469_D004421 CID sulpiride_0\NNP\0| (r_npadvmod) induced_2\VBN\1627355|sulpiride|-|dystonia|. (l_dobj) dystonia_4\NN\0|tardive
D013469_D004421 CID sulpiride_17\NN\0| (r_compound) therapy_18\NN\657604|sulpiride (r_dobj) starting_16\VBG\457382|therapy (r_pcomp) after_15\IN\0|starting (r_prep) developed_8\VBD\1753788|who|dystonia|within|after (l_dobj) dystonia_11\NN\0|persistent|segmental
D013469_D004421 CID sulpiride_8\NN\0| (r_npadvmod) induced_10\VBN\1627355|sulpiride|- (r_amod) dystonia_12\NN\0|induced|tardive
D013469_D004409 NONE sulpiride_11\NN\0| (r_npadvmod) induced_13\VBN\1627355|thought|,|sulpiride|-|dyskinesia (l_dobj) dyskinesia_15\JJ\14084880|tardive|and|parkinsonism
D013469_D010302 NONE sulpiride_11\NN\0| (r_npadvmod) induced_13\VBN\1627355|thought|,|sulpiride|-|dyskinesia (l_dobj) dyskinesia_15\JJ\14084880|tardive|and|parkinsonism (l_conj) parkinsonism_17\NN\14085708|
12716030
D006493_D002543 NONE heparin_7\VBN\2718259| (r_nsubj) enhanced_8\VBD\227165|in|,|heparin|volume|. (l_prep) in_0\IN\13603305|induction (l_pobj) induction_2\NN\7450842|ich|using (l_compound) ich_1\NNP\0|
D006493_D002543 NONE heparin_7\VBN\2718259| (r_nsubj) enhanced_8\VBD\227165|in|,|heparin|volume|. (l_dobj) volume_11\NN\33615|the|hematoma|3.4-fold|over (l_prep) over_13\IN\5867413|that (l_pobj) that_14\DT\0|seen (l_acl) seen_15\VBN\2106506|in (l_prep) in_16\IN\13603305|control (l_pobj) control_17\NN\5190804|animals (l_dobj) animals_19\NNS\4475|ich|and|bleeding (l_compound) ich_18\NNP\0|
D006493_D006406 CID heparin_7\VBN\2718259| (r_nsubj) enhanced_8\VBD\227165|in|,|heparin|volume|. (l_dobj) volume_11\NN\33615|the|hematoma|3.4-fold|over (l_compound) hematoma_10\NN\14317720|
D006493_D006470 NONE heparin_7\VBN\2718259| (r_nsubj) enhanced_8\VBD\227165|in|,|heparin|volume|. (l_dobj) volume_11\NN\33615|the|hematoma|3.4-fold|over (l_prep) over_13\IN\5867413|that (l_pobj) that_14\DT\0|seen (l_acl) seen_15\VBN\2106506|in (l_prep) in_16\IN\13603305|control (l_pobj) control_17\NN\5190804|animals (l_dobj) animals_19\NNS\4475|ich|and|bleeding (l_conj) bleeding_22\NN\14285662|the|7.6-fold
10520387
D004809_D007022 NONE ephedrine_11\NN\14712692| (r_pobj) of_10\IN\0|ephedrine (r_prep) doses_9\NNS\3740161|different|of (r_dobj) adding_7\VBG\156601|doses|propofol (l_xcomp) propofol_13\NN\0|to|in (l_prep) in_14\IN\13603305|order (l_pobj) order_15\NN\7168131|obtund (l_acl) obtund_17\VB\192051|to|response (l_dobj) response_20\NN\11410625|the|hypotensive (l_amod) hypotensive_19\JJ\10405694|
D004809_D007022 NONE ephedrine_3\NN\14712692| (r_pobj) of_2\IN\0|ephedrine (r_prep) addition_1\NN\3081021|the|of|propofol (r_nsubj) appears_6\VBZ\2604760|addition|be|. (l_xcomp) be_8\VB\14625458|to|method (l_attr) method_11\NN\5616786|an|effective|of (l_prep) of_12\IN\0|obtunding (l_pcomp) obtunding_13\VBG\192051|response|propofol (l_dobj) response_16\NN\11410625|the|hypotensive (l_amod) hypotensive_15\JJ\10405694|
D015742_D007022 CID propofol_13\NN\0|to|in (l_prep) in_14\IN\13603305|order (l_pobj) order_15\NN\7168131|obtund (l_acl) obtund_17\VB\192051|to|response (l_dobj) response_20\NN\11410625|the|hypotensive (l_amod) hypotensive_19\JJ\10405694|
D015742_D007022 CID propofol_5\NN\0|to (r_acl) addition_1\NN\3081021|the|of|propofol (r_nsubj) appears_6\VBZ\2604760|addition|be|. (l_xcomp) be_8\VB\14625458|to|method (l_attr) method_11\NN\5616786|an|effective|of (l_prep) of_12\IN\0|obtunding (l_pcomp) obtunding_13\VBG\192051|response|propofol (l_dobj) response_16\NN\11410625|the|hypotensive (l_amod) hypotensive_15\JJ\10405694|
D015742_D007022 CID propofol_18\NN\0|to|at (r_advcl) obtunding_13\VBG\192051|response|propofol (l_dobj) response_16\NN\11410625|the|hypotensive (l_amod) hypotensive_15\JJ\10405694|
D004809_D013610 CID ephedrine_9\NN\14712692| (r_pobj) of_8\IN\0|ephedrine (r_prep) use_7\NN\407535|the|of|in (r_pobj) with_5\IN\0|use (r_prep) associated_4\VBN\628491|with (r_acl) tachycardia_3\NNS\14110674|marked|associated
D004809_D013610 CID ephedrine_24\NN\14712692| (r_nmod) mixtures_28\NNS\19613|the|ephedrine|/|propofol|/ (r_pobj) of_22\IN\0|mixtures (r_prep) any_21\DT\0|of (r_pobj) of_20\IN\0|any (r_prep) patients_19\NNS\9898892|elderly|of (r_pobj) in_17\IN\13603305|patients (r_prep) use_16\NN\407535|the|in|studied (r_dobj) recommend_14\VB\875394|due|,|we|would|not|use|. (l_prep) due_0\IN\5174653|to|risk (l_pobj) risk_3\NN\14541044|the|of (l_prep) of_4\IN\0|tachycardia (l_pobj) tachycardia_6\NN\14110674|this|inducing
D015742_D013610 CID propofol_13\NN\0| (r_pobj) with_12\IN\0|propofol (r_prep) combination_11\NN\7951464|with (r_pobj) in_10\IN\13603305|combination (r_prep) use_7\NN\407535|the|of|in (r_pobj) with_5\IN\0|use (r_prep) associated_4\VBN\628491|with (r_acl) tachycardia_3\NNS\14110674|marked|associated
D015742_D013610 CID propofol_26\NN\0| (r_nmod) mixtures_28\NNS\19613|the|ephedrine|/|propofol|/ (r_pobj) of_22\IN\0|mixtures (r_prep) any_21\DT\0|of (r_pobj) of_20\IN\0|any (r_prep) patients_19\NNS\9898892|elderly|of (r_pobj) in_17\IN\13603305|patients (r_prep) use_16\NN\407535|the|in|studied (r_dobj) recommend_14\VB\875394|due|,|we|would|not|use|. (l_prep) due_0\IN\5174653|to|risk (l_pobj) risk_3\NN\14541044|the|of (l_prep) of_4\IN\0|tachycardia (l_pobj) tachycardia_6\NN\14110674|this|inducing
D004809_D017202 NONE ephedrine_24\NN\14712692| (r_nmod) mixtures_28\NNS\19613|the|ephedrine|/|propofol|/ (r_pobj) of_22\IN\0|mixtures (r_prep) any_21\DT\0|of (r_pobj) of_20\IN\0|any (r_prep) patients_19\NNS\9898892|elderly|of (r_pobj) in_17\IN\13603305|patients (r_prep) use_16\NN\407535|the|in|studied (r_dobj) recommend_14\VB\875394|due|,|we|would|not|use|. (l_prep) due_0\IN\5174653|to|risk (l_pobj) risk_3\NN\14541044|the|of (l_prep) of_4\IN\0|tachycardia (l_pobj) tachycardia_6\NN\14110674|this|inducing (l_acl) inducing_7\VBG\42311|ischemia (l_dobj) ischemia_9\NN\14195315|myocardial
D015742_D017202 NONE propofol_26\NN\0| (r_nmod) mixtures_28\NNS\19613|the|ephedrine|/|propofol|/ (r_pobj) of_22\IN\0|mixtures (r_prep) any_21\DT\0|of (r_pobj) of_20\IN\0|any (r_prep) patients_19\NNS\9898892|elderly|of (r_pobj) in_17\IN\13603305|patients (r_prep) use_16\NN\407535|the|in|studied (r_dobj) recommend_14\VB\875394|due|,|we|would|not|use|. (l_prep) due_0\IN\5174653|to|risk (l_pobj) risk_3\NN\14541044|the|of (l_prep) of_4\IN\0|tachycardia (l_pobj) tachycardia_6\NN\14110674|this|inducing (l_acl) inducing_7\VBG\42311|ischemia (l_dobj) ischemia_9\NN\14195315|myocardial
19058010
D010936_D009203 NONE tea_3\NN\7881800|green|and|e (r_nmod) combination_7\NN\7951464|tea|in (r_pobj) of_1\IN\0|combination (r_prep) effect_0\NN\34213|of (r_nsubj) induced_10\VBN\1627355|effect|infarction|. (l_dobj) infarction_12\NN\14204950|myocardial|in
D010936_D009203 NONE tea_12\NN\7881800|green|and|e (r_pobj) of_10\IN\0|tea (r_prep) effects_9\NNS\13245626|the|combined|of|on|,|weight|bound (r_dobj) investigate_6\VB\644583|to|effects (r_xcomp) aimed_4\VBN\1987160|study|was|investigate|iso)-induced|. (l_parataxis) iso)-induced_39\VBN\0|(|infarction (l_dobj) infarction_41\NN\14204950|myocardial|in
D010936_D009203 NONE tea_9\NN\7881800|green|and|e (r_pobj) of_7\IN\0|tea (r_prep) effect_6\NN\34213|the|synergistic|protective|of|during (r_dobj) indicate_2\VBP\952524|findings|effect|induced|. (l_ccomp) induced_15\VBN\1627355|infarction (l_dobj) infarction_17\NN\14204950|myocardial|in
D014810_D009203 NONE e_6\NN\14724645|vitamin (r_conj) tea_3\NN\7881800|green|and|e (r_nmod) combination_7\NN\7951464|tea|in (r_pobj) of_1\IN\0|combination (r_prep) effect_0\NN\34213|of (r_nsubj) induced_10\VBN\1627355|effect|infarction|. (l_dobj) infarction_12\NN\14204950|myocardial|in
D014810_D009203 NONE e_15\NN\14724645|vitamin (r_conj) tea_12\NN\7881800|green|and|e (r_pobj) of_10\IN\0|tea (r_prep) effects_9\NNS\13245626|the|combined|of|on|,|weight|bound (r_dobj) investigate_6\VB\644583|to|effects (r_xcomp) aimed_4\VBN\1987160|study|was|investigate|iso)-induced|. (l_parataxis) iso)-induced_39\VBN\0|(|infarction (l_dobj) infarction_41\NN\14204950|myocardial|in
D014810_D009203 NONE e_12\NN\14724645|vitamin (r_conj) tea_9\NN\7881800|green|and|e (r_pobj) of_7\IN\0|tea (r_prep) effect_6\NN\34213|the|synergistic|protective|of|during (r_dobj) indicate_2\VBP\952524|findings|effect|induced|. (l_ccomp) induced_15\VBN\1627355|infarction (l_dobj) infarction_17\NN\14204950|myocardial|in
D007545_D009203 CID isoproterenol_9\JJ\3740161| (r_pobj) in_8\IN\13603305|isoproterenol (r_prep) combination_7\NN\7951464|tea|in (r_pobj) of_1\IN\0|combination (r_prep) effect_0\NN\34213|of (r_nsubj) induced_10\VBN\1627355|effect|infarction|. (l_dobj) infarction_12\NN\14204950|myocardial|in
D007545_D009203 CID isoproterenol_37\NN\3740161| (r_pobj) in_36\IN\13603305|isoproterenol (r_prep) bound_34\VBN\13863771|atpases|in (r_acl) effects_9\NNS\13245626|the|combined|of|on|,|weight|bound (r_dobj) investigate_6\VB\644583|to|effects (r_xcomp) aimed_4\VBN\1987160|study|was|investigate|iso)-induced|. (l_parataxis) iso)-induced_39\VBN\0|(|infarction (l_dobj) infarction_41\NN\14204950|myocardial|in
D007545_D009203 CID iso)-induced_39\VBN\0|(|infarction (l_dobj) infarction_41\NN\14204950|myocardial|in
D007545_D009203 CID iso_14\NN\0| (r_pobj) during_13\IN\0|iso (r_prep) effect_6\NN\34213|the|synergistic|protective|of|during (r_dobj) indicate_2\VBP\952524|findings|effect|induced|. (l_ccomp) induced_15\VBN\1627355|infarction (l_dobj) infarction_17\NN\14204950|myocardial|in
6203452
D002945_D002277 NONE cisplatin_24\NN\0| (r_pobj) with_23\IN\0|cisplatin (r_prep) treatment_22\NN\654885|with|,|bleomycin (r_pobj) after_21\IN\0|treatment (r_prep) developed_4\VBD\1753788|patients|microangiopathy|after|. (l_nsubj) patients_1\NNS\9898892|five|with (l_prep) with_2\IN\0|carcinoma (l_pobj) carcinoma_3\NN\14239918|
D002945_D057049 NONE cisplatin_24\NN\0| (r_pobj) with_23\IN\0|cisplatin (r_prep) treatment_22\NN\654885|with|,|bleomycin (r_pobj) after_21\IN\0|treatment (r_prep) developed_4\VBD\1753788|patients|microangiopathy|after|. (l_dobj) microangiopathy_6\NN\0|thrombotic|characterized
D002945_D051437 NONE cisplatin_24\NN\0| (r_pobj) with_23\IN\0|cisplatin (r_prep) treatment_22\NN\654885|with|,|bleomycin (r_pobj) after_21\IN\0|treatment (r_prep) developed_4\VBD\1753788|patients|microangiopathy|after|. (l_dobj) microangiopathy_6\NN\0|thrombotic|characterized (l_acl) characterized_8\VBN\609683|(|by|,|anemia|) (l_agent) by_9\IN\0|insufficiency (l_pobj) insufficiency_11\NN\14462946|renal
D002945_D051437 NONE cisplatin_30\VB\0| (r_amod) nephrotoxicity_31\NN\0|cisplatin|and|anemia|and|thrombocytopenia (r_pobj) to_29\IN\0|nephrotoxicity (r_prep) ascribed_28\VBN\670261|because|failure|may|be|to (l_nsubjpass) failure_25\NN\66216|renal
D002945_D000743 NONE cisplatin_24\NN\0| (r_pobj) with_23\IN\0|cisplatin (r_prep) treatment_22\NN\654885|with|,|bleomycin (r_pobj) after_21\IN\0|treatment (r_prep) developed_4\VBD\1753788|patients|microangiopathy|after|. (l_dobj) microangiopathy_6\NN\0|thrombotic|characterized (l_acl) characterized_8\VBN\609683|(|by|,|anemia|) (l_conj) anemia_15\NN\14189204|microangiopathic|hemolytic|,|and|thrombocytopenia
D002945_D013921 NONE cisplatin_24\NN\0| (r_pobj) with_23\IN\0|cisplatin (r_prep) treatment_22\NN\654885|with|,|bleomycin (r_pobj) after_21\IN\0|treatment (r_prep) developed_4\VBD\1753788|patients|microangiopathy|after|. (l_dobj) microangiopathy_6\NN\0|thrombotic|characterized (l_acl) characterized_8\VBN\609683|(|by|,|anemia|) (l_conj) anemia_15\NN\14189204|microangiopathic|hemolytic|,|and|thrombocytopenia (l_conj) thrombocytopenia_19\JJ\14189204|usually
D002945_D013921 NONE cisplatin_30\VB\0| (r_amod) nephrotoxicity_31\NN\0|cisplatin|and|anemia|and|thrombocytopenia (l_conj) thrombocytopenia_36\NN\14189204|to
D001761_D002277 NONE bleomycin_26\NNS\0|,|and|vinca (r_conj) treatment_22\NN\654885|with|,|bleomycin (r_pobj) after_21\IN\0|treatment (r_prep) developed_4\VBD\1753788|patients|microangiopathy|after|. (l_nsubj) patients_1\NNS\9898892|five|with (l_prep) with_2\IN\0|carcinoma (l_pobj) carcinoma_3\NN\14239918|
D001761_D057049 NONE bleomycin_26\NNS\0|,|and|vinca (r_conj) treatment_22\NN\654885|with|,|bleomycin (r_pobj) after_21\IN\0|treatment (r_prep) developed_4\VBD\1753788|patients|microangiopathy|after|. (l_dobj) microangiopathy_6\NN\0|thrombotic|characterized
D001761_D051437 NONE bleomycin_26\NNS\0|,|and|vinca (r_conj) treatment_22\NN\654885|with|,|bleomycin (r_pobj) after_21\IN\0|treatment (r_prep) developed_4\VBD\1753788|patients|microangiopathy|after|. (l_dobj) microangiopathy_6\NN\0|thrombotic|characterized (l_acl) characterized_8\VBN\609683|(|by|,|anemia|) (l_agent) by_9\IN\0|insufficiency (l_pobj) insufficiency_11\NN\14462946|renal
D001761_D000743 NONE bleomycin_26\NNS\0|,|and|vinca (r_conj) treatment_22\NN\654885|with|,|bleomycin (r_pobj) after_21\IN\0|treatment (r_prep) developed_4\VBD\1753788|patients|microangiopathy|after|. (l_dobj) microangiopathy_6\NN\0|thrombotic|characterized (l_acl) characterized_8\VBN\609683|(|by|,|anemia|) (l_conj) anemia_15\NN\14189204|microangiopathic|hemolytic|,|and|thrombocytopenia
D001761_D013921 NONE bleomycin_26\NNS\0|,|and|vinca (r_conj) treatment_22\NN\654885|with|,|bleomycin (r_pobj) after_21\IN\0|treatment (r_prep) developed_4\VBD\1753788|patients|microangiopathy|after|. (l_dobj) microangiopathy_6\NN\0|thrombotic|characterized (l_acl) characterized_8\VBN\609683|(|by|,|anemia|) (l_conj) anemia_15\NN\14189204|microangiopathic|hemolytic|,|and|thrombocytopenia (l_conj) thrombocytopenia_19\JJ\14189204|usually
D014748_D002277 NONE alkaloid_31\NN\14727670| (r_amod) vinca_30\JJ\11567411|a|alkaloid (r_conj) bleomycin_26\NNS\0|,|and|vinca (r_conj) treatment_22\NN\654885|with|,|bleomycin (r_pobj) after_21\IN\0|treatment (r_prep) developed_4\VBD\1753788|patients|microangiopathy|after|. (l_nsubj) patients_1\NNS\9898892|five|with (l_prep) with_2\IN\0|carcinoma (l_pobj) carcinoma_3\NN\14239918|
D014748_D057049 NONE alkaloid_31\NN\14727670| (r_amod) vinca_30\JJ\11567411|a|alkaloid (r_conj) bleomycin_26\NNS\0|,|and|vinca (r_conj) treatment_22\NN\654885|with|,|bleomycin (r_pobj) after_21\IN\0|treatment (r_prep) developed_4\VBD\1753788|patients|microangiopathy|after|. (l_dobj) microangiopathy_6\NN\0|thrombotic|characterized
D014748_D051437 NONE alkaloid_31\NN\14727670| (r_amod) vinca_30\JJ\11567411|a|alkaloid (r_conj) bleomycin_26\NNS\0|,|and|vinca (r_conj) treatment_22\NN\654885|with|,|bleomycin (r_pobj) after_21\IN\0|treatment (r_prep) developed_4\VBD\1753788|patients|microangiopathy|after|. (l_dobj) microangiopathy_6\NN\0|thrombotic|characterized (l_acl) characterized_8\VBN\609683|(|by|,|anemia|) (l_agent) by_9\IN\0|insufficiency (l_pobj) insufficiency_11\NN\14462946|renal
D014748_D000743 NONE alkaloid_31\NN\14727670| (r_amod) vinca_30\JJ\11567411|a|alkaloid (r_conj) bleomycin_26\NNS\0|,|and|vinca (r_conj) treatment_22\NN\654885|with|,|bleomycin (r_pobj) after_21\IN\0|treatment (r_prep) developed_4\VBD\1753788|patients|microangiopathy|after|. (l_dobj) microangiopathy_6\NN\0|thrombotic|characterized (l_acl) characterized_8\VBN\609683|(|by|,|anemia|) (l_conj) anemia_15\NN\14189204|microangiopathic|hemolytic|,|and|thrombocytopenia
D014748_D013921 NONE alkaloid_31\NN\14727670| (r_amod) vinca_30\JJ\11567411|a|alkaloid (r_conj) bleomycin_26\NNS\0|,|and|vinca (r_conj) treatment_22\NN\654885|with|,|bleomycin (r_pobj) after_21\IN\0|treatment (r_prep) developed_4\VBD\1753788|patients|microangiopathy|after|. (l_dobj) microangiopathy_6\NN\0|thrombotic|characterized (l_acl) characterized_8\VBN\609683|(|by|,|anemia|) (l_conj) anemia_15\NN\14189204|microangiopathic|hemolytic|,|and|thrombocytopenia (l_conj) thrombocytopenia_19\JJ\14189204|usually
D002945_D007674 CID cisplatin_30\VB\0| (r_amod) nephrotoxicity_31\NN\0|cisplatin|and|anemia|and|thrombocytopenia
D002945_D000740 NONE cisplatin_30\VB\0| (r_amod) nephrotoxicity_31\NN\0|cisplatin|and|anemia|and|thrombocytopenia (l_conj) anemia_34\NN\14189204|the
D002945_D001855 NONE cisplatin_30\VB\0| (r_amod) nephrotoxicity_31\NN\0|cisplatin|and|anemia|and|thrombocytopenia (l_conj) thrombocytopenia_36\NN\14189204|to (l_prep) to_37\IN\0|suppression (l_pobj) suppression_43\NN\13489037|induced|marrow
12684739
D020888_D019966 NONE gvg_35\NNP\0|chronic|dose|on (r_pobj) of_29\IN\0|gvg (r_prep) effects_28\NNS\13245626|the|of (r_dobj) explored_26\VBD\789138|given|,|we|effects|accumbens|. (l_prep) given_0\VBN\5892096|success (l_pobj) success_3\NN\7283608|its|preclinical|for (l_prep) for_4\IN\0|treating (l_pcomp) treating_5\VBG\2376958|abuse (l_dobj) abuse_7\NN\418025|substance|and|risk
D020888_D005128 CID gvg_35\NNP\0|chronic|dose|on (r_pobj) of_29\IN\0|gvg (r_prep) effects_28\NNS\13245626|the|of (r_dobj) explored_26\VBD\789138|given|,|we|effects|accumbens|. (l_prep) given_0\VBN\5892096|success (l_pobj) success_3\NN\7283608|its|preclinical|for (l_prep) for_4\IN\0|treating (l_pcomp) treating_5\VBG\2376958|abuse (l_dobj) abuse_7\NN\418025|substance|and|risk (l_conj) risk_11\NN\14541044|the|increased|of (l_prep) of_12\IN\0|defects (l_pobj) defects_15\NNS\14462666|visual|field|vfd|associated
D020888_D005128 CID gvg_35\NNP\0|chronic|dose|on (r_pobj) of_29\IN\0|gvg (r_prep) effects_28\NNS\13245626|the|of (r_dobj) explored_26\VBD\789138|given|,|we|effects|accumbens|. (l_prep) given_0\VBN\5892096|success (l_pobj) success_3\NN\7283608|its|preclinical|for (l_prep) for_4\IN\0|treating (l_pcomp) treating_5\VBG\2376958|abuse (l_dobj) abuse_7\NN\418025|substance|and|risk (l_conj) risk_11\NN\14541044|the|increased|of (l_prep) of_12\IN\0|defects (l_pobj) defects_15\NNS\14462666|visual|field|vfd|associated (l_appos) vfd_17\NNP\0|(|)
D003042_D019966 NONE cocaine_37\NN\3492717| (r_npadvmod) induced_39\VBN\1627355|cocaine|- (r_amod) increases_40\NNS\13576355|induced|in (r_pobj) on_36\IN\0|increases (r_prep) gvg_35\NNP\0|chronic|dose|on (r_pobj) of_29\IN\0|gvg (r_prep) effects_28\NNS\13245626|the|of (r_dobj) explored_26\VBD\789138|given|,|we|effects|accumbens|. (l_prep) given_0\VBN\5892096|success (l_pobj) success_3\NN\7283608|its|preclinical|for (l_prep) for_4\IN\0|treating (l_pcomp) treating_5\VBG\2376958|abuse (l_dobj) abuse_7\NN\418025|substance|and|risk
D003042_D005128 NONE cocaine_37\NN\3492717| (r_npadvmod) induced_39\VBN\1627355|cocaine|- (r_amod) increases_40\NNS\13576355|induced|in (r_pobj) on_36\IN\0|increases (r_prep) gvg_35\NNP\0|chronic|dose|on (r_pobj) of_29\IN\0|gvg (r_prep) effects_28\NNS\13245626|the|of (r_dobj) explored_26\VBD\789138|given|,|we|effects|accumbens|. (l_prep) given_0\VBN\5892096|success (l_pobj) success_3\NN\7283608|its|preclinical|for (l_prep) for_4\IN\0|treating (l_pcomp) treating_5\VBG\2376958|abuse (l_dobj) abuse_7\NN\418025|substance|and|risk (l_conj) risk_11\NN\14541044|the|increased|of (l_prep) of_12\IN\0|defects (l_pobj) defects_15\NNS\14462666|visual|field|vfd|associated
D003042_D005128 NONE cocaine_37\NN\3492717| (r_npadvmod) induced_39\VBN\1627355|cocaine|- (r_amod) increases_40\NNS\13576355|induced|in (r_pobj) on_36\IN\0|increases (r_prep) gvg_35\NNP\0|chronic|dose|on (r_pobj) of_29\IN\0|gvg (r_prep) effects_28\NNS\13245626|the|of (r_dobj) explored_26\VBD\789138|given|,|we|effects|accumbens|. (l_prep) given_0\VBN\5892096|success (l_pobj) success_3\NN\7283608|its|preclinical|for (l_prep) for_4\IN\0|treating (l_pcomp) treating_5\VBG\2376958|abuse (l_dobj) abuse_7\NN\418025|substance|and|risk (l_conj) risk_11\NN\14541044|the|increased|of (l_prep) of_12\IN\0|defects (l_pobj) defects_15\NNS\14462666|visual|field|vfd|associated (l_appos) vfd_17\NNP\0|(|)
D004298_D019966 NONE dopamine_47\NN\14807737|nacc|)|(|da|) (r_appos) accumbens_43\NNS\0|(|dopamine (r_oprd) explored_26\VBD\789138|given|,|we|effects|accumbens|. (l_prep) given_0\VBN\5892096|success (l_pobj) success_3\NN\7283608|its|preclinical|for (l_prep) for_4\IN\0|treating (l_pcomp) treating_5\VBG\2376958|abuse (l_dobj) abuse_7\NN\418025|substance|and|risk
D004298_D019966 NONE da_49\NNP\10484858| (r_appos) dopamine_47\NN\14807737|nacc|)|(|da|) (r_appos) accumbens_43\NNS\0|(|dopamine (r_oprd) explored_26\VBD\789138|given|,|we|effects|accumbens|. (l_prep) given_0\VBN\5892096|success (l_pobj) success_3\NN\7283608|its|preclinical|for (l_prep) for_4\IN\0|treating (l_pcomp) treating_5\VBG\2376958|abuse (l_dobj) abuse_7\NN\418025|substance|and|risk
D004298_D005128 NONE dopamine_47\NN\14807737|nacc|)|(|da|) (r_appos) accumbens_43\NNS\0|(|dopamine (r_oprd) explored_26\VBD\789138|given|,|we|effects|accumbens|. (l_prep) given_0\VBN\5892096|success (l_pobj) success_3\NN\7283608|its|preclinical|for (l_prep) for_4\IN\0|treating (l_pcomp) treating_5\VBG\2376958|abuse (l_dobj) abuse_7\NN\418025|substance|and|risk (l_conj) risk_11\NN\14541044|the|increased|of (l_prep) of_12\IN\0|defects (l_pobj) defects_15\NNS\14462666|visual|field|vfd|associated
D004298_D005128 NONE dopamine_47\NN\14807737|nacc|)|(|da|) (r_appos) accumbens_43\NNS\0|(|dopamine (r_oprd) explored_26\VBD\789138|given|,|we|effects|accumbens|. (l_prep) given_0\VBN\5892096|success (l_pobj) success_3\NN\7283608|its|preclinical|for (l_prep) for_4\IN\0|treating (l_pcomp) treating_5\VBG\2376958|abuse (l_dobj) abuse_7\NN\418025|substance|and|risk (l_conj) risk_11\NN\14541044|the|increased|of (l_prep) of_12\IN\0|defects (l_pobj) defects_15\NNS\14462666|visual|field|vfd|associated (l_appos) vfd_17\NNP\0|(|)
D004298_D005128 NONE da_49\NNP\10484858| (r_appos) dopamine_47\NN\14807737|nacc|)|(|da|) (r_appos) accumbens_43\NNS\0|(|dopamine (r_oprd) explored_26\VBD\789138|given|,|we|effects|accumbens|. (l_prep) given_0\VBN\5892096|success (l_pobj) success_3\NN\7283608|its|preclinical|for (l_prep) for_4\IN\0|treating (l_pcomp) treating_5\VBG\2376958|abuse (l_dobj) abuse_7\NN\418025|substance|and|risk (l_conj) risk_11\NN\14541044|the|increased|of (l_prep) of_12\IN\0|defects (l_pobj) defects_15\NNS\14462666|visual|field|vfd|associated
D004298_D005128 NONE da_49\NNP\10484858| (r_appos) dopamine_47\NN\14807737|nacc|)|(|da|) (r_appos) accumbens_43\NNS\0|(|dopamine (r_oprd) explored_26\VBD\789138|given|,|we|effects|accumbens|. (l_prep) given_0\VBN\5892096|success (l_pobj) success_3\NN\7283608|its|preclinical|for (l_prep) for_4\IN\0|treating (l_pcomp) treating_5\VBG\2376958|abuse (l_dobj) abuse_7\NN\418025|substance|and|risk (l_conj) risk_11\NN\14541044|the|increased|of (l_prep) of_12\IN\0|defects (l_pobj) defects_15\NNS\14462666|visual|field|vfd|associated (l_appos) vfd_17\NNP\0|(|)
19889778
9727773
D001067_D006976 CID suppressants_9\NNS\3247620|appetite|in (r_pobj) with_7\IN\0|suppressants (r_prep) associated_6\VBN\628491|with (r_acl) incidence_1\NN\13821570|high|of|associated|. (l_prep) of_2\IN\0|hypertension (l_pobj) hypertension_5\NN\14057371|primary|pulmonary
D001067_D006976 CID suppressant_21\NN\3247620|appetite (r_compound) drugs_22\NNS\14778436|suppressant (r_pobj) of_19\IN\0|drugs (r_prep) intake_18\NN\13440063|the|of (r_pobj) with_16\IN\0|intake (r_prep) associated_15\VBN\628491|which|has|been|with (r_relcl) disease_10\NN\14061805|a|rare|,|associated (r_attr) is_3\VBZ\0|hypertension|disease|. (l_nsubj) hypertension_2\NN\14057371|primary|pulmonary
D001067_D006976 CID suppressants_18\NNS\3247620|appetite (r_dobj) taken_16\VBN\2367363|was|,|5|had|suppressants|. (l_ccomp) was_9\VBD\0|in|diagnosis|uncertain (l_nsubj) diagnosis_4\NN\152018|the|of (l_prep) of_5\IN\0|hypertension (l_pobj) hypertension_8\NN\14057371|primary|pulmonary
D001067_D006976 CID suppressants_7\NNS\3247620|appetite (r_pobj) of_5\IN\0|suppressants (r_prep) prescription_4\NN\6786629|unrestricted|of (r_pobj) of_2\IN\0|prescription (r_prep) policy_1\NN\5902545|a|of (r_nsubj) lead_9\VB\5155821|policy|may|to|. (l_prep) to_10\IN\0|incidence (l_pobj) incidence_13\NN\13821570|a|high|of (l_prep) of_14\IN\0|hypertension (l_pobj) hypertension_18\NN\14057371|associated|primary|pulmonary
14513889
D007654_D009422 NONE ketoconazole_0\NNP\0| (r_npadvmod) induced_2\VBN\1627355|ketoconazole|-|sequelae|. (l_dobj) sequelae_4\NNS\14501726|neurologic
983936
D001241_D009202 NONE acid_3\NN\14818238|acetylsalicylic|,|dipyridamole (l_conj) dipyridamole_5\NN\0|,|and|hydrocortisone (l_conj) hydrocortisone_8\NN\14751417|on (l_prep) on_9\IN\0|injury (l_pobj) injury_14\NN\14052046|induced|myocardial|in
D004176_D009202 NONE dipyridamole_5\NN\0|,|and|hydrocortisone (l_conj) hydrocortisone_8\NN\14751417|on (l_prep) on_9\IN\0|injury (l_pobj) injury_14\NN\14052046|induced|myocardial|in
D006854_D009202 NONE hydrocortisone_8\NN\14751417|on (l_prep) on_9\IN\0|injury (l_pobj) injury_14\NN\14052046|induced|myocardial|in
D004837_D009202 CID epinephrine_10\NN\14807929| (r_npadvmod) induced_12\VBN\1627355|epinephrine|- (r_amod) injury_14\NN\14052046|induced|myocardial|in
D004837_D009202 CID epinephrine_9\NN\14807929| (r_amod) infusion_10\NN\14589223|(|epinephrine (r_appos) injury_7\NN\14052046|diffuse|myocardial|infusion
D004837_D009203 NONE epinephrine_9\NN\14807929| (r_amod) infusion_10\NN\14589223|(|epinephrine (r_appos) injury_7\NN\14052046|diffuse|myocardial|infusion (r_dobj) producing_4\VBG\1617192|injury (r_pcomp) for_3\IN\0|producing (r_prep) model_2\NN\5888929|a|reproducible|for|) (r_nsubjpass) developed_14\VBN\1753788|model|has|been|study|. (l_advcl) study_16\VB\635850|to|effects (l_dobj) effects_19\NNS\13245626|the|cardioprotective|of (l_prep) of_20\IN\0|agents (l_pobj) agents_21\NNS\7347|or|maneuvers|alter (l_relcl) alter_26\VB\0|which|might|evolution (l_dobj) evolution_28\NN\29677|the|of (l_prep) of_29\IN\0|infarction (l_pobj) infarction_32\NN\14204950|acute|myocardial
18182964
D003000_D001289 NONE clonidine_0\NNP\2721160|for|ii (l_prep) for_1\IN\0|disorder (l_pobj) disorder_7\NN\14034177|hyperactivity
D003000_D001289 NONE clonidine_7\NN\2721160| (r_pobj) of_6\IN\0|clonidine (r_prep) safety_3\NN\13920835|the|and|tolerability|of (r_dobj) examine_1\VB\0|to|safety (r_csubj) used_8\VBN\0|examine|alone|or|with (l_conj) with_11\IN\0|methylphenidate (l_pobj) methylphenidate_12\NN\4320126|in|with (l_prep) with_15\IN\0|disorder (l_pobj) disorder_21\NN\14034177|hyperactivity|(|adhd|)
D003000_D001289 NONE clonidine_7\NN\2721160| (r_pobj) of_6\IN\0|clonidine (r_prep) safety_3\NN\13920835|the|and|tolerability|of (r_dobj) examine_1\VB\0|to|safety (r_csubj) used_8\VBN\0|examine|alone|or|with (l_conj) with_11\IN\0|methylphenidate (l_pobj) methylphenidate_12\NN\4320126|in|with (l_prep) with_15\IN\0|disorder (l_pobj) disorder_21\NN\14034177|hyperactivity|(|adhd|) (l_appos) adhd_23\NNP\14304060|
D003000_D001289 NONE clonidine_18\NN\2721160|to|n|,|methylphenidate (r_xcomp) assigned_16\VBN\2475922|in|,|children|were|randomly|clonidine|. (l_nsubjpass) children_11\NNS\9622049|122|with (l_prep) with_12\IN\0|adhd (l_pobj) adhd_13\NNP\14304060|
D003000_D001289 NONE clonidine_32\NN\2721160|and|methylphenidate (r_conj) methylphenidate_25\NN\4320126|(|n|29|)|,|clonidine|(|n|32|,|or|placebo (r_conj) clonidine_18\NN\2721160|to|n|,|methylphenidate (r_xcomp) assigned_16\VBN\2475922|in|,|children|were|randomly|clonidine|. (l_nsubjpass) children_11\NNS\9622049|122|with (l_prep) with_12\IN\0|adhd (l_pobj) adhd_13\NNP\14304060|
D003000_D001289 NONE clonidine_0\NNP\2721160|,|used|, (r_nsubj) appears_8\VBZ\2604760|clonidine|safe|and|tolerated|. (l_conj) tolerated_12\VBN\802318|well|in (l_prep) in_13\IN\13603305|adhd (l_pobj) adhd_15\NNP\14304060|childhood
D008774_D001289 NONE methylphenidate_12\NN\4320126|in|with (l_prep) with_15\IN\0|disorder (l_pobj) disorder_21\NN\14034177|hyperactivity|(|adhd|)
D008774_D001289 NONE methylphenidate_12\NN\4320126|in|with (l_prep) with_15\IN\0|disorder (l_pobj) disorder_21\NN\14034177|hyperactivity|(|adhd|) (l_appos) adhd_23\NNP\14304060|
D008774_D001289 NONE methylphenidate_25\NN\4320126|(|n|29|)|,|clonidine|(|n|32|,|or|placebo (r_conj) clonidine_18\NN\2721160|to|n|,|methylphenidate (r_xcomp) assigned_16\VBN\2475922|in|,|children|were|randomly|clonidine|. (l_nsubjpass) children_11\NNS\9622049|122|with (l_prep) with_12\IN\0|adhd (l_pobj) adhd_13\NNP\14304060|
D008774_D001289 NONE methylphenidate_34\NN\4320126| (r_conj) clonidine_32\NN\2721160|and|methylphenidate (r_conj) methylphenidate_25\NN\4320126|(|n|29|)|,|clonidine|(|n|32|,|or|placebo (r_conj) clonidine_18\NN\2721160|to|n|,|methylphenidate (r_xcomp) assigned_16\VBN\2475922|in|,|children|were|randomly|clonidine|. (l_nsubjpass) children_11\NNS\9622049|122|with (l_prep) with_12\IN\0|adhd (l_pobj) adhd_13\NNP\14304060|
D008774_D001289 NONE methylphenidate_6\NN\4320126| (r_pobj) with_5\IN\0|methylphenidate (r_conj) used_2\VBN\0|alone|or|with (r_acl) clonidine_0\NNP\2721160|,|used|, (r_nsubj) appears_8\VBZ\2604760|clonidine|safe|and|tolerated|. (l_conj) tolerated_12\VBN\802318|well|in (l_prep) in_13\IN\13603305|adhd (l_pobj) adhd_15\NNP\14304060|childhood
D003000_D001919 CID clonidine_10\NN\2721160| (r_pobj) with_9\IN\0|clonidine (r_prep) treated_8\VBN\2376958|with|compared (r_acl) subjects_7\NNS\6598915|treated (r_pobj) in_6\IN\13603305|subjects (r_prep) incidents_3\NNS\7283608|more|of|in (l_prep) of_4\IN\0|bradycardia (l_pobj) bradycardia_5\NN\14110674|
D003000_D001919 CID clonidine_17\NN\2721160| (r_pobj) with_16\IN\0|clonidine (r_prep) treated_15\VBN\2376958|not|with (r_acl) those_13\DT\0|treated|%|but|differences (r_pobj) with_12\IN\0|those (r_prep) compared_11\VBN\644583|with (r_prep) treated_8\VBN\2376958|with|compared (r_acl) subjects_7\NNS\6598915|treated (r_pobj) in_6\IN\13603305|subjects (r_prep) incidents_3\NNS\7283608|more|of|in (l_prep) of_4\IN\0|bradycardia (l_pobj) bradycardia_5\NN\14110674|
D003000_D001919 CID clonidine_2\NN\2721160| (r_dobj) prescribing_1\VBG\748282|clonidine (r_acl) physicians_0\NNS\10305802|prescribing (r_nsubj) monitor_4\VB\10676877|physicians|should|for|and|advise|. (l_prep) for_5\IN\0|bradycardia (l_pobj) bradycardia_6\NN\14110674|
D003000_D006970 NONE clonidine_4\NN\2721160| (r_pobj) on_3\IN\0|clonidine (r_prep) was_1\VBD\0|drowsiness|common|on|,|but|resolved|. (l_nsubj) drowsiness_0\NN\14015731|
D003000_D006970 NONE clonidine_2\NN\2721160| (r_dobj) prescribing_1\VBG\748282|clonidine (r_acl) physicians_0\NNS\10305802|prescribing (r_nsubj) monitor_4\VB\10676877|physicians|should|for|and|advise|. (l_conj) advise_8\VB\813978|patients (l_dobj) patients_9\NNS\9898892|about (l_prep) about_10\IN\0|likelihood (l_pobj) likelihood_13\NN\4756172|the|high|of (l_prep) of_14\IN\0|drowsiness (l_pobj) drowsiness_16\NN\14015731|initial
2950248
D004176_D017202 NONE dipyridamole_0\NNP\0| (r_npadvmod) induced_2\VBN\1627355|dipyridamole|- (r_amod) ischemia_4\NN\14195315|induced|myocardial|.
D004176_D017202 NONE dipyridamole_16\NN\0| (r_compound) therapy_17\NN\657604|preoperative|dipyridamole (r_pobj) of_14\IN\0|therapy (r_prep) effect_13\NN\34213|a|side|of (r_pobj) as_10\IN\14622893|effect (r_prep) reported_9\VBN\831651|to|,|this|has|not|previously|been|as|,|demonstrated|. (l_advcl) demonstrated_27\VBN\2137132|although|ischemia|has|been|occur (l_nsubjpass) ischemia_24\NN\14195315|induced|myocardial
D004176_D017202 NONE dipyridamole_20\NN\0| (r_dep) induced_22\VBN\1627355|dipyridamole|- (r_amod) ischemia_24\NN\14195315|induced|myocardial
D004176_D000787 CID dipyridamole_10\NN\0|oral (r_pobj) of_8\IN\0|dipyridamole (r_prep) administration_7\NN\1133281|of (r_pobj) after_6\IN\0|administration (r_prep) occurred_5\VBD\0|angina|after|in|. (l_nsubj) angina_0\NNP\14171682|and|changes
D004176_D003324 NONE dipyridamole_16\NN\0| (r_compound) therapy_17\NN\657604|preoperative|dipyridamole (r_pobj) of_14\IN\0|therapy (r_prep) effect_13\NN\34213|a|side|of (r_pobj) as_10\IN\14622893|effect (r_prep) reported_9\VBN\831651|to|,|this|has|not|previously|been|as|,|demonstrated|. (l_advcl) demonstrated_27\VBN\2137132|although|ischemia|has|been|occur (l_xcomp) occur_29\VB\0|to|in|with (l_prep) with_34\IN\0|disease (l_pobj) disease_37\NN\14061805|coronary|artery
D004176_D003324 NONE dipyridamole_20\NN\0| (r_dep) induced_22\VBN\1627355|dipyridamole|- (r_amod) ischemia_24\NN\14195315|induced|myocardial (r_nsubjpass) demonstrated_27\VBN\2137132|although|ischemia|has|been|occur (l_xcomp) occur_29\VB\0|to|in|with (l_prep) with_34\IN\0|disease (l_pobj) disease_37\NN\14061805|coronary|artery
D004176_D007511 NONE dipyridamole_23\NN\0| (r_npadvmod) induced_25\VBN\1627355|dipyridamole|- (r_amod) ischemia_26\NN\14195315|the|induced
3828020
D010665_D002544 CID phenylpropanolamine_8\NN\2682038| (r_pobj) of_7\IN\0|phenylpropanolamine (r_prep) dose_6\NN\3740161|a|single|oral|of (r_pobj) with_2\IN\0|dose (r_prep) infarction_1\NN\14204950|cerebral|with|.
D010665_D002544 CID ppa_20\NNP\0| (r_pobj) of_19\IN\0|ppa (r_prep) dose_18\NN\3740161|a|single|oral|of (r_dobj) taking_14\VBG\37396|dose (r_pcomp) after_13\IN\0|taking (r_prep) suffered_9\VBD\2110220|who|infarction|after (l_dobj) infarction_12\NN\14204950|a|cerebral
15325671
D003520_D066126 NONE cyclophosphamide_9\NN\0| (r_npadvmod) based_11\VBN\0|cyclophosphamide|- (r_amod) chemotherapy_12\NN\661091|dose|based|for (r_pobj) with_5\IN\0|chemotherapy (r_prep) association_4\NN\8008335|with (r_pobj) in_3\IN\13603305|association (r_prep) observed_2\VBD\2163746|toxicity|in|. (l_nsubj) toxicity_1\NN\13576101|cardiac
D003520_D066126 NONE cyclophosphamide_3\NN\0| (r_npadvmod) related_5\VBN\628491|cyclophosphamide|- (r_amod) toxicity_7\NN\13576101|transient|related|cardiac|(|%|)
D003520_D001943 NONE cyclophosphamide_9\NN\0| (r_npadvmod) based_11\VBN\0|cyclophosphamide|- (r_amod) chemotherapy_12\NN\661091|dose|based|for (l_prep) for_13\IN\0|cancer (l_pobj) cancer_16\NN\14239425|metastatic|breast
D003520_D001943 NONE cyclophosphamide_9\NN\0|dose|,|thiotepa (l_conj) thiotepa_11\NNS\2722458|,|and|carboplatin (l_conj) carboplatin_14\VB\0|in|regimen (l_dobj) regimen_22\NN\5898568|a|triple|sequential|dose|for (l_prep) for_23\IN\0|patients (l_pobj) patients_24\NNS\9898892|with (l_prep) with_25\IN\0|cancer (l_pobj) cancer_28\NN\14239425|metastatic|breast
D003520_D001943 NONE cyclophosphamide_16\NN\0|96-h|infusional (r_dobj) receiving_13\VBG\2210855|cyclophosphamide|as (r_acl) cancer_12\NN\14239425|responsive|metastatic|breast|receiving|and|characteristics
D017239_D001943 NONE paclitaxel_2\NN\0|combined|,|melphalan (l_conj) melphalan_4\NN\2722458|and|cyclophosphamide (l_conj) cyclophosphamide_9\NN\0|dose|,|thiotepa (l_conj) thiotepa_11\NNS\2722458|,|and|carboplatin (l_conj) carboplatin_14\VB\0|in|regimen (l_dobj) regimen_22\NN\5898568|a|triple|sequential|dose|for (l_prep) for_23\IN\0|patients (l_pobj) patients_24\NNS\9898892|with (l_prep) with_25\IN\0|cancer (l_pobj) cancer_28\NN\14239425|metastatic|breast
D008558_D001943 NONE melphalan_4\NN\2722458|and|cyclophosphamide (l_conj) cyclophosphamide_9\NN\0|dose|,|thiotepa (l_conj) thiotepa_11\NNS\2722458|,|and|carboplatin (l_conj) carboplatin_14\VB\0|in|regimen (l_dobj) regimen_22\NN\5898568|a|triple|sequential|dose|for (l_prep) for_23\IN\0|patients (l_pobj) patients_24\NNS\9898892|with (l_prep) with_25\IN\0|cancer (l_pobj) cancer_28\NN\14239425|metastatic|breast
D013852_D001943 NONE thiotepa_11\NNS\2722458|,|and|carboplatin (l_conj) carboplatin_14\VB\0|in|regimen (l_dobj) regimen_22\NN\5898568|a|triple|sequential|dose|for (l_prep) for_23\IN\0|patients (l_pobj) patients_24\NNS\9898892|with (l_prep) with_25\IN\0|cancer (l_pobj) cancer_28\NN\14239425|metastatic|breast
D016190_D001943 NONE carboplatin_14\VB\0|in|regimen (l_dobj) regimen_22\NN\5898568|a|triple|sequential|dose|for (l_prep) for_23\IN\0|patients (l_pobj) patients_24\NNS\9898892|with (l_prep) with_25\IN\0|cancer (l_pobj) cancer_28\NN\14239425|metastatic|breast
D003520_D006333 CID cyclophosphamide_16\NN\0|96-h|infusional (r_dobj) receiving_13\VBG\2210855|cyclophosphamide|as (l_prep) as_17\IN\14622893|part (l_pobj) part_18\NN\31921|of (l_prep) of_19\IN\0|regimen (l_pobj) regimen_26\NN\5898568|a|triple|sequential|dose|assess (l_acl) assess_28\VB\5220461|to|association (l_dobj) association_29\NN\8008335|between (l_prep) between_30\IN\0|presence (l_pobj) presence_31\NN\13954253|of (l_prep) of_32\IN\0|failure (l_pobj) failure_36\NN\66216|peritransplant|heart|chf
D003520_D006333 CID cyclophosphamide_16\NN\0|96-h|infusional (r_dobj) receiving_13\VBG\2210855|cyclophosphamide|as (l_prep) as_17\IN\14622893|part (l_pobj) part_18\NN\31921|of (l_prep) of_19\IN\0|regimen (l_pobj) regimen_26\NN\5898568|a|triple|sequential|dose|assess (l_acl) assess_28\VB\5220461|to|association (l_dobj) association_29\NN\8008335|between (l_prep) between_30\IN\0|presence (l_pobj) presence_31\NN\13954253|of (l_prep) of_32\IN\0|failure (l_pobj) failure_36\NN\66216|peritransplant|heart|chf (l_appos) chf_38\NNP\0|(|)
D003520_D006333 CID cyclophosphamide_16\NN\0|infusional (r_dobj) following_14\VBG\8180190|cyclophosphamide|with (r_prep) developed_8\VBD\1753788|six|grade|following|. (l_dobj) grade_11\NN\7975026|reversible|chf (l_appos) chf_13\NNP\0|3
D003520_D006333 CID cyclophosphamide_5\NN\0|infusional (r_pobj) during_3\IN\0|cyclophosphamide (r_prep) monitoring_2\NN\879759|ekg|during (r_nsubj) predict_8\VB\916909|monitoring|did|not|development|. (l_dobj) development_10\NN\248977|chf (l_compound) chf_9\NNP\0|
D003520_D006973 NONE cyclophosphamide_16\NN\0|96-h|infusional (r_dobj) receiving_13\VBG\2210855|cyclophosphamide|as (r_acl) cancer_12\NN\14239425|responsive|metastatic|breast|receiving|and|characteristics (l_conj) characteristics_44\NNS\5849040|the|following|pretreatment|:|presence (l_appos) presence_46\NN\13954253|of|,|history (l_prep) of_47\IN\0|electrocardiogram (l_pobj) electrocardiogram_48\NN\7000195|(|ekg|abnormalities (l_appos) abnormalities_52\NNS\14034177|,|age|hypertension (l_appos) hypertension_56\NN\14057371|
D003520_D003920 NONE cyclophosphamide_16\NN\0|96-h|infusional (r_dobj) receiving_13\VBG\2210855|cyclophosphamide|as (r_acl) cancer_12\NN\14239425|responsive|metastatic|breast|receiving|and|characteristics (l_conj) characteristics_44\NNS\5849040|the|following|pretreatment|:|presence (l_appos) presence_46\NN\13954253|of|,|history (l_appos) history_60\NN\15120823|prior|cardiac|,|smoking (l_conj) smoking_62\NN\831191|,|mellitus (l_conj) mellitus_65\NN\0|diabetes|,|use
D018943_D001943 NONE anthracyclines_70\NNS\0| (r_pobj) of_69\IN\0|anthracyclines (r_prep) use_68\NN\407535|prior|of|,|and|irradiation (r_conj) mellitus_65\NN\0|diabetes|,|use (r_conj) smoking_62\NN\831191|,|mellitus (r_conj) history_60\NN\15120823|prior|cardiac|,|smoking (r_appos) presence_46\NN\13954253|of|,|history (r_appos) characteristics_44\NNS\5849040|the|following|pretreatment|:|presence (r_conj) cancer_12\NN\14239425|responsive|metastatic|breast|receiving|and|characteristics
D018943_D006333 NONE anthracyclines_70\NNS\0| (r_pobj) of_69\IN\0|anthracyclines (r_prep) use_68\NN\407535|prior|of|,|and|irradiation (r_conj) mellitus_65\NN\0|diabetes|,|use (r_conj) smoking_62\NN\831191|,|mellitus (r_conj) history_60\NN\15120823|prior|cardiac|,|smoking (r_appos) presence_46\NN\13954253|of|,|history (r_appos) characteristics_44\NNS\5849040|the|following|pretreatment|:|presence (r_conj) cancer_12\NN\14239425|responsive|metastatic|breast|receiving|and|characteristics (l_acl) receiving_13\VBG\2210855|cyclophosphamide|as (l_prep) as_17\IN\14622893|part (l_pobj) part_18\NN\31921|of (l_prep) of_19\IN\0|regimen (l_pobj) regimen_26\NN\5898568|a|triple|sequential|dose|assess (l_acl) assess_28\VB\5220461|to|association (l_dobj) association_29\NN\8008335|between (l_prep) between_30\IN\0|presence (l_pobj) presence_31\NN\13954253|of (l_prep) of_32\IN\0|failure (l_pobj) failure_36\NN\66216|peritransplant|heart|chf
D018943_D006333 NONE anthracyclines_70\NNS\0| (r_pobj) of_69\IN\0|anthracyclines (r_prep) use_68\NN\407535|prior|of|,|and|irradiation (r_conj) mellitus_65\NN\0|diabetes|,|use (r_conj) smoking_62\NN\831191|,|mellitus (r_conj) history_60\NN\15120823|prior|cardiac|,|smoking (r_appos) presence_46\NN\13954253|of|,|history (r_appos) characteristics_44\NNS\5849040|the|following|pretreatment|:|presence (r_conj) cancer_12\NN\14239425|responsive|metastatic|breast|receiving|and|characteristics (l_acl) receiving_13\VBG\2210855|cyclophosphamide|as (l_prep) as_17\IN\14622893|part (l_pobj) part_18\NN\31921|of (l_prep) of_19\IN\0|regimen (l_pobj) regimen_26\NN\5898568|a|triple|sequential|dose|assess (l_acl) assess_28\VB\5220461|to|association (l_dobj) association_29\NN\8008335|between (l_prep) between_30\IN\0|presence (l_pobj) presence_31\NN\13954253|of (l_prep) of_32\IN\0|failure (l_pobj) failure_36\NN\66216|peritransplant|heart|chf (l_appos) chf_38\NNP\0|(|)
D018943_D006973 NONE anthracyclines_70\NNS\0| (r_pobj) of_69\IN\0|anthracyclines (r_prep) use_68\NN\407535|prior|of|,|and|irradiation (r_conj) mellitus_65\NN\0|diabetes|,|use (r_conj) smoking_62\NN\831191|,|mellitus (r_conj) history_60\NN\15120823|prior|cardiac|,|smoking (r_appos) presence_46\NN\13954253|of|,|history (l_prep) of_47\IN\0|electrocardiogram (l_pobj) electrocardiogram_48\NN\7000195|(|ekg|abnormalities (l_appos) abnormalities_52\NNS\14034177|,|age|hypertension (l_appos) hypertension_56\NN\14057371|
D018943_D003920 NONE anthracyclines_70\NNS\0| (r_pobj) of_69\IN\0|anthracyclines (r_prep) use_68\NN\407535|prior|of|,|and|irradiation (r_conj) mellitus_65\NN\0|diabetes|,|use
3503576
D003676_D006311 NONE deferoxamine_8\NN\0| (r_compound) therapy_9\NN\657604|deferoxamine (r_dobj) receiving_7\VBG\2210855|therapy (r_acl) patients_6\NNS\9898892|receiving (r_pobj) in_5\IN\13603305|patients (r_prep) studies_1\NNS\635850|serial|of|in|. (l_prep) of_2\IN\0|neurotoxicity (l_pobj) neurotoxicity_4\NN\0|auditory
D003676_D006311 NONE deferoxamine_26\NN\0|daily|subcutaneous (r_pobj) with_23\IN\0|deferoxamine (r_prep) receiving_19\VBG\2210855|who|were|therapy|with (r_relcl) anemia_16\NN\14189204|dependent|receiving (r_pobj) with_12\IN\0|anemia (r_prep) patients_11\NNS\9898892|89|with (r_pobj) in_7\IN\13603305|patients (r_prep) documented_6\VBN\1000214|neurotoxicity|was|previously|in|. (l_nsubjpass) neurotoxicity_3\NN\0|visual
D003676_D006311 NONE deferoxamine_9\NN\0| (r_compound) doses_10\NNS\3740161|deferoxamine (r_dobj) receiving_8\VBG\2210855|since|18|were|initially|doses|in (r_advcl) restarted_24\VBN\1857717|receiving|,|therapy|was|with|,|and|demonstrated (l_prep) with_25\IN\0|doses (l_pobj) doses_27\NNS\3740161|lower|,|mg/kg|depending (l_prep) depending_36\VBG\2604760|on (l_prep) on_37\IN\0|degree (l_pobj) degree_39\NN\4916342|the|of (l_prep) of_40\IN\0|abnormality (l_pobj) abnormality_42\NN\14034177|auditory
D003676_D006311 NONE deferoxamine_14\NN\0| (r_dobj) receiving_13\VBG\2210855|not|deferoxamine (r_conj) receiving_10\VBG\2210855|and|receiving (r_acl) patients_9\NNS\9898892|individual|receiving (r_pobj) in_7\IN\13603305|patients (r_prep) demonstrated_5\VBD\2137132|deterioration|,|serially|in|,|respectively|,|provided|. (l_prep) provided_18\VBD\2199590|convincing (l_pcomp) convincing_19\JJ\766418|evidence (l_dobj) evidence_20\NN\5816287|for (l_prep) for_21\IN\0|relation (l_pobj) relation_28\NN\2137|a|cause|between (l_prep) between_29\IN\0|administration (l_pobj) administration_31\NN\1133281|deferoxamine|and|ototoxicity (l_conj) ototoxicity_33\NN\0|
D003676_D006311 NONE deferoxamine_30\NN\0| (r_compound) administration_31\NN\1133281|deferoxamine|and|ototoxicity (l_conj) ototoxicity_33\NN\0|
D007501_D014786 NONE iron_20\NN\14625458| (r_compound) therapy_22\NN\657604|iron|chelation (r_dobj) receiving_19\VBG\2210855|who|were|therapy|with (r_relcl) anemia_16\NN\14189204|dependent|receiving (r_pobj) with_12\IN\0|anemia (r_prep) patients_11\NNS\9898892|89|with (r_pobj) in_7\IN\13603305|patients (r_prep) documented_6\VBN\1000214|neurotoxicity|was|previously|in|. (l_nsubjpass) neurotoxicity_3\NN\0|visual
D007501_D006311 NONE iron_20\NN\14625458| (r_compound) therapy_22\NN\657604|iron|chelation (r_dobj) receiving_19\VBG\2210855|who|were|therapy|with (r_relcl) anemia_16\NN\14189204|dependent|receiving (r_pobj) with_12\IN\0|anemia (r_prep) patients_11\NNS\9898892|89|with (r_pobj) in_7\IN\13603305|patients (r_prep) documented_6\VBN\1000214|neurotoxicity|was|previously|in|. (l_nsubjpass) neurotoxicity_3\NN\0|visual
D007501_D000740 NONE iron_20\NN\14625458| (r_compound) therapy_22\NN\657604|iron|chelation (r_dobj) receiving_19\VBG\2210855|who|were|therapy|with (r_relcl) anemia_16\NN\14189204|dependent|receiving
D003676_D014786 NONE deferoxamine_26\NN\0|daily|subcutaneous (r_pobj) with_23\IN\0|deferoxamine (r_prep) receiving_19\VBG\2210855|who|were|therapy|with (r_relcl) anemia_16\NN\14189204|dependent|receiving (r_pobj) with_12\IN\0|anemia (r_prep) patients_11\NNS\9898892|89|with (r_pobj) in_7\IN\13603305|patients (r_prep) documented_6\VBN\1000214|neurotoxicity|was|previously|in|. (l_nsubjpass) neurotoxicity_3\NN\0|visual
D003676_D000740 NONE deferoxamine_26\NN\0|daily|subcutaneous (r_pobj) with_23\IN\0|deferoxamine (r_prep) receiving_19\VBG\2210855|who|were|therapy|with (r_relcl) anemia_16\NN\14189204|dependent|receiving
D003676_D064420 NONE deferoxamine_9\NN\0| (r_compound) doses_10\NNS\3740161|deferoxamine (r_dobj) receiving_8\VBG\2210855|since|18|were|initially|doses|in (r_advcl) restarted_24\VBN\1857717|receiving|,|therapy|was|with|,|and|demonstrated (l_conj) demonstrated_55\VBN\2137132|with|toxicity|was|. (l_nsubjpass) toxicity_53\NN\13576101|no|further
16330293
8996652
D000617_D006311 NONE aminoglycosides_17\NNS\0|particularly|and|furosemide (r_appos) administration_7\NN\1133281|a|prolonged|and|dose|,|aminoglycosides (r_pobj) to_4\IN\0|administration (r_prep) related_3\JJ\628491|closely|to (r_oprd) appeared_1\VBD\2604760|ototoxicity|related|. (l_nsubj) ototoxicity_0\NN\0|
D000617_D006311 NONE aminoglycosides_17\NNS\0|particularly|and|furosemide (r_appos) administration_7\NN\1133281|a|prolonged|and|dose|,|aminoglycosides (l_conj) dose_11\NN\3740161|higher|total|of (l_prep) of_12\IN\0|drugs (l_pobj) drugs_14\NNS\14778436|ototoxic (l_compound) ototoxic_13\JJ\0|
D005665_D006311 NONE furosemide_19\NN\3214670| (r_conj) aminoglycosides_17\NNS\0|particularly|and|furosemide (r_appos) administration_7\NN\1133281|a|prolonged|and|dose|,|aminoglycosides (r_pobj) to_4\IN\0|administration (r_prep) related_3\JJ\628491|closely|to (r_oprd) appeared_1\VBD\2604760|ototoxicity|related|. (l_nsubj) ototoxicity_0\NN\0|
D005665_D006311 NONE furosemide_19\NN\3214670| (r_conj) aminoglycosides_17\NNS\0|particularly|and|furosemide (r_appos) administration_7\NN\1133281|a|prolonged|and|dose|,|aminoglycosides (l_conj) dose_11\NN\3740161|higher|total|of (l_prep) of_12\IN\0|drugs (l_pobj) drugs_14\NNS\14778436|ototoxic (l_compound) ototoxic_13\JJ\0|
14596845
D000661_D019966 NONE amphetamine_15\NN\3248958| (r_pobj) of_14\IN\0|amphetamine (r_prep) dose_13\NN\3740161|a|low|of (r_pobj) to_10\IN\0|dose (r_prep) sensitization_9\NN\14531772|behavioral|cross|-|to (r_dobj) causes_5\VBZ\7323922|diet|sensitization|. (l_nsubj) diet_1\NN\7560652|a|promoting (l_acl) promoting_2\VBG\2556126|dependency (l_dobj) dependency_4\NN\24720|sugar
D000661_D006948 CID amphetamine_15\NN\3248958| (r_pobj) of_14\IN\0|amphetamine (r_prep) dose_13\NN\3740161|a|low|of (r_pobj) to_10\IN\0|dose (r_prep) sensitization_9\NN\14531772|behavioral|cross|-|to
D000661_D006948 CID amphetamine_24\NN\3248958| (r_pobj) of_23\IN\0|amphetamine (r_prep) dose_22\NN\3740161|a|low|of (r_pobj) to_19\IN\0|dose (r_prep) show_14\VB\429048|whether|rats|would|sensitization|to (l_dobj) sensitization_18\NN\14531772|behavioral|cross|-
D000661_D006948 CID amphetamine_14\NN\3248958| (r_pobj) to_13\IN\0|amphetamine (r_prep) response_12\NN\11410625|to (r_pobj) in_11\IN\13603305|response (r_prep) were_9\VBD\0|animals|hyperactive|in|compared|. (l_acomp) hyperactive_10\JJ\0|
D000661_D006948 CID amphetamine_30\NN\3248958| (r_compound) injection_31\NN\320852|amphetamine (r_pobj) by_29\IN\0|injection (r_agent) followed_28\VBN\1835496|by (r_acl) sucrose_25\NN\14836642|libitum|%|and|chow|followed (r_appos) groups_19\NNS\2137|four|control|(|sucrose|,|chow|,|chow|) (r_pobj) with_16\IN\0|groups (r_prep) compared_15\VBN\644583|with (r_prep) were_9\VBD\0|animals|hyperactive|in|compared|. (l_acomp) hyperactive_10\JJ\0|
D000661_D006948 CID amphetamine_37\NN\3248958| (r_compound) injection_38\NN\320852|amphetamine (r_pobj) by_36\IN\0|injection (r_agent) followed_35\VBN\1835496|by (r_acl) chow_34\NN\7971582|cyclic|followed (r_appos) groups_19\NNS\2137|four|control|(|sucrose|,|chow|,|chow|) (r_pobj) with_16\IN\0|groups (r_prep) compared_15\VBN\644583|with (r_prep) were_9\VBD\0|animals|hyperactive|in|compared|. (l_acomp) hyperactive_10\JJ\0|
D000661_D006948 CID amphetamine_44\NN\3248958|,|or|sucrose (r_pobj) with_43\IN\0|amphetamine (r_prep) chow_42\NN\7971582|ad|libitum|with (r_appos) groups_19\NNS\2137|four|control|(|sucrose|,|chow|,|chow|) (r_pobj) with_16\IN\0|groups (r_prep) compared_15\VBN\644583|with (r_prep) were_9\VBD\0|animals|hyperactive|in|compared|. (l_acomp) hyperactive_10\JJ\0|
D013395_D006948 CID sucrose_6\NN\14836642|cyclic|and|chow (r_dobj) experienced_4\VBN\2108377|that|had|sucrose (r_relcl) animals_1\NNS\4475|the|experienced (r_nsubj) were_9\VBD\0|animals|hyperactive|in|compared|. (l_acomp) hyperactive_10\JJ\0|
D013395_D006948 CID sucrose_25\NN\14836642|libitum|%|and|chow|followed (r_appos) groups_19\NNS\2137|four|control|(|sucrose|,|chow|,|chow|) (r_pobj) with_16\IN\0|groups (r_prep) compared_15\VBN\644583|with (r_prep) were_9\VBD\0|animals|hyperactive|in|compared|. (l_acomp) hyperactive_10\JJ\0|
D013395_D006948 CID sucrose_50\NN\14836642|cyclic|%|and|chow|with (r_conj) amphetamine_44\NN\3248958|,|or|sucrose (r_pobj) with_43\IN\0|amphetamine (r_prep) chow_42\NN\7971582|ad|libitum|with (r_appos) groups_19\NNS\2137|four|control|(|sucrose|,|chow|,|chow|) (r_pobj) with_16\IN\0|groups (r_prep) compared_15\VBN\644583|with (r_prep) were_9\VBD\0|animals|hyperactive|in|compared|. (l_acomp) hyperactive_10\JJ\0|
3719553
D005472_D004342 NONE 5-fluorouracil_3\CD\0| (r_punct) infusion_4\NN\14589223|5-fluorouracil (r_pobj) to_2\IN\0|infusion (r_prep) reaction_1\NN\13446390|allergic|to|.
D005472_D004342 NONE 5-fluorouracil_11\CD\0| (r_punct) reaction_2\NN\13446390|an|allergic|consisting|5-fluorouracil
D005472_D000799 CID 5-fluorouracil_11\CD\0| (r_punct) reaction_2\NN\13446390|an|allergic|consisting|5-fluorouracil (l_acl) consisting_3\VBG\2603699|of (l_prep) of_4\IN\0|angioneurotic|edema (l_pobj) edema_6\NN\14315192|secondary
D005472_D009062 NONE 5-fluorouracil_11\CD\0| (r_punct) reaction_2\NN\13446390|an|allergic|consisting|5-fluorouracil (r_nsubj) occurred_12\VBD\0|reaction|in|. (l_prep) in_13\IN\13603305|patient (l_pobj) patient_15\NN\9898892|a|with (l_prep) with_16\IN\0|carcinoma (l_pobj) carcinoma_18\NN\14239918|recurrent|of (l_prep) of_19\IN\0|cavity (l_pobj) cavity_22\NN\9304750|the|oral|,|cirrhosis
D005472_D005355 NONE 5-fluorouracil_11\CD\0| (r_punct) reaction_2\NN\13446390|an|allergic|consisting|5-fluorouracil (r_nsubj) occurred_12\VBD\0|reaction|in|. (l_prep) in_13\IN\13603305|patient (l_pobj) patient_15\NN\9898892|a|with (l_prep) with_16\IN\0|carcinoma (l_pobj) carcinoma_18\NN\14239918|recurrent|of (l_prep) of_19\IN\0|cavity (l_pobj) cavity_22\NN\9304750|the|oral|,|cirrhosis (l_conj) cirrhosis_24\NN\14116321|,|and|function
D005472_D007674 NONE 5-fluorouracil_11\CD\0| (r_punct) reaction_2\NN\13446390|an|allergic|consisting|5-fluorouracil (r_nsubj) occurred_12\VBD\0|reaction|in|. (l_prep) in_13\IN\13603305|patient (l_pobj) patient_15\NN\9898892|a|with (l_prep) with_16\IN\0|carcinoma (l_pobj) carcinoma_18\NN\14239918|recurrent|of (l_prep) of_19\IN\0|cavity (l_pobj) cavity_22\NN\9304750|the|oral|,|cirrhosis (l_conj) cirrhosis_24\NN\14116321|,|and|function (l_conj) function_32\NN\13783581|induced|impaired|renal
D002945_D004342 NONE cisplatin_27\NN\0| (r_advmod) induced_29\VBN\1627355|cisplatin|- (r_amod) function_32\NN\13783581|induced|impaired|renal (r_conj) cirrhosis_24\NN\14116321|,|and|function (r_conj) cavity_22\NN\9304750|the|oral|,|cirrhosis (r_pobj) of_19\IN\0|cavity (r_prep) carcinoma_18\NN\14239918|recurrent|of (r_pobj) with_16\IN\0|carcinoma (r_prep) patient_15\NN\9898892|a|with (r_pobj) in_13\IN\13603305|patient (r_prep) occurred_12\VBD\0|reaction|in|. (l_nsubj) reaction_2\NN\13446390|an|allergic|consisting|5-fluorouracil
D002945_D000799 NONE cisplatin_27\NN\0| (r_advmod) induced_29\VBN\1627355|cisplatin|- (r_amod) function_32\NN\13783581|induced|impaired|renal (r_conj) cirrhosis_24\NN\14116321|,|and|function (r_conj) cavity_22\NN\9304750|the|oral|,|cirrhosis (r_pobj) of_19\IN\0|cavity (r_prep) carcinoma_18\NN\14239918|recurrent|of (r_pobj) with_16\IN\0|carcinoma (r_prep) patient_15\NN\9898892|a|with (r_pobj) in_13\IN\13603305|patient (r_prep) occurred_12\VBD\0|reaction|in|. (l_nsubj) reaction_2\NN\13446390|an|allergic|consisting|5-fluorouracil (l_acl) consisting_3\VBG\2603699|of (l_prep) of_4\IN\0|angioneurotic|edema (l_pobj) edema_6\NN\14315192|secondary
D002945_D009062 NONE cisplatin_27\NN\0| (r_advmod) induced_29\VBN\1627355|cisplatin|- (r_amod) function_32\NN\13783581|induced|impaired|renal (r_conj) cirrhosis_24\NN\14116321|,|and|function (r_conj) cavity_22\NN\9304750|the|oral|,|cirrhosis
D002945_D005355 NONE cisplatin_27\NN\0| (r_advmod) induced_29\VBN\1627355|cisplatin|- (r_amod) function_32\NN\13783581|induced|impaired|renal (r_conj) cirrhosis_24\NN\14116321|,|and|function
D002945_D007674 NONE cisplatin_27\NN\0| (r_advmod) induced_29\VBN\1627355|cisplatin|- (r_amod) function_32\NN\13783581|induced|impaired|renal
D004155_D004342 NONE diphenhydramine_1\NN\2720725|oral|and|prednisone (r_nsubj) were_4\VBD\0|diphenhydramine|ineffective|in|. (l_prep) in_6\IN\13603305|preventing (l_pcomp) preventing_7\VBG\0|recurrence (l_dobj) recurrence_9\NN\7342049|the|of (l_prep) of_10\IN\0|reaction (l_pobj) reaction_13\NN\13446390|the|allergic
D011241_D004342 NONE prednisone_3\NNP\2721538| (r_conj) diphenhydramine_1\NN\2720725|oral|and|prednisone (r_nsubj) were_4\VBD\0|diphenhydramine|ineffective|in|. (l_prep) in_6\IN\13603305|preventing (l_pcomp) preventing_7\VBG\0|recurrence (l_dobj) recurrence_9\NN\7342049|the|of (l_prep) of_10\IN\0|reaction (l_pobj) reaction_13\NN\13446390|the|allergic
8649546
D007980_D004409 CID levodopa_2\NN\14604959| (r_npadvmod) induced_4\VBN\1627355|levodopa|- (r_amod) dyskinesia_5\NN\14084880|induced
D007980_D004409 CID levodopa_14\RB\14604959| (r_npadvmod) induced_16\VBN\1627355|levodopa|- (r_amod) dyskinesia_20\NN\14084880|induced|ballistic|in
D007980_D010300 NONE levodopa_2\NN\14604959| (r_npadvmod) induced_4\VBN\1627355|levodopa|- (r_amod) dyskinesia_5\NN\14084880|induced (r_pobj) of_1\IN\0|dyskinesia (r_prep) improvement_0\NN\7359599|of|by|. (l_prep) by_6\IN\0|propranolol (l_pcomp) propranolol_7\NN\0|in (l_prep) in_8\IN\13603305|disease (l_pobj) disease_11\NN\14061805|parkinson
D007980_D010300 NONE levodopa_14\RB\14604959| (r_npadvmod) induced_16\VBN\1627355|levodopa|- (r_amod) dyskinesia_20\NN\14084880|induced|ballistic|in (l_prep) in_21\IN\13603305|pd (l_pobj) pd_22\NNP\14625458|
D011433_D004409 NONE propranolol_7\NN\0|in (r_pcomp) by_6\IN\0|propranolol (r_prep) improvement_0\NN\7359599|of|by|. (l_prep) of_1\IN\0|dyskinesia (l_pobj) dyskinesia_5\NN\14084880|induced
D011433_D004409 NONE propranolol_18\NN\0|dose|as (r_dobj) received_14\VBN\2210855|patients|propranolol|. (l_nsubj) patients_1\NNS\9898892|seven|suffering (l_acl) suffering_2\VBG\14322699|from|with (l_prep) with_10\IN\0|dyskinesia (l_pobj) dyskinesia_13\NN\14084880|disabling
D011433_D010300 NONE propranolol_7\NN\0|in (l_prep) in_8\IN\13603305|disease (l_pobj) disease_11\NN\14061805|parkinson
D011433_D010300 NONE propranolol_18\NN\0|dose|as (r_dobj) received_14\VBN\2210855|patients|propranolol|. (l_nsubj) patients_1\NNS\9898892|seven|suffering (l_acl) suffering_2\VBG\14322699|from|with (l_prep) from_3\IN\0|disease (l_pobj) disease_6\NN\14061805|parkinson|(|pd|)
D011433_D010300 NONE propranolol_18\NN\0|dose|as (r_dobj) received_14\VBN\2210855|patients|propranolol|. (l_nsubj) patients_1\NNS\9898892|seven|suffering (l_acl) suffering_2\VBG\14322699|from|with (l_prep) from_3\IN\0|disease (l_pobj) disease_6\NN\14061805|parkinson|(|pd|) (l_appos) pd_8\NNP\14625458|
9812111
D006220_D011618 NONE haloperidol_11\NN\3713736|for (l_prep) for_12\IN\0|psychosis (l_pobj) psychosis_13\NN\14380140|and|behaviors|in
D006220_D011618 NONE haloperidol_17\NN\3713736|and|placebo (r_pobj) of_16\IN\0|haloperidol (r_prep) doses_15\NNS\3740161|two|of (r_pobj) of_13\IN\0|doses (r_prep) efficacy_9\NN\5199286|the|and|effects|of (r_dobj) compare_7\VB\4744814|to|efficacy|in (l_prep) in_20\IN\13603305|treatment (l_pobj) treatment_22\NN\654885|the|of|in (l_prep) of_23\IN\0|psychosis (l_pobj) psychosis_24\NN\14380140|and|behaviors
D006220_D011618 NONE haloperidol_12\NN\3713736|dose (r_appos) a_7\NNP\13649268|phase|,|haloperidol (r_dobj) completed_5\VBD\352826|who|a (r_relcl) patients_3\NNS\9898892|the|60|completed (r_pobj) for_0\IN\0|patients (r_prep) was_13\VBD\0|for|efficacious|. (l_acomp) efficacious_14\JJ\0|and|superior|to (l_prep) to_17\IN\0|haloperidol (l_pobj) haloperidol_22\NN\3713736|both|dose|and|placebo|for (l_prep) for_25\IN\0|scores (l_pobj) scores_26\NNS\13757724|on (l_prep) on_27\IN\0|factor|and|on (l_pobj) factor_34\NN\7326557|the|brief|scale|psychosis (l_compound) psychosis_33\NN\14380140|
D006220_D011618 NONE haloperidol_22\NN\3713736|both|dose|and|placebo|for (l_prep) for_25\IN\0|scores (l_pobj) scores_26\NNS\13757724|on (l_prep) on_27\IN\0|factor|and|on (l_pobj) factor_34\NN\7326557|the|brief|scale|psychosis (l_compound) psychosis_33\NN\14380140|
D006220_D011618 NONE haloperidol_6\NN\3713736| (r_pobj) with_5\IN\0|haloperidol (r_prep) observed_4\VBN\2163746|window|with (r_nsubj) apply_9\VB\0|observed|may|also|to|. (l_prep) to_10\IN\0|neuroleptics (l_pobj) neuroleptics_12\NNS\4470232|other|used (l_acl) used_13\VBN\0|in (l_prep) in_14\IN\13603305|patients (l_pobj) patients_18\NNS\9898892|alzheimer|disease|with (l_prep) with_19\IN\0|psychosis (l_pobj) psychosis_20\NN\14380140|and|behaviors
D006220_D019958 NONE haloperidol_11\NN\3713736|for (l_prep) for_12\IN\0|psychosis (l_pobj) psychosis_13\NN\14380140|and|behaviors|in (l_conj) behaviors_16\NNS\407535|disruptive
D006220_D019958 NONE haloperidol_17\NN\3713736|and|placebo (r_pobj) of_16\IN\0|haloperidol (r_prep) doses_15\NNS\3740161|two|of (r_pobj) of_13\IN\0|doses (r_prep) efficacy_9\NN\5199286|the|and|effects|of (r_dobj) compare_7\VB\4744814|to|efficacy|in (l_prep) in_20\IN\13603305|treatment (l_pobj) treatment_22\NN\654885|the|of|in (l_prep) of_23\IN\0|psychosis (l_pobj) psychosis_24\NN\14380140|and|behaviors (l_conj) behaviors_27\NNS\407535|disruptive
D006220_D019958 NONE haloperidol_6\NN\3713736| (r_pobj) with_5\IN\0|haloperidol (r_prep) observed_4\VBN\2163746|window|with (r_nsubj) apply_9\VB\0|observed|may|also|to|. (l_prep) to_10\IN\0|neuroleptics (l_pobj) neuroleptics_12\NNS\4470232|other|used (l_acl) used_13\VBN\0|in (l_prep) in_14\IN\13603305|patients (l_pobj) patients_18\NNS\9898892|alzheimer|disease|with (l_prep) with_19\IN\0|psychosis (l_pobj) psychosis_20\NN\14380140|and|behaviors (l_conj) behaviors_23\NNS\407535|disruptive
D006220_D000544 NONE haloperidol_11\NN\3713736|for (l_prep) for_12\IN\0|psychosis (l_pobj) psychosis_13\NN\14380140|and|behaviors|in (l_prep) in_17\IN\13603305|disease (l_pobj) disease_20\NN\14061805|alzheimer
D006220_D000544 NONE haloperidol_17\NN\3713736|and|placebo (r_pobj) of_16\IN\0|haloperidol (r_prep) doses_15\NNS\3740161|two|of (r_pobj) of_13\IN\0|doses (r_prep) efficacy_9\NN\5199286|the|and|effects|of (r_dobj) compare_7\VB\4744814|to|efficacy|in (l_prep) in_20\IN\13603305|treatment (l_pobj) treatment_22\NN\654885|the|of|in (l_prep) in_28\IN\13603305|patients (l_pobj) patients_29\NNS\9898892|with (l_prep) with_30\IN\0|disease (l_pobj) disease_33\NN\14061805|alzheimer
D006220_D000544 NONE haloperidol_20\NN\3713736|,|day|(|dose|) (r_appos) phase_16\NN\15113229|(|a|)|,|haloperidol|,|and|haloperidol (r_preconj) in_0\IN\13603305|trial|phase (r_prep) compared_48\VBN\644583|in|,|were|in|. (l_prep) in_49\IN\13603305|outpatients (l_pobj) outpatients_51\NNS\10405694|71|with (l_prep) with_52\IN\0|disease (l_pobj) disease_55\NN\14061805|alzheimer
D006220_D000544 NONE haloperidol_34\NN\3713736|,|day|(|dose|) (r_conj) phase_16\NN\15113229|(|a|)|,|haloperidol|,|and|haloperidol (r_preconj) in_0\IN\13603305|trial|phase (r_prep) compared_48\VBN\644583|in|,|were|in|. (l_prep) in_49\IN\13603305|outpatients (l_pobj) outpatients_51\NNS\10405694|71|with (l_prep) with_52\IN\0|disease (l_pobj) disease_55\NN\14061805|alzheimer
D006220_D000544 NONE haloperidol_6\NN\3713736| (r_pobj) with_5\IN\0|haloperidol (r_prep) observed_4\VBN\2163746|window|with (r_nsubj) apply_9\VB\0|observed|may|also|to|. (l_prep) to_10\IN\0|neuroleptics (l_pobj) neuroleptics_12\NNS\4470232|other|used (l_acl) used_13\VBN\0|in (l_prep) in_14\IN\13603305|patients (l_pobj) patients_18\NNS\9898892|alzheimer|disease|with (l_compound) disease_17\NN\14061805|
D006220_D011595 NONE haloperidol_12\NN\3713736|dose (r_appos) a_7\NNP\13649268|phase|,|haloperidol (r_dobj) completed_5\VBD\352826|who|a (r_relcl) patients_3\NNS\9898892|the|60|completed (r_pobj) for_0\IN\0|patients (r_prep) was_13\VBD\0|for|efficacious|. (l_acomp) efficacious_14\JJ\0|and|superior|to (l_prep) to_17\IN\0|haloperidol (l_pobj) haloperidol_22\NN\3713736|both|dose|and|placebo|for (l_prep) for_25\IN\0|scores (l_pobj) scores_26\NNS\13757724|on (l_prep) on_27\IN\0|factor|and|on (l_conj) on_36\IN\0|agitation (l_pobj) agitation_38\NN\14373582|psychomotor
D006220_D011595 NONE haloperidol_22\NN\3713736|both|dose|and|placebo|for (l_prep) for_25\IN\0|scores (l_pobj) scores_26\NNS\13757724|on (l_prep) on_27\IN\0|factor|and|on (l_conj) on_36\IN\0|agitation (l_pobj) agitation_38\NN\14373582|psychomotor
D006220_D001480 CID haloperidol_8\NN\3713736| (r_pobj) for_7\IN\0|haloperidol (r_prep) profile_6\NN\6999802|a|favorable|therapeutic|for|in (r_dobj) indicated_2\VBD\952524|results|profile|,|developed|. (l_advcl) developed_22\VBD\1753788|although|subgroup|moderate (l_acomp) moderate_23\JJ\9605289|to (l_prep) to_24\TO\0|signs (l_pobj) signs_27\NNS\6643763|severe|extrapyramidal
3560096
D013467_D006947 CID sulindac_3\NN\3828465| (r_compound) therapy_4\NN\657604|sulindac (r_pobj) with_2\IN\0|therapy (r_prep) associated_1\VBN\628491|with (r_acl) hyperkalemia_0\NNP\14299637|associated|.
D013467_D006947 CID sulindac_22\NN\3828465| (r_compound) administration_23\NN\1133281|sulindac (r_pobj) of_21\IN\0|administration (r_prep) days_20\NNS\15140892|8|of (r_pobj) within_16\IN\0|days (r_prep) developed_15\VBD\1753788|hyperkalemia|within (l_nsubj) hyperkalemia_6\VBD\14299637|in|ranging
D013467_D006947 CID sulindac_29\NN\3828465|and|hyperkalemia (l_conj) hyperkalemia_31\NN\14299637|
D007213_D006947 CID indomethacin_17\NN\3828465| (r_pobj) as_16\IN\14622893|such|indomethacin (r_prep) nsaid_13\NNP\2721538|(|)|as (r_appos) agents_11\NNS\7347|nonsteroidal|antiinflammatory|nsaid (r_pobj) of_8\IN\0|agents (r_prep) complication_7\NN\1073995|a|of (r_pobj) as_5\IN\14622893|complication (r_prep) recognized_4\VBN\686447|hyperkalemia|has|recently|been|as|. (l_nsubjpass) hyperkalemia_0\NNP\14299637|
D011188_D006947 NONE potassium_8\NN\14625458|serum (r_dobj) effect_6\NN\34213|to|potassium (r_xcomp) known_4\VBN\0|effect (r_acl) medications_3\NNS\3247620|no|other|known (r_nsubjpass) given_11\VBN\5892096|as|medications|had|been|concomitantly (r_advcl) is_18\VBZ\0|given|,|course|suggestive|. (l_acomp) suggestive_19\JJ\0|of (l_prep) of_20\IN\0|relationship (l_pobj) relationship_27\NN\31921|a|cause|between (l_prep) between_28\IN\0|sulindac (l_pobj) sulindac_29\NN\3828465|and|hyperkalemia (l_conj) hyperkalemia_31\NN\14299637|
2096243
C017367_D019965 CID carmofur_0\NN\0| (r_npadvmod) induced_2\VBN\1627355|carmofur|- (r_amod) disorders_5\NNS\14034177|induced|organic|mental|.
C017367_D019965 CID carmofur_19\NN\0| (r_npadvmod) induced_21\VBN\1627355|carmofur|- (r_amod) leukoencephalopathy_22\NN\0|induced (r_pobj) of_18\IN\0|leukoencephalopathy (r_prep) onset_17\NN\7325190|the|of (r_pobj) after_15\IN\0|onset (r_prep) period_14\NN\13575869|the|prognostic|after (r_pobj) in_11\IN\13603305|period (r_prep) female_10\NN\15388|a|old|in (r_pobj) in_5\IN\13603305|female (r_prep) observed_4\VBN\2163746|disorder|was|in|. (l_nsubjpass) disorder_2\NN\14034177|organic|mental
C017367_D056784 CID carmofur_19\NN\0| (r_npadvmod) induced_21\VBN\1627355|carmofur|- (r_amod) leukoencephalopathy_22\NN\0|induced
C017367_D056784 CID carmofur_2\NN\0| (r_npadvmod) induced_4\VBN\1627355|carmofur|- (r_amod) leukoencephalopathy_5\JJ\0|induced
C017367_D010554 NONE carmofur_2\NN\0| (r_npadvmod) induced_4\VBN\1627355|carmofur|- (r_amod) leukoencephalopathy_5\JJ\0|induced (r_nsubj) result_8\VB\34213|consequently|,|leukoencephalopathy|may|uncommonly|in|. (l_prep) in_9\IN\13603305|syndrome (l_pobj) syndrome_12\NN\5870365|personality|in
14657095
D000666_D002311 CID b_6\NNP\1355326| (r_compound) therapy_7\NN\657604|amphotericin|b (r_pobj) to_4\IN\0|therapy (r_prep) related_3\VBN\628491|to (r_acl) cardiomyopathy_2\NN\14103288|reversible|dilated|related|.
D000666_D002311 CID b_20\NNP\1355326|amphotericin|amb (r_pobj) with_18\IN\0|b (r_prep) developed_5\VBD\1753788|who|failure|after|with|for (l_dobj) failure_12\NN\66216|dilated|cardiomyopathy|heart (l_amod) cardiomyopathy_7\NN\14103288|and|clinical
D000666_D002311 CID amb_22\NNP\0|(|) (r_appos) b_20\NNP\1355326|amphotericin|amb (r_pobj) with_18\IN\0|b (r_prep) developed_5\VBD\1753788|who|failure|after|with|for (l_dobj) failure_12\NN\66216|dilated|cardiomyopathy|heart (l_amod) cardiomyopathy_7\NN\14103288|and|clinical
D000666_D006333 CID b_20\NNP\1355326|amphotericin|amb (r_pobj) with_18\IN\0|b (r_prep) developed_5\VBD\1753788|who|failure|after|with|for (l_dobj) failure_12\NN\66216|dilated|cardiomyopathy|heart
D000666_D006333 CID amb_22\NNP\0|(|) (r_appos) b_20\NNP\1355326|amphotericin|amb (r_pobj) with_18\IN\0|b (r_prep) developed_5\VBD\1753788|who|failure|after|with|for (l_dobj) failure_12\NN\66216|dilated|cardiomyopathy|heart
D000666_D006333 CID amb._12\NN\0| (r_pobj) for_11\IN\0|amb. (r_prep) substituted_10\VBN\126264|after|posaconazole|was|for (r_advcl) resolved_6\VBD\352826|substituted (r_acl) abnormalities_2\NNS\14034177|his|echocardiographic|and|failure|resolved (l_conj) failure_5\NN\66216|heart
D000666_D003047 NONE b_20\NNP\1355326|amphotericin|amb (r_pobj) with_18\IN\0|b (r_prep) developed_5\VBD\1753788|who|failure|after|with|for (l_prep) for_24\IN\0|coccidioidomycosis (l_pobj) coccidioidomycosis_26\NN\14176895|disseminated
D000666_D003047 NONE amb_22\NNP\0|(|) (r_appos) b_20\NNP\1355326|amphotericin|amb (r_pobj) with_18\IN\0|b (r_prep) developed_5\VBD\1753788|who|failure|after|with|for (l_prep) for_24\IN\0|coccidioidomycosis (l_pobj) coccidioidomycosis_26\NN\14176895|disseminated
C101425_D006333 NONE posaconazole_8\NN\0| (r_nsubjpass) substituted_10\VBN\126264|after|posaconazole|was|for (r_advcl) resolved_6\VBD\352826|substituted (r_acl) abnormalities_2\NNS\14034177|his|echocardiographic|and|failure|resolved (l_conj) failure_5\NN\66216|heart
D000666_D064420 NONE amb._12\NN\0| (r_pobj) of_11\IN\0|amb. (r_prep) toxicity_10\NN\13576101|the|rare|of
18023325
D004221_D014826 CID disulfiram_6\NN\3740161| (r_compound) intoxication_7\NN\14034177|acute|disulfiram (r_pobj) after_4\IN\0|intoxication (r_prep) palsy_3\JJ\14557898|acute|fold|after|.
D004221_D014826 CID disulfiram_6\NN\3740161| (r_compound) overdose_7\NN\84738|a|disulfiram (r_pobj) by_4\IN\0|overdose (r_agent) caused_3\VBN\1617192|by (r_acl) neuropathy_2\NN\14204950|acute|peripheral|caused (r_nsubj) is_8\VBZ\0|neuropathy|rare|and|is (l_conj) is_13\VBZ\0|there|report|. (l_attr) report_15\NN\6470073|no|of|leading (l_acl) leading_18\VBG\4339291|to (l_prep) to_19\IN\0|palsy (l_pobj) palsy_22\JJ\14557898|fold
D004221_D010523 CID disulfiram_6\NN\3740161| (r_compound) overdose_7\NN\84738|a|disulfiram (r_pobj) by_4\IN\0|overdose (r_agent) caused_3\VBN\1617192|by (r_acl) neuropathy_2\NN\14204950|acute|peripheral|caused
D004221_D062787 NONE disulfiram_6\NN\3740161| (r_compound) overdose_7\NN\84738|a|disulfiram
D004221_D010243 NONE disulfiram_24\NN\3740161| (r_compound) intoxication_25\NN\14034177|dose|disulfiram (r_pobj) by_20\IN\0|intoxication (r_agent) caused_19\VBN\1617192|by (r_acl) polyneuropathy_18\NN\0|severe|acute|sensorimotor|axonal|caused (r_dobj) superimposed_13\VBN\1494310|polyneuropathy (r_conj) was_1\VBD\0|this|case|and|superimposed|. (l_attr) case_3\NN\7283608|a|of (l_prep) of_4\IN\0|palsy (l_pobj) palsy_6\JJ\14557898|acute|of
D004221_D011115 NONE disulfiram_24\NN\3740161| (r_compound) intoxication_25\NN\14034177|dose|disulfiram (r_pobj) by_20\IN\0|intoxication (r_agent) caused_19\VBN\1617192|by (r_acl) polyneuropathy_18\NN\0|severe|acute|sensorimotor|axonal|caused
2484011
D000547_D003866 NONE amantadine_4\JJ\0| (r_nmod) activity_7\NN\30358|amantadine|depressed|locomotor (l_amod) depressed_5\JJ\1819147|
D000547_D011596 CID amantadine_2\NN\0| (r_pobj) of_1\IN\0|amantadine (r_prep) readministration_0\NN\0|of (r_nsubj) increased_12\VBN\169651|readministration|,|after|,|motility|from|in|with|. (l_prep) with_21\IN\0|exception (l_pobj) exception_22\NN\5706954|of (l_prep) of_23\IN\0|mice (l_pobj) mice_28\NNS\2329401|the|c|occurred (l_relcl) occurred_33\VBD\0|where|suppression (l_nsubj) suppression_30\NN\13489037|of (l_prep) of_31\IN\0|motility (l_pobj) motility_32\NN\4773351|
D000547_D011596 CID amantadine_45\NN\0| (r_pobj) by_44\IN\0|amantadine (r_agent) caused_43\VBN\1617192|by|in (r_acl) depression_42\NN\14373582|a|behavioral|caused
D000588_D011596 NONE amines_6\NNS\14951377|brain|biogenic|of (r_pobj) of_3\IN\0|amines (r_prep) results_2\NNS\34213|the|biochemical|of (r_nsubj) suggest_13\VBP\1010118|results|decrease|. (l_dobj) decrease_16\NN\7296428|a|probable|of|by|and|increase (l_conj) increase_29\NN\13576355|a|resulting|in|account (l_relcl) account_38\VB\6647206|which|may|for (l_prep) for_39\IN\0|depression (l_pobj) depression_42\NN\14373582|a|behavioral|caused
D002395_D011596 NONE catecholamine_18\NN\5407119| (r_compound) rate_20\NN\13815152|catecholamine|turnover|and/or|metabolism (r_pobj) of_17\IN\0|rate (r_prep) decrease_16\NN\7296428|a|probable|of|by|and|increase (l_conj) increase_29\NN\13576355|a|resulting|in|account (l_relcl) account_38\VB\6647206|which|may|for (l_prep) for_39\IN\0|depression (l_pobj) depression_42\NN\14373582|a|behavioral|caused
D009638_D011596 NONE norepinephrine_35\NN\14807929| (r_pobj) of_34\IN\0|norepinephrine (r_prep) methylation_33\NN\0|o|-|of (r_pobj) in_30\IN\13603305|methylation (r_prep) increase_29\NN\13576355|a|resulting|in|account (l_relcl) account_38\VB\6647206|which|may|for (l_prep) for_39\IN\0|depression (l_pobj) depression_42\NN\14373582|a|behavioral|caused
7420681
D014031_D007674 NONE tobramycin_3\JJ\2716866| (r_pobj) of_2\IN\0|tobramycin (r_prep) nephrotoxicity_1\NN\0|clinical|of|and|gentamicin|.
D014031_D007674 NONE sulfate_4\NN\15010703|tobramycin (r_conj) sulfate_1\NN\15010703|gentamicin|and|sulfate (r_nsubj) continue_5\VBP\2367363|sulfate|demonstrate|. (l_xcomp) demonstrate_7\VB\2137132|to|ototoxicity (l_dobj) ototoxicity_8\NN\0|and|nephrotoxicity|in (l_conj) nephrotoxicity_10\NN\0|
D005839_D007674 NONE gentamicin_5\NN\2716866| (r_conj) nephrotoxicity_1\NN\0|clinical|of|and|gentamicin|.
D005839_D007674 NONE sulfate_1\NN\15010703|gentamicin|and|sulfate (r_nsubj) continue_5\VBP\2367363|sulfate|demonstrate|. (l_xcomp) demonstrate_7\VB\2137132|to|ototoxicity (l_dobj) ototoxicity_8\NN\0|and|nephrotoxicity|in (l_conj) nephrotoxicity_10\NN\0|
D005839_D006311 NONE sulfate_1\NN\15010703|gentamicin|and|sulfate (r_nsubj) continue_5\VBP\2367363|sulfate|demonstrate|. (l_xcomp) demonstrate_7\VB\2137132|to|ototoxicity (l_dobj) ototoxicity_8\NN\0|and|nephrotoxicity|in
D014031_D006311 NONE sulfate_4\NN\15010703|tobramycin (r_conj) sulfate_1\NN\15010703|gentamicin|and|sulfate (r_nsubj) continue_5\VBP\2367363|sulfate|demonstrate|. (l_xcomp) demonstrate_7\VB\2137132|to|ototoxicity (l_dobj) ototoxicity_8\NN\0|and|nephrotoxicity|in
D005839_D051437 CID sulfate_25\NN\15010703|gentamicin|or|sulfate|for (r_pobj) of_23\IN\0|sulfate (r_prep) day_22\NN\15154774|of (r_appos) kg_20\NNS\13717155|5|mg|/|/|day (r_pobj) with_14\IN\0|kg (r_prep) treated_13\VBN\2376958|with (r_conj) patients_5\NNS\9898892|62|with|and|treated (r_nsubjpass) followed_36\VBN\1835496|in|,|patients|were|up|prospectively|for|. (l_prep) for_39\IN\0|development (l_pobj) development_41\NN\248977|the|of (l_prep) of_42\IN\0|failure (l_pobj) failure_47\NN\66216|related|renal|,|defined
D005839_D051437 CID gentamicin_23\NN\2716866| (r_npadvmod) treated_25\VBN\2376958|gentamicin|- (r_amod) patients_26\NNS\9898892|the|treated (r_pobj) of_21\IN\0|patients (r_prep) 16_14\CD\13745420|of|%|)|of (r_nsubj) had_27\VBD\0|five|16|failure|. (l_dobj) failure_29\NN\66216|renal
D005839_D051437 CID gentamicin_2\NN\2716866| (r_nsubjpass) associated_4\VBN\628491|thus|,|gentamicin|was|with|was|. (l_prep) with_5\IN\0|failure (l_pobj) failure_7\NN\66216|renal
D014031_D051437 CID sulfate_28\NN\15010703|tobramycin (r_conj) sulfate_25\NN\15010703|gentamicin|or|sulfate|for (r_pobj) of_23\IN\0|sulfate (r_prep) day_22\NN\15154774|of (r_appos) kg_20\NNS\13717155|5|mg|/|/|day (r_pobj) with_14\IN\0|kg (r_prep) treated_13\VBN\2376958|with (r_conj) patients_5\NNS\9898892|62|with|and|treated (r_nsubjpass) followed_36\VBN\1835496|in|,|patients|were|up|prospectively|for|. (l_prep) for_39\IN\0|development (l_pobj) development_41\NN\248977|the|of (l_prep) of_42\IN\0|failure (l_pobj) failure_47\NN\66216|related|renal|,|defined
D014031_D051437 CID tobramycin_9\RB\2716866| (r_npadvmod) treated_11\VBN\2376958|tobramycin|- (r_amod) patients_12\NNS\9898892|the|treated (r_pobj) of_7\IN\0|patients (r_prep) %_5\NN\0|33|(|15|)|of|and (r_pobj) of_1\IN\0|% (r_prep) five_0\CD\13741022|of (r_nsubj) had_27\VBD\0|five|16|failure|. (l_dobj) failure_29\NN\66216|renal
D014031_D051437 CID tobramycin_16\JJ\2716866| (r_acomp) was_15\VBD\0|often|as|tobramycin (r_advcl) associated_4\VBN\628491|thus|,|gentamicin|was|with|was|. (l_prep) with_5\IN\0|failure (l_pobj) failure_7\NN\66216|renal
D000617_D051437 NONE aminoglycoside_43\NN\0| (r_npadvmod) related_45\VBN\628491|aminoglycoside|- (r_amod) failure_47\NN\66216|related|renal|,|defined
347884
D006220_D019967 NONE haloperidol_6\NN\3713736| (r_pobj) with_5\IN\0|haloperidol (r_prep) study_4\NN\635850|the|double|blind|with (r_pobj) in_0\IN\13603305|study (r_prep) found_11\VBN\13279262|in|,|substances|were|be|. (l_xcomp) be_13\VB\14625458|to|effective (l_acomp) effective_15\JJ\0|highly|in (l_prep) in_16\IN\13603305|treatment (l_pobj) treatment_18\NN\654885|the|of (l_prep) of_19\IN\0|syndromes (l_pobj) syndromes_21\NNS\5870365|psychotic|belonging (l_acl) belonging_22\VBG\7526757|predominantly|to (l_prep) to_24\IN\0|group (l_pobj) group_27\NN\2137|the|schizophrenia
1420741
D005672_D003424 NONE acid_7\NN\14818238|fusidic (r_pobj) with_5\IN\0|acid (r_prep) disease_4\NN\14061805|crohn|with
D005672_D003424 NONE acid_28\NN\14818238| (r_compound) treatment_29\NN\654885|fusidic|acid|in (r_pobj) of_26\IN\0|treatment (r_prep) tolerability_25\NN\0|of (r_conj) pharmacodynamics_23\NNS\0|the|and|tolerability (r_dobj) estimate_21\VB\5802185|to|pharmacodynamics (r_advcl) undertaken_19\VBN\1641914|because|,|study|was|estimate|. (l_prep) because_0\IN\0|of|need (l_pobj) need_3\NN\13920835|the|for (l_prep) for_4\IN\0|development (l_pobj) development_6\NN\248977|the|of (l_prep) of_7\IN\0|treatments (l_pobj) treatments_9\NNS\654885|new|for (l_prep) for_10\IN\0|disease (l_pobj) disease_13\NN\14061805|crohn
D005672_D003424 NONE acid_9\NN\14818238| (r_nsubj) be_11\VB\14625458|that|fusidic|acid|may|of|in (l_prep) in_14\IN\13603305|patients (l_pobj) patients_21\NNS\9898892|selected|chronic|active|crohn|disease|is (l_compound) disease_20\NN\14061805|
D016572_D003424 NONE cyclosporin_16\NN\0| (r_pobj) to_15\IN\0|cyclosporin (r_prep) similar_14\JJ\0|to (r_amod) properties_13\NNS\32613|immunosuppressive|similar (r_pobj) with_11\IN\0|properties (r_prep) antibiotic_10\NN\2716205|an|with (r_appos) treatment_0\NN\654885|of|:|antibiotic|. (l_prep) of_1\IN\0|disease (l_pobj) disease_4\NN\14061805|crohn|with
D005672_D015212 NONE acid_13\NN\14818238|fusidic (r_pobj) of_11\IN\0|acid (r_prep) use_10\NN\407535|the|of|at (l_prep) at_14\IN\14622893|level (l_pobj) level_17\NN\4916342|the|cytokine|in (l_prep) in_18\IN\13603305|disease (l_pobj) disease_21\NN\14061805|inflammatory|bowel
17400887
D013726_D020078 NONE terbutaline_6\JJ\0| (r_compound) treatment_7\NN\654885|neonatal|terbutaline|in (r_pobj) after_4\IN\0|treatment (r_prep) abnormalities_3\NNS\14034177|neuroinflammation|after|:|implications|. (l_nmod) neuroinflammation_0\NN\0|and|behavioral
D013726_D001523 NONE terbutaline_6\JJ\0| (r_compound) treatment_7\NN\654885|neonatal|terbutaline|in (r_pobj) after_4\IN\0|treatment (r_prep) abnormalities_3\NNS\14034177|neuroinflammation|after|:|implications|.
D013726_D001321 CID terbutaline_6\JJ\0| (r_compound) treatment_7\NN\654885|neonatal|terbutaline|in (r_pobj) after_4\IN\0|treatment (r_prep) abnormalities_3\NNS\14034177|neuroinflammation|after|:|implications|. (l_appos) implications_11\NNS\5774614|for (l_prep) for_12\IN\0|autism (l_pobj) autism_13\NN\14304060|
D013726_D001321 CID terbutaline_0\NNP\0|,|agonist|, (r_nsubjpass) associated_13\VBN\628491|terbutaline|has|been|with|. (l_prep) with_14\IN\0|concordance (l_pobj) concordance_16\NN\13968547|increased|for (l_prep) for_17\IN\0|autism (l_pobj) autism_18\NN\14304060|in
D013726_D007752 NONE terbutaline_0\NNP\0|,|agonist|, (l_appos) agonist_4\NN\0|a|beta2-adrenoceptor|used (l_acl) used_5\VBN\0|arrest (l_xcomp) arrest_7\VB\88481|to|labor (l_dobj) labor_9\NN\7974025|preterm
1130930
D002512_D007674 NONE cephalothin_3\NN\2996840| (r_compound) gentamicin_5\NN\2716866|cephalothin|- (r_compound) regimen_6\NN\5898568|combined|gentamicin (r_pobj) of_1\IN\0|regimen (r_prep) nephrotoxicity_0\NN\0|of|.
D005839_D007674 NONE gentamicin_5\NN\2716866|cephalothin|- (r_compound) regimen_6\NN\5898568|combined|gentamicin (r_pobj) of_1\IN\0|regimen (r_prep) nephrotoxicity_0\NN\0|of|.
D002512_D007683 CID sodium_23\NN\14625458|cephalothin (r_pobj) of_21\IN\0|sodium (r_prep) combination_20\NN\7951464|a|of (r_dobj) receiving_18\VBG\2210855|while|they|were|combination|and|gentamicin (r_advcl) developed_2\VBD\1753788|patients|necrosis|,|receiving|. (l_dobj) necrosis_5\NN\11444117|acute|tubular|,|characterized
D002512_D009846 NONE sodium_23\NN\14625458|cephalothin (r_pobj) of_21\IN\0|sodium (r_prep) combination_20\NN\7951464|a|of (r_dobj) receiving_18\VBG\2210855|while|they|were|combination|and|gentamicin (r_advcl) developed_2\VBD\1753788|patients|necrosis|,|receiving|. (l_dobj) necrosis_5\NN\11444117|acute|tubular|,|characterized (l_acl) characterized_7\VBN\609683|by (l_agent) by_9\IN\0|clinically|failure (l_pobj) failure_13\NN\66216|acute|oliguric|renal
D002512_D051437 NONE sodium_23\NN\14625458|cephalothin (r_pobj) of_21\IN\0|sodium (r_prep) combination_20\NN\7951464|a|of (r_dobj) receiving_18\VBG\2210855|while|they|were|combination|and|gentamicin (r_advcl) developed_2\VBD\1753788|patients|necrosis|,|receiving|. (l_dobj) necrosis_5\NN\11444117|acute|tubular|,|characterized (l_acl) characterized_7\VBN\609683|by (l_agent) by_9\IN\0|clinically|failure (l_pobj) failure_13\NN\66216|acute|oliguric|renal
D005839_D007683 CID sulfate_26\NN\15010703| (r_compound) therapy_27\NN\657604|sulfate (r_dobj) gentamicin_25\NN\2716866|therapy (r_conj) receiving_18\VBG\2210855|while|they|were|combination|and|gentamicin (r_advcl) developed_2\VBD\1753788|patients|necrosis|,|receiving|. (l_dobj) necrosis_5\NN\11444117|acute|tubular|,|characterized
D005839_D009846 NONE sulfate_26\NN\15010703| (r_compound) therapy_27\NN\657604|sulfate (r_dobj) gentamicin_25\NN\2716866|therapy (r_conj) receiving_18\VBG\2210855|while|they|were|combination|and|gentamicin (r_advcl) developed_2\VBD\1753788|patients|necrosis|,|receiving|. (l_dobj) necrosis_5\NN\11444117|acute|tubular|,|characterized (l_acl) characterized_7\VBN\609683|by (l_agent) by_9\IN\0|clinically|failure (l_pobj) failure_13\NN\66216|acute|oliguric|renal
D005839_D051437 NONE sulfate_26\NN\15010703| (r_compound) therapy_27\NN\657604|sulfate (r_dobj) gentamicin_25\NN\2716866|therapy (r_conj) receiving_18\VBG\2210855|while|they|were|combination|and|gentamicin (r_advcl) developed_2\VBD\1753788|patients|necrosis|,|receiving|. (l_dobj) necrosis_5\NN\11444117|acute|tubular|,|characterized (l_acl) characterized_7\VBN\609683|by (l_agent) by_9\IN\0|clinically|failure (l_pobj) failure_13\NN\66216|acute|oliguric|renal
19581773
C417083_D009157 CID interferon_6\NN\2725367|and|ribavirin (r_nmod) treatment_9\NN\654885|pegylated|interferon|for (r_pobj) during_4\IN\0|treatment (r_prep) development_0\NN\248977|of|during (l_prep) of_1\IN\0|myasthenia (l_pobj) myasthenia_3\NN\14187378|ocular
C417083_D009157 CID alpha-2b_10\CD\0|pegylated|ifn|and|ribavirin|for (r_pobj) of_7\IN\0|alpha-2b (r_prep) therapy_6\NN\657604|combination|of (r_pobj) with_4\IN\0|therapy (r_prep) associated_3\VBN\628491|with (r_acl) myasthenia_2\NN\14187378|the|ocular|associated
C417083_D009157 CID ifn_35\NNP\0| (r_compound) therapy_36\NN\657604|ifn (r_pobj) of_34\IN\0|therapy (r_prep) complications_33\NNS\1073995|the|various|eye|of (r_pobj) of_29\IN\0|complications (r_prep) review_28\NN\5733583|a|of (r_pobj) with_26\IN\0|review (r_prep) present_23\VBP\28270|reported|;|therefore|,|we|case|with|. (l_ccomp) reported_18\VBN\831651|myasthenia|is|rarely (l_nsubjpass) myasthenia_2\NN\14187378|the|ocular|associated
C417083_D019698 NONE interferon_6\NN\2725367|and|ribavirin (r_nmod) treatment_9\NN\654885|pegylated|interferon|for (l_prep) for_10\IN\0|c. (l_pobj) c._13\NNP\0|chronic|hepatitis
C417083_D019698 NONE alpha-2b_19\CD\0|and|ribavirin (r_conj) ifn_17\NNP\0|(|)|alpha-2b (r_appos) interferon_15\NN\2725367|pegylated|ifn (r_pobj) of_13\IN\0|interferon (r_prep) administration_12\NN\1133281|of (r_pobj) of_11\IN\0|administration (r_prep) weeks_10\NNS\15113229|9|of (r_pobj) after_8\IN\0|weeks (r_prep) diplopia_7\NN\14552802|a|old|experienced|sudden|after|for|. (l_prep) for_22\IN\0|c (l_pobj) c_25\NNP\13714184|chronic|hepatitis|(|chc|)
C417083_D019698 NONE alpha-2b_19\CD\0|and|ribavirin (r_conj) ifn_17\NNP\0|(|)|alpha-2b (r_appos) interferon_15\NN\2725367|pegylated|ifn (r_pobj) of_13\IN\0|interferon (r_prep) administration_12\NN\1133281|of (r_pobj) of_11\IN\0|administration (r_prep) weeks_10\NNS\15113229|9|of (r_pobj) after_8\IN\0|weeks (r_prep) diplopia_7\NN\14552802|a|old|experienced|sudden|after|for|. (l_prep) for_22\IN\0|c (l_pobj) c_25\NNP\13714184|chronic|hepatitis|(|chc|) (l_appos) chc_27\NNP\0|
C417083_D019698 NONE alpha-2b_10\CD\0|pegylated|ifn|and|ribavirin|for (l_prep) for_13\IN\0|chc (l_pobj) chc_14\NNP\0|
C417083_D019698 NONE ifn_35\NNP\0| (r_compound) therapy_36\NN\657604|ifn (r_pobj) of_34\IN\0|therapy (r_prep) complications_33\NNS\1073995|the|various|eye|of (r_pobj) of_29\IN\0|complications (r_prep) review_28\NN\5733583|a|of (r_pobj) with_26\IN\0|review (r_prep) present_23\VBP\28270|reported|;|therefore|,|we|case|with|. (l_ccomp) reported_18\VBN\831651|myasthenia|is|rarely (l_nsubjpass) myasthenia_2\NN\14187378|the|ocular|associated (l_acl) associated_3\VBN\628491|with (l_prep) with_4\IN\0|therapy (l_pobj) therapy_6\NN\657604|combination|of (l_prep) of_7\IN\0|alpha-2b (l_pobj) alpha-2b_10\CD\0|pegylated|ifn|and|ribavirin|for (l_prep) for_13\IN\0|chc (l_pobj) chc_14\NNP\0|
D012254_D009157 CID ribavirin_8\JJ\2725367| (r_conj) interferon_6\NN\2725367|and|ribavirin (r_nmod) treatment_9\NN\654885|pegylated|interferon|for (r_pobj) during_4\IN\0|treatment (r_prep) development_0\NN\248977|of|during (l_prep) of_1\IN\0|myasthenia (l_pobj) myasthenia_3\NN\14187378|ocular
D012254_D009157 CID ribavirin_12\RB\2725367| (r_conj) alpha-2b_10\CD\0|pegylated|ifn|and|ribavirin|for (r_pobj) of_7\IN\0|alpha-2b (r_prep) therapy_6\NN\657604|combination|of (r_pobj) with_4\IN\0|therapy (r_prep) associated_3\VBN\628491|with (r_acl) myasthenia_2\NN\14187378|the|ocular|associated
D012254_D019698 NONE ribavirin_8\JJ\2725367| (r_conj) interferon_6\NN\2725367|and|ribavirin (r_nmod) treatment_9\NN\654885|pegylated|interferon|for (l_prep) for_10\IN\0|c. (l_pobj) c._13\NNP\0|chronic|hepatitis
D012254_D019698 NONE ribavirin_21\RB\2725367| (r_conj) alpha-2b_19\CD\0|and|ribavirin (r_conj) ifn_17\NNP\0|(|)|alpha-2b (r_appos) interferon_15\NN\2725367|pegylated|ifn (r_pobj) of_13\IN\0|interferon (r_prep) administration_12\NN\1133281|of (r_pobj) of_11\IN\0|administration (r_prep) weeks_10\NNS\15113229|9|of (r_pobj) after_8\IN\0|weeks (r_prep) diplopia_7\NN\14552802|a|old|experienced|sudden|after|for|. (l_prep) for_22\IN\0|c (l_pobj) c_25\NNP\13714184|chronic|hepatitis|(|chc|)
D012254_D019698 NONE ribavirin_21\RB\2725367| (r_conj) alpha-2b_19\CD\0|and|ribavirin (r_conj) ifn_17\NNP\0|(|)|alpha-2b (r_appos) interferon_15\NN\2725367|pegylated|ifn (r_pobj) of_13\IN\0|interferon (r_prep) administration_12\NN\1133281|of (r_pobj) of_11\IN\0|administration (r_prep) weeks_10\NNS\15113229|9|of (r_pobj) after_8\IN\0|weeks (r_prep) diplopia_7\NN\14552802|a|old|experienced|sudden|after|for|. (l_prep) for_22\IN\0|c (l_pobj) c_25\NNP\13714184|chronic|hepatitis|(|chc|) (l_appos) chc_27\NNP\0|
D012254_D019698 NONE ribavirin_12\RB\2725367| (r_conj) alpha-2b_10\CD\0|pegylated|ifn|and|ribavirin|for (l_prep) for_13\IN\0|chc (l_pobj) chc_14\NNP\0|
C417083_D004172 NONE alpha-2b_19\CD\0|and|ribavirin (r_conj) ifn_17\NNP\0|(|)|alpha-2b (r_appos) interferon_15\NN\2725367|pegylated|ifn (r_pobj) of_13\IN\0|interferon (r_prep) administration_12\NN\1133281|of (r_pobj) of_11\IN\0|administration (r_prep) weeks_10\NNS\15113229|9|of (r_pobj) after_8\IN\0|weeks (r_prep) diplopia_7\NN\14552802|a|old|experienced|sudden|after|for|.
D012254_D004172 NONE ribavirin_21\RB\2725367| (r_conj) alpha-2b_19\CD\0|and|ribavirin (r_conj) ifn_17\NNP\0|(|)|alpha-2b (r_appos) interferon_15\NN\2725367|pegylated|ifn (r_pobj) of_13\IN\0|interferon (r_prep) administration_12\NN\1133281|of (r_pobj) of_11\IN\0|administration (r_prep) weeks_10\NNS\15113229|9|of (r_pobj) after_8\IN\0|weeks (r_prep) diplopia_7\NN\14552802|a|old|experienced|sudden|after|for|.
88336
D002719_D013375 NONE chlormethiazole_6\NN\0| (r_pobj) of_5\IN\0|chlormethiazole (r_prep) doses_4\NNS\3740161|high|of (r_dobj) received_2\VBD\2210855|patients|doses|for|,|and|took (l_prep) for_7\IN\0|symptoms (l_pobj) symptoms_10\NNS\5823932|withdrawal
D002719_D062787 NONE chlormethiazole_6\NN\0| (r_pobj) of_5\IN\0|chlormethiazole (r_prep) doses_4\NNS\3740161|high|of (r_dobj) received_2\VBD\2210855|patients|doses|for|,|and|took (l_conj) took_14\VBD\2367363|one|overdose|. (l_dobj) overdose_17\NN\84738|a|suicidal|of
D002719_D062787 NONE chlormethiazole_10\NN\0| (r_compound) intoxication_11\NN\14034177|chlormethiazole (r_pobj) with_9\IN\0|intoxication (r_prep) those_8\DT\0|with (r_pobj) of_7\IN\0|those (r_prep) two_6\CD\13741022|of (r_conj) overdose_4\NN\84738|nitrazepam|and|two
D000431_D013375 NONE alcohol_8\NN\7881800| (r_compound) withdrawal_9\NN\7206096|alcohol (r_compound) symptoms_10\NNS\5823932|withdrawal
D000431_D062787 NONE alcohol_8\NN\7881800| (r_compound) withdrawal_9\NN\7206096|alcohol (r_compound) symptoms_10\NNS\5823932|withdrawal (r_pobj) for_7\IN\0|symptoms (r_prep) received_2\VBD\2210855|patients|doses|for|,|and|took (l_conj) took_14\VBD\2367363|one|overdose|. (l_dobj) overdose_17\NN\84738|a|suicidal|of
D009567_D013375 NONE nitrazepam_19\NN\2830852| (r_pobj) of_18\IN\0|nitrazepam (r_prep) overdose_17\NN\84738|a|suicidal|of (r_dobj) took_14\VBD\2367363|one|overdose|. (r_conj) received_2\VBD\2210855|patients|doses|for|,|and|took (l_prep) for_7\IN\0|symptoms (l_pobj) symptoms_10\NNS\5823932|withdrawal
D009567_D062787 CID nitrazepam_19\NN\2830852| (r_pobj) of_18\IN\0|nitrazepam (r_prep) overdose_17\NN\84738|a|suicidal|of
D009567_D062787 CID nitrazepam_3\JJ\2830852| (r_amod) overdose_4\NN\84738|nitrazepam|and|two
D009567_D003128 CID nitrazepam_3\JJ\2830852| (r_amod) overdose_4\NN\84738|nitrazepam|and|two (r_pobj) with_2\IN\0|overdose (r_prep) patient_1\NN\9898892|the|with (r_nsubj) conformed_12\VBD\0|patient|to|,|showing|. (l_prep) to_13\IN\0|criteria (l_pobj) criteria_15\NNS\13577171|the|of (l_prep) of_16\IN\0|'|coma|' (l_pobj) coma_19\NN\5678932|alpha
D002719_D003128 CID chlormethiazole_10\NN\0| (r_compound) intoxication_11\NN\14034177|chlormethiazole (r_pobj) with_9\IN\0|intoxication (r_prep) those_8\DT\0|with (r_pobj) of_7\IN\0|those (r_prep) two_6\CD\13741022|of (r_conj) overdose_4\NN\84738|nitrazepam|and|two (r_pobj) with_2\IN\0|overdose (r_prep) patient_1\NN\9898892|the|with (r_nsubj) conformed_12\VBD\0|patient|to|,|showing|. (l_prep) to_13\IN\0|criteria (l_pobj) criteria_15\NNS\13577171|the|of (l_prep) of_16\IN\0|'|coma|' (l_pobj) coma_19\NN\5678932|alpha
12483326
D016190_D005128 NONE carboplatin_9\NN\0| (r_pobj) of_8\IN\0|carboplatin (r_prep) injection_7\NN\320852|intracarotid|of|for (r_pobj) after_5\IN\0|injection (r_prep) toxicity_4\NN\13576101|severe|ocular|after|.
D016190_D005128 NONE carboplatin_2\NN\0| (r_nsubjpass) said_4\VBN\940384|generally|,|carboplatin|is|have|known|. (l_ccomp) known_20\JJ\0|are|well (l_auxpass) are_18\VBP\13600404|toxicity (l_nsubj) toxicity_17\NN\13576101|whose|ocular
D016190_D005128 NONE carboplatin_16\NN\0| (r_pobj) of_15\IN\0|carboplatin (r_prep) injection_14\NN\320852|intracarotid|of|,|reported (r_pobj) after_12\IN\0|injection (r_prep) experienced_3\VBD\2108377|however|,|we|case|after|. (l_dobj) case_5\NN\7283608|a|of (l_prep) of_6\IN\0|toxicity (l_pobj) toxicity_11\NN\13576101|severe|ocular
D016190_D005128 NONE carboplatin_5\NN\0| (r_pobj) of_4\IN\0|carboplatin (r_prep) injection_3\NN\320852|intracarotid|of (r_dobj) performing_1\VBG\407535|when|injection (r_advcl) be_9\VB\14625458|performing|,|we|must|aware|. (l_acomp) aware_10\JJ\0|of (l_prep) of_11\IN\0|toxicity (l_pobj) toxicity_16\NN\13576101|its|blinding|ocular
D016190_D009916 NONE carboplatin_9\NN\0| (r_pobj) of_8\IN\0|carboplatin (r_prep) injection_7\NN\320852|intracarotid|of|for (r_pobj) after_5\IN\0|injection (r_prep) toxicity_4\NN\13576101|severe|ocular|after|.
D016190_D009916 NONE carboplatin_2\NN\0| (r_nsubjpass) said_4\VBN\940384|generally|,|carboplatin|is|have|known|. (l_ccomp) known_20\JJ\0|are|well (l_auxpass) are_18\VBP\13600404|toxicity (l_nsubj) toxicity_17\NN\13576101|whose|ocular
D016190_D009916 NONE carboplatin_16\NN\0| (r_pobj) of_15\IN\0|carboplatin (r_prep) injection_14\NN\320852|intracarotid|of|,|reported (r_pobj) after_12\IN\0|injection (r_prep) experienced_3\VBD\2108377|however|,|we|case|after|. (l_dobj) case_5\NN\7283608|a|of (l_prep) of_6\IN\0|toxicity (l_pobj) toxicity_11\NN\13576101|severe|ocular
D016190_D005909 NONE carboplatin_9\NN\0| (r_pobj) of_8\IN\0|carboplatin (r_prep) injection_7\NN\320852|intracarotid|of|for (l_prep) for_10\IN\0|glioblastomas (l_pobj) glioblastomas_12\NNS\14236743|recurrent
D016190_D005909 NONE carboplatin_10\NN\0| (r_pobj) of_9\IN\0|carboplatin (r_prep) injection_8\NN\320852|an|intracarotid|of|for|in (l_prep) for_11\IN\0|glioblastomas (l_pobj) glioblastomas_13\NNS\14236743|recurrent
D002945_D005128 NONE cisplatin_11\NN\0| (r_pcomp) than_10\IN\0|cisplatin (r_prep) effects_9\NNS\13245626|milder|side|than|, (r_dobj) have_6\VB\7846|to|effects (r_xcomp) said_4\VBN\940384|generally|,|carboplatin|is|have|known|. (l_ccomp) known_20\JJ\0|are|well (l_auxpass) are_18\VBP\13600404|toxicity (l_nsubj) toxicity_17\NN\13576101|whose|ocular
D002945_D009916 NONE cisplatin_11\NN\0| (r_pcomp) than_10\IN\0|cisplatin (r_prep) effects_9\NNS\13245626|milder|side|than|, (r_dobj) have_6\VB\7846|to|effects (r_xcomp) said_4\VBN\940384|generally|,|carboplatin|is|have|known|. (l_ccomp) known_20\JJ\0|are|well (l_auxpass) are_18\VBP\13600404|toxicity (l_nsubj) toxicity_17\NN\13576101|whose|ocular
D016190_D064420 NONE carboplatin_7\NN\0| (r_amod) toxicity_8\NN\13576101|carboplatin
17919553
C106791_D056486 CID telithromycin_6\NNS\0|to (r_relcl) exposure_4\NN\5042871|telithromycin (r_pobj) after_3\IN\0|exposure (r_prep) attack_2\NN\955060|acute|hepatitis|after|. (l_compound) hepatitis_1\NNP\14127211|
C106791_D056486 CID telithromycin_19\NNS\0| (r_compound) usage_20\NN\407535|telithromycin (r_pobj) after_18\IN\0|usage (r_prep) occurred_17\VBD\0|suffered|,|"|that|after|. (l_ccomp) suffered_3\VBN\2110220|patient|had|episode (l_dobj) episode_6\NN\7283608|a|previous|of (l_prep) of_7\IN\0|hepatitis (l_pobj) hepatitis_10\NN\14127211|"|acute|of
C106791_D056486 CID telithromycin_15\NNS\0| (r_nsubj) was_16\VBD\0|based|,|telithromycin|cause|,|and|suggested (l_attr) cause_19\NN\7323922|the|probable|of (l_prep) of_20\IN\0|hepatitis (l_pobj) hepatitis_22\NN\14127211|acute|in
C106791_D056486 CID telithromycin_15\NNS\0| (r_nsubj) was_16\VBD\0|based|,|telithromycin|cause|,|and|suggested (l_conj) suggested_30\VBD\1010118|findings|hepatitis|. (l_dobj) hepatitis_35\NN\14127211|induced|toxic
C106791_D056486 CID telithromycin_21\NNS\0| (r_dobj) prescribed_20\VBD\748282|who|telithromycin|time (r_relcl) physician_18\NN\10305802|the|attending|prescribed (r_pobj) to_15\IN\0|physician (r_prep) communicated_14\VBN\2231661|if|incident|had|been|to (r_advcl) avoided_7\VBN\0|recurrence|might|have|been|communicated|. (l_nsubjpass) recurrence_0\NN\7342049|of (l_prep) of_1\IN\0|attack (l_pobj) attack_3\NN\955060|hepatitis (l_compound) hepatitis_2\NN\14127211|
C106791_D056486 CID telithromycin_14\NNS\0| (r_pobj) of_13\IN\0|telithromycin (r_prep) administration_12\NN\1133281|the|of (r_pobj) with_10\IN\0|administration (r_prep) associated_9\VBN\628491|probably|with (r_acl) case_4\NN\7283608|a|of|associated (l_prep) of_5\IN\0|hepatitis (l_pobj) hepatitis_7\NN\14127211|acute
C106791_D064420 NONE telithromycin_15\NNS\0| (r_nsubj) was_16\VBD\0|based|,|telithromycin|cause|,|and|suggested (l_prep) based_0\VBN\0|on (l_prep) on_1\IN\0|score (l_pobj) score_3\NN\5736149|a|of|on (l_prep) on_6\IN\0|scale (l_pobj) scale_13\NN\7260623|the|probability (l_compound) probability_12\NN\33615|reaction (l_compound) reaction_11\NN\13446390|naranjo|adverse|drug
2522601
D002220_D004342 CID carbamazepine_2\NN\0| (r_pobj) to_1\IN\0|carbamazepine (r_prep) hypersensitivity_0\NN\14531772|to|presenting|.
D002220_D004342 CID carbamazepine_8\NN\0| (r_pobj) to_7\IN\0|carbamazepine (r_prep) hypersensitivity_6\NN\14531772|to
D002220_D007955 CID carbamazepine_2\NN\0| (r_pobj) to_1\IN\0|carbamazepine (r_prep) hypersensitivity_0\NN\14531772|to|presenting|. (l_acl) presenting_3\VBG\2137132|with (l_prep) with_4\IN\0|reaction (l_pobj) reaction_7\NN\13446390|a|leukemoid|,|eosinophilia|failure
D002220_D007955 CID carbamazepine_8\NN\0| (r_pobj) to_7\IN\0|carbamazepine (r_prep) hypersensitivity_6\NN\14531772|to (r_nsubj) presented_9\VBN\2137132|in|hypersensitivity|with (r_relcl) patient_3\NN\9898892|a|presented|,|reaction (l_conj) reaction_17\NN\13446390|a|severe|leukemoid|,|eosinophilia
D002220_D004802 NONE carbamazepine_2\NN\0| (r_pobj) to_1\IN\0|carbamazepine (r_prep) hypersensitivity_0\NN\14531772|to|presenting|. (l_acl) presenting_3\VBG\2137132|with (l_prep) with_4\IN\0|reaction (l_pobj) reaction_7\NN\13446390|a|leukemoid|,|eosinophilia|failure (l_conj) eosinophilia_9\NN\14299637|,|erythroderma
D002220_D004802 NONE carbamazepine_8\NN\0| (r_pobj) to_7\IN\0|carbamazepine (r_prep) hypersensitivity_6\NN\14531772|to (r_nsubj) presented_9\VBN\2137132|in|hypersensitivity|with (r_relcl) patient_3\NN\9898892|a|presented|,|reaction (l_conj) reaction_17\NN\13446390|a|severe|leukemoid|,|eosinophilia (l_conj) eosinophilia_19\NN\14299637|,|hyponatremia
D002220_D003873 CID carbamazepine_2\NN\0| (r_pobj) to_1\IN\0|carbamazepine (r_prep) hypersensitivity_0\NN\14531772|to|presenting|. (l_acl) presenting_3\VBG\2137132|with (l_prep) with_4\IN\0|reaction (l_pobj) reaction_7\NN\13446390|a|leukemoid|,|eosinophilia|failure (l_conj) eosinophilia_9\NN\14299637|,|erythroderma (l_conj) erythroderma_11\NN\14219661|,|and
D002220_D003873 CID carbamazepine_8\NN\0| (r_pobj) to_7\IN\0|carbamazepine (r_prep) hypersensitivity_6\NN\14531772|to (r_nsubj) presented_9\VBN\2137132|in|hypersensitivity|with (l_prep) with_10\IN\0|erythroderma (l_pobj) erythroderma_12\NN\14219661|generalized
D002220_D051437 CID carbamazepine_2\NN\0| (r_pobj) to_1\IN\0|carbamazepine (r_prep) hypersensitivity_0\NN\14531772|to|presenting|. (l_acl) presenting_3\VBG\2137132|with (l_prep) with_4\IN\0|reaction (l_pobj) reaction_7\NN\13446390|a|leukemoid|,|eosinophilia|failure (l_conj) failure_15\NN\66216|renal
D002220_D051437 CID carbamazepine_8\NN\0| (r_pobj) to_7\IN\0|carbamazepine (r_prep) hypersensitivity_6\NN\14531772|to (r_nsubj) presented_9\VBN\2137132|in|hypersensitivity|with (r_relcl) patient_3\NN\9898892|a|presented|,|reaction (l_conj) reaction_17\NN\13446390|a|severe|leukemoid|,|eosinophilia (l_conj) eosinophilia_19\NN\14299637|,|hyponatremia (l_conj) hyponatremia_21\NN\14299637|,|and|failure (l_conj) failure_25\NN\66216|renal
D002220_D007010 CID carbamazepine_8\NN\0| (r_pobj) to_7\IN\0|carbamazepine (r_prep) hypersensitivity_6\NN\14531772|to (r_nsubj) presented_9\VBN\2137132|in|hypersensitivity|with (r_relcl) patient_3\NN\9898892|a|presented|,|reaction (l_conj) reaction_17\NN\13446390|a|severe|leukemoid|,|eosinophilia (l_conj) eosinophilia_19\NN\14299637|,|hyponatremia (l_conj) hyponatremia_21\NN\14299637|,|and|failure
19820426
C558899_D066126 NONE ritonavir_10\NNS\4013993| (r_compound) therapy_11\NN\657604|ritonavir (r_appos) lopinavir_8\NNS\0|/|therapy (r_pobj) to_7\IN\0|lopinavir (r_prep) related_6\VBN\628491|to (r_acl) toxicity_5\NN\13576101|cardiac|related
C558899_D006327 CID ritonavir_15\NNS\4013993| (r_compound) therapy_16\NN\657604|ritonavir|,|agent (r_appos) lopinavir_13\NNS\0|/|therapy (r_pobj) to_12\IN\0|lopinavir (r_prep) related_11\VBN\628491|to (r_acl) cardiomyopathy_10\NN\14103288|dilated|related (r_conj) block_7\NN\21939|complete|heart|and|cardiomyopathy
C558899_D002311 CID ritonavir_15\NNS\4013993| (r_compound) therapy_16\NN\657604|ritonavir|,|agent (r_appos) lopinavir_13\NNS\0|/|therapy (r_pobj) to_12\IN\0|lopinavir (r_prep) related_11\VBN\628491|to (r_acl) cardiomyopathy_10\NN\14103288|dilated|related
C558899_D001919 CID ritonavir_15\NNS\4013993| (r_compound) therapy_16\NN\657604|ritonavir|,|agent (r_appos) lopinavir_13\NNS\0|/|therapy (r_pobj) to_12\IN\0|lopinavir (r_prep) related_11\VBN\628491|to (r_acl) cardiomyopathy_10\NN\14103288|dilated|related (r_conj) block_7\NN\21939|complete|heart|and|cardiomyopathy (r_dobj) developed_4\VBD\1753788|one|block|,|developed|. (l_advcl) developed_29\VBD\1753788|while|twin|bradycardia (l_dobj) bradycardia_31\NNS\14110674|mild
11928786
D016642_D064420 NONE bupropion_0\NNP\0| (r_nmod) toxicity_4\NN\13576101|bupropion|(|zyban|)|.
D016642_D064420 NONE zyban_2\NNP\0| (r_nmod) toxicity_4\NN\13576101|bupropion|(|zyban|)|.
D003975_D012640 NONE diazepam_5\NN\2830852|and|tachycardia (r_pobj) with_4\IN\0|diazepam (r_prep) treated_3\VBN\2376958|seizures|were|with|treated|. (l_nsubjpass) seizures_1\NNS\14081375|recurrent
D003975_D013610 NONE diazepam_5\NN\2830852|and|tachycardia (l_conj) tachycardia_9\NN\14110674|broad|complex
D000241_D012640 NONE adenosine_14\NN\14964367| (r_pobj) with_13\IN\0|adenosine (r_prep) treated_12\VBN\2376958|was|successfully|with (r_conj) treated_3\VBN\2376958|seizures|were|with|treated|. (l_nsubjpass) seizures_1\NNS\14081375|recurrent
D000241_D013610 NONE adenosine_14\NN\14964367| (r_pobj) with_13\IN\0|adenosine (r_prep) treated_12\VBN\2376958|was|successfully|with (r_conj) treated_3\VBN\2376958|seizures|were|with|treated|. (l_prep) with_4\IN\0|diazepam (l_pobj) diazepam_5\NN\2830852|and|tachycardia (l_conj) tachycardia_9\NN\14110674|broad|complex
D016642_D020258 NONE zyban_0\NNP\0| (r_nsubj) caused_1\VBD\1617192|zyban|toxicity|. (l_dobj) toxicity_6\NN\13576101|significant|neurological|in
D016642_D002318 NONE zyban_0\NNP\0| (r_nsubj) caused_1\VBD\1617192|zyban|toxicity|. (l_dobj) toxicity_6\NN\13576101|significant|neurological|in
D016642_D062787 NONE zyban_0\NNP\0| (r_nsubj) caused_1\VBD\1617192|zyban|toxicity|. (l_dobj) toxicity_6\NN\13576101|significant|neurological|in (l_prep) in_7\IN\13603305|overdose (l_pobj) overdose_8\NN\84738|
15036754
D010755_D012640 NONE organophosphate_0\NNP\14919948| (r_npadvmod) induced_2\VBN\1627355|organophosphate|- (r_amod) convulsions_3\NNS\14081375|induced|and|prevention|of|.
D010755_D004194 NONE organophosphate_0\NNP\14919948| (r_npadvmod) induced_2\VBN\1627355|organophosphate|- (r_amod) convulsions_3\NNS\14081375|induced|and|prevention|of|. (l_prep) of_6\IN\0|damages (l_pobj) damages_8\NNS\13282550|neuropathological
D010755_D064420 NONE ops_4\NNS\0| (r_pobj) of_3\IN\0|ops (r_prep) toxicity_2\NN\13576101|the|acute|of
D010755_D064420 NONE op_10\NN\0| (r_npadvmod) induced_12\VBN\1627355|op|- (r_amod) signs_14\NNS\6643763|severe|typical|induced|toxicity (l_compound) toxicity_13\NN\13576101|
D000109_D064420 NONE acetylcholine_25\NN\14807558| (r_nmod) levels_29\NNS\4916342|acetylcholine|(|ach|) (r_dobj) elevates_24\VBZ\2391803|which|levels (r_relcl) system_18\NN\3575240|the|central|nervous|(|cns|)|,|elevates (r_pobj) in_14\IN\13603305|system (r_prep) aches_13\NNP\14322699|in (r_pobj) with_12\IN\0|aches (r_prep) binding_11\NN\4688246|their|irreversible|with (r_pobj) of_8\IN\0|binding (r_prep) result_7\NN\34213|the|of (r_attr) is_5\VBZ\0|toxicity|result|. (l_nsubj) toxicity_2\NN\13576101|the|acute|of
D000109_D064420 NONE ach_27\NNS\0| (r_nmod) levels_29\NNS\4916342|acetylcholine|(|ach|) (r_dobj) elevates_24\VBZ\2391803|which|levels (r_relcl) system_18\NN\3575240|the|central|nervous|(|cns|)|,|elevates (r_pobj) in_14\IN\13603305|system (r_prep) aches_13\NNP\14322699|in (r_pobj) with_12\IN\0|aches (r_prep) binding_11\NN\4688246|their|irreversible|with (r_pobj) of_8\IN\0|binding (r_prep) result_7\NN\34213|the|of (r_attr) is_5\VBZ\0|toxicity|result|. (l_nsubj) toxicity_2\NN\13576101|the|acute|of
D007531_D064420 NONE dfp_4\NNP\0| (r_compound) atropine_6\NN\14712692|dfp|- (r_pobj) with_3\IN\0|atropine (r_prep) treated_2\VBD\2376958|rats|with|showed|. (l_conj) showed_7\VBD\2137132|signs (l_dobj) signs_14\NNS\6643763|severe|typical|induced|toxicity (l_compound) toxicity_13\NN\13576101|
D007531_D064420 NONE dfp_10\NNP\0| (r_compound) toxicity_11\NN\13576101|dfp
D007531_D064420 NONE dfp_26\NNP\0| (r_pobj) of_25\IN\0|dfp (r_prep) toxicity_24\NN\13576101|the|of|in
D001285_D064420 NONE atropine_6\NN\14712692|dfp|- (r_pobj) with_3\IN\0|atropine (r_prep) treated_2\VBD\2376958|rats|with|showed|. (l_conj) showed_7\VBD\2137132|signs (l_dobj) signs_14\NNS\6643763|severe|typical|induced|toxicity (l_compound) toxicity_13\NN\13576101|
D001285_D064420 NONE atropine_0\NNP\14712692| (r_compound) mk801_2\NNP\0|atropine|- (r_nsubj) offer_5\VB\7160883|mk801|did|not|protection|. (l_dobj) protection_8\NN\407535|any|additional|against (l_prep) against_9\IN\0|toxicity (l_pobj) toxicity_11\NN\13576101|dfp
D001285_D064420 NONE atropine_11\NN\14712692| (r_pobj) with_10\IN\0|atropine (r_prep) combination_9\NN\7951464|with (r_pobj) in_8\IN\13603305|combination (r_prep) diazepam_5\NN\2830852|and|2pam|in (r_conj) cpa_3\NN\9761403|,|diazepam (r_nsubj) prevented_12\VBD\0|in|,|cpa|occurrence|and|reduced|. (l_conj) reduced_22\VBD\441445|thus|toxicity (l_dobj) toxicity_24\NN\13576101|the|of|in
C048599_D011041 NONE cpa_1\NN\9761403| (r_nsubjpass) given_7\VBN\5892096|when|cpa|,|diazepam|was|immediately|after (r_advcl) prevented_16\VBD\0|given|,|treatments|,|delayed|. (l_conj) delayed_18\VBN\439958|or|shortened (l_conj) shortened_20\VBN\429060|occurrence (l_dobj) occurrence_22\NN\29378|the|of (l_prep) of_23\IN\0|signs (l_pobj) signs_25\NNS\6643763|serious|of (l_prep) of_26\IN\0|poisoning (l_pobj) poisoning_27\NN\14034177|
C048599_D011041 NONE cpa_3\NN\9761403|,|diazepam (r_nsubj) prevented_12\VBD\0|in|,|cpa|occurrence|and|reduced|. (l_dobj) occurrence_14\NN\29378|the|of (l_prep) of_15\IN\0|signs (l_pobj) signs_17\NNS\6643763|serious|of (l_prep) of_18\IN\0|poisoning (l_pobj) poisoning_19\NN\14034177|
D003975_D011041 NONE diazepam_3\NN\2830852|or|2pam (r_nsubjpass) given_7\VBN\5892096|when|cpa|,|diazepam|was|immediately|after (r_advcl) prevented_16\VBD\0|given|,|treatments|,|delayed|. (l_conj) delayed_18\VBN\439958|or|shortened (l_conj) shortened_20\VBN\429060|occurrence (l_dobj) occurrence_22\NN\29378|the|of (l_prep) of_23\IN\0|signs (l_pobj) signs_25\NNS\6643763|serious|of (l_prep) of_26\IN\0|poisoning (l_pobj) poisoning_27\NN\14034177|
D003975_D011041 NONE diazepam_5\NN\2830852|and|2pam|in (r_conj) cpa_3\NN\9761403|,|diazepam (r_nsubj) prevented_12\VBD\0|in|,|cpa|occurrence|and|reduced|. (l_dobj) occurrence_14\NN\29378|the|of (l_prep) of_15\IN\0|signs (l_pobj) signs_17\NNS\6643763|serious|of (l_prep) of_18\IN\0|poisoning (l_pobj) poisoning_19\NN\14034177|
D011220_D011041 NONE 2pam_5\CD\0| (r_conj) diazepam_3\NN\2830852|or|2pam (r_nsubjpass) given_7\VBN\5892096|when|cpa|,|diazepam|was|immediately|after (r_advcl) prevented_16\VBD\0|given|,|treatments|,|delayed|. (l_conj) delayed_18\VBN\439958|or|shortened (l_conj) shortened_20\VBN\429060|occurrence (l_dobj) occurrence_22\NN\29378|the|of (l_prep) of_23\IN\0|signs (l_pobj) signs_25\NNS\6643763|serious|of (l_prep) of_26\IN\0|poisoning (l_pobj) poisoning_27\NN\14034177|
D011220_D011041 NONE 2pam_7\CD\0| (r_conj) diazepam_5\NN\2830852|and|2pam|in (r_conj) cpa_3\NN\9761403|,|diazepam (r_nsubj) prevented_12\VBD\0|in|,|cpa|occurrence|and|reduced|. (l_dobj) occurrence_14\NN\29378|the|of (l_prep) of_15\IN\0|signs (l_pobj) signs_17\NNS\6643763|serious|of (l_prep) of_18\IN\0|poisoning (l_pobj) poisoning_19\NN\14034177|
D007531_D011041 NONE dfp_10\NNP\0| (r_compound) atropine_12\NN\14712692|dfp|- (r_pobj) after_9\IN\0|atropine (r_prep) given_7\VBN\5892096|when|cpa|,|diazepam|was|immediately|after (r_advcl) prevented_16\VBD\0|given|,|treatments|,|delayed|. (l_conj) delayed_18\VBN\439958|or|shortened (l_conj) shortened_20\VBN\429060|occurrence (l_dobj) occurrence_22\NN\29378|the|of (l_prep) of_23\IN\0|signs (l_pobj) signs_25\NNS\6643763|serious|of (l_prep) of_26\IN\0|poisoning (l_pobj) poisoning_27\NN\14034177|
D007531_D011041 NONE dfp_26\NNP\0| (r_pobj) of_25\IN\0|dfp (r_prep) toxicity_24\NN\13576101|the|of|in (r_dobj) reduced_22\VBD\441445|thus|toxicity (r_conj) prevented_12\VBD\0|in|,|cpa|occurrence|and|reduced|. (l_dobj) occurrence_14\NN\29378|the|of (l_prep) of_15\IN\0|signs (l_pobj) signs_17\NNS\6643763|serious|of (l_prep) of_18\IN\0|poisoning (l_pobj) poisoning_19\NN\14034177|
D001285_D011041 NONE atropine_12\NN\14712692|dfp|- (r_pobj) after_9\IN\0|atropine (r_prep) given_7\VBN\5892096|when|cpa|,|diazepam|was|immediately|after (r_advcl) prevented_16\VBD\0|given|,|treatments|,|delayed|. (l_conj) delayed_18\VBN\439958|or|shortened (l_conj) shortened_20\VBN\429060|occurrence (l_dobj) occurrence_22\NN\29378|the|of (l_prep) of_23\IN\0|signs (l_pobj) signs_25\NNS\6643763|serious|of (l_prep) of_26\IN\0|poisoning (l_pobj) poisoning_27\NN\14034177|
D001285_D011041 NONE atropine_11\NN\14712692| (r_pobj) with_10\IN\0|atropine (r_prep) combination_9\NN\7951464|with (r_pobj) in_8\IN\13603305|combination (r_prep) diazepam_5\NN\2830852|and|2pam|in (r_conj) cpa_3\NN\9761403|,|diazepam (r_nsubj) prevented_12\VBD\0|in|,|cpa|occurrence|and|reduced|. (l_dobj) occurrence_14\NN\29378|the|of (l_prep) of_15\IN\0|signs (l_pobj) signs_17\NNS\6643763|serious|of (l_prep) of_18\IN\0|poisoning (l_pobj) poisoning_19\NN\14034177|
D016291_D064420 NONE mk801_2\NNP\0|atropine|- (r_nsubj) offer_5\VB\7160883|mk801|did|not|protection|. (l_dobj) protection_8\NN\407535|any|additional|against (l_prep) against_9\IN\0|toxicity (l_pobj) toxicity_11\NN\13576101|dfp
C048599_D064420 NONE cpa_3\NN\9761403|,|diazepam (r_nsubj) prevented_12\VBD\0|in|,|cpa|occurrence|and|reduced|. (l_conj) reduced_22\VBD\441445|thus|toxicity (l_dobj) toxicity_24\NN\13576101|the|of|in
D003975_D064420 NONE diazepam_5\NN\2830852|and|2pam|in (r_conj) cpa_3\NN\9761403|,|diazepam (r_nsubj) prevented_12\VBD\0|in|,|cpa|occurrence|and|reduced|. (l_conj) reduced_22\VBD\441445|thus|toxicity (l_dobj) toxicity_24\NN\13576101|the|of|in
D011220_D064420 NONE 2pam_7\CD\0| (r_conj) diazepam_5\NN\2830852|and|2pam|in (r_conj) cpa_3\NN\9761403|,|diazepam (r_nsubj) prevented_12\VBD\0|in|,|cpa|occurrence|and|reduced|. (l_conj) reduced_22\VBD\441445|thus|toxicity (l_dobj) toxicity_24\NN\13576101|the|of|in
9199746
D000583_D064420 NONE amikacin_4\RB\0|toxicity|. (l_nsubj) toxicity_1\NN\13576101|macula|after
D000617_D009877 NONE aminoglycosides_2\NNS\0|intravitreal (r_nsubj) improved_5\VBN\126264|although|aminoglycosides|have|substantially|prognosis (l_dobj) prognosis_7\NN\6748969|visual|in (l_prep) in_8\IN\13603305|endophthalmitis (l_pobj) endophthalmitis_9\NN\0|
D000617_D007238 NONE aminoglycosides_2\NNS\0|intravitreal (r_nsubj) improved_5\VBN\126264|although|aminoglycosides|have|substantially|prognosis (r_advcl) impair_14\VB\258857|improved|,|infarction|may|recovery|. (l_nsubj) infarction_12\NN\14204950|macular
D000583_D012164 CID amikacin_6\JJ\0|toxicity (l_pobj) toxicity_8\NN\13576101|retinal
D000583_D012164 CID amikacin_12\JJ\0|and|vancomycin (r_pobj) with_11\IN\0|amikacin (r_prep) treatment_10\NN\654885|with (r_pobj) following_9\VBG\8180190|treatment (r_prep) presumed_5\VBN\719734|amikacin|following (l_prep) amikacin_6\JJ\0|toxicity (l_pobj) toxicity_8\NN\13576101|retinal
D000583_D013290 NONE amikacin_6\JJ\0|toxicity (r_prep) presumed_5\VBN\719734|amikacin|following (l_prep) following_9\VBG\8180190|treatment (l_pobj) treatment_10\NN\654885|with (l_prep) with_11\IN\0|amikacin (l_pobj) amikacin_12\JJ\0|and|vancomycin (l_conj) vancomycin_14\NNP\2716866|for (l_prep) for_15\IN\0|endophthalmitis (l_pobj) endophthalmitis_20\NN\0|haemolytic|streptococcal
D000583_D013290 NONE amikacin_12\JJ\0|and|vancomycin (l_conj) vancomycin_14\NNP\2716866|for (l_prep) for_15\IN\0|endophthalmitis (l_pobj) endophthalmitis_20\NN\0|haemolytic|streptococcal
D014640_D012164 NONE vancomycin_14\NNP\2716866|for (r_conj) amikacin_12\JJ\0|and|vancomycin (r_pobj) with_11\IN\0|amikacin (r_prep) treatment_10\NN\654885|with (r_pobj) following_9\VBG\8180190|treatment (r_prep) presumed_5\VBN\719734|amikacin|following (l_prep) amikacin_6\JJ\0|toxicity (l_pobj) toxicity_8\NN\13576101|retinal
D014640_D013290 NONE vancomycin_14\NNP\2716866|for (l_prep) for_15\IN\0|endophthalmitis (l_pobj) endophthalmitis_20\NN\0|haemolytic|streptococcal
D019793_D013684 NONE fluorescein_1\NN\14598383| (r_amod) angiography_2\NN\904623|fluorescein (r_nsubj) confirmed_3\VBD\0|fundus|angiography|closure|. (l_dobj) closure_6\NN\280853|macular|capillary|and|telangiectasis (l_conj) telangiectasis_8\NN\0|
18951540
D007980_D004409 CID levodopa_5\NN\14604959| (r_npadvmod) induced_7\VBN\1627355|levodopa|- (r_amod) dyskinesias_8\NNS\14084880|induced|in
D007980_D010300 NONE levodopa_5\NN\14604959| (r_npadvmod) induced_7\VBN\1627355|levodopa|- (r_amod) dyskinesias_8\NNS\14084880|induced|in (l_prep) in_9\IN\13603305|disease (l_pobj) disease_12\NN\14061805|parkinson
17111419
C102006_D064420 NONE citrate_1\JJ\14850483| (r_compound) toxicity_2\NN\13576101|severe|citrate
C102006_D064420 NONE citrate_6\JJ\14850483| (r_compound) toxicity_7\NN\13576101|severe|citrate
C102006_D064420 NONE citrate_22\JJ\14850483| (r_compound) toxicity_23\NN\13576101|citrate
D002125_C536214 NONE gluconate_5\NN\0|intravenous|calcium (r_pobj) with_2\IN\0|gluconate (r_prep) treatment_1\NN\654885|empirical|with (r_nsubjpass) initiated_7\VBN\1617192|treatment|was|,|and|subsided (l_conj) subsided_13\VBD\223500|contractions|slowly|over|. (l_nsubj) contractions_11\NNS\358931|muscle
D002118_D006996 NONE calcium_9\NN\14625458| (r_compound) chelation_10\NN\29677|calcium (r_pobj) to_8\IN\0|chelation (r_prep) reaction_7\NN\13446390|a|severe|to|by|resulting (l_acl) resulting_15\VBG\2633881|in (l_prep) in_16\IN\13603305|hypocalcemia (l_pobj) hypocalcemia_19\NN\14299637|symptomatic|systemic
C102006_D006996 CID citrate_13\NN\14850483|sodium (r_compound) anticoagulant_14\NN\3740161|citrate (r_pobj) by_11\IN\0|anticoagulant (r_prep) reaction_7\NN\13446390|a|severe|to|by|resulting (l_acl) resulting_15\VBG\2633881|in (l_prep) in_16\IN\13603305|hypocalcemia (l_pobj) hypocalcemia_19\NN\14299637|symptomatic|systemic
C102006_D006996 CID citrate_22\JJ\14850483| (r_compound) toxicity_23\NN\13576101|citrate (r_pobj) to_21\IN\0|toxicity (r_pcomp) due_20\IN\5174653|to (r_amod) reactions_19\NNS\13446390|severe|due (r_dobj) prevent_17\VB\0|reactions (r_xcomp) help_16\VB\407535|to|prevent (r_xcomp) recommended_14\VBN\875394|that|screening|is|help (l_nsubjpass) screening_4\NN\6887726|careful|for (l_prep) for_5\IN\0|medications (l_pobj) medications_6\NNS\3247620|and|conditions (l_conj) conditions_9\NNS\14512817|underlying|predisposing (l_acl) predisposing_10\VBG\680841|to (l_prep) to_11\IN\0|hypocalcemia (l_pobj) hypocalcemia_12\NN\14299637|
D002034_D006996 NONE bumetanide_9\NN\0| (r_nsubj) is_10\VBZ\0|that|bumetanide|loop (l_attr) loop_12\NN\3323703|a|diuretic|cause (l_relcl) cause_16\VB\7323922|that|may|hypocalcemia (l_dobj) hypocalcemia_18\NN\14299637|significant
D049994_D006996 NONE diuretic_13\NN\3247620| (r_amod) loop_12\NN\3323703|a|diuretic|cause (l_relcl) cause_16\VB\7323922|that|may|hypocalcemia (l_dobj) hypocalcemia_18\NN\14299637|significant
18560792
D010479_D006349 NONE pergolide_11\NN\0| (r_pobj) with_10\IN\0|pergolide (r_prep) treated_9\VBN\2376958|disease|with|. (l_nsubj) disease_2\NN\14061805|valvular|heart|in
D010479_D006349 NONE pergolide_17\NN\0| (r_pobj) with_16\IN\0|pergolide (r_prep) treated_15\VBN\2376958|with (r_acl) patients_7\NNS\9898892|with|treated (r_pobj) in_6\IN\13603305|patients (r_prep) reported_5\VBN\831651|abnormalities|have|been|in|. (l_nsubjpass) abnormalities_2\NNS\14034177|valvular|heart
D010479_D006349 NONE pergolide_12\NN\0| (r_pobj) of_11\IN\0|pergolide (r_prep) role_10\NN\719494|the|of (r_pobj) of_8\IN\0|role (r_prep) suggestive_7\JJ\0|of (r_amod) pattern_2\NN\5726345|a|restrictive|of|,|suggestive (l_prep) of_3\IN\0|regurgitation (l_pobj) regurgitation_5\NN\7406350|valvular
D010479_D006349 NONE pergolide_0\NNP\0| (r_nsubjpass) discontinued_2\VBN\0|pergolide|was|in|,|resulting|returned|. (l_prep) in_3\IN\13603305|patients (l_pobj) patients_5\NNS\9898892|10|with (l_prep) with_6\IN\0|disease (l_pobj) disease_9\NN\14061805|valvular|heart
D010479_D006349 NONE pergolide_15\NN\0| (r_pobj) with_14\IN\0|pergolide (r_prep) treated_13\VBN\2376958|with|and|reveals (r_acl) frequency_5\NN\15286249|the|high|of|treated (l_prep) of_6\IN\0|regurgitation (l_pobj) regurgitation_9\NN\7406350|restrictive|valve|in
D010479_D010300 NONE pergolide_11\NN\0| (r_pobj) with_10\IN\0|pergolide (r_prep) treated_9\VBN\2376958|disease|with|. (l_nsubj) disease_2\NN\14061805|valvular|heart|in (l_prep) in_3\IN\13603305|patients (l_pobj) patients_4\NNS\9898892|with (l_prep) with_5\IN\0|disease (l_pobj) disease_8\NN\14061805|parkinson
D010479_D010300 NONE pergolide_17\NN\0| (r_pobj) with_16\IN\0|pergolide (r_prep) treated_15\VBN\2376958|with (r_acl) patients_7\NNS\9898892|with|treated (l_prep) with_8\IN\0|disease (l_pobj) disease_11\NN\14061805|parkinson|(|pd|)
D010479_D010300 NONE pergolide_17\NN\0| (r_pobj) with_16\IN\0|pergolide (r_prep) treated_15\VBN\2376958|with (r_acl) patients_7\NNS\9898892|with|treated (l_prep) with_8\IN\0|disease (l_pobj) disease_11\NN\14061805|parkinson|(|pd|) (l_appos) pd_13\NNP\14625458|
D010479_D010300 NONE pergolide_9\NN\0| (r_pobj) with_8\IN\0|pergolide (r_prep) treated_7\VBN\2376958|patients|with (l_nsubj) patients_2\NNS\9898892|all|pd|in (l_compound) pd_1\NNP\14625458|
D010479_D010300 NONE pergolide_15\NN\0| (r_pobj) with_14\IN\0|pergolide (r_prep) treated_13\VBN\2376958|with|and|reveals (r_acl) frequency_5\NN\15286249|the|high|of|treated (l_prep) of_6\IN\0|regurgitation (l_pobj) regurgitation_9\NN\7406350|restrictive|valve|in (l_prep) in_10\IN\13603305|patients (l_pobj) patients_12\NNS\9898892|pd (l_compound) pd_11\NNP\14625458|
D010479_D006333 NONE pergolide_12\NN\0| (r_pobj) of_11\IN\0|pergolide (r_prep) role_10\NN\719494|the|of (r_pobj) of_8\IN\0|role (r_prep) suggestive_7\JJ\0|of (r_amod) pattern_2\NN\5726345|a|restrictive|of|,|suggestive (r_nsubjpass) observed_15\VBN\2163746|pattern|,|was|in|patients|. (l_dobj) patients_22\NNS\9898892|including (l_prep) including_23\VBG\0|two (l_pobj) two_24\CD\13741022|with (l_prep) with_25\IN\0|failure (l_pobj) failure_27\NN\66216|heart
D010479_D006333 NONE pergolide_0\NNP\0| (r_nsubjpass) discontinued_2\VBN\0|pergolide|was|in|,|resulting|returned|. (l_advcl) resulting_11\VBG\2633881|in (l_prep) in_12\IN\13603305|grade (l_pobj) grade_16\NN\7975026|a|lower|regurgitation|p=0.01|at (l_prep) at_20\IN\14622893|transthoracic (l_pobj) transthoracic_23\NN\0|the|second|echocardiography|and|patients (l_conj) patients_28\NNS\9898892|the|two|with (l_prep) with_29\IN\0|failure (l_pobj) failure_31\NN\66216|heart
D004298_D006349 NONE dopamine_33\NN\14807737| (r_compound) agonists_34\NNS\0|ergot|dopamine (r_pobj) to_29\IN\0|agonists (r_prep) converted_28\VBN\126264|when|treatment|is|to (r_advcl) is_22\VBZ\0|that|improvement|usual|converted (r_ccomp) reveals_17\VBZ\2137132|is (r_conj) treated_13\VBN\2376958|with|and|reveals (r_acl) frequency_5\NN\15286249|the|high|of|treated (l_prep) of_6\IN\0|regurgitation (l_pobj) regurgitation_9\NN\7406350|restrictive|valve|in
D004298_D010300 NONE dopamine_33\NN\14807737| (r_compound) agonists_34\NNS\0|ergot|dopamine (r_pobj) to_29\IN\0|agonists (r_prep) converted_28\VBN\126264|when|treatment|is|to (r_advcl) is_22\VBZ\0|that|improvement|usual|converted (r_ccomp) reveals_17\VBZ\2137132|is (r_conj) treated_13\VBN\2376958|with|and|reveals (r_acl) frequency_5\NN\15286249|the|high|of|treated (l_prep) of_6\IN\0|regurgitation (l_pobj) regurgitation_9\NN\7406350|restrictive|valve|in (l_prep) in_10\IN\13603305|patients (l_pobj) patients_12\NNS\9898892|pd (l_compound) pd_11\NNP\14625458|
11569530
D016593_D016171 CID terfenadine_19\NN\0|e.g.|and|terodiline (r_appos) market_16\NN\407535|the|(|terfenadine|) (r_pobj) from_14\IN\0|market (r_prep) withdrawal_10\NN\7206096|of|from (r_pobj) to_9\IN\0|withdrawal (r_prep) led_8\VBN\3202760|that|has|to (r_relcl) effect_5\NN\34213|a|side|-|led (r_attr) is_1\VBZ\0|tdp|effect|. (l_nsubj) tdp_0\NNP\0|
D016593_D016171 CID terfenadine_13\NN\0|,|terodiline (r_appos) investigated_11\VBN\644583|tdp|were|:|terfenadine (l_nsubjpass) tdp_9\NNP\0|
D016593_D016171 CID terfenadine_10\NN\0|,|terodiline (r_appos) clinic_8\NN\8053905|the|(|terfenadine|) (r_pobj) in_6\IN\13603305|clinic (r_prep) shown_4\VBN\2137132|that|have|tdp|in (l_dobj) tdp_5\NNP\0|
C010637_D016171 CID terodiline_21\NN\0| (r_conj) terfenadine_19\NN\0|e.g.|and|terodiline (r_appos) market_16\NN\407535|the|(|terfenadine|) (r_pobj) from_14\IN\0|market (r_prep) withdrawal_10\NN\7206096|of|from (r_pobj) to_9\IN\0|withdrawal (r_prep) led_8\VBN\3202760|that|has|to (r_relcl) effect_5\NN\34213|a|side|-|led (r_attr) is_1\VBZ\0|tdp|effect|. (l_nsubj) tdp_0\NNP\0|
C010637_D016171 CID terodiline_15\NN\0|,|cisapride (r_conj) terfenadine_13\NN\0|,|terodiline (r_appos) investigated_11\VBN\644583|tdp|were|:|terfenadine (l_nsubjpass) tdp_9\NNP\0|
C010637_D016171 CID terodiline_12\NN\0|,|cisapride (r_conj) terfenadine_10\NN\0|,|terodiline (r_appos) clinic_8\NN\8053905|the|(|terfenadine|) (r_pobj) in_6\IN\13603305|clinic (r_prep) shown_4\VBN\2137132|that|have|tdp|in (l_dobj) tdp_5\NNP\0|
D020117_D016171 CID cisapride_17\NN\0|and|e4031 (r_conj) terodiline_15\NN\0|,|cisapride (r_conj) terfenadine_13\NN\0|,|terodiline (r_appos) investigated_11\VBN\644583|tdp|were|:|terfenadine (l_nsubjpass) tdp_9\NNP\0|
D020117_D016171 CID cisapride_14\JJ\0| (r_conj) terodiline_12\NN\0|,|cisapride (r_conj) terfenadine_10\NN\0|,|terodiline (r_appos) clinic_8\NN\8053905|the|(|terfenadine|) (r_pobj) in_6\IN\13603305|clinic (r_prep) shown_4\VBN\2137132|that|have|tdp|in (l_dobj) tdp_5\NNP\0|
C063968_D016171 NONE e4031_19\NNP\0| (r_conj) cisapride_17\NN\0|and|e4031 (r_conj) terodiline_15\NN\0|,|cisapride (r_conj) terfenadine_13\NN\0|,|terodiline (r_appos) investigated_11\VBN\644583|tdp|were|:|terfenadine (l_nsubjpass) tdp_9\NNP\0|
